<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="0" size="13" family="Times" color="#000000"/>
	<fontspec id="1" size="18" family="Times" color="#000000"/>
	<fontspec id="2" size="14" family="Times" color="#000000"/>
	<fontspec id="3" size="22" family="Times" color="#000000"/>
	<fontspec id="4" size="14" family="Times" color="#000000"/>
<text top="804" left="574" width="44" height="19" font="0">Page 1 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="121" width="950" height="27" font="1"><b>2018 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Bradycardia and Cardiac </b></text>
<text top="112" left="444" width="315" height="27" font="1"><b>Conduction Delay Data Supplement </b></text>
<text top="137" left="594" width="5" height="27" font="1"><b> </b></text>
<text top="163" left="534" width="124" height="21" font="2"><b>Table of Contents </b></text>
<text top="201" left="86" width="5" height="31" font="3"> </text>
<text top="231" left="107" width="955" height="21" font="4"><a href="data supplement.html#4">Abbreviations: ........................................................................................................................................................................................................... 4 </a></text>
<text top="251" left="107" width="977" height="21" font="4"><a href="data supplement.html#6">Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of 12-Lead Electrocardiography in Bradycardia or Conduction </a></text>
<text top="271" left="107" width="955" height="21" font="4"><a href="data supplement.html#6">Disturbance (Section 4.2.1) ....................................................................................................................................................................................... 6 </a></text>
<text top="291" left="107" width="945" height="21" font="4"><a href="data supplement.html#9">Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Exercise Stress Testing in Bradycardia and Conduction </a></text>
<text top="311" left="107" width="955" height="21" font="4"><a href="data supplement.html#9">Disturbances (Section 4.2.2) ..................................................................................................................................................................................... 9 </a></text>
<text top="331" left="107" width="921" height="21" font="4"><a href="data supplement.html#14">Data Supplement 3. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Electrocardiography in Bradycardia or </a></text>
<text top="351" left="107" width="955" height="21" font="4"><a href="data supplement.html#14">Conduction Disorders (Sections 4.2.3 and 4.2.4) .................................................................................................................................................... 14 </a></text>
<text top="372" left="107" width="921" height="21" font="4"><a href="data supplement.html#47">Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Electrocardiography in Bradycardia or </a></text>
<text top="392" left="107" width="955" height="21" font="4"><a href="data supplement.html#47">Conduction Disorders (Section 4.2.4) ...................................................................................................................................................................... 47 </a></text>
<text top="412" left="107" width="962" height="21" font="4"><a href="data supplement.html#49">Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Nocturnal / Sleeping Bradyarrhythmias and Sleep Apnea </a></text>
<text top="432" left="107" width="955" height="21" font="4"><a href="data supplement.html#49">(Section-4.2.7) ......................................................................................................................................................................................................... 49 </a></text>
<text top="452" left="107" width="977" height="21" font="4"><a href="data supplement.html#65">Data Supplement 6. RCTs of Implantable Loop Recorder in Patients With Documented or Suspected Bradycardia or Conduction Disorders (Section </a></text>
<text top="472" left="107" width="955" height="21" font="4"><a href="data supplement.html#65">4.3.1) ....................................................................................................................................................................................................................... 65 </a></text>
<text top="492" left="107" width="976" height="21" font="4"><a href="data supplement.html#67">Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries of Electrophysiology Testing in Patients With Documented or </a></text>
<text top="513" left="107" width="955" height="21" font="4"><a href="data supplement.html#67">Suspected Bradycardia or Conduction Disorders (Section 4.3.2) ........................................................................................................................... 67 </a></text>
<text top="533" left="107" width="955" height="21" font="4"><a href="data supplement.html#67">Data Supplement 8. RCTs Comparing Atropine to Placebo for Bradycardia (Section 5.3.2.1) ............................................................................... 67 </a></text>
<text top="553" left="107" width="919" height="21" font="4"><a href="data supplement.html#69">Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of Atropine in SND and Hemodynamically Significant </a></text>
<text top="573" left="107" width="955" height="21" font="4"><a href="data supplement.html#69">Bradycardia (Section 5.3.2.1) .................................................................................................................................................................................. 69 </a></text>
<text top="593" left="107" width="943" height="21" font="4"><a href="data supplement.html#72">Data Supplement 10. Nonrandomized Trials, Observational Studies, and/or Registries of Isoproterenol Effect in Electrophysiology Laboratory </a></text>
<text top="613" left="107" width="955" height="21" font="4"><a href="data supplement.html#72">(Section 5.3.2.1) ...................................................................................................................................................................................................... 72 </a></text>
<text top="633" left="107" width="955" height="21" font="4"><a href="data supplement.html#73">Data Supplement 11. RCTs of Dopamine in Bradycardia (Section 5.3.2.1) ............................................................................................................. 73 </a></text>
<text top="654" left="107" width="979" height="21" font="4"><a href="data supplement.html#73">Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of Calcium, Glucagon and High Dose Insulin Therapy to treat </a></text>
<text top="674" left="107" width="955" height="21" font="4"><a href="data supplement.html#73">Beta-Blocker and Calcium Channel Blocker Toxicity (CCB) (Section 5.3.2.2) .......................................................................................................... 73 </a></text>
<text top="694" left="107" width="955" height="21" font="4"><a href="data supplement.html#76">Data Supplement 13. RCTs Comparing Anti-Digoxin Fab to placebo (Section 5.3.2.3) ........................................................................................... 76 </a></text>
<text top="714" left="107" width="955" height="21" font="4"><a href="data supplement.html#77">Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of Digoxin Fab Antibody Fragments (Section 5.3.2.3) .. 77 </a></text>
<text top="734" left="107" width="966" height="21" font="4"><a href="data supplement.html#79">Data Supplement 15. Nonrandomized Trials, Observational Studies, and/or Registries of Dialysis for Digoxin Toxicity (Section 5.3.2.3 – Patton)79 </a></text>
<text top="754" left="107" width="955" height="21" font="4"><a href="data supplement.html#79">Data Supplement 16. RCTs Comparing Methylxanthines in Bradycardic Arrest (Section 5.3.2.4) ......................................................................... 79 </a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="574" width="44" height="19" font="0">Page 2 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="107" width="975" height="21" font="4"><a href="data supplement.html#80">Data Supplement 17. Nonrandomized Trials, Observational Studies, and/or Registries of Methylxanthines for acute therapy of bradycardia due to </a></text>
<text top="106" left="107" width="955" height="21" font="4"><a href="data supplement.html#80">spinal cord injury or post-heart transplant (Section 5.3.2.4) .................................................................................................................................. 80 </a></text>
<text top="127" left="107" width="955" height="21" font="4"><a href="data supplement.html#81">Data Supplement 18. Trials of Temporary Transesophageal or Transvenous Pacing (Section 5.3.3)..................................................................... 81 </a></text>
<text top="147" left="107" width="969" height="21" font="4"><a href="data supplement.html#82">Data Supplement 19. Nonrandomized Trials, Observational Studies, and/or Registries of Temporary Transvenous Pacing (TTVP) (Section 5.3.3)82 </a></text>
<text top="167" left="107" width="955" height="21" font="4"><a href="data supplement.html#87">Data Supplement 20. RCTs of Transcutaneous Pacing (Section 5.3.3) ................................................................................................................... 87 </a></text>
<text top="187" left="107" width="955" height="21" font="4"><a href="data supplement.html#87">Data Supplement 21. Nonrandomized Trials, Observational Studies, and/or Registries of Transcutaneous Pacing (Section 5.3.3) ..................... 87 </a></text>
<text top="207" left="107" width="958" height="21" font="4"><a href="data supplement.html#89">Data Supplement 22. RCTs of General Principles of Chronic Therapy/Management of Bradycardia due to Sinus Node Dysfunction (Section 5.4.1)</a></text>
<text top="227" left="107" width="955" height="21" font="4"><a href="data supplement.html#89"> ................................................................................................................................................................................................................................. 89 </a></text>
<text top="247" left="107" width="960" height="21" font="4"><a href="data supplement.html#90">Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of General Principles of Chronic Therapy/Management of </a></text>
<text top="268" left="107" width="955" height="21" font="4"><a href="data supplement.html#90">Bradycardia due to Sinus Node Dysfunction (Section 5.4.1) ................................................................................................................................... 90 </a></text>
<text top="288" left="107" width="955" height="21" font="4"><a href="data supplement.html#92">Data Supplement 24. RCTs of Clinical Presentation of Bradycardia due to Sinus Node Dysfunction (Section 5.3) ............................................... 92 </a></text>
<text top="308" left="107" width="965" height="21" font="4"><a href="data supplement.html#94">Data Supplement 25. RCTs of Permanent Pacing for Chronic Therapy/Management of Bradycardia due to Sinus Node Dysfunction (Section 5.4.4)</a></text>
<text top="328" left="107" width="955" height="21" font="4"><a href="data supplement.html#94"> ................................................................................................................................................................................................................................. 94 </a></text>
<text top="348" left="107" width="955" height="21" font="4"><a href="data supplement.html#101">Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Reversible Causes of AV block (Section 6.3.1) ........ 101 </a></text>
<text top="368" left="107" width="955" height="21" font="4"><a href="data supplement.html#104">Data Supplement 27. RCTs Comparing Medical treatment for AV block (Section 6.3.2) ..................................................................................... 104 </a></text>
<text top="388" left="107" width="955" height="21" font="4"><a href="data supplement.html#104">Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Medical Treatment for AV block (Section 6.3.2) .... 104 </a></text>
<text top="409" left="107" width="955" height="21" font="4"><a href="data supplement.html#107">Data Supplement 29. RCTs Comparing Temporary Pacing (Section 6.3.3) ........................................................................................................... 107 </a></text>
<text top="429" left="107" width="955" height="21" font="4"><a href="data supplement.html#109">Data Supplement 30. Nonrandomized Trials, Observational Studies, and/or Registries of Temporary Pacing (Section 6.3.3) ........................... 109 </a></text>
<text top="449" left="107" width="955" height="21" font="4"><a href="data supplement.html#116">Data Supplement 31. RCTs of clinical presentation of bradycardia due to AV block (Section 6.3) ...................................................................... 116 </a></text>
<text top="469" left="107" width="955" height="21" font="4"><a href="data supplement.html#117">Data Supplement 32. Nonrandomized data of Clinical Presentation of Bradycardia due to AV block (Section 6.3) ........................................... 117 </a></text>
<text top="489" left="107" width="955" height="21" font="4"><a href="data supplement.html#135">Data Supplement 33. RCTs of General Principles of Chronic Therapy/Management of Bradycardia due to AV block (Section 6.4.1) ................ 135 </a></text>
<text top="509" left="107" width="955" height="21" font="4"><a href="data supplement.html#135">Data Supplement 34. Nonrandomized data of General Principles of Chronic Therapy/Management of Bradycardia due to AV block (Section 6.4)</a></text>
<text top="529" left="107" width="955" height="21" font="4"><a href="data supplement.html#135"> ............................................................................................................................................................................................................................... 135 </a></text>
<text top="550" left="107" width="955" height="21" font="4"><a href="data supplement.html#146">Data Supplement 35. RCTs of meds/reversible/transient causes of bradycardia due to AVB (Section 6.4.2) ..................................................... 146 </a></text>
<text top="570" left="107" width="955" height="21" font="4"><a href="data supplement.html#146">Data Supplement 36. Nonrandomized data of Medications/Reversible/Transient Causes of Bradycardia due to AVB (Section 6.4.2) .............. 146 </a></text>
<text top="590" left="107" width="955" height="21" font="4"><a href="data supplement.html#150">Data Supplement 37. RCT data of additional testing for Bradycardia due to AV block (Section 6.4.3) ................................................................ 150 </a></text>
<text top="610" left="107" width="955" height="21" font="4"><a href="data supplement.html#151">Data Supplement 38. Nonrandomized data of additional testing for Bradycardia due to AV block (Section 6.4.3) ............................................ 151 </a></text>
<text top="630" left="107" width="955" height="21" font="4"><a href="data supplement.html#154">Data Supplement 39. RCTs for Permanent Pacing for AV block (Section 6.4.4) ................................................................................................... 154 </a></text>
<text top="650" left="107" width="955" height="21" font="4"><a href="data supplement.html#158">Data Supplement 40. Nonrandomized data for Permanent Pacing for AV block (Section 6.4.4) ......................................................................... 158 </a></text>
<text top="670" left="107" width="955" height="21" font="4"><a href="data supplement.html#162">Data Supplement 41. Nonrandomized Trials, Observational Studies, and/or Registries of Conduction Disorders (Section 7) ........................... 162 </a></text>
<text top="691" left="107" width="955" height="21" font="4"><a href="data supplement.html#167">Data Supplement 42. Randomized Data for Predicting Perioperative Bradycardia (Section 8.1.1) ..................................................................... 167 </a></text>
<text top="711" left="107" width="955" height="21" font="4"><a href="data supplement.html#167">Data Supplement 43. RCTs of Conduction Disorders (Section 7) .......................................................................................................................... 167 </a></text>
<text top="731" left="107" width="955" height="21" font="4"><a href="data supplement.html#167">Data Supplement 44. Nonrandomized Data for predicting perioperative bradycardia (Section 8.1.1) ............................................................... 167 </a></text>
<text top="751" left="106" width="955" height="21" font="4"><a href="data supplement.html#175">Data Supplement 45. Nonrandomized Data for predicting complete heart block with pulmonary artery catheter insertion (Section 8.1.1) .... 175 </a></text>
<text top="771" left="106" width="955" height="21" font="4"><a href="data supplement.html#176">Data Supplement 46. Nonrandomized data for Permanent Pacing for TAVI/valve surgery ................................................................................. 176 </a></text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="5" size="16" family="Times" color="#000000"/>
<text top="804" left="574" width="44" height="19" font="0">Page 3 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="107" width="955" height="21" font="2"><a href="data supplement.html#178"><b>The Birmingham Trial</b> ........................................................................................................................................................................................... 178 </a></text>
<text top="106" left="107" width="955" height="21" font="4"><a href="data supplement.html#194">Data Supplement 47. Nonrandomized Trials, Observational Studies, and/or Registries of CABG (Section 8.1.2.1) ............................................ 194 </a></text>
<text top="127" left="107" width="955" height="21" font="4"><a href="data supplement.html#197">Data Supplement 48. Nonrandomized Trials, Observational Studies, and/or Registries of Open Surgery for Atrial Fibrillation or Valvular Surgery </a></text>
<text top="147" left="107" width="955" height="21" font="4"><a href="data supplement.html#197">(Section 8.1.2.2. and 8.1.2.3) ................................................................................................................................................................................ 197 </a></text>
<text top="167" left="107" width="955" height="21" font="4"><a href="data supplement.html#200">Data Supplement 49. Nonrandomized Trials, Observational Studies, and/or Registries of Conduction Abnormalities After TAVR (Section 8.1.2.4)</a></text>
<text top="187" left="107" width="955" height="21" font="4"><a href="data supplement.html#200"> ............................................................................................................................................................................................................................... 200 </a></text>
<text top="207" left="107" width="955" height="21" font="4"><a href="data supplement.html#206">Data Supplement 50. Nonrandomized Trials, Observational Studies, and/or Registries of Pacing after Heart Transplant (Section 8.1.2.5.1) .. 206 </a></text>
<text top="227" left="107" width="955" height="21" font="4"><a href="data supplement.html#208">Data Supplement 51. Nonrandomized Studies for Alcohol Septal Ablation/Septal Myectomy (Section 8.1.2.5.2) ............................................. 208 </a></text>
<text top="247" left="107" width="955" height="21" font="4"><a href="data supplement.html#215">Data Supplement 52. Nonrandomized Studies for ICDs for Alcohol Septal Ablation/Septal Myectomy (Section 8.1.2.5.2) ............................... 215 </a></text>
<text top="268" left="107" width="967" height="21" font="4"><a href="data supplement.html#216">Data Supplement 53. Nonrandomized Trials, Observational Studies, and/or Registries of Adult Congenital Heart Disease (ACHD) (Section 8.2)216 </a></text>
<text top="288" left="107" width="985" height="21" font="4"><a href="data supplement.html#221">Data Supplement 54. RCTs, Nonrandomized Trials, Observational Studies, and/or Registries of Bradycardia and Pacemaker Implantation in Patients </a></text>
<text top="308" left="107" width="955" height="21" font="4"><a href="data supplement.html#221">with an Acute MI (Section 8.3) .............................................................................................................................................................................. 221 </a></text>
<text top="328" left="107" width="955" height="21" font="4"><a href="data supplement.html#227">Data Supplement 55. Nonrandomized Data for Predicting Bradycardia Associated with Seizures (Section 8.4.1) ............................................. 227 </a></text>
<text top="348" left="107" width="955" height="21" font="4"><a href="data supplement.html#228">Data Supplement 56. Nonrandomized Data for Device Type (Section 9) ............................................................................................................. 228 </a></text>
<text top="368" left="107" width="955" height="21" font="4"><a href="data supplement.html#236">References ............................................................................................................................................................................................................. 236 </a></text>
<text top="388" left="86" width="4" height="21" font="4"> </text>
<text top="408" left="594" width="4" height="23" font="5"><b> </b></text>
<text top="430" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="430" left="302" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="6" size="13" family="Times" color="#000000"/>
<text top="804" left="574" width="44" height="19" font="0">Page 4 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="244" height="21" font="2"><b>Methodology and Evidence Review </b></text>
<text top="106" left="86" width="1012" height="19" font="0">The recommendations listed in this guideline are, whenever possible, evidence based. An extensive evidence review was conducted from January through September </text>
<text top="125" left="86" width="972" height="19" font="0">2017, that included literature published through September 2017. Other selected references published through January 2018 were incorporated by the writing </text>
<text top="143" left="86" width="1003" height="19" font="0">committee. Literature included was derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the </text>
<text top="161" left="86" width="999" height="19" font="0">Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Key search words included but were not </text>
<text top="180" left="86" width="952" height="19" font="0">limited to the following: <i>adult, adult congenital heart disease, ACS, AF, AL amyloid, AL amyloidosis, alcohol septal ablation, ambulatory electrocardiography, </i></text>
<text top="197" left="86" width="969" height="19" font="6"><i>aminophylline, amyloidosis, antiarrhythmic drugs, antibradycardia, aortic dissection, aortic valve, asystole, arrhythmia, atrial fibrillation, atrioventricular block, </i></text>
<text top="215" left="86" width="934" height="19" font="6"><i>atropine, AV block, AV block symptoms, beta-adrenergic agonist, beta-blocker, Birmingham trial, biventricular pacemaker, bradyarrest, bradyarrhythmia, </i></text>
<text top="234" left="86" width="995" height="19" font="6"><i>bradyasystole, bradycardia, bundle branch block, cardiac, cardiac AL amyloid, cardiac arrest, cardiac pacing, cardiac resynchronization therapy, cardiac sarcoidosis, </i></text>
<text top="252" left="86" width="991" height="19" font="6"><i>cardiac surgery, cardiology, cardiovascular implantable electronic devices, catecholamines, cilostazol, clinical presentation, clinical trial, complications, conduction, </i></text>
<text top="270" left="86" width="1012" height="19" font="6"><i>conduction disturbance, congenital AV block, coronary artery bypass, cost, cost-effectiveness, cost-effectiveness analysis, CPAP, deactivation, defibrillator, defibrillator </i></text>
<text top="289" left="86" width="979" height="19" font="6"><i>versus pacemaker, device, device implantation, devices, device therapy, digoxin, digoxin antibody, dialysis, dizziness, dopamine, drug therapy, drug induced, dual </i></text>
<text top="307" left="86" width="982" height="19" font="6"><i>chamber, dyssynchrony, echocardiogram, electrocardiogram, endocarditis, English, EP study, epidemiology, epinephrine, evaluation studies, event monitor, event </i></text>
<text top="325" left="86" width="991" height="19" font="6"><i>recorder, exercise induced, exercise test, exercise treadmill, first degree, first degree AV block, genetic variation, genetics, genotype, glucagon, health status, heart, </i></text>
<text top="344" left="86" width="985" height="19" font="6"><i>heart block, heart transplant, hemochromatosis, Holter, Holter monitor, human, hypertrophic cardiomyopathy, ICD, ILR, implantable loop recorder, intraoperative </i></text>
<text top="362" left="86" width="993" height="19" font="6"><i>bradycardia, isoproterenol, lamin A/C, left bundle branch block, life, LMNA, loop recorder, Lyme carditis, Lyme disease, magnetic resonance imaging, management, </i></text>
<text top="380" left="86" width="993" height="19" font="6"><i>medical, medical therapy, medications, mitral valve, mortality, muscular dystrophies, myectomy, myocardial infarction, myocardial perfusion imaging, myocarditis, </i></text>
<text top="399" left="86" width="994" height="19" font="6"><i>myotonic dystrophy, natural history, orthotopic heart transplant, OSA, pacemaker, pacemaker syndrome, pacing, pacing induced cardiomyopathy, patients nearing </i></text>
<text top="417" left="86" width="1012" height="19" font="6"><i>end, pauses, permanent pacemaker, PM, pregnancy, preoperative bradycardia, preoperative risk, procainamide, procedure, prognosis, prophylactic temporary pacing, </i></text>
<text top="435" left="86" width="974" height="19" font="6"><i>pulmonary artery catheter, quality of life, radionuclide imaging, RCT, rejection, reversal, reversible causes, review, right bundle branch block, RV pacing, sarcoid, </i></text>
<text top="454" left="86" width="1016" height="19" font="6"><i>sarcoidosis, seizure, shared decision making, sick sinus syndrome, sinus, sinus arrest, sinus bradycardia, sinus node, sinus node dysfunction, sinus of Valsalva aneurysm, </i></text>
<text top="472" left="86" width="994" height="19" font="6"><i>sleep apnea, sleep apnea syndromes, spinal cord dysfunction, spinal cord injury, steroid, sudden cardiac death, syncope, symptomatic, TAVR, temporary, temporary </i></text>
<text top="490" left="86" width="1006" height="19" font="6"><i>pacemaker, temporary pacing, theophylline, thyroid disease, tomography-emission-computed-single photon, tomography-X-ray computed, transcatheter aortic valve </i></text>
<text top="509" left="86" width="986" height="19" font="6"><i>replacement, transcutaneous pacemaker, transesophageal echocardiogram, transient, treatment, vagal, vagally mediated, vagally mediated AV block, ventricular </i></text>
<text top="527" left="86" width="245" height="19" font="6"><i>arrhythmia risk, ventricular remodeling  </i></text>
<text top="546" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="566" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="586" left="86" width="110" height="23" font="5"><b>Abbreviations:</b></text>
<text top="587" left="196" width="4" height="21" font="2"><b> </b></text>
<text top="589" left="200" width="863" height="19" font="0">1° indicates primary; 2°, secondary; AAD, antiarrhythmic drug; ABP, atrial-based pacing; ACEI, angiotensin-converting enzyme inhibitor; ACLS, </text>
<text top="608" left="86" width="942" height="19" font="0">advanced cardiac life support; AED, antiepileptic drug; AF, atrial fibrillation; AMI, acute myocardial infarction; AS, aortic stenosis; ASA, American Society of </text>
<text top="626" left="86" width="988" height="19" font="0">Anesthesiology OR alcohol septal ablation; asx, asymptomatic; ATP, antitachycardia pacing; AV, atrioventricular; AVB, atrioventricular block; AVN, atrioventricular </text>
<text top="645" left="86" width="972" height="19" font="0">nodal; AVR, aortic valve replacement; BB, beta blocker; BBB, bundle branch block; BiV, biventricular; BMI, body mass index; BP, blood pressure; bpm, beats per </text>
<text top="663" left="86" width="939" height="19" font="0">minute; C, comparator; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; ccTGA, congenitally corrected </text>
<text top="681" left="86" width="949" height="19" font="0">transposition of the great arteries; CEA, carotid endarterectomy; CHB, complete heart block; CHD, coronary heart disease; CHF, congestive heart failure; CI, </text>
<text top="700" left="86" width="993" height="19" font="0">confidence interval; CIED, cardiac implantable electronic device; CMP, cardiomyopathy; CPAP, continuous positive airway pressure; CRT, cardiac resynchronization </text>
<text top="718" left="86" width="977" height="19" font="0">therapy; CRT-D, device that provides both cardiac resynchronization therapy and defibrillator capabilities; CRT-P, device that provides cardiac resynchronization </text>
<text top="736" left="86" width="997" height="19" font="0">therapy only; CSM, carotid sinus massage; CV, cardiovascular; CVA, cerebrovascular accident; Cum%VP, cumulative percentage of ventricular pacing; Cx, circumflex </text>
<text top="755" left="86" width="1007" height="19" font="0">coronary artery; CXR, chest X-ray; DC, dual chamber; DCCV, direct current cardioversion; DM, diabetes mellitus; DOE, dyspnea on exertion; D-TGA, d-transposition of </text>
<text top="773" left="86" width="1012" height="19" font="0">the great arteries; Dx, diagnosis; echo, echocardiogram; ECG, electrocardiogram; ED, emergency department; EEG, electroencephalogram; EF, ejection fraction; EMD, </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="7" size="7" family="Times" color="#000000"/>
<text top="804" left="574" width="44" height="19" font="0">Page 5 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="993" height="19" font="0">electromechanical dissociation; EMS, emergency medical service; EP, electrophysiologic; EPS, electrophysiologic study; GDMT, guideline-directed medical therapy; </text>
<text top="104" left="86" width="1011" height="19" font="0">HCM, hypertrophic cardiomyopathy; HDIT, high-dose insulin therapy; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection </text>
<text top="123" left="86" width="1002" height="19" font="0">fraction; HFrEF, heart failure with reduced ejection fraction; HOCM, hypertrophic obstructive cardiomyopathy; HR, hazard ratio;  HTN, hypertension; HUTT, head-up </text>
<text top="141" left="86" width="1006" height="19" font="0">tilt test; Hx, history; I, intervention; ICD, implantable cardioverter defibrillator; ICM, ischemic cardiomyopathy; ILR, implantable loop recorder; IV, intraventricular OR </text>
<text top="159" left="86" width="1010" height="19" font="0">intravenous; LA, left atrial; LAD, left anterior descending coronary artery; LAH, left anterior hemiblock; LBBB, left bundle branch block; LHC, left heart catheterization; </text>
<text top="178" left="86" width="1011" height="19" font="0">LMNA, Lamin A/C; LR, lower rate; LV, left ventricular OR left ventricle; LVED, left ventricular end-diastolic; LVEF, left ventricular ejection fraction; LVES, left ventricular </text>
<text top="196" left="86" width="997" height="19" font="0">end-systolic; LVFS, left ventricular fractional shortening; LVH, left ventricular hypertrophy; LVOT, left ventricular outflow tract; MACE, major adverse cardiovascular </text>
<text top="214" left="86" width="966" height="19" font="0">event; MDT, Medtronic; MI, myocardial infarction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MMSE, Mini Mental State Examination; MPHR, </text>
<text top="233" left="86" width="1000" height="19" font="0">maximum predicted heart rate; ms, millisecond; MVP, mitral valve prolapse; N/A, not applicable; nCPAP, nasal continuous positive airway pressure; nLBBB, new left </text>
<text top="251" left="86" width="986" height="19" font="0">bundle branch block; NICM, nonischemic cardiomyopathy; NR, not relevant; NS, not significant; NSVT, nonsustained ventricular tachycardia; NSVT, non-sustained </text>
<text top="269" left="86" width="1005" height="19" font="0">ventricular tachycardia; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OR, odds ratio; OSA, obstructive sleep apnea; PA, </text>
<text top="288" left="86" width="990" height="19" font="0">pulmonary artery; PAF, paroxysmal atrial fibrillation; PCI, percutaneous coronary intervention; PerAF, persistent atrial fibrillation; PFO, patent foramen ovale; PM, </text>
<text top="306" left="86" width="1001" height="19" font="0">pacemaker; postop, postoperative; PPI, permanent pacemaker implantation; PPM, permanent pacemaker; ppm, paced beats per minute; preop, preoperative; PSG, </text>
<text top="324" left="86" width="215" height="19" font="0">polysomnography; pt, patient; pVO</text>
<text top="331" left="301" width="5" height="12" font="7">2</text>
<text top="324" left="306" width="788" height="19" font="0">, peak oxygen consumption; PVC, premature ventricular contraction; QOL, quality of life; QRSd, QRS duration; RBBB, right bundle </text>
<text top="342" left="86" width="1017" height="19" font="0">branch block; RCA, right coronary artery; RCT, randomized controlled trial; ROSC, return of spontaneous circulation; RR, relative risk; RV, right ventricle; SA, sino-atrial; </text>
<text top="361" left="86" width="1018" height="19" font="0">SAS, sleep apnea syndrome; SACT, sino-atrial conduction time; SAVR, surgical aortic valve replacement; SB, sinus bradycardia; SCD, sudden cardiac death; SD, standard </text>
<text top="379" left="86" width="993" height="19" font="0">deviation; SLE, systemic lupus erythematosus; SND, sinus node dysfunction; SNRT, sinus node recovery time; SR, sinus rhythm; SSS, sick sinus syndrome; STEMI, ST-</text>
<text top="397" left="86" width="995" height="21" font="0">elevation myocardial infarction; SVT, supraventricular tachycardia; sx, symptom; TAP, transesophageal atrial pacing; TAVI, transcatheter aortic valve implantation; </text>
<text top="416" left="86" width="984" height="19" font="0">TCP, transcutaneous pacing OR transcutaneous pacemaker; TE, thromboembolism; TIA, transient ischemic attack; TPM, temporary pacemaker; TPPM, temporary </text>
<text top="434" left="86" width="989" height="19" font="0">permanent pacemaker; TTT, tilt table testing; TTVP, temporary transvenous pacing; TVP, transvenous pacemaker; tx, treatment; UNOS, United Network for Organ </text>
<text top="452" left="86" width="989" height="19" font="0">Sharing; V, volts: VA, ventricular arrhythmia OR ventriculoatrial; VF, ventricular fibrillation; Vp, ventricular pacing; VT, ventricular tachycardia; WHO, World Health </text>
<text top="471" left="86" width="82" height="19" font="0">Organization.</text>
<text top="469" left="168" width="4" height="21" font="2"><b> </b></text>
<text top="489" left="97" width="4" height="21" font="2"><b> </b></text>
<text top="489" left="313" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="8" size="13" family="Times" color="#000000"/>
	<fontspec id="9" size="13" family="Times" color="#0000ff"/>
<text top="804" left="574" width="44" height="19" font="0">Page 6 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="1000" height="23" font="5"><b>Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of 12-Lead Electrocardiography in Bradycardia or </b></text>
<text top="108" left="86" width="295" height="23" font="5"><b>Conduction Disturbance (Section 4.2.1) </b></text>
<text top="131" left="115" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="125" width="83" height="19" font="8"><b>Author; Year </b></text>
<text top="167" left="119" width="107" height="19" font="8"><b>Published; PMID </b></text>
<text top="131" left="269" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="298" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="443" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="629" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="628" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="131" left="912" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="940" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="96" width="127" height="19" font="0">Linzer M, et al. 1997 </text>
<text top="205" left="96" width="20" height="19" font="0">(1)<b> </b></text>
<text top="223" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9182479">9182479</a></text>
<text top="223" left="149" width="7" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9182479">  </a></text>
<text top="186" left="250" width="138" height="19" font="8"><b>Study type:</b> Literature </text>
<text top="205" left="250" width="155" height="19" font="0">Review- MEDLINE search </text>
<text top="223" left="250" width="136" height="19" font="0">and manual review of </text>
<text top="241" left="250" width="89" height="19" font="0">bibliographies </text>
<text top="260" left="250" width="3" height="19" font="0"> </text>
<text top="278" left="250" width="154" height="19" font="8"><b>Size:</b> 4 population-based </text>
<text top="296" left="250" width="114" height="19" font="0">studies evaluating </text>
<text top="315" left="250" width="157" height="19" font="0">diagnostic yield of ECG in </text>
<text top="333" left="250" width="147" height="19" font="0">syncope were included, </text>
<text top="351" left="250" width="43" height="19" font="0">N=902 </text>
<text top="186" left="425" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="205" left="425" width="105" height="19" font="0">English language </text>
<text top="223" left="425" width="149" height="19" font="0">publications from 1980–</text>
<text top="241" left="425" width="114" height="19" font="0">1995 reporting on </text>
<text top="260" left="425" width="151" height="19" font="0">diagnostic yield of a test </text>
<text top="278" left="425" width="135" height="19" font="0">(e.g., Hx and physical, </text>
<text top="296" left="425" width="109" height="19" font="0">ECG, EEG, Holter, </text>
<text top="315" left="425" width="145" height="19" font="0">external LR, EPS, HUTT, </text>
<text top="333" left="425" width="135" height="19" font="0">SAE, ETT, carotid U/S, </text>
<text top="351" left="425" width="94" height="19" font="0">head CT, psych </text>
<text top="370" left="425" width="151" height="19" font="0">evaluation) evaluated in </text>
<text top="388" left="425" width="155" height="19" font="0">10 or more subjects over </text>
<text top="406" left="425" width="113" height="19" font="0">18 y with syncope </text>
<text top="425" left="425" width="91" height="19" font="0">(±presyncope) </text>
<text top="443" left="425" width="3" height="19" font="0"> </text>
<text top="461" left="425" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="480" left="425" width="151" height="19" font="0">Review articles and case </text>
<text top="498" left="425" width="51" height="19" font="0">reports  </text>
<text top="187" left="594" width="234" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of a test </text>
<text top="206" left="594" width="204" height="19" font="0">analyzed separately for each test </text>
<text top="224" left="594" width="3" height="19" font="0"> </text>
<text top="242" left="594" width="211" height="19" font="8"><b>Results:</b> Diagnostic yield of ECG at </text>
<text top="261" left="594" width="219" height="19" font="0">presentation was 5% (47/902). This </text>
<text top="279" left="594" width="247" height="19" font="0">compares to 45% (504/1110) for Hx and </text>
<text top="297" left="594" width="52" height="19" font="0">physical </text>
<text top="187" left="864" width="173" height="20" font="0">• Despite low yield, authors </text>
<text top="206" left="875" width="203" height="19" font="0">recommend ECG at presentation </text>
<text top="224" left="875" width="197" height="19" font="0">for virtually all pts with syncope </text>
<text top="242" left="875" width="214" height="19" font="0">due to its lack of risk and relatively </text>
<text top="261" left="875" width="212" height="19" font="0">low expense. Further they cite the </text>
<text top="279" left="875" width="210" height="19" font="0">value of ECG findings indicative of </text>
<text top="297" left="875" width="164" height="19" font="0">structural heart disease or </text>
<text top="315" left="875" width="171" height="19" font="0">indicative of potentially life-</text>
<text top="334" left="875" width="216" height="19" font="0">threatening conditions (e.g., NSVT) </text>
<text top="352" left="875" width="110" height="19" font="0">in this population </text>
<text top="371" left="864" width="205" height="20" font="0">• This review did not identify any </text>
<text top="390" left="875" width="165" height="19" font="0">suitable studies evaluating </text>
<text top="408" left="875" width="181" height="19" font="0">echocardiography in syncope </text>
<text top="517" left="96" width="99" height="19" font="0">Thiruganasamb-</text>
<text top="535" left="96" width="140" height="19" font="0">amdamoorthy V, et al. </text>
<text top="554" left="96" width="54" height="19" font="0">2012 (2)<b> </b></text>
<text top="572" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22813399">22813399</a></text>
<text top="572" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22813399"> </a></text>
<text top="517" left="250" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="535" left="250" width="150" height="19" font="0">single-center evaluation </text>
<text top="554" left="250" width="147" height="19" font="0">of pt characteristics, 12-</text>
<text top="572" left="250" width="132" height="19" font="0">lead ECG and ED ECG </text>
<text top="590" left="250" width="153" height="19" font="0">monitoring as predictors </text>
<text top="608" left="250" width="146" height="19" font="0">of adverse outcomes in </text>
<text top="627" left="250" width="153" height="19" font="0">consecutive adult ED pts </text>
<text top="645" left="250" width="117" height="19" font="0">with syncope from </text>
<text top="663" left="250" width="102" height="19" font="0">8/1/05–1/30/07 </text>
<text top="682" left="250" width="3" height="19" font="0"> </text>
<text top="700" left="250" width="151" height="19" font="8"><b>Size:</b> 505 visits from 490 </text>
<text top="718" left="250" width="141" height="19" font="0">separate pts [of whom </text>
<text top="737" left="250" width="150" height="19" font="0">470 (93%) had at least 1 </text>
<text top="755" left="250" width="33" height="19" font="0">ECG] </text>
<text top="517" left="425" width="148" height="19" font="8"><b>Inclusion criteria:</b> ≥16 y </text>
<text top="535" left="425" width="139" height="19" font="0">with local address and </text>
<text top="554" left="425" width="54" height="19" font="0">syncope </text>
<text top="572" left="425" width="3" height="19" font="0"> </text>
<text top="590" left="425" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="608" left="425" width="154" height="19" font="0">Presyncope, LOC &gt;5 min, </text>
<text top="627" left="425" width="146" height="19" font="0">ongoing altered mental </text>
<text top="645" left="425" width="152" height="19" font="0">status, or LOC caused by </text>
<text top="663" left="425" width="146" height="19" font="0">ETOH or illicit drug use, </text>
<text top="682" left="425" width="143" height="19" font="0">seizure, head injury, or </text>
<text top="700" left="425" width="150" height="19" font="0">severe trauma requiring </text>
<text top="718" left="425" width="65" height="19" font="0">admission </text>
<text top="518" left="594" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Composite of death, MI, </text>
<text top="536" left="594" width="239" height="19" font="0">arrhythmias, and “cardiac procedures” </text>
<text top="554" left="594" width="61" height="19" font="0">over 30 d </text>
<text top="573" left="594" width="3" height="19" font="0"> </text>
<text top="591" left="594" width="240" height="19" font="8"><b>Results:</b> 49 serious outcomes including </text>
<text top="609" left="594" width="249" height="19" font="0">27cardiac outcomes (including 2 deaths, </text>
<text top="627" left="594" width="117" height="19" font="0">18 PPM, 7 SND, 6 3</text>
<text top="627" left="711" width="9" height="12" font="7">rd</text>
<text top="627" left="719" width="93" height="19" font="0"> degree AVB, 2 </text>
<text top="646" left="594" width="233" height="19" font="0">profound bradycardia) and 22 serious </text>
<text top="664" left="594" width="254" height="19" font="0">noncardiac outcomes. Of 19 primary ECG </text>
<text top="682" left="594" width="239" height="19" font="0">variables, 2 combination ECG variables </text>
<text top="701" left="594" width="106" height="19" font="0">(e.g., LBBB with 1</text>
<text top="701" left="700" width="7" height="12" font="7">st</text>
<text top="701" left="707" width="120" height="19" font="0"> degree AVB) and 8 </text>
<text top="719" left="594" width="249" height="19" font="0">variables based on QRS or QTc duration) </text>
<text top="737" left="594" width="242" height="19" font="0">16 variables were significant predictors </text>
<text top="756" left="594" width="221" height="19" font="0">of adverse cardiac events at 30 d by </text>
<text top="774" left="594" width="216" height="19" font="0">univariate analysis. Using recursive </text>
<text top="517" left="864" width="212" height="20" font="0">• ECG findings in pts presenting to </text>
<text top="536" left="875" width="199" height="19" font="0">the ED with syncope can predict </text>
<text top="554" left="875" width="216" height="19" font="0">adverse cardiac events in the short </text>
<text top="573" left="875" width="40" height="19" font="0">term.  </text>
<text top="591" left="864" width="175" height="20" font="0">• Bradycardia or conduction </text>
<text top="610" left="875" width="167" height="19" font="0">disorders are an important </text>
<text top="628" left="875" width="212" height="19" font="0">component to the constellation of </text>
<text top="647" left="875" width="200" height="19" font="0">predictive ECG findings (19/132 -</text>
<text top="665" left="875" width="34" height="19" font="0">14%) </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="574" width="44" height="19" font="0">Page 7 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="594" width="248" height="19" font="0">partitioning they developed ECG criteria </text>
<text top="105" left="594" width="218" height="19" font="0">for risk that included 5 predictors: 2</text>
<text top="105" left="812" width="12" height="12" font="7">nd </text>
<text top="123" left="594" width="158" height="19" font="0">degree Mobitz type 2 or 3</text>
<text top="123" left="752" width="9" height="12" font="7">rd</text>
<text top="123" left="761" width="82" height="19" font="0"> degree AVB, </text>
<text top="142" left="594" width="230" height="19" font="0">bundle branch block +first-degree AV </text>
<text top="160" left="594" width="234" height="19" font="0">block, right bundle branch with either </text>
<text top="178" left="594" width="253" height="19" font="0">left anterior or posterior fascicular block, </text>
<text top="197" left="594" width="243" height="19" font="0">new ischemic changes, non-SR, left axis </text>
<text top="215" left="594" width="200" height="19" font="0">deviation, or ED cardiac monitor </text>
<text top="233" left="594" width="231" height="19" font="0">abnormalities. Using these predictors </text>
<text top="252" left="594" width="244" height="19" font="0">yielded a sensitivity of 96% (95% CI: 80–</text>
<text top="270" left="594" width="253" height="19" font="0">100), a specificity of 76% (95% CI: 75–76) </text>
<text top="288" left="594" width="251" height="19" font="0">and an area under the ROC curve of 0.89 </text>
<text top="307" left="594" width="125" height="19" font="0">(95% CI: 0.82–0.95). </text>
<text top="326" left="96" width="112" height="19" font="0">Del Rosso A, et al. </text>
<text top="344" left="96" width="54" height="19" font="0">2008 (3)<b> </b></text>
<text top="362" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18519550">18519550</a></text>
<text top="362" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18519550"> </a></text>
<text top="326" left="250" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="344" left="250" width="157" height="19" font="0">cohort of consecutive pts </text>
<text top="362" left="250" width="3" height="19" font="0"> </text>
<text top="381" left="250" width="89" height="19" font="8"><b>Size:</b> 516 (260 </text>
<text top="399" left="250" width="94" height="19" font="0">derivation/256 </text>
<text top="417" left="250" width="68" height="19" font="0">validation) </text>
<text top="326" left="425" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="344" left="427" width="134" height="19" font="0">Unexplained syncope </text>
<text top="362" left="427" width="130" height="19" font="0">presenting to 1 of 14 </text>
<text top="381" left="427" width="71" height="19" font="0">Italian EDs  </text>
<text top="399" left="425" width="3" height="19" font="0"> </text>
<text top="417" left="425" width="153" height="19" font="8"><b>Exclusion criteria:</b> &lt;18 y, </text>
<text top="436" left="425" width="142" height="19" font="0">syncope of known non-</text>
<text top="454" left="425" width="119" height="19" font="0">cardiac cause (e.g., </text>
<text top="472" left="425" width="123" height="19" font="0">seizure, TIA or drop </text>
<text top="491" left="425" width="46" height="19" font="0">attack) </text>
<text top="326" left="594" width="233" height="19" font="8"><b>1</b>°<b> endpoint:</b> Dx of cardiac syncope or </text>
<text top="345" left="594" width="39" height="19" font="0">death </text>
<text top="363" left="594" width="3" height="19" font="0"> </text>
<text top="381" left="594" width="208" height="19" font="8"><b>Results:</b> A risk score composed of </text>
<text top="400" left="594" width="205" height="19" font="0">historical features, exam findings </text>
<text top="418" left="594" width="249" height="19" font="0">suggesting structural heart disease/CHF, </text>
<text top="436" left="594" width="218" height="19" font="0">or abnormal ECG (including but not </text>
<text top="455" left="594" width="243" height="19" font="0">exclusively bradycardia and conduction </text>
<text top="473" left="594" width="246" height="19" font="0">abnormalities) was predictive of cardiac </text>
<text top="491" left="594" width="251" height="19" font="0">syncope or death at an avg. Follow-up of </text>
<text top="510" left="594" width="240" height="19" font="0">614 d in both derivation and validation </text>
<text top="528" left="594" width="245" height="19" font="0">cohorts. 56/79 (71%) pts with a defined </text>
<text top="546" left="594" width="239" height="19" font="0">mechanism of syncope had arrhythmic </text>
<text top="565" left="594" width="229" height="19" font="0">syncope. Of these, 38/56 (68%) were </text>
<text top="583" left="594" width="210" height="19" font="0">attributed to bradyarrhythmias or </text>
<text top="601" left="594" width="219" height="19" font="0">conduction disturbances and 24/38 </text>
<text top="620" left="594" width="245" height="19" font="0">(63%) syncopal episodes attributable to </text>
<text top="638" left="594" width="245" height="19" font="0">bradycardia or conduction disturbances </text>
<text top="656" left="594" width="199" height="19" font="0">were diagnosed on 12 lead ECG. </text>
<text top="674" left="594" width="3" height="19" font="0"> </text>
<text top="326" left="864" width="220" height="20" font="0">• 12 lead ECG in the ED can identify </text>
<text top="345" left="875" width="222" height="19" font="0">syncope attributable to bradycardia </text>
<text top="363" left="875" width="205" height="19" font="0">and conduction disturbances in a </text>
<text top="381" left="875" width="213" height="19" font="0">majority of those with bradycardic </text>
<text top="400" left="875" width="186" height="19" font="0">syncope presenting to the ED. </text>
<text top="418" left="864" width="231" height="20" font="0">• As part of the EGSYS risk score, ECG </text>
<text top="437" left="875" width="162" height="19" font="0">abnormalities (both those </text>
<text top="455" left="875" width="217" height="19" font="0">indicative of bradyarrhythmias and </text>
<text top="474" left="875" width="207" height="19" font="0">those indicative of other forms of </text>
<text top="492" left="875" width="208" height="19" font="0">heart disease) can predict cardiac </text>
<text top="510" left="875" width="197" height="19" font="0">causes of syncope and all-cause </text>
<text top="529" left="875" width="192" height="19" font="0">mortality more than 1.5 y after </text>
<text top="547" left="875" width="123" height="19" font="0">initial presentation. </text>
<text top="693" left="96" width="63" height="19" font="8"><b>GESINUR  </b></text>
<text top="712" left="96" width="135" height="19" font="0">Perez-Rondon J, et al. </text>
<text top="730" left="96" width="54" height="19" font="0">2014 (4)<b> </b></text>
<text top="748" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24993462">24993462</a></text>
<text top="748" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24993462"> </a></text>
<text top="767" left="96" width="3" height="19" font="0"> </text>
<text top="693" left="250" width="150" height="19" font="8"><b>Study type:</b> Multicenter </text>
<text top="712" left="250" width="161" height="19" font="0">prospective observational </text>
<text top="730" left="250" width="3" height="19" font="0"> </text>
<text top="748" left="250" width="154" height="19" font="8"><b>Size:</b> 524 (from a total of </text>
<text top="767" left="250" width="154" height="19" font="0">1,080 pts and from 14 of </text>
<text top="693" left="425" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="712" left="425" width="141" height="19" font="0">≥14 y presenting to ED </text>
<text top="730" left="425" width="116" height="19" font="0">with transient LOC </text>
<text top="748" left="425" width="135" height="19" font="0">within 24 h for whom </text>
<text top="767" left="425" width="125" height="19" font="0">initial questionnaire </text>
<text top="694" left="594" width="217" height="19" font="8"><b>1</b>°<b> endpoint:</b> Power of specific ECG </text>
<text top="713" left="594" width="214" height="19" font="0">criteria to predict 12 mo mortality  </text>
<text top="731" left="594" width="3" height="19" font="0"> </text>
<text top="749" left="594" width="255" height="19" font="8"><b>Results:</b> 65.6% had an abnormal ECG and </text>
<text top="767" left="594" width="242" height="19" font="0">6 (6.3%) died at 1 y (only 1 SCD). 22 pts </text>
<text top="694" left="864" width="223" height="20" font="0">• Specific ECG abnormalities predict </text>
<text top="713" left="875" width="197" height="19" font="0">1 y mortality in adolescents and </text>
<text top="731" left="875" width="193" height="19" font="0">adults presenting with syncope </text>
<text top="749" left="875" width="201" height="19" font="0">(ventricular pacing, LVH, AF, and </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="574" width="44" height="19" font="0">Page 8 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="250" width="162" height="19" font="0">19 centers participating in </text>
<text top="105" left="250" width="70" height="19" font="0">main trial)  </text>
<text top="87" left="425" width="131" height="19" font="0">data, presenting ECG </text>
<text top="105" left="425" width="138" height="19" font="0">and 1-y follow-up was </text>
<text top="123" left="425" width="57" height="19" font="0">available </text>
<text top="142" left="425" width="3" height="19" font="0"> </text>
<text top="160" left="425" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="594" width="245" height="19" font="0">(4.2%) manifested AV nodal conduction </text>
<text top="105" left="594" width="239" height="19" font="0">disturbance (13 first-degree, 2 second- </text>
<text top="123" left="594" width="236" height="19" font="0">degree and 7 third-degree AVB) which </text>
<text top="142" left="594" width="245" height="19" font="0">did not predict mortality (p=0.642). 108 </text>
<text top="160" left="594" width="239" height="19" font="0">(20.6%) manifested an intraventricular </text>
<text top="178" left="594" width="251" height="19" font="0">conduction disturbance [13 LBBB (2.5%), </text>
<text top="197" left="594" width="223" height="19" font="0">28 RBBB (5.4%), 18 IRBBB (3.4%), 17 </text>
<text top="215" left="594" width="235" height="19" font="0">NSIVCD (3.3%), 13 LAFB (2.5%) and 19 </text>
<text top="233" left="594" width="244" height="19" font="0">assorted others (18%)]. Intraventricular </text>
<text top="252" left="594" width="226" height="19" font="0">conduction disturbances were 1 of 4 </text>
<text top="270" left="594" width="236" height="19" font="0">independently predictive indicators of </text>
<text top="288" left="594" width="217" height="19" font="0">mortality (OR: 3.8; 95% CI: 1.7–8.3; </text>
<text top="307" left="594" width="222" height="19" font="0">p=0.001). Other predictive variables </text>
<text top="325" left="594" width="248" height="19" font="0">included ventricular pacing, AF and LVH. </text>
<text top="343" left="594" width="3" height="19" font="0"> </text>
<text top="87" left="875" width="170" height="19" font="0">intraventricular conduction </text>
<text top="105" left="875" width="80" height="19" font="0">disturbance) </text>
<text top="124" left="864" width="210" height="20" font="0">• AV nodal block is uncommon on </text>
<text top="143" left="875" width="202" height="19" font="0">presenting ECG (4.2%) and is not </text>
<text top="161" left="875" width="180" height="19" font="0">predictive of mortality at 1 y. </text>
<text top="179" left="864" width="181" height="20" font="0">• Intraventricular conduction </text>
<text top="198" left="875" width="198" height="19" font="0">disturbances are more common </text>
<text top="217" left="875" width="163" height="19" font="0">(20.8%) and do predict 1 y </text>
<text top="235" left="875" width="217" height="19" font="0">mortality in adolescents and adults </text>
<text top="253" left="875" width="88" height="19" font="0">with syncope. </text>
<text top="362" left="82" width="3" height="19" font="0"> </text>
<text top="382" left="97" width="4" height="21" font="4"> </text>
<text top="381" left="313" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="574" width="44" height="19" font="0">Page 9 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="966" height="23" font="5"><b>Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Exercise Stress Testing in Bradycardia and </b></text>
<text top="108" left="86" width="302" height="23" font="5"><b>Conduction Disturbances (Section 4.2.2) </b></text>
<text top="131" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="115" width="83" height="19" font="8"><b>Author; Year </b></text>
<text top="167" left="109" width="107" height="19" font="8"><b>Published; PMID </b></text>
<text top="131" left="271" width="39" height="19" font="8"><b>Study </b></text>
<text top="149" left="253" width="86" height="19" font="8"><b>Type/Design; </b></text>
<text top="167" left="257" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="392" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="609" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="607" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="131" left="912" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="940" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="96" width="98" height="19" font="0">Lauer MS, et al. </text>
<text top="205" left="96" width="30" height="19" font="0">1999</text>
<text top="203" left="127" width="4" height="21" font="4"> </text>
<text top="205" left="130" width="20" height="19" font="0">(5)<b> </b></text>
<text top="223" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10022108">10022108</a></text>
<text top="223" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10022108"> </a></text>
<text top="241" left="96" width="3" height="19" font="0"> </text>
<text top="186" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="205" left="230" width="118" height="19" font="0">Prospective cohort </text>
<text top="223" left="230" width="94" height="19" font="0">study between </text>
<text top="241" left="230" width="76" height="19" font="0">9/90–12/93 </text>
<text top="260" left="230" width="3" height="19" font="0"> </text>
<text top="278" left="230" width="66" height="19" font="8"><b>Size:</b> 2953 </text>
<text top="296" left="230" width="98" height="19" font="0">consecutive pts </text>
<text top="315" left="230" width="92" height="19" font="0">referred for sx-</text>
<text top="333" left="230" width="102" height="19" font="0">limited ETT with </text>
<text top="351" left="230" width="101" height="19" font="0">thallium MPI, of </text>
<text top="370" left="230" width="114" height="19" font="0">whom 1078 (37%) </text>
<text top="388" left="230" width="72" height="19" font="0">manifested </text>
<text top="406" left="230" width="82" height="19" font="0">chronotropic </text>
<text top="425" left="230" width="121" height="19" font="0">incompetence [316 </text>
<text top="443" left="230" width="112" height="19" font="0">(11%) by % MPHR </text>
<text top="461" left="230" width="109" height="19" font="0">and 762 (26%) by </text>
<text top="480" left="230" width="108" height="19" font="0">low chronotropic </text>
<text top="498" left="230" width="41" height="19" font="0">index] </text>
<text top="186" left="365" width="168" height="19" font="8"><b>Inclusion criteria:</b> Referred </text>
<text top="205" left="365" width="163" height="19" font="0">for sx-limited ETT thallium </text>
<text top="223" left="365" width="166" height="19" font="0">and with failure to achieve </text>
<text top="241" left="365" width="154" height="19" font="0">≥85% MPHR or failure to </text>
<text top="260" left="365" width="103" height="19" font="0">achieve ≥80% of </text>
<text top="278" left="365" width="126" height="19" font="0">chronotropic index* </text>
<text top="296" left="365" width="3" height="19" font="0"> </text>
<text top="315" left="365" width="146" height="19" font="8"><b>Exclusion criteria:</b> Prior </text>
<text top="333" left="365" width="153" height="19" font="0">coronary angiography or </text>
<text top="351" left="365" width="158" height="19" font="0">PCI, cardiac surgery, CHF, </text>
<text top="370" left="365" width="165" height="19" font="0">valvular heart disease, pre-</text>
<text top="388" left="365" width="174" height="19" font="0">excitation syndrome, ACHD, </text>
<text top="406" left="365" width="132" height="19" font="0">or ß-blocker therapy. </text>
<text top="187" left="554" width="252" height="19" font="8"><b>1</b>°<b> endpoint: </b>Association of chronotropic </text>
<text top="206" left="554" width="281" height="19" font="0">incompetence with all-cause mortality at 2 y.  </text>
<text top="224" left="554" width="3" height="19" font="0"> </text>
<text top="242" left="554" width="280" height="19" font="8"><b>Results:</b> 91 deaths (8.4%) - 22 cardiac deaths. </text>
<text top="261" left="554" width="277" height="19" font="0">Those with chronotropic incompetence were </text>
<text top="279" left="554" width="285" height="19" font="0">older and sicker with more ASCVD risk factors, </text>
<text top="297" left="554" width="278" height="19" font="0">lower exercise capacity and more angina and </text>
<text top="315" left="554" width="292" height="19" font="0">perfusion defects during the test (but not more </text>
<text top="334" left="554" width="252" height="19" font="0">ischemic ECG changes). Cox proportional </text>
<text top="352" left="554" width="255" height="19" font="0">hazards analyses incorporating 13 clinical </text>
<text top="370" left="554" width="276" height="19" font="0">confounders (age, sex perfusion defects, etc. </text>
<text top="389" left="554" width="247" height="19" font="0">but not EF): chronotropic incompetence </text>
<text top="407" left="554" width="293" height="19" font="0">independently associated with increased risk of </text>
<text top="425" left="554" width="271" height="19" font="0">death (adjusted RR:1.85; 95% CI: 1.13–3.00; </text>
<text top="444" left="554" width="278" height="19" font="0">p=0.01) when measured by failure to achieve </text>
<text top="462" left="554" width="290" height="19" font="0">85% MPHR and adjusted RR:2.19; 95% CI: 1.43–</text>
<text top="480" left="553" width="237" height="19" font="0">3.44; p&lt;0.001) when measured by low </text>
<text top="499" left="554" width="260" height="19" font="0">chronotropic index. 612 (21%) manifested </text>
<text top="517" left="554" width="265" height="19" font="0">perfusion defects [reversible in 311 (11%)]. </text>
<text top="535" left="554" width="290" height="19" font="0">Perfusion defects predictive of mortality with a </text>
<text top="554" left="554" width="212" height="19" font="0">similar magnitude as chronotropic </text>
<text top="572" left="554" width="278" height="19" font="0">incompetence. Mortality risk of chronotropic </text>
<text top="590" left="554" width="261" height="19" font="0">incompetence and perfusion defects were </text>
<text top="609" left="554" width="273" height="19" font="0">additive (e.g., adjusted RR for combined low </text>
<text top="627" left="554" width="287" height="19" font="0">chronotropic index and perfusion defect: 3.31; </text>
<text top="645" left="554" width="174" height="19" font="0">95% CI: 1.82–6.02; p&lt;0.001) </text>
<text top="187" left="864" width="197" height="20" font="0">• Chronotropic incompetence is </text>
<text top="206" left="875" width="172" height="19" font="0">independently predictive of </text>
<text top="224" left="875" width="203" height="19" font="0">mortality in those with known or </text>
<text top="242" left="875" width="94" height="19" font="0">suspected CAD </text>
<text top="664" left="96" width="112" height="19" font="0">Savonen KP, et al. </text>
<text top="682" left="96" width="30" height="19" font="0">2008</text>
<text top="681" left="127" width="4" height="21" font="4"> </text>
<text top="682" left="130" width="20" height="19" font="0">(6)<b> </b></text>
<text top="701" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18556711">18556711</a></text>
<text top="701" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18556711"> </a></text>
<text top="719" left="96" width="3" height="19" font="0"> </text>
<text top="664" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="682" left="230" width="118" height="19" font="0">Prospective cohort </text>
<text top="701" left="230" width="91" height="19" font="0">study (derived </text>
<text top="719" left="230" width="103" height="19" font="0">from the Kuopio </text>
<text top="737" left="230" width="94" height="19" font="0">Ischemic Heart </text>
<text top="756" left="230" width="120" height="19" font="0">Disease Risk Factor </text>
<text top="774" left="230" width="59" height="19" font="0">Study – a </text>
<text top="664" left="365" width="165" height="19" font="8"><b>Inclusion criteria:</b> Enrolled </text>
<text top="682" left="365" width="153" height="19" font="0">in KIHD with clinical CAD </text>
<text top="701" left="365" width="142" height="19" font="0">and underwent bicycle </text>
<text top="719" left="365" width="68" height="19" font="0">ergometry </text>
<text top="737" left="365" width="3" height="19" font="0"> </text>
<text top="756" left="365" width="163" height="19" font="8"><b>Exclusion criteria:</b> Cancer, </text>
<text top="774" left="365" width="140" height="19" font="0">heart rate-lowering Rx </text>
<text top="665" left="554" width="85" height="19" font="8"><b>1</b>°<b> endpoint:  </b></text>
<text top="683" left="554" width="277" height="19" font="0">1)<b> </b>Association of chronotropic incompetence </text>
<text top="702" left="553" width="297" height="19" font="0">with mortality over an average follow-up of 11 y </text>
<text top="720" left="553" width="264" height="19" font="0">(0.8–14.8 y) of chronotropic incompetence </text>
<text top="738" left="553" width="270" height="19" font="0">calculated during bicycle ergometry with VO</text>
<text top="745" left="823" width="5" height="12" font="7">2</text>
<text top="738" left="828" width="3" height="19" font="0"> </text>
<text top="756" left="554" width="264" height="19" font="0">testing and defined as change in heart rate </text>
<text top="664" left="864" width="200" height="20" font="0">• Conclusion: Heart rate 40–100 </text>
<text top="683" left="875" width="208" height="19" font="0">independently predicts long-term </text>
<text top="702" left="875" width="208" height="19" font="0">all-cause mortality in Finnish men </text>
<text top="720" left="875" width="186" height="19" font="0">with known or suspected CAD </text>
<text top="739" left="864" width="92" height="20" font="0">• Heart rate 40</text>
<text top="738" left="956" width="8" height="21" font="4">–</text>
<text top="740" left="964" width="101" height="19" font="0">100 intended to </text>
<text top="758" left="875" width="182" height="19" font="0">isolate the effects of exercise-</text>
<text top="777" left="875" width="205" height="19" font="0">induced increases in sympathetic </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 10 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="76" height="19" font="0">longitudinal </text>
<text top="105" left="230" width="116" height="19" font="0">Finnish population </text>
<text top="123" left="230" width="38" height="19" font="0">study-</text>
<text top="142" left="230" width="93" height="19" font="0">representative </text>
<text top="160" left="230" width="110" height="19" font="0">sample of middle-</text>
<text top="178" left="230" width="97" height="19" font="0">aged men from </text>
<text top="197" left="230" width="73" height="19" font="0">Kuopio and </text>
<text top="215" left="230" width="115" height="19" font="0">environs recruited </text>
<text top="233" left="230" width="111" height="19" font="0">3/1984–12/1989) </text>
<text top="252" left="230" width="3" height="19" font="0"> </text>
<text top="270" left="230" width="96" height="19" font="8"><b>Size:</b> <b>294 </b>(3235 </text>
<text top="288" left="230" width="83" height="19" font="0">eligible/2682 </text>
<text top="307" left="230" width="92" height="19" font="0">participated in </text>
<text top="325" left="230" width="51" height="19" font="0">primary </text>
<text top="343" left="230" width="73" height="19" font="0">study/2240 </text>
<text top="362" left="230" width="114" height="19" font="0">exercise tests/294 </text>
<text top="380" left="230" width="105" height="19" font="0">with CAD and no </text>
<text top="398" left="230" width="71" height="19" font="0">exclusions) </text>
<text top="87" left="554" width="277" height="19" font="0">between 40% of maximal workload and peak </text>
<text top="105" left="554" width="187" height="19" font="0">exercise (heart rate: 40–100).  </text>
<text top="123" left="554" width="269" height="19" font="0">2) Compared ability of heart rate 40–100 to </text>
<text top="142" left="554" width="259" height="19" font="0">predict death with that of other indices of </text>
<text top="160" left="554" width="173" height="19" font="0">chronotropic incompetence </text>
<text top="178" left="554" width="3" height="19" font="0"> </text>
<text top="197" left="554" width="273" height="19" font="8"><b>Results:</b> 61 (20.7%) deaths. Mean (SD) heart </text>
<text top="215" left="554" width="248" height="19" font="0">rate 40–100 =45 (15) bpm. Risk of death </text>
<text top="233" left="554" width="235" height="19" font="0">increased 41% for each 1-SD (15 bpm) </text>
<text top="252" left="554" width="280" height="19" font="0">decrement in heart rate 40–100. Multivariate </text>
<text top="270" left="554" width="289" height="19" font="0">analysis identified a heart rate 40–100 value at </text>
<text top="288" left="554" width="278" height="19" font="0">or below the mean (&lt;46 bpm) as a significant </text>
<text top="307" left="554" width="295" height="19" font="0">predictor of all-cause mortality relative to those </text>
<text top="325" left="554" width="285" height="19" font="0">with a heart rate 40–100 above the mean (RR: </text>
<text top="343" left="554" width="270" height="19" font="0">2.9; 95% CI: 2.0–5.0). With propensity score </text>
<text top="362" left="554" width="291" height="19" font="0">added to model, the risk decreased to 2.0; 95% </text>
<text top="380" left="554" width="255" height="19" font="0">CI: 1.22–3.70. Only 1 of 6 other indices of </text>
<text top="398" left="554" width="236" height="19" font="0">chronotropic incompetence that were </text>
<text top="417" left="554" width="270" height="19" font="0">evaluated was predictive of mortality, heart </text>
<text top="435" left="554" width="251" height="19" font="0">rate reserve RR: 1.30; 95% CI: 1.02–1.69. </text>
<text top="453" left="554" width="213" height="19" font="0">(Chronotropic index not included). </text>
<text top="87" left="875" width="190" height="19" font="0">tone on CV physiology and risk </text>
<text top="105" left="875" width="192" height="19" font="0">from those of parasympathetic </text>
<text top="123" left="875" width="215" height="19" font="0">withdrawal which predominates in </text>
<text top="142" left="875" width="220" height="19" font="0">modulating chronotropic responses </text>
<text top="160" left="875" width="172" height="19" font="0">from baseline to ~100 bpm. </text>
<text top="179" left="864" width="217" height="20" font="0">• Heart rate 40–100 was predictive </text>
<text top="198" left="875" width="193" height="19" font="0">of mortality in members of this </text>
<text top="216" left="875" width="178" height="19" font="0">same population w/o clinical </text>
<text top="234" left="875" width="205" height="19" font="0">evidence of CAD (separate study, </text>
<text top="252" left="875" width="97" height="19" font="0">Savonen, et al.) </text>
<text top="271" left="864" width="192" height="20" font="0">• Bicycle exercise has a greater </text>
<text top="290" left="875" width="165" height="19" font="0">isometric component than </text>
<text top="308" left="875" width="193" height="19" font="0">treadmill walking and is usually </text>
<text top="327" left="875" width="191" height="19" font="0">associated with lower maximal </text>
<text top="345" left="875" width="203" height="19" font="0">workloads and brisker heart rate </text>
<text top="363" left="875" width="211" height="19" font="0">response, all of which may reduce </text>
<text top="381" left="875" width="216" height="19" font="0">generalizability of findings to other </text>
<text top="400" left="875" width="124" height="19" font="0">exercise modalities. </text>
<text top="472" left="96" width="104" height="19" font="0">Doi A, et al. 2002</text>
<text top="471" left="200" width="4" height="21" font="4"> </text>
<text top="491" left="96" width="20" height="19" font="0">(7)<b> </b></text>
<text top="509" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12368930">12368930</a></text>
<text top="509" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12368930"> </a></text>
<text top="527" left="96" width="3" height="19" font="0"> </text>
<text top="472" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="491" left="230" width="118" height="19" font="0">Prospective cohort </text>
<text top="509" left="230" width="37" height="19" font="0">study </text>
<text top="527" left="230" width="3" height="19" font="0"> </text>
<text top="545" left="230" width="118" height="19" font="8"><b>Size:</b> 44 pts and 20 </text>
<text top="564" left="230" width="100" height="19" font="0">normal controls </text>
<text top="472" left="365" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="491" left="365" width="150" height="19" font="0">Unexplained syncope or </text>
<text top="509" left="365" width="152" height="19" font="0">presyncope (18 exercise-</text>
<text top="527" left="365" width="124" height="19" font="0">related, 26 exercise-</text>
<text top="545" left="365" width="67" height="19" font="0">unrelated) </text>
<text top="564" left="365" width="3" height="19" font="0"> </text>
<text top="582" left="365" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="600" left="365" width="152" height="19" font="0">Structural heart disease, </text>
<text top="619" left="365" width="127" height="19" font="0">PAF, thyroid disease </text>
<text top="473" left="554" width="284" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic accuracy of HUTT and </text>
<text top="491" left="554" width="294" height="19" font="0">modified exercise treadmill testing according to </text>
<text top="510" left="554" width="297" height="19" font="0">relationship of unexplained syncope to exercise. </text>
<text top="528" left="554" width="260" height="19" font="0">Modified ETT included abrupt termination </text>
<text top="546" left="554" width="278" height="19" font="0">followed by prolonged standing (positive ETT </text>
<text top="565" left="554" width="290" height="19" font="0">defined as syncope or presyncope with SBP&lt;80 </text>
<text top="583" left="554" width="215" height="19" font="0">mm Hg and/or heart rate&lt;40 bpm) </text>
<text top="601" left="554" width="3" height="19" font="0"> </text>
<text top="619" left="554" width="159" height="19" font="8"><b>Results:</b> HUTT: Sensitivity </text>
<text top="638" left="554" width="258" height="19" font="0">=84% and 77%; Specificity =84% and 85%; </text>
<text top="656" left="554" width="293" height="19" font="0">Accuracy= 84% and 80% in exercise-related and </text>
<text top="674" left="553" width="287" height="19" font="0">exercise-unrelated syncope respectively. None </text>
<text top="693" left="553" width="296" height="19" font="0">of these differences were statistically significant </text>
<text top="711" left="553" width="210" height="19" font="0">Modified Exercise Test: Sensitivity </text>
<text top="729" left="554" width="298" height="19" font="0">=78% and 19% (p&lt;0.05); Specificity =95 and 95% </text>
<text top="748" left="554" width="268" height="19" font="0">(p=NS); Accuracy =86% and 52% (p&lt;0.05) in </text>
<text top="766" left="554" width="245" height="19" font="0">exercise-related and exercise-unrelated </text>
<text top="784" left="554" width="134" height="19" font="0">syncope respectively. </text>
<text top="472" left="864" width="233" height="20" font="0">• Modified exercise testing may be as </text>
<text top="491" left="875" width="210" height="19" font="0">accurate as HUTT with provisional </text>
<text top="510" left="875" width="187" height="19" font="0">isoproterenol infusion to elicit </text>
<text top="528" left="875" width="161" height="19" font="0">syncope/presyncope with </text>
<text top="546" left="875" width="158" height="19" font="0">associated hemodynamic </text>
<text top="565" left="875" width="212" height="19" font="0">compromise in pts with suspected </text>
<text top="583" left="875" width="216" height="19" font="0">exercise-related neurally mediated </text>
<text top="601" left="875" width="158" height="19" font="0">syncope and presyncope. </text>
<text top="620" left="864" width="210" height="20" font="0">•  Modified exercise testing is less </text>
<text top="639" left="875" width="200" height="19" font="0">sensitive but similarly specific to </text>
<text top="657" left="875" width="138" height="19" font="0">HUTT with provisional </text>
<text top="675" left="875" width="187" height="19" font="0">isoproterenol infusion to elicit </text>
<text top="693" left="875" width="161" height="19" font="0">syncope/presyncope with </text>
<text top="712" left="875" width="158" height="19" font="0">associated hemodynamic </text>
<text top="730" left="875" width="212" height="19" font="0">compromise in pts with suspected </text>
<text top="748" left="875" width="194" height="19" font="0">neurally mediated syncope and </text>
<text top="767" left="875" width="210" height="19" font="0">presyncope unrelated to exercise. </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 11 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="108" height="19" font="0">Woelfel AK, et al. </text>
<text top="105" left="96" width="30" height="19" font="0">1983</text>
<text top="104" left="127" width="4" height="21" font="4"> </text>
<text top="105" left="130" width="20" height="19" font="0">(8)<b> </b></text>
<text top="123" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6875122">6875122</a></text>
<text top="123" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6875122"> </a></text>
<text top="142" left="96" width="3" height="19" font="0"> </text>
<text top="87" left="230" width="106" height="19" font="8"><b>Study type:</b> Case </text>
<text top="105" left="230" width="39" height="19" font="0">series </text>
<text top="123" left="230" width="3" height="19" font="0"> </text>
<text top="142" left="230" width="65" height="19" font="8"><b>Size:</b> 3 pts </text>
<text top="87" left="365" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="105" left="365" width="102" height="19" font="0">exercise-related </text>
<text top="123" left="364" width="170" height="19" font="0">palpitations or dizziness, or </text>
<text top="142" left="364" width="97" height="19" font="0">asx progressive </text>
<text top="160" left="364" width="170" height="19" font="0">intraventricular conduction </text>
<text top="178" left="364" width="128" height="19" font="0">disorder with 1:1 AV </text>
<text top="197" left="364" width="144" height="19" font="0">conduction at rest who </text>
<text top="215" left="364" width="158" height="19" font="0">demonstrate rate related </text>
<text top="233" left="364" width="148" height="19" font="0">2:1 and 3:1 rate-related </text>
<text top="252" left="364" width="127" height="19" font="0">conduction block on </text>
<text top="270" left="364" width="157" height="19" font="0">exercise treadmill testing </text>
<text top="288" left="364" width="162" height="19" font="0">w/o overt ischemia. 2 had </text>
<text top="307" left="364" width="152" height="19" font="0">baseline intraventricular </text>
<text top="325" left="364" width="147" height="19" font="0">conduction disturbance </text>
<text top="343" left="365" width="3" height="19" font="0"> </text>
<text top="361" left="365" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="554" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="106" left="554" width="3" height="19" font="0"> </text>
<text top="124" left="554" width="293" height="19" font="8"><b>Results:</b> All had evidence of infranodal block on </text>
<text top="143" left="554" width="281" height="19" font="0">EP study. 2 of 3 underwent rapid atrial pacing </text>
<text top="161" left="554" width="285" height="19" font="0">with evidence of rate related infranodal block. </text>
<text top="179" left="554" width="296" height="19" font="0">One underwent coronary angiography revealing </text>
<text top="198" left="554" width="258" height="19" font="0">a 90% RCA and a 60% LAD stenosis but no </text>
<text top="216" left="554" width="295" height="19" font="0">ischemia on exercise, stress MUGA, no ischemic </text>
<text top="234" left="554" width="275" height="19" font="0">ECG changes on exercise ECG and no angina. </text>
<text top="252" left="554" width="285" height="19" font="0">Exercise-related symptoms were relieved with </text>
<text top="271" left="554" width="90" height="19" font="0">pacing in all 3. </text>
<text top="289" left="554" width="3" height="19" font="0"> </text>
<text top="87" left="864" width="187" height="20" font="0">• Exercise testing can uncover </text>
<text top="106" left="875" width="205" height="19" font="0">apparent rate -related infranodal </text>
<text top="124" left="875" width="178" height="19" font="0">conduction block in carefully </text>
<text top="143" left="875" width="207" height="19" font="0">selected pts with exercise related </text>
<text top="161" left="875" width="157" height="19" font="0">symptoms or progressive </text>
<text top="179" left="875" width="170" height="19" font="0">intraventricular conduction </text>
<text top="198" left="875" width="206" height="19" font="0">disturbance w/o clinical evidence </text>
<text top="216" left="875" width="182" height="19" font="0">of exercise induced ischemia. </text>
<text top="234" left="864" width="190" height="20" font="0">• The authors suggest such pts </text>
<text top="253" left="875" width="211" height="19" font="0">should be considered for PPM but </text>
<text top="272" left="875" width="186" height="19" font="0">acknowledge the natural Hx is </text>
<text top="290" left="875" width="218" height="19" font="0">undefined. They draw correlates to </text>
<text top="308" left="875" width="172" height="19" font="0">the high rate of subsequent </text>
<text top="327" left="875" width="194" height="19" font="0">symptomatic AVB in those with </text>
<text top="345" left="875" width="209" height="19" font="0">either spontaneous or rapid atrial </text>
<text top="363" left="875" width="167" height="19" font="0">pacing-induced infra-nodal </text>
<text top="381" left="875" width="213" height="19" font="0">advanced AVB in previous reports. </text>
<text top="401" left="96" width="93" height="19" font="0">Boran KJ, et al. </text>
<text top="419" left="96" width="30" height="19" font="0">1983</text>
<text top="417" left="127" width="4" height="21" font="4"> </text>
<text top="419" left="130" width="20" height="19" font="0">(9)<b> </b></text>
<text top="437" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6837453">6837453</a></text>
<text top="437" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6837453"> </a></text>
<text top="455" left="96" width="3" height="19" font="0"> </text>
<text top="400" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="419" left="230" width="118" height="19" font="0">Retrospective case </text>
<text top="437" left="230" width="42" height="19" font="0">series  </text>
<text top="455" left="230" width="3" height="19" font="0"> </text>
<text top="474" left="230" width="100" height="19" font="8"><b>Size:</b> 10 of 2200 </text>
<text top="492" left="230" width="50" height="19" font="0">(0.45%) </text>
<text top="510" left="230" width="80" height="19" font="0">consecutive, </text>
<text top="529" left="230" width="110" height="19" font="0">clinically-referred </text>
<text top="547" left="230" width="52" height="19" font="0">pts who </text>
<text top="565" left="230" width="71" height="19" font="0">underwent </text>
<text top="584" left="230" width="108" height="19" font="0">symptom-limited </text>
<text top="602" left="229" width="112" height="19" font="0">exercise treadmill </text>
<text top="620" left="229" width="120" height="19" font="0">testing (9/10 Bruce </text>
<text top="639" left="229" width="86" height="19" font="0">protocol) at a </text>
<text top="657" left="229" width="88" height="19" font="0">single referral </text>
<text top="675" left="229" width="101" height="19" font="0">center (includes </text>
<text top="694" left="229" width="90" height="19" font="0">the 2 pts from </text>
<text top="712" left="229" width="102" height="19" font="0">Oliveros below)  </text>
<text top="400" left="365" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="419" left="365" width="153" height="19" font="0">1) Symptom-limited ECG </text>
<text top="437" left="364" width="128" height="19" font="0">showing ischemic ST </text>
<text top="455" left="364" width="136" height="19" font="0">segment changes and </text>
<text top="474" left="364" width="170" height="19" font="0">intraventricular conduction </text>
<text top="492" left="364" width="83" height="19" font="0">disturbance.  </text>
<text top="510" left="364" width="152" height="19" font="0"> 2) Subsequent coronary </text>
<text top="529" left="364" width="79" height="19" font="0">angiography </text>
<text top="547" left="364" width="3" height="19" font="0"> </text>
<text top="565" left="365" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="584" left="365" width="164" height="19" font="0">Reproducible rate–related </text>
<text top="602" left="365" width="170" height="19" font="0">intraventricular conduction </text>
<text top="620" left="365" width="167" height="19" font="0">disturbances w/o evidence </text>
<text top="639" left="365" width="164" height="19" font="0">of ischemia or a clinical Dx </text>
<text top="657" left="365" width="171" height="19" font="0">of CAD (N=4 – 3 LAFB and 1 </text>
<text top="675" left="365" width="39" height="19" font="0">LBBB) </text>
<text top="401" left="554" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="420" left="554" width="3" height="19" font="0"> </text>
<text top="438" left="554" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="456" left="554" width="285" height="19" font="0">1) Exercise-induced conduction abnormalities: </text>
<text top="475" left="553" width="281" height="19" font="0">LAFB in 4, LPFB in 2, RBBB in 2, RBBB with left </text>
<text top="493" left="553" width="295" height="19" font="0">axis deviation in 1, and LAFB evolving to LBBB in </text>
<text top="511" left="553" width="18" height="19" font="0">1.  </text>
<text top="529" left="553" width="291" height="19" font="0">2) Demographics: 9/10 were men, age 37–71 y. </text>
<text top="548" left="553" width="161" height="19" font="0">1 prior MI. All had angina. </text>
<text top="566" left="553" width="282" height="19" font="0">3). Stress Test: All had angina and ischemic ST </text>
<text top="584" left="553" width="243" height="19" font="0">segment changes on ETT that preceded </text>
<text top="603" left="553" width="242" height="19" font="0">conduction disturbance. All conduction </text>
<text top="621" left="553" width="290" height="19" font="0">disturbances resolved in recovery as chest pain </text>
<text top="639" left="553" width="212" height="19" font="0">and ST segment changes resolved. </text>
<text top="658" left="553" width="277" height="19" font="0">4) Coronary angiogram: All had proximal LAD </text>
<text top="676" left="553" width="259" height="19" font="0">stenosis [9/10 ≥90% (one=60%)].7/10 had </text>
<text top="694" left="553" width="266" height="19" font="0">anterior and/or apical regional wall motion </text>
<text top="713" left="553" width="293" height="19" font="0">abnormalities. EF mildly to moderately reduced </text>
<text top="731" left="553" width="289" height="19" font="0">in 3. 2 had LMCA stenosis ≥50%. 3 single vessel </text>
<text top="749" left="553" width="219" height="19" font="0">disease/3 2 V disease/4 3V disease. </text>
<text top="401" left="864" width="208" height="20" font="0">• Ischemically mediated transient </text>
<text top="420" left="875" width="170" height="19" font="0">intraventricular conduction </text>
<text top="438" left="875" width="194" height="19" font="0">disturbance elicited by exercise </text>
<text top="456" left="875" width="198" height="19" font="0">treadmill testing is rare (&lt;0.5%). </text>
<text top="475" left="864" width="168" height="20" font="0">• When present in pts with </text>
<text top="494" left="875" width="205" height="19" font="0">significant CAD, exercise-induced </text>
<text top="512" left="875" width="183" height="19" font="0">conduction abnormalities are </text>
<text top="530" left="875" width="203" height="19" font="0">typically preceded by angina and </text>
<text top="549" left="875" width="137" height="19" font="0">ischemic ECG changes </text>
<text top="567" left="864" width="228" height="20" font="0">• The constellation of ischemic signs, </text>
<text top="586" left="875" width="151" height="19" font="0">symptoms and transient </text>
<text top="604" left="875" width="190" height="19" font="0">conduction disturbance during </text>
<text top="623" left="875" width="207" height="19" font="0">exercise stress testing connotes a </text>
<text top="641" left="875" width="210" height="19" font="0">high probability of advanced CAD, </text>
<text top="659" left="875" width="176" height="19" font="0">and in particular, high-grade </text>
<text top="678" left="875" width="137" height="19" font="0">proximal LAD disease  </text>
<text top="696" left="864" width="200" height="20" font="0">• Revascularization can alleviate </text>
<text top="715" left="875" width="139" height="19" font="0">ischemically mediated </text>
<text top="733" left="875" width="170" height="19" font="0">intraventricular conduction </text>
<text top="752" left="875" width="81" height="19" font="0">disturbances </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 12 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="554" width="265" height="19" font="0">5) Response to therapy: 9/10 repeated ETT </text>
<text top="105" left="554" width="295" height="19" font="0">after CABG or institution of medical Rx. Exercise </text>
<text top="123" left="553" width="282" height="19" font="0">duration and peak heart rate increased. None </text>
<text top="142" left="553" width="263" height="19" font="0">manifested angina, ischemic ST changes or </text>
<text top="160" left="554" width="263" height="19" font="0">conduction disturbance on the repeat ETT. </text>
<text top="179" left="96" width="111" height="19" font="0">Oliveros RA, et al. </text>
<text top="197" left="96" width="62" height="19" font="0">1977 (10)<b> </b></text>
<text top="216" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=908218">908218</a></text>
<text top="216" left="142" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=908218"> </a></text>
<text top="234" left="96" width="3" height="19" font="0"> </text>
<text top="179" left="230" width="106" height="19" font="8"><b>Study type:</b> Case </text>
<text top="197" left="230" width="39" height="19" font="0">series </text>
<text top="216" left="230" width="3" height="19" font="0"> </text>
<text top="234" left="230" width="43" height="19" font="8"><b>Size:</b> 2 </text>
<text top="179" left="365" width="28" height="19" font="0">N/A </text>
<text top="180" left="554" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="198" left="554" width="3" height="19" font="0"> </text>
<text top="217" left="554" width="214" height="19" font="8"><b>Results:</b> ETT in both revealed LAFB </text>
<text top="235" left="554" width="280" height="19" font="0">concomitantly with ST segment depression in </text>
<text top="253" left="554" width="291" height="19" font="0">the lateral leads (V5 in one and I and aVL in the </text>
<text top="272" left="554" width="272" height="19" font="0">other). In one, LAFB progressed to LBBB and </text>
<text top="290" left="554" width="284" height="19" font="0">then reverted back to LAFB in recovery before </text>
<text top="308" left="554" width="297" height="19" font="0">resolving. In the other LAFB resolved after 2 min </text>
<text top="326" left="554" width="76" height="19" font="0">of recovery. </text>
<text top="179" left="864" width="174" height="20" font="0">• Exercise-induced ischemia </text>
<text top="198" left="875" width="183" height="19" font="0">associated with proximal LAD </text>
<text top="217" left="875" width="170" height="19" font="0">stenosis can be manifest as </text>
<text top="235" left="875" width="208" height="19" font="0">transient LAFB on treadmill stress </text>
<text top="253" left="875" width="34" height="19" font="0">test.  </text>
<text top="346" left="96" width="91" height="19" font="0">Bobba P, et al. </text>
<text top="364" left="96" width="30" height="19" font="0">1972</text>
<text top="362" left="127" width="4" height="21" font="4"> </text>
<text top="364" left="130" width="28" height="19" font="0">(11)<b> </b></text>
<text top="382" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5081145">5081145</a></text>
<text top="382" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5081145"> </a></text>
<text top="401" left="96" width="3" height="19" font="0"> </text>
<text top="345" left="230" width="106" height="19" font="8"><b>Study type:</b> Case </text>
<text top="364" left="230" width="39" height="19" font="0">series </text>
<text top="382" left="230" width="3" height="19" font="0"> </text>
<text top="400" left="230" width="43" height="19" font="8"><b>Size:</b> 4 </text>
<text top="345" left="365" width="146" height="19" font="8"><b>Inclusion criteria:</b> New, </text>
<text top="364" left="365" width="134" height="19" font="0">transient LPFB during </text>
<text top="382" left="365" width="171" height="19" font="0">supine bicycle ergometry in </text>
<text top="401" left="365" width="152" height="19" font="0">middle-aged Italian men </text>
<text top="419" left="364" width="167" height="19" font="0">referred for chest pain and </text>
<text top="437" left="364" width="112" height="19" font="0">suspicion of CAD.  </text>
<text top="455" left="365" width="3" height="19" font="0"> </text>
<text top="474" left="365" width="144" height="19" font="8"><b>Exclusion criteria:</b> N/A  </text>
<text top="346" left="554" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="365" left="554" width="3" height="19" font="0"> </text>
<text top="383" left="554" width="275" height="19" font="8"><b>Results:</b> All had significant ECG changes with </text>
<text top="401" left="554" width="270" height="19" font="0">exercise. 3 had inferior ST elevation prior to </text>
<text top="420" left="554" width="255" height="19" font="0">LPFB (2 of whom had inferior Q waves on </text>
<text top="438" left="554" width="252" height="19" font="0">baseline ECG). 2 of those with inferior ST </text>
<text top="456" left="554" width="296" height="19" font="0">elevation also had significant lateral ST segment </text>
<text top="475" left="554" width="98" height="19" font="0">depression). A 4</text>
<text top="474" left="652" width="8" height="12" font="7">th</text>
<text top="474" left="660" width="170" height="19" font="0"> had significant inferior and </text>
<text top="493" left="554" width="280" height="19" font="0">lateral ST segment depression w/o inferior ST </text>
<text top="511" left="554" width="291" height="19" font="0">elevation or baseline Q waves. Exercise-related </text>
<text top="529" left="554" width="246" height="19" font="0">symptoms were not reported. All 3 who </text>
<text top="548" left="554" width="280" height="19" font="0">underwent coronary angiography manifested </text>
<text top="566" left="554" width="235" height="19" font="0">significant proximal-mid RCA stenosis. </text>
<text top="346" left="864" width="203" height="20" font="0">• Exercise-related transient LPFB </text>
<text top="365" left="875" width="187" height="19" font="0">accompanied by ischemic ECG </text>
<text top="383" left="875" width="195" height="19" font="0">changes can be associated with </text>
<text top="401" left="875" width="180" height="19" font="0">significant, symptomatic RCA </text>
<text top="420" left="875" width="56" height="19" font="0">stenosis. </text>
<text top="585" left="96" width="95" height="19" font="0">Bharati S, et al. </text>
<text top="603" left="96" width="30" height="19" font="0">1977</text>
<text top="602" left="127" width="4" height="21" font="4"> </text>
<text top="603" left="130" width="28" height="19" font="0">(12)<b> </b></text>
<text top="622" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=299790">299790</a></text>
<text top="622" left="142" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=299790"> </a></text>
<text top="640" left="96" width="3" height="19" font="0"> </text>
<text top="585" left="230" width="106" height="19" font="8"><b>Study type:</b> Case </text>
<text top="603" left="230" width="42" height="19" font="0">report </text>
<text top="622" left="230" width="3" height="19" font="0"> </text>
<text top="640" left="230" width="43" height="19" font="8"><b>Size:</b> 1<b> </b></text>
<text top="585" left="365" width="140" height="19" font="8"><b>Inclusion criteria:</b> 33 y </text>
<text top="603" left="365" width="162" height="19" font="0">woman with hypertensive </text>
<text top="622" left="365" width="110" height="19" font="0">urgency, LVH and </text>
<text top="640" left="365" width="145" height="19" font="0">pulmonary edema, and </text>
<text top="658" left="365" width="147" height="19" font="0">angina accompanied by </text>
<text top="677" left="365" width="122" height="19" font="0">inferior ST segment </text>
<text top="695" left="365" width="160" height="19" font="0">elevation and progressive </text>
<text top="713" left="365" width="168" height="19" font="0">AVB (normal conduction at </text>
<text top="732" left="365" width="82" height="19" font="0">baseline, to 1</text>
<text top="732" left="446" width="9" height="12" font="7">st </text>
<text top="732" left="455" width="81" height="19" font="0">degree, then </text>
<text top="750" left="364" width="30" height="19" font="0">2:1 2</text>
<text top="750" left="395" width="10" height="12" font="7">nd</text>
<text top="750" left="405" width="79" height="19" font="0"> degree, and </text>
<text top="768" left="365" width="174" height="19" font="0">ultimately CHB). Symptoms, </text>
<text top="586" left="554" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="604" left="554" width="3" height="19" font="0"> </text>
<text top="622" left="554" width="280" height="19" font="8"><b>Results:</b> EPS during cath revealed normal A-H </text>
<text top="641" left="554" width="284" height="19" font="0">and A-V intervals while asx. During an episode </text>
<text top="659" left="554" width="290" height="19" font="0">of chest pain with ST elevation, she manifested </text>
<text top="677" left="554" width="282" height="19" font="0">progressive AVB again, culminating in CHB. At </text>
<text top="696" left="554" width="271" height="19" font="0">all stages of conduction disturbance, the AV </text>
<text top="714" left="554" width="252" height="19" font="0">node was implicated with prolonged A-H </text>
<text top="732" left="554" width="287" height="19" font="0">intervals and normal H-V intervals. The pt died </text>
<text top="751" left="554" width="278" height="19" font="0">1 d following emergent single vessel CABG to </text>
<text top="769" left="554" width="263" height="19" font="0">RCA. Pathology revealed slight fibrosis and </text>
<text top="585" left="864" width="215" height="20" font="0">• Authors speculate right coronary </text>
<text top="604" left="875" width="220" height="19" font="0">vasospasm or ischemia due to fixed </text>
<text top="623" left="875" width="191" height="19" font="0">obstruction led to transient AV </text>
<text top="641" left="875" width="208" height="19" font="0">nodal block w/o evidence of infra-</text>
<text top="659" left="875" width="74" height="19" font="0">nodal block </text>
<text top="678" left="864" width="210" height="20" font="0">• Extrapolating from other clinical </text>
<text top="697" left="875" width="159" height="19" font="0">scenarios, there may be a </text>
<text top="715" left="875" width="218" height="19" font="0">significant component of neurally—</text>
<text top="733" left="875" width="207" height="19" font="0">mediated AV node dysfunction at </text>
<text top="752" left="875" width="77" height="19" font="0">play, as well </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 13 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="365" width="169" height="19" font="0">ST changes and conduction </text>
<text top="105" left="365" width="127" height="19" font="0">disturbance were all </text>
<text top="123" left="365" width="140" height="19" font="0">transient and resolved </text>
<text top="142" left="365" width="174" height="19" font="0">together. There was no ECG </text>
<text top="160" left="365" width="165" height="19" font="0">evidence of associated MI. </text>
<text top="178" left="365" width="128" height="19" font="0">Cath revealed a 90% </text>
<text top="197" left="365" width="136" height="19" font="0">proximal stenosis of a </text>
<text top="215" left="365" width="117" height="19" font="0">dominant RCA and </text>
<text top="233" left="365" width="142" height="19" font="0">moderate LAD and LCx </text>
<text top="252" left="365" width="168" height="19" font="0">disease. Normal LV systolic </text>
<text top="270" left="365" width="161" height="19" font="0">function and LVEDP when </text>
<text top="288" left="365" width="30" height="19" font="0">asx.  </text>
<text top="307" left="365" width="3" height="19" font="0"> </text>
<text top="325" left="365" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="87" left="554" width="278" height="19" font="0">“distinct arteriosclerosis” of the AV node and </text>
<text top="105" left="554" width="239" height="19" font="0">HIS bundle along with advanced “fibro-</text>
<text top="123" left="554" width="261" height="19" font="0">elastosis” of the main left bundle w/o ECG </text>
<text top="142" left="554" width="143" height="19" font="0">correlate antemortem. </text>
<text top="160" left="554" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="864" width="232" height="20" font="0">• Coronary vasospasm can be elicited </text>
<text top="106" left="875" width="199" height="19" font="0">during exercise testing and such </text>
<text top="124" left="875" width="206" height="19" font="0">exercise-induced vasospasm may </text>
<text top="143" left="875" width="193" height="19" font="0">also be manifest as progressive </text>
<text top="161" left="875" width="148" height="19" font="0">AVB as seen in this case </text>
<text top="344" left="96" width="102" height="19" font="0">Coplan NL, et al. </text>
<text top="362" left="96" width="30" height="19" font="0">1991</text>
<text top="361" left="127" width="4" height="21" font="4"> </text>
<text top="362" left="130" width="28" height="19" font="0">(13)<b> </b></text>
<text top="381" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1959424">1959424</a></text>
<text top="381" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1959424"> </a></text>
<text top="399" left="96" width="3" height="19" font="0"> </text>
<text top="344" left="230" width="106" height="19" font="8"><b>Study type:</b> Case </text>
<text top="362" left="230" width="42" height="19" font="0">report </text>
<text top="381" left="230" width="3" height="19" font="0"> </text>
<text top="399" left="230" width="43" height="19" font="8"><b>Size:</b> 1<b> </b></text>
<text top="344" left="365" width="140" height="19" font="8"><b>Inclusion criteria:</b> 62 y </text>
<text top="362" left="365" width="120" height="19" font="0">woman underwent </text>
<text top="381" left="365" width="153" height="19" font="0">treadmill exercise test in </text>
<text top="399" left="365" width="148" height="19" font="0">evaluation of exertional </text>
<text top="417" left="365" width="73" height="19" font="0">chest pain.  </text>
<text top="436" left="365" width="3" height="19" font="0"> </text>
<text top="454" left="365" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="345" left="554" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="363" left="554" width="3" height="19" font="0"> </text>
<text top="381" left="554" width="265" height="19" font="8"><b>Results:</b> She exercised for only 2.5 min of a </text>
<text top="400" left="554" width="273" height="19" font="0">Bruce protocol and stopped due to dizziness </text>
<text top="418" left="554" width="274" height="19" font="0">and non-sustained VT. ECG revealed marked </text>
<text top="436" left="554" width="279" height="19" font="0">anterior ST elevation. 2:1 second-degree AVB </text>
<text top="455" left="554" width="247" height="19" font="0">developed in early recovery, evolving to </text>
<text top="473" left="554" width="296" height="19" font="0">complete AVB. By 8 min of recovery both the ST </text>
<text top="491" left="554" width="274" height="19" font="0">segment changes and the AVB had resolved. </text>
<text top="510" left="554" width="253" height="19" font="0">She manifested no evidence of infarction </text>
<text top="528" left="554" width="283" height="19" font="0">related to these events while evaluated in the </text>
<text top="546" left="554" width="291" height="19" font="0">hospital. Coronary angiography revealed a 90% </text>
<text top="565" left="554" width="231" height="19" font="0">proximal RCA stenosis w/o significant </text>
<text top="583" left="554" width="268" height="19" font="0">obstructive CAD elsewhere. Uncomplicated </text>
<text top="601" left="554" width="257" height="19" font="0">balloon angioplasty of the RCA lesion was </text>
<text top="620" left="554" width="262" height="19" font="0">followed 3 wk later with a normal exercise </text>
<text top="638" left="554" width="251" height="19" font="0">thallium myocardial perfusion study w/o </text>
<text top="656" left="554" width="267" height="19" font="0">ischemic ST segment changes, scintigraphic </text>
<text top="674" left="554" width="223" height="19" font="0">evidence of ischemia, or conduction </text>
<text top="693" left="554" width="79" height="19" font="0">disturbance.<b> </b></text>
<text top="344" left="864" width="207" height="20" font="0">• Authors speculate that exercise-</text>
<text top="363" left="875" width="181" height="19" font="0">induced ischemia (more than </text>
<text top="381" left="875" width="185" height="19" font="0">coronary vasospasm or occult </text>
<text top="400" left="875" width="204" height="19" font="0">intrinsic conduction disease) was </text>
<text top="418" left="875" width="177" height="19" font="0">responsible for the transient </text>
<text top="436" left="875" width="219" height="19" font="0">exercise-induced AVB that resolved </text>
<text top="455" left="875" width="141" height="19" font="0">with revascularization. </text>
<text top="473" left="864" width="187" height="20" font="0">• Cause of marked anterior ST </text>
<text top="492" left="875" width="168" height="19" font="0">elevation in the absence of </text>
<text top="510" left="875" width="225" height="19" font="0">significant LAD disease was unclear.  </text>
<text top="529" left="864" width="192" height="20" font="0">•  Based on this and other case </text>
<text top="548" left="875" width="187" height="19" font="0">reports, exercise-induced AVB </text>
<text top="566" left="875" width="190" height="19" font="0">when accompanied by signs of </text>
<text top="584" left="875" width="204" height="19" font="0">ischemia is frequently associated </text>
<text top="603" left="875" width="157" height="19" font="0">with significant right CAD </text>
<text top="712" left="86" width="553" height="19" font="8"><b>* Chronotropic index</b> = % heart rate (HR) reserve used <b>/</b> % of metabolic reserve used <b>= </b>(HR</text>
<text top="718" left="639" width="23" height="12" font="7">stage </text>
<text top="712" left="663" width="26" height="19" font="0">- HR</text>
<text top="718" left="688" width="15" height="12" font="7">rest</text>
<text top="712" left="703" width="100" height="19" font="0">) <b>/</b> (220-age - HR</text>
<text top="718" left="804" width="15" height="12" font="7">rest</text>
<text top="712" left="819" width="51" height="19" font="0">) <b>÷</b> (MET</text>
<text top="718" left="870" width="21" height="12" font="7">stage</text>
<text top="712" left="891" width="42" height="19" font="0"> <b>–</b> MET</text>
<text top="718" left="933" width="15" height="12" font="7">rest</text>
<text top="712" left="948" width="50" height="19" font="0">) <b>/ </b>(MET</text>
<text top="718" left="998" width="19" height="12" font="7">peak</text>
<text top="712" left="1017" width="42" height="19" font="0"> <b>–</b> MET</text>
<text top="718" left="1059" width="15" height="12" font="7">rest</text>
<text top="712" left="1074" width="8" height="19" font="0">) </text>
<text top="732" left="97" width="4" height="21" font="4"> </text>
<text top="730" left="313" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 14 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="1009" height="23" font="5"><b>Data Supplement 3. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Electrocardiography in Bradycardia </b></text>
<text top="108" left="86" width="377" height="23" font="5"><b>or Conduction Disorders (Sections 4.2.3 and 4.2.4) </b></text>
<text top="131" left="116" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="141" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="117" width="100" height="19" font="8"><b>Year Published’ </b></text>
<text top="186" left="148" width="38" height="19" font="8"><b>PMID </b></text>
<text top="131" left="261" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="290" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="430" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="619" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="618" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="131" left="907" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="936" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="205" left="96" width="91" height="19" font="0">Gibson TC and </text>
<text top="223" left="96" width="117" height="19" font="0">Heitzman MR 1984</text>
<text top="222" left="213" width="4" height="21" font="4"> </text>
<text top="241" left="96" width="28" height="19" font="0">(14)<b> </b></text>
<text top="260" left="96" width="57" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6702676">6702676 </a></text>
<text top="260" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6702676"> </a></text>
<text top="205" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="223" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="241" left="251" width="90" height="19" font="0">observational  </text>
<text top="260" left="251" width="3" height="19" font="0"> </text>
<text top="278" left="251" width="134" height="19" font="8"><b>Size:</b> 1,512 of all ages </text>
<text top="296" left="251" width="129" height="19" font="0">(66% &gt;60 y) referred </text>
<text top="315" left="251" width="138" height="19" font="0">for Holter for syncope </text>
<text top="333" left="251" width="131" height="19" font="0">(7,364 total over 5 y) </text>
<text top="205" left="409" width="153" height="19" font="8"><b>Inclusion criteria:</b> 24 h 2-</text>
<text top="223" left="409" width="93" height="19" font="0">channel Holter </text>
<text top="241" left="409" width="153" height="19" font="0">monitoring in evaluation </text>
<text top="260" left="409" width="69" height="19" font="0">of syncope </text>
<text top="278" left="409" width="3" height="19" font="0"> </text>
<text top="296" left="409" width="160" height="19" font="8"><b>Exclusion criteria:</b> Unable </text>
<text top="315" left="409" width="100" height="19" font="0">to keep diary or </text>
<text top="333" left="409" width="141" height="19" font="0">technically inadequate </text>
<text top="351" left="409" width="68" height="19" font="0">recordings </text>
<text top="206" left="585" width="238" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of Holter </text>
<text top="224" left="595" width="175" height="19" font="0">for syncope and presyncope </text>
<text top="242" left="585" width="3" height="19" font="0"> </text>
<text top="261" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="279" left="585" width="241" height="20" font="0">• 7 (0.5%) experienced syncope and 23 </text>
<text top="298" left="595" width="195" height="19" font="0">(1.5%) experienced presyncope </text>
<text top="316" left="595" width="241" height="19" font="0">(total=2%) associated with a significant </text>
<text top="335" left="595" width="78" height="19" font="0">arrhythmia.  </text>
<text top="353" left="585" width="212" height="20" font="0">• 225 (17%) had either syncope or </text>
<text top="372" left="595" width="232" height="19" font="0">presyncope unrelated to arrhythmia.  </text>
<text top="391" left="585" width="203" height="20" font="0">• 2/7 (29%) of syncopal episodes </text>
<text top="410" left="595" width="210" height="19" font="0">associated with bradyarrhythmia/ </text>
<text top="428" left="595" width="210" height="19" font="0">conduction disorder: 1 SB, 1 AVB.  </text>
<text top="446" left="585" width="239" height="20" font="0">• 5/23 (22%) of presyncope associated </text>
<text top="465" left="595" width="215" height="19" font="0">with bradyarrhythmia/ conduction </text>
<text top="484" left="595" width="169" height="19" font="0">disorder: 1 SB, 2 “sinoatrial </text>
<text top="502" left="595" width="127" height="19" font="0">abnormality”, 2 AVB </text>
<text top="520" left="585" width="218" height="20" font="0">• 0.5% of the 1,521 pts studied had </text>
<text top="539" left="595" width="240" height="19" font="0">symptoms associated with bradycardia </text>
<text top="558" left="595" width="150" height="19" font="0">or conduction disorder.  </text>
<text top="576" left="585" width="228" height="20" font="0">• 15 (1%) manifested Mobitz type 2 2</text>
<text top="577" left="813" width="10" height="12" font="7">nd</text>
<text top="577" left="823" width="3" height="19" font="0"> </text>
<text top="595" left="595" width="70" height="19" font="0">degree or 3</text>
<text top="595" left="665" width="9" height="12" font="7">rd</text>
<text top="595" left="674" width="166" height="19" font="0"> degree AVB. 3 (20%) were </text>
<text top="613" left="595" width="87" height="19" font="0">symptomatic. </text>
<text top="632" left="585" width="254" height="20" font="0">•  Of 1,004 pts &gt;60 y, 32 (3%) had SSS: 13 </text>
<text top="651" left="599" width="201" height="19" font="0">SB while awake, 2 sinus pause, 2 </text>
<text top="669" left="599" width="206" height="19" font="0">junctional rhythm, 2 AF, 13 tachy-</text>
<text top="687" left="599" width="201" height="19" font="0">brady. 2 (6%) were symptomatic </text>
<text top="205" left="854" width="234" height="20" font="0">• 24 h Holter rarely yields evidence of </text>
<text top="224" left="865" width="218" height="19" font="0">bradycardia or conduction disorder </text>
<text top="242" left="865" width="203" height="19" font="0">temporally related to syncope or </text>
<text top="261" left="865" width="174" height="19" font="0">presyncope in pts who have </text>
<text top="279" left="865" width="202" height="19" font="0">previously experienced syncope. </text>
<text top="297" left="854" width="234" height="20" font="0">• Findings of advanced AVB were rare </text>
<text top="316" left="865" width="167" height="19" font="0">in this population (1%) and </text>
<text top="335" left="865" width="220" height="19" font="0">symptomatic only 20% of the time.  </text>
<text top="353" left="854" width="238" height="20" font="0">• Findings of SSS increase with age but </text>
<text top="372" left="865" width="230" height="19" font="0">were present in only 3% of those &gt;60 </text>
<text top="390" left="865" width="233" height="19" font="0">y in this cohort and symptomatic only </text>
<text top="409" left="865" width="93" height="19" font="0">6% of the time </text>
<text top="427" left="854" width="3" height="19" font="0"> </text>
<text top="706" left="94" width="124" height="19" font="0">Linzer M, et al. 1997</text>
<text top="705" left="218" width="4" height="21" font="4"> </text>
<text top="725" left="94" width="28" height="19" font="0">(15)<b> </b></text>
<text top="743" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9214258">9214258</a></text>
<text top="743" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9214258"> </a></text>
<text top="761" left="96" width="3" height="19" font="0"> </text>
<text top="706" left="251" width="138" height="19" font="8"><b>Study type:</b> Literature </text>
<text top="725" left="251" width="109" height="19" font="0">review- MEDLINE </text>
<text top="743" left="251" width="119" height="19" font="0">search and manual </text>
<text top="761" left="251" width="60" height="19" font="0">review of </text>
<text top="780" left="251" width="89" height="19" font="0">bibliographies </text>
<text top="706" left="409" width="158" height="19" font="8"><b>Inclusion criteria:</b> English </text>
<text top="725" left="409" width="136" height="19" font="0">language publications </text>
<text top="743" left="409" width="105" height="19" font="0">from 1980–1995 </text>
<text top="761" left="409" width="145" height="19" font="0">reporting on diagnostic </text>
<text top="780" left="409" width="139" height="19" font="0">yield of a test (e.g., Hx </text>
<text top="707" left="585" width="196" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of </text>
<text top="725" left="585" width="248" height="19" font="0">prolonged ambulatory monitoring in pts </text>
<text top="744" left="585" width="158" height="19" font="0">with syncope or dizziness </text>
<text top="762" left="585" width="3" height="19" font="0"> </text>
<text top="780" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="707" left="854" width="209" height="20" font="0">•Authors recommend 24-h Holter </text>
<text top="725" left="865" width="200" height="19" font="0">monitor (or inpatient telemetry) </text>
<text top="744" left="865" width="224" height="19" font="0">when symptoms suggest arrhythmic </text>
<text top="762" left="865" width="188" height="19" font="0">syncope, the ECG is abnormal, </text>
<text top="780" left="865" width="231" height="19" font="0">structural heart disease is present, or </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 15 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="251" width="3" height="19" font="0"> </text>
<text top="105" left="251" width="105" height="19" font="8"><b>Size:</b> Identified 8 </text>
<text top="123" left="251" width="139" height="19" font="0">studies that evaluated </text>
<text top="142" left="251" width="123" height="19" font="0">pts with syncope or </text>
<text top="160" left="251" width="120" height="19" font="0">presyncope with at </text>
<text top="178" left="251" width="120" height="19" font="0">least 12 h of Holter </text>
<text top="197" left="251" width="97" height="19" font="0">monitoring and </text>
<text top="215" left="251" width="77" height="19" font="0">reported on </text>
<text top="233" left="251" width="121" height="19" font="0">symptoms, N=2612 </text>
<text top="87" left="409" width="146" height="19" font="0">and physical, ECG, EEG, </text>
<text top="105" left="409" width="150" height="19" font="0">Holter, external LR, EPS, </text>
<text top="123" left="409" width="146" height="19" font="0">HUTT, SAE, ETT, carotid </text>
<text top="142" left="409" width="155" height="19" font="0">U/S, head CT, psychiatric </text>
<text top="160" left="409" width="151" height="19" font="0">evaluation) evaluated in </text>
<text top="178" left="409" width="155" height="19" font="0">10 or more subjects over </text>
<text top="197" left="409" width="128" height="19" font="0">18 y with syncope (± </text>
<text top="215" left="409" width="79" height="19" font="0">presyncope) </text>
<text top="233" left="409" width="3" height="19" font="0"> </text>
<text top="252" left="409" width="161" height="19" font="8"><b>Exclusion criteria:</b> Review </text>
<text top="270" left="409" width="152" height="19" font="0">articles and case reports </text>
<text top="87" left="585" width="253" height="20" font="0">• 15% symptoms w/o arrhythmia (range: </text>
<text top="106" left="595" width="49" height="19" font="0">7–39%) </text>
<text top="124" left="585" width="229" height="20" font="0">• 14% Arrhythmia with no symptoms </text>
<text top="143" left="595" width="99" height="19" font="0">(range 10–41%) </text>
<text top="162" left="585" width="244" height="20" font="0">• 4% symptoms with arrhythmia (range </text>
<text top="181" left="595" width="49" height="19" font="0">1–26%) </text>
<text top="199" left="585" width="237" height="20" font="0">• Note: includes Gibson et al. (14), the </text>
<text top="218" left="595" width="137" height="19" font="0">largest study included </text>
<text top="87" left="865" width="184" height="19" font="0">the cause of syncope remains </text>
<text top="105" left="865" width="213" height="19" font="0">unexplained after Hx, physical and </text>
<text top="123" left="865" width="81" height="19" font="0">12-lead ECG. </text>
<text top="289" left="94" width="127" height="19" font="0">Reiffel JA, et al. 2005</text>
<text top="288" left="221" width="4" height="21" font="4"> </text>
<text top="307" left="94" width="28" height="19" font="0">(16)<b> </b></text>
<text top="326" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15842970">15842970</a></text>
<text top="326" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15842970"> </a></text>
<text top="344" left="96" width="3" height="19" font="0"> </text>
<text top="289" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="307" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="326" left="251" width="90" height="19" font="0">observational  </text>
<text top="344" left="251" width="3" height="19" font="0"> </text>
<text top="362" left="251" width="131" height="19" font="8"><b>Size:</b> 1,800 randomly </text>
<text top="381" left="251" width="145" height="19" font="0">selected studies from a </text>
<text top="399" left="251" width="118" height="19" font="0">single year derived </text>
<text top="417" left="251" width="111" height="19" font="0">from ~100,000-pt </text>
<text top="436" left="251" width="145" height="19" font="0">ambulatory monitoring </text>
<text top="454" left="251" width="85" height="19" font="0">database of a </text>
<text top="472" left="251" width="75" height="19" font="0">commercial </text>
<text top="491" left="251" width="134" height="19" font="0">monitoring company. </text>
<text top="509" left="251" width="132" height="19" font="0">600 studies each of 3 </text>
<text top="527" left="251" width="118" height="19" font="0">different classes of </text>
<text top="545" left="251" width="141" height="19" font="0">monitoring equipment </text>
<text top="564" left="251" width="129" height="19" font="0">were reviewed [24 h </text>
<text top="582" left="251" width="130" height="19" font="0">Holter, 30 d memory </text>
<text top="600" left="251" width="141" height="19" font="0">loop recording, and 30 </text>
<text top="619" left="251" width="129" height="19" font="0">d autotriggered loop </text>
<text top="637" left="251" width="66" height="19" font="0">recording] </text>
<text top="289" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="307" left="409" width="149" height="19" font="0">Referred for monitoring </text>
<text top="326" left="409" width="147" height="19" font="0">for known or suspected </text>
<text top="344" left="409" width="85" height="19" font="0">dysrhythmias </text>
<text top="362" left="409" width="3" height="19" font="0"> </text>
<text top="381" left="409" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="290" left="585" width="247" height="19" font="8"><b>1</b>°<b> endpoint:</b> Relative diagnostic yield of </text>
<text top="308" left="585" width="201" height="19" font="0">the different monitoring devices </text>
<text top="326" left="585" width="3" height="19" font="0"> </text>
<text top="345" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="363" left="585" width="214" height="20" font="0">• Groups were identical in age and </text>
<text top="382" left="595" width="231" height="19" font="0">symptoms that prompted monitoring </text>
<text top="401" left="585" width="252" height="20" font="0">• Fewer women were referred for Holter </text>
<text top="420" left="585" width="76" height="20" font="0">• 12% &lt;20 y </text>
<text top="439" left="585" width="255" height="20" font="0">• Majority (50%) referred for palpitations </text>
<text top="458" left="585" width="204" height="20" font="0">• 292 (16%) referred for syncope </text>
<text top="477" left="585" width="192" height="20" font="0">• 80 (4%) referred for dizziness </text>
<text top="496" left="585" width="168" height="20" font="0">• 6 (0.3%) referred for AVB </text>
<text top="515" left="585" width="193" height="20" font="0">• 5 (0.3%) referred for dyspnea </text>
<text top="534" left="585" width="238" height="20" font="0">• 42 (23%) pts manifested bradycardia </text>
<text top="553" left="595" width="209" height="19" font="0">(heart rate &lt;40 for those &gt;10 y). 7 </text>
<text top="572" left="595" width="236" height="19" font="0">detected by Holter, 4 by memory loop </text>
<text top="590" left="595" width="220" height="19" font="0">recording, 31 by autotriggered loop </text>
<text top="608" left="595" width="62" height="19" font="0">recording </text>
<text top="627" left="584" width="129" height="20" font="0">• For other detected </text>
<text top="646" left="595" width="186" height="19" font="0">bradyarrhythmias/conduction </text>
<text top="664" left="595" width="239" height="19" font="0">disorders the events were too few and </text>
<text top="682" left="595" width="240" height="19" font="0">the differences too slight to suggest an </text>
<text top="701" left="595" width="234" height="19" font="0">advantage of 1 device over the others </text>
<text top="719" left="595" width="200" height="19" font="0">(7 (0.4%) pauses &gt;3 s,15 (0.8%) 2</text>
<text top="719" left="795" width="10" height="12" font="7">nd</text>
<text top="719" left="805" width="3" height="19" font="0"> </text>
<text top="737" left="595" width="139" height="19" font="0">degree AVB, 7 (0.4%) 3</text>
<text top="737" left="735" width="9" height="12" font="7">rd</text>
<text top="737" left="743" width="83" height="19" font="0"> degree AVB) </text>
<text top="756" left="585" width="254" height="20" font="0">• Autotriggered loop recording produced </text>
<text top="775" left="595" width="211" height="19" font="0">a higher yield of diagnostic events </text>
<text top="289" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="308" left="854" width="189" height="20" font="0">• Auto-triggered memory loop </text>
<text top="326" left="865" width="221" height="19" font="0">recorders detects a greater number </text>
<text top="345" left="865" width="200" height="19" font="0">of arrhythmias than Holter or pt-</text>
<text top="363" left="865" width="205" height="19" font="0">triggered memory loop recorder, </text>
<text top="381" left="865" width="208" height="19" font="0">including a greater number of asx </text>
<text top="400" left="865" width="44" height="19" font="0">events </text>
<text top="418" left="854" width="229" height="20" font="0">• It is unclear from this analysis what </text>
<text top="437" left="865" width="219" height="19" font="0">the clinical impact of this enhanced </text>
<text top="455" left="865" width="158" height="19" font="0">detection might be in the </text>
<text top="474" left="865" width="202" height="19" font="0">management of bradycardia and </text>
<text top="492" left="865" width="199" height="19" font="0">conduction disorders due to the </text>
<text top="510" left="865" width="228" height="19" font="0">limited scope of this analysis and the </text>
<text top="529" left="865" width="136" height="19" font="0">infrequency of events </text>
<text top="547" left="854" width="3" height="19" font="0"> </text>
<text top="565" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="584" left="854" width="227" height="20" font="0">• Selection of monitoring device was </text>
<text top="603" left="865" width="215" height="19" font="0">not randomized, chosen on clinical </text>
<text top="621" left="865" width="231" height="19" font="0">grounds by the referring practitioner. </text>
<text top="639" left="865" width="220" height="19" font="0">Selection bias may influence results </text>
<text top="658" left="854" width="235" height="20" font="0">• Statistical significance of differences </text>
<text top="677" left="865" width="203" height="19" font="0">in detection rates not reported – </text>
<text top="695" left="865" width="150" height="19" font="0">data is descriptive only.  </text>
<text top="714" left="854" width="182" height="20" font="0">• No data available regarding </text>
<text top="733" left="865" width="231" height="19" font="0">associated structural heart disease or </text>
<text top="751" left="865" width="78" height="19" font="0">medications </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 16 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="595" width="225" height="19" font="0">(36%) than Holter (6.2%) or memory </text>
<text top="105" left="595" width="135" height="19" font="0">loop recording (17%). </text>
<text top="87" left="854" width="229" height="20" font="0">• Timing of bradycardia not reported </text>
<text top="106" left="865" width="114" height="19" font="0">(asleep vs. awake) </text>
<text top="124" left="854" width="236" height="20" font="0">• Proportion of arrhythmias that were </text>
<text top="143" left="865" width="177" height="19" font="0">symptomatic is not reported </text>
<text top="162" left="96" width="130" height="19" font="0">Sivakumaran S, et al. </text>
<text top="181" left="96" width="30" height="19" font="0">2003</text>
<text top="179" left="127" width="4" height="21" font="4"> </text>
<text top="181" left="130" width="28" height="19" font="0">(17)<b> </b></text>
<text top="199" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12867227">12867227</a></text>
<text top="199" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12867227"> </a></text>
<text top="217" left="96" width="3" height="19" font="0"> </text>
<text top="162" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="181" left="251" width="75" height="19" font="0">Prospective </text>
<text top="199" left="251" width="76" height="19" font="0">randomized </text>
<text top="217" left="251" width="87" height="19" font="0">observational </text>
<text top="236" left="251" width="3" height="19" font="0"> </text>
<text top="254" left="251" width="134" height="19" font="8"><b>Size:</b> 100 pts referred </text>
<text top="272" left="251" width="123" height="19" font="0">for ambulatory ECG </text>
<text top="291" left="251" width="86" height="19" font="0">monitoring in </text>
<text top="309" left="251" width="84" height="19" font="0">evaluation of </text>
<text top="327" left="251" width="130" height="19" font="0">syncope/presyncope </text>
<text top="346" left="251" width="135" height="19" font="0">randomized to 48 h 2-</text>
<text top="364" left="251" width="138" height="19" font="0">channel Holter (N=51) </text>
<text top="382" left="251" width="131" height="19" font="0">or 30 d external loop </text>
<text top="401" left="251" width="101" height="19" font="0">recorder (N=49) </text>
<text top="162" left="409" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="181" left="409" width="126" height="19" font="0">with syncope or pre-</text>
<text top="199" left="409" width="158" height="19" font="0">syncope referred from all </text>
<text top="217" left="409" width="113" height="19" font="0">sources for Holter </text>
<text top="236" left="409" width="154" height="19" font="0">monitor or external loop </text>
<text top="254" left="409" width="56" height="19" font="0">recorder </text>
<text top="272" left="409" width="3" height="19" font="0"> </text>
<text top="291" left="409" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="163" left="585" width="247" height="19" font="8"><b>1</b>°<b> endpoint:</b> Relative diagnostic yield of </text>
<text top="182" left="585" width="252" height="19" font="0">the 2 monitoring strategies for “clinically </text>
<text top="200" left="585" width="245" height="19" font="0">important arrhythmias” (sinus pause &gt;3 </text>
<text top="218" left="585" width="111" height="19" font="0">s, CHB, Mobitz II 2</text>
<text top="218" left="695" width="10" height="12" font="7">nd</text>
<text top="218" left="706" width="131" height="19" font="0"> degree AVB, AF with </text>
<text top="237" left="585" width="244" height="19" font="0">slow VR, symptomatic SB &lt;40 bpm, SVT </text>
<text top="255" left="585" width="192" height="19" font="0">&gt;10 s or symptomatic, and VT). </text>
<text top="273" left="585" width="3" height="19" font="0"> </text>
<text top="291" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="310" left="585" width="231" height="20" font="0">• 31/49 (63%) pts assigned initially to </text>
<text top="329" left="595" width="238" height="19" font="0">external loop recorder had arrhythmia </text>
<text top="347" left="595" width="211" height="19" font="0">diagnosed or excluded as cause of </text>
<text top="366" left="595" width="184" height="19" font="0">symptoms (30 symptoms w/o </text>
<text top="384" left="595" width="190" height="19" font="0">arrhythmia, 1 symptomatic 5-s </text>
<text top="402" left="595" width="148" height="19" font="0">conversion pause in AF) </text>
<text top="421" left="585" width="251" height="20" font="0">• 12/51 (24%) assigned initially to Holter </text>
<text top="440" left="595" width="208" height="19" font="0">had arrhythmia excluded through </text>
<text top="458" left="595" width="191" height="19" font="0">symptoms w/o arrhythmia. No </text>
<text top="476" left="595" width="221" height="19" font="0">symptomatic or asx arrhythmia was </text>
<text top="495" left="595" width="126" height="19" font="0">diagnosed by Holter </text>
<text top="513" left="585" width="222" height="20" font="0">• 29/51 randomized to initial Holter </text>
<text top="532" left="595" width="226" height="19" font="0">accepted cross-over to external loop </text>
<text top="550" left="595" width="234" height="19" font="0">recorder, while 4/18 with unrevealing </text>
<text top="569" left="595" width="236" height="19" font="0">initial external loop recorder accepted </text>
<text top="587" left="595" width="125" height="19" font="0">cross-over to Holter </text>
<text top="605" left="585" width="255" height="20" font="0">• 13/29 (45%) of cross-over external loop </text>
<text top="624" left="595" width="183" height="19" font="0">recorders had symptoms w/o </text>
<text top="643" left="595" width="198" height="19" font="0">arrhythmia during external loop </text>
<text top="661" left="595" width="212" height="19" font="0">recorder. None had an arrhythmia </text>
<text top="679" left="585" width="221" height="20" font="0">• None of the 4 pts who underwent </text>
<text top="698" left="595" width="222" height="19" font="0">cross-over Holter following external </text>
<text top="717" left="595" width="177" height="19" font="0">loop recorder manifested an </text>
<text top="735" left="595" width="182" height="19" font="0">arrhythmia or symptoms w/o </text>
<text top="753" left="595" width="75" height="19" font="0">arrhythmia. </text>
<text top="162" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="181" left="854" width="241" height="20" font="0">• Ambulatory monitoring is more likely </text>
<text top="200" left="865" width="175" height="19" font="0">to document the absence of </text>
<text top="218" left="865" width="212" height="19" font="0">arrhythmia during symptoms than </text>
<text top="237" left="865" width="154" height="19" font="0">symptomatic arrhythmia </text>
<text top="255" left="854" width="180" height="20" font="0">• In this cohort, arrhythmias, </text>
<text top="274" left="865" width="230" height="19" font="0">symptomatic or otherwise, were rare </text>
<text top="292" left="865" width="31" height="19" font="0">(1%) </text>
<text top="311" left="854" width="234" height="20" font="0">• The diagnostic yield of 30 d external </text>
<text top="330" left="865" width="232" height="19" font="0">loop recorder is more than twice that </text>
<text top="348" left="865" width="205" height="19" font="0">of 48 h Holter, almost exclusively </text>
<text top="366" left="865" width="193" height="19" font="0">through its ability to document </text>
<text top="385" left="865" width="166" height="19" font="0">symptoms w/o arrhythmia </text>
<text top="403" left="854" width="208" height="20" font="0">• Despite careful instructions and </text>
<text top="422" left="865" width="223" height="19" font="0">confirmatory test activations, 13/57 </text>
<text top="440" left="865" width="199" height="19" font="0">(23%) of pts who had symptoms </text>
<text top="459" left="865" width="183" height="19" font="0">during external loop recorder </text>
<text top="477" left="865" width="200" height="19" font="0">monitoring failed to successfully </text>
<text top="495" left="865" width="127" height="19" font="0">activate their device </text>
<text top="514" left="854" width="3" height="19" font="0"> </text>
<text top="532" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="550" left="854" width="234" height="20" font="0">• Low incidence of arrhythmias in this </text>
<text top="569" left="865" width="224" height="19" font="0">unselected population with syncope </text>
<text top="588" left="865" width="95" height="19" font="0">or pre-syncope </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 17 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="237" height="20" font="0">• In all 55 pts had Holter. None had an </text>
<text top="106" left="595" width="227" height="19" font="0">arrhythmia identified as the cause of </text>
<text top="124" left="595" width="222" height="19" font="0">presenting symptoms, 12 (22%) had </text>
<text top="143" left="595" width="198" height="19" font="0">arrhythmia excluded as a cause. </text>
<text top="161" left="585" width="239" height="20" font="0">• In all 78 pts underwent external loop </text>
<text top="180" left="595" width="187" height="19" font="0">recorder monitoring. 1 had an </text>
<text top="198" left="595" width="236" height="19" font="0">arrhythmia thought to be the cause of </text>
<text top="217" left="595" width="230" height="19" font="0">the presenting symptoms and 43 had </text>
<text top="235" left="595" width="195" height="19" font="0">arrhythmia excluded as a cause </text>
<text top="253" left="595" width="242" height="19" font="0">[Diagnostic yield 44/78 (56%; p&lt;0.0001 </text>
<text top="272" left="595" width="71" height="19" font="0">vs. Holter)] </text>
<text top="291" left="96" width="131" height="19" font="0">Brown AP, et al. 1987</text>
<text top="289" left="227" width="4" height="21" font="4"> </text>
<text top="309" left="96" width="28" height="19" font="0">(18)<b> </b></text>
<text top="327" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3663425">3663425</a></text>
<text top="327" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3663425"> </a></text>
<text top="346" left="96" width="3" height="19" font="0"> </text>
<text top="291" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="309" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="327" left="251" width="87" height="19" font="0">observational </text>
<text top="346" left="251" width="3" height="19" font="0"> </text>
<text top="364" left="251" width="128" height="19" font="8"><b>Size:</b> 100 unselected </text>
<text top="382" left="251" width="104" height="19" font="0">pts experiencing </text>
<text top="401" left="251" width="140" height="19" font="0">palpitations, dizziness, </text>
<text top="419" left="251" width="133" height="19" font="0">or syncope (collected </text>
<text top="437" left="251" width="111" height="19" font="0">from 106 pts who </text>
<text top="455" left="251" width="124" height="19" font="0">underwent external </text>
<text top="474" left="251" width="129" height="19" font="0">loop recorder over 3 </text>
<text top="492" left="251" width="144" height="19" font="0">y). 39% had some form </text>
<text top="510" left="251" width="114" height="19" font="0">of structural heart </text>
<text top="529" left="251" width="49" height="19" font="0">disease </text>
<text top="291" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="309" left="409" width="150" height="19" font="0">Unselected pts who had </text>
<text top="327" left="409" width="147" height="19" font="0">undergone pt-activated </text>
<text top="346" left="409" width="74" height="19" font="0">ambulatory </text>
<text top="364" left="409" width="148" height="19" font="0">electrocardiography for </text>
<text top="382" left="409" width="116" height="19" font="0">up to 3 wk. 42 had </text>
<text top="401" left="409" width="133" height="19" font="0">undergone prior 24 h </text>
<text top="419" left="409" width="154" height="19" font="0">Holter of which 17 (40%) </text>
<text top="437" left="409" width="96" height="19" font="0">were abnormal </text>
<text top="455" left="409" width="3" height="19" font="0"> </text>
<text top="474" left="409" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="492" left="409" width="140" height="19" font="0">Incomplete case notes </text>
<text top="510" left="409" width="37" height="19" font="0">(N=6) </text>
<text top="291" left="585" width="250" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of external </text>
<text top="310" left="595" width="87" height="19" font="0">loop recorder </text>
<text top="328" left="585" width="3" height="19" font="0"> </text>
<text top="346" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="365" left="588" width="224" height="20" font="0">• “Clinically useful information” was </text>
<text top="384" left="599" width="102" height="19" font="0">obtained in 68% </text>
<text top="402" left="588" width="225" height="20" font="0">• Of 56 diagnostic recordings and 13 </text>
<text top="421" left="599" width="234" height="19" font="0">recordings “of some diagnostic value” </text>
<text top="440" left="599" width="209" height="19" font="0">there were 6 bradyarrhythmias (4 </text>
<text top="458" left="599" width="242" height="19" font="0">reflecting sinus node dysfunction and 2 </text>
<text top="476" left="599" width="201" height="19" font="0">implicating conduction disorder) </text>
<text top="495" left="588" width="182" height="20" font="0">• 6 of 17 pts with paroxysmal </text>
<text top="514" left="599" width="238" height="19" font="0">arrhythmias had returned to SR by the </text>
<text top="532" left="599" width="216" height="19" font="0">time the event button was pressed </text>
<text top="291" left="854" width="228" height="20" font="0">• Early study of pt-activated external </text>
<text top="310" left="865" width="87" height="19" font="0">loop recorder </text>
<text top="328" left="854" width="225" height="20" font="0">• Authors noted the advantages of a </text>
<text top="347" left="865" width="218" height="19" font="0">pt-activated external loop recorder </text>
<text top="366" left="865" width="209" height="19" font="0">over pt-activated recorders w/o a </text>
<text top="384" left="865" width="232" height="19" font="0">looping memory available at the time </text>
<text top="402" left="854" width="223" height="20" font="0">• Study demonstrates the feasibility </text>
<text top="421" left="865" width="211" height="19" font="0">and utility of pt-activated external </text>
<text top="440" left="865" width="223" height="19" font="0">loop recorder in a population with a </text>
<text top="458" left="865" width="176" height="19" font="0">relatively high prevalence of </text>
<text top="476" left="865" width="217" height="19" font="0">structural heart disease and Holter-</text>
<text top="495" left="865" width="158" height="19" font="0">documented arrhythmias </text>
<text top="513" left="854" width="197" height="20" font="0">• Authors suggested that the pt-</text>
<text top="532" left="865" width="227" height="19" font="0">activated external loop recorder was </text>
<text top="550" left="865" width="223" height="19" font="0">complimentary to 24 h Holter, not a </text>
<text top="569" left="865" width="196" height="19" font="0">substitute, in part due to the pt-</text>
<text top="587" left="865" width="210" height="19" font="0">activated external loop recorder’s </text>
<text top="605" left="865" width="189" height="19" font="0">inability to capture asx events. </text>
<text top="624" left="96" width="110" height="19" font="0">Cumbee SR, et al. </text>
<text top="643" left="96" width="62" height="19" font="0">1990 (19)<b> </b></text>
<text top="661" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2300833">2300833</a></text>
<text top="661" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2300833"> </a></text>
<text top="679" left="96" width="3" height="19" font="0"> </text>
<text top="624" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="643" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="661" left="251" width="87" height="19" font="0">observational </text>
<text top="679" left="251" width="3" height="19" font="0"> </text>
<text top="697" left="251" width="71" height="19" font="8"><b>Size:</b> N=39  </text>
<text top="716" left="251" width="130" height="19" font="0">Derived from first 48 </text>
<text top="734" left="251" width="115" height="19" font="0">pts referred for pt-</text>
<text top="752" left="251" width="113" height="19" font="0">activated external </text>
<text top="771" left="251" width="134" height="19" font="0">cardiac loop recorder </text>
<text top="624" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="643" left="420" width="150" height="19" font="0">Unexplained syncope or </text>
<text top="661" left="420" width="132" height="19" font="0">presyncope, referred </text>
<text top="679" left="420" width="98" height="19" font="0">for pt-activated </text>
<text top="697" left="420" width="140" height="19" font="0">external loop recorder </text>
<text top="716" left="409" width="3" height="19" font="0"> </text>
<text top="734" left="409" width="134" height="19" font="8"><b>Exclusion criteria:</b> No </text>
<text top="752" left="420" width="116" height="19" font="0">documented Hx of </text>
<text top="771" left="420" width="144" height="19" font="0">syncope or presyncope </text>
<text top="625" left="585" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="644" left="585" width="210" height="20" font="0">• Diagnostic yield of external loop </text>
<text top="662" left="595" width="56" height="19" font="0">recorder </text>
<text top="681" left="585" width="232" height="20" font="0">• Frequency with which external loop </text>
<text top="700" left="595" width="244" height="19" font="0">recorder provided relevant information </text>
<text top="718" left="595" width="222" height="19" font="0">missed by preceding Holter and EPS </text>
<text top="737" left="585" width="250" height="20" font="0">• Extent to which external loop recorder </text>
<text top="756" left="595" width="172" height="19" font="0">influenced pt management  </text>
<text top="774" left="585" width="3" height="19" font="0"> </text>
<text top="624" left="854" width="241" height="20" font="0">• Small early evaluation of pt-activated </text>
<text top="643" left="865" width="208" height="19" font="0">external loop recorder suggesting </text>
<text top="662" left="865" width="104" height="19" font="0">diagnostic utility </text>
<text top="680" left="854" width="190" height="20" font="0">• Diagnostic yield in this highly </text>
<text top="699" left="865" width="213" height="19" font="0">selected population referred to an </text>
<text top="717" left="865" width="230" height="19" font="0">academic medical center for syncope </text>
<text top="736" left="865" width="191" height="19" font="0">and presyncope that remained </text>
<text top="754" left="865" width="206" height="19" font="0">unexplained after fairly extensive </text>
<text top="772" left="865" width="209" height="19" font="0">testing was understandably lower </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="10" size="13" family="Times" color="#262626"/>
<text top="804" left="570" width="51" height="19" font="0">Page 18 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="251" width="95" height="19" font="0">at an academic </text>
<text top="105" left="251" width="123" height="19" font="0">medical center (see </text>
<text top="123" left="251" width="111" height="19" font="0">exclusion criteria) </text>
<text top="87" left="420" width="131" height="19" font="0">(1), cause of syncope </text>
<text top="105" left="420" width="145" height="19" font="0">already established (1), </text>
<text top="123" left="420" width="127" height="19" font="0">inaccessible medical </text>
<text top="142" left="420" width="147" height="19" font="0">record or loop recorder </text>
<text top="160" left="420" width="123" height="19" font="0">ongoing at the time </text>
<text top="178" left="420" width="120" height="19" font="0">data collection was </text>
<text top="197" left="420" width="89" height="19" font="0">completed (7) </text>
<text top="87" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="105" left="585" width="234" height="20" font="0">• 92% had prior Holter, 46% had prior </text>
<text top="124" left="595" width="25" height="19" font="0">EPS </text>
<text top="143" left="585" width="242" height="20" font="0">• 35/39 (90%) wore the monitor (2 pts. </text>
<text top="162" left="595" width="194" height="19" font="0">declined, 1 stopped due to skin </text>
<text top="180" left="595" width="211" height="19" font="0">irritation, 1 device malfunctioned) </text>
<text top="199" left="585" width="191" height="20" font="0">• 32/35 (91%) pts were able to </text>
<text top="217" left="595" width="245" height="19" font="0">successfully record symptomatic events </text>
<text top="236" left="595" width="172" height="19" font="0">(others were incapacitated) </text>
<text top="254" left="585" width="255" height="20" font="0">• Diagnostic in 14/39 (yield=36%; 95% CI, </text>
<text top="275" left="595" width="26" height="19" font="0">21%</text>
<text top="273" left="621" width="8" height="21" font="4">–</text>
<text top="275" left="630" width="208" height="19" font="0">53%). 11/39 (28%) = syncope w/o </text>
<text top="293" left="595" width="172" height="19" font="0">arrhythmia and 3/39 (7.6%) </text>
<text top="312" left="595" width="215" height="19" font="0">symptomatic arrhythmia (asystole, </text>
<text top="330" left="595" width="243" height="19" font="0">junctional bradycardia, and paroxysmal </text>
<text top="348" left="595" width="113" height="19" font="0">atrial tachycardia) </text>
<text top="367" left="585" width="190" height="20" font="0">• External loop recorder led to </text>
<text top="386" left="595" width="233" height="19" font="0">management changes in all 3 pts with </text>
<text top="404" left="595" width="244" height="19" font="0">symptomatic arrhythmia including PPM </text>
<text top="422" left="595" width="111" height="19" font="0">implantation in 2. </text>
<text top="87" left="865" width="221" height="19" font="0">than some other studies of external </text>
<text top="105" left="865" width="204" height="19" font="0">loop recorder (36%). Most of the </text>
<text top="123" left="865" width="208" height="19" font="0">diagnostic yield was derived from </text>
<text top="142" left="865" width="212" height="19" font="0">those with syncope or presyncope </text>
<text top="160" left="865" width="215" height="19" font="0">w/o associated arrhythmia (11/14, </text>
<text top="178" left="865" width="45" height="19" font="0">78.5%) </text>
<text top="197" left="854" width="193" height="20" font="0">•  7/39 (17.9%) pts referred for </text>
<text top="216" left="865" width="180" height="19" font="0">external loop recorder either </text>
<text top="234" left="865" width="218" height="19" font="0">couldn’t/wouldn’t tolerate wearing </text>
<text top="252" left="865" width="216" height="19" font="0">the monitor, had it malfunction, or </text>
<text top="271" left="865" width="211" height="19" font="0">were too incapacitated to capture </text>
<text top="289" left="865" width="127" height="19" font="0">symptomatic events </text>
<text top="441" left="96" width="91" height="19" font="8"><b>SYNAAR-Flash </b></text>
<text top="460" left="96" width="126" height="19" font="0">Locati ET, et al. 2016</text>
<text top="458" left="222" width="4" height="21" font="4"> </text>
<text top="478" left="96" width="28" height="19" font="0">(20) </text>
<text top="496" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26519025">26519025</a></text>
<text top="496" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26519025"> </a></text>
<text top="515" left="96" width="3" height="19" font="0"> </text>
<text top="533" left="96" width="3" height="19" font="0"> </text>
<text top="441" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="460" left="251" width="75" height="19" font="0">Prospective </text>
<text top="478" left="251" width="87" height="19" font="0">observational </text>
<text top="496" left="251" width="75" height="19" font="0">multicenter </text>
<text top="515" left="251" width="3" height="19" font="0"> </text>
<text top="533" left="251" width="110" height="19" font="8"><b>Size:</b> 392 pts; 282 </text>
<text top="551" left="251" width="114" height="19" font="0">(72%) enrolled for </text>
<text top="570" left="251" width="128" height="19" font="0">palpitations and 110 </text>
<text top="588" left="251" width="113" height="19" font="0">(28%) for syncope </text>
<text top="441" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="460" left="409" width="131" height="19" font="0">Recent (within 1 mo) </text>
<text top="478" left="409" width="137" height="19" font="0">episode of syncope or </text>
<text top="496" left="409" width="137" height="19" font="0">sustained palpitations </text>
<text top="515" left="409" width="157" height="19" font="0">(index event), after being </text>
<text top="533" left="409" width="103" height="19" font="0">discharged from </text>
<text top="551" left="409" width="124" height="19" font="0">emergency room or </text>
<text top="570" left="409" width="131" height="19" font="0">hospitalization w/o a </text>
<text top="588" left="409" width="126" height="19" font="0">conclusive Dx, and a </text>
<text top="606" left="409" width="135" height="19" font="0">suspected arrhythmic </text>
<text top="624" left="409" width="42" height="19" font="0">origin  </text>
<text top="643" left="409" width="3" height="19" font="0"> </text>
<text top="661" left="409" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="442" left="585" width="236" height="19" font="8"><b>1</b>°<b> endpoint:</b> Evaluate the role of 4 wk </text>
<text top="460" left="585" width="247" height="19" font="0">auto-triggered external loop recorder in </text>
<text top="479" left="585" width="230" height="19" font="0">the clinical evaluation of unexplained </text>
<text top="497" left="585" width="223" height="19" font="0">syncope or sustained palpitations of </text>
<text top="515" left="585" width="236" height="19" font="0">suspected arrhythmic origin. Analyzed </text>
<text top="534" left="585" width="251" height="19" font="0">rhythm at the time of symptoms and asx </text>
<text top="552" left="585" width="230" height="19" font="0">arrhythmias predefined as significant </text>
<text top="570" left="585" width="245" height="19" font="0">(sustained SVT or VT, advanced AVB, SB </text>
<text top="589" left="585" width="139" height="19" font="0">&lt;30 bpm, pauses &gt;6 s) </text>
<text top="607" left="585" width="3" height="19" font="0"> </text>
<text top="625" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="644" left="585" width="223" height="20" font="0">• 27/110 (25%) of pts. evaluated for </text>
<text top="663" left="595" width="242" height="19" font="0">syncope had a diagnostic test. Of these </text>
<text top="681" left="595" width="241" height="19" font="0">11/110 (10%) experienced a conclusive </text>
<text top="699" left="595" width="238" height="19" font="0">event regarding the arrhythmic nature </text>
<text top="718" left="595" width="245" height="19" font="0">of the symptoms and 16/110 (15%) had </text>
<text top="736" left="595" width="178" height="19" font="0">an asx significant arrhythmia </text>
<text top="754" left="585" width="250" height="20" font="0">•  Of the 11 pts. with a conclusive event, </text>
<text top="773" left="595" width="236" height="19" font="0">5 manifested recurrence of symptoms </text>
<text top="441" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="460" left="854" width="11" height="18" font="0">• </text>
<text top="460" left="865" width="195" height="19" font="10">Authors conclude that the 4 wk </text>
<text top="479" left="865" width="196" height="19" font="10">external ECG monitoring can be </text>
<text top="497" left="865" width="208" height="19" font="10">considered as first-line tool in the </text>
<text top="515" left="865" width="216" height="19" font="10">diagnostic work-up of syncope and </text>
<text top="534" left="865" width="227" height="19" font="10">palpitation. Early recorder use, Hx of </text>
<text top="552" left="865" width="214" height="19" font="10">supraventricular (tachy and brady) </text>
<text top="570" left="865" width="214" height="19" font="10">arrhythmia, and frequent previous </text>
<text top="589" left="865" width="209" height="19" font="10">events increased the likelihood of </text>
<text top="607" left="865" width="208" height="19" font="10">diagnostic events during the 4 wk </text>
<text top="625" left="865" width="150" height="19" font="10">external ECG monitoring</text>
<text top="625" left="1014" width="3" height="19" font="0"> </text>
<text top="644" left="865" width="3" height="19" font="0"> </text>
<text top="662" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="680" left="854" width="210" height="20" font="0">• Reliance on pt diary in efforts to </text>
<text top="699" left="865" width="194" height="19" font="0">correlate rhythm and symptom </text>
<text top="718" left="865" width="161" height="19" font="0">introduces potential error </text>
<text top="736" left="854" width="241" height="20" font="0">• The precise mechanism of a syncopal </text>
<text top="755" left="865" width="213" height="19" font="0">event associated with arrhythmias </text>
<text top="773" left="865" width="184" height="19" font="0">documented on external loop </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 19 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="595" width="228" height="19" font="0">w/o significant arrhythmia and 6 had </text>
<text top="105" left="595" width="221" height="19" font="0">symptomatic arrhythmia (all 6 were </text>
<text top="123" left="595" width="204" height="19" font="0">either bradycardia or conduction </text>
<text top="142" left="595" width="59" height="19" font="0">disorder) </text>
<text top="160" left="585" width="240" height="20" font="0">• Of the 16 asx significant arrhythmias, </text>
<text top="179" left="595" width="224" height="19" font="0">one third (5/16) were either pauses, </text>
<text top="198" left="595" width="221" height="19" font="0">advanced AVB, or sinus bradycardia </text>
<text top="216" left="585" width="254" height="20" font="0">• Predictors of diagnostic events in those </text>
<text top="235" left="595" width="238" height="19" font="0">evaluated for syncope were early start </text>
<text top="253" left="595" width="214" height="19" font="0">of recording (≤15 d between index </text>
<text top="272" left="595" width="227" height="19" font="0">event and enrollment vs. &gt;15 d) (OR: </text>
<text top="290" left="595" width="216" height="19" font="0">3.2; 95%CI: 1.3–26.6; p=0.021) and </text>
<text top="308" left="595" width="194" height="19" font="0">previous Hx of supraventricular </text>
<text top="327" left="595" width="235" height="19" font="0">arrhythmias (OR: 3.6; 95% CI: 1.4–9.7; </text>
<text top="345" left="595" width="57" height="19" font="0">p=0.018) </text>
<text top="363" left="585" width="217" height="20" font="0">• 202/282 (72%) of pts referred for </text>
<text top="382" left="595" width="239" height="19" font="0">palpitations had a diagnostic test (68% </text>
<text top="401" left="595" width="227" height="19" font="0">conclusive event and 23% symptoms </text>
<text top="419" left="595" width="205" height="19" font="0">w/o arrhythmia). Less than 3% of </text>
<text top="437" left="595" width="232" height="19" font="0">referred pts experienced a conclusive </text>
<text top="456" left="595" width="245" height="19" font="0">event due to bradycardia or conduction </text>
<text top="474" left="595" width="58" height="19" font="0">disorder. </text>
<text top="492" left="585" width="247" height="20" font="0">• Predictors of a diagnostic test in those </text>
<text top="511" left="595" width="230" height="19" font="0">evaluated for palpitations were Hx of </text>
<text top="530" left="595" width="225" height="19" font="0">recurrent palpitations (p&lt;0.001) and </text>
<text top="548" left="595" width="209" height="19" font="0">early start of recording (p=0.001). </text>
<text top="87" left="865" width="210" height="19" font="0">recorder can be uncertain despite </text>
<text top="105" left="865" width="163" height="19" font="0">the associated arrhythmia </text>
<text top="124" left="854" width="229" height="20" font="0">• The clinical benefit of external loop </text>
<text top="143" left="865" width="213" height="19" font="0">recorder remains undefined in the </text>
<text top="161" left="865" width="184" height="19" font="0">absence of data documenting </text>
<text top="179" left="865" width="214" height="19" font="0">improved outcomes predicated on </text>
<text top="198" left="865" width="198" height="19" font="0">therapy guided by external loop </text>
<text top="216" left="865" width="100" height="19" font="0">recorder results </text>
<text top="567" left="96" width="108" height="19" font="0">Barrett PM, et al. </text>
<text top="585" left="96" width="30" height="19" font="0">2014</text>
<text top="584" left="127" width="4" height="21" font="4"> </text>
<text top="585" left="130" width="28" height="19" font="0">(21)<b> </b></text>
<text top="604" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24384108">24384108</a></text>
<text top="604" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24384108"> </a></text>
<text top="622" left="96" width="3" height="19" font="0"> </text>
<text top="567" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="585" left="251" width="75" height="19" font="0">Prospective </text>
<text top="604" left="251" width="90" height="19" font="0">observational  </text>
<text top="622" left="251" width="3" height="19" font="0"> </text>
<text top="640" left="251" width="97" height="19" font="8"><b>Size:</b> N=146 pts </text>
<text top="658" left="251" width="75" height="19" font="0">referred for </text>
<text top="677" left="251" width="102" height="19" font="0">ambulatory ECG </text>
<text top="695" left="251" width="101" height="19" font="0">monitoring who </text>
<text top="713" left="251" width="71" height="19" font="0">underwent </text>
<text top="732" left="251" width="115" height="19" font="0">simultaneous 24 h </text>
<text top="750" left="251" width="132" height="19" font="0">Holter monitor and a </text>
<text top="768" left="251" width="141" height="19" font="0">novel, single-lead 14-d </text>
<text top="567" left="409" width="159" height="19" font="8"><b>Inclusion criteria:</b> Pts ≥18 </text>
<text top="585" left="409" width="153" height="19" font="0">y referred for evaluation </text>
<text top="604" left="409" width="134" height="19" font="0">of cardiac arrhythmia </text>
<text top="622" left="409" width="148" height="19" font="0">able to provide consent </text>
<text top="640" left="409" width="104" height="19" font="0">and comply with </text>
<text top="658" left="409" width="100" height="19" font="0">continuous ECG </text>
<text top="677" left="409" width="122" height="19" font="0">monitoring for 14 d </text>
<text top="695" left="409" width="3" height="19" font="0"> </text>
<text top="713" left="409" width="142" height="19" font="8"><b>Exclusion criteria:</b> Skin </text>
<text top="732" left="409" width="145" height="19" font="0">allergies, conditions, or </text>
<text top="750" left="409" width="156" height="19" font="0">sensitivities to any of the </text>
<text top="768" left="409" width="119" height="19" font="0">components of the </text>
<text top="568" left="585" width="228" height="19" font="8"><b>1</b>°<b> endpoint:</b> Comparative diagnostic </text>
<text top="586" left="585" width="138" height="19" font="0">utility of the 2 devices </text>
<text top="604" left="585" width="3" height="19" font="0"> </text>
<text top="623" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="641" left="585" width="237" height="20" font="0">• Adhesive patch monitor detected 96 </text>
<text top="660" left="595" width="220" height="19" font="0">pre-defined arrhythmic events over </text>
<text top="678" left="595" width="197" height="19" font="0">total wear time compared to 61 </text>
<text top="697" left="595" width="237" height="19" font="0">arrhythmia events by Holter (p&lt;0.001) </text>
<text top="715" left="585" width="230" height="20" font="0">• Median wear time for Holter =1.0 d </text>
<text top="734" left="595" width="239" height="19" font="0">(range 0.9–1.0) and for adhesive patch </text>
<text top="752" left="595" width="194" height="19" font="0">monitor =11.1 d (range 0.9–14) </text>
<text top="567" left="854" width="226" height="20" font="0">• Despite slightly lower sensitivity to </text>
<text top="586" left="865" width="214" height="19" font="0">supraventricular tachyarrhythmias </text>
<text top="604" left="865" width="233" height="19" font="0">during simultaneous monitoring, 14 d </text>
<text top="623" left="865" width="206" height="19" font="0">adhesive patch monitor provided </text>
<text top="641" left="865" width="196" height="19" font="0">greater diastolic yield than 24 h </text>
<text top="659" left="865" width="227" height="19" font="0">Holter monitoring, primarily through </text>
<text top="678" left="865" width="224" height="19" font="0">the benefit of prolonged monitoring </text>
<text top="696" left="865" width="31" height="19" font="0">time </text>
<text top="714" left="854" width="212" height="20" font="0">• The adhesive patch monitor was </text>
<text top="733" left="865" width="230" height="19" font="0">considered preferable to wear by the </text>
<text top="752" left="865" width="220" height="19" font="0">pts in this study with less impact on </text>
<text top="770" left="865" width="30" height="19" font="0">QOL </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 20 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="251" width="95" height="19" font="0">adhesive patch </text>
<text top="105" left="251" width="128" height="19" font="0">monitor (Zio Patch).  </text>
<text top="123" left="251" width="3" height="19" font="0"> </text>
<text top="142" left="251" width="108" height="19" font="0">238 screened, 88 </text>
<text top="160" left="251" width="143" height="19" font="0">declined, 150 enrolled, </text>
<text top="178" left="251" width="118" height="19" font="0">4 lost to follow-up. </text>
<text top="87" left="409" width="152" height="19" font="0">adhesive patch monitor, </text>
<text top="105" left="409" width="147" height="19" font="0">receiving or anticipated </text>
<text top="123" left="409" width="124" height="19" font="0">to receive pacing or </text>
<text top="142" left="409" width="157" height="19" font="0">external DCCV during the </text>
<text top="160" left="409" width="158" height="19" font="0">monitoring period, or the </text>
<text top="178" left="409" width="129" height="19" font="0">anticipation of being </text>
<text top="197" left="409" width="102" height="19" font="0">exposed to high-</text>
<text top="215" left="409" width="115" height="19" font="0">frequency surgical </text>
<text top="233" left="409" width="137" height="19" font="0">equipment during the </text>
<text top="252" left="409" width="114" height="19" font="0">monitoring period </text>
<text top="87" left="585" width="253" height="20" font="0">• During the 24 h period of simultaneous </text>
<text top="106" left="595" width="228" height="19" font="0">monitoring with both devices, Holter </text>
<text top="124" left="595" width="212" height="19" font="0">monitor detected more of the pre-</text>
<text top="143" left="595" width="228" height="19" font="0">specified arrhythmias than the patch </text>
<text top="161" left="595" width="224" height="19" font="0">monitor. However, in nearly all such </text>
<text top="179" left="595" width="225" height="19" font="0">pts, the patch monitor subsequently </text>
<text top="198" left="595" width="199" height="19" font="0">detected the missed arrhythmia </text>
<text top="216" left="595" width="246" height="19" font="0">through prolonged monitoring. None of </text>
<text top="234" left="595" width="173" height="19" font="0">the discrepancies related to </text>
<text top="253" left="595" width="228" height="19" font="0">bradycardia or conduction disorders. </text>
<text top="271" left="585" width="214" height="20" font="0">• 81% of pts preferred to wear the </text>
<text top="290" left="595" width="230" height="19" font="0">adhesive patch to the Holter monitor </text>
<text top="308" left="595" width="189" height="19" font="0">and the participants found the </text>
<text top="327" left="595" width="240" height="19" font="0">adhesive patch more comfortable with </text>
<text top="345" left="595" width="228" height="19" font="0">less impact on their activities of daily </text>
<text top="363" left="595" width="39" height="19" font="0">living. </text>
<text top="87" left="854" width="3" height="19" font="0"> </text>
<text top="382" left="96" width="131" height="19" font="0">Rosenberg MA, et al. </text>
<text top="401" left="96" width="30" height="19" font="0">2013</text>
<text top="399" left="127" width="4" height="21" font="4"> </text>
<text top="401" left="130" width="28" height="19" font="0">(22)<b> </b></text>
<text top="419" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23240827">23240827</a></text>
<text top="419" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23240827"> </a></text>
<text top="437" left="96" width="3" height="19" font="0"> </text>
<text top="382" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="401" left="251" width="75" height="19" font="0">Prospective </text>
<text top="419" left="251" width="87" height="19" font="0">observational </text>
<text top="437" left="251" width="3" height="19" font="0"> </text>
<text top="455" left="251" width="143" height="19" font="8"><b>Size:</b> N=74 consecutive </text>
<text top="474" left="251" width="143" height="19" font="0">pts. referred for Holter </text>
<text top="492" left="251" width="98" height="19" font="0">monitor for the </text>
<text top="510" left="251" width="140" height="19" font="0">evaluation of PAF who </text>
<text top="529" left="251" width="71" height="19" font="0">underwent </text>
<text top="547" left="251" width="115" height="19" font="0">simultaneous 24 h </text>
<text top="565" left="251" width="140" height="19" font="0">Holter monitor and 14 </text>
<text top="584" left="251" width="138" height="19" font="0">d single-lead adhesive </text>
<text top="602" left="251" width="117" height="19" font="0">patch monitor (Zio </text>
<text top="620" left="251" width="46" height="19" font="0">Patch)  </text>
<text top="382" left="409" width="142" height="19" font="8"><b>Inclusion criteria:</b> PAF, </text>
<text top="401" left="409" width="117" height="19" font="0">referred for Holter </text>
<text top="419" left="409" width="159" height="19" font="0">monitor as part of clinical </text>
<text top="437" left="409" width="84" height="19" font="0">management </text>
<text top="455" left="409" width="3" height="19" font="0"> </text>
<text top="474" left="409" width="124" height="19" font="8"><b>Exclusion criteria:</b> 1 </text>
<text top="492" left="409" width="156" height="19" font="0">potential participant was </text>
<text top="510" left="409" width="136" height="19" font="0">excluded because the </text>
<text top="529" left="409" width="148" height="19" font="0">adhesive patch monitor </text>
<text top="547" left="409" width="136" height="19" font="0">was inadvertently not </text>
<text top="565" left="409" width="103" height="19" font="0">activated during </text>
<text top="584" left="409" width="68" height="19" font="0">placement </text>
<text top="383" left="585" width="228" height="19" font="8"><b>1</b>°<b> endpoint:</b> Comparative diagnostic </text>
<text top="401" left="595" width="138" height="19" font="0">utility of the 2 devices </text>
<text top="420" left="585" width="3" height="19" font="0"> </text>
<text top="438" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="456" left="585" width="244" height="20" font="0">•  Mean wear time for adhesive patch </text>
<text top="475" left="608" width="209" height="19" font="0">monitor =10.8±2.8 d (range 4–14) </text>
<text top="494" left="608" width="212" height="19" font="0">and the mean monitoring time for </text>
<text top="512" left="608" width="165" height="19" font="0">the Holter was 22.5±1.8 h) </text>
<text top="530" left="585" width="257" height="20" font="0">•  All 25 AF events detected by Holter in </text>
<text top="549" left="608" width="215" height="19" font="0">the first 24 h were detected by the </text>
<text top="568" left="608" width="232" height="19" font="0">adhesive patch monitor. Recorded AF </text>
<text top="586" left="608" width="176" height="19" font="0">burden during simultaneous </text>
<text top="604" left="608" width="174" height="19" font="0">monitoring was comparable </text>
<text top="623" left="608" width="167" height="19" font="0">(58.4±42.7% on Holter and </text>
<text top="641" left="608" width="189" height="19" font="0">54.7±41.2% on adhesive patch </text>
<text top="659" left="608" width="169" height="19" font="0">monitor (r=0.96; p&lt;0.0001) </text>
<text top="678" left="585" width="233" height="20" font="0">•  During prolonged monitoring, the </text>
<text top="697" left="608" width="229" height="19" font="0">adhesive patch monitor identified AF </text>
<text top="715" left="608" width="220" height="19" font="0">in 18 (24%) additional individuals in </text>
<text top="733" left="608" width="211" height="19" font="0">whom it was not detected by 24 h </text>
<text top="752" left="608" width="231" height="19" font="0">Holter and reclassified pts’ pattern of </text>
<text top="770" left="608" width="223" height="19" font="0">AF (i.e., persistent or paroxysmal) in </text>
<text top="382" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="401" left="854" width="230" height="20" font="0">• 14 d adhesive patch monitoring is a </text>
<text top="420" left="865" width="214" height="19" font="0">useful tool to refine assessment of </text>
<text top="438" left="865" width="232" height="19" font="0">PAF, due to the benefits of prolonged </text>
<text top="456" left="865" width="75" height="19" font="0">monitoring  </text>
<text top="475" left="854" width="218" height="20" font="0">• When compared to simultaneous </text>
<text top="494" left="865" width="198" height="19" font="0">Holter monitoring, the adhesive </text>
<text top="512" left="865" width="175" height="19" font="0">patch monitor performs in a </text>
<text top="530" left="865" width="224" height="19" font="0">comparable fashion in the detection </text>
<text top="549" left="865" width="195" height="19" font="0">of AF and in the quantitation of </text>
<text top="567" left="865" width="141" height="19" font="0">cumulative AF burden. </text>
<text top="585" left="854" width="243" height="20" font="0">• The adhesive patch monitor fell off of </text>
<text top="604" left="865" width="222" height="19" font="0">16 pts, was removed by 6 others, or </text>
<text top="623" left="865" width="233" height="19" font="0">had battery malfunction in one. In all, </text>
<text top="641" left="865" width="210" height="19" font="0">23/74 (49%) of participants in this </text>
<text top="659" left="865" width="188" height="19" font="0">trial failed to complete 14 d of </text>
<text top="678" left="865" width="182" height="19" font="0">monitoring for non-medically </text>
<text top="696" left="865" width="213" height="19" font="0">directed reasons. Mean wear time </text>
<text top="714" left="865" width="215" height="19" font="0">for those whose device fell off was </text>
<text top="733" left="865" width="182" height="19" font="0">7.9±1.8 d (range 5.8–12.2 d).  </text>
<text top="751" left="854" width="3" height="19" font="0"> </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 21 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="608" width="210" height="19" font="0">21 (28%). The prolonged adhesive </text>
<text top="105" left="608" width="218" height="19" font="0">patch monitoring also documented </text>
<text top="123" left="608" width="224" height="19" font="0">from 1 to 99 pauses of 3.1–9.7 s in 4 </text>
<text top="142" left="608" width="223" height="19" font="0">pts, as well as Mobitz type 1 second-</text>
<text top="160" left="608" width="208" height="19" font="0">degree AVB in 1 pt. Of the pauses </text>
<text top="178" left="608" width="222" height="19" font="0">only 2 were &gt;5 s and only 1 of these </text>
<text top="197" left="608" width="199" height="19" font="0">was only detected by prolonged </text>
<text top="215" left="608" width="173" height="19" font="0">adhesive patch monitoring.  </text>
<text top="234" left="96" width="118" height="19" font="0">Turakhia MP, et al. </text>
<text top="252" left="96" width="30" height="19" font="0">2013</text>
<text top="251" left="127" width="4" height="21" font="4"> </text>
<text top="252" left="130" width="28" height="19" font="0">(23)<b> </b></text>
<text top="271" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23672988">23672988</a></text>
<text top="271" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23672988"> </a></text>
<text top="289" left="96" width="3" height="19" font="0"> </text>
<text top="234" left="251" width="112" height="19" font="8"><b>Study type:</b> Cross-</text>
<text top="252" left="251" width="143" height="19" font="0">sectional retrospective </text>
<text top="271" left="251" width="87" height="19" font="0">observational </text>
<text top="289" left="251" width="3" height="19" font="0"> </text>
<text top="307" left="251" width="94" height="19" font="8"><b>Size:</b> N=26,751 </text>
<text top="326" left="251" width="132" height="19" font="0">consecutive pts. who </text>
<text top="344" left="251" width="135" height="19" font="0">underwent first-time, </text>
<text top="362" left="251" width="116" height="19" font="0">clinically-indicated </text>
<text top="381" left="251" width="123" height="19" font="0">prolonged adhesive </text>
<text top="399" left="251" width="135" height="19" font="0">patch monitoring (Zio </text>
<text top="417" left="251" width="123" height="19" font="0">Patch) during 2011. </text>
<text top="436" left="251" width="134" height="19" font="0">Investigators used de-</text>
<text top="454" left="251" width="93" height="19" font="0">identified data </text>
<text top="472" left="251" width="115" height="19" font="0">obtained from the </text>
<text top="491" left="251" width="141" height="19" font="0">manufacturer/servicer </text>
<text top="509" left="251" width="59" height="19" font="0">(iRhythm </text>
<text top="527" left="251" width="88" height="19" font="0">Technologies) </text>
<text top="234" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="252" left="409" width="154" height="19" font="0">Consecutive pts referred </text>
<text top="271" left="409" width="140" height="19" font="0">for first-time, clinically </text>
<text top="289" left="409" width="119" height="19" font="0">indicated Zio Patch </text>
<text top="307" left="409" width="56" height="19" font="0">monitor  </text>
<text top="326" left="409" width="3" height="19" font="0"> </text>
<text top="344" left="409" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="362" left="409" width="122" height="19" font="0">Excluded data from </text>
<text top="381" left="409" width="150" height="19" font="0">repeated or subsequent </text>
<text top="399" left="409" width="47" height="19" font="0">studies </text>
<text top="235" left="585" width="217" height="19" font="8"><b>1</b>°<b> endpoint:</b> Analyzed compliance, </text>
<text top="253" left="585" width="207" height="19" font="0">analyzable signal time, interval to </text>
<text top="272" left="585" width="225" height="19" font="0">arrhythmia detection and diagnostic </text>
<text top="290" left="585" width="132" height="19" font="0">yield of the Zio patch </text>
<text top="308" left="585" width="3" height="19" font="0"> </text>
<text top="326" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="345" left="585" width="179" height="20" font="0">• Mean wear time =7.6±36 d </text>
<text top="364" left="585" width="245" height="20" font="0">• Median analyzable time =99% of total </text>
<text top="383" left="595" width="65" height="19" font="0">wear time </text>
<text top="401" left="585" width="240" height="20" font="0">• Arrhythmia was detected in 60.3% of </text>
<text top="420" left="595" width="26" height="19" font="0">pts. </text>
<text top="439" left="585" width="253" height="20" font="0">• 29.9% of all arrhythmias occurred after </text>
<text top="458" left="595" width="235" height="19" font="0">the first 48 h of monitoring and 51.1% </text>
<text top="476" left="595" width="214" height="19" font="0">of symptom-triggered arrhythmias </text>
<text top="494" left="595" width="124" height="19" font="0">occurred after 48 h. </text>
<text top="513" left="585" width="203" height="20" font="0">• Compared to the first 48 h, the </text>
<text top="532" left="595" width="177" height="19" font="0">diagnostic yield of the entire </text>
<text top="550" left="595" width="232" height="19" font="0">monitoring period for any arrhythmia </text>
<text top="569" left="595" width="191" height="19" font="0">was superior (62.2% vs. 43.9%; </text>
<text top="587" left="595" width="211" height="19" font="0">p&lt;0.0001) as was the yield for any </text>
<text top="605" left="595" width="212" height="19" font="0">symptomatic arrhythmia (9.7% vs. </text>
<text top="623" left="595" width="106" height="19" font="0">4.4%; p&lt;0.0001)  </text>
<text top="642" left="585" width="227" height="20" font="0">• 3.7% of pts manifested pauses &gt;3 s </text>
<text top="661" left="595" width="229" height="19" font="0">(42.9 % of which occurred after 48 h) </text>
<text top="679" left="595" width="244" height="19" font="0">and 1.4% of pts manifested Mobitz II or </text>
<text top="698" left="595" width="191" height="19" font="0">complete AVB (36.6% of which </text>
<text top="716" left="595" width="125" height="19" font="0">occurred after 48 h) </text>
<text top="234" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="253" left="854" width="207" height="20" font="0">• ≤14 d of Zio Patch monitoring is </text>
<text top="272" left="865" width="232" height="19" font="0">feasible, with high compliance, a high </text>
<text top="290" left="865" width="226" height="19" font="0">percentage of analyzable signal time </text>
<text top="308" left="865" width="201" height="19" font="0">and incremental diagnostic yield </text>
<text top="326" left="865" width="225" height="19" font="0">beyond 48 h for all arrhythmia types </text>
<text top="345" left="854" width="180" height="20" font="0">• The incidence of significant </text>
<text top="364" left="865" width="224" height="19" font="0">bradycardia or conduction disorders </text>
<text top="382" left="865" width="199" height="19" font="0">in a large unselected population </text>
<text top="401" left="865" width="225" height="19" font="0">referred for Zio Patch monitoring on </text>
<text top="419" left="865" width="212" height="19" font="0">clinical grounds is very low (5.1%). </text>
<text top="437" left="865" width="190" height="19" font="0">Only 4% of those studied were </text>
<text top="455" left="865" width="159" height="19" font="0">referred for evaluation of </text>
<text top="474" left="865" width="207" height="19" font="0">bradycardia, pauses, or advanced </text>
<text top="492" left="865" width="29" height="19" font="0">AVB </text>
<text top="510" left="854" width="3" height="19" font="0"> </text>
<text top="735" left="96" width="121" height="19" font="0">Joshi AK, et al. 2005</text>
<text top="733" left="217" width="4" height="21" font="4"> </text>
<text top="753" left="96" width="28" height="19" font="0">(24)<b> </b></text>
<text top="771" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15781022">15781022</a></text>
<text top="771" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15781022"> </a></text>
<text top="735" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="753" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="771" left="251" width="87" height="19" font="0">observational </text>
<text top="735" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="753" left="409" width="133" height="19" font="0">Referred for clinically </text>
<text top="736" left="585" width="180" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield </text>
<text top="754" left="585" width="3" height="19" font="0"> </text>
<text top="772" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="735" left="854" width="244" height="20" font="0">• Early evaluation of new technology at </text>
<text top="754" left="865" width="55" height="19" font="0">the time </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 22 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="3" height="19" font="0"> </text>
<text top="87" left="251" width="3" height="19" font="0"> </text>
<text top="105" left="251" width="88" height="19" font="8"><b>Size:</b> First 100 </text>
<text top="123" left="251" width="102" height="19" font="0">consecutive pts. </text>
<text top="142" left="251" width="98" height="19" font="0">monitored by 2-</text>
<text top="160" left="251" width="125" height="19" font="0">channel MCOT for a </text>
<text top="178" left="251" width="130" height="19" font="0">mean of 9.9 d (range </text>
<text top="197" left="251" width="53" height="19" font="0">2–28 d). </text>
<text top="87" left="409" width="101" height="19" font="0">indicated MCOT </text>
<text top="105" left="409" width="71" height="19" font="0">monitoring </text>
<text top="123" left="409" width="3" height="19" font="0"> </text>
<text top="142" left="409" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="588" width="220" height="20" font="0">•  “Clinically significant” arrhythmia </text>
<text top="106" left="601" width="229" height="19" font="0">detected in 51 (51%) pts, 25 (49%) of </text>
<text top="124" left="601" width="101" height="19" font="0">which were asx. </text>
<text top="143" left="588" width="253" height="20" font="0">•  3 pts manifested “sinus node disease,” </text>
<text top="162" left="601" width="225" height="19" font="0">2 symptomatic sinus bradycardias, 2 </text>
<text top="180" left="601" width="8" height="19" font="0">2</text>
<text top="180" left="609" width="10" height="12" font="7">nd</text>
<text top="180" left="619" width="200" height="19" font="0"> degree AVB, 1 CHB, 1 junctional </text>
<text top="198" left="601" width="190" height="19" font="0">rhythm, and 1 PM malfunction </text>
<text top="217" left="588" width="197" height="20" font="0">•  Monitoring led to a change in </text>
<text top="236" left="601" width="186" height="19" font="0">management in 34 (34%) pts., </text>
<text top="254" left="601" width="214" height="19" font="0">including implantation of PPM in 5 </text>
<text top="272" left="601" width="184" height="19" font="0">and ICD in 2, as well as 1 PPM </text>
<text top="291" left="601" width="85" height="19" font="0">replacement. </text>
<text top="87" left="854" width="237" height="20" font="0">• MCOT detected clinically significant” </text>
<text top="106" left="865" width="225" height="19" font="0">arrhythmias in approximately half of </text>
<text top="124" left="865" width="229" height="19" font="0">those referred and led to a change in </text>
<text top="143" left="865" width="143" height="19" font="0">management in a third </text>
<text top="161" left="854" width="238" height="20" font="0">• Authors note that 30 of their pts had </text>
<text top="180" left="865" width="178" height="19" font="0">previously undergone Holter </text>
<text top="198" left="865" width="219" height="19" font="0">monitoring or event recorder. In 16 </text>
<text top="217" left="865" width="171" height="19" font="0">of these MCOT detected an </text>
<text top="235" left="865" width="223" height="19" font="0">arrhythmia not previously detected. </text>
<text top="253" left="854" width="3" height="19" font="0"> </text>
<text top="310" left="96" width="116" height="19" font="0">Rothman SA, et al. </text>
<text top="328" left="96" width="30" height="19" font="0">2007</text>
<text top="327" left="127" width="4" height="21" font="4"> </text>
<text top="328" left="130" width="28" height="19" font="0">(25)<b> </b></text>
<text top="346" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17318994">17318994</a></text>
<text top="346" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17318994"> </a></text>
<text top="365" left="96" width="3" height="19" font="0"> </text>
<text top="310" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="328" left="251" width="78" height="19" font="0">Prospective, </text>
<text top="346" left="251" width="75" height="19" font="0">multicenter </text>
<text top="365" left="251" width="87" height="19" font="0">observational </text>
<text top="383" left="251" width="3" height="19" font="0"> </text>
<text top="401" left="251" width="75" height="19" font="8"><b>Size:</b> N=266 </text>
<text top="420" left="251" width="110" height="19" font="0">randomized to pt-</text>
<text top="438" left="251" width="144" height="19" font="0">activated external loop </text>
<text top="456" left="251" width="108" height="19" font="0">recorder (132) or </text>
<text top="475" left="251" width="92" height="19" font="0">MCOT (134) in </text>
<text top="493" left="251" width="141" height="19" font="0">evaluation of syncope, </text>
<text top="511" left="251" width="134" height="19" font="0">presyncope or severe </text>
<text top="530" left="251" width="76" height="19" font="0">palpitations </text>
<text top="310" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="328" left="409" width="141" height="19" font="0">Symptoms of syncope, </text>
<text top="346" left="409" width="134" height="19" font="0">presyncope or severe </text>
<text top="365" left="409" width="106" height="19" font="0">palpitations (less </text>
<text top="383" left="409" width="145" height="19" font="0">frequent than once per </text>
<text top="401" left="409" width="76" height="19" font="0">24 h) with a </text>
<text top="420" left="409" width="161" height="19" font="0">nondiagnostic 24 h Holter </text>
<text top="438" left="409" width="133" height="19" font="0">or telemetry monitor </text>
<text top="456" left="409" width="88" height="19" font="0">within 45 d of </text>
<text top="475" left="409" width="75" height="19" font="0">enrollment. </text>
<text top="493" left="409" width="3" height="19" font="0"> </text>
<text top="511" left="409" width="152" height="19" font="8"><b>Exclusion criteria:</b> NYHA </text>
<text top="529" left="409" width="133" height="19" font="0">class IV HF; MI within </text>
<text top="548" left="409" width="100" height="19" font="0">past 3 mo; USA; </text>
<text top="566" left="409" width="144" height="19" font="0">candidate for or recent </text>
<text top="584" left="409" width="151" height="19" font="0">valvular cardiac surgery; </text>
<text top="603" left="409" width="146" height="19" font="0">h/o sustained VT or VF; </text>
<text top="621" left="409" width="158" height="19" font="0">≥10 VPCs/h and EF ≤35%; </text>
<text top="639" left="409" width="109" height="19" font="0">&lt;18 y; inability to </text>
<text top="658" left="409" width="156" height="19" font="0">complete or comply with </text>
<text top="676" left="409" width="55" height="19" font="0">protocol </text>
<text top="310" left="585" width="242" height="19" font="8"><b>1</b>°<b> endpoint:</b> Confirmation or exclusion </text>
<text top="329" left="585" width="242" height="19" font="0">of a probable arrhythmic cause of their </text>
<text top="347" left="585" width="67" height="19" font="0">symptoms </text>
<text top="365" left="585" width="3" height="19" font="0"> </text>
<text top="384" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="402" left="585" width="248" height="20" font="0">• 266/305 randomized pts completed at </text>
<text top="421" left="595" width="157" height="19" font="0">least 225 d of monitoring </text>
<text top="440" left="585" width="254" height="20" font="0">• 114/266 (43%) presented with syncope </text>
<text top="459" left="595" width="91" height="19" font="0">or presyncope </text>
<text top="477" left="585" width="245" height="20" font="0">• Overall diagnostic yield: MCOT =88%.  </text>
<text top="496" left="595" width="239" height="19" font="0">external loop recorder =75% (p=0.008) </text>
<text top="515" left="585" width="241" height="20" font="0">• For those presenting with syncope or </text>
<text top="533" left="595" width="234" height="19" font="0">presyncope, comparison of diagnostic </text>
<text top="552" left="595" width="193" height="19" font="0">yield was similar: MCOT =89%.  </text>
<text top="570" left="595" width="239" height="19" font="0">external loop recorder =69% (p=0.008) </text>
<text top="589" left="585" width="241" height="20" font="0">• MCOT was superior in confirming the </text>
<text top="608" left="595" width="233" height="19" font="0">Dx of clinically significant arrhythmias </text>
<text top="626" left="595" width="200" height="19" font="0">[55/134 (41%) vs. 19/132 (15%); </text>
<text top="644" left="595" width="58" height="19" font="0">p&lt;0.001] </text>
<text top="663" left="585" width="245" height="20" font="0">• 8/266 (3%) manifested bradycardia or </text>
<text top="682" left="595" width="201" height="19" font="0">conduction disorder, 6 pauses, 1 </text>
<text top="700" left="595" width="169" height="19" font="0">complete AVB, 1 Mobitz II 2</text>
<text top="700" left="765" width="10" height="12" font="7">nd</text>
<text top="700" left="775" width="49" height="19" font="0"> degree </text>
<text top="718" left="595" width="240" height="19" font="0">AVB, and no symptomatic bradycardia. </text>
<text top="310" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="328" left="854" width="229" height="20" font="0">• MCOT provided a higher diagnostic </text>
<text top="347" left="865" width="225" height="19" font="0">yield than pt-activated external loop </text>
<text top="366" left="865" width="232" height="19" font="0">recorder in this cohort of pts referred </text>
<text top="384" left="865" width="226" height="19" font="0">for syncope, presyncope, and severe </text>
<text top="402" left="865" width="230" height="19" font="0">palpitations in a randomized head-to-</text>
<text top="420" left="865" width="109" height="19" font="0">head comparison </text>
<text top="439" left="854" width="230" height="20" font="0">• Authors speculate this likely relates </text>
<text top="458" left="865" width="204" height="19" font="0">to pt inability to properly use the </text>
<text top="476" left="865" width="221" height="19" font="0">external loop recorder, compliance, </text>
<text top="495" left="865" width="226" height="19" font="0">and/or the ability of MCOT to detect </text>
<text top="513" left="865" width="104" height="19" font="0">asx arrhythmias. </text>
<text top="531" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="550" left="859" width="214" height="20" font="0">•  external loop recorder w/o auto-</text>
<text top="569" left="873" width="199" height="19" font="0">trigger functionality was utilized </text>
<text top="587" left="873" width="196" height="19" font="0">which could bias results toward </text>
<text top="605" left="873" width="41" height="19" font="0">MCOT </text>
<text top="624" left="859" width="197" height="20" font="0">•  Pt and investigator unblinded </text>
<text top="643" left="859" width="184" height="20" font="0">•  Noncompliance =12.7% (23 </text>
<text top="662" left="873" width="181" height="19" font="0">randomized to MCOT did not </text>
<text top="680" left="873" width="216" height="19" font="0">complete 25 d of monitoring vs. 16 </text>
<text top="698" left="873" width="223" height="19" font="0">in the external loop recorder group) </text>
<text top="737" left="96" width="124" height="19" font="0">Linzer M, et al. 1990</text>
<text top="736" left="220" width="4" height="21" font="4"> </text>
<text top="756" left="96" width="28" height="19" font="0">(26)<b> </b></text>
<text top="774" left="96" width="57" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2371954">2371954 </a></text>
<text top="774" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2371954"> </a></text>
<text top="737" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="756" left="251" width="75" height="19" font="0">Prospective </text>
<text top="774" left="251" width="90" height="19" font="0">observational  </text>
<text top="737" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="756" left="409" width="86" height="19" font="0">≥1 episode of </text>
<text top="774" left="409" width="135" height="19" font="0">unexplained syncope  </text>
<text top="738" left="585" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="756" left="585" width="229" height="19" font="0">Utility of external loop recorder after </text>
<text top="775" left="585" width="133" height="19" font="0">indeterminate Holter </text>
<text top="737" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="756" left="854" width="237" height="20" font="0">• Early study of external loop recorder </text>
<text top="775" left="865" width="219" height="19" font="0">in syncope that suggests utility, but </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 23 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="3" height="19" font="0"> </text>
<text top="87" left="251" width="3" height="19" font="0"> </text>
<text top="105" left="251" width="90" height="19" font="8"><b>Size:</b> N=57 pts </text>
<text top="87" left="409" width="3" height="19" font="0"> </text>
<text top="105" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="123" left="409" width="58" height="19" font="0">Prior EPS </text>
<text top="87" left="585" width="3" height="19" font="0"> </text>
<text top="105" left="585" width="244" height="19" font="8"><b>Results:</b> In 14 /57 (25%) of pts, external </text>
<text top="123" left="585" width="186" height="19" font="0">loop recorder was diagnostic.  </text>
<text top="142" left="585" width="233" height="20" font="0">• Half of these diagnoses (7/14) came </text>
<text top="161" left="595" width="195" height="19" font="0">from symptoms w/o associated </text>
<text top="179" left="595" width="75" height="19" font="0">arrhythmia  </text>
<text top="198" left="585" width="254" height="20" font="0">• Symptomatic arrhythmias include VT (1 </text>
<text top="217" left="595" width="235" height="19" font="0">pt), high-grade AVB (2 pts), SVT (1 pt), </text>
<text top="235" left="595" width="242" height="19" font="0">asystole or junctional bradycardia from </text>
<text top="253" left="595" width="210" height="19" font="0">neurally mediated syncope (3 pts) </text>
<text top="87" left="865" width="183" height="19" font="0">only rarely by identifying non-</text>
<text top="105" left="865" width="207" height="19" font="0">neurally mediated bradycardia or </text>
<text top="123" left="865" width="213" height="19" font="0">conduction disorder (&lt;4% of those </text>
<text top="142" left="865" width="57" height="19" font="0">studied). </text>
<text top="160" left="854" width="3" height="19" font="0"> </text>
<text top="178" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="197" left="854" width="91" height="20" font="0">• Referral bias </text>
<text top="216" left="854" width="120" height="20" font="0">• Small sample size </text>
<text top="272" left="96" width="82" height="19" font="8"><b>Framingham </b></text>
<text top="291" left="96" width="116" height="19" font="0">Schneider JF, et al. </text>
<text top="309" left="96" width="30" height="19" font="0">1979</text>
<text top="308" left="127" width="4" height="21" font="4"> </text>
<text top="309" left="130" width="28" height="19" font="0">(27)<b> </b></text>
<text top="327" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=154870">154870</a></text>
<text top="327" left="142" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=154870"> </a></text>
<text top="346" left="96" width="3" height="19" font="0"> </text>
<text top="364" left="96" width="3" height="19" font="0"> </text>
<text top="272" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="291" left="251" width="75" height="19" font="0">Prospective </text>
<text top="309" left="251" width="87" height="19" font="0">observational </text>
<text top="327" left="251" width="114" height="19" font="0">community-based </text>
<text top="346" left="251" width="37" height="19" font="0">study </text>
<text top="364" left="251" width="3" height="19" font="0"> </text>
<text top="382" left="251" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="401" left="251" width="117" height="19" font="0">N=55 cases of new </text>
<text top="419" left="251" width="38" height="19" font="0">LBBB. </text>
<text top="437" left="251" width="95" height="19" font="0">N=110 age/sex-</text>
<text top="455" left="251" width="138" height="19" font="0">matched controls w/o </text>
<text top="474" left="251" width="87" height="19" font="0">incident LBBB </text>
<text top="492" left="251" width="130" height="19" font="0">N=5,209 total cohort </text>
<text top="510" left="251" width="138" height="19" font="0">followed biennially up </text>
<text top="529" left="251" width="45" height="19" font="0">to 18 y<b> </b></text>
<text top="272" left="409" width="143" height="19" font="8"><b>Inclusion criteria:</b> New </text>
<text top="291" left="409" width="111" height="19" font="0">LBBB detected on </text>
<text top="309" left="409" width="98" height="19" font="0">biennial exams  </text>
<text top="327" left="409" width="3" height="19" font="0"> </text>
<text top="345" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="364" left="409" width="147" height="19" font="0">17 with LBBB at start of </text>
<text top="382" left="409" width="61" height="19" font="0">the study<b> </b></text>
<text top="273" left="595" width="239" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the incidence of </text>
<text top="291" left="595" width="233" height="19" font="0">new LBBB, describe the prevalence of </text>
<text top="310" left="595" width="245" height="19" font="0">antecedent, coincident and subsequent </text>
<text top="328" left="595" width="217" height="19" font="0">CV disease and risk factors in those </text>
<text top="346" left="595" width="235" height="19" font="0">with vs. w/o incident LBBB (HTN, CHF, </text>
<text top="365" left="595" width="196" height="19" font="0">CHD, DM, cardiac enlargement) </text>
<text top="383" left="595" width="3" height="19" font="0"> </text>
<text top="401" left="595" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="420" left="585" width="138" height="20" font="0">•  31 men, 24 women </text>
<text top="439" left="585" width="214" height="20" font="0">•  Mean age at LBBB=62 y (36–78) </text>
<text top="458" left="585" width="246" height="20" font="0">•  Mean follow-up = 18 y (12 pre- and 6 </text>
<text top="477" left="601" width="156" height="19" font="0">post-LBBB) range: 4–22 y </text>
<text top="495" left="585" width="201" height="20" font="0">•  Those with LBBB had a higher </text>
<text top="514" left="601" width="205" height="19" font="0">prevalence of HTN (65%), cardiac </text>
<text top="533" left="601" width="234" height="19" font="0">enlargement (44%), CHF, CAD, DM vs. </text>
<text top="551" left="601" width="100" height="19" font="0">those w/o LBBB </text>
<text top="569" left="585" width="238" height="20" font="0">•  Only 27% of LBBB group was free of </text>
<text top="588" left="601" width="186" height="19" font="0">obvious CVD at the time of Dx </text>
<text top="607" left="585" width="237" height="20" font="0">•  5/15 (33%) free of antecedent CVD, </text>
<text top="626" left="601" width="175" height="19" font="0">developed evidence thereof </text>
<text top="644" left="601" width="183" height="19" font="0">coincident to or following the </text>
<text top="662" left="601" width="112" height="19" font="0">detection of LBBB </text>
<text top="681" left="585" width="241" height="20" font="0">•  6/15 of those with incident CVD had </text>
<text top="700" left="602" width="217" height="19" font="0">evidence thereof at the time of the </text>
<text top="718" left="602" width="120" height="19" font="0">new LBBB (all CAD) </text>
<text top="737" left="585" width="250" height="20" font="0">•  14/55 (28%) developed new CHF with </text>
<text top="756" left="601" width="233" height="19" font="0">(N=4) or after (N=10) LBBB first noted </text>
<text top="272" left="854" width="67" height="19" font="8"><b>Strengths: </b></text>
<text top="291" left="854" width="228" height="20" font="0">•  Large population-based study with </text>
<text top="310" left="867" width="222" height="19" font="0">lengthy follow-up and rigorous data </text>
<text top="328" left="867" width="63" height="19" font="0">collection </text>
<text top="346" left="854" width="3" height="19" font="0"> </text>
<text top="365" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="383" left="854" width="219" height="20" font="0">• Small number of incident cases of </text>
<text top="402" left="868" width="220" height="19" font="0">LBBB with wide confidence margins </text>
<text top="420" left="868" width="175" height="19" font="0">of estimated rates of events </text>
<text top="439" left="854" width="191" height="20" font="0">•  No echocardiogram or other </text>
<text top="458" left="868" width="194" height="19" font="0">assessment for structural heart </text>
<text top="476" left="868" width="166" height="19" font="0">disease with incident LBBB </text>
<text top="494" left="854" width="7" height="19" font="0">  </text>
<text top="513" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="531" left="854" width="181" height="19" font="0">Incident LBBB in middle aged </text>
<text top="549" left="854" width="223" height="19" font="0">populations is often associated with </text>
<text top="568" left="854" width="219" height="19" font="0">antecedent or subsequent clinically </text>
<text top="586" left="854" width="238" height="19" font="0">apparent CV disease, and is associated </text>
<text top="604" left="854" width="217" height="19" font="0">with increased CV mortality in men </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 24 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="229" height="20" font="0">•  Rate of incident CAD in those with </text>
<text top="106" left="601" width="217" height="19" font="0">LBBB =2x controls during follow-up </text>
<text top="124" left="585" width="227" height="20" font="0">•  Rate of incident CHF in those with </text>
<text top="143" left="601" width="213" height="19" font="0">LBBB=7x controls during follow-up </text>
<text top="162" left="585" width="212" height="20" font="0">•  Median time to first recognized </text>
<text top="181" left="601" width="66" height="19" font="0">CAD=3.7 y </text>
<text top="199" left="585" width="212" height="20" font="0">•  Median time to first recognized </text>
<text top="218" left="601" width="64" height="19" font="0">CHF=3.3 y </text>
<text top="237" left="585" width="207" height="20" font="0">•  11% of LBBB group and 48% of </text>
<text top="256" left="601" width="184" height="19" font="0">controls remained free of any </text>
<text top="274" left="601" width="208" height="19" font="0">evidence of CVD during follow-up </text>
<text top="292" left="601" width="62" height="19" font="0">(p&lt;0.001) </text>
<text top="311" left="585" width="229" height="20" font="0">•  No advanced AVB or PPM in those </text>
<text top="330" left="601" width="65" height="19" font="0">with LBBB </text>
<text top="348" left="585" width="188" height="20" font="0">•  LBBB: 50% mortality at 10 y </text>
<text top="367" left="585" width="216" height="20" font="0">•  Controls 11.6% mortality at 10 y </text>
<text top="386" left="602" width="107" height="19" font="0">(p=not provided) </text>
<text top="405" left="585" width="255" height="19" font="0">Prevalence cohort (17 with LBBB at initial </text>
<text top="423" left="585" width="245" height="19" font="0">screening) were younger (mean age=49 </text>
<text top="441" left="585" width="253" height="19" font="0">y), but had similar incidence of CVD (94% </text>
<text top="459" left="585" width="250" height="19" font="0">developed one or more forms of CVD on </text>
<text top="478" left="585" width="167" height="19" font="0">average 3 y after initial Dx)<b> </b></text>
<text top="497" left="93" width="82" height="19" font="8"><b>Framingham </b></text>
<text top="515" left="93" width="116" height="19" font="0">Schneider JF, et al. </text>
<text top="533" left="93" width="62" height="19" font="0">1980 (28)<b> </b></text>
<text top="552" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7350871">7350871</a></text>
<text top="552" left="146" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7350871"><b> </b></a></text>
<text top="497" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="515" left="251" width="75" height="19" font="0">Prospective </text>
<text top="533" left="251" width="87" height="19" font="0">observational </text>
<text top="552" left="251" width="114" height="19" font="0">community-based </text>
<text top="570" left="251" width="37" height="19" font="0">study </text>
<text top="588" left="251" width="3" height="19" font="0"> </text>
<text top="607" left="251" width="28" height="19" font="8"><b>Size </b></text>
<text top="625" left="251" width="128" height="19" font="0">N=70 cases of newly </text>
<text top="643" left="251" width="102" height="19" font="0">diagnosed RBBB </text>
<text top="662" left="251" width="119" height="19" font="0">N=140 sex and age-</text>
<text top="680" left="251" width="110" height="19" font="0">matched controls </text>
<text top="698" left="251" width="130" height="19" font="0">N=5,209 total cohort </text>
<text top="717" left="251" width="138" height="19" font="0">followed biennially up </text>
<text top="735" left="251" width="45" height="19" font="0">to 18 y<b> </b></text>
<text top="497" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="515" left="409" width="67" height="19" font="0">New RBBB </text>
<text top="533" left="409" width="3" height="19" font="0"> </text>
<text top="552" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="570" left="409" width="139" height="19" font="0">Extant RBBB (N=16) at </text>
<text top="588" left="409" width="56" height="19" font="0">first visit </text>
<text top="607" left="409" width="3" height="19" font="8"><b> </b></text>
<text top="498" left="585" width="251" height="19" font="8"><b>1</b>°<b> endpoint:</b> Compare the prevalence of </text>
<text top="516" left="585" width="245" height="19" font="0">antecedent, coincident and subsequent </text>
<text top="534" left="585" width="248" height="19" font="0">CV disease and risk factors in those with </text>
<text top="553" left="585" width="221" height="19" font="0">incident RBBB (HTN, CHF, CHD, DM, </text>
<text top="571" left="585" width="133" height="19" font="0">cardiac enlargement) </text>
<text top="589" left="585" width="3" height="19" font="0"> </text>
<text top="608" left="585" width="3" height="19" font="0"> </text>
<text top="626" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="644" left="585" width="251" height="20" font="0">•  Mean age at Dx of RBBB=60 y (38–77) </text>
<text top="663" left="585" width="205" height="20" font="0">•  Prevalence increased with age </text>
<text top="683" left="585" width="252" height="20" font="0">•  At all ages &lt;70 y, RBBB more common </text>
<text top="701" left="601" width="126" height="19" font="0">in men than women </text>
<text top="720" left="585" width="248" height="20" font="0">•  70% of cases of RBBB associated with </text>
<text top="739" left="601" width="238" height="19" font="0">antecedent CVD, most commonly HTN </text>
<text top="757" left="601" width="38" height="19" font="0">(60%) </text>
<text top="497" left="854" width="66" height="19" font="8"><b> Strengths </b></text>
<text top="515" left="854" width="228" height="20" font="0">•  Large population-based study with </text>
<text top="534" left="867" width="222" height="19" font="0">lengthy follow-up and rigorous data </text>
<text top="553" left="867" width="63" height="19" font="0">collection </text>
<text top="571" left="854" width="3" height="19" font="0"> </text>
<text top="589" left="854" width="84" height="19" font="8"><b> Limitations:  </b></text>
<text top="608" left="854" width="222" height="20" font="0">•  Small number of incident cases of </text>
<text top="627" left="868" width="222" height="19" font="0">RBBB with wide confidence margins </text>
<text top="645" left="868" width="175" height="19" font="0">of estimated rates of events </text>
<text top="663" left="868" width="224" height="19" font="0">rendering several trends statistically </text>
<text top="682" left="868" width="77" height="19" font="0">insignificant </text>
<text top="700" left="854" width="191" height="20" font="0">•  No echocardiogram or other </text>
<text top="719" left="868" width="194" height="19" font="0">assessment for structural heart </text>
<text top="737" left="868" width="166" height="19" font="0">disease with incident LBBB </text>
<text top="756" left="854" width="7" height="19" font="0">  </text>
<text top="774" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 25 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="215" height="20" font="0">•  Only the prevalence of HTN and </text>
<text top="106" left="601" width="225" height="19" font="0">valvular heart disease antecedent to </text>
<text top="124" left="601" width="205" height="19" font="0">the Dx of RBBB were significantly </text>
<text top="143" left="601" width="240" height="19" font="0">greater than controls (roughly twice as </text>
<text top="161" left="601" width="115" height="19" font="0">common for both) </text>
<text top="179" left="585" width="250" height="20" font="0">•  15/53 (28%) of those w/o evidence of </text>
<text top="198" left="601" width="230" height="19" font="0">CHD at the time RBBB was diagnosed </text>
<text top="217" left="601" width="212" height="19" font="0">developed CHD subsequent to the </text>
<text top="235" left="601" width="197" height="19" font="0">development of RBBB, (OR: 2.5; </text>
<text top="253" left="601" width="57" height="19" font="0">p&lt;0.001) </text>
<text top="272" left="585" width="243" height="20" font="0">•  7/64 (11%) of those w/o evidence of </text>
<text top="291" left="601" width="227" height="19" font="0">CHF at the time RBBB was diagnosed </text>
<text top="309" left="601" width="210" height="19" font="0">developed CHF subsequent to the </text>
<text top="327" left="601" width="235" height="19" font="0">development of RBBB, (OR~4; p=0.02) </text>
<text top="346" left="585" width="226" height="20" font="0">•  Multivariate analysis suggests the </text>
<text top="365" left="601" width="196" height="19" font="0">relationship between RBBB and </text>
<text top="383" left="601" width="211" height="19" font="0">subsequent CHD and CHF remains </text>
<text top="401" left="601" width="219" height="19" font="0">valid for women but not men when </text>
<text top="420" left="601" width="208" height="19" font="0">age, SBP, and DM are considered. </text>
<text top="438" left="585" width="208" height="20" font="0">•  20 individuals (15 men) had no </text>
<text top="457" left="601" width="237" height="19" font="0">evidence of CVD at the time RBBB was </text>
<text top="475" left="601" width="214" height="19" font="0">noted. Of these, CHD developed in </text>
<text top="494" left="602" width="233" height="19" font="0">25% (2/5 women and 2/15 men), CHF </text>
<text top="512" left="602" width="225" height="19" font="0">developed in 5%, and 75% remained </text>
<text top="530" left="602" width="122" height="19" font="0">free of clinical CVD. </text>
<text top="549" left="585" width="200" height="20" font="0">•  In these 20 individuals free of </text>
<text top="568" left="602" width="235" height="19" font="0">apparent CVD at the time RBBB is first </text>
<text top="586" left="602" width="194" height="19" font="0">diagnosed, subsequent 10-y CV </text>
<text top="604" left="602" width="198" height="19" font="0">mortality=9% vs. 40% for the 50 </text>
<text top="623" left="602" width="178" height="19" font="0">individuals with at least 1 CV </text>
<text top="641" left="602" width="222" height="19" font="0">abnormality prior to the Dx of RBBB </text>
<text top="659" left="602" width="106" height="19" font="0">(p=not reported) </text>
<text top="678" left="585" width="192" height="20" font="0">•  Total prevalence of most CV </text>
<text top="697" left="601" width="226" height="19" font="0">abnormalities at any time during the </text>
<text top="715" left="601" width="203" height="19" font="0">study was higher in RBBB than in </text>
<text top="733" left="601" width="229" height="19" font="0">controls: CHF=19% vs. 4 % (p&lt;0.001), </text>
<text top="752" left="601" width="213" height="19" font="0">Cardiac Enlargement=31% vs. 14% </text>
<text top="770" left="601" width="229" height="19" font="0">(p&lt;0.01), CHD=46% vs. 24% (p&lt;0.01), </text>
<text top="87" left="854" width="183" height="20" font="0">•  Incident RBBB is commonly </text>
<text top="106" left="868" width="221" height="19" font="0">associated with CV abnormalities at </text>
<text top="124" left="868" width="94" height="19" font="0">the time of Dx. </text>
<text top="143" left="854" width="235" height="20" font="0">•  Incident RBBB associated with a 2.5-</text>
<text top="162" left="868" width="205" height="19" font="0">fold increased risk of subsequent </text>
<text top="180" left="868" width="230" height="19" font="0">CHD and 4-fold increased risk of CHF. </text>
<text top="199" left="854" width="236" height="20" font="0">•  Incident RBBB is associated with a 3-</text>
<text top="217" left="868" width="219" height="19" font="0">fold increased 10-y risk of CV death </text>
<text top="236" left="868" width="187" height="19" font="0">compared to those w/o RBBB, </text>
<text top="254" left="868" width="177" height="19" font="0">however, most of that risk is </text>
<text top="272" left="868" width="181" height="19" font="0">attributable to underlying CV </text>
<text top="291" left="868" width="52" height="19" font="0">disease. </text>
<text top="309" left="854" width="231" height="20" font="0">•  Those with QRSD &gt;130 ms and LAD </text>
<text top="328" left="868" width="182" height="19" font="0">(frontal plane axis: -45°–-90°) </text>
<text top="346" left="867" width="201" height="19" font="0">identified those with RBBB Most </text>
<text top="365" left="867" width="172" height="19" font="0">likely to have underlying CV </text>
<text top="383" left="867" width="87" height="19" font="0">abnormalities </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 26 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="601" width="200" height="19" font="0">valvular heart disease=6% vs.1% </text>
<text top="105" left="601" width="54" height="19" font="0">(p&lt;0.05) </text>
<text top="124" left="585" width="255" height="20" font="0">•  No statistically significant difference in </text>
<text top="143" left="601" width="197" height="19" font="0">total prevalence of HTN, DM, or </text>
<text top="161" left="601" width="198" height="19" font="0">absence of all CV abnormalities. </text>
<text top="179" left="585" width="243" height="20" font="0">•  Those with RBBB had “about 3 times </text>
<text top="198" left="601" width="228" height="19" font="0">greater” 10 y CV mortality compared </text>
<text top="217" left="601" width="208" height="19" font="0">to those w/o conduction disorder </text>
<text top="235" left="601" width="211" height="19" font="0">(p&lt;0.001). 34% in men and 23% in </text>
<text top="253" left="602" width="227" height="19" font="0">women vs. 11% in controls (p=NS for </text>
<text top="272" left="602" width="224" height="19" font="0">men vs women with incident RBBB). </text>
<text top="290" left="585" width="195" height="20" font="0">•  10 y rate of SCD: RBBB=11%, </text>
<text top="309" left="602" width="137" height="19" font="0">controls=3% (p=0.05). </text>
<text top="328" left="585" width="251" height="20" font="0">•  RBBB was a univariate predictor of CV </text>
<text top="346" left="602" width="203" height="19" font="0">mortality but not by multivariate </text>
<text top="365" left="602" width="225" height="19" font="0">analysis incorporating age, SBP, DM, </text>
<text top="383" left="602" width="65" height="19" font="0">CHD, CHF. </text>
<text top="401" left="595" width="230" height="19" font="0">In the 50 individuals with evidence of </text>
<text top="420" left="595" width="240" height="19" font="0">CV abnormalities prior to or coincident </text>
<text top="438" left="595" width="178" height="19" font="0">with the Dx of RBBB, 10 y CV </text>
<text top="456" left="595" width="192" height="19" font="0">mortality=40% vs. 9% in the 20 </text>
<text top="475" left="595" width="231" height="19" font="0">individuals free of such abnormalities </text>
<text top="493" left="595" width="222" height="19" font="0">prior to or coincident with the Dx of </text>
<text top="511" left="595" width="142" height="19" font="0">RBBB (p=not reported)<b> </b></text>
<text top="530" left="93" width="82" height="19" font="8"><b>Framingham </b></text>
<text top="549" left="93" width="116" height="19" font="0">Schneider JF, et al. </text>
<text top="567" left="93" width="62" height="19" font="0">1981 (29)<b> </b></text>
<text top="585" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6452050">6452050</a></text>
<text top="585" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6452050"> </a></text>
<text top="604" left="96" width="3" height="19" font="0"> </text>
<text top="622" left="96" width="3" height="19" font="0"> </text>
<text top="530" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="549" left="251" width="75" height="19" font="0">Prospective </text>
<text top="567" left="251" width="87" height="19" font="0">observational </text>
<text top="585" left="251" width="114" height="19" font="0">community-based </text>
<text top="604" left="251" width="37" height="19" font="0">study </text>
<text top="622" left="251" width="3" height="19" font="0"> </text>
<text top="640" left="251" width="120" height="19" font="8"><b>Size:</b> N=55 cases of </text>
<text top="658" left="251" width="126" height="19" font="0">new LBBB and N=70 </text>
<text top="677" left="251" width="121" height="19" font="0">cases of new RBBB. </text>
<text top="695" left="251" width="130" height="19" font="0">N=5,209 total cohort </text>
<text top="713" left="251" width="138" height="19" font="0">followed biennially up </text>
<text top="732" left="251" width="45" height="19" font="0">to 18 y<b> </b></text>
<text top="530" left="409" width="143" height="19" font="8"><b>Inclusion criteria:</b> New </text>
<text top="549" left="409" width="87" height="19" font="0">LBBB or RBBB </text>
<text top="567" left="409" width="3" height="19" font="0"> </text>
<text top="585" left="409" width="156" height="19" font="8"><b>Exclusion criteria:</b> Extant </text>
<text top="604" left="409" width="155" height="19" font="0">L (N=17) or R (N=16) BBB </text>
<text top="622" left="409" width="71" height="19" font="0">at first visit </text>
<text top="640" left="409" width="3" height="19" font="8"><b> </b></text>
<text top="531" left="585" width="251" height="19" font="8"><b>1</b>°<b> endpoint:</b> Compare the prevalence of </text>
<text top="549" left="585" width="245" height="19" font="0">antecedent, coincident and subsequent </text>
<text top="568" left="585" width="248" height="19" font="0">CV disease and risk factors in those with </text>
<text top="586" left="585" width="234" height="19" font="0">incident LBBB vs. incident RBBB (HTN, </text>
<text top="604" left="585" width="227" height="19" font="0">CHF, CHD, DM, cardiac enlargement) </text>
<text top="623" left="585" width="3" height="19" font="0"> </text>
<text top="641" left="585" width="3" height="19" font="0"> </text>
<text top="659" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="678" left="585" width="235" height="20" font="0">•  No difference in prevalence of HTN, </text>
<text top="697" left="598" width="176" height="19" font="0">CAD or DM in LBBB vs. RBBB </text>
<text top="715" left="585" width="237" height="20" font="0">•  Trend toward higher CV mortality in </text>
<text top="734" left="598" width="216" height="19" font="0">LBBB vs. RBBB that was stronger in </text>
<text top="752" left="598" width="166" height="19" font="0">men than women (p&gt;0.05) </text>
<text top="530" left="854" width="67" height="19" font="8"><b>Strengths: </b></text>
<text top="549" left="854" width="227" height="20" font="0">• Large population-based study with </text>
<text top="568" left="866" width="222" height="19" font="0">lengthy follow-up and rigorous data </text>
<text top="586" left="866" width="63" height="19" font="0">collection </text>
<text top="604" left="854" width="3" height="19" font="0"> </text>
<text top="623" left="854" width="80" height="19" font="8"><b>Limitations:  </b></text>
<text top="641" left="854" width="221" height="20" font="0">• Small number of incident cases of </text>
<text top="660" left="866" width="231" height="19" font="0">LBBB and RBBB with wide confidence </text>
<text top="678" left="866" width="227" height="19" font="0">margins of estimated rates of events </text>
<text top="697" left="866" width="195" height="19" font="0">rendering several strong trends </text>
<text top="715" left="866" width="148" height="19" font="0">statistically insignificant </text>
<text top="734" left="854" width="189" height="20" font="0">• No echocardiogram or other </text>
<text top="752" left="866" width="194" height="19" font="0">assessment for structural heart </text>
<text top="771" left="866" width="166" height="19" font="0">disease with incident LBBB </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 27 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="239" height="20" font="0">•  Overall those with LBBB had a 4-fold </text>
<text top="106" left="598" width="224" height="19" font="0">increased 10-y CV mortality after Dx </text>
<text top="124" left="598" width="207" height="19" font="0">and those with RBBB had a 3-fold </text>
<text top="143" left="598" width="236" height="19" font="0">increased 10 y CV mortality compared </text>
<text top="161" left="598" width="208" height="19" font="0">to those w/o conduction disorder </text>
<text top="179" left="598" width="115" height="19" font="0">(p&lt;0.001 for both) </text>
<text top="198" left="585" width="242" height="20" font="0">•  Men with incident LBBB had a higher </text>
<text top="217" left="598" width="225" height="19" font="0">cumulative prevalence of “advanced </text>
<text top="235" left="598" width="231" height="19" font="0">CV abnormalities” before or after the </text>
<text top="253" left="598" width="227" height="19" font="0">development of LBBB than men who </text>
<text top="272" left="598" width="88" height="19" font="0">develop RBBB </text>
<text top="290" left="585" width="253" height="20" font="0">•  Women with incident LBBB had similar </text>
<text top="309" left="598" width="175" height="19" font="0">prevalence of “advanced CV </text>
<text top="327" left="598" width="211" height="19" font="0">abnormalities” before or after the </text>
<text top="346" left="598" width="215" height="19" font="0">development of LBBB than women </text>
<text top="364" left="598" width="118" height="19" font="0">who develop RBBB </text>
<text top="382" left="585" width="247" height="20" font="0">•  In both men and women and for both </text>
<text top="401" left="598" width="225" height="19" font="0">RBBB and LBBB, the development of </text>
<text top="420" left="598" width="206" height="19" font="0">BBB was a univariate predictor of </text>
<text top="438" left="598" width="127" height="19" font="0">incident CHD or CHF </text>
<text top="457" left="585" width="243" height="20" font="0">•  Multivariate analysis: LBBB and RBBB </text>
<text top="475" left="598" width="230" height="19" font="0">remained predictive for incident CHD </text>
<text top="494" left="598" width="197" height="19" font="0">and CHF in women but not men </text>
<text top="512" left="598" width="196" height="19" font="0">(p&lt;0.05 for LBBB in women and </text>
<text top="530" left="598" width="179" height="19" font="0">P&lt;0.001 for RBBB in women) </text>
<text top="549" left="585" width="248" height="20" font="0">•  Only 11% of those with LBBB and only </text>
<text top="568" left="598" width="239" height="19" font="0">21% of those with RBBB remained free </text>
<text top="586" left="598" width="226" height="19" font="0">of all CV abnormalities during follow-</text>
<text top="604" left="598" width="19" height="19" font="0">up </text>
<text top="623" left="585" width="254" height="20" font="0">•  Multivariate analysis: LBBB in men was </text>
<text top="642" left="598" width="222" height="19" font="0">independently predictive of 10-y CV </text>
<text top="660" left="598" width="226" height="19" font="0">mortality (p&lt;0.01). RBBB in men and </text>
<text top="679" left="598" width="227" height="19" font="0">both LBBB and RBBB in women were </text>
<text top="697" left="598" width="213" height="19" font="0">not predictive of 10 y CV mortality </text>
<text top="715" left="598" width="242" height="19" font="0">independent of age, SBP, DM, CHD and </text>
<text top="733" left="598" width="28" height="19" font="0">CHF </text>
<text top="752" left="585" width="247" height="20" font="0">•  Amongst the 33 individuals with LBBB </text>
<text top="771" left="598" width="220" height="19" font="0">or RBBB at first visit (excluded form </text>
<text top="87" left="854" width="7" height="19" font="0">  </text>
<text top="105" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="124" left="854" width="232" height="20" font="0">• Both LBBB and RBBB are associated </text>
<text top="143" left="866" width="222" height="19" font="0">with increased 10-y risk of CV death </text>
<text top="161" left="866" width="174" height="19" font="0">in a middle aged unselected </text>
<text top="179" left="866" width="194" height="19" font="0">population than those w/o BBB </text>
<text top="198" left="854" width="202" height="20" font="0">• Strong trend toward higher CV </text>
<text top="217" left="866" width="231" height="19" font="0">mortality in LBBB than RBBB that was </text>
<text top="235" left="866" width="181" height="19" font="0">stronger in men than women </text>
<text top="253" left="854" width="236" height="20" font="0">• The vast majority of individuals with </text>
<text top="272" left="866" width="196" height="19" font="0">incident LBBB or RBBB manifest </text>
<text top="291" left="866" width="222" height="19" font="0">some form of CV abnormality (most </text>
<text top="309" left="866" width="214" height="19" font="0">commonly HTN) during follow-up.  </text>
<text top="328" left="854" width="191" height="20" font="0">• Although LBBB and RBBB are </text>
<text top="346" left="866" width="229" height="19" font="0">univariate predictors of incident CHD </text>
<text top="365" left="866" width="211" height="19" font="0">and CHF in both men and women, </text>
<text top="383" left="866" width="208" height="19" font="0">controlling for age, SBP, DM, CHD </text>
<text top="401" left="866" width="201" height="19" font="0">and CHF renders LBBB and RBBB </text>
<text top="420" left="866" width="225" height="19" font="0">independently predictive of incident </text>
<text top="438" left="866" width="226" height="19" font="0">CHD and CHF only in women but not </text>
<text top="456" left="866" width="45" height="19" font="0">in men </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 28 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="598" width="214" height="19" font="0">analysis above), there was a 2-fold </text>
<text top="105" left="598" width="239" height="19" font="0">higher prevalence of HTN (p&lt;0.05) and </text>
<text top="123" left="598" width="179" height="19" font="0">a 4-fold higher prevalence of </text>
<text top="142" left="598" width="209" height="19" font="0">radiographic cardiac enlargement </text>
<text top="160" left="598" width="163" height="19" font="0">(p&lt;0.01) in LBBB vs. RBBB. </text>
<text top="179" left="585" width="234" height="20" font="0">•   2-fold higher rate of CHD, CHF, and </text>
<text top="198" left="598" width="240" height="19" font="0">DM was also evident in those with BBB </text>
<text top="216" left="598" width="114" height="19" font="0">at baseline (p=NS)<b> </b></text>
<text top="234" left="585" width="219" height="20" font="0">•  Overall there was a trend toward </text>
<text top="253" left="598" width="186" height="19" font="0">increased prevalence of all CV </text>
<text top="272" left="598" width="213" height="19" font="0">abnormalities during follow-up for </text>
<text top="290" left="598" width="232" height="19" font="0">LBBB vs. RBBB (94% vs. 75%; p=NS) in </text>
<text top="308" left="598" width="206" height="19" font="0">those with BBB at baseline exam.<b> </b></text>
<text top="327" left="93" width="136" height="19" font="0">Eriksson P, et al. 1998 </text>
<text top="346" left="93" width="28" height="19" font="0">(30) </text>
<text top="364" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9832497">9832497</a></text>
<text top="364" left="146" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9832497"><b> </b></a></text>
<text top="327" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="346" left="251" width="79" height="19" font="0">Longitudinal </text>
<text top="364" left="251" width="75" height="19" font="0">prospective </text>
<text top="382" left="251" width="114" height="19" font="0">community-based </text>
<text top="401" left="251" width="37" height="19" font="0">study </text>
<text top="419" left="251" width="3" height="19" font="0"> </text>
<text top="437" left="251" width="75" height="19" font="8"><b>Size:</b> N=855<b> </b></text>
<text top="327" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="346" left="409" width="158" height="20" font="0">• Sample of men living in </text>
<text top="365" left="422" width="149" height="19" font="0">Göteborg, Sweden born </text>
<text top="383" left="422" width="147" height="19" font="0">on days divisible by 3 in </text>
<text top="401" left="422" width="149" height="19" font="0">1913 obtained from the </text>
<text top="420" left="422" width="146" height="19" font="0">county census bureau’s </text>
<text top="438" left="422" width="110" height="19" font="0">register of names </text>
<text top="456" left="422" width="45" height="19" font="0">(N973) </text>
<text top="475" left="409" width="146" height="20" font="0">• Agreed to participate </text>
<text top="494" left="422" width="52" height="19" font="0">(N=855) </text>
<text top="512" left="409" width="152" height="20" font="0">• Followed for 30 y with </text>
<text top="531" left="422" width="130" height="19" font="0">serial exams at 4–8 y </text>
<text top="549" left="422" width="121" height="19" font="0">intervals starting in </text>
<text top="568" left="422" width="141" height="19" font="0">1963 when all were 50 </text>
<text top="586" left="422" width="14" height="19" font="0">y. </text>
<text top="604" left="409" width="3" height="19" font="8"><b> </b></text>
<text top="623" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="641" left="409" width="28" height="19" font="0">N/A<b> </b></text>
<text top="328" left="585" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the cumulative </text>
<text top="346" left="585" width="256" height="19" font="0">incidence of BBB and its relationship with </text>
<text top="365" left="585" width="235" height="19" font="0">CV disease, risk factors, and prognosis </text>
<text top="383" left="585" width="247" height="19" font="0">based on ECGs obtained at baseline and </text>
<text top="401" left="585" width="244" height="19" font="0">3 subsequent exams in 1980, 1988, and </text>
<text top="420" left="585" width="38" height="19" font="0">1993. </text>
<text top="438" left="585" width="3" height="19" font="0"> </text>
<text top="456" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="475" left="585" width="166" height="20" font="0">•  follow-up 98% complete </text>
<text top="494" left="585" width="244" height="20" font="0">•  Prevalence of BBB=82/855 (9.6%), 22 </text>
<text top="513" left="598" width="243" height="19" font="0">(2.6%) LBBB, 60 (7.0%) RBBB, 86% after </text>
<text top="531" left="598" width="58" height="19" font="0">age 50 y. </text>
<text top="550" left="585" width="244" height="20" font="0">•  26% of LBBB and 6% of RBBB showed </text>
<text top="569" left="598" width="231" height="19" font="0">LVH on ECGs prior to development of </text>
<text top="587" left="598" width="178" height="19" font="0">BBB (p&lt;0.01 for comparison) </text>
<text top="605" left="585" width="253" height="20" font="0">•  At age 80 y, cumulative incidence rate: </text>
<text top="624" left="598" width="152" height="19" font="0">LBBB=6.5% RBBB=12.9% </text>
<text top="643" left="585" width="244" height="20" font="0">•  Prevalence of LBBB in survivors: 0.4% </text>
<text top="662" left="598" width="152" height="19" font="0">at 50 y. and 5.7% at 80 y </text>
<text top="680" left="585" width="246" height="20" font="0">•  Prevalence of RBBB in survivors: 0.8% </text>
<text top="699" left="598" width="156" height="19" font="0">at 50 y and 11.3% at 80 y </text>
<text top="718" left="585" width="214" height="20" font="0">•  No difference in baseline CV risk </text>
<text top="736" left="598" width="225" height="19" font="0">factors between those with and w/o </text>
<text top="755" left="598" width="176" height="19" font="0">incident BBB, except greater </text>
<text top="327" left="854" width="67" height="19" font="8"><b>Strengths</b>: </text>
<text top="346" left="854" width="231" height="20" font="0">• Long-term prospective follow-up of </text>
<text top="365" left="866" width="225" height="19" font="0">moderately large and homogeneous </text>
<text top="383" left="866" width="70" height="19" font="0">population </text>
<text top="401" left="855" width="3" height="19" font="0"> </text>
<text top="419" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="438" left="854" width="198" height="20" font="0">• Too few LBBB cases rendering </text>
<text top="457" left="866" width="210" height="19" font="0">statistical significance elusive as it </text>
<text top="475" left="866" width="229" height="19" font="0">relates to underlying structural heart </text>
<text top="494" left="866" width="146" height="19" font="0">disease and outcomes.  </text>
<text top="512" left="854" width="243" height="20" font="0">• Small number of cases also precludes </text>
<text top="531" left="866" width="205" height="19" font="0">meaningful comparison between </text>
<text top="549" left="866" width="104" height="19" font="0">LBBB and RBBB.  </text>
<text top="568" left="854" width="212" height="20" font="0">• Combining RBBB and LBBB likely </text>
<text top="587" left="866" width="172" height="19" font="0">dilutes the potential impact </text>
<text top="605" left="866" width="153" height="19" font="0">compared to LBBB alone </text>
<text top="624" left="854" width="108" height="20" font="0">• Limited to men </text>
<text top="643" left="855" width="3" height="19" font="0"> </text>
<text top="661" left="854" width="75" height="19" font="8"><b>Conclusion: </b></text>
<text top="679" left="853" width="196" height="20" font="0">•  Prevalence of LBBB and RBBB </text>
<text top="698" left="866" width="116" height="19" font="0">increases with age </text>
<text top="717" left="853" width="223" height="20" font="0">•  RBBB is twice as common as LBBB </text>
<text top="736" left="853" width="229" height="20" font="0">•  Those who develop LBBB are more </text>
<text top="755" left="866" width="229" height="19" font="0">likely to have LVH on ECGs preceding </text>
<text top="773" left="866" width="227" height="19" font="0">the development of LBBB than those </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 29 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="598" width="217" height="19" font="0">radiographic heart volume in those </text>
<text top="105" left="598" width="211" height="19" font="0">with BBB (794 vs. 746 ml; p&lt;0.05)  </text>
<text top="124" left="585" width="211" height="20" font="0">•  Those with incident BBB: higher </text>
<text top="143" left="598" width="234" height="19" font="0">prevalence of CHF in follow-up (36 vs. </text>
<text top="161" left="598" width="219" height="19" font="0">14%; p&lt;0.01 vs. no BBB) and higher </text>
<text top="179" left="598" width="233" height="19" font="0">prevalence of DM (36 vs. 17%; p&lt;0.05 </text>
<text top="198" left="598" width="71" height="19" font="0">vs. no BBB) </text>
<text top="216" left="585" width="251" height="20" font="0">•  No apparent difference between LBBB </text>
<text top="235" left="598" width="218" height="19" font="0">and RBBB in baseline risk factors or </text>
<text top="253" left="598" width="64" height="19" font="0">outcomes </text>
<text top="272" left="585" width="248" height="20" font="0">•  Trend toward increased mortality and </text>
<text top="291" left="598" width="232" height="19" font="0">CV mortality with BBB vs. no BBB, but </text>
<text top="309" left="598" width="39" height="19" font="0">p=NS. </text>
<text top="327" left="585" width="248" height="19" font="0">73/262 (28%) CV deaths associated with </text>
<text top="346" left="585" width="224" height="19" font="0">prior Dx of CHF in those w/o BBB vs. </text>
<text top="364" left="585" width="256" height="19" font="0">14/23 (61%) of CV deaths associated with </text>
<text top="382" left="585" width="206" height="19" font="0">prior Dx of CHF in those with BBB </text>
<text top="401" left="585" width="54" height="19" font="0">(p&lt;0.01)<b> </b></text>
<text top="87" left="866" width="192" height="19" font="0">who develop RBBB (a potential </text>
<text top="105" left="866" width="217" height="19" font="0">indicator that underlying structural </text>
<text top="123" left="866" width="199" height="19" font="0">heart disease is more likely with </text>
<text top="142" left="866" width="95" height="19" font="0">LBBB vs. RBBB) </text>
<text top="160" left="853" width="244" height="20" font="0">•  Those who develop BBB have greater </text>
<text top="179" left="866" width="191" height="19" font="0">radiographic cardiac volume at </text>
<text top="198" left="866" width="222" height="19" font="0">baseline compared to those who do </text>
<text top="216" left="866" width="181" height="19" font="0">not (again suggesting greater </text>
<text top="234" left="866" width="210" height="19" font="0">likelihood of underlying structural </text>
<text top="252" left="866" width="219" height="19" font="0">heart disease in those who develop </text>
<text top="271" left="866" width="32" height="19" font="0">BBB) </text>
<text top="289" left="853" width="222" height="20" font="0">•  Those with BBB are more likely to </text>
<text top="308" left="866" width="226" height="19" font="0">develop clinically evident CHF or DM </text>
<text top="327" left="853" width="240" height="20" font="0">•  BBB associated with a trend towards </text>
<text top="346" left="866" width="212" height="19" font="0">higher mortality that fails to reach </text>
<text top="364" left="866" width="139" height="19" font="0">statistical significance. </text>
<text top="420" left="96" width="121" height="19" font="0">Fahy GJ, et al. 1996 </text>
<text top="438" left="94" width="28" height="19" font="0">(31)<b> </b></text>
<text top="456" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8651093">8651093</a></text>
<text top="456" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8651093"> </a></text>
<text top="475" left="96" width="3" height="19" font="0"> </text>
<text top="493" left="96" width="3" height="19" font="0"> </text>
<text top="419" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="438" left="251" width="75" height="19" font="0">Prospective </text>
<text top="456" left="251" width="87" height="19" font="0">observational </text>
<text top="475" left="251" width="114" height="19" font="0">community-based </text>
<text top="493" left="251" width="37" height="19" font="0">study </text>
<text top="511" left="251" width="3" height="19" font="0"> </text>
<text top="529" left="251" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="548" left="251" width="84" height="20" font="0">•  N=110,000 </text>
<text top="567" left="264" width="109" height="19" font="0">participants in an </text>
<text top="585" left="264" width="120" height="19" font="0">Irish CV prevention </text>
<text top="604" left="264" width="130" height="19" font="0">screening study over </text>
<text top="622" left="264" width="33" height="19" font="0">25 y. </text>
<text top="640" left="251" width="139" height="20" font="0">•  N=310 with BBB but </text>
<text top="659" left="264" width="122" height="19" font="0">w/o suspected CVD </text>
<text top="677" left="251" width="3" height="19" font="8"><b> </b></text>
<text top="419" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="438" left="409" width="146" height="20" font="0">• BBB at baseline exam </text>
<text top="457" left="421" width="97" height="19" font="0">(N=480, 0.44%) </text>
<text top="476" left="409" width="145" height="20" font="0">• Age and sex matched </text>
<text top="494" left="421" width="109" height="19" font="0">controls w/o BBB </text>
<text top="513" left="409" width="3" height="19" font="0"> </text>
<text top="531" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="550" left="409" width="148" height="20" font="0">• HTN at baseline exam </text>
<text top="569" left="421" width="52" height="19" font="0">(N=109) </text>
<text top="587" left="409" width="137" height="20" font="0">• H/o CVD at baseline </text>
<text top="606" left="421" width="81" height="19" font="0">exam (N=84)<b> </b></text>
<text top="624" left="409" width="152" height="20" font="0">• Both HTN and CVD=23<b> </b></text>
<text top="420" left="585" width="244" height="19" font="8"><b>1</b>°<b> endpoint:</b> Determine the prevalence </text>
<text top="439" left="595" width="213" height="19" font="0">of isolated BBB and the associated </text>
<text top="457" left="595" width="241" height="19" font="0">long-term prognosis over a 25-y period </text>
<text top="475" left="585" width="3" height="19" font="0"> </text>
<text top="494" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="512" left="585" width="227" height="20" font="0">•  Prevalence of isolated BBB=0.28% </text>
<text top="531" left="585" width="243" height="20" font="0">•  RBBB: N=198 (0.18%) more common </text>
<text top="550" left="601" width="216" height="19" font="0">than LBBB: N=112 (0.1%); p&lt;0.001. </text>
<text top="569" left="585" width="249" height="20" font="0">•  Those with LBBB (51±13 y) older than </text>
<text top="588" left="601" width="157" height="19" font="0">RBBB (44±13 y); p=0.001. </text>
<text top="606" left="585" width="256" height="20" font="0">•  RBBB but not LBBB was more common </text>
<text top="625" left="601" width="188" height="19" font="0">in men than women (p&lt;0.001) </text>
<text top="644" left="585" width="250" height="20" font="0">•  Mean follow-up=9.5 y. median follow-</text>
<text top="662" left="601" width="67" height="19" font="0">up=87.5 y. </text>
<text top="681" left="585" width="112" height="20" font="0">•  49 total deaths </text>
<text top="700" left="585" width="206" height="20" font="0">•  No difference in mortality rate </text>
<text top="719" left="602" width="236" height="19" font="0">between BBB vs. no BBB and between </text>
<text top="737" left="602" width="97" height="19" font="0">RBBB and LBBB </text>
<text top="419" left="854" width="67" height="19" font="8"><b>Strengths: </b></text>
<text top="438" left="854" width="231" height="20" font="0">• Long-term prospective follow-up of </text>
<text top="457" left="866" width="183" height="19" font="0">large middle-aged population </text>
<text top="475" left="866" width="200" height="19" font="0">including men and at least some </text>
<text top="494" left="866" width="187" height="19" font="0">women (&lt;25% in this analysis) </text>
<text top="512" left="854" width="234" height="20" font="0">• Larger number of cases of LBBB and </text>
<text top="531" left="866" width="201" height="19" font="0">RBBB compared to other studies </text>
<text top="550" left="854" width="217" height="20" font="0">• Protracted prospective follow-up </text>
<text top="569" left="862" width="3" height="19" font="0"> </text>
<text top="587" left="854" width="80" height="19" font="8"><b>Limitations:  </b></text>
<text top="605" left="854" width="235" height="20" font="0">• Lack of physical exam, CXR, echo, or </text>
<text top="624" left="866" width="161" height="19" font="0">CAD screening at baseline </text>
<text top="643" left="855" width="3" height="19" font="0"> </text>
<text top="661" left="854" width="75" height="19" font="8"><b>Conclusion: </b></text>
<text top="679" left="854" width="223" height="20" font="0">• RBBB and LBBB rare in middle age </text>
<text top="698" left="866" width="76" height="19" font="0">(~0.1–0.2%) </text>
<text top="717" left="854" width="207" height="20" font="0">• RBBB more common than LBBB </text>
<text top="736" left="854" width="233" height="20" font="0">• RBBB (but not LBBB) more common </text>
<text top="755" left="866" width="130" height="19" font="0">in men than women. </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 30 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="242" height="20" font="0">•  Actuarial freedom from CV death up </text>
<text top="106" left="601" width="207" height="19" font="0">to 15 y worse in LBBB vs. controls </text>
<text top="124" left="601" width="54" height="19" font="0">(p=0.01) </text>
<text top="143" left="585" width="242" height="20" font="0">•  Actuarial freedom from CV death up </text>
<text top="162" left="601" width="190" height="19" font="0">to 15 y worse in LBBB vs. RBBB </text>
<text top="180" left="601" width="66" height="19" font="0">(p=0.001). </text>
<text top="199" left="585" width="232" height="20" font="0">•  When age included in Cox multiple </text>
<text top="217" left="601" width="219" height="19" font="0">regression model, differences in CV </text>
<text top="236" left="601" width="221" height="19" font="0">mortality were no longer significant </text>
<text top="254" left="601" width="54" height="19" font="0">(p=0.08) </text>
<text top="273" left="585" width="242" height="20" font="0">•  Overt CV disease developed in more </text>
<text top="292" left="601" width="218" height="19" font="0">individuals with LBBB than controls </text>
<text top="310" left="601" width="214" height="19" font="0">(21% vs. 11%; p=0.04). Not so with </text>
<text top="328" left="601" width="36" height="19" font="0">RBBB </text>
<text top="347" left="585" width="176" height="20" font="0">•  No increased rate of PPM </text>
<text top="366" left="601" width="82" height="19" font="0">implantation<b> </b></text>
<text top="87" left="854" width="243" height="20" font="0">• Overt CV disease develops in ~20% in </text>
<text top="106" left="866" width="207" height="19" font="0">those with LBBB during follow-up </text>
<text top="124" left="866" width="186" height="19" font="0">(nearly twice as often) than in </text>
<text top="143" left="866" width="214" height="19" font="0">controls w/o conduction disorder.  </text>
<text top="161" left="854" width="181" height="20" font="0">• CV death (but not all-cause </text>
<text top="180" left="866" width="172" height="19" font="0">mortality) more common in </text>
<text top="198" left="866" width="192" height="19" font="0">combined left and right bundle </text>
<text top="217" left="866" width="193" height="19" font="0">branch block than in those w/o </text>
<text top="235" left="866" width="126" height="19" font="0">conduction disorder </text>
<text top="253" left="854" width="181" height="20" font="0">• CV death (but not all-cause </text>
<text top="272" left="866" width="210" height="19" font="0">mortality) more common in those </text>
<text top="291" left="866" width="120" height="19" font="0">with LBBB vs. RBBB<b> </b></text>
<text top="309" left="854" width="187" height="20" font="0">• In multivariate analyses, the </text>
<text top="328" left="866" width="213" height="19" font="0">differences in CV death associated </text>
<text top="346" left="866" width="221" height="19" font="0">with BBB and amongst types of BBB </text>
<text top="365" left="866" width="226" height="19" font="0">are no longer significant when age is </text>
<text top="383" left="866" width="78" height="19" font="0">considered. <b> </b></text>
<text top="402" left="100" width="138" height="19" font="0">Imanishi R, et al. 2006 </text>
<text top="420" left="100" width="28" height="19" font="0">(32)<b> </b></text>
<text top="439" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16923453">16923453</a></text>
<text top="439" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16923453"> </a></text>
<text top="457" left="96" width="3" height="19" font="0"> </text>
<text top="475" left="96" width="3" height="19" font="0"> </text>
<text top="402" left="251" width="107" height="19" font="8"><b>Study type:</b> Case-</text>
<text top="420" left="251" width="51" height="19" font="0">control  </text>
<text top="439" left="251" width="3" height="19" font="0"> </text>
<text top="457" left="251" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="475" left="251" width="140" height="19" font="0">N=17,361 (6,663 men) </text>
<text top="494" left="251" width="59" height="19" font="0">screened </text>
<text top="512" left="251" width="130" height="19" font="0">N=110 incident LBBB </text>
<text top="530" left="251" width="58" height="19" font="0">(41 men) </text>
<text top="549" left="251" width="109" height="19" font="0">N=456 (156 men) </text>
<text top="567" left="251" width="141" height="19" font="0">randomly selected age </text>
<text top="585" left="251" width="108" height="19" font="0">and sex-matched </text>
<text top="604" left="251" width="145" height="19" font="0">controls w/o LBBB, 3–5 </text>
<text top="622" left="251" width="130" height="19" font="0">controls per incident </text>
<text top="640" left="251" width="80" height="19" font="0">case of LBBB<b> </b></text>
<text top="402" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="420" left="409" width="159" height="19" font="0">Atomic bomb survivors in </text>
<text top="439" left="409" width="154" height="19" font="0">Hiroshima and Nagasaki, </text>
<text top="457" left="409" width="133" height="19" font="0">Japan, participants in </text>
<text top="475" left="409" width="137" height="19" font="0">biennial health exams </text>
<text top="494" left="409" width="150" height="19" font="0">(including CXR and ECG) </text>
<text top="512" left="409" width="105" height="19" font="0">from 1958–2002 </text>
<text top="530" left="409" width="3" height="19" font="0"> </text>
<text top="548" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="567" left="409" width="161" height="19" font="0">LBBB at initial exam (N=9) </text>
<text top="585" left="409" width="152" height="19" font="0">Controls with PPM or AF </text>
<text top="604" left="409" width="160" height="19" font="0">(no cases of LBBB had AF)<b> </b></text>
<text top="403" left="585" width="245" height="19" font="8"><b>1</b>°<b> endpoint:</b> Incidence and mortality of </text>
<text top="421" left="595" width="38" height="19" font="0">LBBB  </text>
<text top="440" left="585" width="3" height="19" font="0"> </text>
<text top="458" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="476" left="585" width="227" height="20" font="0">•  Mean age at LBBB=69.6 ± 10.0 y in </text>
<text top="495" left="598" width="195" height="19" font="0">men and 68.3±10.9 y in women </text>
<text top="514" left="585" width="165" height="20" font="0">•  LBBB increased with age </text>
<text top="533" left="585" width="229" height="20" font="0">•  Incident LBBB associated with HTN </text>
<text top="552" left="598" width="229" height="19" font="0">(54.6% of LBBB vs. 43.2% of controls; </text>
<text top="570" left="598" width="202" height="19" font="0">p=0.033), ischemic heart disease </text>
<text top="588" left="598" width="218" height="19" font="0">(22.7% vs. 5.7%; p&lt;0.001), and non-</text>
<text top="607" left="598" width="205" height="19" font="0">cardiac disease (43.6% vs. 33.3%; </text>
<text top="625" left="598" width="57" height="19" font="0">p=0.045) </text>
<text top="644" left="585" width="203" height="20" font="0">•  Incident LBBB associated with: </text>
<text top="663" left="585" width="223" height="20" font="0">•  Radiographic cardiothoracic ratio: </text>
<text top="682" left="598" width="237" height="19" font="0">(51.9±6.1 at Dx of LBBB vs. 50.3±5.5 in </text>
<text top="700" left="598" width="114" height="19" font="0">controls; p=0.010) </text>
<text top="718" left="585" width="235" height="20" font="0">•  ECG-derived LVH (60.9% of LBBB vs. </text>
<text top="737" left="598" width="171" height="19" font="0">22.3% of controls; p&lt;0.001) </text>
<text top="756" left="585" width="246" height="20" font="0">•  ST-T abnormalities (39.1% of LBBB vs. </text>
<text top="775" left="598" width="174" height="19" font="0">16.2% of controls; p&lt;0.001)  </text>
<text top="402" left="854" width="70" height="19" font="8"><b>Strengths</b>:  </text>
<text top="421" left="854" width="227" height="20" font="0">• Large population-based study with </text>
<text top="440" left="866" width="222" height="19" font="0">lengthy follow-up and rigorous data </text>
<text top="458" left="866" width="63" height="19" font="0">collection </text>
<text top="476" left="854" width="104" height="20" font="0">• 40-y follow-up </text>
<text top="495" left="854" width="3" height="19" font="0"> </text>
<text top="513" left="854" width="80" height="19" font="8"><b>Limitations</b>:  </text>
<text top="532" left="854" width="222" height="20" font="0">• Although larger than Framingham </text>
<text top="551" left="866" width="226" height="19" font="0">study, still a limited number of cases </text>
<text top="569" left="866" width="172" height="19" font="0">of incident LBBB to analyze  </text>
<text top="588" left="854" width="197" height="20" font="0">• Lack of echo or cath data may </text>
<text top="607" left="866" width="204" height="19" font="0">underestimate the prevalence of </text>
<text top="625" left="866" width="204" height="19" font="0">underlying CMP or valvular heart </text>
<text top="643" left="866" width="49" height="19" font="0">disease </text>
<text top="662" left="866" width="3" height="19" font="0"> </text>
<text top="680" left="854" width="82" height="19" font="0"> <b>Conclusion</b>:  </text>
<text top="698" left="854" width="204" height="20" font="0">• Incident LBBB is independently </text>
<text top="717" left="866" width="216" height="19" font="0">predictive of CHF-related mortality </text>
<text top="736" left="866" width="212" height="19" font="0">(RR &gt;3) but not all-cause mortality<b> </b></text>
<text top="754" left="854" width="210" height="20" font="0">• Incident LBBB is associated with </text>
<text top="773" left="866" width="226" height="19" font="0">antecedent or coincident markers of </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 31 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="227" height="20" font="0">•  antecedent to the development of </text>
<text top="106" left="598" width="38" height="19" font="0">LBBB  </text>
<text top="124" left="585" width="248" height="20" font="0">•  LBBB independently predictive of CHF </text>
<text top="143" left="598" width="190" height="19" font="0">mortality; RR: 3.08 (1.62–5.87; </text>
<text top="162" left="598" width="226" height="19" font="0">p&lt;0.001) but not all-cause mortality; </text>
<text top="180" left="598" width="184" height="19" font="0">RR: 1.22 (0.90–1.65; p=0.206)<b> </b></text>
<text top="87" left="866" width="195" height="19" font="0">structural heart disease such as </text>
<text top="105" left="866" width="210" height="19" font="0">increased radiographic CT ratio or </text>
<text top="123" left="866" width="203" height="19" font="0">electrocardiographic LVH or ST-T </text>
<text top="142" left="866" width="87" height="19" font="0">abnormalities<b> </b></text>
<text top="199" left="93" width="85" height="19" font="8"><b>Framingham  </b></text>
<text top="217" left="93" width="134" height="19" font="0">Dhingra R, et al. 2006 </text>
<text top="236" left="93" width="28" height="19" font="0">(33)<b> </b></text>
<text top="254" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16585411">16585411</a></text>
<text top="254" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16585411"> </a></text>
<text top="272" left="96" width="3" height="19" font="0"> </text>
<text top="199" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="217" left="251" width="78" height="19" font="0">Prospective, </text>
<text top="236" left="251" width="80" height="19" font="0">longitudinal, </text>
<text top="254" left="251" width="114" height="19" font="0">community-based </text>
<text top="272" left="251" width="40" height="19" font="0">study  </text>
<text top="291" left="251" width="3" height="19" font="0"> </text>
<text top="309" left="251" width="129" height="19" font="8"><b>Size:</b> N=1,759 (1,113 </text>
<text top="327" left="251" width="57" height="19" font="0">women) <b> </b></text>
<text top="199" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="217" left="409" width="121" height="19" font="0">Attendees of the 16</text>
<text top="217" left="530" width="8" height="12" font="7">th</text>
<text top="217" left="539" width="3" height="19" font="0"> </text>
<text top="236" left="409" width="113" height="19" font="0">(1979–1981) or 17</text>
<text top="236" left="522" width="8" height="12" font="7">th</text>
<text top="236" left="530" width="3" height="19" font="0"> </text>
<text top="254" left="409" width="133" height="19" font="0">(1982–1984) biennial </text>
<text top="272" left="409" width="156" height="19" font="0">exam of the Framingham </text>
<text top="291" left="409" width="106" height="19" font="0">Heart Study with </text>
<text top="309" left="409" width="145" height="19" font="0">available ECG and echo </text>
<text top="327" left="409" width="123" height="19" font="0">data (2-D guided M-</text>
<text top="346" left="409" width="43" height="19" font="0">mode) </text>
<text top="364" left="409" width="3" height="19" font="0"> </text>
<text top="382" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="401" left="409" width="154" height="19" font="0">Prevalent HF or previous </text>
<text top="419" left="409" width="72" height="19" font="0">MI (N=135) </text>
<text top="437" left="409" width="151" height="19" font="0">Anti-arrhythmic therapy </text>
<text top="455" left="409" width="101" height="19" font="0">or PPM (N=187)<b> </b></text>
<text top="200" left="585" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="218" left="585" width="239" height="19" font="0">Assess the relationship of QRSd to CHF </text>
<text top="237" left="585" width="250" height="19" font="0">incidence during mean follow-up of 12.7 </text>
<text top="255" left="585" width="123" height="19" font="0">y; range 0.4–22.3 y. </text>
<text top="273" left="585" width="3" height="19" font="0"> </text>
<text top="291" left="587" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="310" left="585" width="245" height="20" font="0">•  324 participants developed CHF (205 </text>
<text top="329" left="601" width="214" height="19" font="0">women); 231 (17.3%) of 1339 with </text>
<text top="347" left="601" width="228" height="19" font="0">QRS &lt;100 ms, 62 (20.2%) of 307 with </text>
<text top="366" left="601" width="223" height="19" font="0">incomplete BBB (QRS=100–119 ms), </text>
<text top="384" left="601" width="228" height="19" font="0">and 31 (27.4%) of 113 with complete </text>
<text top="402" left="601" width="124" height="19" font="0">BBB (QRS ≥120 ms). </text>
<text top="421" left="585" width="236" height="20" font="0">•  Survival free of CHF decreased with </text>
<text top="440" left="601" width="216" height="19" font="0">increasing QRSd category (log-rank </text>
<text top="458" left="601" width="57" height="19" font="0">p&lt;0.001) </text>
<text top="476" left="585" width="244" height="20" font="0">•  In multivariable time-dependent Cox </text>
<text top="495" left="601" width="219" height="19" font="0">models, BBB associated with a 1.74-</text>
<text top="514" left="601" width="239" height="19" font="0">fold risk of CHF (p&lt;0.001) compared to </text>
<text top="532" left="601" width="121" height="19" font="0">the referent group. </text>
<text top="550" left="585" width="255" height="20" font="0">•  In multivariable analyses LBBB had the </text>
<text top="569" left="601" width="196" height="19" font="0">highest incidence of CHF during </text>
<text top="588" left="601" width="206" height="19" font="0">follow-up compared to QRS &lt;100 </text>
<text top="606" left="601" width="39" height="19" font="0">msec. </text>
<text top="629" left="605" width="9" height="12" font="0">o</text>
<text top="628" left="614" width="4" height="14" font="0"> </text>
<text top="624" left="618" width="202" height="19" font="0">LBBB: adjusted HR: 4.45 (95% CI: </text>
<text top="643" left="618" width="133" height="19" font="0">2.33–8.51; p=0.0001) </text>
<text top="666" left="605" width="9" height="12" font="0">o</text>
<text top="665" left="614" width="4" height="14" font="0"> </text>
<text top="661" left="618" width="204" height="19" font="0">Indeterminate BBB: adjusted HR: </text>
<text top="679" left="618" width="201" height="19" font="0">2.18 (95% CI: 1.13–4.20; p=0.02)<b> </b></text>
<text top="703" left="605" width="9" height="12" font="0">o</text>
<text top="701" left="614" width="4" height="14" font="0"> </text>
<text top="698" left="618" width="204" height="19" font="0">RBBB: adjusted HR: 1.73 (95% CI: </text>
<text top="716" left="618" width="118" height="19" font="0">0.93–3.21; p=0.08)<b> </b></text>
<text top="199" left="854" width="70" height="19" font="8"><b>Strengths:  </b></text>
<text top="218" left="854" width="232" height="20" font="0">• Large community-based population </text>
<text top="237" left="854" width="237" height="20" font="0">• Long duration of follow-up (up to 22 </text>
<text top="256" left="866" width="15" height="19" font="0">y) </text>
<text top="274" left="854" width="190" height="20" font="0">• Prospective, systematic data </text>
<text top="293" left="866" width="70" height="19" font="0">acquisition </text>
<text top="311" left="854" width="188" height="20" font="0">• Both sexes well represented </text>
<text top="330" left="854" width="3" height="19" font="0"> </text>
<text top="349" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="367" left="854" width="231" height="20" font="0">• Limited statistical power to analyze </text>
<text top="386" left="866" width="175" height="19" font="0">relations of BBB type to CHF </text>
<text top="404" left="866" width="62" height="19" font="0">incidence </text>
<text top="423" left="854" width="178" height="20" font="0">• Single assessment of QRSd </text>
<text top="442" left="854" width="240" height="20" font="0">• Predominantly Caucasian population </text>
<text top="461" left="854" width="3" height="19" font="0"> </text>
<text top="479" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="498" left="854" width="197" height="20" font="0">• There is a positive association </text>
<text top="517" left="866" width="230" height="19" font="0">between ECG QRSd with CHF risk in a </text>
<text top="535" left="866" width="217" height="19" font="0">large community-based population </text>
<text top="553" left="866" width="178" height="19" font="0">free of CHF or MI at baseline </text>
<text top="572" left="854" width="228" height="20" font="0">• Association strongest for complete </text>
<text top="591" left="866" width="227" height="19" font="0">BBB who experienced a 2-fold risk of </text>
<text top="609" left="866" width="206" height="19" font="0">CHF compared to those with QRS </text>
<text top="627" left="866" width="73" height="19" font="0">&lt;100 msec. </text>
<text top="646" left="854" width="226" height="20" font="0">• Baseline incomplete and complete </text>
<text top="665" left="866" width="191" height="19" font="0">BBB accounted for only 30% of </text>
<text top="683" left="866" width="189" height="19" font="0">incident CHF during follow-up. </text>
<text top="702" left="854" width="197" height="20" font="0">• In an exploratory analysis of a </text>
<text top="721" left="866" width="219" height="19" font="0">subgroup (N=82, 25% of CHF cases) </text>
<text top="739" left="866" width="232" height="19" font="0">of pts undergoing echo within 30 d of </text>
<text top="757" left="866" width="210" height="19" font="0">CHF Dx, incomplete and complete </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 32 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="866" width="205" height="19" font="0">BBB both associated equally with </text>
<text top="105" left="866" width="111" height="19" font="0">HFrEF and HFpEF. </text>
<text top="124" left="93" width="139" height="19" font="0">Rotman M, et al. 1975 </text>
<text top="143" left="93" width="28" height="19" font="0">(34) </text>
<text top="161" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1132086">1132086</a></text>
<text top="161" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1132086"> </a></text>
<text top="124" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="143" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="161" left="251" width="130" height="19" font="0">observational cohort </text>
<text top="179" left="251" width="37" height="19" font="0">study </text>
<text top="197" left="251" width="3" height="19" font="0"> </text>
<text top="216" left="251" width="32" height="19" font="8"><b>Size: </b></text>
<text top="234" left="251" width="134" height="19" font="0">N=237,000 with ECGs </text>
<text top="252" left="251" width="145" height="19" font="0">in the United States Air </text>
<text top="271" left="251" width="85" height="19" font="0">Force Central </text>
<text top="289" left="251" width="129" height="19" font="0">Electrocardiographic </text>
<text top="307" left="251" width="121" height="19" font="0">Library, 1957–1972 </text>
<text top="326" left="251" width="79" height="19" font="0">N=394 RBBB </text>
<text top="344" left="251" width="78" height="19" font="0">N=125 LBBB </text>
<text top="362" left="251" width="3" height="19" font="0"> </text>
<text top="381" left="251" width="7" height="19" font="0"> <b> </b></text>
<text top="124" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="143" left="409" width="122" height="19" font="0">Routine initial ECGs </text>
<text top="161" left="409" width="88" height="19" font="0">obtained on a </text>
<text top="179" left="409" width="151" height="19" font="0">heterogeneous group of </text>
<text top="197" left="409" width="155" height="19" font="0">Airforce Academy cadets </text>
<text top="216" left="409" width="148" height="19" font="0">and applicants for flight </text>
<text top="234" left="409" width="147" height="19" font="0">training and serial ECGs </text>
<text top="252" left="409" width="156" height="19" font="0">on rated flying personnel </text>
<text top="271" left="409" width="143" height="19" font="0">taken throughout their </text>
<text top="289" left="409" width="104" height="19" font="0">Air Force career. </text>
<text top="307" left="409" width="3" height="19" font="0"> </text>
<text top="326" left="409" width="152" height="19" font="0">The population that was </text>
<text top="344" left="409" width="117" height="19" font="0">critically examined </text>
<text top="362" left="409" width="122" height="19" font="0">included only those </text>
<text top="381" left="409" width="135" height="19" font="0">subjects that had had </text>
<text top="399" left="409" width="96" height="19" font="0">either an initial </text>
<text top="417" left="409" width="158" height="19" font="0">clinical evaluation and/or </text>
<text top="436" left="409" width="118" height="19" font="0">available complete </text>
<text top="454" left="409" width="141" height="19" font="0">follow-up information. </text>
<text top="472" left="409" width="3" height="19" font="8"><b> </b></text>
<text top="490" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="509" left="409" width="28" height="19" font="0">N/A<b> </b></text>
<text top="125" left="585" width="240" height="19" font="8"><b>1</b>°<b> endpoint:</b> Review clinical status and </text>
<text top="143" left="585" width="255" height="19" font="0">mortality of those with BBB at the United </text>
<text top="162" left="585" width="226" height="19" font="0">States Air Force School of Aerospace </text>
<text top="180" left="585" width="241" height="19" font="0">Medicine. Compare and contrast those </text>
<text top="198" left="585" width="255" height="19" font="0">with RBBB with LBBB and explore various </text>
<text top="217" left="585" width="226" height="19" font="0">combinations of fascicular blocks for </text>
<text top="235" left="585" width="201" height="19" font="0">their impact on findings at initial </text>
<text top="253" left="585" width="213" height="19" font="0">evaluation and subsequent clinical </text>
<text top="272" left="585" width="48" height="19" font="0">course. </text>
<text top="290" left="585" width="3" height="19" font="0"> </text>
<text top="308" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="327" left="585" width="239" height="20" font="0">•  Mean age=36±9 (range 17–58) y for </text>
<text top="346" left="601" width="36" height="19" font="0">RBBB </text>
<text top="364" left="585" width="239" height="20" font="0">•  Mean age=40±7 (range 20–56) y for </text>
<text top="383" left="601" width="218" height="19" font="0">LBBB (higher % of RBBB were &lt;25 y </text>
<text top="401" left="601" width="211" height="19" font="0">and a higher % of LBBB was &gt;45 y; </text>
<text top="420" left="601" width="57" height="19" font="0">p&lt;0.001) </text>
<text top="438" left="585" width="227" height="20" font="0">•  251/394 (63.7%) RBBB present on </text>
<text top="457" left="601" width="231" height="19" font="0">initial ECG and 143/394 (36.3%) were </text>
<text top="475" left="601" width="161" height="19" font="0">noted on subsequent ECG </text>
<text top="494" left="585" width="255" height="20" font="0">•  44/125 (35.2%) LBBB present on initial </text>
<text top="513" left="601" width="225" height="19" font="0">ECG and 81/125 (64.8%) were noted </text>
<text top="531" left="601" width="122" height="19" font="0">on subsequent ECG </text>
<text top="550" left="585" width="195" height="20" font="0">•  372/394 RBBB had complete </text>
<text top="569" left="601" width="236" height="19" font="0">evaluation at time of initial Dx, 97% of </text>
<text top="587" left="601" width="231" height="19" font="0">these were asx, 94% had a normal CV </text>
<text top="605" left="601" width="187" height="19" font="0">evaluation, 10/372 (2.7%) had </text>
<text top="623" left="601" width="215" height="19" font="0">evidence of CAD, 9/372 (2.4%) had </text>
<text top="642" left="601" width="237" height="19" font="0">hypertension, 5/372 (1.3%) congenital </text>
<text top="660" left="601" width="85" height="19" font="0">heart disease </text>
<text top="679" left="585" width="193" height="20" font="0">•  121/125 LBBB had complete </text>
<text top="698" left="601" width="214" height="19" font="0">evaluation at the time of initial Dx, </text>
<text top="716" left="601" width="209" height="19" font="0">95% of these were asx, 89% had a </text>
<text top="734" left="601" width="228" height="19" font="0">normal CV evaluation, 11/121 (9.1%) </text>
<text top="752" left="601" width="229" height="19" font="0">had evidence of CAD (4 confirmed by </text>
<text top="771" left="601" width="230" height="19" font="0">cath), 8/121 (6.6%) had hypertension </text>
<text top="124" left="854" width="70" height="19" font="8"><b>Strengths:  </b></text>
<text top="143" left="854" width="239" height="20" font="0">• Large pool of routine screening ECGs </text>
<text top="162" left="866" width="182" height="19" font="0">in a young, generally healthy, </text>
<text top="180" left="866" width="186" height="19" font="0">predominantly asx population </text>
<text top="198" left="854" width="212" height="20" font="0">• Fairly long duration of follow-up </text>
<text top="217" left="854" width="3" height="19" font="0"> </text>
<text top="236" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="254" left="854" width="184" height="20" font="0">• Exclusively male population </text>
<text top="273" left="854" width="197" height="20" font="0">• Low prevalence of BBB and of </text>
<text top="292" left="866" width="216" height="19" font="0">underlying structural heart disease </text>
<text top="311" left="866" width="225" height="19" font="0">renders the study largely descriptive </text>
<text top="329" left="854" width="3" height="19" font="0"> </text>
<text top="347" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="366" left="854" width="227" height="20" font="0">• The majority of young airmen with </text>
<text top="385" left="866" width="210" height="19" font="0">right and left bundle branch block </text>
<text top="403" left="866" width="185" height="19" font="0">are asx and free of underlying </text>
<text top="421" left="866" width="183" height="19" font="0">structural heart disease/CAD. </text>
<text top="440" left="854" width="218" height="20" font="0">• Although underpowered to allow </text>
<text top="459" left="866" width="196" height="19" font="0">conclusions, LBBB may be more </text>
<text top="477" left="866" width="206" height="19" font="0">predictive of CV death than RBBB </text>
<text top="495" left="854" width="242" height="20" font="0">• The prognosis of BBB relates more to </text>
<text top="514" left="866" width="191" height="19" font="0">the underlying structural heart </text>
<text top="533" left="866" width="176" height="19" font="0">disease than the conduction </text>
<text top="551" left="866" width="114" height="19" font="0">abnormality itself. </text>
<text top="569" left="854" width="217" height="20" font="0">• “Significant progressive electrical </text>
<text top="588" left="866" width="219" height="19" font="0">dysfunction is a rare occurrence” in </text>
<text top="607" left="866" width="226" height="19" font="0">this population (1 PPM for advanced </text>
<text top="625" left="866" width="221" height="19" font="0">AVB in each group, and 1 additional </text>
<text top="643" left="866" width="213" height="19" font="0">PPM for unexplained syncope w/o </text>
<text top="662" left="866" width="213" height="19" font="0">advanced AVB in the RBBB group). </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 33 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="231" height="20" font="0">•  54 subjects with RBBB and 29 with </text>
<text top="106" left="601" width="179" height="19" font="0">LBBB had a complete cardiac </text>
<text top="124" left="601" width="96" height="19" font="0">catheterization </text>
<text top="143" left="585" width="240" height="20" font="0">•  LBBB had a significant higher rate of </text>
<text top="162" left="601" width="226" height="19" font="0">CAD (p&lt;0.01) and HTN (p&lt;0.05) than </text>
<text top="180" left="601" width="166" height="19" font="0">RBBB, independent of age. </text>
<text top="199" left="585" width="232" height="20" font="0">•  Mean follow-up: RBBB=10.8±4.7 y, </text>
<text top="217" left="601" width="97" height="19" font="0">LBBB=8.8±4.8 y </text>
<text top="236" left="585" width="246" height="20" font="0">•  During follow-up of those with RBBB, </text>
<text top="255" left="601" width="235" height="19" font="0">21 (6%) new cases of CAD and 21 new </text>
<text top="273" left="601" width="184" height="19" font="0">cases (6%) of HTN developed. </text>
<text top="292" left="585" width="256" height="20" font="0">•  During follow-up of those with LBBB, 6 </text>
<text top="311" left="601" width="236" height="19" font="0">(5%) new cases of CAD and 7(6%) new </text>
<text top="329" left="601" width="153" height="19" font="0">cases of HTN developed  </text>
<text top="347" left="585" width="238" height="20" font="0">•  14 (4%) of those with RBBB died, all </text>
<text top="366" left="601" width="187" height="19" font="0">but 3 from non-cardiac causes </text>
<text top="385" left="585" width="252" height="20" font="0">•  9 (8%) of those with LBBB died, all but </text>
<text top="404" left="601" width="186" height="19" font="0">2 from cardiac related causes. </text>
<text top="422" left="585" width="253" height="19" font="0">Combinations of fascicular blocks did not </text>
<text top="440" left="585" width="253" height="19" font="0">inform clinical status at the time of initial </text>
<text top="459" left="585" width="225" height="19" font="0">evaluation or subsequent prognosis.<b> </b></text>
<text top="478" left="96" width="121" height="19" font="0">Froelicher VF, et al. </text>
<text top="496" left="96" width="62" height="19" font="0">1977 (35) </text>
<text top="514" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=831426">831426</a></text>
<text top="514" left="142" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=831426"> </a></text>
<text top="478" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="496" left="251" width="130" height="19" font="0">Retrospective cross –</text>
<text top="514" left="251" width="95" height="19" font="0">sectional study </text>
<text top="533" left="251" width="3" height="19" font="0"> </text>
<text top="551" left="251" width="32" height="19" font="8"><b>Size: </b></text>
<text top="569" left="251" width="123" height="19" font="0">N=34 with asx LBBB </text>
<text top="588" left="251" width="125" height="19" font="0">N=41 with asx RBBB </text>
<text top="606" left="251" width="110" height="19" font="0">Derived from 325 </text>
<text top="624" left="251" width="122" height="19" font="0">airmen referred for </text>
<text top="643" left="251" width="143" height="19" font="0">cardiac catheterization<b> </b></text>
<text top="478" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="496" left="409" width="149" height="19" font="0">Airmen who underwent </text>
<text top="514" left="409" width="158" height="19" font="0">coronary angiography for </text>
<text top="533" left="409" width="115" height="19" font="0">clinical indications </text>
<text top="551" left="409" width="131" height="19" font="0">between 2/1971 and </text>
<text top="569" left="409" width="151" height="19" font="0">12/1974. All but 27 with </text>
<text top="588" left="409" width="158" height="19" font="0">possible angina were asx. </text>
<text top="606" left="409" width="3" height="19" font="0"> </text>
<text top="624" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="643" left="409" width="152" height="19" font="0">Declined catheterization </text>
<text top="661" left="409" width="108" height="19" font="0">(N=not provided)<b> </b></text>
<text top="478" left="585" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="497" left="585" width="222" height="19" font="0">Prevalence of significant CAD (&gt;50% </text>
<text top="515" left="585" width="238" height="19" font="0">stenosis) according to referral Dx (e.g., </text>
<text top="533" left="585" width="201" height="19" font="0">abnormal ETT, angina, BBB, etc.) </text>
<text top="552" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="570" left="585" width="129" height="20" font="0">•  Mean age=42±7 y </text>
<text top="589" left="585" width="117" height="20" font="0">•  Significant CAD: </text>
<text top="608" left="591" width="112" height="19" font="0"> LBBB=8/34 (24%) </text>
<text top="627" left="591" width="114" height="19" font="0"> RBBB=8/41 (20%) </text>
<text top="645" left="591" width="134" height="19" font="0"> All pts=98/325 (30%) </text>
<text top="663" left="585" width="209" height="20" font="0">•  5/34 (14.7%) with LBBB and no </text>
<text top="682" left="602" width="220" height="19" font="0">significant CAD had “generalized LV </text>
<text top="701" left="602" width="214" height="19" font="0">dyskinesia” and LVEDP &gt;12 mm Hg </text>
<text top="719" left="585" width="229" height="20" font="0">•  1/34 (2.9%) with LBBB and normal </text>
<text top="738" left="601" width="216" height="19" font="0">coronary arteries manifested overt </text>
<text top="756" left="601" width="226" height="19" font="0">HFrEF subsequent to catheterization </text>
<text top="775" left="601" width="228" height="19" font="0">and died suddenly 2 months after Dx </text>
<text top="478" left="854" width="70" height="19" font="8"><b>Strengths:  </b></text>
<text top="496" left="854" width="234" height="20" font="0">• Coronary angiography performed in </text>
<text top="515" left="866" width="207" height="19" font="0">asx pts with isolated LBBB and no </text>
<text top="533" left="866" width="185" height="19" font="0">other indication of CV disease </text>
<text top="552" left="866" width="219" height="19" font="0">(justified by public safety concerns) </text>
<text top="570" left="855" width="3" height="19" font="0"> </text>
<text top="588" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="607" left="854" width="75" height="20" font="0">• Small size </text>
<text top="626" left="854" width="216" height="20" font="0">• Potential selection bias (clinically </text>
<text top="645" left="866" width="194" height="19" font="0">referred for cardiac evaluation) </text>
<text top="663" left="854" width="163" height="20" font="0">• No systematic follow-up </text>
<text top="682" left="855" width="3" height="19" font="0"> </text>
<text top="701" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="719" left="854" width="190" height="19" font="0">ECG abnormalities are “poorer </text>
<text top="737" left="854" width="204" height="19" font="0">predictors of heart disease in asx </text>
<text top="756" left="854" width="195" height="19" font="0">apparently healthy men than in </text>
<text top="774" left="854" width="189" height="19" font="0">hospital or clinic populations.” </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 34 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="142" height="19" font="8"><b>Manitoba Heart Study </b></text>
<text top="105" left="96" width="140" height="19" font="0">Rabkin SW, et al. 1980 </text>
<text top="123" left="96" width="28" height="19" font="0">(36)<b> </b></text>
<text top="142" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6444828">6444828</a></text>
<text top="142" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6444828"> </a></text>
<text top="87" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="105" left="251" width="78" height="19" font="0">Prospective, </text>
<text top="123" left="251" width="130" height="19" font="0">observational cohort </text>
<text top="142" left="251" width="37" height="19" font="0">study </text>
<text top="160" left="251" width="3" height="19" font="0"> </text>
<text top="178" left="251" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="197" left="251" width="36" height="19" font="0">N=29 </text>
<text top="215" left="251" width="3" height="19" font="0"> </text>
<text top="233" left="251" width="121" height="19" font="0">Derived from 3,983 </text>
<text top="252" left="251" width="127" height="19" font="0">male pilots from the </text>
<text top="270" left="251" width="118" height="19" font="0">Royal Canadian Air </text>
<text top="288" left="251" width="125" height="19" font="0">Force or licensed by </text>
<text top="307" left="251" width="136" height="19" font="0">the Canadian Dept. of </text>
<text top="325" left="251" width="143" height="19" font="0">Transport participating </text>
<text top="343" left="251" width="104" height="19" font="0">in regular health </text>
<text top="362" left="251" width="138" height="19" font="0">exams (including ECG) </text>
<text top="380" left="251" width="106" height="19" font="0">every 3–5 y from </text>
<text top="398" left="251" width="72" height="19" font="0">1948–1977<b> </b></text>
<text top="87" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="105" left="409" width="137" height="19" font="0">Participants in regular </text>
<text top="123" left="408" width="138" height="19" font="0">annual medical exams </text>
<text top="142" left="408" width="153" height="19" font="0">with no clinical evidence </text>
<text top="160" left="408" width="150" height="19" font="0">of CHD or valvular heart </text>
<text top="178" left="408" width="155" height="19" font="0">disease antecedent to or </text>
<text top="197" left="408" width="121" height="19" font="0">coincident with the </text>
<text top="215" left="408" width="115" height="19" font="0">discovery of LBBB  </text>
<text top="233" left="409" width="3" height="19" font="8"><b> </b></text>
<text top="252" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="270" left="409" width="129" height="19" font="0">One participant with </text>
<text top="288" left="408" width="149" height="19" font="0">LBBB at entry exam was </text>
<text top="307" left="408" width="158" height="19" font="0">excluded from analysis of </text>
<text top="325" left="408" width="140" height="19" font="0">factors contributing to </text>
<text top="343" left="408" width="158" height="19" font="0">the development of LBBB </text>
<text top="362" left="408" width="146" height="19" font="0">but was included in the </text>
<text top="380" left="408" width="105" height="19" font="0">prognostic study<b> </b></text>
<text top="88" left="585" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Death, including sudden </text>
<text top="106" left="595" width="234" height="19" font="0">death during follow-up, association of </text>
<text top="124" left="595" width="228" height="19" font="0">ECG findings antecedent to the Dx of </text>
<text top="143" left="595" width="189" height="19" font="0">LBBB with the development of </text>
<text top="161" left="595" width="112" height="19" font="0">subsequent LBBB  </text>
<text top="179" left="585" width="3" height="19" font="0"> </text>
<text top="197" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="216" left="585" width="180" height="20" font="0">•  Mean age at entry=30.8 y. </text>
<text top="235" left="585" width="165" height="20" font="0">•  Average follow-up=29 y </text>
<text top="254" left="585" width="241" height="20" font="0">•  Only 1 case of LBBB present at entry </text>
<text top="273" left="585" width="238" height="20" font="0">•  13/28 (46.4%) who developed LBBB </text>
<text top="292" left="602" width="193" height="19" font="0">after the initial exam had some </text>
<text top="311" left="602" width="239" height="19" font="0">antecedent ECG abnormality (14% had </text>
<text top="329" left="602" width="232" height="19" font="0">LVH, 14% has ST-T abnormalities, and </text>
<text top="347" left="602" width="213" height="19" font="0">14% had some form of conduction </text>
<text top="366" left="602" width="230" height="19" font="0">abnormality such as PR prolongation, </text>
<text top="384" left="602" width="95" height="19" font="0">IVCD, LAD, etc) </text>
<text top="402" left="585" width="213" height="20" font="0">•  Only the prevalence of LVH was </text>
<text top="421" left="602" width="190" height="19" font="0">significantly different from the </text>
<text top="440" left="602" width="235" height="19" font="0">population free of incident LBBB (14% </text>
<text top="458" left="602" width="107" height="19" font="0">vs. 3.5%; p&lt;0.05) </text>
<text top="476" left="585" width="254" height="20" font="0">•  Risk of SCD: 6/29 (20.7%) was &gt;10 fold </text>
<text top="495" left="601" width="234" height="19" font="0">higher than in those w/o LBBB (1.6%); </text>
<text top="514" left="601" width="45" height="19" font="0">p&lt;0.01 </text>
<text top="87" left="854" width="67" height="19" font="8"><b>Strengths: </b></text>
<text top="105" left="854" width="200" height="20" font="0">• Long period of close follow-up </text>
<text top="124" left="854" width="3" height="19" font="0"> </text>
<text top="143" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="161" left="854" width="178" height="20" font="0">• Highly selected population </text>
<text top="180" left="854" width="114" height="20" font="0">• Exclusively male </text>
<text top="199" left="854" width="227" height="20" font="0">• Young at the start with predictably </text>
<text top="218" left="866" width="176" height="19" font="0">very low prevalence of LBBB </text>
<text top="237" left="854" width="194" height="20" font="0">• Low number of cases of LBBB </text>
<text top="256" left="855" width="3" height="19" font="0"> </text>
<text top="274" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="293" left="854" width="238" height="20" font="0">• Incident LBBB is associated with LVH </text>
<text top="311" left="866" width="86" height="19" font="0">on prior ECGs </text>
<text top="330" left="854" width="209" height="20" font="0">• LBBB in a relatively young, male </text>
<text top="349" left="866" width="218" height="19" font="0">population is associated with a &gt;10-</text>
<text top="367" left="866" width="206" height="19" font="0">fold risk of sudden cardiac death. </text>
<text top="533" left="96" width="108" height="19" font="8"><b>Women’s Health </b></text>
<text top="551" left="96" width="59" height="19" font="8"><b>Initiative </b></text>
<text top="569" left="96" width="135" height="19" font="0">Zhang ZM, et al. 2012 </text>
<text top="588" left="96" width="28" height="19" font="0">(37)<b> </b></text>
<text top="606" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22858187">22858187</a></text>
<text top="606" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22858187"> </a></text>
<text top="624" left="96" width="3" height="19" font="0"> </text>
<text top="643" left="96" width="3" height="19" font="0"> </text>
<text top="533" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="551" left="251" width="75" height="19" font="0">Prospective </text>
<text top="569" left="251" width="130" height="19" font="0">observational cohort </text>
<text top="588" left="251" width="37" height="19" font="0">study </text>
<text top="606" left="251" width="3" height="19" font="0"> </text>
<text top="624" left="251" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="643" left="251" width="135" height="19" font="0">N=66,450 (1,739 with </text>
<text top="661" left="251" width="140" height="19" font="0">BBB, of which 708 had </text>
<text top="679" left="251" width="139" height="19" font="0">clinical evidence of CV </text>
<text top="698" left="251" width="53" height="19" font="0">disease) </text>
<text top="716" left="251" width="129" height="19" font="0">Derived from 68,133 </text>
<text top="734" left="251" width="114" height="19" font="0">participants in the </text>
<text top="752" left="251" width="105" height="19" font="0">Women’s Health </text>
<text top="771" left="251" width="94" height="19" font="0">Initiative study<b> </b></text>
<text top="533" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="551" left="409" width="114" height="19" font="0">Participants in the </text>
<text top="569" left="409" width="162" height="19" font="0">Women’s Health Initiative </text>
<text top="588" left="409" width="143" height="19" font="0">with interpretable ECG </text>
<text top="606" left="409" width="3" height="19" font="0"> </text>
<text top="624" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="643" left="409" width="154" height="20" font="0">• No available electronic </text>
<text top="662" left="421" width="81" height="19" font="0">ECG (N=960) </text>
<text top="680" left="409" width="158" height="20" font="0">• Inadequate quality ECG </text>
<text top="699" left="421" width="52" height="19" font="0">(N=614)<b> </b></text>
<text top="718" left="409" width="151" height="20" font="0">• PPM or WPW (N=109)<b> </b></text>
<text top="533" left="585" width="243" height="19" font="8"><b>1</b>°<b> endpoint:</b> CHD-related and all-cause </text>
<text top="552" left="595" width="236" height="19" font="0">mortality associated with L and R BBB  </text>
<text top="570" left="585" width="3" height="19" font="0"> </text>
<text top="588" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="607" left="585" width="162" height="20" font="0">•  Mean follow-up=14.2 y </text>
<text top="626" left="585" width="246" height="20" font="0">•  Avg. age=63 y; 10% African American </text>
<text top="645" left="585" width="246" height="20" font="0">•  19% had h/o CVD or ECG evidence of </text>
<text top="664" left="601" width="53" height="19" font="0">prior MI </text>
<text top="683" left="585" width="234" height="20" font="0">•  2.6% BBB (714 LBBB, 832 RBBB, 122</text>
<text top="682" left="819" width="4" height="21" font="4"> </text>
<text top="683" left="823" width="3" height="19" font="0"> </text>
<text top="701" left="600" width="176" height="19" font="0">NSIVCD, 71 RBBB with LAFB) </text>
<text top="720" left="585" width="135" height="20" font="0">•  18% with BBB died </text>
<text top="739" left="585" width="234" height="20" font="0">•  8% with LBBB had fatal CHD events </text>
<text top="533" left="854" width="67" height="19" font="8"><b>Strengths: </b></text>
<text top="551" left="854" width="228" height="20" font="0">• Relatively large number of cases of </text>
<text top="570" left="866" width="97" height="19" font="0">LBBB and RBBB </text>
<text top="589" left="854" width="175" height="20" font="0">• Long systematic follow-up </text>
<text top="608" left="855" width="3" height="19" font="0"> </text>
<text top="626" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="644" left="854" width="134" height="20" font="0">• Exclusively women  </text>
<text top="663" left="855" width="3" height="19" font="0"> </text>
<text top="681" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="700" left="853" width="228" height="20" font="0">•  In women with baseline CVD, after </text>
<text top="719" left="866" width="223" height="19" font="0">adjusting for potential confounders, </text>
<text top="737" left="866" width="211" height="19" font="0">LBBB and RBBB were predictive of </text>
<text top="756" left="866" width="187" height="19" font="0">CHD death, but only LBBB was </text>
<text top="774" left="866" width="176" height="19" font="0">predictive of all-cause death </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 35 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="247" height="20" font="0">•  HR for CHD death for LBBB in women </text>
<text top="106" left="601" width="215" height="19" font="0">with CVD: 2.92 (95% CI: 2.08–4.08; </text>
<text top="124" left="601" width="54" height="19" font="0">p&lt;0.01). </text>
<text top="143" left="585" width="249" height="20" font="0">•  HR for CHD death for RBBB in women </text>
<text top="162" left="601" width="215" height="19" font="0">with CVD: 1.62 (95% CI: 1.08–2.43; </text>
<text top="180" left="601" width="50" height="19" font="0">p&lt;0.05) </text>
<text top="199" left="585" width="245" height="20" font="0">•  HR for all-cause mortality for LBBB in </text>
<text top="217" left="601" width="230" height="19" font="0">women with CVD: 1.43 (95% CI: 1.11–</text>
<text top="236" left="601" width="84" height="19" font="0">1.83; p&lt;0.01) </text>
<text top="254" left="585" width="247" height="20" font="0">•  HR for all-cause mortality for RBBB in </text>
<text top="273" left="601" width="223" height="19" font="0">women with CVD: 1.1 (95% CI: 0.84–</text>
<text top="292" left="601" width="74" height="19" font="0">1.44. p=NS)<b> </b></text>
<text top="310" left="585" width="247" height="20" font="0">•  HR for CHD death for LBBB in women </text>
<text top="329" left="601" width="234" height="19" font="0">free of baseline CVD: 2.17 (1.37–3.43; </text>
<text top="347" left="601" width="53" height="19" font="0">p&lt;0.01) <b> </b></text>
<text top="87" left="853" width="218" height="20" font="0">•  In women free of CVD, only LBBB </text>
<text top="106" left="866" width="206" height="19" font="0">was predictive of CHD death, and </text>
<text top="124" left="866" width="208" height="19" font="0">neither BBB was a predictor of all-</text>
<text top="143" left="866" width="77" height="19" font="0">cause death </text>
<text top="161" left="854" width="201" height="20" font="0">• NSIVCD and RBBB with LAFB is </text>
<text top="180" left="866" width="191" height="19" font="0">associated with a 2.5- to 3-fold </text>
<text top="198" left="866" width="224" height="19" font="0">increased risk of CHD death in those </text>
<text top="217" left="866" width="157" height="19" font="0">with baseline CV disease. </text>
<text top="235" left="854" width="229" height="20" font="0">• Most repolarization parameters do </text>
<text top="254" left="866" width="174" height="19" font="0">not predict CHD or all-cause </text>
<text top="272" left="866" width="63" height="19" font="0">mortality. </text>
<text top="366" left="96" width="71" height="19" font="8"><b>OPTIMAAL </b></text>
<text top="385" left="96" width="129" height="19" font="0">Bogale N, et al. 2007 </text>
<text top="403" left="96" width="28" height="19" font="0">(38) </text>
<text top="421" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17317365">17317365</a></text>
<text top="421" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17317365"> </a></text>
<text top="366" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="385" left="251" width="75" height="19" font="0">Prospective </text>
<text top="403" left="251" width="123" height="19" font="0">observational study </text>
<text top="421" left="251" width="144" height="19" font="0">derived from an RCT of </text>
<text top="440" left="251" width="146" height="19" font="0">losartan vs. captopril in </text>
<text top="458" left="251" width="144" height="19" font="0">pts with AMI and HF or </text>
<text top="476" left="251" width="113" height="19" font="0">asx impaired LVEF </text>
<text top="494" left="251" width="3" height="19" font="0"> </text>
<text top="513" left="251" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="531" left="251" width="116" height="19" font="0">N=356 (6.5%) with </text>
<text top="549" left="251" width="120" height="19" font="0">LBBB at baseline or </text>
<text top="568" left="251" width="85" height="19" font="0">subsequently </text>
<text top="586" left="251" width="105" height="19" font="0">developing LBBB </text>
<text top="604" left="251" width="113" height="19" font="0">during 2.7 y mean </text>
<text top="623" left="251" width="62" height="19" font="0">follow-up </text>
<text top="641" left="251" width="116" height="19" font="0">N=354 (6.5%) with </text>
<text top="659" left="251" width="122" height="19" font="0">RBBB at baseline or </text>
<text top="678" left="251" width="85" height="19" font="0">subsequently </text>
<text top="696" left="251" width="107" height="19" font="0">developing RBBB </text>
<text top="714" left="251" width="113" height="19" font="0">during 2.7 y mean </text>
<text top="733" left="251" width="62" height="19" font="0">follow-up </text>
<text top="751" left="251" width="120" height="19" font="0">N=5,477 in the RCT </text>
<text top="769" left="251" width="3" height="19" font="0"> </text>
<text top="366" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="385" left="409" width="150" height="19" font="0"> Acute MI (average time </text>
<text top="403" left="409" width="162" height="19" font="0">to enrollment=3 d), ≥50 y, </text>
<text top="421" left="409" width="154" height="19" font="0">HF, impaired LVEF &lt;35%, </text>
<text top="440" left="409" width="140" height="19" font="0">or LVEDD &gt;65 mm and </text>
<text top="458" left="409" width="155" height="19" font="0">anterior Q waves on ECG </text>
<text top="476" left="409" width="78" height="19" font="0">(old or new) </text>
<text top="494" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="513" left="409" width="144" height="20" font="0">• Supine SBP &lt;100 mm </text>
<text top="532" left="421" width="106" height="19" font="0">Hg at the time of </text>
<text top="550" left="421" width="71" height="19" font="0">enrollment </text>
<text top="569" left="409" width="155" height="20" font="0">• Rx with an ACEI or ARB<b> </b></text>
<text top="588" left="409" width="114" height="20" font="0">• Unstable angina<b> </b></text>
<text top="607" left="409" width="125" height="20" font="0">• Hemodynamically </text>
<text top="626" left="421" width="117" height="19" font="0">significant valvular </text>
<text top="644" left="421" width="53" height="19" font="0">stenosis<b> </b></text>
<text top="663" left="409" width="125" height="20" font="0">• Hemodynamically </text>
<text top="682" left="421" width="137" height="19" font="0">significant arrhythmia<b> </b></text>
<text top="700" left="409" width="65" height="20" font="0">• Planned </text>
<text top="719" left="421" width="107" height="19" font="0">revascularization<b> </b></text>
<text top="737" left="409" width="136" height="20" font="0">• Unable/unwilling to </text>
<text top="756" left="421" width="80" height="19" font="0">give consent<b> </b></text>
<text top="367" left="585" width="248" height="19" font="8"><b>1</b>°<b> endpoint:</b> All-cause death. Outcomes </text>
<text top="385" left="585" width="254" height="19" font="0">and crude rates were stratified according </text>
<text top="404" left="585" width="251" height="19" font="0">to presence of LBBB or RBBB at baseline. </text>
<text top="402" left="836" width="4" height="21" font="4"> </text>
<text top="422" left="585" width="240" height="19" font="0">Kaplan–Meier curves plotted for death </text>
<text top="440" left="585" width="223" height="19" font="0">and SCD stratified by BBB pattern at </text>
<text top="459" left="585" width="255" height="19" font="0">baseline. Cox regression models assessed </text>
<text top="477" left="585" width="220" height="19" font="0">effect of BBB pattern at baseline on </text>
<text top="495" left="585" width="221" height="19" font="0">death and SCD and the effect of the </text>
<text top="514" left="585" width="233" height="19" font="0">development of BBB during follow-up </text>
<text top="532" left="585" width="241" height="19" font="0">adjusted for age, pulse rate, h/o CABG, </text>
<text top="550" left="585" width="126" height="19" font="0">DM, CHF or prior MI </text>
<text top="569" left="585" width="3" height="19" font="0"> </text>
<text top="587" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="605" left="585" width="226" height="20" font="0">•  Pts with BBB patterns were older, </text>
<text top="624" left="601" width="191" height="19" font="0">fewer were smokers at time of </text>
<text top="643" left="601" width="239" height="19" font="0">inclusion, and more had previous HTN, </text>
<text top="661" left="601" width="129" height="19" font="0">AMI, CABG, and DM. </text>
<text top="679" left="585" width="234" height="20" font="0">•  946/5477 (17.3%) all-cause deaths. </text>
<text top="698" left="601" width="174" height="19" font="0">442/5477 (46.7%) were SCD </text>
<text top="717" left="585" width="240" height="20" font="0">•  Baseline: 203/5477 (3.7%) had LBBB </text>
<text top="736" left="601" width="193" height="19" font="0">and 235/5477 (4.3%) had RBBB </text>
<text top="366" left="854" width="66" height="19" font="0">Strengths: </text>
<text top="385" left="854" width="228" height="20" font="0">• Relatively large number of cases of </text>
<text top="404" left="866" width="97" height="19" font="0">LBBB and RBBB </text>
<text top="422" left="854" width="195" height="20" font="0">• Systematic follow-up for fatal </text>
<text top="441" left="866" width="64" height="19" font="0">outcomes </text>
<text top="459" left="855" width="3" height="19" font="0"> </text>
<text top="478" left="854" width="75" height="19" font="0">Limitations: </text>
<text top="496" left="854" width="225" height="20" font="0">• No core lab interpretation of ECGs </text>
<text top="515" left="854" width="215" height="20" font="0">• No data to correlate BBB with EF </text>
<text top="534" left="854" width="228" height="20" font="0">• No data on presence or absence of </text>
<text top="553" left="866" width="140" height="19" font="0">BBB before index AMI  </text>
<text top="572" left="854" width="242" height="20" font="0">• No ability to assess reversion rates of </text>
<text top="591" left="866" width="184" height="19" font="0">BBB back to normal after AMI </text>
<text top="609" left="866" width="167" height="19" font="0">(reported to be &gt;10% after </text>
<text top="627" left="866" width="210" height="19" font="0">revascularization in some studies) </text>
<text top="646" left="854" width="241" height="20" font="0">• Only 10% received PCI (54% received </text>
<text top="665" left="866" width="87" height="19" font="0">thrombolysis) </text>
<text top="683" left="855" width="3" height="19" font="0"> </text>
<text top="701" left="854" width="77" height="19" font="0">Conclusion:  </text>
<text top="720" left="853" width="222" height="20" font="0">•  In middle-aged and older pts with </text>
<text top="739" left="866" width="201" height="19" font="0">high-risk findings after acute MI, </text>
<text top="757" left="866" width="180" height="19" font="0">LBBB present at time of MI is </text>
<text top="776" left="866" width="229" height="19" font="0">independently predictive of all-cause </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 36 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="251" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="409" width="160" height="20" font="0">• Participation in another </text>
<text top="106" left="421" width="84" height="19" font="0">research trial<b> </b></text>
<text top="87" left="585" width="218" height="20" font="0">•  Follow-up: additional 153 (2.8%) </text>
<text top="106" left="601" width="197" height="19" font="0">developed LBBB and 119 (2.2%) </text>
<text top="124" left="601" width="107" height="19" font="0">developed RBBB. </text>
<text top="143" left="585" width="213" height="20" font="0">•  LBBB at baseline independently </text>
<text top="162" left="601" width="239" height="19" font="0">predictive of all-cause death (HR: 1.48; </text>
<text top="180" left="601" width="213" height="19" font="0">95% CI: 1.25–1.77; p&lt;0.01) and CV </text>
<text top="198" left="601" width="219" height="19" font="0">death (HR: 1.53; 95% CI: 1.17–1.99; </text>
<text top="217" left="601" width="210" height="19" font="0">p&lt;0.01), but not SCD/resuscitated </text>
<text top="235" left="601" width="229" height="19" font="0">cardiac arrest (HR:1.28; 95% CI: 0.96–</text>
<text top="253" left="601" width="74" height="19" font="0">1.71; p=NS) </text>
<text top="272" left="585" width="210" height="20" font="0">•  Late onset LBBB independently </text>
<text top="291" left="601" width="239" height="19" font="0">predictive of all-cause death (HR: 2.06; </text>
<text top="309" left="601" width="229" height="19" font="0">95% CI: 1.49–2.90; p&lt;0.01), CV death </text>
<text top="327" left="601" width="177" height="19" font="0">(HR:2.70; 95% CI: 1.68–4.35; </text>
<text top="346" left="601" width="203" height="19" font="0">p&lt;0.0001), and SCD/resuscitated </text>
<text top="364" left="601" width="232" height="19" font="0">cardiac arrest (HR: 2.38; 95% CI, 1.48–</text>
<text top="382" left="601" width="84" height="19" font="0">3.83; p=0.01) </text>
<text top="401" left="585" width="214" height="20" font="0">•  RBBB at baseline independently </text>
<text top="420" left="601" width="235" height="19" font="0">predictive of SCD/resuscitated cardiac </text>
<text top="438" left="601" width="216" height="19" font="0">arrest (HR:1.60; 95% CI: 1.25–2.04; </text>
<text top="456" left="601" width="194" height="19" font="0">p&lt;0.01) but not all-cause death </text>
<text top="475" left="601" width="233" height="19" font="0">(HR:1.16; 95% CI, 0.96–1.39; p=NS) or </text>
<text top="493" left="601" width="239" height="19" font="0">CV death (HR: 1.25; 95% CI: 0.95–1.64; </text>
<text top="511" left="601" width="40" height="19" font="0">p=NS)<b> </b></text>
<text top="530" left="585" width="213" height="20" font="0">•  Late-onset RBBB independently </text>
<text top="549" left="601" width="235" height="19" font="0">predictive of SCD/resuscitated cardiac </text>
<text top="567" left="601" width="219" height="19" font="0">arrest (HR: 2.02; 95% CI: 1.22–3.34; </text>
<text top="585" left="601" width="223" height="19" font="0">p=0.05) but not all-cause death (HR: </text>
<text top="604" left="601" width="227" height="19" font="0">1.26; 95% CI: 0.84–1.89; p=NS) or CV </text>
<text top="622" left="601" width="219" height="19" font="0">death (HR: 1.42; 95% CI: 0.76–2.67; </text>
<text top="640" left="601" width="40" height="19" font="0">p=NS)<b> </b></text>
<text top="87" left="866" width="176" height="19" font="0">death and CV death, but not </text>
<text top="105" left="866" width="198" height="19" font="0">SCD/resuscitated cardiac arrest. </text>
<text top="123" left="866" width="191" height="19" font="0">Subsequently developing LBBB </text>
<text top="142" left="866" width="224" height="19" font="0">during an average of 2.7-y follow-up </text>
<text top="160" left="866" width="143" height="19" font="0">is associated with all 3. </text>
<text top="179" left="853" width="222" height="20" font="0">•  In middle-aged and older pts with </text>
<text top="198" left="866" width="201" height="19" font="0">high-risk findings after acute MI, </text>
<text top="216" left="866" width="195" height="19" font="0">RBBB present at time of MI and </text>
<text top="234" left="866" width="191" height="19" font="0">subsequently developing RBBB </text>
<text top="252" left="866" width="224" height="19" font="0">during an average of 2.7-y follow-up </text>
<text top="271" left="866" width="185" height="19" font="0">is independently predictive of </text>
<text top="289" left="866" width="219" height="19" font="0">SCD/resuscitated cardiac arrest but </text>
<text top="307" left="866" width="199" height="19" font="0">not all-cause death or CV death. </text>
<text top="659" left="96" width="129" height="19" font="0">Baldasseroni S, et al. </text>
<text top="678" left="96" width="62" height="19" font="0">2002 (39) </text>
<text top="696" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11868043">11868043</a></text>
<text top="696" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11868043"> </a></text>
<text top="659" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="678" left="251" width="91" height="19" font="0">Retrospective, </text>
<text top="696" left="251" width="136" height="19" font="0">observational registry </text>
<text top="714" left="251" width="37" height="19" font="0">study </text>
<text top="733" left="251" width="3" height="19" font="0"> </text>
<text top="751" left="251" width="87" height="19" font="8"><b>Size:</b> N=5,517<b> </b></text>
<text top="659" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="678" left="409" width="156" height="19" font="0">Participants in the Italian </text>
<text top="696" left="409" width="140" height="19" font="0">Network CHF Registry, </text>
<text top="714" left="409" width="140" height="19" font="0">created in 1995 by the </text>
<text top="733" left="409" width="130" height="19" font="0">Italian Association of </text>
<text top="751" left="409" width="162" height="19" font="0">Hospital Cardiologists and </text>
<text top="660" left="585" width="255" height="19" font="8"><b>1</b>°<b> endpoint:</b> 1-y, all-cause mortality rate  </text>
<text top="678" left="585" width="3" height="19" font="0"> </text>
<text top="697" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="715" left="585" width="136" height="20" font="0">•  Mean age=63±12 y </text>
<text top="734" left="585" width="186" height="20" font="0">•  1295/5517 (23.5%) women </text>
<text top="753" left="585" width="233" height="20" font="0">•  1544/5517 (28.0%) NYHA class 3–4 </text>
<text top="772" left="585" width="171" height="20" font="0">•  LBBB 1391/5517 (25.2%) </text>
<text top="659" left="854" width="67" height="19" font="8"><b>Strengths: </b></text>
<text top="678" left="854" width="241" height="20" font="0">• Large prospective outpatient registry </text>
<text top="697" left="866" width="209" height="19" font="0">of pts referred to cardiologists for </text>
<text top="715" left="866" width="128" height="19" font="0">management of CHF </text>
<text top="734" left="854" width="221" height="20" font="0">• Standardized definitions and data </text>
<text top="752" left="866" width="180" height="19" font="0">collection methods (for most </text>
<text top="771" left="866" width="65" height="19" font="0">elements) </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 37 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="409" width="150" height="19" font="0">derived from 150 Italian </text>
<text top="105" left="409" width="109" height="19" font="0">medical facilities. </text>
<text top="123" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="142" left="409" width="134" height="20" font="0">• CHF due to valvular </text>
<text top="161" left="421" width="137" height="19" font="0">heart disease (N=745) </text>
<text top="179" left="409" width="158" height="20" font="0">• Inadequate quality ECG </text>
<text top="198" left="421" width="52" height="19" font="0">(N=270) </text>
<text top="217" left="409" width="146" height="19" font="0">Cardiac transplantation </text>
<text top="235" left="420" width="73" height="19" font="0">within the 1</text>
<text top="235" left="493" width="7" height="12" font="7">st</text>
<text top="235" left="500" width="49" height="19" font="0"> year of </text>
<text top="253" left="420" width="62" height="19" font="0">follow-up<b> </b></text>
<text top="87" left="585" width="162" height="20" font="0">•  RBBB: 336/5517 (6.1%) </text>
<text top="106" left="585" width="252" height="20" font="0">•  Other forms of IVCD: 339/5517 (6.1%) </text>
<text top="125" left="585" width="227" height="20" font="0">•  Those with LBBB more likely to be </text>
<text top="144" left="601" width="233" height="19" font="0">female, have non-ischemic CM, NYHA </text>
<text top="163" left="601" width="227" height="19" font="0">3–4 status, S3, cardiomegaly on CXR, </text>
<text top="181" left="601" width="217" height="19" font="0">EF &lt;30%, or receive diuretics, ACEI, </text>
<text top="199" left="601" width="211" height="19" font="0">digoxin, and amiodarone, and less </text>
<text top="217" left="601" width="231" height="19" font="0">likely to have AF and receive nitrates, </text>
<text top="236" left="601" width="211" height="19" font="0">BBs, antiplatelet agents, and CCBs </text>
<text top="254" left="585" width="212" height="20" font="0">•  Overall 1-y mortality: 659/5517 </text>
<text top="273" left="601" width="50" height="19" font="0">(11.9%) </text>
<text top="292" left="585" width="248" height="20" font="0">•  306/659 (46.4%) deaths attributed to </text>
<text top="311" left="601" width="87" height="19" font="0">sudden death </text>
<text top="329" left="585" width="256" height="20" font="0">•  LBBB 1-y all-cause mortality: 224/1391 </text>
<text top="348" left="601" width="50" height="19" font="0">(16.1%) </text>
<text top="367" left="585" width="243" height="20" font="0">•  RBBB 1-y all-cause mortality: 40/336 </text>
<text top="386" left="601" width="50" height="19" font="0">(11.9%) </text>
<text top="404" left="585" width="231" height="20" font="0">•  Other IVCD 1-y all-cause mortality: </text>
<text top="423" left="601" width="89" height="19" font="0">30/339 (8.8%) </text>
<text top="441" left="585" width="208" height="20" font="0">•  By multivariable analysis, LBBB </text>
<text top="460" left="601" width="234" height="19" font="0">remained independently predictive of </text>
<text top="479" left="601" width="236" height="19" font="0">all-cause mortality (HR: 1.360; 95% CI: </text>
<text top="497" left="601" width="148" height="19" font="0">1.148–1.610; p=0.0004) </text>
<text top="515" left="585" width="208" height="20" font="0">•  By multivariable analysis, LBBB </text>
<text top="534" left="601" width="234" height="19" font="0">remained independently predictive of </text>
<text top="553" left="601" width="207" height="19" font="0">sudden death (HR: 1.348; 95% CI: </text>
<text top="571" left="601" width="148" height="19" font="0">1.051–1.729; p=0.0188) </text>
<text top="87" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="105" left="854" width="225" height="20" font="0">• No core lab interpretation of ECGs </text>
<text top="124" left="854" width="206" height="20" font="0">• Chose QRSd &gt;140 ms to reduce </text>
<text top="143" left="866" width="208" height="19" font="0">likelihood of false classification of </text>
<text top="162" left="866" width="216" height="19" font="0">IVCD as LBBB. This may exaggerate </text>
<text top="180" left="866" width="203" height="19" font="0">the prognostic impact of LBBB as </text>
<text top="198" left="866" width="221" height="19" font="0">QRSd itself is predictive of outcome </text>
<text top="217" left="866" width="205" height="19" font="0">with higher mortality with longer </text>
<text top="235" left="866" width="40" height="19" font="0">QRSd. </text>
<text top="253" left="854" width="228" height="20" font="0">• No systematic coronary angiogram </text>
<text top="272" left="866" width="176" height="19" font="0">to determine etiology of CM </text>
<text top="291" left="854" width="228" height="20" font="0">• No systematic definition of sudden </text>
<text top="310" left="866" width="39" height="19" font="0">death </text>
<text top="328" left="855" width="3" height="19" font="0"> </text>
<text top="346" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="365" left="854" width="243" height="19" font="0">Amongst outpatients referred to Italian </text>
<text top="383" left="854" width="243" height="19" font="0">cardiologists for HF management, LBBB </text>
<text top="401" left="854" width="221" height="19" font="0">is associated with both a higher risk </text>
<text top="420" left="854" width="214" height="19" font="0">population (as indicated by clinical </text>
<text top="438" left="854" width="208" height="19" font="0">status and co-morbidities) and an </text>
<text top="456" left="854" width="236" height="19" font="0">approximate 35% increased 1-y risk of </text>
<text top="475" left="854" width="202" height="19" font="0">both all-cause death and sudden </text>
<text top="493" left="854" width="236" height="19" font="0">death, independent of a large number </text>
<text top="511" left="854" width="176" height="19" font="0">of other CHF risk indicators.  </text>
<text top="590" left="96" width="141" height="19" font="0">Erne P, et al. 2017 (40) </text>
<text top="608" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28224924">28224924</a></text>
<text top="608" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28224924"> </a></text>
<text top="590" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="608" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="627" left="251" width="136" height="19" font="0">observational registry </text>
<text top="645" left="251" width="37" height="19" font="0">study </text>
<text top="663" left="251" width="3" height="19" font="0"> </text>
<text top="681" left="251" width="32" height="19" font="8"><b>Size: </b></text>
<text top="700" left="253" width="140" height="20" font="0">•  N=29,114 in registry<b> </b></text>
<text top="719" left="253" width="102" height="20" font="0">•  N=28,421 had </text>
<text top="738" left="266" width="127" height="19" font="0">presenting ECG data<b> </b></text>
<text top="757" left="253" width="117" height="20" font="0">•  N=26,090 STEMI </text>
<text top="776" left="266" width="62" height="19" font="0">w/o LBBB<b> </b></text>
<text top="590" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="609" left="409" width="162" height="20" font="0">• Participants in the AMIS </text>
<text top="627" left="421" width="103" height="19" font="0">Plus Registry, an </text>
<text top="646" left="421" width="89" height="19" font="0">ongoing Swiss </text>
<text top="664" left="421" width="147" height="19" font="0">nationwide prospective </text>
<text top="682" left="421" width="141" height="19" font="0">cohort of pts admitted </text>
<text top="701" left="421" width="134" height="19" font="0">with ACS, founded by </text>
<text top="719" left="421" width="133" height="19" font="0">the Swiss Societies of </text>
<text top="737" left="421" width="123" height="19" font="0">Cardiology, Internal </text>
<text top="756" left="421" width="149" height="19" font="0">Medicine, and Intensive </text>
<text top="774" left="421" width="144" height="19" font="0">Care Medicine in 1997. </text>
<text top="591" left="585" width="211" height="19" font="8"><b>1</b>°<b> endpoint:</b> All-cause, in-hospital </text>
<text top="609" left="585" width="63" height="19" font="0">mortality  </text>
<text top="627" left="585" width="3" height="19" font="0"> </text>
<text top="646" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="664" left="585" width="237" height="20" font="0">•  Age: STE=64.3 [SD 13.2], LBBB=75.0 </text>
<text top="683" left="601" width="96" height="19" font="0">[10.7]; p&lt;0.001 </text>
<text top="702" left="585" width="245" height="20" font="0">•  Those with LBBB at the time of acute </text>
<text top="721" left="601" width="209" height="19" font="0">MI were more likely to be female, </text>
<text top="739" left="601" width="237" height="19" font="0">present later, have less chest pain and </text>
<text top="757" left="601" width="208" height="19" font="0">more dyspnea as chief complaint, </text>
<text top="776" left="601" width="212" height="19" font="0">have higher heart rate, and higher </text>
<text top="590" left="854" width="67" height="19" font="8"><b>Strengths</b>: </text>
<text top="609" left="854" width="200" height="20" font="0">• Largest prospective registry of </text>
<text top="627" left="866" width="225" height="19" font="0">unselected pts with suspected acute </text>
<text top="646" left="866" width="128" height="19" font="0">MI and LBBB to date </text>
<text top="664" left="854" width="221" height="20" font="0">• Standardized definitions and data </text>
<text top="683" left="866" width="120" height="19" font="0">collection methods </text>
<text top="701" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="720" left="854" width="231" height="20" font="0">• No core laboratory for ECG analysis </text>
<text top="739" left="854" width="180" height="20" font="0">• No systematic algorithm to </text>
<text top="758" left="866" width="199" height="19" font="0">differentiate isolated LBBB from </text>
<text top="776" left="866" width="202" height="19" font="0">LBBB associated with transmural </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 38 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="251" width="145" height="19" font="0">2,295 had LBBB with or </text>
<text top="105" left="251" width="133" height="19" font="0">w/o concomitant STE<b> </b></text>
<text top="87" left="409" width="162" height="20" font="0">• Definitive acute MI with </text>
<text top="106" left="421" width="117" height="19" font="0">either STE or new/ </text>
<text top="124" left="421" width="130" height="19" font="0">presumed to be new </text>
<text top="143" left="421" width="34" height="19" font="0">LBBB </text>
<text top="161" left="411" width="3" height="19" font="0"> </text>
<text top="179" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="198" left="409" width="28" height="19" font="0">N/A<b> </b></text>
<text top="87" left="601" width="200" height="19" font="0">prevalence of AF, Killip class 3–4 </text>
<text top="105" left="601" width="232" height="19" font="0">status, DM, HTN, hyperlipidemia, and </text>
<text top="123" left="601" width="190" height="19" font="0">prior MI, HF, CVA, PAD, or CKD </text>
<text top="142" left="601" width="101" height="19" font="0">(p&lt;0.001 for all) </text>
<text top="160" left="585" width="190" height="20" font="0">•  Those with LBBB had higher </text>
<text top="179" left="601" width="229" height="19" font="0">prevalence of impaired EF (354/1530 </text>
<text top="198" left="601" width="194" height="19" font="0">[23.1%] vs. 1582/18622 [8.5%]; </text>
<text top="216" left="601" width="61" height="19" font="0">p&lt;0.001). </text>
<text top="234" left="585" width="182" height="20" font="0">•  Those with LBBB were less </text>
<text top="253" left="601" width="234" height="19" font="0">aggressively treated with antiplatelet, </text>
<text top="272" left="601" width="191" height="19" font="0">antithrombotic, BB, statin, and </text>
<text top="290" left="601" width="225" height="19" font="0">revascularization therapies (p&lt;0.001 </text>
<text top="308" left="601" width="43" height="19" font="0">for all) </text>
<text top="327" left="585" width="207" height="20" font="0">•  All-cause in-hospital mortality: </text>
<text top="346" left="602" width="158" height="19" font="0">LBBB=371/2,295 (16.2%); </text>
<text top="364" left="602" width="213" height="19" font="0">STE=1,707/26,090 (6.5%); p&lt;0.001 </text>
<text top="382" left="585" width="232" height="20" font="0">•  Cardiogenic shock after admission: </text>
<text top="401" left="602" width="151" height="19" font="0">LBBB=286/2252 (11.6%) </text>
<text top="420" left="602" width="209" height="19" font="0">STE=1642/25,834 (6.4%); p&lt;0.001 </text>
<text top="438" left="585" width="69" height="20" font="0">•  MACCE: </text>
<text top="457" left="591" width="150" height="19" font="0">LBBB=394/2244 (17.6%) </text>
<text top="475" left="591" width="209" height="19" font="0">STE=2102/25,751 (8.2%); p&lt;0.001 </text>
<text top="494" left="585" width="248" height="19" font="0">Multivariate analysis: LBBB no longer an </text>
<text top="512" left="595" width="225" height="19" font="0">independent predictor of in-hospital </text>
<text top="530" left="595" width="239" height="19" font="0">mortality, HR: 1.01 (95% CI: 0.86–1.19; </text>
<text top="549" left="595" width="40" height="19" font="0">p=NS)<b> </b></text>
<text top="87" left="855" width="203" height="19" font="0">Ischemia (e.g. Sgarbossa criteria) </text>
<text top="105" left="854" width="224" height="20" font="0">• No prior or subsequent ECGs after </text>
<text top="124" left="866" width="215" height="19" font="0">admission to know if the LBBB was </text>
<text top="143" left="866" width="210" height="19" font="0">new or not and whether the LBBB </text>
<text top="161" left="866" width="86" height="19" font="0">was transient </text>
<text top="179" left="854" width="232" height="20" font="0">• No assessments of clinical eligibility </text>
<text top="198" left="866" width="175" height="19" font="0">for each therapeutic option. </text>
<text top="217" left="866" width="174" height="19" font="0">Therefore, hard to interpret </text>
<text top="235" left="866" width="212" height="19" font="0">differences in treatment rendered </text>
<text top="253" left="866" width="214" height="19" font="0">between those with and w/o LBBB </text>
<text top="272" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="290" left="854" width="218" height="20" font="0">• LBBB identifies a pt subset with a </text>
<text top="309" left="866" width="211" height="19" font="0">higher baseline CV risk profile and </text>
<text top="327" left="866" width="202" height="19" font="0">greater burden of preexisting CV </text>
<text top="346" left="866" width="168" height="19" font="0">diseases and comorbidities </text>
<text top="364" left="866" width="173" height="19" font="0">compared with pts with STE </text>
<text top="382" left="854" width="199" height="20" font="0">• Pts with LBBB are less likely to </text>
<text top="401" left="866" width="147" height="19" font="0">receive evidence-based </text>
<text top="420" left="866" width="225" height="19" font="0">antithrombotic therapy and invasive </text>
<text top="438" left="866" width="215" height="19" font="0">treatment strategy compared with </text>
<text top="456" left="866" width="47" height="19" font="0">STE pts </text>
<text top="475" left="854" width="198" height="19" font="0">LBBB is associated with a higher </text>
<text top="493" left="865" width="217" height="19" font="0">incidence of unadjusted in-hospital </text>
<text top="511" left="865" width="207" height="19" font="0">MACE, mortality, and cardiogenic </text>
<text top="530" left="865" width="213" height="19" font="0">shock rates but the same adjusted </text>
<text top="548" left="865" width="25" height="19" font="0">risk </text>
<text top="568" left="96" width="120" height="19" font="0">Yeo KK, et al., 2012 </text>
<text top="586" left="96" width="28" height="19" font="0">(41)<b> </b></text>
<text top="604" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22152973">22152973</a></text>
<text top="604" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22152973"><b> </b></a></text>
<text top="623" left="100" width="3" height="19" font="0"> </text>
<text top="568" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="586" left="262" width="87" height="19" font="0">Retrospective </text>
<text top="604" left="262" width="86" height="19" font="0">registry study </text>
<text top="623" left="262" width="123" height="19" font="0">utilizing the NCDR’s </text>
<text top="641" left="262" width="105" height="19" font="0">ACTION registry- </text>
<text top="659" left="262" width="43" height="19" font="0">GTWG </text>
<text top="678" left="251" width="3" height="19" font="0"> </text>
<text top="696" left="251" width="32" height="19" font="8"><b>Size: </b></text>
<text top="714" left="253" width="140" height="20" font="0">•  N=46,006 in registry </text>
<text top="733" left="266" width="118" height="19" font="0">with STEMI (STE or </text>
<text top="752" left="266" width="47" height="19" font="0">nLBBB)<b> </b></text>
<text top="568" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="586" left="409" width="126" height="20" font="0">• Participants in the </text>
<text top="605" left="421" width="133" height="19" font="0">ACTION registry from </text>
<text top="623" left="421" width="143" height="19" font="0">January 2007 to March </text>
<text top="642" left="421" width="93" height="19" font="0">2009 from 343 </text>
<text top="660" left="421" width="100" height="19" font="0">participating US </text>
<text top="678" left="421" width="119" height="19" font="0">hospitals, enrolling </text>
<text top="697" left="421" width="132" height="19" font="0">117,781 pts with ACS </text>
<text top="715" left="421" width="140" height="19" font="0">presenting within 24 h </text>
<text top="733" left="421" width="114" height="19" font="0">of symptom onset </text>
<text top="752" left="411" width="3" height="19" font="0"> </text>
<text top="770" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="568" left="585" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="587" left="585" width="249" height="20" font="0">•  Prevalence of presumed nLBBB in the </text>
<text top="606" left="601" width="90" height="19" font="0">setting of AMI </text>
<text top="624" left="585" width="194" height="20" font="0">•  Compare characteristics and </text>
<text top="643" left="601" width="210" height="19" font="0">treatments of those with AMI and </text>
<text top="662" left="601" width="188" height="19" font="0">either nLBBB or persistent STE </text>
<text top="680" left="585" width="213" height="20" font="0">•  Compare the risk for adverse in-</text>
<text top="699" left="602" width="230" height="19" font="0">hospital CV outcomes in the 2 groups </text>
<text top="717" left="591" width="3" height="19" font="0"> </text>
<text top="736" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="568" left="854" width="67" height="19" font="8"><b>Strengths: </b></text>
<text top="586" left="854" width="189" height="20" font="0">• Large prospective registry of </text>
<text top="605" left="866" width="225" height="19" font="0">unselected pts with suspected acute </text>
<text top="623" left="866" width="81" height="19" font="0">MI and LBBB </text>
<text top="642" left="854" width="221" height="20" font="0">• Standardized definitions and data </text>
<text top="661" left="866" width="120" height="19" font="0">collection methods </text>
<text top="679" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="698" left="854" width="231" height="20" font="0">• No core laboratory for ECG analysis </text>
<text top="717" left="854" width="180" height="20" font="0">• No systematic algorithm to </text>
<text top="736" left="866" width="199" height="19" font="0">differentiate isolated LBBB from </text>
<text top="754" left="866" width="202" height="19" font="0">LBBB associated with transmural </text>
<text top="772" left="855" width="203" height="19" font="0">Ischemia (e.g. Sgarbossa criteria) </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 39 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="253" width="126" height="20" font="0">•  N=44,405 (96.5%) </text>
<text top="106" left="266" width="113" height="19" font="0">had STE w/o LBBB<b> </b></text>
<text top="124" left="251" width="126" height="19" font="0">N=1,601 (3.5%) AMI </text>
<text top="143" left="251" width="73" height="19" font="0">with nLBBB<b> </b></text>
<text top="87" left="409" width="135" height="20" font="0">• NSTEMI (N=71,536) </text>
<text top="106" left="409" width="137" height="20" font="0">• Missing ECG data or </text>
<text top="125" left="421" width="131" height="19" font="0">isolated posterior MI </text>
<text top="143" left="421" width="52" height="19" font="0">(N=160) </text>
<text top="162" left="409" width="158" height="20" font="0">• Subsequent admissions </text>
<text top="181" left="421" width="137" height="19" font="0">in those with multiple </text>
<text top="199" left="421" width="129" height="19" font="0">admissions (only the </text>
<text top="217" left="421" width="129" height="19" font="0">index admission was </text>
<text top="236" left="421" width="77" height="19" font="0">used; N=79) </text>
<text top="254" left="409" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="585" width="228" height="20" font="0">•  Median age: STE=60 [interquartile </text>
<text top="106" left="601" width="225" height="19" font="0">range 51.0, 71.0], nLBBB=74.0 [63.0, </text>
<text top="124" left="601" width="99" height="19" font="0">82.0]; p&lt;0.0001 </text>
<text top="143" left="585" width="253" height="20" font="0">•  Those with nLBBB at the time of acute </text>
<text top="162" left="601" width="209" height="19" font="0">MI were more likely to be female, </text>
<text top="180" left="601" width="201" height="19" font="0">non-smoker, have h/o DM, HTN, </text>
<text top="198" left="601" width="220" height="19" font="0">hyperlipidemia, prior MI, CABG, HF, </text>
<text top="217" left="601" width="225" height="19" font="0">CVA, PAD, or CKD, have higher heart </text>
<text top="235" left="601" width="206" height="19" font="0">rate, or present with signs of CHF </text>
<text top="253" left="601" width="101" height="19" font="0">(p&lt;0.001 for all) </text>
<text top="272" left="585" width="227" height="20" font="0">•  Also those with nLBBB were more </text>
<text top="291" left="601" width="230" height="19" font="0">likely to have prior PCI (p=0.0013), or </text>
<text top="309" left="601" width="209" height="19" font="0">cardiogenic shock at presentation </text>
<text top="327" left="601" width="70" height="19" font="0">(p=0.0052) </text>
<text top="346" left="585" width="190" height="20" font="0">•  Those with nLBBB were less </text>
<text top="365" left="601" width="230" height="19" font="0">aggressively treated with antiplatelet </text>
<text top="383" left="601" width="202" height="19" font="0">therapy, beta blocker, and statin </text>
<text top="401" left="601" width="216" height="19" font="0">medications and were less likely to </text>
<text top="420" left="601" width="235" height="19" font="0">receive reperfusion therapy, including </text>
<text top="438" left="601" width="182" height="19" font="0">primary PCI (p&lt;0.0001 for all) </text>
<text top="457" left="585" width="239" height="20" font="0">•  Time to primary PCI was delayed on </text>
<text top="475" left="601" width="228" height="19" font="0">average 33 min for those with nLBBB </text>
<text top="494" left="601" width="175" height="19" font="0">relative to those with STEMI </text>
<text top="512" left="601" width="70" height="19" font="0">(p&lt;0.0001) </text>
<text top="531" left="585" width="254" height="20" font="0">•  More pts in the STEMI group had LVEF </text>
<text top="550" left="601" width="224" height="19" font="0">≥50% compared to the nLBBB group </text>
<text top="568" left="601" width="228" height="19" font="0">(47.9% vs. 27.2%) and fewer pts with </text>
<text top="586" left="601" width="237" height="19" font="0">LVEF &lt;25% (4.8% vs. 17.4%; p&lt;0.0001) </text>
<text top="605" left="585" width="236" height="20" font="0">•  Median peak troponin and creatine </text>
<text top="624" left="601" width="219" height="19" font="0">kinase-MB levels were higher in pts </text>
<text top="642" left="601" width="222" height="19" font="0">with STEMI compared to those with </text>
<text top="660" left="601" width="229" height="19" font="0">nLBBB (131.9 vs. 32.3; p&lt;0.0001, and </text>
<text top="679" left="601" width="222" height="19" font="0">21.8 vs. 6.0; p&lt;0.0001, respectively) </text>
<text top="697" left="585" width="220" height="20" font="0">•  <b>Unadjusted all-cause in-hospital </b></text>
<text top="716" left="601" width="69" height="19" font="8"><b>mortality:</b>  </text>
<text top="734" left="591" width="230" height="19" font="0">nLBBB compared to STEMI (13.3% vs. </text>
<text top="752" left="601" width="106" height="19" font="0">5.6%; p&lt;0.0001)  </text>
<text top="87" left="854" width="213" height="20" font="0">• Insufficient angiographic data to </text>
<text top="106" left="866" width="219" height="19" font="0">distinguish AMI with LBBB vs. other </text>
<text top="124" left="866" width="225" height="19" font="0">causes of biomarker elevation in the </text>
<text top="143" left="866" width="95" height="19" font="0">setting of LBBB </text>
<text top="161" left="854" width="242" height="20" font="0">• No data on pre-existing LBBB prior to </text>
<text top="180" left="866" width="81" height="19" font="0">incident AMI </text>
<text top="198" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="217" left="854" width="218" height="20" font="0">• LBBB identifies a pt subset with a </text>
<text top="236" left="866" width="211" height="19" font="0">higher baseline CV risk profile and </text>
<text top="254" left="866" width="202" height="19" font="0">greater burden of preexisting CV </text>
<text top="272" left="866" width="168" height="19" font="0">diseases and comorbidities </text>
<text top="291" left="866" width="173" height="19" font="0">compared with pts with STE </text>
<text top="309" left="854" width="199" height="20" font="0">• Pts with LBBB are less likely to </text>
<text top="328" left="866" width="147" height="19" font="0">receive evidence-based </text>
<text top="346" left="866" width="225" height="19" font="0">antithrombotic therapy and invasive </text>
<text top="365" left="866" width="215" height="19" font="0">treatment strategy compared with </text>
<text top="383" left="866" width="47" height="19" font="0">STE pts </text>
<text top="401" left="854" width="198" height="19" font="0">LBBB is associated with a higher </text>
<text top="420" left="865" width="217" height="19" font="0">incidence of unadjusted in-hospital </text>
<text top="438" left="865" width="224" height="19" font="0">mortality but the same adjusted risk </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 40 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="241" height="19" font="8"><b>Multivariate analysis:</b> nLBBB no longer </text>
<text top="105" left="595" width="244" height="19" font="0">an independent predictor of in-hospital </text>
<text top="123" left="595" width="244" height="19" font="0">mortality, (OR: 0.91; 95% CI: 0.75–1.12; </text>
<text top="142" left="595" width="50" height="19" font="0">p=0.38)<b> </b></text>
<text top="161" left="96" width="82" height="19" font="8"><b>Framingham </b></text>
<text top="179" left="96" width="134" height="19" font="0">Dhingra R, et al. 2005 </text>
<text top="197" left="96" width="28" height="19" font="0">(42)<b> </b></text>
<text top="216" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15734611">15734611</a></text>
<text top="216" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15734611"> </a></text>
<text top="234" left="100" width="3" height="19" font="0"> </text>
<text top="252" left="96" width="3" height="19" font="0"> </text>
<text top="161" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="179" left="251" width="114" height="19" font="0">Prospective, cross-</text>
<text top="197" left="251" width="136" height="19" font="0">sectional, community-</text>
<text top="216" left="251" width="80" height="19" font="0">based study  </text>
<text top="234" left="251" width="3" height="19" font="0"> </text>
<text top="252" left="251" width="129" height="19" font="8"><b>Size:</b> N=4,534 (2,583 </text>
<text top="271" left="251" width="57" height="19" font="0">women) <b> </b></text>
<text top="161" left="409" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="179" left="409" width="121" height="19" font="0">Attendees of the 16</text>
<text top="179" left="530" width="8" height="12" font="7">th</text>
<text top="179" left="539" width="20" height="19" font="0"> or </text>
<text top="197" left="409" width="15" height="19" font="0">17</text>
<text top="197" left="425" width="8" height="12" font="7">th</text>
<text top="197" left="433" width="132" height="19" font="0"> biennial exam of the </text>
<text top="216" left="409" width="156" height="19" font="0">Framingham Heart Study </text>
<text top="234" left="409" width="48" height="19" font="0">or the 2</text>
<text top="234" left="457" width="10" height="12" font="7">nd</text>
<text top="234" left="468" width="80" height="19" font="0"> exam of the </text>
<text top="252" left="409" width="140" height="19" font="0">Framingham Offspring </text>
<text top="271" left="409" width="154" height="19" font="0">Study with available ECG </text>
<text top="289" left="409" width="119" height="19" font="0">and echo data (2-D </text>
<text top="307" left="409" width="106" height="19" font="0">guided M-mode) </text>
<text top="326" left="409" width="3" height="19" font="0"> </text>
<text top="344" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="362" left="409" width="7" height="19" font="0">  </text>
<text top="381" left="409" width="138" height="20" font="0">• Prevalent HF (N=51) </text>
<text top="400" left="409" width="140" height="20" font="0">• Previous MI (N=146) </text>
<text top="419" left="409" width="138" height="20" font="0">• Digoxin or quinidine </text>
<text top="438" left="421" width="77" height="19" font="0">use (N=206) </text>
<text top="456" left="409" width="69" height="19" font="0">PPM (N=3)<b> </b></text>
<text top="162" left="585" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="180" left="585" width="252" height="19" font="0">Gender-specific linear regression models </text>
<text top="198" left="585" width="226" height="19" font="0">to assess the relationship of QRSd to </text>
<text top="217" left="585" width="232" height="19" font="0">echo parameters of LV size, mass and </text>
<text top="235" left="585" width="154" height="19" font="0">fractional shortening and</text>
<text top="234" left="738" width="4" height="21" font="4"> </text>
<text top="235" left="742" width="85" height="19" font="0">left atrial size </text>
<text top="253" left="585" width="93" height="19" font="0">at end-systole. </text>
<text top="271" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="290" left="585" width="245" height="20" font="0">•  In linear regression models, LV mass, </text>
<text top="309" left="601" width="219" height="19" font="0">end-diastolic dimension, and septal </text>
<text top="327" left="601" width="208" height="19" font="0">and posterior wall thickness were </text>
<text top="346" left="601" width="184" height="19" font="0">positively related to log-QRSd </text>
<text top="364" left="601" width="62" height="19" font="0">(p&lt;0.001) </text>
<text top="382" left="585" width="235" height="20" font="0">•  Fractional shortening was inversely </text>
<text top="401" left="601" width="185" height="19" font="0">related to log-QRSd (p&lt;0.001) </text>
<text top="420" left="585" width="221" height="20" font="0">•  LBBB (N=32) was associated with </text>
<text top="439" left="601" width="221" height="19" font="0">higher LV mass and lower fractional </text>
<text top="457" left="601" width="208" height="19" font="0">shortening compared to a normal </text>
<text top="475" left="601" width="98" height="19" font="0">QRSd (p&lt;0.001) </text>
<text top="494" left="585" width="247" height="20" font="0">•  RBBB (N=92) was not associated with </text>
<text top="513" left="602" width="208" height="19" font="0">significant differences in LV mass, </text>
<text top="531" left="602" width="181" height="19" font="0">dimensions, wall thickness or </text>
<text top="549" left="602" width="231" height="19" font="0">fractional shortening in men, but was </text>
<text top="568" left="602" width="193" height="19" font="0">associated with higher LV mass </text>
<text top="586" left="602" width="224" height="19" font="0">(p=0.02) and greater septal (p=0.01) </text>
<text top="604" left="602" width="236" height="19" font="0">and posterior (p=0.001) wall thickness </text>
<text top="623" left="602" width="68" height="19" font="0">in women. </text>
<text top="641" left="585" width="237" height="19" font="0">A stronger association of LV mass with </text>
<text top="659" left="595" width="220" height="19" font="0">QRSd was seen in obese men, older </text>
<text top="678" left="595" width="226" height="19" font="0">women, and in hypertensive women<b> </b></text>
<text top="161" left="854" width="70" height="19" font="8"><b>Strengths</b>:  </text>
<text top="179" left="854" width="232" height="20" font="0">• Large community-based population </text>
<text top="198" left="854" width="178" height="20" font="0">• Long duration of follow-up </text>
<text top="218" left="854" width="190" height="20" font="0">• Prospective, systematic data </text>
<text top="237" left="866" width="70" height="19" font="0">acquisition </text>
<text top="255" left="854" width="188" height="20" font="0">• Both sexes well represented </text>
<text top="274" left="854" width="3" height="19" font="0"> </text>
<text top="292" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="311" left="854" width="231" height="20" font="0">• Limited statistical power to analyze </text>
<text top="330" left="866" width="166" height="19" font="0">relations of BBB type to LV </text>
<text top="348" left="866" width="95" height="19" font="0">measurements </text>
<text top="367" left="854" width="218" height="20" font="0">• Use of M-mode for EF estimation </text>
<text top="385" left="866" width="199" height="19" font="0">(reflects only basal function of 2 </text>
<text top="404" left="866" width="67" height="19" font="0">segments) </text>
<text top="422" left="854" width="178" height="20" font="0">• Single assessment of QRSd </text>
<text top="441" left="854" width="240" height="20" font="0">• Predominantly Caucasian population </text>
<text top="460" left="854" width="3" height="19" font="0"> </text>
<text top="478" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="497" left="854" width="242" height="19" font="0">There is a positive association between </text>
<text top="515" left="854" width="243" height="19" font="0">ECG QRSd, as well as LBBB pattern, and </text>
<text top="533" left="854" width="184" height="19" font="0">LV mass, dimensions and wall </text>
<text top="552" left="854" width="223" height="19" font="0">thickness, and an inverse relation to </text>
<text top="570" left="854" width="239" height="19" font="0">systolic function in a large, community-</text>
<text top="588" left="854" width="197" height="19" font="0">based cohort free of MI and HF. </text>
<text top="697" left="96" width="129" height="19" font="0">Talreja D, et al. 2000 </text>
<text top="715" left="96" width="28" height="19" font="0">(43) </text>
<text top="733" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10689252">10689252</a></text>
<text top="733" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10689252"> </a></text>
<text top="752" left="96" width="3" height="19" font="0"> </text>
<text top="696" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="715" left="251" width="106" height="19" font="0">Prospective case-</text>
<text top="733" left="251" width="84" height="19" font="0">control study </text>
<text top="752" left="251" width="3" height="19" font="0"> </text>
<text top="770" left="251" width="79" height="19" font="8"><b>Size:</b> N= 300<b> </b></text>
<text top="696" left="409" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="715" left="409" width="142" height="19" font="0">Consecutive inpatients </text>
<text top="733" left="409" width="75" height="19" font="0">referred for </text>
<text top="752" left="409" width="116" height="19" font="0">echocardiographic </text>
<text top="770" left="409" width="156" height="19" font="0">assessment of LV systolic </text>
<text top="697" left="585" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="716" left="585" width="233" height="19" font="0">Predictive value of historical features, </text>
<text top="734" left="585" width="214" height="19" font="0">symptoms, physical findings, chest </text>
<text top="752" left="585" width="218" height="19" font="0">radiography and/or ECG findings to </text>
<text top="771" left="585" width="116" height="19" font="0">predict LVEF &lt;45% </text>
<text top="696" left="854" width="70" height="19" font="8"><b>Strengths:  </b></text>
<text top="715" left="854" width="216" height="20" font="0">• Systematic assessment of clinical </text>
<text top="734" left="866" width="224" height="19" font="0">features including ECG features that </text>
<text top="752" left="866" width="226" height="19" font="0">might predict LVSD in those referred </text>
<text top="771" left="866" width="134" height="19" font="0">for echocardiography </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="11" size="13" family="Times" color="#292526"/>
<text top="804" left="570" width="51" height="19" font="0">Page 41 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="409" width="136" height="19" font="0">function of which 124 </text>
<text top="105" left="409" width="138" height="19" font="0">(41%) had LVEF &lt;45%. </text>
<text top="123" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="142" left="409" width="156" height="19" font="0">No ECG within 1 wk prior </text>
<text top="160" left="409" width="94" height="19" font="0">to echo (N=30) </text>
<text top="178" left="409" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="585" width="3" height="19" font="8"><b> </b></text>
<text top="105" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="124" left="585" width="229" height="20" font="0">•  LBBB was the most predictive ECG </text>
<text top="143" left="601" width="210" height="19" font="0">finding to suggest LVSD; p&lt;0.0001 </text>
<text top="161" left="585" width="219" height="20" font="0">•  Multivariate predictors of LVSD:  </text>
<text top="180" left="591" width="223" height="19" font="0"> Radiographic cardiomegaly. OR: 3.8 </text>
<text top="198" left="602" width="156" height="19" font="0">(95% CI: 1.6–4.6; p&lt;0.01) </text>
<text top="217" left="591" width="204" height="19" font="0"> LBBB. OR: 3.7 (3.6–67.2; p&lt;0.01) </text>
<text top="235" left="591" width="231" height="19" font="0"> Male sex. OR: 3.45 (1.4–4.9; p&lt;0.01)  </text>
<text top="253" left="591" width="222" height="19" font="0"> Normal ECG: OR: 0.30 (0.02—0.45,  </text>
<text top="272" left="585" width="61" height="19" font="0"> p&lt;0.004)<b> </b></text>
<text top="87" left="854" width="3" height="19" font="0"> </text>
<text top="105" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="124" left="854" width="185" height="20" font="0">• Small sample size with wide </text>
<text top="143" left="866" width="123" height="19" font="0">confidence margins </text>
<text top="161" left="854" width="79" height="19" font="8"><b>Conclusion:  </b></text>
<text top="179" left="854" width="166" height="19" font="0">The presence of LBBB is an </text>
<text top="198" left="854" width="157" height="19" font="0">independent predictor of </text>
<text top="216" left="854" width="213" height="19" font="0">echocardiographically-determined </text>
<text top="234" left="854" width="234" height="19" font="0">LVSD in inpatients for whom LVSD is a </text>
<text top="252" left="854" width="101" height="19" font="0">clinical concern  </text>
<text top="291" left="96" width="141" height="19" font="0">Mendu ML, et al. 2009 </text>
<text top="309" left="96" width="28" height="19" font="0">(44)<b> </b></text>
<text top="327" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19636031">19636031</a></text>
<text top="327" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19636031"> </a></text>
<text top="346" left="96" width="3" height="19" font="0"> </text>
<text top="291" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="309" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="327" left="251" width="87" height="19" font="0">observational </text>
<text top="346" left="251" width="3" height="19" font="0"> </text>
<text top="364" left="251" width="83" height="19" font="8"><b>Size:</b> N=2106 </text>
<text top="382" left="251" width="76" height="19" font="0">consecutive </text>
<text top="401" left="251" width="126" height="19" font="0">admissions for 1920 </text>
<text top="419" left="251" width="105" height="19" font="0">individuals ≥65 y </text>
<text top="437" left="251" width="119" height="19" font="0">admitted following </text>
<text top="455" left="251" width="134" height="19" font="0">syncope from 7/2002 </text>
<text top="474" left="251" width="75" height="19" font="0">to 12/2006 <b> </b></text>
<text top="291" left="409" width="148" height="19" font="8"><b>Inclusion criteria:</b> ≥65 y </text>
<text top="309" left="409" width="119" height="19" font="0">admitted following </text>
<text top="327" left="409" width="54" height="19" font="0">syncope </text>
<text top="346" left="409" width="3" height="19" font="0"> </text>
<text top="364" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="382" left="409" width="108" height="19" font="0">Documented pre-</text>
<text top="401" left="420" width="120" height="19" font="0">syncope, 103 cases </text>
<text top="419" left="420" width="134" height="19" font="0">omitted for complete </text>
<text top="437" left="420" width="74" height="19" font="0">lack of data<b> </b></text>
<text top="291" left="585" width="246" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of a broad </text>
<text top="310" left="585" width="202" height="19" font="0">spectrum of clinical assessments </text>
<text top="328" left="585" width="3" height="19" font="0"> </text>
<text top="346" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="365" left="585" width="255" height="20" font="0">•  163 (8.5%) had more than 1 admission </text>
<text top="384" left="585" width="248" height="20" font="0">•  32% known CAD, 18% h/o AF, 9% h/o </text>
<text top="403" left="601" width="99" height="19" font="0">MI, 5% h/o AVB </text>
<text top="421" left="585" width="224" height="20" font="0">•  980 (47%) etiology unknown, 453 </text>
<text top="440" left="601" width="170" height="19" font="0">(22%) vasovagal, 282 (13%) </text>
<text top="459" left="601" width="108" height="19" font="0">orthostatic hypo. </text>
<text top="477" left="585" width="214" height="20" font="0">•  821 (39%) had echocardiogram, </text>
<text top="496" left="601" width="231" height="19" font="0">abnormal in 516 (63%), “affected Dx” </text>
<text top="514" left="601" width="187" height="19" font="0">in 35 (4%), “helped determine </text>
<text top="533" left="601" width="229" height="19" font="0">etiology” in 13 (2%)- most frequently </text>
<text top="551" left="602" width="233" height="19" font="0">aortic stenosis, affected management </text>
<text top="569" left="602" width="64" height="19" font="0">in 36 (4%) </text>
<text top="588" left="585" width="191" height="20" font="0">•  Yield in defining etiology for </text>
<text top="607" left="602" width="226" height="19" font="0">echocardiogram similar to ECG (3%), </text>
<text top="625" left="602" width="226" height="19" font="0">ETT (2%), Head MRI (2%), Carotid US </text>
<text top="643" left="602" width="233" height="19" font="0">(2%) but less than telemetry (5%) and </text>
<text top="662" left="602" width="131" height="19" font="0">orthostatic VS (15%). </text>
<text top="680" left="585" width="251" height="20" font="0">•  Of 11 tests analyzed, echo yielded the </text>
<text top="699" left="602" width="8" height="19" font="0">4</text>
<text top="699" left="609" width="8" height="12" font="7">th</text>
<text top="699" left="617" width="203" height="19" font="0"> lowest cost per test affecting Dx </text>
<text top="717" left="601" width="239" height="19" font="0">($6,272/ influential test) after postural </text>
<text top="736" left="601" width="144" height="19" font="0">BP, telemetry and ECG  </text>
<text top="754" left="585" width="236" height="19" font="0">Diagnostic impact of echo was greater </text>
<text top="772" left="585" width="254" height="19" font="0">and cost per test affecting Dx were lower </text>
<text top="291" left="854" width="63" height="19" font="8"><b>Strengths </b></text>
<text top="309" left="854" width="240" height="19" font="0"> Sample size, standardized abstraction, </text>
<text top="327" left="854" width="205" height="19" font="0">consistent definitions, blinded re-</text>
<text top="346" left="854" width="115" height="19" font="0">abstraction (mean </text>
<text top="346" left="969" width="95" height="19" font="11">bias-adjusted κ </text>
<text top="364" left="854" width="194" height="19" font="11">statistic = 87% (SD 20%) for the </text>
<text top="382" left="854" width="232" height="19" font="11">diagnostic test variables), inclusion of </text>
<text top="401" left="854" width="212" height="19" font="11">effect on management not just Dx </text>
<text top="419" left="854" width="32" height="19" font="11">yield </text>
<text top="437" left="854" width="3" height="19" font="0"> </text>
<text top="455" left="854" width="80" height="19" font="8"><b>Limitations</b>:  </text>
<text top="474" left="854" width="241" height="19" font="0">Reliance on administrative database to </text>
<text top="492" left="854" width="196" height="19" font="0">identify cases, reliance on chart </text>
<text top="510" left="854" width="216" height="19" font="0">documentation to assess impact of </text>
<text top="529" left="854" width="196" height="19" font="0">tests on clinical management (? </text>
<text top="547" left="854" width="211" height="19" font="0">underestimated effect of negative </text>
<text top="565" left="854" width="231" height="19" font="0">tests), using charges adjusted by cost-</text>
<text top="584" left="854" width="228" height="19" font="0">charge ratio rather than actual costs. </text>
<text top="602" left="854" width="233" height="19" font="0">Test ordering was not protocol driven </text>
<text top="620" left="854" width="232" height="19" font="0">and at the discretion of the clinicians, </text>
<text top="639" left="854" width="220" height="19" font="0">likely affecting the yield of the tests </text>
<text top="657" left="854" width="230" height="19" font="0">(echocardiogram likely ordered more </text>
<text top="675" left="854" width="223" height="19" font="0">indiscriminately than some others).  </text>
<text top="694" left="854" width="3" height="19" font="0"> </text>
<text top="712" left="854" width="79" height="19" font="8"><b>Conclusion</b>:  </text>
<text top="730" left="854" width="241" height="19" font="0">Echocardiogram was a frequent part of </text>
<text top="748" left="854" width="181" height="19" font="0">syncope evaluation in elderly </text>
<text top="767" left="854" width="233" height="19" font="0">hospitalized pts (39%) at an academic </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 42 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="585" width="210" height="19" font="0">in those who met SFSR criteria for </text>
<text top="105" left="585" width="87" height="19" font="0">increased risk<b> </b></text>
<text top="87" left="854" width="227" height="19" font="0">medical center and only occasionally </text>
<text top="105" left="854" width="216" height="19" font="0">provided information that affected </text>
<text top="123" left="854" width="234" height="19" font="0">management (4% of those studied) or </text>
<text top="142" left="854" width="213" height="19" font="0">established an etiology of syncope </text>
<text top="160" left="854" width="195" height="19" font="0">(2%). Compared to the litany of </text>
<text top="178" left="854" width="171" height="19" font="0">diagnostic tests used in this </text>
<text top="197" left="854" width="233" height="19" font="0">population, however, it was relatively </text>
<text top="215" left="854" width="90" height="19" font="0">cost-effective. </text>
<text top="234" left="96" width="134" height="19" font="0">Recchia D, et al. 1995 </text>
<text top="252" left="96" width="28" height="19" font="0">(45)<b> </b></text>
<text top="271" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8770716">8770716</a></text>
<text top="271" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8770716"> </a></text>
<text top="234" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="252" left="251" width="87" height="19" font="0">Retrospective </text>
<text top="271" left="251" width="87" height="19" font="0">observational </text>
<text top="289" left="251" width="3" height="19" font="0"> </text>
<text top="307" left="251" width="75" height="19" font="8"><b>Size:</b> N=128<b> </b></text>
<text top="234" left="409" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="252" left="409" width="149" height="19" font="0">admitted to a university </text>
<text top="271" left="409" width="151" height="19" font="0">teaching hospital due to </text>
<text top="289" left="409" width="129" height="19" font="0">syncope over a 7 mo </text>
<text top="307" left="409" width="47" height="19" font="0">period  </text>
<text top="326" left="409" width="3" height="19" font="0"> </text>
<text top="344" left="409" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="362" left="409" width="157" height="19" font="0">Syncope of known cause, </text>
<text top="381" left="409" width="129" height="19" font="0">presyncope, obvious </text>
<text top="399" left="409" width="151" height="19" font="0">seizure, referred for EPS<b> </b></text>
<text top="235" left="585" width="231" height="19" font="8"><b>1</b>°<b> endpoint:</b> Dx yield of echo beyond </text>
<text top="253" left="595" width="238" height="19" font="0">that provided by Hx, physical, and ECG </text>
<text top="272" left="585" width="3" height="19" font="0"> </text>
<text top="290" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="308" left="585" width="205" height="20" font="0">•  48/128 (37.5%) had a cause of </text>
<text top="327" left="601" width="214" height="19" font="0">syncope identified. Of these 37/48 </text>
<text top="346" left="601" width="232" height="19" font="0">(77%) were diagnosed by Hx, physical </text>
<text top="364" left="601" width="58" height="19" font="0">and ECG. </text>
<text top="382" left="585" width="206" height="20" font="0">•  82/128 (64%) underwent echo </text>
<text top="402" left="585" width="189" height="20" font="0">•  Echo normal in 52% of total </text>
<text top="420" left="602" width="229" height="19" font="0">population and 63% of those with no </text>
<text top="439" left="602" width="237" height="19" font="0">clinical evidence of heart disease (46% </text>
<text top="457" left="602" width="234" height="19" font="0">of population had no clinical evidence </text>
<text top="475" left="602" width="105" height="19" font="0">of heart disease) </text>
<text top="494" left="585" width="230" height="20" font="0">•  Echo confirmatory in 48% of those </text>
<text top="513" left="602" width="207" height="19" font="0">with suspected heart disease and </text>
<text top="531" left="602" width="105" height="19" font="0">refuted it in 52% </text>
<text top="550" left="585" width="249" height="20" font="0">•  Echo provided no etiology of syncope </text>
<text top="569" left="602" width="201" height="19" font="0">that was unsuspected on clinical </text>
<text top="587" left="602" width="53" height="19" font="0">grounds </text>
<text top="605" left="585" width="3" height="19" font="8"><b> </b></text>
<text top="234" left="854" width="227" height="20" font="0">• <b>Limitations</b>: Small sample size, test </text>
<text top="253" left="865" width="198" height="19" font="0">ordering at the discretion of the </text>
<text top="272" left="865" width="229" height="19" font="0">clinicians, did not address the impact </text>
<text top="290" left="865" width="205" height="19" font="0">of echo on management in those </text>
<text top="308" left="865" width="187" height="19" font="0">with clinically suspected heart </text>
<text top="326" left="865" width="227" height="19" font="0">disease in whom it was confirmatory </text>
<text top="345" left="865" width="82" height="19" font="0">half the time </text>
<text top="624" left="94" width="136" height="19" font="0">Sarasin FP, et al. 2002 </text>
<text top="643" left="94" width="28" height="19" font="0">(46)<b> </b></text>
<text top="661" left="94" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12231593">12231593</a></text>
<text top="661" left="155" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12231593"> </a></text>
<text top="679" left="94" width="3" height="19" font="0"> </text>
<text top="624" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="643" left="252" width="75" height="19" font="0">Prospective </text>
<text top="661" left="252" width="136" height="19" font="0">observational with 18 </text>
<text top="679" left="252" width="86" height="19" font="0">mo-follow-up </text>
<text top="697" left="251" width="3" height="19" font="0"> </text>
<text top="716" left="251" width="75" height="19" font="8"><b>Size:</b> N=650 </text>
<text top="734" left="251" width="98" height="19" font="0">consecutive pts </text>
<text top="752" left="251" width="145" height="19" font="0">presenting to the ED of </text>
<text top="771" left="251" width="129" height="19" font="0">a university teaching </text>
<text top="624" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="643" left="409" width="130" height="19" font="0">Syncope with clinical </text>
<text top="661" left="409" width="158" height="19" font="0">suspicion of cardiac valve </text>
<text top="679" left="409" width="143" height="19" font="0">disease or unexplained </text>
<text top="697" left="409" width="162" height="19" font="0">syncope after Hx, physical </text>
<text top="716" left="409" width="55" height="19" font="0">and ECG </text>
<text top="734" left="409" width="3" height="19" font="0"> </text>
<text top="752" left="409" width="153" height="19" font="8"><b>Exclusion criteria:</b> Those </text>
<text top="771" left="409" width="153" height="19" font="0">presenting with syncope </text>
<text top="625" left="585" width="233" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of echo, </text>
<text top="643" left="595" width="220" height="19" font="0">either confirming a suspected Dx or </text>
<text top="662" left="595" width="180" height="19" font="0">revealing an unexpected one </text>
<text top="680" left="585" width="3" height="19" font="0"> </text>
<text top="698" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="717" left="585" width="234" height="20" font="0">•  61/650 (9%) had a systolic murmur </text>
<text top="736" left="601" width="215" height="19" font="0">and severe AS was suspected in 20 </text>
<text top="754" left="601" width="225" height="19" font="0">(3% of total). Echo confirmed severe </text>
<text top="772" left="601" width="229" height="19" font="0">AS in 8 (40%). In 18 months of follow-</text>
<text top="624" left="854" width="76" height="19" font="0">Conclusions </text>
<text top="643" left="854" width="212" height="20" font="0">• Echo is most useful to assess the </text>
<text top="662" left="865" width="201" height="19" font="0">severity of suspected underlying </text>
<text top="680" left="865" width="168" height="19" font="0">cardiac disease and for risk </text>
<text top="698" left="865" width="230" height="19" font="0">stratification in those whose syncope </text>
<text top="717" left="865" width="230" height="19" font="0">is unexplained but have a Hx of heart </text>
<text top="735" left="865" width="178" height="19" font="0">disease or an abnormal ECG. </text>
<text top="753" left="854" width="221" height="20" font="0">• Echo is unlikely to yield a clinically </text>
<text top="772" left="865" width="212" height="19" font="0">unexpected etiology of syncope in </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 43 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="251" width="82" height="19" font="0">hospital who </text>
<text top="105" left="251" width="81" height="19" font="0">underwent a </text>
<text top="123" left="251" width="120" height="19" font="0">standardized initial </text>
<text top="142" left="251" width="143" height="19" font="0">clinical evaluation, and </text>
<text top="160" left="251" width="143" height="19" font="0">for those with syncope </text>
<text top="178" left="251" width="107" height="19" font="0">of undetermined </text>
<text top="197" left="251" width="133" height="19" font="0">etiology thereafter, a </text>
<text top="215" left="251" width="102" height="19" font="0">stepwise testing </text>
<text top="233" left="251" width="138" height="19" font="0">algorithm that started </text>
<text top="252" left="251" width="31" height="19" font="0">with </text>
<text top="270" left="251" width="117" height="19" font="0">echocardiography.<b> </b></text>
<text top="87" left="409" width="161" height="19" font="0">who did not complete the </text>
<text top="105" left="409" width="150" height="19" font="0">standardized evaluation </text>
<text top="123" left="409" width="118" height="19" font="0">(105) or refused to </text>
<text top="142" left="409" width="97" height="19" font="0">participate (33)<b> </b></text>
<text top="87" left="601" width="200" height="19" font="0">up no further cases of severe AS </text>
<text top="105" left="601" width="58" height="19" font="0">emerged </text>
<text top="124" left="585" width="215" height="20" font="0">•  155/650 (24%) had unexplained </text>
<text top="143" left="601" width="188" height="19" font="0">syncope and echo revealed no </text>
<text top="161" left="601" width="237" height="19" font="0">abnormalities that established a cause </text>
<text top="179" left="601" width="213" height="19" font="0">in them (this group was older with </text>
<text top="198" left="601" width="223" height="19" font="0">more comorbidities than those with </text>
<text top="216" left="601" width="203" height="19" font="0">an established cause of syncope) </text>
<text top="234" left="585" width="247" height="20" font="0">•  71/155 (46%) had “abnormal but not-</text>
<text top="253" left="601" width="221" height="19" font="0">relevant” echo findings that include </text>
<text top="272" left="601" width="208" height="19" font="0">clinically relevant findings such as </text>
<text top="290" left="601" width="223" height="19" font="0">severe MR, moderate PH, moderate </text>
<text top="308" left="601" width="54" height="19" font="0">MS, LVH </text>
<text top="327" left="585" width="234" height="20" font="0">•  In those with a normal ECG (N=67), </text>
<text top="346" left="601" width="233" height="19" font="0">echo was normal or “non-relevant” in </text>
<text top="364" left="601" width="17" height="19" font="0">all </text>
<text top="382" left="585" width="255" height="20" font="0">•  In those with a cardiac Hx or abnormal </text>
<text top="401" left="601" width="222" height="19" font="0">ECG (88/650=13.5%), echo revealed </text>
<text top="420" left="601" width="213" height="19" font="0">EF ≤40% in 24/88 (27%) and minor </text>
<text top="438" left="601" width="199" height="19" font="0">non-relevant findings in the rest </text>
<text top="457" left="585" width="250" height="20" font="0">•  Arrhythmias were diagnosed in 12/24 </text>
<text top="475" left="601" width="194" height="19" font="0">(50%) of those with Hx of heart </text>
<text top="494" left="601" width="225" height="19" font="0">disease or abnormal ECG and low EF </text>
<text top="512" left="602" width="210" height="19" font="0">on echo and 12/64 (19%) of those </text>
<text top="530" left="602" width="191" height="19" font="0">with EF &gt;40% on echo (P&lt;0.01) </text>
<text top="549" left="585" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="865" width="186" height="19" font="0">those w/o evidence of cardiac </text>
<text top="105" left="865" width="173" height="19" font="0">disease on initial evaluation </text>
<text top="123" left="854" width="3" height="19" font="0"> </text>
<text top="142" left="854" width="185" height="20" font="0">• Comment: Echo has greater </text>
<text top="161" left="866" width="205" height="19" font="0">relevance than these conclusions </text>
<text top="179" left="866" width="209" height="19" font="0">suggest due to the possibility that </text>
<text top="198" left="866" width="181" height="19" font="0">the clinically relevant but not </text>
<text top="216" left="866" width="224" height="19" font="0">definitively diagnostic abnormalities </text>
<text top="234" left="866" width="205" height="19" font="0">(other than low EF) will influence </text>
<text top="252" left="866" width="84" height="19" font="0">management </text>
<text top="271" left="854" width="3" height="19" font="0"> </text>
<text top="568" left="94" width="130" height="19" font="0">Dagres N, et al. 2013 </text>
<text top="586" left="94" width="28" height="19" font="0">(47)<b> </b></text>
<text top="604" left="94" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24280765">24280765</a></text>
<text top="604" left="155" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24280765"> </a></text>
<text top="604" left="204" width="3" height="19" font="0"> </text>
<text top="568" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="586" left="251" width="131" height="19" font="0">Descriptive survey of </text>
<text top="604" left="251" width="143" height="19" font="0">member institutions of </text>
<text top="623" left="251" width="135" height="19" font="0">the EHRA EP research </text>
<text top="641" left="251" width="54" height="19" font="0">network </text>
<text top="659" left="251" width="3" height="19" font="0"> </text>
<text top="677" left="251" width="132" height="19" font="8"><b>Size:</b> 43 centers from </text>
<text top="696" left="251" width="112" height="19" font="0">17 countries from </text>
<text top="714" left="251" width="78" height="19" font="0">Europe (and </text>
<text top="733" left="251" width="71" height="19" font="0">Argentina) <b> </b></text>
<text top="568" left="409" width="148" height="19" font="8"><b>Inclusion criteria:</b> EHRA </text>
<text top="586" left="409" width="160" height="19" font="0">members who responded </text>
<text top="604" left="409" width="83" height="19" font="0">to the survey </text>
<text top="623" left="409" width="3" height="19" font="0"> </text>
<text top="641" left="409" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="568" left="585" width="226" height="19" font="8"><b>1</b>°<b> endpoint:</b> Define current practice </text>
<text top="587" left="585" width="207" height="19" font="0">habits regarding the work-up and </text>
<text top="605" left="585" width="207" height="19" font="0">management of pts with syncope </text>
<text top="623" left="585" width="3" height="19" font="0"> </text>
<text top="642" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="660" left="585" width="241" height="20" font="0">•  ECG used “always or almost always” </text>
<text top="679" left="601" width="239" height="19" font="0">by 98% of respondents (“in most case” </text>
<text top="698" left="601" width="34" height="19" font="0">=2%) </text>
<text top="716" left="585" width="243" height="20" font="0">•  Echo used “always or almost always’ </text>
<text top="735" left="601" width="237" height="19" font="0">by 66% (“in most cases” =27%, “only if </text>
<text top="753" left="601" width="153" height="19" font="0">specific indication” =7%) </text>
<text top="568" left="854" width="220" height="20" font="0">• Offers little regarding appropriate </text>
<text top="587" left="865" width="220" height="19" font="0">use of tests but does define current </text>
<text top="605" left="865" width="231" height="19" font="0">practice suggesting stubborn reliance </text>
<text top="623" left="865" width="210" height="19" font="0">on echo in contemporary practice </text>
<text top="642" left="865" width="230" height="19" font="0">despite data to suggest relatively low </text>
<text top="660" left="865" width="139" height="19" font="0">yield in unselected pts </text>
<text top="679" left="854" width="211" height="20" font="0">• 42% of respondents used formal </text>
<text top="698" left="865" width="219" height="19" font="0">diagnostic algorithms and only 26% </text>
<text top="716" left="865" width="182" height="19" font="0">had a dedicated syncope unit </text>
<text top="734" left="854" width="230" height="20" font="0">• Compared to other tests, there was </text>
<text top="753" left="865" width="213" height="19" font="0">relative uniformity of utilization of </text>
<text top="771" left="865" width="157" height="19" font="0">echo, second only to ECG </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 44 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="588" width="251" height="20" font="0">•  Holter used “always or almost always” </text>
<text top="106" left="601" width="51" height="19" font="0">by 59%  </text>
<text top="124" left="588" width="240" height="20" font="0">•  All other tests queried &lt;50% “always </text>
<text top="143" left="601" width="112" height="19" font="0">or almost always” </text>
<text top="87" left="854" width="3" height="19" font="0"> </text>
<text top="162" left="94" width="115" height="19" font="0">Badheka AO, et al. </text>
<text top="181" left="94" width="62" height="19" font="0">2013 (48) </text>
<text top="199" left="94" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23726176">23726176</a></text>
<text top="199" left="155" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23726176"> </a></text>
<text top="162" left="251" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="181" left="251" width="131" height="19" font="0">Retrospective cohort </text>
<text top="199" left="251" width="141" height="19" font="0">study on prospectively </text>
<text top="217" left="251" width="122" height="19" font="0">collected data from </text>
<text top="236" left="251" width="70" height="19" font="0">NHANES III </text>
<text top="254" left="251" width="3" height="19" font="0"> </text>
<text top="272" left="251" width="123" height="19" font="8"><b>Size:</b> 8,527 of 8,561 </text>
<text top="291" left="251" width="135" height="19" font="0">individuals &gt;40 y who </text>
<text top="309" left="251" width="136" height="19" font="0">underwent resting 12-</text>
<text top="327" left="251" width="119" height="19" font="0">lead ECG as part of </text>
<text top="346" left="251" width="77" height="19" font="0">NHANES III. <b> </b></text>
<text top="162" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="181" left="409" width="154" height="19" font="0">NHANES III enrollee with </text>
<text top="199" left="409" width="116" height="19" font="0">available ECG data </text>
<text top="217" left="409" width="3" height="19" font="0"> </text>
<text top="236" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="254" left="409" width="154" height="19" font="0">Missing QRS data (N=30) </text>
<text top="272" left="409" width="140" height="19" font="0">Missing mortality data </text>
<text top="291" left="409" width="37" height="19" font="0">(N=4)<b> </b></text>
<text top="163" left="585" width="237" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the relationship </text>
<text top="182" left="585" width="161" height="19" font="0">between QRSd on routine </text>
<text top="200" left="585" width="134" height="19" font="0">ECG and CV mortality </text>
<text top="218" left="585" width="3" height="19" font="0"> </text>
<text top="236" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="255" left="588" width="179" height="20" font="0">•  Mean age was 60.5±13.6 y </text>
<text top="274" left="588" width="130" height="20" font="0">•  “White” race: 87% </text>
<text top="293" left="588" width="95" height="20" font="0">•  Female: 53% </text>
<text top="312" left="588" width="203" height="20" font="0">•  Follow-up: 106,244.6 person-y </text>
<text top="331" left="588" width="232" height="20" font="0">•  HR for risk adjusted CV mortality of </text>
<text top="350" left="601" width="230" height="19" font="0">highest quartile of QRSd: 1.3; 95% CI: </text>
<text top="369" left="601" width="106" height="19" font="0">1.01–1.7; p=0.04 </text>
<text top="387" left="588" width="200" height="20" font="0">•  LBBB HR: 2.4; 95% CI: 1.3–4.7; </text>
<text top="406" left="601" width="57" height="19" font="0">p=0.009) </text>
<text top="425" left="588" width="202" height="20" font="0">•  RBBB HR: 1.9; 95% CI: 1.2–3.0; </text>
<text top="444" left="601" width="57" height="19" font="0">p=0.008) </text>
<text top="462" left="588" width="240" height="20" font="0">•  Adding QRSd in 10-ms increments to </text>
<text top="481" left="601" width="226" height="19" font="0">Framingham Risk Score yielded 4.4% </text>
<text top="499" left="601" width="163" height="19" font="0">overall net reclassification </text>
<text top="518" left="601" width="208" height="19" font="0">improvement (95% CI: 0.02–0.04; </text>
<text top="536" left="601" width="76" height="19" font="0">p=0.00006)  </text>
<text top="554" left="585" width="3" height="19" font="8"><b> </b></text>
<text top="162" left="854" width="70" height="19" font="8"><b>Strengths:  </b></text>
<text top="181" left="854" width="230" height="20" font="0">•  Large representative cross section </text>
<text top="200" left="873" width="225" height="19" font="0">of US population (part of a cohort of </text>
<text top="218" left="873" width="165" height="19" font="0">72,062,796 in NHANES III). </text>
<text top="237" left="854" width="191" height="20" font="0">•  Prospectively acquired data </text>
<text top="256" left="862" width="3" height="19" font="0"> </text>
<text top="274" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="292" left="854" width="219" height="20" font="0">•  Retrospective and observational </text>
<text top="311" left="873" width="51" height="19" font="0">analysis </text>
<text top="330" left="854" width="230" height="20" font="0">•  Single ECG at baseline interpreted </text>
<text top="349" left="873" width="75" height="19" font="0">by software </text>
<text top="367" left="854" width="182" height="20" font="0">•  Diagnoses based on death </text>
<text top="386" left="873" width="172" height="19" font="0">certificate w/o chart review </text>
<text top="405" left="854" width="117" height="20" font="0">•  No data on SCD </text>
<text top="424" left="854" width="3" height="19" font="0"> </text>
<text top="442" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="460" left="854" width="223" height="19" font="0">Increased QRSd in general and LBBB </text>
<text top="479" left="854" width="240" height="19" font="0">and RBBB specifically are all associated </text>
<text top="497" left="854" width="235" height="19" font="0">with increased risk of risk-adjusted CV </text>
<text top="515" left="854" width="43" height="19" font="0">death. </text>
<text top="573" left="95" width="122" height="19" font="0">Chiu DT, et al. 2014 </text>
<text top="592" left="95" width="28" height="19" font="0">(49) </text>
<text top="610" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24698512">24698512</a></text>
<text top="610" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24698512"> </a></text>
<text top="573" left="251" width="78" height="19" font="8"><b>Study type:</b>  </text>
<text top="592" left="251" width="145" height="19" font="0">Secondary analysis of a </text>
<text top="610" left="251" width="78" height="19" font="0">prospective, </text>
<text top="628" left="251" width="134" height="19" font="0">observational, cohort </text>
<text top="646" left="251" width="40" height="19" font="0">study  </text>
<text top="665" left="251" width="3" height="19" font="0"> </text>
<text top="683" left="251" width="134" height="19" font="8"><b>Size:</b> 570 consecutive </text>
<text top="701" left="251" width="111" height="19" font="0">ED pts aged ≥18 y </text>
<text top="720" left="251" width="99" height="19" font="0">presenting with </text>
<text top="738" left="251" width="111" height="19" font="0">syncope between </text>
<text top="756" left="251" width="121" height="19" font="0">9/2003 and 6/2006 </text>
<text top="573" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="592" left="409" width="135" height="19" font="0">Presented to a single, </text>
<text top="610" left="409" width="129" height="19" font="0">large urban teaching </text>
<text top="628" left="409" width="123" height="19" font="0">hospital emergency </text>
<text top="646" left="409" width="160" height="19" font="0">department with syncope </text>
<text top="665" left="409" width="3" height="19" font="0"> </text>
<text top="683" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="701" left="409" width="86" height="19" font="0">Near syncope </text>
<text top="720" left="409" width="158" height="19" font="0">Persistent altered mental </text>
<text top="738" left="409" width="40" height="19" font="0">status </text>
<text top="756" left="409" width="162" height="19" font="0">Syncope due to alcohol or </text>
<text top="775" left="409" width="69" height="19" font="0">illicit drugs </text>
<text top="574" left="585" width="229" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of tests </text>
<text top="592" left="595" width="150" height="19" font="0">performed in ED, during </text>
<text top="611" left="595" width="202" height="19" font="0">hospitalization, or during 30 d of </text>
<text top="629" left="595" width="216" height="19" font="0">follow-up. Tests chosen at clinician </text>
<text top="647" left="595" width="224" height="19" font="0">discretion. Positive tests identified a </text>
<text top="666" left="595" width="236" height="19" font="0">serious condition deemed responsible </text>
<text top="684" left="595" width="176" height="19" font="0">for the index syncopal event </text>
<text top="702" left="585" width="3" height="19" font="0"> </text>
<text top="720" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="739" left="588" width="185" height="20" font="0">•  Mean age was 57.2 ± 24.5 y </text>
<text top="758" left="588" width="95" height="20" font="0">•  Female: 64% </text>
<text top="777" left="588" width="187" height="20" font="0">•  Admitted to hospital: 60.2% </text>
<text top="573" left="854" width="70" height="19" font="8"><b>Strengths:  </b></text>
<text top="592" left="854" width="225" height="20" font="0">•  Busy ED with 55,000 annual visits </text>
<text top="611" left="854" width="191" height="20" font="0">•  Prospectively acquired data </text>
<text top="630" left="854" width="110" height="20" font="0">•  99% follow-up </text>
<text top="649" left="854" width="223" height="20" font="0">•  Assessed current clinical practice </text>
<text top="668" left="873" width="213" height="19" font="0">(tests ordered according to clinical </text>
<text top="686" left="873" width="64" height="19" font="0">suspicion) </text>
<text top="705" left="862" width="3" height="19" font="0"> </text>
<text top="723" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="741" left="854" width="108" height="20" font="0">•  Observational </text>
<text top="761" left="854" width="232" height="20" font="0">•  Testing not ordered systematically </text>
<text top="779" left="873" width="149" height="19" font="0">(not all pts had all tests) </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 45 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="409" width="48" height="19" font="0">Seizure </text>
<text top="105" left="409" width="82" height="19" font="0">Coma due to </text>
<text top="123" left="420" width="138" height="19" font="0">hypoglycemia or head </text>
<text top="142" left="420" width="48" height="19" font="0">trauma </text>
<text top="160" left="409" width="142" height="19" font="0">Lost to follow-up (n=5)<b> </b></text>
<text top="87" left="588" width="217" height="20" font="0">•  330 (58%) underwent in-hospital </text>
<text top="106" left="601" width="234" height="19" font="0">telemetry, 317 (55%) serum troponin, </text>
<text top="124" left="601" width="238" height="19" font="0">150 (26%) echocardiography, 56 (10%) </text>
<text top="143" left="601" width="145" height="19" font="0">ambulatory monitoring </text>
<text top="161" left="588" width="239" height="20" font="0">•  Overall yield of all tests analyzed: 73 </text>
<text top="180" left="601" width="150" height="19" font="0">pts (8%; 95% CI: 7–10%) </text>
<text top="198" left="585" width="214" height="19" font="0">Diagnostic yield: Echo – 22% (5.8% </text>
<text top="217" left="585" width="216" height="19" font="0">overall yield for the entire syncope </text>
<text top="235" left="585" width="243" height="19" font="0">population – κ=0.78); Telemetry – 5.8% </text>
<text top="253" left="585" width="254" height="19" font="0">(overall yield 3.3% – κ=0.66); Ambulatory </text>
<text top="272" left="585" width="242" height="19" font="0">Monitoring – 3.6% (overall yield 0.4% – </text>
<text top="290" left="585" width="45" height="19" font="0">κ=0.5); </text>
<text top="289" left="630" width="4" height="21" font="4"> </text>
<text top="290" left="634" width="181" height="19" font="0">Serum troponin – 3% (overall </text>
<text top="308" left="585" width="106" height="19" font="0">yield 3.3% – κ=1)<b> </b></text>
<text top="87" left="854" width="101" height="20" font="0">•  Single center </text>
<text top="106" left="854" width="128" height="20" font="0">•  Small sample size </text>
<text top="125" left="854" width="151" height="20" font="0">•  Short-term follow-up </text>
<text top="144" left="854" width="190" height="20" font="0">•  Limited range of commonly </text>
<text top="163" left="873" width="208" height="19" font="0">employed testing studied (i.e., no </text>
<text top="182" left="873" width="211" height="19" font="0">head CT, routine blood tests, CXR, </text>
<text top="200" left="873" width="62" height="19" font="0">EEG, etc.) </text>
<text top="218" left="854" width="3" height="19" font="0"> </text>
<text top="236" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="255" left="854" width="242" height="19" font="0">Although routine testing is prevalent in </text>
<text top="273" left="854" width="219" height="19" font="0">ED pts with syncope, the diagnostic </text>
<text top="292" left="854" width="221" height="19" font="0">yield is relatively low. Nevertheless, </text>
<text top="310" left="854" width="85" height="19" font="0">some testing, </text>
<text top="328" left="854" width="219" height="19" font="0">particularly echocardiography, may </text>
<text top="346" left="854" width="131" height="19" font="0">yield critical findings.<b> </b></text>
<text top="365" left="95" width="104" height="19" font="0">Menozzi C, et al. </text>
<text top="384" left="95" width="62" height="19" font="0">1998 (50) </text>
<text top="402" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9832095">9832095</a></text>
<text top="402" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9832095"> </a></text>
<text top="365" left="251" width="78" height="19" font="8"><b>Study type:</b>  </text>
<text top="384" left="251" width="75" height="19" font="0">Prospective </text>
<text top="402" left="251" width="139" height="19" font="0">observational study of </text>
<text top="420" left="251" width="137" height="19" font="0">the placebo arm of an </text>
<text top="439" left="251" width="70" height="19" font="0">RCT of oral </text>
<text top="457" left="251" width="106" height="19" font="0">theophylline and </text>
<text top="475" left="251" width="129" height="19" font="0">permanent pacing in </text>
<text top="494" left="251" width="136" height="19" font="0">pts with symptomatic </text>
<text top="512" left="251" width="135" height="19" font="0">SND (THEOPACE trial) </text>
<text top="530" left="251" width="3" height="19" font="0"> </text>
<text top="548" left="251" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="567" left="251" width="85" height="19" font="0">162 screened </text>
<text top="585" left="253" width="121" height="19" font="0">55 excluded (12 for </text>
<text top="604" left="253" width="85" height="19" font="0">“severe” SSS) </text>
<text top="622" left="253" width="136" height="19" font="0">N=107 randomized to </text>
<text top="640" left="253" width="110" height="19" font="0">3 treatment arms </text>
<text top="658" left="253" width="130" height="19" font="0">35 randomized to no </text>
<text top="677" left="253" width="66" height="19" font="0">treatment<b> </b></text>
<text top="365" left="409" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="384" left="420" width="142" height="19" font="0">Symptomatic SND, age </text>
<text top="402" left="420" width="26" height="19" font="0">≥45 </text>
<text top="420" left="409" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="439" left="409" width="157" height="20" font="0">•  Severe SSS (heart rate </text>
<text top="458" left="428" width="108" height="19" font="0">&lt;30 bpm or sinus </text>
<text top="476" left="428" width="78" height="19" font="0">pauses &gt;3 s) </text>
<text top="495" left="409" width="106" height="20" font="0">•  Refractory HF </text>
<text top="514" left="409" width="153" height="20" font="0">•  Recent MI or CVA (&lt;3 </text>
<text top="533" left="428" width="28" height="19" font="0">mo) </text>
<text top="551" left="409" width="149" height="20" font="0">•  “Very severe general </text>
<text top="570" left="428" width="61" height="19" font="0">diseases” </text>
<text top="589" left="409" width="143" height="20" font="0">•  “Significant renal or </text>
<text top="608" left="428" width="103" height="19" font="0">hepatic disease” </text>
<text top="626" left="409" width="128" height="20" font="0">•  H/O sustained VT </text>
<text top="645" left="409" width="162" height="20" font="0">•  Secondary bradycardia </text>
<text top="664" left="428" width="34" height="19" font="0">(e.g., </text>
<text top="682" left="428" width="144" height="19" font="0">hypothyroidism/drugs) </text>
<text top="701" left="409" width="140" height="20" font="0">•  Need for BB or CCB </text>
<text top="720" left="409" width="118" height="20" font="0">•  Other causes of </text>
<text top="739" left="428" width="132" height="19" font="0">syncope besides SND </text>
<text top="757" left="409" width="80" height="20" font="0">•  Pt refusal </text>
<text top="776" left="409" width="124" height="19" font="0">Unable to follow up<b> </b></text>
<text top="366" left="585" width="89" height="19" font="8"><b>1</b>°<b> endpoint:</b> 1</text>
<text top="366" left="673" width="7" height="12" font="7">st</text>
<text top="366" left="680" width="156" height="19" font="0"> episode of syncope, CHF </text>
<text top="385" left="595" width="243" height="19" font="0">requiring hospitalization, persistent AF, </text>
<text top="403" left="595" width="177" height="19" font="0">“poorly tolerated” sustained </text>
<text top="421" left="595" width="237" height="19" font="0">paroxysmal tachyarrhythmia requiring </text>
<text top="440" left="595" width="213" height="19" font="0">treatment, thromboembolic event </text>
<text top="458" left="585" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="476" left="588" width="163" height="20" font="0">•  Mean age was 71 ± 11 y </text>
<text top="495" left="588" width="95" height="20" font="0">•  Female: 49% </text>
<text top="515" left="588" width="195" height="20" font="0">•  “Organic” heart disease: 63% </text>
<text top="534" left="588" width="130" height="20" font="0">•  H/O Syncope: 57% </text>
<text top="553" left="588" width="235" height="20" font="0">•  Mean ambulatory heart rate: 51 ± 8 </text>
<text top="572" left="601" width="31" height="19" font="0">bpm </text>
<text top="590" left="588" width="180" height="20" font="0">•  Follow-up: 17 ± 15 months </text>
<text top="609" left="588" width="213" height="20" font="0">•  20 (57%) experienced CV events </text>
<text top="628" left="601" width="236" height="19" font="0">requiring treatment [8 (23%) syncope, </text>
<text top="647" left="601" width="195" height="19" font="0">6 (17%) CHF, 4 (11%) AF, 2 (6%) </text>
<text top="665" left="601" width="182" height="19" font="0">paroxysmal tachyarrhythmia] </text>
<text top="683" left="588" width="245" height="20" font="0">•  Actuarial rates at 1, 2, and 4 y for any </text>
<text top="702" left="601" width="184" height="19" font="0">CV event: 35%, 49%, and 63% </text>
<text top="721" left="601" width="77" height="19" font="0">respectively </text>
<text top="739" left="588" width="219" height="20" font="0">•  Actuarial rates at 1, 2, and 4 y for </text>
<text top="758" left="601" width="179" height="19" font="0">syncope: 16%, 31%, and 31% </text>
<text top="776" left="601" width="77" height="19" font="0">respectively </text>
<text top="365" left="854" width="70" height="19" font="8"><b>Strengths:  </b></text>
<text top="384" left="854" width="93" height="20" font="0">•  Prospective </text>
<text top="403" left="854" width="140" height="20" font="0">•  Up to 4-y follow-up </text>
<text top="422" left="862" width="3" height="19" font="0"> </text>
<text top="440" left="854" width="77" height="19" font="8"><b>Limitations: </b></text>
<text top="459" left="854" width="128" height="20" font="0">•  Small sample size </text>
<text top="478" left="862" width="3" height="19" font="0"> </text>
<text top="496" left="854" width="81" height="19" font="8"><b>Conclusions: </b></text>
<text top="514" left="854" width="196" height="19" font="0">Clinical CV events occur in most </text>
<text top="533" left="854" width="217" height="19" font="0">untreated SSS pts during long-term </text>
<text top="551" left="854" width="238" height="19" font="0">follow-up. The outcome can be “partly </text>
<text top="569" left="854" width="234" height="19" font="0">predicted” on initial evaluation. Along </text>
<text top="588" left="854" width="201" height="19" font="0">with age ≥65, echocardiographic </text>
<text top="606" left="854" width="208" height="19" font="0">parameters of LV size and EF help </text>
<text top="624" left="854" width="241" height="19" font="0">identify those at risk for CV events (but </text>
<text top="643" left="854" width="242" height="19" font="0">not necessarily syncope per se). A prior </text>
<text top="661" left="854" width="223" height="19" font="0">Hx of syncope and a corrected SNRT </text>
<text top="679" left="854" width="230" height="19" font="0">≥800 ms identifies those at increased </text>
<text top="698" left="854" width="202" height="19" font="0">risk of syncope during follow-up. </text>
<text top="716" left="854" width="3" height="19" font="8"><b> </b></text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 46 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="290" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="290" left="302" width="4" height="23" font="5"><b> </b></text>
<text top="87" left="588" width="196" height="20" font="0">•  Predictors of any CV event by </text>
<text top="106" left="601" width="223" height="19" font="0">multivariate analysis: age ≥65 y (HR: </text>
<text top="124" left="601" width="214" height="19" font="0">7.80 [95% CI:1.97–30.9]; p=0.001), </text>
<text top="143" left="601" width="232" height="19" font="0">LVEDD ≥52 by <b>echo </b>(HR: 2.89 [1.07 to </text>
<text top="161" left="601" width="228" height="19" font="0">7.81]; p=0.04), EF &lt;55% by <b>echo</b> (HR: </text>
<text top="179" left="601" width="177" height="19" font="0">3.68 [1.28 to 10.52]; p=0.01) </text>
<text top="198" left="585" width="230" height="19" font="0">Predictors of syncope by multivariate </text>
<text top="216" left="585" width="243" height="19" font="0">analysis: corrected sinus node recovery </text>
<text top="234" left="585" width="211" height="19" font="0">time ≥800 ms (HR: 7.80 [0.94–65]; </text>
<text top="252" left="585" width="230" height="19" font="0">p=0.02), h/o syncope (HR: 5.96 [0.71–</text>
<text top="271" left="585" width="88" height="19" font="0">49.7]; p=0.05)<b> </b></text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 47 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="1009" height="23" font="5"><b>Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Electrocardiography in Bradycardia </b></text>
<text top="108" left="86" width="297" height="23" font="5"><b>or Conduction Disorders (Section 4.2.4) </b></text>
<text top="131" left="119" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="145" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="121" width="100" height="19" font="8"><b>Year Published’ </b></text>
<text top="186" left="152" width="38" height="19" font="8"><b>PMID </b></text>
<text top="131" left="269" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="298" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="438" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="627" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="626" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="131" left="912" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="940" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="205" left="96" width="141" height="19" font="0">Mendu ML, et al. 2009 </text>
<text top="223" left="96" width="28" height="19" font="0">(44)<b> </b></text>
<text top="241" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19636031">19636031</a></text>
<text top="241" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19636031"> </a></text>
<text top="260" left="96" width="3" height="19" font="0"> </text>
<text top="205" left="258" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="223" left="258" width="87" height="19" font="0">Retrospective </text>
<text top="241" left="258" width="87" height="19" font="0">observational </text>
<text top="260" left="258" width="3" height="19" font="0"> </text>
<text top="278" left="258" width="83" height="19" font="8"><b>Size:</b> N=2106 </text>
<text top="296" left="258" width="146" height="19" font="0">consecutive admissions </text>
<text top="315" left="258" width="124" height="19" font="0">for 1920 individuals </text>
<text top="333" left="258" width="96" height="19" font="0">≥65 y admitted </text>
<text top="351" left="258" width="147" height="19" font="0">following syncope from </text>
<text top="370" left="258" width="122" height="19" font="0">7/2002 to 12/2006  </text>
<text top="205" left="418" width="151" height="19" font="8"><b>Inclusion criteria:</b> ≥65 y. </text>
<text top="223" left="418" width="119" height="19" font="0">admitted following </text>
<text top="241" left="418" width="54" height="19" font="0">syncope </text>
<text top="260" left="418" width="3" height="19" font="0"> </text>
<text top="278" left="418" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="296" left="418" width="108" height="19" font="0">Documented pre-</text>
<text top="315" left="418" width="120" height="19" font="0">syncope, 103 cases </text>
<text top="333" left="418" width="134" height="19" font="0">omitted for complete </text>
<text top="351" left="418" width="74" height="19" font="0">lack of data </text>
<text top="206" left="591" width="246" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of a broad </text>
<text top="224" left="591" width="202" height="19" font="0">spectrum of clinical assessments </text>
<text top="242" left="591" width="3" height="19" font="0"> </text>
<text top="260" left="591" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="279" left="591" width="189" height="20" font="0">• 163 (8.5%) had &gt;1 admission </text>
<text top="298" left="591" width="242" height="20" font="0">• 32% known CAD, 18% h/o AF, 9% h/o </text>
<text top="317" left="601" width="99" height="19" font="0">MI, 5% h/o AVB </text>
<text top="336" left="591" width="257" height="20" font="0">• 980 (47%) etiology unknown, 453 (22%) </text>
<text top="355" left="601" width="201" height="19" font="0">vasovagal, 282 (13%) orthostatic </text>
<text top="373" left="601" width="83" height="19" font="0">hypotension. </text>
<text top="391" left="591" width="242" height="20" font="0">• 821 (39%) had echo, abnormal in 516 </text>
<text top="410" left="601" width="247" height="19" font="0">(63%), “affected Dx” in 35 (4%), “helped </text>
<text top="429" left="601" width="229" height="19" font="0">determine etiology” in 13 (2%)- most </text>
<text top="447" left="601" width="243" height="19" font="0">frequently AS, affected management in </text>
<text top="465" left="601" width="49" height="19" font="0">36 (4%) </text>
<text top="484" left="591" width="218" height="20" font="0">• Yield in defining etiology for echo </text>
<text top="503" left="601" width="246" height="19" font="0">similar to ECG (3%), ETT (2%), Head MRI </text>
<text top="521" left="601" width="215" height="19" font="0">(2%), Carotid US (2%) but less than </text>
<text top="539" left="601" width="210" height="19" font="0">telemetry (5%) and orthostatic VS </text>
<text top="558" left="601" width="42" height="19" font="0">(15%). </text>
<text top="576" left="591" width="245" height="20" font="0">• Of 11 tests analyzed, echo yielded the </text>
<text top="595" left="601" width="8" height="19" font="0">4</text>
<text top="595" left="609" width="8" height="12" font="7">th</text>
<text top="595" left="617" width="203" height="19" font="0"> lowest cost per test affecting Dx </text>
<text top="613" left="601" width="239" height="19" font="0">($6,272/ influential test) after postural </text>
<text top="632" left="601" width="141" height="19" font="0">BP, telemetry and ECG </text>
<text top="650" left="591" width="247" height="20" font="0">• Diagnostic impact of echo was greater </text>
<text top="669" left="601" width="246" height="19" font="0">ad cost per test affecting Dx were lower </text>
<text top="687" left="601" width="210" height="19" font="0">in those who met SFSR criteria for </text>
<text top="706" left="601" width="87" height="19" font="0">increased risk </text>
<text top="205" left="864" width="11" height="18" font="0">• </text>
<text top="206" left="875" width="198" height="19" font="11">87% (SD 20%) for the diagnostic </text>
<text top="224" left="875" width="205" height="19" font="11">test variables), inclusion of effect </text>
<text top="242" left="875" width="202" height="19" font="11">on management not just Dx yield</text>
<text top="242" left="1077" width="3" height="19" font="0"> </text>
<text top="261" left="864" width="162" height="20" font="0">• <b>Limitations</b>: Reliance on </text>
<text top="280" left="875" width="217" height="19" font="0">administrative database to identify </text>
<text top="298" left="875" width="146" height="19" font="0">cases, reliance on chart </text>
<text top="316" left="875" width="216" height="19" font="0">documentation to assess impact of </text>
<text top="335" left="875" width="196" height="19" font="0">tests on clinical management (? </text>
<text top="353" left="875" width="211" height="19" font="0">underestimated effect of negative </text>
<text top="371" left="875" width="201" height="19" font="0">tests), using charges adjusted by </text>
<text top="390" left="875" width="220" height="19" font="0">cost-charge ratio rather than actual </text>
<text top="408" left="875" width="174" height="19" font="0">costs. Test ordering was not </text>
<text top="426" left="875" width="163" height="19" font="0">protocol driven and at the </text>
<text top="444" left="875" width="201" height="19" font="0">discretion of the clinicians, likely </text>
<text top="463" left="875" width="185" height="19" font="0">affecting the yield of the tests </text>
<text top="481" left="875" width="161" height="19" font="0">(echo likely ordered more </text>
<text top="499" left="875" width="223" height="19" font="0">indiscriminately than some others).  </text>
<text top="518" left="864" width="213" height="20" font="0">• <b>Conclusion</b>: Echo was a frequent </text>
<text top="537" left="875" width="180" height="19" font="0">part of syncope evaluation in </text>
<text top="555" left="875" width="217" height="19" font="0">elderly hospitalized pts (39%) at an </text>
<text top="573" left="875" width="211" height="19" font="0">academic medical center and only </text>
<text top="592" left="875" width="211" height="19" font="0">occasionally provided information </text>
<text top="610" left="875" width="209" height="19" font="0">that affected management (4% of </text>
<text top="628" left="875" width="199" height="19" font="0">those studied) or established an </text>
<text top="647" left="875" width="156" height="19" font="0">etiology of syncope (2%). </text>
<text top="665" left="875" width="160" height="19" font="0">Compared to the litany of </text>
<text top="683" left="875" width="171" height="19" font="0">diagnostic tests used in this </text>
<text top="702" left="875" width="173" height="19" font="0">population, however, it was </text>
<text top="720" left="875" width="150" height="19" font="0">relatively cost-effective. </text>
<text top="739" left="96" width="131" height="19" font="0">Recchia D, et al.1995 </text>
<text top="757" left="96" width="28" height="19" font="0">(45)<b> </b></text>
<text top="776" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8770716">8770716</a></text>
<text top="776" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8770716"> </a></text>
<text top="739" left="258" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="757" left="258" width="87" height="19" font="0">Retrospective </text>
<text top="776" left="258" width="87" height="19" font="0">observational </text>
<text top="739" left="418" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="757" left="418" width="149" height="19" font="0">admitted to a university </text>
<text top="776" left="418" width="151" height="19" font="0">teaching hospital due to </text>
<text top="740" left="591" width="259" height="19" font="8"><b>1</b>°<b> endpoint:</b> Dx yield of echo beyond that </text>
<text top="758" left="591" width="209" height="19" font="0">provided by Hx, physical, and ECG </text>
<text top="776" left="591" width="3" height="19" font="0"> </text>
<text top="741" left="864" width="11" height="18" font="0">• </text>
<text top="739" left="875" width="8" height="20" font="4">•</text>
<text top="741" left="882" width="188" height="19" font="0">Limitations: Small sample size, </text>
<text top="760" left="875" width="201" height="19" font="0">test ordering at the discretion of </text>
<text top="778" left="875" width="208" height="19" font="0">the clinicians, did not address the </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 48 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="3" height="19" font="0"> </text>
<text top="87" left="258" width="3" height="19" font="0"> </text>
<text top="105" left="258" width="75" height="19" font="8"><b>Size:</b> N=128 </text>
<text top="87" left="418" width="129" height="19" font="0">syncope over a 7 mo </text>
<text top="105" left="418" width="47" height="19" font="0">period  </text>
<text top="123" left="418" width="3" height="19" font="0"> </text>
<text top="142" left="418" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="160" left="418" width="157" height="19" font="0">Syncope of known cause, </text>
<text top="178" left="418" width="129" height="19" font="0">presyncope, obvious </text>
<text top="197" left="418" width="151" height="19" font="0">seizure, referred for EPS </text>
<text top="87" left="591" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="105" left="591" width="252" height="20" font="0">• 48/128 (37.5%) had a cause of syncope </text>
<text top="124" left="601" width="233" height="19" font="0">identified. Of these 37/48 (77%) were </text>
<text top="143" left="601" width="218" height="19" font="0">diagnosed by Hx, physical and ECG. </text>
<text top="161" left="591" width="200" height="20" font="0">• 82/128 (64%) underwent echo </text>
<text top="180" left="591" width="252" height="20" font="0">• Echo normal in 52% of total population </text>
<text top="199" left="601" width="204" height="19" font="0">and 63% of those with no clinical </text>
<text top="217" left="601" width="208" height="19" font="0">evidence of heart disease (46% of </text>
<text top="236" left="601" width="234" height="19" font="0">population had no clinical evidence of </text>
<text top="254" left="601" width="89" height="19" font="0">heart disease) </text>
<text top="273" left="591" width="255" height="20" font="0">• Echo confirmatory in 48% of those with </text>
<text top="292" left="601" width="243" height="19" font="0">suspected heart diseases and refuted it </text>
<text top="310" left="601" width="44" height="19" font="0">in 52% </text>
<text top="328" left="591" width="243" height="20" font="0">• Echo provided no etiology of syncope </text>
<text top="347" left="601" width="201" height="19" font="0">that was unsuspected on clinical </text>
<text top="365" left="601" width="53" height="19" font="0">grounds </text>
<text top="87" left="875" width="213" height="19" font="0">impact of echo on management in </text>
<text top="105" left="875" width="188" height="19" font="0">those with clinically suspected </text>
<text top="123" left="875" width="180" height="19" font="0">heart disease in whom it was </text>
<text top="142" left="875" width="165" height="19" font="0">confirmatory half the time </text>
<text top="385" left="96" width="136" height="19" font="0">Sarasin FP, et al. 2002 </text>
<text top="403" left="96" width="28" height="19" font="0">(46)<b> </b></text>
<text top="421" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12231593">12231593</a></text>
<text top="421" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12231593"> </a></text>
<text top="440" left="96" width="3" height="19" font="0"> </text>
<text top="384" left="258" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="403" left="258" width="75" height="19" font="0">Prospective </text>
<text top="421" left="258" width="137" height="19" font="0">observational with 18-</text>
<text top="440" left="258" width="85" height="19" font="0">mo follow-up </text>
<text top="458" left="258" width="3" height="19" font="0"> </text>
<text top="476" left="258" width="75" height="19" font="8"><b>Size:</b> N=650 </text>
<text top="494" left="258" width="98" height="19" font="0">consecutive pts </text>
<text top="513" left="258" width="145" height="19" font="0">presenting to the ED of </text>
<text top="531" left="258" width="129" height="19" font="0">a university teaching </text>
<text top="549" left="258" width="86" height="19" font="0">hospital, who </text>
<text top="568" left="258" width="81" height="19" font="0">underwent a </text>
<text top="586" left="258" width="120" height="19" font="0">standardized initial </text>
<text top="604" left="258" width="143" height="19" font="0">clinical evaluation, and </text>
<text top="623" left="258" width="143" height="19" font="0">for those with syncope </text>
<text top="641" left="258" width="107" height="19" font="0">of undetermined </text>
<text top="659" left="258" width="133" height="19" font="0">etiology thereafter, a </text>
<text top="678" left="258" width="102" height="19" font="0">stepwise testing </text>
<text top="696" left="258" width="138" height="19" font="0">algorithm that started </text>
<text top="714" left="258" width="147" height="19" font="0">with echocardiography. </text>
<text top="384" left="418" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="403" left="418" width="130" height="19" font="0">Syncope with clinical </text>
<text top="421" left="418" width="158" height="19" font="0">suspicion of cardiac valve </text>
<text top="440" left="418" width="143" height="19" font="0">disease or unexplained </text>
<text top="458" left="418" width="109" height="19" font="0">syncope after Hx, </text>
<text top="476" left="418" width="107" height="19" font="0">physical and ECG </text>
<text top="494" left="418" width="3" height="19" font="0"> </text>
<text top="513" left="418" width="153" height="19" font="8"><b>Exclusion criteria:</b> Those </text>
<text top="531" left="418" width="153" height="19" font="0">presenting with syncope </text>
<text top="549" left="418" width="138" height="19" font="0">who did not complete </text>
<text top="568" left="418" width="106" height="19" font="0">the standardized </text>
<text top="586" left="418" width="119" height="19" font="0">evaluation (105) or </text>
<text top="604" left="418" width="136" height="19" font="0">refused to participate </text>
<text top="623" left="418" width="28" height="19" font="0">(33) </text>
<text top="385" left="591" width="233" height="19" font="8"><b>1</b>°<b> endpoint:</b> Diagnostic yield of echo, </text>
<text top="404" left="591" width="220" height="19" font="0">either confirming a suspected Dx or </text>
<text top="422" left="591" width="180" height="19" font="0">revealing an unexpected one </text>
<text top="440" left="591" width="3" height="19" font="0"> </text>
<text top="459" left="591" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="477" left="591" width="254" height="20" font="0">• 61/650 (9%) had a systolic murmur and </text>
<text top="496" left="601" width="230" height="19" font="0">severe AS was suspected in 20 (3% of </text>
<text top="514" left="601" width="228" height="19" font="0">total). Echo confirmed severe AS in 8 </text>
<text top="533" left="601" width="243" height="19" font="0">(40%). In 18 mo of follow-up no further </text>
<text top="551" left="601" width="173" height="19" font="0">cases of severe AS emerged </text>
<text top="569" left="591" width="209" height="20" font="0">• 155/650 (24%) had unexplained </text>
<text top="588" left="601" width="188" height="19" font="0">syncope and echo revealed no </text>
<text top="607" left="601" width="237" height="19" font="0">abnormalities that established a cause </text>
<text top="625" left="601" width="249" height="19" font="0">in them (this group was older with more </text>
<text top="643" left="601" width="205" height="19" font="0">comorbidities than those with an </text>
<text top="662" left="601" width="185" height="19" font="0">established cause of syncope) </text>
<text top="680" left="591" width="241" height="20" font="0">• 71/155 (46%) had “abnormal but not-</text>
<text top="699" left="601" width="221" height="19" font="0">relevant” echo findings that include </text>
<text top="717" left="601" width="208" height="19" font="0">clinically relevant findings such as </text>
<text top="736" left="601" width="223" height="19" font="0">severe MR, moderate PH, moderate </text>
<text top="754" left="601" width="54" height="19" font="0">MS, LVH </text>
<text top="384" left="864" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="403" left="864" width="213" height="20" font="0">• Echo is most useful to assess the </text>
<text top="422" left="875" width="201" height="19" font="0">severity of suspected underlying </text>
<text top="440" left="875" width="168" height="19" font="0">cardiac disease and for risk </text>
<text top="459" left="875" width="177" height="19" font="0">stratification in those whose </text>
<text top="477" left="875" width="212" height="19" font="0">syncope is unexplained but have a </text>
<text top="495" left="875" width="217" height="19" font="0">Hx of heart disease or an abnormal </text>
<text top="514" left="875" width="32" height="19" font="0">ECG. </text>
<text top="532" left="864" width="221" height="20" font="0">• Echo is unlikely to yield a clinically </text>
<text top="551" left="875" width="212" height="19" font="0">unexpected etiology of syncope in </text>
<text top="569" left="875" width="186" height="19" font="0">those w/o evidence of cardiac </text>
<text top="588" left="875" width="173" height="19" font="0">disease on initial evaluation </text>
<text top="606" left="864" width="185" height="20" font="0">• <b>Comment</b>: Echo has greater </text>
<text top="625" left="875" width="205" height="19" font="0">relevance than these conclusions </text>
<text top="643" left="875" width="209" height="19" font="0">suggest due to the possibility that </text>
<text top="662" left="875" width="181" height="19" font="0">the clinically relevant but not </text>
<text top="680" left="875" width="137" height="19" font="0">definitively diagnostic </text>
<text top="698" left="875" width="208" height="19" font="0">abnormalities (other than low EF) </text>
<text top="717" left="875" width="169" height="19" font="0">will influence management </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 49 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="591" width="228" height="20" font="0">• In those with a normal ECG (N=67), </text>
<text top="106" left="601" width="233" height="19" font="0">echo was normal or “non-relevant” in </text>
<text top="124" left="601" width="17" height="19" font="0">all </text>
<text top="143" left="591" width="249" height="20" font="0">• In those with a cardiac Hx or abnormal </text>
<text top="162" left="601" width="243" height="19" font="0">ECG (88/650 =13.5%), echo revealed EF </text>
<text top="180" left="601" width="224" height="19" font="0">≤40% in 24/88 (27%) and minor non-</text>
<text top="198" left="601" width="171" height="19" font="0">relevant findings in the rest </text>
<text top="217" left="591" width="244" height="20" font="0">• Arrhythmias were diagnosed in 12/24 </text>
<text top="236" left="601" width="242" height="19" font="0">(50%) of those with Hx of heart disease </text>
<text top="254" left="601" width="229" height="19" font="0">or abnormal ECG and low EF on echo </text>
<text top="272" left="601" width="243" height="19" font="0">and 12/64 (19%) of those with EF &gt;40% </text>
<text top="291" left="601" width="107" height="19" font="0">on echo (p&lt;0.01) </text>
<text top="310" left="96" width="130" height="19" font="0">Dagres N, et al. 2013 </text>
<text top="328" left="96" width="28" height="19" font="0">(47)<b> </b></text>
<text top="346" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24280765">24280765</a></text>
<text top="346" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24280765"> </a></text>
<text top="365" left="96" width="3" height="19" font="0"> </text>
<text top="383" left="96" width="14" height="19" font="0">   </text>
<text top="310" left="258" width="146" height="19" font="8"><b>Study type:</b> Descriptive </text>
<text top="328" left="258" width="115" height="19" font="0">survey of member </text>
<text top="346" left="258" width="112" height="19" font="0">institutions of the </text>
<text top="365" left="258" width="111" height="19" font="0">EHRA EP research </text>
<text top="383" left="258" width="54" height="19" font="0">network </text>
<text top="401" left="258" width="3" height="19" font="0"> </text>
<text top="419" left="258" width="132" height="19" font="8"><b>Size:</b> 43 centers from </text>
<text top="438" left="258" width="112" height="19" font="0">17 countries from </text>
<text top="456" left="258" width="149" height="19" font="0">Europe (and Argentina)  </text>
<text top="310" left="418" width="148" height="19" font="8"><b>Inclusion criteria:</b> EHRA </text>
<text top="328" left="429" width="91" height="19" font="0">members who </text>
<text top="346" left="429" width="109" height="19" font="0">responded to the </text>
<text top="365" left="429" width="43" height="19" font="0">survey </text>
<text top="383" left="418" width="3" height="19" font="0"> </text>
<text top="401" left="418" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="310" left="591" width="226" height="19" font="8"><b>1</b>°<b> endpoint:</b> Define current practice </text>
<text top="329" left="601" width="207" height="19" font="0">habits regarding the work-up and </text>
<text top="347" left="601" width="207" height="19" font="0">management of pts with syncope </text>
<text top="365" left="591" width="3" height="19" font="0"> </text>
<text top="384" left="591" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="402" left="585" width="259" height="20" font="0">•  ECG used “always or almost always” by </text>
<text top="421" left="601" width="221" height="19" font="0">98% of respondents (“in most case” </text>
<text top="440" left="601" width="34" height="19" font="0">=2%) </text>
<text top="458" left="585" width="261" height="20" font="0">•  Echo used “always or almost always’ by </text>
<text top="477" left="601" width="219" height="19" font="0">66% (“in most cases” =27%, “only if </text>
<text top="495" left="601" width="153" height="19" font="0">specific indication” =7%) </text>
<text top="514" left="588" width="251" height="20" font="0">•  Holter used “always or almost always” </text>
<text top="533" left="601" width="51" height="19" font="0">by 59%  </text>
<text top="551" left="588" width="257" height="20" font="0">•  All other tests queried &lt;50% “always or </text>
<text top="570" left="601" width="96" height="19" font="0">almost always” </text>
<text top="310" left="864" width="221" height="20" font="0">• Offers little regarding appropriate </text>
<text top="329" left="875" width="220" height="19" font="0">use of tests but does define current </text>
<text top="347" left="875" width="179" height="19" font="0">practice suggesting stubborn </text>
<text top="366" left="875" width="209" height="19" font="0">reliance on echo in contemporary </text>
<text top="384" left="875" width="197" height="19" font="0">practice despite data to suggest </text>
<text top="402" left="875" width="202" height="19" font="0">relatively low yield in unselected </text>
<text top="420" left="875" width="22" height="19" font="0">pts </text>
<text top="439" left="864" width="212" height="20" font="0">• 42% of respondents used formal </text>
<text top="458" left="875" width="219" height="19" font="0">diagnostic algorithms and only 26% </text>
<text top="476" left="875" width="182" height="19" font="0">had a dedicated syncope unit </text>
<text top="495" left="864" width="231" height="20" font="0">• Compared to other tests, there was </text>
<text top="514" left="875" width="213" height="19" font="0">relative uniformity of utilization of </text>
<text top="532" left="875" width="157" height="19" font="0">echo, second only to ECG </text>
<text top="550" left="864" width="3" height="19" font="0"> </text>
<text top="589" left="86" width="4" height="21" font="4"> </text>
<text top="609" left="86" width="979" height="23" font="5"><b>Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Nocturnal / Sleeping Bradyarrhythmias and </b></text>
<text top="631" left="86" width="210" height="23" font="5"><b>Sleep Apnea (Section-4.2.7) </b></text>
<text top="654" left="107" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="672" left="117" width="83" height="19" font="8"><b>Author; Year </b></text>
<text top="690" left="131" width="65" height="19" font="8"><b>Published</b> </text>
<text top="654" left="237" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="672" left="266" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="654" left="423" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="654" left="646" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="672" left="644" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="654" left="925" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="672" left="954" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="710" left="96" width="67" height="19" font="8"><b>NORMALS </b></text>
<text top="729" left="96" width="106" height="19" font="0">Brodsky M, et al. </text>
<text top="747" left="96" width="62" height="19" font="0">1977 (51) </text>
<text top="765" left="96" width="38" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/65912">65912</a></text>
<text top="765" left="134" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/65912"> </a></text>
<text top="784" left="96" width="3" height="19" font="0"> </text>
<text top="729" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="747" left="233" width="75" height="19" font="0">Prospective </text>
<text top="765" left="233" width="124" height="19" font="0">observational – 24h </text>
<text top="784" left="233" width="42" height="19" font="0">Holter </text>
<text top="729" left="378" width="166" height="19" font="8"><b>Inclusion criteria:</b> Healthy, </text>
<text top="747" left="378" width="153" height="19" font="0">Caucasian, male medical </text>
<text top="765" left="378" width="167" height="19" font="0">students, age 23–27 y with </text>
<text top="729" left="601" width="265" height="19" font="8"><b>1</b>°<b> endpoint:</b> Define rates of arrhythmia on </text>
<text top="748" left="612" width="239" height="19" font="0">24 h Holter in normal young Caucasian </text>
<text top="766" left="612" width="31" height="19" font="0">men </text>
<text top="784" left="601" width="3" height="19" font="0"> </text>
<text top="729" left="891" width="192" height="20" font="0">• Sinus bradycardia &lt;40 bpm is </text>
<text top="748" left="902" width="193" height="19" font="0">common in healthy young men </text>
<text top="766" left="902" width="151" height="19" font="0">(none trained athletes),  </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 50 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="233" width="3" height="19" font="0"> </text>
<text top="105" left="233" width="54" height="19" font="8"><b>Size:</b> 50  </text>
<text top="87" left="378" width="166" height="19" font="0">normal exam, ECG, cardiac </text>
<text top="105" left="378" width="174" height="19" font="0">silhouette on CXR, and echo </text>
<text top="123" left="378" width="3" height="19" font="0"> </text>
<text top="142" left="378" width="3" height="19" font="0"> </text>
<text top="160" left="378" width="150" height="19" font="8"><b>Exclusion criteria:</b> Of 61 </text>
<text top="178" left="378" width="201" height="19" font="0">volunteers, 9 excluded and 2 did </text>
<text top="197" left="378" width="199" height="19" font="0">not complete study. Excluded: 2 </text>
<text top="215" left="378" width="177" height="19" font="0">with DM,1 each with ASH on </text>
<text top="233" left="378" width="139" height="19" font="0">echo, MVP, WPW, h/o </text>
<text top="252" left="378" width="205" height="19" font="0">pericarditis, IVCD, MVP and HTN, </text>
<text top="270" left="378" width="98" height="19" font="0">QRS axis of -100</text>
<text top="270" left="476" width="5" height="12" font="7">○</text>
<text top="270" left="482" width="3" height="19" font="0"> </text>
<text top="87" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="105" left="601" width="196" height="20" font="0">• 50% marked sinus arrhythmia </text>
<text top="124" left="601" width="234" height="20" font="0">• 24% SB &lt;40 bpm at least once/night </text>
<text top="144" left="601" width="127" height="20" font="0">• 28% &gt;1.75 s pause </text>
<text top="163" left="601" width="100" height="20" font="0">• 4% pause &gt;2 s </text>
<text top="182" left="601" width="40" height="20" font="0">• 8% 1</text>
<text top="182" left="641" width="3" height="12" font="7">◦</text>
<text top="182" left="644" width="220" height="19" font="0"> AVB (1/2 exclusively nocturnal. 1/2 </text>
<text top="201" left="612" width="109" height="19" font="0">both d and night) </text>
<text top="219" left="601" width="82" height="20" font="0">• 6% type 1 2</text>
<text top="220" left="682" width="10" height="12" font="7">nd</text>
<text top="220" left="693" width="149" height="19" font="0"> degree AVB-virtually all </text>
<text top="238" left="612" width="66" height="19" font="0">nocturnal  </text>
<text top="257" left="601" width="3" height="19" font="0"> </text>
<text top="87" left="891" width="200" height="20" font="0">• Pauses &gt;2 s and type 1 second-</text>
<text top="106" left="902" width="171" height="19" font="0">degree AVB are uncommon </text>
<text top="126" left="902" width="23" height="19" font="0">(4%</text>
<text top="124" left="925" width="8" height="21" font="4">–</text>
<text top="126" left="933" width="26" height="19" font="0">6%) </text>
<text top="145" left="891" width="193" height="20" font="0">• No specific screening for OSA </text>
<text top="164" left="902" width="183" height="19" font="0">and no information regarding </text>
<text top="182" left="902" width="52" height="19" font="0">obesity. </text>
<text top="200" left="891" width="3" height="19" font="0"> </text>
<text top="289" left="96" width="90" height="19" font="0">Bjerregaard P, </text>
<text top="307" left="96" width="62" height="19" font="0">1983 (52) </text>
<text top="326" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7160388">7160388</a></text>
<text top="326" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7160388"> </a></text>
<text top="344" left="96" width="3" height="19" font="0"> </text>
<text top="289" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="307" left="233" width="75" height="19" font="0">Prospective </text>
<text top="326" left="233" width="127" height="19" font="0">observational – 24 h </text>
<text top="344" left="233" width="42" height="19" font="0">Holter </text>
<text top="362" left="233" width="3" height="19" font="0"> </text>
<text top="381" left="233" width="58" height="19" font="8"><b>Size:</b> 260 </text>
<text top="289" left="378" width="207" height="19" font="8"><b>Inclusion criteria:</b> Healthy middle </text>
<text top="307" left="378" width="201" height="19" font="0">age and older volunteers (40–79 </text>
<text top="326" left="378" width="186" height="19" font="0">y). 65% male. Mean age: male </text>
<text top="344" left="378" width="122" height="19" font="0">=53 y; female =56 y </text>
<text top="362" left="378" width="3" height="19" font="0"> </text>
<text top="381" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="399" left="378" width="204" height="20" font="0">• technically inadequate tracings </text>
<text top="418" left="389" width="37" height="19" font="0">(N=9) </text>
<text top="437" left="378" width="85" height="20" font="0">• HTN (N=17) </text>
<text top="456" left="378" width="199" height="20" font="0">• Abnormal 12-lead ECG x 2 min </text>
<text top="475" left="389" width="180" height="19" font="0">except for arrhythmias (N=9) </text>
<text top="493" left="378" width="85" height="20" font="0">• CV Sx (N=7) </text>
<text top="512" left="378" width="165" height="20" font="0">• Illness within 3 mo (N=3) </text>
<text top="531" left="378" width="183" height="20" font="0">• Abnormal CV physical exam </text>
<text top="550" left="389" width="37" height="19" font="0">(N=5) </text>
<text top="569" left="378" width="195" height="20" font="0">• CM or pul. venous congestion </text>
<text top="588" left="389" width="84" height="19" font="0">on CXR (N=0) </text>
<text top="290" left="601" width="270" height="19" font="8"><b>1</b>°<b> endpoint:</b> Establish norms for mean 24 h </text>
<text top="308" left="612" width="221" height="19" font="0">heart rate, minimal HR, and pauses  </text>
<text top="326" left="601" width="3" height="19" font="0"> </text>
<text top="345" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="363" left="601" width="259" height="20" font="0">• Mean heart rate =74±18 bpm (range 53–</text>
<text top="382" left="612" width="23" height="19" font="0">95) </text>
<text top="401" left="601" width="263" height="20" font="0">• Mean min heart rate =56±16 bpm (range </text>
<text top="420" left="612" width="46" height="19" font="0">36–78) </text>
<text top="438" left="601" width="149" height="20" font="0">• 30% had pause ≥1.5 s  </text>
<text top="457" left="601" width="238" height="20" font="0">• &lt;1% had pause &gt;2 s (longest =2.24 s) </text>
<text top="476" left="601" width="244" height="20" font="0">• 60% of those with pauses had longest </text>
<text top="495" left="611" width="90" height="19" font="0">pause at night </text>
<text top="514" left="601" width="118" height="20" font="0">• 4.6% sinus arrest </text>
<text top="533" left="601" width="132" height="20" font="0">•  3.5% blocked PACs </text>
<text top="552" left="601" width="229" height="20" font="0">• 0.8% Wenckebach (both nocturnal) </text>
<text top="571" left="601" width="243" height="20" font="0">• 1.1% marked SB (heart rate &lt;40 bpm) </text>
<text top="590" left="601" width="270" height="20" font="0">• Males, non-smokers, and physically active </text>
<text top="609" left="611" width="221" height="19" font="0">had lower mean and minimal HR by </text>
<text top="627" left="611" width="213" height="19" font="0">ANOVA (no p value reported). Age </text>
<text top="646" left="611" width="95" height="19" font="0">differences NS. </text>
<text top="664" left="601" width="3" height="19" font="0"> </text>
<text top="289" left="891" width="202" height="20" font="0">• Nocturnal pauses &gt;2 s, marked </text>
<text top="308" left="902" width="152" height="19" font="0">sinus brady, and type 1 2</text>
<text top="308" left="1054" width="10" height="12" font="7">nd</text>
<text top="308" left="1064" width="3" height="19" font="0"> </text>
<text top="326" left="902" width="152" height="19" font="0">degree AVB are rare in a </text>
<text top="345" left="902" width="131" height="19" font="0">middle aged, healthy </text>
<text top="363" left="902" width="143" height="19" font="0">population (1% or less) </text>
<text top="382" left="891" width="192" height="20" font="0">• Sinus arrest is more common </text>
<text top="401" left="902" width="162" height="19" font="0">but still uncommon in this </text>
<text top="419" left="902" width="111" height="19" font="0">population (~ 5%) </text>
<text top="437" left="891" width="191" height="20" font="0">• No information on obesity or </text>
<text top="456" left="902" width="112" height="19" font="0">screening for OSA </text>
<text top="475" left="891" width="3" height="19" font="0"> </text>
<text top="683" left="96" width="100" height="19" font="0">Clarke JM, et al. </text>
<text top="701" left="96" width="30" height="19" font="0">1976</text>
<text top="700" left="127" width="4" height="21" font="4"> </text>
<text top="701" left="130" width="28" height="19" font="0">(53) </text>
<text top="720" left="96" width="38" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/74472">74472</a></text>
<text top="720" left="134" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/74472"> </a></text>
<text top="738" left="96" width="3" height="19" font="0"> </text>
<text top="683" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="701" left="233" width="75" height="19" font="0">Prospective </text>
<text top="720" left="233" width="101" height="19" font="0">observational, 2 </text>
<text top="738" left="233" width="128" height="19" font="0">separate 24 h Holter </text>
<text top="756" left="233" width="3" height="19" font="0"> </text>
<text top="683" left="378" width="162" height="19" font="8"><b>Inclusion criteria:</b> Healthy </text>
<text top="701" left="378" width="206" height="19" font="0">volunteers (16–65 y) with normal </text>
<text top="720" left="378" width="143" height="19" font="0">clinical exam, ECG, and </text>
<text top="738" left="378" width="158" height="19" font="0">biochemical/hematologic </text>
<text top="756" left="378" width="62" height="19" font="0">screening </text>
<text top="775" left="378" width="3" height="19" font="0"> </text>
<text top="684" left="601" width="262" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the distribution and </text>
<text top="702" left="612" width="259" height="19" font="0">frequency of arrhythmias in 2 separate 24 </text>
<text top="721" left="612" width="252" height="19" font="0">h Holter monitors in healthy subjects (41 </text>
<text top="739" left="612" width="106" height="19" font="0">male, 45 female) </text>
<text top="757" left="601" width="3" height="19" font="0"> </text>
<text top="775" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="683" left="891" width="177" height="20" font="0">• In healthy adolescents and </text>
<text top="702" left="902" width="52" height="19" font="0">adults, 2</text>
<text top="702" left="954" width="10" height="12" font="7">nd</text>
<text top="702" left="964" width="119" height="19" font="0"> degree AVB is rare </text>
<text top="721" left="902" width="157" height="19" font="0">and exclusively nocturnal </text>
<text top="739" left="902" width="42" height="19" font="0">(2.5%) </text>
<text top="757" left="891" width="172" height="20" font="0">• Heart rate drops ~20 bpm </text>
<text top="776" left="902" width="144" height="19" font="0">during sleep relative to </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 51 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="233" width="109" height="19" font="8"><b>Size:</b> 86/101 G.D. </text>
<text top="105" left="233" width="78" height="19" font="0">Searle &amp; Co. </text>
<text top="123" left="233" width="64" height="19" font="0">employee </text>
<text top="142" left="233" width="117" height="19" font="0">volunteers, mostly </text>
<text top="160" left="233" width="90" height="19" font="0">office workers<b> </b></text>
<text top="87" left="378" width="195" height="19" font="8"><b>Exclusion criteria:</b> HTN (6), BBB </text>
<text top="105" left="378" width="191" height="19" font="0">(2), heart murmur (1), epilepsy </text>
<text top="123" left="378" width="199" height="19" font="0">(1), sedative use (3), anemia (1), </text>
<text top="142" left="378" width="71" height="19" font="0">anxiety (1) <b> </b></text>
<text top="87" left="604" width="184" height="20" font="0">•  2/81 (2.5%) had nocturnal 2</text>
<text top="88" left="788" width="10" height="12" font="7">nd</text>
<text top="88" left="798" width="49" height="19" font="0"> degree </text>
<text top="106" left="618" width="219" height="19" font="0">AVB: 1 had both type 1 and type 2 2</text>
<text top="106" left="837" width="10" height="12" font="7">nd</text>
<text top="106" left="847" width="3" height="19" font="0"> </text>
<text top="124" left="618" width="215" height="19" font="0">degree AVB, the other had type 1 2</text>
<text top="124" left="832" width="10" height="12" font="7">nd</text>
<text top="124" left="842" width="3" height="19" font="0"> </text>
<text top="143" left="618" width="104" height="19" font="0">degree AVB only </text>
<text top="161" left="604" width="106" height="20" font="0">•  1 subject had 1</text>
<text top="162" left="710" width="7" height="12" font="7">st</text>
<text top="162" left="717" width="78" height="19" font="0"> degree AVB </text>
<text top="180" left="604" width="255" height="20" font="0">•  8 (10%) subjects had junctional rhythm </text>
<text top="199" left="618" width="148" height="19" font="0">both awake and asleep. </text>
<text top="217" left="601" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="902" width="182" height="19" font="0">wakefulness in both men and </text>
<text top="105" left="902" width="49" height="19" font="0">women </text>
<text top="124" left="891" width="173" height="20" font="0">• Average daily heart rate is </text>
<text top="143" left="902" width="169" height="19" font="0">higher in women than men </text>
<text top="161" left="902" width="170" height="19" font="0">(p&lt;0.05) and in smokers vs. </text>
<text top="179" left="902" width="145" height="19" font="0">non-smokers (p&lt;0.001) </text>
<text top="198" left="891" width="191" height="20" font="0">• No information on obesity or </text>
<text top="217" left="902" width="112" height="19" font="0">screening for OSA </text>
<text top="237" left="96" width="114" height="19" font="0">Fleg JL, et al. 1982 </text>
<text top="255" left="96" width="28" height="19" font="0">(54) </text>
<text top="273" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7056104">7056104</a></text>
<text top="273" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7056104"> </a></text>
<text top="291" left="96" width="3" height="19" font="0"> </text>
<text top="236" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="255" left="233" width="75" height="19" font="0">Prospective </text>
<text top="273" left="233" width="127" height="19" font="0">observational – 24 h </text>
<text top="291" left="233" width="42" height="19" font="0">Holter </text>
<text top="310" left="233" width="3" height="19" font="0"> </text>
<text top="328" left="233" width="128" height="19" font="8"><b>Size:</b> 98/110 healthy </text>
<text top="346" left="233" width="128" height="19" font="0">active subjects, ages </text>
<text top="365" left="233" width="114" height="19" font="0">60–85 y (69 men). </text>
<text top="383" left="233" width="121" height="19" font="0">59/98 (60%) in 60s, </text>
<text top="401" left="233" width="117" height="19" font="0">32/98 (33%) in 70s </text>
<text top="420" left="233" width="132" height="19" font="0">and 7/98 (7%) in 80s.<b> </b></text>
<text top="236" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="255" left="378" width="189" height="20" font="0">• Participants in the Baltimore </text>
<text top="274" left="390" width="173" height="19" font="0">Longitudinal Study on Aging </text>
<text top="292" left="378" width="48" height="20" font="0">• &gt;60 y </text>
<text top="311" left="378" width="104" height="20" font="0">• No CV Hx or sx </text>
<text top="331" left="378" width="130" height="20" font="0">• No systemic illness </text>
<text top="350" left="378" width="68" height="20" font="0">• NL exam </text>
<text top="369" left="378" width="86" height="20" font="0">• BP &lt;160/95 </text>
<text top="388" left="378" width="59" height="20" font="0">• NL CXR </text>
<text top="407" left="378" width="204" height="20" font="0">• No MI, atrial abnormality, LVH, </text>
<text top="426" left="390" width="121" height="19" font="0">RVH or BBB on ECG </text>
<text top="444" left="378" width="57" height="20" font="0">• NL PFT </text>
<text top="464" left="378" width="57" height="20" font="0">• NL ETT </text>
<text top="483" left="378" width="163" height="20" font="0">• No meds affecting heart </text>
<text top="502" left="390" width="79" height="19" font="0">rate/rhythm </text>
<text top="520" left="378" width="3" height="19" font="0"> </text>
<text top="538" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="557" left="378" width="186" height="20" font="0">• 8/38 had abnormal thallium </text>
<text top="576" left="378" width="165" height="20" font="0">• 1/38 had abnormal echo </text>
<text top="595" left="378" width="181" height="20" font="0">• 3 technically unsatisfactory </text>
<text top="614" left="390" width="42" height="19" font="0">Holter </text>
<text top="237" left="601" width="229" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe frequency and </text>
<text top="256" left="599" width="276" height="19" font="0">distribution of arrhythmias in healthy elderly </text>
<text top="274" left="599" width="41" height="19" font="0">adults </text>
<text top="292" left="601" width="3" height="19" font="0"> </text>
<text top="310" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="329" left="601" width="247" height="20" font="0">• Marked SB (heart rate &lt;40 bpm): 2/98 </text>
<text top="348" left="612" width="31" height="19" font="0">(2%) </text>
<text top="366" left="601" width="275" height="20" font="0">• Sinus pause &gt;1.5 s: 2/98 (2%). No pause &gt;2 </text>
<text top="385" left="612" width="9" height="19" font="0">s </text>
<text top="404" left="601" width="18" height="20" font="0">• 2</text>
<text top="404" left="619" width="10" height="12" font="7">nd</text>
<text top="405" left="629" width="145" height="19" font="0"> degree AVB: 1/98 (1%) </text>
<text top="423" left="601" width="242" height="20" font="0">• All bradyarrhythmias occurred during </text>
<text top="442" left="612" width="36" height="19" font="0">sleep </text>
<text top="460" left="601" width="3" height="19" font="8"><b> </b></text>
<text top="236" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="255" left="890" width="153" height="20" font="0">•  Healthy, active elderly </text>
<text top="274" left="903" width="149" height="19" font="0">individuals screened for </text>
<text top="292" left="903" width="139" height="19" font="0">significant cardiac and </text>
<text top="311" left="903" width="175" height="19" font="0">pulmonary disease manifest </text>
<text top="329" left="903" width="91" height="19" font="0">rare nocturnal </text>
<text top="347" left="903" width="161" height="19" font="0">bradyarrhythmias (1–2%)  </text>
<text top="633" left="564" width="65" height="19" font="8"><b>ATHLETES </b></text>
<text top="652" left="96" width="93" height="19" font="0">Meytes I, et al. </text>
<text top="670" left="96" width="62" height="19" font="0">1975 (55) </text>
<text top="689" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1163436">1163436</a></text>
<text top="689" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1163436"> </a></text>
<text top="707" left="100" width="3" height="19" font="0"> </text>
<text top="652" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="670" left="233" width="75" height="19" font="0">Prospective </text>
<text top="689" left="233" width="97" height="19" font="0">observational – </text>
<text top="707" left="233" width="120" height="19" font="0">awake 12-lead ECG </text>
<text top="725" left="233" width="3" height="19" font="0"> </text>
<text top="743" left="233" width="58" height="19" font="8"><b>Size:</b> 126 </text>
<text top="652" left="378" width="199" height="19" font="8"><b>Inclusion criteria:</b> Athletes from </text>
<text top="670" left="378" width="134" height="19" font="0">Israeli national teams </text>
<text top="689" left="378" width="3" height="19" font="0"> </text>
<text top="707" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="653" left="601" width="236" height="19" font="8"><b>1</b>°<b> endpoint:</b> Frequency of conduction </text>
<text top="671" left="612" width="254" height="19" font="0">disturbances on awake 12-lead ECG after </text>
<text top="689" left="612" width="189" height="19" font="0">15 min. of resting recumbency </text>
<text top="708" left="601" width="3" height="19" font="0"> </text>
<text top="726" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="745" left="601" width="108" height="20" font="0">• 11/126 (8.7%) 1</text>
<text top="745" left="709" width="7" height="12" font="7">st</text>
<text top="745" left="716" width="158" height="19" font="0"> degree AVB (P-R ≥0.21 s) </text>
<text top="652" left="891" width="110" height="20" font="0">• Wakeful type I 2</text>
<text top="653" left="1001" width="10" height="12" font="7">nd</text>
<text top="653" left="1012" width="78" height="19" font="0"> degree AVB </text>
<text top="671" left="902" width="148" height="19" font="0">is rare in athletes and is </text>
<text top="689" left="902" width="182" height="19" font="0">presumed to be physiological </text>
<text top="708" left="891" width="151" height="20" font="0">• Authors point out it is, </text>
<text top="727" left="902" width="161" height="19" font="0">nonetheless, “much more </text>
<text top="745" left="902" width="141" height="19" font="0">frequent than hitherto </text>
<text top="763" left="902" width="75" height="19" font="0">suspected.” </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 52 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="601" width="138" height="20" font="0">• 3/126 (2.4%) type I 2</text>
<text top="88" left="739" width="10" height="12" font="7">nd</text>
<text top="88" left="749" width="78" height="19" font="0"> degree AVB </text>
<text top="106" left="612" width="216" height="19" font="0">(abolished by sitting, standing, and </text>
<text top="124" left="612" width="60" height="19" font="0">atropine) </text>
<text top="143" left="601" width="270" height="20" font="0">• Followed the 3 athletes with Wenckebach </text>
<text top="162" left="612" width="258" height="19" font="0">for 6 y – Wenckebach present only during </text>
<text top="180" left="612" width="257" height="19" font="0">intense training and resolved consistently </text>
<text top="198" left="612" width="265" height="19" font="0">within a few weeks of reducing intensity of </text>
<text top="217" left="612" width="51" height="19" font="0">training </text>
<text top="235" left="601" width="195" height="20" font="0">• No heart disease or decline in </text>
<text top="254" left="612" width="202" height="19" font="0">performance developed over 6 y </text>
<text top="87" left="891" width="190" height="20" font="0">• By comparison: 1/67,375 asx </text>
<text top="106" left="902" width="151" height="19" font="0">healthy male USAF fliers </text>
<text top="124" left="902" width="118" height="19" font="0">manifested type I 2</text>
<text top="124" left="1019" width="10" height="12" font="7">nd</text>
<text top="124" left="1030" width="49" height="19" font="0"> degree </text>
<text top="143" left="902" width="171" height="19" font="0">AVB on awake routine ECG  </text>
<text top="273" left="96" width="116" height="19" font="0">Viitasalo MT, et al. </text>
<text top="291" left="96" width="30" height="19" font="0">1982</text>
<text top="290" left="127" width="4" height="21" font="4"> </text>
<text top="291" left="130" width="28" height="19" font="0">(56) </text>
<text top="310" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7059398">7059398</a></text>
<text top="310" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7059398"> </a></text>
<text top="328" left="96" width="3" height="19" font="0"> </text>
<text top="273" left="233" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="291" left="233" width="75" height="19" font="0">Prospective </text>
<text top="310" left="233" width="97" height="19" font="0">observational – </text>
<text top="328" left="233" width="109" height="19" font="0">Nocturnal Holter  </text>
<text top="346" left="233" width="3" height="19" font="0"> </text>
<text top="365" left="233" width="131" height="19" font="8"><b>Size:</b> 35 Finnish male </text>
<text top="383" left="233" width="70" height="19" font="0">“top-class” </text>
<text top="401" left="233" width="64" height="19" font="0">nationally </text>
<text top="420" left="233" width="76" height="19" font="0">competitive </text>
<text top="438" left="233" width="121" height="19" font="0">endurance athletes </text>
<text top="456" left="233" width="124" height="19" font="0">(mean age 23.1±6.1 </text>
<text top="475" left="233" width="113" height="19" font="0">y) and 35 controls </text>
<text top="493" left="233" width="131" height="19" font="0">(age 23.0±5.8 y) who </text>
<text top="511" left="233" width="121" height="19" font="0">were med students </text>
<text top="530" left="233" width="126" height="19" font="0">and army conscripts </text>
<text top="548" left="233" width="88" height="19" font="0">who were not </text>
<text top="566" left="233" width="117" height="19" font="0">engaged in regular </text>
<text top="584" left="233" width="111" height="19" font="0">intensive physical </text>
<text top="603" left="233" width="130" height="19" font="0">training, normal ECG </text>
<text top="621" left="233" width="57" height="19" font="0">and CXR  </text>
<text top="273" left="378" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="292" left="378" width="166" height="20" font="0">• ≥5 y of intensive physical </text>
<text top="311" left="389" width="51" height="19" font="0">training </text>
<text top="329" left="378" width="141" height="20" font="0">• Normal clinical exam </text>
<text top="348" left="378" width="207" height="20" font="0">• No “changes” in resting 12-lead </text>
<text top="367" left="389" width="28" height="19" font="0">ECG </text>
<text top="385" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="404" left="378" width="210" height="20" font="0">• H/O CV disease or other disease </text>
<text top="423" left="389" width="190" height="19" font="0">known to affect the CV system </text>
<text top="441" left="378" width="195" height="20" font="0">• CXR findings other than those </text>
<text top="460" left="389" width="183" height="19" font="0">associated with athletic heart </text>
<text top="479" left="378" width="145" height="20" font="0">• “Permanently” under </text>
<text top="498" left="389" width="72" height="19" font="0">medication </text>
<text top="516" left="378" width="201" height="20" font="0">• Taking meds at the time of the </text>
<text top="535" left="389" width="37" height="19" font="0">study </text>
<text top="554" left="378" width="60" height="20" font="0">• Smoker </text>
<text top="573" left="378" width="188" height="20" font="0">• URI within 1 mo of the study </text>
<text top="274" left="601" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the range of </text>
<text top="292" left="601" width="208" height="19" font="0">arrhythmias including conduction </text>
<text top="311" left="601" width="226" height="19" font="0">disturbances on nocturnal 2-channel </text>
<text top="329" left="601" width="254" height="19" font="0">ambulatory ECG monitor (4pm–8am). No </text>
<text top="347" left="601" width="241" height="19" font="0">training or alcohol consumption during </text>
<text top="366" left="601" width="37" height="19" font="0">study </text>
<text top="384" left="601" width="3" height="19" font="0"> </text>
<text top="402" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="421" left="601" width="264" height="20" font="0">• Slowest heart rate =37.7±4.3 bpm (range </text>
<text top="440" left="612" width="227" height="19" font="0">24–48) in athletes and 45.4±6.3 bpm </text>
<text top="458" left="612" width="218" height="19" font="0">(range 33–63) in controls (p&lt;0.001) </text>
<text top="476" left="601" width="269" height="20" font="0">• 13/35 (37.1%) of athletes and 2/35 (5.7%) </text>
<text top="495" left="612" width="252" height="19" font="0">of controls had sinus pause &gt;2 s (all from </text>
<text top="514" left="612" width="258" height="19" font="0">10pm–6am). Longest pause =2.76 and 2.6 </text>
<text top="532" left="612" width="86" height="19" font="0">s respectively </text>
<text top="550" left="601" width="18" height="20" font="0">• 1</text>
<text top="551" left="619" width="7" height="12" font="7">st</text>
<text top="551" left="626" width="237" height="19" font="0"> degree AVB (PR &gt;0.22): 13/35 (37.1%) </text>
<text top="569" left="612" width="246" height="19" font="0">of athletes and 5/35 (14.3%) of controls </text>
<text top="588" left="612" width="238" height="19" font="0">(p&lt;0.05) – 6 exclusively during sleep, 4 </text>
<text top="606" left="612" width="253" height="19" font="0">asleep and awake, 3 exclusively awake in </text>
<text top="624" left="612" width="163" height="19" font="0">athletes. All controls had 1</text>
<text top="624" left="774" width="7" height="12" font="7">st</text>
<text top="624" left="781" width="78" height="19" font="0"> degree AVB </text>
<text top="643" left="612" width="147" height="19" font="0">exclusively during sleep </text>
<text top="661" left="601" width="62" height="20" font="0">• Type 1 2</text>
<text top="662" left="663" width="10" height="12" font="7">nd</text>
<text top="662" left="673" width="180" height="19" font="0"> degree AVB: 8/35 (22.9%) of </text>
<text top="680" left="612" width="222" height="19" font="0">athletes and 2/35 (5.7%) of controls </text>
<text top="698" left="612" width="239" height="19" font="0">(p&lt;0.05) – 5 exclusively while asleep, 2 </text>
<text top="717" left="612" width="247" height="19" font="0">awake and asleep, and exclusively while </text>
<text top="735" left="612" width="209" height="19" font="0">awake in 1. All controls had type 1</text>
<text top="735" left="820" width="2" height="12" font="7"> </text>
<text top="735" left="823" width="8" height="19" font="0">2</text>
<text top="735" left="830" width="10" height="12" font="7">nd</text>
<text top="735" left="840" width="3" height="19" font="0"> </text>
<text top="753" left="612" width="222" height="19" font="0">degree AVB exclusively during sleep </text>
<text top="273" left="891" width="194" height="20" font="0">• Heart rate slows substantially </text>
<text top="292" left="902" width="160" height="19" font="0">(&gt;20 bpm) while asleep in </text>
<text top="311" left="902" width="192" height="19" font="0">athletes and non-athletes alike </text>
<text top="329" left="891" width="182" height="20" font="0">• Nocturnal sinus pauses &gt;2 s </text>
<text top="348" left="902" width="170" height="19" font="0">are common in young male </text>
<text top="366" left="902" width="185" height="19" font="0">athletes (present in &gt;1/3) and </text>
<text top="385" left="902" width="146" height="19" font="0">infrequent in untrained </text>
<text top="403" left="902" width="162" height="19" font="0">healthy young men (&lt;6%)  </text>
<text top="421" left="891" width="18" height="20" font="0">• 1</text>
<text top="422" left="909" width="7" height="12" font="7">st</text>
<text top="422" left="916" width="163" height="19" font="0"> degree AVB at any time is </text>
<text top="440" left="902" width="147" height="19" font="0">common in young male </text>
<text top="459" left="902" width="185" height="19" font="0">athletes (present in &gt;1/3) and </text>
<text top="477" left="902" width="186" height="19" font="0">occasional in untrained young </text>
<text top="495" left="902" width="142" height="19" font="0">men (present in ~15%) </text>
<text top="514" left="891" width="198" height="20" font="0">• AVN Wenckebach and SB with </text>
<text top="533" left="902" width="173" height="19" font="0">junctional or idioventricular </text>
<text top="551" left="902" width="183" height="19" font="0">escape rhythm are both fairly </text>
<text top="569" left="902" width="147" height="19" font="0">common in young male </text>
<text top="588" left="902" width="162" height="19" font="0">athletes (≥20%) and occur </text>
<text top="606" left="902" width="144" height="19" font="0">primarily while asleep.  </text>
<text top="624" left="891" width="204" height="20" font="0">• AVN Wenckebach is infrequent </text>
<text top="643" left="902" width="188" height="19" font="0">in untrained young men (&lt;6%) </text>
<text top="662" left="902" width="175" height="19" font="0">and occurs exclusively while </text>
<text top="680" left="902" width="43" height="19" font="0">asleep </text>
<text top="698" left="891" width="140" height="20" font="0">• SB with junctional or </text>
<text top="717" left="902" width="186" height="19" font="0">idioventricular escape rhythm </text>
<text top="736" left="902" width="191" height="19" font="0">and type 2 second-degree AVB </text>
<text top="754" left="902" width="142" height="19" font="0">are exceedingly rare in </text>
<text top="772" left="902" width="184" height="19" font="0">untrained healthy young men </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 53 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="601" width="62" height="20" font="0">• Type 2 2</text>
<text top="88" left="663" width="10" height="12" font="7">nd</text>
<text top="88" left="673" width="172" height="19" font="0"> degree AVB: 3/35 (8.6%) of </text>
<text top="106" left="612" width="250" height="19" font="0">athletes but no controls – 1 while awake </text>
<text top="124" left="612" width="237" height="19" font="0">and asleep, 1 only while awake, 1 only </text>
<text top="143" left="612" width="79" height="19" font="0">while asleep </text>
<text top="161" left="601" width="209" height="20" font="0">• SB with competing junctional or </text>
<text top="180" left="612" width="241" height="19" font="0">idioventricular rhythm in 7/35 (20%) of </text>
<text top="198" left="612" width="240" height="19" font="0">athletes but no controls – 3 exclusively </text>
<text top="217" left="612" width="246" height="19" font="0">while asleep, 3 while awake and asleep, </text>
<text top="235" left="612" width="185" height="19" font="0">and 1 exclusively while awake </text>
<text top="87" left="902" width="191" height="19" font="0">while awake or asleep (neither </text>
<text top="105" left="902" width="176" height="19" font="0">demonstrated in this study). </text>
<text top="254" left="96" width="120" height="19" font="0">Northcote RJ, et al. </text>
<text top="272" left="96" width="62" height="19" font="0">1989 (57) </text>
<text top="291" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2923752">2923752</a></text>
<text top="291" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2923752"> </a></text>
<text top="309" left="96" width="3" height="19" font="0"> </text>
<text top="254" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="272" left="233" width="75" height="19" font="0">Prospective </text>
<text top="291" left="233" width="127" height="19" font="0">observational – 48 h </text>
<text top="309" left="233" width="42" height="19" font="0">Holter </text>
<text top="327" left="233" width="3" height="19" font="0"> </text>
<text top="345" left="233" width="84" height="19" font="8"><b>Size:</b> 20 male </text>
<text top="364" left="233" width="102" height="19" font="0">Scottish veteran </text>
<text top="382" left="233" width="122" height="19" font="0">runners and 20 age-</text>
<text top="401" left="233" width="121" height="19" font="0">matched sedentary </text>
<text top="419" left="233" width="86" height="19" font="0">male controls </text>
<text top="254" left="378" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="273" left="378" width="163" height="20" font="0">• Age &gt;45 y (mean =56±7) </text>
<text top="292" left="378" width="146" height="20" font="0">• &gt;25 y regular running </text>
<text top="311" left="378" width="97" height="20" font="0">• &gt;25 miles/wk </text>
<text top="330" left="378" width="3" height="19" font="0"> </text>
<text top="348" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="366" left="378" width="67" height="20" font="0">• Smoking </text>
<text top="386" left="378" width="91" height="20" font="0">• Medications </text>
<text top="405" left="378" width="104" height="20" font="0">• Hx CV disease. </text>
<text top="255" left="601" width="256" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe distribution of ECG </text>
<text top="273" left="601" width="252" height="19" font="0">abnormalities and arrhythmias in middle-</text>
<text top="291" left="601" width="257" height="19" font="0">aged male athletes detected with resting, </text>
<text top="310" left="601" width="217" height="19" font="0">exercise, and 48 H ambulatory ECG </text>
<text top="328" left="601" width="3" height="19" font="0"> </text>
<text top="346" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="365" left="601" width="143" height="20" font="0">•  Heart rate &lt;35 bpm  </text>
<text top="384" left="620" width="132" height="19" font="0">Athletes: 8/20 (40%)  </text>
<text top="402" left="601" width="125" height="19" font="0"> Controls: 1/20 (5%) </text>
<text top="421" left="601" width="186" height="20" font="0">•  Mean nocturnal heart rate  </text>
<text top="440" left="607" width="138" height="19" font="0"> Athletes: 51±8.5 bpm </text>
<text top="458" left="607" width="146" height="19" font="0"> Controls: 66±13.2 bpm </text>
<text top="476" left="601" width="161" height="20" font="0">•  Sinus pauses (1.8–15 s) </text>
<text top="495" left="607" width="239" height="19" font="0"> Athletes: 8/20 (40%) - &gt;80% nocturnal </text>
<text top="514" left="607" width="136" height="19" font="0"> Controls: 2/20 (10%)  </text>
<text top="532" left="601" width="25" height="20" font="0">•  1</text>
<text top="533" left="625" width="7" height="12" font="7">st</text>
<text top="533" left="632" width="163" height="19" font="0"> Degree AVB (PR &gt;220 ms) </text>
<text top="551" left="607" width="136" height="19" font="0"> Athletes: 6/20 (30%)  </text>
<text top="569" left="607" width="125" height="19" font="0"> Controls: 0/20 (0%) </text>
<text top="588" left="601" width="68" height="20" font="0">•  Type 2 2</text>
<text top="588" left="669" width="10" height="12" font="7">nd</text>
<text top="588" left="679" width="83" height="19" font="0"> Degree AVB  </text>
<text top="607" left="607" width="132" height="19" font="0"> Athletes: 4/20 (20%) </text>
<text top="625" left="607" width="128" height="19" font="0"> Controls: 0/20 (0%)  </text>
<text top="644" left="601" width="49" height="20" font="0">•  CHB  </text>
<text top="662" left="607" width="136" height="19" font="0"> Athletes: 3/20 (15%)  </text>
<text top="681" left="607" width="125" height="19" font="0"> Controls: 0/20 (0%) </text>
<text top="254" left="891" width="201" height="20" font="0">• In this older cohort of distance </text>
<text top="273" left="902" width="185" height="19" font="0">runners, bradycardia and AVB </text>
<text top="291" left="902" width="167" height="19" font="0">was more common than in </text>
<text top="310" left="902" width="169" height="19" font="0">previously studied younger </text>
<text top="328" left="902" width="118" height="19" font="0">cohorts of athletes </text>
<text top="347" left="891" width="201" height="20" font="0">• Bradycardia and AVB are more </text>
<text top="365" left="902" width="177" height="19" font="0">frequent in distance runners </text>
<text top="384" left="902" width="165" height="19" font="0">than in healthy, active age-</text>
<text top="402" left="902" width="137" height="19" font="0">matched controls and </text>
<text top="420" left="902" width="170" height="19" font="0">predominantly nocturnal in </text>
<text top="439" left="902" width="77" height="19" font="0">both groups </text>
<text top="700" left="96" width="86" height="19" font="8"><b>SLEEP APNEA </b></text>
<text top="719" left="96" width="102" height="19" font="0">Tilkian AG, et al. </text>
<text top="737" left="96" width="62" height="19" font="0">1977 (58) </text>
<text top="755" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/331948">331948</a></text>
<text top="755" left="142" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/331948"> </a></text>
<text top="774" left="96" width="3" height="19" font="0"> </text>
<text top="719" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="737" left="234" width="75" height="19" font="0">Prospective </text>
<text top="755" left="234" width="87" height="19" font="0">observational </text>
<text top="774" left="233" width="3" height="19" font="0"> </text>
<text top="719" left="378" width="202" height="19" font="8"><b>Inclusion criteria:</b> OSA identified </text>
<text top="737" left="378" width="207" height="19" font="0">on PSG. All male. Mean age =44 y </text>
<text top="755" left="378" width="180" height="19" font="0">(30–60). Mean time in apnea </text>
<text top="720" left="601" width="262" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the distribution and </text>
<text top="738" left="601" width="263" height="19" font="0">frequency of arrhythmias while awake and </text>
<text top="756" left="601" width="245" height="19" font="0">asleep in pts with OSA and evaluate the </text>
<text top="719" left="891" width="76" height="19" font="0">Conclusions </text>
<text top="737" left="891" width="205" height="20" font="0">• In pts with fairly profound OSA, </text>
<text top="756" left="902" width="174" height="19" font="0">bradycardia and conduction </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 54 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="233" width="132" height="19" font="8"><b>Size:</b> 15 pts with OSA </text>
<text top="105" left="233" width="101" height="19" font="0">who underwent </text>
<text top="123" left="233" width="61" height="19" font="0">extensive </text>
<text top="142" left="233" width="75" height="19" font="0">monitoring: </text>
<text top="160" left="233" width="108" height="20" font="0">• 2 separate 24 h </text>
<text top="179" left="244" width="74" height="19" font="0">Holters and </text>
<text top="198" left="244" width="113" height="19" font="0">simultaneous PSG </text>
<text top="216" left="244" width="32" height="19" font="0">in all </text>
<text top="234" left="233" width="128" height="20" font="0">• 12/15 participated </text>
<text top="253" left="244" width="77" height="19" font="0">in overnight </text>
<text top="272" left="244" width="52" height="19" font="0">invasive </text>
<text top="290" left="244" width="90" height="19" font="0">hemodynamic </text>
<text top="308" left="244" width="71" height="19" font="0">monitoring </text>
<text top="327" left="233" width="107" height="20" font="0">•  6 underwent a </text>
<text top="346" left="244" width="121" height="19" font="0">third 24 h Holter to </text>
<text top="364" left="244" width="120" height="19" font="0">assess the effect of </text>
<text top="382" left="244" width="59" height="19" font="0">atropine  </text>
<text top="401" left="233" width="93" height="20" font="0">• 6 underwent </text>
<text top="420" left="244" width="68" height="19" font="0">awake EPS </text>
<text top="438" left="233" width="93" height="20" font="0">• 8 underwent </text>
<text top="457" left="244" width="118" height="19" font="0">repeat Holter after </text>
<text top="475" left="244" width="88" height="19" font="0">tracheostomy </text>
<text top="494" left="233" width="121" height="20" font="0">• 4 underwent ECG </text>
<text top="513" left="244" width="107" height="19" font="0">monitoring while </text>
<text top="531" left="244" width="112" height="19" font="0">the tracheostomy </text>
<text top="549" left="244" width="102" height="19" font="0">was temporarily </text>
<text top="568" left="244" width="95" height="19" font="0">plugged during </text>
<text top="586" left="244" width="43" height="19" font="0">sleep.  </text>
<text top="87" left="378" width="196" height="19" font="0">=51% (35–72%). Mean duration </text>
<text top="105" left="378" width="95" height="19" font="0">=24 s (11–40 s) </text>
<text top="123" left="378" width="3" height="19" font="0"> </text>
<text top="142" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="601" width="265" height="19" font="0">influence of atropine and tracheostomy on </text>
<text top="105" left="601" width="118" height="19" font="0">those arrhythmias  </text>
<text top="123" left="601" width="3" height="19" font="0"> </text>
<text top="142" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="160" left="601" width="271" height="20" font="0">• 14/15 (93.3%) marked sinus arr. (&gt;30 bpm </text>
<text top="179" left="612" width="43" height="19" font="0">swing) </text>
<text top="198" left="601" width="245" height="20" font="0">• 6/15 (40%) marked SB (heart rate &lt;30 </text>
<text top="217" left="612" width="119" height="19" font="0">bpm), all nocturnal </text>
<text top="235" left="601" width="263" height="20" font="0">• 5/15 (33%) “Asystole” (pauses of 2.5–6.3 </text>
<text top="254" left="612" width="97" height="19" font="0">s), all nocturnal </text>
<text top="273" left="601" width="100" height="20" font="0">• 2/15 (13.3%) 2</text>
<text top="273" left="701" width="10" height="12" font="7">nd</text>
<text top="273" left="711" width="161" height="19" font="0"> degree AVB, all nocturnal </text>
<text top="292" left="601" width="195" height="20" font="0">• 2/15 (13.3%) VT, all nocturnal </text>
<text top="311" left="601" width="247" height="20" font="0">• Tracheostomy eliminated arrhythmias </text>
<text top="330" left="612" width="219" height="19" font="0">which recurred when transiently re-</text>
<text top="348" left="612" width="52" height="19" font="0">plugged </text>
<text top="366" left="601" width="261" height="20" font="0">• Atropine (1.2–2.4 mg) blunted degree of </text>
<text top="385" left="612" width="253" height="19" font="0">sinus arrhythmia but did not eliminate. It </text>
<text top="404" left="612" width="199" height="19" font="0">prevented marked SB in 3 of 6, 2</text>
<text top="404" left="810" width="10" height="12" font="7">nd</text>
<text top="404" left="821" width="49" height="19" font="0"> degree </text>
<text top="422" left="612" width="213" height="19" font="0">AVB in 1 of 2, and pauses in 3 of 5. </text>
<text top="441" left="601" width="268" height="20" font="0">• 5 with wakeful EPS had normal SNRT, A-H </text>
<text top="459" left="612" width="254" height="19" font="0">and H-V intervals. Of these 2 had marked </text>
<text top="478" left="612" width="257" height="19" font="0">SB, 2 had prolonged pauses (3–6 s), and 1 </text>
<text top="496" left="612" width="139" height="19" font="0">had AVN Wenckebach </text>
<text top="87" left="902" width="188" height="19" font="0">disturbances are common and </text>
<text top="105" left="902" width="104" height="19" font="0">can be profound </text>
<text top="124" left="891" width="186" height="20" font="0">• Tracheostomy can eliminate </text>
<text top="143" left="902" width="163" height="19" font="0">the nocturnal arrhythmias </text>
<text top="161" left="902" width="127" height="19" font="0">associated with OSA </text>
<text top="179" left="891" width="201" height="20" font="0">• The nocturnal bradycardia and </text>
<text top="198" left="902" width="153" height="19" font="0">conduction disturbances </text>
<text top="217" left="902" width="166" height="19" font="0">associated with OSA are at </text>
<text top="235" left="902" width="193" height="19" font="0">least partially vagally mediated </text>
<text top="253" left="902" width="178" height="19" font="0">based on partial suppression </text>
<text top="272" left="902" width="86" height="19" font="0">with atropine </text>
<text top="290" left="891" width="3" height="19" font="0"> </text>
<text top="308" left="891" width="82" height="19" font="0">Confounders </text>
<text top="327" left="891" width="114" height="20" font="0">• No AHI reported </text>
<text top="346" left="891" width="178" height="20" font="0">• Highly selected population </text>
<text top="365" left="891" width="201" height="20" font="0">• Particularly unnatural sleeping </text>
<text top="384" left="903" width="82" height="19" font="0">environment </text>
<text top="402" left="891" width="198" height="20" font="0">• No normal comparator group  </text>
<text top="605" left="96" width="116" height="19" font="0">Guilleminault C, et </text>
<text top="623" left="96" width="79" height="19" font="0">al. 1983 (59) </text>
<text top="642" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6193700">6193700</a></text>
<text top="642" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6193700"> </a></text>
<text top="660" left="96" width="3" height="19" font="0"> </text>
<text top="605" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="623" left="233" width="87" height="19" font="0">Retrospective </text>
<text top="642" left="233" width="127" height="19" font="0">observational – 24 h </text>
<text top="660" left="233" width="42" height="19" font="0">Holter </text>
<text top="678" left="233" width="3" height="19" font="0"> </text>
<text top="697" left="233" width="111" height="19" font="8"><b>Size: </b>400 pts with </text>
<text top="715" left="233" width="127" height="19" font="0">SAS who underwent </text>
<text top="733" left="233" width="98" height="19" font="0">24 h Holter and </text>
<text top="752" left="233" width="116" height="19" font="0">simultaneous PSG. </text>
<text top="770" left="233" width="110" height="19" font="0">384 men, median </text>
<text top="605" left="378" width="198" height="19" font="8"><b>Inclusion criteria:</b> AHI &gt;5 (range </text>
<text top="623" left="378" width="184" height="19" font="0">25–92) and had simultaneous </text>
<text top="642" left="378" width="96" height="19" font="0">Holter and PSG </text>
<text top="660" left="378" width="3" height="19" font="0"> </text>
<text top="678" left="378" width="134" height="19" font="8"><b>Exclusion criteria:</b> No </text>
<text top="697" left="378" width="196" height="19" font="0">simultaneous testing or no SAS. </text>
<text top="715" left="378" width="189" height="19" font="0">187 excluded of which 111 did </text>
<text top="733" left="378" width="76" height="19" font="0">have AHI &gt;5 </text>
<text top="606" left="601" width="229" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe frequency and </text>
<text top="624" left="601" width="260" height="19" font="0">distribution of arrhythmias during sleep in </text>
<text top="643" left="601" width="78" height="19" font="0">pts with SAS </text>
<text top="661" left="601" width="3" height="19" font="0"> </text>
<text top="679" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="698" left="601" width="270" height="20" font="0">• 193/400 (48%) had nocturnal arrhythmias </text>
<text top="718" left="601" width="11" height="17" font="0"> </text>
<text top="717" left="612" width="241" height="19" font="0">98% of arrhythmias occurred during an </text>
<text top="735" left="612" width="110" height="19" font="0">obstructive event </text>
<text top="605" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="624" left="891" width="155" height="20" font="0">• In aggregate, nocturnal </text>
<text top="643" left="902" width="195" height="19" font="0">arrhythmias are common in pts </text>
<text top="661" left="902" width="180" height="19" font="0">with moderate to severe SAS </text>
<text top="679" left="902" width="177" height="19" font="0">and occur almost exclusively </text>
<text top="698" left="902" width="159" height="19" font="0">during obstructive events </text>
<text top="716" left="891" width="165" height="20" font="0">• There appears to be an O</text>
<text top="723" left="1056" width="5" height="12" font="7">2</text>
<text top="717" left="1061" width="25" height="19" font="0"> sat </text>
<text top="735" left="902" width="190" height="19" font="0">threshold of 72% for nocturnal </text>
<text top="753" left="902" width="152" height="19" font="0">bradyarrhythmias in this </text>
<text top="771" left="902" width="44" height="19" font="0">cohort </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 55 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="233" width="126" height="19" font="0">age =48 y (19–71 y). </text>
<text top="105" left="233" width="121" height="19" font="0">16 women, median </text>
<text top="123" left="233" width="104" height="19" font="0">age 59 (25–68 y) </text>
<text top="87" left="601" width="259" height="20" font="0">• Arrhythmias (except for PVCs) seen only </text>
<text top="106" left="612" width="40" height="19" font="0">with O</text>
<text top="113" left="652" width="5" height="12" font="7">2</text>
<text top="106" left="657" width="194" height="19" font="0"> sat &lt;72% (93% occurred with O</text>
<text top="113" left="851" width="5" height="12" font="7">2</text>
<text top="106" left="855" width="3" height="19" font="0"> </text>
<text top="124" left="612" width="67" height="19" font="0">sat ≤65%). </text>
<text top="143" left="601" width="117" height="20" font="0">• 8/400 (2%) NSVT </text>
<text top="162" left="601" width="265" height="20" font="0">• 43/400 (10.8%) Sinus arrest (2.5–13 s). In </text>
<text top="181" left="612" width="169" height="19" font="0">32/43 (74.4%) it lasted ≥4 s </text>
<text top="199" left="601" width="108" height="20" font="0">• 31/400 (7.8%) 2</text>
<text top="200" left="709" width="10" height="12" font="7">nd</text>
<text top="200" left="719" width="143" height="19" font="0"> degree AVB (19 type 1 </text>
<text top="218" left="612" width="148" height="19" font="0">(5%) and 12 type 2 (3%) </text>
<text top="237" left="601" width="267" height="20" font="0">• 29/400 (7.2%) had profound SB (&lt;30 bpm </text>
<text top="256" left="612" width="61" height="19" font="0">for ≥10 s) </text>
<text top="274" left="601" width="153" height="20" font="0">• 10/400 (2.5%) had PAF </text>
<text top="293" left="601" width="133" height="20" font="0">• 3/400 (1%) had AFL </text>
<text top="312" left="601" width="265" height="20" font="0">• 75 /400 (18.8%) &gt;2 VPC/min during sleep </text>
<text top="331" left="601" width="273" height="20" font="0">• 50 with significant arrhythmias underwent </text>
<text top="350" left="612" width="253" height="19" font="0">trach: repeat monitoring 3–6 mo postop: </text>
<text top="369" left="612" width="243" height="19" font="0">no arrhythmias except VPCs in 4 (vs. 18 </text>
<text top="387" left="612" width="38" height="19" font="0">prior) </text>
<text top="87" left="891" width="203" height="20" font="0">• Profound SB, sinus pauses ≥2.5 </text>
<text top="106" left="902" width="47" height="19" font="0">s, and 2</text>
<text top="106" left="949" width="10" height="12" font="7">nd</text>
<text top="106" left="959" width="115" height="19" font="0"> degree AVB occur </text>
<text top="124" left="902" width="176" height="19" font="0">occasionally (~7–10% of pts) </text>
<text top="143" left="891" width="167" height="20" font="0">• Tracheostomy eliminates </text>
<text top="162" left="902" width="189" height="19" font="0">nocturnal bradyarrhythmias in </text>
<text top="180" left="902" width="82" height="19" font="0">pts with OSA </text>
<text top="198" left="891" width="3" height="19" font="0"> </text>
<text top="217" left="891" width="83" height="19" font="8"><b>Confounders </b></text>
<text top="235" left="891" width="178" height="20" font="0">• Highly selected population </text>
<text top="254" left="891" width="195" height="20" font="0">• No normal comparator group </text>
<text top="406" left="96" width="108" height="19" font="0">Shepard JW Jr, et </text>
<text top="424" left="96" width="79" height="19" font="0">al. 1985 (60) </text>
<text top="443" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2411477">2411477</a></text>
<text top="443" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2411477"> </a></text>
<text top="461" left="96" width="3" height="19" font="0"> </text>
<text top="406" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="424" left="233" width="75" height="19" font="0">Prospective </text>
<text top="443" left="233" width="97" height="19" font="0">observational – </text>
<text top="461" left="233" width="120" height="19" font="0">nocturnal ECG only </text>
<text top="479" left="233" width="3" height="19" font="0"> </text>
<text top="498" left="233" width="54" height="19" font="8"><b>Size</b>: 31  </text>
<text top="406" left="378" width="168" height="19" font="8"><b>Inclusion criteria:</b> Clinically </text>
<text top="424" left="378" width="198" height="19" font="0">referred males with OSA (apnea </text>
<text top="443" left="378" width="182" height="19" font="0">index 44±26/h and hypopnea </text>
<text top="461" left="378" width="174" height="19" font="0">index 1 ±24/h). Age 55±11 y </text>
<text top="479" left="378" width="89" height="19" font="0">(range 30–76) </text>
<text top="498" left="378" width="3" height="19" font="0"> </text>
<text top="516" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="407" left="601" width="250" height="19" font="8"><b>1</b>°<b> endpoint:</b> Determine the relationship </text>
<text top="425" left="601" width="273" height="19" font="0">between ventricular ectopy and the severity </text>
<text top="444" left="601" width="273" height="19" font="0">of oxyhemoglobin desaturation during sleep </text>
<text top="462" left="601" width="3" height="19" font="0"> </text>
<text top="480" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="499" left="597" width="263" height="20" font="0">•  Profound SB (heart rate &lt;30 bpm): 10% </text>
<text top="518" left="597" width="187" height="20" font="0">•  Sinus pauses (2–13 s): 10% </text>
<text top="537" left="597" width="28" height="20" font="0">•  2</text>
<text top="537" left="625" width="10" height="12" font="7">nd</text>
<text top="537" left="636" width="104" height="19" font="0"> degree AVB: 6% </text>
<text top="406" left="891" width="76" height="19" font="0">Conclusions </text>
<text top="425" left="891" width="178" height="20" font="0">• Bradycardia and AVB occur </text>
<text top="444" left="902" width="192" height="19" font="0">occasionally during sleep in pts </text>
<text top="462" left="902" width="183" height="19" font="0">with moderate to severe OSA </text>
<text top="482" left="902" width="23" height="19" font="0">(6%</text>
<text top="480" left="925" width="8" height="21" font="4">–</text>
<text top="482" left="933" width="34" height="19" font="0">10%) </text>
<text top="500" left="891" width="3" height="19" font="0"> </text>
<text top="519" left="891" width="82" height="19" font="0">Confounders </text>
<text top="537" left="891" width="188" height="20" font="0">• Primary data not reported in </text>
<text top="556" left="902" width="192" height="19" font="0">original study or in subsequent </text>
<text top="574" left="902" width="90" height="19" font="0">review article. </text>
<text top="593" left="96" width="109" height="19" font="0">Hoffstein V, et al. </text>
<text top="612" left="96" width="62" height="19" font="0">1994 (61) </text>
<text top="630" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7774322">7774322</a></text>
<text top="630" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7774322"> </a></text>
<text top="648" left="96" width="3" height="19" font="0"> </text>
<text top="593" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="612" left="233" width="75" height="19" font="0">Prospective </text>
<text top="630" left="233" width="97" height="19" font="0">observational – </text>
<text top="648" left="233" width="122" height="19" font="0">Nocturnal ECG only </text>
<text top="667" left="233" width="3" height="19" font="0"> </text>
<text top="685" left="233" width="113" height="19" font="8"><b>Size:</b> 458 clinically </text>
<text top="703" left="233" width="103" height="19" font="0">referred for PSG </text>
<text top="722" left="233" width="111" height="19" font="0">(214 (46.7%) with </text>
<text top="740" left="233" width="93" height="19" font="0">SAS – AHI &gt;10) </text>
<text top="593" left="378" width="192" height="19" font="8"><b>Inclusion criteria:</b> Consecutive, </text>
<text top="612" left="378" width="195" height="19" font="0">unselected pts referred for PSG </text>
<text top="630" left="378" width="209" height="19" font="0">(primarily for snoring). Age 48±13 </text>
<text top="648" left="378" width="107" height="19" font="0">y. BMI 31±7 kg/m</text>
<text top="648" left="485" width="5" height="12" font="7">2</text>
<text top="648" left="490" width="3" height="19" font="0"> </text>
<text top="667" left="378" width="3" height="19" font="0"> </text>
<text top="685" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="594" left="601" width="245" height="19" font="8"><b>1</b>°<b> endpoint:</b> Compare the frequency of </text>
<text top="612" left="612" width="244" height="19" font="0">sleep-related arrhythmias in those with </text>
<text top="631" left="612" width="252" height="19" font="0">and w/o SAS and examine separately the </text>
<text top="649" left="612" width="267" height="19" font="0">relationships between arrhythmias and the </text>
<text top="667" left="612" width="268" height="19" font="0">severity of apnea, hypoxemia, and snoring,  </text>
<text top="686" left="601" width="3" height="19" font="0"> </text>
<text top="704" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="723" left="599" width="275" height="20" font="0">•  121 (26%) AHI 10–30, 41 (9%) AHI 30–50, </text>
<text top="741" left="619" width="116" height="19" font="0">52 (11%) AHI &gt;50)  </text>
<text top="760" left="601" width="248" height="20" font="0">•  Arrhythmia prevalence: SAS: 58%; No </text>
<text top="779" left="618" width="72" height="19" font="0">SAS: 42% (Χ</text>
<text top="779" left="689" width="7" height="12" font="7">2 </text>
<text top="779" left="696" width="166" height="19" font="0">=16.7; p&lt;0.0001); AHI ≥40: </text>
<text top="593" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="612" left="891" width="168" height="20" font="0">• AVB or junctional rhythm </text>
<text top="631" left="903" width="164" height="19" font="0">during sleep in adults with </text>
<text top="649" left="903" width="155" height="19" font="0">severe SAS is uncommon </text>
<text top="667" left="903" width="189" height="19" font="0">(&lt;3%) but does not occur at all </text>
<text top="686" left="903" width="193" height="19" font="0">in pts referred for PSG w/o SAS </text>
<text top="704" left="890" width="194" height="20" font="0">•  Arrhythmias in aggregate are </text>
<text top="723" left="903" width="176" height="19" font="0">more frequent in those with </text>
<text top="741" left="903" width="164" height="19" font="0">more profound SAS and in </text>
<text top="760" left="903" width="130" height="19" font="0">those with nocturnal </text>
<text top="778" left="903" width="70" height="19" font="0">hypoxemia </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 56 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="618" width="42" height="19" font="0">70% (Χ</text>
<text top="87" left="659" width="7" height="12" font="7">2 </text>
<text top="87" left="667" width="143" height="19" font="0">=9.2; p=0.002); mean O</text>
<text top="93" left="810" width="5" height="12" font="7">2</text>
<text top="87" left="815" width="25" height="19" font="0"> sat </text>
<text top="105" left="618" width="122" height="19" font="0">&lt;90%: 82%; mean O</text>
<text top="112" left="740" width="5" height="12" font="7">2</text>
<text top="105" left="745" width="107" height="19" font="0"> sat &gt;90%: 40% (Χ</text>
<text top="105" left="852" width="7" height="12" font="7">2 </text>
<text top="123" left="618" width="91" height="19" font="0">=7.4; p=0.006) </text>
<text top="142" left="601" width="274" height="20" font="0">•  Most frequent arrhythmias in all groups = </text>
<text top="161" left="618" width="189" height="19" font="0">ventricular or supraventricular </text>
<text top="179" left="618" width="110" height="19" font="0">tachyarrhythmias </text>
<text top="198" left="601" width="218" height="20" font="0">•  6/214 (2.8%) with SAS had some </text>
<text top="217" left="618" width="229" height="19" font="0">bradyarrhythmia (AVB, junctional) all </text>
<text top="235" left="618" width="256" height="19" font="0">associated with other arrhythmias and all </text>
<text top="253" left="618" width="89" height="19" font="0">with AHI &gt;30.  </text>
<text top="272" left="601" width="275" height="20" font="0">•   0/244 (0%) had AVB or junctional rhythm </text>
<text top="291" left="618" width="85" height="19" font="0">with AHI ≤10. </text>
<text top="309" left="601" width="264" height="20" font="0">•  Significance for difference in prevalence </text>
<text top="328" left="618" width="242" height="19" font="0">of bradyarrhythmias among the groups </text>
<text top="346" left="618" width="82" height="19" font="0">not reported </text>
<text top="87" left="891" width="3" height="19" font="0"> </text>
<text top="105" left="891" width="83" height="19" font="8"><b>Confounders </b></text>
<text top="124" left="891" width="200" height="20" font="0">• Too few bradycardic events to </text>
<text top="143" left="903" width="131" height="19" font="0">correlate with AHI or </text>
<text top="161" left="903" width="74" height="19" font="0">hypoxemia. </text>
<text top="179" left="891" width="186" height="20" font="0">• No data regarding profound </text>
<text top="198" left="903" width="185" height="19" font="0">bradycardia, sinus pauses, etc </text>
<text top="365" left="96" width="118" height="19" font="0">Boudoulas H, et al. </text>
<text top="384" left="96" width="62" height="19" font="0">1983 (62) </text>
<text top="402" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6580372">6580372</a></text>
<text top="402" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6580372"> </a></text>
<text top="420" left="96" width="3" height="19" font="0"> </text>
<text top="365" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="384" left="233" width="75" height="19" font="0">Prospective </text>
<text top="402" left="233" width="95" height="19" font="0">observational - </text>
<text top="420" left="233" width="42" height="19" font="0">Holter </text>
<text top="439" left="233" width="3" height="19" font="0"> </text>
<text top="457" left="233" width="111" height="19" font="8"><b>Size:</b> 120 pts with </text>
<text top="475" left="233" width="105" height="19" font="0">sleep disordered </text>
<text top="494" left="233" width="66" height="19" font="0">breathing: </text>
<text top="512" left="233" width="129" height="20" font="0">• SAS =61 (46 males; </text>
<text top="531" left="244" width="116" height="19" font="0">mean age 49.6±12 </text>
<text top="549" left="244" width="108" height="19" font="0">y; 15 with HTN, 4 </text>
<text top="568" left="244" width="55" height="19" font="0">with MI) </text>
<text top="586" left="233" width="108" height="20" font="0">• Narcolepsy =35 </text>
<text top="605" left="233" width="75" height="20" font="0">• Idiopathic </text>
<text top="624" left="244" width="113" height="19" font="0">hypersomnolence </text>
<text top="643" left="244" width="26" height="19" font="0">=24 </text>
<text top="365" left="378" width="199" height="19" font="8"><b>Inclusion criteria:</b> Pts with sleep </text>
<text top="384" left="378" width="198" height="19" font="0">disordered breathing previously </text>
<text top="402" left="378" width="198" height="19" font="0">diagnosed by PSG admitted to a </text>
<text top="420" left="378" width="195" height="19" font="0">clinical research center for ≥3 d </text>
<text top="439" left="378" width="210" height="19" font="0">to undergo echo, 24 h Holter, and </text>
<text top="457" left="378" width="206" height="19" font="0">24 h urinary catecholamines on 3 </text>
<text top="475" left="378" width="78" height="19" font="0">successive d </text>
<text top="494" left="378" width="3" height="19" font="0"> </text>
<text top="512" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="366" left="601" width="239" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the incidence of </text>
<text top="385" left="601" width="253" height="19" font="0">primary cardiac abnormalities in pts with </text>
<text top="403" left="601" width="28" height="19" font="0">SDB </text>
<text top="421" left="601" width="3" height="19" font="0"> </text>
<text top="439" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="458" left="601" width="227" height="20" font="0">• 1st degree AVB: 2/61 (3.3%) of SAS </text>
<text top="477" left="601" width="212" height="20" font="0">• SN exit block: 2/61 (3.3%) of SAS </text>
<text top="496" left="601" width="207" height="20" font="0">• Neither evident in other groups </text>
<text top="515" left="601" width="272" height="20" font="0">• Malignant ventricular arrhythmias: 26% of </text>
<text top="534" left="612" width="266" height="19" font="0">SAS, 3% in narcolepsy, and 4% in idiopathic </text>
<text top="553" left="612" width="113" height="19" font="0">hypersomnolence </text>
<text top="571" left="601" width="269" height="20" font="0">• Urinary catecholamines similarly elevated </text>
<text top="590" left="612" width="88" height="19" font="0">in all 3 groups </text>
<text top="365" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="384" left="891" width="176" height="20" font="0">• First degree AVB and sinus </text>
<text top="403" left="891" width="133" height="19" font="0">node exit block occur </text>
<text top="421" left="891" width="186" height="19" font="0">occasionally in pts with SAS (~ </text>
<text top="440" left="891" width="26" height="19" font="0">3%) </text>
<text top="458" left="891" width="164" height="20" font="0">• SDB of disparate types is </text>
<text top="477" left="891" width="160" height="19" font="0">associated with increased </text>
<text top="495" left="891" width="146" height="19" font="0">urinary catecholamines </text>
<text top="661" left="96" width="37" height="19" font="8"><b>SHHS </b></text>
<text top="680" left="96" width="93" height="19" font="0">Mehra R, et al. </text>
<text top="698" left="96" width="62" height="19" font="0">2006 (63) </text>
<text top="716" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16424443">16424443</a></text>
<text top="716" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16424443"> </a></text>
<text top="735" left="96" width="3" height="19" font="0"> </text>
<text top="661" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="680" left="233" width="114" height="19" font="0">Prospective, cross-</text>
<text top="698" left="233" width="62" height="19" font="0">sectional, </text>
<text top="717" left="233" width="90" height="19" font="0">observational  </text>
<text top="735" left="233" width="3" height="19" font="0"> </text>
<text top="753" left="233" width="113" height="19" font="8"><b>Size:</b> 228 SAS (RDI </text>
<text top="771" left="244" width="31" height="19" font="0">≥30) </text>
<text top="661" left="378" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="680" left="378" width="181" height="20" font="0">• Participant of original SHHS </text>
<text top="699" left="389" width="163" height="19" font="0">(N=6,441) who were alive, </text>
<text top="717" left="389" width="188" height="19" font="0">agreed to undergo repeat PSG </text>
<text top="736" left="389" width="197" height="19" font="0">3–7 y after enrollment and who </text>
<text top="754" left="389" width="177" height="19" font="0">were not on CPAP (N=3,295) </text>
<text top="772" left="378" width="74" height="20" font="0">• Age ≥40 y </text>
<text top="662" left="601" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Examine the association </text>
<text top="681" left="601" width="235" height="19" font="0">between SDB and cardiac arrhythmias </text>
<text top="699" left="601" width="3" height="19" font="0"> </text>
<text top="717" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="736" left="601" width="231" height="20" font="0">•  Mean age 70.6±9.72 vs. 68.6±9.1 y </text>
<text top="755" left="618" width="54" height="19" font="0">(p=0.01) </text>
<text top="662" left="891" width="165" height="20" font="0">• In this community-based </text>
<text top="681" left="902" width="188" height="19" font="0">cohort, there was no evidence </text>
<text top="699" left="902" width="183" height="19" font="0">of an increased prevalence of </text>
<text top="717" left="902" width="168" height="19" font="0">conduction disturbances in </text>
<text top="736" left="902" width="166" height="19" font="0">those with severe SDB and </text>
<text top="754" left="902" width="96" height="19" font="0">those w/o SDB  </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 57 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="378" width="61" height="20" font="0">• RDI ≥30 </text>
<text top="106" left="378" width="170" height="20" font="0">• Comparison group RDI &lt;5 </text>
<text top="125" left="389" width="135" height="19" font="0">Matched for age, sex, </text>
<text top="143" left="389" width="147" height="19" font="0">race/ethnicity, and BMI </text>
<text top="162" left="389" width="52" height="19" font="0">(N=338) </text>
<text top="180" left="378" width="3" height="19" font="0"> </text>
<text top="198" left="378" width="184" height="19" font="8"><b>Exclusion criteria:</b> BMI &lt;18 or </text>
<text top="217" left="389" width="58" height="19" font="0">&gt;40 kg/m</text>
<text top="217" left="447" width="5" height="12" font="7">2</text>
<text top="217" left="451" width="3" height="19" font="0"> </text>
<text top="87" left="601" width="255" height="20" font="0">•  3.1% of SDB had PPM and 0.9% of non-</text>
<text top="106" left="618" width="140" height="19" font="0">SDB had PPM (p=0.05) </text>
<text top="124" left="601" width="271" height="20" font="0">•  No difference in frequency of conduction </text>
<text top="143" left="618" width="145" height="19" font="0">delays (SDB vs. no SDB) </text>
<text top="162" left="601" width="245" height="20" font="0">•  Sinus pause ≥3 s: 11 vs. 8.6%; p=0.34 </text>
<text top="181" left="601" width="25" height="20" font="0">•  1</text>
<text top="182" left="625" width="7" height="12" font="7">st</text>
<text top="182" left="632" width="211" height="19" font="0"> degree AVB: 25 vs. 22.5%; p=0.49 </text>
<text top="200" left="601" width="65" height="20" font="0">•  Type I 2</text>
<text top="201" left="665" width="10" height="12" font="7">nd</text>
<text top="201" left="676" width="161" height="19" font="0"> degree AVB: 1.8 vs. 0.3%; </text>
<text top="219" left="618" width="45" height="19" font="0">p=0.07 </text>
<text top="238" left="601" width="68" height="20" font="0">•  Type II 2</text>
<text top="238" left="669" width="10" height="12" font="7">nd</text>
<text top="238" left="679" width="161" height="19" font="0"> degree AVB: 2.2 vs. 0.9%; </text>
<text top="257" left="618" width="45" height="19" font="0">p=0.20 </text>
<text top="275" left="601" width="268" height="20" font="0">•  AF (OR: 4.02), NSVT (OR: 3.4), complex V </text>
<text top="294" left="618" width="252" height="19" font="0">ectopy (OR: 1.74) were more common in </text>
<text top="312" left="618" width="166" height="19" font="0">SDB than non SDB groups.  </text>
<text top="331" left="601" width="245" height="20" font="0">•  No dose response relationship noted </text>
<text top="350" left="618" width="191" height="19" font="0">between severity of SDB and V </text>
<text top="368" left="618" width="71" height="19" font="0">arrhythmia </text>
<text top="386" left="601" width="269" height="20" font="0">•  SDB much more strongly associated with </text>
<text top="405" left="618" width="229" height="19" font="0">complex ectopy in younger members </text>
<text top="424" left="618" width="257" height="19" font="0">than older [OR:9.3 (2.8–30.6) at age 50 to </text>
<text top="442" left="618" width="206" height="19" font="0">2.0 (1.3–3.1) at age 70 (p=0.002)] </text>
<text top="87" left="891" width="159" height="20" font="0">• The prevalence of sinus </text>
<text top="106" left="903" width="83" height="19" font="0">pauses, and 2</text>
<text top="106" left="986" width="10" height="12" font="7">nd</text>
<text top="106" left="997" width="78" height="19" font="0"> degree AVB </text>
<text top="124" left="903" width="173" height="19" font="0">was ~15% in the SDB group, </text>
<text top="143" left="903" width="61" height="19" font="0">however. </text>
<text top="461" left="96" width="101" height="19" font="0">Miller WP, et al. </text>
<text top="479" left="96" width="62" height="19" font="0">1982 (64) </text>
<text top="498" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7124758">7124758</a></text>
<text top="498" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7124758"> </a></text>
<text top="516" left="96" width="3" height="19" font="0"> </text>
<text top="461" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="479" left="233" width="75" height="19" font="0">Prospective </text>
<text top="498" left="233" width="95" height="19" font="0">observational - </text>
<text top="516" left="233" width="42" height="19" font="0">Holter </text>
<text top="534" left="233" width="3" height="19" font="0"> </text>
<text top="552" left="233" width="106" height="19" font="8"><b>Size:</b> 23 SAS (AHI </text>
<text top="571" left="233" width="128" height="19" font="0">12.5–62.5; 78% with </text>
<text top="589" left="233" width="128" height="19" font="0">AHI &gt;43.75). Age 25–</text>
<text top="608" left="233" width="99" height="19" font="0">57 y, 87% male.<b> </b></text>
<text top="461" left="378" width="181" height="19" font="8"><b>Inclusion criteria:</b> SAS severe </text>
<text top="479" left="378" width="188" height="19" font="0">enough to warrant referral for </text>
<text top="498" left="378" width="88" height="19" font="0">tracheostomy </text>
<text top="516" left="378" width="3" height="19" font="0"> </text>
<text top="534" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="552" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="462" left="601" width="253" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the frequency and </text>
<text top="480" left="601" width="260" height="19" font="0">distribution of arrhythmias during sleep in </text>
<text top="498" left="601" width="78" height="19" font="0">pts with SAS </text>
<text top="517" left="601" width="3" height="19" font="0"> </text>
<text top="535" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="554" left="601" width="255" height="20" font="0">•  Marked sinus arrhythmia: 18/23 (78%) </text>
<text top="573" left="601" width="218" height="20" font="0">•  Heart rate &lt;30 bpm: 2/23 (8.7%) </text>
<text top="592" left="601" width="209" height="20" font="0">•  Sinus pause &gt;1.8 s: 2/23 (8.7%) </text>
<text top="611" left="601" width="25" height="20" font="0">•  1</text>
<text top="611" left="625" width="7" height="12" font="7">st</text>
<text top="612" left="632" width="156" height="19" font="0"> degree AVB: 1/23 (4.3%) </text>
<text top="630" left="601" width="68" height="20" font="0">•  Type 1 2</text>
<text top="631" left="669" width="10" height="12" font="7">nd</text>
<text top="631" left="679" width="156" height="19" font="0"> degree AVB: 1/23 (4.3%) </text>
<text top="649" left="601" width="266" height="20" font="0">•  Aggregate: 6/23 (26%) brady (non- sinus </text>
<text top="668" left="618" width="249" height="19" font="0">arrhythmia) while asleep vs. 1/23 (4.3%) </text>
<text top="686" left="618" width="79" height="19" font="0">while awake </text>
<text top="705" left="601" width="3" height="19" font="8"><b> </b></text>
<text top="461" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="480" left="890" width="159" height="20" font="0">• Nocturnal marked sinus </text>
<text top="498" left="901" width="178" height="19" font="0">arrhythmia is common in pts </text>
<text top="517" left="901" width="154" height="19" font="0">with SAS (predominantly </text>
<text top="535" left="901" width="74" height="19" font="0">severe SAS) </text>
<text top="554" left="890" width="135" height="20" font="0">• Nocturnal profound </text>
<text top="573" left="901" width="182" height="19" font="0">bradycardia and sinus pauses </text>
<text top="591" left="901" width="182" height="19" font="0">occur occasionally in pts with </text>
<text top="609" left="901" width="64" height="19" font="0">SAS (~9%) </text>
<text top="628" left="890" width="205" height="20" font="0">• Nocturnal first degree and type </text>
<text top="647" left="901" width="15" height="19" font="0">I 2</text>
<text top="646" left="916" width="10" height="12" font="7">nd</text>
<text top="647" left="926" width="117" height="19" font="0"> degree AVN occur </text>
<text top="665" left="901" width="172" height="19" font="0">infrequently in pts with SAS </text>
<text top="683" left="901" width="71" height="19" font="0">(&lt;5% each) </text>
<text top="702" left="890" width="199" height="20" font="0">• Such bradyarrhythmias are far </text>
<text top="721" left="901" width="173" height="19" font="0">more common while asleep </text>
<text top="739" left="901" width="162" height="19" font="0">than awake in this cohort. </text>
<text top="757" left="891" width="3" height="19" font="0"> </text>
<text top="775" left="891" width="71" height="19" font="8"><b>Comments </b></text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 58 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="890" width="120" height="20" font="0">• Small sample size </text>
<text top="106" left="890" width="107" height="20" font="0">• No comparator </text>
<text top="125" left="890" width="107" height="20" font="0">• Highly selected </text>
<text top="145" left="96" width="122" height="19" font="0">Flemons WW, et al. </text>
<text top="163" left="96" width="62" height="19" font="0">1993 (65) </text>
<text top="182" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8368632">8368632</a></text>
<text top="182" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8368632"> </a></text>
<text top="200" left="100" width="3" height="19" font="0"> </text>
<text top="145" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="163" left="233" width="75" height="19" font="0">Prospective </text>
<text top="182" left="233" width="97" height="19" font="0">observational – </text>
<text top="200" left="233" width="104" height="19" font="0">nocturnal Holter </text>
<text top="218" left="233" width="3" height="19" font="0"> </text>
<text top="236" left="233" width="90" height="19" font="8"><b>Size:</b> 173 /263 </text>
<text top="255" left="233" width="98" height="19" font="0">consecutive pts </text>
<text top="273" left="233" width="129" height="19" font="0">referred for PSG and </text>
<text top="291" left="233" width="132" height="19" font="0">underwent complete </text>
<text top="310" left="233" width="54" height="19" font="0">PSG and </text>
<text top="328" left="233" width="127" height="19" font="0">simultaneous Holter<b> </b></text>
<text top="145" left="378" width="209" height="19" font="8"><b>Inclusion criteria:</b> Completed PSG </text>
<text top="163" left="378" width="201" height="19" font="0">and Holter overnight. Compared </text>
<text top="182" left="378" width="200" height="19" font="0">76 with SAS (AHI &gt;10) vs. no SAS </text>
<text top="200" left="378" width="3" height="19" font="0"> </text>
<text top="218" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="237" left="375" width="176" height="20" font="0">•  Previous assessment of or </text>
<text top="256" left="389" width="150" height="19" font="0">treatment for SAS (N=7) </text>
<text top="274" left="375" width="212" height="20" font="0">•  Referred for a specific condition </text>
<text top="293" left="389" width="131" height="19" font="0">other than SAS (N=9) </text>
<text top="312" left="375" width="165" height="20" font="0">•  Rx for severe psychiatric </text>
<text top="330" left="389" width="98" height="19" font="0">condition (N=8) </text>
<text top="349" left="375" width="211" height="20" font="0">•  Major medical condition (N=21) </text>
<text top="368" left="377" width="180" height="20" font="0">• 9 technically inadequate (7 </text>
<text top="387" left="389" width="111" height="19" font="0">Holter and 2 PSG) </text>
<text top="405" left="377" width="86" height="20" font="0">• 14 no show </text>
<text top="425" left="377" width="142" height="20" font="0">• 3 Intercurrent illness </text>
<text top="444" left="378" width="164" height="20" font="0">• 1 declined to participate </text>
<text top="462" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="146" left="601" width="253" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the frequency and </text>
<text top="164" left="601" width="260" height="19" font="0">distribution of arrhythmias during sleep in </text>
<text top="182" left="601" width="78" height="19" font="0">pts with SAS </text>
<text top="201" left="601" width="3" height="19" font="0"> </text>
<text top="219" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="238" left="601" width="192" height="20" font="0">• Median AHI in SAS group =33 </text>
<text top="257" left="601" width="183" height="20" font="0">• Age of SAS group 48.5±11.3 </text>
<text top="276" left="601" width="230" height="20" font="0">• SAS: 87% male; mean BMI 32.9±6.1 </text>
<text top="295" left="601" width="118" height="20" font="0">• 26% of SAS had O</text>
<text top="302" left="719" width="5" height="12" font="7">2</text>
<text top="295" left="724" width="140" height="19" font="0"> sat &lt;80 more than 3% </text>
<text top="314" left="612" width="172" height="19" font="0">of the study time,11% has O</text>
<text top="320" left="783" width="5" height="12" font="7">2</text>
<text top="314" left="788" width="87" height="19" font="0"> sat &lt;70 more </text>
<text top="332" left="612" width="254" height="19" font="0">than 1 % of the study time, and 2.7% had </text>
<text top="350" left="612" width="10" height="19" font="0">O</text>
<text top="357" left="622" width="5" height="12" font="7">2</text>
<text top="350" left="626" width="248" height="19" font="0"> sat &lt;60 more than 1% of the study time </text>
<text top="369" left="601" width="18" height="20" font="0">• 2</text>
<text top="369" left="619" width="10" height="12" font="7">nd</text>
<text top="369" left="629" width="228" height="19" font="0"> degree AVB: SAS =1.3% (95% CI: 0.4–</text>
<text top="388" left="612" width="252" height="19" font="0">6.9) vs. No SAS =4.1% (95% CI: 1.6–10.1). </text>
<text top="406" left="612" width="35" height="19" font="0">p=NS </text>
<text top="425" left="601" width="270" height="20" font="0">• Sinus arrest: SAS =5.2% (95% CI: 2.2–12.6) </text>
<text top="444" left="612" width="249" height="19" font="0">vs. No SAS =1.0% (95% CI: 0.2–5.6) p=NS </text>
<text top="462" left="601" width="258" height="20" font="0">•  Complex ventricular ectopy: SAS =1.3% </text>
<text top="481" left="618" width="248" height="19" font="0">(95% CI: 0.4–6.9) vs. No SAS =4.1% (95% </text>
<text top="499" left="618" width="119" height="19" font="0">CI: 1.6–10.1). p=NS<b> </b></text>
<text top="145" left="891" width="194" height="19" font="8"><b>Conclusions: </b>The prevalence of </text>
<text top="163" left="902" width="186" height="19" font="0">nocturnal cardiac arrhythmias </text>
<text top="182" left="902" width="150" height="19" font="0">is low in pts w/o serious </text>
<text top="200" left="902" width="134" height="19" font="0">cardiac or respiratory </text>
<text top="218" left="902" width="184" height="19" font="0">comorbidity who are referred </text>
<text top="237" left="902" width="191" height="19" font="0">for assessment of sleep apnea, </text>
<text top="255" left="902" width="173" height="19" font="0">and no different from those </text>
<text top="273" left="902" width="108" height="19" font="0">w/o sleep apnea. </text>
<text top="291" left="891" width="3" height="19" font="0"> </text>
<text top="310" left="891" width="75" height="19" font="8"><b>Comments: </b></text>
<text top="328" left="891" width="146" height="20" font="0">• Potential referral bias </text>
<text top="347" left="891" width="157" height="20" font="0">• Authors speculate their </text>
<text top="366" left="902" width="173" height="19" font="0">population consisted of less </text>
<text top="385" left="902" width="166" height="19" font="0">severe SAS and less severe </text>
<text top="403" left="902" width="177" height="19" font="0">underlying disease (minority </text>
<text top="421" left="902" width="194" height="19" font="0">fell below previously suggested </text>
<text top="440" left="902" width="160" height="19" font="0">thresholds for arrhythmia </text>
<text top="458" left="902" width="175" height="19" font="0">(Guilleminault and Shepard) </text>
<text top="476" left="891" width="86" height="20" font="0">• Only 2 prior </text>
<text top="495" left="902" width="149" height="19" font="0">studies=consecutive pts </text>
<text top="514" left="902" width="188" height="19" font="0">(Guilleminault and Boudoulas) </text>
<text top="532" left="902" width="189" height="19" font="0">and the others may have been </text>
<text top="550" left="902" width="150" height="19" font="0">subject to selection bias </text>
<text top="569" left="891" width="201" height="20" font="0">• Only Boudoulas compared SAS </text>
<text top="588" left="902" width="173" height="19" font="0">to comparator group (albeit </text>
<text top="606" left="902" width="177" height="19" font="0">pts with other types of sleep </text>
<text top="624" left="902" width="59" height="19" font="0">disorder) </text>
<text top="643" left="891" width="166" height="20" font="0">• Excluded “major medical </text>
<text top="662" left="902" width="195" height="19" font="0">conditions” and there may be a </text>
<text top="680" left="902" width="182" height="19" font="0">complex interaction between </text>
<text top="698" left="902" width="121" height="19" font="0">CV disease and SAS </text>
<text top="717" left="96" width="342" height="19" font="8"><b>EFFECT OF CPAP ON ARRHYTHMIAS - OBSERVATIONAL </b></text>
<text top="736" left="96" width="95" height="19" font="0">Becker H, et al. </text>
<text top="755" left="96" width="62" height="19" font="0">1995 (66) </text>
<text top="773" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7812557">7812557</a></text>
<text top="773" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7812557"> </a></text>
<text top="736" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="755" left="233" width="75" height="19" font="0">Prospective </text>
<text top="773" left="233" width="90" height="19" font="0">observational  </text>
<text top="736" left="378" width="189" height="19" font="8"><b>Inclusion criteria:</b> Sleep apnea </text>
<text top="755" left="389" width="111" height="19" font="0">and Mobitz type 2</text>
<text top="755" left="500" width="10" height="12" font="7">nd</text>
<text top="755" left="510" width="49" height="19" font="0"> degree </text>
<text top="737" left="601" width="253" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the frequency and </text>
<text top="755" left="601" width="260" height="19" font="0">distribution of arrhythmias during sleep in </text>
<text top="774" left="601" width="268" height="19" font="0">pts with SAS and assess the effect of nCPAP </text>
<text top="736" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="755" left="891" width="192" height="20" font="0">•  CPAP effectively suppresses </text>
<text top="774" left="910" width="138" height="19" font="0">sleep and sleep apnea </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 59 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="3" height="19" font="0"> </text>
<text top="87" left="233" width="3" height="19" font="0"> </text>
<text top="105" left="233" width="79" height="19" font="8"><b>Size:</b> 17/239 </text>
<text top="123" left="233" width="98" height="19" font="0">consecutive pts </text>
<text top="142" left="233" width="81" height="19" font="0">referred to a </text>
<text top="160" left="233" width="122" height="19" font="0">German sleep clinic </text>
<text top="178" left="233" width="103" height="19" font="0">over 17 mo who </text>
<text top="197" left="233" width="130" height="19" font="0">manifested both SAS </text>
<text top="215" left="233" width="130" height="19" font="0">and “heart block” on </text>
<text top="233" left="233" width="74" height="19" font="0">ambulatory </text>
<text top="252" left="233" width="131" height="19" font="0">screening tests. They </text>
<text top="270" left="233" width="102" height="19" font="0">then underwent </text>
<text top="288" left="233" width="100" height="19" font="0">serial PSGs with </text>
<text top="307" left="233" width="117" height="19" font="0">Holter monitoring, </text>
<text top="325" left="233" width="54" height="19" font="0">w/o and </text>
<text top="343" left="233" width="115" height="19" font="0">subsequently with </text>
<text top="362" left="233" width="36" height="19" font="0">CPAP<b> </b></text>
<text top="87" left="389" width="40" height="19" font="0">AVB, 3</text>
<text top="87" left="429" width="9" height="12" font="7">rd</text>
<text top="87" left="437" width="129" height="19" font="0"> degree AVB or sinus </text>
<text top="105" left="389" width="181" height="19" font="0">pause &gt;2 s on Holter monitor </text>
<text top="123" left="378" width="3" height="19" font="0"> </text>
<text top="142" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="87" left="601" width="51" height="19" font="0">on the 2</text>
<text top="87" left="651" width="10" height="12" font="7">nd</text>
<text top="87" left="662" width="211" height="19" font="0"> night of treatment and after 4 wk </text>
<text top="105" left="601" width="82" height="19" font="0">of treatment </text>
<text top="123" left="601" width="3" height="19" font="0"> </text>
<text top="142" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="160" left="601" width="169" height="20" font="0">•  Mean age =50.7 (27–78) </text>
<text top="179" left="601" width="247" height="20" font="0">•  Median RDI =90/h (±36.1) at baseline </text>
<text top="199" left="601" width="225" height="20" font="0">•  Median RDI =6/h (±6.2) on nCPAP </text>
<text top="218" left="601" width="250" height="20" font="0">•  No. of HB episodes =1,575 at baseline </text>
<text top="237" left="601" width="224" height="20" font="0">•  No. of HB episodes =165 on CPAP </text>
<text top="256" left="618" width="257" height="19" font="0">(p&lt;0.001 vs. baseline) – an 89% reduction </text>
<text top="274" left="601" width="269" height="20" font="0">•  12/17 (70.6%) manifested no arrhythmia </text>
<text top="293" left="618" width="55" height="19" font="0">on CPAP </text>
<text top="312" left="601" width="234" height="20" font="0">•  3/17 (17.6%) manifested a 71–97% </text>
<text top="330" left="618" width="226" height="19" font="0">reduction in heart block episodes on </text>
<text top="349" left="618" width="248" height="19" font="0">CPAP (2 of these 3: resolution of HB at 4 </text>
<text top="367" left="618" width="25" height="19" font="0">wk) </text>
<text top="386" left="601" width="251" height="20" font="0">•  2/17 (11.8%) demonstrated increased </text>
<text top="405" left="618" width="252" height="19" font="0">heart block on CPAP but 1 demonstrated </text>
<text top="423" left="618" width="154" height="19" font="0">resolution of HB at 4 wk. </text>
<text top="441" left="601" width="257" height="20" font="0">•  15/17 (88%) manifested no arrhythmia </text>
<text top="460" left="618" width="116" height="19" font="0">after 4 wk of CPAP<b> </b></text>
<text top="87" left="910" width="167" height="19" font="0">associated “heart block” in </text>
<text top="105" left="910" width="171" height="19" font="0">pts with fairly advanced SA. </text>
<text top="123" left="891" width="3" height="19" font="0"> </text>
<text top="142" left="891" width="71" height="19" font="8"><b>Comments </b></text>
<text top="160" left="891" width="154" height="20" font="0">•  Potential referral bias </text>
<text top="179" left="891" width="129" height="20" font="0">•  Non-randomized, </text>
<text top="198" left="910" width="87" height="19" font="0">observational </text>
<text top="217" left="891" width="180" height="20" font="0">•  16/17 subjects were male </text>
<text top="479" left="96" width="101" height="19" font="0">Koehler U, et al. </text>
<text top="498" left="96" width="62" height="19" font="0">1998 (67) </text>
<text top="516" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9551750">9551750</a></text>
<text top="516" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9551750"> </a></text>
<text top="534" left="96" width="3" height="19" font="0"> </text>
<text top="479" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="498" left="233" width="75" height="19" font="0">Prospective </text>
<text top="516" left="233" width="90" height="19" font="0">observational  </text>
<text top="534" left="233" width="3" height="19" font="0"> </text>
<text top="552" left="233" width="54" height="19" font="8"><b>Size:</b> 16 <b> </b></text>
<text top="479" left="378" width="189" height="19" font="8"><b>Inclusion criteria:</b> Sleep apnea </text>
<text top="498" left="378" width="200" height="19" font="0">(AHI &gt;10/h), no evidence of SAN </text>
<text top="516" left="378" width="196" height="19" font="0">or AVN dysfunction on EPS, and </text>
<text top="534" left="378" width="177" height="19" font="0">nocturnal “heart block” who </text>
<text top="553" left="378" width="206" height="19" font="0">underwent baseline PSG and PSG </text>
<text top="571" left="378" width="173" height="19" font="0">on CPAP the following night </text>
<text top="589" left="378" width="3" height="19" font="0"> </text>
<text top="607" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="626" left="378" width="137" height="19" font="0">AVN blocking or AADs<b> </b></text>
<text top="480" left="601" width="246" height="19" font="8"><b>1</b>°<b> endpoint:</b> Correlate the frequency of </text>
<text top="498" left="612" width="226" height="19" font="0">bradyarrhythmias to stages of sleep, </text>
<text top="517" left="612" width="261" height="19" font="0">oxygen desaturation and apnea, as well as </text>
<text top="535" left="612" width="254" height="19" font="0">the effect of nCPAP/nasal bilevel positive </text>
<text top="553" left="612" width="207" height="19" font="0">airway pressure therapy on these </text>
<text top="572" left="612" width="251" height="19" font="0">arrhythmias in pts w/o EP abnormalities. </text>
<text top="590" left="601" width="3" height="19" font="0"> </text>
<text top="608" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="627" left="601" width="165" height="20" font="0">• Mean age=49.6 (±10.4) y </text>
<text top="646" left="601" width="140" height="20" font="0">• BMI 36.8 (±7.9) kg/m</text>
<text top="646" left="740" width="5" height="12" font="7">2</text>
<text top="647" left="745" width="3" height="19" font="0"> </text>
<text top="665" left="601" width="251" height="20" font="0">• 13/16 (81.3%) HTN; 0 MI; 2/16 (12.5%) </text>
<text top="684" left="612" width="234" height="19" font="0">DM; 11/16 (68.8%) LVH by echo; 7/16 </text>
<text top="702" left="612" width="88" height="19" font="0">(43.8%) COPD<b> </b></text>
<text top="721" left="601" width="277" height="20" font="0">• 651 episodes of HB; 87.9% during REM and </text>
<text top="740" left="612" width="234" height="19" font="0">12.1% during stages 1 and 2 non-REM </text>
<text top="758" left="601" width="73" height="20" font="0">• (p&lt;0.001) </text>
<text top="479" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="498" left="891" width="184" height="20" font="0">• CPAP effectively suppresses </text>
<text top="517" left="902" width="187" height="19" font="0">sleep apnea associated “heart </text>
<text top="535" left="902" width="144" height="19" font="0">block” in pts with fairly </text>
<text top="553" left="902" width="85" height="19" font="0">advanced SA. </text>
<text top="572" left="891" width="3" height="19" font="0"> </text>
<text top="590" left="891" width="71" height="19" font="8"><b>Comments </b></text>
<text top="609" left="891" width="146" height="20" font="0">• Potential referral bias </text>
<text top="628" left="891" width="121" height="20" font="0">• Non-randomized, </text>
<text top="647" left="902" width="87" height="19" font="0">observational </text>
<text top="665" left="891" width="172" height="20" font="0">• 14/16 subjects were male </text>
<text top="684" left="891" width="3" height="19" font="0"> </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 60 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="601" width="216" height="20" font="0">• 609/651 (93.5%) occurred during </text>
<text top="106" left="612" width="249" height="19" font="0">apnea/hypopnea with desaturation ≥4% </text>
<text top="124" left="612" width="180" height="19" font="0">(but no correlation to nadir O</text>
<text top="131" left="791" width="5" height="12" font="7">2</text>
<text top="124" left="796" width="25" height="19" font="0"> sat </text>
<text top="143" left="612" width="118" height="19" font="0">above/below 72%) </text>
<text top="161" left="601" width="256" height="20" font="0">• Mean AHI =75.5±39.6/h at baseline and </text>
<text top="180" left="612" width="221" height="19" font="0">3.0±6.6/h on nCPAP/BiPAP (p&lt;0.01) </text>
<text top="199" left="601" width="248" height="20" font="0">• Bradyarrhythmia: 651 at baseline (432 </text>
<text top="217" left="612" width="81" height="19" font="0">episodes of 2</text>
<text top="217" left="692" width="10" height="12" font="7">nd</text>
<text top="217" left="702" width="142" height="19" font="0"> degree AVB, 178 sinus </text>
<text top="236" left="612" width="103" height="19" font="0">pauses &gt;2 s, 41 3</text>
<text top="236" left="715" width="9" height="12" font="7">rd</text>
<text top="236" left="723" width="83" height="19" font="0"> degree AVB) </text>
<text top="254" left="601" width="247" height="20" font="0">•  Bradyarrhythmia on nCPAP/BiPAP: 72 </text>
<text top="273" left="612" width="190" height="19" font="0">(p&lt;0.01) – an 89% reduction in </text>
<text top="292" left="612" width="110" height="19" font="0">bradyarrhythmia. </text>
<text top="311" left="96" width="100" height="19" font="0">Grimm W, et al. </text>
<text top="329" left="96" width="62" height="19" font="0">2000 (68) </text>
<text top="347" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10980227">10980227</a></text>
<text top="347" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10980227"> </a></text>
<text top="365" left="96" width="3" height="19" font="0"> </text>
<text top="310" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="329" left="233" width="75" height="19" font="0">Prospective </text>
<text top="347" left="233" width="90" height="19" font="0">observational  </text>
<text top="365" left="233" width="3" height="19" font="0"> </text>
<text top="384" left="233" width="50" height="19" font="8"><b>Size</b>: 29<b> </b></text>
<text top="310" left="378" width="193" height="19" font="8"><b>Inclusion criteria:</b> Sleep apnea, </text>
<text top="329" left="378" width="169" height="19" font="0">no evidence of SAN or AVN </text>
<text top="347" left="378" width="150" height="19" font="0">dysfunction on EPS, and </text>
<text top="366" left="378" width="196" height="19" font="0">ventricular asystole of 6.7±3.3 s </text>
<text top="384" left="378" width="186" height="19" font="0">(3.1–16.8 s) exclusively during </text>
<text top="402" left="378" width="194" height="19" font="0">sleep who underwent PSG with </text>
<text top="420" left="378" width="207" height="19" font="0">and w/o CPAP and were followed </text>
<text top="439" left="378" width="141" height="19" font="0">clinically for 54±10 mo </text>
<text top="457" left="378" width="3" height="19" font="0"> </text>
<text top="475" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="494" left="378" width="149" height="20" font="0">• AVN blocking or AADs<b> </b></text>
<text top="513" left="378" width="164" height="20" font="0">• “Advanced” SAN or AVN </text>
<text top="532" left="390" width="90" height="19" font="0">disease at EPS<b> </b></text>
<text top="550" left="378" width="209" height="20" font="0">• Symptomatic bradycardia on 24 </text>
<text top="569" left="390" width="157" height="19" font="0">h Holter (or symptoms of </text>
<text top="588" left="390" width="148" height="19" font="0">bradycardia, otherwise)<b> </b></text>
<text top="311" left="601" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Describe the long-term </text>
<text top="330" left="601" width="273" height="19" font="0">prognosis for symptomatic bradyarrhythmia </text>
<text top="348" left="601" width="270" height="19" font="0">in pts with asx bradyarrhythmias associated </text>
<text top="366" left="601" width="227" height="19" font="0">with sleep apnea and w/o significant </text>
<text top="385" left="601" width="208" height="19" font="0">conduction abnormalities on EPS. </text>
<text top="403" left="601" width="3" height="19" font="0"> </text>
<text top="421" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="440" left="601" width="80" height="20" font="0">•  93% male </text>
<text top="459" left="601" width="114" height="20" font="0">•  Mean age: 49 y </text>
<text top="478" left="601" width="99" height="20" font="0">•  BMI: 36 kg/m</text>
<text top="478" left="700" width="5" height="12" font="7">2</text>
<text top="479" left="705" width="3" height="19" font="0"> </text>
<text top="497" left="601" width="264" height="20" font="0">•  HTN: 19/29 (66%); CAD: 6/29 (21%); MI: </text>
<text top="516" left="618" width="66" height="19" font="0">2/29 (7%)  </text>
<text top="534" left="601" width="240" height="20" font="0">•  Bradyarrhythmia: 14/29 (48%) sinus </text>
<text top="553" left="618" width="129" height="19" font="0">arrest, 12/29 (41%) 3</text>
<text top="553" left="747" width="8" height="12" font="7">rd</text>
<text top="553" left="755" width="114" height="19" font="0"> degree AVB, 3/29 </text>
<text top="572" left="618" width="178" height="19" font="0">(10%) both sinus arrest and 3</text>
<text top="572" left="796" width="9" height="12" font="7">rd</text>
<text top="572" left="804" width="49" height="19" font="0"> degree </text>
<text top="590" left="618" width="29" height="19" font="0">AVB </text>
<text top="609" left="601" width="271" height="20" font="0">•   nCPAP abolished all pauses &gt;3 s in 21/29 </text>
<text top="627" left="618" width="38" height="19" font="0">(72%) </text>
<text top="646" left="601" width="271" height="20" font="0">•  nCPAP failed to abolish all pauses in 8/29 </text>
<text top="665" left="618" width="230" height="19" font="0">(28%) with persistent pauses of 3–5 s </text>
<text top="683" left="601" width="205" height="20" font="0">•  No pt developed symptomatic </text>
<text top="702" left="618" width="249" height="19" font="0">bradycardia over 54±10 mo of follow-up </text>
<text top="721" left="601" width="159" height="20" font="0">•  58% always used CPAP </text>
<text top="740" left="601" width="153" height="20" font="0">•  10% never used CPAP </text>
<text top="310" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="329" left="891" width="188" height="20" font="0">• Pts free of significant SAN or </text>
<text top="348" left="902" width="179" height="19" font="0">AVN dysfunction by EPS who </text>
<text top="366" left="902" width="172" height="19" font="0">are chronically treated with </text>
<text top="385" left="902" width="161" height="19" font="0">CPAP for SA c/b nocturnal </text>
<text top="403" left="902" width="164" height="19" font="0">bradycardia are extremely </text>
<text top="421" left="902" width="182" height="19" font="0">unlikely to have symptomatic </text>
<text top="440" left="902" width="191" height="19" font="0">bradycardia or syncope in long-</text>
<text top="458" left="902" width="147" height="19" font="0">term follow-up of 4.5 y. </text>
<text top="476" left="891" width="201" height="20" font="0">• Such pts who receive a PM are </text>
<text top="495" left="902" width="188" height="19" font="0">unlikely to require pacing very </text>
<text top="514" left="902" width="181" height="19" font="0">much, at all, if PMs are set to </text>
<text top="532" left="902" width="159" height="19" font="0">low back-up pacing rates. </text>
<text top="550" left="899" width="3" height="19" font="0"> </text>
<text top="568" left="891" width="71" height="19" font="8"><b>Comments </b></text>
<text top="587" left="891" width="146" height="20" font="0">• Potential referral bias </text>
<text top="606" left="891" width="121" height="20" font="0">• Non-randomized, </text>
<text top="625" left="902" width="87" height="19" font="0">observational </text>
<text top="644" left="891" width="154" height="20" font="0">• Same group as Koehler </text>
<text top="663" left="891" width="177" height="20" font="0">• 93% of subjects were male </text>
<text top="682" left="891" width="3" height="19" font="0"> </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 61 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="601" width="252" height="20" font="0">•  23/29 had follow-up 24 h Holter: 1/14 </text>
<text top="106" left="618" width="236" height="19" font="0">w/o PPM had asx pauses up to 3.6 s in </text>
<text top="124" left="618" width="139" height="19" font="0">duration, while asleep </text>
<text top="143" left="601" width="277" height="20" font="0">•  12/29 (41%) received PPM at discretion of </text>
<text top="162" left="618" width="260" height="19" font="0">their care provider during study (including </text>
<text top="180" left="618" width="227" height="19" font="0">7/8 with persistent pauses on CPAP.  </text>
<text top="199" left="601" width="275" height="20" font="0">•  8 PPM programmed in VDI at 30–40 bpm: </text>
<text top="217" left="618" width="147" height="19" font="0">&lt;1% paced at follow-up </text>
<text top="236" left="601" width="245" height="20" font="0">•  3 PPM programmed in DDD at 40–50 </text>
<text top="255" left="618" width="190" height="19" font="0">bpm: &lt;10% paced at follow-up </text>
<text top="273" left="601" width="258" height="20" font="0">•  1 PPM programmed in DDD at 60 bpm: </text>
<text top="292" left="618" width="154" height="19" font="0">&gt;10% paced at follow-up </text>
<text top="311" left="96" width="104" height="19" font="0">Harbison J, et al. </text>
<text top="330" left="96" width="30" height="19" font="0">2000</text>
<text top="328" left="127" width="4" height="21" font="4"> </text>
<text top="330" left="130" width="28" height="19" font="0">(69) </text>
<text top="348" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10988177">10988177</a></text>
<text top="348" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10988177"> </a></text>
<text top="366" left="96" width="3" height="19" font="0"> </text>
<text top="311" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="330" left="233" width="75" height="19" font="0">Prospective </text>
<text top="348" left="233" width="90" height="19" font="0">observational  </text>
<text top="366" left="233" width="3" height="19" font="0"> </text>
<text top="384" left="233" width="126" height="19" font="8"><b>Size:</b> 45 consecutive </text>
<text top="403" left="233" width="113" height="19" font="0">eligible pts from a </text>
<text top="421" left="233" width="125" height="19" font="0">university hospital’s </text>
<text top="440" left="233" width="100" height="19" font="0">dedicated sleep </text>
<text top="458" left="233" width="88" height="19" font="0">disorders unit </text>
<text top="476" left="233" width="117" height="19" font="0">referred to initiate </text>
<text top="494" left="233" width="43" height="19" font="0">nCPAP </text>
<text top="311" left="378" width="177" height="19" font="8"><b>Inclusion criteria:</b> Previously </text>
<text top="330" left="378" width="203" height="19" font="0">diagnosed moderate-severe OSA </text>
<text top="348" left="378" width="190" height="19" font="0">(AHI 50±23/h) who underwent </text>
<text top="366" left="378" width="146" height="19" font="0">overnight oximetry and </text>
<text top="385" left="378" width="206" height="19" font="0">concurrent 18 h 2-channel Holter </text>
<text top="403" left="378" width="201" height="19" font="0">prior to and after initiating CPAP </text>
<text top="421" left="378" width="201" height="19" font="0">(Becker, Koehler, within 2 nights </text>
<text top="440" left="378" width="198" height="19" font="0">of initiating). Studies performed </text>
<text top="458" left="378" width="71" height="19" font="0">in hospital. </text>
<text top="476" left="378" width="3" height="19" font="0"> </text>
<text top="494" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="513" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="312" left="601" width="243" height="19" font="8"><b>1</b>°<b> endpoint: </b>Establish the frequency of </text>
<text top="330" left="601" width="249" height="19" font="0">pathologically significant cardiac rhythm </text>
<text top="349" left="601" width="270" height="19" font="0">disturbances in the group and, in particular, </text>
<text top="367" left="601" width="262" height="19" font="0">to determine the effect of nCPAP on these </text>
<text top="385" left="601" width="85" height="19" font="0">disturbances. </text>
<text top="404" left="601" width="3" height="19" font="0"> </text>
<text top="422" left="601" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="440" left="601" width="80" height="20" font="0">•  91% male </text>
<text top="460" left="601" width="176" height="20" font="0">•  Mean age: 50 (SD: 13.1) y </text>
<text top="479" left="601" width="166" height="20" font="0">•  BMI: 32.7 (SD: 6.0) kg/m</text>
<text top="479" left="767" width="5" height="12" font="7">2</text>
<text top="479" left="771" width="3" height="19" font="0"> </text>
<text top="498" left="601" width="206" height="20" font="0">•  35/45 (78%) had some rhythm </text>
<text top="517" left="618" width="145" height="19" font="0">disturbance at baseline </text>
<text top="535" left="601" width="244" height="20" font="0">•  8/45 (18%) manifested “pathological </text>
<text top="554" left="618" width="242" height="19" font="0">arrhythmia (complex ectopy, SVT other </text>
<text top="572" left="618" width="200" height="19" font="0">than sinus tach, or pauses &gt;2 s, 2</text>
<text top="572" left="818" width="10" height="12" font="7">nd</text>
<text top="572" left="828" width="37" height="19" font="0"> and 3</text>
<text top="572" left="866" width="9" height="12" font="7">rd</text>
<text top="572" left="874" width="3" height="19" font="0"> </text>
<text top="591" left="618" width="79" height="19" font="0">degree AVB) </text>
<text top="609" left="601" width="201" height="20" font="0">•  7/45 (15.6%) sinus pause &gt;2 s </text>
<text top="628" left="618" width="257" height="19" font="0">(frequencies reflect individuals with more </text>
<text top="647" left="618" width="251" height="19" font="0">than 1 type of arrhythmia and sum is &gt;8) </text>
<text top="665" left="601" width="248" height="20" font="0">•  2/45 (4.4%) from among these 7 with </text>
<text top="684" left="618" width="258" height="19" font="0">pauses had sinus pauses &gt;3 s (longest =10 </text>
<text top="702" left="618" width="14" height="19" font="0">s) </text>
<text top="721" left="601" width="245" height="20" font="0">•  2 /45 (4.4%) had complex ventricular </text>
<text top="740" left="618" width="244" height="19" font="0">ectopy (1 NSVT, 1 ventricular bigeminy) </text>
<text top="758" left="601" width="125" height="20" font="0">•  1/45 (2.2%) had 2</text>
<text top="759" left="726" width="10" height="12" font="7">nd</text>
<text top="759" left="736" width="78" height="19" font="0"> degree AVB </text>
<text top="311" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="330" left="891" width="197" height="20" font="0">•  Cardiac rhythm disturbances </text>
<text top="349" left="910" width="174" height="19" font="0">during sleep are common in </text>
<text top="367" left="910" width="82" height="19" font="0">pts with OSA </text>
<text top="386" left="891" width="153" height="20" font="0">•  Potentially significant </text>
<text top="404" left="910" width="179" height="19" font="0">arrhythmias during sleep are </text>
<text top="423" left="910" width="155" height="19" font="0">relatively common (18%) </text>
<text top="441" left="891" width="153" height="20" font="0">•  Potentially significant </text>
<text top="460" left="910" width="139" height="19" font="0">nocturnal arrhythmias </text>
<text top="479" left="910" width="169" height="19" font="0">correlate with OSA severity </text>
<text top="497" left="891" width="153" height="20" font="0">•  Potentially significant </text>
<text top="516" left="910" width="179" height="19" font="0">arrhythmias during sleep are </text>
<text top="534" left="910" width="177" height="19" font="0">effectively treated by nCPAP </text>
<text top="553" left="910" width="55" height="19" font="0">therapy. </text>
<text top="571" left="899" width="3" height="19" font="0"> </text>
<text top="589" left="891" width="71" height="19" font="8"><b>Comments </b></text>
<text top="608" left="891" width="128" height="20" font="0">•  Small sample size </text>
<text top="627" left="891" width="154" height="20" font="0">•  Potential referral bias </text>
<text top="646" left="891" width="126" height="20" font="0">•  No control group </text>
<text top="665" left="891" width="129" height="20" font="0">•  Non-randomized, </text>
<text top="684" left="910" width="130" height="19" font="0">observational design </text>
<text top="702" left="891" width="185" height="20" font="0">•  91% of subjects were male </text>
<text top="722" left="891" width="186" height="20" font="0">•  Absence of data to suggest </text>
<text top="740" left="910" width="176" height="19" font="0">the presence of arrhythmias </text>
<text top="759" left="910" width="127" height="19" font="0">during sleep directly </text>
<text top="777" left="910" width="155" height="19" font="0">influences morbidity and </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 62 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="601" width="234" height="20" font="0">•   nCPAP abolished all “pathological” </text>
<text top="106" left="618" width="166" height="19" font="0">arrhythmias in 7/8 (87.5%) </text>
<text top="124" left="601" width="264" height="20" font="0">•  The outlier had ischemic CM and severe </text>
<text top="143" left="618" width="244" height="19" font="0">AS and had both ventricular ectopy and </text>
<text top="162" left="618" width="200" height="19" font="0">sinus pauses with and w/o CPAP </text>
<text top="180" left="601" width="251" height="20" font="0">•  “Pathological” arrhythmias correlated </text>
<text top="199" left="618" width="246" height="19" font="0">with severity of OSA as indicated by AHI </text>
<text top="217" left="618" width="208" height="19" font="0">(p=0.04), but not to mean oxygen </text>
<text top="236" left="618" width="258" height="19" font="0">saturation, BMI, age, BP, glucose, or lipids </text>
<text top="87" left="910" width="180" height="19" font="0">mortality in OSA and the lack </text>
<text top="105" left="910" width="179" height="19" font="0">of evidence that suppression </text>
<text top="123" left="910" width="159" height="19" font="0">of arrhythmias with CPAP </text>
<text top="142" left="910" width="152" height="19" font="0">contributes to improved </text>
<text top="160" left="910" width="111" height="19" font="0">outcomes in OSA. </text>
<text top="255" left="96" width="388" height="19" font="8"><b>ASYX BRADYCARDIA AS A MARKER OF OSA - OBSERVATIONAL </b></text>
<text top="274" left="96" width="111" height="19" font="0">Stegman SS, et al. </text>
<text top="292" left="96" width="30" height="19" font="0">1996</text>
<text top="291" left="127" width="4" height="21" font="4"> </text>
<text top="292" left="130" width="28" height="19" font="0">(70) </text>
<text top="311" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8774819">8774819</a></text>
<text top="311" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8774819"> </a></text>
<text top="329" left="96" width="3" height="19" font="0"> </text>
<text top="274" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="292" left="233" width="75" height="19" font="0">Prospective </text>
<text top="311" left="233" width="130" height="19" font="0">observational cohort </text>
<text top="329" left="233" width="37" height="19" font="0">study </text>
<text top="347" left="233" width="3" height="19" font="0"> </text>
<text top="365" left="233" width="96" height="19" font="8"><b>Size:</b> 7 pts with </text>
<text top="384" left="233" width="115" height="19" font="0">clinical indications </text>
<text top="402" left="233" width="116" height="19" font="0">for cardiac rhythm </text>
<text top="420" left="233" width="110" height="19" font="0">assessment (ECG, </text>
<text top="439" left="233" width="119" height="19" font="0">hospital telemetry, </text>
<text top="457" left="233" width="100" height="19" font="0">and ambulatory </text>
<text top="475" left="233" width="130" height="19" font="0">monitoring) referred </text>
<text top="494" left="233" width="120" height="19" font="0">to an EP service for </text>
<text top="512" left="233" width="76" height="19" font="0">PPM for asx </text>
<text top="530" left="233" width="115" height="19" font="0">bradyarrhythmias <b> </b></text>
<text top="274" left="378" width="189" height="19" font="8"><b>Inclusion criteria:</b> Referred for </text>
<text top="292" left="389" width="193" height="19" font="0">PPM for asx profound SB, sinus </text>
<text top="311" left="389" width="163" height="19" font="0">pauses of 2.08–7.52 s, or 2</text>
<text top="310" left="552" width="10" height="12" font="7">nd</text>
<text top="311" left="562" width="20" height="19" font="0"> or </text>
<text top="329" left="389" width="8" height="19" font="0">3</text>
<text top="329" left="396" width="9" height="12" font="7">rd</text>
<text top="329" left="405" width="155" height="19" font="0"> degree AVB detected on </text>
<text top="347" left="389" width="163" height="19" font="0">clinically indicated rhythm </text>
<text top="365" left="389" width="193" height="19" font="0">assessment. Screened clinically </text>
<text top="384" left="389" width="188" height="19" font="0">for SAS. Those with suggestive </text>
<text top="402" left="389" width="160" height="19" font="0">sx were referred for PSG.  </text>
<text top="420" left="378" width="3" height="19" font="0"> </text>
<text top="439" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="457" left="378" width="169" height="20" font="0">• Medications include beta </text>
<text top="476" left="390" width="184" height="19" font="0">blocker, digoxin or verapamil. </text>
<text top="495" left="378" width="183" height="20" font="0">• None were trained athletes<b> </b></text>
<text top="275" left="601" width="270" height="19" font="8"><b>1</b>°<b> endpoint:</b> Prevalence of SAS as indicated </text>
<text top="293" left="612" width="253" height="19" font="0">by PSG in those with asx bradycardia and </text>
<text top="311" left="612" width="129" height="19" font="0">sx suggestive of SAS. </text>
<text top="330" left="601" width="3" height="19" font="0"> </text>
<text top="348" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="366" left="601" width="262" height="20" font="0">• All had normal resting awake heart rates </text>
<text top="385" left="612" width="250" height="19" font="0">during all EP clinic visits before and after </text>
<text top="404" left="612" width="71" height="19" font="0">enrollment </text>
<text top="422" left="601" width="274" height="20" font="0">• Bradyarrhythmias prompting referral were </text>
<text top="441" left="612" width="228" height="19" font="0">all nocturnal or during daytime sleep </text>
<text top="460" left="601" width="244" height="20" font="0">• OSA diagnosed in all by PSG (1 mild, 2 </text>
<text top="479" left="612" width="157" height="19" font="0">moderate, and 4 severe). </text>
<text top="497" left="601" width="95" height="20" font="0">• Mean nadir O</text>
<text top="504" left="695" width="5" height="12" font="7">2</text>
<text top="498" left="700" width="131" height="19" font="0"> sat: 70.6% (45–88%) </text>
<text top="516" left="601" width="241" height="20" font="0">• 6 treated with CPAP or sleep position </text>
<text top="535" left="612" width="80" height="19" font="0">modification </text>
<text top="554" left="601" width="274" height="20" font="0">• 1 received tracheostomy after failing CPAP </text>
<text top="573" left="601" width="231" height="20" font="0">• Mean follow-up: 22 mo (18–32 mo) </text>
<text top="592" left="601" width="223" height="20" font="0">• 6/7 (86%) remained free of typical </text>
<text top="611" left="612" width="258" height="19" font="0">bradyarrhythmia symptoms on treatment </text>
<text top="629" left="612" width="54" height="19" font="0">for OSA. </text>
<text top="647" left="601" width="234" height="20" font="0">• 7/7 reported improved sx of OSA on </text>
<text top="666" left="612" width="66" height="19" font="0">treatment </text>
<text top="685" left="601" width="249" height="20" font="0">• 1 with AS and severe CHF had syncope </text>
<text top="704" left="612" width="208" height="19" font="0">during follow-up but also showed </text>
<text top="722" left="612" width="238" height="19" font="0">resolution of nocturnal bradycardia on </text>
<text top="740" left="612" width="203" height="19" font="0">hospital tele after tracheostomy. </text>
<text top="759" left="601" width="271" height="20" font="0">• Authors describe 1 additional subject with </text>
<text top="778" left="612" width="248" height="19" font="0">daytime and nocturnal profound resting </text>
<text top="274" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="292" left="891" width="149" height="20" font="0">• Asx bradyarrhythmias </text>
<text top="311" left="903" width="183" height="19" font="0">occurring during sleep should </text>
<text top="330" left="903" width="162" height="19" font="0">prompt screening for SAS. </text>
<text top="348" left="891" width="182" height="20" font="0">• Those with sx suggestive of </text>
<text top="367" left="903" width="180" height="19" font="0">SAS and significant nocturnal </text>
<text top="385" left="903" width="149" height="19" font="0">bradycardia have a high </text>
<text top="404" left="903" width="155" height="19" font="0">likelihood of OSA on PSG </text>
<text top="422" left="891" width="188" height="20" font="0">• Such pts are likely to remain </text>
<text top="441" left="903" width="186" height="19" font="0">asx on treatment for OSA w/o </text>
<text top="459" left="903" width="179" height="19" font="0">PPM implantation during 18–</text>
<text top="478" left="903" width="150" height="19" font="0">32 months of follow-up. </text>
<text top="496" left="891" width="177" height="20" font="0">• Establishing a Dx of OSA in </text>
<text top="515" left="903" width="161" height="19" font="0">these pts may obviate the </text>
<text top="533" left="903" width="173" height="19" font="0">need for PPM by facilitating </text>
<text top="552" left="903" width="174" height="19" font="0">treatment of the underlying </text>
<text top="570" left="903" width="184" height="19" font="0">cause of the bradyarrhythmia </text>
<text top="588" left="903" width="187" height="19" font="0">and identify pts at (potentially </text>
<text top="607" left="903" width="181" height="19" font="0">modifiable) increased risk for </text>
<text top="625" left="903" width="68" height="19" font="0">CV events. </text>
<text top="643" left="891" width="3" height="19" font="0"> </text>
<text top="661" left="891" width="71" height="19" font="8"><b>Comments </b></text>
<text top="680" left="891" width="122" height="20" font="0">• Small sample size </text>
<text top="699" left="891" width="148" height="20" font="0">• Potential referral bias </text>
<text top="718" left="891" width="150" height="20" font="0">• No control group with </text>
<text top="737" left="903" width="193" height="19" font="0">negative response to screening </text>
<text top="756" left="903" width="191" height="19" font="0">questions who also underwent </text>
<text top="774" left="903" width="28" height="19" font="0">PSG </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 63 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="612" width="203" height="19" font="0">sinus bradycardia in the 30s with </text>
<text top="105" left="612" width="222" height="19" font="0">preserved chronotropic response to </text>
<text top="123" left="612" width="233" height="19" font="0">exercise and no sx of SAS who did not </text>
<text top="142" left="612" width="259" height="19" font="0">undergo PSG and refused PPM. Remained </text>
<text top="160" left="612" width="266" height="19" font="0">asx over 17 mo of follow-up. They highlight </text>
<text top="178" left="612" width="239" height="19" font="0">the distinct pattern of persistent d and </text>
<text top="197" left="612" width="249" height="19" font="0">night time bradycardia in this subject vs. </text>
<text top="215" left="612" width="258" height="19" font="0">exclusively nocturnal bradyarrhythmias in </text>
<text top="233" left="612" width="94" height="19" font="0">those with SAS </text>
<text top="87" left="891" width="122" height="20" font="0">• Non-randomized, </text>
<text top="106" left="903" width="182" height="19" font="0">observational design and size </text>
<text top="124" left="903" width="193" height="19" font="0">preclude conclusions regarding </text>
<text top="143" left="903" width="166" height="19" font="0">the impact of treatment of </text>
<text top="161" left="903" width="112" height="19" font="0">OSA on outcomes </text>
<text top="179" left="891" width="151" height="20" font="0">•  Most did not present </text>
<text top="198" left="910" width="183" height="19" font="0">definitive indications for PPM </text>
<text top="217" left="910" width="124" height="19" font="0">in the absence of sx </text>
<text top="252" left="96" width="63" height="19" font="8"><b>European </b></text>
<text top="271" left="96" width="77" height="19" font="8"><b>Multicenter </b></text>
<text top="289" left="96" width="120" height="19" font="8"><b>Polysomno-graphy </b></text>
<text top="307" left="96" width="39" height="19" font="8"><b>Study </b></text>
<text top="326" left="96" width="104" height="19" font="0">Garrigue S, et al. </text>
<text top="344" left="96" width="62" height="19" font="0">2007 (71) </text>
<text top="362" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17353437">17353437</a></text>
<text top="362" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17353437"> </a></text>
<text top="381" left="96" width="3" height="19" font="0"> </text>
<text top="252" left="233" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="271" left="233" width="75" height="19" font="0">Prospective </text>
<text top="289" left="233" width="130" height="19" font="0">observational cohort </text>
<text top="307" left="233" width="37" height="19" font="0">study </text>
<text top="326" left="233" width="3" height="19" font="0"> </text>
<text top="344" left="233" width="126" height="19" font="8"><b>Size:</b> 98 consecutive </text>
<text top="362" left="233" width="117" height="19" font="0">pts with PPM from </text>
<text top="381" left="233" width="133" height="19" font="0">11 European centers <b> </b></text>
<text top="252" left="379" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="271" left="378" width="187" height="20" font="0">• PPM for at least a month for </text>
<text top="290" left="389" width="178" height="19" font="0">symptomatic SND, advanced </text>
<text top="308" left="389" width="191" height="19" font="0">AVB, or CRT for HFrEF and QRS </text>
<text top="326" left="389" width="59" height="19" font="0">&gt;120 ms. </text>
<text top="345" left="378" width="194" height="20" font="0">• Mean spontaneous nocturnal </text>
<text top="364" left="389" width="124" height="19" font="0">atrial rate ≥50 bpm  </text>
<text top="382" left="378" width="200" height="20" font="0">• PPM settings during PSG = DDI </text>
<text top="401" left="389" width="180" height="19" font="0">at lower rate of 50 bpm in all </text>
<text top="420" left="378" width="3" height="19" font="0"> </text>
<text top="438" left="378" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="456" left="378" width="181" height="20" font="0">• Recent (&lt;6 mo) MI, USA, or </text>
<text top="475" left="390" width="168" height="19" font="0">coronary revascularization <b> </b></text>
<text top="494" left="378" width="169" height="20" font="0">• Permanent atrially paced </text>
<text top="513" left="390" width="48" height="19" font="0">rhythm </text>
<text top="253" left="601" width="262" height="19" font="8"><b>1</b>°<b> endpoint:</b> Prevalence and consequence </text>
<text top="272" left="601" width="260" height="19" font="0">of undiagnosed SAS as indicated by PSG in </text>
<text top="290" left="601" width="264" height="19" font="0">those with PPM according to indication for </text>
<text top="308" left="601" width="212" height="19" font="0">pacing: HF, symptomatic “diurnal” </text>
<text top="326" left="601" width="196" height="19" font="0">bradycardia, and advanced AVB </text>
<text top="345" left="601" width="3" height="19" font="0"> </text>
<text top="363" left="601" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="382" left="601" width="125" height="20" font="0">•  Mean age 64±8 y </text>
<text top="401" left="601" width="272" height="20" font="0">•  Pacing indication: 29/98 (30%) DCM/CRT; </text>
<text top="420" left="618" width="251" height="19" font="0">33/98 (34%) advanced AVB; 36/98 (37%) </text>
<text top="438" left="618" width="50" height="19" font="0">for SND </text>
<text top="456" left="601" width="80" height="20" font="0">•  77% male </text>
<text top="476" left="601" width="133" height="20" font="0">•  BMI 26.8±5.2 kg/m</text>
<text top="476" left="734" width="5" height="12" font="7">2</text>
<text top="476" left="739" width="3" height="19" font="0"> </text>
<text top="495" left="601" width="210" height="20" font="0">•  HTN: 49%; CAD: 22%; DM: 10% </text>
<text top="514" left="601" width="253" height="20" font="0">•  Mean Epworth Sleepiness Score =7±4, </text>
<text top="533" left="618" width="233" height="19" font="0">similar in all pacing indications. 13/98 </text>
<text top="551" left="618" width="123" height="19" font="0">(25%) had ESS &gt;11.  </text>
<text top="569" left="601" width="265" height="20" font="0">•  Prevalence of SAS: 59% (95% CI: 46–69), </text>
<text top="588" left="618" width="241" height="19" font="0">over twice the estimated prevalence in </text>
<text top="607" left="618" width="241" height="19" font="0">the general population in other studies </text>
<text top="625" left="601" width="270" height="20" font="0">•  SND prevalence of SAS: 58% (27% severe-</text>
<text top="644" left="618" width="69" height="19" font="0">AHI &gt;30/h) </text>
<text top="663" left="601" width="273" height="20" font="0">•  AVB prevalence of SAS: 68% (27% severe) </text>
<text top="682" left="601" width="276" height="20" font="0">•  HFrEF prevalence of SAS: 50% (5% severe) </text>
<text top="701" left="601" width="229" height="20" font="0">•  V-pacing during PSG: AVB=97±4%; </text>
<text top="720" left="618" width="258" height="19" font="0">SND=15±12%, CRT: 0% (p&lt;0.01 by ANOVA </text>
<text top="738" left="618" width="108" height="19" font="0">for AVB and CRT) </text>
<text top="757" left="601" width="261" height="20" font="0">•  A-pacing rate similar in all groups at 15–</text>
<text top="776" left="618" width="74" height="19" font="0">20% (p=NS) </text>
<text top="252" left="891" width="77" height="19" font="8"><b>Conclusions </b></text>
<text top="271" left="891" width="181" height="20" font="0">• Regardless of indication for </text>
<text top="290" left="902" width="190" height="19" font="0">pacing, those with PPM have a </text>
<text top="308" left="902" width="189" height="19" font="0">significantly higher prevalence </text>
<text top="326" left="902" width="184" height="19" font="0">of SAS (59%) than the general </text>
<text top="345" left="902" width="178" height="19" font="0">population despite relatively </text>
<text top="363" left="902" width="177" height="19" font="0">few symptoms of SAS (mean </text>
<text top="381" left="902" width="47" height="19" font="0">ESS =7) </text>
<text top="400" left="891" width="163" height="20" font="0">• The majority of the SA is </text>
<text top="419" left="902" width="188" height="19" font="0">obstructive even in those with </text>
<text top="437" left="902" width="72" height="19" font="0">HFrEF/CRT  </text>
<text top="456" left="891" width="176" height="20" font="0">• Authors call for systematic </text>
<text top="475" left="902" width="194" height="19" font="0">screening of PPM recipients for </text>
<text top="493" left="902" width="193" height="19" font="0">SAS due to the high prevalence </text>
<text top="511" left="902" width="194" height="19" font="0">and potential CV consequences </text>
<text top="530" left="902" width="42" height="19" font="0">of SAS </text>
<text top="548" left="891" width="3" height="19" font="0"> </text>
<text top="566" left="891" width="71" height="19" font="8"><b>Comments </b></text>
<text top="585" left="891" width="199" height="20" font="0">• No control group w/o PPM for </text>
<text top="604" left="902" width="169" height="19" font="0">comparison of ESS and PSG </text>
<text top="622" left="902" width="44" height="19" font="0">results </text>
<text top="640" left="891" width="186" height="20" font="0">• Some elements inconsistent </text>
<text top="659" left="902" width="168" height="19" font="0">with previous observations </text>
<text top="678" left="902" width="188" height="19" font="0">including lack of correlation of </text>
<text top="696" left="902" width="176" height="19" font="0">AHI with age or BMI and the </text>
<text top="714" left="902" width="183" height="19" font="0">preponderance of OSA rather </text>
<text top="733" left="902" width="165" height="19" font="0">than CSA in the HFrEF/CRT </text>
<text top="751" left="902" width="39" height="19" font="0">group </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 64 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="601" width="252" height="20" font="0">•  Prevalence of SAS was similar in those </text>
<text top="106" left="618" width="249" height="19" font="0">with or w/o HTN, CAD or DM, regardless </text>
<text top="124" left="618" width="127" height="19" font="0">of pacing indication. </text>
<text top="143" left="601" width="238" height="20" font="0">•  75% of SDB events were hypopneas </text>
<text top="162" left="601" width="246" height="20" font="0">•  All pts had mixed OSA and CSA. Most </text>
<text top="181" left="618" width="256" height="19" font="0">apneic events were obstructive, including </text>
<text top="199" left="618" width="105" height="19" font="0">in the CRT group </text>
<text top="218" left="601" width="235" height="20" font="0">•  &lt;5% of pts had predominantly CSA, </text>
<text top="237" left="618" width="189" height="19" font="0">regardless of pacing indication </text>
<text top="255" left="601" width="242" height="20" font="0">•  No correlation between ESS and AHI </text>
<text top="274" left="618" width="91" height="19" font="0">(r=0.01; p=NS) </text>
<text top="87" left="891" width="148" height="20" font="0">• Although atrial pacing </text>
<text top="106" left="902" width="165" height="19" font="0">occurred &lt;20% of the time </text>
<text top="124" left="902" width="175" height="19" font="0">with lower pacing rate of 50 </text>
<text top="143" left="902" width="148" height="19" font="0">bpm, it was not entirely </text>
<text top="161" left="902" width="171" height="19" font="0">eliminated atrial pacing has </text>
<text top="179" left="902" width="189" height="19" font="0">been linked in some studies to </text>
<text top="198" left="902" width="111" height="19" font="0">reductions in SDB </text>
<text top="216" left="891" width="3" height="19" font="0"> </text>
<text top="293" left="82" width="3" height="19" font="0"> </text>
<text top="311" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="311" left="302" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 65 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="947" height="23" font="5"><b>Data Supplement 6. RCTs of Implantable Loop Recorder in Patients With Documented or Suspected Bradycardia or Conduction </b></text>
<text top="108" left="86" width="191" height="23" font="5"><b>Disorders (Section 4.3.1)  </b></text>
<text top="131" left="126" width="39" height="19" font="8"><b>Study </b></text>
<text top="149" left="119" width="64" height="19" font="8"><b>Acronym; </b></text>
<text top="167" left="125" width="51" height="19" font="8"><b>Author; </b></text>
<text top="186" left="96" width="100" height="19" font="8"><b>Year Published; </b></text>
<text top="204" left="132" width="38" height="19" font="8"><b>PMID </b></text>
<text top="131" left="235" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="149" left="241" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="167" left="234" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="131" left="384" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="549" width="205" height="19" font="8"><b>Study Intervention (# patients) / </b></text>
<text top="149" left="556" width="192" height="19" font="8"><b>Study Comparator (# patients) </b></text>
<text top="131" left="800" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="149" left="776" width="156" height="19" font="8"><b>(Absolute Event Rates, P </b></text>
<text top="167" left="800" width="119" height="19" font="8"><b>value; OR or RR; &amp; </b></text>
<text top="186" left="835" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="132" left="953" width="135" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint </b></text>
<text top="150" left="1001" width="51" height="19" font="8"><b>(if any); </b></text>
<text top="168" left="963" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="186" left="971" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="223" left="95" width="35" height="19" font="8"><b>RAST </b></text>
<text top="241" left="95" width="98" height="19" font="0">Krahn AD, et al. </text>
<text top="260" left="95" width="62" height="19" font="0">2001 (72) </text>
<text top="278" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11435336">11435336</a></text>
<text top="278" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11435336"> </a></text>
<text top="223" left="209" width="103" height="19" font="8"><b>Aim:</b> To find out </text>
<text top="241" left="209" width="121" height="19" font="0">whether prolonged </text>
<text top="260" left="209" width="137" height="19" font="0">monitoring strategy is </text>
<text top="278" left="209" width="73" height="19" font="0">better than </text>
<text top="296" left="209" width="136" height="19" font="0">conventional strategy </text>
<text top="315" left="209" width="122" height="19" font="0">in the evaluation of </text>
<text top="333" left="209" width="115" height="19" font="0">recurrent syncope </text>
<text top="351" left="209" width="3" height="19" font="0"> </text>
<text top="370" left="209" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="388" left="209" width="75" height="19" font="0">Prospective </text>
<text top="406" left="209" width="104" height="19" font="0">randomized trial </text>
<text top="425" left="209" width="3" height="19" font="0"> </text>
<text top="443" left="209" width="73" height="19" font="8"><b>Size:</b> 60 pts </text>
<text top="223" left="361" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="241" left="361" width="142" height="19" font="0">Recurrent unexplained </text>
<text top="260" left="361" width="146" height="19" font="0">syncope or syncope X 1 </text>
<text top="278" left="361" width="136" height="19" font="0">associated with injury </text>
<text top="296" left="361" width="3" height="19" font="8"><b> </b></text>
<text top="315" left="361" width="146" height="19" font="8"><b>Exclusion criteria:</b> LVEF </text>
<text top="333" left="361" width="129" height="19" font="0">&lt;35%, &lt;1 y expected </text>
<text top="351" left="361" width="165" height="19" font="0">survival, unable to provide </text>
<text top="370" left="361" width="134" height="19" font="0">follow-up or consent, </text>
<text top="388" left="361" width="66" height="19" font="0">clear NMS </text>
<text top="223" left="540" width="193" height="19" font="8"><b>Intervention:</b> ILR (MDT Reveal) </text>
<text top="241" left="540" width="158" height="19" font="0">monitoring for 1 y (N=27)<b> </b></text>
<text top="260" left="540" width="3" height="19" font="8"><b> </b></text>
<text top="278" left="540" width="223" height="19" font="8"><b>Comparator:</b> Conventional testing – </text>
<text top="296" left="540" width="219" height="19" font="0">2 to 4 wk of external loop recorder, </text>
<text top="315" left="540" width="197" height="19" font="0">TTT and EP testing (SNRT, SACT, </text>
<text top="333" left="540" width="213" height="19" font="0">antegrade/retrograde conduction, </text>
<text top="351" left="540" width="219" height="19" font="0">programmed electrical stimulation) </text>
<text top="370" left="540" width="45" height="19" font="0">(N=30) </text>
<text top="388" left="540" width="3" height="19" font="0"> </text>
<text top="406" left="540" width="200" height="19" font="0">Crossover was allowed if Dx was </text>
<text top="425" left="540" width="122" height="19" font="0">unable to be made. </text>
<text top="223" left="776" width="156" height="20" font="0">• Dx obtained in 14 of 27 </text>
<text top="242" left="787" width="139" height="19" font="0">pts (ILR group) vs. 6 of </text>
<text top="261" left="787" width="128" height="19" font="0">30 pts (conventional </text>
<text top="279" left="787" width="131" height="19" font="0">group) (52% vs. 20%; </text>
<text top="297" left="787" width="57" height="19" font="0">p=0.012) </text>
<text top="223" left="945" width="3" height="19" font="0"> </text>
<text top="462" left="95" width="48" height="19" font="8"><b>EaSyAS </b></text>
<text top="480" left="95" width="85" height="19" font="0">Farwell DJ, et </text>
<text top="499" left="95" width="79" height="19" font="0">al. 2004 (73) </text>
<text top="517" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15246645">15246645</a></text>
<text top="517" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15246645"> </a></text>
<text top="462" left="209" width="127" height="19" font="8"><b>Aim:</b> Investigate the </text>
<text top="480" left="209" width="108" height="19" font="0">impact of ILRs on </text>
<text top="499" left="209" width="70" height="19" font="0">unselected </text>
<text top="517" left="209" width="86" height="19" font="0">population of </text>
<text top="535" left="209" width="79" height="19" font="0">syncopal pts </text>
<text top="554" left="209" width="112" height="19" font="0">presenting to one </text>
<text top="572" left="209" width="66" height="19" font="0">institution </text>
<text top="590" left="209" width="3" height="19" font="0"> </text>
<text top="608" left="209" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="627" left="209" width="107" height="19" font="0">Randomized trial </text>
<text top="645" left="209" width="3" height="19" font="0"> </text>
<text top="663" left="209" width="80" height="19" font="8"><b>Size: </b>201 pts </text>
<text top="462" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="480" left="361" width="158" height="19" font="0">recurrent syncope but no </text>
<text top="499" left="361" width="140" height="19" font="0">definitive Dx following </text>
<text top="517" left="361" width="110" height="19" font="0">initial clinical w/u </text>
<text top="535" left="361" width="150" height="19" font="0">(including CSM and TTT) </text>
<text top="553" left="361" width="3" height="19" font="8"><b> </b></text>
<text top="572" left="361" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="590" left="361" width="148" height="19" font="0">Structural heart disease </text>
<text top="462" left="540" width="91" height="19" font="8"><b>Interventions: </b></text>
<text top="480" left="540" width="193" height="19" font="0">CSM+TTT+implantation of loop </text>
<text top="499" left="540" width="109" height="19" font="0">recorder (N=103) </text>
<text top="517" left="540" width="3" height="19" font="8"><b> </b></text>
<text top="535" left="540" width="83" height="19" font="8"><b>Comparator: </b></text>
<text top="554" left="540" width="147" height="19" font="0">CSM+TTT+conventional </text>
<text top="572" left="540" width="127" height="19" font="0">investigation (N=98) </text>
<text top="590" left="540" width="3" height="19" font="0"> </text>
<text top="608" left="540" width="138" height="19" font="0">Mean follow-up 276 d </text>
<text top="462" left="776" width="146" height="19" font="0">EKG Dx made: 34 (33%) </text>
<text top="480" left="776" width="152" height="19" font="0">in ILR group vs. 4 (4%) in </text>
<text top="499" left="776" width="151" height="19" font="0">conventional group (HR: </text>
<text top="517" left="776" width="139" height="19" font="0">8.93; 95% CI: 3.17–25; </text>
<text top="535" left="776" width="65" height="19" font="0">p&lt;0.0001) </text>
<text top="462" left="945" width="135" height="20" font="0">• Total medical costs: </text>
<text top="481" left="956" width="129" height="19" font="0">£406 in ILR group vs. </text>
<text top="499" left="956" width="139" height="19" font="0">£1210 in conventional </text>
<text top="518" left="956" width="82" height="19" font="0">group (mean </text>
<text top="536" left="956" width="133" height="19" font="0">difference £809; 95% </text>
<text top="554" left="956" width="88" height="19" font="0">CI: 123–2730) </text>
<text top="682" left="95" width="43" height="19" font="8"><b>FRESH </b></text>
<text top="701" left="95" width="100" height="19" font="0">Podoleanu C, et </text>
<text top="719" left="95" width="79" height="19" font="0">al. 2014 (74) </text>
<text top="737" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25241220">25241220</a></text>
<text top="737" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25241220"> </a></text>
<text top="682" left="209" width="108" height="19" font="8"><b>Aim:</b> To compare </text>
<text top="701" left="209" width="83" height="19" font="0">conventional </text>
<text top="719" left="209" width="121" height="19" font="0">evaluation vs. early </text>
<text top="737" left="209" width="128" height="19" font="0">use of ILR in low-risk </text>
<text top="756" left="209" width="121" height="19" font="0">pts with syncope in </text>
<text top="774" left="209" width="44" height="19" font="0">France </text>
<text top="682" left="361" width="138" height="19" font="8"><b>Inclusion criteria:</b> Any </text>
<text top="701" left="361" width="121" height="19" font="0">recent unexplained </text>
<text top="719" left="361" width="125" height="19" font="0">syncope (after basic </text>
<text top="737" left="361" width="86" height="19" font="0">clinical exam) </text>
<text top="756" left="361" width="3" height="19" font="8"><b> </b></text>
<text top="682" left="540" width="191" height="19" font="8"><b>Intervention:</b> ILR group (N=39) </text>
<text top="701" left="540" width="3" height="19" font="8"><b> </b></text>
<text top="719" left="540" width="167" height="19" font="8"><b>Comparator: </b>Conventional </text>
<text top="737" left="540" width="205" height="19" font="0">evaluation strategy group (N=39) </text>
<text top="756" left="540" width="3" height="19" font="0"> </text>
<text top="774" left="540" width="66" height="19" font="0">F/u 14 mo </text>
<text top="683" left="776" width="154" height="20" font="0">• Identification of cause: </text>
<text top="701" left="787" width="127" height="19" font="0">18 (46.2%) pts in ILR </text>
<text top="720" left="787" width="138" height="19" font="0">group vs. 2 (5%) pts in </text>
<text top="738" left="787" width="122" height="19" font="0">conventional group </text>
<text top="756" left="787" width="62" height="19" font="0">(p&lt;0.001) </text>
<text top="683" left="945" width="143" height="20" font="0">• Quality of life was no </text>
<text top="701" left="956" width="138" height="19" font="0">different between the </text>
<text top="720" left="956" width="56" height="19" font="0">2 groups </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 66 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="209" width="3" height="19" font="0"> </text>
<text top="105" left="209" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="123" left="209" width="110" height="19" font="0">Prospective open-</text>
<text top="142" left="209" width="109" height="19" font="0">label randomized </text>
<text top="160" left="209" width="111" height="19" font="0">multicenter study </text>
<text top="178" left="209" width="3" height="19" font="0"> </text>
<text top="197" left="209" width="73" height="19" font="8"><b>Size:</b> 78 pts </text>
<text top="87" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="105" left="361" width="155" height="19" font="0">Significant heart disease, </text>
<text top="123" left="361" width="130" height="19" font="0">EF &lt;40%, Hx of MI or </text>
<text top="142" left="361" width="124" height="19" font="0">unstable CAD, Hx of </text>
<text top="160" left="361" width="151" height="19" font="0">arrhythmia, family Hx of </text>
<text top="178" left="361" width="103" height="19" font="0">SCD, conduction </text>
<text top="197" left="361" width="126" height="19" font="0">disturbance on EKG, </text>
<text top="215" left="361" width="139" height="19" font="0">HOCM, AS, potentially </text>
<text top="233" left="361" width="157" height="19" font="0">arrhythmogenic drug use </text>
<text top="87" left="776" width="156" height="20" font="0">• Days of hospitalization: </text>
<text top="106" left="787" width="129" height="19" font="0">5.7 d in ILR group vs. </text>
<text top="124" left="787" width="131" height="19" font="0">8.0 d in conventional </text>
<text top="143" left="787" width="94" height="19" font="0">group (p=0.55) </text>
<text top="161" left="776" width="142" height="20" font="0">• Number of advanced </text>
<text top="180" left="787" width="133" height="19" font="0">cardiac tests needed: </text>
<text top="198" left="787" width="144" height="19" font="0">0.03/pt in ILR group vs. </text>
<text top="217" left="787" width="138" height="19" font="0">0.2/pt in conventional </text>
<text top="235" left="787" width="94" height="19" font="0">group (p=0.05) </text>
<text top="254" left="86" width="3" height="19" font="0"> </text>
<text top="274" left="97" width="4" height="21" font="4"> </text>
<text top="272" left="313" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 67 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="969" height="23" font="5"><b>Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries of Electrophysiology Testing in Patients With </b></text>
<text top="108" left="86" width="591" height="23" font="5"><b>Documented or Suspected Bradycardia or Conduction Disorders (Section 4.3.2) </b></text>
<text top="131" left="99" width="113" height="21" font="2"><b>Study Acronym; </b></text>
<text top="151" left="115" width="91" height="21" font="2"><b>Author; Year </b></text>
<text top="171" left="123" width="67" height="21" font="2"><b>Published</b></text>
<text top="173" left="190" width="8" height="19" font="8"><b>; </b></text>
<text top="191" left="141" width="38" height="19" font="8"><b>PMID </b></text>
<text top="131" left="267" width="43" height="21" font="2"><b>Study </b></text>
<text top="151" left="246" width="95" height="21" font="2"><b>Type/Design; </b></text>
<text top="171" left="245" width="94" height="21" font="2"><b>Study Size (N)</b></text>
<text top="173" left="339" width="3" height="19" font="8"><b> </b></text>
<text top="131" left="392" width="128" height="21" font="2"><b>Patient Population</b></text>
<text top="132" left="520" width="3" height="19" font="8"><b> </b></text>
<text top="131" left="620" width="202" height="21" font="2"><b>Primary Endpoint and Results</b></text>
<text top="132" left="822" width="3" height="19" font="8"><b> </b></text>
<text top="131" left="916" width="155" height="21" font="2"><b>Summary/Conclusion; </b></text>
<text top="151" left="960" width="78" height="21" font="2"><b>Comments </b></text>
<text top="210" left="93" width="109" height="19" font="0">Denniss AR, et al. </text>
<text top="229" left="93" width="62" height="19" font="0">1992 (75) </text>
<text top="247" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1572741">1572741</a></text>
<text top="247" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/1572741"> </a></text>
<text top="210" left="228" width="36" height="19" font="8"><b>Aim:  </b></text>
<text top="229" left="228" width="114" height="19" font="0">Electrophysiologic </text>
<text top="247" left="228" width="114" height="19" font="0">studies in pts with </text>
<text top="265" left="228" width="78" height="19" font="0">unexplained </text>
<text top="284" left="228" width="54" height="19" font="0">syncope </text>
<text top="302" left="228" width="3" height="19" font="8"><b> </b></text>
<text top="320" left="228" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="338" left="228" width="118" height="19" font="0">Prospective cohort </text>
<text top="357" left="228" width="3" height="19" font="8"><b> </b></text>
<text top="375" left="228" width="80" height="19" font="8"><b>Size:</b> 111 pts </text>
<text top="210" left="362" width="191" height="19" font="8"><b>Inclusion criteria: </b>Unexplained </text>
<text top="229" left="362" width="191" height="19" font="0">syncope, prior general medical </text>
<text top="247" left="362" width="175" height="19" font="0">evaluation (H&amp;P, CXR, echo, </text>
<text top="265" left="362" width="147" height="19" font="0">LHC, neuro exam, heart </text>
<text top="284" left="362" width="83" height="19" font="0">monitor, etc) </text>
<text top="302" left="362" width="3" height="19" font="8"><b> </b></text>
<text top="320" left="362" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="338" left="362" width="136" height="19" font="0">Documented tachy or </text>
<text top="357" left="362" width="145" height="19" font="0">bradyarrhythmia, Dx of </text>
<text top="375" left="362" width="174" height="19" font="0">vasovagal syncope, postural </text>
<text top="393" left="362" width="166" height="19" font="0">hypotension, AS, HOCM or </text>
<text top="412" left="362" width="137" height="19" font="0">prolonged QT interval </text>
<text top="430" left="362" width="3" height="19" font="0"> </text>
<text top="448" left="362" width="142" height="19" font="0">Mean follow-up 20 mo </text>
<text top="210" left="567" width="52" height="19" font="8"><b>Results: </b></text>
<text top="229" left="567" width="204" height="20" font="0">• No mortality within 30 d of EPS<b> </b></text>
<text top="248" left="567" width="292" height="20" font="0">• Pts with heart disease (CAD, HTN, MVP, CMP) </text>
<text top="267" left="578" width="267" height="19" font="0">had higher incidence of conduction disease </text>
<text top="285" left="578" width="300" height="19" font="0">(26%) than those w/o heart disease (8%; p&lt;0.05)<b> </b></text>
<text top="304" left="567" width="282" height="20" font="0">• Abnormal EPS (conduction disease, SVT, VT) </text>
<text top="323" left="578" width="273" height="19" font="0">findings in 42% of pts with heart disease but </text>
<text top="341" left="578" width="234" height="19" font="0">16% of pts w/o heart disease (p&lt;0.01)<b> </b></text>
<text top="359" left="567" width="306" height="20" font="0">• Syncope occurred in only 5% of treated pts with </text>
<text top="378" left="578" width="282" height="19" font="0">abnormal findings at EPS vs. 24% in the group </text>
<text top="397" left="578" width="180" height="19" font="0">not receiving any Rx (p&lt;0.05) </text>
<text top="415" left="567" width="281" height="20" font="0">• No recurrent syncope in 27 pts treated with </text>
<text top="434" left="578" width="295" height="19" font="0">PPM vs. recurrent syncope in 20 of 84 pts (24%) </text>
<text top="452" left="578" width="146" height="19" font="0">not given PPM (p&lt;0.05) </text>
<text top="211" left="891" width="164" height="20" font="0">• Diagnostic yield of EPS is </text>
<text top="229" left="902" width="166" height="19" font="0">increased in pts with heart </text>
<text top="248" left="902" width="52" height="19" font="0">disease. </text>
<text top="266" left="891" width="194" height="20" font="0">• Pts with no heart disease had </text>
<text top="285" left="902" width="82" height="19" font="0">no mortality. </text>
<text top="471" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="493" left="86" width="675" height="23" font="5"><b>Data Supplement 8. RCTs Comparing Atropine to Placebo for Bradycardia (Section 5.3.2.1) </b></text>
<text top="516" left="109" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="534" left="135" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="553" left="113" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="516" left="270" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="534" left="276" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="553" left="269" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="516" left="437" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="516" left="609" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="534" left="626" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="553" left="610" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="571" left="631" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="516" left="784" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="534" left="766" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="553" left="770" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="571" left="813" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="517" left="944" width="152" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="535" left="1008" width="35" height="19" font="8"><b>any); </b></text>
<text top="553" left="962" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="572" left="970" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="591" left="95" width="114" height="19" font="0">Smith I, et al. 1994</text>
<text top="589" left="209" width="4" height="21" font="4"> </text>
<text top="609" left="95" width="28" height="19" font="0">(76) </text>
<text top="627" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7906108">7906108</a></text>
<text top="627" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7906108"> </a></text>
<text top="591" left="239" width="132" height="19" font="8"><b>Aim:</b> To compare the </text>
<text top="609" left="239" width="122" height="19" font="0">effectiveness in the </text>
<text top="627" left="239" width="82" height="19" font="0">treatment of </text>
<text top="646" left="239" width="91" height="19" font="0">intraoperative </text>
<text top="664" left="239" width="92" height="19" font="0">bradycardia of </text>
<text top="682" left="239" width="139" height="19" font="0">transesophageal atrial </text>
<text top="701" left="239" width="132" height="19" font="0">pacing, atropine, and </text>
<text top="719" left="239" width="91" height="19" font="0">glycopyrrolate </text>
<text top="737" left="239" width="3" height="19" font="0"> </text>
<text top="756" left="239" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="774" left="239" width="3" height="19" font="0"> </text>
<text top="591" left="402" width="143" height="19" font="8"><b>Inclusion criteria:</b> Men </text>
<text top="609" left="402" width="168" height="19" font="0">undergoing elective radical </text>
<text top="627" left="402" width="124" height="19" font="0">prostatectomy with </text>
<text top="646" left="402" width="76" height="19" font="0">sufentanil/N</text>
<text top="652" left="478" width="5" height="12" font="7">2</text>
<text top="646" left="483" width="92" height="19" font="0">O/vecuronium </text>
<text top="664" left="402" width="138" height="19" font="0">anesthetic resulting in </text>
<text top="682" left="402" width="180" height="19" font="0">bradycardia (&lt;50 bpm or &lt;60 </text>
<text top="701" left="402" width="145" height="19" font="0">bpm and hypotension)  </text>
<text top="719" left="402" width="3" height="19" font="0"> </text>
<text top="737" left="402" width="187" height="19" font="8"><b>Exclusion criteria:</b> Pts not ASA </text>
<text top="756" left="402" width="70" height="19" font="0">status I–III. </text>
<text top="591" left="605" width="104" height="19" font="8"><b>Intervention:</b> 15 </text>
<text top="609" left="605" width="88" height="19" font="0">patients were </text>
<text top="627" left="605" width="125" height="19" font="0">randomized to each </text>
<text top="646" left="605" width="43" height="19" font="0">group. </text>
<text top="664" left="605" width="7" height="19" font="0">  </text>
<text top="682" left="605" width="110" height="19" font="8"><b>Comparator</b>: TAP </text>
<text top="701" left="605" width="95" height="19" font="0">vs. atropine vs. </text>
<text top="719" left="605" width="91" height="19" font="0">glycopyrrolate<b> </b></text>
<text top="592" left="746" width="172" height="19" font="8"><b>1</b>°<b> endpoint:</b> Time for heart </text>
<text top="610" left="746" width="173" height="19" font="0">rate to increase to &gt;70 bpm </text>
<text top="628" left="746" width="119" height="19" font="0">was shortest in the </text>
<text top="647" left="746" width="154" height="19" font="0">temporary pacing group. </text>
<text top="665" left="746" width="158" height="19" font="0">There were no significant </text>
<text top="683" left="746" width="175" height="19" font="0">differences in postoperative </text>
<text top="702" left="746" width="143" height="19" font="0">course in the 3 groups. </text>
<text top="720" left="746" width="3" height="19" font="0"> </text>
<text top="738" left="746" width="134" height="19" font="8"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="591" left="943" width="38" height="20" font="0">• N/A </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 68 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="239" width="145" height="19" font="8"><b>Size:</b> N=64, of which 45 </text>
<text top="105" left="239" width="113" height="19" font="0">had treatment for </text>
<text top="123" left="239" width="76" height="19" font="0">bradycardia </text>
<text top="173" left="95" width="106" height="19" font="0">Sodeck GH et. al. </text>
<text top="191" left="95" width="30" height="19" font="0">2007</text>
<text top="190" left="125" width="4" height="21" font="4"> </text>
<text top="191" left="129" width="28" height="19" font="0">(77) </text>
<text top="209" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976">17212976</a></text>
<text top="209" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976"> </a></text>
<text top="173" left="239" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="191" left="239" width="92" height="19" font="0">Observational, </text>
<text top="209" left="239" width="127" height="19" font="0">retrospective, single </text>
<text top="228" left="239" width="43" height="19" font="0">center </text>
<text top="246" left="239" width="3" height="19" font="0"> </text>
<text top="264" left="239" width="79" height="19" font="8"><b>Size:</b> N= 277 </text>
<text top="173" left="402" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="191" left="402" width="135" height="19" font="0">presenting to ED with </text>
<text top="209" left="402" width="174" height="19" font="0">symptomatic bradycardia of </text>
<text top="228" left="402" width="57" height="19" font="0">&lt;60 bpm </text>
<text top="246" left="402" width="3" height="19" font="0"> </text>
<text top="264" left="402" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="283" left="402" width="167" height="19" font="0">Asymptomatic bradycardia </text>
<text top="173" left="605" width="170" height="19" font="8"><b>1° endpoint:</b> 30 d mortality </text>
<text top="191" left="605" width="3" height="19" font="0"> </text>
<text top="209" left="605" width="323" height="19" font="8"><b>Results:</b> 107 of 277 pts did well with flat positioning. </text>
<text top="228" left="605" width="289" height="19" font="0">Of 170 with persisting symptoms, 141 received </text>
<text top="246" left="605" width="302" height="19" font="0">atropine, 92 catecholamines (orciprenaline in 62, </text>
<text top="264" left="605" width="307" height="19" font="0">adrenaline in 24 and dopamine/dobutamine in 6), </text>
<text top="283" left="605" width="288" height="19" font="0">and 7 required transcutaneous pacing. Neither </text>
<text top="301" left="605" width="317" height="19" font="0">medical therapy nor cause-specific treatment could </text>
<text top="319" left="605" width="317" height="19" font="0">stabilize 54 of the 170 pts, who required temporary </text>
<text top="338" left="605" width="47" height="19" font="0">pacing.<b> </b></text>
<text top="173" left="943" width="128" height="20" font="0">•  Initial stabilization </text>
<text top="192" left="956" width="107" height="19" font="0">with bedrest and </text>
<text top="210" left="956" width="131" height="19" font="0">intravenous atropine </text>
<text top="228" left="956" width="115" height="19" font="0">or catecholamines </text>
<text top="247" left="956" width="122" height="19" font="0">was effective in the </text>
<text top="265" left="956" width="96" height="19" font="0">majority of pts.<b> </b></text>
<text top="357" left="95" width="115" height="19" font="0">Aghamohammadi, </text>
<text top="376" left="95" width="84" height="19" font="0">H., et al. 2009</text>
<text top="374" left="179" width="4" height="21" font="4"> </text>
<text top="376" left="183" width="28" height="19" font="0">(78) </text>
<text top="394" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19472126">19472126</a></text>
<text top="394" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19472126"> </a></text>
<text top="357" left="239" width="142" height="19" font="8"><b>Aim:</b> To determine the </text>
<text top="376" left="239" width="91" height="19" font="0">efficacy of pre-</text>
<text top="394" left="239" width="131" height="19" font="0">induction atropine in </text>
<text top="412" left="239" width="145" height="19" font="0">preventing bradycardia </text>
<text top="431" left="239" width="123" height="19" font="0">during laparoscopic </text>
<text top="449" left="239" width="101" height="19" font="0">urologic surgery </text>
<text top="467" left="239" width="3" height="19" font="0"> </text>
<text top="485" left="239" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="504" left="239" width="3" height="19" font="0"> </text>
<text top="522" left="239" width="68" height="19" font="8"><b>Size:</b> N=64 </text>
<text top="357" left="402" width="185" height="19" font="8"><b>Inclusion criteria:</b> 15–50 y old </text>
<text top="376" left="402" width="177" height="19" font="0">undergoing elective urologic </text>
<text top="394" left="402" width="129" height="19" font="0">laparoscopic surgery </text>
<text top="412" left="402" width="3" height="19" font="0"> </text>
<text top="430" left="402" width="176" height="19" font="8"><b>Exclusion criteria:</b> History of </text>
<text top="449" left="402" width="153" height="19" font="0">cardiac arrhythmia, drug </text>
<text top="467" left="402" width="179" height="19" font="0">induced bradycardia, cardiac </text>
<text top="485" left="402" width="172" height="19" font="0">disease, contraindication to </text>
<text top="504" left="402" width="102" height="19" font="0">general surgery. </text>
<text top="357" left="605" width="85" height="19" font="8"><b>Intervention:</b> </text>
<text top="376" left="605" width="124" height="19" font="0">Atropine sulfate 0.6 </text>
<text top="394" left="605" width="38" height="19" font="0">mg IV </text>
<text top="412" left="605" width="7" height="19" font="0">  </text>
<text top="430" left="605" width="123" height="19" font="8"><b>Comparator:</b> <b>Saline </b></text>
<text top="358" left="746" width="164" height="19" font="8"><b>1</b>°<b> endpoint:</b> Frequency of </text>
<text top="376" left="746" width="175" height="19" font="0">bradycardia was 28% in non-</text>
<text top="395" left="746" width="171" height="19" font="0">atropine group and 0 in the </text>
<text top="413" left="746" width="149" height="19" font="0">atropine group (p&lt;0.01) </text>
<text top="431" left="746" width="3" height="19" font="0"> </text>
<text top="450" left="746" width="183" height="19" font="8"><b>Safety endpoint (if relevant):</b> </text>
<text top="468" left="746" width="165" height="19" font="0">Mean systolic BP decrease </text>
<text top="486" left="746" width="142" height="19" font="0">was 15.7±10 mm Hg in </text>
<text top="505" left="746" width="178" height="19" font="0">atropine group and 23.5±9.8 </text>
<text top="523" left="746" width="169" height="19" font="0">mm Hg in controls (p&lt;0.01) </text>
<text top="357" left="943" width="108" height="20" font="0">• None of the pts </text>
<text top="376" left="943" width="135" height="19" font="0">treated with atropine </text>
<text top="395" left="943" width="106" height="19" font="0">had bradycardia, </text>
<text top="413" left="943" width="138" height="19" font="0">compared to 28.1% of </text>
<text top="431" left="943" width="142" height="19" font="0">pts in the saline group  </text>
<text top="450" left="943" width="3" height="19" font="0"> </text>
<text top="468" left="943" width="124" height="20" font="0">• Mean systolic and </text>
<text top="487" left="943" width="136" height="19" font="0">diastolic BP was more </text>
<text top="505" left="943" width="134" height="19" font="0">stable in the atropine </text>
<text top="524" left="943" width="43" height="19" font="0">group. </text>
<text top="543" left="82" width="3" height="19" font="0"> </text>
<text top="561" left="97" width="4" height="21" font="4"> </text>
<text top="561" left="313" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 69 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="945" height="23" font="5"><b>Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of Atropine in SND and Hemodynamically </b></text>
<text top="108" left="86" width="301" height="23" font="5"><b>Significant Bradycardia (Section 5.3.2.1) </b></text>
<text top="131" left="122" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="148" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="126" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="131" left="275" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="304" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="446" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="604" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="635" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="167" left="666" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="131" left="870" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="899" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="96" width="128" height="19" font="0">Brady WJ, et al. 1999</text>
<text top="185" left="224" width="4" height="21" font="4"> </text>
<text top="205" left="96" width="28" height="19" font="0">(79)<b> </b></text>
<text top="223" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10459592">10459592</a></text>
<text top="223" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10459592"> </a></text>
<text top="186" left="264" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="205" left="264" width="87" height="19" font="0">Retrospective </text>
<text top="223" left="264" width="139" height="19" font="0">observational study of </text>
<text top="241" left="264" width="76" height="19" font="0">prehospital, </text>
<text top="260" left="264" width="71" height="19" font="0">emergency </text>
<text top="278" left="264" width="106" height="19" font="0">department, and </text>
<text top="296" left="264" width="101" height="19" font="0">hospital records </text>
<text top="315" left="264" width="3" height="19" font="0"> </text>
<text top="333" left="264" width="144" height="19" font="8"><b>Size:</b> 172 pts met entry </text>
<text top="351" left="264" width="115" height="19" font="0">criteria, data were </text>
<text top="370" left="264" width="105" height="19" font="0">available for 131 </text>
<text top="186" left="424" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="205" left="424" width="125" height="19" font="0">Prehospital pts with </text>
<text top="223" left="424" width="111" height="19" font="0">hemodynamically </text>
<text top="241" left="424" width="162" height="19" font="0">unstable bradycardia who </text>
<text top="260" left="424" width="163" height="19" font="0">received atropine by EMS. </text>
<text top="278" left="424" width="4" height="21" font="4"> </text>
<text top="298" left="424" width="101" height="21" font="4">Hemodynamic </text>
<text top="318" left="424" width="154" height="21" font="4">instability was defined </text>
<text top="339" left="424" width="154" height="21" font="4">as the presence of any </text>
<text top="359" left="424" width="114" height="21" font="4">of the following: </text>
<text top="379" left="424" width="138" height="21" font="4">ischemic chest pain, </text>
<text top="399" left="424" width="127" height="21" font="4">dyspnea, syncope, </text>
<text top="419" left="424" width="151" height="21" font="4">altered mental status, </text>
<text top="439" left="424" width="132" height="21" font="4">and systolic BP less </text>
<text top="460" left="424" width="111" height="21" font="4">than 90 mm Hg. </text>
<text top="480" left="424" width="113" height="21" font="4">Bradycardia was </text>
<text top="500" left="424" width="111" height="21" font="4">defined as sinus </text>
<text top="520" left="424" width="158" height="21" font="4">bradycardia, junctional </text>
<text top="540" left="424" width="106" height="21" font="4">bradycardia, or </text>
<text top="560" left="424" width="101" height="21" font="4">idioventricular </text>
<text top="580" left="424" width="148" height="21" font="4">bradycardia (grouped </text>
<text top="600" left="424" width="146" height="21" font="4">as bradycardia) while </text>
<text top="621" left="424" width="132" height="21" font="4">AVB included first-, </text>
<text top="641" left="424" width="159" height="21" font="4">second- (types I and II), </text>
<text top="661" left="424" width="106" height="21" font="4">or third-degree </text>
<text top="681" left="424" width="124" height="21" font="4">(grouped as AVB). </text>
<text top="701" left="424" width="3" height="19" font="0"> </text>
<text top="719" left="424" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="187" left="602" width="147" height="19" font="8"><b>1</b>°<b> endpoint:</b> Heart rate </text>
<text top="206" left="602" width="187" height="19" font="0">response that occurred within </text>
<text top="224" left="602" width="166" height="19" font="0">one minute following each </text>
<text top="242" left="602" width="111" height="19" font="0">dose of atropine.  </text>
<text top="261" left="602" width="3" height="19" font="0"> </text>
<text top="279" left="602" width="175" height="19" font="8"><b>Results:</b> 45 pts with AVB, 86 </text>
<text top="297" left="602" width="181" height="19" font="0">bradycardia. 26 (19.8%)had a </text>
<text top="315" left="602" width="174" height="19" font="0">partial response, 36 (27.5%) </text>
<text top="334" left="602" width="171" height="19" font="0">complete, 65 (49.6%) none, </text>
<text top="352" left="602" width="176" height="19" font="0">and 4 (2.3%) had an adverse </text>
<text top="370" left="602" width="62" height="19" font="0">response  </text>
<text top="187" left="807" width="262" height="20" font="0">• One-half of pts had a complete or partial </text>
<text top="206" left="818" width="208" height="19" font="0">response to atropine and adverse </text>
<text top="224" left="818" width="171" height="19" font="0">reactions were uncommon. </text>
<text top="242" left="807" width="216" height="20" font="0">• Pts who presented with non-AVB </text>
<text top="261" left="818" width="239" height="19" font="0">bradycardia received less atropine and </text>
<text top="280" left="818" width="199" height="19" font="0">were more likely to arrive in the </text>
<text top="298" left="818" width="200" height="19" font="0">emergency department with SR. </text>
<text top="316" left="807" width="3" height="19" font="0"> </text>
<text top="738" left="96" width="123" height="19" font="0">Swart, G, et al. 1999</text>
<text top="737" left="219" width="4" height="21" font="4"> </text>
<text top="738" left="223" width="28" height="19" font="0">(80)<b> </b></text>
<text top="757" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10597081">10597081</a></text>
<text top="757" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10597081"> </a></text>
<text top="738" left="264" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="757" left="264" width="87" height="19" font="0">Retrospective </text>
<text top="775" left="264" width="139" height="19" font="0">observational study of </text>
<text top="738" left="424" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="757" left="424" width="125" height="19" font="0">Prehospital pts with </text>
<text top="775" left="424" width="111" height="19" font="0">hemodynamically </text>
<text top="739" left="602" width="147" height="19" font="8"><b>1</b>°<b> endpoint:</b> Heart rate </text>
<text top="758" left="602" width="187" height="19" font="0">response that occurred within </text>
<text top="739" left="807" width="248" height="20" font="0">• There were no differences in response </text>
<text top="758" left="818" width="245" height="19" font="0">to atropine in AMI vs. non-AMI pts with </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 70 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="264" width="76" height="19" font="0">prehospital, </text>
<text top="105" left="264" width="71" height="19" font="0">emergency </text>
<text top="123" left="264" width="106" height="19" font="0">department, and </text>
<text top="142" left="264" width="101" height="19" font="0">hospital records </text>
<text top="160" left="264" width="3" height="19" font="0"> </text>
<text top="178" left="264" width="108" height="19" font="8"><b>Size:</b> 172 pts met </text>
<text top="197" left="264" width="139" height="19" font="0">criteria, data available </text>
<text top="215" left="264" width="135" height="19" font="0">for 131; 45 presented </text>
<text top="233" left="264" width="59" height="19" font="0">with AMI </text>
<text top="87" left="424" width="148" height="19" font="0">unstable bradycardia or </text>
<text top="105" left="424" width="114" height="19" font="0">AVB who received </text>
<text top="123" left="424" width="108" height="19" font="0">atropine by EMS. </text>
<text top="142" left="424" width="3" height="19" font="0"> </text>
<text top="160" left="424" width="101" height="21" font="4">Hemodynamic </text>
<text top="180" left="424" width="154" height="21" font="4">instability was defined </text>
<text top="201" left="424" width="154" height="21" font="4">as the presence of any </text>
<text top="221" left="424" width="114" height="21" font="4">of the following: </text>
<text top="241" left="424" width="138" height="21" font="4">ischemic chest pain, </text>
<text top="261" left="424" width="127" height="21" font="4">dyspnea, syncope, </text>
<text top="281" left="424" width="151" height="21" font="4">altered mental status, </text>
<text top="301" left="424" width="132" height="21" font="4">and systolic BP less </text>
<text top="321" left="424" width="111" height="21" font="4">than 90 mm Hg. </text>
<text top="342" left="424" width="113" height="21" font="4">Bradycardia was </text>
<text top="362" left="424" width="111" height="21" font="4">defined as sinus </text>
<text top="382" left="424" width="158" height="21" font="4">bradycardia, junctional </text>
<text top="402" left="424" width="106" height="21" font="4">bradycardia, or </text>
<text top="422" left="424" width="101" height="21" font="4">idioventricular </text>
<text top="442" left="424" width="148" height="21" font="4">bradycardia (grouped </text>
<text top="462" left="424" width="110" height="21" font="4">as bradycardia), </text>
<text top="483" left="424" width="153" height="21" font="4">whereas AVB included </text>
<text top="503" left="424" width="149" height="21" font="4">first-, second- (types I </text>
<text top="523" left="424" width="156" height="21" font="4">and II), or third-degree </text>
<text top="543" left="424" width="124" height="21" font="4">(grouped as AVB). </text>
<text top="563" left="424" width="3" height="19" font="0"> </text>
<text top="581" left="424" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="602" width="178" height="19" font="0">1 min following each dose of </text>
<text top="105" left="602" width="55" height="19" font="0">atropine </text>
<text top="123" left="602" width="3" height="19" font="0"> </text>
<text top="142" left="602" width="188" height="19" font="8"><b>Results:</b> No differences in AMI </text>
<text top="160" left="602" width="160" height="19" font="0">vs. non-AMI groups in the </text>
<text top="178" left="602" width="192" height="19" font="0">likelihood of achieving SR (40% </text>
<text top="197" left="602" width="185" height="19" font="0">vs. 18.6%; p=0.07), amount of </text>
<text top="215" left="602" width="140" height="19" font="0">atropine, or additional </text>
<text top="233" left="602" width="181" height="19" font="0">resuscitative therapies given. </text>
<text top="87" left="818" width="243" height="19" font="0">hemodynamically unstable bradycardia </text>
<text top="105" left="818" width="49" height="19" font="0">or AVB. </text>
<text top="124" left="807" width="235" height="20" font="0">• Hemodynamically unstable AVB was </text>
<text top="143" left="818" width="224" height="19" font="0">associated with AMI in 55.6% of pts. </text>
<text top="600" left="96" width="138" height="19" font="0">Warren JV, et al.<b> </b>1976 </text>
<text top="619" left="96" width="28" height="19" font="0">(81)<b> </b></text>
<text top="637" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1244735">1244735</a></text>
<text top="637" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1244735"> </a></text>
<text top="600" left="264" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="619" left="264" width="87" height="19" font="0">Retrospective </text>
<text top="637" left="264" width="139" height="19" font="0">observational study of </text>
<text top="655" left="264" width="108" height="19" font="0">pts with AMI and </text>
<text top="674" left="264" width="76" height="19" font="0">bradycardia </text>
<text top="692" left="264" width="3" height="19" font="0"> </text>
<text top="710" left="264" width="68" height="19" font="8"><b>Size:</b> N=70 </text>
<text top="600" left="424" width="148" height="19" font="8"><b>Inclusion criteria:</b> Pts in </text>
<text top="619" left="424" width="148" height="19" font="0">early phase of AMI with </text>
<text top="637" left="424" width="125" height="19" font="0">heart rate &lt;60 bpm. </text>
<text top="655" left="424" width="3" height="19" font="0"> </text>
<text top="673" left="424" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="601" left="602" width="141" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality </text>
<text top="619" left="602" width="3" height="19" font="0"> </text>
<text top="638" left="602" width="120" height="19" font="8"><b>Results:</b> In pts with </text>
<text top="656" left="602" width="161" height="19" font="0">hypotension complicating </text>
<text top="674" left="602" width="167" height="19" font="0">presentation with AMI and </text>
<text top="693" left="602" width="166" height="19" font="0">hypotension, the mortality </text>
<text top="711" left="602" width="168" height="19" font="0">rate was 75% w/o atropine </text>
<text top="729" left="602" width="177" height="19" font="0">and 25% with atropine. In pt </text>
<text top="748" left="602" width="184" height="19" font="0">with normal BP, the mortality </text>
<text top="766" left="602" width="179" height="19" font="0">rate was 13 and 14% and did </text>
<text top="784" left="602" width="167" height="19" font="0">not differ between groups. </text>
<text top="600" left="807" width="258" height="20" font="0">• The use of atropine to treat bradycardia </text>
<text top="619" left="818" width="248" height="19" font="0">with and w/o hypotension was effective </text>
<text top="638" left="818" width="59" height="19" font="0">and safe. </text>
<text top="656" left="807" width="3" height="19" font="0"> </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="12" size="16" family="Times" color="#000000"/>
<text top="804" left="570" width="51" height="19" font="0">Page 71 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="602" width="137" height="19" font="0">Ventricular fibrillation </text>
<text top="105" left="602" width="175" height="19" font="0">occurred in 1/45 pts treated </text>
<text top="123" left="602" width="170" height="19" font="0">with atropine, and 2/45 pts </text>
<text top="142" left="602" width="163" height="19" font="0">not treated with atropine. </text>
<text top="160" left="602" width="3" height="19" font="0"> </text>
<text top="178" left="602" width="192" height="19" font="0">Atropine at a dose of 0.5–1 mg </text>
<text top="197" left="602" width="164" height="19" font="0">was effective in increasing </text>
<text top="215" left="602" width="68" height="19" font="0">heart rate. </text>
<text top="234" left="96" width="137" height="19" font="0">Scheinman MM, et al. </text>
<text top="252" left="96" width="30" height="19" font="0">1975</text>
<text top="251" left="127" width="4" height="21" font="4"> </text>
<text top="252" left="130" width="28" height="19" font="0">(82)<b> </b></text>
<text top="271" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1157275">1157275</a></text>
<text top="271" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1157275"> </a></text>
<text top="234" left="264" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="252" left="264" width="131" height="19" font="0">Observational, single </text>
<text top="271" left="264" width="43" height="19" font="0">center </text>
<text top="289" left="264" width="3" height="19" font="0"> </text>
<text top="307" left="264" width="68" height="19" font="8"><b>Size:</b> N=56 </text>
<text top="234" left="424" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="252" left="424" width="165" height="19" font="0">AMI and sinus bradycardia </text>
<text top="271" left="424" width="3" height="19" font="0"> </text>
<text top="289" left="424" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="307" left="424" width="161" height="19" font="0">Preterminal pts, during or </text>
<text top="326" left="424" width="152" height="19" font="0">after CPR, AMI and AVB, </text>
<text top="344" left="424" width="94" height="19" font="0">use of digitalis, </text>
<text top="362" left="424" width="121" height="19" font="0">propranolol, or pre-</text>
<text top="381" left="424" width="164" height="19" font="0">existing sinus bradycardia. </text>
<text top="235" left="602" width="147" height="19" font="8"><b>1</b>°<b> endpoint:</b> Heart rate </text>
<text top="253" left="602" width="3" height="19" font="0"> </text>
<text top="271" left="602" width="172" height="19" font="8"><b>Results:</b> Atropine increased </text>
<text top="290" left="602" width="176" height="19" font="0">heart rate and BP, abolished </text>
<text top="308" left="602" width="134" height="19" font="0">PVCs and accelerated </text>
<text top="326" left="602" width="177" height="19" font="0">idioventricular rhythm. 7 pts </text>
<text top="345" left="602" width="173" height="19" font="0">had serious adverse effects, </text>
<text top="363" left="602" width="128" height="19" font="0">including ventricular </text>
<text top="381" left="602" width="127" height="19" font="0">fibrillation and sinus </text>
<text top="400" left="602" width="78" height="19" font="0">tachycardia. </text>
<text top="418" left="602" width="3" height="19" font="0"> </text>
<text top="234" left="807" width="238" height="20" font="0">• Atropine had beneficial effects in pts </text>
<text top="253" left="818" width="190" height="19" font="0">with AMI complicated by sinus </text>
<text top="272" left="818" width="236" height="19" font="0">bradycardia, particularly at dosages of </text>
<text top="290" left="818" width="192" height="19" font="0">0.5–0.6 mg. Higher doses were </text>
<text top="308" left="818" width="228" height="19" font="0">associated with a higher incidence of </text>
<text top="326" left="818" width="100" height="19" font="0">adverse effects. </text>
<text top="345" left="807" width="3" height="19" font="0"> </text>
<text top="437" left="86" width="4" height="23" font="12"> </text>
<text top="461" left="97" width="4" height="21" font="4"> </text>
<text top="459" left="313" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 72 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="967" height="23" font="5"><b>Data Supplement 10. Nonrandomized Trials, Observational Studies, and/or Registries of Isoproterenol Effect in Electrophysiology </b></text>
<text top="108" left="86" width="211" height="23" font="5"><b>Laboratory (Section 5.3.2.1) </b></text>
<text top="131" left="104" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="130" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="131" left="252" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="281" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="433" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="626" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="664" width="113" height="19" font="8"><b>(P values; OR RR;  </b></text>
<text top="167" left="687" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="131" left="912" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="940" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="95" width="100" height="19" font="0">Ogawa H, et. al. </text>
<text top="205" left="95" width="62" height="19" font="0">1991 (83)<b> </b></text>
<text top="223" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2010943">2010943</a></text>
<text top="223" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2010943"> </a></text>
<text top="186" left="230" width="157" height="19" font="8"><b>Study type:</b> Single center </text>
<text top="205" left="230" width="158" height="19" font="0">study of IV isoproterenol, </text>
<text top="223" left="230" width="161" height="19" font="0">propranolol, atropine and </text>
<text top="241" left="230" width="103" height="19" font="0">methoxamine in </text>
<text top="260" left="230" width="137" height="19" font="0">electrophysiology lab  </text>
<text top="278" left="230" width="3" height="19" font="0"> </text>
<text top="296" left="230" width="68" height="19" font="8"><b>Size:</b> N=36 </text>
<text top="186" left="412" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="205" left="412" width="103" height="19" font="0">SND and normal </text>
<text top="223" left="412" width="3" height="19" font="0"> </text>
<text top="241" left="412" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="187" left="587" width="244" height="19" font="8"><b>1</b>°<b> endpoint:</b> 28 pts with SND, 8 normal </text>
<text top="206" left="587" width="250" height="19" font="0">pts. Heart rate and recovery time before </text>
<text top="224" left="587" width="233" height="19" font="0">and after IV drug administration were </text>
<text top="242" left="587" width="68" height="19" font="0">measured. </text>
<text top="261" left="587" width="3" height="19" font="0"> </text>
<text top="279" left="587" width="261" height="19" font="8"><b>Results:</b> 17 pts with SND w/o syncope had </text>
<text top="297" left="587" width="197" height="19" font="0">a normal heart rate response to </text>
<text top="315" left="587" width="254" height="19" font="0">isoproterenol compared to a significantly </text>
<text top="334" left="587" width="248" height="19" font="0">lower heart rate response in 11 pts with </text>
<text top="352" left="587" width="54" height="19" font="0">syncope </text>
<text top="187" left="864" width="218" height="20" font="0">• Many pts with SND showed heart </text>
<text top="206" left="875" width="207" height="19" font="0">rate increases with isuprel similar </text>
<text top="224" left="875" width="205" height="19" font="0">to normal controls; this was seen </text>
<text top="242" left="875" width="185" height="19" font="0">less often in pts with SND and </text>
<text top="261" left="875" width="54" height="19" font="0">syncope </text>
<text top="279" left="864" width="3" height="19" font="0"> </text>
<text top="297" left="864" width="3" height="19" font="0"> </text>
<text top="371" left="95" width="109" height="19" font="0">Mandel WJ, et al. </text>
<text top="389" left="95" width="62" height="19" font="0">1972 (84)<b> </b></text>
<text top="408" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5072776">5072776</a></text>
<text top="408" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5072776"> </a></text>
<text top="371" left="230" width="157" height="19" font="8"><b>Study type:</b> Single center </text>
<text top="389" left="230" width="148" height="19" font="0">electrophysiology study </text>
<text top="408" left="230" width="3" height="19" font="0"> </text>
<text top="426" left="230" width="68" height="19" font="8"><b>Size:</b> N=31 </text>
<text top="371" left="412" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="389" left="412" width="114" height="19" font="0">with ECG/monitor </text>
<text top="408" left="412" width="110" height="19" font="0">documented SND </text>
<text top="426" left="412" width="3" height="19" font="0"> </text>
<text top="444" left="412" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="372" left="587" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Response to autonomic, </text>
<text top="390" left="587" width="198" height="19" font="0">exercise and pacing maneuvers, </text>
<text top="409" left="587" width="242" height="19" font="0">isoproterenol infusion at 1–2 mcg/min. </text>
<text top="427" left="587" width="3" height="19" font="0"> </text>
<text top="445" left="587" width="251" height="19" font="8"><b>Results:</b> 12 pts underwent Isoproterenol </text>
<text top="464" left="587" width="253" height="19" font="0">testing, all responded with an increase in </text>
<text top="482" left="587" width="229" height="19" font="0">heart rate to infusion (mean 52 bpm–</text>
<text top="500" left="587" width="223" height="19" font="0">mean 118 bpm). Comparatively, the </text>
<text top="518" left="587" width="261" height="19" font="0">response to atropine was less (52 bpm–64 </text>
<text top="537" left="587" width="36" height="19" font="0">bpm) </text>
<text top="371" left="864" width="222" height="20" font="0">• In an SND population, response to </text>
<text top="390" left="875" width="193" height="19" font="0">exercise and isoproterenol was </text>
<text top="409" left="875" width="214" height="19" font="0">within the expected normal range. </text>
<text top="427" left="864" width="227" height="20" font="0">• Relative unresponsiveness of heart </text>
<text top="446" left="875" width="182" height="19" font="0">rate to atropine was noted in </text>
<text top="464" left="875" width="73" height="19" font="0">several pts. </text>
<text top="483" left="864" width="201" height="20" font="0">• The study concluded this small </text>
<text top="502" left="875" width="160" height="19" font="0">group of pts with SND are </text>
<text top="520" left="875" width="151" height="19" font="0">characterized by normal </text>
<text top="538" left="875" width="165" height="19" font="0">sympathetic reactivity and </text>
<text top="557" left="875" width="168" height="19" font="0">abnormal parasympathetic </text>
<text top="575" left="875" width="64" height="19" font="0">reactivity. </text>
<text top="594" left="95" width="105" height="19" font="0">Strauss HC, et al. </text>
<text top="612" left="95" width="62" height="19" font="0">1976 (85)<b> </b></text>
<text top="631" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1260979">1260979</a></text>
<text top="631" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1260979"> </a></text>
<text top="594" left="230" width="157" height="19" font="8"><b>Study type:</b> Single center </text>
<text top="612" left="230" width="148" height="19" font="0">electrophysiology study </text>
<text top="631" left="230" width="3" height="19" font="0"> </text>
<text top="649" left="230" width="68" height="19" font="8"><b>Size:</b> N=20 </text>
<text top="594" left="412" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="612" left="412" width="140" height="19" font="0">with ECG documented </text>
<text top="631" left="412" width="33" height="19" font="0">SND  </text>
<text top="649" left="412" width="3" height="19" font="0"> </text>
<text top="667" left="412" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="595" left="587" width="255" height="19" font="8"><b>1</b>°<b> endpoint:</b> Conduction times, response </text>
<text top="613" left="587" width="236" height="19" font="0">to atropine and isoproterenol infusion </text>
<text top="631" left="587" width="3" height="19" font="0"> </text>
<text top="650" left="587" width="255" height="19" font="8"><b>Results:</b> Graded infusion of isoproterenol </text>
<text top="668" left="587" width="237" height="19" font="0">resulted in 19 pts, 4 required a dosage </text>
<text top="686" left="587" width="252" height="19" font="0">higher than 28.3 ng/kg/min to produce a </text>
<text top="705" left="587" width="257" height="19" font="0">20% decrease in sinus cycle length. 19 pts </text>
<text top="723" left="587" width="246" height="19" font="0">received 1 mg of atropine, resulting in a </text>
<text top="741" left="587" width="242" height="19" font="0">mean reduction of sinus cycle length of </text>
<text top="760" left="587" width="29" height="19" font="0">19% </text>
<text top="594" left="864" width="229" height="20" font="0">• Heart rate increased in response to </text>
<text top="613" left="875" width="194" height="19" font="0">atropine and isuprel in pts with </text>
<text top="631" left="875" width="33" height="19" font="0">SND. </text>
<text top="650" left="864" width="224" height="20" font="0">• Higher doses of isoproterenol may </text>
<text top="669" left="875" width="78" height="19" font="0">be required. </text>
<text top="687" left="864" width="3" height="19" font="0"> </text>
<text top="779" left="86" width="4" height="21" font="4"> </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 73 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="539" height="23" font="5"><b>Data Supplement 11. RCTs of Dopamine in Bradycardia (Section 5.3.2.1) </b></text>
<text top="109" left="100" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="127" left="131" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="145" left="104" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="109" left="246" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="127" left="251" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="145" left="245" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="109" left="389" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="109" left="553" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="127" left="570" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="145" left="554" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="164" left="575" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="109" left="731" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="127" left="713" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="145" left="717" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="164" left="760" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="110" left="898" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="128" left="933" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="146" left="941" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="183" left="95" width="75" height="20" font="0">• <b>‘PrePACE’ </b></text>
<text top="202" left="95" width="112" height="19" font="0">Morrison LJ, et al. </text>
<text top="220" left="95" width="62" height="19" font="0">2006 (86) </text>
<text top="239" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452">17933452</a></text>
<text top="239" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452"> </a></text>
<text top="183" left="221" width="131" height="19" font="8"><b>Aim:</b> To evaluate the </text>
<text top="201" left="221" width="131" height="19" font="0">feasibility of a RCT of </text>
<text top="220" left="221" width="98" height="19" font="0">transcutaneous </text>
<text top="238" left="221" width="128" height="19" font="0">pacing vs. dopamine </text>
<text top="256" left="221" width="134" height="19" font="0">for atropine and fluid </text>
<text top="274" left="221" width="64" height="19" font="0">refractory </text>
<text top="293" left="221" width="114" height="19" font="0">bradycardia in the </text>
<text top="311" left="221" width="122" height="19" font="0">prehospital setting. </text>
<text top="329" left="221" width="3" height="19" font="0"> </text>
<text top="348" left="221" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="366" left="221" width="3" height="19" font="0"> </text>
<text top="384" left="221" width="136" height="19" font="8"><b>Size:</b> 151 met criteria, </text>
<text top="403" left="221" width="73" height="19" font="0">82 enrolled </text>
<text top="183" left="371" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="201" left="371" width="133" height="19" font="0">Unstable bradycardia </text>
<text top="220" left="371" width="132" height="19" font="0">unresponsive to fluid </text>
<text top="238" left="371" width="150" height="19" font="0">and atropine: heart rate </text>
<text top="256" left="371" width="149" height="19" font="0">&lt;60/min and systolic BP </text>
<text top="274" left="371" width="129" height="19" font="0">(SBP) &lt;80 mm Hg; or </text>
<text top="293" left="371" width="146" height="19" font="0">heart rate &lt;60/min and </text>
<text top="311" left="371" width="149" height="19" font="0">SBP &lt;100 mm Hg and at </text>
<text top="329" left="371" width="124" height="19" font="0">least one additional </text>
<text top="348" left="371" width="94" height="19" font="0">sign/symptom  </text>
<text top="366" left="371" width="3" height="19" font="0"> </text>
<text top="384" left="371" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="403" left="371" width="122" height="19" font="0">Advance directives, </text>
<text top="421" left="371" width="142" height="19" font="0">trauma, hyperthermia, </text>
<text top="439" left="371" width="146" height="19" font="0">hypothermia or cardiac </text>
<text top="457" left="371" width="134" height="19" font="0">arrest, pts in whom it </text>
<text top="476" left="371" width="153" height="19" font="0">was not possible to start </text>
<text top="494" left="371" width="124" height="19" font="0">an intravenous line. </text>
<text top="183" left="540" width="127" height="19" font="8"><b>Intervention:</b> All pts </text>
<text top="201" left="540" width="139" height="19" font="0">received 250 ml saline </text>
<text top="220" left="540" width="68" height="19" font="0">IV bolus. If </text>
<text top="238" left="540" width="109" height="19" font="0">nonresponse, pts </text>
<text top="256" left="540" width="122" height="19" font="0">received atropine 1 </text>
<text top="274" left="540" width="97" height="19" font="0">mg, repeated if </text>
<text top="293" left="540" width="137" height="19" font="0">improved. If pts failed </text>
<text top="311" left="540" width="139" height="19" font="0">to respond, they were </text>
<text top="329" left="540" width="93" height="19" font="0">randomized to </text>
<text top="348" left="540" width="141" height="19" font="0">transcutaneous pacing </text>
<text top="366" left="540" width="130" height="19" font="0">(with midazolam) vs. </text>
<text top="384" left="540" width="65" height="19" font="0">dopamine </text>
<text top="403" left="540" width="7" height="19" font="0">  </text>
<text top="421" left="540" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="439" left="540" width="143" height="19" font="0">Dopamine starting at 5 </text>
<text top="457" left="540" width="81" height="19" font="0">mcg/kg/min, </text>
<text top="476" left="540" width="140" height="19" font="0">increasing the dose by </text>
<text top="494" left="540" width="134" height="19" font="0">5 mcg/kg min every 2 </text>
<text top="512" left="540" width="76" height="19" font="0">min until an </text>
<text top="531" left="540" width="135" height="19" font="0">improvement in signs </text>
<text top="549" left="540" width="120" height="19" font="0">and symptoms was </text>
<text top="567" left="540" width="128" height="19" font="0">observed, maximum </text>
<text top="586" left="540" width="145" height="19" font="0">dose of 20 mcg/kg/min<b> </b></text>
<text top="184" left="698" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="202" left="698" width="114" height="19" font="0">hospital discharge </text>
<text top="220" left="698" width="3" height="19" font="0"> </text>
<text top="238" left="698" width="119" height="19" font="8"><b>Safety endpoint (if </b></text>
<text top="257" left="698" width="67" height="19" font="8"><b>relevant):</b>  </text>
<text top="275" left="698" width="146" height="19" font="0">Ventricular arrhythmia, </text>
<text top="293" left="698" width="173" height="19" font="0">cutaneous burns, chest wall </text>
<text top="312" left="698" width="164" height="19" font="0">discomfort, cardiac arrest, </text>
<text top="330" left="698" width="73" height="19" font="0">TCP failure.<b> </b></text>
<text top="183" left="885" width="191" height="20" font="0">• Survival to hospital discharge </text>
<text top="202" left="896" width="197" height="19" font="0">was similar in both groups (70% </text>
<text top="220" left="896" width="174" height="19" font="0">vs. 69%; p=0.93), as were 2° </text>
<text top="239" left="896" width="68" height="19" font="0">outcomes. </text>
<text top="257" left="885" width="3" height="19" font="0"> </text>
<text top="605" left="82" width="3" height="19" font="0"> </text>
<text top="623" left="86" width="967" height="23" font="5"><b>Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of Calcium, Glucagon and High Dose Insulin </b></text>
<text top="645" left="86" width="678" height="23" font="5"><b>Therapy to treat Beta-Blocker and Calcium Channel Blocker Toxicity (CCB) (Section 5.3.2.2) </b></text>
<text top="668" left="108" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="686" left="134" width="51" height="19" font="8"><b>Author; </b></text>
<text top="704" left="111" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="668" left="242" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="686" left="271" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="668" left="416" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="668" left="627" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="686" left="658" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="704" left="689" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="668" left="917" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="686" left="946" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="723" left="95" width="120" height="19" font="0">Howarth DM, et al. </text>
<text top="742" left="95" width="30" height="19" font="0">1994</text>
<text top="740" left="125" width="4" height="21" font="4"> </text>
<text top="742" left="129" width="28" height="19" font="0">(87)<b> </b></text>
<text top="760" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7909677">7909677</a></text>
<text top="760" left="148" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7909677"><b> </b></a></text>
<text top="723" left="236" width="112" height="19" font="8"><b>Study type:</b> Multi-</text>
<text top="742" left="236" width="129" height="19" font="0">center observational </text>
<text top="760" left="236" width="80" height="19" font="0">study of CCB </text>
<text top="723" left="385" width="178" height="19" font="8"><b>Inclusion criteria:</b> Admission </text>
<text top="742" left="385" width="112" height="19" font="0">for CCB overdose  </text>
<text top="760" left="385" width="3" height="19" font="0"> </text>
<text top="778" left="385" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="724" left="580" width="186" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcome </text>
<text top="743" left="580" width="3" height="19" font="0"> </text>
<text top="724" left="875" width="214" height="20" font="0">• Atropine was only effective after </text>
<text top="743" left="886" width="177" height="19" font="0">IV calcium was administered </text>
<text top="761" left="875" width="155" height="20" font="0">• Calcium often reversed </text>
<text top="780" left="886" width="209" height="19" font="0">hypotension and bradycardia, but </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 74 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="236" width="93" height="19" font="0">overdose in an </text>
<text top="105" left="236" width="135" height="19" font="0">Australian population </text>
<text top="123" left="236" width="3" height="19" font="0"> </text>
<text top="142" left="236" width="68" height="19" font="8"><b>Size:</b> N=15<b> </b></text>
<text top="87" left="580" width="260" height="19" font="8"><b>Results:</b> All pts treated with oral activated </text>
<text top="105" left="580" width="262" height="19" font="0">charcoal, most required calcium, atropine, </text>
<text top="123" left="580" width="210" height="19" font="0">and inotropic support. 4 pts died.  </text>
<text top="87" left="886" width="191" height="19" font="0">atropine and inotropic support </text>
<text top="105" left="886" width="157" height="19" font="0">were frequently required </text>
<text top="161" left="95" width="115" height="19" font="0">Ramoska EA, et al. </text>
<text top="179" left="95" width="62" height="19" font="0">1993 (88)<b> </b></text>
<text top="197" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8427431">8427431</a></text>
<text top="197" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8427431"> </a></text>
<text top="161" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="179" left="236" width="91" height="19" font="0">Retrospective, </text>
<text top="197" left="236" width="101" height="19" font="0">observational, 3 </text>
<text top="216" left="236" width="91" height="19" font="0">poison control </text>
<text top="234" left="236" width="49" height="19" font="0">centers </text>
<text top="252" left="236" width="3" height="19" font="0"> </text>
<text top="271" left="236" width="79" height="19" font="8"><b>Size:</b> N= 138<b> </b></text>
<text top="161" left="385" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="179" left="385" width="158" height="19" font="0">Hospitalized pts with CCB </text>
<text top="197" left="385" width="59" height="19" font="0">ingestion </text>
<text top="216" left="385" width="3" height="19" font="0"> </text>
<text top="234" left="385" width="144" height="19" font="8"><b>Exclusion criteria:</b> N/A <b> </b></text>
<text top="162" left="580" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcomes </text>
<text top="180" left="580" width="3" height="19" font="0"> </text>
<text top="198" left="580" width="278" height="19" font="8"><b>Results:</b> There were no deaths. Ipecac (26%), </text>
<text top="217" left="580" width="226" height="19" font="0">lavage (40%), and activated charcoal </text>
<text top="235" left="580" width="236" height="19" font="0">(81%)were administered. Calcium was </text>
<text top="253" left="580" width="241" height="19" font="0">administered to 23 pts with sinus node </text>
<text top="272" left="580" width="228" height="19" font="0">suppression; 64% responded with an </text>
<text top="290" left="580" width="281" height="19" font="0">increased heart rate. Dopamine had no effect </text>
<text top="308" left="580" width="263" height="19" font="0">on bradycardia. Atropine was used in 7 pts </text>
<text top="326" left="580" width="273" height="19" font="0">with SND, 29% responded with an increased </text>
<text top="345" left="580" width="278" height="19" font="0">heart rate. Transvenous pacing was used in 4 </text>
<text top="363" left="580" width="265" height="19" font="0">pts. Isoproterenol increased heart rate in 2 </text>
<text top="381" left="580" width="237" height="19" font="0">pts with SND, but not the pt with AVB. </text>
<text top="400" left="580" width="264" height="19" font="0">Glucagon increased BP w/o effect on heart </text>
<text top="418" left="580" width="32" height="19" font="0">rate.<b> </b></text>
<text top="161" left="875" width="211" height="20" font="0">• Hypotension, dysrhythmias, and </text>
<text top="180" left="886" width="179" height="19" font="0">depression of the sinus node </text>
<text top="198" left="886" width="205" height="19" font="0">occurred with equal frequency in </text>
<text top="217" left="886" width="163" height="19" font="0">verapamil, nifedipine, and </text>
<text top="235" left="886" width="179" height="19" font="0">diltiazem overdose. AVB was </text>
<text top="253" left="886" width="194" height="19" font="0">more common and severe with </text>
<text top="272" left="886" width="68" height="19" font="0">verapamil. </text>
<text top="290" left="875" width="187" height="20" font="0">• Although IV calcium was not </text>
<text top="309" left="886" width="198" height="19" font="0">universally effective, its use was </text>
<text top="327" left="886" width="143" height="19" font="0">associated with clinical </text>
<text top="346" left="886" width="191" height="19" font="0">improvement in hemodynamic </text>
<text top="364" left="886" width="171" height="19" font="0">parameters in the majority. </text>
<text top="382" left="875" width="220" height="20" font="0">• No dose response relationship for </text>
<text top="401" left="886" width="170" height="19" font="0">either calcium gluconate or </text>
<text top="420" left="886" width="170" height="19" font="0">calcium chloride was noted </text>
<text top="439" left="95" width="106" height="19" font="0">St-Onge M, et al. </text>
<text top="457" left="95" width="30" height="19" font="0">2014</text>
<text top="456" left="125" width="4" height="21" font="4"> </text>
<text top="457" left="129" width="28" height="19" font="0">(89)<b> </b></text>
<text top="475" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25283255">25283255</a></text>
<text top="475" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25283255"> </a></text>
<text top="439" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="457" left="236" width="114" height="19" font="0">Systematic review </text>
<text top="475" left="236" width="3" height="19" font="0"> </text>
<text top="494" left="236" width="105" height="19" font="8"><b>Size:</b> 216 studies </text>
<text top="439" left="385" width="159" height="19" font="8"><b>Inclusion criteria:</b> Studies </text>
<text top="457" left="385" width="175" height="19" font="0">examining effects of various </text>
<text top="475" left="385" width="120" height="19" font="0">treatments for CCB </text>
<text top="494" left="385" width="138" height="19" font="0">poisoning for efficacy. </text>
<text top="512" left="385" width="3" height="19" font="0"> </text>
<text top="530" left="385" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="439" left="580" width="267" height="19" font="8"><b>1</b>°<b> endpoint:</b> Efficacy of treatments for CCB </text>
<text top="458" left="580" width="224" height="19" font="0">poisoning with primary outcomes of </text>
<text top="476" left="580" width="250" height="19" font="0">mortality and hemodynamic parameters </text>
<text top="494" left="580" width="3" height="19" font="0"> </text>
<text top="513" left="580" width="261" height="19" font="8"><b>Results:</b> 117 case reports of 216 studies. 7 </text>
<text top="531" left="580" width="262" height="19" font="0">animal studies showing hemodynamic and </text>
<text top="549" left="580" width="245" height="19" font="0">mortality improvement with calcium. In </text>
<text top="568" left="580" width="267" height="19" font="0">humans, 11 case series and 21 case reports </text>
<text top="586" left="580" width="271" height="19" font="0">were inconsistent in demonstrating benefit. </text>
<text top="439" left="875" width="217" height="20" font="0">• Evidence to support IV calcium in </text>
<text top="458" left="886" width="190" height="19" font="0">CCB overdose is of low quality, </text>
<text top="476" left="886" width="188" height="19" font="0">but animal studies and human </text>
<text top="494" left="886" width="180" height="19" font="0">case reports and series often </text>
<text top="513" left="886" width="144" height="19" font="0">demonstrate improved </text>
<text top="531" left="886" width="194" height="19" font="0">hemodynamic parameters, and </text>
<text top="549" left="886" width="197" height="19" font="0">adverse effects (hypercalcemia) </text>
<text top="568" left="886" width="56" height="19" font="0">are rare. </text>
<text top="586" left="875" width="3" height="19" font="0"> </text>
<text top="605" left="95" width="76" height="19" font="8"><b>GLUCAGON</b> </text>
<text top="624" left="95" width="121" height="19" font="0"> Love JN, et al. 1998</text>
<text top="623" left="216" width="4" height="21" font="4"> </text>
<text top="642" left="95" width="28" height="19" font="0">(90)<b> </b></text>
<text top="661" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9674488">9674488</a></text>
<text top="661" left="148" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9674488"><b> </b></a></text>
<text top="624" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="642" left="236" width="91" height="19" font="0">Retrospective, </text>
<text top="661" left="236" width="129" height="19" font="0">observational, single </text>
<text top="679" left="236" width="43" height="19" font="0">center </text>
<text top="697" left="236" width="3" height="19" font="0"> </text>
<text top="715" left="236" width="60" height="19" font="8"><b>Size:</b> N=9 </text>
<text top="624" left="385" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="642" left="385" width="182" height="19" font="0">presenting with symptomatic </text>
<text top="661" left="385" width="161" height="19" font="0">bradycardia who received </text>
<text top="679" left="385" width="113" height="19" font="0">glucagon therapy. </text>
<text top="697" left="385" width="3" height="19" font="0"> </text>
<text top="715" left="385" width="160" height="19" font="8"><b>Exclusion criteria:</b> Clinical </text>
<text top="734" left="385" width="131" height="19" font="0">response to atropine </text>
<text top="625" left="580" width="265" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical improvement in heart </text>
<text top="643" left="580" width="120" height="19" font="0">rate and perfusion. </text>
<text top="662" left="580" width="3" height="19" font="0"> </text>
<text top="680" left="580" width="250" height="19" font="8"><b>Results:</b> 9 pts were receiving BB, CCB, or </text>
<text top="698" left="580" width="276" height="19" font="0">digoxin therapy. Heart rate and BP increased </text>
<text top="716" left="580" width="260" height="19" font="0">significantly in all but one pt who received </text>
<text top="735" left="580" width="62" height="19" font="0">glucagon. </text>
<text top="624" left="875" width="156" height="20" font="0">• 8/9 pts presenting with </text>
<text top="643" left="886" width="191" height="19" font="0">symptomatic bradycardia, that </text>
<text top="662" left="886" width="159" height="19" font="0">may have been caused or </text>
<text top="680" left="886" width="200" height="19" font="0">exacerbated by chronic BB, CCB, </text>
<text top="698" left="886" width="205" height="19" font="0">or digoxin therapy demonstrated </text>
<text top="716" left="886" width="162" height="19" font="0">clinical improvement with </text>
<text top="735" left="886" width="187" height="19" font="0">glucagon after failing atropine </text>
<text top="753" left="886" width="55" height="19" font="0">therapy. </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 75 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="82" height="19" font="0">Bailey B 2003</text>
<text top="85" left="177" width="4" height="21" font="4"> </text>
<text top="87" left="180" width="28" height="19" font="0">(91)<b> </b></text>
<text top="105" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14514004">14514004</a></text>
<text top="105" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14514004"> </a></text>
<text top="123" left="95" width="3" height="19" font="0"> </text>
<text top="87" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="105" left="236" width="114" height="19" font="0">Systematic review </text>
<text top="123" left="236" width="3" height="19" font="0"> </text>
<text top="142" left="236" width="90" height="19" font="8"><b>Size:</b> N=30 (all </text>
<text top="160" left="236" width="49" height="19" font="0">animal)<b> </b></text>
<text top="87" left="385" width="159" height="19" font="8"><b>Inclusion criteria:</b> Studies </text>
<text top="105" left="385" width="164" height="19" font="0">evaluating glucagon use in </text>
<text top="123" left="385" width="137" height="19" font="0">BB and CCB overdose. </text>
<text top="142" left="385" width="3" height="19" font="0"> </text>
<text top="160" left="385" width="145" height="19" font="8"><b>Exclusion criteria:</b> Case </text>
<text top="178" left="385" width="131" height="19" font="0">report or case series.<b> </b></text>
<text top="88" left="580" width="281" height="19" font="8"><b>1</b>°<b> endpoint:</b> Effect of glucagon on heart rate, </text>
<text top="106" left="580" width="280" height="19" font="0">arterial pressure, contractility, cardiac output </text>
<text top="124" left="580" width="219" height="19" font="0">and survival in BB or CCB overdose. </text>
<text top="143" left="580" width="3" height="19" font="0"> </text>
<text top="161" left="580" width="254" height="19" font="8"><b>Results:</b> 5 animal studies of BB overdose, </text>
<text top="179" left="580" width="271" height="19" font="0">glucagon increased heart rate, but effect on </text>
<text top="198" left="580" width="263" height="19" font="0">survival was unclear. In 6 animal studies of </text>
<text top="216" left="580" width="280" height="19" font="0">CCB overdose, glucagon transiently increased </text>
<text top="234" left="580" width="262" height="19" font="0">heart rate and reversed AVB w/o effect on </text>
<text top="252" left="580" width="54" height="19" font="0">survival.<b> </b></text>
<text top="87" left="875" width="202" height="20" font="0">• Evidence supporting the use of </text>
<text top="106" left="886" width="197" height="19" font="0">glucagon in the management of </text>
<text top="124" left="886" width="189" height="19" font="0">pts with BB or CCB overdose is </text>
<text top="143" left="886" width="162" height="19" font="0">limited, but demonstrates </text>
<text top="161" left="886" width="196" height="19" font="0">transient improvement in heart </text>
<text top="179" left="886" width="130" height="19" font="0">rate and conduction. </text>
<text top="272" left="95" width="106" height="19" font="0">St-Onge M, et al. </text>
<text top="290" left="95" width="30" height="19" font="0">2014</text>
<text top="288" left="125" width="4" height="21" font="4"> </text>
<text top="290" left="129" width="28" height="19" font="0">(89)<b> </b></text>
<text top="308" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25283255">25283255</a></text>
<text top="308" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25283255"> </a></text>
<text top="271" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="290" left="236" width="114" height="19" font="0">Systematic review </text>
<text top="308" left="236" width="3" height="19" font="0"> </text>
<text top="326" left="236" width="105" height="19" font="8"><b>Size:</b> 216 studies </text>
<text top="271" left="385" width="159" height="19" font="8"><b>Inclusion criteria:</b> Studies </text>
<text top="290" left="385" width="175" height="19" font="0">examining effects of various </text>
<text top="308" left="385" width="120" height="19" font="0">treatments for CCB </text>
<text top="326" left="385" width="138" height="19" font="0">poisoning for efficacy. </text>
<text top="345" left="385" width="3" height="19" font="0"> </text>
<text top="363" left="385" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="272" left="580" width="267" height="19" font="8"><b>1</b>°<b> endpoint:</b> Efficacy of treatments for CCB </text>
<text top="291" left="580" width="224" height="19" font="0">poisoning with primary outcomes of </text>
<text top="309" left="580" width="250" height="19" font="0">mortality and hemodynamic parameters </text>
<text top="327" left="580" width="3" height="19" font="0"> </text>
<text top="345" left="580" width="250" height="19" font="8"><b>Results:</b> 2 of 3 animal studies, and 1 of 3 </text>
<text top="364" left="580" width="268" height="19" font="0">human case series showed improvement in </text>
<text top="382" left="580" width="157" height="19" font="0">heart rate with glucagon. </text>
<text top="272" left="875" width="200" height="20" font="0">• Evidence to support the use of </text>
<text top="291" left="886" width="173" height="19" font="0">glucagon in CCB overdose is </text>
<text top="309" left="886" width="160" height="19" font="0">scant. Hyperglycemia and </text>
<text top="327" left="886" width="211" height="19" font="0">vomiting were side effects seen in </text>
<text top="346" left="886" width="82" height="19" font="0">case reports. </text>
<text top="364" left="875" width="3" height="19" font="0"> </text>
<text top="401" left="95" width="189" height="19" font="8"><b>HIGH DOSE INSULIN THERAPY </b></text>
<text top="420" left="93" width="124" height="19" font="0">Engebretsen KM, et </text>
<text top="439" left="93" width="14" height="19" font="0">al.</text>
<text top="437" left="107" width="4" height="21" font="4"> </text>
<text top="439" left="111" width="62" height="19" font="0">2011 (92)<b> </b></text>
<text top="457" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21563902">21563902</a></text>
<text top="457" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21563902"> </a></text>
<text top="420" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="439" left="236" width="114" height="19" font="0">Systematic review </text>
<text top="457" left="236" width="3" height="19" font="0"> </text>
<text top="475" left="236" width="97" height="19" font="8"><b>Size:</b> 72 studies<b> </b></text>
<text top="420" left="385" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="439" left="385" width="3" height="19" font="0"> </text>
<text top="457" left="385" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="421" left="580" width="131" height="19" font="8"><b>1</b>°<b> endpoint:</b> Efficacy </text>
<text top="439" left="580" width="3" height="19" font="0"> </text>
<text top="458" left="580" width="248" height="19" font="8"><b>Results:</b> Clinical data are limited; animal </text>
<text top="476" left="580" width="274" height="19" font="0">studies and case reports demonstrate safety </text>
<text top="494" left="580" width="240" height="19" font="0">and survival in BB and CCB poisoning is </text>
<text top="513" left="580" width="269" height="19" font="0">superior when treated with HDIT compared </text>
<text top="531" left="580" width="254" height="19" font="0">with calcium, glucagon, epinephrine, and </text>
<text top="549" left="580" width="82" height="19" font="0">vasopressin. <b> </b></text>
<text top="420" left="875" width="198" height="20" font="0">• Evidence to support HDIT is of </text>
<text top="439" left="886" width="196" height="19" font="0">low quality, but validates safety </text>
<text top="458" left="886" width="197" height="19" font="0">and efficacy in the treatment of </text>
<text top="476" left="886" width="125" height="19" font="0">BB and CCB toxicity. </text>
<text top="494" left="875" width="3" height="19" font="0"> </text>
<text top="568" left="95" width="106" height="19" font="0">St-Onge M, et al. </text>
<text top="587" left="95" width="30" height="19" font="0">2014</text>
<text top="585" left="125" width="4" height="21" font="4"> </text>
<text top="587" left="129" width="28" height="19" font="0">(89)<b> </b></text>
<text top="605" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25283255">25283255</a></text>
<text top="605" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25283255"> </a></text>
<text top="568" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="587" left="236" width="114" height="19" font="0">Systematic review </text>
<text top="605" left="236" width="3" height="19" font="0"> </text>
<text top="623" left="236" width="105" height="19" font="8"><b>Size:</b> 216 studies<b> </b></text>
<text top="568" left="385" width="159" height="19" font="8"><b>Inclusion criteria:</b> Studies </text>
<text top="587" left="385" width="175" height="19" font="0">examining effects of various </text>
<text top="605" left="385" width="120" height="19" font="0">treatments for CCB </text>
<text top="623" left="385" width="138" height="19" font="0">poisoning for efficacy. </text>
<text top="642" left="385" width="3" height="19" font="0"> </text>
<text top="660" left="385" width="3" height="19" font="0"> </text>
<text top="678" left="385" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="569" left="580" width="267" height="19" font="8"><b>1</b>°<b> endpoint:</b> Efficacy of treatments for CCB </text>
<text top="587" left="580" width="224" height="19" font="0">poisoning with primary outcomes of </text>
<text top="606" left="580" width="250" height="19" font="0">mortality and hemodynamic parameters </text>
<text top="624" left="580" width="3" height="19" font="0"> </text>
<text top="642" left="580" width="271" height="19" font="8"><b>Results:</b> One observational study in humans </text>
<text top="661" left="580" width="252" height="19" font="0">of HDIT showed improved hemodynamic </text>
<text top="679" left="580" width="281" height="19" font="0">parameters and decreased mortality with risk </text>
<text top="697" left="580" width="215" height="19" font="0">of hypoglycemia and hypokalemia.<b> </b></text>
<text top="569" left="875" width="212" height="20" font="0">• Evidence to support HDIT in CCB </text>
<text top="587" left="886" width="187" height="19" font="0">overdose is of low quality, but </text>
<text top="606" left="886" width="200" height="19" font="0">observational data demonstrate </text>
<text top="624" left="886" width="184" height="19" font="0">improved hemodynamics and </text>
<text top="642" left="886" width="54" height="19" font="0">survival. </text>
<text top="716" left="95" width="102" height="19" font="0">Greene SL, et al.<b> </b></text>
<text top="735" left="95" width="62" height="19" font="0">2007 (93) </text>
<text top="753" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17622512">17622512</a></text>
<text top="753" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17622512"> </a></text>
<text top="716" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="735" left="236" width="117" height="19" font="0">Prospective, single </text>
<text top="753" left="236" width="133" height="19" font="0">center, observational </text>
<text top="771" left="236" width="3" height="19" font="0"> </text>
<text top="716" left="385" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="735" left="385" width="181" height="19" font="0">CCB toxicity and hypotension </text>
<text top="753" left="385" width="112" height="19" font="0">treated with HDIT </text>
<text top="771" left="385" width="3" height="19" font="0"> </text>
<text top="717" left="580" width="277" height="19" font="8"><b>1</b>°<b> endpoint:</b> Safety of HDIT in CCB overdose. </text>
<text top="735" left="580" width="3" height="19" font="0"> </text>
<text top="754" left="580" width="157" height="19" font="8"><b>Results:</b> 6/7 pts survived. </text>
<text top="772" left="580" width="3" height="19" font="8"><b> </b></text>
<text top="717" left="875" width="147" height="20" font="0">•  HDIT in the setting of </text>
<text top="735" left="886" width="204" height="19" font="0">hemodynamically significant CCB </text>
<text top="754" left="886" width="185" height="19" font="0">overdose was safe in a critical </text>
<text top="772" left="886" width="174" height="19" font="0">care setting. Systolic BP was </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 76 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="236" width="60" height="19" font="8"><b>Size:</b> N=7<b> </b></text>
<text top="87" left="385" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="87" left="886" width="206" height="19" font="0">increased by insulin loading. Mild </text>
<text top="105" left="886" width="195" height="19" font="0">hypoglycemia and hypokalemia </text>
<text top="123" left="886" width="78" height="19" font="0">were noted. </text>
<text top="143" left="86" width="4" height="23" font="12"> </text>
<text top="164" left="86" width="623" height="23" font="5"><b>Data Supplement 13. RCTs Comparing Anti-Digoxin Fab to placebo (Section 5.3.2.3) </b></text>
<text top="187" left="100" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="205" left="131" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="224" left="103" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="187" left="242" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="205" left="248" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="224" left="242" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="187" left="382" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="187" left="542" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="205" left="560" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="224" left="544" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="242" left="565" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="187" left="716" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="205" left="698" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="224" left="702" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="242" left="745" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="188" left="887" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="206" left="922" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="225" left="931" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="261" left="95" width="100" height="19" font="0">Eddleston M, et </text>
<text top="280" left="95" width="48" height="19" font="0">al. 2000</text>
<text top="278" left="143" width="4" height="21" font="4"> </text>
<text top="280" left="147" width="28" height="19" font="0">(94) </text>
<text top="298" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10768435">10768435</a></text>
<text top="298" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10768435"> </a></text>
<text top="261" left="220" width="118" height="19" font="8"><b>Aim:</b> To determine </text>
<text top="280" left="220" width="128" height="19" font="0">effectiveness of anti-</text>
<text top="298" left="220" width="73" height="19" font="0">digoxin Fab </text>
<text top="316" left="220" width="80" height="19" font="0">fragments in </text>
<text top="335" left="220" width="118" height="19" font="0">reversing oleander </text>
<text top="353" left="220" width="129" height="19" font="0">induced arrhythmias </text>
<text top="371" left="220" width="3" height="19" font="0"> </text>
<text top="389" left="220" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="408" left="220" width="3" height="19" font="0"> </text>
<text top="426" left="220" width="68" height="19" font="8"><b>Size:</b> N=66 </text>
<text top="261" left="365" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="280" left="365" width="109" height="19" font="0">with Hx of yellow </text>
<text top="298" left="366" width="148" height="19" font="0">oleander ingestion with </text>
<text top="316" left="366" width="136" height="19" font="0">sinus bradycardia &lt;40 </text>
<text top="335" left="366" width="125" height="19" font="0">bpm, sinus arrest or </text>
<text top="353" left="366" width="75" height="19" font="0">block, atrial </text>
<text top="371" left="366" width="138" height="19" font="0">tachyarrhythmias, or 2</text>
<text top="371" left="504" width="10" height="12" font="7">nd</text>
<text top="371" left="514" width="3" height="19" font="0"> </text>
<text top="389" left="365" width="24" height="19" font="0">or 3</text>
<text top="389" left="390" width="9" height="12" font="7">rd</text>
<text top="389" left="398" width="86" height="19" font="0"> degree heart </text>
<text top="408" left="365" width="40" height="19" font="0">block. </text>
<text top="426" left="365" width="3" height="19" font="0"> </text>
<text top="444" left="365" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="463" left="365" width="141" height="19" font="0">Hypotension (SBP &lt; 80 </text>
<text top="481" left="365" width="125" height="19" font="0">mm Hg), ventricular </text>
<text top="499" left="365" width="143" height="19" font="0">tachycardia with shock </text>
<text top="261" left="532" width="119" height="19" font="8"><b>Intervention:</b> 1200 </text>
<text top="280" left="532" width="114" height="19" font="0">mg of anti-digoxin </text>
<text top="298" left="532" width="67" height="19" font="0">antibodies </text>
<text top="316" left="532" width="7" height="19" font="0">  </text>
<text top="334" left="532" width="122" height="19" font="8"><b>Comparator:</b> Saline </text>
<text top="353" left="532" width="51" height="19" font="0">placebo<b> </b></text>
<text top="262" left="686" width="152" height="19" font="8"><b>1</b>°<b> endpoint:</b> Reversal of </text>
<text top="280" left="686" width="135" height="19" font="0">original arrhythmia in </text>
<text top="299" left="686" width="162" height="19" font="0">15/24 treated pts vs. 2/32 </text>
<text top="317" left="686" width="123" height="19" font="0">controls. Heart rate </text>
<text top="335" left="686" width="156" height="19" font="0">increased from 49.1 bpm </text>
<text top="354" left="686" width="129" height="19" font="0">to 66.8 bpm in 2 h in </text>
<text top="372" left="686" width="121" height="19" font="0">treated pts, did not </text>
<text top="390" left="686" width="115" height="19" font="0">change in controls </text>
<text top="409" left="686" width="109" height="19" font="0">(p&lt;0.001). Serum </text>
<text top="427" left="686" width="166" height="19" font="0">potassium decreased from </text>
<text top="445" left="686" width="163" height="19" font="0">4.9 mmol/L to 4.1 mmol/L </text>
<text top="464" left="686" width="131" height="19" font="0">at 2 h in cases, not in </text>
<text top="482" left="686" width="122" height="19" font="0">controls (p&lt; 0.001). </text>
<text top="500" left="686" width="3" height="19" font="0"> </text>
<text top="518" left="686" width="119" height="19" font="8"><b>Safety endpoint (if </b></text>
<text top="537" left="686" width="92" height="19" font="8"><b>relevant):</b> N/A </text>
<text top="555" left="686" width="3" height="19" font="8"><b> </b></text>
<text top="261" left="867" width="222" height="20" font="0">• Anti-digoxin Fab antibody therapy </text>
<text top="280" left="877" width="215" height="19" font="0">increased heart rate and improved </text>
<text top="299" left="877" width="195" height="19" font="0">time to reversal of bradycardia. </text>
<text top="317" left="867" width="3" height="19" font="0"> </text>
<text top="574" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="598" left="97" width="4" height="21" font="4"> </text>
<text top="596" left="313" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 77 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="971" height="23" font="5"><b>Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of Digoxin Fab Antibody Fragments (Section </b></text>
<text top="108" left="86" width="61" height="23" font="5"><b>5.3.2.3) </b></text>
<text top="131" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="131" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="131" left="235" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="264" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="409" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="605" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="636" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="167" left="667" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="131" left="897" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="926" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="96" width="114" height="19" font="0">Lapostolle F, et al. </text>
<text top="205" left="96" width="30" height="19" font="0">2008</text>
<text top="203" left="127" width="4" height="21" font="4"> </text>
<text top="205" left="130" width="28" height="19" font="0">(95)<b> </b></text>
<text top="223" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18824911">18824911</a></text>
<text top="223" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18824911"> </a></text>
<text top="186" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="205" left="230" width="130" height="19" font="0">Retrospective, single </text>
<text top="223" left="230" width="133" height="19" font="0">center, observational </text>
<text top="241" left="230" width="3" height="19" font="0"> </text>
<text top="260" left="230" width="75" height="19" font="8"><b>Size:</b> N=141 </text>
<text top="186" left="378" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="205" left="378" width="140" height="19" font="0">admitted with digitalis </text>
<text top="223" left="378" width="63" height="19" font="0">poisoning </text>
<text top="241" left="378" width="3" height="19" font="0"> </text>
<text top="260" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="187" left="574" width="132" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival </text>
<text top="206" left="574" width="3" height="19" font="0"> </text>
<text top="224" left="574" width="226" height="19" font="8"><b>Results:</b> 66/141 pts received Digoxin </text>
<text top="242" left="574" width="247" height="19" font="0">Fab. 5 pts died. No adverse effects were </text>
<text top="261" left="574" width="43" height="19" font="0">noted. </text>
<text top="187" left="837" width="220" height="20" font="0">• Therapy of digitalis overdose with </text>
<text top="206" left="848" width="209" height="19" font="0">digoxin Fab was associated with a </text>
<text top="224" left="848" width="137" height="19" font="0">mortality rate of 7.6% </text>
<text top="242" left="837" width="3" height="19" font="0"> </text>
<text top="280" left="96" width="114" height="19" font="0">Lapostolle F, et al. </text>
<text top="298" left="96" width="62" height="19" font="0">2008 (96)<b> </b></text>
<text top="316" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18389220">18389220</a></text>
<text top="316" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18389220"> </a></text>
<text top="280" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="298" left="230" width="91" height="19" font="0">Retrospective, </text>
<text top="316" left="230" width="127" height="19" font="0">observational, multi-</text>
<text top="335" left="230" width="70" height="19" font="0">center (20) </text>
<text top="353" left="230" width="3" height="19" font="0"> </text>
<text top="371" left="230" width="75" height="19" font="8"><b>Size:</b> N=838 </text>
<text top="280" left="378" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="298" left="378" width="155" height="19" font="0">presenting with elevated </text>
<text top="316" left="378" width="143" height="19" font="0">digitalis concentration. </text>
<text top="335" left="378" width="3" height="19" font="0"> </text>
<text top="353" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="280" left="574" width="247" height="19" font="8"><b>1</b>°<b> endpoint:</b> Use and efficacy of digoxin </text>
<text top="299" left="574" width="61" height="19" font="0">antibody. </text>
<text top="317" left="574" width="3" height="19" font="0"> </text>
<text top="335" left="574" width="225" height="19" font="8"><b>Results:</b> 67/838 pts received digoxin </text>
<text top="354" left="574" width="224" height="19" font="0">antibody. Mortality was significantly </text>
<text top="372" left="574" width="229" height="19" font="0">lower in Fab treated pts (6% vs. 15%) </text>
<text top="280" left="837" width="216" height="20" font="0">• Digoxin antibody therapy may be </text>
<text top="299" left="848" width="210" height="19" font="0">underused, and is associated with </text>
<text top="317" left="848" width="125" height="19" font="0">improved mortality. </text>
<text top="335" left="837" width="3" height="19" font="0"> </text>
<text top="391" left="96" width="79" height="19" font="0">Chan BS and </text>
<text top="409" left="96" width="106" height="19" font="0">Buckley NA, 2014</text>
<text top="408" left="203" width="4" height="21" font="4"> </text>
<text top="428" left="96" width="28" height="19" font="0">(97)<b> </b></text>
<text top="446" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25089630">25089630</a></text>
<text top="446" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25089630"> </a></text>
<text top="391" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="409" left="230" width="117" height="19" font="0">Systematic Review </text>
<text top="428" left="230" width="3" height="19" font="0"> </text>
<text top="446" left="230" width="125" height="19" font="8"><b>Size:</b> N= 140 studies </text>
<text top="391" left="378" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="409" left="378" width="3" height="19" font="0"> </text>
<text top="428" left="378" width="145" height="19" font="8"><b>Exclusion criteria:</b> Case </text>
<text top="446" left="378" width="169" height="19" font="0">reports w/o pharmacologic </text>
<text top="464" left="378" width="34" height="19" font="0">data. </text>
<text top="392" left="574" width="168" height="19" font="8"><b>1</b>°<b> endpoint:</b> Effectiveness, </text>
<text top="410" left="574" width="223" height="19" font="0">pharmacology, safety and dosage of </text>
<text top="428" left="574" width="189" height="19" font="0">digoxin-Fab in pts with digoxin </text>
<text top="447" left="574" width="64" height="19" font="0">overdose. </text>
<text top="465" left="574" width="3" height="19" font="0"> </text>
<text top="483" left="574" width="235" height="19" font="8"><b>Results:</b> There were no RCT of digoxin </text>
<text top="502" left="574" width="199" height="19" font="0">Fab for the treatment of digoxin </text>
<text top="520" left="574" width="226" height="19" font="0">toxicity. 10 case series with 2080 pts </text>
<text top="538" left="574" width="250" height="19" font="0">were evaluated. Clinical response occurs </text>
<text top="557" left="574" width="218" height="19" font="0">in 50–90% of pts within 30–45 min. </text>
<text top="575" left="574" width="200" height="19" font="0">Exacerbation of HF, tachycardia, </text>
<text top="593" left="574" width="218" height="19" font="0">hypokalemia, and allergic reactions </text>
<text top="612" left="574" width="105" height="19" font="0">happen in &lt;10%. </text>
<text top="391" left="837" width="249" height="20" font="0">• Digoxin Fab is safe and indicated in pts </text>
<text top="410" left="848" width="232" height="19" font="0">with life-threatening arrhythmias and </text>
<text top="428" left="848" width="215" height="19" font="0">an elevated digoxin concentration. </text>
<text top="447" left="837" width="236" height="20" font="0">• Full neutralizing dosages may not be </text>
<text top="466" left="848" width="208" height="19" font="0">required. In acute toxicity, 80 mg, </text>
<text top="484" left="848" width="218" height="19" font="0">repeated as required, is likely to be </text>
<text top="502" left="848" width="216" height="19" font="0">effective. In chronic toxicity, 40 mg </text>
<text top="521" left="848" width="241" height="19" font="0">with repeat in 60 min (or sooner if pt is </text>
<text top="539" left="848" width="213" height="19" font="0">unstable) is likely to be beneficial.  </text>
<text top="557" left="840" width="3" height="19" font="0"> </text>
<text top="631" left="96" width="100" height="19" font="0">Smith TW, et al. </text>
<text top="649" left="96" width="30" height="19" font="0">1982</text>
<text top="648" left="127" width="4" height="21" font="4"> </text>
<text top="649" left="130" width="28" height="19" font="0">(98)<b> </b></text>
<text top="667" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6752715">6752715</a></text>
<text top="667" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6752715"> </a></text>
<text top="631" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="649" left="230" width="131" height="19" font="0">Observational, single </text>
<text top="667" left="230" width="43" height="19" font="0">center </text>
<text top="686" left="230" width="3" height="19" font="0"> </text>
<text top="704" left="230" width="71" height="19" font="8"><b>Size:</b> N=26  </text>
<text top="631" left="378" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="649" left="378" width="124" height="19" font="0">digitalis toxicity and </text>
<text top="667" left="378" width="174" height="19" font="0">arrhythmia or hyperkalemia </text>
<text top="686" left="378" width="169" height="19" font="0">refractory to initial therapy </text>
<text top="704" left="378" width="3" height="19" font="0"> </text>
<text top="722" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="631" left="574" width="136" height="19" font="8"><b>1</b>°<b> endpoint:</b> Morality </text>
<text top="650" left="574" width="3" height="19" font="0"> </text>
<text top="668" left="574" width="245" height="19" font="8"><b>Results:</b> 21/26 pts survived. Arrhythmia </text>
<text top="686" left="574" width="249" height="19" font="0">and hyperkalemia were rapidly reversed </text>
<text top="705" left="574" width="191" height="19" font="0">by digoxin Fab, and no adverse </text>
<text top="723" left="574" width="130" height="19" font="0">reactions were seen. </text>
<text top="631" left="837" width="228" height="20" font="0">• Digoxin Fab is an effective and safe </text>
<text top="650" left="848" width="238" height="19" font="0">therapy for digitalis toxicity associated </text>
<text top="668" left="848" width="210" height="19" font="0">with arrhythmias or hyperkalemia </text>
<text top="742" left="96" width="106" height="19" font="0">Wenger TL, et al. </text>
<text top="760" left="96" width="30" height="19" font="0">1985</text>
<text top="759" left="127" width="4" height="21" font="4"> </text>
<text top="760" left="130" width="28" height="19" font="0">(99)<b> </b></text>
<text top="779" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886748">3886748</a></text>
<text top="779" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886748"> </a></text>
<text top="742" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="760" left="230" width="125" height="19" font="0">Observational multi-</text>
<text top="779" left="230" width="74" height="19" font="0">center (20)  </text>
<text top="742" left="378" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="760" left="378" width="149" height="19" font="0">life-threatening digitalis </text>
<text top="779" left="378" width="52" height="19" font="0">toxicity. </text>
<text top="743" left="574" width="186" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcome </text>
<text top="761" left="574" width="3" height="19" font="0"> </text>
<text top="742" left="837" width="251" height="20" font="0">• Life-threatening digoxin toxicity can be </text>
<text top="761" left="848" width="211" height="19" font="0">safely and effectively treated with </text>
<text top="779" left="848" width="77" height="19" font="0">digoxin Fab. </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 78 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="3" height="19" font="0"> </text>
<text top="105" left="230" width="68" height="19" font="8"><b>Size:</b> N=63 </text>
<text top="87" left="378" width="3" height="19" font="0"> </text>
<text top="105" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="574" width="216" height="19" font="8"><b>Results:</b> Reversal of clinical toxicity </text>
<text top="105" left="574" width="248" height="19" font="0">within 30 min of administration. Digoxin </text>
<text top="123" left="574" width="171" height="19" font="0">concentration decreased to </text>
<text top="142" left="574" width="224" height="19" font="0">undetectable. No adverse reactions. </text>
<text top="161" left="96" width="113" height="19" font="0">Antman EM, et al. </text>
<text top="179" left="96" width="30" height="19" font="0">1990</text>
<text top="178" left="127" width="4" height="21" font="4"> </text>
<text top="179" left="130" width="35" height="19" font="0">(100)<b> </b></text>
<text top="197" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2188752">2188752</a></text>
<text top="197" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2188752"> </a></text>
<text top="161" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="179" left="230" width="125" height="19" font="0">Observational multi-</text>
<text top="197" left="230" width="70" height="19" font="0">center (21) </text>
<text top="216" left="230" width="3" height="19" font="0"> </text>
<text top="234" left="230" width="75" height="19" font="8"><b>Size:</b> N=150 </text>
<text top="161" left="378" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="179" left="378" width="148" height="19" font="0">digitalis toxicity and life-</text>
<text top="197" left="378" width="170" height="19" font="0">threatening cardiac rhythm </text>
<text top="216" left="378" width="98" height="19" font="0">disturbances or </text>
<text top="234" left="378" width="167" height="19" font="0">hyperkalemia refractory or </text>
<text top="252" left="378" width="151" height="19" font="0">likely to be refractory to </text>
<text top="271" left="378" width="137" height="19" font="0">conventional therapy. </text>
<text top="289" left="378" width="3" height="19" font="0"> </text>
<text top="307" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="162" left="574" width="214" height="19" font="8"><b>1</b>°<b> endpoint:</b> Response to therapy. </text>
<text top="180" left="574" width="3" height="19" font="0"> </text>
<text top="198" left="574" width="225" height="19" font="8"><b>Results:</b> 119/148 resolved all clinical </text>
<text top="217" left="574" width="229" height="19" font="0">evidence of toxicity, 14 improved, 15 </text>
<text top="235" left="574" width="220" height="19" font="0">showed no response. 5 pts were on </text>
<text top="253" left="574" width="175" height="19" font="0">hemodialysis and improved. </text>
<text top="161" left="837" width="244" height="20" font="0">• Digoxin Fab is an effective antidote to </text>
<text top="180" left="848" width="102" height="19" font="0">digitalis toxicity. </text>
<text top="326" left="96" width="101" height="19" font="0">Hickey AR, et al. </text>
<text top="345" left="96" width="30" height="19" font="0">1991</text>
<text top="343" left="127" width="4" height="21" font="4"> </text>
<text top="345" left="130" width="35" height="19" font="0">(101)<b> </b></text>
<text top="363" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1993775">1993775</a></text>
<text top="363" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1993775"> </a></text>
<text top="326" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="345" left="230" width="92" height="19" font="0">Observational, </text>
<text top="363" left="230" width="88" height="19" font="0">retrospective. </text>
<text top="381" left="230" width="3" height="19" font="0"> </text>
<text top="400" left="230" width="79" height="19" font="8"><b>Size:</b> N=717  </text>
<text top="326" left="378" width="153" height="19" font="8"><b>Inclusion criteria:</b> Adults </text>
<text top="345" left="378" width="179" height="19" font="0">who received digoxin Fab for </text>
<text top="363" left="378" width="129" height="19" font="0">digitalis intoxication. </text>
<text top="381" left="378" width="3" height="19" font="0"> </text>
<text top="400" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="327" left="574" width="187" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical response </text>
<text top="346" left="574" width="3" height="19" font="0"> </text>
<text top="364" left="574" width="249" height="19" font="8"><b>Results:</b> 50% complete, 24% partial, and </text>
<text top="382" left="574" width="216" height="19" font="0">12% had no response. 0.8% had an </text>
<text top="401" left="574" width="202" height="19" font="0">allergic reaction.2.8% developed </text>
<text top="419" left="574" width="247" height="19" font="0">recurrent toxicity, which was associated </text>
<text top="437" left="574" width="154" height="19" font="0">with inadequate dosing.  </text>
<text top="327" left="837" width="227" height="20" font="0">• Digoxin Fab was well tolerated and </text>
<text top="346" left="848" width="226" height="19" font="0">effective in pts with digitalis toxicity. </text>
<text top="456" left="96" width="103" height="19" font="0">Wenger TL, 1991</text>
<text top="455" left="199" width="4" height="21" font="4"> </text>
<text top="474" left="96" width="35" height="19" font="0">(102)<b> </b></text>
<text top="493" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1997017">1997017</a></text>
<text top="493" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1997017"> </a></text>
<text top="456" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="474" left="230" width="90" height="19" font="0">observational, </text>
<text top="493" left="230" width="88" height="19" font="0">retrospective  </text>
<text top="511" left="230" width="3" height="19" font="0"> </text>
<text top="529" left="230" width="59" height="19" font="8"><b>Size:</b> N/A<b> </b></text>
<text top="456" left="378" width="148" height="19" font="8"><b>Inclusion criteria:</b> Pts in </text>
<text top="474" left="378" width="175" height="19" font="0">multicenter study of digoxin </text>
<text top="493" left="378" width="113" height="19" font="0">Fab, a postmarket </text>
<text top="511" left="378" width="168" height="19" font="0">surveillance study, and any </text>
<text top="529" left="378" width="163" height="19" font="0">reports in the literature of </text>
<text top="548" left="378" width="174" height="19" font="0">pts treated with digoxin Fab </text>
<text top="566" left="378" width="144" height="19" font="0">with renal dysfunction. </text>
<text top="584" left="378" width="3" height="19" font="0"> </text>
<text top="603" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="457" left="574" width="187" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical response </text>
<text top="475" left="574" width="3" height="19" font="0"> </text>
<text top="493" left="574" width="214" height="19" font="8"><b>Results:</b> No evidence of decreased </text>
<text top="512" left="574" width="202" height="19" font="0">safety or efficacy with respect to </text>
<text top="530" left="574" width="221" height="19" font="0">response or recurrence. 28 subjects </text>
<text top="548" left="574" width="249" height="19" font="0">were anephric, one of these pts possibly </text>
<text top="567" left="574" width="221" height="19" font="0">had recrudescent toxicity with AVB.<b> </b></text>
<text top="456" left="837" width="238" height="20" font="0">• Digoxin Fab was effective and safe in </text>
<text top="475" left="848" width="212" height="19" font="0">pts with digitalis toxicity and renal </text>
<text top="494" left="848" width="79" height="19" font="0">dysfunction. </text>
<text top="622" left="82" width="3" height="19" font="0"> </text>
<text top="640" left="82" width="3" height="19" font="0"> </text>
<text top="660" left="97" width="4" height="21" font="4"> </text>
<text top="658" left="313" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 79 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="1001" height="23" font="5"><b>Data Supplement 15. Nonrandomized Trials, Observational Studies, and/or Registries of Dialysis for Digoxin Toxicity (Section 5.3.2.3 – </b></text>
<text top="108" left="86" width="60" height="23" font="5"><b>Patton) </b></text>
<text top="131" left="122" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="148" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="126" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="131" left="275" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="304" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="445" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="603" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="633" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="167" left="665" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="131" left="878" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="907" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="96" width="50" height="19" font="8"><b>EXTRIP</b> <b> </b></text>
<text top="205" left="96" width="131" height="19" font="0">Mowry JB, et al. 2016</text>
<text top="203" left="227" width="4" height="21" font="4"> </text>
<text top="223" left="96" width="35" height="19" font="0">(103)<b> </b></text>
<text top="241" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26795743">26795743</a></text>
<text top="241" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26795743"> </a></text>
<text top="186" left="264" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="205" left="264" width="45" height="19" font="0">review </text>
<text top="223" left="264" width="3" height="19" font="0"> </text>
<text top="241" left="264" width="118" height="19" font="8"><b>Size:</b> N= 77 articles </text>
<text top="186" left="424" width="154" height="19" font="8"><b>Inclusion criteria:</b> Use of </text>
<text top="205" left="424" width="160" height="19" font="0">dialysis in digitalis toxicity </text>
<text top="223" left="424" width="3" height="19" font="0"> </text>
<text top="241" left="424" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="187" left="600" width="186" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcome </text>
<text top="206" left="600" width="142" height="19" font="0">and toxicokinetic data. </text>
<text top="224" left="600" width="3" height="19" font="0"> </text>
<text top="242" left="600" width="179" height="19" font="8"><b>Results:</b> Only in vitro, animal </text>
<text top="261" left="600" width="189" height="19" font="0">studies, case reports, and case </text>
<text top="279" left="600" width="180" height="19" font="0">series were identified, with a </text>
<text top="297" left="600" width="154" height="19" font="0">total of 84 pts. Digoxin is </text>
<text top="315" left="600" width="188" height="19" font="0">slightly dialyzable, and dialysis </text>
<text top="334" left="600" width="158" height="19" font="0">is unlikely to improve the </text>
<text top="352" left="600" width="173" height="19" font="0">outcome of digoxin toxicity. </text>
<text top="187" left="806" width="267" height="20" font="0">• The workgroup suggested against the use </text>
<text top="206" left="817" width="229" height="19" font="0">of dialysis in cases of digoxin toxicity, </text>
<text top="224" left="817" width="257" height="19" font="0">whether or not digoxin Fab was available. </text>
<text top="371" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="393" left="86" width="703" height="23" font="5"><b>Data Supplement 16. RCTs Comparing Methylxanthines in Bradycardic Arrest (Section 5.3.2.4) </b></text>
<text top="416" left="96" width="157" height="19" font="8"><b>Study Acronym; Author;  </b></text>
<text top="434" left="125" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="416" left="298" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="434" left="304" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="452" left="297" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="416" left="451" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="416" left="620" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="434" left="638" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="452" left="622" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="471" left="643" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="416" left="795" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="434" left="777" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="452" left="781" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="471" left="825" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="417" left="946" width="135" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint </b></text>
<text top="435" left="994" width="51" height="19" font="8"><b>(if any); </b></text>
<text top="453" left="956" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="471" left="965" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="491" left="95" width="126" height="19" font="0">Abu-Laban RB, et al. </text>
<text top="509" left="95" width="30" height="19" font="0">2006</text>
<text top="508" left="125" width="4" height="21" font="4"> </text>
<text top="509" left="129" width="35" height="19" font="0">(104) </text>
<text top="527" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16698410">16698410</a></text>
<text top="527" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16698410"> </a></text>
<text top="491" left="264" width="130" height="19" font="8"><b>Aim:</b> To determine if </text>
<text top="509" left="264" width="109" height="19" font="0">administration of </text>
<text top="527" left="264" width="150" height="19" font="0">aminophylline increases </text>
<text top="546" left="264" width="126" height="19" font="0">ROSC in bradycardic </text>
<text top="564" left="264" width="86" height="19" font="0">cardiac arrest </text>
<text top="582" left="264" width="3" height="19" font="0"> </text>
<text top="600" left="264" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="619" left="264" width="3" height="19" font="0"> </text>
<text top="637" left="264" width="79" height="19" font="8"><b>Size:</b> N= 971 </text>
<text top="491" left="433" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="509" left="433" width="128" height="19" font="0">Asystole, or PEA &lt;60 </text>
<text top="527" left="433" width="136" height="19" font="0">bpm, unresponsive to </text>
<text top="546" left="433" width="104" height="19" font="0">epinephrine and </text>
<text top="564" left="433" width="55" height="19" font="0">atropine </text>
<text top="582" left="433" width="3" height="19" font="0"> </text>
<text top="600" left="433" width="140" height="19" font="8"><b>Exclusion criteria:</b> Age </text>
<text top="619" left="433" width="145" height="19" font="0">&lt;16 y, pregnancy, DNR, </text>
<text top="637" left="433" width="74" height="19" font="0">evidence of </text>
<text top="655" left="433" width="147" height="19" font="0">hemorrhage, trauma or </text>
<text top="674" left="433" width="137" height="19" font="0">hypothermia, dialysis, </text>
<text top="692" left="433" width="144" height="19" font="0">theophylline sensitivity </text>
<text top="710" left="433" width="45" height="19" font="0">or use. </text>
<text top="491" left="602" width="134" height="19" font="8"><b>Intervention:</b> 250 mg </text>
<text top="509" left="602" width="127" height="19" font="0">aminophylline IV x2. </text>
<text top="527" left="602" width="7" height="19" font="0">  </text>
<text top="545" left="602" width="134" height="19" font="8"><b>Comparator:</b> Placebo<b> </b></text>
<text top="491" left="771" width="118" height="19" font="8"><b>1</b>°<b> endpoint:</b> ROSC </text>
<text top="510" left="771" width="3" height="19" font="0"> </text>
<text top="528" left="771" width="119" height="19" font="8"><b>Safety endpoint (if </b></text>
<text top="546" left="771" width="92" height="19" font="8"><b>relevant):</b> N/A<b> </b></text>
<text top="491" left="940" width="12" height="20" font="4">• </text>
<text top="493" left="951" width="85" height="19" font="0">There was no </text>
<text top="511" left="951" width="132" height="19" font="0">difference in ROSC in </text>
<text top="530" left="951" width="92" height="19" font="0">the group that </text>
<text top="548" left="951" width="56" height="19" font="0">received </text>
<text top="566" left="951" width="90" height="19" font="0">aminophylline </text>
<text top="585" left="951" width="122" height="19" font="0">adjunctive therapy. </text>
<text top="603" left="951" width="132" height="19" font="0">Use of aminophylline </text>
<text top="621" left="951" width="125" height="19" font="0">was associated with </text>
<text top="640" left="951" width="116" height="19" font="0">an increase in non-</text>
<text top="658" left="951" width="111" height="19" font="0">sinus tachycardias</text>
<text top="656" left="1062" width="4" height="21" font="4"> </text>
<text top="729" left="95" width="130" height="19" font="0">Hurley KF, et al. 2015</text>
<text top="728" left="224" width="4" height="21" font="4"> </text>
<text top="748" left="95" width="35" height="19" font="0">(105) </text>
<text top="766" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26593309">26593309</a></text>
<text top="766" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26593309"> </a></text>
<text top="729" left="264" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="748" left="264" width="124" height="19" font="0">Review of effects of </text>
<text top="766" left="264" width="128" height="19" font="0">aminophylline in the </text>
<text top="784" left="264" width="82" height="19" font="0">treatment of </text>
<text top="729" left="433" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="748" left="433" width="126" height="19" font="0">randomized trials of </text>
<text top="766" left="433" width="110" height="19" font="0">aminophylline vs. </text>
<text top="784" left="433" width="137" height="19" font="0">placebo in adults with </text>
<text top="729" left="602" width="3" height="19" font="8"><b> </b></text>
<text top="730" left="771" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="749" left="771" width="118" height="19" font="0">hospital discharge. </text>
<text top="767" left="771" width="3" height="19" font="0"> </text>
<text top="730" left="940" width="83" height="20" font="0">• Prehospital </text>
<text top="749" left="951" width="109" height="19" font="0">administration of </text>
<text top="767" left="951" width="105" height="19" font="0">aminophylline in </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 80 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="264" width="122" height="19" font="0">bradycardic cardiac </text>
<text top="105" left="264" width="39" height="19" font="0">arrest </text>
<text top="123" left="264" width="3" height="19" font="0"> </text>
<text top="142" left="264" width="153" height="19" font="8"><b>Size:</b> 5 trials, N=1254 pts<b> </b></text>
<text top="87" left="433" width="86" height="19" font="0">nontraumatic </text>
<text top="105" left="433" width="122" height="19" font="0">bradycardic cardiac </text>
<text top="123" left="433" width="152" height="19" font="0">arrest treated with ACLS </text>
<text top="87" left="771" width="138" height="19" font="8"><b>Results:</b> There was no </text>
<text top="105" left="771" width="113" height="19" font="0">survival benefit of </text>
<text top="123" left="771" width="152" height="19" font="0">aminophylline (RR: 0.58; </text>
<text top="142" left="771" width="138" height="19" font="0">95% CI: 0.12–1.39); or </text>
<text top="160" left="771" width="138" height="19" font="0">on survival to hospital </text>
<text top="178" left="771" width="127" height="19" font="0">admission (RR: 0.92; </text>
<text top="197" left="771" width="138" height="19" font="0">95% CI: 0.61–1.39); or </text>
<text top="215" left="771" width="147" height="19" font="0">ROSC (RR: 1.15; 95% CI: </text>
<text top="233" left="771" width="72" height="19" font="0">0.89–1.49).<b> </b></text>
<text top="87" left="951" width="130" height="19" font="0">bradyasystolic arrest </text>
<text top="105" left="951" width="135" height="19" font="0">is not associated with </text>
<text top="123" left="951" width="116" height="19" font="0">improved survival, </text>
<text top="142" left="951" width="123" height="19" font="0">ROSC, or survival to </text>
<text top="160" left="951" width="121" height="19" font="0">hospital admission. </text>
<text top="252" left="82" width="3" height="19" font="0"> </text>
<text top="271" left="86" width="4" height="21" font="4"> </text>
<text top="291" left="86" width="943" height="23" font="5"><b>Data Supplement 17. Nonrandomized Trials, Observational Studies, and/or Registries of Methylxanthines for acute therapy of </b></text>
<text top="313" left="86" width="588" height="23" font="5"><b>bradycardia due to spinal cord injury or post-heart transplant (Section 5.3.2.4) </b></text>
<text top="336" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="354" left="138" width="51" height="19" font="8"><b>Author; </b></text>
<text top="372" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="336" left="255" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="354" left="284" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="336" left="430" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="336" left="606" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="354" left="636" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="372" left="668" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="336" left="891" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="354" left="920" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="391" left="96" width="139" height="19" font="8"><b>Post-heart Transplant </b></text>
<text top="410" left="96" width="121" height="19" font="0">Redmond JM, et al. </text>
<text top="429" left="96" width="69" height="19" font="0">2005 (106)<b> </b></text>
<text top="447" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8443190">8443190</a></text>
<text top="447" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8443190"> </a></text>
<text top="410" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="429" left="243" width="145" height="19" font="0">Nonrandomized trial of </text>
<text top="447" left="243" width="107" height="19" font="0">oral theophylline </text>
<text top="465" left="243" width="3" height="19" font="0"> </text>
<text top="483" left="243" width="68" height="19" font="8"><b>Size:</b> N=15 </text>
<text top="410" left="405" width="163" height="19" font="8"><b>Inclusion criteria:</b> Sinus or </text>
<text top="429" left="405" width="164" height="19" font="0">nodal bradycardia or sinus </text>
<text top="447" left="405" width="107" height="19" font="0">arrest post-heart </text>
<text top="465" left="405" width="66" height="19" font="0">transplant </text>
<text top="484" left="405" width="3" height="19" font="0"> </text>
<text top="502" left="405" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="411" left="587" width="216" height="19" font="8"><b>1</b>°<b> endpoint:</b> restoration of normal </text>
<text top="429" left="587" width="18" height="19" font="0">SR </text>
<text top="448" left="587" width="3" height="19" font="0"> </text>
<text top="466" left="587" width="202" height="19" font="8"><b>Results:</b> Normal SR was restored </text>
<text top="484" left="587" width="218" height="19" font="0">with a rate &gt;90 bpm in 93.3% given </text>
<text top="503" left="587" width="80" height="19" font="0">theophylline </text>
<text top="521" left="587" width="223" height="20" font="0">• Therapy was initiated 3–24 d after </text>
<text top="540" left="587" width="97" height="19" font="0">transplantation </text>
<text top="559" left="587" width="214" height="20" font="0">• Mean duration of treatment was </text>
<text top="578" left="587" width="41" height="19" font="0">57.4 d </text>
<text top="411" left="825" width="219" height="20" font="0">• Oral theophylline was effective at </text>
<text top="429" left="836" width="231" height="19" font="0">restoring SR at a desirable heart rate. </text>
<text top="448" left="825" width="210" height="20" font="0">• Compared to historical controls, </text>
<text top="467" left="836" width="240" height="19" font="0">placement of a PPM was reduced from </text>
<text top="485" left="836" width="90" height="19" font="0">16.1% to 2.6% </text>
<text top="597" left="96" width="111" height="19" font="0">Bertolet BD, et al. </text>
<text top="615" left="96" width="69" height="19" font="0">1996 (107)<b> </b></text>
<text top="633" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8800116">8800116</a></text>
<text top="633" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8800116"> </a></text>
<text top="597" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="615" left="243" width="145" height="19" font="0">Nonrandomized trial of </text>
<text top="633" left="243" width="107" height="19" font="0">oral theophylline </text>
<text top="652" left="243" width="3" height="19" font="0"> </text>
<text top="670" left="243" width="68" height="19" font="8"><b>Size:</b> N=29 </text>
<text top="597" left="405" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="615" left="405" width="147" height="19" font="0">Bradyarrhythmia (heart </text>
<text top="633" left="405" width="156" height="19" font="0">rate &lt;70 bpm) in in heart </text>
<text top="652" left="405" width="129" height="19" font="0">transplant recipients </text>
<text top="670" left="405" width="3" height="19" font="0"> </text>
<text top="688" left="405" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="597" left="587" width="188" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mean heart rate, </text>
<text top="616" left="587" width="86" height="19" font="0">length of stay </text>
<text top="634" left="587" width="3" height="19" font="0"> </text>
<text top="652" left="587" width="218" height="19" font="8"><b>Results:</b> Mean heart rate increased </text>
<text top="671" left="587" width="161" height="19" font="0">from 62± 7 to 89±10 after </text>
<text top="689" left="587" width="192" height="19" font="0">administration of theophylline. </text>
<text top="707" left="587" width="176" height="19" font="0">Length of stay did not differ. </text>
<text top="597" left="825" width="258" height="20" font="0">• Theophylline was effective at increasing </text>
<text top="616" left="836" width="162" height="19" font="0">heart rate post-transplant </text>
<text top="726" left="96" width="116" height="19" font="0">Rothman SA, et al. </text>
<text top="745" left="96" width="69" height="19" font="0">1995 (108)<b> </b></text>
<text top="763" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7654727">7654727</a></text>
<text top="763" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7654727"> </a></text>
<text top="726" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="745" left="243" width="125" height="19" font="0">Observational study </text>
<text top="763" left="243" width="3" height="19" font="0"> </text>
<text top="726" left="405" width="142" height="19" font="8"><b>Inclusion criteria:</b> Post-</text>
<text top="745" left="405" width="124" height="19" font="0">heart transplant pts </text>
<text top="763" left="405" width="3" height="19" font="0"> </text>
<text top="781" left="405" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="727" left="587" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Effects of IV </text>
<text top="745" left="587" width="211" height="19" font="0">aminophylline on heart transplant </text>
<text top="764" left="587" width="63" height="19" font="0">recipients </text>
<text top="782" left="587" width="3" height="19" font="0"> </text>
<text top="726" left="825" width="246" height="20" font="0">• Both groups had abnormal sinus node </text>
<text top="745" left="836" width="236" height="19" font="0">recovery times. Aminophylline did not </text>
<text top="764" left="836" width="247" height="19" font="0">correct this in transplant recipients with </text>
<text top="782" left="836" width="77" height="19" font="0">or w/o SND. </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 81 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="243" width="147" height="19" font="8"><b>Size:</b> N=26 (13 with and </text>
<text top="105" left="243" width="115" height="19" font="0">13 w/o sinus node </text>
<text top="123" left="243" width="79" height="19" font="0">dysfunction) </text>
<text top="87" left="587" width="195" height="19" font="8"><b>Results:</b> Sinus node testing was </text>
<text top="105" left="587" width="217" height="19" font="0">performed in electrophysiology lab </text>
<text top="123" left="587" width="224" height="19" font="0">before and after infusion of 6 mg/kg </text>
<text top="142" left="587" width="113" height="19" font="0">of aminophylline.  </text>
<text top="161" left="96" width="122" height="19" font="0">Heinz G, et al. 1993 </text>
<text top="179" left="96" width="35" height="19" font="0">(109)<b> </b></text>
<text top="197" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8427182">8427182</a></text>
<text top="197" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8427182"> </a></text>
<text top="161" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="179" left="243" width="125" height="19" font="0">observational single </text>
<text top="197" left="243" width="47" height="19" font="0">center. </text>
<text top="216" left="243" width="3" height="19" font="0"> </text>
<text top="234" left="243" width="60" height="19" font="8"><b>Size:</b> N=9 </text>
<text top="161" left="405" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="179" left="405" width="152" height="19" font="0">and w/o SND after heart </text>
<text top="197" left="405" width="66" height="19" font="0">transplant </text>
<text top="216" left="405" width="3" height="19" font="0"> </text>
<text top="234" left="405" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="162" left="587" width="220" height="19" font="8"><b>1</b>°<b> endpoint:</b> Changes in sinus node </text>
<text top="180" left="587" width="208" height="19" font="0">recovery time from baseline after </text>
<text top="198" left="587" width="142" height="19" font="0">aminophylline infusion </text>
<text top="217" left="587" width="3" height="19" font="0"> </text>
<text top="235" left="587" width="192" height="19" font="8"><b>Results:</b> Normalization of sinus </text>
<text top="253" left="587" width="181" height="19" font="0">node function was seen after </text>
<text top="272" left="587" width="224" height="19" font="0">aminophylline 0.48 gm IV in all 3 pts </text>
<text top="290" left="587" width="220" height="19" font="0">with abnormal sinus node function. </text>
<text top="161" left="825" width="250" height="20" font="0">• Aminophylline can improve sinus node </text>
<text top="180" left="836" width="235" height="19" font="0">function in heart transplant recipients </text>
<text top="198" left="836" width="60" height="19" font="0">with SND </text>
<text top="309" left="96" width="114" height="19" font="8"><b>Spinal Cord Injury </b></text>
<text top="328" left="96" width="114" height="19" font="0">Pasnoori VR, et al. </text>
<text top="346" left="96" width="69" height="19" font="0">2004 (110)<b> </b></text>
<text top="365" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14766019">14766019</a></text>
<text top="365" left="157" width="21" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14766019">  </a> </text>
<text top="328" left="243" width="145" height="19" font="8"><b>Study type:</b> Case series </text>
<text top="346" left="243" width="3" height="19" font="0"> </text>
<text top="364" left="243" width="60" height="19" font="8"><b>Size:</b> N=2 </text>
<text top="328" left="405" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="346" left="405" width="146" height="19" font="0">severe bradycardia and </text>
<text top="365" left="405" width="108" height="19" font="0">spinal cord injury </text>
<text top="383" left="405" width="3" height="19" font="0"> </text>
<text top="401" left="405" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="329" left="587" width="142" height="19" font="8"><b>1</b>°<b> endpoint:</b> Effects of </text>
<text top="347" left="587" width="93" height="19" font="0">aminophylline  </text>
<text top="365" left="587" width="3" height="19" font="0"> </text>
<text top="384" left="587" width="225" height="19" font="8"><b>Results:</b> Increased heart rate and BP </text>
<text top="402" left="587" width="222" height="19" font="0">with 300 mg IV aminophylline and 5 </text>
<text top="420" left="587" width="183" height="19" font="0">mg/kg/h infusion, changed to </text>
<text top="439" left="587" width="135" height="19" font="0">theophylline after 2 d </text>
<text top="328" left="825" width="222" height="20" font="0">• Use of aminophylline, followed by </text>
<text top="347" left="836" width="206" height="19" font="0">theophylline in atropine resistant </text>
<text top="365" left="836" width="201" height="19" font="0">bradycardia was associated with </text>
<text top="384" left="836" width="234" height="19" font="0">increased heart rate and avoidance of </text>
<text top="402" left="836" width="92" height="19" font="0">PM placement </text>
<text top="458" left="96" width="128" height="19" font="0">Sadaka F, et al. 2010 </text>
<text top="476" left="96" width="35" height="19" font="0">(111)<b> </b></text>
<text top="494" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20878263">20878263</a></text>
<text top="494" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20878263"> </a></text>
<text top="458" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="476" left="243" width="119" height="19" font="0">Observational case </text>
<text top="494" left="243" width="39" height="19" font="0">series </text>
<text top="513" left="243" width="3" height="19" font="0"> </text>
<text top="531" left="243" width="63" height="19" font="8"><b>Size:</b> N=6  </text>
<text top="458" left="405" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="476" left="405" width="162" height="19" font="0">severe bradycardia due to </text>
<text top="494" left="405" width="108" height="19" font="0">spinal cord injury </text>
<text top="513" left="405" width="3" height="19" font="0"> </text>
<text top="531" left="405" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="458" left="587" width="223" height="19" font="8"><b>1</b>°<b> endpoint:</b> Heart rate response to </text>
<text top="477" left="587" width="80" height="19" font="0">theophylline </text>
<text top="495" left="587" width="3" height="19" font="0"> </text>
<text top="513" left="587" width="219" height="19" font="8"><b>Results:</b> Heart rates improved in all </text>
<text top="532" left="587" width="215" height="19" font="0">6 pts with severe bradycardias and </text>
<text top="550" left="587" width="225" height="19" font="0">hypotension. Theophylline was used </text>
<text top="568" left="587" width="176" height="19" font="0">as a second-line agent (after </text>
<text top="587" left="587" width="213" height="19" font="0">atropine and/or dopamine) in 4/6, </text>
<text top="605" left="587" width="120" height="19" font="0">and first-line in 2/6 </text>
<text top="458" left="825" width="259" height="20" font="0">• Theophylline was effective and safe as a </text>
<text top="477" left="836" width="250" height="19" font="0">second-line agent, and potentially a first-</text>
<text top="495" left="836" width="166" height="19" font="0">line agent for treatment of </text>
<text top="513" left="836" width="257" height="19" font="0">hemodynamically unstable bradycardia in </text>
<text top="532" left="836" width="202" height="19" font="0">pts with acute spinal cord injury. </text>
<text top="550" left="825" width="268" height="20" font="0">• Effective dosages resulted in serum levels </text>
<text top="569" left="836" width="234" height="19" font="0">below the therapeutic range of 10–20 </text>
<text top="587" left="836" width="57" height="19" font="0">mcg/ml.  </text>
<text top="606" left="825" width="142" height="20" font="0">• No pt required a PM. </text>
<text top="626" left="96" width="109" height="19" font="0">Schulz-Stübner S, </text>
<text top="644" left="96" width="69" height="19" font="0">2005 (112)<b> </b></text>
<text top="662" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16301263">16301263</a></text>
<text top="662" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16301263"> </a></text>
<text top="625" left="243" width="145" height="19" font="8"><b>Study type:</b> Case series </text>
<text top="644" left="243" width="3" height="19" font="0"> </text>
<text top="662" left="243" width="60" height="19" font="8"><b>Size:</b> N=3 </text>
<text top="625" left="405" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="644" left="405" width="162" height="19" font="0">severe bradycardia due to </text>
<text top="662" left="405" width="108" height="19" font="0">spinal cord injury </text>
<text top="681" left="405" width="3" height="19" font="0"> </text>
<text top="699" left="405" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="626" left="587" width="223" height="19" font="8"><b>1</b>°<b> endpoint:</b> Heart rate response to </text>
<text top="645" left="587" width="80" height="19" font="0">theophylline </text>
<text top="663" left="587" width="3" height="19" font="0"> </text>
<text top="681" left="587" width="220" height="19" font="8"><b>Results:</b> Heart rates increased from </text>
<text top="700" left="587" width="208" height="19" font="0">30–40 with pauses to 60–70 after </text>
<text top="718" left="587" width="217" height="19" font="0">theophylline. Increased respiratory </text>
<text top="736" left="587" width="155" height="19" font="0">drive was seen in one pt. </text>
<text top="626" left="825" width="262" height="20" font="0">• Improved heart rate was seen in all 3 pts </text>
<text top="645" left="836" width="231" height="19" font="0">after IV theophylline, and maintained </text>
<text top="663" left="836" width="137" height="19" font="0">with oral theophylline </text>
<text top="682" left="825" width="243" height="20" font="0">• Dosages were 200 mg IV theophylline </text>
<text top="700" left="836" width="180" height="19" font="0">and 50–100 mg po every 8 h  </text>
<text top="755" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="775" left="86" width="724" height="23" font="5"><b>Data Supplement 18. Trials of Temporary Transesophageal or Transvenous Pacing (Section 5.3.3) </b></text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 82 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="101" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="105" left="132" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="123" left="105" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="87" left="255" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="105" left="260" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="123" left="254" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="87" left="413" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="87" left="581" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="105" left="599" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="123" left="582" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="142" left="603" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="87" left="749" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="105" left="731" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="123" left="736" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="142" left="779" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="88" left="904" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="106" left="939" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="124" left="948" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="161" left="95" width="83" height="19" font="0">Smith I, et al. </text>
<text top="179" left="95" width="62" height="19" font="0">1994 (76) </text>
<text top="197" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7906108">7906108</a></text>
<text top="197" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7906108"> </a></text>
<text top="161" left="223" width="132" height="19" font="8"><b>Aim:</b> To compare the </text>
<text top="179" left="223" width="122" height="19" font="0">effectiveness in the </text>
<text top="197" left="223" width="82" height="19" font="0">treatment of </text>
<text top="216" left="223" width="91" height="19" font="0">intraoperative </text>
<text top="234" left="223" width="92" height="19" font="0">bradycardia of </text>
<text top="252" left="223" width="139" height="19" font="0">transesophageal atrial </text>
<text top="271" left="223" width="132" height="19" font="0">pacing, atropine, and </text>
<text top="289" left="223" width="91" height="19" font="0">glycopyrrolate </text>
<text top="307" left="223" width="3" height="19" font="0"> </text>
<text top="326" left="223" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="344" left="223" width="3" height="19" font="0"> </text>
<text top="362" left="223" width="145" height="19" font="8"><b>Size:</b> N=64, of which 45 </text>
<text top="381" left="223" width="113" height="19" font="0">had treatment for </text>
<text top="399" left="223" width="76" height="19" font="0">bradycardia </text>
<text top="161" left="386" width="143" height="19" font="8"><b>Inclusion criteria:</b> Men </text>
<text top="179" left="386" width="168" height="19" font="0">undergoing elective radical </text>
<text top="197" left="386" width="124" height="19" font="0">prostatectomy with </text>
<text top="216" left="386" width="76" height="19" font="0">sufentanil/N</text>
<text top="222" left="463" width="5" height="12" font="7">2</text>
<text top="216" left="467" width="92" height="19" font="0">O/vecuronium </text>
<text top="234" left="386" width="138" height="19" font="0">anesthetic resulting in </text>
<text top="252" left="386" width="154" height="19" font="0">bradycardia (&lt;50 bpm or </text>
<text top="271" left="386" width="171" height="19" font="0">&lt;60 bpm and hypotension)  </text>
<text top="289" left="386" width="3" height="19" font="0"> </text>
<text top="307" left="386" width="160" height="19" font="8"><b>Exclusion criteria:</b> Pts not </text>
<text top="326" left="386" width="102" height="19" font="0">ASA status I-IFII. </text>
<text top="161" left="572" width="126" height="19" font="8"><b>Intervention:</b> 15 pts </text>
<text top="179" left="572" width="127" height="19" font="0">were randomized to </text>
<text top="197" left="572" width="75" height="19" font="0">each group. </text>
<text top="216" left="572" width="7" height="19" font="0">  </text>
<text top="234" left="572" width="129" height="19" font="8"><b>Comparator</b>: TAP vs. </text>
<text top="252" left="572" width="75" height="19" font="0">atropine vs. </text>
<text top="271" left="572" width="91" height="19" font="0">glycopyrrolate<b> </b></text>
<text top="162" left="722" width="136" height="19" font="8"><b>1</b>°<b> endpoint:</b> Time for </text>
<text top="180" left="722" width="151" height="19" font="0">heart rate to increase to </text>
<text top="198" left="722" width="153" height="19" font="0">&gt;70 bpm was shortest in </text>
<text top="217" left="722" width="135" height="19" font="0">the temporary pacing </text>
<text top="235" left="722" width="135" height="19" font="0">group. There were no </text>
<text top="253" left="722" width="152" height="19" font="0">significant differences in </text>
<text top="272" left="722" width="147" height="19" font="0">postoperative course in </text>
<text top="290" left="722" width="84" height="19" font="0">the 3 groups. </text>
<text top="308" left="722" width="3" height="19" font="0"> </text>
<text top="326" left="722" width="134" height="19" font="8"><b>Safety endpoint:</b> N/A </text>
<text top="345" left="722" width="3" height="19" font="8"><b> </b></text>
<text top="161" left="898" width="197" height="20" font="0">• Transesophageal pacing route </text>
<text top="180" left="908" width="116" height="19" font="0">is relevant to SND. </text>
<text top="198" left="898" width="3" height="19" font="0"> </text>
<text top="217" left="898" width="3" height="19" font="0"> </text>
<text top="418" left="95" width="115" height="19" font="0">Ferguson JD, et.al. </text>
<text top="436" left="95" width="69" height="19" font="0">1997 (113) </text>
<text top="455" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9217762">9217762</a></text>
<text top="455" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9217762"> </a></text>
<text top="418" left="223" width="108" height="19" font="8"><b>Aim:</b> To compare </text>
<text top="436" left="223" width="100" height="19" font="0">effectiveness of </text>
<text top="455" left="223" width="147" height="19" font="0">conventional TTVP with </text>
<text top="473" left="223" width="112" height="19" font="0">balloon floatation </text>
<text top="491" left="223" width="108" height="19" font="0">pacing catheters. </text>
<text top="509" left="223" width="3" height="19" font="0"> </text>
<text top="528" left="223" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="546" left="223" width="133" height="19" font="0">Randomized, parallel-</text>
<text top="564" left="223" width="67" height="19" font="0">group trial </text>
<text top="583" left="223" width="3" height="19" font="0"> </text>
<text top="601" left="223" width="71" height="19" font="8"><b>Size:</b> N= 40 </text>
<text top="418" left="386" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="436" left="386" width="91" height="19" font="0">needing TTVP. </text>
<text top="455" left="386" width="3" height="19" font="0"> </text>
<text top="473" left="386" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="418" left="572" width="135" height="19" font="8"><b>Intervention:</b> Balloon </text>
<text top="436" left="572" width="99" height="19" font="0">flotation pacing </text>
<text top="455" left="572" width="59" height="19" font="0">catheter. </text>
<text top="473" left="572" width="7" height="19" font="0">  </text>
<text top="491" left="572" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="509" left="572" width="122" height="19" font="0">Conventional TTVP.<b> </b></text>
<text top="419" left="722" width="151" height="19" font="8"><b>1</b>°<b> endpoint:</b> Procedural </text>
<text top="437" left="722" width="64" height="19" font="0">outcomes </text>
<text top="455" left="722" width="3" height="19" font="0"> </text>
<text top="474" left="722" width="107" height="19" font="8"><b>Safety endpoint:</b> </text>
<text top="492" left="722" width="90" height="19" font="0">Complications </text>
<text top="510" left="722" width="3" height="19" font="8"><b> </b></text>
<text top="419" left="898" width="123" height="20" font="0">• Only 1/40 pts had </text>
<text top="418" left="1020" width="38" height="21" font="4">sinus </text>
<text top="438" left="908" width="44" height="21" font="4">arrest.</text>
<text top="440" left="952" width="3" height="19" font="0"> </text>
<text top="458" left="898" width="179" height="20" font="0">• Satisfactory TTVP positions </text>
<text top="477" left="908" width="137" height="19" font="0">were more frequently </text>
<text top="496" left="908" width="176" height="19" font="0">achieved with a reduction in </text>
<text top="514" left="908" width="168" height="19" font="0">procedure and fluoroscopy </text>
<text top="532" left="908" width="140" height="19" font="0">time using the balloon </text>
<text top="551" left="908" width="59" height="19" font="0">catheter. </text>
<text top="569" left="898" width="136" height="20" font="0">• Adverse event rates </text>
<text top="588" left="908" width="161" height="19" font="0">(crossover, dislodgement) </text>
<text top="606" left="908" width="171" height="19" font="0">were similar, but death and </text>
<text top="625" left="908" width="172" height="19" font="0">perforation did not occur in </text>
<text top="643" left="908" width="171" height="19" font="0">the balloon catheter group. </text>
<text top="662" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="684" left="86" width="1015" height="23" font="5"><b>Data Supplement 19. Nonrandomized Trials, Observational Studies, and/or Registries of Temporary Transvenous Pacing (TTVP) (Section </b></text>
<text top="706" left="86" width="47" height="23" font="5"><b>5.3.3) </b></text>
<text top="729" left="115" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="747" left="140" width="51" height="19" font="8"><b>Author; </b></text>
<text top="765" left="118" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="729" left="283" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="747" left="312" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="729" left="474" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="729" left="666" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="747" left="696" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="765" left="728" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="729" left="932" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="747" left="960" width="80" height="19" font="8"><b>Comment(s) </b></text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 83 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="131" height="19" font="0">Lopez Ayerbe J, et al. </text>
<text top="105" left="95" width="30" height="19" font="0">2004</text>
<text top="104" left="125" width="4" height="21" font="4"> </text>
<text top="105" left="129" width="35" height="19" font="0">(114)<b> </b></text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15544753">15544753</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15544753"> </a></text>
<text top="87" left="250" width="166" height="19" font="8"><b>Study type:</b> Retrospective, </text>
<text top="105" left="250" width="173" height="19" font="0">observational, single-center </text>
<text top="123" left="250" width="3" height="19" font="0"> </text>
<text top="142" left="250" width="75" height="19" font="8"><b>Size:</b> N=530 </text>
<text top="87" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="105" left="454" width="156" height="19" font="0">who underwent TTVP for </text>
<text top="123" left="454" width="83" height="19" font="0">symptomatic </text>
<text top="142" left="454" width="79" height="19" font="0">bradycardia. </text>
<text top="160" left="454" width="3" height="19" font="0"> </text>
<text top="178" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="627" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcomes </text>
<text top="106" left="627" width="3" height="19" font="0"> </text>
<text top="124" left="627" width="257" height="19" font="8"><b>Results:</b> Indications induced symptomatic </text>
<text top="143" left="627" width="251" height="19" font="0">SSS in 7.5% of implants, use in generator </text>
<text top="161" left="627" width="246" height="19" font="0">replacement in 14.7%, bradycardic drug </text>
<text top="179" left="627" width="263" height="19" font="0">toxicity in 12.2%. Femoral access was used </text>
<text top="198" left="627" width="251" height="19" font="0">in 99%, and duration was 4.2 d. 69.6% of </text>
<text top="216" left="627" width="240" height="19" font="0">pts required a PPM. 6.4% of pts died, 3 </text>
<text top="234" left="627" width="240" height="19" font="0">deaths were attributable to temporary </text>
<text top="252" left="627" width="256" height="19" font="0">pacing. There were complications in 22%, </text>
<text top="271" left="627" width="186" height="19" font="0">including dislodgement in 9%. </text>
<text top="87" left="904" width="176" height="20" font="0">• TTVP is effective, yet has a </text>
<text top="106" left="915" width="159" height="19" font="0">complication rate of 22%, </text>
<text top="124" left="915" width="166" height="19" font="0">including an associated 6% </text>
<text top="143" left="915" width="92" height="19" font="0">mortality rate. </text>
<text top="161" left="904" width="190" height="20" font="0">• Use of TTVP for treatment of </text>
<text top="180" left="915" width="168" height="19" font="0">SND is comparatively rare.  </text>
<text top="290" left="95" width="125" height="19" font="0">Hynes JK, et al. 1983</text>
<text top="288" left="220" width="4" height="21" font="4"> </text>
<text top="308" left="95" width="35" height="19" font="0">(115)<b> </b></text>
<text top="326" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157">6823157</a></text>
<text top="326" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157"> </a></text>
<text top="290" left="250" width="166" height="19" font="8"><b>Study type:</b> Retrospective, </text>
<text top="308" left="250" width="176" height="19" font="0">observational, single-center  </text>
<text top="326" left="250" width="3" height="19" font="0"> </text>
<text top="345" left="250" width="83" height="19" font="8"><b>Size:</b> N=1022 </text>
<text top="290" left="454" width="148" height="19" font="8"><b>Inclusion criteria:</b> Pts in </text>
<text top="308" left="454" width="139" height="19" font="0">the coronary care unit </text>
<text top="326" left="454" width="69" height="19" font="0">with TTVP. </text>
<text top="345" left="454" width="3" height="19" font="0"> </text>
<text top="363" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="291" left="627" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcomes </text>
<text top="309" left="627" width="3" height="19" font="0"> </text>
<text top="327" left="627" width="244" height="19" font="8"><b>Results:</b> Access was antecubital in 59%, </text>
<text top="346" left="627" width="258" height="19" font="0">subclavian in 17%, right internal jugular in </text>
<text top="364" left="627" width="241" height="19" font="0">11%, and femoral in 5%. Complications </text>
<text top="382" left="627" width="237" height="19" font="0">occurred in 13.7% with no deaths. The </text>
<text top="401" left="627" width="217" height="19" font="0">right internal jugular approach was </text>
<text top="419" left="627" width="215" height="19" font="0">associated with a decreased risk of </text>
<text top="437" left="627" width="92" height="19" font="0">complications. </text>
<text top="290" left="904" width="189" height="20" font="0">• TTVP was associated with an </text>
<text top="309" left="915" width="174" height="19" font="0">overall risk of complications </text>
<text top="327" left="915" width="177" height="19" font="0">in approximately 14% of pts. </text>
<text top="346" left="904" width="3" height="19" font="0"> </text>
<text top="456" left="95" width="99" height="19" font="0">Murphy JJ, 1996</text>
<text top="455" left="194" width="4" height="21" font="4"> </text>
<text top="456" left="198" width="35" height="19" font="0">(116)<b> </b></text>
<text top="474" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8620131">8620131</a></text>
<text top="474" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8620131"> </a></text>
<text top="456" left="250" width="166" height="19" font="8"><b>Study type:</b> Retrospective, </text>
<text top="474" left="250" width="165" height="19" font="0">observational, multicenter </text>
<text top="493" left="250" width="28" height="19" font="0">(18) </text>
<text top="511" left="250" width="3" height="19" font="0"> </text>
<text top="529" left="250" width="79" height="19" font="8"><b>Size:</b> N=194  </text>
<text top="456" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="474" left="454" width="111" height="19" font="0">undergoing TTVP. </text>
<text top="493" left="454" width="3" height="19" font="0"> </text>
<text top="511" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="457" left="627" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcomes </text>
<text top="475" left="627" width="3" height="19" font="0"> </text>
<text top="494" left="627" width="263" height="19" font="8"><b>Results:</b> 129/194 TTVP were implanted for </text>
<text top="512" left="627" width="259" height="19" font="0">CHB. Immediate or delayed complications </text>
<text top="530" left="627" width="117" height="19" font="0">occurred in 68 pts. </text>
<text top="456" left="904" width="170" height="20" font="0">• TTVP was associated with </text>
<text top="475" left="915" width="174" height="19" font="0">complications in 35% of pts, </text>
<text top="494" left="915" width="154" height="19" font="0">including vascular access </text>
<text top="512" left="915" width="161" height="19" font="0">difficulties, dislodgement, </text>
<text top="530" left="915" width="131" height="19" font="0">infection, and sepsis. </text>
<text top="549" left="904" width="3" height="19" font="0"> </text>
<text top="568" left="95" width="125" height="19" font="0">Austin JL, et al. 1982</text>
<text top="566" left="220" width="4" height="21" font="4"> </text>
<text top="586" left="95" width="35" height="19" font="0">(117)<b> </b></text>
<text top="604" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7058746">7058746</a></text>
<text top="604" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7058746"> </a></text>
<text top="568" left="250" width="166" height="19" font="8"><b>Study type:</b> Retrospective, </text>
<text top="586" left="250" width="173" height="19" font="0">observational. Single center </text>
<text top="604" left="250" width="3" height="19" font="0"> </text>
<text top="622" left="250" width="75" height="19" font="8"><b>Size:</b> N=100 </text>
<text top="568" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="586" left="454" width="123" height="19" font="0">who received TTVP. </text>
<text top="604" left="454" width="3" height="19" font="0"> </text>
<text top="622" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="568" left="627" width="197" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications and </text>
<text top="587" left="627" width="77" height="19" font="0">malfunction </text>
<text top="605" left="627" width="3" height="19" font="0"> </text>
<text top="623" left="627" width="264" height="19" font="8"><b>Results:</b> 113 TTVPs were placed in 100 pts. </text>
<text top="642" left="627" width="238" height="19" font="0">Failure to capture or sense occurred in </text>
<text top="660" left="627" width="231" height="19" font="0">37% and complications in 20%. These </text>
<text top="678" left="627" width="239" height="19" font="0">included ventricular arrhythmia, fever, </text>
<text top="697" left="627" width="262" height="19" font="0">pulmonary emboli, perforation, sepsis and </text>
<text top="715" left="627" width="200" height="19" font="0">phlebitis. There were no deaths. </text>
<text top="568" left="904" width="181" height="20" font="0">• TTVP was associated with a </text>
<text top="587" left="915" width="180" height="19" font="0">20% complication rate, and a </text>
<text top="605" left="915" width="155" height="19" font="0">high rate of malfunction. </text>
<text top="624" left="904" width="182" height="20" font="0">• 21/100 subjects underwent </text>
<text top="642" left="915" width="152" height="19" font="0">TTVP for SND; 18 for PM </text>
<text top="661" left="915" width="131" height="19" font="0">failure not otherwise </text>
<text top="679" left="915" width="58" height="19" font="0">specified </text>
<text top="734" left="95" width="140" height="19" font="0">Munoz Bono JM, et al. </text>
<text top="752" left="95" width="30" height="19" font="0">2011</text>
<text top="751" left="125" width="4" height="21" font="4"> </text>
<text top="752" left="129" width="35" height="19" font="0">(118)<b> </b></text>
<text top="771" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21640435">21640435</a></text>
<text top="771" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21640435"> </a></text>
<text top="734" left="250" width="153" height="19" font="8"><b>Study type:</b> Prospective, </text>
<text top="752" left="250" width="87" height="19" font="0">observational </text>
<text top="771" left="250" width="3" height="19" font="0"> </text>
<text top="734" left="454" width="148" height="19" font="8"><b>Inclusion criteria:</b> Pts in </text>
<text top="752" left="454" width="135" height="19" font="0">cardiac intensive care </text>
<text top="735" left="627" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical indications, </text>
<text top="753" left="627" width="130" height="19" font="0">morbidity, mortality. </text>
<text top="771" left="627" width="3" height="19" font="0"> </text>
<text top="734" left="904" width="181" height="20" font="0">• TTVP was associated with a </text>
<text top="753" left="915" width="176" height="19" font="0">risk of complications in 40%. </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 84 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="250" width="75" height="19" font="8"><b>Size:</b> N=182 </text>
<text top="87" left="454" width="128" height="19" font="0">unit who underwent </text>
<text top="105" left="454" width="38" height="19" font="0">TTVP. </text>
<text top="123" left="454" width="3" height="19" font="0"> </text>
<text top="142" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="627" width="243" height="19" font="8"><b>Results:</b> Indication for TTVP was CHB in </text>
<text top="105" left="627" width="242" height="19" font="0">77%, access was via the femoral vein in </text>
<text top="123" left="627" width="220" height="19" font="0">92%, and complications occurred in </text>
<text top="142" left="627" width="256" height="19" font="0">40.11%. Predictors of complications were </text>
<text top="160" left="627" width="263" height="19" font="0">restlessness, CV risk factors, and jugular or </text>
<text top="178" left="627" width="113" height="19" font="0">subclavian access. </text>
<text top="87" left="904" width="183" height="20" font="0">• TTVP was indicated for SND </text>
<text top="106" left="915" width="154" height="19" font="0">in 9.3%, and bradycardia </text>
<text top="124" left="915" width="155" height="19" font="0">from drug intoxication in </text>
<text top="143" left="915" width="41" height="19" font="0">12.1% </text>
<text top="161" left="904" width="3" height="19" font="0"> </text>
<text top="197" left="95" width="88" height="19" font="0">Betts TR, 2003</text>
<text top="196" left="183" width="4" height="21" font="4"> </text>
<text top="197" left="186" width="35" height="19" font="0">(119)<b> </b></text>
<text top="216" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12954959">12954959</a></text>
<text top="216" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12954959"> </a></text>
<text top="197" left="250" width="153" height="19" font="8"><b>Study type:</b> Prospective, </text>
<text top="216" left="250" width="170" height="19" font="0">observational, multi-center </text>
<text top="234" left="250" width="24" height="19" font="0">(5). </text>
<text top="252" left="250" width="3" height="19" font="0"> </text>
<text top="271" left="250" width="75" height="19" font="8"><b>Size:</b> N=111 </text>
<text top="197" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="216" left="454" width="93" height="19" font="0">requiring TTVP </text>
<text top="234" left="454" width="3" height="19" font="0"> </text>
<text top="252" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="198" left="627" width="194" height="19" font="8"><b>1</b>°<b> endpoint:</b> Procedural and pt </text>
<text top="217" left="627" width="163" height="19" font="0">characteristics, outcomes. </text>
<text top="235" left="627" width="3" height="19" font="0"> </text>
<text top="253" left="627" width="218" height="19" font="8"><b>Results:</b> 144 procedures in 111 pts. </text>
<text top="272" left="627" width="234" height="19" font="0">Venous access was subclavian in 47%, </text>
<text top="290" left="627" width="257" height="19" font="0">jugular in 33%, and femoral in 20%. There </text>
<text top="308" left="627" width="252" height="19" font="0">were procedural complications in 32% of </text>
<text top="326" left="627" width="240" height="19" font="0">the procedures; risk was decreased for </text>
<text top="345" left="627" width="228" height="19" font="0">experienced operators. Infection risk </text>
<text top="363" left="627" width="201" height="19" font="0">increased with dwell time &gt;48 h. </text>
<text top="381" left="627" width="263" height="19" font="0">Complications delayed permanent implant </text>
<text top="400" left="627" width="86" height="19" font="0">in 23% of pts. </text>
<text top="198" left="904" width="181" height="20" font="0">• TTVP was associated with a </text>
<text top="217" left="915" width="162" height="19" font="0">high risk of complications. </text>
<text top="235" left="904" width="174" height="20" font="0">• Infectious risk is increased </text>
<text top="254" left="915" width="174" height="19" font="0">with longer time of implant. </text>
<text top="273" left="904" width="187" height="20" font="0">• Immediate complication risk </text>
<text top="291" left="915" width="165" height="19" font="0">was lower for experienced </text>
<text top="310" left="915" width="67" height="19" font="0">operators. </text>
<text top="328" left="904" width="169" height="20" font="0">• Pacing indication was not </text>
<text top="347" left="915" width="67" height="19" font="0">described. </text>
<text top="419" left="95" width="129" height="19" font="0">Jowett NI, et al. 1989</text>
<text top="417" left="224" width="4" height="21" font="4"> </text>
<text top="437" left="95" width="35" height="19" font="0">(120)<b> </b></text>
<text top="455" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2594596">2594596</a></text>
<text top="455" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2594596"> </a></text>
<text top="419" left="250" width="166" height="19" font="8"><b>Study type:</b> Retrospective, </text>
<text top="437" left="250" width="172" height="19" font="0">observational, single center </text>
<text top="455" left="250" width="3" height="19" font="0"> </text>
<text top="474" left="250" width="75" height="19" font="8"><b>Size:</b> N=162 </text>
<text top="419" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="437" left="454" width="133" height="19" font="0">admitted to coronary </text>
<text top="455" left="454" width="158" height="19" font="0">care unit who underwent </text>
<text top="474" left="454" width="38" height="19" font="0">TTVP. </text>
<text top="492" left="454" width="3" height="19" font="0"> </text>
<text top="510" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="419" left="627" width="195" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcomes. </text>
<text top="438" left="627" width="3" height="19" font="0"> </text>
<text top="456" left="627" width="260" height="19" font="8"><b>Results:</b> The majority of TTVP was for CHB </text>
<text top="474" left="627" width="231" height="19" font="0">and MI (84.6%). 15.4% of TTVPs were </text>
<text top="493" left="627" width="227" height="19" font="0">placed for symptomatic bradycardia, </text>
<text top="511" left="627" width="254" height="19" font="0">including SND. Complications occurred in </text>
<text top="529" left="627" width="223" height="19" font="0">19.8%, including arrhythmias during </text>
<text top="548" left="627" width="250" height="19" font="0">insertion, dislodgement, pneumothorax, </text>
<text top="566" left="627" width="103" height="19" font="0">and perforation. </text>
<text top="419" left="904" width="181" height="20" font="0">• TTVP was associated with a </text>
<text top="438" left="915" width="155" height="19" font="0">19.8% complication rate. </text>
<text top="456" left="915" width="99" height="19" font="0">Some TTVP was </text>
<text top="474" left="915" width="162" height="19" font="0">prophylactic, and may not </text>
<text top="493" left="915" width="131" height="19" font="0">have been indicated. </text>
<text top="511" left="904" width="155" height="20" font="0">• A minority of TTVP was </text>
<text top="530" left="915" width="158" height="19" font="0">performed for SND (15%) </text>
<text top="585" left="95" width="111" height="19" font="0">Weinstein J, et al. </text>
<text top="603" left="95" width="30" height="19" font="0">1973</text>
<text top="602" left="125" width="4" height="21" font="4"> </text>
<text top="603" left="129" width="35" height="19" font="0">(121) </text>
<text top="622" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4697639">4697639</a></text>
<text top="622" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4697639"> </a></text>
<text top="585" left="250" width="153" height="19" font="8"><b>Study type:</b> Prospective, </text>
<text top="603" left="250" width="172" height="19" font="0">observational, single center </text>
<text top="622" left="250" width="3" height="19" font="0"> </text>
<text top="640" left="250" width="75" height="19" font="8"><b>Size:</b> N=100 </text>
<text top="585" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="603" left="454" width="132" height="19" font="0">with bradycardia and </text>
<text top="622" left="454" width="159" height="19" font="0">conduction disease in the </text>
<text top="640" left="454" width="82" height="19" font="0">acute setting </text>
<text top="658" left="454" width="3" height="19" font="0"> </text>
<text top="677" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="586" left="627" width="213" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical response and </text>
<text top="604" left="627" width="55" height="19" font="0">stability. </text>
<text top="623" left="627" width="3" height="19" font="0"> </text>
<text top="641" left="627" width="228" height="19" font="8"><b>Results:</b> 17% of placements required </text>
<text top="659" left="627" width="244" height="19" font="0">repositioning, 2 instances of ventricular </text>
<text top="677" left="627" width="249" height="19" font="0">tachycardia, 2 perforations, 2 infections. </text>
<text top="696" left="627" width="235" height="19" font="0">Placement and stability was improved </text>
<text top="714" left="627" width="243" height="19" font="0">compared with prior historical series of </text>
<text top="732" left="627" width="218" height="19" font="0">100 pts with jugular and subclavian </text>
<text top="751" left="627" width="65" height="19" font="0">approach. </text>
<text top="769" left="627" width="3" height="19" font="0"> </text>
<text top="585" left="904" width="141" height="20" font="0">• TTVP via the femoral </text>
<text top="604" left="915" width="163" height="19" font="0">approach was found to be </text>
<text top="623" left="915" width="155" height="19" font="0">reliable, and rapid with a </text>
<text top="641" left="915" width="153" height="19" font="0">reasonable complication </text>
<text top="659" left="915" width="137" height="19" font="0">rate in critically ill pts. </text>
<text top="678" left="904" width="146" height="20" font="0">• Pts were restricted to </text>
<text top="697" left="915" width="176" height="19" font="0">bedrest after dislodgements </text>
<text top="715" left="915" width="177" height="19" font="0">were noted to be associated </text>
<text top="733" left="915" width="82" height="19" font="0">with activity. </text>
<text top="752" left="904" width="189" height="20" font="0">• 10% of TTVP were placed for </text>
<text top="771" left="915" width="110" height="19" font="0">sinus bradycardia </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 85 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="134" height="19" font="0">Garcia Guerrero JJ, et </text>
<text top="105" left="95" width="48" height="19" font="0">al. 2010</text>
<text top="104" left="143" width="4" height="21" font="4"> </text>
<text top="105" left="147" width="35" height="19" font="0">(122) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20667893">20667893</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20667893"> </a></text>
<text top="87" left="250" width="153" height="19" font="8"><b>Study type:</b> Prospective, </text>
<text top="105" left="250" width="172" height="19" font="0">observational, single center </text>
<text top="123" left="250" width="3" height="19" font="0"> </text>
<text top="142" left="250" width="68" height="19" font="8"><b>Size:</b> N=47 </text>
<text top="87" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="105" left="454" width="123" height="19" font="0">requiring TTVP who </text>
<text top="123" left="454" width="147" height="19" font="0">underwent novel active </text>
<text top="142" left="454" width="139" height="19" font="0">fixation femoral TTVP. </text>
<text top="160" left="454" width="3" height="19" font="0"> </text>
<text top="178" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="627" width="210" height="19" font="8"><b>1</b>°<b> endpoint:</b> Rate of deep venous </text>
<text top="106" left="627" width="72" height="19" font="0">thrombosis </text>
<text top="124" left="627" width="3" height="19" font="0"> </text>
<text top="143" left="627" width="244" height="19" font="8"><b>Results:</b> Asymptomatic thrombosis was </text>
<text top="161" left="627" width="246" height="19" font="0">seen in 6.4%, compared with 25–39% in </text>
<text top="179" left="627" width="196" height="19" font="0">other observational reports. No </text>
<text top="198" left="627" width="238" height="19" font="0">pulmonary emboli were noted on lung </text>
<text top="216" left="627" width="34" height="19" font="0">scan. </text>
<text top="234" left="627" width="3" height="19" font="0"> </text>
<text top="87" left="904" width="158" height="20" font="0">• Mobility afforded by an </text>
<text top="106" left="915" width="136" height="19" font="0">active fixation TTVP is </text>
<text top="124" left="915" width="175" height="19" font="0">associated with a decreased </text>
<text top="143" left="915" width="122" height="19" font="0">risk of deep venous </text>
<text top="161" left="915" width="80" height="19" font="0">thrombosis.  </text>
<text top="179" left="904" width="182" height="20" font="0">• Pacing indications were not </text>
<text top="198" left="915" width="61" height="19" font="0">reported. </text>
<text top="253" left="95" width="122" height="19" font="0">Nolewajka AJ, et al. </text>
<text top="272" left="95" width="30" height="19" font="0">1980</text>
<text top="270" left="125" width="4" height="21" font="4"> </text>
<text top="272" left="129" width="35" height="19" font="0">(123) </text>
<text top="290" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7398027">7398027</a></text>
<text top="290" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7398027"> </a></text>
<text top="253" left="250" width="153" height="19" font="8"><b>Study type:</b> Prospective, </text>
<text top="272" left="250" width="87" height="19" font="0">observational </text>
<text top="290" left="250" width="3" height="19" font="0"> </text>
<text top="308" left="250" width="68" height="19" font="8"><b>Size:</b> N=29 </text>
<text top="253" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="272" left="454" width="97" height="19" font="0">requiring TTVP. </text>
<text top="290" left="454" width="3" height="19" font="0"> </text>
<text top="308" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="254" left="627" width="262" height="19" font="8"><b>1</b>°<b> endpoint:</b> Femoral vein thrombosis and </text>
<text top="272" left="627" width="115" height="19" font="0">pulmonary emboli </text>
<text top="291" left="627" width="3" height="19" font="0"> </text>
<text top="309" left="627" width="226" height="19" font="8"><b>Results:</b> 34% of pts had femoral vein </text>
<text top="327" left="627" width="219" height="19" font="0">thrombosis, and 60% had lung scan </text>
<text top="346" left="627" width="196" height="19" font="0">evidence of pulmonary emboli.  </text>
<text top="253" left="904" width="189" height="20" font="0">• TTVP via femoral vein access </text>
<text top="272" left="915" width="179" height="19" font="0">is associated with a high rate </text>
<text top="291" left="915" width="122" height="19" font="0">of thromboembolic </text>
<text top="309" left="915" width="167" height="19" font="0">complications, despite low-</text>
<text top="327" left="915" width="87" height="19" font="0">dose heparin. </text>
<text top="346" left="904" width="176" height="20" font="0">• 2/29 pts received TTVP for </text>
<text top="365" left="915" width="33" height="19" font="0">SND. </text>
<text top="384" left="95" width="137" height="19" font="0">Sodeck GH, et al. 2006</text>
<text top="382" left="232" width="4" height="21" font="4"> </text>
<text top="402" left="95" width="28" height="19" font="0">(77) </text>
<text top="420" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976">17212976</a></text>
<text top="420" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976"> </a></text>
<text top="439" left="95" width="3" height="19" font="0"> </text>
<text top="384" left="250" width="167" height="19" font="8"><b>Study type: </b>Observational, </text>
<text top="402" left="250" width="170" height="19" font="0">retrospective, single center </text>
<text top="420" left="250" width="3" height="19" font="0"> </text>
<text top="439" left="250" width="75" height="19" font="8"><b>Size:</b> N=277<b> </b></text>
<text top="384" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="402" left="454" width="135" height="19" font="0">presenting to ED with </text>
<text top="420" left="454" width="90" height="19" font="0">compromising </text>
<text top="439" left="454" width="76" height="19" font="0">bradycardia </text>
<text top="457" left="454" width="3" height="19" font="0"> </text>
<text top="475" left="454" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="494" left="454" width="92" height="19" font="0">Asymptomatic </text>
<text top="512" left="454" width="76" height="19" font="0">bradycardia<b> </b></text>
<text top="384" left="627" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> 30 d mortality </text>
<text top="403" left="627" width="3" height="19" font="0"> </text>
<text top="421" left="627" width="232" height="19" font="8"><b>Results:</b> 48% AVB, 17% SB/AVB, Sinus </text>
<text top="439" left="627" width="246" height="19" font="0">arrest 15%, AF 14%, PM failure 6%. 20% </text>
<text top="458" left="627" width="198" height="19" font="0">required transvenous pacing for </text>
<text top="476" left="627" width="225" height="19" font="0">stabilization, 50% permanent pacing </text>
<text top="494" left="627" width="3" height="19" font="8"><b> </b></text>
<text top="384" left="904" width="183" height="20" font="0">• Not all pts with bradycardia </text>
<text top="403" left="915" width="167" height="19" font="0">required temporary pacing </text>
<text top="531" left="95" width="112" height="19" font="0">Jou YL, et al. 2010 </text>
<text top="549" left="95" width="35" height="19" font="0">(124) </text>
<text top="568" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20946290">20946290</a></text>
<text top="568" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20946290"> </a></text>
<text top="531" left="250" width="167" height="19" font="8"><b>Study type:</b> Observational, </text>
<text top="549" left="250" width="174" height="19" font="0">retrospective, single-center  </text>
<text top="568" left="250" width="3" height="19" font="0"> </text>
<text top="586" left="250" width="75" height="19" font="8"><b>Size: </b>N=509<b> </b></text>
<text top="531" left="454" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="549" left="454" width="99" height="19" font="0">presenting with </text>
<text top="568" left="454" width="135" height="19" font="0">bradycardia requiring </text>
<text top="586" left="454" width="111" height="19" font="0">temporary pacing </text>
<text top="604" left="454" width="3" height="19" font="0"> </text>
<text top="622" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="532" left="627" width="245" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical characteristics and </text>
<text top="550" left="627" width="131" height="19" font="0">underlying etiologies </text>
<text top="568" left="627" width="3" height="19" font="0"> </text>
<text top="587" left="627" width="243" height="19" font="8"><b>Results:</b> 64% of temporary pacers were </text>
<text top="605" left="627" width="249" height="19" font="0">for AVB. AAD use correlated with SND in </text>
<text top="623" left="627" width="222" height="19" font="0">38%. Increasing AVB seen over time<b> </b></text>
<text top="531" left="904" width="187" height="20" font="0">• Idiopathic degeneration was </text>
<text top="550" left="915" width="151" height="19" font="0">related to AVB, whereas </text>
<text top="568" left="915" width="151" height="19" font="0">extrinsic etiologies were </text>
<text top="587" left="915" width="96" height="19" font="0">related to SND. </text>
<text top="642" left="95" width="137" height="19" font="0">McCann P, 2006 (125) </text>
<text top="661" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17235372">17235372</a></text>
<text top="661" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17235372"> </a></text>
<text top="679" left="95" width="3" height="19" font="0"> </text>
<text top="642" left="250" width="188" height="19" font="8"><b>Study type:</b> Systematic review </text>
<text top="661" left="250" width="178" height="19" font="0">of temporary cardiac pacing  </text>
<text top="679" left="250" width="3" height="19" font="0"> </text>
<text top="697" left="250" width="152" height="19" font="8"><b>Size:</b> N=15 studies, 3817 </text>
<text top="716" left="250" width="57" height="19" font="0">subjects <b> </b></text>
<text top="642" left="454" width="159" height="19" font="8"><b>Inclusion criteria:</b> Studies </text>
<text top="661" left="454" width="127" height="19" font="0">of temporary pacing </text>
<text top="679" left="454" width="36" height="19" font="0">wires </text>
<text top="697" left="454" width="3" height="19" font="0"> </text>
<text top="715" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="643" left="627" width="255" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complication by access site, </text>
<text top="662" left="627" width="64" height="19" font="0">outcomes </text>
<text top="680" left="627" width="3" height="19" font="0"> </text>
<text top="698" left="627" width="261" height="19" font="8"><b>Results:</b> The most common indication was </text>
<text top="716" left="627" width="250" height="19" font="0">AVB. Mean complication rate was 26.5% </text>
<text top="735" left="627" width="253" height="19" font="0">(10–59.9%), including access failure, lead </text>
<text top="753" left="627" width="263" height="19" font="0">malposition, sepsis, arterial puncture, lung </text>
<text top="771" left="627" width="238" height="19" font="0">or myocardial puncture, or arrhythmia<b> </b></text>
<text top="643" left="904" width="179" height="20" font="0">• Internal jugular vein access </text>
<text top="662" left="915" width="174" height="19" font="0">was associated with a lower </text>
<text top="680" left="915" width="176" height="19" font="0">complication rate compared </text>
<text top="698" left="915" width="175" height="19" font="0">with subclavian and femoral </text>
<text top="716" left="915" width="35" height="19" font="0">veins </text>
<text top="735" left="904" width="182" height="20" font="0">• Complications appear to be </text>
<text top="754" left="915" width="120" height="19" font="0">lower if operator is </text>
<text top="772" left="915" width="70" height="19" font="0">specialized </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 86 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="904" width="175" height="20" font="0">• Antibiotics and ultrasound </text>
<text top="106" left="915" width="160" height="19" font="0">access reduced the risk of </text>
<text top="124" left="915" width="92" height="19" font="0">complications. </text>
<text top="143" left="904" width="167" height="20" font="0">• Methodologic limitations </text>
<text top="162" left="95" width="119" height="19" font="0">Bjornstad CC, et al. </text>
<text top="181" left="95" width="30" height="19" font="0">2012</text>
<text top="179" left="125" width="4" height="21" font="4"> </text>
<text top="181" left="129" width="35" height="19" font="0">(126) </text>
<text top="199" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22390277">22390277</a></text>
<text top="199" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22390277"> </a></text>
<text top="217" left="95" width="3" height="19" font="0"> </text>
<text top="162" left="250" width="167" height="19" font="8"><b>Study type:</b> Observational, </text>
<text top="181" left="250" width="169" height="19" font="0">prospective, 5 center study </text>
<text top="199" left="250" width="3" height="19" font="0"> </text>
<text top="217" left="250" width="78" height="19" font="8"><b>Size:</b> N = 50  </text>
<text top="162" left="454" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="181" left="454" width="146" height="19" font="0">with temporary cardiac </text>
<text top="199" left="454" width="79" height="19" font="0">pacing wires </text>
<text top="217" left="454" width="3" height="19" font="0"> </text>
<text top="236" left="454" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="163" left="627" width="238" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, outcomes </text>
<text top="182" left="627" width="3" height="19" font="0"> </text>
<text top="200" left="627" width="260" height="19" font="8"><b>Results:</b> 30% with SND. Permanent pacing </text>
<text top="218" left="627" width="235" height="19" font="0">required in 60%, repeat procedures in </text>
<text top="237" left="627" width="224" height="19" font="0">12%, mortality 18%, bacteremia 6%. </text>
<text top="255" left="627" width="3" height="19" font="0"> </text>
<text top="163" left="904" width="166" height="20" font="0">• High rates of subsequent </text>
<text top="182" left="915" width="113" height="19" font="0">PPM implantation </text>
<text top="200" left="904" width="184" height="20" font="0">• High rates of complications. </text>
<text top="275" left="86" width="4" height="23" font="12"> </text>
<text top="298" left="97" width="4" height="21" font="4"> </text>
<text top="296" left="313" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 87 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="507" height="23" font="5"><b>Data Supplement 20. RCTs of Transcutaneous Pacing (Section 5.3.3) </b></text>
<text top="109" left="98" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="127" left="129" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="145" left="101" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="109" left="247" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="127" left="252" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="145" left="246" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="109" left="403" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="109" left="602" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="127" left="620" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="145" left="603" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="164" left="625" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="109" left="797" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="127" left="779" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="145" left="783" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="164" left="826" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="110" left="941" width="152" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="128" left="1005" width="35" height="19" font="8"><b>any); </b></text>
<text top="146" left="959" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="165" left="968" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="183" left="95" width="57" height="19" font="8"><b>PrePACE </b></text>
<text top="202" left="95" width="94" height="19" font="0">Morrison LJ, et </text>
<text top="220" left="95" width="48" height="19" font="0">al. 2006</text>
<text top="219" left="143" width="4" height="21" font="4"> </text>
<text top="220" left="147" width="28" height="19" font="0">(86) </text>
<text top="239" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452">17933452</a></text>
<text top="239" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452"> </a></text>
<text top="183" left="216" width="131" height="19" font="8"><b>Aim:</b> To evaluate the </text>
<text top="202" left="216" width="131" height="19" font="0">feasibility of a RCT of </text>
<text top="220" left="216" width="141" height="19" font="0">transcutaneous pacing </text>
<text top="239" left="216" width="106" height="19" font="0">vs. dopamine for </text>
<text top="257" left="216" width="112" height="19" font="0">atropine and fluid </text>
<text top="275" left="216" width="140" height="19" font="0">refractory bradycardia </text>
<text top="294" left="216" width="111" height="19" font="0">in the prehospital </text>
<text top="312" left="216" width="49" height="19" font="0">setting. </text>
<text top="330" left="216" width="3" height="19" font="0"> </text>
<text top="348" left="216" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="367" left="216" width="3" height="19" font="0"> </text>
<text top="385" left="216" width="136" height="19" font="8"><b>Size:</b> 151 met criteria, </text>
<text top="403" left="216" width="73" height="19" font="0">82 enrolled </text>
<text top="183" left="378" width="169" height="19" font="8"><b>Inclusion criteria:</b> Unstable </text>
<text top="202" left="378" width="161" height="19" font="0">bradycardia unresponsive </text>
<text top="220" left="378" width="169" height="19" font="0">to fluid and atropine: heart </text>
<text top="239" left="378" width="152" height="19" font="0">rate &lt;60 per minute and </text>
<text top="257" left="378" width="156" height="19" font="0">systolic BP (SBP) &lt;80 mm </text>
<text top="275" left="378" width="160" height="19" font="0">Hg; or heart rate &lt;60/min </text>
<text top="294" left="378" width="160" height="19" font="0">and SBP &lt;100 mm Hg and </text>
<text top="312" left="378" width="139" height="19" font="0">at least one additional </text>
<text top="330" left="378" width="94" height="19" font="0">sign/symptom  </text>
<text top="348" left="378" width="3" height="19" font="0"> </text>
<text top="367" left="378" width="169" height="19" font="8"><b>Exclusion criteria:</b> Advance </text>
<text top="385" left="378" width="118" height="19" font="0">directives, trauma, </text>
<text top="403" left="378" width="91" height="19" font="0">hyperthermia, </text>
<text top="422" left="378" width="146" height="19" font="0">hypothermia or cardiac </text>
<text top="440" left="378" width="161" height="19" font="0">arrest, pts in whom it was </text>
<text top="458" left="378" width="144" height="19" font="0">not possible to start an </text>
<text top="477" left="378" width="105" height="19" font="0">intravenous line. </text>
<text top="183" left="560" width="182" height="19" font="8"><b>Intervention:</b> All pts received </text>
<text top="202" left="560" width="151" height="19" font="0">250 ml saline IV bolus. If </text>
<text top="220" left="560" width="164" height="19" font="0">nonresponse, pts received </text>
<text top="239" left="560" width="163" height="19" font="0">atropine 1 mg, repeated if </text>
<text top="257" left="560" width="153" height="19" font="0">improved. If pts failed to </text>
<text top="275" left="560" width="198" height="19" font="0">respond, they were randomized </text>
<text top="294" left="560" width="193" height="19" font="0">to transcutaneous pacing (with </text>
<text top="312" left="560" width="174" height="19" font="0">midazolam) vs. comparator. </text>
<text top="330" left="560" width="7" height="19" font="0">  </text>
<text top="348" left="560" width="199" height="19" font="8"><b>Comparator:</b> Dopamine starting </text>
<text top="367" left="560" width="194" height="19" font="0">at 5 mcg/kg min, increasing the </text>
<text top="385" left="560" width="185" height="19" font="0">dose by 5 mcg/kg min every 2 </text>
<text top="403" left="560" width="177" height="19" font="0">min until an improvement in </text>
<text top="422" left="560" width="154" height="19" font="0">signs and symptoms was </text>
<text top="440" left="560" width="195" height="19" font="0">observed, maximum dose of 20 </text>
<text top="458" left="560" width="75" height="19" font="0">mcg/kg min<b> </b></text>
<text top="184" left="776" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="203" left="776" width="114" height="19" font="0">hospital discharge </text>
<text top="221" left="776" width="3" height="19" font="0"> </text>
<text top="239" left="776" width="119" height="19" font="8"><b>Safety endpoint (if </b></text>
<text top="258" left="776" width="67" height="19" font="8"><b>relevant):</b>  </text>
<text top="276" left="776" width="146" height="19" font="0">Ventricular arrhythmia, </text>
<text top="294" left="776" width="145" height="19" font="0">cutaneous burns, chest </text>
<text top="313" left="776" width="149" height="19" font="0">wall discomfort, cardiac </text>
<text top="331" left="776" width="116" height="19" font="0">arrest, TCP failure. </text>
<text top="184" left="938" width="130" height="20" font="0">• Survival to hospital </text>
<text top="203" left="949" width="133" height="19" font="0">discharge was similar </text>
<text top="221" left="949" width="146" height="19" font="0">in both groups (70% vs. </text>
<text top="239" left="949" width="138" height="19" font="0">69%; p=0.93), as were </text>
<text top="258" left="949" width="84" height="19" font="0">2° outcomes. </text>
<text top="276" left="938" width="148" height="20" font="0">• Paramedics chose not </text>
<text top="295" left="949" width="139" height="19" font="0">to enroll 20 pts due to </text>
<text top="313" left="949" width="137" height="19" font="0">pain concerns. 71% of </text>
<text top="332" left="949" width="127" height="19" font="0">TCP pts experienced </text>
<text top="350" left="949" width="106" height="19" font="0">chest discomfort </text>
<text top="368" left="949" width="90" height="19" font="0">during pacing. </text>
<text top="496" left="95" width="99" height="19" font="0">Barthell E, et al. </text>
<text top="514" left="95" width="30" height="19" font="0">1988</text>
<text top="513" left="125" width="4" height="21" font="4"> </text>
<text top="514" left="129" width="35" height="19" font="0">(127) </text>
<text top="532" left="95" width="53" height="19" font="9"><a href="">3056132</a></text>
<text top="532" left="148" width="3" height="19" font="0"><a href=""> </a></text>
<text top="496" left="216" width="130" height="19" font="8"><b>Aim:</b> To determine if </text>
<text top="514" left="216" width="120" height="19" font="0">prehospital cardiac </text>
<text top="532" left="216" width="150" height="19" font="0">pacing affects mortality  </text>
<text top="551" left="216" width="3" height="19" font="0"> </text>
<text top="569" left="216" width="109" height="19" font="8"><b>Study type:</b> RCT)  </text>
<text top="587" left="216" width="3" height="19" font="0"> </text>
<text top="605" left="216" width="105" height="19" font="8"><b>Size:</b> N=239; 226 </text>
<text top="624" left="216" width="142" height="19" font="0">pulseless (asystole and </text>
<text top="642" left="216" width="91" height="19" font="0">EMD); 13 with </text>
<text top="661" left="216" width="111" height="19" font="0">hemodynamically </text>
<text top="679" left="216" width="141" height="19" font="0">significant bradycardia<b> </b></text>
<text top="496" left="378" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="514" left="378" width="111" height="19" font="0">hemodynamically </text>
<text top="532" left="378" width="145" height="19" font="0">significant bradycardia  </text>
<text top="551" left="378" width="3" height="19" font="0"> </text>
<text top="569" left="378" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="496" left="560" width="186" height="19" font="8"><b>Intervention:</b> Transcutaneous </text>
<text top="514" left="560" width="43" height="19" font="0">pacing </text>
<text top="532" left="560" width="7" height="19" font="0">  </text>
<text top="551" left="560" width="119" height="19" font="8"><b>Comparator:</b> ACLS <b> </b></text>
<text top="496" left="776" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="515" left="776" width="117" height="19" font="0">hospital admission </text>
<text top="533" left="776" width="143" height="19" font="0">(21.4% in pacing group </text>
<text top="551" left="776" width="141" height="19" font="0">vs. 20.6%) and survival </text>
<text top="570" left="776" width="136" height="19" font="0">to discharge (6.8% vs. </text>
<text top="588" left="776" width="38" height="19" font="0">4.4%) </text>
<text top="606" left="776" width="3" height="19" font="0"> </text>
<text top="624" left="776" width="143" height="19" font="8"><b>Safety endpoint:</b> None </text>
<text top="643" left="776" width="3" height="19" font="8"><b> </b></text>
<text top="496" left="938" width="149" height="20" font="0">• Randomization by day </text>
<text top="515" left="938" width="112" height="20" font="0">• No difference in </text>
<text top="534" left="949" width="131" height="19" font="0">rhythm subgroups of </text>
<text top="552" left="949" width="106" height="19" font="0">asystole vs. EMD </text>
<text top="571" left="938" width="138" height="20" font="0">• Improved survival in </text>
<text top="590" left="949" width="78" height="19" font="0">hypotensive </text>
<text top="608" left="949" width="143" height="19" font="0">bradycardic group (6/6 </text>
<text top="626" left="949" width="106" height="19" font="0">resuscitated, 5/6 </text>
<text top="645" left="949" width="129" height="19" font="0">survived, vs. 2/7 and </text>
<text top="663" left="949" width="82" height="19" font="0">1/7 controls) </text>
<text top="698" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="720" left="86" width="946" height="23" font="5"><b>Data Supplement 21. Nonrandomized Trials, Observational Studies, and/or Registries of Transcutaneous Pacing (Section 5.3.3) </b></text>
<text top="742" left="111" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="761" left="137" width="51" height="19" font="8"><b>Author; </b></text>
<text top="779" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="742" left="282" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="761" left="311" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="742" left="480" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="742" left="646" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="761" left="676" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="779" left="708" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="742" left="908" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="761" left="937" width="80" height="19" font="8"><b>Comment(s) </b></text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 88 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="104" height="19" font="0">Sherbino J, et al. </text>
<text top="105" left="95" width="30" height="19" font="0">2006</text>
<text top="104" left="125" width="4" height="21" font="4"> </text>
<text top="105" left="129" width="35" height="19" font="0">(128)<b> </b></text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16814446">16814446</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16814446"> </a></text>
<text top="87" left="243" width="188" height="19" font="8"><b>Study type:</b> Systematic review </text>
<text top="105" left="243" width="106" height="19" font="0">of the efficacy of </text>
<text top="123" left="243" width="180" height="19" font="0">transcutaneous pacing in the </text>
<text top="142" left="243" width="183" height="19" font="0">management of symptomatic </text>
<text top="160" left="243" width="192" height="19" font="0">bradycardia and bradyasystolic </text>
<text top="178" left="243" width="196" height="19" font="0">arrest in the prehospital setting </text>
<text top="197" left="243" width="3" height="19" font="0"> </text>
<text top="215" left="243" width="90" height="19" font="8"><b>Size:</b> 7 studies </text>
<text top="87" left="459" width="143" height="19" font="8"><b>Inclusion criteria:</b> Case </text>
<text top="105" left="459" width="132" height="19" font="0">series, RCTs, and one </text>
<text top="123" left="459" width="128" height="19" font="0">subgroup analysis of </text>
<text top="142" left="459" width="156" height="19" font="0">transcutaneous pacing in </text>
<text top="160" left="459" width="159" height="19" font="0">symptomatic bradycardia </text>
<text top="178" left="459" width="150" height="19" font="0">or bradyasystolic arrest. </text>
<text top="197" left="459" width="138" height="19" font="0">inclusion criteria were </text>
<text top="215" left="459" width="70" height="19" font="0">euthermic, </text>
<text top="233" left="459" width="146" height="19" font="0">nontraumatized adults, </text>
<text top="252" left="459" width="108" height="19" font="0">who experienced </text>
<text top="270" left="459" width="73" height="19" font="0">prehospital </text>
<text top="288" left="459" width="111" height="19" font="0">hemodynamically </text>
<text top="307" left="459" width="159" height="19" font="0">symptomatic bradycardia </text>
<text top="325" left="459" width="154" height="19" font="0">or bradyasystolic cardiac </text>
<text top="343" left="459" width="127" height="19" font="0">arrest. Symptomatic </text>
<text top="362" left="459" width="153" height="19" font="0">bradycardia was defined </text>
<text top="380" left="459" width="139" height="19" font="0">a priori as a heart rate </text>
<text top="398" left="459" width="149" height="19" font="0">less than 60 bpm and at </text>
<text top="417" left="459" width="163" height="19" font="0">least one of the following: </text>
<text top="435" left="459" width="143" height="19" font="0">systolic BP less than 80 </text>
<text top="453" left="459" width="124" height="19" font="0">mm Hg; a change in </text>
<text top="472" left="459" width="135" height="19" font="0">mental status; angina </text>
<text top="490" left="459" width="110" height="19" font="0">pectoris; or acute </text>
<text top="508" left="459" width="134" height="19" font="0">pulmonary oedema.8 </text>
<text top="526" left="459" width="138" height="19" font="0">Bradyasystolic cardiac </text>
<text top="545" left="459" width="157" height="19" font="0">arrest was defined as the </text>
<text top="563" left="459" width="136" height="19" font="0">absence of a palpable </text>
<text top="581" left="459" width="149" height="19" font="0">pulse in the presence of </text>
<text top="600" left="459" width="148" height="19" font="0">an electrocardiographic </text>
<text top="618" left="459" width="147" height="19" font="0">bradycardic or asystolic </text>
<text top="636" left="459" width="52" height="19" font="0">rhythm. </text>
<text top="654" left="459" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="635" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to hospital </text>
<text top="106" left="635" width="62" height="19" font="0">discharge </text>
<text top="124" left="635" width="3" height="19" font="0"> </text>
<text top="143" left="635" width="204" height="19" font="8"><b>Results:</b> No difference in survival </text>
<text top="161" left="635" width="197" height="19" font="0">to hospital discharge was noted </text>
<text top="179" left="635" width="207" height="19" font="0">in bradyasystolic cardiac arrest. A </text>
<text top="198" left="635" width="210" height="19" font="0">subgroup analysis in symptomatic </text>
<text top="216" left="635" width="164" height="19" font="0">bradycardia study showed </text>
<text top="234" left="635" width="196" height="19" font="0">borderline improved survival to </text>
<text top="252" left="635" width="66" height="19" font="0">discharge. </text>
<text top="271" left="635" width="3" height="19" font="0"> </text>
<text top="87" left="857" width="200" height="20" font="0">• Evidence to support the use of </text>
<text top="106" left="868" width="180" height="19" font="0">transcutaneous pacing in the </text>
<text top="124" left="868" width="222" height="19" font="0">prehospital setting for symptomatic </text>
<text top="143" left="868" width="163" height="19" font="0">bradycardia is insufficient. </text>
<text top="161" left="857" width="197" height="20" font="0">• Symptomatic bradycardia was </text>
<text top="180" left="868" width="218" height="19" font="0">defined as a heart rate less than 60 </text>
<text top="198" left="868" width="219" height="19" font="0">bpm and at least one of: systolic BP </text>
<text top="217" left="868" width="185" height="19" font="0">&lt;80 mm Hg, change in mental </text>
<text top="235" left="868" width="227" height="19" font="0">status, angina, or pulmonary edema; </text>
<text top="253" left="868" width="182" height="19" font="0">the relevance to acute SND is </text>
<text top="272" left="868" width="114" height="19" font="0">therefore unclear. </text>
<text top="674" left="95" width="102" height="19" font="0">Hedges JR, et al. </text>
<text top="692" left="95" width="30" height="19" font="0">1991</text>
<text top="691" left="125" width="4" height="21" font="4"> </text>
<text top="692" left="129" width="35" height="19" font="0">(129) </text>
<text top="710" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1721129">1721129</a></text>
<text top="710" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1721129"> </a></text>
<text top="673" left="243" width="142" height="19" font="8"><b>Aim:</b> To determine the </text>
<text top="692" left="243" width="180" height="19" font="0">importance of hemodynamic </text>
<text top="710" left="243" width="194" height="19" font="0">status and effect of prehospital </text>
<text top="728" left="243" width="178" height="19" font="0">transcutaneous pacing in pts </text>
<text top="747" left="243" width="189" height="19" font="0">with symptomatic bradycardia </text>
<text top="765" left="243" width="3" height="19" font="0"> </text>
<text top="783" left="243" width="163" height="19" font="8"><b>Study type:</b> Observational </text>
<text top="673" left="459" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="692" left="459" width="88" height="19" font="0">Witnessed CV </text>
<text top="710" left="459" width="132" height="19" font="0">decompensation and </text>
<text top="728" left="459" width="113" height="19" font="0">initial bradycardia </text>
<text top="747" left="459" width="3" height="19" font="0"> </text>
<text top="765" left="459" width="117" height="19" font="8"><b>Exclusion criteria:</b> <b> </b></text>
<text top="674" left="635" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to hospital </text>
<text top="693" left="635" width="66" height="19" font="0">discharge. </text>
<text top="711" left="635" width="3" height="19" font="0"> </text>
<text top="729" left="635" width="134" height="19" font="8"><b>Safety endpoint:</b> N/A </text>
<text top="674" left="857" width="192" height="20" font="0">• Survival to hospital discharge </text>
<text top="693" left="868" width="152" height="19" font="0">showed a trend towards </text>
<text top="711" left="868" width="208" height="19" font="0">improvement in the pacing group </text>
<text top="729" left="868" width="129" height="19" font="0">(15% vs. 0%; p=0.07) </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 89 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="243" width="3" height="19" font="0"> </text>
<text top="105" left="243" width="186" height="19" font="8"><b>Intervention:</b> Transcutaneous </text>
<text top="123" left="243" width="43" height="19" font="0">pacing </text>
<text top="142" left="243" width="3" height="19" font="0"> </text>
<text top="160" left="243" width="147" height="19" font="8"><b>Comparator</b>: No pacing </text>
<text top="178" left="243" width="3" height="19" font="0"> </text>
<text top="197" left="243" width="68" height="19" font="8"><b>Size:</b> N=51<b> </b></text>
<text top="87" left="857" width="12" height="20" font="4">• </text>
<text top="89" left="868" width="204" height="19" font="0">Pts with a palpable pulse on EMS </text>
<text top="107" left="868" width="208" height="19" font="0">arrival had better survival (80% in </text>
<text top="126" left="868" width="175" height="19" font="0">paced group vs. 0%; p= 0.02)</text>
<text top="124" left="1043" width="4" height="21" font="4"> </text>
<text top="216" left="95" width="121" height="19" font="0">Zoll PM, et al., 1985</text>
<text top="214" left="216" width="4" height="21" font="4"> </text>
<text top="234" left="95" width="35" height="19" font="0">(130) </text>
<text top="252" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886190">3886190</a></text>
<text top="252" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886190"> </a></text>
<text top="216" left="243" width="131" height="19" font="8"><b>Aim:</b> To evaluate the </text>
<text top="234" left="243" width="153" height="19" font="0">effectiveness of external </text>
<text top="252" left="243" width="102" height="19" font="0">noninvasive TCP </text>
<text top="271" left="243" width="3" height="19" font="0"> </text>
<text top="289" left="243" width="153" height="19" font="8"><b>Study type:</b> Prospective, </text>
<text top="307" left="243" width="185" height="19" font="0">observational, multicenter (3) </text>
<text top="326" left="243" width="3" height="19" font="0"> </text>
<text top="344" left="243" width="75" height="19" font="8"><b>Size:</b> N=134 </text>
<text top="216" left="459" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="234" left="459" width="127" height="19" font="0">requiring or likely to </text>
<text top="252" left="459" width="116" height="19" font="0">require temporary </text>
<text top="271" left="459" width="47" height="19" font="0">pacing. </text>
<text top="289" left="459" width="3" height="19" font="0"> </text>
<text top="307" left="459" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="217" left="635" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcomes </text>
<text top="235" left="635" width="3" height="19" font="0"> </text>
<text top="253" left="635" width="209" height="19" font="8"><b>Results:</b> TCP was well tolerated in </text>
<text top="272" left="635" width="210" height="19" font="0">73/82 awake pts, and successfully </text>
<text top="290" left="635" width="183" height="19" font="0">evoked response in 105/134.  </text>
<text top="216" left="857" width="164" height="20" font="0">• TCP was clinically useful. </text>
<text top="235" left="857" width="223" height="20" font="0">• Over 25% of enrolled subjects had </text>
<text top="254" left="868" width="196" height="19" font="0">SND as an indication for pacing. </text>
<text top="363" left="95" width="130" height="19" font="0">Clinton JE, et al. 1985</text>
<text top="362" left="225" width="4" height="21" font="4"> </text>
<text top="381" left="95" width="35" height="19" font="0">(131)<b> </b></text>
<text top="400" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3914511">3914511</a></text>
<text top="400" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3914511"> </a></text>
<text top="363" left="243" width="167" height="19" font="8"><b>Study type:</b> Observational, </text>
<text top="381" left="243" width="81" height="19" font="0">single center </text>
<text top="400" left="243" width="3" height="19" font="0"> </text>
<text top="418" left="243" width="71" height="19" font="8"><b>Size:</b> N=37  </text>
<text top="363" left="459" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="381" left="459" width="160" height="19" font="0">Emergency room pts with </text>
<text top="400" left="459" width="106" height="19" font="0">hypotension and </text>
<text top="418" left="459" width="76" height="19" font="0">bradycardia </text>
<text top="436" left="459" width="3" height="19" font="0"> </text>
<text top="454" left="459" width="144" height="19" font="8"><b>Exclusion criteria:</b> N/A  </text>
<text top="364" left="635" width="190" height="19" font="8"><b>1</b>°<b> endpoint:</b> Successful pacing </text>
<text top="382" left="635" width="167" height="19" font="0">capture and hemodynamic </text>
<text top="401" left="635" width="109" height="19" font="0">pacing response.  </text>
<text top="419" left="635" width="3" height="19" font="0"> </text>
<text top="437" left="635" width="141" height="19" font="8"><b>Results:</b> 8/37 pts were </text>
<text top="455" left="635" width="185" height="19" font="0">successfully treated with TCP. </text>
<text top="474" left="635" width="201" height="19" font="0">Surviving responders were more </text>
<text top="492" left="635" width="166" height="19" font="0">likely to present with sinus </text>
<text top="510" left="635" width="208" height="19" font="0">bradycardia, AF with bradycardia, </text>
<text top="529" left="635" width="187" height="19" font="0">or CHB, compared to asystole. </text>
<text top="363" left="857" width="162" height="20" font="0">• TCP can effectively treat </text>
<text top="382" left="868" width="177" height="19" font="0">hemodynamically significant </text>
<text top="401" left="868" width="223" height="19" font="0">bradycardia, but does not appear to </text>
<text top="419" left="868" width="131" height="19" font="0">be useful in asystole. </text>
<text top="437" left="857" width="219" height="20" font="0">• 2/37 pts had SND as an indication </text>
<text top="456" left="868" width="68" height="19" font="0">for pacing. </text>
<text top="548" left="86" width="3" height="19" font="8"><b> </b></text>
<text top="566" left="86" width="960" height="23" font="5"><b>Data Supplement 22. RCTs of General Principles of Chronic Therapy/Management of Bradycardia due to Sinus Node Dysfunction </b></text>
<text top="588" left="86" width="111" height="23" font="5"><b>(Section 5.4.1) </b></text>
<text top="591" left="198" width="3" height="19" font="8"><b> </b></text>
<text top="611" left="126" width="39" height="19" font="8"><b>Study </b></text>
<text top="629" left="119" width="64" height="19" font="8"><b>Acronym; </b></text>
<text top="647" left="125" width="51" height="19" font="8"><b>Author; </b></text>
<text top="666" left="96" width="100" height="19" font="8"><b>Year Published; </b></text>
<text top="684" left="132" width="38" height="19" font="8"><b>PMID </b></text>
<text top="611" left="223" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="629" left="229" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="647" left="222" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="611" left="372" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="611" left="550" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="629" left="589" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="647" left="552" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="666" left="594" width="59" height="19" font="8"><b>patients) </b></text>
<text top="611" left="756" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="629" left="712" width="197" height="19" font="8"><b>(Absolute Event Rates, P value; </b></text>
<text top="647" left="752" width="127" height="19" font="8"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="611" left="935" width="152" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="630" left="999" width="35" height="19" font="8"><b>any); </b></text>
<text top="648" left="953" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="666" left="961" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="703" left="95" width="45" height="19" font="8"><b>ADEPT </b></text>
<text top="721" left="95" width="101" height="19" font="0">Lamas GA, et al. </text>
<text top="740" left="95" width="69" height="19" font="0">2007 (132) </text>
<text top="758" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17765608">17765608</a></text>
<text top="758" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17765608"> </a></text>
<text top="703" left="209" width="51" height="19" font="8"><b>Aim:</b> To </text>
<text top="721" left="209" width="67" height="19" font="0">determine </text>
<text top="740" left="209" width="94" height="19" font="0">whether DDDR </text>
<text top="758" left="209" width="103" height="19" font="0">pacing improves </text>
<text top="776" left="209" width="67" height="19" font="0">QOL when </text>
<text top="703" left="338" width="178" height="19" font="8"><b>Inclusion criteria: </b>Age<b> </b>≥21 y, </text>
<text top="721" left="338" width="162" height="19" font="0">Class I or 2A indication for </text>
<text top="740" left="338" width="137" height="19" font="0">pacing, demonstrated </text>
<text top="758" left="338" width="177" height="19" font="0">chronotropic incompetence, </text>
<text top="703" left="540" width="118" height="19" font="8"><b>Intervention:</b> MDT </text>
<text top="721" left="540" width="107" height="19" font="0">Kappa 400 DDDR </text>
<text top="740" left="540" width="154" height="19" font="0">pacemaker programmed </text>
<text top="758" left="540" width="108" height="19" font="0">to DDDR (N=443) </text>
<text top="776" left="540" width="3" height="19" font="8"><b> </b></text>
<text top="703" left="709" width="201" height="20" font="0">• Total exercise time (6 mo): 7.3 </text>
<text top="722" left="721" width="123" height="19" font="0">vs. 7.1 min (p=0.98) </text>
<text top="741" left="709" width="196" height="20" font="0">• Specific Activity Scale (SAS) at </text>
<text top="760" left="721" width="144" height="19" font="0">1 y: 1.5 vs. 1.6 (p=0.96) </text>
<text top="703" left="925" width="171" height="20" font="0">• No differences in other 2° </text>
<text top="722" left="935" width="94" height="19" font="0">QOL endpoints </text>
<text top="741" left="925" width="152" height="20" font="0">• CHF hospitalizations in </text>
<text top="760" left="935" width="129" height="19" font="0">DDDR group vs. DDD </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 90 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="209" width="113" height="19" font="0">compared to DDD </text>
<text top="105" left="209" width="80" height="19" font="0">pacing alone </text>
<text top="123" left="209" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="209" width="112" height="19" font="8"><b>Study type: </b>Multi-</text>
<text top="160" left="209" width="83" height="19" font="0">center single-</text>
<text top="178" left="209" width="61" height="19" font="0">blind RCT </text>
<text top="197" left="209" width="3" height="19" font="8"><b> </b></text>
<text top="215" left="209" width="80" height="19" font="8"><b>Size:</b> 872 pts </text>
<text top="87" left="338" width="179" height="19" font="0">cannot exceed 80% of MPHR </text>
<text top="105" left="338" width="163" height="19" font="0">(220-age) at peak exercise<b> </b></text>
<text top="123" left="338" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="338" width="172" height="19" font="8"><b>Exclusion criteria:</b> AF for &gt;1 </text>
<text top="160" left="338" width="190" height="19" font="0">mo, overt CHF, serious chronic </text>
<text top="178" left="338" width="189" height="19" font="0">illness, score of &lt;17 on MMSE, </text>
<text top="197" left="338" width="180" height="19" font="0">inability to tolerate high-rate </text>
<text top="215" left="337" width="175" height="19" font="0">pacing, severe limitations of </text>
<text top="233" left="338" width="119" height="19" font="0">functional capacity </text>
<text top="87" left="540" width="115" height="19" font="8"><b>Comparator:</b> MDT </text>
<text top="105" left="540" width="107" height="19" font="0">Kappa 400 DDDR </text>
<text top="123" left="540" width="154" height="19" font="0">pacemaker programmed </text>
<text top="142" left="540" width="100" height="19" font="0">to DDD (N=429) </text>
<text top="160" left="540" width="3" height="19" font="0"> </text>
<text top="178" left="540" width="122" height="19" font="0">Mean follow-up 1 y </text>
<text top="197" left="540" width="85" height="19" font="0">64% had SND </text>
<text top="215" left="540" width="149" height="19" font="0">Vp% &gt;90 in both groups </text>
<text top="87" left="935" width="133" height="19" font="0">group: 7.3% vs. 3.5%; </text>
<text top="105" left="935" width="45" height="19" font="0">p=0.01 </text>
<text top="124" left="925" width="155" height="20" font="0">• No differences in other </text>
<text top="143" left="935" width="110" height="19" font="0">clinical endpoints </text>
<text top="252" left="95" width="70" height="19" font="8"><b>THEOPACE </b></text>
<text top="271" left="95" width="91" height="19" font="0">Alboni P, et al. </text>
<text top="289" left="95" width="69" height="19" font="0">1997 (133) </text>
<text top="307" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9236443">9236443</a></text>
<text top="307" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9236443"> </a></text>
<text top="252" left="209" width="51" height="19" font="8"><b>Aim:</b> To </text>
<text top="271" left="209" width="85" height="19" font="0">prospectively </text>
<text top="289" left="209" width="110" height="19" font="0">assess the effects </text>
<text top="307" left="209" width="80" height="19" font="0">of PPMs and </text>
<text top="326" left="209" width="95" height="19" font="0">theophylline in </text>
<text top="344" left="209" width="77" height="19" font="0">pts with SSS </text>
<text top="362" left="209" width="3" height="19" font="0"> </text>
<text top="381" left="209" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="399" left="209" width="79" height="19" font="0">Randomized </text>
<text top="417" left="209" width="94" height="19" font="0">controlled trial </text>
<text top="436" left="209" width="3" height="19" font="0"> </text>
<text top="454" left="209" width="80" height="19" font="8"><b>Size:</b> 107 pts </text>
<text top="252" left="338" width="178" height="19" font="8"><b>Inclusion criteria:</b> Age ≥45 y, </text>
<text top="271" left="338" width="172" height="19" font="0">mean resting sinus rate &lt;50 </text>
<text top="289" left="338" width="174" height="19" font="0">bpm and/or intermittent SA </text>
<text top="307" left="338" width="182" height="19" font="0">block, symptoms attributable </text>
<text top="326" left="338" width="46" height="19" font="0">to SND </text>
<text top="344" left="338" width="3" height="19" font="8"><b> </b></text>
<text top="362" left="338" width="187" height="19" font="8"><b>Exclusion criteria:</b> very severe </text>
<text top="381" left="338" width="178" height="19" font="0">SSS, refractory HF, recent MI </text>
<text top="399" left="338" width="189" height="19" font="0">or stroke, life expectancy &lt;2 y, </text>
<text top="417" left="338" width="165" height="19" font="0">significant renal or hepatic </text>
<text top="436" left="338" width="182" height="19" font="0">disease, Hx of VT, prior usage </text>
<text top="454" left="338" width="174" height="19" font="0">of theophylline, need for BB </text>
<text top="472" left="338" width="44" height="19" font="0">or CCB </text>
<text top="252" left="540" width="124" height="19" font="8"><b>Intervention 1:</b> oral </text>
<text top="271" left="540" width="142" height="19" font="0">theophylline 550 mg/d </text>
<text top="289" left="540" width="45" height="19" font="0">(N=36)<b> </b></text>
<text top="307" left="540" width="136" height="19" font="8"><b>Intervention 2:</b> DDDR </text>
<text top="326" left="540" width="131" height="19" font="0">PPM programmed to </text>
<text top="344" left="540" width="155" height="19" font="0">lower rate of 60–70 ppm </text>
<text top="362" left="540" width="149" height="19" font="0">and prolonged AV delay </text>
<text top="381" left="540" width="45" height="19" font="0">(N=36) </text>
<text top="399" left="540" width="3" height="19" font="8"><b> </b></text>
<text top="417" left="540" width="104" height="19" font="8"><b>Comparator:</b> No </text>
<text top="436" left="540" width="110" height="19" font="0">treatment (N=35) </text>
<text top="454" left="540" width="3" height="19" font="0"> </text>
<text top="472" left="540" width="142" height="19" font="0">Mean follow-up 19±14 </text>
<text top="491" left="540" width="23" height="19" font="0">mo </text>
<text top="253" left="709" width="120" height="20" font="0">• Syncope: 6 (17%) </text>
<text top="272" left="721" width="169" height="19" font="0">theophylline, 2(6%) PPM, 8 </text>
<text top="290" left="721" width="163" height="19" font="0">(23%) control arm: p=0.02 </text>
<text top="308" left="721" width="157" height="19" font="0">(PPM vs. control); p=0.07 </text>
<text top="326" left="721" width="156" height="19" font="0">(theophylline vs. control) </text>
<text top="345" left="709" width="196" height="20" font="0">• HF: 1(3%) theophylline, 1(3%) </text>
<text top="364" left="721" width="161" height="19" font="0">PPM, 6(17%) control arm: </text>
<text top="382" left="721" width="180" height="19" font="0">p=0.05 (lower HF in PPM and </text>
<text top="401" left="721" width="175" height="19" font="0">theophylline vs. control arm </text>
<text top="419" left="709" width="145" height="20" font="0">• Permanent AF: 2(6%) </text>
<text top="438" left="721" width="158" height="19" font="0">theophylline, 3(9%) PPM, </text>
<text top="456" left="721" width="144" height="19" font="0">4(11%) control arm: no </text>
<text top="475" left="721" width="110" height="19" font="0">difference (p=NS) </text>
<text top="253" left="925" width="134" height="20" font="0">• Thromboembolism: </text>
<text top="272" left="935" width="161" height="19" font="0">3(9%) theophylline, 3(9%) </text>
<text top="290" left="935" width="153" height="19" font="0">PPM, 1(3%) control arm: </text>
<text top="308" left="935" width="129" height="19" font="0">no difference (p=NS) </text>
<text top="509" left="86" width="3" height="19" font="0"> </text>
<text top="528" left="86" width="879" height="23" font="5"><b>Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of General Principles of Chronic </b></text>
<text top="550" left="86" width="636" height="23" font="5"><b>Therapy/Management of Bradycardia due to Sinus Node Dysfunction (Section 5.4.1)  </b></text>
<text top="573" left="96" width="113" height="21" font="2"><b>Study Acronym; </b></text>
<text top="593" left="124" width="56" height="21" font="2"><b>Author; </b></text>
<text top="613" left="99" width="106" height="21" font="2"><b>Year Published </b></text>
<text top="573" left="225" width="137" height="21" font="2"><b>Study Type/Design; </b></text>
<text top="593" left="257" width="73" height="21" font="2"><b>Study Size </b></text>
<text top="573" left="407" width="132" height="21" font="2"><b>Patient Population </b></text>
<text top="573" left="593" width="206" height="21" font="2"><b>Primary Endpoint and Results </b></text>
<text top="593" left="626" width="143" height="21" font="2"><b>(P values; OR or RR;  </b></text>
<text top="613" left="661" width="70" height="21" font="2"><b>&amp; 95% CI) </b></text>
<text top="573" left="840" width="151" height="21" font="2"><b>Summary/Conclusion </b></text>
<text top="593" left="840" width="88" height="21" font="2"><b>Comment(s) </b></text>
<text top="634" left="95" width="89" height="19" font="0">Sasaki Y, et al. </text>
<text top="652" left="95" width="69" height="19" font="0">1988 (134) </text>
<text top="670" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2462243">2462243</a></text>
<text top="669" left="148" width="4" height="21" font="2"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2462243"><b> </b></a></text>
<text top="634" left="222" width="129" height="19" font="0">Long-term follow-up </text>
<text top="652" left="222" width="93" height="19" font="0">of pts with SSS </text>
<text top="670" left="222" width="3" height="19" font="8"><b> </b></text>
<text top="689" left="222" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="707" left="222" width="118" height="19" font="0">Prospective cohort </text>
<text top="725" left="222" width="3" height="19" font="8"><b> </b></text>
<text top="743" left="222" width="69" height="19" font="8"><b>Size:</b> 49 pts</text>
<text top="742" left="291" width="4" height="21" font="2"><b> </b></text>
<text top="634" left="378" width="188" height="19" font="8"><b>Inclusion criteria:</b> Pts with SSS </text>
<text top="652" left="378" width="187" height="19" font="0">who underwent EPS and were </text>
<text top="670" left="378" width="116" height="19" font="0">symptomatic from </text>
<text top="689" left="378" width="161" height="19" font="0">bradycardia and requiring </text>
<text top="707" left="378" width="149" height="19" font="0">pacing, sinus pause &gt;3 s </text>
<text top="725" left="378" width="68" height="19" font="0">during EPS </text>
<text top="744" left="378" width="3" height="19" font="0"> </text>
<text top="762" left="378" width="138" height="19" font="8"><b>Exclusion criteria: </b>N/A</text>
<text top="760" left="516" width="4" height="21" font="2"><b> </b></text>
<text top="634" left="581" width="52" height="19" font="8"><b>Results: </b></text>
<text top="652" left="581" width="192" height="20" font="0">• VVI pacing – 25 pts; atrial/DC </text>
<text top="671" left="591" width="95" height="19" font="0">pacing – 24 pts </text>
<text top="690" left="581" width="199" height="20" font="0">• Chronic AF: VVI vs. physiologic </text>
<text top="709" left="591" width="212" height="19" font="0">pacing group (36% vs. 0%; p&lt;0.01) </text>
<text top="727" left="581" width="12" height="20" font="4">• </text>
<text top="729" left="591" width="168" height="19" font="0">Thromboembolism: VVI vs. </text>
<text top="747" left="591" width="208" height="19" font="0">physiologic pacing group (20% vs. </text>
<text top="766" left="591" width="72" height="19" font="0">0%; p&lt;0.05)</text>
<text top="764" left="664" width="4" height="21" font="2"><b> </b></text>
<text top="634" left="823" width="12" height="20" font="4">• </text>
<text top="636" left="834" width="232" height="19" font="0">In this group of pts with SSS requiring </text>
<text top="654" left="834" width="240" height="19" font="0">PPM, mode of pacing did not influence </text>
<text top="673" left="834" width="231" height="19" font="0">the survival rate; however, CV deaths </text>
<text top="691" left="834" width="226" height="19" font="0">were fewer in the physiologic pacing </text>
<text top="709" left="834" width="40" height="19" font="0">group.</text>
<text top="708" left="874" width="4" height="21" font="2"><b> </b></text>
<text top="728" left="823" width="4" height="21" font="2"><b> </b></text>
<text top="748" left="823" width="12" height="20" font="4">• </text>
<text top="750" left="834" width="259" height="19" font="0">There were significantly higher incidences </text>
<text top="768" left="834" width="242" height="19" font="0">of chronic AF and thromboembolism in </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 91 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="581" width="12" height="20" font="4">• </text>
<text top="89" left="591" width="189" height="19" font="0">No difference in HF occurrence</text>
<text top="88" left="781" width="4" height="21" font="2"><b> </b></text>
<text top="87" left="834" width="237" height="19" font="0">the VVI group although this group was </text>
<text top="105" left="834" width="250" height="19" font="0">followed for a significantly longer period </text>
<text top="123" left="834" width="256" height="19" font="0">of time than the physiologic pacing group </text>
<text top="142" left="834" width="158" height="19" font="0">(35.1 vs. 19.7 mo; p&lt;0.01)</text>
<text top="140" left="992" width="4" height="21" font="2"><b> </b></text>
<text top="161" left="95" width="105" height="19" font="0">Goldberger JJ, et </text>
<text top="179" left="95" width="87" height="19" font="0">al. 2011 (135) </text>
<text top="197" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21757182">21757182</a></text>
<text top="196" left="156" width="4" height="21" font="2"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21757182"><b> </b></a></text>
<text top="161" left="222" width="114" height="19" font="0">Significance of asx </text>
<text top="179" left="222" width="97" height="19" font="0">bradycardia for </text>
<text top="197" left="222" width="99" height="19" font="0">subsequent PM </text>
<text top="216" left="222" width="108" height="19" font="0">implantation and </text>
<text top="234" left="222" width="122" height="19" font="0">mortality in pts age </text>
<text top="252" left="222" width="40" height="19" font="0">&gt;60 y  </text>
<text top="271" left="222" width="3" height="19" font="0"> </text>
<text top="289" left="222" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="307" left="222" width="131" height="19" font="0">Retrospective cohort </text>
<text top="326" left="222" width="3" height="19" font="0"> </text>
<text top="344" left="222" width="88" height="19" font="8"><b>Size:</b> 2,560 pts</text>
<text top="342" left="310" width="4" height="21" font="2"><b> </b></text>
<text top="161" left="378" width="178" height="19" font="8"><b>Inclusion criteria:</b> Age &gt;60 y, </text>
<text top="179" left="378" width="167" height="19" font="0">resting heart rate &lt;55 bpm </text>
<text top="197" left="378" width="188" height="19" font="0">(bradycardia group, N=470) or </text>
<text top="216" left="378" width="163" height="19" font="0">heart rate between 60–70 </text>
<text top="234" left="378" width="185" height="19" font="0">bpm (control group, N=2,090) </text>
<text top="252" left="378" width="3" height="19" font="0"> </text>
<text top="271" left="378" width="145" height="19" font="8"><b>Exclusion criteria:</b> PPM </text>
<text top="289" left="378" width="171" height="19" font="0">implantation within 2 wk of </text>
<text top="307" left="378" width="182" height="19" font="0">initial EKG, heart rate outside </text>
<text top="326" left="378" width="103" height="19" font="0">the above range </text>
<text top="344" left="378" width="163" height="19" font="0">Mean follow-up 7.2 ± 2.9 y</text>
<text top="342" left="541" width="4" height="21" font="2"><b> </b></text>
<text top="161" left="581" width="52" height="19" font="8"><b>Results: </b></text>
<text top="179" left="581" width="12" height="20" font="4">• </text>
<text top="182" left="591" width="218" height="19" font="0">Incidence of PPM placement: 9% in </text>
<text top="200" left="591" width="176" height="19" font="0">bradycardia cohort vs. 5% in </text>
<text top="218" left="591" width="140" height="19" font="0">control group; p&lt;0.001</text>
<text top="217" left="731" width="4" height="21" font="2"><b> </b></text>
<text top="237" left="581" width="12" height="20" font="4">• </text>
<text top="239" left="591" width="212" height="19" font="0">Protection against mortality in the </text>
<text top="257" left="591" width="208" height="19" font="0">bradycardia group (HR: 0.78; 95% </text>
<text top="275" left="591" width="141" height="19" font="0">CI: 0.65–0.94; p=0.010)</text>
<text top="274" left="733" width="4" height="21" font="2"><b> </b></text>
<text top="161" left="823" width="260" height="20" font="0">• Higher incidence of PPM implantation in </text>
<text top="180" left="834" width="232" height="19" font="0">the bradycardia group did not appear </text>
<text top="198" left="834" width="140" height="19" font="0">until after the first 4 y. </text>
<text top="217" left="823" width="12" height="20" font="4">• </text>
<text top="219" left="834" width="242" height="19" font="0">Older outpatients with bradycardia not </text>
<text top="237" left="834" width="249" height="19" font="0">requiring urgent PPM implantation have </text>
<text top="256" left="834" width="256" height="19" font="0">very low rate (&lt;1%/y) of subsequent PPM </text>
<text top="274" left="834" width="82" height="19" font="0">implantation.</text>
<text top="272" left="916" width="4" height="21" font="2"><b> </b></text>
<text top="292" left="823" width="12" height="20" font="4">• </text>
<text top="294" left="834" width="262" height="19" font="0">Asymptomatic bradycardia has no adverse </text>
<text top="313" left="834" width="236" height="19" font="0">impact on all-cause mortality and may </text>
<text top="331" left="834" width="118" height="19" font="0">even be protective.</text>
<text top="330" left="952" width="4" height="21" font="2"><b> </b></text>
<text top="363" left="95" width="109" height="19" font="0">Denniss AR, et al. </text>
<text top="381" left="95" width="62" height="19" font="0">1992 (75) </text>
<text top="400" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1572741">1572741</a></text>
<text top="398" left="148" width="4" height="21" font="2"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1572741"><b> </b></a></text>
<text top="363" left="222" width="114" height="19" font="0">Electrophysiologic </text>
<text top="381" left="222" width="114" height="19" font="0">studies in pts with </text>
<text top="400" left="222" width="132" height="19" font="0">unexplained syncope </text>
<text top="418" left="222" width="3" height="19" font="8"><b> </b></text>
<text top="436" left="222" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="455" left="222" width="118" height="19" font="0">Prospective cohort </text>
<text top="473" left="222" width="3" height="19" font="8"><b> </b></text>
<text top="491" left="222" width="77" height="19" font="8"><b>Size:</b> 111 pts</text>
<text top="490" left="299" width="4" height="21" font="2"><b> </b></text>
<text top="363" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="381" left="378" width="170" height="19" font="0">Unexplained syncope, prior </text>
<text top="400" left="378" width="168" height="19" font="0">general medical evaluation </text>
<text top="418" left="378" width="177" height="19" font="0">(H&amp;P, CXR, echo, LHC, neuro </text>
<text top="436" left="378" width="160" height="19" font="0">exam, heart monitor, etc) </text>
<text top="454" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="473" left="378" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="491" left="378" width="136" height="19" font="0">Documented tachy or </text>
<text top="509" left="378" width="145" height="19" font="0">bradyarrhythmia, Dx of </text>
<text top="528" left="378" width="174" height="19" font="0">vasovagal syncope, postural </text>
<text top="546" left="378" width="166" height="19" font="0">hypotension, AS, HOCM or </text>
<text top="565" left="378" width="137" height="19" font="0">prolonged QT interval </text>
<text top="583" left="378" width="3" height="19" font="0"> </text>
<text top="601" left="378" width="139" height="19" font="0">Mean follow-up 20 mo</text>
<text top="600" left="517" width="4" height="21" font="2"><b> </b></text>
<text top="363" left="581" width="52" height="19" font="8"><b>Results: </b></text>
<text top="382" left="581" width="204" height="20" font="0">• No mortality within 30 d of EPS<b> </b></text>
<text top="401" left="581" width="219" height="20" font="0">• Pts with heart disease (CAD, HTN, </text>
<text top="420" left="591" width="219" height="19" font="0">MVP, CMP) had higher incidence of </text>
<text top="438" left="591" width="190" height="19" font="0">conduction disease (26%) than </text>
<text top="456" left="591" width="180" height="19" font="0">those w/o heart disease (8%; </text>
<text top="475" left="591" width="50" height="19" font="0">p&lt;0.05)<b> </b></text>
<text top="493" left="581" width="228" height="20" font="0">• Abnormal EPS (conduction disease, </text>
<text top="512" left="591" width="218" height="19" font="0">SVT, VT) findings in 42% of pts with </text>
<text top="530" left="591" width="204" height="19" font="0">heart disease but 16% of pts w/o </text>
<text top="549" left="591" width="139" height="19" font="0">heart disease (p&lt;0.01)<b> </b></text>
<text top="567" left="581" width="12" height="20" font="4">• </text>
<text top="569" left="591" width="194" height="19" font="0">Syncope occurred in only 5% of </text>
<text top="587" left="591" width="215" height="19" font="0">treated pts with abnormal findings </text>
<text top="606" left="591" width="192" height="19" font="0">at EPS vs. 24% in the group not </text>
<text top="624" left="591" width="153" height="19" font="0">receiving any Rx (p&lt;0.05)</text>
<text top="623" left="744" width="4" height="21" font="2"><b> </b></text>
<text top="643" left="581" width="12" height="20" font="4">• </text>
<text top="645" left="591" width="191" height="19" font="0">No recurrent syncope in 27 pts </text>
<text top="663" left="591" width="192" height="19" font="0">treated with PPM vs. recurrent </text>
<text top="681" left="591" width="206" height="19" font="0">syncope in 20 of 84 pts (24%) not </text>
<text top="700" left="591" width="119" height="19" font="0">given PPM (p&lt;0.05)</text>
<text top="698" left="710" width="4" height="21" font="2"><b> </b></text>
<text top="363" left="823" width="12" height="20" font="4">• </text>
<text top="365" left="834" width="252" height="19" font="0">Diagnostic yield of EPS is increased in pts </text>
<text top="384" left="834" width="116" height="19" font="0">with heart disease.</text>
<text top="382" left="950" width="4" height="21" font="2"><b> </b></text>
<text top="402" left="823" width="12" height="20" font="4">• </text>
<text top="404" left="834" width="202" height="19" font="0">Pts with no heart disease had no </text>
<text top="423" left="834" width="60" height="19" font="0">mortality.</text>
<text top="421" left="894" width="4" height="21" font="2"><b> </b></text>
<text top="719" left="95" width="99" height="19" font="0">Teichman SL, et </text>
<text top="737" left="95" width="87" height="19" font="0">al. 1985 (136) </text>
<text top="755" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4025122">4025122</a></text>
<text top="754" left="148" width="4" height="21" font="2"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4025122"><b> </b></a></text>
<text top="719" left="222" width="118" height="19" font="0">The value of EPS in </text>
<text top="737" left="222" width="69" height="19" font="0">syncope of </text>
<text top="755" left="222" width="133" height="19" font="0">undetermined origin: </text>
<text top="774" left="222" width="123" height="19" font="0">Report of 150 cases </text>
<text top="719" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="737" left="378" width="168" height="19" font="0">Pts with syncopal and near-</text>
<text top="755" left="378" width="139" height="19" font="0">syncopal events (SUO) </text>
<text top="774" left="378" width="160" height="19" font="0">unexplained after general </text>
<text top="719" left="581" width="219" height="20" font="0">• EP abnormality that could explain </text>
<text top="738" left="591" width="207" height="19" font="0">SUO was demonstrated in 36% of </text>
<text top="756" left="591" width="22" height="19" font="0">pts<b> </b></text>
<text top="719" left="823" width="219" height="20" font="0">• Presence of organic heart disease </text>
<text top="738" left="834" width="240" height="19" font="0">increased the incidence of positive EPS </text>
<text top="756" left="834" width="49" height="19" font="0">finding. </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 92 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="222" width="3" height="19" font="8"><b> </b></text>
<text top="105" left="222" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="123" left="222" width="118" height="19" font="0">Prospective cohort </text>
<text top="142" left="222" width="3" height="19" font="8"><b> </b></text>
<text top="160" left="222" width="77" height="19" font="8"><b>Size:</b> 150 pts</text>
<text top="159" left="299" width="4" height="21" font="2"><b> </b></text>
<text top="87" left="378" width="162" height="19" font="0">medical evaluation, neuro </text>
<text top="105" left="378" width="176" height="19" font="0">evaluation, CXR, orthostatic, </text>
<text top="123" left="378" width="155" height="19" font="0">CSM, continuous rhythm </text>
<text top="142" left="378" width="170" height="19" font="0">monitoring for at least 24 h </text>
<text top="160" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="178" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="197" left="378" width="157" height="19" font="0">Heart block, bradycardia, </text>
<text top="215" left="378" width="179" height="19" font="0">pauses &gt;2.5 s, PVCs, VT, SVT, </text>
<text top="233" left="378" width="71" height="19" font="0">orthostasis </text>
<text top="252" left="378" width="3" height="19" font="0"> </text>
<text top="270" left="378" width="139" height="19" font="0">Mean follow-up 31 mo</text>
<text top="268" left="517" width="4" height="21" font="2"><b> </b></text>
<text top="87" left="581" width="219" height="20" font="0">• Presence of organic heart disease </text>
<text top="106" left="591" width="218" height="19" font="0">was associated with increase in the </text>
<text top="124" left="591" width="212" height="19" font="0">incidence of EP findings (85% with </text>
<text top="143" left="591" width="214" height="19" font="0">vs. 64% w/o organic heart disease; </text>
<text top="161" left="591" width="57" height="19" font="0">p&lt;0.005)<b> </b></text>
<text top="179" left="581" width="12" height="20" font="4">• </text>
<text top="182" left="591" width="208" height="19" font="0">Pts with LBBB were more likely to </text>
<text top="200" left="591" width="204" height="19" font="0">have abnormal EPS than pts with </text>
<text top="218" left="591" width="87" height="19" font="0">RBBB (p&lt;0.02)</text>
<text top="217" left="678" width="4" height="21" font="2"><b> </b></text>
<text top="87" left="823" width="12" height="20" font="4">• </text>
<text top="89" left="834" width="249" height="19" font="0">Pts who had EPS abnormalities detected </text>
<text top="107" left="834" width="252" height="19" font="0">and treated had had fewer recurrence of </text>
<text top="126" left="834" width="211" height="19" font="0">SUO than those with negative EPS.</text>
<text top="124" left="1045" width="4" height="21" font="2"><b> </b></text>
<text top="144" left="823" width="12" height="20" font="4">• </text>
<text top="146" left="834" width="242" height="19" font="0">SUO pts overall had low mortality rates </text>
<text top="165" left="834" width="143" height="19" font="0">during follow-up (±EPS)</text>
<text top="163" left="977" width="4" height="21" font="2"><b> </b></text>
<text top="289" left="95" width="81" height="19" font="0">Seidl K, et al. </text>
<text top="307" left="95" width="69" height="19" font="0">2000 (137) </text>
<text top="326" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11227598">11227598</a></text>
<text top="324" left="156" width="4" height="21" font="2"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11227598"><b> </b></a></text>
<text top="289" left="222" width="141" height="19" font="0">Diagnostic assessment </text>
<text top="307" left="222" width="77" height="19" font="0">of recurrent </text>
<text top="326" left="222" width="132" height="19" font="0">unexplained syncope </text>
<text top="344" left="222" width="71" height="19" font="0">with a new </text>
<text top="362" left="222" width="120" height="19" font="0">subcutaneously ILR </text>
<text top="381" left="222" width="3" height="19" font="8"><b> </b></text>
<text top="399" left="222" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="417" left="222" width="118" height="19" font="0">Prospective cohort </text>
<text top="436" left="222" width="3" height="19" font="0"> </text>
<text top="454" left="222" width="77" height="19" font="8"><b>Size:</b> 133 pts</text>
<text top="452" left="299" width="4" height="21" font="2"><b> </b></text>
<text top="289" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="307" left="378" width="142" height="19" font="0">Recurrent unexplained </text>
<text top="326" left="378" width="121" height="19" font="0">syncope with initial </text>
<text top="344" left="378" width="177" height="19" font="0">nondiagnostic investigations </text>
<text top="362" left="378" width="118" height="19" font="0">(resting EKG, echo, </text>
<text top="381" left="378" width="157" height="19" font="0">ambulatory monitor, etc) </text>
<text top="399" left="378" width="3" height="19" font="0"> </text>
<text top="417" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="436" left="378" width="36" height="19" font="0">None </text>
<text top="454" left="378" width="3" height="19" font="0"> </text>
<text top="472" left="378" width="150" height="19" font="0">Mean follow-up 10.8 mo</text>
<text top="471" left="528" width="4" height="21" font="2"><b> </b></text>
<text top="289" left="581" width="228" height="20" font="0">• Device-related complications in 9% </text>
<text top="308" left="581" width="225" height="20" font="0">• Definite determination of whether </text>
<text top="327" left="591" width="216" height="19" font="0">arrhythmia was the cause or not in </text>
<text top="346" left="591" width="71" height="19" font="0">54% of pts. </text>
<text top="364" left="581" width="12" height="20" font="4">• </text>
<text top="366" left="591" width="209" height="19" font="0">87% diagnostic yield (72 out of 83 </text>
<text top="384" left="591" width="23" height="19" font="0">pts)</text>
<text top="383" left="615" width="4" height="21" font="2"><b> </b></text>
<text top="403" left="581" width="12" height="20" font="4">• </text>
<text top="405" left="591" width="219" height="19" font="0">Arrhythmic cause of syncope found </text>
<text top="423" left="591" width="83" height="19" font="0">in 44% of pts.</text>
<text top="422" left="674" width="4" height="21" font="2"><b> </b></text>
<text top="289" left="823" width="12" height="20" font="4">• </text>
<text top="291" left="834" width="239" height="19" font="0">ILR is useful for establishing a Dx when </text>
<text top="310" left="834" width="200" height="19" font="0">symptoms are recurrent but too </text>
<text top="328" left="834" width="248" height="19" font="0">infrequent for conventional noninvasive </text>
<text top="346" left="834" width="72" height="19" font="0">monitoring.</text>
<text top="345" left="906" width="4" height="21" font="2"><b> </b></text>
<text top="491" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="513" left="86" width="822" height="23" font="5"><b>Data Supplement 24. RCTs of Clinical Presentation of Bradycardia due to Sinus Node Dysfunction (Section 5.3) </b></text>
<text top="536" left="101" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="554" left="132" width="51" height="19" font="8"><b>Author; </b></text>
<text top="572" left="102" width="100" height="19" font="8"><b>Year Published; </b></text>
<text top="591" left="139" width="38" height="19" font="8"><b>PMID </b></text>
<text top="536" left="230" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="554" left="235" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="572" left="229" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="536" left="348" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="536" left="502" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="554" left="541" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="572" left="504" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="591" left="546" width="59" height="19" font="8"><b>patients) </b></text>
<text top="536" left="702" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="554" left="679" width="156" height="19" font="8"><b>(Absolute Event Rates, P </b></text>
<text top="572" left="678" width="168" height="19" font="8"><b>value; OR or RR; &amp; 95% CI) </b></text>
<text top="537" left="887" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="555" left="922" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="573" left="931" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="610" left="95" width="64" height="19" font="8"><b>DANPACE </b></text>
<text top="628" left="95" width="102" height="19" font="0">Nielsen JC, et al. </text>
<text top="647" left="95" width="30" height="19" font="0">2011</text>
<text top="645" left="125" width="4" height="21" font="4"> </text>
<text top="647" left="129" width="35" height="19" font="0">(138) </text>
<text top="665" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21300730">21300730</a></text>
<text top="665" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21300730"> </a></text>
<text top="610" left="223" width="51" height="19" font="8"><b>Aim: </b>To </text>
<text top="628" left="223" width="81" height="19" font="0">compare the </text>
<text top="647" left="223" width="99" height="19" font="0">efficacy of AAIR </text>
<text top="665" left="223" width="102" height="19" font="0">vs. DDDR pacing </text>
<text top="683" left="223" width="92" height="19" font="0">in pts with SSS </text>
<text top="701" left="223" width="102" height="19" font="0">and bradycardia </text>
<text top="720" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="738" left="223" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="756" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="775" left="223" width="92" height="19" font="8"><b>Size: </b>1,415 pts </text>
<text top="610" left="338" width="130" height="19" font="8"><b>Inclusion criteria: </b>SA </text>
<text top="628" left="338" width="126" height="19" font="0">block or sinus arrest </text>
<text top="647" left="338" width="127" height="19" font="0">with pauses &gt;2 s, PR </text>
<text top="665" left="338" width="121" height="19" font="0">≤260 ms, QRS &lt;120 </text>
<text top="683" left="338" width="116" height="19" font="0">ms, heart rate &lt;40 </text>
<text top="701" left="338" width="79" height="19" font="0">while awake </text>
<text top="720" left="338" width="3" height="19" font="8"><b> </b></text>
<text top="738" left="338" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="756" left="338" width="95" height="19" font="0">AVB, BBB, long-</text>
<text top="775" left="338" width="125" height="19" font="0">standing PerAF, and </text>
<text top="610" left="491" width="132" height="19" font="8"><b>Intervention: </b>Bipolar </text>
<text top="628" left="492" width="131" height="19" font="0">atrial lead only (AAIR </text>
<text top="647" left="492" width="143" height="19" font="0">pacing programmed to </text>
<text top="665" left="492" width="133" height="19" font="0">LR of 60 ppm) – must </text>
<text top="683" left="492" width="148" height="19" font="0">have 1:1 AV conduction </text>
<text top="701" left="492" width="157" height="19" font="0">at paced rate of 100 bpm </text>
<text top="720" left="492" width="52" height="19" font="0">(N=707) </text>
<text top="738" left="491" width="3" height="19" font="8"><b> </b></text>
<text top="756" left="491" width="122" height="19" font="8"><b>Comparator: </b>DDDR </text>
<text top="775" left="492" width="143" height="19" font="0">pacing programmed to </text>
<text top="610" left="662" width="177" height="20" font="0">• Mortality: 29.6% (AAIR) vs. </text>
<text top="629" left="672" width="175" height="19" font="0">27.3% (DDDR) (adjusted HR: </text>
<text top="647" left="672" width="151" height="19" font="0">0.94; 95% CI: 0.77–1.14; </text>
<text top="666" left="672" width="50" height="19" font="0">p=0.52) </text>
<text top="610" left="864" width="185" height="20" font="0">• PAF: 28.4% (AAIR) vs. 23.0% </text>
<text top="629" left="875" width="216" height="19" font="0">(DDDR) (adjusted HR: 1.24; 95% CI: </text>
<text top="647" left="875" width="126" height="19" font="0">1.01–1.52; p=0.042) </text>
<text top="666" left="864" width="227" height="20" font="0">• Chronic AF: 11.2% (AAIR) vs. 10.7% </text>
<text top="685" left="875" width="216" height="19" font="0">(DDDR) (adjusted HR: 1.01; 95% CI: </text>
<text top="703" left="875" width="118" height="19" font="0">0.74–1.39; p=0.93) </text>
<text top="722" left="864" width="185" height="20" font="0">• Stroke: 5.5% (AAIR) vs. 4.8% </text>
<text top="740" left="875" width="216" height="19" font="0">(DDDR) (adjusted HR: 1.11; 95% CI: </text>
<text top="759" left="875" width="118" height="19" font="0">0.70–1.77; p=0.65) </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 93 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="338" width="81" height="19" font="0">carotid sinus </text>
<text top="105" left="338" width="103" height="19" font="0">hypersensitivity, </text>
<text top="123" left="338" width="100" height="19" font="0">planned cardiac </text>
<text top="142" left="338" width="75" height="19" font="0">surgery, life </text>
<text top="160" left="338" width="101" height="19" font="0">expectancy &lt;1 y </text>
<text top="87" left="492" width="131" height="19" font="0">LR of 60 ppm AND to </text>
<text top="105" left="492" width="114" height="19" font="0">minimize V pacing </text>
<text top="123" left="492" width="153" height="19" font="0">(N=708) [mean Vp%=65] </text>
<text top="87" left="864" width="187" height="20" font="0">• HFH: 27 pts (AAIR) vs. 28 pts </text>
<text top="106" left="875" width="103" height="19" font="0">(DDDR) (p=0.90) </text>
<text top="124" left="864" width="225" height="20" font="0">• PPM reoperation: 22.1% (AAIR) vs. </text>
<text top="143" left="875" width="209" height="19" font="0">11.9% (DDDR) (adjusted HR: 2.00; </text>
<text top="162" left="875" width="174" height="19" font="0">95% CI: 1.54–2.61; p&lt;0.001) </text>
<text top="181" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="181" left="302" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 94 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="108" left="86" width="967" height="23" font="5"><b>Data Supplement 25. RCTs of Permanent Pacing for Chronic Therapy/Management of Bradycardia due to Sinus Node Dysfunction </b></text>
<text top="130" left="86" width="115" height="23" font="5"><b>(Section 5.4.4)  </b></text>
<text top="153" left="104" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="171" left="135" width="51" height="19" font="8"><b>Author; </b></text>
<text top="189" left="105" width="100" height="19" font="8"><b>Year Published: </b></text>
<text top="208" left="141" width="38" height="19" font="8"><b>PMID </b></text>
<text top="153" left="252" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="171" left="258" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="189" left="252" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="153" left="389" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="153" left="543" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="171" left="582" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="189" left="545" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="208" left="587" width="59" height="19" font="8"><b>patients) </b></text>
<text top="153" left="743" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="171" left="719" width="156" height="19" font="8"><b>(Absolute Event Rates, P </b></text>
<text top="189" left="718" width="168" height="19" font="8"><b>value; OR or RR; &amp; 95% CI) </b></text>
<text top="154" left="907" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="172" left="942" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="190" left="951" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="227" left="95" width="52" height="19" font="8"><b>DANISH </b></text>
<text top="245" left="95" width="102" height="19" font="0">Andersen HR, et </text>
<text top="263" left="95" width="87" height="19" font="0">al. 1997 (139) </text>
<text top="282" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9652562">9652562</a></text>
<text top="282" left="148" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9652562"><b> </b></a></text>
<text top="227" left="228" width="99" height="19" font="8"><b>Aim: </b>Long-term </text>
<text top="245" left="228" width="133" height="19" font="0">follow-up of pts from </text>
<text top="263" left="228" width="130" height="19" font="0">a randomized trial of </text>
<text top="282" left="228" width="124" height="19" font="0">atrial vs. ventricular </text>
<text top="300" left="228" width="126" height="19" font="0">pacing for sick-sinus </text>
<text top="318" left="227" width="87" height="19" font="0">syndrome. To </text>
<text top="337" left="227" width="134" height="19" font="0">examine whether the </text>
<text top="355" left="227" width="117" height="19" font="0">beneficial effect of </text>
<text top="373" left="227" width="91" height="19" font="0">atrial pacing is </text>
<text top="392" left="227" width="116" height="19" font="0">maintained during </text>
<text top="410" left="227" width="123" height="19" font="0">extended follow-up </text>
<text top="428" left="227" width="73" height="19" font="0">of up to 8 y </text>
<text top="446" left="228" width="3" height="19" font="0"> </text>
<text top="465" left="228" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="483" left="228" width="80" height="19" font="8"><b>Size:</b> 225 pts<b> </b></text>
<text top="227" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="245" left="378" width="84" height="19" font="0">Symptomatic </text>
<text top="263" left="378" width="133" height="19" font="0">bradycardia &lt;50 bpm </text>
<text top="282" left="378" width="84" height="19" font="0">or pause &gt;2 s </text>
<text top="300" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="318" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="337" left="378" width="135" height="19" font="0">AVB, chronic AF, BBB, </text>
<text top="355" left="378" width="108" height="19" font="0">age &lt;50, planned </text>
<text top="373" left="378" width="100" height="19" font="0">cardiac surgery, </text>
<text top="392" left="378" width="101" height="19" font="0">cancer, cerebral </text>
<text top="410" left="378" width="134" height="19" font="0">disease, CVA within 3 </text>
<text top="428" left="378" width="119" height="19" font="0">mo, major surgery, </text>
<text top="447" left="378" width="26" height="19" font="0">etc.<b> </b></text>
<text top="227" left="533" width="125" height="19" font="8"><b>Intervention: </b>Single </text>
<text top="245" left="533" width="135" height="19" font="0">chamber atrial pacing </text>
<text top="263" left="533" width="89" height="19" font="0">(only if 1:1 AV </text>
<text top="282" left="533" width="122" height="19" font="0">conduction at atrial </text>
<text top="300" left="533" width="149" height="19" font="0">pacing rate of 100 bpm) </text>
<text top="318" left="533" width="52" height="19" font="0">(N=110) </text>
<text top="337" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="355" left="533" width="122" height="19" font="8"><b>Comparator: </b>Single </text>
<text top="373" left="533" width="127" height="19" font="0">chamber ventricular </text>
<text top="392" left="533" width="96" height="19" font="0">pacing (N=115) </text>
<text top="410" left="533" width="3" height="19" font="0"> </text>
<text top="428" left="533" width="133" height="19" font="0">Mean follow-up 5.5 y<b> </b></text>
<text top="227" left="702" width="186" height="20" font="0">• All-cause mortality: 39 atrial </text>
<text top="246" left="713" width="170" height="19" font="0">vs. 57 ventricular (RR: 0.66; </text>
<text top="264" left="713" width="174" height="19" font="0">95% CI: 0.44–0.99; p=0.045) </text>
<text top="283" left="702" width="186" height="20" font="0">• CV mortality: 19 atrial vs. 39 </text>
<text top="302" left="713" width="161" height="19" font="0">ventricular (RR: 0.47; 95% </text>
<text top="320" left="713" width="152" height="19" font="0">CI: 0.27–0.82; p=0.0065) </text>
<text top="338" left="702" width="126" height="20" font="0">• AF: 26 atrial vs. 40 </text>
<text top="357" left="713" width="161" height="19" font="0">ventricular (RR: 0.54; 95% </text>
<text top="376" left="713" width="145" height="19" font="0">CI: 0.33–0.89; p=0.012) </text>
<text top="394" left="702" width="188" height="20" font="0">• Thromboembolism: 13 atrial </text>
<text top="413" left="713" width="170" height="19" font="0">vs. 26 ventricular (RR: 0.47; </text>
<text top="431" left="713" width="174" height="19" font="0">95% CI: 0.24–0.92; p=0.023) </text>
<text top="227" left="904" width="189" height="20" font="0">• Use of diuretics: significantly </text>
<text top="246" left="915" width="155" height="19" font="0">higher in the atrial group </text>
<text top="264" left="915" width="54" height="19" font="0">(p&lt;0.05) </text>
<text top="502" left="95" width="35" height="19" font="8"><b>PASE</b> </text>
<text top="520" left="95" width="101" height="19" font="0">Lamas GA, et al. </text>
<text top="539" left="95" width="69" height="19" font="0">1998 (140) </text>
<text top="557" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9545357">9545357</a></text>
<text top="557" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9545357"> </a></text>
<text top="502" left="228" width="129" height="19" font="8"><b>Aim: </b>To compare DC </text>
<text top="520" left="228" width="119" height="19" font="0">vs. ventricular only </text>
<text top="539" left="228" width="117" height="19" font="0">pacing for pts with </text>
<text top="557" left="228" width="83" height="19" font="0">symptomatic </text>
<text top="575" left="228" width="76" height="19" font="0">bradycardia </text>
<text top="594" left="228" width="3" height="19" font="0"> </text>
<text top="612" left="228" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="630" left="228" width="80" height="19" font="8"><b>Size:</b> 407 pts </text>
<text top="502" left="378" width="137" height="19" font="8"><b>Inclusion criteria: </b>≥65 </text>
<text top="520" left="378" width="129" height="19" font="0">y old, in SR, required </text>
<text top="539" left="378" width="140" height="19" font="0">PPM for prevention or </text>
<text top="557" left="378" width="82" height="19" font="0">treatment of </text>
<text top="575" left="378" width="76" height="19" font="0">bradycardia </text>
<text top="594" left="378" width="3" height="19" font="0"> </text>
<text top="612" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="630" left="378" width="138" height="19" font="0">Overt CHF, AF with no </text>
<text top="649" left="378" width="131" height="19" font="0">documentation of SR </text>
<text top="667" left="378" width="127" height="19" font="0">within 6 mo, serious </text>
<text top="685" left="378" width="129" height="19" font="0">noncardiac illnesses, </text>
<text top="704" left="378" width="130" height="19" font="0">cannot participate in </text>
<text top="722" left="378" width="86" height="19" font="0">quality-of-life </text>
<text top="740" left="378" width="80" height="19" font="0">assessments </text>
<text top="502" left="533" width="117" height="19" font="8"><b>Intervention: </b>Dual </text>
<text top="520" left="533" width="89" height="19" font="0">chamber PPM </text>
<text top="539" left="533" width="142" height="19" font="0">programmed VVIR and </text>
<text top="557" left="533" width="148" height="19" font="0">programmed to LR limit </text>
<text top="575" left="533" width="126" height="19" font="0">of ≥50 bpm (N=204) </text>
<text top="594" left="533" width="3" height="19" font="0"> </text>
<text top="612" left="533" width="114" height="19" font="8"><b>Comparator: </b>Dual </text>
<text top="630" left="533" width="89" height="19" font="0">chamber PPM </text>
<text top="649" left="533" width="149" height="19" font="0">programmed DDDR and </text>
<text top="667" left="533" width="148" height="19" font="0">programmed to LR limit </text>
<text top="685" left="533" width="126" height="19" font="0">of ≥50 bpm (N=203) </text>
<text top="502" left="702" width="178" height="20" font="0">• PPM indications: AVB 49%, </text>
<text top="521" left="713" width="58" height="19" font="0">SND 43% </text>
<text top="540" left="702" width="155" height="20" font="0">• 26% (53) of VVIR group </text>
<text top="559" left="713" width="176" height="19" font="0">crossed over to DDDR group </text>
<text top="577" left="713" width="131" height="19" font="0">due to PM syndrome </text>
<text top="596" left="702" width="181" height="20" font="0">• QOL (as measured by SF-36 </text>
<text top="614" left="713" width="110" height="19" font="0">survey) improved </text>
<text top="633" left="713" width="141" height="19" font="0">significantly after PPM </text>
<text top="651" left="713" width="168" height="19" font="0">implantation (p&lt;0.001) but </text>
<text top="669" left="713" width="157" height="19" font="0">NO difference between 2 </text>
<text top="688" left="713" width="132" height="19" font="0">pacing modes in QOL </text>
<text top="706" left="702" width="162" height="20" font="0">• In SND group (but not in </text>
<text top="725" left="713" width="140" height="19" font="0">AVB group), DC pacing </text>
<text top="743" left="713" width="144" height="19" font="0">resulted in significantly </text>
<text top="762" left="713" width="117" height="19" font="0">better QOL and CV </text>
<text top="780" left="713" width="105" height="19" font="0">functional status </text>
<text top="502" left="904" width="184" height="20" font="0">• No significant differences in </text>
<text top="521" left="915" width="163" height="19" font="0">the rates of death from all </text>
<text top="540" left="915" width="149" height="19" font="0">causes, stroke or death, </text>
<text top="558" left="915" width="114" height="19" font="0">stroke or death or </text>
<text top="576" left="915" width="164" height="19" font="0">hospitalization for HF, and </text>
<text top="595" left="915" width="119" height="19" font="0">development of AF </text>
<text top="613" left="904" width="185" height="20" font="0">• Risk of AF development was </text>
<text top="632" left="915" width="171" height="19" font="0">higher in VVIR compared to </text>
<text top="650" left="915" width="154" height="19" font="0">DDDR group but was not </text>
<text top="669" left="915" width="171" height="19" font="0">statistically significant (28% </text>
<text top="687" left="915" width="103" height="19" font="0">vs. 19%; p=0.06) </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 95 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="41" height="19" font="8"><b>MOST</b> </text>
<text top="105" left="95" width="101" height="19" font="0">Lamas GA, et al. </text>
<text top="123" left="95" width="69" height="19" font="0">2002 (141) </text>
<text top="142" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12063369">12063369</a></text>
<text top="142" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12063369"> </a></text>
<text top="87" left="228" width="129" height="19" font="8"><b>Aim: </b>To compare DC </text>
<text top="105" left="228" width="119" height="19" font="0">vs. ventricular only </text>
<text top="123" left="228" width="109" height="19" font="0">pacing to treat pt </text>
<text top="142" left="228" width="86" height="19" font="0">with clinically </text>
<text top="160" left="228" width="66" height="19" font="0">significant </text>
<text top="178" left="228" width="119" height="19" font="0">bradycardia due to </text>
<text top="197" left="228" width="29" height="19" font="0">SND </text>
<text top="215" left="228" width="3" height="19" font="0"> </text>
<text top="233" left="228" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="252" left="228" width="92" height="19" font="8"><b>Size: </b>2,010 pts </text>
<text top="87" left="378" width="137" height="19" font="8"><b>Inclusion criteria: </b>≥21 </text>
<text top="105" left="378" width="74" height="19" font="0">y old, in SR, </text>
<text top="123" left="378" width="125" height="19" font="0">undergoing DC PPM </text>
<text top="142" left="378" width="71" height="19" font="0">implant for </text>
<text top="160" left="378" width="112" height="19" font="0">symptomatic SND<b> </b></text>
<text top="178" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="197" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="215" left="378" width="119" height="19" font="0">Serious concurrent </text>
<text top="233" left="378" width="54" height="19" font="0">illnesses </text>
<text top="87" left="533" width="117" height="19" font="8"><b>Intervention: </b>Dual </text>
<text top="105" left="533" width="89" height="19" font="0">chamber PPM </text>
<text top="123" left="533" width="149" height="19" font="0">programmed DDDR and </text>
<text top="142" left="533" width="148" height="19" font="0">programmed to LR limit </text>
<text top="160" left="533" width="137" height="19" font="0">of ≥60 bpm (N=1,014) </text>
<text top="178" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="197" left="533" width="114" height="19" font="8"><b>Comparator: </b>Dual </text>
<text top="215" left="533" width="89" height="19" font="0">chamber PPM </text>
<text top="233" left="533" width="142" height="19" font="0">programmed VVIR and </text>
<text top="252" left="533" width="148" height="19" font="0">programmed to LR limit </text>
<text top="270" left="533" width="126" height="19" font="0">of ≥60 bpm (N=996) </text>
<text top="87" left="702" width="164" height="20" font="0">• Death or nonfatal stroke </text>
<text top="106" left="713" width="168" height="19" font="0">occurred in 21.5% of DDDR </text>
<text top="124" left="713" width="153" height="19" font="0">pts vs. 23.0% of VVIR pts </text>
<text top="143" left="713" width="54" height="19" font="0">(p=0.48) </text>
<text top="161" left="702" width="163" height="20" font="0">• 31.4% (313) of pts in the </text>
<text top="180" left="713" width="149" height="19" font="0">VVIR group was crossed </text>
<text top="198" left="713" width="126" height="19" font="0">over to DDDR group </text>
<text top="87" left="904" width="190" height="20" font="0">• Incidence of AF was 21.4% in </text>
<text top="106" left="915" width="154" height="19" font="0">DDDR group vs. 27.1% in </text>
<text top="124" left="915" width="132" height="19" font="0">VVIR group (adjusted </text>
<text top="143" left="915" width="172" height="19" font="0">HR:0.77; 95% CI: 0.64–0.92; </text>
<text top="161" left="915" width="57" height="19" font="0">p=0.004) </text>
<text top="179" left="904" width="173" height="20" font="0">• Hospitalization for HF was </text>
<text top="198" left="915" width="154" height="19" font="0">10.3% in DDDR group vs. </text>
<text top="217" left="915" width="127" height="19" font="0">12.3% in VVIR group </text>
<text top="235" left="915" width="165" height="19" font="0">(adjusted HR:0.73; 95% CI: </text>
<text top="253" left="915" width="118" height="19" font="0">0.56–0.95; p=0.02) </text>
<text top="272" left="904" width="180" height="20" font="0">• Combined clinical endpoint </text>
<text top="291" left="915" width="166" height="19" font="0">(death, stroke or HFH) was </text>
<text top="309" left="915" width="154" height="19" font="0">27.6% in DDDR group vs. </text>
<text top="327" left="915" width="127" height="19" font="0">29.9% in VVIR group </text>
<text top="346" left="915" width="165" height="19" font="0">(adjusted HR:0.85; 95% CI: </text>
<text top="364" left="915" width="118" height="19" font="0">0.72–1.00; p=0.05) </text>
<text top="382" left="904" width="162" height="20" font="0">• DDDR pacing resulted in </text>
<text top="401" left="915" width="172" height="19" font="0">better improvement in QOL </text>
<text top="420" left="915" width="145" height="19" font="0">as compared with VVIR </text>
<text top="438" left="915" width="47" height="19" font="0">pacing.<b> </b></text>
<text top="456" left="904" width="178" height="20" font="0">• <b>Adverse events: </b>Total 30 d </text>
<text top="475" left="915" width="159" height="19" font="0">rate of complication 4.8% </text>
<text top="494" left="915" width="151" height="19" font="0">(1.8% A-lead issue, 1.5% </text>
<text top="512" left="915" width="174" height="19" font="0">pneumothorax, 1.1% V-lead </text>
<text top="530" left="915" width="38" height="19" font="0">issue) </text>
<text top="549" left="95" width="45" height="19" font="8"><b>CTOPP</b> </text>
<text top="568" left="95" width="109" height="19" font="0">Connolly SJ, et al. </text>
<text top="586" left="95" width="69" height="19" font="0">2000 (142) </text>
<text top="604" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10805823">10805823</a></text>
<text top="604" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10805823"> </a></text>
<text top="549" left="228" width="93" height="19" font="8"><b>Aim: </b>To assess </text>
<text top="568" left="228" width="126" height="19" font="0">whether physiologic </text>
<text top="586" left="228" width="129" height="19" font="0">pacing or ventricular </text>
<text top="604" left="228" width="119" height="19" font="0">pacing is better for </text>
<text top="623" left="228" width="136" height="19" font="0">pts with symptomatic </text>
<text top="641" left="228" width="76" height="19" font="0">bradycardia </text>
<text top="659" left="228" width="3" height="19" font="0"> </text>
<text top="677" left="228" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="696" left="228" width="92" height="19" font="8"><b>Size: </b>2,568 pts </text>
<text top="549" left="378" width="137" height="19" font="8"><b>Inclusion criteria: </b>≥18 </text>
<text top="568" left="378" width="33" height="19" font="0">y old </text>
<text top="586" left="378" width="3" height="19" font="0"> </text>
<text top="604" left="378" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="623" left="378" width="116" height="19" font="0">Chronic AF, s/p AV </text>
<text top="641" left="378" width="117" height="19" font="0">nodal ablation, life </text>
<text top="659" left="378" width="101" height="19" font="0">expectancy &lt;2 y </text>
<text top="549" left="533" width="152" height="19" font="8"><b>Intervention: </b>Atrial-only </text>
<text top="568" left="533" width="87" height="19" font="0">pacing can be </text>
<text top="586" left="533" width="145" height="19" font="0">considered (if evidence </text>
<text top="604" left="533" width="147" height="19" font="0">of 1:1 AV conduction at </text>
<text top="623" left="533" width="146" height="19" font="0">paced rate of up to 130 </text>
<text top="641" left="533" width="131" height="19" font="0">bpm), o/w DC pacing </text>
<text top="659" left="533" width="123" height="19" font="0">(only 5.2% received </text>
<text top="678" left="533" width="113" height="19" font="0">atrial-only pacing) </text>
<text top="696" left="533" width="64" height="19" font="0">(N=1,094) </text>
<text top="714" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="732" left="533" width="150" height="19" font="8"><b>Comparator: </b>VVI pacing </text>
<text top="751" left="533" width="64" height="19" font="0">(N=1,474)<b> </b></text>
<text top="550" left="702" width="178" height="20" font="0">• PPM indications: 60% AVB, </text>
<text top="569" left="713" width="58" height="19" font="0">42% SND </text>
<text top="587" left="702" width="160" height="20" font="0">• Annual rate of stroke or </text>
<text top="606" left="713" width="144" height="19" font="0">death was 5.5% for VVI </text>
<text top="624" left="713" width="117" height="19" font="0">pacing vs. 4.9% for </text>
<text top="643" left="713" width="168" height="19" font="0">physiologic pacing (95% CI: </text>
<text top="661" left="713" width="118" height="19" font="0">10.5–25.7; p=0.33) </text>
<text top="679" left="702" width="175" height="20" font="0">• Subgroup analysis showed </text>
<text top="698" left="713" width="160" height="19" font="0">that pt with SND received </text>
<text top="717" left="713" width="162" height="19" font="0">no particular benefit from </text>
<text top="735" left="713" width="114" height="19" font="0">physiologic pacing </text>
<text top="753" left="713" width="149" height="19" font="0">compared to VVI pacing </text>
<text top="550" left="904" width="181" height="20" font="0">• Annual rate of AF was 6.6% </text>
<text top="569" left="915" width="163" height="19" font="0">for VVI pacing vs. 5.3% for </text>
<text top="587" left="915" width="168" height="19" font="0">physiologic pacing (18% RR </text>
<text top="605" left="915" width="175" height="19" font="0">reduction; 95% CI: 0.3–32.6; </text>
<text top="623" left="915" width="50" height="19" font="0">p=0.05) </text>
<text top="642" left="904" width="101" height="20" font="0">• Annual rate of </text>
<text top="661" left="915" width="161" height="19" font="0">hospitalization for HF was </text>
<text top="679" left="915" width="175" height="19" font="0">3.5% for VVI pacing vs. 3.1% </text>
<text top="698" left="915" width="170" height="19" font="0">for physiologic pacing (95% </text>
<text top="716" left="915" width="152" height="19" font="0">CI: -18.5–28.3%; p=0.52) </text>
<text top="734" left="904" width="170" height="20" font="0">• Annual rate of stroke was </text>
<text top="753" left="915" width="175" height="19" font="0">1.1% for VVI pacing vs. 1.0% </text>
<text top="771" left="915" width="136" height="19" font="0">for physiologic pacing </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 96 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="904" width="151" height="20" font="0">• <b>Adverse events: </b>More </text>
<text top="106" left="915" width="144" height="19" font="0">common in physiologic </text>
<text top="124" left="915" width="167" height="19" font="0">pacing group primarily due </text>
<text top="143" left="915" width="169" height="19" font="0">to atrial lead complications </text>
<text top="162" left="95" width="72" height="19" font="8"><b>SAVE PACe </b></text>
<text top="180" left="95" width="104" height="19" font="0">Sweeney MO, et </text>
<text top="198" left="95" width="87" height="19" font="0">al. 2007 (143) </text>
<text top="217" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17804844">17804844</a></text>
<text top="217" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17804844"> </a></text>
<text top="162" left="228" width="133" height="19" font="8"><b> Aim:</b> To compare DC </text>
<text top="180" left="228" width="122" height="19" font="0">minimal ventricular </text>
<text top="198" left="228" width="127" height="19" font="0">pacing vs. DC pacing </text>
<text top="217" left="228" width="131" height="19" font="0">only in pts with sinus </text>
<text top="235" left="228" width="83" height="19" font="0">node disease </text>
<text top="253" left="228" width="3" height="19" font="0"> </text>
<text top="271" left="228" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="290" left="228" width="92" height="19" font="8"><b>Size: </b>1,065 pts </text>
<text top="162" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="180" left="378" width="84" height="19" font="0">Symptomatic </text>
<text top="198" left="378" width="119" height="19" font="0">bradycardia due to </text>
<text top="217" left="378" width="132" height="19" font="0">SND, &gt;18 y old, QRSd </text>
<text top="235" left="378" width="130" height="19" font="0">≤120, AV conduction </text>
<text top="253" left="378" width="111" height="19" font="0">of 1:1 at 100 ppm </text>
<text top="272" left="378" width="3" height="19" font="0"> </text>
<text top="290" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="308" left="378" width="106" height="19" font="0">Persistent AF, ≥2 </text>
<text top="326" left="378" width="130" height="19" font="0">DCCV for AF within 6 </text>
<text top="345" left="378" width="131" height="19" font="0">mo, 2° or 3° AVB, life </text>
<text top="363" left="378" width="101" height="19" font="0">expectancy &lt;2 y </text>
<text top="162" left="533" width="107" height="19" font="8"><b>Intervention: </b>DC-</text>
<text top="180" left="533" width="122" height="19" font="0">minimal ventricular </text>
<text top="198" left="533" width="96" height="19" font="0">pacing (N=530) </text>
<text top="217" left="533" width="3" height="19" font="0"> </text>
<text top="235" left="533" width="146" height="19" font="8"><b>Comparator: </b>DC pacing </text>
<text top="253" left="533" width="85" height="19" font="0">only (N=535)  </text>
<text top="162" left="702" width="137" height="20" font="0">• Median % of Vp (DC-</text>
<text top="181" left="713" width="165" height="19" font="0">minimal ventricular pacing </text>
<text top="199" left="713" width="148" height="19" font="0">9.1% vs. DC only 99.0%; </text>
<text top="217" left="713" width="57" height="19" font="0">p&lt;0.001) </text>
<text top="236" left="702" width="177" height="20" font="0">• Development of persistent </text>
<text top="255" left="713" width="167" height="19" font="0">AF (DC-minimal ventricular </text>
<text top="273" left="713" width="146" height="19" font="0">pacing 7.9% vs. DC only </text>
<text top="291" left="713" width="169" height="19" font="0">12.7%; p=0.004); thus, 40% </text>
<text top="310" left="713" width="103" height="19" font="0">RR reduction for </text>
<text top="328" left="713" width="165" height="19" font="0">development of persistent </text>
<text top="346" left="713" width="165" height="19" font="0">AF (HR: 0.60; 95% CI: 0.41–</text>
<text top="365" left="713" width="92" height="19" font="0">0.88; p=0.009) </text>
<text top="383" left="702" width="68" height="20" font="0">• Time to 1</text>
<text top="384" left="770" width="7" height="12" font="7">st</text>
<text top="384" left="777" width="99" height="19" font="0"> DCCV, AV node </text>
<text top="402" left="713" width="166" height="19" font="0">ablation or PVI favored DC-</text>
<text top="420" left="713" width="165" height="19" font="0">minimal ventricular pacing </text>
<text top="439" left="713" width="146" height="19" font="0">(HR: 0.62; 95% CI: 0.37–</text>
<text top="457" left="713" width="84" height="19" font="0">1.03; p=0.06) </text>
<text top="162" left="904" width="178" height="20" font="0">• No significant difference in </text>
<text top="181" left="915" width="179" height="19" font="0">mortality (4.9% vs. 5.4%; HR: </text>
<text top="199" left="915" width="151" height="19" font="0">0.85; 95% CI: 0.50–1.44; </text>
<text top="217" left="915" width="111" height="19" font="0">p=0.54) or rate of </text>
<text top="236" left="915" width="171" height="19" font="0">hospitalization for HF (2.8% </text>
<text top="254" left="915" width="164" height="19" font="0">vs. 3.1%; HR: 0.84; 95% CI: </text>
<text top="272" left="915" width="118" height="19" font="0">0.42–1.68; p=0.62) </text>
<text top="291" left="904" width="176" height="20" font="0">• <b>Adverse events: </b>4.0% lead </text>
<text top="310" left="915" width="141" height="19" font="0">problems, 0.3% device </text>
<text top="328" left="915" width="179" height="19" font="0">infections requiring removal, </text>
<text top="346" left="915" width="102" height="19" font="0">1 intra-op death </text>
<text top="476" left="95" width="64" height="19" font="8"><b>DANPACE </b></text>
<text top="494" left="95" width="102" height="19" font="0">Nielsen JC, et al. </text>
<text top="513" left="95" width="69" height="19" font="0">2011 (138) </text>
<text top="531" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21300730">21300730</a></text>
<text top="531" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21300730"> </a></text>
<text top="476" left="228" width="132" height="19" font="8"><b>Aim: </b>To compare the </text>
<text top="494" left="228" width="119" height="19" font="0">efficacy of AAIR vs. </text>
<text top="513" left="228" width="119" height="19" font="0">DDDR pacing in pts </text>
<text top="531" left="228" width="81" height="19" font="0">with SSS and </text>
<text top="549" left="228" width="76" height="19" font="0">bradycardia </text>
<text top="568" left="228" width="3" height="19" font="0"> </text>
<text top="586" left="228" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="604" left="228" width="3" height="19" font="0"> </text>
<text top="623" left="228" width="92" height="19" font="8"><b>Size: </b>1,415 pts </text>
<text top="476" left="378" width="130" height="19" font="8"><b>Inclusion criteria: </b>SA </text>
<text top="494" left="378" width="126" height="19" font="0">block or sinus arrest </text>
<text top="513" left="378" width="127" height="19" font="0">with pauses &gt;2 s, PR </text>
<text top="531" left="378" width="121" height="19" font="0">≤260 ms, QRS &lt;120 </text>
<text top="549" left="378" width="116" height="19" font="0">ms, heart rate &lt;40 </text>
<text top="568" left="378" width="79" height="19" font="0">while awake </text>
<text top="586" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="604" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="623" left="378" width="124" height="19" font="0">AVB, BBB, LS PerAF, </text>
<text top="641" left="378" width="88" height="19" font="0">+carotid sinus </text>
<text top="659" left="378" width="103" height="19" font="0">hypersensitivity, </text>
<text top="678" left="378" width="100" height="19" font="0">planned cardiac </text>
<text top="696" left="378" width="75" height="19" font="0">surgery, life </text>
<text top="714" left="378" width="101" height="19" font="0">expectancy &lt;1 y </text>
<text top="476" left="533" width="132" height="19" font="8"><b>Intervention: </b>Bipolar </text>
<text top="494" left="533" width="131" height="19" font="0">atrial lead only (AAIR </text>
<text top="513" left="533" width="143" height="19" font="0">pacing programmed to </text>
<text top="531" left="533" width="133" height="19" font="0">LR of 60 ppm) – must </text>
<text top="549" left="533" width="148" height="19" font="0">have 1:1 AV conduction </text>
<text top="568" left="533" width="126" height="19" font="0">at paced rate of 100 </text>
<text top="586" left="533" width="84" height="19" font="0">bpm (N=707) </text>
<text top="604" left="533" width="3" height="19" font="0"> </text>
<text top="623" left="533" width="122" height="19" font="8"><b>Comparator: </b>DDDR </text>
<text top="641" left="533" width="143" height="19" font="0">pacing programmed to </text>
<text top="659" left="533" width="131" height="19" font="0">LR of 60 ppm AND to </text>
<text top="678" left="533" width="114" height="19" font="0">minimize V pacing </text>
<text top="696" left="533" width="153" height="19" font="0">(N=708) (mean Vp%=65)<b> </b></text>
<text top="476" left="702" width="177" height="20" font="0">• Mortality: 29.6% (AAIR) vs. </text>
<text top="495" left="713" width="175" height="19" font="0">27.3% (DDDR) (adjusted HR: </text>
<text top="514" left="713" width="151" height="19" font="0">0.94; 95% CI: 0.77–1.14; </text>
<text top="532" left="713" width="50" height="19" font="0">p=0.52) </text>
<text top="476" left="904" width="185" height="20" font="0">• PAF: 28.4% (AAIR) vs. 23.0% </text>
<text top="495" left="915" width="168" height="19" font="0">(DDDR) (adjusted HR: 1.24; </text>
<text top="514" left="915" width="174" height="19" font="0">95% CI: 1.01–1.52; p=0.042) </text>
<text top="532" left="904" width="186" height="20" font="0">• Chronic AF: 11.2% (AAIR) vs. </text>
<text top="551" left="915" width="175" height="19" font="0">10.7% (DDDR) (adjusted HR: </text>
<text top="569" left="915" width="151" height="19" font="0">1.01; 95% CI: 0.74–1.39; </text>
<text top="588" left="915" width="50" height="19" font="0">p=0.93) </text>
<text top="606" left="904" width="185" height="20" font="0">• Stroke: 5.5% (AAIR) vs. 4.8% </text>
<text top="625" left="915" width="168" height="19" font="0">(DDDR) (adjusted HR: 1.11; </text>
<text top="643" left="915" width="166" height="19" font="0">95% CI: 0.70–1.77; p=0.65) </text>
<text top="662" left="904" width="187" height="20" font="0">• HFH: 27 pts (AAIR) vs. 28 pts </text>
<text top="681" left="915" width="103" height="19" font="0">(DDDR) (p=0.90) </text>
<text top="699" left="904" width="163" height="20" font="0">• PPM reoperation: 22.1% </text>
<text top="718" left="915" width="151" height="19" font="0">(AAIR) vs. 11.9% (DDDR) </text>
<text top="736" left="915" width="164" height="19" font="0">(adjusted HR 2.00; 95% CI: </text>
<text top="755" left="915" width="126" height="19" font="0">1.54–2.61; p&lt;0.001) </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 97 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="98" height="19" font="0">Healey JS, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">2006 (144) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16801463">16801463</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16801463"> </a></text>
<text top="87" left="228" width="118" height="19" font="8"><b>Aim:</b> To determine </text>
<text top="105" left="228" width="131" height="19" font="0">whether atrial-based </text>
<text top="123" left="228" width="124" height="19" font="0">pacing (AAI or DDD) </text>
<text top="142" left="228" width="114" height="19" font="0">prevents MACE as </text>
<text top="160" left="228" width="106" height="19" font="0">compared to VVI </text>
<text top="178" left="228" width="111" height="19" font="0">pacing in pts with </text>
<text top="197" left="228" width="76" height="19" font="0">bradycardia </text>
<text top="215" left="228" width="3" height="19" font="0"> </text>
<text top="233" left="228" width="111" height="19" font="8"><b>Study type: </b>Meta-</text>
<text top="252" left="228" width="51" height="19" font="0">analysis </text>
<text top="270" left="228" width="92" height="19" font="8"><b>Size:</b> 7,231 pts </text>
<text top="87" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="105" left="378" width="112" height="19" font="0">Publications since </text>
<text top="123" left="378" width="114" height="19" font="0">1980, randomized </text>
<text top="142" left="378" width="115" height="19" font="0">controlled parallel </text>
<text top="160" left="378" width="128" height="19" font="0">design, have pt level </text>
<text top="178" left="378" width="114" height="19" font="0">data on outcomes </text>
<text top="197" left="378" width="3" height="19" font="0"> </text>
<text top="215" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="233" left="378" width="142" height="19" font="0">Post cardiac surgery or </text>
<text top="252" left="378" width="134" height="19" font="0">AV node ablation pts, </text>
<text top="270" left="378" width="102" height="19" font="0">multi-site A or V </text>
<text top="288" left="378" width="127" height="19" font="0">pacing, follow-up &lt;6 </text>
<text top="307" left="378" width="23" height="19" font="0">mo </text>
<text top="87" left="533" width="85" height="19" font="8"><b>Intervention: </b></text>
<text top="105" left="533" width="129" height="19" font="0">Studies including pts </text>
<text top="123" left="533" width="136" height="19" font="0">who were AAI or DDD </text>
<text top="142" left="533" width="125" height="19" font="0">paced (atrial-based) </text>
<text top="160" left="533" width="43" height="19" font="0">pacing </text>
<text top="178" left="533" width="3" height="19" font="0"> </text>
<text top="197" left="533" width="82" height="19" font="8"><b>Comparator: </b></text>
<text top="215" left="533" width="129" height="19" font="0">Studies including pts </text>
<text top="233" left="533" width="129" height="19" font="0">who were VVI paced </text>
<text top="252" left="533" width="119" height="19" font="0">(ventricular-based) </text>
<text top="270" left="533" width="43" height="19" font="0">pacing </text>
<text top="87" left="702" width="94" height="19" font="0">SND subgroup: </text>
<text top="105" left="702" width="169" height="20" font="0">• Overall mortality: ABP vs. </text>
<text top="124" left="713" width="171" height="19" font="0">VVI pacing (HR 0.92; 95% CI </text>
<text top="143" left="713" width="103" height="19" font="0">0.81–1.05; p=NS </text>
<text top="161" left="702" width="3" height="19" font="0"> </text>
<text top="179" left="702" width="83" height="19" font="0">Entire group: </text>
<text top="198" left="702" width="178" height="20" font="0">• AF: ABP vs. VVI pacing (HR: </text>
<text top="217" left="713" width="151" height="19" font="0">0.80; 95% CI: 0.72–0.89; </text>
<text top="235" left="713" width="73" height="19" font="0">p=0.00003) </text>
<text top="253" left="702" width="173" height="20" font="0">• Stroke: ABP vs. VVI pacing </text>
<text top="272" left="713" width="146" height="19" font="0">(HR: 0.81; 95% CI: 0.67–</text>
<text top="291" left="713" width="92" height="19" font="0">0.99; p=0.035) </text>
<text top="309" left="702" width="176" height="20" font="0">• Implant complication rate: </text>
<text top="328" left="713" width="148" height="19" font="0">ABP 6.2% vs. VVI pacing </text>
<text top="346" left="713" width="33" height="19" font="0">3.2% </text>
<text top="87" left="904" width="94" height="19" font="0">SND subgroup: </text>
<text top="105" left="904" width="174" height="20" font="0">• Composite of stroke or CV </text>
<text top="124" left="915" width="158" height="19" font="0">death: ABP vs. VVI pacing </text>
<text top="143" left="915" width="180" height="19" font="0">(HR: 0.83; 95% CI: 0.72–0.97; </text>
<text top="161" left="915" width="50" height="19" font="0">p=0.04) </text>
<text top="179" left="904" width="178" height="20" font="0">• AF: ABP vs. VVI pacing (HR: </text>
<text top="198" left="915" width="151" height="19" font="0">0.76; 95% CI: 0.67–0.86; </text>
<text top="217" left="915" width="65" height="19" font="0">p&lt;0.0001) </text>
<text top="235" left="904" width="173" height="20" font="0">• Stroke: ABP vs. VVI pacing </text>
<text top="254" left="915" width="180" height="19" font="0">(HR: 0.84; 95% CI: 0.64–1.11; </text>
<text top="272" left="915" width="40" height="19" font="0">p=NS) </text>
<text top="291" left="904" width="188" height="20" font="0">• HFH: ABP vs. VVI pacing (HR: </text>
<text top="310" left="915" width="151" height="19" font="0">0.92; 95% CI: 0.75–1.13; </text>
<text top="328" left="915" width="40" height="19" font="0">p=NS) </text>
<text top="365" left="95" width="56" height="19" font="8"><b>DANISH </b> </text>
<text top="384" left="95" width="102" height="19" font="0">Andersen HR, et </text>
<text top="402" left="95" width="87" height="19" font="0">al. 1994 (145) </text>
<text top="420" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7983951">7983951</a></text>
<text top="420" left="148" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7983951"><b> </b></a></text>
<text top="365" left="228" width="107" height="19" font="8"><b>Aim:</b> Prospective </text>
<text top="384" left="228" width="120" height="19" font="0">randomized trial of </text>
<text top="402" left="228" width="124" height="19" font="0">atrial vs. ventricular </text>
<text top="420" left="228" width="119" height="19" font="0">pacing in sick-sinus </text>
<text top="439" left="227" width="87" height="19" font="0">syndrome. To </text>
<text top="457" left="227" width="122" height="19" font="0">determine whether </text>
<text top="475" left="227" width="131" height="19" font="0">single chamber atrial </text>
<text top="494" left="227" width="129" height="19" font="0">or ventricular pacing </text>
<text top="512" left="227" width="122" height="19" font="0">is better in pts with </text>
<text top="530" left="227" width="27" height="19" font="0">SSS<b>  </b></text>
<text top="549" left="228" width="3" height="19" font="0"> </text>
<text top="567" left="228" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="585" left="228" width="75" height="19" font="0">Prospective </text>
<text top="604" left="228" width="76" height="19" font="0">randomized </text>
<text top="622" left="228" width="3" height="19" font="0"> </text>
<text top="640" left="228" width="80" height="19" font="8"><b>Size:</b> 225 pts<b> </b></text>
<text top="365" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="384" left="378" width="84" height="19" font="0">Symptomatic </text>
<text top="402" left="378" width="133" height="19" font="0">bradycardia &lt;50 bpm </text>
<text top="420" left="378" width="84" height="19" font="0">or pause &gt;2 s </text>
<text top="439" left="378" width="3" height="19" font="0"> </text>
<text top="457" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="475" left="378" width="135" height="19" font="0">AVB, chronic AF, BBB, </text>
<text top="494" left="378" width="118" height="19" font="0">age &lt;50 y, planned </text>
<text top="512" left="378" width="100" height="19" font="0">cardiac surgery, </text>
<text top="530" left="378" width="101" height="19" font="0">cancer, cerebral </text>
<text top="549" left="378" width="134" height="19" font="0">disease, CVA within 3 </text>
<text top="567" left="378" width="119" height="19" font="0">mo, major surgery, </text>
<text top="585" left="378" width="26" height="19" font="0">etc.<b> </b></text>
<text top="365" left="533" width="125" height="19" font="8"><b>Intervention: </b>Single </text>
<text top="384" left="533" width="135" height="19" font="0">chamber atrial pacing </text>
<text top="402" left="533" width="89" height="19" font="0">(only if 1:1 AV </text>
<text top="420" left="533" width="122" height="19" font="0">conduction at atrial </text>
<text top="439" left="533" width="146" height="19" font="0">pacing rate of 100bpm) </text>
<text top="457" left="533" width="52" height="19" font="0">(N=110) </text>
<text top="475" left="533" width="3" height="19" font="0"> </text>
<text top="494" left="533" width="122" height="19" font="8"><b>Comparator: </b>Single </text>
<text top="512" left="533" width="127" height="19" font="0">chamber ventricular </text>
<text top="530" left="533" width="96" height="19" font="0">pacing (N=115) </text>
<text top="549" left="533" width="3" height="19" font="0"> </text>
<text top="567" left="533" width="3" height="19" font="0"> </text>
<text top="585" left="533" width="142" height="19" font="0">Mean follow-up 40±18 </text>
<text top="604" left="533" width="23" height="19" font="0">mo<b> </b></text>
<text top="366" left="702" width="156" height="20" font="0">• Death: 21 (atrial) vs. 25 </text>
<text top="385" left="713" width="133" height="19" font="0">(ventricular) (p=0.74) </text>
<text top="403" left="702" width="175" height="20" font="0">• CV death: 11 (atrial) vs. 20 </text>
<text top="422" left="713" width="133" height="19" font="0">(ventricular) (p=0.16) </text>
<text top="440" left="702" width="180" height="20" font="0">• AF: higher frequency in the </text>
<text top="459" left="713" width="167" height="19" font="0">ventricular group at follow-</text>
<text top="478" left="713" width="19" height="19" font="0">up </text>
<text top="496" left="702" width="189" height="20" font="0">• Thromboembolism: 6 (atrial) </text>
<text top="515" left="713" width="117" height="19" font="0">vs. 20 (ventricular) </text>
<text top="533" left="713" width="70" height="19" font="0">(p=0.0083) </text>
<text top="552" left="702" width="182" height="20" font="0">• HF did not differ between 2 </text>
<text top="571" left="713" width="45" height="19" font="0">groups </text>
<text top="366" left="904" width="169" height="20" font="0">• LA diameter increased by </text>
<text top="385" left="915" width="144" height="19" font="0">more in the ventricular </text>
<text top="403" left="915" width="153" height="19" font="0">(p=0.0001) group vs. the </text>
<text top="421" left="915" width="136" height="19" font="0">atrial group (p=0.037) </text>
<text top="440" left="915" width="177" height="19" font="0">compared with preop values </text>
<text top="458" left="904" width="157" height="20" font="0">• 2 pts in the atrial group </text>
<text top="477" left="915" width="96" height="19" font="0">developed AVB </text>
<text top="495" left="904" width="3" height="19" font="0"> </text>
<text top="513" left="904" width="103" height="19" font="8"><b>Adverse events: </b></text>
<text top="532" left="904" width="155" height="20" font="0">• More common in atrial </text>
<text top="551" left="915" width="169" height="19" font="0">group (most common, lead </text>
<text top="569" left="915" width="123" height="19" font="0">dislodgement) than </text>
<text top="588" left="915" width="147" height="19" font="0">ventricular group (most </text>
<text top="606" left="915" width="162" height="19" font="0">common, PPM syndrome) </text>
<text top="659" left="95" width="106" height="19" font="8"><b>MOST sub-study </b></text>
<text top="678" left="95" width="104" height="19" font="0">Sweeney MO, et </text>
<text top="696" left="95" width="87" height="19" font="0">al. 2003 (146) </text>
<text top="714" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12782566">12782566</a></text>
<text top="714" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12782566"><b> </b></a></text>
<text top="659" left="228" width="130" height="19" font="8"><b>Aim:</b> To examine the </text>
<text top="678" left="228" width="99" height="19" font="0">effect of pacing-</text>
<text top="696" left="228" width="122" height="19" font="0">induced ventricular </text>
<text top="714" left="228" width="130" height="19" font="0">desynchronization in </text>
<text top="732" left="228" width="108" height="19" font="0">pts with SND and </text>
<text top="751" left="228" width="83" height="19" font="0">normal QRSd </text>
<text top="769" left="228" width="3" height="19" font="0"> </text>
<text top="659" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="678" left="378" width="138" height="19" font="0">SND, SR at the time of </text>
<text top="696" left="378" width="131" height="19" font="0">assignment, baseline </text>
<text top="714" left="378" width="91" height="19" font="0">QRSd &lt;120 ms </text>
<text top="732" left="378" width="3" height="19" font="0"> </text>
<text top="659" left="533" width="125" height="19" font="8"><b>Intervention: </b>DDDR </text>
<text top="678" left="533" width="96" height="19" font="0">pacing (N=707) </text>
<text top="696" left="533" width="3" height="19" font="0"> </text>
<text top="714" left="533" width="115" height="19" font="8"><b>Comparator: </b>VVIR </text>
<text top="732" left="533" width="96" height="19" font="0">pacing (N=632) </text>
<text top="751" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="769" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="659" left="702" width="165" height="20" font="0">• Cum%VP: DDDR 90% vs.  </text>
<text top="678" left="713" width="119" height="19" font="0">VVIR 58%; p=0.001 </text>
<text top="697" left="702" width="189" height="20" font="0">• HFH: In DDDR mode, the risk </text>
<text top="716" left="713" width="155" height="19" font="0">increased with increased </text>
<text top="734" left="713" width="152" height="19" font="0">Cum VP% from 0% up to </text>
<text top="752" left="713" width="159" height="19" font="0">~40% pacing then leveled </text>
<text top="771" left="713" width="148" height="19" font="0">out. Vp &gt;40% of time as </text>
<text top="659" left="904" width="185" height="20" font="0">• AF: Risk increased by 1% for </text>
<text top="678" left="915" width="181" height="19" font="0">each 1% increase in Cum%VP </text>
<text top="697" left="915" width="174" height="19" font="0">up to 85%; p=0.012 (DDDR). </text>
<text top="715" left="915" width="141" height="19" font="0">Risk increased by 0.7% </text>
<text top="733" left="915" width="163" height="19" font="0">increase in Cum%VP up to </text>
<text top="752" left="915" width="131" height="19" font="0">80%; p=0.039 (VVIR). </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 98 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="228" width="131" height="19" font="8"><b>Study type: </b>Post-hoc </text>
<text top="105" left="228" width="94" height="19" font="0">analysis of RCT </text>
<text top="123" left="228" width="3" height="19" font="0"> </text>
<text top="142" left="228" width="92" height="19" font="8"><b>Size:</b> 1,339 pts<b> </b></text>
<text top="87" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="105" left="378" width="124" height="19" font="0">Baseline QRSd &gt;120 </text>
<text top="123" left="378" width="21" height="19" font="0">ms<b> </b></text>
<text top="87" left="533" width="142" height="19" font="0">Median follow-up 33.1 </text>
<text top="105" left="533" width="23" height="19" font="0">mo<b> </b></text>
<text top="87" left="713" width="166" height="19" font="0">compared to &lt;40% of time </text>
<text top="105" left="713" width="150" height="19" font="0">was associated with HR: </text>
<text top="123" left="713" width="143" height="19" font="0">2.60 (p=0.040). In VVIR </text>
<text top="142" left="713" width="150" height="19" font="0">mode, the risk was level </text>
<text top="160" left="713" width="128" height="19" font="0">between 0–80% and </text>
<text top="178" left="713" width="178" height="19" font="0">increased from 80–100%. Vp </text>
<text top="197" left="713" width="166" height="19" font="0">&gt;80% of time as compared </text>
<text top="215" left="713" width="128" height="19" font="0">to &lt;80% of time was </text>
<text top="233" left="713" width="123" height="19" font="0">associated HR: 2.50 </text>
<text top="252" left="713" width="70" height="19" font="0">(p=0.0012) </text>
<text top="271" left="95" width="102" height="19" font="0">Nielsen JC, et al. </text>
<text top="289" left="95" width="69" height="19" font="0">2003 (147) </text>
<text top="307" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12932590">12932590</a></text>
<text top="307" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12932590"><b> </b></a></text>
<text top="271" left="228" width="121" height="19" font="8"><b>Aim:</b> A randomized </text>
<text top="289" left="228" width="126" height="19" font="0">comparison of atrial </text>
<text top="307" left="228" width="115" height="19" font="0">and dual-chamber </text>
<text top="326" left="228" width="84" height="19" font="0">pacing in 177 </text>
<text top="344" left="228" width="129" height="19" font="0">consecutive patients </text>
<text top="362" left="228" width="134" height="19" font="0">with SSS. To compare </text>
<text top="381" left="228" width="125" height="19" font="0">AAI and DDD pacing </text>
<text top="399" left="228" width="91" height="19" font="0">in pts with SSS </text>
<text top="417" left="228" width="3" height="19" font="0"> </text>
<text top="435" left="228" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="454" left="228" width="3" height="19" font="0"> </text>
<text top="472" left="228" width="80" height="19" font="8"><b>Size:</b> 177 pts<b> </b></text>
<text top="271" left="378" width="139" height="19" font="8"><b>Inclusion criteria: </b>SSS, </text>
<text top="289" left="378" width="68" height="19" font="0">normal AV </text>
<text top="307" left="378" width="76" height="19" font="0">conduction, </text>
<text top="326" left="378" width="83" height="19" font="0">symptomatic </text>
<text top="344" left="378" width="113" height="19" font="0">bradycardia &lt;40 b </text>
<text top="362" left="378" width="111" height="19" font="0">symptomatic QRS </text>
<text top="381" left="378" width="135" height="19" font="0">pause of &gt;2 s, age&gt;18 </text>
<text top="399" left="378" width="10" height="19" font="0">y </text>
<text top="417" left="378" width="3" height="19" font="0"> </text>
<text top="435" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="454" left="378" width="135" height="19" font="0">BBB, AVB, chronic AF, </text>
<text top="472" left="378" width="106" height="19" font="0">cerebral disease, </text>
<text top="491" left="378" width="117" height="19" font="0">planned cardiac or </text>
<text top="509" left="378" width="136" height="19" font="0">major surgery, cancer<b> </b></text>
<text top="271" left="533" width="129" height="19" font="8"><b>Intervention 1: </b>AAIR </text>
<text top="289" left="533" width="45" height="19" font="0">(N=54) </text>
<text top="307" left="533" width="3" height="19" font="0"> </text>
<text top="326" left="533" width="136" height="19" font="8"><b>Intervention 2: </b>DDDR </text>
<text top="344" left="533" width="122" height="19" font="0">with short AV delay </text>
<text top="362" left="533" width="123" height="19" font="0">(&lt;150 ms) (DDDR-s) </text>
<text top="381" left="533" width="45" height="19" font="0">(N=60) </text>
<text top="399" left="533" width="3" height="19" font="0"> </text>
<text top="417" left="533" width="136" height="19" font="8"><b>Intervention 3: </b>DDDR </text>
<text top="436" left="533" width="150" height="19" font="0">with fixed long AV delay </text>
<text top="454" left="533" width="113" height="19" font="0">(300 ms) (DDDR-l) </text>
<text top="472" left="533" width="45" height="19" font="0">(N=63) </text>
<text top="491" left="533" width="3" height="19" font="0"> </text>
<text top="509" left="533" width="133" height="19" font="0">Mean follow-up 2.9 y<b> </b></text>
<text top="271" left="702" width="151" height="20" font="0">• LA diameter increased </text>
<text top="290" left="713" width="162" height="19" font="0">significantly in both DDDR </text>
<text top="308" left="713" width="100" height="19" font="0">groups (p&lt;0.05) </text>
<text top="327" left="702" width="164" height="20" font="0">• LVES diameter increased </text>
<text top="346" left="713" width="162" height="19" font="0">significantly in both DDDR </text>
<text top="364" left="713" width="100" height="19" font="0">groups (p&lt;0.05) </text>
<text top="382" left="702" width="167" height="20" font="0">• LVED diameter increased </text>
<text top="401" left="713" width="177" height="19" font="0">significantly in DDDR-l group </text>
<text top="420" left="713" width="54" height="19" font="0">(p&lt;0.01) </text>
<text top="438" left="702" width="185" height="20" font="0">• LVFS decreased significantly </text>
<text top="457" left="713" width="158" height="19" font="0">in DDDR-s group (p&lt;0.01) </text>
<text top="476" left="702" width="179" height="20" font="0">• Percent Vp: 90% in DDDR-s </text>
<text top="494" left="713" width="114" height="19" font="0">vs.  17% in DDDR-l </text>
<text top="271" left="904" width="173" height="20" font="0">• AF incidence at follow-up: </text>
<text top="290" left="915" width="164" height="19" font="0">AAIR 7.4%, DDDR-s 23.3%, </text>
<text top="308" left="915" width="142" height="19" font="0">DDDR-l 17.5% (p=0.03) </text>
<text top="327" left="904" width="177" height="20" font="0">• Stroke: AAIR 5.6%, DDDR-s </text>
<text top="346" left="915" width="179" height="19" font="0">11.7%, DDDR-l 6.3% (p=0.32) </text>
<text top="364" left="904" width="182" height="20" font="0">• Death: AAIR 16.7%, DDDR-s </text>
<text top="383" left="915" width="132" height="19" font="0">23.3%, DDDR-l 22.2% </text>
<text top="401" left="915" width="54" height="19" font="0">(p=0.51) </text>
<text top="420" left="904" width="184" height="20" font="0">• CV death: AAIR 7.4%, DDDR-</text>
<text top="439" left="915" width="142" height="19" font="0">s 11.7%, DDDR-l 14.3% </text>
<text top="457" left="915" width="54" height="19" font="0">(p=0.43) </text>
<text top="528" left="95" width="64" height="19" font="8"><b>DANPACE </b></text>
<text top="546" left="95" width="105" height="19" font="0">Brandt NH, et al. </text>
<text top="564" left="95" width="69" height="19" font="0">2016 (148) </text>
<text top="583" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28039212">28039212</a></text>
<text top="583" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28039212"><b> </b></a></text>
<text top="528" left="228" width="112" height="19" font="8"><b>Aim:</b> To present a </text>
<text top="546" left="228" width="122" height="19" font="0">long-term outcome </text>
<text top="564" left="228" width="116" height="19" font="0">of initial DANPACE </text>
<text top="583" left="228" width="28" height="19" font="0">trial </text>
<text top="601" left="228" width="3" height="19" font="0"> </text>
<text top="619" left="228" width="108" height="19" font="8"><b>Study type: </b>Long-</text>
<text top="638" left="228" width="138" height="19" font="0">term follow-up of RCT </text>
<text top="656" left="228" width="3" height="19" font="0"> </text>
<text top="674" left="228" width="92" height="19" font="8"><b>Size:</b> 1,384 pts<b> </b></text>
<text top="528" left="378" width="130" height="19" font="8"><b>Inclusion criteria: </b>SA </text>
<text top="546" left="378" width="126" height="19" font="0">block or sinus arrest </text>
<text top="564" left="378" width="127" height="19" font="0">with pauses &gt;2 s, PR </text>
<text top="583" left="378" width="121" height="19" font="0">≤260 ms, QRS &lt;120 </text>
<text top="601" left="378" width="116" height="19" font="0">ms, heart rate &lt;40 </text>
<text top="619" left="378" width="79" height="19" font="0">while awake </text>
<text top="638" left="378" width="3" height="19" font="0"> </text>
<text top="656" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="674" left="378" width="95" height="19" font="0">AVB, BBB, long-</text>
<text top="693" left="378" width="129" height="19" font="0">standing PerAF, with </text>
<text top="711" left="378" width="81" height="19" font="0">carotid sinus </text>
<text top="729" left="378" width="103" height="19" font="0">hypersensitivity, </text>
<text top="748" left="378" width="100" height="19" font="0">planned cardiac </text>
<text top="766" left="378" width="75" height="19" font="0">surgery, life </text>
<text top="784" left="378" width="101" height="19" font="0">expectancy &lt;1 y<b> </b></text>
<text top="528" left="533" width="132" height="19" font="8"><b>Intervention: </b>Bipolar </text>
<text top="546" left="533" width="131" height="19" font="0">atrial lead only (AAIR </text>
<text top="564" left="533" width="143" height="19" font="0">pacing programmed to </text>
<text top="583" left="533" width="133" height="19" font="0">LR of 60 ppm) – must </text>
<text top="601" left="533" width="148" height="19" font="0">have 1:1 AV conduction </text>
<text top="619" left="533" width="126" height="19" font="0">at paced rate of 100 </text>
<text top="638" left="533" width="84" height="19" font="0">bpm (N=696) </text>
<text top="656" left="533" width="3" height="19" font="0"> </text>
<text top="674" left="533" width="122" height="19" font="8"><b>Comparator: </b>DDDR </text>
<text top="693" left="533" width="143" height="19" font="0">pacing programmed to </text>
<text top="711" left="533" width="131" height="19" font="0">LR of 60 ppm AND to </text>
<text top="729" left="533" width="114" height="19" font="0">minimize V pacing </text>
<text top="748" left="533" width="52" height="19" font="0">(N=688) </text>
<text top="766" left="533" width="3" height="19" font="0"> </text>
<text top="784" left="533" width="133" height="19" font="0">Mean follow-up 8.9 y<b> </b></text>
<text top="528" left="702" width="173" height="20" font="0">• All-cause mortality: 59.3% </text>
<text top="547" left="713" width="165" height="19" font="0">AAIR vs.  53.3% DDDR (HR: </text>
<text top="565" left="713" width="151" height="19" font="0">1.03; 95% CI: 0.90–1.19; </text>
<text top="584" left="713" width="50" height="19" font="0">p=0.65) </text>
<text top="528" left="904" width="171" height="20" font="0">• AF: 28.6% AAIR vs.  29.1% </text>
<text top="547" left="915" width="158" height="19" font="0">DDDR (aHR: 0.98; 95% CI: </text>
<text top="565" left="915" width="118" height="19" font="0">0.80–1.19; p=0.82) </text>
<text top="584" left="904" width="179" height="20" font="0">• Ischemic stroke: 9.0% AAIR </text>
<text top="603" left="915" width="163" height="19" font="0">vs.  8.6% DDDR (Ahr: 1.00; </text>
<text top="621" left="915" width="166" height="19" font="0">95% CI: 0.69–1.43; p=0.99) </text>
<text top="639" left="904" width="181" height="20" font="0">• HFH: 12.0% AAIR vs.  11.5% </text>
<text top="658" left="915" width="158" height="19" font="0">DDDR (aHR: 1.01; 95% CI: </text>
<text top="677" left="915" width="118" height="19" font="0">0.74–1.38; p=0.95) </text>
<text top="695" left="904" width="183" height="20" font="0">• Annual rate of pacing mode </text>
<text top="714" left="915" width="169" height="19" font="0">change from AAIR to DDDR </text>
<text top="732" left="915" width="37" height="19" font="0">4.5%  </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="570" width="51" height="19" font="0">Page 99 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="45" height="19" font="8"><b>ADEPT </b></text>
<text top="105" left="95" width="101" height="19" font="0">Lamas GA, et al. </text>
<text top="123" left="95" width="69" height="19" font="0">2007 (132) </text>
<text top="142" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17765608">17765608</a></text>
<text top="142" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17765608"><b> </b></a></text>
<text top="87" left="228" width="118" height="19" font="8"><b>Aim:</b> To determine </text>
<text top="105" left="228" width="137" height="19" font="0">whether DDDR pacing </text>
<text top="123" left="228" width="127" height="19" font="0">improves QOL when </text>
<text top="142" left="228" width="113" height="19" font="0">compared to DDD </text>
<text top="160" left="228" width="80" height="19" font="0">pacing alone </text>
<text top="178" left="228" width="3" height="19" font="0"> </text>
<text top="197" left="228" width="112" height="19" font="8"><b>Study type: </b>Multi-</text>
<text top="215" left="228" width="117" height="19" font="0">center single-blind </text>
<text top="233" left="228" width="27" height="19" font="0">RCT </text>
<text top="252" left="228" width="3" height="19" font="0"> </text>
<text top="270" left="228" width="80" height="19" font="8"><b>Size:</b> 872 pts<b> </b></text>
<text top="87" left="378" width="138" height="19" font="8"><b>Inclusion criteria: </b>Age </text>
<text top="105" left="378" width="117" height="19" font="0">≥21 y, Class I or 2A </text>
<text top="123" left="378" width="132" height="19" font="0">indication for pacing, </text>
<text top="142" left="378" width="90" height="19" font="0">demonstrated </text>
<text top="160" left="378" width="82" height="19" font="0">chronotropic </text>
<text top="178" left="378" width="140" height="19" font="0">incompetence, cannot </text>
<text top="197" left="378" width="133" height="19" font="0">exceed 80% of MPHR </text>
<text top="215" left="378" width="110" height="19" font="0">(220-age) at peak </text>
<text top="233" left="378" width="53" height="19" font="0">exercise </text>
<text top="252" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="270" left="378" width="132" height="19" font="8"><b>Exclusion criteria:</b> AF </text>
<text top="288" left="378" width="134" height="19" font="0">for &gt;1 mo, overt CHF, </text>
<text top="307" left="378" width="140" height="19" font="0">serious chronic illness, </text>
<text top="325" left="378" width="97" height="19" font="0">score of &lt;17 on </text>
<text top="343" left="378" width="115" height="19" font="0">MMSE, inability to </text>
<text top="362" left="378" width="111" height="19" font="0">tolerate high-rate </text>
<text top="380" left="378" width="91" height="19" font="0">pacing, severe </text>
<text top="398" left="378" width="84" height="19" font="0">limitations of </text>
<text top="416" left="378" width="119" height="19" font="0">functional capacity<b> </b></text>
<text top="87" left="533" width="118" height="19" font="8"><b>Intervention:</b> MDT </text>
<text top="105" left="533" width="107" height="19" font="0">Kappa 400 DDDR </text>
<text top="123" left="533" width="154" height="19" font="0">pacemaker programmed </text>
<text top="142" left="533" width="108" height="19" font="0">to DDDR (N=443) </text>
<text top="160" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="178" left="533" width="115" height="19" font="8"><b>Comparator:</b> MDT </text>
<text top="197" left="533" width="107" height="19" font="0">Kappa 400 DDDR </text>
<text top="215" left="533" width="154" height="19" font="0">pacemaker programmed </text>
<text top="233" left="533" width="100" height="19" font="0">to DDD (N=429) </text>
<text top="252" left="533" width="3" height="19" font="0"> </text>
<text top="270" left="533" width="3" height="19" font="0"> </text>
<text top="288" left="533" width="122" height="19" font="0">Mean follow-up 1 y </text>
<text top="307" left="533" width="85" height="19" font="0">64% had SND </text>
<text top="325" left="533" width="114" height="19" font="0">Vp% &gt;90% in both </text>
<text top="343" left="533" width="45" height="19" font="0">groups<b> </b></text>
<text top="87" left="702" width="179" height="20" font="0">• Total exercise time (6 mo): </text>
<text top="106" left="714" width="149" height="19" font="0">7.3 vs.  7.1 min (p=0.98) </text>
<text top="124" left="702" width="181" height="20" font="0">• Specific Activity Scale (SAS) </text>
<text top="143" left="714" width="163" height="19" font="0">at 1 y: 1.5 vs.  1.6 (p=0.96) </text>
<text top="87" left="904" width="173" height="20" font="0">• No differences in other 2° </text>
<text top="106" left="917" width="94" height="19" font="0">QOL endpoints </text>
<text top="124" left="904" width="154" height="20" font="0">• CHF hospitalizations in </text>
<text top="143" left="917" width="176" height="19" font="0">DDDR group vs.  DDD group: </text>
<text top="162" left="917" width="139" height="19" font="0">7.3% vs.  3.5%; p=0.01 </text>
<text top="180" left="904" width="157" height="20" font="0">• No differences in other </text>
<text top="199" left="917" width="110" height="19" font="0">clinical endpoints </text>
<text top="435" left="95" width="35" height="19" font="8"><b>RAST </b></text>
<text top="454" left="95" width="98" height="19" font="0">Krahn AD, et al. </text>
<text top="472" left="95" width="30" height="19" font="0">2001</text>
<text top="471" left="125" width="4" height="21" font="4"> </text>
<text top="472" left="129" width="28" height="19" font="0">(72) </text>
<text top="491" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11435336">11435336</a></text>
<text top="490" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11435336"><b> </b></a></text>
<text top="435" left="228" width="106" height="19" font="8"><b> Aim:</b> To find out </text>
<text top="454" left="228" width="121" height="19" font="0">whether prolonged </text>
<text top="472" left="228" width="137" height="19" font="0">monitoring strategy is </text>
<text top="491" left="228" width="73" height="19" font="0">better than </text>
<text top="509" left="228" width="136" height="19" font="0">conventional strategy </text>
<text top="527" left="228" width="122" height="19" font="0">in the evaluation of </text>
<text top="545" left="228" width="115" height="19" font="0">recurrent syncope </text>
<text top="564" left="228" width="3" height="19" font="0"> </text>
<text top="582" left="228" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="600" left="228" width="75" height="19" font="0">Prospective </text>
<text top="619" left="228" width="104" height="19" font="0">randomized trial </text>
<text top="637" left="228" width="3" height="19" font="0"> </text>
<text top="655" left="228" width="73" height="19" font="8"><b>Size:</b> 60 pts<b> </b></text>
<text top="435" left="378" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="454" left="378" width="142" height="19" font="0">Recurrent unexplained </text>
<text top="472" left="378" width="135" height="19" font="0">syncope or syncope X </text>
<text top="491" left="378" width="109" height="19" font="0">1 associated with </text>
<text top="509" left="378" width="38" height="19" font="0">injury </text>
<text top="527" left="378" width="3" height="19" font="8"><b> </b></text>
<text top="545" left="378" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="564" left="378" width="102" height="19" font="0">LVEF &lt;35%, &lt;1 y </text>
<text top="582" left="378" width="113" height="19" font="0">expected survival, </text>
<text top="600" left="378" width="111" height="19" font="0">unable to provide </text>
<text top="619" left="378" width="134" height="19" font="0">follow-up or consent, </text>
<text top="637" left="378" width="66" height="19" font="0">clear NMS<b> </b></text>
<text top="435" left="533" width="144" height="19" font="8"><b>Intervention:</b> ILR (MDT </text>
<text top="454" left="533" width="152" height="19" font="0">Reveal) monitoring for 1 </text>
<text top="472" left="533" width="55" height="19" font="0">y (N=27)<b> </b></text>
<text top="490" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="509" left="533" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="527" left="533" width="151" height="19" font="0">Conventional testing – 2 </text>
<text top="545" left="533" width="148" height="19" font="0">to 4 wk of external loop </text>
<text top="564" left="533" width="130" height="19" font="0">recorder, TTT and EP </text>
<text top="582" left="533" width="127" height="19" font="0">testing (SNRT, SACT, </text>
<text top="600" left="533" width="137" height="19" font="0">antegrade/retrograde </text>
<text top="619" left="533" width="76" height="19" font="0">conduction, </text>
<text top="637" left="533" width="142" height="19" font="0">programmed electrical </text>
<text top="655" left="533" width="122" height="19" font="0">stimulation) (N=30) </text>
<text top="674" left="533" width="3" height="19" font="0"> </text>
<text top="692" left="533" width="154" height="19" font="0">Crossover was allowed if </text>
<text top="710" left="533" width="127" height="19" font="0">Dx was unable to be </text>
<text top="728" left="533" width="42" height="19" font="0">made.<b> </b></text>
<text top="436" left="702" width="178" height="20" font="0">• Dx obtained in 14 of 27 pts </text>
<text top="455" left="713" width="161" height="19" font="0">(ILR group) vs.  6 of 30 pts </text>
<text top="473" left="713" width="165" height="19" font="0">(conventional group) (52% </text>
<text top="491" left="713" width="114" height="19" font="0">vs.  20%; p=0.012) </text>
<text top="436" left="904" width="28" height="19" font="0">N/A </text>
<text top="747" left="95" width="48" height="19" font="8"><b>EaSyAS </b></text>
<text top="766" left="95" width="103" height="19" font="0">Farwell DJ, et al. </text>
<text top="784" left="95" width="30" height="19" font="0">2004</text>
<text top="783" left="125" width="4" height="21" font="4"> </text>
<text top="784" left="129" width="28" height="19" font="0">(73) </text>
<text top="747" left="228" width="127" height="19" font="8"><b>Aim:</b> Investigate the </text>
<text top="766" left="228" width="108" height="19" font="0">impact of ILRs on </text>
<text top="784" left="228" width="70" height="19" font="0">unselected </text>
<text top="747" left="378" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="766" left="378" width="142" height="19" font="0">Recurrent syncope but </text>
<text top="784" left="378" width="99" height="19" font="0">no definitive Dx </text>
<text top="747" left="533" width="133" height="19" font="8"><b>Interventions: </b>CSM + </text>
<text top="766" left="533" width="134" height="19" font="0">TTT + implantation of </text>
<text top="784" left="533" width="139" height="19" font="0">loop recorder (N=103) </text>
<text top="748" left="702" width="172" height="20" font="0">• EKG Dx made: 34 (33%) in </text>
<text top="767" left="713" width="137" height="19" font="0">ILR group vs. 4 (4%) in </text>
<text top="748" left="904" width="185" height="20" font="0">• Total medical costs: £406 in </text>
<text top="767" left="931" width="137" height="19" font="0">ILR group vs. £1210 in </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 100 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15246645">15246645</a></text>
<text top="87" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15246645"><b> </b></a></text>
<text top="87" left="228" width="86" height="19" font="0">population of </text>
<text top="105" left="228" width="79" height="19" font="0">syncopal pts </text>
<text top="123" left="228" width="112" height="19" font="0">presenting to one </text>
<text top="142" left="228" width="66" height="19" font="0">institution </text>
<text top="160" left="228" width="3" height="19" font="0"> </text>
<text top="178" left="228" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="197" left="228" width="107" height="19" font="0">Randomized trial </text>
<text top="215" left="228" width="3" height="19" font="0"> </text>
<text top="233" left="228" width="80" height="19" font="8"><b>Size: </b>201 pts<b> </b></text>
<text top="87" left="378" width="142" height="19" font="0">following initial clinical </text>
<text top="105" left="378" width="122" height="19" font="0">w/u (including CSM </text>
<text top="123" left="378" width="56" height="19" font="0">and TTT) </text>
<text top="142" left="378" width="3" height="19" font="0"> </text>
<text top="160" left="378" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="178" left="378" width="100" height="19" font="0">Structural heart </text>
<text top="197" left="378" width="49" height="19" font="0">disease<b> </b></text>
<text top="87" left="533" width="3" height="19" font="0"> </text>
<text top="105" left="533" width="150" height="19" font="8"><b>Comparator: </b>CSM + TTT </text>
<text top="123" left="533" width="93" height="19" font="0">+ conventional </text>
<text top="142" left="533" width="127" height="19" font="0">investigation (N=98) </text>
<text top="160" left="533" width="3" height="19" font="0"> </text>
<text top="178" left="533" width="138" height="19" font="0">Mean follow-up 276 d<b> </b></text>
<text top="87" left="713" width="151" height="19" font="0">conventional group (HR: </text>
<text top="105" left="713" width="139" height="19" font="0">8.93; 95% CI: 3.17–25; </text>
<text top="123" left="713" width="65" height="19" font="0">p&lt;0.0001) </text>
<text top="87" left="931" width="164" height="19" font="0">conventional group (mean </text>
<text top="105" left="931" width="152" height="19" font="0">difference £809; 95% CI: </text>
<text top="123" left="931" width="69" height="19" font="0">123–2730) </text>
<text top="252" left="95" width="43" height="19" font="8"><b>FRESH </b></text>
<text top="271" left="95" width="118" height="19" font="0">Podoleanu C, et al. </text>
<text top="289" left="95" width="30" height="19" font="0">2014</text>
<text top="288" left="125" width="4" height="21" font="4"> </text>
<text top="289" left="129" width="28" height="19" font="0">(74) </text>
<text top="307" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25241220">25241220</a></text>
<text top="307" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25241220"><b> </b></a></text>
<text top="252" left="228" width="108" height="19" font="8"><b>Aim:</b> To compare </text>
<text top="271" left="228" width="83" height="19" font="0">conventional </text>
<text top="289" left="228" width="121" height="19" font="0">evaluation vs. early </text>
<text top="307" left="228" width="128" height="19" font="0">use of ILR in low-risk </text>
<text top="326" left="228" width="121" height="19" font="0">pts with syncope in </text>
<text top="344" left="228" width="44" height="19" font="0">France </text>
<text top="362" left="228" width="3" height="19" font="0"> </text>
<text top="381" left="228" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="399" left="228" width="110" height="19" font="0">Prospective open-</text>
<text top="417" left="228" width="109" height="19" font="0">label randomized </text>
<text top="436" left="228" width="111" height="19" font="0">multicenter study </text>
<text top="454" left="228" width="3" height="19" font="0"> </text>
<text top="472" left="228" width="73" height="19" font="8"><b>Size:</b> 78 pts<b> </b></text>
<text top="252" left="378" width="138" height="19" font="8"><b>Inclusion criteria:</b> Any </text>
<text top="271" left="378" width="121" height="19" font="0">recent unexplained </text>
<text top="289" left="378" width="125" height="19" font="0">syncope (after basic </text>
<text top="307" left="378" width="86" height="19" font="0">clinical exam) </text>
<text top="326" left="378" width="3" height="19" font="0"> </text>
<text top="344" left="378" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="362" left="378" width="103" height="19" font="0">Significant heart </text>
<text top="381" left="378" width="130" height="19" font="0">disease, EF &lt;40%, Hx </text>
<text top="399" left="378" width="142" height="19" font="0">of MI or unstable CAD, </text>
<text top="417" left="378" width="110" height="19" font="0">Hx of arrhythmia, </text>
<text top="436" left="378" width="107" height="19" font="0">family Hx of SCD, </text>
<text top="454" left="378" width="72" height="19" font="0">conduction </text>
<text top="472" left="378" width="126" height="19" font="0">disturbance on EKG, </text>
<text top="491" left="378" width="139" height="19" font="0">HOCM, AS, potentially </text>
<text top="509" left="378" width="132" height="19" font="0">arrhythmogenic drug </text>
<text top="527" left="378" width="25" height="19" font="0">use<b> </b></text>
<text top="252" left="533" width="146" height="19" font="8"><b>Intervention:</b> ILR group </text>
<text top="271" left="533" width="45" height="19" font="0">(N=39) </text>
<text top="289" left="533" width="3" height="19" font="0"> </text>
<text top="307" left="533" width="83" height="19" font="8"><b>Comparator: </b></text>
<text top="326" left="533" width="152" height="19" font="0">Conventional evaluation </text>
<text top="344" left="533" width="137" height="19" font="0">strategy group (N=39) </text>
<text top="362" left="533" width="3" height="19" font="0"> </text>
<text top="381" left="533" width="66" height="19" font="0">F/u 14 mo<b> </b></text>
<text top="253" left="702" width="172" height="20" font="0">• Identification of cause: 18 </text>
<text top="272" left="713" width="179" height="19" font="0">(46.2%) pts in ILR group vs. 2 </text>
<text top="290" left="713" width="150" height="19" font="0">(5%) pts in conventional </text>
<text top="308" left="713" width="101" height="19" font="0">group (p&lt;0.001) </text>
<text top="327" left="702" width="190" height="20" font="0">• Days of hospitalization: 5.7 d </text>
<text top="346" left="713" width="144" height="19" font="0">in ILR group vs. 8.0 d in </text>
<text top="364" left="713" width="176" height="19" font="0">conventional group (p=0.55) </text>
<text top="382" left="702" width="189" height="20" font="0">• Number of advanced cardiac </text>
<text top="401" left="713" width="171" height="19" font="0">tests needed: 0.03/pt in ILR </text>
<text top="420" left="713" width="115" height="19" font="0">group vs. 0.2/pt in </text>
<text top="438" left="713" width="176" height="19" font="0">conventional group (p=0.05) </text>
<text top="253" left="904" width="143" height="20" font="0">• Quality of life was no </text>
<text top="272" left="915" width="149" height="19" font="0">different between the 2 </text>
<text top="290" left="915" width="45" height="19" font="0">groups </text>
<text top="546" left="95" width="70" height="19" font="8"><b>THEOPACE </b></text>
<text top="564" left="95" width="91" height="19" font="0">Alboni P, et al. </text>
<text top="583" left="95" width="30" height="19" font="0">1997</text>
<text top="581" left="125" width="4" height="21" font="4"> </text>
<text top="583" left="129" width="35" height="19" font="0">(133) </text>
<text top="601" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9236443">9236443</a></text>
<text top="601" left="148" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9236443"><b> </b></a></text>
<text top="546" left="228" width="136" height="19" font="8"><b>Aim:</b> To prospectively </text>
<text top="564" left="228" width="126" height="19" font="0">assess the effects of </text>
<text top="583" left="228" width="64" height="19" font="0">PPMs and </text>
<text top="601" left="228" width="117" height="19" font="0">theophylline in pts </text>
<text top="619" left="228" width="58" height="19" font="0">with SSS  </text>
<text top="638" left="228" width="3" height="19" font="0"> </text>
<text top="656" left="228" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="674" left="228" width="79" height="19" font="0">Randomized </text>
<text top="693" left="228" width="94" height="19" font="0">controlled trial </text>
<text top="711" left="228" width="3" height="19" font="0"> </text>
<text top="729" left="228" width="80" height="19" font="8"><b>Size:</b> 107 pts<b> </b></text>
<text top="546" left="378" width="138" height="19" font="8"><b>Inclusion criteria:</b> Age </text>
<text top="564" left="378" width="123" height="19" font="0">≥45 y, mean resting </text>
<text top="583" left="378" width="120" height="19" font="0">sinus rate &lt;50 bpm </text>
<text top="601" left="378" width="142" height="19" font="0">and/or intermittent SA </text>
<text top="619" left="378" width="106" height="19" font="0">block, symptoms </text>
<text top="638" left="378" width="122" height="19" font="0">attributable to SND </text>
<text top="656" left="378" width="3" height="19" font="0"> </text>
<text top="674" left="378" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="693" left="378" width="103" height="19" font="0">Very severe SSS, </text>
<text top="711" left="378" width="131" height="19" font="0">refractory HF, recent </text>
<text top="729" left="378" width="104" height="19" font="0">MI or stroke, life </text>
<text top="748" left="378" width="105" height="19" font="0">expectancy &lt;2 y, </text>
<text top="766" left="378" width="117" height="19" font="0">significant renal or </text>
<text top="784" left="378" width="136" height="19" font="0">hepatic disease, Hx of </text>
<text top="546" left="533" width="124" height="19" font="8"><b>Intervention 1:</b> oral </text>
<text top="564" left="533" width="142" height="19" font="0">theophylline 550 mg/d </text>
<text top="583" left="533" width="45" height="19" font="0">(N=36) </text>
<text top="601" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="619" left="533" width="136" height="19" font="8"><b>Intervention 2:</b> DDDR </text>
<text top="638" left="533" width="131" height="19" font="0">PPM programmed to </text>
<text top="656" left="533" width="155" height="19" font="0">lower rate of 60–70 ppm </text>
<text top="674" left="533" width="149" height="19" font="0">and prolonged AV delay </text>
<text top="693" left="533" width="45" height="19" font="0">(N=36)<b> </b></text>
<text top="711" left="533" width="3" height="19" font="8"><b> </b></text>
<text top="729" left="533" width="104" height="19" font="8"><b>Comparator:</b> No </text>
<text top="748" left="533" width="111" height="19" font="0">treatment (N=35) </text>
<text top="766" left="533" width="3" height="19" font="0"> </text>
<text top="546" left="702" width="115" height="20" font="0">• Syncope: 6(17%) </text>
<text top="565" left="713" width="158" height="19" font="0">theophylline, 2(6%) PPM, </text>
<text top="584" left="713" width="170" height="19" font="0">8(23%) control arm: p=0.02 </text>
<text top="602" left="713" width="157" height="19" font="0">(PPM vs. control); p=0.07 </text>
<text top="620" left="713" width="156" height="19" font="0">(theophylline vs. control) </text>
<text top="639" left="702" width="156" height="20" font="0">• HF: 1(3%) theophylline, </text>
<text top="658" left="713" width="167" height="19" font="0">1(3%) PPM, 6(17%) control </text>
<text top="676" left="713" width="154" height="19" font="0">arm: p=0.05 (lower HF in </text>
<text top="694" left="713" width="158" height="19" font="0">PPM and theophylline vs. </text>
<text top="713" left="713" width="75" height="19" font="0">control arm </text>
<text top="731" left="702" width="143" height="20" font="0">• Permanent AF: 2(6%) </text>
<text top="750" left="713" width="158" height="19" font="0">theophylline, 3(9%) PPM, </text>
<text top="546" left="904" width="173" height="20" font="0">• Thromboembolism: 3(9%) </text>
<text top="565" left="915" width="158" height="19" font="0">theophylline, 3(9%) PPM, </text>
<text top="584" left="915" width="136" height="19" font="0">1(3%) control arm: no </text>
<text top="602" left="915" width="110" height="19" font="0">difference (p=NS) </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 101 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="378" width="111" height="19" font="0">VT, prior usage of </text>
<text top="105" left="378" width="139" height="19" font="0">theophylline, need for </text>
<text top="123" left="378" width="64" height="19" font="0">BB or CCB<b> </b></text>
<text top="87" left="533" width="142" height="19" font="0">Mean follow-up 19±14 </text>
<text top="105" left="533" width="23" height="19" font="0">mo<b> </b></text>
<text top="87" left="713" width="144" height="19" font="0">4(11%) control arm: no </text>
<text top="105" left="713" width="110" height="19" font="0">difference (p=NS) </text>
<text top="143" left="86" width="4" height="21" font="4"> </text>
<text top="163" left="86" width="4" height="21" font="4"> </text>
<text top="183" left="86" width="997" height="23" font="5"><b>Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Reversible Causes of AV block (Section 6.3.1) </b></text>
<text top="205" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="224" left="138" width="51" height="19" font="8"><b>Author; </b></text>
<text top="242" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="205" left="255" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="224" left="284" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="205" left="446" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="205" left="649" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="224" left="680" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="242" left="711" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="205" left="918" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="224" left="947" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="261" left="96" width="124" height="19" font="0">Kenneback G, et al. <b> </b></text>
<text top="280" left="96" width="69" height="19" font="0">2007 (149) </text>
<text top="298" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17255148">17255148</a></text>
<text top="298" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17255148"> </a></text>
<text top="261" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="280" left="243" width="121" height="19" font="0">center, prospective </text>
<text top="298" left="243" width="104" height="19" font="0">cohort (Sweden) </text>
<text top="316" left="243" width="3" height="19" font="0"> </text>
<text top="334" left="243" width="140" height="19" font="8"><b>Size:</b> N=17 (53% men), </text>
<text top="353" left="243" width="92" height="19" font="0">mean age 77 y </text>
<text top="261" left="405" width="193" height="19" font="8"><b>Inclusion criteria:</b> Pts admitted </text>
<text top="280" left="405" width="155" height="19" font="0">with high-degree AVB on </text>
<text top="298" left="405" width="179" height="19" font="0">antiarrhythmic therapy (88% </text>
<text top="316" left="405" width="169" height="19" font="0">beta blocker) who received </text>
<text top="335" left="405" width="153" height="19" font="0">PPM, who then had AAD </text>
<text top="353" left="405" width="178" height="19" font="0">withdrawn with return of AV </text>
<text top="371" left="405" width="76" height="19" font="0">conduction. </text>
<text top="389" left="405" width="3" height="19" font="0"> </text>
<text top="408" left="405" width="199" height="19" font="8"><b>Exclusion criteria:</b> Valve surgery </text>
<text top="426" left="405" width="168" height="19" font="0">in past year, permanent AF </text>
<text top="262" left="621" width="199" height="19" font="8"><b>1</b>°<b> endpoint:</b> Recurrence of AVB </text>
<text top="280" left="621" width="214" height="19" font="0">detected by PM algorithm over 2 y </text>
<text top="299" left="621" width="3" height="19" font="0"> </text>
<text top="317" left="621" width="238" height="19" font="8"><b>Results:</b> 9/12 pts (75%) with QRS &gt;120 </text>
<text top="335" left="621" width="200" height="19" font="0">ms and 1/5 pts (20%) developed </text>
<text top="354" left="621" width="186" height="19" font="0">recurrent AVB. 6/17 pts (35%) </text>
<text top="372" left="621" width="213" height="19" font="0">developed atrial tachyarrhythmias </text>
<text top="390" left="621" width="104" height="19" font="0">requiring AAD tx </text>
<text top="261" left="878" width="212" height="20" font="0">•  Appropriate to place PPM in pts </text>
<text top="280" left="888" width="197" height="19" font="0">with AVB and QRS &gt;120 ms w/o </text>
<text top="299" left="888" width="171" height="19" font="0">further delay or evaluation. </text>
<text top="445" left="96" width="118" height="19" font="0">Knudsen MB, et al. </text>
<text top="463" left="96" width="73" height="19" font="0">2013 (150) <b> </b></text>
<text top="482" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746">23869746</a></text>
<text top="482" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746"> </a></text>
<text top="445" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="463" left="243" width="131" height="19" font="0">center, retrospective </text>
<text top="482" left="243" width="112" height="19" font="0">cohort (Denmark) </text>
<text top="500" left="243" width="3" height="19" font="0"> </text>
<text top="518" left="243" width="139" height="19" font="8"><b>Size:</b> N=55 (55% male, </text>
<text top="537" left="243" width="96" height="19" font="0">mean age 77 y) </text>
<text top="445" left="405" width="193" height="19" font="8"><b>Inclusion criteria:</b> Pts admitted </text>
<text top="463" left="405" width="182" height="19" font="0">with 2/3 AVB, had temporary </text>
<text top="482" left="405" width="200" height="19" font="0">wire, were on class II-IV AADs or </text>
<text top="500" left="405" width="55" height="19" font="0">digoxin.  </text>
<text top="518" left="405" width="3" height="19" font="0"> </text>
<text top="537" left="405" width="163" height="19" font="8"><b>Exclusion criteria:</b> No ECG </text>
<text top="555" left="405" width="173" height="19" font="0">documentation, AVB due to </text>
<text top="573" left="405" width="174" height="19" font="0">other identified cause, prior </text>
<text top="592" left="405" width="203" height="19" font="0">PPM explant, died within several </text>
<text top="610" left="405" width="31" height="19" font="0">days </text>
<text top="446" left="621" width="174" height="19" font="8"><b>1</b>°<b> endpoint:</b> Need for PPM; </text>
<text top="464" left="621" width="135" height="19" font="0">complications of TPM </text>
<text top="482" left="621" width="3" height="19" font="0"> </text>
<text top="501" left="621" width="233" height="19" font="8"><b>Results:</b> 47/55 (85%) required PPM in </text>
<text top="519" left="621" width="230" height="19" font="0">hospital. 2/55 had recurrent AVB and </text>
<text top="537" left="621" width="185" height="19" font="0">required PPM. 11% of pts had </text>
<text top="556" left="621" width="197" height="19" font="0">complication of TPM (infection/ </text>
<text top="574" left="621" width="233" height="19" font="0">dislodgment), also prolonged hospital </text>
<text top="592" left="621" width="28" height="19" font="0">stay </text>
<text top="445" left="878" width="200" height="20" font="0">• Pts with AVB on AADs /digoxin </text>
<text top="464" left="888" width="181" height="19" font="0">do not benefit from TPM and </text>
<text top="483" left="888" width="206" height="19" font="0">drug washout. Should proceed to </text>
<text top="501" left="888" width="100" height="19" font="0">PPM w/o delay. </text>
<text top="519" left="878" width="176" height="20" font="0">•  “In the elderly, the drug is </text>
<text top="538" left="888" width="189" height="19" font="0">virtually never the sole culprit; </text>
<text top="557" left="888" width="159" height="19" font="0">rather, it just exposes the </text>
<text top="575" left="888" width="207" height="19" font="0">underlying weakness of the aging </text>
<text top="593" left="888" width="125" height="19" font="0">conduction system” </text>
<text top="629" left="96" width="115" height="19" font="0">Osmonov D, et al. <b> </b></text>
<text top="647" left="96" width="69" height="19" font="0">2012 (151)<b> </b></text>
<text top="666" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22530749">22530749</a></text>
<text top="666" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22530749"> </a></text>
<text top="629" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="647" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="666" left="243" width="98" height="19" font="0">cohort (Turkey) </text>
<text top="684" left="243" width="3" height="19" font="0"> </text>
<text top="702" left="243" width="143" height="19" font="8"><b>Size:</b> N=108 (16% of all </text>
<text top="721" left="243" width="142" height="19" font="0">668 pts admit with 2/3 </text>
<text top="739" left="243" width="149" height="19" font="0">AVB). 30/108 (28%) had </text>
<text top="757" left="243" width="76" height="19" font="0">AF with SVR </text>
<text top="629" left="405" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="647" left="405" width="173" height="19" font="0">admitted with 2/3 AVB who </text>
<text top="666" left="405" width="166" height="19" font="0">were on AV nodal blocking </text>
<text top="684" left="405" width="86" height="19" font="0">drugs 2008–9 </text>
<text top="702" left="405" width="3" height="19" font="0"> </text>
<text top="720" left="405" width="137" height="19" font="8"><b>Exclusion criteria:</b> MI, </text>
<text top="739" left="405" width="202" height="19" font="0">electrolyte disturbances, digoxin </text>
<text top="757" left="405" width="168" height="19" font="0">toxicity, vasovagal syncope </text>
<text top="630" left="621" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution/ recurrence </text>
<text top="648" left="621" width="119" height="19" font="0">AVB, need for PPM </text>
<text top="666" left="621" width="3" height="19" font="0"> </text>
<text top="685" left="621" width="241" height="19" font="8"><b>Results:</b> Resolution of AVB with 72 h in </text>
<text top="703" left="621" width="194" height="19" font="0">78/108 (72%). 21/78 (27%) had </text>
<text top="721" left="621" width="213" height="19" font="0">recurrence of AVB. Overall 51/108 </text>
<text top="740" left="621" width="235" height="19" font="0">(48%) had persistent of recurrent AVB </text>
<text top="758" left="621" width="156" height="19" font="0">despite drug withdrawal. </text>
<text top="629" left="878" width="194" height="20" font="0">• Half of pts with AVB on nodal-</text>
<text top="648" left="888" width="171" height="19" font="0">blocking drugs require PPM </text>
<text top="666" left="888" width="186" height="19" font="0">before discharge despite drug </text>
<text top="685" left="888" width="76" height="19" font="0">withdrawal. </text>
<text top="703" left="878" width="195" height="20" font="0">•  Limited follow-up – other pts </text>
<text top="722" left="888" width="197" height="19" font="0">may have required PPM at later </text>
<text top="740" left="888" width="31" height="19" font="0">date </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 102 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="129" height="19" font="0">Zeltser D, et al. 2004 </text>
<text top="105" left="96" width="35" height="19" font="0">(152)<b> </b></text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15234417">15234417</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15234417"> </a></text>
<text top="87" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="105" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="123" left="243" width="89" height="19" font="0">cohort (Israel) </text>
<text top="142" left="243" width="3" height="19" font="0"> </text>
<text top="160" left="243" width="146" height="19" font="8"><b>Size:</b> N=169 (60% male, </text>
<text top="178" left="243" width="147" height="19" font="0">mean age 78 y). 92/169 </text>
<text top="197" left="243" width="118" height="19" font="0">(54%) receiving AV </text>
<text top="215" left="243" width="92" height="19" font="0">nodal blockers </text>
<text top="87" left="405" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="105" left="405" width="181" height="19" font="0">admitted with 2/3 AVB 1999–</text>
<text top="123" left="405" width="38" height="19" font="0">2003. </text>
<text top="142" left="405" width="3" height="19" font="0"> </text>
<text top="160" left="405" width="185" height="19" font="8"><b>Exclusion criteria:</b> MI, digoxin </text>
<text top="178" left="405" width="168" height="19" font="0">toxicity, vasovagal syncope </text>
<text top="88" left="621" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution/ recurrence </text>
<text top="106" left="621" width="119" height="19" font="0">AVB, need for PPM </text>
<text top="124" left="621" width="3" height="19" font="0"> </text>
<text top="143" left="621" width="188" height="19" font="8"><b>Results:</b> 79/92 (86%) had drug </text>
<text top="161" left="621" width="187" height="19" font="0">discontinued. 32/79(41%) had </text>
<text top="179" left="621" width="244" height="19" font="0">resolution of AVB. 18/32 had relapse of </text>
<text top="198" left="621" width="106" height="19" font="0">AVB within 3 wk  </text>
<text top="87" left="878" width="217" height="20" font="0">• Overall, only 15% of pts with AVB </text>
<text top="106" left="888" width="203" height="19" font="0">on nodal blocking drugs had AVB </text>
<text top="124" left="888" width="114" height="19" font="0">“caused by drugs” </text>
<text top="143" left="878" width="128" height="20" font="0">• F-u limited to 3 wk </text>
<text top="234" left="96" width="108" height="19" font="0">Risgaard B, et al. <b> </b></text>
<text top="252" left="96" width="69" height="19" font="0">2012 (153)<b> </b></text>
<text top="271" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22333242">22333242</a></text>
<text top="271" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22333242"> </a></text>
<text top="234" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="252" left="243" width="127" height="19" font="0">Retrospective single-</text>
<text top="271" left="243" width="131" height="19" font="0">center/region cohort </text>
<text top="289" left="243" width="105" height="19" font="0">study (Denmark) </text>
<text top="307" left="243" width="3" height="19" font="0"> </text>
<text top="326" left="243" width="143" height="19" font="8"><b>Size:</b> N=259 (mean age </text>
<text top="344" left="243" width="144" height="19" font="0">78 y, 46% male). 49.7% </text>
<text top="362" left="243" width="139" height="19" font="0">had 2/3 AVB. 15% had </text>
<text top="381" left="243" width="121" height="19" font="0">AF-slow ventricular </text>
<text top="399" left="243" width="59" height="19" font="0">response </text>
<text top="234" left="405" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="252" left="405" width="199" height="19" font="0">referred for urgent PPM in 2009 </text>
<text top="271" left="405" width="3" height="19" font="0"> </text>
<text top="289" left="405" width="184" height="19" font="8"><b>Exclusion criteria:</b> Discharged </text>
<text top="307" left="405" width="183" height="19" font="0">from hospital before implant, </text>
<text top="326" left="405" width="155" height="19" font="0">referred from outpatient </text>
<text top="344" left="405" width="76" height="19" font="0">department </text>
<text top="235" left="621" width="163" height="19" font="8"><b>1</b>°<b> endpoint:</b> d to implant, </text>
<text top="253" left="621" width="161" height="19" font="0">complications during wait </text>
<text top="272" left="621" width="3" height="19" font="0"> </text>
<text top="290" left="621" width="234" height="19" font="8"><b>Results:</b> Mean 8.3 d hospitalization to </text>
<text top="308" left="621" width="231" height="19" font="0">implant (3.2 d to Dx; 5.1 d waiting for </text>
<text top="326" left="621" width="174" height="19" font="0">PPM). 83/259 pts (32%) had </text>
<text top="345" left="621" width="241" height="19" font="0">complications while waiting – Infection </text>
<text top="363" left="621" width="208" height="19" font="0">(11%), asystole (20%), NSVT (5%), </text>
<text top="381" left="621" width="191" height="19" font="0">cardiac arrest (3%), death (1%) </text>
<text top="234" left="878" width="196" height="20" font="0">•  Pt harm results from delay to </text>
<text top="253" left="888" width="150" height="19" font="0">PPM for capacity issues. </text>
<text top="418" left="96" width="120" height="19" font="0">Farre N, et al.<b> </b>2014 </text>
<text top="436" left="96" width="35" height="19" font="0">(154)<b> </b></text>
<text top="455" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24491864">24491864</a></text>
<text top="455" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24491864"> </a></text>
<text top="418" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="436" left="243" width="127" height="19" font="0">Retrospective single-</text>
<text top="455" left="243" width="132" height="19" font="0">center cohort (Spain) </text>
<text top="473" left="243" width="3" height="19" font="0"> </text>
<text top="491" left="243" width="135" height="19" font="8"><b>Size:</b> N=79; mean age </text>
<text top="509" left="243" width="99" height="19" font="0">72 y, 50% male  </text>
<text top="418" left="405" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="436" left="405" width="136" height="19" font="0">pts with “reversible” 3</text>
<text top="436" left="542" width="9" height="12" font="7">rd</text>
<text top="436" left="550" width="49" height="19" font="0"> degree </text>
<text top="455" left="405" width="195" height="19" font="0">AVB not undergoing initial PPM </text>
<text top="473" left="405" width="50" height="19" font="0">implant </text>
<text top="491" left="405" width="3" height="19" font="0"> </text>
<text top="509" left="405" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="419" left="621" width="243" height="19" font="8"><b>1</b>°<b> endpoint:</b> Persistence/recurrence of </text>
<text top="437" left="621" width="114" height="19" font="0">AVB, PPM implant </text>
<text top="455" left="621" width="3" height="19" font="0"> </text>
<text top="474" left="621" width="148" height="19" font="8"><b>Results:</b> 39% of pts w/o </text>
<text top="492" left="621" width="188" height="19" font="0">ischemic/infarction developed </text>
<text top="510" left="621" width="152" height="19" font="0">recurrent AVB, had PPM </text>
<text top="418" left="878" width="206" height="20" font="0">• Outside setting of MI/ischemia, </text>
<text top="437" left="888" width="176" height="19" font="0">high proportion of pts with 3</text>
<text top="437" left="1064" width="8" height="12" font="7">rd</text>
<text top="437" left="1072" width="3" height="19" font="0"> </text>
<text top="455" left="888" width="171" height="19" font="0">degree AVB and “reversible </text>
<text top="474" left="888" width="196" height="19" font="0">causes” develop recurrent AVB. </text>
<text top="492" left="878" width="135" height="20" font="0">• Close f-u warranted </text>
<text top="511" left="878" width="199" height="20" font="0">• Study was research letter with </text>
<text top="530" left="888" width="127" height="19" font="0">little data presented </text>
<text top="549" left="96" width="116" height="19" font="0">Antman EM, et al. <b> </b></text>
<text top="568" left="96" width="69" height="19" font="0">1990 (100)<b> </b></text>
<text top="586" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2188752">2188752</a></text>
<text top="586" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2188752"> </a></text>
<text top="549" left="243" width="149" height="19" font="8"><b>Study type:</b> Open-label, </text>
<text top="568" left="243" width="137" height="19" font="0">21-center prospective </text>
<text top="586" left="243" width="137" height="19" font="0">cohort study 1974–86 </text>
<text top="604" left="243" width="3" height="19" font="0"> </text>
<text top="622" left="243" width="97" height="19" font="8"><b>Size:</b> N=150 pts </text>
<text top="641" left="243" width="118" height="19" font="0">(79=53% with high-</text>
<text top="659" left="243" width="112" height="19" font="0">degree AVB). 46% </text>
<text top="677" left="243" width="129" height="19" font="0">male, mean age 65 y </text>
<text top="549" left="405" width="163" height="19" font="8"><b>Inclusion criteria:</b> Pts who </text>
<text top="568" left="405" width="178" height="19" font="0">received digoxin-specific Fab </text>
<text top="586" left="405" width="168" height="19" font="0">fragments in trial 1974–86. </text>
<text top="604" left="405" width="3" height="19" font="0"> </text>
<text top="622" left="405" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="550" left="621" width="199" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical “response” </text>
<text top="568" left="621" width="3" height="19" font="0"> </text>
<text top="587" left="621" width="224" height="19" font="8"><b>Results:</b> 80% complete resolution of </text>
<text top="605" left="621" width="220" height="19" font="0">signs/sx. 10% partial response, 10% </text>
<text top="623" left="621" width="124" height="19" font="0">complete response. </text>
<text top="549" left="878" width="213" height="20" font="0">•  AVB pts not separately analyzed </text>
<text top="697" left="96" width="101" height="19" font="0">Hickey AR, et al. </text>
<text top="715" left="96" width="69" height="19" font="0">1991 (101) </text>
<text top="733" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1993775">1993775</a></text>
<text top="733" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1993775"> </a></text>
<text top="696" left="243" width="112" height="19" font="8"><b>Study type:</b> Multi-</text>
<text top="715" left="243" width="116" height="19" font="0">center US national </text>
<text top="733" left="243" width="118" height="19" font="0">prospective cohort </text>
<text top="751" left="243" width="3" height="19" font="0"> </text>
<text top="696" left="405" width="187" height="19" font="8"><b>Inclusion criteria:</b> All pts in US </text>
<text top="715" left="405" width="159" height="19" font="0">receiving anti-digoxin Fab </text>
<text top="733" left="405" width="66" height="19" font="0">fragments </text>
<text top="751" left="405" width="3" height="19" font="0"> </text>
<text top="770" left="405" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="697" left="621" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution of symptoms </text>
<text top="716" left="621" width="111" height="19" font="0">of digoxin toxicity </text>
<text top="734" left="621" width="3" height="19" font="0"> </text>
<text top="697" left="878" width="210" height="20" font="0">•  No separate analysis of AVB pts </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 103 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="243" width="143" height="19" font="8"><b>Size:</b> N=717; 40% men, </text>
<text top="105" left="243" width="92" height="19" font="0">mean age 74 y </text>
<text top="87" left="621" width="235" height="19" font="8"><b>Results:</b> 50% complete response, 24% </text>
<text top="105" left="621" width="242" height="19" font="0">partial response; 12 % no response. 3% </text>
<text top="123" left="621" width="235" height="19" font="0">recurrence rate. 1% allergy to therapy </text>
<text top="143" left="96" width="106" height="19" font="0">Sadek MM, et al. </text>
<text top="161" left="96" width="69" height="19" font="0">2013 (155)<b> </b></text>
<text top="179" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23623644">23623644</a></text>
<text top="179" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23623644"> </a></text>
<text top="142" left="243" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="161" left="243" width="45" height="19" font="0">review </text>
<text top="179" left="243" width="3" height="19" font="0"> </text>
<text top="197" left="243" width="132" height="19" font="8"><b>Size:</b> 10 publications; </text>
<text top="216" left="243" width="48" height="19" font="0">299 pts </text>
<text top="142" left="405" width="158" height="19" font="8"><b>Inclusion criteria:</b> English </text>
<text top="161" left="405" width="200" height="19" font="0">language, original outcome data </text>
<text top="179" left="405" width="189" height="19" font="0">on pts with cardiac sarcoidosis </text>
<text top="197" left="405" width="101" height="19" font="0">tx with steroids. </text>
<text top="216" left="405" width="3" height="19" font="0"> </text>
<text top="234" left="405" width="190" height="19" font="8"><b>Exclusion criteria:</b> Reports less </text>
<text top="252" left="405" width="182" height="19" font="0">than 5 subjects or less than 3-</text>
<text top="271" left="405" width="88" height="19" font="0">mo follow-up  </text>
<text top="143" left="621" width="239" height="19" font="8"><b>1</b>°<b> endpoint:</b> Reversal or improvement </text>
<text top="162" left="621" width="43" height="19" font="0">in AVB </text>
<text top="180" left="621" width="3" height="19" font="0"> </text>
<text top="198" left="621" width="215" height="19" font="8"><b>Results:</b> 27/57 (47%) cases treated </text>
<text top="217" left="621" width="187" height="19" font="0">with steroids had improved or </text>
<text top="235" left="621" width="235" height="19" font="0">recovered AV conduction vs. 0/16 pts. </text>
<text top="253" left="621" width="143" height="19" font="0">w/o steroid treatment. </text>
<text top="143" left="878" width="131" height="20" font="0">• Considerable study </text>
<text top="162" left="888" width="90" height="19" font="0">heterogeneity </text>
<text top="180" left="878" width="217" height="20" font="0">• “Improvement” in AV conduction </text>
<text top="199" left="888" width="74" height="19" font="0">not defined </text>
<text top="218" left="878" width="218" height="20" font="0">•  Outcome not defined in terms of </text>
<text top="237" left="888" width="79" height="19" font="0">need for PM </text>
<text top="290" left="96" width="106" height="19" font="0">Kandolin R, et al. </text>
<text top="308" left="96" width="69" height="19" font="0">2011 (156)<b> </b></text>
<text top="326" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21427276">21427276</a></text>
<text top="326" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21427276"> </a></text>
<text top="290" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="308" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="326" left="243" width="104" height="19" font="0">cohort (Finland)  </text>
<text top="345" left="243" width="3" height="19" font="0"> </text>
<text top="363" left="243" width="120" height="19" font="8"><b>Size:</b> N=133; 72 pts </text>
<text top="381" left="243" width="141" height="19" font="0">with unexplained AVB  </text>
<text top="290" left="405" width="189" height="19" font="8"><b>Inclusion criteria:</b> Pts. 18–55 y </text>
<text top="308" left="405" width="159" height="19" font="0">who had PPM implant for </text>
<text top="326" left="405" width="86" height="19" font="0">unexplained 2</text>
<text top="326" left="491" width="10" height="12" font="7">nd</text>
<text top="326" left="501" width="13" height="19" font="0">/3</text>
<text top="326" left="515" width="8" height="12" font="7">rd</text>
<text top="326" left="523" width="83" height="19" font="0">-degree AVB  </text>
<text top="345" left="405" width="3" height="19" font="0"> </text>
<text top="363" left="405" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="381" left="405" width="63" height="19" font="0">described </text>
<text top="291" left="621" width="238" height="19" font="8"><b>1</b>°<b> endpoint:</b> Dx of cardiac sarcoidosis; </text>
<text top="309" left="621" width="197" height="19" font="0">reversal of AVB with treatment. </text>
<text top="327" left="621" width="3" height="19" font="0"> </text>
<text top="345" left="621" width="235" height="19" font="8"><b>Results:</b> 18/72 (25%) had probable (4) </text>
<text top="364" left="621" width="241" height="19" font="0">or definite (14) cardiac sarcoidosis AVB </text>
<text top="382" left="621" width="242" height="19" font="0">reversed in only 2/16 pts (13%) treated </text>
<text top="401" left="621" width="83" height="19" font="0">with steroids </text>
<text top="290" left="878" width="189" height="20" font="0">• Selected population, tertiary </text>
<text top="309" left="888" width="92" height="19" font="0">referral center </text>
<text top="327" left="878" width="206" height="20" font="0">• Little data about AVB described </text>
<text top="347" left="877" width="201" height="20" font="0">• Overall suggests low chance of </text>
<text top="365" left="888" width="165" height="19" font="0">reversing AVB with steroid </text>
<text top="384" left="888" width="66" height="19" font="0">treatment </text>
<text top="419" left="96" width="130" height="19" font="0">Ozcan KS, et al. 2012 </text>
<text top="438" left="96" width="35" height="19" font="0">(157)<b> </b></text>
<text top="456" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22738687">22738687</a></text>
<text top="456" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22738687"> </a></text>
<text top="419" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="438" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="456" left="243" width="101" height="19" font="0">cohort (Turkey)  </text>
<text top="474" left="243" width="3" height="19" font="0"> </text>
<text top="493" left="243" width="91" height="19" font="8"><b>Size:</b> N=50 (29 </text>
<text top="511" left="243" width="100" height="19" font="0">hypothyroid, 21 </text>
<text top="529" left="243" width="87" height="19" font="0">hyperthyroid) </text>
<text top="419" left="405" width="187" height="19" font="8"><b>Inclusion criteria:</b> All pts. with </text>
<text top="438" left="405" width="8" height="19" font="0">2</text>
<text top="438" left="413" width="10" height="12" font="7">nd</text>
<text top="438" left="423" width="13" height="19" font="0">/3</text>
<text top="438" left="436" width="9" height="12" font="7">rd</text>
<text top="438" left="445" width="134" height="19" font="0"> degree AVB who had </text>
<text top="456" left="405" width="159" height="19" font="0">hyper- or hypothyroidism </text>
<text top="474" left="405" width="3" height="19" font="0"> </text>
<text top="493" left="405" width="137" height="19" font="8"><b>Exclusion criteria:</b> MI, </text>
<text top="511" left="405" width="166" height="19" font="0">electrolytes abnormalities, </text>
<text top="529" left="405" width="162" height="19" font="0">digoxin toxicity, vasovagal </text>
<text top="548" left="405" width="116" height="19" font="0">syncope, on AADs  </text>
<text top="420" left="621" width="223" height="19" font="8"><b>1</b>°<b> endpoint:</b> Persistent AVB despite </text>
<text top="439" left="621" width="217" height="19" font="0">treatment of thyroid abnormalities </text>
<text top="457" left="621" width="3" height="19" font="0"> </text>
<text top="475" left="621" width="208" height="19" font="8"><b>Results:</b> 46/50 (92%) pts required </text>
<text top="494" left="621" width="224" height="19" font="0">PPM; 2 additional pts had persistent </text>
<text top="512" left="621" width="240" height="19" font="0">AVB. 22/29 (76%) with hypothyroidism </text>
<text top="530" left="621" width="239" height="19" font="0">and 18/21 (86%) with hyperthyroidism </text>
<text top="548" left="621" width="131" height="19" font="0">had irreversible AVB. </text>
<text top="420" left="878" width="213" height="20" font="0">•  Thyroid abnormalities are rarely </text>
<text top="439" left="888" width="161" height="19" font="0">a cause of reversible AVB. </text>
<text top="568" left="96" width="115" height="19" font="0">Forrester JD, et al. </text>
<text top="586" left="96" width="69" height="19" font="0">2014 (158)<b> </b></text>
<text top="604" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24879781">24879781</a></text>
<text top="604" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24879781"> </a></text>
<text top="567" left="243" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="586" left="243" width="139" height="19" font="0">review of case reports </text>
<text top="604" left="243" width="99" height="19" font="0">and case series  </text>
<text top="622" left="243" width="3" height="19" font="0"> </text>
<text top="641" left="243" width="128" height="19" font="8"><b>Size:</b> 34 manuscripts </text>
<text top="659" left="243" width="119" height="19" font="0">reporting 45 cases  </text>
<text top="567" left="405" width="158" height="19" font="8"><b>Inclusion criteria:</b> English </text>
<text top="586" left="405" width="192" height="19" font="0">language case reports or series </text>
<text top="604" left="405" width="192" height="19" font="0">in peer-reviewed journal of pts </text>
<text top="622" left="405" width="171" height="19" font="0">with Lyme disease and ECG-</text>
<text top="641" left="405" width="89" height="19" font="0">documented 3</text>
<text top="641" left="494" width="8" height="12" font="7">rd</text>
<text top="641" left="502" width="81" height="19" font="0"> degree AVB  </text>
<text top="659" left="405" width="3" height="19" font="0"> </text>
<text top="677" left="405" width="154" height="19" font="8"><b>Exclusion criteria:</b> Not in </text>
<text top="696" left="405" width="150" height="19" font="0">English, pt not US, no pt </text>
<text top="714" left="405" width="115" height="19" font="0">variables reported </text>
<text top="568" left="621" width="242" height="19" font="8"><b>1</b>°<b> endpoint:</b> Outcomes, need for PPM, </text>
<text top="587" left="621" width="118" height="19" font="0">persistence of AVB </text>
<text top="605" left="621" width="3" height="19" font="0"> </text>
<text top="623" left="621" width="221" height="19" font="8"><b>Results:</b> 18/45 (40%) required TPM, </text>
<text top="642" left="621" width="234" height="19" font="0">2/45 (4%) had PPM, both in 1980s. All </text>
<text top="660" left="621" width="229" height="19" font="0">other cases resolved, median time to </text>
<text top="678" left="621" width="184" height="19" font="0">resolution 6 d (range 1–42 d). </text>
<text top="697" left="621" width="3" height="19" font="0"> </text>
<text top="568" left="878" width="199" height="20" font="0">• AVB with Lyme carditis almost </text>
<text top="587" left="888" width="194" height="19" font="0">always resolves with treatment </text>
<text top="733" left="96" width="119" height="19" font="0">Van der Linde, MR, </text>
<text top="751" left="96" width="69" height="19" font="0">1991 (159)<b> </b></text>
<text top="770" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1947815">1947815</a></text>
<text top="770" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1947815"> </a></text>
<text top="733" left="243" width="138" height="19" font="8"><b>Study type:</b> Review of </text>
<text top="751" left="243" width="141" height="19" font="0">published case reports </text>
<text top="770" left="243" width="127" height="19" font="0">in Europe and North </text>
<text top="733" left="405" width="174" height="19" font="8"><b>Inclusion criteria:</b> Published </text>
<text top="751" left="405" width="139" height="19" font="0">case reports 1977–90, </text>
<text top="734" left="621" width="226" height="19" font="8"><b>1</b>°<b> endpoint:</b> Outcome, resolution of </text>
<text top="752" left="621" width="119" height="19" font="0">AVB, need for PPM </text>
<text top="770" left="621" width="3" height="19" font="0"> </text>
<text top="733" left="878" width="215" height="20" font="0">• PPM rarely needed after episode </text>
<text top="752" left="888" width="100" height="19" font="0">of Lyme carditis </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 104 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="243" width="120" height="19" font="0">America, European </text>
<text top="105" left="243" width="148" height="19" font="0">questionnaire, personal </text>
<text top="123" left="243" width="102" height="19" font="0">communication, </text>
<text top="142" left="243" width="85" height="19" font="0">observations  </text>
<text top="160" left="243" width="3" height="19" font="0"> </text>
<text top="178" left="243" width="98" height="19" font="8"><b>Size:</b> 105 cases  </text>
<text top="87" left="405" width="148" height="19" font="0">questionnaire, personal </text>
<text top="105" left="405" width="184" height="19" font="0">communication, observations </text>
<text top="123" left="405" width="3" height="19" font="0"> </text>
<text top="142" left="405" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="87" left="621" width="116" height="19" font="8"><b>Results:</b> 49% had 3</text>
<text top="87" left="737" width="9" height="12" font="7">rd</text>
<text top="87" left="745" width="111" height="19" font="0"> degree AVB, 16% </text>
<text top="105" left="621" width="34" height="19" font="0">had 2</text>
<text top="105" left="655" width="10" height="12" font="7">nd</text>
<text top="105" left="665" width="167" height="19" font="0"> degree AVB. 35% required </text>
<text top="123" left="621" width="228" height="19" font="0">TPM, 94% with complete recovery of </text>
<text top="142" left="621" width="210" height="19" font="0">AV conduction, only 1 pt (1%) had </text>
<text top="160" left="621" width="72" height="19" font="0">persistent 3</text>
<text top="160" left="693" width="9" height="12" font="7">rd</text>
<text top="160" left="702" width="78" height="19" font="0"> degree AVB </text>
<text top="178" left="621" width="3" height="19" font="0"> </text>
<text top="197" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="219" left="86" width="638" height="23" font="5"><b>Data Supplement 27. RCTs Comparing Medical treatment for AV block (Section 6.3.2) </b></text>
<text top="242" left="108" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="260" left="139" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="279" left="111" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="242" left="257" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="260" left="262" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="279" left="256" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="242" left="409" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="242" left="578" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="260" left="596" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="279" left="580" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="297" left="601" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="242" left="756" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="260" left="738" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="279" left="742" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="297" left="786" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="243" left="918" width="135" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint </b></text>
<text top="261" left="965" width="51" height="19" font="8"><b>(if any); </b></text>
<text top="280" left="928" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="298" left="936" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="317" left="95" width="129" height="19" font="0">Abu-Laban RB, et al.  </text>
<text top="335" left="95" width="69" height="19" font="0">2006 (104) </text>
<text top="354" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16698410">16698410</a></text>
<text top="354" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16698410"> </a></text>
<text top="317" left="236" width="118" height="19" font="8"><b>Aim:</b> To determine </text>
<text top="335" left="236" width="55" height="19" font="0">whether </text>
<text top="354" left="236" width="90" height="19" font="0">aminophylline </text>
<text top="372" left="236" width="104" height="19" font="0">increases rate of </text>
<text top="390" left="236" width="109" height="19" font="0">ROSC after out of </text>
<text top="409" left="236" width="99" height="19" font="0">hospital cardiac </text>
<text top="427" left="236" width="39" height="19" font="0">arrest </text>
<text top="445" left="236" width="3" height="19" font="0"> </text>
<text top="463" left="236" width="105" height="19" font="8"><b>Study type:</b> RCT  </text>
<text top="482" left="236" width="3" height="19" font="0"> </text>
<text top="500" left="236" width="75" height="19" font="8"><b>Size:</b> N=971 </text>
<text top="317" left="378" width="183" height="19" font="8"><b>Inclusion criteria: </b>Pts over 16 </text>
<text top="335" left="378" width="177" height="19" font="0">y in British Columbia 2001–3 </text>
<text top="354" left="378" width="165" height="19" font="0">with brady-asystolic arrest </text>
<text top="372" left="378" width="151" height="19" font="0">refractory to intubation, </text>
<text top="390" left="378" width="162" height="19" font="0">atropine and epinephrine  </text>
<text top="409" left="378" width="3" height="19" font="0"> </text>
<text top="427" left="378" width="161" height="19" font="8"><b>Exclusion criteria:</b> Do-not-</text>
<text top="445" left="378" width="182" height="19" font="0">resuscitate order, pregnancy, </text>
<text top="464" left="378" width="146" height="19" font="0">hemorrhage/trauma or </text>
<text top="482" left="378" width="150" height="19" font="0">hypothermia, end-stage </text>
<text top="500" left="378" width="106" height="19" font="0">renal disease, on </text>
<text top="518" left="378" width="80" height="19" font="0">theophylline </text>
<text top="317" left="574" width="112" height="19" font="8"><b>Intervention:</b> 500 </text>
<text top="335" left="574" width="128" height="19" font="0">mg IV aminophylline </text>
<text top="354" left="574" width="36" height="19" font="0">bolus </text>
<text top="372" left="574" width="7" height="19" font="0">  </text>
<text top="390" left="574" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="409" left="574" width="112" height="19" font="0">Matching placebo<b> </b></text>
<text top="318" left="716" width="122" height="19" font="8"><b>1</b>°<b> endpoint:</b> ROSC: </text>
<text top="336" left="716" width="166" height="19" font="0">24.5% I vs. 23.7% C (0.8%, -</text>
<text top="354" left="716" width="110" height="19" font="0">4.6–6.2; p=0.778) </text>
<text top="373" left="715" width="188" height="19" font="0">Survival to hospital admission: </text>
<text top="391" left="715" width="182" height="19" font="0">6.6% I vs. 7.6% C (-1.0%, -4.3–</text>
<text top="409" left="715" width="84" height="19" font="0">2.2; p=0.527) </text>
<text top="428" left="715" width="170" height="19" font="0">Survival to hosp. discharge: </text>
<text top="446" left="715" width="182" height="19" font="0">0.4% I vs. 0.6% C (-0.2%, -1.1–</text>
<text top="464" left="715" width="95" height="19" font="0">0.7%; p=0.653) </text>
<text top="483" left="715" width="3" height="19" font="0"> </text>
<text top="501" left="716" width="187" height="19" font="8"><b>Safety endpoint (if relevant):</b>  </text>
<text top="519" left="716" width="36" height="19" font="0">None </text>
<text top="317" left="918" width="123" height="20" font="0">• Did not call out pt </text>
<text top="336" left="929" width="59" height="19" font="0">with AVB </text>
<text top="355" left="918" width="129" height="20" font="0">• Prehospital setting </text>
<text top="374" left="929" width="29" height="19" font="0">only </text>
<text top="538" left="95" width="56" height="19" font="0">PrePACE </text>
<text top="557" left="95" width="119" height="19" font="0">Morrison, LJ, et al.  </text>
<text top="575" left="95" width="62" height="19" font="0">2008 (86) </text>
<text top="593" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452">17933452</a></text>
<text top="593" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452"> </a></text>
<text top="538" left="236" width="108" height="19" font="8"><b>Aim:</b> To compare </text>
<text top="557" left="236" width="126" height="19" font="0">outcome of pts with </text>
<text top="575" left="236" width="129" height="19" font="0">prehospital unstable </text>
<text top="593" left="236" width="106" height="19" font="0">bradycardia with </text>
<text top="611" left="236" width="111" height="19" font="0">TCP vs. dopamine </text>
<text top="630" left="236" width="3" height="19" font="0"> </text>
<text top="648" left="236" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="666" left="236" width="3" height="19" font="0"> </text>
<text top="685" left="236" width="110" height="19" font="8"><b>Size:</b> N=82; mean </text>
<text top="703" left="236" width="124" height="19" font="0">age 71 y; 57% male  </text>
<text top="538" left="378" width="175" height="19" font="8"><b>In Inclusion criteria: </b>Pts ≥18 </text>
<text top="557" left="378" width="178" height="19" font="0">y presenting to Toronto EMS </text>
<text top="575" left="378" width="142" height="19" font="0">with hemodynamically </text>
<text top="593" left="378" width="132" height="19" font="0">unstable bradycardia </text>
<text top="611" left="378" width="164" height="19" font="0">unresponsive to fluids and </text>
<text top="630" left="378" width="59" height="19" font="0">atropine  </text>
<text top="648" left="378" width="3" height="19" font="0"> </text>
<text top="666" left="378" width="167" height="19" font="8"><b>Exclusion criteria:</b> Trauma, </text>
<text top="685" left="378" width="176" height="19" font="0">hyperthermia, hypothermia, </text>
<text top="703" left="378" width="86" height="19" font="0">cardiac arrest </text>
<text top="538" left="574" width="112" height="19" font="8"><b>Intervention:</b> TCP </text>
<text top="557" left="574" width="50" height="19" font="0">80 bpm </text>
<text top="575" left="574" width="7" height="19" font="0">  </text>
<text top="593" left="574" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="611" left="574" width="100" height="19" font="0">Dopamine 5–20 </text>
<text top="630" left="574" width="78" height="19" font="0">mcg/kg/min<b> </b></text>
<text top="539" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="557" left="716" width="114" height="19" font="0">hospital discharge </text>
<text top="576" left="716" width="141" height="19" font="0">69% I vs. 70% C (p=NS) </text>
<text top="594" left="716" width="3" height="19" font="0"> </text>
<text top="612" left="716" width="110" height="19" font="8"><b>Safety endpoint:</b>  </text>
<text top="631" left="716" width="168" height="19" font="0">VT/VF/cardiac arrest/burn: </text>
<text top="649" left="716" width="153" height="19" font="0">7.1% C vs. 7.5% C (p=NS<b>) </b></text>
<text top="538" left="918" width="124" height="20" font="0">• Half of eligible pts </text>
<text top="557" left="929" width="100" height="19" font="0">not randomized </text>
<text top="576" left="918" width="108" height="20" font="0">• This was a pilot </text>
<text top="595" left="929" width="117" height="19" font="0">study for potential </text>
<text top="613" left="929" width="66" height="19" font="0">larger RCT </text>
<text top="632" left="918" width="81" height="20" font="0">•  Dopamine </text>
<text top="651" left="929" width="111" height="19" font="0">equivalent to TCP </text>
<text top="669" left="929" width="107" height="19" font="0">in this small pilot </text>
<text top="687" left="929" width="37" height="19" font="0">study </text>
<text top="722" left="86" width="4" height="21" font="4"> </text>
<text top="742" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="764" left="86" width="1013" height="23" font="5"><b>Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Medical Treatment for AV block (Section 6.3.2) </b></text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 105 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="109" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="105" left="134" width="51" height="19" font="8"><b>Author; </b></text>
<text top="123" left="112" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="87" left="248" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="105" left="278" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="87" left="440" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="87" left="653" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="105" left="683" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="123" left="714" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="87" left="925" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="105" left="954" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="143" left="96" width="101" height="19" font="0">Brady WJ, et al.  </text>
<text top="161" left="96" width="62" height="19" font="0">1999 (79) </text>
<text top="179" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10459592">10459592</a></text>
<text top="179" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10459592"> </a></text>
<text top="142" left="236" width="146" height="19" font="8"><b>Study type:</b> Single-EMS </text>
<text top="161" left="236" width="131" height="19" font="0">system retrospective </text>
<text top="179" left="236" width="78" height="19" font="0">cohort in US </text>
<text top="197" left="236" width="3" height="19" font="0"> </text>
<text top="216" left="236" width="128" height="19" font="8"><b>Size:</b> N=131; 45 with </text>
<text top="234" left="236" width="130" height="19" font="0">AVB; Mean age 69 y; </text>
<text top="252" left="236" width="66" height="19" font="0">53% male  </text>
<text top="142" left="398" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="161" left="398" width="195" height="19" font="0">nontraumatized pts from 1990–</text>
<text top="179" left="398" width="142" height="19" font="0">1993 who experienced </text>
<text top="197" left="398" width="174" height="19" font="0">bradycardia with associated </text>
<text top="216" left="398" width="183" height="19" font="0">hemodynamic instability who </text>
<text top="234" left="398" width="160" height="19" font="0">received atropine in field. </text>
<text top="252" left="398" width="3" height="19" font="0"> </text>
<text top="271" left="398" width="185" height="19" font="8"><b>Exclusion criteria:</b> Not stated, </text>
<text top="289" left="398" width="189" height="19" font="0">but presumably cardiac arrest. </text>
<text top="307" left="398" width="165" height="19" font="0">Also excluded pre-hospital </text>
<text top="326" left="398" width="90" height="19" font="0">deaths (N=16) </text>
<text top="143" left="614" width="259" height="19" font="8"><b>1</b>°<b> endpoint:</b> “Response” in 4 categories – </text>
<text top="162" left="614" width="201" height="19" font="0">adverse, none, partial, complete </text>
<text top="180" left="614" width="3" height="19" font="0"> </text>
<text top="198" left="614" width="262" height="19" font="8"><b>Results:</b> Mean dose 1.1 mg. Of 37 pts with </text>
<text top="217" left="614" width="8" height="19" font="0">3</text>
<text top="217" left="622" width="9" height="12" font="7">rd</text>
<text top="217" left="630" width="227" height="19" font="0"> degree AVB in field, 21 arrived in ED </text>
<text top="235" left="614" width="38" height="19" font="0">with 3</text>
<text top="235" left="652" width="9" height="12" font="7">rd</text>
<text top="235" left="661" width="189" height="19" font="0"> degree AVB and only 9 left ED </text>
<text top="253" left="614" width="38" height="19" font="0">with 3</text>
<text top="253" left="652" width="9" height="12" font="7">rd</text>
<text top="253" left="661" width="199" height="19" font="0"> degree AVB. Of all pts, 27% had </text>
<text top="272" left="614" width="229" height="19" font="0">complete response, 20% partial, 50% </text>
<text top="290" left="614" width="111" height="19" font="0">none; 3% adverse </text>
<text top="143" left="891" width="192" height="20" font="0">• Limited methodology, results </text>
<text top="162" left="902" width="105" height="19" font="0">poorly described </text>
<text top="345" left="96" width="85" height="19" font="0">Feigl D, et al.  </text>
<text top="363" left="96" width="69" height="19" font="0">1984 (160) </text>
<text top="381" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6736451">6736451</a></text>
<text top="381" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6736451"> </a></text>
<text top="345" left="236" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="363" left="236" width="127" height="19" font="0">center retrospective </text>
<text top="381" left="236" width="132" height="19" font="0">cohort study in Israel </text>
<text top="400" left="236" width="75" height="19" font="0">1978–1982  </text>
<text top="418" left="236" width="3" height="19" font="0"> </text>
<text top="436" left="236" width="135" height="19" font="8"><b>Size:</b> N=34; mean age </text>
<text top="455" left="236" width="99" height="19" font="0">62 y; 82% male  </text>
<text top="345" left="398" width="119" height="19" font="8"><b>Inclusion criteria:</b> 2</text>
<text top="345" left="517" width="10" height="12" font="7">nd</text>
<text top="345" left="527" width="28" height="19" font="0"> or 3</text>
<text top="345" left="555" width="9" height="12" font="7">rd</text>
<text top="345" left="563" width="3" height="19" font="0"> </text>
<text top="363" left="398" width="160" height="19" font="0">degree AVB developing in </text>
<text top="381" left="398" width="194" height="19" font="0">course of IMI who survived &gt;72 </text>
<text top="400" left="398" width="15" height="19" font="0">h  </text>
<text top="418" left="398" width="3" height="19" font="0"> </text>
<text top="436" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="345" left="614" width="226" height="19" font="8"><b>1</b>°<b> endpoint:</b> Outcomes, response to </text>
<text top="364" left="614" width="55" height="19" font="0">atropine </text>
<text top="382" left="614" width="3" height="19" font="0"> </text>
<text top="400" left="614" width="246" height="19" font="8"><b>Results:</b> Of 15 pts with early AVB (&lt;6 h). </text>
<text top="419" left="614" width="248" height="19" font="0">Atropine normalized conduction in 20%, </text>
<text top="437" left="614" width="201" height="19" font="0">increased V rate in others. 5 had </text>
<text top="455" left="614" width="249" height="19" font="0">normalization with isoproterenol. 14 pts </text>
<text top="474" left="614" width="249" height="19" font="0">had late AVB – less response to atropine </text>
<text top="492" left="614" width="217" height="19" font="0">(mean 16 bpm). 50% required TPM </text>
<text top="345" left="891" width="205" height="20" font="0">• Descriptive, uncontrolled study </text>
<text top="364" left="891" width="175" height="20" font="0">• No adverse events to drug </text>
<text top="383" left="902" width="108" height="19" font="0">therapy reported </text>
<text top="511" left="96" width="115" height="19" font="0">Sclarovsky S, 1984 </text>
<text top="529" left="96" width="35" height="19" font="0">(161) </text>
<text top="548" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6731277">6731277</a></text>
<text top="548" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6731277"> </a></text>
<text top="511" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="529" left="236" width="127" height="19" font="0">center retrospective </text>
<text top="548" left="236" width="132" height="19" font="0">cohort study in Israel </text>
<text top="566" left="236" width="72" height="19" font="0">1972–1982 </text>
<text top="584" left="236" width="3" height="19" font="0"> </text>
<text top="603" left="236" width="71" height="19" font="8"><b>Size:</b> N=76  </text>
<text top="511" left="398" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="529" left="398" width="136" height="19" font="0">acute inferior MI who </text>
<text top="548" left="398" width="75" height="19" font="0">developed 2</text>
<text top="548" left="473" width="10" height="12" font="7">nd</text>
<text top="548" left="484" width="28" height="19" font="0"> or 3</text>
<text top="548" left="511" width="9" height="12" font="7">rd</text>
<text top="548" left="520" width="78" height="19" font="0"> degree AVB </text>
<text top="566" left="398" width="67" height="19" font="0">in hospital </text>
<text top="584" left="398" width="3" height="19" font="0"> </text>
<text top="603" left="398" width="179" height="19" font="8"><b>Exclusion criteria:</b> Combined </text>
<text top="621" left="398" width="79" height="19" font="0">AMI and IMI </text>
<text top="512" left="614" width="238" height="19" font="8"><b>1</b>°<b> endpoint:</b> Description of outcomes, </text>
<text top="530" left="614" width="243" height="19" font="0">response to atropine and isoproterenol </text>
<text top="548" left="614" width="3" height="19" font="0"> </text>
<text top="567" left="614" width="254" height="19" font="8"><b>Results:</b> 6/14 (36%) of pts with early AVB </text>
<text top="585" left="614" width="239" height="19" font="0">improved vs. 13/17 (77%) pts with late </text>
<text top="603" left="614" width="252" height="19" font="0">AVB (p&lt;0.05). 2/8 (25%) of pts with early </text>
<text top="622" left="614" width="254" height="19" font="0">block and 2/6 (33%). 50% of pts had TPM </text>
<text top="511" left="891" width="201" height="20" font="0">• Descriptive uncontrolled study </text>
<text top="530" left="891" width="175" height="20" font="0">• No adverse events to drug </text>
<text top="549" left="902" width="108" height="19" font="0">therapy reported </text>
<text top="641" left="96" width="111" height="19" font="0">Chihrin SM, et al.  </text>
<text top="659" left="96" width="69" height="19" font="0">2008 (162) </text>
<text top="677" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18308011">18308011</a></text>
<text top="677" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18308011"> </a></text>
<text top="641" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="659" left="236" width="117" height="19" font="0">center prospective </text>
<text top="677" left="236" width="111" height="19" font="0">cohort in Canada  </text>
<text top="696" left="236" width="3" height="19" font="0"> </text>
<text top="714" left="236" width="142" height="19" font="8"><b>Size:</b> N=100; mean age </text>
<text top="732" left="236" width="96" height="19" font="0">75 y; 56% male </text>
<text top="641" left="398" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="659" left="398" width="200" height="19" font="0">pts from 2003–2006 undergoing </text>
<text top="677" left="398" width="173" height="19" font="0">PPM generator change who </text>
<text top="696" left="398" width="128" height="19" font="0">were PM dependent </text>
<text top="714" left="398" width="3" height="19" font="0"> </text>
<text top="732" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="642" left="614" width="255" height="19" font="8"><b>1</b>°<b> endpoint:</b> Elicitation of escape rhythm </text>
<text top="660" left="614" width="201" height="19" font="0">with PM stepdown to 30 bpm or </text>
<text top="678" left="614" width="170" height="19" font="0">isoproterenol 1–2 mcg/min </text>
<text top="697" left="614" width="3" height="19" font="0"> </text>
<text top="715" left="614" width="224" height="19" font="8"><b>Results:</b> 59% demonstrated intrinsic </text>
<text top="733" left="614" width="202" height="19" font="0">rhythm with stepdown alone. Of </text>
<text top="751" left="614" width="257" height="19" font="0">remaining 41 pts, 28 (68%) demonstrated </text>
<text top="641" left="891" width="182" height="20" font="0">• Suggests that isoproterenol </text>
<text top="660" left="902" width="164" height="19" font="0">can be used to elicit faster </text>
<text top="678" left="902" width="170" height="19" font="0">escape rate in pts with AVB </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 106 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="614" width="242" height="19" font="0">intrinsic rhythm with isoproterenol. No </text>
<text top="105" left="614" width="99" height="19" font="0">adverse events. </text>
<text top="124" left="96" width="99" height="19" font="0">Hurley KF, et al. </text>
<text top="143" left="96" width="69" height="19" font="0">2015 (105) </text>
<text top="161" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26593309">26593309</a></text>
<text top="161" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26593309"> </a></text>
<text top="124" left="236" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="143" left="236" width="104" height="19" font="0">review of 5 RCTs </text>
<text top="161" left="236" width="3" height="19" font="0"> </text>
<text top="179" left="236" width="86" height="19" font="8"><b>Size:</b> N=1254  </text>
<text top="124" left="398" width="160" height="19" font="8"><b>Inclusion criteria: </b>RCTs of </text>
<text top="143" left="398" width="169" height="19" font="0">aminophylline used for pre-</text>
<text top="161" left="398" width="138" height="19" font="0">hospital resuscitate of </text>
<text top="179" left="398" width="180" height="19" font="0">bradyasystolic cardiac arrest  </text>
<text top="197" left="398" width="3" height="19" font="0"> </text>
<text top="216" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="125" left="614" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="143" left="614" width="169" height="19" font="0">discharge/admission, ROSC </text>
<text top="162" left="614" width="3" height="19" font="0"> </text>
<text top="180" left="614" width="251" height="19" font="8"><b>Results:</b> No improvement in outcome by </text>
<text top="198" left="614" width="253" height="19" font="0">any measure with aminophylline. Overall </text>
<text top="217" left="614" width="140" height="19" font="0">survival extremely low </text>
<text top="124" left="891" width="183" height="20" font="0">• Aminophylline not useful in </text>
<text top="143" left="903" width="182" height="19" font="0">out of hospital bradyasystolic </text>
<text top="162" left="903" width="39" height="19" font="0">arrest </text>
<text top="236" left="96" width="106" height="19" font="0">Sodeck GH, et al. </text>
<text top="254" left="96" width="62" height="19" font="0">2007 (77) </text>
<text top="272" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976">17212976</a></text>
<text top="272" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976"> </a></text>
<text top="236" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="254" left="236" width="138" height="19" font="0">Retrospective analysis </text>
<text top="272" left="236" width="124" height="19" font="0">of single ED registry </text>
<text top="291" left="236" width="139" height="19" font="0">from tertiary center in </text>
<text top="309" left="236" width="50" height="19" font="0">Austria  </text>
<text top="327" left="236" width="3" height="19" font="0"> </text>
<text top="345" left="236" width="142" height="19" font="8"><b>Size:</b> N=277; mean age </text>
<text top="364" left="236" width="139" height="19" font="0">68 y; 62% male; about </text>
<text top="382" left="236" width="61" height="19" font="0">50% AVB  </text>
<text top="236" left="398" width="189" height="19" font="8"><b>Inclusion criteria: </b>Consecutive </text>
<text top="254" left="398" width="189" height="19" font="0">pts admitted to ED 1994–2004 </text>
<text top="272" left="398" width="117" height="19" font="0">with symptomatic, </text>
<text top="291" left="398" width="177" height="19" font="0">hemodynamically significant </text>
<text top="309" left="398" width="79" height="19" font="0">bradycardia<b> </b> </text>
<text top="327" left="398" width="3" height="19" font="0"> </text>
<text top="345" left="398" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="364" left="398" width="197" height="19" font="0">Asymptomatic and terminally ill </text>
<text top="382" left="398" width="22" height="19" font="0">pts </text>
<text top="236" left="614" width="261" height="19" font="8"><b>1</b>°<b> endpoint:</b> Use of drugs for bradycardia, </text>
<text top="255" left="614" width="84" height="19" font="0">use of pacing </text>
<text top="273" left="614" width="3" height="19" font="0"> </text>
<text top="291" left="614" width="247" height="19" font="8"><b>Results:</b> IV medications given to 170 pts </text>
<text top="310" left="614" width="189" height="19" font="0">(61%) – Atropine in 141 (51%), </text>
<text top="328" left="614" width="220" height="19" font="0">orciprenaline 62 (22%), epi 24 (9%), </text>
<text top="346" left="614" width="212" height="19" font="0">dopamine 6 (2%). 7 pts had TCP (4 </text>
<text top="365" left="614" width="256" height="19" font="0">successful); 54 (20%) had temporary TVP. </text>
<text top="383" left="614" width="180" height="19" font="0">137/277 (50%) received PPM </text>
<text top="236" left="891" width="169" height="20" font="0">• Descriptive study with no </text>
<text top="255" left="902" width="86" height="19" font="0">control group </text>
<text top="273" left="891" width="183" height="20" font="0">• Pts with AVB not separately </text>
<text top="292" left="902" width="131" height="19" font="0">reported or analyzed </text>
<text top="311" left="891" width="204" height="20" font="0">• Minimal information on clinical </text>
<text top="330" left="902" width="175" height="19" font="0">effects of intervention given </text>
<text top="402" left="96" width="111" height="19" font="0">Bertolet BD, et al. </text>
<text top="420" left="96" width="69" height="19" font="0">1995 (163) </text>
<text top="439" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7661495">7661495</a></text>
<text top="439" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7661495"> </a></text>
<text top="402" left="236" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="420" left="236" width="129" height="19" font="0">center observational </text>
<text top="439" left="236" width="78" height="19" font="0">cohort in US </text>
<text top="457" left="236" width="3" height="19" font="0"> </text>
<text top="475" left="236" width="105" height="19" font="8"><b>Size: </b>N=8; 3 with </text>
<text top="494" left="236" width="93" height="19" font="0">complete AVB  </text>
<text top="402" left="398" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="420" left="398" width="165" height="19" font="0">significant AVB developing </text>
<text top="439" left="398" width="203" height="19" font="0">within 4 h of admission for acute </text>
<text top="457" left="398" width="145" height="19" font="0">inferior MI, resistant to </text>
<text top="475" left="398" width="191" height="19" font="0">atropine, given IV theophylline </text>
<text top="494" left="398" width="84" height="19" font="0">up to 250 mg </text>
<text top="512" left="398" width="3" height="19" font="0"> </text>
<text top="530" left="398" width="165" height="19" font="8"><b>Exclusion criteria:</b> Pts who </text>
<text top="548" left="398" width="167" height="19" font="0">received BBs or CCBs prior  </text>
<text top="403" left="614" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Restoration of 1-1 AV </text>
<text top="421" left="614" width="72" height="19" font="0">conduction </text>
<text top="439" left="614" width="3" height="19" font="0"> </text>
<text top="458" left="614" width="262" height="19" font="8"><b>Results:</b> All 8 pts had restoration of 1-1 AV </text>
<text top="476" left="614" width="261" height="19" font="0">conduction within 3 min lasting at least 24 </text>
<text top="494" left="614" width="11" height="19" font="0">h </text>
<text top="402" left="891" width="85" height="20" font="0">• No controls </text>
<text top="421" left="891" width="164" height="20" font="0">• Very small, single-center </text>
<text top="440" left="902" width="71" height="19" font="0">experience </text>
<text top="568" left="96" width="120" height="19" font="0">Altun A, et al. 1998 </text>
<text top="586" left="96" width="35" height="19" font="0">(164) </text>
<text top="604" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9789698">9789698</a></text>
<text top="604" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9789698"> </a></text>
<text top="567" left="236" width="115" height="19" font="8"><b>Study type: </b>Single-</text>
<text top="586" left="236" width="129" height="19" font="0">center observational </text>
<text top="604" left="236" width="107" height="19" font="0">cohort in Turkey  </text>
<text top="622" left="236" width="3" height="19" font="0"> </text>
<text top="641" left="236" width="105" height="19" font="8"><b>Size:</b> N=8; 6 with </text>
<text top="659" left="236" width="132" height="19" font="0">complete AVB; mean </text>
<text top="677" left="236" width="57" height="19" font="0">age 68 y  </text>
<text top="567" left="398" width="171" height="19" font="8"><b>Inclusion criteria: </b>Pts with 2</text>
<text top="567" left="570" width="10" height="12" font="7">nd</text>
<text top="568" left="580" width="20" height="19" font="0"> or </text>
<text top="586" left="398" width="8" height="19" font="0">3</text>
<text top="586" left="406" width="9" height="12" font="7">rd</text>
<text top="586" left="414" width="171" height="19" font="0"> degree AVB after IMI for at </text>
<text top="604" left="398" width="190" height="19" font="0">least 1 h, resistant to atropine. </text>
<text top="622" left="398" width="194" height="19" font="0">Given 2 doses of aminophylline </text>
<text top="641" left="398" width="110" height="19" font="0">240 mg 1 h apart  </text>
<text top="659" left="398" width="3" height="19" font="0"> </text>
<text top="677" left="398" width="150" height="19" font="8"><b>Exclusion criteria: </b>Pts in </text>
<text top="696" left="398" width="152" height="19" font="0">hyperacute phase of MI, </text>
<text top="714" left="398" width="168" height="19" font="0">received AV nodal blocking </text>
<text top="732" left="398" width="41" height="19" font="0">drugs  </text>
<text top="568" left="614" width="192" height="19" font="8"><b>1</b>°<b> endpoint:</b> Restoration of AV </text>
<text top="587" left="614" width="72" height="19" font="0">conduction </text>
<text top="605" left="614" width="3" height="19" font="0"> </text>
<text top="623" left="614" width="243" height="19" font="8"><b>Results:</b> Aminophylline restored 1-1 AV </text>
<text top="642" left="614" width="258" height="19" font="0">conduction in 7 pts and Mobitz I AVB in 1. </text>
<text top="660" left="614" width="247" height="19" font="0">No adverse effects. AVB relapsed in 1 pt </text>
<text top="678" left="614" width="29" height="19" font="0">only </text>
<text top="697" left="614" width="3" height="19" font="0"> </text>
<text top="568" left="891" width="85" height="20" font="0">• No controls </text>
<text top="587" left="891" width="164" height="20" font="0">• Very small, single-center </text>
<text top="606" left="902" width="71" height="19" font="0">experience </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 107 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="123" height="19" font="0">Goodfellow J, et al.  </text>
<text top="105" left="96" width="69" height="19" font="0">1995 (165) </text>
<text top="123" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7588933">7588933</a></text>
<text top="123" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7588933"> </a></text>
<text top="87" left="236" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="105" left="236" width="127" height="19" font="0">center case series in </text>
<text top="123" left="236" width="102" height="19" font="0">United Kingdom </text>
<text top="142" left="236" width="3" height="19" font="0"> </text>
<text top="160" left="236" width="63" height="19" font="8"><b>Size:</b> N=3  </text>
<text top="87" left="398" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="105" left="398" width="172" height="19" font="0">atropine-resistant AVB with </text>
<text top="123" left="398" width="185" height="19" font="0">acute inferior MI treated with </text>
<text top="142" left="398" width="136" height="19" font="0">streptokinase. All had </text>
<text top="160" left="398" width="79" height="19" font="0">hypotension </text>
<text top="178" left="398" width="3" height="19" font="0"> </text>
<text top="197" left="398" width="153" height="19" font="8"><b>Exclusion criteria:</b> None  </text>
<text top="88" left="614" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Restoration of 1-1 AV </text>
<text top="106" left="614" width="72" height="19" font="0">conduction </text>
<text top="124" left="614" width="3" height="19" font="0"> </text>
<text top="143" left="614" width="224" height="19" font="8"><b>Results:</b> 1-1 AV conduction restored </text>
<text top="161" left="614" width="251" height="19" font="0">promptly with resolution of hypotension </text>
<text top="179" left="614" width="32" height="19" font="0">in all </text>
<text top="198" left="614" width="3" height="19" font="0"> </text>
<text top="87" left="891" width="85" height="20" font="0">• No controls </text>
<text top="106" left="891" width="146" height="20" font="0">• Very small case series </text>
<text top="217" left="96" width="125" height="19" font="0">Love, JN, et al. 1998 </text>
<text top="235" left="96" width="28" height="19" font="0">(90) </text>
<text top="253" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9674488">9674488</a></text>
<text top="253" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9674488"> </a></text>
<text top="217" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="235" left="236" width="150" height="19" font="0">center case series in US  </text>
<text top="253" left="236" width="3" height="19" font="0"> </text>
<text top="271" left="236" width="63" height="19" font="8"><b>Size:</b> N=9  </text>
<text top="217" left="398" width="202" height="19" font="8"><b>Inclusion criteria:</b> Pts presenting </text>
<text top="235" left="398" width="189" height="19" font="0">with symptomatic bradycardia </text>
<text top="253" left="398" width="192" height="19" font="0">resistant to atropine 1 mg who </text>
<text top="272" left="398" width="178" height="19" font="0">received IV glucagon 1–7 mg </text>
<text top="290" left="398" width="94" height="19" font="0">then 3–5 mg/h </text>
<text top="308" left="398" width="3" height="19" font="0"> </text>
<text top="326" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="217" left="614" width="258" height="19" font="8"><b>1</b>°<b> endpoint:</b> Improvement in bradycardia </text>
<text top="236" left="614" width="122" height="19" font="0">and hemodynamics </text>
<text top="254" left="614" width="3" height="19" font="0"> </text>
<text top="272" left="614" width="204" height="19" font="8"><b>Results:</b> All pts improved at least </text>
<text top="291" left="614" width="69" height="19" font="0">transiently </text>
<text top="309" left="614" width="3" height="19" font="0"> </text>
<text top="217" left="891" width="199" height="20" font="0">• Most pts had BBs and/or CCBs </text>
<text top="236" left="902" width="146" height="19" font="0">as significant co-factors </text>
<text top="254" left="891" width="195" height="20" font="0">• Unknown how many had AVB </text>
<text top="346" left="96" width="108" height="19" font="0">Dhingra RC, et al. </text>
<text top="364" left="96" width="69" height="19" font="0">1973 (166) </text>
<text top="382" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4744693">4744693</a></text>
<text top="382" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4744693"> </a></text>
<text top="345" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="364" left="236" width="87" height="19" font="0">center cohort </text>
<text top="382" left="236" width="144" height="19" font="0">undergoing invasive EP </text>
<text top="401" left="236" width="71" height="19" font="0">study in US </text>
<text top="419" left="236" width="3" height="19" font="0"> </text>
<text top="437" left="236" width="121" height="19" font="8"><b>Size:</b> N=42; 8 with 3</text>
<text top="437" left="357" width="9" height="12" font="7">rd</text>
<text top="437" left="365" width="3" height="19" font="0"> </text>
<text top="455" left="236" width="128" height="19" font="0">degree AVB, 3 with 2</text>
<text top="455" left="364" width="10" height="12" font="7">nd</text>
<text top="455" left="374" width="3" height="19" font="0"> </text>
<text top="474" left="236" width="78" height="19" font="0">degree AVB  </text>
<text top="345" left="398" width="182" height="19" font="8"><b>Inclusion criteria:</b> 42 pts with </text>
<text top="364" left="398" width="158" height="19" font="0">heart disease undergoing </text>
<text top="382" left="398" width="162" height="19" font="0">invasive EPS w/o and with </text>
<text top="401" left="398" width="86" height="19" font="0">isoproterenol </text>
<text top="419" left="398" width="3" height="19" font="0"> </text>
<text top="437" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="346" left="614" width="203" height="19" font="8"><b>1</b>°<b> endpoint:</b> Improvement in AV </text>
<text top="365" left="614" width="258" height="19" font="0">conduction and change in ventricular rate </text>
<text top="383" left="614" width="3" height="19" font="0"> </text>
<text top="401" left="614" width="137" height="19" font="8"><b>Results:</b> 2/8 pts with 3</text>
<text top="401" left="751" width="8" height="12" font="7">rd</text>
<text top="401" left="760" width="104" height="19" font="0"> degree AVB had </text>
<text top="420" left="614" width="254" height="19" font="0">improved conduction with isoproterenol, </text>
<text top="438" left="614" width="124" height="19" font="0">as did 3/3 pts with 3</text>
<text top="438" left="738" width="9" height="12" font="7">rd</text>
<text top="438" left="746" width="82" height="19" font="0"> degree AVB. </text>
<text top="456" left="614" width="247" height="19" font="0">Ventricular rate improved in all subjects </text>
<text top="474" left="614" width="206" height="19" font="0">from mean of 45 bpm to 62 bpm, </text>
<text top="493" left="614" width="159" height="19" font="0">regardless of site of block </text>
<text top="346" left="891" width="118" height="20" font="0">• Very small study  </text>
<text top="365" left="891" width="186" height="20" font="0">• Bias in reflects those able to </text>
<text top="384" left="902" width="80" height="19" font="0">undergo EPS </text>
<text top="402" left="891" width="158" height="20" font="0">• Hemodynamics/ BP not </text>
<text top="421" left="902" width="64" height="19" font="0">measured </text>
<text top="440" left="891" width="194" height="20" font="0">• Suggests isoproterenol useful </text>
<text top="459" left="902" width="161" height="19" font="0">to augment heart rate in 2</text>
<text top="458" left="1063" width="10" height="12" font="7">nd</text>
<text top="459" left="1073" width="3" height="19" font="0"> </text>
<text top="477" left="902" width="34" height="19" font="0">and 3</text>
<text top="477" left="936" width="9" height="12" font="7">rd</text>
<text top="477" left="944" width="78" height="19" font="0"> degree AVB </text>
<text top="512" left="96" width="117" height="19" font="0">Hatle L, et al. 1971 </text>
<text top="530" left="96" width="35" height="19" font="0">(167) </text>
<text top="548" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5557475">5557475</a></text>
<text top="548" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5557475"> </a></text>
<text top="512" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="530" left="236" width="117" height="19" font="0">center prospective </text>
<text top="548" left="236" width="131" height="19" font="0">cohort from Norway  </text>
<text top="567" left="236" width="3" height="19" font="0"> </text>
<text top="585" left="236" width="128" height="19" font="8"><b>Size:</b> N=105 pts with </text>
<text top="603" left="236" width="51" height="19" font="0">2nd or 3</text>
<text top="603" left="287" width="9" height="12" font="7">rd</text>
<text top="603" left="296" width="78" height="19" font="0"> degree AVB </text>
<text top="622" left="236" width="136" height="19" font="0">in setting of acute MI  </text>
<text top="512" left="398" width="201" height="19" font="8"><b>Inclusion criteria:</b> Pts with acute </text>
<text top="530" left="398" width="178" height="19" font="0">MI treated 1966–1970 with 2</text>
<text top="530" left="577" width="10" height="12" font="7">nd</text>
<text top="530" left="587" width="3" height="19" font="0"> </text>
<text top="548" left="398" width="24" height="19" font="0">or 3</text>
<text top="548" left="422" width="9" height="12" font="7">rd</text>
<text top="548" left="431" width="157" height="19" font="0"> degree AVB treated with </text>
<text top="567" left="398" width="175" height="19" font="0">isoproterenol, generally 1–3 </text>
<text top="585" left="398" width="58" height="19" font="0">mcg/min </text>
<text top="603" left="398" width="3" height="19" font="0"> </text>
<text top="622" left="398" width="195" height="19" font="8"><b>Exclusion criteria:</b> None stated  </text>
<text top="513" left="614" width="251" height="19" font="8"><b>1</b>°<b> endpoint:</b> Improvement in heart rate  </text>
<text top="531" left="614" width="3" height="19" font="0"> </text>
<text top="549" left="614" width="253" height="19" font="8"><b>Results:</b> In hospital mortality 48%. 60 pts </text>
<text top="568" left="614" width="229" height="19" font="0">received isoproterenol: 38 (63%) had </text>
<text top="586" left="614" width="240" height="19" font="0">increase in heart rate and BP; 12 (20%) </text>
<text top="604" left="614" width="245" height="19" font="0">had increased in heart rate but minimal </text>
<text top="623" left="614" width="214" height="19" font="0">change in BP; 8 (13%) had minimal </text>
<text top="641" left="614" width="251" height="19" font="0">change; 2 (3%) isoproterenol terminated </text>
<text top="659" left="614" width="220" height="19" font="0">due to ventricular ectopy. 3 pts had </text>
<text top="677" left="614" width="256" height="19" font="0">ventricular fibrillation on isoproterenol, 1 </text>
<text top="696" left="614" width="251" height="19" font="0">of which died. 14 pts treated with TVP, 3 </text>
<text top="714" left="614" width="256" height="19" font="0">of whom died from ventricular fibrillation </text>
<text top="512" left="891" width="193" height="20" font="0">• Very early cohort when there </text>
<text top="531" left="902" width="167" height="19" font="0">was minimal treatment for </text>
<text top="549" left="902" width="57" height="19" font="0">acute MI </text>
<text top="568" left="891" width="164" height="20" font="0">• Extremely high mortality </text>
<text top="587" left="891" width="181" height="20" font="0">• In this group, isoproterenol </text>
<text top="606" left="902" width="186" height="19" font="0">appeared safe compared with </text>
<text top="624" left="902" width="27" height="19" font="0">TVP </text>
<text top="643" left="891" width="175" height="20" font="0">• Uncontrolled cohort study </text>
<text top="733" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="755" left="86" width="537" height="23" font="5"><b>Data Supplement 29. RCTs Comparing Temporary Pacing (Section 6.3.3) </b></text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 108 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="100" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="105" left="131" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="123" left="104" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="87" left="256" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="105" left="262" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="123" left="255" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="87" left="406" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="87" left="568" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="105" left="586" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="123" left="569" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="142" left="591" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="87" left="760" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="105" left="742" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="123" left="746" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="142" left="789" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="88" left="935" width="152" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="106" left="999" width="35" height="19" font="8"><b>any); </b></text>
<text top="124" left="953" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="143" left="961" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="162" left="95" width="97" height="19" font="0">Ferguson JD, et </text>
<text top="180" left="95" width="87" height="19" font="0">al. 1997 (113) </text>
<text top="198" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9217762">9217762</a></text>
<text top="198" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9217762"> </a></text>
<text top="162" left="221" width="155" height="19" font="8"><b>Aim:</b> Compare 2 types of </text>
<text top="180" left="221" width="109" height="19" font="0">TVP catheters for </text>
<text top="198" left="221" width="75" height="19" font="0">success and </text>
<text top="217" left="221" width="116" height="19" font="0">complication rates </text>
<text top="235" left="221" width="3" height="19" font="0"> </text>
<text top="253" left="221" width="141" height="19" font="8"><b>Study type:</b> Unblinded </text>
<text top="272" left="221" width="27" height="19" font="0">RCT </text>
<text top="290" left="221" width="3" height="19" font="0"> </text>
<text top="308" left="221" width="139" height="19" font="8"><b>Size:</b> 40 pts, mean age </text>
<text top="326" left="221" width="121" height="19" font="0">72 y. 85% with AVB </text>
<text top="162" left="392" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="180" left="392" width="143" height="19" font="0">Undergoing temporary </text>
<text top="198" left="392" width="132" height="19" font="0">VVI pacing (85% with </text>
<text top="217" left="392" width="96" height="19" font="0">AVB) guided by </text>
<text top="235" left="392" width="75" height="19" font="0">fluoroscopy </text>
<text top="253" left="392" width="3" height="19" font="0"> </text>
<text top="271" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="290" left="392" width="78" height="19" font="0">None stated </text>
<text top="162" left="554" width="128" height="19" font="8"><b>Intervention:</b> Use of </text>
<text top="180" left="554" width="93" height="19" font="0">balloon-tipped </text>
<text top="198" left="554" width="106" height="19" font="0">electrode (N=20) </text>
<text top="217" left="554" width="7" height="19" font="0">  </text>
<text top="235" left="554" width="125" height="19" font="8"><b>Comparator:</b> Use of </text>
<text top="253" left="554" width="125" height="19" font="0">semi-rigid electrode </text>
<text top="272" left="553" width="45" height="19" font="0">(N=20)<b> </b></text>
<text top="162" left="716" width="148" height="19" font="8"><b>1</b>°<b> endpoint:</b> Procedure </text>
<text top="181" left="716" width="146" height="19" font="0">duration (264 vs. 540 s; </text>
<text top="199" left="716" width="191" height="19" font="0">p&lt;0.002), fluoroscopy time (87 </text>
<text top="217" left="716" width="192" height="19" font="0">vs. 189 s; p&lt;0.01), suitability of </text>
<text top="236" left="716" width="184" height="19" font="0">final position (0 unacceptable </text>
<text top="254" left="716" width="174" height="19" font="0">vs. 7; p&lt;0.0001). Thresholds </text>
<text top="272" left="716" width="44" height="19" font="0">similar </text>
<text top="291" left="716" width="3" height="19" font="0"> </text>
<text top="309" left="716" width="187" height="19" font="8"><b>Safety endpoint (if relevant):</b>  </text>
<text top="327" left="716" width="139" height="19" font="0">Dislodgement (1 vs. 3) </text>
<text top="346" left="716" width="91" height="19" font="0">Death (0 vs. 2)<b> </b></text>
<text top="162" left="925" width="114" height="20" font="0">• When guided by </text>
<text top="181" left="936" width="129" height="19" font="0">fluoroscopy, balloon-</text>
<text top="199" left="936" width="127" height="19" font="0">tipped catheters are </text>
<text top="217" left="936" width="92" height="19" font="0">easier to place </text>
<text top="236" left="936" width="140" height="19" font="0">successfully than semi-</text>
<text top="254" left="936" width="91" height="19" font="0">rigid catheters </text>
<text top="273" left="925" width="146" height="20" font="0">• Use of balloon-tipped </text>
<text top="291" left="936" width="153" height="19" font="0">catheter associated with </text>
<text top="310" left="936" width="122" height="19" font="0">trend toward lower </text>
<text top="328" left="936" width="111" height="19" font="0">complication rate </text>
<text top="365" left="95" width="99" height="19" font="0">Barthell E, 1988 </text>
<text top="383" left="95" width="35" height="19" font="0">(127) </text>
<text top="401" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3056132">3056132</a></text>
<text top="401" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3056132"> </a></text>
<text top="365" left="221" width="126" height="19" font="8"><b>Aim:</b> Compared TCP </text>
<text top="383" left="221" width="144" height="19" font="0">added to ACLS vs. ACLS </text>
<text top="401" left="221" width="136" height="19" font="0">alone for pre-hospital </text>
<text top="420" left="221" width="146" height="19" font="0">pts with asystole, EMD, </text>
<text top="438" left="221" width="94" height="19" font="0">or hypotensive </text>
<text top="456" left="221" width="76" height="19" font="0">bradycardia </text>
<text top="474" left="221" width="3" height="19" font="0"> </text>
<text top="493" left="221" width="141" height="19" font="8"><b>Study type:</b> Unblinded </text>
<text top="511" left="221" width="102" height="19" font="0">RCT (alternate d </text>
<text top="529" left="221" width="100" height="19" font="0">randomization)  </text>
<text top="548" left="221" width="3" height="19" font="0"> </text>
<text top="566" left="221" width="136" height="19" font="8"><b>Size:</b> N=239; 142 with </text>
<text top="584" left="221" width="143" height="19" font="0">asystole; 84 with EMD; </text>
<text top="603" left="221" width="127" height="19" font="0">13 with hypotensive </text>
<text top="621" left="221" width="76" height="19" font="0">bradycardia </text>
<text top="365" left="392" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="383" left="392" width="125" height="19" font="0">adult, nontraumatic </text>
<text top="401" left="392" width="147" height="19" font="0">bradyasystolic episodes </text>
<text top="420" left="392" width="129" height="19" font="0">or arrests treated by </text>
<text top="438" left="392" width="118" height="19" font="0">Milwaukee County </text>
<text top="456" left="392" width="140" height="19" font="0">Paramedic System Oct </text>
<text top="475" left="392" width="105" height="19" font="0">1986–May 1987  </text>
<text top="493" left="392" width="3" height="19" font="0"> </text>
<text top="511" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="529" left="392" width="78" height="19" font="0">None stated </text>
<text top="365" left="554" width="123" height="19" font="8"><b>Intervention:</b> TCP + </text>
<text top="383" left="554" width="33" height="19" font="0">ACLS </text>
<text top="401" left="554" width="7" height="19" font="0">  </text>
<text top="419" left="554" width="116" height="19" font="8"><b>Comparator:</b> ACLS </text>
<text top="438" left="554" width="37" height="19" font="0">alone<b> </b></text>
<text top="365" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="384" left="716" width="121" height="19" font="0">hospital admission: </text>
<text top="402" left="716" width="187" height="19" font="0">Asystole/EMD 17% I vs. 20% C </text>
<text top="420" left="716" width="44" height="19" font="0">(p=NS) </text>
<text top="439" left="716" width="180" height="19" font="0">Hypo-brady 100% I vs. 29% C </text>
<text top="457" left="716" width="54" height="19" font="0">(p=0.01) </text>
<text top="475" left="716" width="3" height="19" font="0"> </text>
<text top="494" left="716" width="185" height="19" font="0">Survival to hospital discharge: </text>
<text top="512" left="716" width="172" height="19" font="0">Asystole/EMD 2% I vs. 4% C </text>
<text top="530" left="716" width="44" height="19" font="0">(p=NS) </text>
<text top="549" left="716" width="172" height="19" font="0">Hypo-brady 83% I vs. 14% C </text>
<text top="567" left="716" width="54" height="19" font="0">(p=0.01) </text>
<text top="585" left="716" width="3" height="19" font="0"> </text>
<text top="603" left="716" width="143" height="19" font="8"><b>Safety endpoint:</b> None </text>
<text top="622" left="716" width="3" height="19" font="8"><b> </b></text>
<text top="365" left="925" width="109" height="20" font="0">• Limited form of </text>
<text top="384" left="936" width="92" height="19" font="0">randomization </text>
<text top="402" left="925" width="162" height="20" font="0">• Overall, no effect of TCP </text>
<text top="421" left="936" width="144" height="19" font="0">for pre-hospital use for </text>
<text top="439" left="936" width="127" height="19" font="0">asystole/EMD arrest </text>
<text top="458" left="925" width="132" height="20" font="0">• Possible benefit for </text>
<text top="477" left="936" width="157" height="19" font="0">hypotensive bradycardia, </text>
<text top="495" left="936" width="144" height="19" font="0">but number of pts very </text>
<text top="514" left="936" width="35" height="19" font="0">small </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 109 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="101" height="19" font="0">Cummins RO, et </text>
<text top="105" left="95" width="87" height="19" font="0">al. 1993 (168) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8474514">8474514</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8474514"> </a></text>
<text top="87" left="221" width="151" height="19" font="8"><b>Aim:</b> Determine efficacy </text>
<text top="105" left="221" width="154" height="19" font="0">of TCP of asystolic out of </text>
<text top="123" left="221" width="138" height="19" font="0">hospital cardiac arrest </text>
<text top="142" left="221" width="3" height="19" font="0"> </text>
<text top="160" left="221" width="133" height="19" font="8"><b>Study type:</b> Modified </text>
<text top="178" left="221" width="91" height="19" font="0">RCT by center  </text>
<text top="197" left="221" width="3" height="19" font="0"> </text>
<text top="215" left="221" width="130" height="19" font="8"><b>Size:</b> N=1056 cardiac </text>
<text top="233" left="221" width="123" height="19" font="0">arrests; N=537 with </text>
<text top="252" left="221" width="149" height="19" font="0">asystole as first rhythm; </text>
<text top="270" left="221" width="127" height="19" font="0">N=305 with asystole </text>
<text top="288" left="221" width="52" height="19" font="0">after VF </text>
<text top="87" left="392" width="130" height="19" font="8"><b>Inclusion criteria: </b>All </text>
<text top="105" left="392" width="107" height="19" font="0">cardiac arrests in </text>
<text top="123" left="392" width="128" height="19" font="0">Seattle area over 3 y </text>
<text top="142" left="392" width="138" height="19" font="0">period; Primary group </text>
<text top="160" left="392" width="148" height="19" font="0">was those with asystole </text>
<text top="178" left="392" width="96" height="19" font="0">as first rhythm  </text>
<text top="197" left="392" width="3" height="19" font="0"> </text>
<text top="215" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="233" left="392" width="36" height="19" font="0">None </text>
<text top="87" left="554" width="104" height="19" font="8"><b>Intervention: </b>16 </text>
<text top="105" left="554" width="144" height="19" font="0">EMS/fire districts given </text>
<text top="123" left="554" width="140" height="19" font="0">TCP and trained in use </text>
<text top="142" left="554" width="7" height="19" font="0">  </text>
<text top="160" left="554" width="101" height="19" font="8"><b>Comparator:</b> 23 </text>
<text top="178" left="554" width="144" height="19" font="0">EMS/fire districts given </text>
<text top="197" left="554" width="143" height="19" font="0">TCP and trained in use <b> </b></text>
<text top="88" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="106" left="716" width="174" height="19" font="0">hospital admission/ primary </text>
<text top="124" left="716" width="57" height="19" font="0">asystole: </text>
<text top="143" left="716" width="126" height="19" font="0">8% I vs. 8% C (p=NS) </text>
<text top="161" left="716" width="133" height="19" font="0">Survival to discharge: </text>
<text top="179" left="716" width="186" height="19" font="0">4% I vs. 2% C (OR: 2.05; p=NS) </text>
<text top="198" left="716" width="3" height="19" font="0"> </text>
<text top="216" left="716" width="143" height="19" font="8"><b>Safety endpoint:</b> None </text>
<text top="234" left="716" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="925" width="162" height="20" font="0">• No improvement for pts </text>
<text top="106" left="936" width="86" height="19" font="0">with initial VF </text>
<text top="124" left="925" width="109" height="20" font="0">• Limited form of </text>
<text top="143" left="936" width="92" height="19" font="0">randomization </text>
<text top="307" left="95" width="102" height="19" font="0">Hedges JR, et al. </text>
<text top="326" left="95" width="69" height="19" font="0">1987 (169) </text>
<text top="344" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3315295">3315295</a></text>
<text top="344" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3315295"> </a></text>
<text top="307" left="221" width="151" height="19" font="8"><b>Aim:</b> Determine efficacy </text>
<text top="326" left="221" width="155" height="19" font="0">of TCP added to ACLS for </text>
<text top="344" left="221" width="73" height="19" font="0">prehospital </text>
<text top="362" left="221" width="111" height="19" font="0">hemodynamically </text>
<text top="381" left="221" width="141" height="19" font="0">significant bradycardia </text>
<text top="399" left="221" width="69" height="19" font="0">or asystole </text>
<text top="417" left="221" width="3" height="19" font="0"> </text>
<text top="435" left="221" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="454" left="221" width="97" height="19" font="0">(alternate day)  </text>
<text top="472" left="221" width="3" height="19" font="0"> </text>
<text top="490" left="221" width="75" height="19" font="8"><b>Size: </b>N=202 </text>
<text top="307" left="392" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="326" left="392" width="148" height="19" font="0">pts over 14 y treated by </text>
<text top="344" left="392" width="139" height="19" font="0">Thurston County, EMS </text>
<text top="362" left="392" width="133" height="19" font="0">for hemodynamically-</text>
<text top="381" left="392" width="141" height="19" font="0">significant bradycardia </text>
<text top="399" left="392" width="143" height="19" font="0">with decreased mental </text>
<text top="417" left="392" width="137" height="19" font="0">status (Glasgow coma </text>
<text top="436" left="392" width="67" height="19" font="0">score ≤12) </text>
<text top="454" left="392" width="3" height="19" font="0"> </text>
<text top="472" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="491" left="392" width="78" height="19" font="0">None stated </text>
<text top="307" left="554" width="134" height="19" font="8"><b>Intervention:</b> On odd </text>
<text top="326" left="554" width="121" height="19" font="0">calendar days, EMS </text>
<text top="344" left="554" width="132" height="19" font="0">used TCP 100 bpm at </text>
<text top="362" left="554" width="117" height="19" font="0">max output for pts </text>
<text top="381" left="554" width="7" height="19" font="0">  </text>
<text top="399" left="554" width="137" height="19" font="8"><b>Comparator:</b> On even </text>
<text top="417" left="554" width="144" height="19" font="0">calendar days, TCP was </text>
<text top="436" left="554" width="60" height="19" font="0">not used <b> </b></text>
<text top="308" left="716" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="326" left="716" width="188" height="19" font="0">Survival to hospital admission: </text>
<text top="345" left="716" width="141" height="19" font="0">17% I vs. 17% C (p=NS) </text>
<text top="363" left="716" width="185" height="19" font="0">Survival to hospital discharge: </text>
<text top="381" left="716" width="126" height="19" font="0">6% I vs. 4% C (p=NS) </text>
<text top="400" left="716" width="3" height="19" font="0"> </text>
<text top="418" left="716" width="143" height="19" font="8"><b>Safety endpoint:</b> None </text>
<text top="436" left="716" width="3" height="19" font="8"><b> </b></text>
<text top="308" left="925" width="109" height="20" font="0">• Limited form of </text>
<text top="326" left="936" width="92" height="19" font="0">randomization </text>
<text top="345" left="925" width="149" height="20" font="0">• No improvement with </text>
<text top="364" left="936" width="26" height="19" font="0">TCP </text>
<text top="509" left="95" width="57" height="19" font="8"><b>PrePACE </b></text>
<text top="528" left="95" width="98" height="19" font="0">Morrison, LJ, et </text>
<text top="546" left="95" width="79" height="19" font="0">al. 2008 (86) </text>
<text top="564" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452">17933452</a></text>
<text top="564" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452"> </a></text>
<text top="509" left="221" width="108" height="19" font="8"><b>Aim:</b> To compare </text>
<text top="528" left="221" width="126" height="19" font="0">outcome of pts with </text>
<text top="546" left="221" width="129" height="19" font="0">prehospital unstable </text>
<text top="564" left="221" width="152" height="19" font="0">bradycardia with TCP vs. </text>
<text top="583" left="221" width="65" height="19" font="0">dopamine </text>
<text top="601" left="221" width="3" height="19" font="0"> </text>
<text top="619" left="221" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="638" left="221" width="3" height="19" font="0"> </text>
<text top="656" left="221" width="153" height="19" font="8"><b>Size:</b> N=82; mean age 71 </text>
<text top="674" left="221" width="80" height="19" font="0">y; 57% male  </text>
<text top="509" left="392" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="528" left="392" width="81" height="19" font="0">18 y or older </text>
<text top="546" left="392" width="137" height="19" font="0">presenting to Toronto </text>
<text top="564" left="392" width="61" height="19" font="0">EMS with </text>
<text top="583" left="392" width="111" height="19" font="0">hemodynamically </text>
<text top="601" left="392" width="132" height="19" font="0">unstable bradycardia </text>
<text top="619" left="392" width="138" height="19" font="0">unresponsive to fluids </text>
<text top="638" left="392" width="85" height="19" font="0">and atropine  </text>
<text top="656" left="392" width="3" height="19" font="0"> </text>
<text top="674" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="693" left="392" width="145" height="19" font="0">Trauma, hyperthermia, </text>
<text top="711" left="392" width="133" height="19" font="0">hypothermia, cardiac </text>
<text top="729" left="392" width="43" height="19" font="0">arrest  </text>
<text top="509" left="554" width="130" height="19" font="8"><b>Intervention:</b> TCP 80 </text>
<text top="528" left="554" width="31" height="19" font="0">bpm </text>
<text top="546" left="554" width="7" height="19" font="0">  </text>
<text top="564" left="554" width="149" height="19" font="8"><b>Comparator:</b> Dopamine </text>
<text top="583" left="554" width="115" height="19" font="0">5–20 mcg/kg/min<b>  </b></text>
<text top="510" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="529" left="716" width="114" height="19" font="0">hospital discharge </text>
<text top="547" left="716" width="141" height="19" font="0">69% I vs. 70% C (p=NS) </text>
<text top="565" left="716" width="3" height="19" font="0"> </text>
<text top="583" left="716" width="110" height="19" font="8"><b>Safety endpoint:</b>  </text>
<text top="602" left="716" width="168" height="19" font="0">VT/VF/cardiac arrest/burn: </text>
<text top="620" left="716" width="153" height="19" font="0">7.1% C vs. 7.5% C (p=NS<b>) </b></text>
<text top="510" left="925" width="148" height="20" font="0">• Half of eligible pts not </text>
<text top="529" left="936" width="76" height="19" font="0">randomized </text>
<text top="547" left="925" width="166" height="20" font="0">• This was a pilot study for </text>
<text top="566" left="936" width="124" height="19" font="0">potential larger RCT </text>
<text top="585" left="925" width="157" height="20" font="0">• No benefit to TCP seen  </text>
<text top="748" left="86" width="3" height="19" font="0"> </text>
<text top="767" left="86" width="910" height="23" font="5"><b>Data Supplement 30. Nonrandomized Trials, Observational Studies, and/or Registries of Temporary Pacing (Section 6.3.3) </b></text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 110 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="105" left="131" width="51" height="19" font="8"><b>Author; </b></text>
<text top="123" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="87" left="238" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="105" left="267" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="87" left="423" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="87" left="619" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="105" left="649" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="123" left="681" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="87" left="880" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="105" left="909" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="143" left="96" width="106" height="19" font="0">Sodeck GH, et al. </text>
<text top="161" left="96" width="62" height="19" font="0">2006 (77) </text>
<text top="179" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976">17212976</a></text>
<text top="179" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976"> </a></text>
<text top="142" left="230" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="161" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="179" left="230" width="105" height="19" font="0">cohort in Austria </text>
<text top="197" left="230" width="3" height="19" font="0"> </text>
<text top="216" left="230" width="114" height="19" font="8"><b>Size:</b> 277 pts (62% </text>
<text top="234" left="230" width="100" height="19" font="0">male, 48% AVB) </text>
<text top="142" left="385" width="170" height="19" font="8"><b>Inclusion criteria:</b> Pts &gt;18 y </text>
<text top="161" left="385" width="135" height="19" font="0">presenting to ED with </text>
<text top="179" left="385" width="172" height="19" font="0">“compromising bradycardia </text>
<text top="197" left="385" width="183" height="19" font="0">from 1994–2004; mean heart </text>
<text top="216" left="385" width="78" height="19" font="0">rate 33 bpm </text>
<text top="234" left="385" width="3" height="19" font="0"> </text>
<text top="252" left="385" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="271" left="385" width="171" height="19" font="0">Asymptomatic bradycardia, </text>
<text top="289" left="385" width="96" height="19" font="0">terminal illness </text>
<text top="143" left="594" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> 30 d mortality </text>
<text top="162" left="594" width="3" height="19" font="0"> </text>
<text top="180" left="594" width="228" height="19" font="8"><b>Results:</b> 5% mortality at 30 d. 20% of </text>
<text top="198" left="594" width="229" height="19" font="0">pts treated with temporary TVP. 50% </text>
<text top="217" left="594" width="178" height="19" font="0">of those pts went on to have </text>
<text top="235" left="594" width="115" height="19" font="0">permanent pacing </text>
<text top="253" left="594" width="3" height="19" font="0"> </text>
<text top="143" left="844" width="179" height="20" font="0">• Temporary TVP required in </text>
<text top="162" left="855" width="192" height="19" font="0">about 20% of pts presenting to </text>
<text top="180" left="855" width="133" height="19" font="0">ED with symptomatic </text>
<text top="198" left="855" width="76" height="19" font="0">bradycardia </text>
<text top="217" left="844" width="200" height="20" font="0">• Half of those pts go on to PPM </text>
<text top="308" left="96" width="116" height="19" font="0">Brikhahn RH, et al. </text>
<text top="326" left="96" width="69" height="19" font="0">2004 (170) </text>
<text top="345" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15039689">15039689</a></text>
<text top="345" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15039689"> </a></text>
<text top="308" left="230" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="326" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="345" left="230" width="78" height="19" font="0">cohort in US </text>
<text top="363" left="230" width="3" height="19" font="0"> </text>
<text top="381" left="230" width="110" height="19" font="8"><b>Size:</b> 154 pts, 117 </text>
<text top="400" left="230" width="117" height="19" font="0">meeting inclusion/ </text>
<text top="418" left="230" width="111" height="19" font="0">exclusion criteria. </text>
<text top="436" left="230" width="126" height="19" font="0">Mean age 78 y, 38% </text>
<text top="455" left="230" width="100" height="19" font="0">male, 51% AVB) </text>
<text top="308" left="385" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="326" left="385" width="177" height="19" font="0">temporary TVP placed in ED, </text>
<text top="345" left="385" width="171" height="19" font="0">intensive care unit, or ward </text>
<text top="363" left="385" width="172" height="19" font="0">1999–2002. Only 3% placed </text>
<text top="381" left="385" width="118" height="19" font="0">under fluoroscopy  </text>
<text top="400" left="385" width="3" height="19" font="0"> </text>
<text top="418" left="385" width="178" height="19" font="8"><b>Exclusion criteria:</b> Indication </text>
<text top="436" left="385" width="188" height="19" font="0">asystole, TVP placed in cath or </text>
<text top="455" left="385" width="126" height="19" font="0">EP lab, no attending </text>
<text top="473" left="385" width="73" height="19" font="0">supervision </text>
<text top="309" left="594" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Successful temporary </text>
<text top="327" left="594" width="215" height="19" font="0">TVP placement. Complication rate. </text>
<text top="346" left="594" width="3" height="19" font="0"> </text>
<text top="364" left="594" width="234" height="19" font="8"><b>Results:</b> 88% success on first attempt. </text>
<text top="382" left="594" width="220" height="19" font="0">17% serious complication rate. 96% </text>
<text top="401" left="594" width="235" height="19" font="0">placed by cephalic approach. 67% had </text>
<text top="419" left="594" width="192" height="19" font="0">PPM. 23% in-hospital mortality </text>
<text top="437" left="594" width="3" height="19" font="0"> </text>
<text top="308" left="844" width="196" height="20" font="0">• Similar success rates between </text>
<text top="327" left="855" width="192" height="19" font="0">ED physicians and cardiologists </text>
<text top="346" left="844" width="180" height="20" font="0">• High overall success rate of </text>
<text top="365" left="855" width="124" height="19" font="0">implantation of TVP </text>
<text top="383" left="844" width="189" height="20" font="0">• Cephalic route rarely used in </text>
<text top="402" left="855" width="140" height="19" font="0">general practice today </text>
<text top="492" left="96" width="92" height="19" font="0">Betts TR, 2003 </text>
<text top="510" left="96" width="35" height="19" font="0">(119) </text>
<text top="529" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12954959">12954959</a></text>
<text top="529" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12954959"> </a></text>
<text top="492" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="510" left="230" width="139" height="19" font="0">Prospective registry in </text>
<text top="529" left="230" width="137" height="19" font="0">5 regional hospitals in </text>
<text top="547" left="230" width="101" height="19" font="0">England in 1999 </text>
<text top="565" left="230" width="3" height="19" font="0"> </text>
<text top="583" left="230" width="131" height="19" font="8"><b>Size:</b> 144 procedures </text>
<text top="602" left="230" width="130" height="19" font="0">in 111 pts; mean age </text>
<text top="620" left="230" width="133" height="19" font="0">75 y.; 63% male; 51% </text>
<text top="638" left="230" width="32" height="19" font="0">AVB  </text>
<text top="492" left="385" width="163" height="19" font="8"><b>Inclusion criteria:</b> All TVPs </text>
<text top="510" left="385" width="167" height="19" font="0">placed over 9 mo period in </text>
<text top="529" left="385" width="34" height="19" font="0">1999 </text>
<text top="547" left="385" width="3" height="19" font="0"> </text>
<text top="565" left="385" width="183" height="19" font="8"><b>Exclusion criteria:</b> None cited </text>
<text top="493" left="594" width="208" height="19" font="8"><b>1</b>°<b> endpoint:</b> General overview of </text>
<text top="511" left="594" width="203" height="19" font="0">procedure technique, outcomes, </text>
<text top="529" left="594" width="88" height="19" font="0">complications </text>
<text top="548" left="594" width="3" height="19" font="0"> </text>
<text top="566" left="594" width="225" height="19" font="8"><b>Results:</b> Procedure times shorter for </text>
<text top="584" left="594" width="227" height="19" font="0">cardiologists, 28% complication rate. </text>
<text top="603" left="594" width="224" height="19" font="0">Immediate complication rates lower </text>
<text top="621" left="594" width="162" height="19" font="0">with experience (1/81) vs. </text>
<text top="639" left="594" width="198" height="19" font="0">inexperienced (5/59) operators. </text>
<text top="658" left="594" width="226" height="19" font="0">Infection occurred more in wires left </text>
<text top="676" left="594" width="214" height="19" font="0">in &gt;48 h (17/86) than &lt;48 h (2/55). </text>
<text top="694" left="594" width="208" height="19" font="0">23% of comps resulted in delayed </text>
<text top="713" left="594" width="32" height="19" font="0">PPM </text>
<text top="731" left="594" width="3" height="19" font="0"> </text>
<text top="492" left="844" width="208" height="20" font="0">• Suggests benefit to TVP implant </text>
<text top="511" left="855" width="182" height="19" font="0">by cardiologists/ experienced </text>
<text top="529" left="855" width="63" height="19" font="0">operators </text>
<text top="548" left="844" width="192" height="20" font="0">• Greater infection risk for TVP </text>
<text top="567" left="855" width="112" height="19" font="0">wires left in &gt;48 h </text>
<text top="585" left="844" width="131" height="20" font="0">• High rate of overall </text>
<text top="604" left="855" width="120" height="19" font="0">complications seen </text>
<text top="623" left="844" width="183" height="20" font="0">• 23% of comps delayed PPM </text>
<text top="642" left="855" width="82" height="19" font="0">implantation </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 111 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="119" height="19" font="0">Mahapatra S, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2005 (171) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16171740">16171740</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16171740"> </a></text>
<text top="87" left="230" width="107" height="19" font="8"><b>Study type:</b> Case-</text>
<text top="105" left="230" width="130" height="19" font="0">control derived from </text>
<text top="123" left="230" width="134" height="19" font="0">prospective database </text>
<text top="142" left="230" width="125" height="19" font="0">1995–2003 at Mayo </text>
<text top="160" left="230" width="36" height="19" font="0">Clinic </text>
<text top="178" left="230" width="3" height="19" font="0"> </text>
<text top="197" left="230" width="103" height="19" font="8"><b>Size:</b> 50 pts with </text>
<text top="215" left="230" width="120" height="19" font="0">cardiac perforation </text>
<text top="233" left="230" width="111" height="19" font="0">after PPM vs. 100 </text>
<text top="252" left="230" width="56" height="19" font="0">controls  </text>
<text top="87" left="385" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="105" left="385" width="177" height="19" font="0">undergoing PPM 1995–2003 </text>
<text top="123" left="385" width="159" height="19" font="0">with perforation and new </text>
<text top="142" left="385" width="57" height="19" font="0">effusion. </text>
<text top="160" left="385" width="3" height="19" font="0"> </text>
<text top="178" left="385" width="180" height="19" font="8"><b>Exclusion criteria:</b> Age &lt;18 y, </text>
<text top="197" left="385" width="150" height="19" font="0">prior effusion or cardiac </text>
<text top="215" left="385" width="170" height="19" font="0">surgery within 4 wk of PPM </text>
<text top="88" left="594" width="176" height="19" font="8"><b>1</b>°<b> endpoint:</b> Risk factors for </text>
<text top="106" left="594" width="138" height="19" font="0">perforation after PPM </text>
<text top="124" left="594" width="3" height="19" font="0"> </text>
<text top="143" left="594" width="167" height="19" font="8"><b>Results:</b> 1.2% of all pts had </text>
<text top="161" left="594" width="232" height="19" font="0">perforation. Predictors of perforation </text>
<text top="179" left="594" width="232" height="19" font="0">in multivariate analysis included prior </text>
<text top="198" left="594" width="231" height="19" font="0">TVP (HR: 2.7; 95% CI: 1.4–3.9], helical </text>
<text top="216" left="594" width="235" height="19" font="0">screw leads (HR: 2.5), steroid use (HR: </text>
<text top="234" left="594" width="27" height="19" font="0">3.2) </text>
<text top="252" left="594" width="3" height="19" font="0"> </text>
<text top="87" left="844" width="186" height="20" font="0">• Suggests benefit to avoiding </text>
<text top="106" left="855" width="191" height="19" font="0">TVP prior to permanent pacing </text>
<text top="124" left="855" width="99" height="19" font="0">unless essential </text>
<text top="272" left="96" width="118" height="19" font="0">Lang R, et al.  1981 </text>
<text top="290" left="96" width="35" height="19" font="0">(172) </text>
<text top="308" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6169032">6169032</a></text>
<text top="308" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6169032"> </a></text>
<text top="271" left="230" width="115" height="19" font="8"><b>Study type: </b>Single-</text>
<text top="290" left="230" width="43" height="19" font="0">center </text>
<text top="308" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="326" left="230" width="103" height="19" font="0">controlled study </text>
<text top="345" left="230" width="119" height="19" font="0">comparing balloon-</text>
<text top="363" left="230" width="123" height="19" font="0">tipped, flow-guided </text>
<text top="381" left="229" width="138" height="19" font="0">TVP vs. standard semi-</text>
<text top="400" left="229" width="89" height="19" font="0">rigid catheter  </text>
<text top="418" left="230" width="3" height="19" font="0"> </text>
<text top="436" left="230" width="134" height="19" font="8"><b>Size:</b> 111 consecutive </text>
<text top="455" left="230" width="125" height="19" font="0">pts (67 flow-guided, </text>
<text top="473" left="230" width="90" height="19" font="0">44 semi-rigid)  </text>
<text top="271" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="290" left="385" width="169" height="19" font="0">pts requiring emergency or </text>
<text top="308" left="385" width="188" height="19" font="0">semi-urgent temporary TVP at </text>
<text top="326" left="385" width="132" height="19" font="0">a single Israeli center </text>
<text top="345" left="385" width="3" height="19" font="0"> </text>
<text top="363" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="272" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Successful implant, </text>
<text top="291" left="594" width="221" height="19" font="0">procedure time, threshold, multiple </text>
<text top="309" left="594" width="105" height="19" font="0">safety endpoints </text>
<text top="327" left="594" width="3" height="19" font="0"> </text>
<text top="345" left="594" width="200" height="19" font="8"><b>Results:</b> Flow-guided TVP had 1) </text>
<text top="364" left="594" width="218" height="19" font="0">shorter insertion time (7 min vs. 14 </text>
<text top="382" left="594" width="202" height="19" font="0">min); less dislodgement (13% vs. </text>
<text top="401" left="594" width="200" height="19" font="0">32%), lower incidence of serious </text>
<text top="419" left="594" width="233" height="19" font="0">ventricular arrhythmia (1.5 vs. 20.4%) </text>
<text top="437" left="594" width="118" height="19" font="0">Thresholds similar. </text>
<text top="272" left="844" width="194" height="20" font="0">• Superiority of balloon-tipped, </text>
<text top="291" left="855" width="192" height="19" font="0">flow guided electrode catheter </text>
<text top="309" left="855" width="116" height="19" font="0">for temporary TVP </text>
<text top="327" left="855" width="94" height="19" font="0">demonstrated. </text>
<text top="492" left="96" width="94" height="19" font="0">Hynes JK, et al. </text>
<text top="510" left="96" width="69" height="19" font="0">1983 (115) </text>
<text top="529" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157">6823157</a></text>
<text top="529" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157"> </a></text>
<text top="492" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="510" left="230" width="127" height="19" font="0">Retrospective single-</text>
<text top="529" left="230" width="140" height="19" font="0">center cohort at Mayo </text>
<text top="547" left="230" width="36" height="19" font="0">Clinic </text>
<text top="565" left="230" width="3" height="19" font="0"> </text>
<text top="583" left="230" width="129" height="19" font="8"><b>Size:</b> 1022 pts, mean </text>
<text top="602" left="230" width="129" height="19" font="0">age 68 y, (65% male) </text>
<text top="492" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="510" left="385" width="190" height="19" font="0">pts undergoing temporary TVP </text>
<text top="529" left="385" width="177" height="19" font="0">wire in Mayo Clinic coronary </text>
<text top="547" left="385" width="118" height="19" font="0">care unit 1976–81. </text>
<text top="565" left="385" width="3" height="19" font="0"> </text>
<text top="583" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="493" left="594" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications </text>
<text top="511" left="594" width="3" height="19" font="0"> </text>
<text top="529" left="594" width="223" height="19" font="8"><b>Results:</b> Implanted mean 3.1 d, 64% </text>
<text top="548" left="594" width="186" height="19" font="0">placed antecubital route, 19% </text>
<text top="566" left="594" width="229" height="19" font="0">subclavian vein, 12 % internal jugular </text>
<text top="584" left="594" width="188" height="19" font="0">vein. 13.7% complication rate, </text>
<text top="603" left="594" width="198" height="19" font="0">increasing with duration of TVP. </text>
<text top="621" left="594" width="194" height="19" font="0">Lowest comp rate with internal </text>
<text top="639" left="594" width="215" height="19" font="0">jugular vein 5.3% pericarditis. PPM </text>
<text top="658" left="594" width="151" height="19" font="0">implanted in 58% of pts. </text>
<text top="492" left="844" width="199" height="20" font="0">• Preference for internal jugular </text>
<text top="511" left="855" width="170" height="19" font="0">rand subclavian vein access </text>
<text top="529" left="855" width="97" height="19" font="0">sites confirmed </text>
<text top="677" left="96" width="85" height="19" font="0">Winner S and </text>
<text top="695" left="96" width="86" height="19" font="0">Boon N, 1989 </text>
<text top="713" left="96" width="35" height="19" font="0">(173) </text>
<text top="732" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2769615">2769615</a></text>
<text top="732" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2769615"> </a></text>
<text top="677" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="695" left="230" width="126" height="19" font="0">Retrospective single </text>
<text top="713" left="230" width="123" height="19" font="0">region cohort study </text>
<text top="732" left="230" width="3" height="19" font="0"> </text>
<text top="677" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="695" left="385" width="188" height="19" font="0">pts referred to regional center </text>
<text top="713" left="385" width="53" height="19" font="0">for PPM </text>
<text top="732" left="385" width="3" height="19" font="0"> </text>
<text top="750" left="385" width="163" height="19" font="8"><b>Exclusion criteria:</b> Missing </text>
<text top="768" left="385" width="49" height="19" font="0">records </text>
<text top="677" left="594" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, defined </text>
<text top="696" left="594" width="224" height="19" font="0">as “major problems”: dislodgement, </text>
<text top="714" left="594" width="212" height="19" font="0">infection, pericarditis/perforation, </text>
<text top="732" left="594" width="201" height="19" font="0">thrombosis, wire in left ventricle </text>
<text top="751" left="594" width="3" height="19" font="0"> </text>
<text top="677" left="844" width="180" height="20" font="0">• Advise avoiding TVP before </text>
<text top="696" left="855" width="140" height="19" font="0">PPM unless absolutely </text>
<text top="714" left="855" width="64" height="19" font="0">necessary </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 112 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="112" height="19" font="8"><b>Size: </b>266 pts/ 158 </text>
<text top="105" left="230" width="133" height="19" font="0">(59%) had temporary </text>
<text top="123" left="230" width="30" height="19" font="0">TVP  </text>
<text top="87" left="594" width="230" height="19" font="8"><b>Results:</b> 36% rate of major problems, </text>
<text top="105" left="594" width="221" height="19" font="0">much higher rate at smaller referral </text>
<text top="123" left="594" width="233" height="19" font="0">hospitals. 6% infection; 30% failure to </text>
<text top="142" left="594" width="130" height="19" font="0">pace, 4% pericarditis </text>
<text top="161" left="96" width="114" height="19" font="0">López Ayerbe J, et </text>
<text top="179" left="96" width="21" height="19" font="0">al.  </text>
<text top="197" left="96" width="69" height="19" font="0">2004 (114) </text>
<text top="216" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15544753">15544753</a></text>
<text top="216" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15544753"> </a></text>
<text top="161" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="179" left="230" width="126" height="19" font="0">Retrospective single </text>
<text top="197" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="216" left="230" width="108" height="19" font="0">Barcelona, Spain  </text>
<text top="234" left="230" width="3" height="19" font="0"> </text>
<text top="252" left="230" width="142" height="19" font="8"><b>Size: </b>N=530; mean age </text>
<text top="271" left="230" width="129" height="19" font="0">74 y, 54% male; 51% </text>
<text top="289" left="230" width="36" height="19" font="0">AVB.  </text>
<text top="161" left="385" width="192" height="19" font="8"><b>Inclusion criteria:</b> Pts receiving </text>
<text top="179" left="385" width="193" height="19" font="0">TVP 1997–2003. All via femoral </text>
<text top="197" left="385" width="184" height="19" font="0">route (99%) with fluoroscopic </text>
<text top="216" left="385" width="62" height="19" font="0">guidance  </text>
<text top="234" left="385" width="3" height="19" font="0"> </text>
<text top="252" left="385" width="135" height="19" font="8"><b>Exclusion criteria: </b>Pts </text>
<text top="271" left="385" width="146" height="19" font="0">transferred out with no </text>
<text top="289" left="385" width="126" height="19" font="0">available f-u (N=38)  </text>
<text top="162" left="594" width="175" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, </text>
<text top="180" left="594" width="64" height="19" font="0">outcomes </text>
<text top="198" left="594" width="3" height="19" font="0"> </text>
<text top="217" left="594" width="214" height="19" font="8"><b>Results:</b> Mean duration 4.2 d. 22% </text>
<text top="235" left="594" width="191" height="19" font="0">complication rate: 1% death (3 </text>
<text top="253" left="594" width="189" height="19" font="0">tamponade, 1 asystole, 1 PE, 1 </text>
<text top="272" left="594" width="225" height="19" font="0">sepsis). 9% migration/dislodgement’ </text>
<text top="290" left="594" width="212" height="19" font="0">9% other (VTE, effusion, infection) </text>
<text top="161" left="844" width="191" height="20" font="0">• Complication rates improved </text>
<text top="180" left="855" width="168" height="19" font="0">compared with series from </text>
<text top="198" left="855" width="167" height="19" font="0">1980s and 1990s (18–43%) </text>
<text top="217" left="844" width="201" height="20" font="0">• Lower use in pts with acute MI </text>
<text top="236" left="855" width="32" height="19" font="0">seen </text>
<text top="309" left="96" width="119" height="19" font="0">Bjornstad CC, et al. </text>
<text top="327" left="96" width="69" height="19" font="0">2012 (126) </text>
<text top="346" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22390277">22390277</a></text>
<text top="346" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22390277"> </a></text>
<text top="309" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="327" left="230" width="139" height="19" font="0">Prospective regional 5 </text>
<text top="346" left="230" width="104" height="19" font="0">hospital study in </text>
<text top="364" left="230" width="115" height="19" font="0">Norway 2010–11.  </text>
<text top="382" left="230" width="3" height="19" font="0"> </text>
<text top="400" left="230" width="134" height="19" font="8"><b>Size:</b> N=50; 45% AVB; </text>
<text top="419" left="230" width="125" height="19" font="0">mean age 79 y, 62% </text>
<text top="437" left="230" width="37" height="19" font="0">male  </text>
<text top="309" left="385" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="327" left="385" width="191" height="19" font="0">TVP in 5 hospitals March 2010–</text>
<text top="346" left="385" width="130" height="19" font="0">March 2011. All with </text>
<text top="364" left="385" width="75" height="19" font="0">fluoroscopy </text>
<text top="382" left="385" width="3" height="19" font="0"> </text>
<text top="400" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="310" left="594" width="175" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, </text>
<text top="328" left="594" width="64" height="19" font="0">outcomes </text>
<text top="346" left="594" width="3" height="19" font="0"> </text>
<text top="365" left="594" width="194" height="19" font="8"><b>Results:</b> 96% TVP; 4% TCP. 60% </text>
<text top="383" left="594" width="228" height="19" font="0">received PPM; 14% died. 30% rate of </text>
<text top="401" left="594" width="228" height="19" font="0">“serious complications” including 6% </text>
<text top="420" left="594" width="112" height="19" font="0">death from sepsis </text>
<text top="309" left="844" width="209" height="20" font="0">• Fewer TVPs being performed by </text>
<text top="328" left="855" width="159" height="19" font="0">more physicians with less </text>
<text top="346" left="855" width="71" height="19" font="0">experience </text>
<text top="365" left="844" width="193" height="20" font="0">• Lower complication rate with </text>
<text top="384" left="855" width="183" height="19" font="0">more experienced implanters </text>
<text top="456" left="96" width="102" height="19" font="0">McCann P, 2006 </text>
<text top="474" left="96" width="35" height="19" font="0">(125) </text>
<text top="493" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17235372">17235372</a></text>
<text top="493" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17235372"> </a></text>
<text top="456" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="474" left="230" width="114" height="19" font="0">Systematic review </text>
<text top="493" left="230" width="75" height="19" font="0">1973–2004  </text>
<text top="511" left="230" width="3" height="19" font="0"> </text>
<text top="529" left="230" width="101" height="19" font="8"><b>Size:</b> 15 studies; </text>
<text top="548" left="230" width="137" height="19" font="0">N=3737; mean age 71 </text>
<text top="566" left="230" width="14" height="19" font="0">y  </text>
<text top="456" left="385" width="157" height="19" font="8"><b>Inclusion criteria:</b> Cohort </text>
<text top="474" left="385" width="191" height="19" font="0">studies of TVP published 1973–</text>
<text top="493" left="385" width="34" height="19" font="0">2004 </text>
<text top="511" left="385" width="3" height="19" font="0"> </text>
<text top="529" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="457" left="594" width="175" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, </text>
<text top="475" left="594" width="64" height="19" font="0">outcomes </text>
<text top="494" left="594" width="3" height="19" font="0"> </text>
<text top="512" left="594" width="210" height="19" font="8"><b>Results:</b> Overall complication rate </text>
<text top="530" left="594" width="224" height="19" font="0">26.5%: 15% failed access, 10% failed </text>
<text top="548" left="594" width="206" height="19" font="0">placement, 9% sepsis, 4% arterial </text>
<text top="567" left="594" width="196" height="19" font="0">puncture, 2% lung/myocardium </text>
<text top="585" left="594" width="59" height="19" font="0">puncture </text>
<text top="456" left="844" width="166" height="20" font="0">• Methodologically limited </text>
<text top="475" left="855" width="113" height="19" font="0">systematic review </text>
<text top="494" left="844" width="180" height="20" font="0">• Higher complication rate in </text>
<text top="513" left="855" width="57" height="19" font="0">older pts </text>
<text top="531" left="844" width="200" height="20" font="0">• Lower complication rate when </text>
<text top="550" left="855" width="149" height="19" font="0">implanted by specialists </text>
<text top="569" left="844" width="186" height="20" font="0">• Trend toward greater use of </text>
<text top="588" left="855" width="171" height="19" font="0">right internal jugular access </text>
<text top="606" left="855" width="62" height="19" font="0">over time </text>
<text top="625" left="96" width="112" height="19" font="0">Jou YL, et al. 2010 </text>
<text top="643" left="96" width="35" height="19" font="0">(124) </text>
<text top="662" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20946290">20946290</a></text>
<text top="662" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20946290"> </a></text>
<text top="625" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="643" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="662" left="230" width="106" height="19" font="0">cohort in Taiwan </text>
<text top="680" left="230" width="52" height="19" font="0">2002–8  </text>
<text top="698" left="230" width="3" height="19" font="0"> </text>
<text top="716" left="230" width="142" height="19" font="8"><b>Size: </b>N=509; mean age </text>
<text top="735" left="230" width="129" height="19" font="0">77 y, 74% male; 64% </text>
<text top="753" left="230" width="32" height="19" font="0">AVB  </text>
<text top="625" left="385" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="643" left="385" width="169" height="19" font="0">TVP 2002 8 at single center </text>
<text top="662" left="385" width="3" height="19" font="0"> </text>
<text top="680" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="626" left="594" width="166" height="19" font="8"><b>1</b>°<b> endpoint:</b> Trends in use </text>
<text top="644" left="594" width="3" height="19" font="0"> </text>
<text top="662" left="594" width="208" height="19" font="8"><b>Results:</b> Greater use for AVB with </text>
<text top="681" left="594" width="220" height="19" font="0">intrinsic disease, less for sinus node </text>
<text top="699" left="594" width="216" height="19" font="0">dysfunction and MI over time. 48% </text>
<text top="717" left="594" width="233" height="19" font="0">had PPM implant within 30 d (mean 6 </text>
<text top="736" left="594" width="206" height="19" font="0">d) with increasing rate over time. </text>
<text top="754" left="594" width="3" height="19" font="0"> </text>
<text top="625" left="844" width="139" height="20" font="0">• High rate of PPM for </text>
<text top="644" left="855" width="112" height="19" font="0">degenerative AVB </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 113 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="118" height="19" font="0">Knudsen MB, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2013 (150) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746">23869746</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746"> </a></text>
<text top="87" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="105" left="230" width="127" height="19" font="0">Retrospective single-</text>
<text top="123" left="230" width="102" height="19" font="0">center cohort at </text>
<text top="142" left="230" width="112" height="19" font="0">academic medical </text>
<text top="160" left="230" width="117" height="19" font="0">center in Denmark </text>
<text top="178" left="230" width="64" height="19" font="0">2000–11.  </text>
<text top="197" left="230" width="3" height="19" font="0"> </text>
<text top="215" left="230" width="137" height="19" font="8"><b>Size:</b> N=575 with TVP. </text>
<text top="233" left="230" width="121" height="19" font="0">N=55 with AVB and </text>
<text top="252" left="230" width="137" height="19" font="0">potential culprit drug. </text>
<text top="270" left="230" width="126" height="19" font="0">Mean age 77 y, 56% </text>
<text top="288" left="230" width="37" height="19" font="0">male  </text>
<text top="87" left="385" width="180" height="19" font="8"><b>Inclusion criteria:</b> Pts getting </text>
<text top="105" left="385" width="170" height="19" font="0">TVP wire 2000–11 who had </text>
<text top="123" left="385" width="188" height="19" font="0">AVB and potential culprit drug </text>
<text top="142" left="385" width="86" height="19" font="0">discontinued  </text>
<text top="160" left="385" width="3" height="19" font="0"> </text>
<text top="178" left="385" width="163" height="19" font="8"><b>Exclusion criteria:</b> No ECG </text>
<text top="197" left="385" width="191" height="19" font="0">documentation; other etiology </text>
<text top="215" left="385" width="177" height="19" font="0">of bradycardia documented; </text>
<text top="233" left="385" width="160" height="19" font="0">PPM infection; in hospital </text>
<text top="252" left="385" width="39" height="19" font="0">death </text>
<text top="88" left="594" width="198" height="19" font="8"><b>1</b>°<b> endpoint:</b> Indication for PPM </text>
<text top="106" left="594" width="182" height="19" font="0">despite drug discontinuation; </text>
<text top="124" left="594" width="182" height="19" font="0">complications and outcomes  </text>
<text top="143" left="594" width="3" height="19" font="0"> </text>
<text top="161" left="594" width="195" height="19" font="8"><b>Results:</b> 49/55 (89%) ultimately </text>
<text top="179" left="594" width="228" height="19" font="0">required PPM, including 26/27 (96%) </text>
<text top="198" left="594" width="208" height="19" font="0">on BBs. 11% comp rate from TVP. </text>
<text top="216" left="594" width="230" height="19" font="0">PPM postponed mean of 7 d for drug </text>
<text top="234" left="594" width="72" height="19" font="0">withdrawal </text>
<text top="87" left="844" width="154" height="20" font="0">• Authors conclude that: </text>
<text top="106" left="855" width="171" height="19" font="0">“Primary PPM implantation </text>
<text top="124" left="855" width="171" height="19" font="0">should be considered in pts </text>
<text top="143" left="855" width="162" height="19" font="0">with high-degree AVB and </text>
<text top="161" left="855" width="155" height="19" font="0">concomitant AV blocking </text>
<text top="179" left="855" width="197" height="19" font="0">therapy, unless other reversible </text>
<text top="198" left="855" width="93" height="19" font="0">causes…exist.” </text>
<text top="216" left="844" width="176" height="20" font="0">•  “In the elderly, the drug is </text>
<text top="235" left="855" width="189" height="19" font="0">virtually never the sole culprit; </text>
<text top="253" left="855" width="159" height="19" font="0">rather, it just exposes the </text>
<text top="272" left="855" width="171" height="19" font="0">underlying weakness of the </text>
<text top="290" left="855" width="154" height="19" font="0">aging conduction system </text>
<text top="309" left="96" width="102" height="19" font="0">Murphy JJ, 1996 </text>
<text top="327" left="96" width="35" height="19" font="0">(116) </text>
<text top="346" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=620131">8620131</a></text>
<text top="346" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=620131"> </a></text>
<text top="309" left="230" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="327" left="230" width="133" height="19" font="0">Prospective cohort in </text>
<text top="346" left="230" width="91" height="19" font="0">18 hospitals in </text>
<text top="364" left="230" width="112" height="19" font="0">Northern England </text>
<text top="382" left="230" width="68" height="19" font="0">over 6 mo  </text>
<text top="401" left="230" width="3" height="19" font="0"> </text>
<text top="419" left="230" width="118" height="19" font="8"><b>Size:</b> N=194. Mean </text>
<text top="437" left="230" width="129" height="19" font="0">age 71 y; AVB (67%). </text>
<text top="455" left="230" width="103" height="19" font="0">Acute MI in 53% </text>
<text top="309" left="385" width="157" height="19" font="8"><b>Inclusion criteria:</b> All TVP </text>
<text top="327" left="385" width="151" height="19" font="0">implants in 18 hospitals. </text>
<text top="346" left="385" width="3" height="19" font="0"> </text>
<text top="364" left="385" width="195" height="19" font="8"><b>Exclusion criteria:</b> None stated  </text>
<text top="310" left="594" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications </text>
<text top="328" left="594" width="3" height="19" font="0"> </text>
<text top="346" left="594" width="225" height="19" font="8"><b>Results:</b> Immediate complications in </text>
<text top="365" left="594" width="206" height="19" font="0">12/194 (6%) – VT/VF in 6, arterial </text>
<text top="383" left="594" width="201" height="19" font="0">puncture (3), pneumothorax (2), </text>
<text top="401" left="594" width="229" height="19" font="0">brachial plexus injury (1). Late comps </text>
<text top="420" left="594" width="174" height="19" font="0">in 22/194 (11%) – VT/VF 10, </text>
<text top="438" left="594" width="232" height="19" font="0">definite/possible sepsis in 10 (5.2%) – </text>
<text top="456" left="594" width="201" height="19" font="0">almost all had TVP&gt;48 h. 38/194 </text>
<text top="475" left="594" width="210" height="19" font="0">(20%) needed repositioning. Total </text>
<text top="493" left="594" width="196" height="19" font="0">comps 35%. 11/194 (5.5%) died </text>
<text top="511" left="594" width="236" height="19" font="0">within 1 h of procedure. 56/194 (29%) </text>
<text top="529" left="594" width="58" height="19" font="0">had PPM </text>
<text top="309" left="844" width="194" height="20" font="0">• High rate of implant by junior </text>
<text top="328" left="855" width="99" height="19" font="0">staff (residents) </text>
<text top="347" left="844" width="151" height="20" font="0">• Continued high rate of </text>
<text top="365" left="855" width="196" height="19" font="0">complications in British medical </text>
<text top="384" left="855" width="101" height="19" font="0">system in 1990s </text>
<text top="549" left="96" width="94" height="19" font="0">Pinneri F, et al. </text>
<text top="567" left="96" width="69" height="19" font="0">2013 (174) </text>
<text top="585" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22240748">22240748</a></text>
<text top="585" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22240748"> </a></text>
<text top="548" left="230" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="567" left="230" width="43" height="19" font="0">center </text>
<text top="585" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="603" left="230" width="110" height="19" font="0">controlled study.  </text>
<text top="622" left="230" width="3" height="19" font="0"> </text>
<text top="640" left="230" width="142" height="19" font="8"><b>Size: </b>N=106; mean age </text>
<text top="658" left="230" width="129" height="19" font="0">77 y, 51% male; 75% </text>
<text top="677" left="230" width="88" height="19" font="0">had AVB; 59% </text>
<text top="695" left="230" width="121" height="19" font="0">ultimately required </text>
<text top="713" left="230" width="32" height="19" font="0">PPM </text>
<text top="548" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="567" left="385" width="184" height="19" font="0">pts requiring TVP 2003–2010. </text>
<text top="585" left="385" width="183" height="19" font="0">Pts underwent TVP guided by </text>
<text top="603" left="385" width="170" height="19" font="0">echo (N=53) or fluoroscopy </text>
<text top="622" left="385" width="161" height="19" font="0">(N=53) based on operator </text>
<text top="640" left="385" width="74" height="19" font="0">preference. </text>
<text top="658" left="385" width="3" height="19" font="0"> </text>
<text top="677" left="385" width="186" height="19" font="8"><b>Exclusion criteria:</b> Incomplete </text>
<text top="695" left="385" width="99" height="19" font="0">follow-up (N=4) </text>
<text top="549" left="594" width="209" height="19" font="8"><b>1</b>°<b> endpoint:</b> The primary efficacy </text>
<text top="568" left="594" width="237" height="19" font="0">endpoints were time to pacing, pacing </text>
<text top="586" left="594" width="222" height="19" font="0">threshold, changes in threshold and </text>
<text top="604" left="594" width="221" height="19" font="0">need for catheter replacement. The </text>
<text top="623" left="594" width="235" height="19" font="0">primary safety endpoints were overall </text>
<text top="641" left="594" width="217" height="19" font="0">complications and death related to </text>
<text top="659" left="594" width="81" height="19" font="0">TVP implant. </text>
<text top="678" left="594" width="3" height="19" font="0"> </text>
<text top="696" left="594" width="233" height="19" font="8"><b>Results:</b> Successful in all but 1 in each </text>
<text top="714" left="594" width="231" height="19" font="0">group (98%). Time to pacing and 24 h </text>
<text top="732" left="594" width="197" height="19" font="0">threshold better in echo-guided </text>
<text top="751" left="594" width="203" height="19" font="0">group. TVP repositioned in 6% of </text>
<text top="769" left="594" width="227" height="19" font="0">echo-guided and 22% of fluoroscopy-</text>
<text top="549" left="844" width="204" height="20" font="0">• Echo-guided TVP was safer and </text>
<text top="568" left="855" width="171" height="19" font="0">more effective in this single </text>
<text top="586" left="855" width="197" height="19" font="0">center cohort with cardiologists </text>
<text top="604" left="855" width="177" height="19" font="0">comfortable with technique. </text>
<text top="623" left="844" width="206" height="20" font="0">• Not clear why dislodgment rate </text>
<text top="642" left="855" width="195" height="19" font="0">and thresholds would be worse </text>
<text top="660" left="855" width="133" height="19" font="0">in fluoroscopy group. </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 114 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="594" width="223" height="19" font="0">guided groups (p&lt;0.001), Comp rate </text>
<text top="105" left="594" width="231" height="19" font="0">lower in echo (11%) than fluoroscopy </text>
<text top="123" left="594" width="143" height="19" font="0">(41%) group; p&lt;0.001). </text>
<text top="148" left="96" width="106" height="19" font="0">Braun MU, et al.  </text>
<text top="166" left="96" width="69" height="19" font="0">2006 (175) </text>
<text top="184" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16923004">16923004</a></text>
<text top="184" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16923004"> </a></text>
<text top="147" left="230" width="104" height="19" font="8"><b>Study type:</b> Non-</text>
<text top="166" left="230" width="76" height="19" font="0">randomized </text>
<text top="184" left="230" width="141" height="19" font="0">prospective controlled </text>
<text top="203" left="230" width="105" height="19" font="0">study comparing </text>
<text top="221" left="230" width="119" height="19" font="0">externalized active-</text>
<text top="239" left="230" width="99" height="19" font="0">fixation lead vs. </text>
<text top="258" left="230" width="126" height="19" font="0">standard temporary </text>
<text top="276" left="230" width="62" height="19" font="0">TVP wire) </text>
<text top="294" left="230" width="3" height="19" font="0"> </text>
<text top="312" left="230" width="139" height="19" font="8"><b>Size:</b> 49 pts, mean age </text>
<text top="331" left="230" width="95" height="19" font="0">72 y, 63% male </text>
<text top="147" left="385" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="166" left="385" width="173" height="19" font="0">systemic infection requiring </text>
<text top="184" left="385" width="108" height="19" font="0">VVI pacing &gt;48 h  </text>
<text top="203" left="385" width="3" height="19" font="0"> </text>
<text top="221" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="148" left="594" width="228" height="19" font="8"><b>1</b>°<b> endpoint:</b> Implant success, pacing </text>
<text top="167" left="594" width="201" height="19" font="0">thresholds, acute complications, </text>
<text top="185" left="594" width="115" height="19" font="0">dislodgement rate </text>
<text top="203" left="594" width="3" height="19" font="0"> </text>
<text top="222" left="594" width="236" height="19" font="8"><b>Results:</b> 100% implant success in both </text>
<text top="240" left="594" width="208" height="19" font="0">groups, paced median 8 d, similar </text>
<text top="258" left="594" width="229" height="19" font="0">procedure time, acute comps, pacing </text>
<text top="277" left="594" width="157" height="19" font="0">threshold. There were 24 </text>
<text top="295" left="594" width="202" height="19" font="0">dislodgments in 12 pts in control </text>
<text top="313" left="594" width="218" height="19" font="0">group, only 1 in active-fixation lead </text>
<text top="332" left="594" width="94" height="19" font="0">group (p&lt;0.01) </text>
<text top="148" left="844" width="205" height="20" font="0">• Externalized active fixation TVP </text>
<text top="167" left="855" width="165" height="19" font="0">lead associated with much </text>
<text top="185" left="855" width="177" height="19" font="0">lower dislodgment rate than </text>
<text top="203" left="855" width="194" height="19" font="0">standard TVP wire. Equally safe </text>
<text top="222" left="855" width="67" height="19" font="0">to implant </text>
<text top="240" left="844" width="205" height="20" font="0">• Externalized active fixation TVP </text>
<text top="259" left="855" width="167" height="19" font="0">preferred if pacing &gt;48 h is </text>
<text top="277" left="855" width="76" height="19" font="0">anticipated. </text>
<text top="351" left="96" width="108" height="19" font="0">de Cock CC, et al. </text>
<text top="369" left="96" width="69" height="19" font="0">2003 (176) </text>
<text top="387" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12765453">12765453</a></text>
<text top="387" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12765453"> </a></text>
<text top="350" left="230" width="104" height="19" font="8"><b>Study type: </b>Non-</text>
<text top="369" left="230" width="116" height="19" font="0">randomized single-</text>
<text top="387" left="230" width="134" height="19" font="0">center comparison of </text>
<text top="406" left="230" width="133" height="19" font="0">TVP by femoral route </text>
<text top="424" left="230" width="138" height="19" font="0">with active vs. passive </text>
<text top="442" left="230" width="94" height="19" font="0">fixation wire in </text>
<text top="460" left="230" width="116" height="19" font="0">Netherlands 1998–</text>
<text top="479" left="230" width="34" height="19" font="0">2001 </text>
<text top="497" left="230" width="3" height="19" font="0"> </text>
<text top="515" left="230" width="132" height="19" font="8"><b>Size:</b> N=72 pts; mean </text>
<text top="534" left="230" width="124" height="19" font="0">age 70 y, 51% male  </text>
<text top="350" left="385" width="189" height="19" font="8"><b>Inclusion criteria: </b>Consecutive </text>
<text top="369" left="385" width="162" height="19" font="0">pts requiring TVP at single </text>
<text top="387" left="385" width="168" height="19" font="0">center requiring prolonged </text>
<text top="406" left="385" width="169" height="19" font="0">temporary pacing (&gt;48 h) – </text>
<text top="424" left="385" width="60" height="19" font="0">mean 6 d </text>
<text top="442" left="385" width="3" height="19" font="0"> </text>
<text top="460" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="351" left="594" width="209" height="19" font="8"><b>1</b>°<b> endpoint:</b> Implant parameters, </text>
<text top="370" left="594" width="221" height="19" font="0">dislodgments, other adverse events </text>
<text top="388" left="594" width="3" height="19" font="0"> </text>
<text top="406" left="594" width="213" height="19" font="8"><b>Results:</b> Threshold higher in active </text>
<text top="425" left="594" width="171" height="19" font="0">(1.38V) than passive (0.7V). </text>
<text top="443" left="594" width="222" height="19" font="0">Dislodgement lower in active (2/36) </text>
<text top="461" left="594" width="173" height="19" font="0">than passive (12/36) groups </text>
<text top="480" left="594" width="192" height="19" font="0">(p&lt;0.001). Other comps similar </text>
<text top="498" left="594" width="3" height="19" font="0"> </text>
<text top="351" left="844" width="191" height="20" font="0">• Fewer dislodgments using an </text>
<text top="370" left="855" width="154" height="19" font="0">active fixation lead using </text>
<text top="388" left="855" width="112" height="19" font="0">femoral approach </text>
<text top="553" left="96" width="99" height="19" font="0">Kawata H, et al. </text>
<text top="571" left="96" width="69" height="19" font="0">2013 (177) </text>
<text top="589" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23482613">23482613</a></text>
<text top="589" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23482613"> </a></text>
<text top="553" left="230" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="571" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="589" left="230" width="132" height="19" font="0">cohort study of temp </text>
<text top="608" left="230" width="135" height="19" font="0">active fix lead (TPPM) </text>
<text top="626" left="230" width="128" height="19" font="0">after lead extraction </text>
<text top="644" left="230" width="56" height="19" font="0">at UCSD  </text>
<text top="663" left="230" width="3" height="19" font="0"> </text>
<text top="681" left="230" width="135" height="19" font="8"><b>Size: </b>N=23; mean age </text>
<text top="699" left="230" width="129" height="19" font="0">72 y, 70% male; 87% </text>
<text top="718" left="230" width="29" height="19" font="0">AVB </text>
<text top="553" left="385" width="173" height="19" font="8"><b>Inclusion criteria:</b> 23/47 pts </text>
<text top="571" left="385" width="191" height="19" font="0">undergoing extraction for CIED </text>
<text top="589" left="385" width="147" height="19" font="0">infection who were PM-</text>
<text top="608" left="385" width="127" height="19" font="0">dependent 2010–12 </text>
<text top="626" left="385" width="3" height="19" font="0"> </text>
<text top="644" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="553" left="594" width="197" height="19" font="8"><b>1</b>°<b> endpoint:</b> Duration of TPPM, </text>
<text top="572" left="594" width="88" height="19" font="0">complications </text>
<text top="590" left="594" width="3" height="19" font="0"> </text>
<text top="608" left="594" width="236" height="19" font="8"><b>Results:</b> Duration of TPPM mean 12 d. </text>
<text top="627" left="594" width="222" height="19" font="0">12/23 discharged to home or SNF. 1 </text>
<text top="645" left="594" width="186" height="19" font="0">pt died of sepsis from primary </text>
<text top="663" left="594" width="225" height="19" font="0">infection; 1 pt developed vegetation </text>
<text top="682" left="594" width="183" height="19" font="0">on TPPM lead – removed and </text>
<text top="700" left="594" width="228" height="19" font="0">replaced. No dislodgements. One pts </text>
<text top="718" left="594" width="188" height="19" font="0">had late pocket infection after </text>
<text top="737" left="594" width="67" height="19" font="0">reimplant. </text>
<text top="553" left="844" width="185" height="20" font="0">• TPPM is a safe and effective </text>
<text top="572" left="855" width="182" height="19" font="0">option for PM-dependent pts </text>
<text top="590" left="855" width="183" height="19" font="0">awaiting reimplant after CIED </text>
<text top="609" left="855" width="57" height="19" font="0">infection </text>
<text top="627" left="844" width="202" height="20" font="0">• Allows earlier mobilization and </text>
<text top="646" left="855" width="137" height="19" font="0">potential discharge to </text>
<text top="664" left="855" width="187" height="19" font="0">home/nursing facility to await </text>
<text top="683" left="855" width="95" height="19" font="0">CIED reimplant </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 115 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="108" height="19" font="0">Chihrin SM, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2006 (178) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17145220">17145220</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17145220"> </a></text>
<text top="87" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="105" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="123" left="230" width="107" height="19" font="0">cohort in Canada </text>
<text top="142" left="230" width="52" height="19" font="0">2001–5  </text>
<text top="160" left="230" width="3" height="19" font="0"> </text>
<text top="178" left="230" width="94" height="19" font="8"><b>Size:</b> N=20 pts; </text>
<text top="197" left="230" width="139" height="19" font="0">median 2 d; mean age </text>
<text top="215" left="230" width="99" height="19" font="0">62 y; 75% male  </text>
<text top="87" left="385" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="105" left="385" width="180" height="19" font="0">implanted with TPPM via left </text>
<text top="123" left="385" width="196" height="19" font="0">subclavian vein or right internal </text>
<text top="142" left="385" width="173" height="19" font="0">jugular vein over 5 y period  </text>
<text top="160" left="385" width="3" height="19" font="0"> </text>
<text top="178" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="88" left="594" width="184" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pacing duration, </text>
<text top="106" left="594" width="126" height="19" font="0">complications, costs </text>
<text top="124" left="594" width="3" height="19" font="0"> </text>
<text top="143" left="594" width="219" height="19" font="8"><b>Results:</b> Duration median 2 d (1–83 </text>
<text top="161" left="594" width="176" height="19" font="0">d); 1 dislodgement requiring </text>
<text top="179" left="594" width="218" height="19" font="0">repositioning (5%). Using economic </text>
<text top="198" left="594" width="206" height="19" font="0">modeling, costs lower with TPPM </text>
<text top="216" left="594" width="186" height="19" font="0">than conventional TVP at 48 h </text>
<text top="87" left="844" width="203" height="20" font="0">• Despite higher lead cost, TPPM </text>
<text top="106" left="855" width="192" height="19" font="0">cost-effective after 24 h due to </text>
<text top="124" left="855" width="179" height="19" font="0">lower complications and less </text>
<text top="143" left="855" width="110" height="19" font="0">intensive bed use </text>
<text top="235" left="96" width="87" height="19" font="0">Lever N, et al. </text>
<text top="253" left="96" width="69" height="19" font="0">2003 (179) </text>
<text top="272" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12527682">12527682</a></text>
<text top="272" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12527682"> </a></text>
<text top="235" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="253" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="272" left="230" width="102" height="19" font="0">United Kingdom </text>
<text top="290" left="230" width="3" height="19" font="0"> </text>
<text top="308" left="230" width="135" height="19" font="8"><b>Size:</b> N=20; mean age </text>
<text top="326" left="230" width="99" height="19" font="0">66 y, 85% male  </text>
<text top="235" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="253" left="385" width="183" height="19" font="0">pts requiring prolonged temp </text>
<text top="272" left="385" width="192" height="19" font="0">pacing due to infection or drug </text>
<text top="290" left="385" width="170" height="19" font="0">washout who had tunneled </text>
<text top="308" left="385" width="39" height="19" font="0">TPPM </text>
<text top="326" left="385" width="3" height="19" font="0"> </text>
<text top="345" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="236" left="594" width="184" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pacing duration, </text>
<text top="254" left="594" width="150" height="19" font="0">outcome, complications </text>
<text top="272" left="594" width="3" height="19" font="0"> </text>
<text top="291" left="594" width="227" height="19" font="8"><b>Results:</b> Duration median 28 d (9–81 </text>
<text top="309" left="594" width="229" height="19" font="0">d); no dislodgments or repositioning; </text>
<text top="327" left="594" width="194" height="19" font="0">2 minor local site infections, no </text>
<text top="346" left="594" width="226" height="19" font="0">systemic infection. One pt died from </text>
<text top="364" left="594" width="158" height="19" font="0">sepsis unrelated to TPPM </text>
<text top="235" left="844" width="207" height="20" font="0">• TPPM safe and effective, allows </text>
<text top="254" left="855" width="189" height="19" font="0">early mobility for pts requiring </text>
<text top="272" left="855" width="177" height="19" font="0">prolonged temporary pacing </text>
<text top="383" left="96" width="104" height="19" font="0">Kornberger A, et </text>
<text top="401" left="96" width="87" height="19" font="0">al. 2013 (180) </text>
<text top="420" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23718817">23718817</a></text>
<text top="420" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23718817"> </a></text>
<text top="383" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="401" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="420" left="230" width="59" height="19" font="0">Germany </text>
<text top="438" left="230" width="3" height="19" font="0"> </text>
<text top="456" left="230" width="135" height="19" font="8"><b>Size:</b> N=60; mean age </text>
<text top="474" left="230" width="95" height="19" font="0">73 y, 73% male </text>
<text top="383" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="401" left="385" width="179" height="19" font="0">pts implanted with TPPM for </text>
<text top="420" left="385" width="181" height="19" font="0">CIED infection (70%) or other </text>
<text top="438" left="385" width="161" height="19" font="0">reasons (30%) 2000–2009 </text>
<text top="456" left="385" width="3" height="19" font="0"> </text>
<text top="474" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="384" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Duration of pacing, </text>
<text top="402" left="594" width="201" height="19" font="0">outcomes, complications at 30 d </text>
<text top="420" left="594" width="3" height="19" font="0"> </text>
<text top="439" left="594" width="232" height="19" font="8"><b>Results:</b> Successful in 98% - VVI in 56, </text>
<text top="457" left="594" width="190" height="19" font="0">DDD in 3) Duration mean 15 d. </text>
<text top="475" left="594" width="228" height="19" font="0">Intraoperative comps in 2 pts (3.3% - </text>
<text top="494" left="594" width="217" height="19" font="0">one venous thromboembolism and </text>
<text top="512" left="594" width="234" height="19" font="0">tamponade, one dislodgement during </text>
<text top="530" left="594" width="226" height="19" font="0">lead extraction). 4 late comps (6.7%) </text>
<text top="549" left="594" width="182" height="19" font="0">– 3 possible lead infections, 1 </text>
<text top="567" left="594" width="94" height="19" font="0">dislodgement.  </text>
<text top="383" left="844" width="205" height="20" font="0">• TPPM safe and effective option </text>
<text top="402" left="855" width="198" height="19" font="0">for prolonged temporary pacing </text>
<text top="586" left="96" width="104" height="19" font="0">Zei P, et al. 2006 </text>
<text top="604" left="96" width="35" height="19" font="0">(181) </text>
<text top="623" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16580542">16580542</a></text>
<text top="623" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16580542"> </a></text>
<text top="586" left="230" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="604" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="623" left="230" width="71" height="19" font="0">Boston MA </text>
<text top="641" left="230" width="3" height="19" font="0"> </text>
<text top="659" left="230" width="132" height="19" font="8"><b>Size:</b> N=62 pts; mean </text>
<text top="677" left="230" width="121" height="19" font="0">age 68 y; 60% male </text>
<text top="586" left="385" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="604" left="385" width="173" height="19" font="0">getting TPPM for prolonged </text>
<text top="623" left="385" width="167" height="19" font="0">temp pacing at BWH 2000–</text>
<text top="641" left="385" width="34" height="19" font="0">2004 </text>
<text top="659" left="385" width="3" height="19" font="0"> </text>
<text top="677" left="385" width="195" height="19" font="8"><b>Exclusion criteria:</b> None stated  </text>
<text top="587" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Duration of pacing, </text>
<text top="605" left="594" width="156" height="19" font="0">outcomes, complications </text>
<text top="623" left="594" width="3" height="19" font="0"> </text>
<text top="642" left="594" width="225" height="19" font="8"><b>Results:</b> Median duration 7.5 d. 66% </text>
<text top="660" left="594" width="204" height="19" font="0">went on to have PPM. No deaths </text>
<text top="678" left="594" width="215" height="19" font="0">from arrhythmia, no complications </text>
<text top="697" left="594" width="188" height="19" font="0">from TPPM, no dislodgements </text>
<text top="586" left="844" width="205" height="20" font="0">• TPPM safe and effective option </text>
<text top="605" left="855" width="155" height="19" font="0">for prolonged temporary </text>
<text top="623" left="855" width="47" height="19" font="0">pacing. </text>
<text top="642" left="844" width="192" height="20" font="0">• Allows management in lower </text>
<text top="661" left="855" width="158" height="19" font="0">cost less intensive setting </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 116 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="121" height="19" font="0">Zoll PM, et al. 1985 </text>
<text top="105" left="96" width="35" height="19" font="0">(130) </text>
<text top="123" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886190">3886190</a></text>
<text top="123" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886190"> </a></text>
<text top="87" left="230" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="105" left="230" width="130" height="19" font="0">Prospective 5-center </text>
<text top="123" left="230" width="119" height="19" font="0">cohort study in US  </text>
<text top="142" left="230" width="3" height="19" font="0"> </text>
<text top="160" left="230" width="122" height="19" font="8"><b>Size:</b> 134 pts; mean </text>
<text top="178" left="230" width="121" height="19" font="0">age 70 y; 65% men  </text>
<text top="87" left="385" width="177" height="19" font="8"><b>Inclusion criteria:</b> All ED and </text>
<text top="105" left="385" width="157" height="19" font="0">hospital pts in whom TCP </text>
<text top="123" left="385" width="49" height="19" font="0">applied </text>
<text top="142" left="385" width="3" height="19" font="0"> </text>
<text top="160" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="88" left="594" width="155" height="19" font="8"><b>1</b>°<b> endpoint:</b> Stimulation </text>
<text top="106" left="594" width="203" height="19" font="0">effectiveness, clinical usefulness, </text>
<text top="124" left="594" width="118" height="19" font="0">survival in-hospital </text>
<text top="143" left="594" width="3" height="19" font="0"> </text>
<text top="161" left="594" width="231" height="19" font="8"><b>Results:</b> QRS response to TCP in 78%, </text>
<text top="179" left="594" width="197" height="19" font="0">deemed clinically useful in 61%, </text>
<text top="198" left="594" width="94" height="19" font="0">survival in 62% </text>
<text top="216" left="594" width="3" height="19" font="0"> </text>
<text top="87" left="844" width="148" height="20" font="0">• Methodology for data </text>
<text top="106" left="855" width="150" height="19" font="0">collection not described </text>
<text top="124" left="844" width="85" height="20" font="0">• No controls </text>
<text top="144" left="844" width="207" height="20" font="0">• Endpoints not well described or </text>
<text top="163" left="855" width="81" height="19" font="0">documented </text>
<text top="181" left="844" width="207" height="20" font="0">• “This extensive experience with </text>
<text top="200" left="855" width="162" height="19" font="0">134 pts treated by several </text>
<text top="218" left="855" width="179" height="19" font="0">investigators in 5 institutions </text>
<text top="237" left="855" width="171" height="19" font="0">under varied circumstances </text>
<text top="255" left="855" width="197" height="19" font="0">confirms the safety and efficacy </text>
<text top="273" left="855" width="152" height="19" font="0">of this new technique of </text>
<text top="292" left="855" width="197" height="19" font="0">noninvasive temporary pacing.” </text>
<text top="311" left="96" width="104" height="19" font="0">Sherbino J, et al. </text>
<text top="329" left="96" width="69" height="19" font="0">2006 (128) </text>
<text top="347" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16814446">16814446</a></text>
<text top="347" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16814446"> </a></text>
<text top="310" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="329" left="230" width="141" height="19" font="0">Systematic review of 7 </text>
<text top="347" left="230" width="110" height="19" font="0">studies of TCP for </text>
<text top="366" left="230" width="73" height="19" font="0">prehospital </text>
<text top="384" left="230" width="88" height="19" font="0">bradyasystole </text>
<text top="402" left="230" width="3" height="19" font="0"> </text>
<text top="420" left="230" width="111" height="19" font="8"><b>Size:</b>7 studies, N= </text>
<text top="439" left="230" width="37" height="19" font="0">1487  </text>
<text top="310" left="385" width="181" height="19" font="8"><b>Inclusion criteria:</b> Euthermic, </text>
<text top="329" left="385" width="172" height="19" font="0">nontraumatized adults who </text>
<text top="347" left="385" width="143" height="19" font="0">experience prehospital </text>
<text top="366" left="385" width="194" height="19" font="0">hemodynamically symptomatic </text>
<text top="384" left="385" width="182" height="19" font="0">bradycardia or bradyasystolic </text>
<text top="402" left="385" width="90" height="19" font="0">cardiac arrest  </text>
<text top="420" left="385" width="3" height="19" font="0"> </text>
<text top="439" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="311" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to hospital </text>
<text top="330" left="594" width="62" height="19" font="0">discharge </text>
<text top="348" left="594" width="3" height="19" font="0"> </text>
<text top="366" left="594" width="190" height="19" font="8"><b>Results:</b> No benefits to TCP for </text>
<text top="385" left="594" width="212" height="19" font="0">bradyasystolic cardiac arrest. Data </text>
<text top="403" left="594" width="222" height="19" font="0">inadequate to determine efficacy of </text>
<text top="421" left="594" width="66" height="19" font="0">TCP for SB </text>
<text top="440" left="594" width="3" height="19" font="0"> </text>
<text top="311" left="844" width="177" height="20" font="0">• Limited systematic review: </text>
<text top="330" left="855" width="193" height="19" font="0">Heterogeneity of study designs </text>
<text top="348" left="855" width="177" height="19" font="0">precluded statistical analysis </text>
<text top="459" left="96" width="102" height="19" font="0">Hedges JR, et al. </text>
<text top="477" left="96" width="69" height="19" font="0">1991 (129) </text>
<text top="495" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1721129">1721129</a></text>
<text top="495" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1721129"> </a></text>
<text top="458" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="477" left="230" width="136" height="19" font="0">EMS-system cohort in </text>
<text top="495" left="229" width="20" height="19" font="0">US </text>
<text top="514" left="230" width="3" height="19" font="0"> </text>
<text top="532" left="230" width="135" height="19" font="8"><b>Size: </b>N=51; mean age </text>
<text top="550" left="230" width="103" height="19" font="0">73 y, 67% male;  </text>
<text top="458" left="385" width="194" height="19" font="8"><b>Inclusion criteria:</b> Pt &gt;17 y with </text>
<text top="477" left="385" width="111" height="19" font="0">hemodynamically </text>
<text top="495" left="385" width="193" height="19" font="0">compromised bradycardia with </text>
<text top="514" left="385" width="106" height="19" font="0">witness collapse  </text>
<text top="532" left="385" width="3" height="19" font="0"> </text>
<text top="550" left="385" width="167" height="19" font="8"><b>Exclusion criteria:</b> Trauma, </text>
<text top="568" left="385" width="171" height="19" font="0">hypothermia, initial rhythm </text>
<text top="587" left="385" width="98" height="19" font="0">asystole, VT, VF </text>
<text top="459" left="594" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrival to ED with </text>
<text top="478" left="594" width="96" height="19" font="0">palpable pulse: </text>
<text top="496" left="594" width="205" height="19" font="0">26% paced group vs. 13% control </text>
<text top="514" left="594" width="185" height="19" font="0">Survival to hospital discharge: </text>
<text top="533" left="594" width="197" height="19" font="0">15% paced group vs. 0% control </text>
<text top="551" left="594" width="3" height="19" font="0"> </text>
<text top="569" left="594" width="95" height="19" font="8"><b>Results:</b> Above </text>
<text top="459" left="844" width="117" height="20" font="0">• Non-randomized </text>
<text top="478" left="844" width="188" height="20" font="0">• Potential for confounding by </text>
<text top="497" left="855" width="64" height="19" font="0">indication </text>
<text top="606" left="86" width="3" height="19" font="0"> </text>
<text top="624" left="86" width="4" height="21" font="4"> </text>
<text top="644" left="86" width="704" height="23" font="5"><b>Data Supplement 31. RCTs of clinical presentation of bradycardia due to AV block (Section 6.3)</b></text>
<text top="647" left="790" width="3" height="19" font="8"><b> </b></text>
<text top="667" left="123" width="39" height="19" font="8"><b>Study </b></text>
<text top="685" left="116" width="64" height="19" font="8"><b>Acronym; </b></text>
<text top="704" left="123" width="51" height="19" font="8"><b>Author; </b></text>
<text top="722" left="95" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="740" left="124" width="38" height="19" font="8"><b>PMID </b></text>
<text top="667" left="221" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="685" left="226" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="704" left="220" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="667" left="348" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="667" left="502" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="685" left="541" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="704" left="504" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="722" left="546" width="59" height="19" font="8"><b>patients) </b></text>
<text top="667" left="713" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="685" left="669" width="197" height="19" font="8"><b>(Absolute Event Rates, P value; </b></text>
<text top="704" left="709" width="127" height="19" font="8"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="668" left="898" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="686" left="933" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="704" left="942" width="99" height="19" font="8"><b>Adverse Events </b></text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 117 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="41" height="19" font="8"><b>PRESS </b></text>
<text top="105" left="95" width="81" height="19" font="0">Santini M, et </text>
<text top="123" left="95" width="48" height="19" font="0">al. 2013</text>
<text top="122" left="143" width="4" height="21" font="4"> </text>
<text top="123" left="147" width="35" height="19" font="0">(182) </text>
<text top="142" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23390123">23390123</a></text>
<text top="142" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23390123"> </a></text>
<text top="160" left="95" width="3" height="19" font="0"> </text>
<text top="87" left="204" width="76" height="19" font="8"><b>Aim:</b> Assess </text>
<text top="105" left="204" width="116" height="19" font="0">whether PM in pts </text>
<text top="123" left="204" width="103" height="19" font="0">with bifascicular </text>
<text top="142" left="204" width="93" height="19" font="0">block+syncope </text>
<text top="160" left="204" width="118" height="19" font="0">reduces symptoms </text>
<text top="178" left="204" width="3" height="19" font="8"><b> </b></text>
<text top="197" left="204" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="215" left="204" width="3" height="19" font="0"> </text>
<text top="233" left="204" width="75" height="19" font="8"><b>Size: </b>N=101 </text>
<text top="87" left="338" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="105" left="338" width="51" height="19" font="0">LBBB or </text>
<text top="123" left="338" width="135" height="19" font="0">RBBB+LPFB/LAFB and </text>
<text top="142" left="338" width="57" height="19" font="0">syncope. </text>
<text top="160" left="338" width="135" height="19" font="0">Negative EKG, Holter, </text>
<text top="178" left="338" width="54" height="19" font="0">TTT, EPS </text>
<text top="197" left="338" width="3" height="19" font="8"><b> </b></text>
<text top="215" left="338" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="233" left="338" width="137" height="19" font="0">Known PM indication  </text>
<text top="87" left="491" width="150" height="19" font="8"><b>Intervention:</b> All pts got </text>
<text top="105" left="491" width="138" height="19" font="0">PM; DDD 60 or DDI 30 </text>
<text top="123" left="491" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="491" width="149" height="19" font="8"><b>Comparator:</b> DDI 30 pts </text>
<text top="88" left="662" width="205" height="19" font="8"><b>1</b>°<b> combined endpoint</b>: Syncope, </text>
<text top="106" left="662" width="198" height="19" font="0">presyncope, or other symptoms </text>
<text top="124" left="662" width="177" height="19" font="0">due to AVB occurred in 23%. </text>
<text top="143" left="662" width="3" height="19" font="0"> </text>
<text top="161" left="662" width="197" height="19" font="8"><b>Results</b>: Reduction in combined </text>
<text top="179" left="662" width="189" height="19" font="0">events (HR: 0.32; p=0.042) but </text>
<text top="198" left="662" width="176" height="19" font="0">syncope alone not reduced.  </text>
<text top="87" left="886" width="164" height="20" font="0">• 5% developed a new PM </text>
<text top="106" left="897" width="123" height="19" font="0">indication with AVB </text>
<text top="253" left="86" width="4" height="21" font="4"> </text>
<text top="273" left="86" width="833" height="23" font="5"><b>Data Supplement 32. Nonrandomized data of Clinical Presentation of Bradycardia due to AV block (Section 6.3) </b></text>
<text top="295" left="108" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="313" left="139" width="51" height="19" font="8"><b>Author; </b></text>
<text top="332" left="111" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="350" left="140" width="38" height="19" font="8"><b>PMID </b></text>
<text top="295" left="260" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="313" left="266" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="332" left="259" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="295" left="402" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="295" left="564" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="313" left="602" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="332" left="565" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="350" left="607" width="59" height="19" font="8"><b>patients) </b></text>
<text top="295" left="855" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="313" left="747" width="324" height="19" font="8"><b>(Absolute Event Rates, P value; OR or RR; &amp; 95% CI) </b></text>
<text top="369" left="101" width="60" height="19" font="0">Guerrero-</text>
<text top="388" left="101" width="110" height="19" font="0">Marquez FJ, et al. </text>
<text top="406" left="101" width="30" height="19" font="0">2016</text>
<text top="405" left="132" width="4" height="21" font="4"> </text>
<text top="406" left="135" width="35" height="19" font="0">(183) </text>
<text top="424" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28496928">28496928</a></text>
<text top="424" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28496928"> </a></text>
<text top="369" left="229" width="97" height="19" font="8"><b>Aim:</b> To write a </text>
<text top="388" left="229" width="117" height="19" font="0">featured review of </text>
<text top="406" left="229" width="102" height="19" font="0">paroxysmal AVB </text>
<text top="424" left="229" width="3" height="19" font="0"> </text>
<text top="442" left="229" width="122" height="19" font="8"><b>Study type: </b>Review </text>
<text top="461" left="229" width="3" height="19" font="0"> </text>
<text top="479" left="229" width="59" height="19" font="8"><b>Size: </b>N/A </text>
<text top="369" left="391" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A </text>
<text top="388" left="391" width="3" height="19" font="0"> </text>
<text top="406" left="391" width="141" height="19" font="8"><b>Exclusion criteria: </b>N/A </text>
<text top="369" left="547" width="113" height="19" font="8"><b>Intervention: </b>N/A </text>
<text top="388" left="547" width="3" height="19" font="0"> </text>
<text top="406" left="547" width="110" height="19" font="8"><b>Comparator: </b>N/A </text>
<text top="369" left="721" width="200" height="20" font="0">•  Idiopathic AVB is paroxysmal 3</text>
<text top="370" left="922" width="9" height="12" font="7">rd</text>
<text top="370" left="930" width="121" height="19" font="0"> degree heart block </text>
<text top="388" left="735" width="354" height="19" font="0">(sudden CHB) with no other rhythm abnormal pre or post </text>
<text top="407" left="735" width="177" height="19" font="0">in pts with NL heart and EKG </text>
<text top="425" left="721" width="126" height="20" font="0">•  Etiology unknown </text>
<text top="444" left="721" width="338" height="20" font="0">•  Intrinsic AVB occurs in pts with underlying HD due to </text>
<text top="463" left="735" width="331" height="19" font="0">phase 3 or phase 4 block, degeneration of HP or valve </text>
<text top="482" left="735" width="151" height="19" font="0">disease, ACS (infant MI)  </text>
<text top="500" left="721" width="355" height="20" font="0">•  Other causes of AVB; extrinsic vagal effect, Lev-Lenegre </text>
<text top="519" left="735" width="351" height="19" font="0">disease, SLE, bacterial endocarditis with abscess, sarcoid, </text>
<text top="537" left="735" width="149" height="19" font="0">Lyme disease, sickle cell </text>
<text top="556" left="101" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="575" left="101" width="73" height="19" font="0">2011;<b> </b>(184)<b> </b></text>
<text top="593" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21570228">21570228</a></text>
<text top="593" left="162" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21570228"><b> </b></a></text>
<text top="556" left="229" width="120" height="19" font="8"><b> Aim: </b>Follow 18 pts </text>
<text top="575" left="229" width="109" height="19" font="0">with unexplained </text>
<text top="593" left="229" width="54" height="19" font="0">syncope </text>
<text top="611" left="229" width="3" height="19" font="0"> </text>
<text top="630" left="229" width="3" height="19" font="0"> </text>
<text top="556" left="391" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="575" left="391" width="136" height="19" font="0">Normal EKG, no SHD , </text>
<text top="593" left="391" width="91" height="19" font="0">parox CHB per </text>
<text top="611" left="391" width="71" height="19" font="0">monitoring<b> </b></text>
<text top="556" left="547" width="115" height="19" font="8"><b>Intervention: </b>EPS, </text>
<text top="575" left="547" width="151" height="19" font="0">Adenosine plasma level, </text>
<text top="593" left="547" width="118" height="19" font="0">ATP test, TTT, CSM </text>
<text top="556" left="729" width="205" height="19" font="0">PPM relieved symptoms in all pts </text>
<text top="575" left="729" width="189" height="19" font="0">None progressed to perm AVB </text>
<text top="649" left="101" width="42" height="19" font="8"><b>ISSUE  </b></text>
<text top="667" left="101" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="685" left="101" width="69" height="19" font="0">2001 (185) </text>
<text top="704" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11673344">11673344</a></text>
<text top="704" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11673344"> </a></text>
<text top="649" left="229" width="101" height="19" font="8"><b>Aim: </b>Determine </text>
<text top="667" left="229" width="143" height="19" font="0">mechanism of syncope </text>
<text top="685" left="229" width="147" height="19" font="0">in pts with BBB and neg </text>
<text top="704" left="229" width="25" height="19" font="0">EPS </text>
<text top="722" left="229" width="3" height="19" font="0"> </text>
<text top="740" left="229" width="142" height="19" font="8"><b>Study type:</b> Single arm </text>
<text top="759" left="229" width="75" height="19" font="0">prospective </text>
<text top="777" left="229" width="3" height="19" font="0"> </text>
<text top="649" left="391" width="130" height="19" font="8"><b>Inclusion criteria: </b>52 </text>
<text top="667" left="391" width="142" height="19" font="0">pts with syncope, BBB, </text>
<text top="685" left="391" width="117" height="19" font="0">QRS &gt;100, neg EPS </text>
<text top="649" left="547" width="107" height="19" font="8"><b>Intervention: </b>ILR </text>
<text top="649" left="729" width="332" height="19" font="8"><b>Results</b>: Most frequent cause of recurrent finding was </text>
<text top="667" left="729" width="346" height="19" font="0">sudden onset AVB with pauses (63%); CHB typically lasts </text>
<text top="685" left="729" width="45" height="19" font="0">2–10 d </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 118 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="229" width="67" height="19" font="8"><b>Size</b>: N=52 </text>
<text top="115" left="101" width="97" height="19" font="0">Carano N, et al. </text>
<text top="134" left="101" width="30" height="19" font="0">2012</text>
<text top="132" left="132" width="4" height="21" font="4"> </text>
<text top="134" left="135" width="35" height="19" font="0">(186) </text>
<text top="152" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23110777">23110777</a></text>
<text top="152" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23110777"> </a></text>
<text top="115" left="229" width="133" height="19" font="8"><b>Aim: </b>Case report and </text>
<text top="134" left="229" width="146" height="19" font="0">review of RHD and CHB </text>
<text top="152" left="229" width="3" height="19" font="0"> </text>
<text top="170" left="229" width="3" height="19" font="0"> </text>
<text top="188" left="229" width="60" height="19" font="8"><b>Size</b>: N=1 </text>
<text top="115" left="391" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="134" left="391" width="100" height="19" font="0">Case report and </text>
<text top="152" left="391" width="98" height="19" font="0">PubMed search </text>
<text top="115" left="547" width="155" height="19" font="8"><b>Intervention: </b>Amoxicillin </text>
<text top="115" left="729" width="166" height="19" font="8"><b>Results: </b>Resolution of CHB </text>
<text top="208" left="101" width="86" height="19" font="0">Ando G, et al. </text>
<text top="226" left="101" width="69" height="19" font="0">2005 (187) </text>
<text top="244" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16091145">16091145</a></text>
<text top="244" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16091145"> </a></text>
<text top="207" left="229" width="76" height="19" font="8"><b>Aim: </b>Assess </text>
<text top="226" left="229" width="136" height="19" font="0">hemodynamic of long </text>
<text top="244" left="229" width="30" height="19" font="0">AVD </text>
<text top="262" left="229" width="7" height="19" font="0">  </text>
<text top="207" left="391" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="226" left="391" width="74" height="19" font="0">Case report </text>
<text top="207" left="547" width="117" height="19" font="8"><b>Intervention: </b>PPM </text>
<text top="207" left="729" width="339" height="19" font="8"><b>Results: </b>AVD from 290 to 150 and improved symptoms </text>
<text top="282" left="101" width="101" height="19" font="0">Koehler U, et al. </text>
<text top="300" left="101" width="62" height="19" font="0">1998 (67) </text>
<text top="318" left="101" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9551750">9551750</a></text>
<text top="318" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9551750"> </a></text>
<text top="281" left="229" width="130" height="19" font="8"><b>Aim: </b>Assess effect of </text>
<text top="300" left="229" width="108" height="19" font="0">OSA Rx on brady  </text>
<text top="318" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="336" left="229" width="75" height="19" font="8"><b>Size: </b>N=651 </text>
<text top="281" left="391" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="300" left="391" width="122" height="19" font="0">Mod- sec  OSA, neg </text>
<text top="318" left="391" width="136" height="19" font="0">EPS, echo, EKG, stress </text>
<text top="336" left="391" width="27" height="19" font="0">test<b> </b></text>
<text top="281" left="547" width="121" height="19" font="8"><b>Intervention: </b>CPAP </text>
<text top="281" left="729" width="305" height="19" font="8"><b>Results: </b>651 brady episodes in 16 pts- 73% were 2</text>
<text top="281" left="1035" width="10" height="12" font="7">nd</text>
<text top="282" left="1045" width="30" height="19" font="0"> and </text>
<text top="300" left="729" width="8" height="19" font="0">3</text>
<text top="300" left="737" width="11" height="12" font="7">rd </text>
<text top="300" left="748" width="335" height="19" font="0">AVB; reduced to 72 episodes post CPAP, 3 got PPM for </text>
<text top="318" left="729" width="174" height="19" font="0">&gt;5 s pauses despite good Rx </text>
<text top="356" left="101" width="95" height="19" font="0">Maeno K, et al. </text>
<text top="374" left="101" width="69" height="19" font="0">2009 (188) </text>
<text top="392" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19466526">19466526</a></text>
<text top="392" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19466526"> </a></text>
<text top="355" left="229" width="101" height="19" font="8"><b>Aim: </b>Report the </text>
<text top="374" left="229" width="137" height="19" font="0">interaction of hypoxia </text>
<text top="392" left="229" width="133" height="19" font="0">and bradyarrhythmia </text>
<text top="410" left="229" width="3" height="19" font="0"> </text>
<text top="429" left="229" width="106" height="19" font="8"><b>Study type: </b>Case </text>
<text top="447" left="229" width="107" height="19" font="0">report, literature </text>
<text top="465" left="229" width="45" height="19" font="0">review </text>
<text top="484" left="229" width="3" height="19" font="0"> </text>
<text top="502" left="229" width="60" height="19" font="8"><b>Size</b>: N=1 </text>
<text top="355" left="391" width="276" height="19" font="8"><b>Inclusion criteria: </b>N/A<b>  Intervention: </b>CPAP </text>
<text top="355" left="729" width="197" height="19" font="8"><b>Results: </b>Profound AVB resolved </text>
<text top="521" left="101" width="88" height="19" font="0">Moya A, et al. </text>
<text top="539" left="101" width="69" height="19" font="0">2011 (189) </text>
<text top="558" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21444367">21444367</a></text>
<text top="558" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21444367"> </a></text>
<text top="521" left="229" width="146" height="19" font="8"><b>Aim: </b>Ability of protocol </text>
<text top="539" left="229" width="104" height="19" font="0">to Dx etiology of </text>
<text top="558" left="229" width="54" height="19" font="0">syncope </text>
<text top="576" left="229" width="3" height="19" font="0"> </text>
<text top="594" left="229" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="613" left="229" width="137" height="19" font="0">nonrandomized study </text>
<text top="631" left="229" width="96" height="19" font="0">using 3 phases; </text>
<text top="649" left="229" width="111" height="19" font="0">EKG/echo/Holter, </text>
<text top="668" left="229" width="84" height="19" font="0">EPS/CSM, ILR </text>
<text top="686" left="229" width="3" height="19" font="0"> </text>
<text top="704" left="229" width="75" height="19" font="8"><b>Size</b>: N=323 </text>
<text top="521" left="391" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="539" left="391" width="94" height="19" font="0">Syncope +BBB, </text>
<text top="558" left="391" width="82" height="19" font="0">preserved EF </text>
<text top="521" left="547" width="75" height="19" font="0">Prospective </text>
<text top="539" left="547" width="137" height="19" font="0">nonrandomized study </text>
<text top="558" left="547" width="96" height="19" font="0">using 3 phases; </text>
<text top="576" left="547" width="111" height="19" font="0">EKG/echo/Holter, </text>
<text top="594" left="547" width="84" height="19" font="0">EPS/CSM, ILR </text>
<text top="521" left="729" width="352" height="19" font="8"><b>Results: </b>158 (about 50%) were due to paroxysmal AVB or </text>
<text top="539" left="729" width="201" height="19" font="0">infraHisian abnormalities on EPS<b> </b></text>
<text top="723" left="101" width="86" height="19" font="0">Panic G, et al. </text>
<text top="742" left="101" width="69" height="19" font="0">2011 (190) </text>
<text top="760" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226549">20226549</a></text>
<text top="760" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226549"> </a></text>
<text top="723" left="229" width="107" height="19" font="8"><b>Aim: </b>Case report </text>
<text top="742" left="229" width="3" height="19" font="0"> </text>
<text top="760" left="229" width="3" height="19" font="0"> </text>
<text top="723" left="391" width="28" height="19" font="0">N/A </text>
<text top="723" left="547" width="28" height="19" font="0">N/A </text>
<text top="723" left="729" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="742" left="728" width="339" height="20" font="0">•  Presented with high-grade AVB, resolution after 12 d </text>
<text top="761" left="741" width="25" height="19" font="0">abx </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 119 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="728" width="327" height="20" font="0">•  5% of pts with Lyme will have cardiac involvement, </text>
<text top="106" left="741" width="83" height="19" font="0">typically AVB </text>
<text top="125" left="101" width="92" height="19" font="0">Carroz P, et al. </text>
<text top="143" left="101" width="69" height="19" font="0">2010 (191) </text>
<text top="162" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19946114">19946114</a></text>
<text top="162" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19946114"> </a></text>
<text top="125" left="229" width="129" height="19" font="8"><b>Aim:</b> Discuss pseudo </text>
<text top="143" left="229" width="88" height="19" font="0">PM syndrome </text>
<text top="162" left="229" width="3" height="19" font="0"> </text>
<text top="180" left="229" width="3" height="19" font="0"> </text>
<text top="125" left="391" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="143" left="391" width="74" height="19" font="8"><b>C</b>ase report </text>
<text top="125" left="547" width="74" height="19" font="0">Case report </text>
<text top="125" left="729" width="315" height="19" font="8"><b>Results: </b>PR was 480 ms, had intermittent cannon A </text>
<text top="143" left="729" width="325" height="19" font="0">waves, symptoms of fatigue due to atrial contraction </text>
<text top="162" left="729" width="339" height="19" font="0">before complete A filling, increase PCWP, decrease CO, </text>
<text top="180" left="729" width="124" height="19" font="0">improved with PPM<b> </b></text>
<text top="199" left="101" width="107" height="19" font="0">Marti-Almor J, et </text>
<text top="217" left="101" width="87" height="19" font="0">al. 2009 (192) </text>
<text top="236" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19578058">19578058</a></text>
<text top="236" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19578058"> </a></text>
<text top="199" left="229" width="137" height="19" font="8"><b>Aim: </b>N=259 with BFB, </text>
<text top="217" left="229" width="126" height="19" font="0">82% had syncope or </text>
<text top="236" left="229" width="126" height="19" font="0">presyncope, 18% no </text>
<text top="254" left="229" width="145" height="19" font="0">symptoms; 61% on EPS </text>
<text top="272" left="229" width="98" height="19" font="0">had conduction </text>
<text top="291" left="229" width="144" height="19" font="0">abnormal and received </text>
<text top="309" left="229" width="32" height="19" font="0">PPM </text>
<text top="327" left="229" width="3" height="19" font="0"> </text>
<text top="345" left="229" width="74" height="19" font="8"><b>Study typ</b>e: </text>
<text top="364" left="229" width="89" height="19" font="0">Observational </text>
<text top="382" left="229" width="3" height="19" font="0"> </text>
<text top="400" left="229" width="75" height="19" font="8"><b>Size</b>; N=259 </text>
<text top="199" left="391" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="217" left="391" width="141" height="19" font="0">LBBB or RBBB+LAFB or </text>
<text top="236" left="391" width="73" height="19" font="0">RBBB+LPFB </text>
<text top="254" left="391" width="109" height="19" font="0">82% had syncope </text>
<text top="199" left="547" width="150" height="19" font="0">Prospective consecutive </text>
<text top="217" left="547" width="123" height="19" font="0">observational study </text>
<text top="199" left="729" width="345" height="19" font="8"><b>Results: </b>82% had symptoms (syncope, presyncope) 61% </text>
<text top="217" left="729" width="338" height="19" font="0">had pos. EPS (HV &gt;70 if sx, HV&gt;100 if asx, or infraHisian </text>
<text top="236" left="729" width="352" height="19" font="0">with RAP) and almost all got PPM, 2/3 had progression of </text>
<text top="254" left="729" width="29" height="19" font="0">AVB<b> </b></text>
<text top="419" left="101" width="98" height="19" font="0">Barold SS, et al. </text>
<text top="438" left="101" width="69" height="19" font="0">1996 (193) </text>
<text top="456" left="101" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8734740">8734740</a></text>
<text top="456" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8734740"> </a></text>
<text top="419" left="229" width="87" height="19" font="8"><b>Aim: </b>Editorial </text>
<text top="438" left="229" width="3" height="19" font="0"> </text>
<text top="456" left="229" width="102" height="19" font="8"><b>Study type: </b>N/A </text>
<text top="474" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="493" left="229" width="76" height="19" font="8"><b>Size: </b>N=N/A<b> </b></text>
<text top="419" left="391" width="159" height="19" font="8"><b>Inclusion criteria: </b>N/A  <b> </b></text>
<text top="419" left="729" width="340" height="19" font="8"><b>Opinion: </b>PMs can be used especially in pts with normal </text>
<text top="438" left="729" width="32" height="19" font="0">LVEF </text>
<text top="512" left="101" width="98" height="19" font="0">Barold SS, et al. </text>
<text top="530" left="101" width="69" height="19" font="0">2006 (194) </text>
<text top="548" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17334913">17334913</a></text>
<text top="548" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17334913"> </a></text>
<text top="512" left="229" width="134" height="19" font="8"><b>Aim: </b>Describe clinical </text>
<text top="530" left="229" width="118" height="19" font="0">manifestations of 1</text>
<text top="530" left="347" width="7" height="12" font="7">st</text>
<text top="530" left="354" width="3" height="19" font="0"> </text>
<text top="548" left="229" width="29" height="19" font="0">AVB </text>
<text top="567" left="229" width="3" height="19" font="0"> </text>
<text top="585" left="229" width="122" height="19" font="8"><b>Study type: </b>Review </text>
<text top="603" left="229" width="39" height="19" font="0">paper </text>
<text top="622" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="640" left="229" width="76" height="19" font="8"><b>Size: </b>N=N/A<b> </b></text>
<text top="512" left="391" width="295" height="19" font="8"><b>Inclusion criteria:</b> N/A<b>  Intervention: </b>PM, CRT<b> </b></text>
<text top="512" left="729" width="354" height="19" font="8"><b>Results</b>: Pacing addresses symptoms, CRT response is less </text>
<text top="530" left="729" width="180" height="19" font="0">than in those with normal PR<b> </b></text>
<text top="659" left="101" width="97" height="19" font="0">Barra SN, et al.  </text>
<text top="677" left="101" width="69" height="19" font="0">2012 (195) </text>
<text top="696" left="101" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22897386">22897386</a></text>
<text top="696" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22897386"> </a></text>
<text top="659" left="229" width="140" height="19" font="8"><b>Aim: </b>Review the more </text>
<text top="677" left="229" width="117" height="19" font="0">common and rarer </text>
<text top="696" left="229" width="144" height="19" font="0">causes of AVB in young </text>
<text top="714" left="229" width="41" height="19" font="0">adults<b> </b></text>
<text top="659" left="391" width="316" height="19" font="8"><b>Inclusion criteria:</b> N/A<b>  Recommendations: </b>Work </text>
<text top="677" left="547" width="147" height="19" font="0">up for underlying cause </text>
<text top="696" left="547" width="145" height="19" font="0">based on family Hx and </text>
<text top="714" left="547" width="163" height="19" font="0">symptoms and risk factors </text>
<text top="732" left="547" width="50" height="19" font="0">for CAD<b> </b></text>
<text top="659" left="729" width="324" height="19" font="8"><b>Results: </b>More common causes in young adults: CAD, </text>
<text top="677" left="729" width="320" height="19" font="0">degenerative diseases, cardiomyopathies, infection, </text>
<text top="696" left="729" width="327" height="19" font="0">rheumatic, autoimmune, infiltrative, vagally induced, </text>
<text top="714" left="729" width="37" height="19" font="0">drugs<b> </b></text>
<text top="751" left="140" width="7" height="21" font="4">  </text>
<text top="771" left="86" width="3" height="19" font="0"> </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 120 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="108" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="131" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="138" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="131" left="255" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="284" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="446" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="649" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="680" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="167" left="711" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="131" left="918" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="947" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="96" width="124" height="19" font="0">Kenneback G, et al. <b> </b></text>
<text top="205" left="96" width="69" height="19" font="0">2007 (149) </text>
<text top="223" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17255148">17255148</a></text>
<text top="223" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17255148"> </a></text>
<text top="186" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="205" left="243" width="121" height="19" font="0">center, prospective </text>
<text top="223" left="243" width="104" height="19" font="0">cohort (Sweden) </text>
<text top="241" left="243" width="3" height="19" font="0"> </text>
<text top="260" left="243" width="140" height="19" font="8"><b>Size:</b> N=17 (53% men), </text>
<text top="278" left="243" width="92" height="19" font="0">mean age 77 y </text>
<text top="186" left="405" width="193" height="19" font="8"><b>Inclusion criteria:</b> Pts admitted </text>
<text top="205" left="405" width="155" height="19" font="0">with high-degree AVB on </text>
<text top="223" left="405" width="179" height="19" font="0">antiarrhythmic therapy (88% </text>
<text top="241" left="405" width="169" height="19" font="0">beta blocker) who received </text>
<text top="260" left="405" width="153" height="19" font="0">PPM, who then had AAD </text>
<text top="278" left="405" width="178" height="19" font="0">withdrawn with return of AV </text>
<text top="296" left="405" width="76" height="19" font="0">conduction. </text>
<text top="315" left="405" width="3" height="19" font="0"> </text>
<text top="333" left="405" width="199" height="19" font="8"><b>Exclusion criteria:</b> Valve surgery </text>
<text top="351" left="405" width="168" height="19" font="0">in past year, permanent AF </text>
<text top="187" left="621" width="199" height="19" font="8"><b>1</b>°<b> endpoint:</b> Recurrence of AVB </text>
<text top="206" left="621" width="214" height="19" font="0">detected by PM algorithm over 2 y </text>
<text top="224" left="621" width="3" height="19" font="0"> </text>
<text top="242" left="621" width="238" height="19" font="8"><b>Results:</b> 9/12 pts (75%) with QRS &gt;120 </text>
<text top="261" left="621" width="200" height="19" font="0">ms and 1/5 pts (20%) developed </text>
<text top="279" left="621" width="186" height="19" font="0">recurrent AVB. 6/17 pts (35%) </text>
<text top="297" left="621" width="213" height="19" font="0">developed atrial tachyarrhythmias </text>
<text top="315" left="621" width="104" height="19" font="0">requiring AAD tx </text>
<text top="187" left="878" width="212" height="20" font="0">•  Appropriate to place PPM in pts </text>
<text top="206" left="888" width="197" height="19" font="0">with AVB and QRS &gt;120 ms w/o </text>
<text top="224" left="888" width="171" height="19" font="0">further delay or evaluation. </text>
<text top="370" left="96" width="118" height="19" font="0">Knudsen MB, et al. </text>
<text top="389" left="96" width="73" height="19" font="0">2013 (150) <b> </b></text>
<text top="407" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746">23869746</a></text>
<text top="407" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746"> </a></text>
<text top="370" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="389" left="243" width="131" height="19" font="0">center, retrospective </text>
<text top="407" left="243" width="112" height="19" font="0">cohort (Denmark) </text>
<text top="425" left="243" width="3" height="19" font="0"> </text>
<text top="444" left="243" width="139" height="19" font="8"><b>Size:</b> N=55 (55% male, </text>
<text top="462" left="243" width="96" height="19" font="0">mean age 77 y) </text>
<text top="370" left="405" width="193" height="19" font="8"><b>Inclusion criteria:</b> Pts admitted </text>
<text top="389" left="405" width="182" height="19" font="0">with 2/3 AVB, had temporary </text>
<text top="407" left="405" width="200" height="19" font="0">wire, were on class II-IV AADs or </text>
<text top="425" left="405" width="55" height="19" font="0">digoxin.  </text>
<text top="444" left="405" width="3" height="19" font="0"> </text>
<text top="462" left="405" width="163" height="19" font="8"><b>Exclusion criteria:</b> No ECG </text>
<text top="480" left="405" width="173" height="19" font="0">documentation, AVB due to </text>
<text top="499" left="405" width="174" height="19" font="0">other identified cause, prior </text>
<text top="517" left="405" width="203" height="19" font="0">PPM explant, died within several </text>
<text top="535" left="405" width="31" height="19" font="0">days </text>
<text top="371" left="621" width="174" height="19" font="8"><b>1</b>°<b> endpoint:</b> Need for PPM; </text>
<text top="389" left="621" width="135" height="19" font="0">complications of TPM </text>
<text top="408" left="621" width="3" height="19" font="0"> </text>
<text top="426" left="621" width="233" height="19" font="8"><b>Results:</b> 47/55 (85%) required PPM in </text>
<text top="444" left="621" width="231" height="19" font="0">hospital. 2/55 had recurrent AVB and </text>
<text top="463" left="621" width="185" height="19" font="0">required PPM. 11% of pts had </text>
<text top="481" left="621" width="197" height="19" font="0">complication of TPM (infection/ </text>
<text top="499" left="621" width="233" height="19" font="0">dislodgment), also prolonged hospital </text>
<text top="518" left="621" width="28" height="19" font="0">stay </text>
<text top="371" left="878" width="200" height="20" font="0">• Pts with AVB on AADs /digoxin </text>
<text top="389" left="888" width="181" height="19" font="0">do not benefit from TPM and </text>
<text top="408" left="888" width="206" height="19" font="0">drug washout. Should proceed to </text>
<text top="426" left="888" width="100" height="19" font="0">PPM w/o delay. </text>
<text top="445" left="878" width="176" height="20" font="0">•  “In the elderly, the drug is </text>
<text top="464" left="888" width="189" height="19" font="0">virtually never the sole culprit; </text>
<text top="482" left="888" width="159" height="19" font="0">rather, it just exposes the </text>
<text top="500" left="888" width="207" height="19" font="0">underlying weakness of the aging </text>
<text top="518" left="888" width="125" height="19" font="0">conduction system” </text>
<text top="554" left="96" width="115" height="19" font="0">Osmonov D, et al. <b> </b></text>
<text top="572" left="96" width="69" height="19" font="0">2012 (151)<b> </b></text>
<text top="591" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22530749">22530749</a></text>
<text top="591" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22530749"> </a></text>
<text top="554" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="572" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="591" left="243" width="98" height="19" font="0">cohort (Turkey) </text>
<text top="609" left="243" width="3" height="19" font="0"> </text>
<text top="627" left="243" width="143" height="19" font="8"><b>Size:</b> N=108 (16% of all </text>
<text top="646" left="243" width="142" height="19" font="0">668 pts admit with 2/3 </text>
<text top="664" left="243" width="149" height="19" font="0">AVB). 30/108 (28%) had </text>
<text top="682" left="243" width="76" height="19" font="0">AF with SVR </text>
<text top="554" left="405" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="572" left="405" width="173" height="19" font="0">admitted with 2/3 AVB who </text>
<text top="591" left="405" width="166" height="19" font="0">were on AV nodal blocking </text>
<text top="609" left="405" width="86" height="19" font="0">drugs 2008–9 </text>
<text top="627" left="405" width="3" height="19" font="0"> </text>
<text top="646" left="405" width="137" height="19" font="8"><b>Exclusion criteria:</b> MI, </text>
<text top="664" left="405" width="202" height="19" font="0">electrolyte disturbances, digoxin </text>
<text top="682" left="405" width="168" height="19" font="0">toxicity, vasovagal syncope </text>
<text top="555" left="621" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution/ recurrence </text>
<text top="573" left="621" width="119" height="19" font="0">AVB, need for PPM </text>
<text top="592" left="621" width="3" height="19" font="0"> </text>
<text top="610" left="621" width="241" height="19" font="8"><b>Results:</b> Resolution of AVB with 72 h in </text>
<text top="628" left="621" width="194" height="19" font="0">78/108 (72%). 21/78 (27%) had </text>
<text top="647" left="621" width="212" height="19" font="0">recurrence of AVB. Overall 51/108 </text>
<text top="665" left="621" width="235" height="19" font="0">(48%) had persistent of recurrent AVB </text>
<text top="683" left="621" width="156" height="19" font="0">despite drug withdrawal. </text>
<text top="554" left="878" width="194" height="20" font="0">• Half of pts with AVB on nodal-</text>
<text top="573" left="888" width="171" height="19" font="0">blocking drugs require PPM </text>
<text top="592" left="888" width="186" height="19" font="0">before discharge despite drug </text>
<text top="610" left="888" width="76" height="19" font="0">withdrawal. </text>
<text top="628" left="878" width="195" height="20" font="0">•  Limited follow-up – other pts </text>
<text top="647" left="888" width="197" height="19" font="0">may have required PPM at later </text>
<text top="666" left="888" width="31" height="19" font="0">date </text>
<text top="702" left="96" width="129" height="19" font="0">Zeltser D, et al. 2004 </text>
<text top="721" left="96" width="35" height="19" font="0">(152)<b> </b></text>
<text top="739" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15234417">15234417</a></text>
<text top="739" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15234417"> </a></text>
<text top="702" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="721" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="739" left="243" width="89" height="19" font="0">cohort (Israel) </text>
<text top="757" left="243" width="3" height="19" font="0"> </text>
<text top="702" left="405" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="721" left="405" width="181" height="19" font="0">admitted with 2/3 AVB 1999–</text>
<text top="739" left="405" width="38" height="19" font="0">2003. </text>
<text top="757" left="405" width="3" height="19" font="0"> </text>
<text top="703" left="621" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution/ recurrence </text>
<text top="721" left="621" width="119" height="19" font="0">AVB, need for PPM </text>
<text top="740" left="621" width="3" height="19" font="0"> </text>
<text top="758" left="621" width="188" height="19" font="8"><b>Results:</b> 79/92 (86%) had drug </text>
<text top="776" left="621" width="187" height="19" font="0">discontinued. 32/79(41%) had </text>
<text top="702" left="878" width="217" height="20" font="0">• Overall, only 15% of pts with AVB </text>
<text top="721" left="888" width="203" height="19" font="0">on nodal blocking drugs had AVB </text>
<text top="740" left="888" width="114" height="19" font="0">“caused by drugs” </text>
<text top="758" left="878" width="128" height="20" font="0">• F-u limited to 3 wk </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 121 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="243" width="146" height="19" font="8"><b>Size:</b> N=169 (60% male, </text>
<text top="105" left="243" width="147" height="19" font="0">mean age 78 y). 92/169 </text>
<text top="123" left="243" width="118" height="19" font="0">(54%) receiving AV </text>
<text top="142" left="243" width="92" height="19" font="0">nodal blockers </text>
<text top="87" left="405" width="185" height="19" font="8"><b>Exclusion criteria:</b> MI, digoxin </text>
<text top="105" left="405" width="168" height="19" font="0">toxicity, vasovagal syncope </text>
<text top="87" left="621" width="244" height="19" font="0">resolution of AVB. 18/32 had relapse of </text>
<text top="105" left="621" width="106" height="19" font="0">AVB within 3 wk  </text>
<text top="161" left="96" width="108" height="19" font="0">Risgaard B, et al. <b> </b></text>
<text top="179" left="96" width="69" height="19" font="0">2012 (153)<b> </b></text>
<text top="197" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22333242">22333242</a></text>
<text top="197" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22333242"> </a></text>
<text top="161" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="179" left="243" width="127" height="19" font="0">Retrospective single-</text>
<text top="197" left="243" width="131" height="19" font="0">center/region cohort </text>
<text top="216" left="243" width="105" height="19" font="0">study (Denmark) </text>
<text top="234" left="243" width="3" height="19" font="0"> </text>
<text top="252" left="243" width="143" height="19" font="8"><b>Size:</b> N=259 (mean age </text>
<text top="271" left="243" width="144" height="19" font="0">78 y, 46% male). 49.7% </text>
<text top="289" left="243" width="139" height="19" font="0">had 2/3 AVB. 15% had </text>
<text top="307" left="243" width="121" height="19" font="0">AF-slow ventricular </text>
<text top="326" left="243" width="59" height="19" font="0">response </text>
<text top="161" left="405" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="179" left="405" width="199" height="19" font="0">referred for urgent PPM in 2009 </text>
<text top="197" left="405" width="3" height="19" font="0"> </text>
<text top="216" left="405" width="184" height="19" font="8"><b>Exclusion criteria:</b> Discharged </text>
<text top="234" left="405" width="183" height="19" font="0">from hospital before implant, </text>
<text top="252" left="405" width="155" height="19" font="0">referred from outpatient </text>
<text top="271" left="405" width="76" height="19" font="0">department </text>
<text top="162" left="621" width="163" height="19" font="8"><b>1</b>°<b> endpoint:</b> d to implant, </text>
<text top="180" left="621" width="161" height="19" font="0">complications during wait </text>
<text top="198" left="621" width="3" height="19" font="0"> </text>
<text top="217" left="621" width="234" height="19" font="8"><b>Results:</b> Mean 8.3 d hospitalization to </text>
<text top="235" left="621" width="231" height="19" font="0">implant (3.2 d to Dx; 5.1 d waiting for </text>
<text top="253" left="621" width="174" height="19" font="0">PPM). 83/259 pts (32%) had </text>
<text top="272" left="621" width="241" height="19" font="0">complications while waiting – Infection </text>
<text top="290" left="621" width="208" height="19" font="0">(11%), asystole (20%), NSVT (5%), </text>
<text top="308" left="621" width="191" height="19" font="0">cardiac arrest (3%), death (1%) </text>
<text top="161" left="878" width="196" height="20" font="0">•  Pt harm results from delay to </text>
<text top="180" left="888" width="150" height="19" font="0">PPM for capacity issues. </text>
<text top="345" left="96" width="120" height="19" font="0">Farre N, et al.<b> </b>2014 </text>
<text top="363" left="96" width="35" height="19" font="0">(154)<b> </b></text>
<text top="381" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24491864">24491864</a></text>
<text top="381" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24491864"> </a></text>
<text top="345" left="243" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="363" left="243" width="127" height="19" font="0">Retrospective single-</text>
<text top="381" left="243" width="132" height="19" font="0">center cohort (Spain) </text>
<text top="400" left="243" width="3" height="19" font="0"> </text>
<text top="418" left="243" width="135" height="19" font="8"><b>Size:</b> N=79; mean age </text>
<text top="436" left="243" width="99" height="19" font="0">72 y, 50% male  </text>
<text top="345" left="405" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="363" left="405" width="136" height="19" font="0">pts with “reversible” 3</text>
<text top="363" left="542" width="9" height="12" font="7">rd</text>
<text top="363" left="550" width="49" height="19" font="0"> degree </text>
<text top="381" left="405" width="195" height="19" font="0">AVB not undergoing initial PPM </text>
<text top="400" left="405" width="50" height="19" font="0">implant </text>
<text top="418" left="405" width="3" height="19" font="0"> </text>
<text top="436" left="405" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="345" left="621" width="243" height="19" font="8"><b>1</b>°<b> endpoint:</b> Persistence/recurrence of </text>
<text top="364" left="621" width="114" height="19" font="0">AVB, PPM implant </text>
<text top="382" left="621" width="3" height="19" font="0"> </text>
<text top="400" left="621" width="148" height="19" font="8"><b>Results:</b> 39% of pts w/o </text>
<text top="419" left="621" width="188" height="19" font="0">ischemic/infarction developed </text>
<text top="437" left="621" width="152" height="19" font="0">recurrent AVB, had PPM </text>
<text top="345" left="878" width="206" height="20" font="0">• Outside setting of MI/ischemia, </text>
<text top="364" left="888" width="176" height="19" font="0">high proportion of pts with 3</text>
<text top="364" left="1064" width="8" height="12" font="7">rd</text>
<text top="364" left="1072" width="3" height="19" font="0"> </text>
<text top="382" left="888" width="171" height="19" font="0">degree AVB and “reversible </text>
<text top="401" left="888" width="196" height="19" font="0">causes” develop recurrent AVB. </text>
<text top="419" left="878" width="135" height="20" font="0">• Close f-u warranted </text>
<text top="438" left="878" width="199" height="20" font="0">• Study was research letter with </text>
<text top="457" left="888" width="127" height="19" font="0">little data presented </text>
<text top="476" left="96" width="116" height="19" font="0">Antman EM, et al. <b> </b></text>
<text top="494" left="96" width="69" height="19" font="0">1990 (100)<b> </b></text>
<text top="513" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2188752">2188752</a></text>
<text top="513" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2188752"> </a></text>
<text top="476" left="243" width="149" height="19" font="8"><b>Study type:</b> Open-label, </text>
<text top="494" left="243" width="137" height="19" font="0">21-center prospective </text>
<text top="513" left="243" width="137" height="19" font="0">cohort study 1974–86 </text>
<text top="531" left="243" width="3" height="19" font="0"> </text>
<text top="549" left="243" width="97" height="19" font="8"><b>Size:</b> N=150 pts </text>
<text top="568" left="243" width="118" height="19" font="0">(79=53% with high-</text>
<text top="586" left="243" width="112" height="19" font="0">degree AVB). 46% </text>
<text top="604" left="243" width="129" height="19" font="0">male, mean age 65 y </text>
<text top="476" left="405" width="163" height="19" font="8"><b>Inclusion criteria:</b> Pts who </text>
<text top="494" left="405" width="178" height="19" font="0">received digoxin-specific Fab </text>
<text top="513" left="405" width="168" height="19" font="0">fragments in trial 1974–86. </text>
<text top="531" left="405" width="3" height="19" font="0"> </text>
<text top="549" left="405" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="477" left="621" width="199" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical “response” </text>
<text top="495" left="621" width="3" height="19" font="0"> </text>
<text top="513" left="621" width="224" height="19" font="8"><b>Results:</b> 80% complete resolution of </text>
<text top="532" left="621" width="220" height="19" font="0">signs/sx. 10% partial response, 10% </text>
<text top="550" left="621" width="124" height="19" font="0">complete response. </text>
<text top="476" left="878" width="213" height="20" font="0">•  AVB pts not separately analyzed </text>
<text top="623" left="96" width="101" height="19" font="0">Hickey AR, et al. </text>
<text top="642" left="96" width="69" height="19" font="0">1991 (101) </text>
<text top="660" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1993775">1993775</a></text>
<text top="660" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1993775"> </a></text>
<text top="623" left="243" width="112" height="19" font="8"><b>Study type:</b> Multi-</text>
<text top="642" left="243" width="116" height="19" font="0">center US national </text>
<text top="660" left="243" width="118" height="19" font="0">prospective cohort </text>
<text top="678" left="243" width="3" height="19" font="0"> </text>
<text top="696" left="243" width="143" height="19" font="8"><b>Size:</b> N=717; 40% men, </text>
<text top="715" left="243" width="92" height="19" font="0">mean age 74 y </text>
<text top="623" left="405" width="187" height="19" font="8"><b>Inclusion criteria:</b> All pts in US </text>
<text top="642" left="405" width="159" height="19" font="0">receiving anti-digoxin Fab </text>
<text top="660" left="405" width="66" height="19" font="0">fragments </text>
<text top="678" left="405" width="3" height="19" font="0"> </text>
<text top="696" left="405" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="624" left="621" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution of symptoms </text>
<text top="642" left="621" width="111" height="19" font="0">of digoxin toxicity </text>
<text top="661" left="621" width="3" height="19" font="0"> </text>
<text top="679" left="621" width="235" height="19" font="8"><b>Results:</b> 50% complete response, 24% </text>
<text top="697" left="621" width="242" height="19" font="0">partial response; 12 % no response. 3% </text>
<text top="716" left="621" width="235" height="19" font="0">recurrence rate. 1% allergy to therapy </text>
<text top="623" left="878" width="210" height="20" font="0">•  No separate analysis of AVB pts </text>
<text top="735" left="96" width="106" height="19" font="0">Sadek MM, et al. </text>
<text top="753" left="96" width="69" height="19" font="0">2013 (155)<b> </b></text>
<text top="771" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23623644">23623644</a></text>
<text top="771" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23623644"> </a></text>
<text top="735" left="243" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="753" left="243" width="45" height="19" font="0">review </text>
<text top="771" left="243" width="3" height="19" font="0"> </text>
<text top="735" left="405" width="158" height="19" font="8"><b>Inclusion criteria:</b> English </text>
<text top="753" left="405" width="200" height="19" font="0">language, original outcome data </text>
<text top="735" left="621" width="239" height="19" font="8"><b>1</b>°<b> endpoint:</b> Reversal or improvement </text>
<text top="754" left="621" width="43" height="19" font="0">in AVB </text>
<text top="772" left="621" width="3" height="19" font="0"> </text>
<text top="735" left="878" width="131" height="20" font="0">• Considerable study </text>
<text top="754" left="888" width="90" height="19" font="0">heterogeneity </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 122 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="243" width="132" height="19" font="8"><b>Size:</b> 10 publications; </text>
<text top="105" left="243" width="48" height="19" font="0">299 pts </text>
<text top="87" left="405" width="189" height="19" font="0">on pts with cardiac sarcoidosis </text>
<text top="105" left="405" width="101" height="19" font="0">tx with steroids. </text>
<text top="123" left="405" width="3" height="19" font="0"> </text>
<text top="142" left="405" width="190" height="19" font="8"><b>Exclusion criteria:</b> Reports less </text>
<text top="160" left="405" width="182" height="19" font="0">than 5 subjects or less than 3-</text>
<text top="178" left="405" width="88" height="19" font="0">mo follow-up  </text>
<text top="87" left="621" width="215" height="19" font="8"><b>Results:</b> 27/57 (47%) cases treated </text>
<text top="105" left="621" width="187" height="19" font="0">with steroids had improved or </text>
<text top="123" left="621" width="235" height="19" font="0">recovered AV conduction vs. 0/16 pts. </text>
<text top="142" left="621" width="143" height="19" font="0">w/o steroid treatment. </text>
<text top="87" left="878" width="217" height="20" font="0">• “Improvement” in AV conduction </text>
<text top="106" left="888" width="74" height="19" font="0">not defined </text>
<text top="124" left="878" width="218" height="20" font="0">•  Outcome not defined in terms of </text>
<text top="143" left="888" width="79" height="19" font="0">need for PM </text>
<text top="197" left="96" width="106" height="19" font="0">Kandolin R, et al. </text>
<text top="216" left="96" width="69" height="19" font="0">2011 (156)<b> </b></text>
<text top="234" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21427276">21427276</a></text>
<text top="234" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21427276"> </a></text>
<text top="197" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="216" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="234" left="243" width="104" height="19" font="0">cohort (Finland)  </text>
<text top="252" left="243" width="3" height="19" font="0"> </text>
<text top="271" left="243" width="120" height="19" font="8"><b>Size:</b> N=133; 72 pts </text>
<text top="289" left="243" width="141" height="19" font="0">with unexplained AVB  </text>
<text top="197" left="405" width="189" height="19" font="8"><b>Inclusion criteria:</b> Pts. 18–55 y </text>
<text top="216" left="405" width="159" height="19" font="0">who had PPM implant for </text>
<text top="234" left="405" width="86" height="19" font="0">unexplained 2</text>
<text top="234" left="491" width="10" height="12" font="7">nd</text>
<text top="234" left="501" width="13" height="19" font="0">/3</text>
<text top="234" left="515" width="8" height="12" font="7">rd</text>
<text top="234" left="523" width="83" height="19" font="0">-degree AVB  </text>
<text top="252" left="405" width="3" height="19" font="0"> </text>
<text top="271" left="405" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="289" left="405" width="63" height="19" font="0">described </text>
<text top="198" left="621" width="238" height="19" font="8"><b>1</b>°<b> endpoint:</b> Dx of cardiac sarcoidosis; </text>
<text top="217" left="621" width="197" height="19" font="0">reversal of AVB with treatment. </text>
<text top="235" left="621" width="3" height="19" font="0"> </text>
<text top="253" left="621" width="235" height="19" font="8"><b>Results:</b> 18/72 (25%) had probable (4) </text>
<text top="272" left="621" width="241" height="19" font="0">or definite (14) cardiac sarcoidosis AVB </text>
<text top="290" left="621" width="242" height="19" font="0">reversed in only 2/16 pts (13%) treated </text>
<text top="308" left="621" width="83" height="19" font="0">with steroids </text>
<text top="198" left="878" width="189" height="20" font="0">• Selected population, tertiary </text>
<text top="217" left="888" width="92" height="19" font="0">referral center </text>
<text top="235" left="878" width="206" height="20" font="0">• Little data about AVB described </text>
<text top="254" left="878" width="201" height="20" font="0">• Overall suggests low chance of </text>
<text top="273" left="888" width="165" height="19" font="0">reversing AVB with steroid </text>
<text top="291" left="888" width="66" height="19" font="0">treatment </text>
<text top="327" left="96" width="130" height="19" font="0">Ozcan KS, et al. 2012 </text>
<text top="346" left="96" width="35" height="19" font="0">(157)<b> </b></text>
<text top="364" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22738687">22738687</a></text>
<text top="364" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22738687"> </a></text>
<text top="327" left="243" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="346" left="243" width="127" height="19" font="0">center retrospective </text>
<text top="364" left="243" width="101" height="19" font="0">cohort (Turkey)  </text>
<text top="382" left="243" width="3" height="19" font="0"> </text>
<text top="400" left="243" width="91" height="19" font="8"><b>Size:</b> N=50 (29 </text>
<text top="419" left="243" width="100" height="19" font="0">hypothyroid, 21 </text>
<text top="437" left="243" width="87" height="19" font="0">hyperthyroid) </text>
<text top="327" left="405" width="187" height="19" font="8"><b>Inclusion criteria:</b> All pts. with </text>
<text top="346" left="405" width="8" height="19" font="0">2</text>
<text top="345" left="413" width="10" height="12" font="7">nd</text>
<text top="346" left="423" width="13" height="19" font="0">/3</text>
<text top="345" left="436" width="9" height="12" font="7">rd</text>
<text top="346" left="445" width="134" height="19" font="0"> degree AVB who had </text>
<text top="364" left="405" width="159" height="19" font="0">hyper- or hypothyroidism </text>
<text top="382" left="405" width="3" height="19" font="0"> </text>
<text top="400" left="405" width="137" height="19" font="8"><b>Exclusion criteria:</b> MI, </text>
<text top="419" left="405" width="166" height="19" font="0">electrolytes abnormalities, </text>
<text top="437" left="405" width="162" height="19" font="0">digoxin toxicity, vasovagal </text>
<text top="455" left="405" width="116" height="19" font="0">syncope, on AADs  </text>
<text top="328" left="621" width="223" height="19" font="8"><b>1</b>°<b> endpoint:</b> Persistent AVB despite </text>
<text top="346" left="621" width="217" height="19" font="0">treatment of thyroid abnormalities </text>
<text top="365" left="621" width="3" height="19" font="0"> </text>
<text top="383" left="621" width="208" height="19" font="8"><b>Results:</b> 46/50 (92%) pts required </text>
<text top="401" left="621" width="224" height="19" font="0">PPM; 2 additional pts had persistent </text>
<text top="420" left="621" width="240" height="19" font="0">AVB. 22/29 (76%) with hypothyroidism </text>
<text top="438" left="621" width="239" height="19" font="0">and 18/21 (86%) with hyperthyroidism </text>
<text top="456" left="621" width="131" height="19" font="0">had irreversible AVB. </text>
<text top="327" left="878" width="213" height="20" font="0">•  Thyroid abnormalities are rarely </text>
<text top="346" left="888" width="161" height="19" font="0">a cause of reversible AVB. </text>
<text top="475" left="96" width="115" height="19" font="0">Forrester JD, et al. </text>
<text top="494" left="96" width="69" height="19" font="0">2014 (158)<b> </b></text>
<text top="512" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24879781">24879781</a></text>
<text top="512" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24879781"> </a></text>
<text top="475" left="243" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="494" left="243" width="139" height="19" font="0">review of case reports </text>
<text top="512" left="243" width="99" height="19" font="0">and case series  </text>
<text top="530" left="243" width="3" height="19" font="0"> </text>
<text top="548" left="243" width="128" height="19" font="8"><b>Size:</b> 34 manuscripts </text>
<text top="567" left="243" width="119" height="19" font="0">reporting 45 cases  </text>
<text top="475" left="405" width="158" height="19" font="8"><b>Inclusion criteria:</b> English </text>
<text top="494" left="405" width="192" height="19" font="0">language case reports or series </text>
<text top="512" left="405" width="192" height="19" font="0">in peer-reviewed journal of pts </text>
<text top="530" left="405" width="171" height="19" font="0">with Lyme disease and ECG-</text>
<text top="548" left="405" width="89" height="19" font="0">documented 3</text>
<text top="548" left="494" width="8" height="12" font="7">rd</text>
<text top="548" left="502" width="81" height="19" font="0"> degree AVB  </text>
<text top="567" left="405" width="3" height="19" font="0"> </text>
<text top="585" left="405" width="154" height="19" font="8"><b>Exclusion criteria:</b> Not in </text>
<text top="603" left="405" width="150" height="19" font="0">English, pt not US, no pt </text>
<text top="622" left="405" width="115" height="19" font="0">variables reported </text>
<text top="476" left="621" width="242" height="19" font="8"><b>1</b>°<b> endpoint:</b> Outcomes, need for PPM, </text>
<text top="494" left="621" width="118" height="19" font="0">persistence of AVB </text>
<text top="513" left="621" width="3" height="19" font="0"> </text>
<text top="531" left="621" width="221" height="19" font="8"><b>Results:</b> 18/45 (40%) required TPM, </text>
<text top="549" left="621" width="234" height="19" font="0">2/45 (4%) had PPM, both in 1980s. All </text>
<text top="568" left="621" width="229" height="19" font="0">other cases resolved, median time to </text>
<text top="586" left="621" width="184" height="19" font="0">resolution 6 d (range 1–42 d). </text>
<text top="604" left="621" width="3" height="19" font="0"> </text>
<text top="475" left="878" width="199" height="20" font="0">• AVB with Lyme carditis almost </text>
<text top="494" left="888" width="194" height="19" font="0">always resolves with treatment </text>
<text top="641" left="96" width="119" height="19" font="0">Van der Linde, MR, </text>
<text top="659" left="96" width="69" height="19" font="0">1991 (159)<b> </b></text>
<text top="677" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1947815">1947815</a></text>
<text top="677" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1947815"> </a></text>
<text top="641" left="243" width="138" height="19" font="8"><b>Study type:</b> Review of </text>
<text top="659" left="243" width="141" height="19" font="0">published case reports </text>
<text top="677" left="243" width="127" height="19" font="0">in Europe and North </text>
<text top="696" left="243" width="120" height="19" font="0">America, European </text>
<text top="714" left="243" width="148" height="19" font="0">questionnaire, personal </text>
<text top="732" left="243" width="102" height="19" font="0">communication, </text>
<text top="751" left="243" width="85" height="19" font="0">observations  </text>
<text top="769" left="243" width="3" height="19" font="0"> </text>
<text top="641" left="405" width="174" height="19" font="8"><b>Inclusion criteria:</b> Published </text>
<text top="659" left="405" width="139" height="19" font="0">case reports 1977–90, </text>
<text top="677" left="405" width="148" height="19" font="0">questionnaire, personal </text>
<text top="696" left="405" width="184" height="19" font="0">communication, observations </text>
<text top="714" left="405" width="3" height="19" font="0"> </text>
<text top="732" left="405" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="642" left="621" width="226" height="19" font="8"><b>1</b>°<b> endpoint:</b> Outcome, resolution of </text>
<text top="660" left="621" width="119" height="19" font="0">AVB, need for PPM </text>
<text top="678" left="621" width="3" height="19" font="0"> </text>
<text top="696" left="621" width="116" height="19" font="8"><b>Results:</b> 49% had 3</text>
<text top="696" left="737" width="9" height="12" font="7">rd</text>
<text top="697" left="745" width="111" height="19" font="0"> degree AVB, 16% </text>
<text top="715" left="621" width="34" height="19" font="0">had 2</text>
<text top="715" left="655" width="10" height="12" font="7">nd</text>
<text top="715" left="665" width="167" height="19" font="0"> degree AVB. 35% required </text>
<text top="733" left="621" width="228" height="19" font="0">TPM, 94% with complete recovery of </text>
<text top="751" left="621" width="210" height="19" font="0">AV conduction, only 1 pt (1%) had </text>
<text top="770" left="621" width="72" height="19" font="0">persistent 3</text>
<text top="770" left="693" width="9" height="12" font="7">rd</text>
<text top="770" left="702" width="78" height="19" font="0"> degree AVB </text>
<text top="641" left="878" width="215" height="20" font="0">• PPM rarely needed after episode </text>
<text top="660" left="888" width="100" height="19" font="0">of Lyme carditis </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 123 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="243" width="98" height="19" font="8"><b>Size:</b> 105 cases  </text>
<text top="87" left="621" width="3" height="19" font="0"> </text>
<text top="106" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="128" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="151" left="108" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="169" left="139" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="187" left="111" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="151" left="257" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="169" left="262" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="187" left="256" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="151" left="409" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="151" left="578" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="169" left="596" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="187" left="580" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="205" left="601" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="151" left="756" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="169" left="738" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="187" left="742" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="205" left="786" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="151" left="918" width="135" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint </b></text>
<text top="170" left="965" width="51" height="19" font="8"><b>(if any); </b></text>
<text top="188" left="928" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="206" left="936" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="225" left="95" width="129" height="19" font="0">Abu-Laban RB, et al.  </text>
<text top="244" left="95" width="69" height="19" font="0">2006 (104) </text>
<text top="262" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16698410">16698410</a></text>
<text top="262" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16698410"> </a></text>
<text top="225" left="236" width="118" height="19" font="8"><b>Aim:</b> To determine </text>
<text top="244" left="236" width="55" height="19" font="0">whether </text>
<text top="262" left="236" width="90" height="19" font="0">aminophylline </text>
<text top="280" left="236" width="104" height="19" font="0">increases rate of </text>
<text top="299" left="236" width="109" height="19" font="0">ROSC after out of </text>
<text top="317" left="236" width="99" height="19" font="0">hospital cardiac </text>
<text top="335" left="236" width="39" height="19" font="0">arrest </text>
<text top="354" left="236" width="3" height="19" font="0"> </text>
<text top="372" left="236" width="105" height="19" font="8"><b>Study type:</b> RCT  </text>
<text top="390" left="236" width="3" height="19" font="0"> </text>
<text top="408" left="236" width="75" height="19" font="8"><b>Size:</b> N=971 </text>
<text top="225" left="378" width="183" height="19" font="8"><b>Inclusion criteria: </b>Pts over 16 </text>
<text top="244" left="378" width="177" height="19" font="0">y in British Columbia 2001–3 </text>
<text top="262" left="378" width="165" height="19" font="0">with brady-asystolic arrest </text>
<text top="280" left="378" width="151" height="19" font="0">refractory to intubation, </text>
<text top="299" left="378" width="162" height="19" font="0">atropine and epinephrine  </text>
<text top="317" left="378" width="3" height="19" font="0"> </text>
<text top="335" left="378" width="161" height="19" font="8"><b>Exclusion criteria:</b> Do-not-</text>
<text top="354" left="378" width="182" height="19" font="0">resuscitate order, pregnancy, </text>
<text top="372" left="378" width="146" height="19" font="0">hemorrhage/trauma or </text>
<text top="390" left="378" width="150" height="19" font="0">hypothermia, end-stage </text>
<text top="409" left="378" width="106" height="19" font="0">renal disease, on </text>
<text top="427" left="378" width="80" height="19" font="0">theophylline </text>
<text top="225" left="574" width="112" height="19" font="8"><b>Intervention:</b> 500 </text>
<text top="244" left="574" width="128" height="19" font="0">mg IV aminophylline </text>
<text top="262" left="574" width="36" height="19" font="0">bolus </text>
<text top="280" left="574" width="7" height="19" font="0">  </text>
<text top="299" left="574" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="317" left="574" width="112" height="19" font="0">Matching placebo<b> </b></text>
<text top="226" left="716" width="122" height="19" font="8"><b>1</b>°<b> endpoint:</b> ROSC: </text>
<text top="245" left="716" width="166" height="19" font="0">24.5% I vs. 23.7% C (0.8%, -</text>
<text top="263" left="716" width="110" height="19" font="0">4.6–6.2; p=0.778) </text>
<text top="281" left="715" width="188" height="19" font="0">Survival to hospital admission: </text>
<text top="299" left="715" width="182" height="19" font="0">6.6% I vs. 7.6% C (-1.0%, -4.3–</text>
<text top="318" left="715" width="84" height="19" font="0">2.2; p=0.527) </text>
<text top="336" left="715" width="170" height="19" font="0">Survival to hosp. discharge: </text>
<text top="354" left="715" width="182" height="19" font="0">0.4% I vs. 0.6% C (-0.2%, -1.1–</text>
<text top="373" left="715" width="95" height="19" font="0">0.7%; p=0.653) </text>
<text top="391" left="715" width="3" height="19" font="0"> </text>
<text top="409" left="716" width="187" height="19" font="8"><b>Safety endpoint (if relevant):</b>  </text>
<text top="428" left="716" width="36" height="19" font="0">None </text>
<text top="226" left="918" width="123" height="20" font="0">• Did not call out pt </text>
<text top="245" left="929" width="59" height="19" font="0">with AVB </text>
<text top="263" left="918" width="129" height="20" font="0">• Prehospital setting </text>
<text top="282" left="929" width="29" height="19" font="0">only </text>
<text top="447" left="95" width="56" height="19" font="0">PrePACE </text>
<text top="465" left="95" width="119" height="19" font="0">Morrison, LJ, et al.  </text>
<text top="483" left="95" width="62" height="19" font="0">2008 (86) </text>
<text top="502" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452">17933452</a></text>
<text top="502" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452"> </a></text>
<text top="447" left="236" width="108" height="19" font="8"><b>Aim:</b> To compare </text>
<text top="465" left="236" width="126" height="19" font="0">outcome of pts with </text>
<text top="483" left="236" width="129" height="19" font="0">prehospital unstable </text>
<text top="502" left="236" width="106" height="19" font="0">bradycardia with </text>
<text top="520" left="236" width="111" height="19" font="0">TCP vs. dopamine </text>
<text top="538" left="236" width="3" height="19" font="0"> </text>
<text top="556" left="236" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="575" left="236" width="3" height="19" font="0"> </text>
<text top="593" left="236" width="110" height="19" font="8"><b>Size:</b> N=82; mean </text>
<text top="611" left="236" width="124" height="19" font="0">age 71 y; 57% male  </text>
<text top="447" left="378" width="175" height="19" font="8"><b>In Inclusion criteria: </b>Pts ≥18 </text>
<text top="465" left="378" width="178" height="19" font="0">y presenting to Toronto EMS </text>
<text top="483" left="378" width="142" height="19" font="0">with hemodynamically </text>
<text top="502" left="378" width="132" height="19" font="0">unstable bradycardia </text>
<text top="520" left="378" width="164" height="19" font="0">unresponsive to fluids and </text>
<text top="538" left="378" width="59" height="19" font="0">atropine  </text>
<text top="557" left="378" width="3" height="19" font="0"> </text>
<text top="575" left="378" width="167" height="19" font="8"><b>Exclusion criteria:</b> Trauma, </text>
<text top="593" left="378" width="176" height="19" font="0">hyperthermia, hypothermia, </text>
<text top="611" left="378" width="86" height="19" font="0">cardiac arrest </text>
<text top="447" left="574" width="112" height="19" font="8"><b>Intervention:</b> TCP </text>
<text top="465" left="574" width="50" height="19" font="0">80 bpm </text>
<text top="483" left="574" width="7" height="19" font="0">  </text>
<text top="502" left="574" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="520" left="574" width="100" height="19" font="0">Dopamine 5–20 </text>
<text top="538" left="574" width="78" height="19" font="0">mcg/kg/min<b> </b></text>
<text top="447" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="466" left="716" width="114" height="19" font="0">hospital discharge </text>
<text top="484" left="716" width="141" height="19" font="0">69% I vs. 70% C (p=NS) </text>
<text top="502" left="716" width="3" height="19" font="0"> </text>
<text top="521" left="716" width="110" height="19" font="8"><b>Safety endpoint:</b>  </text>
<text top="539" left="716" width="168" height="19" font="0">VT/VF/cardiac arrest/burn: </text>
<text top="557" left="716" width="153" height="19" font="0">7.1% C vs. 7.5% C (p=NS<b>) </b></text>
<text top="447" left="918" width="124" height="20" font="0">• Half of eligible pts </text>
<text top="466" left="929" width="100" height="19" font="0">not randomized </text>
<text top="484" left="918" width="108" height="20" font="0">• This was a pilot </text>
<text top="503" left="929" width="117" height="19" font="0">study for potential </text>
<text top="522" left="929" width="66" height="19" font="0">larger RCT </text>
<text top="540" left="918" width="81" height="20" font="0">•  Dopamine </text>
<text top="559" left="929" width="111" height="19" font="0">equivalent to TCP </text>
<text top="577" left="929" width="107" height="19" font="0">in this small pilot </text>
<text top="596" left="929" width="37" height="19" font="0">study </text>
<text top="631" left="86" width="4" height="21" font="4"> </text>
<text top="651" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="673" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="695" left="109" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="714" left="134" width="51" height="19" font="8"><b>Author; </b></text>
<text top="732" left="112" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="695" left="248" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="714" left="278" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="695" left="440" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="695" left="653" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="714" left="683" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="732" left="714" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="695" left="925" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="714" left="954" width="80" height="19" font="8"><b>Comment(s) </b></text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 124 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="101" height="19" font="0">Brady WJ, et al.  </text>
<text top="105" left="96" width="62" height="19" font="0">1999 (79) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10459592">10459592</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10459592"> </a></text>
<text top="87" left="236" width="146" height="19" font="8"><b>Study type:</b> Single-EMS </text>
<text top="105" left="236" width="131" height="19" font="0">system retrospective </text>
<text top="123" left="236" width="78" height="19" font="0">cohort in US </text>
<text top="142" left="236" width="3" height="19" font="0"> </text>
<text top="160" left="236" width="128" height="19" font="8"><b>Size:</b> N=131; 45 with </text>
<text top="178" left="236" width="130" height="19" font="0">AVB; Mean age 69 y; </text>
<text top="197" left="236" width="66" height="19" font="0">53% male  </text>
<text top="87" left="398" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="105" left="398" width="195" height="19" font="0">nontraumatized pts from 1990–</text>
<text top="123" left="398" width="142" height="19" font="0">1993 who experienced </text>
<text top="142" left="398" width="174" height="19" font="0">bradycardia with associated </text>
<text top="160" left="398" width="183" height="19" font="0">hemodynamic instability who </text>
<text top="178" left="398" width="160" height="19" font="0">received atropine in field. </text>
<text top="197" left="398" width="3" height="19" font="0"> </text>
<text top="215" left="398" width="185" height="19" font="8"><b>Exclusion criteria:</b> Not stated, </text>
<text top="233" left="398" width="189" height="19" font="0">but presumably cardiac arrest. </text>
<text top="252" left="398" width="165" height="19" font="0">Also excluded pre-hospital </text>
<text top="270" left="398" width="90" height="19" font="0">deaths (N=16) </text>
<text top="88" left="614" width="259" height="19" font="8"><b>1</b>°<b> endpoint:</b> “Response” in 4 categories – </text>
<text top="106" left="614" width="201" height="19" font="0">adverse, none, partial, complete </text>
<text top="124" left="614" width="3" height="19" font="0"> </text>
<text top="143" left="614" width="262" height="19" font="8"><b>Results:</b> Mean dose 1.1 mg. Of 37 pts with </text>
<text top="161" left="614" width="8" height="19" font="0">3</text>
<text top="161" left="622" width="9" height="12" font="7">rd</text>
<text top="161" left="630" width="227" height="19" font="0"> degree AVB in field, 21 arrived in ED </text>
<text top="179" left="614" width="38" height="19" font="0">with 3</text>
<text top="179" left="652" width="9" height="12" font="7">rd</text>
<text top="179" left="661" width="189" height="19" font="0"> degree AVB and only 9 left ED </text>
<text top="198" left="614" width="38" height="19" font="0">with 3</text>
<text top="197" left="652" width="9" height="12" font="7">rd</text>
<text top="198" left="661" width="199" height="19" font="0"> degree AVB. Of all pts, 27% had </text>
<text top="216" left="614" width="229" height="19" font="0">complete response, 20% partial, 50% </text>
<text top="234" left="614" width="111" height="19" font="0">none; 3% adverse </text>
<text top="87" left="891" width="192" height="20" font="0">• Limited methodology, results </text>
<text top="106" left="902" width="105" height="19" font="0">poorly described </text>
<text top="289" left="96" width="85" height="19" font="0">Feigl D, et al.  </text>
<text top="307" left="96" width="69" height="19" font="0">1984 (160) </text>
<text top="326" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6736451">6736451</a></text>
<text top="326" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6736451"> </a></text>
<text top="289" left="236" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="307" left="236" width="127" height="19" font="0">center retrospective </text>
<text top="326" left="236" width="132" height="19" font="0">cohort study in Israel </text>
<text top="344" left="236" width="75" height="19" font="0">1978–1982  </text>
<text top="362" left="236" width="3" height="19" font="0"> </text>
<text top="381" left="236" width="135" height="19" font="8"><b>Size:</b> N=34; mean age </text>
<text top="399" left="236" width="99" height="19" font="0">62 y; 82% male  </text>
<text top="289" left="398" width="119" height="19" font="8"><b>Inclusion criteria:</b> 2</text>
<text top="289" left="517" width="10" height="12" font="7">nd</text>
<text top="289" left="527" width="28" height="19" font="0"> or 3</text>
<text top="289" left="555" width="9" height="12" font="7">rd</text>
<text top="289" left="563" width="3" height="19" font="0"> </text>
<text top="307" left="398" width="160" height="19" font="0">degree AVB developing in </text>
<text top="326" left="398" width="194" height="19" font="0">course of IMI who survived &gt;72 </text>
<text top="344" left="398" width="15" height="19" font="0">h  </text>
<text top="362" left="398" width="3" height="19" font="0"> </text>
<text top="381" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="290" left="614" width="226" height="19" font="8"><b>1</b>°<b> endpoint:</b> Outcomes, response to </text>
<text top="308" left="614" width="55" height="19" font="0">atropine </text>
<text top="326" left="614" width="3" height="19" font="0"> </text>
<text top="345" left="614" width="247" height="19" font="8"><b>Results:</b> Of 15 pts with early AVB (&lt;6 h). </text>
<text top="363" left="614" width="248" height="19" font="0">Atropine normalized conduction in 20%, </text>
<text top="381" left="614" width="201" height="19" font="0">increased V rate in others. 5 had </text>
<text top="400" left="614" width="249" height="19" font="0">normalization with isoproterenol. 14 pts </text>
<text top="418" left="614" width="249" height="19" font="0">had late AVB – less response to atropine </text>
<text top="436" left="614" width="217" height="19" font="0">(mean 16 bpm). 50% required TPM </text>
<text top="289" left="891" width="205" height="20" font="0">• Descriptive, uncontrolled study </text>
<text top="308" left="891" width="175" height="20" font="0">• No adverse events to drug </text>
<text top="327" left="902" width="108" height="19" font="0">therapy reported </text>
<text top="455" left="96" width="115" height="19" font="0">Sclarovsky S, 1984 </text>
<text top="474" left="96" width="35" height="19" font="0">(161) </text>
<text top="492" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6731277">6731277</a></text>
<text top="492" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6731277"> </a></text>
<text top="455" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="474" left="236" width="127" height="19" font="0">center retrospective </text>
<text top="492" left="236" width="132" height="19" font="0">cohort study in Israel </text>
<text top="510" left="236" width="72" height="19" font="0">1972–1982 </text>
<text top="529" left="236" width="3" height="19" font="0"> </text>
<text top="547" left="236" width="71" height="19" font="8"><b>Size:</b> N=76  </text>
<text top="455" left="398" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="474" left="398" width="136" height="19" font="0">acute inferior MI who </text>
<text top="492" left="398" width="75" height="19" font="0">developed 2</text>
<text top="492" left="473" width="10" height="12" font="7">nd</text>
<text top="492" left="484" width="28" height="19" font="0"> or 3</text>
<text top="492" left="511" width="9" height="12" font="7">rd</text>
<text top="492" left="520" width="78" height="19" font="0"> degree AVB </text>
<text top="510" left="398" width="67" height="19" font="0">in hospital </text>
<text top="529" left="398" width="3" height="19" font="0"> </text>
<text top="547" left="398" width="179" height="19" font="8"><b>Exclusion criteria:</b> Combined </text>
<text top="565" left="398" width="79" height="19" font="0">AMI and IMI </text>
<text top="456" left="614" width="238" height="19" font="8"><b>1</b>°<b> endpoint:</b> Description of outcomes, </text>
<text top="474" left="614" width="243" height="19" font="0">response to atropine and isoproterenol </text>
<text top="493" left="614" width="3" height="19" font="0"> </text>
<text top="511" left="614" width="254" height="19" font="8"><b>Results:</b> 6/14 (36%) of pts with early AVB </text>
<text top="529" left="614" width="239" height="19" font="0">improved vs. 13/17 (77%) pts with late </text>
<text top="548" left="614" width="252" height="19" font="0">AVB (p&lt;0.05). 2/8 (25%) of pts with early </text>
<text top="566" left="614" width="254" height="19" font="0">block and 2/6 (33%). 50% of pts had TPM </text>
<text top="456" left="891" width="201" height="20" font="0">• Descriptive uncontrolled study </text>
<text top="475" left="891" width="175" height="20" font="0">• No adverse events to drug </text>
<text top="494" left="902" width="108" height="19" font="0">therapy reported </text>
<text top="585" left="96" width="111" height="19" font="0">Chihrin SM, et al.  </text>
<text top="603" left="96" width="69" height="19" font="0">2008 (162) </text>
<text top="622" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18308011">18308011</a></text>
<text top="622" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18308011"> </a></text>
<text top="585" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="603" left="236" width="117" height="19" font="0">center prospective </text>
<text top="622" left="236" width="111" height="19" font="0">cohort in Canada  </text>
<text top="640" left="236" width="3" height="19" font="0"> </text>
<text top="658" left="236" width="142" height="19" font="8"><b>Size:</b> N=100; mean age </text>
<text top="677" left="236" width="96" height="19" font="0">75 y; 56% male </text>
<text top="585" left="398" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="603" left="398" width="200" height="19" font="0">pts from 2003–2006 undergoing </text>
<text top="622" left="398" width="173" height="19" font="0">PPM generator change who </text>
<text top="640" left="398" width="128" height="19" font="0">were PM dependent </text>
<text top="658" left="398" width="3" height="19" font="0"> </text>
<text top="677" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="586" left="614" width="255" height="19" font="8"><b>1</b>°<b> endpoint:</b> Elicitation of escape rhythm </text>
<text top="604" left="614" width="201" height="19" font="0">with PM stepdown to 30 bpm or </text>
<text top="623" left="614" width="170" height="19" font="0">isoproterenol 1–2 mcg/min </text>
<text top="641" left="614" width="3" height="19" font="0"> </text>
<text top="659" left="614" width="224" height="19" font="8"><b>Results:</b> 59% demonstrated intrinsic </text>
<text top="677" left="614" width="202" height="19" font="0">rhythm with stepdown alone. Of </text>
<text top="696" left="614" width="257" height="19" font="0">remaining 41 pts, 28 (68%) demonstrated </text>
<text top="714" left="614" width="242" height="19" font="0">intrinsic rhythm with isoproterenol. No </text>
<text top="732" left="614" width="99" height="19" font="0">adverse events. </text>
<text top="585" left="891" width="182" height="20" font="0">• Suggests that isoproterenol </text>
<text top="604" left="902" width="164" height="19" font="0">can be used to elicit faster </text>
<text top="623" left="902" width="170" height="19" font="0">escape rate in pts with AVB </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 125 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="99" height="19" font="0">Hurley KF, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2015 (105) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26593309">26593309</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26593309"> </a></text>
<text top="87" left="236" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="105" left="236" width="104" height="19" font="0">review of 5 RCTs </text>
<text top="123" left="236" width="3" height="19" font="0"> </text>
<text top="142" left="236" width="86" height="19" font="8"><b>Size:</b> N=1254  </text>
<text top="87" left="398" width="160" height="19" font="8"><b>Inclusion criteria: </b>RCTs of </text>
<text top="105" left="398" width="169" height="19" font="0">aminophylline used for pre-</text>
<text top="123" left="398" width="138" height="19" font="0">hospital resuscitate of </text>
<text top="142" left="398" width="180" height="19" font="0">bradyasystolic cardiac arrest  </text>
<text top="160" left="398" width="3" height="19" font="0"> </text>
<text top="178" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="614" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="106" left="614" width="169" height="19" font="0">discharge/admission, ROSC </text>
<text top="124" left="614" width="3" height="19" font="0"> </text>
<text top="143" left="614" width="251" height="19" font="8"><b>Results:</b> No improvement in outcome by </text>
<text top="161" left="614" width="253" height="19" font="0">any measure with aminophylline. Overall </text>
<text top="179" left="614" width="140" height="19" font="0">survival extremely low </text>
<text top="87" left="891" width="183" height="20" font="0">• Aminophylline not useful in </text>
<text top="106" left="903" width="182" height="19" font="0">out of hospital bradyasystolic </text>
<text top="124" left="903" width="39" height="19" font="0">arrest </text>
<text top="198" left="96" width="106" height="19" font="0">Sodeck GH, et al. </text>
<text top="217" left="96" width="62" height="19" font="0">2007 (77) </text>
<text top="235" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976">17212976</a></text>
<text top="235" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976"> </a></text>
<text top="198" left="236" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="217" left="236" width="138" height="19" font="0">Retrospective analysis </text>
<text top="235" left="236" width="124" height="19" font="0">of single ED registry </text>
<text top="253" left="236" width="139" height="19" font="0">from tertiary center in </text>
<text top="272" left="236" width="50" height="19" font="0">Austria  </text>
<text top="290" left="236" width="3" height="19" font="0"> </text>
<text top="308" left="236" width="142" height="19" font="8"><b>Size:</b> N=277; mean age </text>
<text top="326" left="236" width="139" height="19" font="0">68 y; 62% male; about </text>
<text top="345" left="236" width="61" height="19" font="0">50% AVB  </text>
<text top="198" left="398" width="189" height="19" font="8"><b>Inclusion criteria: </b>Consecutive </text>
<text top="217" left="398" width="189" height="19" font="0">pts admitted to ED 1994–2004 </text>
<text top="235" left="398" width="117" height="19" font="0">with symptomatic, </text>
<text top="253" left="398" width="177" height="19" font="0">hemodynamically significant </text>
<text top="272" left="398" width="79" height="19" font="0">bradycardia<b> </b> </text>
<text top="290" left="398" width="3" height="19" font="0"> </text>
<text top="308" left="398" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="326" left="398" width="197" height="19" font="0">Asymptomatic and terminally ill </text>
<text top="345" left="398" width="22" height="19" font="0">pts </text>
<text top="199" left="614" width="261" height="19" font="8"><b>1</b>°<b> endpoint:</b> Use of drugs for bradycardia, </text>
<text top="217" left="614" width="84" height="19" font="0">use of pacing </text>
<text top="236" left="614" width="3" height="19" font="0"> </text>
<text top="254" left="614" width="247" height="19" font="8"><b>Results:</b> IV medications given to 170 pts </text>
<text top="272" left="614" width="189" height="19" font="0">(61%) – Atropine in 141 (51%), </text>
<text top="291" left="614" width="220" height="19" font="0">orciprenaline 62 (22%), epi 24 (9%), </text>
<text top="309" left="614" width="212" height="19" font="0">dopamine 6 (2%). 7 pts had TCP (4 </text>
<text top="327" left="614" width="256" height="19" font="0">successful); 54 (20%) had temporary TVP. </text>
<text top="346" left="614" width="180" height="19" font="0">137/277 (50%) received PPM </text>
<text top="198" left="891" width="169" height="20" font="0">• Descriptive study with no </text>
<text top="217" left="902" width="86" height="19" font="0">control group </text>
<text top="236" left="891" width="183" height="20" font="0">• Pts with AVB not separately </text>
<text top="255" left="902" width="131" height="19" font="0">reported or analyzed </text>
<text top="273" left="891" width="204" height="20" font="0">• Minimal information on clinical </text>
<text top="292" left="902" width="175" height="19" font="0">effects of intervention given </text>
<text top="365" left="96" width="111" height="19" font="0">Bertolet BD, et al. </text>
<text top="383" left="96" width="69" height="19" font="0">1995 (163) </text>
<text top="401" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7661495">7661495</a></text>
<text top="401" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7661495"> </a></text>
<text top="365" left="236" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="383" left="236" width="129" height="19" font="0">center observational </text>
<text top="401" left="236" width="78" height="19" font="0">cohort in US </text>
<text top="420" left="236" width="3" height="19" font="0"> </text>
<text top="438" left="236" width="105" height="19" font="8"><b>Size: </b>N=8; 3 with </text>
<text top="456" left="236" width="93" height="19" font="0">complete AVB  </text>
<text top="365" left="398" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="383" left="398" width="165" height="19" font="0">significant AVB developing </text>
<text top="401" left="398" width="203" height="19" font="0">within 4 h of admission for acute </text>
<text top="420" left="398" width="145" height="19" font="0">inferior MI, resistant to </text>
<text top="438" left="398" width="191" height="19" font="0">atropine, given IV theophylline </text>
<text top="456" left="398" width="84" height="19" font="0">up to 250 mg </text>
<text top="474" left="398" width="3" height="19" font="0"> </text>
<text top="493" left="398" width="165" height="19" font="8"><b>Exclusion criteria:</b> Pts who </text>
<text top="511" left="398" width="167" height="19" font="0">received BBs or CCBs prior  </text>
<text top="365" left="614" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Restoration of 1-1 AV </text>
<text top="384" left="614" width="72" height="19" font="0">conduction </text>
<text top="402" left="614" width="3" height="19" font="0"> </text>
<text top="420" left="614" width="262" height="19" font="8"><b>Results:</b> All 8 pts had restoration of 1-1 AV </text>
<text top="439" left="614" width="261" height="19" font="0">conduction within 3 min lasting at least 24 </text>
<text top="457" left="614" width="11" height="19" font="0">h </text>
<text top="365" left="891" width="85" height="20" font="0">• No controls </text>
<text top="384" left="891" width="164" height="20" font="0">• Very small, single-center </text>
<text top="403" left="902" width="71" height="19" font="0">experience </text>
<text top="530" left="96" width="120" height="19" font="0">Altun A, et al. 1998 </text>
<text top="548" left="96" width="35" height="19" font="0">(164) </text>
<text top="567" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9789698">9789698</a></text>
<text top="567" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9789698"> </a></text>
<text top="530" left="236" width="115" height="19" font="8"><b>Study type: </b>Single-</text>
<text top="548" left="236" width="129" height="19" font="0">center observational </text>
<text top="567" left="236" width="107" height="19" font="0">cohort in Turkey  </text>
<text top="585" left="236" width="3" height="19" font="0"> </text>
<text top="603" left="236" width="105" height="19" font="8"><b>Size:</b> N=8; 6 with </text>
<text top="622" left="236" width="132" height="19" font="0">complete AVB; mean </text>
<text top="640" left="236" width="57" height="19" font="0">age 68 y  </text>
<text top="530" left="398" width="171" height="19" font="8"><b>Inclusion criteria: </b>Pts with 2</text>
<text top="530" left="570" width="10" height="12" font="7">nd</text>
<text top="530" left="580" width="20" height="19" font="0"> or </text>
<text top="548" left="398" width="8" height="19" font="0">3</text>
<text top="548" left="406" width="9" height="12" font="7">rd</text>
<text top="548" left="414" width="171" height="19" font="0"> degree AVB after IMI for at </text>
<text top="567" left="398" width="190" height="19" font="0">least 1 h, resistant to atropine. </text>
<text top="585" left="398" width="194" height="19" font="0">Given 2 doses of aminophylline </text>
<text top="603" left="398" width="110" height="19" font="0">240 mg 1 h apart  </text>
<text top="622" left="398" width="3" height="19" font="0"> </text>
<text top="640" left="398" width="150" height="19" font="8"><b>Exclusion criteria: </b>Pts in </text>
<text top="658" left="398" width="152" height="19" font="0">hyperacute phase of MI, </text>
<text top="677" left="398" width="168" height="19" font="0">received AV nodal blocking </text>
<text top="695" left="398" width="41" height="19" font="0">drugs  </text>
<text top="531" left="614" width="192" height="19" font="8"><b>1</b>°<b> endpoint:</b> Restoration of AV </text>
<text top="549" left="614" width="72" height="19" font="0">conduction </text>
<text top="568" left="614" width="3" height="19" font="0"> </text>
<text top="586" left="614" width="243" height="19" font="8"><b>Results:</b> Aminophylline restored 1-1 AV </text>
<text top="604" left="614" width="258" height="19" font="0">conduction in 7 pts and Mobitz I AVB in 1. </text>
<text top="623" left="614" width="247" height="19" font="0">No adverse effects. AVB relapsed in 1 pt </text>
<text top="641" left="614" width="29" height="19" font="0">only </text>
<text top="659" left="614" width="3" height="19" font="0"> </text>
<text top="530" left="891" width="85" height="20" font="0">• No controls </text>
<text top="549" left="891" width="164" height="20" font="0">• Very small, single-center </text>
<text top="568" left="902" width="71" height="19" font="0">experience </text>
<text top="714" left="96" width="123" height="19" font="0">Goodfellow J, et al.  </text>
<text top="732" left="96" width="69" height="19" font="0">1995 (165) </text>
<text top="751" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7588933">7588933</a></text>
<text top="751" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7588933"> </a></text>
<text top="714" left="236" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="732" left="236" width="127" height="19" font="0">center case series in </text>
<text top="751" left="236" width="102" height="19" font="0">United Kingdom </text>
<text top="769" left="236" width="3" height="19" font="0"> </text>
<text top="714" left="398" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="732" left="398" width="172" height="19" font="0">atropine-resistant AVB with </text>
<text top="751" left="398" width="185" height="19" font="0">acute inferior MI treated with </text>
<text top="715" left="614" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Restoration of 1-1 AV </text>
<text top="733" left="614" width="72" height="19" font="0">conduction </text>
<text top="751" left="614" width="3" height="19" font="0"> </text>
<text top="714" left="891" width="85" height="20" font="0">• No controls </text>
<text top="733" left="891" width="146" height="20" font="0">• Very small case series </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 126 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="236" width="63" height="19" font="8"><b>Size:</b> N=3  </text>
<text top="87" left="398" width="136" height="19" font="0">streptokinase. All had </text>
<text top="105" left="398" width="79" height="19" font="0">hypotension </text>
<text top="123" left="398" width="3" height="19" font="0"> </text>
<text top="142" left="398" width="153" height="19" font="8"><b>Exclusion criteria:</b> None  </text>
<text top="87" left="614" width="224" height="19" font="8"><b>Results:</b> 1-1 AV conduction restored </text>
<text top="105" left="614" width="251" height="19" font="0">promptly with resolution of hypotension </text>
<text top="123" left="614" width="32" height="19" font="0">in all </text>
<text top="142" left="614" width="3" height="19" font="0"> </text>
<text top="161" left="96" width="125" height="19" font="0">Love, JN, et al. 1998 </text>
<text top="179" left="96" width="28" height="19" font="0">(90) </text>
<text top="197" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9674488">9674488</a></text>
<text top="197" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9674488"> </a></text>
<text top="161" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="179" left="236" width="150" height="19" font="0">center case series in US  </text>
<text top="197" left="236" width="3" height="19" font="0"> </text>
<text top="216" left="236" width="63" height="19" font="8"><b>Size:</b> N=9  </text>
<text top="161" left="398" width="202" height="19" font="8"><b>Inclusion criteria:</b> Pts presenting </text>
<text top="179" left="398" width="189" height="19" font="0">with symptomatic bradycardia </text>
<text top="197" left="398" width="192" height="19" font="0">resistant to atropine 1 mg who </text>
<text top="216" left="398" width="178" height="19" font="0">received IV glucagon 1–7 mg </text>
<text top="234" left="398" width="94" height="19" font="0">then 3–5 mg/h </text>
<text top="252" left="398" width="3" height="19" font="0"> </text>
<text top="271" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="162" left="614" width="258" height="19" font="8"><b>1</b>°<b> endpoint:</b> Improvement in bradycardia </text>
<text top="180" left="614" width="122" height="19" font="0">and hemodynamics </text>
<text top="198" left="614" width="3" height="19" font="0"> </text>
<text top="217" left="614" width="204" height="19" font="8"><b>Results:</b> All pts improved at least </text>
<text top="235" left="614" width="69" height="19" font="0">transiently </text>
<text top="253" left="614" width="3" height="19" font="0"> </text>
<text top="161" left="891" width="199" height="20" font="0">• Most pts had BBs and/or CCBs </text>
<text top="180" left="902" width="146" height="19" font="0">as significant co-factors </text>
<text top="198" left="891" width="195" height="20" font="0">• Unknown how many had AVB </text>
<text top="290" left="96" width="108" height="19" font="0">Dhingra RC, et al. </text>
<text top="308" left="96" width="69" height="19" font="0">1973 (166) </text>
<text top="326" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4744693">4744693</a></text>
<text top="326" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4744693"> </a></text>
<text top="290" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="308" left="236" width="87" height="19" font="0">center cohort </text>
<text top="326" left="236" width="144" height="19" font="0">undergoing invasive EP </text>
<text top="345" left="236" width="71" height="19" font="0">study in US </text>
<text top="363" left="236" width="3" height="19" font="0"> </text>
<text top="381" left="236" width="121" height="19" font="8"><b>Size:</b> N=42; 8 with 3</text>
<text top="381" left="357" width="9" height="12" font="7">rd</text>
<text top="381" left="365" width="3" height="19" font="0"> </text>
<text top="400" left="236" width="128" height="19" font="0">degree AVB, 3 with 2</text>
<text top="400" left="364" width="10" height="12" font="7">nd</text>
<text top="400" left="374" width="3" height="19" font="0"> </text>
<text top="418" left="236" width="78" height="19" font="0">degree AVB  </text>
<text top="290" left="398" width="183" height="19" font="8"><b>Inclusion criteria:</b> 42 pts with </text>
<text top="308" left="398" width="158" height="19" font="0">heart disease undergoing </text>
<text top="326" left="398" width="162" height="19" font="0">invasive EPS w/o and with </text>
<text top="345" left="398" width="86" height="19" font="0">isoproterenol </text>
<text top="363" left="398" width="3" height="19" font="0"> </text>
<text top="381" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="291" left="614" width="203" height="19" font="8"><b>1</b>°<b> endpoint:</b> Improvement in AV </text>
<text top="309" left="614" width="258" height="19" font="0">conduction and change in ventricular rate </text>
<text top="327" left="614" width="3" height="19" font="0"> </text>
<text top="345" left="614" width="137" height="19" font="8"><b>Results:</b> 2/8 pts with 3</text>
<text top="345" left="751" width="8" height="12" font="7">rd</text>
<text top="346" left="760" width="104" height="19" font="0"> degree AVB had </text>
<text top="364" left="614" width="254" height="19" font="0">improved conduction with isoproterenol, </text>
<text top="382" left="614" width="124" height="19" font="0">as did 3/3 pts with 3</text>
<text top="382" left="738" width="9" height="12" font="7">rd</text>
<text top="382" left="746" width="82" height="19" font="0"> degree AVB. </text>
<text top="401" left="614" width="247" height="19" font="0">Ventricular rate improved in all subjects </text>
<text top="419" left="614" width="206" height="19" font="0">from mean of 45 bpm to 62 bpm, </text>
<text top="437" left="614" width="159" height="19" font="0">regardless of site of block </text>
<text top="290" left="891" width="118" height="20" font="0">• Very small study  </text>
<text top="309" left="891" width="186" height="20" font="0">• Bias in reflects those able to </text>
<text top="328" left="902" width="80" height="19" font="0">undergo EPS </text>
<text top="347" left="891" width="158" height="20" font="0">• Hemodynamics/ BP not </text>
<text top="365" left="902" width="64" height="19" font="0">measured </text>
<text top="384" left="891" width="194" height="20" font="0">• Suggests isoproterenol useful </text>
<text top="403" left="902" width="161" height="19" font="0">to augment heart rate in 2</text>
<text top="403" left="1063" width="10" height="12" font="7">nd</text>
<text top="403" left="1073" width="3" height="19" font="0"> </text>
<text top="421" left="902" width="34" height="19" font="0">and 3</text>
<text top="421" left="936" width="9" height="12" font="7">rd</text>
<text top="421" left="944" width="78" height="19" font="0"> degree AVB </text>
<text top="456" left="96" width="117" height="19" font="0">Hatle L, et al. 1971 </text>
<text top="474" left="96" width="35" height="19" font="0">(167) </text>
<text top="493" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5557475">5557475</a></text>
<text top="493" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5557475"> </a></text>
<text top="456" left="236" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="474" left="236" width="117" height="19" font="0">center prospective </text>
<text top="493" left="236" width="131" height="19" font="0">cohort from Norway  </text>
<text top="511" left="236" width="3" height="19" font="0"> </text>
<text top="529" left="236" width="128" height="19" font="8"><b>Size:</b> N=105 pts with </text>
<text top="548" left="236" width="51" height="19" font="0">2nd or 3</text>
<text top="548" left="287" width="9" height="12" font="7">rd</text>
<text top="548" left="296" width="78" height="19" font="0"> degree AVB </text>
<text top="566" left="236" width="136" height="19" font="0">in setting of acute MI  </text>
<text top="456" left="398" width="201" height="19" font="8"><b>Inclusion criteria:</b> Pts with acute </text>
<text top="474" left="398" width="178" height="19" font="0">MI treated 1966–1970 with 2</text>
<text top="474" left="577" width="10" height="12" font="7">nd</text>
<text top="474" left="587" width="3" height="19" font="0"> </text>
<text top="493" left="398" width="24" height="19" font="0">or 3</text>
<text top="493" left="422" width="9" height="12" font="7">rd</text>
<text top="493" left="431" width="157" height="19" font="0"> degree AVB treated with </text>
<text top="511" left="398" width="175" height="19" font="0">isoproterenol, generally 1–3 </text>
<text top="529" left="398" width="58" height="19" font="0">mcg/min </text>
<text top="548" left="398" width="3" height="19" font="0"> </text>
<text top="566" left="398" width="195" height="19" font="8"><b>Exclusion criteria:</b> None stated  </text>
<text top="457" left="614" width="251" height="19" font="8"><b>1</b>°<b> endpoint:</b> Improvement in heart rate  </text>
<text top="475" left="614" width="3" height="19" font="0"> </text>
<text top="493" left="614" width="253" height="19" font="8"><b>Results:</b> In hospital mortality 48%. 60 pts </text>
<text top="512" left="614" width="229" height="19" font="0">received isoproterenol: 38 (63%) had </text>
<text top="530" left="614" width="240" height="19" font="0">increase in heart rate and BP; 12 (20%) </text>
<text top="548" left="614" width="245" height="19" font="0">had increased in heart rate but minimal </text>
<text top="567" left="614" width="214" height="19" font="0">change in BP; 8 (13%) had minimal </text>
<text top="585" left="614" width="251" height="19" font="0">change; 2 (3%) isoproterenol terminated </text>
<text top="603" left="614" width="220" height="19" font="0">due to ventricular ectopy. 3 pts had </text>
<text top="622" left="614" width="256" height="19" font="0">ventricular fibrillation on isoproterenol, 1 </text>
<text top="640" left="614" width="251" height="19" font="0">of which died. 14 pts treated with TVP, 3 </text>
<text top="658" left="614" width="256" height="19" font="0">of whom died from ventricular fibrillation </text>
<text top="456" left="891" width="193" height="20" font="0">• Very early cohort when there </text>
<text top="475" left="902" width="167" height="19" font="0">was minimal treatment for </text>
<text top="494" left="902" width="57" height="19" font="0">acute MI </text>
<text top="512" left="891" width="164" height="20" font="0">• Extremely high mortality </text>
<text top="531" left="891" width="181" height="20" font="0">• In this group, isoproterenol </text>
<text top="550" left="902" width="186" height="19" font="0">appeared safe compared with </text>
<text top="568" left="902" width="27" height="19" font="0">TVP </text>
<text top="587" left="891" width="175" height="20" font="0">• Uncontrolled cohort study </text>
<text top="677" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="699" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="722" left="100" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="740" left="131" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="759" left="104" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="722" left="256" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="740" left="262" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="759" left="255" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="722" left="406" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="722" left="568" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="740" left="586" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="759" left="569" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="777" left="591" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="722" left="760" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="740" left="742" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="759" left="746" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="777" left="789" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="723" left="935" width="152" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="741" left="999" width="35" height="19" font="8"><b>any); </b></text>
<text top="759" left="953" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="778" left="961" width="99" height="19" font="8"><b>Adverse Events </b></text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 127 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="97" height="19" font="0">Ferguson JD, et </text>
<text top="105" left="95" width="87" height="19" font="0">al. 1997 (113) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9217762">9217762</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9217762"> </a></text>
<text top="87" left="221" width="155" height="19" font="8"><b>Aim:</b> Compare 2 types of </text>
<text top="105" left="221" width="109" height="19" font="0">TVP catheters for </text>
<text top="123" left="221" width="75" height="19" font="0">success and </text>
<text top="142" left="221" width="116" height="19" font="0">complication rates </text>
<text top="160" left="221" width="3" height="19" font="0"> </text>
<text top="178" left="221" width="141" height="19" font="8"><b>Study type:</b> Unblinded </text>
<text top="197" left="221" width="27" height="19" font="0">RCT </text>
<text top="215" left="221" width="3" height="19" font="0"> </text>
<text top="233" left="221" width="139" height="19" font="8"><b>Size:</b> 40 pts, mean age </text>
<text top="252" left="221" width="121" height="19" font="0">72 y. 85% with AVB </text>
<text top="87" left="392" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="392" width="143" height="19" font="0">Undergoing temporary </text>
<text top="123" left="392" width="132" height="19" font="0">VVI pacing (85% with </text>
<text top="142" left="392" width="96" height="19" font="0">AVB) guided by </text>
<text top="160" left="392" width="75" height="19" font="0">fluoroscopy </text>
<text top="178" left="392" width="3" height="19" font="0"> </text>
<text top="197" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="215" left="392" width="78" height="19" font="0">None stated </text>
<text top="87" left="554" width="128" height="19" font="8"><b>Intervention:</b> Use of </text>
<text top="105" left="554" width="93" height="19" font="0">balloon-tipped </text>
<text top="123" left="554" width="106" height="19" font="0">electrode (N=20) </text>
<text top="142" left="554" width="7" height="19" font="0">  </text>
<text top="160" left="554" width="125" height="19" font="8"><b>Comparator:</b> Use of </text>
<text top="178" left="554" width="125" height="19" font="0">semi-rigid electrode </text>
<text top="197" left="553" width="45" height="19" font="0">(N=20)<b> </b></text>
<text top="88" left="716" width="148" height="19" font="8"><b>1</b>°<b> endpoint:</b> Procedure </text>
<text top="106" left="716" width="146" height="19" font="0">duration (264 vs. 540 s; </text>
<text top="124" left="715" width="191" height="19" font="0">p&lt;0.002), fluoroscopy time (87 </text>
<text top="143" left="715" width="192" height="19" font="0">vs. 189 s; p&lt;0.01), suitability of </text>
<text top="161" left="715" width="184" height="19" font="0">final position (0 unacceptable </text>
<text top="179" left="715" width="174" height="19" font="0">vs. 7; p&lt;0.0001). Thresholds </text>
<text top="198" left="715" width="44" height="19" font="0">similar </text>
<text top="216" left="716" width="3" height="19" font="0"> </text>
<text top="234" left="716" width="187" height="19" font="8"><b>Safety endpoint (if relevant):</b>  </text>
<text top="252" left="716" width="139" height="19" font="0">Dislodgement (1 vs. 3) </text>
<text top="271" left="716" width="91" height="19" font="0">Death (0 vs. 2)<b> </b></text>
<text top="87" left="925" width="114" height="20" font="0">• When guided by </text>
<text top="106" left="936" width="129" height="19" font="0">fluoroscopy, balloon-</text>
<text top="124" left="936" width="127" height="19" font="0">tipped catheters are </text>
<text top="143" left="936" width="92" height="19" font="0">easier to place </text>
<text top="161" left="936" width="140" height="19" font="0">successfully than semi-</text>
<text top="179" left="936" width="91" height="19" font="0">rigid catheters </text>
<text top="198" left="925" width="146" height="20" font="0">• Use of balloon-tipped </text>
<text top="217" left="936" width="153" height="19" font="0">catheter associated with </text>
<text top="235" left="936" width="122" height="19" font="0">trend toward lower </text>
<text top="253" left="936" width="111" height="19" font="0">complication rate </text>
<text top="290" left="95" width="100" height="19" font="0">Barthell E, 1988 </text>
<text top="308" left="95" width="35" height="19" font="0">(127) </text>
<text top="326" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3056132">3056132</a></text>
<text top="326" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3056132"> </a></text>
<text top="290" left="221" width="126" height="19" font="8"><b>Aim:</b> Compared TCP </text>
<text top="308" left="221" width="144" height="19" font="0">added to ACLS vs. ACLS </text>
<text top="326" left="221" width="136" height="19" font="0">alone for pre-hospital </text>
<text top="345" left="221" width="146" height="19" font="0">pts with asystole, EMD, </text>
<text top="363" left="221" width="94" height="19" font="0">or hypotensive </text>
<text top="381" left="221" width="76" height="19" font="0">bradycardia </text>
<text top="400" left="221" width="3" height="19" font="0"> </text>
<text top="418" left="221" width="141" height="19" font="8"><b>Study type:</b> Unblinded </text>
<text top="436" left="221" width="102" height="19" font="0">RCT (alternate d </text>
<text top="455" left="221" width="100" height="19" font="0">randomization)  </text>
<text top="473" left="221" width="3" height="19" font="0"> </text>
<text top="491" left="221" width="136" height="19" font="8"><b>Size:</b> N=239; 142 with </text>
<text top="510" left="221" width="143" height="19" font="0">asystole; 84 with EMD; </text>
<text top="528" left="221" width="127" height="19" font="0">13 with hypotensive </text>
<text top="546" left="221" width="76" height="19" font="0">bradycardia </text>
<text top="290" left="392" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="308" left="392" width="125" height="19" font="0">adult, nontraumatic </text>
<text top="326" left="392" width="147" height="19" font="0">bradyasystolic episodes </text>
<text top="345" left="392" width="129" height="19" font="0">or arrests treated by </text>
<text top="363" left="392" width="118" height="19" font="0">Milwaukee County </text>
<text top="381" left="392" width="140" height="19" font="0">Paramedic System Oct </text>
<text top="400" left="392" width="105" height="19" font="0">1986–May 1987  </text>
<text top="418" left="392" width="3" height="19" font="0"> </text>
<text top="436" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="455" left="392" width="78" height="19" font="0">None stated </text>
<text top="290" left="554" width="123" height="19" font="8"><b>Intervention:</b> TCP + </text>
<text top="308" left="554" width="33" height="19" font="0">ACLS </text>
<text top="326" left="554" width="7" height="19" font="0">  </text>
<text top="345" left="554" width="116" height="19" font="8"><b>Comparator:</b> ACLS </text>
<text top="363" left="554" width="37" height="19" font="0">alone<b> </b></text>
<text top="291" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="309" left="716" width="121" height="19" font="0">hospital admission: </text>
<text top="327" left="716" width="187" height="19" font="0">Asystole/EMD 17% I vs. 20% C </text>
<text top="346" left="715" width="44" height="19" font="0">(p=NS) </text>
<text top="364" left="715" width="180" height="19" font="0">Hypo-brady 100% I vs. 29% C </text>
<text top="382" left="715" width="54" height="19" font="0">(p=0.01) </text>
<text top="401" left="715" width="3" height="19" font="0"> </text>
<text top="419" left="715" width="185" height="19" font="0">Survival to hospital discharge: </text>
<text top="437" left="715" width="172" height="19" font="0">Asystole/EMD 2% I vs. 4% C </text>
<text top="455" left="715" width="44" height="19" font="0">(p=NS) </text>
<text top="474" left="715" width="172" height="19" font="0">Hypo-brady 83% I vs. 14% C </text>
<text top="492" left="715" width="54" height="19" font="0">(p=0.01) </text>
<text top="510" left="715" width="3" height="19" font="0"> </text>
<text top="529" left="716" width="143" height="19" font="8"><b>Safety endpoint:</b> None </text>
<text top="547" left="716" width="3" height="19" font="8"><b> </b></text>
<text top="290" left="925" width="109" height="20" font="0">• Limited form of </text>
<text top="309" left="936" width="92" height="19" font="0">randomization </text>
<text top="327" left="925" width="162" height="20" font="0">• Overall, no effect of TCP </text>
<text top="346" left="936" width="144" height="19" font="0">for pre-hospital use for </text>
<text top="365" left="936" width="127" height="19" font="0">asystole/EMD arrest </text>
<text top="383" left="925" width="132" height="20" font="0">• Possible benefit for </text>
<text top="402" left="936" width="157" height="19" font="0">hypotensive bradycardia, </text>
<text top="420" left="936" width="144" height="19" font="0">but number of pts very </text>
<text top="439" left="936" width="35" height="19" font="0">small </text>
<text top="566" left="95" width="102" height="19" font="0">Cummins RO, et </text>
<text top="584" left="95" width="87" height="19" font="0">al. 1993 (168) </text>
<text top="603" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8474514">8474514</a></text>
<text top="603" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8474514"> </a></text>
<text top="566" left="221" width="151" height="19" font="8"><b>Aim:</b> Determine efficacy </text>
<text top="584" left="221" width="154" height="19" font="0">of TCP of asystolic out of </text>
<text top="603" left="221" width="138" height="19" font="0">hospital cardiac arrest </text>
<text top="621" left="221" width="3" height="19" font="0"> </text>
<text top="639" left="221" width="133" height="19" font="8"><b>Study type:</b> Modified </text>
<text top="658" left="221" width="91" height="19" font="0">RCT by center  </text>
<text top="676" left="221" width="3" height="19" font="0"> </text>
<text top="694" left="221" width="130" height="19" font="8"><b>Size:</b> N=1056 cardiac </text>
<text top="713" left="221" width="123" height="19" font="0">arrests; N=537 with </text>
<text top="731" left="221" width="149" height="19" font="0">asystole as first rhythm; </text>
<text top="749" left="221" width="127" height="19" font="0">N=305 with asystole </text>
<text top="767" left="221" width="52" height="19" font="0">after VF </text>
<text top="566" left="392" width="130" height="19" font="8"><b>Inclusion criteria: </b>All </text>
<text top="584" left="392" width="107" height="19" font="0">cardiac arrests in </text>
<text top="603" left="392" width="128" height="19" font="0">Seattle area over 3 y </text>
<text top="621" left="392" width="138" height="19" font="0">period; Primary group </text>
<text top="639" left="392" width="148" height="19" font="0">was those with asystole </text>
<text top="658" left="392" width="96" height="19" font="0">as first rhythm  </text>
<text top="676" left="392" width="3" height="19" font="0"> </text>
<text top="694" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="713" left="392" width="36" height="19" font="0">None </text>
<text top="566" left="554" width="104" height="19" font="8"><b>Intervention: </b>16 </text>
<text top="584" left="554" width="144" height="19" font="0">EMS/fire districts given </text>
<text top="603" left="554" width="140" height="19" font="0">TCP and trained in use </text>
<text top="621" left="554" width="7" height="19" font="0">  </text>
<text top="639" left="554" width="101" height="19" font="8"><b>Comparator:</b> 23 </text>
<text top="658" left="554" width="144" height="19" font="0">EMS/fire districts given </text>
<text top="676" left="554" width="143" height="19" font="0">TCP and trained in use <b> </b></text>
<text top="567" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="585" left="716" width="174" height="19" font="0">hospital admission/ primary </text>
<text top="603" left="716" width="57" height="19" font="0">asystole: </text>
<text top="622" left="716" width="126" height="19" font="0">8% I vs. 8% C (p=NS) </text>
<text top="640" left="716" width="133" height="19" font="0">Survival to discharge: </text>
<text top="658" left="716" width="186" height="19" font="0">4% I vs. 2% C (OR: 2.05; p=NS) </text>
<text top="677" left="716" width="3" height="19" font="0"> </text>
<text top="695" left="716" width="143" height="19" font="8"><b>Safety endpoint:</b> None </text>
<text top="713" left="716" width="3" height="19" font="8"><b> </b></text>
<text top="566" left="925" width="162" height="20" font="0">• No improvement for pts </text>
<text top="585" left="936" width="86" height="19" font="0">with initial VF </text>
<text top="604" left="925" width="109" height="20" font="0">• Limited form of </text>
<text top="623" left="936" width="92" height="19" font="0">randomization </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 128 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="102" height="19" font="0">Hedges JR, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">1987 (169) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3315295">3315295</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3315295"> </a></text>
<text top="87" left="221" width="151" height="19" font="8"><b>Aim:</b> Determine efficacy </text>
<text top="105" left="221" width="155" height="19" font="0">of TCP added to ACLS for </text>
<text top="123" left="221" width="73" height="19" font="0">prehospital </text>
<text top="142" left="221" width="111" height="19" font="0">hemodynamically </text>
<text top="160" left="221" width="141" height="19" font="0">significant bradycardia </text>
<text top="178" left="221" width="69" height="19" font="0">or asystole </text>
<text top="197" left="221" width="3" height="19" font="0"> </text>
<text top="215" left="221" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="233" left="221" width="97" height="19" font="0">(alternate day)  </text>
<text top="252" left="221" width="3" height="19" font="0"> </text>
<text top="270" left="221" width="75" height="19" font="8"><b>Size: </b>N=202 </text>
<text top="87" left="392" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="105" left="392" width="149" height="19" font="0">pts over 14 y treated by </text>
<text top="123" left="392" width="139" height="19" font="0">Thurston County, EMS </text>
<text top="142" left="392" width="133" height="19" font="0">for hemodynamically-</text>
<text top="160" left="392" width="141" height="19" font="0">significant bradycardia </text>
<text top="178" left="392" width="143" height="19" font="0">with decreased mental </text>
<text top="197" left="392" width="137" height="19" font="0">status (Glasgow coma </text>
<text top="215" left="392" width="67" height="19" font="0">score ≤12) </text>
<text top="233" left="392" width="3" height="19" font="0"> </text>
<text top="252" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="270" left="392" width="78" height="19" font="0">None stated </text>
<text top="87" left="554" width="134" height="19" font="8"><b>Intervention:</b> On odd </text>
<text top="105" left="554" width="121" height="19" font="0">calendar days, EMS </text>
<text top="123" left="554" width="132" height="19" font="0">used TCP 100 bpm at </text>
<text top="142" left="554" width="117" height="19" font="0">max output for pts </text>
<text top="160" left="554" width="7" height="19" font="0">  </text>
<text top="178" left="554" width="137" height="19" font="8"><b>Comparator:</b> On even </text>
<text top="197" left="554" width="144" height="19" font="0">calendar days, TCP was </text>
<text top="215" left="554" width="60" height="19" font="0">not used <b> </b></text>
<text top="88" left="716" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="106" left="716" width="188" height="19" font="0">Survival to hospital admission: </text>
<text top="124" left="716" width="141" height="19" font="0">17% I vs. 17% C (p=NS) </text>
<text top="143" left="716" width="185" height="19" font="0">Survival to hospital discharge: </text>
<text top="161" left="716" width="126" height="19" font="0">6% I vs. 4% C (p=NS) </text>
<text top="179" left="716" width="3" height="19" font="0"> </text>
<text top="197" left="716" width="143" height="19" font="8"><b>Safety endpoint:</b> None </text>
<text top="216" left="716" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="925" width="109" height="20" font="0">• Limited form of </text>
<text top="106" left="936" width="92" height="19" font="0">randomization </text>
<text top="124" left="925" width="149" height="20" font="0">• No improvement with </text>
<text top="143" left="936" width="26" height="19" font="0">TCP </text>
<text top="289" left="95" width="57" height="19" font="8"><b>PrePACE </b></text>
<text top="307" left="95" width="98" height="19" font="0">Morrison, LJ, et </text>
<text top="326" left="95" width="79" height="19" font="0">al. 2008 (86) </text>
<text top="344" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452">17933452</a></text>
<text top="344" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17933452"> </a></text>
<text top="289" left="221" width="108" height="19" font="8"><b>Aim:</b> To compare </text>
<text top="307" left="221" width="126" height="19" font="0">outcome of pts with </text>
<text top="326" left="221" width="129" height="19" font="0">prehospital unstable </text>
<text top="344" left="221" width="152" height="19" font="0">bradycardia with TCP vs. </text>
<text top="362" left="221" width="65" height="19" font="0">dopamine </text>
<text top="381" left="221" width="3" height="19" font="0"> </text>
<text top="399" left="221" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="417" left="221" width="3" height="19" font="0"> </text>
<text top="435" left="221" width="153" height="19" font="8"><b>Size:</b> N=82; mean age 71 </text>
<text top="454" left="221" width="80" height="19" font="0">y; 57% male  </text>
<text top="289" left="392" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="307" left="392" width="81" height="19" font="0">18 y or older </text>
<text top="326" left="392" width="137" height="19" font="0">presenting to Toronto </text>
<text top="344" left="392" width="61" height="19" font="0">EMS with </text>
<text top="362" left="392" width="111" height="19" font="0">hemodynamically </text>
<text top="381" left="392" width="132" height="19" font="0">unstable bradycardia </text>
<text top="399" left="392" width="138" height="19" font="0">unresponsive to fluids </text>
<text top="417" left="392" width="85" height="19" font="0">and atropine  </text>
<text top="436" left="392" width="3" height="19" font="0"> </text>
<text top="454" left="392" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="472" left="392" width="145" height="19" font="0">Trauma, hyperthermia, </text>
<text top="491" left="392" width="133" height="19" font="0">hypothermia, cardiac </text>
<text top="509" left="392" width="43" height="19" font="0">arrest  </text>
<text top="289" left="554" width="130" height="19" font="8"><b>Intervention:</b> TCP 80 </text>
<text top="307" left="554" width="31" height="19" font="0">bpm </text>
<text top="326" left="554" width="7" height="19" font="0">  </text>
<text top="344" left="554" width="149" height="19" font="8"><b>Comparator:</b> Dopamine </text>
<text top="362" left="554" width="115" height="19" font="0">5–20 mcg/kg/min<b>  </b></text>
<text top="290" left="716" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="308" left="716" width="114" height="19" font="0">hospital discharge </text>
<text top="326" left="716" width="141" height="19" font="0">69% I vs. 70% C (p=NS) </text>
<text top="345" left="716" width="3" height="19" font="0"> </text>
<text top="363" left="716" width="110" height="19" font="8"><b>Safety endpoint:</b>  </text>
<text top="381" left="716" width="168" height="19" font="0">VT/VF/cardiac arrest/burn: </text>
<text top="400" left="716" width="153" height="19" font="0">7.1% C vs. 7.5% C (p=NS<b>) </b></text>
<text top="289" left="925" width="148" height="20" font="0">• Half of eligible pts not </text>
<text top="308" left="936" width="76" height="19" font="0">randomized </text>
<text top="327" left="925" width="166" height="20" font="0">• This was a pilot study for </text>
<text top="346" left="936" width="124" height="19" font="0">potential larger RCT </text>
<text top="364" left="925" width="157" height="20" font="0">• No benefit to TCP seen  </text>
<text top="528" left="86" width="3" height="19" font="0"> </text>
<text top="546" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="569" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="587" left="131" width="51" height="19" font="8"><b>Author; </b></text>
<text top="605" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="569" left="238" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="587" left="267" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="569" left="423" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="569" left="619" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="587" left="649" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="605" left="681" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="569" left="880" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="587" left="909" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="625" left="96" width="106" height="19" font="0">Sodeck GH, et al. </text>
<text top="643" left="96" width="62" height="19" font="0">2006 (77) </text>
<text top="661" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976">17212976</a></text>
<text top="661" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17212976"> </a></text>
<text top="624" left="230" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="643" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="661" left="230" width="105" height="19" font="0">cohort in Austria </text>
<text top="680" left="230" width="3" height="19" font="0"> </text>
<text top="698" left="230" width="114" height="19" font="8"><b>Size:</b> 277 pts (62% </text>
<text top="716" left="230" width="100" height="19" font="0">male, 48% AVB) </text>
<text top="624" left="385" width="170" height="19" font="8"><b>Inclusion criteria:</b> Pts &gt;18 y </text>
<text top="643" left="385" width="135" height="19" font="0">presenting to ED with </text>
<text top="661" left="385" width="172" height="19" font="0">“compromising bradycardia </text>
<text top="680" left="385" width="183" height="19" font="0">from 1994–2004; mean heart </text>
<text top="698" left="385" width="78" height="19" font="0">rate 33 bpm </text>
<text top="716" left="385" width="3" height="19" font="0"> </text>
<text top="734" left="385" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="753" left="385" width="171" height="19" font="0">Asymptomatic bradycardia, </text>
<text top="771" left="385" width="96" height="19" font="0">terminal illness </text>
<text top="625" left="594" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> 30 d mortality </text>
<text top="644" left="594" width="3" height="19" font="0"> </text>
<text top="662" left="594" width="228" height="19" font="8"><b>Results:</b> 5% mortality at 30 d. 20% of </text>
<text top="680" left="594" width="230" height="19" font="0">pts treated with temporary TVP. 50% </text>
<text top="699" left="594" width="178" height="19" font="0">of those pts went on to have </text>
<text top="717" left="594" width="115" height="19" font="0">permanent pacing </text>
<text top="735" left="594" width="3" height="19" font="0"> </text>
<text top="625" left="844" width="179" height="20" font="0">• Temporary TVP required in </text>
<text top="644" left="855" width="192" height="19" font="0">about 20% of pts presenting to </text>
<text top="662" left="855" width="133" height="19" font="0">ED with symptomatic </text>
<text top="680" left="855" width="76" height="19" font="0">bradycardia </text>
<text top="699" left="844" width="200" height="20" font="0">• Half of those pts go on to PPM </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 129 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="116" height="19" font="0">Brikhahn RH, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2004 (170) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15039689">15039689</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15039689"> </a></text>
<text top="87" left="230" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="105" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="123" left="230" width="78" height="19" font="0">cohort in US </text>
<text top="142" left="230" width="3" height="19" font="0"> </text>
<text top="160" left="230" width="110" height="19" font="8"><b>Size:</b> 154 pts, 117 </text>
<text top="178" left="230" width="117" height="19" font="0">meeting inclusion/ </text>
<text top="197" left="230" width="111" height="19" font="0">exclusion criteria. </text>
<text top="215" left="230" width="126" height="19" font="0">Mean age 78 y, 38% </text>
<text top="233" left="230" width="100" height="19" font="0">male, 51% AVB) </text>
<text top="87" left="385" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="105" left="385" width="177" height="19" font="0">temporary TVP placed in ED, </text>
<text top="123" left="385" width="171" height="19" font="0">intensive care unit, or ward </text>
<text top="142" left="385" width="172" height="19" font="0">1999–2002. Only 3% placed </text>
<text top="160" left="385" width="118" height="19" font="0">under fluoroscopy  </text>
<text top="178" left="385" width="3" height="19" font="0"> </text>
<text top="197" left="385" width="178" height="19" font="8"><b>Exclusion criteria:</b> Indication </text>
<text top="215" left="385" width="188" height="19" font="0">asystole, TVP placed in cath or </text>
<text top="233" left="385" width="126" height="19" font="0">EP lab, no attending </text>
<text top="252" left="385" width="73" height="19" font="0">supervision </text>
<text top="88" left="594" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Successful temporary </text>
<text top="106" left="594" width="215" height="19" font="0">TVP placement. Complication rate. </text>
<text top="124" left="594" width="3" height="19" font="0"> </text>
<text top="143" left="594" width="234" height="19" font="8"><b>Results:</b> 88% success on first attempt. </text>
<text top="161" left="594" width="220" height="19" font="0">17% serious complication rate. 96% </text>
<text top="179" left="594" width="235" height="19" font="0">placed by cephalic approach. 67% had </text>
<text top="198" left="594" width="192" height="19" font="0">PPM. 23% in-hospital mortality </text>
<text top="216" left="594" width="3" height="19" font="0"> </text>
<text top="87" left="844" width="196" height="20" font="0">• Similar success rates between </text>
<text top="106" left="855" width="192" height="19" font="0">ED physicians and cardiologists </text>
<text top="124" left="844" width="180" height="20" font="0">• High overall success rate of </text>
<text top="143" left="855" width="124" height="19" font="0">implantation of TVP </text>
<text top="162" left="844" width="189" height="20" font="0">• Cephalic route rarely used in </text>
<text top="181" left="855" width="140" height="19" font="0">general practice today </text>
<text top="271" left="96" width="91" height="19" font="0">Betts TR, 2003 </text>
<text top="289" left="96" width="35" height="19" font="0">(119) </text>
<text top="307" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12954959">12954959</a></text>
<text top="307" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12954959"> </a></text>
<text top="271" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="289" left="230" width="139" height="19" font="0">Prospective registry in </text>
<text top="307" left="230" width="137" height="19" font="0">5 regional hospitals in </text>
<text top="326" left="230" width="101" height="19" font="0">England in 1999 </text>
<text top="344" left="230" width="3" height="19" font="0"> </text>
<text top="362" left="230" width="131" height="19" font="8"><b>Size:</b> 144 procedures </text>
<text top="381" left="230" width="130" height="19" font="0">in 111 pts; mean age </text>
<text top="399" left="230" width="133" height="19" font="0">75 y.; 63% male; 51% </text>
<text top="417" left="230" width="32" height="19" font="0">AVB  </text>
<text top="271" left="385" width="163" height="19" font="8"><b>Inclusion criteria:</b> All TVPs </text>
<text top="289" left="385" width="167" height="19" font="0">placed over 9 mo period in </text>
<text top="307" left="385" width="34" height="19" font="0">1999 </text>
<text top="326" left="385" width="3" height="19" font="0"> </text>
<text top="344" left="385" width="183" height="19" font="8"><b>Exclusion criteria:</b> None cited </text>
<text top="271" left="594" width="208" height="19" font="8"><b>1</b>°<b> endpoint:</b> General overview of </text>
<text top="290" left="594" width="203" height="19" font="0">procedure technique, outcomes, </text>
<text top="308" left="594" width="88" height="19" font="0">complications </text>
<text top="326" left="594" width="3" height="19" font="0"> </text>
<text top="345" left="594" width="225" height="19" font="8"><b>Results:</b> Procedure times shorter for </text>
<text top="363" left="594" width="227" height="19" font="0">cardiologists, 28% complication rate. </text>
<text top="381" left="594" width="224" height="19" font="0">Immediate complication rates lower </text>
<text top="400" left="594" width="162" height="19" font="0">with experience (1/81) vs. </text>
<text top="418" left="594" width="198" height="19" font="0">inexperienced (5/59) operators. </text>
<text top="436" left="594" width="226" height="19" font="0">Infection occurred more in wires left </text>
<text top="455" left="594" width="214" height="19" font="0">in &gt;48 h (17/86) than &lt;48 h (2/55). </text>
<text top="473" left="594" width="208" height="19" font="0">23% of comps resulted in delayed </text>
<text top="491" left="594" width="32" height="19" font="0">PPM </text>
<text top="510" left="594" width="3" height="19" font="0"> </text>
<text top="271" left="844" width="208" height="20" font="0">• Suggests benefit to TVP implant </text>
<text top="290" left="855" width="182" height="19" font="0">by cardiologists/ experienced </text>
<text top="308" left="855" width="63" height="19" font="0">operators </text>
<text top="327" left="844" width="192" height="20" font="0">• Greater infection risk for TVP </text>
<text top="346" left="855" width="112" height="19" font="0">wires left in &gt;48 h </text>
<text top="364" left="844" width="131" height="20" font="0">• High rate of overall </text>
<text top="383" left="855" width="120" height="19" font="0">complications seen </text>
<text top="402" left="844" width="183" height="20" font="0">• 23% of comps delayed PPM </text>
<text top="420" left="855" width="82" height="19" font="0">implantation </text>
<text top="529" left="96" width="119" height="19" font="0">Mahapatra S, et al. </text>
<text top="547" left="96" width="69" height="19" font="0">2005 (171) </text>
<text top="565" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16171740">16171740</a></text>
<text top="565" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16171740"> </a></text>
<text top="529" left="230" width="107" height="19" font="8"><b>Study type:</b> Case-</text>
<text top="547" left="230" width="130" height="19" font="0">control derived from </text>
<text top="565" left="230" width="134" height="19" font="0">prospective database </text>
<text top="584" left="230" width="125" height="19" font="0">1995–2003 at Mayo </text>
<text top="602" left="230" width="36" height="19" font="0">Clinic </text>
<text top="620" left="230" width="3" height="19" font="0"> </text>
<text top="638" left="230" width="103" height="19" font="8"><b>Size:</b> 50 pts with </text>
<text top="657" left="230" width="120" height="19" font="0">cardiac perforation </text>
<text top="675" left="230" width="111" height="19" font="0">after PPM vs. 100 </text>
<text top="693" left="230" width="56" height="19" font="0">controls  </text>
<text top="529" left="385" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="547" left="385" width="177" height="19" font="0">undergoing PPM 1995–2003 </text>
<text top="565" left="385" width="159" height="19" font="0">with perforation and new </text>
<text top="584" left="385" width="57" height="19" font="0">effusion. </text>
<text top="602" left="385" width="3" height="19" font="0"> </text>
<text top="620" left="385" width="180" height="19" font="8"><b>Exclusion criteria:</b> Age &lt;18 y, </text>
<text top="638" left="385" width="150" height="19" font="0">prior effusion or cardiac </text>
<text top="657" left="385" width="170" height="19" font="0">surgery within 4 wk of PPM </text>
<text top="529" left="594" width="176" height="19" font="8"><b>1</b>°<b> endpoint:</b> Risk factors for </text>
<text top="548" left="594" width="138" height="19" font="0">perforation after PPM </text>
<text top="566" left="594" width="3" height="19" font="0"> </text>
<text top="584" left="594" width="167" height="19" font="8"><b>Results:</b> 1.2% of all pts had </text>
<text top="603" left="594" width="232" height="19" font="0">perforation. Predictors of perforation </text>
<text top="621" left="594" width="232" height="19" font="0">in multivariate analysis included prior </text>
<text top="639" left="594" width="231" height="19" font="0">TVP (HR: 2.7; 95% CI: 1.4–3.9], helical </text>
<text top="658" left="594" width="235" height="19" font="0">screw leads (HR: 2.5), steroid use (HR: </text>
<text top="676" left="594" width="27" height="19" font="0">3.2) </text>
<text top="694" left="594" width="3" height="19" font="0"> </text>
<text top="529" left="844" width="186" height="20" font="0">• Suggests benefit to avoiding </text>
<text top="548" left="855" width="191" height="19" font="0">TVP prior to permanent pacing </text>
<text top="566" left="855" width="99" height="19" font="0">unless essential </text>
<text top="713" left="96" width="118" height="19" font="0">Lang R, et al.  1981 </text>
<text top="732" left="96" width="35" height="19" font="0">(172) </text>
<text top="750" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6169032">6169032</a></text>
<text top="750" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6169032"> </a></text>
<text top="713" left="230" width="115" height="19" font="8"><b>Study type: </b>Single-</text>
<text top="732" left="230" width="43" height="19" font="0">center </text>
<text top="750" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="768" left="230" width="103" height="19" font="0">controlled study </text>
<text top="713" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="732" left="385" width="169" height="19" font="0">pts requiring emergency or </text>
<text top="750" left="385" width="188" height="19" font="0">semi-urgent temporary TVP at </text>
<text top="768" left="385" width="132" height="19" font="0">a single Israeli center </text>
<text top="714" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Successful implant, </text>
<text top="732" left="594" width="221" height="19" font="0">procedure time, threshold, multiple </text>
<text top="751" left="594" width="105" height="19" font="0">safety endpoints </text>
<text top="769" left="594" width="3" height="19" font="0"> </text>
<text top="713" left="844" width="194" height="20" font="0">• Superiority of balloon-tipped, </text>
<text top="732" left="855" width="192" height="19" font="0">flow guided electrode catheter </text>
<text top="751" left="855" width="116" height="19" font="0">for temporary TVP </text>
<text top="769" left="855" width="94" height="19" font="0">demonstrated. </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 130 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="119" height="19" font="0">comparing balloon-</text>
<text top="105" left="230" width="123" height="19" font="0">tipped, flow-guided </text>
<text top="123" left="229" width="138" height="19" font="0">TVP vs. standard semi-</text>
<text top="142" left="229" width="89" height="19" font="0">rigid catheter  </text>
<text top="160" left="230" width="3" height="19" font="0"> </text>
<text top="178" left="230" width="134" height="19" font="8"><b>Size:</b> 111 consecutive </text>
<text top="197" left="230" width="125" height="19" font="0">pts (67 flow-guided, </text>
<text top="215" left="230" width="90" height="19" font="0">44 semi-rigid)  </text>
<text top="87" left="385" width="3" height="19" font="0"> </text>
<text top="105" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="87" left="594" width="200" height="19" font="8"><b>Results:</b> Flow-guided TVP had 1) </text>
<text top="105" left="594" width="218" height="19" font="0">shorter insertion time (7 min vs. 14 </text>
<text top="123" left="594" width="202" height="19" font="0">min); less dislodgement (13% vs. </text>
<text top="142" left="594" width="200" height="19" font="0">32%), lower incidence of serious </text>
<text top="160" left="594" width="233" height="19" font="0">ventricular arrhythmia (1.5 vs. 20.4%) </text>
<text top="178" left="594" width="118" height="19" font="0">Thresholds similar. </text>
<text top="234" left="96" width="94" height="19" font="0">Hynes JK, et al. </text>
<text top="252" left="96" width="69" height="19" font="0">1983 (115) </text>
<text top="271" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157">6823157</a></text>
<text top="271" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157"> </a></text>
<text top="234" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="252" left="230" width="127" height="19" font="0">Retrospective single-</text>
<text top="271" left="230" width="140" height="19" font="0">center cohort at Mayo </text>
<text top="289" left="230" width="36" height="19" font="0">Clinic </text>
<text top="307" left="230" width="3" height="19" font="0"> </text>
<text top="326" left="230" width="129" height="19" font="8"><b>Size:</b> 1022 pts, mean </text>
<text top="344" left="230" width="129" height="19" font="0">age 68 y, (65% male) </text>
<text top="234" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="252" left="385" width="190" height="19" font="0">pts undergoing temporary TVP </text>
<text top="271" left="385" width="177" height="19" font="0">wire in Mayo Clinic coronary </text>
<text top="289" left="385" width="118" height="19" font="0">care unit 1976–81. </text>
<text top="307" left="385" width="3" height="19" font="0"> </text>
<text top="326" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="235" left="594" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications </text>
<text top="253" left="594" width="3" height="19" font="0"> </text>
<text top="271" left="594" width="223" height="19" font="8"><b>Results:</b> Implanted mean 3.1 d, 64% </text>
<text top="290" left="594" width="186" height="19" font="0">placed antecubital route, 19% </text>
<text top="308" left="594" width="229" height="19" font="0">subclavian vein, 12 % internal jugular </text>
<text top="326" left="594" width="188" height="19" font="0">vein. 13.7% complication rate, </text>
<text top="345" left="594" width="198" height="19" font="0">increasing with duration of TVP. </text>
<text top="363" left="594" width="194" height="19" font="0">Lowest comp rate with internal </text>
<text top="381" left="594" width="215" height="19" font="0">jugular vein 5.3% pericarditis. PPM </text>
<text top="400" left="594" width="151" height="19" font="0">implanted in 58% of pts. </text>
<text top="234" left="844" width="199" height="20" font="0">• Preference for internal jugular </text>
<text top="253" left="855" width="170" height="19" font="0">rand subclavian vein access </text>
<text top="272" left="855" width="97" height="19" font="0">sites confirmed </text>
<text top="419" left="96" width="85" height="19" font="0">Winner S and </text>
<text top="437" left="96" width="86" height="19" font="0">Boon N, 1989 </text>
<text top="455" left="96" width="35" height="19" font="0">(173) </text>
<text top="474" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2769615">2769615</a></text>
<text top="474" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2769615"> </a></text>
<text top="419" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="437" left="230" width="126" height="19" font="0">Retrospective single </text>
<text top="455" left="230" width="123" height="19" font="0">region cohort study </text>
<text top="474" left="230" width="3" height="19" font="0"> </text>
<text top="492" left="230" width="112" height="19" font="8"><b>Size: </b>266 pts/ 158 </text>
<text top="510" left="230" width="133" height="19" font="0">(59%) had temporary </text>
<text top="529" left="230" width="30" height="19" font="0">TVP  </text>
<text top="419" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="437" left="385" width="188" height="19" font="0">pts referred to regional center </text>
<text top="455" left="385" width="53" height="19" font="0">for PPM </text>
<text top="474" left="385" width="3" height="19" font="0"> </text>
<text top="492" left="385" width="163" height="19" font="8"><b>Exclusion criteria:</b> Missing </text>
<text top="510" left="385" width="49" height="19" font="0">records </text>
<text top="419" left="594" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, defined </text>
<text top="438" left="594" width="224" height="19" font="0">as “major problems”: dislodgement, </text>
<text top="456" left="594" width="212" height="19" font="0">infection, pericarditis/perforation, </text>
<text top="474" left="594" width="201" height="19" font="0">thrombosis, wire in left ventricle </text>
<text top="493" left="594" width="3" height="19" font="0"> </text>
<text top="511" left="594" width="230" height="19" font="8"><b>Results:</b> 36% rate of major problems, </text>
<text top="529" left="594" width="221" height="19" font="0">much higher rate at smaller referral </text>
<text top="548" left="594" width="233" height="19" font="0">hospitals. 6% infection; 30% failure to </text>
<text top="566" left="594" width="130" height="19" font="0">pace, 4% pericarditis </text>
<text top="419" left="844" width="180" height="20" font="0">• Advise avoiding TVP before </text>
<text top="438" left="855" width="140" height="19" font="0">PPM unless absolutely </text>
<text top="456" left="855" width="64" height="19" font="0">necessary </text>
<text top="585" left="96" width="114" height="19" font="0">López Ayerbe J, et </text>
<text top="603" left="96" width="21" height="19" font="0">al.  </text>
<text top="622" left="96" width="69" height="19" font="0">2004 (114) </text>
<text top="640" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15544753">15544753</a></text>
<text top="640" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15544753"> </a></text>
<text top="585" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="603" left="230" width="126" height="19" font="0">Retrospective single </text>
<text top="622" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="640" left="230" width="108" height="19" font="0">Barcelona, Spain  </text>
<text top="658" left="230" width="3" height="19" font="0"> </text>
<text top="677" left="230" width="142" height="19" font="8"><b>Size: </b>N=530; mean age </text>
<text top="695" left="230" width="129" height="19" font="0">74 y, 54% male; 51% </text>
<text top="713" left="230" width="36" height="19" font="0">AVB.  </text>
<text top="585" left="385" width="192" height="19" font="8"><b>Inclusion criteria:</b> Pts receiving </text>
<text top="603" left="385" width="193" height="19" font="0">TVP 1997–2003. All via femoral </text>
<text top="622" left="385" width="184" height="19" font="0">route (99%) with fluoroscopic </text>
<text top="640" left="385" width="62" height="19" font="0">guidance  </text>
<text top="658" left="385" width="3" height="19" font="0"> </text>
<text top="677" left="385" width="135" height="19" font="8"><b>Exclusion criteria: </b>Pts </text>
<text top="695" left="385" width="146" height="19" font="0">transferred out with no </text>
<text top="713" left="385" width="126" height="19" font="0">available f-u (N=38)  </text>
<text top="586" left="594" width="175" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, </text>
<text top="604" left="594" width="64" height="19" font="0">outcomes </text>
<text top="623" left="594" width="3" height="19" font="0"> </text>
<text top="641" left="594" width="214" height="19" font="8"><b>Results:</b> Mean duration 4.2 d. 22% </text>
<text top="659" left="594" width="191" height="19" font="0">complication rate: 1% death (3 </text>
<text top="677" left="594" width="189" height="19" font="0">tamponade, 1 asystole, 1 PE, 1 </text>
<text top="696" left="594" width="225" height="19" font="0">sepsis). 9% migration/dislodgement’ </text>
<text top="714" left="594" width="212" height="19" font="0">9% other (VTE, effusion, infection) </text>
<text top="585" left="844" width="191" height="20" font="0">• Complication rates improved </text>
<text top="604" left="855" width="168" height="19" font="0">compared with series from </text>
<text top="623" left="855" width="167" height="19" font="0">1980s and 1990s (18–43%) </text>
<text top="641" left="844" width="201" height="20" font="0">• Lower use in pts with acute MI </text>
<text top="660" left="855" width="32" height="19" font="0">seen </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 131 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="119" height="19" font="0">Bjornstad CC, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2012 (126) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22390277">22390277</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22390277"> </a></text>
<text top="87" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="105" left="230" width="139" height="19" font="0">Prospective regional 5 </text>
<text top="123" left="230" width="104" height="19" font="0">hospital study in </text>
<text top="142" left="230" width="115" height="19" font="0">Norway 2010–11.  </text>
<text top="160" left="230" width="3" height="19" font="0"> </text>
<text top="178" left="230" width="134" height="19" font="8"><b>Size:</b> N=50; 45% AVB; </text>
<text top="197" left="230" width="125" height="19" font="0">mean age 79 y, 62% </text>
<text top="215" left="230" width="37" height="19" font="0">male  </text>
<text top="87" left="385" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="105" left="385" width="191" height="19" font="0">TVP in 5 hospitals March 2010–</text>
<text top="123" left="385" width="130" height="19" font="0">March 2011. All with </text>
<text top="142" left="385" width="75" height="19" font="0">fluoroscopy </text>
<text top="160" left="385" width="3" height="19" font="0"> </text>
<text top="178" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="88" left="594" width="175" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, </text>
<text top="106" left="594" width="64" height="19" font="0">outcomes </text>
<text top="124" left="594" width="3" height="19" font="0"> </text>
<text top="143" left="594" width="194" height="19" font="8"><b>Results:</b> 96% TVP; 4% TCP. 60% </text>
<text top="161" left="594" width="228" height="19" font="0">received PPM; 14% died. 30% rate of </text>
<text top="179" left="594" width="228" height="19" font="0">“serious complications” including 6% </text>
<text top="198" left="594" width="112" height="19" font="0">death from sepsis </text>
<text top="87" left="844" width="209" height="20" font="0">• Fewer TVPs being performed by </text>
<text top="106" left="855" width="159" height="19" font="0">more physicians with less </text>
<text top="124" left="855" width="71" height="19" font="0">experience </text>
<text top="143" left="844" width="193" height="20" font="0">• Lower complication rate with </text>
<text top="162" left="855" width="183" height="19" font="0">more experienced implanters </text>
<text top="234" left="96" width="102" height="19" font="0">McCann P, 2006 </text>
<text top="252" left="96" width="35" height="19" font="0">(125) </text>
<text top="271" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17235372">17235372</a></text>
<text top="271" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17235372"> </a></text>
<text top="234" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="252" left="230" width="114" height="19" font="0">Systematic review </text>
<text top="271" left="230" width="75" height="19" font="0">1973–2004  </text>
<text top="289" left="230" width="3" height="19" font="0"> </text>
<text top="307" left="230" width="101" height="19" font="8"><b>Size:</b> 15 studies; </text>
<text top="326" left="230" width="137" height="19" font="0">N=3737; mean age 71 </text>
<text top="344" left="230" width="14" height="19" font="0">y  </text>
<text top="234" left="385" width="157" height="19" font="8"><b>Inclusion criteria:</b> Cohort </text>
<text top="252" left="385" width="191" height="19" font="0">studies of TVP published 1973–</text>
<text top="271" left="385" width="34" height="19" font="0">2004 </text>
<text top="289" left="385" width="3" height="19" font="0"> </text>
<text top="307" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="235" left="594" width="175" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications, </text>
<text top="253" left="594" width="64" height="19" font="0">outcomes </text>
<text top="272" left="594" width="3" height="19" font="0"> </text>
<text top="290" left="594" width="210" height="19" font="8"><b>Results:</b> Overall complication rate </text>
<text top="308" left="594" width="224" height="19" font="0">26.5%: 15% failed access, 10% failed </text>
<text top="326" left="594" width="206" height="19" font="0">placement, 9% sepsis, 4% arterial </text>
<text top="345" left="594" width="196" height="19" font="0">puncture, 2% lung/myocardium </text>
<text top="363" left="594" width="59" height="19" font="0">puncture </text>
<text top="234" left="844" width="166" height="20" font="0">• Methodologically limited </text>
<text top="253" left="855" width="113" height="19" font="0">systematic review </text>
<text top="272" left="844" width="180" height="20" font="0">• Higher complication rate in </text>
<text top="291" left="855" width="57" height="19" font="0">older pts </text>
<text top="309" left="844" width="200" height="20" font="0">• Lower complication rate when </text>
<text top="328" left="855" width="149" height="19" font="0">implanted by specialists </text>
<text top="347" left="844" width="186" height="20" font="0">• Trend toward greater use of </text>
<text top="365" left="855" width="171" height="19" font="0">right internal jugular access </text>
<text top="384" left="855" width="62" height="19" font="0">over time </text>
<text top="403" left="96" width="112" height="19" font="0">Jou YL, et al. 2010 </text>
<text top="421" left="96" width="35" height="19" font="0">(124) </text>
<text top="439" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20946290">20946290</a></text>
<text top="439" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20946290"> </a></text>
<text top="403" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="421" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="439" left="230" width="106" height="19" font="0">cohort in Taiwan </text>
<text top="458" left="230" width="52" height="19" font="0">2002–8  </text>
<text top="476" left="230" width="3" height="19" font="0"> </text>
<text top="494" left="230" width="142" height="19" font="8"><b>Size: </b>N=509; mean age </text>
<text top="513" left="230" width="129" height="19" font="0">77 y, 74% male; 64% </text>
<text top="531" left="230" width="32" height="19" font="0">AVB  </text>
<text top="403" left="385" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="421" left="385" width="169" height="19" font="0">TVP 2002 8 at single center </text>
<text top="439" left="385" width="3" height="19" font="0"> </text>
<text top="458" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="404" left="594" width="166" height="19" font="8"><b>1</b>°<b> endpoint:</b> Trends in use </text>
<text top="422" left="594" width="3" height="19" font="0"> </text>
<text top="440" left="594" width="208" height="19" font="8"><b>Results:</b> Greater use for AVB with </text>
<text top="459" left="594" width="220" height="19" font="0">intrinsic disease, less for sinus node </text>
<text top="477" left="594" width="216" height="19" font="0">dysfunction and MI over time. 48% </text>
<text top="495" left="594" width="233" height="19" font="0">had PPM implant within 30 d (mean 6 </text>
<text top="514" left="594" width="206" height="19" font="0">d) with increasing rate over time. </text>
<text top="532" left="594" width="3" height="19" font="0"> </text>
<text top="403" left="844" width="139" height="20" font="0">• High rate of PPM for </text>
<text top="422" left="855" width="112" height="19" font="0">degenerative AVB </text>
<text top="551" left="96" width="118" height="19" font="0">Knudsen MB, et al. </text>
<text top="569" left="96" width="69" height="19" font="0">2013 (150) </text>
<text top="588" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746">23869746</a></text>
<text top="588" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746"> </a></text>
<text top="551" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="569" left="230" width="127" height="19" font="0">Retrospective single-</text>
<text top="588" left="230" width="102" height="19" font="0">center cohort at </text>
<text top="606" left="230" width="112" height="19" font="0">academic medical </text>
<text top="624" left="230" width="117" height="19" font="0">center in Denmark </text>
<text top="642" left="230" width="64" height="19" font="0">2000–11.  </text>
<text top="661" left="230" width="3" height="19" font="0"> </text>
<text top="679" left="230" width="137" height="19" font="8"><b>Size:</b> N=575 with TVP. </text>
<text top="697" left="230" width="121" height="19" font="0">N=55 with AVB and </text>
<text top="716" left="230" width="137" height="19" font="0">potential culprit drug. </text>
<text top="734" left="230" width="126" height="19" font="0">Mean age 77 y, 56% </text>
<text top="752" left="230" width="37" height="19" font="0">male  </text>
<text top="551" left="385" width="180" height="19" font="8"><b>Inclusion criteria:</b> Pts getting </text>
<text top="569" left="385" width="170" height="19" font="0">TVP wire 2000–11 who had </text>
<text top="588" left="385" width="188" height="19" font="0">AVB and potential culprit drug </text>
<text top="606" left="385" width="86" height="19" font="0">discontinued  </text>
<text top="624" left="385" width="3" height="19" font="0"> </text>
<text top="642" left="385" width="163" height="19" font="8"><b>Exclusion criteria:</b> No ECG </text>
<text top="661" left="385" width="191" height="19" font="0">documentation; other etiology </text>
<text top="679" left="385" width="177" height="19" font="0">of bradycardia documented; </text>
<text top="697" left="385" width="160" height="19" font="0">PPM infection; in hospital </text>
<text top="716" left="385" width="39" height="19" font="0">death </text>
<text top="552" left="594" width="198" height="19" font="8"><b>1</b>°<b> endpoint:</b> Indication for PPM </text>
<text top="570" left="594" width="182" height="19" font="0">despite drug discontinuation; </text>
<text top="588" left="594" width="182" height="19" font="0">complications and outcomes  </text>
<text top="607" left="594" width="3" height="19" font="0"> </text>
<text top="625" left="594" width="195" height="19" font="8"><b>Results:</b> 49/55 (89%) ultimately </text>
<text top="643" left="594" width="228" height="19" font="0">required PPM, including 26/27 (96%) </text>
<text top="662" left="594" width="208" height="19" font="0">on BBs. 11% comp rate from TVP. </text>
<text top="680" left="594" width="230" height="19" font="0">PPM postponed mean of 7 d for drug </text>
<text top="698" left="594" width="72" height="19" font="0">withdrawal </text>
<text top="551" left="844" width="154" height="20" font="0">• Authors conclude that: </text>
<text top="570" left="855" width="171" height="19" font="0">“Primary PPM implantation </text>
<text top="588" left="855" width="171" height="19" font="0">should be considered in pts </text>
<text top="607" left="855" width="162" height="19" font="0">with high-degree AVB and </text>
<text top="625" left="855" width="155" height="19" font="0">concomitant AV blocking </text>
<text top="643" left="855" width="197" height="19" font="0">therapy, unless other reversible </text>
<text top="662" left="855" width="93" height="19" font="0">causes…exist.” </text>
<text top="680" left="844" width="176" height="20" font="0">•  “In the elderly, the drug is </text>
<text top="699" left="855" width="189" height="19" font="0">virtually never the sole culprit; </text>
<text top="717" left="855" width="159" height="19" font="0">rather, it just exposes the </text>
<text top="736" left="855" width="171" height="19" font="0">underlying weakness of the </text>
<text top="754" left="855" width="154" height="19" font="0">aging conduction system </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 132 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="102" height="19" font="0">Murphy JJ, 1996 </text>
<text top="105" left="96" width="35" height="19" font="0">(116) </text>
<text top="123" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=620131">8620131</a></text>
<text top="123" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=620131"> </a></text>
<text top="87" left="230" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="105" left="230" width="133" height="19" font="0">Prospective cohort in </text>
<text top="123" left="230" width="91" height="19" font="0">18 hospitals in </text>
<text top="142" left="230" width="112" height="19" font="0">Northern England </text>
<text top="160" left="230" width="68" height="19" font="0">over 6 mo  </text>
<text top="178" left="230" width="3" height="19" font="0"> </text>
<text top="197" left="230" width="118" height="19" font="8"><b>Size:</b> N=194. Mean </text>
<text top="215" left="230" width="129" height="19" font="0">age 71 y; AVB (67%). </text>
<text top="233" left="230" width="103" height="19" font="0">Acute MI in 53% </text>
<text top="87" left="385" width="157" height="19" font="8"><b>Inclusion criteria:</b> All TVP </text>
<text top="105" left="385" width="151" height="19" font="0">implants in 18 hospitals. </text>
<text top="123" left="385" width="3" height="19" font="0"> </text>
<text top="142" left="385" width="195" height="19" font="8"><b>Exclusion criteria:</b> None stated  </text>
<text top="88" left="594" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications </text>
<text top="106" left="594" width="3" height="19" font="0"> </text>
<text top="124" left="594" width="225" height="19" font="8"><b>Results:</b> Immediate complications in </text>
<text top="143" left="594" width="206" height="19" font="0">12/194 (6%) – VT/VF in 6, arterial </text>
<text top="161" left="594" width="201" height="19" font="0">puncture (3), pneumothorax (2), </text>
<text top="179" left="594" width="229" height="19" font="0">brachial plexus injury (1). Late comps </text>
<text top="198" left="594" width="174" height="19" font="0">in 22/194 (11%) – VT/VF 10, </text>
<text top="216" left="594" width="232" height="19" font="0">definite/possible sepsis in 10 (5.2%) – </text>
<text top="234" left="594" width="201" height="19" font="0">almost all had TVP&gt;48 h. 38/194 </text>
<text top="252" left="594" width="210" height="19" font="0">(20%) needed repositioning. Total </text>
<text top="271" left="594" width="196" height="19" font="0">comps 35%. 11/194 (5.5%) died </text>
<text top="289" left="594" width="236" height="19" font="0">within 1 h of procedure. 56/194 (29%) </text>
<text top="307" left="594" width="58" height="19" font="0">had PPM </text>
<text top="87" left="844" width="194" height="20" font="0">• High rate of implant by junior </text>
<text top="106" left="855" width="99" height="19" font="0">staff (residents) </text>
<text top="124" left="844" width="151" height="20" font="0">• Continued high rate of </text>
<text top="143" left="855" width="196" height="19" font="0">complications in British medical </text>
<text top="162" left="855" width="101" height="19" font="0">system in 1990s </text>
<text top="326" left="96" width="94" height="19" font="0">Pinneri F, et al. </text>
<text top="345" left="96" width="69" height="19" font="0">2013 (174) </text>
<text top="363" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22240748">22240748</a></text>
<text top="363" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22240748"> </a></text>
<text top="326" left="230" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="345" left="230" width="43" height="19" font="0">center </text>
<text top="363" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="381" left="230" width="110" height="19" font="0">controlled study.  </text>
<text top="400" left="230" width="3" height="19" font="0"> </text>
<text top="418" left="230" width="142" height="19" font="8"><b>Size: </b>N=106; mean age </text>
<text top="436" left="230" width="129" height="19" font="0">77 y, 51% male; 75% </text>
<text top="455" left="230" width="88" height="19" font="0">had AVB; 59% </text>
<text top="473" left="230" width="121" height="19" font="0">ultimately required </text>
<text top="491" left="230" width="32" height="19" font="0">PPM </text>
<text top="326" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="345" left="385" width="184" height="19" font="0">pts requiring TVP 2003–2010. </text>
<text top="363" left="385" width="183" height="19" font="0">Pts underwent TVP guided by </text>
<text top="381" left="385" width="170" height="19" font="0">echo (N=53) or fluoroscopy </text>
<text top="400" left="385" width="161" height="19" font="0">(N=53) based on operator </text>
<text top="418" left="385" width="74" height="19" font="0">preference. </text>
<text top="436" left="385" width="3" height="19" font="0"> </text>
<text top="455" left="385" width="186" height="19" font="8"><b>Exclusion criteria:</b> Incomplete </text>
<text top="473" left="385" width="99" height="19" font="0">follow-up (N=4) </text>
<text top="327" left="594" width="209" height="19" font="8"><b>1</b>°<b> endpoint:</b> The primary efficacy </text>
<text top="346" left="594" width="237" height="19" font="0">endpoints were time to pacing, pacing </text>
<text top="364" left="594" width="222" height="19" font="0">threshold, changes in threshold and </text>
<text top="382" left="594" width="221" height="19" font="0">need for catheter replacement. The </text>
<text top="401" left="594" width="235" height="19" font="0">primary safety endpoints were overall </text>
<text top="419" left="594" width="217" height="19" font="0">complications and death related to </text>
<text top="437" left="594" width="81" height="19" font="0">TVP implant. </text>
<text top="455" left="594" width="3" height="19" font="0"> </text>
<text top="474" left="594" width="233" height="19" font="8"><b>Results:</b> Successful in all but 1 in each </text>
<text top="492" left="594" width="231" height="19" font="0">group (98%). Time to pacing and 24 h </text>
<text top="510" left="594" width="197" height="19" font="0">threshold better in echo-guided </text>
<text top="529" left="594" width="203" height="19" font="0">group. TVP repositioned in 6% of </text>
<text top="547" left="594" width="227" height="19" font="0">echo-guided and 22% of fluoroscopy-</text>
<text top="565" left="594" width="223" height="19" font="0">guided groups (p&lt;0.001), Comp rate </text>
<text top="584" left="594" width="231" height="19" font="0">lower in echo (11%) than fluoroscopy </text>
<text top="602" left="594" width="143" height="19" font="0">(41%) group; p&lt;0.001). </text>
<text top="327" left="844" width="204" height="20" font="0">• Echo-guided TVP was safer and </text>
<text top="346" left="855" width="171" height="19" font="0">more effective in this single </text>
<text top="364" left="855" width="197" height="19" font="0">center cohort with cardiologists </text>
<text top="382" left="855" width="177" height="19" font="0">comfortable with technique. </text>
<text top="401" left="844" width="206" height="20" font="0">• Not clear why dislodgment rate </text>
<text top="420" left="855" width="195" height="19" font="0">and thresholds would be worse </text>
<text top="438" left="855" width="133" height="19" font="0">in fluoroscopy group. </text>
<text top="621" left="96" width="106" height="19" font="0">Braun MU, et al.  </text>
<text top="639" left="96" width="69" height="19" font="0">2006 (175) </text>
<text top="658" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16923004">16923004</a></text>
<text top="658" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16923004"> </a></text>
<text top="621" left="230" width="104" height="19" font="8"><b>Study type:</b> Non-</text>
<text top="639" left="230" width="76" height="19" font="0">randomized </text>
<text top="658" left="230" width="141" height="19" font="0">prospective controlled </text>
<text top="676" left="230" width="105" height="19" font="0">study comparing </text>
<text top="694" left="230" width="119" height="19" font="0">externalized active-</text>
<text top="713" left="230" width="99" height="19" font="0">fixation lead vs. </text>
<text top="731" left="230" width="126" height="19" font="0">standard temporary </text>
<text top="749" left="230" width="62" height="19" font="0">TVP wire) </text>
<text top="767" left="230" width="3" height="19" font="0"> </text>
<text top="621" left="385" width="164" height="19" font="8"><b>Inclusion criteria:</b> Pts with </text>
<text top="639" left="385" width="173" height="19" font="0">systemic infection requiring </text>
<text top="658" left="385" width="108" height="19" font="0">VVI pacing &gt;48 h  </text>
<text top="676" left="385" width="3" height="19" font="0"> </text>
<text top="694" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="622" left="594" width="228" height="19" font="8"><b>1</b>°<b> endpoint:</b> Implant success, pacing </text>
<text top="640" left="594" width="201" height="19" font="0">thresholds, acute complications, </text>
<text top="658" left="594" width="115" height="19" font="0">dislodgement rate </text>
<text top="677" left="594" width="3" height="19" font="0"> </text>
<text top="695" left="594" width="236" height="19" font="8"><b>Results:</b> 100% implant success in both </text>
<text top="713" left="594" width="208" height="19" font="0">groups, paced median 8 d, similar </text>
<text top="732" left="594" width="229" height="19" font="0">procedure time, acute comps, pacing </text>
<text top="750" left="594" width="157" height="19" font="0">threshold. There were 24 </text>
<text top="768" left="594" width="202" height="19" font="0">dislodgments in 12 pts in control </text>
<text top="621" left="844" width="205" height="20" font="0">• Externalized active fixation TVP </text>
<text top="640" left="855" width="165" height="19" font="0">lead associated with much </text>
<text top="658" left="855" width="177" height="19" font="0">lower dislodgment rate than </text>
<text top="677" left="855" width="194" height="19" font="0">standard TVP wire. Equally safe </text>
<text top="695" left="855" width="67" height="19" font="0">to implant </text>
<text top="714" left="844" width="205" height="20" font="0">• Externalized active fixation TVP </text>
<text top="732" left="855" width="167" height="19" font="0">preferred if pacing &gt;48 h is </text>
<text top="751" left="855" width="76" height="19" font="0">anticipated. </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 133 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="139" height="19" font="8"><b>Size:</b> 49 pts, mean age </text>
<text top="105" left="230" width="95" height="19" font="0">72 y, 63% male </text>
<text top="87" left="594" width="218" height="19" font="0">group, only 1 in active-fixation lead </text>
<text top="105" left="594" width="94" height="19" font="0">group (p&lt;0.01) </text>
<text top="227" left="96" width="108" height="19" font="0">de Cock CC, et al. </text>
<text top="246" left="96" width="69" height="19" font="0">2003 (176) </text>
<text top="264" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12765453">12765453</a></text>
<text top="264" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12765453"> </a></text>
<text top="227" left="230" width="104" height="19" font="8"><b>Study type: </b>Non-</text>
<text top="246" left="230" width="116" height="19" font="0">randomized single-</text>
<text top="264" left="230" width="134" height="19" font="0">center comparison of </text>
<text top="282" left="230" width="133" height="19" font="0">TVP by femoral route </text>
<text top="301" left="230" width="138" height="19" font="0">with active vs. passive </text>
<text top="319" left="230" width="94" height="19" font="0">fixation wire in </text>
<text top="337" left="230" width="116" height="19" font="0">Netherlands 1998–</text>
<text top="355" left="230" width="34" height="19" font="0">2001 </text>
<text top="374" left="230" width="3" height="19" font="0"> </text>
<text top="392" left="230" width="132" height="19" font="8"><b>Size:</b> N=72 pts; mean </text>
<text top="410" left="230" width="124" height="19" font="0">age 70 y, 51% male  </text>
<text top="227" left="385" width="189" height="19" font="8"><b>Inclusion criteria: </b>Consecutive </text>
<text top="246" left="385" width="162" height="19" font="0">pts requiring TVP at single </text>
<text top="264" left="385" width="168" height="19" font="0">center requiring prolonged </text>
<text top="282" left="385" width="169" height="19" font="0">temporary pacing (&gt;48 h) – </text>
<text top="301" left="385" width="60" height="19" font="0">mean 6 d </text>
<text top="319" left="385" width="3" height="19" font="0"> </text>
<text top="337" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="228" left="594" width="209" height="19" font="8"><b>1</b>°<b> endpoint:</b> Implant parameters, </text>
<text top="246" left="594" width="221" height="19" font="0">dislodgments, other adverse events </text>
<text top="265" left="594" width="3" height="19" font="0"> </text>
<text top="283" left="594" width="213" height="19" font="8"><b>Results:</b> Threshold higher in active </text>
<text top="301" left="594" width="171" height="19" font="0">(1.38V) than passive (0.7V). </text>
<text top="320" left="594" width="222" height="19" font="0">Dislodgement lower in active (2/36) </text>
<text top="338" left="594" width="173" height="19" font="0">than passive (12/36) groups </text>
<text top="356" left="594" width="192" height="19" font="0">(p&lt;0.001). Other comps similar </text>
<text top="375" left="594" width="3" height="19" font="0"> </text>
<text top="227" left="844" width="191" height="20" font="0">• Fewer dislodgments using an </text>
<text top="246" left="855" width="154" height="19" font="0">active fixation lead using </text>
<text top="265" left="855" width="112" height="19" font="0">femoral approach </text>
<text top="429" left="96" width="99" height="19" font="0">Kawata H, et al. </text>
<text top="448" left="96" width="69" height="19" font="0">2013 (177) </text>
<text top="466" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23482613">23482613</a></text>
<text top="466" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23482613"> </a></text>
<text top="429" left="230" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="448" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="466" left="230" width="132" height="19" font="0">cohort study of temp </text>
<text top="484" left="230" width="135" height="19" font="0">active fix lead (TPPM) </text>
<text top="503" left="230" width="128" height="19" font="0">after lead extraction </text>
<text top="521" left="230" width="56" height="19" font="0">at UCSD  </text>
<text top="539" left="230" width="3" height="19" font="0"> </text>
<text top="558" left="230" width="135" height="19" font="8"><b>Size: </b>N=23; mean age </text>
<text top="576" left="230" width="129" height="19" font="0">72 y, 70% male; 87% </text>
<text top="594" left="230" width="29" height="19" font="0">AVB </text>
<text top="429" left="385" width="173" height="19" font="8"><b>Inclusion criteria:</b> 23/47 pts </text>
<text top="448" left="385" width="191" height="19" font="0">undergoing extraction for CIED </text>
<text top="466" left="385" width="147" height="19" font="0">infection who were PM-</text>
<text top="484" left="385" width="127" height="19" font="0">dependent 2010–12 </text>
<text top="503" left="385" width="3" height="19" font="0"> </text>
<text top="521" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="430" left="594" width="197" height="19" font="8"><b>1</b>°<b> endpoint:</b> Duration of TPPM, </text>
<text top="449" left="594" width="88" height="19" font="0">complications </text>
<text top="467" left="594" width="3" height="19" font="0"> </text>
<text top="485" left="594" width="236" height="19" font="8"><b>Results:</b> Duration of TPPM mean 12 d. </text>
<text top="503" left="594" width="222" height="19" font="0">12/23 discharged to home or SNF. 1 </text>
<text top="522" left="594" width="186" height="19" font="0">pt died of sepsis from primary </text>
<text top="540" left="594" width="225" height="19" font="0">infection; 1 pt developed vegetation </text>
<text top="558" left="594" width="183" height="19" font="0">on TPPM lead – removed and </text>
<text top="577" left="594" width="228" height="19" font="0">replaced. No dislodgements. One pts </text>
<text top="595" left="594" width="188" height="19" font="0">had late pocket infection after </text>
<text top="613" left="594" width="67" height="19" font="0">reimplant. </text>
<text top="430" left="844" width="184" height="20" font="0">• TPPM is a safe and effective </text>
<text top="449" left="855" width="182" height="19" font="0">option for PM-dependent pts </text>
<text top="467" left="855" width="183" height="19" font="0">awaiting reimplant after CIED </text>
<text top="485" left="855" width="57" height="19" font="0">infection </text>
<text top="504" left="844" width="202" height="20" font="0">• Allows earlier mobilization and </text>
<text top="523" left="855" width="137" height="19" font="0">potential discharge to </text>
<text top="541" left="855" width="187" height="19" font="0">home/nursing facility to await </text>
<text top="559" left="855" width="95" height="19" font="0">CIED reimplant </text>
<text top="632" left="96" width="108" height="19" font="0">Chihrin SM, et al. </text>
<text top="651" left="96" width="69" height="19" font="0">2006 (178) </text>
<text top="669" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17145220">17145220</a></text>
<text top="669" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17145220"> </a></text>
<text top="632" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="651" left="230" width="127" height="19" font="0">center retrospective </text>
<text top="669" left="230" width="107" height="19" font="0">cohort in Canada </text>
<text top="687" left="230" width="52" height="19" font="0">2001–5  </text>
<text top="706" left="230" width="3" height="19" font="0"> </text>
<text top="724" left="230" width="94" height="19" font="8"><b>Size:</b> N=20 pts; </text>
<text top="742" left="230" width="139" height="19" font="0">median 2 d; mean age </text>
<text top="761" left="230" width="99" height="19" font="0">62 y; 75% male  </text>
<text top="632" left="385" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="651" left="385" width="180" height="19" font="0">implanted with TPPM via left </text>
<text top="669" left="385" width="196" height="19" font="0">subclavian vein or right internal </text>
<text top="687" left="385" width="173" height="19" font="0">jugular vein over 5 y period  </text>
<text top="706" left="385" width="3" height="19" font="0"> </text>
<text top="724" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="633" left="594" width="184" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pacing duration, </text>
<text top="652" left="594" width="126" height="19" font="0">complications, costs </text>
<text top="670" left="594" width="3" height="19" font="0"> </text>
<text top="688" left="594" width="219" height="19" font="8"><b>Results:</b> Duration median 2 d (1–83 </text>
<text top="706" left="594" width="176" height="19" font="0">d); 1 dislodgement requiring </text>
<text top="725" left="594" width="218" height="19" font="0">repositioning (5%). Using economic </text>
<text top="743" left="594" width="206" height="19" font="0">modeling, costs lower with TPPM </text>
<text top="761" left="594" width="186" height="19" font="0">than conventional TVP at 48 h </text>
<text top="633" left="844" width="203" height="20" font="0">• Despite higher lead cost, TPPM </text>
<text top="652" left="855" width="192" height="19" font="0">cost-effective after 24 h due to </text>
<text top="670" left="855" width="179" height="19" font="0">lower complications and less </text>
<text top="688" left="855" width="110" height="19" font="0">intensive bed use </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 134 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="87" height="19" font="0">Lever N, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2003 (179) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12527682">12527682</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12527682"> </a></text>
<text top="87" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="105" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="123" left="230" width="102" height="19" font="0">United Kingdom </text>
<text top="142" left="230" width="3" height="19" font="0"> </text>
<text top="160" left="230" width="135" height="19" font="8"><b>Size:</b> N=20; mean age </text>
<text top="178" left="230" width="99" height="19" font="0">66 y, 85% male  </text>
<text top="87" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="105" left="385" width="183" height="19" font="0">pts requiring prolonged temp </text>
<text top="123" left="385" width="191" height="19" font="0">pacing due to infection or drug </text>
<text top="142" left="385" width="170" height="19" font="0">washout who had tunneled </text>
<text top="160" left="385" width="39" height="19" font="0">TPPM </text>
<text top="178" left="385" width="3" height="19" font="0"> </text>
<text top="197" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="88" left="594" width="184" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pacing duration, </text>
<text top="106" left="594" width="150" height="19" font="0">outcome, complications </text>
<text top="124" left="594" width="3" height="19" font="0"> </text>
<text top="143" left="594" width="227" height="19" font="8"><b>Results:</b> Duration median 28 d (9–81 </text>
<text top="161" left="594" width="229" height="19" font="0">d); no dislodgments or repositioning; </text>
<text top="179" left="594" width="194" height="19" font="0">2 minor local site infections, no </text>
<text top="198" left="594" width="226" height="19" font="0">systemic infection. One pt died from </text>
<text top="216" left="594" width="158" height="19" font="0">sepsis unrelated to TPPM </text>
<text top="87" left="844" width="207" height="20" font="0">• TPPM safe and effective, allows </text>
<text top="106" left="855" width="189" height="19" font="0">early mobility for pts requiring </text>
<text top="124" left="855" width="177" height="19" font="0">prolonged temporary pacing </text>
<text top="235" left="96" width="104" height="19" font="0">Kornberger A, et </text>
<text top="253" left="96" width="87" height="19" font="0">al. 2013 (180) </text>
<text top="272" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23718817">23718817</a></text>
<text top="272" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23718817"> </a></text>
<text top="235" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="253" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="272" left="230" width="59" height="19" font="0">Germany </text>
<text top="290" left="230" width="3" height="19" font="0"> </text>
<text top="308" left="230" width="135" height="19" font="8"><b>Size:</b> N=60; mean age </text>
<text top="326" left="230" width="95" height="19" font="0">73 y, 73% male </text>
<text top="235" left="385" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="253" left="385" width="179" height="19" font="0">pts implanted with TPPM for </text>
<text top="272" left="385" width="181" height="19" font="0">CIED infection (70%) or other </text>
<text top="290" left="385" width="161" height="19" font="0">reasons (30%) 2000–2009 </text>
<text top="308" left="385" width="3" height="19" font="0"> </text>
<text top="326" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="236" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Duration of pacing, </text>
<text top="254" left="594" width="201" height="19" font="0">outcomes, complications at 30 d </text>
<text top="272" left="594" width="3" height="19" font="0"> </text>
<text top="291" left="594" width="232" height="19" font="8"><b>Results:</b> Successful in 98% - VVI in 56, </text>
<text top="309" left="594" width="190" height="19" font="0">DDD in 3) Duration mean 15 d. </text>
<text top="327" left="594" width="228" height="19" font="0">Intraoperative comps in 2 pts (3.3% - </text>
<text top="346" left="594" width="217" height="19" font="0">one venous thromboembolism and </text>
<text top="364" left="594" width="234" height="19" font="0">tamponade, one dislodgement during </text>
<text top="382" left="594" width="226" height="19" font="0">lead extraction). 4 late comps (6.7%) </text>
<text top="401" left="594" width="182" height="19" font="0">– 3 possible lead infections, 1 </text>
<text top="419" left="594" width="94" height="19" font="0">dislodgement.  </text>
<text top="235" left="844" width="205" height="20" font="0">• TPPM safe and effective option </text>
<text top="254" left="855" width="198" height="19" font="0">for prolonged temporary pacing </text>
<text top="438" left="96" width="104" height="19" font="0">Zei P, et al. 2006 </text>
<text top="456" left="96" width="35" height="19" font="0">(181) </text>
<text top="474" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16580542">16580542</a></text>
<text top="474" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16580542"> </a></text>
<text top="438" left="230" width="115" height="19" font="8"><b>Study type:</b> Single-</text>
<text top="456" left="230" width="101" height="19" font="0">center cohort in </text>
<text top="474" left="230" width="71" height="19" font="0">Boston MA </text>
<text top="493" left="230" width="3" height="19" font="0"> </text>
<text top="511" left="230" width="132" height="19" font="8"><b>Size:</b> N=62 pts; mean </text>
<text top="529" left="230" width="121" height="19" font="0">age 68 y; 60% male </text>
<text top="438" left="385" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="456" left="385" width="173" height="19" font="0">getting TPPM for prolonged </text>
<text top="474" left="385" width="167" height="19" font="0">temp pacing at BWH 2000–</text>
<text top="493" left="385" width="34" height="19" font="0">2004 </text>
<text top="511" left="385" width="3" height="19" font="0"> </text>
<text top="529" left="385" width="195" height="19" font="8"><b>Exclusion criteria:</b> None stated  </text>
<text top="439" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Duration of pacing, </text>
<text top="457" left="594" width="156" height="19" font="0">outcomes, complications </text>
<text top="475" left="594" width="3" height="19" font="0"> </text>
<text top="494" left="594" width="225" height="19" font="8"><b>Results:</b> Median duration 7.5 d. 66% </text>
<text top="512" left="594" width="204" height="19" font="0">went on to have PPM. No deaths </text>
<text top="530" left="594" width="215" height="19" font="0">from arrhythmia, no complications </text>
<text top="549" left="594" width="188" height="19" font="0">from TPPM, no dislodgements </text>
<text top="438" left="844" width="205" height="20" font="0">• TPPM safe and effective option </text>
<text top="457" left="855" width="155" height="19" font="0">for prolonged temporary </text>
<text top="475" left="855" width="47" height="19" font="0">pacing. </text>
<text top="494" left="844" width="192" height="20" font="0">• Allows management in lower </text>
<text top="513" left="855" width="158" height="19" font="0">cost less intensive setting </text>
<text top="578" left="96" width="120" height="19" font="0">Zoll PM, et al. 1985 </text>
<text top="597" left="96" width="35" height="19" font="0">(130) </text>
<text top="615" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886190">3886190</a></text>
<text top="615" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3886190"> </a></text>
<text top="578" left="230" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="597" left="230" width="130" height="19" font="0">Prospective 5-center </text>
<text top="615" left="230" width="119" height="19" font="0">cohort study in US  </text>
<text top="633" left="230" width="3" height="19" font="0"> </text>
<text top="651" left="230" width="122" height="19" font="8"><b>Size:</b> 134 pts; mean </text>
<text top="670" left="230" width="121" height="19" font="0">age 70 y; 65% men  </text>
<text top="578" left="385" width="177" height="19" font="8"><b>Inclusion criteria:</b> All ED and </text>
<text top="597" left="385" width="157" height="19" font="0">hospital pts in whom TCP </text>
<text top="615" left="385" width="49" height="19" font="0">applied </text>
<text top="633" left="385" width="3" height="19" font="0"> </text>
<text top="651" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="579" left="594" width="155" height="19" font="8"><b>1</b>°<b> endpoint:</b> Stimulation </text>
<text top="597" left="594" width="203" height="19" font="0">effectiveness, clinical usefulness, </text>
<text top="616" left="594" width="118" height="19" font="0">survival in-hospital </text>
<text top="634" left="594" width="3" height="19" font="0"> </text>
<text top="652" left="594" width="231" height="19" font="8"><b>Results:</b> QRS response to TCP in 78%, </text>
<text top="671" left="594" width="197" height="19" font="0">deemed clinically useful in 61%, </text>
<text top="689" left="594" width="94" height="19" font="0">survival in 62% </text>
<text top="707" left="594" width="3" height="19" font="0"> </text>
<text top="578" left="844" width="148" height="20" font="0">• Methodology for data </text>
<text top="597" left="855" width="150" height="19" font="0">collection not described </text>
<text top="616" left="844" width="85" height="20" font="0">• No controls </text>
<text top="635" left="844" width="207" height="20" font="0">• Endpoints not well described or </text>
<text top="654" left="855" width="81" height="19" font="0">documented </text>
<text top="672" left="844" width="207" height="20" font="0">• “This extensive experience with </text>
<text top="691" left="855" width="162" height="19" font="0">134 pts treated by several </text>
<text top="710" left="855" width="179" height="19" font="0">investigators in 5 institutions </text>
<text top="728" left="855" width="171" height="19" font="0">under varied circumstances </text>
<text top="746" left="855" width="197" height="19" font="0">confirms the safety and efficacy </text>
<text top="765" left="855" width="152" height="19" font="0">of this new technique of </text>
<text top="783" left="855" width="197" height="19" font="0">noninvasive temporary pacing.” </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="13" size="7" family="Times" color="#000000"/>
<text top="804" left="566" width="59" height="19" font="0">Page 135 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="104" height="19" font="0">Sherbino J, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2006 (128) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16814446">16814446</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16814446"> </a></text>
<text top="87" left="230" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="105" left="230" width="141" height="19" font="0">Systematic review of 7 </text>
<text top="123" left="230" width="110" height="19" font="0">studies of TCP for </text>
<text top="142" left="230" width="73" height="19" font="0">prehospital </text>
<text top="160" left="230" width="88" height="19" font="0">bradyasystole </text>
<text top="178" left="230" width="3" height="19" font="0"> </text>
<text top="197" left="230" width="111" height="19" font="8"><b>Size:</b>7 studies, N= </text>
<text top="215" left="230" width="37" height="19" font="0">1487  </text>
<text top="87" left="385" width="181" height="19" font="8"><b>Inclusion criteria:</b> Euthermic, </text>
<text top="105" left="385" width="172" height="19" font="0">nontraumatized adults who </text>
<text top="123" left="385" width="143" height="19" font="0">experience prehospital </text>
<text top="142" left="385" width="194" height="19" font="0">hemodynamically symptomatic </text>
<text top="160" left="385" width="182" height="19" font="0">bradycardia or bradyasystolic </text>
<text top="178" left="385" width="90" height="19" font="0">cardiac arrest  </text>
<text top="197" left="385" width="3" height="19" font="0"> </text>
<text top="215" left="385" width="192" height="19" font="8"><b>Exclusion criteria:</b> None stated </text>
<text top="88" left="594" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Survival to hospital </text>
<text top="106" left="594" width="62" height="19" font="0">discharge </text>
<text top="124" left="594" width="3" height="19" font="0"> </text>
<text top="143" left="594" width="190" height="19" font="8"><b>Results:</b> No benefits to TCP for </text>
<text top="161" left="594" width="212" height="19" font="0">bradyasystolic cardiac arrest. Data </text>
<text top="179" left="594" width="222" height="19" font="0">inadequate to determine efficacy of </text>
<text top="198" left="594" width="66" height="19" font="0">TCP for SB </text>
<text top="216" left="594" width="3" height="19" font="0"> </text>
<text top="87" left="844" width="177" height="20" font="0">• Limited systematic review: </text>
<text top="106" left="855" width="193" height="19" font="0">Heterogeneity of study designs </text>
<text top="124" left="855" width="177" height="19" font="0">precluded statistical analysis </text>
<text top="235" left="96" width="102" height="19" font="0">Hedges JR, et al. </text>
<text top="253" left="96" width="69" height="19" font="0">1991 (129) </text>
<text top="272" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1721129">1721129</a></text>
<text top="272" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1721129"> </a></text>
<text top="235" left="230" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="253" left="230" width="136" height="19" font="0">EMS-system cohort in </text>
<text top="272" left="229" width="20" height="19" font="0">US </text>
<text top="290" left="230" width="3" height="19" font="0"> </text>
<text top="308" left="230" width="135" height="19" font="8"><b>Size: </b>N=51; mean age </text>
<text top="326" left="230" width="103" height="19" font="0">73 y, 67% male;  </text>
<text top="235" left="385" width="194" height="19" font="8"><b>Inclusion criteria:</b> Pt &gt;17 y with </text>
<text top="253" left="385" width="111" height="19" font="0">hemodynamically </text>
<text top="272" left="385" width="193" height="19" font="0">compromised bradycardia with </text>
<text top="290" left="385" width="106" height="19" font="0">witness collapse  </text>
<text top="308" left="385" width="3" height="19" font="0"> </text>
<text top="326" left="385" width="167" height="19" font="8"><b>Exclusion criteria:</b> Trauma, </text>
<text top="345" left="385" width="171" height="19" font="0">hypothermia, initial rhythm </text>
<text top="363" left="385" width="98" height="19" font="0">asystole, VT, VF </text>
<text top="236" left="594" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrival to ED with </text>
<text top="254" left="594" width="96" height="19" font="0">palpable pulse: </text>
<text top="272" left="594" width="205" height="19" font="0">26% paced group vs. 13% control </text>
<text top="291" left="594" width="185" height="19" font="0">Survival to hospital discharge: </text>
<text top="309" left="594" width="197" height="19" font="0">15% paced group vs. 0% control </text>
<text top="327" left="594" width="3" height="19" font="0"> </text>
<text top="345" left="594" width="95" height="19" font="8"><b>Results:</b> Above </text>
<text top="235" left="844" width="117" height="20" font="0">• Non-randomized </text>
<text top="254" left="844" width="188" height="20" font="0">• Potential for confounding by </text>
<text top="273" left="855" width="64" height="19" font="0">indication </text>
<text top="382" left="86" width="3" height="19" font="0"> </text>
<text top="401" left="86" width="4" height="21" font="4"> </text>
<text top="420" left="86" width="960" height="23" font="5"><b>Data Supplement 33. RCTs of General Principles of Chronic Therapy/Management of Bradycardia due to AV block (Section 6.4.1) </b></text>
<text top="443" left="104" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="462" left="135" width="51" height="19" font="8"><b>Author; </b></text>
<text top="480" left="107" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="498" left="153" width="3" height="19" font="8"><b> </b></text>
<text top="443" left="242" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="462" left="248" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="480" left="241" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="443" left="365" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="443" left="514" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="462" left="553" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="480" left="516" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="498" left="558" width="59" height="19" font="8"><b>patients) </b></text>
<text top="443" left="720" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="462" left="676" width="197" height="19" font="8"><b>(Absolute Event Rates, P value; </b></text>
<text top="480" left="717" width="127" height="19" font="8"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="443" left="901" width="66" height="19" font="8"><b>Relevant 2</b></text>
<text top="443" left="967" width="5" height="12" font="13"><b>0</b></text>
<text top="443" left="972" width="114" height="19" font="8"><b> Endpoint (if any); </b></text>
<text top="462" left="935" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="480" left="944" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="517" left="95" width="70" height="19" font="8"><b>THEOPACE </b></text>
<text top="536" left="95" width="88" height="19" font="0">Alboni P et al. </text>
<text top="554" left="95" width="69" height="19" font="0">1997 (133) </text>
<text top="572" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9236443">9236443</a></text>
<text top="572" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9236443"> </a></text>
<text top="517" left="228" width="115" height="19" font="8"><b>Aim: </b>Compare the </text>
<text top="536" left="228" width="101" height="19" font="0">effects of PM to </text>
<text top="554" left="228" width="107" height="19" font="0">oral theophylline </text>
<text top="572" left="228" width="90" height="19" font="0">and to control </text>
<text top="591" left="228" width="3" height="19" font="0"> </text>
<text top="609" left="228" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="627" left="228" width="54" height="19" font="0">(3 arms) </text>
<text top="645" left="228" width="3" height="19" font="0"> </text>
<text top="664" left="228" width="58" height="19" font="8"><b>Size:</b> 107 </text>
<text top="517" left="357" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="536" left="357" width="60" height="19" font="0">with SND </text>
<text top="554" left="357" width="3" height="19" font="0"> </text>
<text top="572" left="357" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="591" left="357" width="127" height="19" font="0">Heart rate &lt;30 bpm, </text>
<text top="609" left="357" width="80" height="19" font="0">pauses &gt;3 s.  </text>
<text top="517" left="506" width="126" height="19" font="8"><b>Intervention: </b>PM or </text>
<text top="536" left="506" width="80" height="19" font="0">theophylline </text>
<text top="554" left="506" width="3" height="19" font="0"> </text>
<text top="572" left="506" width="131" height="19" font="8"><b>Comparator: </b>Control </text>
<text top="517" left="671" width="199" height="19" font="8"><b>Results: </b>Syncope reduced in PM </text>
<text top="536" left="671" width="182" height="19" font="0">group but not in theophylline </text>
<text top="554" left="671" width="168" height="19" font="0">group compared to control </text>
<text top="572" left="671" width="187" height="19" font="0">(p=0.02 and 0.07 respectively) </text>
<text top="518" left="890" width="186" height="20" font="0">• PM and theophylline groups </text>
<text top="536" left="901" width="162" height="19" font="0">had lower incidence of HF </text>
<text top="555" left="901" width="183" height="19" font="0">compared to control (p=0.05)<b> </b></text>
<text top="573" left="890" width="195" height="20" font="0">• Theophylline stopped for side </text>
<text top="592" left="901" width="89" height="19" font="0">effects in 11%<b> </b></text>
<text top="683" left="86" width="4" height="21" font="4"> </text>
<text top="703" left="86" width="4" height="21" font="4"> </text>
<text top="723" left="86" width="971" height="23" font="5"><b>Data Supplement 34. Nonrandomized data of General Principles of Chronic Therapy/Management of Bradycardia due to AV block </b></text>
<text top="745" left="86" width="102" height="23" font="5"><b>(Section 6.4)  </b></text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 136 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="98" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="105" left="129" width="51" height="19" font="8"><b>Author; </b></text>
<text top="123" left="101" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="142" left="147" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="238" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="105" left="243" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="123" left="237" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="87" left="368" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="87" left="518" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="105" left="556" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="123" left="519" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="142" left="561" width="59" height="19" font="8"><b>patients) </b></text>
<text top="87" left="725" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="105" left="680" width="197" height="19" font="8"><b>(Absolute Event Rates, P value; </b></text>
<text top="123" left="721" width="127" height="19" font="8"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="88" left="899" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="106" left="934" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="124" left="942" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="161" left="95" width="108" height="19" font="0">Dhingra RC, et al. </text>
<text top="179" left="95" width="69" height="19" font="0">1974 (196) </text>
<text top="197" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4817704">4817704</a></text>
<text top="197" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4817704"> </a></text>
<text top="161" left="216" width="89" height="19" font="8"><b>Aim: </b>Describe </text>
<text top="179" left="216" width="90" height="19" font="0">natural Hx of 2</text>
<text top="179" left="306" width="10" height="12" font="7">nd</text>
<text top="179" left="316" width="3" height="19" font="0"> </text>
<text top="197" left="216" width="64" height="19" font="0">AVB+ BBB </text>
<text top="216" left="216" width="3" height="19" font="0"> </text>
<text top="234" left="216" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="252" left="216" width="75" height="19" font="0">Prospective </text>
<text top="271" left="216" width="87" height="19" font="0">observational </text>
<text top="289" left="216" width="3" height="19" font="0"> </text>
<text top="307" left="216" width="50" height="19" font="8"><b>Size: </b>15<b> </b></text>
<text top="161" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="179" left="359" width="43" height="19" font="0">BBB+ 2</text>
<text top="179" left="402" width="10" height="12" font="7">nd</text>
<text top="179" left="413" width="78" height="19" font="0"> degree AVB </text>
<text top="197" left="359" width="3" height="19" font="0"> </text>
<text top="216" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="234" left="359" width="59" height="19" font="0">Acute MI<b> </b></text>
<text top="161" left="509" width="111" height="19" font="8"><b>Intervention: </b>EPS </text>
<text top="179" left="509" width="3" height="19" font="0"> </text>
<text top="197" left="509" width="110" height="19" font="8"><b>Comparator: </b>N/A<b> </b></text>
<text top="161" left="675" width="136" height="19" font="8"><b>Results: </b>At EPS, type I </text>
<text top="179" left="674" width="175" height="19" font="0">(Wenckebach) block pts had </text>
<text top="197" left="674" width="181" height="19" font="0">block proximal to the His and </text>
<text top="216" left="674" width="185" height="19" font="0">those with type II block or 2:1 </text>
<text top="234" left="674" width="196" height="19" font="0">block had block distal to the His </text>
<text top="161" left="895" width="173" height="20" font="0">• Syncope more common in </text>
<text top="180" left="906" width="180" height="19" font="0">those with block distal to the </text>
<text top="198" left="906" width="22" height="19" font="0">His </text>
<text top="217" left="895" width="184" height="20" font="0">• All 9 pts with infra-His block </text>
<text top="236" left="906" width="141" height="19" font="0">implanted with PM for </text>
<text top="254" left="906" width="85" height="19" font="0">syncope, CHF </text>
<text top="272" left="895" width="153" height="19" font="0">LBBB, but not RBBB, was </text>
<text top="291" left="906" width="170" height="19" font="0">associated with block distal </text>
<text top="309" left="906" width="62" height="19" font="0">to the His </text>
<text top="328" left="95" width="83" height="19" font="0">Shaw DB and </text>
<text top="346" left="95" width="83" height="19" font="0">Eraut D 1970 </text>
<text top="365" left="95" width="35" height="19" font="0">(197) </text>
<text top="383" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5413952">5413952</a></text>
<text top="383" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5413952"> </a></text>
<text top="328" left="216" width="106" height="19" font="8"><b> Aim: </b>Follow 2nd </text>
<text top="346" left="216" width="34" height="19" font="0">and 3</text>
<text top="346" left="250" width="9" height="12" font="7">rd</text>
<text top="346" left="259" width="70" height="19" font="0"> degree HB </text>
<text top="365" left="216" width="110" height="19" font="0">pts for symptoms </text>
<text top="383" left="216" width="86" height="19" font="0">and mortality </text>
<text top="401" left="216" width="3" height="19" font="0"> </text>
<text top="419" left="216" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="438" left="216" width="89" height="19" font="0">Observational </text>
<text top="456" left="216" width="3" height="19" font="0"> </text>
<text top="474" left="216" width="58" height="19" font="8"><b>Size: </b>100<b> </b></text>
<text top="328" left="359" width="119" height="19" font="8"><b>Inclusion criteria: </b>2</text>
<text top="328" left="478" width="10" height="12" font="7">nd</text>
<text top="328" left="489" width="3" height="19" font="0"> </text>
<text top="346" left="359" width="8" height="19" font="0">3</text>
<text top="346" left="367" width="9" height="12" font="7">rd</text>
<text top="346" left="376" width="70" height="19" font="0"> degree HB </text>
<text top="365" left="359" width="3" height="19" font="8"><b> </b></text>
<text top="383" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="401" left="359" width="65" height="19" font="0">Digoxin or </text>
<text top="420" left="359" width="104" height="19" font="0">propranolol use, </text>
<text top="438" left="359" width="57" height="19" font="0">acute MI<b> </b></text>
<text top="328" left="509" width="122" height="19" font="8"><b>Intervention: </b>None<b> </b></text>
<text top="328" left="675" width="175" height="19" font="8"><b>Results: </b>Prevalence of heart </text>
<text top="346" left="675" width="159" height="19" font="0">block increases with age.  </text>
<text top="328" left="895" width="164" height="20" font="0">• About 50% had syncopal </text>
<text top="347" left="906" width="44" height="19" font="0">events </text>
<text top="366" left="895" width="135" height="20" font="0">• About 10% had CHF </text>
<text top="385" left="895" width="123" height="19" font="0">No reported deaths </text>
<text top="494" left="95" width="99" height="19" font="0">Simon AB, et al. </text>
<text top="512" left="95" width="69" height="19" font="0">1978 (198) </text>
<text top="530" left="95" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=626128">626128</a></text>
<text top="530" left="140" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=626128"> </a></text>
<text top="493" left="216" width="123" height="19" font="8"><b>Aim: </b>Follow natural </text>
<text top="512" left="216" width="117" height="19" font="0">Hx<b> </b>of AVB pts with </text>
<text top="530" left="216" width="30" height="19" font="0">PMs </text>
<text top="548" left="216" width="3" height="19" font="0"> </text>
<text top="567" left="216" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="585" left="216" width="89" height="19" font="0">Observational </text>
<text top="603" left="216" width="3" height="19" font="0"> </text>
<text top="622" left="216" width="58" height="19" font="8"><b>Size: </b>246<b> </b></text>
<text top="493" left="359" width="119" height="19" font="8"><b>Inclusion criteria: </b>2</text>
<text top="493" left="478" width="10" height="12" font="7">nd</text>
<text top="494" left="489" width="3" height="19" font="0"> </text>
<text top="512" left="359" width="24" height="19" font="0">or 3</text>
<text top="512" left="384" width="9" height="12" font="7">rd</text>
<text top="512" left="392" width="78" height="19" font="0"> degree AVB </text>
<text top="530" left="359" width="3" height="19" font="8"><b> </b></text>
<text top="548" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="567" left="359" width="29" height="19" font="0">SND<b> </b></text>
<text top="493" left="509" width="109" height="19" font="8"><b>Intervention: </b>PM </text>
<text top="512" left="509" width="50" height="19" font="0">implant<b> </b></text>
<text top="493" left="675" width="205" height="19" font="8"><b>Results: S</b>urvival at 1 and 5 y was </text>
<text top="512" left="675" width="172" height="19" font="0">88% and 61% mostly due to </text>
<text top="530" left="675" width="190" height="19" font="0">underlying cardiac disease and </text>
<text top="548" left="675" width="25" height="19" font="0">age </text>
<text top="494" left="895" width="172" height="20" font="0">• Using historical data (50% </text>
<text top="513" left="906" width="140" height="19" font="0">mortality in first year), </text>
<text top="531" left="906" width="143" height="19" font="0">authors conclude large </text>
<text top="549" left="906" width="164" height="19" font="0">mortality benefit with PM  </text>
<text top="568" left="895" width="158" height="20" font="0">• Most common mode of </text>
<text top="587" left="906" width="93" height="19" font="0">death was SCD </text>
<text top="605" left="895" width="191" height="19" font="0">3 deaths clearly attributable to </text>
<text top="623" left="906" width="67" height="19" font="0">PM failure </text>
<text top="642" left="95" width="92" height="19" font="0">Strasberg B, et </text>
<text top="661" left="95" width="87" height="19" font="0">al. 1981 (199) </text>
<text top="679" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7471363">7471363</a></text>
<text top="679" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7471363"> </a></text>
<text top="642" left="216" width="126" height="19" font="8"><b> Aim: </b>Assess natural </text>
<text top="661" left="216" width="43" height="19" font="0">Hx of 2</text>
<text top="661" left="259" width="10" height="12" font="7">nd</text>
<text top="661" left="269" width="32" height="19" font="0"> AVB </text>
<text top="679" left="216" width="3" height="19" font="0"> </text>
<text top="697" left="216" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="716" left="216" width="75" height="19" font="0">Prospective </text>
<text top="734" left="216" width="87" height="19" font="0">observational </text>
<text top="752" left="216" width="3" height="19" font="0"> </text>
<text top="770" left="216" width="50" height="19" font="8"><b>Size:</b> 56<b> </b></text>
<text top="642" left="359" width="119" height="19" font="8"><b>Inclusion criteria</b>: 2</text>
<text top="642" left="478" width="10" height="12" font="7">nd</text>
<text top="642" left="488" width="3" height="19" font="0"> </text>
<text top="661" left="359" width="122" height="19" font="0">AVB that is chronic, </text>
<text top="679" left="359" width="113" height="19" font="0">and shown by EPS </text>
<text top="697" left="359" width="3" height="19" font="0"> </text>
<text top="715" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="734" left="359" width="128" height="19" font="0">Acute AVB in setting </text>
<text top="752" left="359" width="36" height="19" font="0">of MI<b> </b></text>
<text top="642" left="509" width="122" height="19" font="8"><b>Intervention: </b>None<b> </b></text>
<text top="642" left="675" width="175" height="19" font="8"><b>Results: </b>2/3 had Hx of heart </text>
<text top="661" left="675" width="192" height="19" font="0">disease which conferred worse </text>
<text top="679" left="675" width="188" height="19" font="0">survival. Causes of death were </text>
<text top="697" left="675" width="109" height="19" font="0">CHF, MI, and SCD </text>
<text top="643" left="895" width="185" height="20" font="0">• All ECGs showed type I AVB. </text>
<text top="662" left="895" width="164" height="20" font="0">• None progressed to CHB </text>
<text top="681" left="895" width="182" height="20" font="0">• 3 deaths were attributed to </text>
<text top="700" left="906" width="67" height="19" font="0">PM failure </text>
<text top="718" left="895" width="3" height="19" font="0"> </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 137 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="92" height="19" font="0">Edhag O, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">1976 (200) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1015354">1015354</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1015354"> </a></text>
<text top="87" left="216" width="125" height="19" font="8"><b>Aim: </b>Report natural </text>
<text top="105" left="216" width="117" height="19" font="0">Hx of pts with CHB </text>
<text top="123" left="216" width="87" height="19" font="0">or arrhythmic </text>
<text top="142" left="216" width="54" height="19" font="0">syncope </text>
<text top="160" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="178" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="197" left="216" width="87" height="19" font="0">Retrospective </text>
<text top="215" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="233" left="216" width="58" height="19" font="8"><b>Size: </b>101<b> </b></text>
<text top="87" left="359" width="135" height="19" font="8"><b>Inclusion criteria: </b>PM </text>
<text top="105" left="359" width="90" height="19" font="0">not implanted </text>
<text top="123" left="359" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="160" left="359" width="106" height="19" font="0">PM implantation<b> </b></text>
<text top="87" left="509" width="122" height="19" font="8"><b>Intervention: </b>None<b> </b></text>
<text top="87" left="675" width="201" height="19" font="8"><b>Results:</b> CHB with Adams-Stokes </text>
<text top="105" left="675" width="200" height="19" font="0">had worse survival than asx CHB </text>
<text top="87" left="895" width="162" height="20" font="0">• Survival at 1 y=68%, at 5 </text>
<text top="106" left="906" width="44" height="19" font="0">y=37% </text>
<text top="252" left="95" width="94" height="19" font="0">Shaw DB, et al. </text>
<text top="271" left="95" width="69" height="19" font="0">1985 (201) </text>
<text top="289" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4005079">4005079</a></text>
<text top="289" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4005079"> </a></text>
<text top="252" left="216" width="92" height="19" font="8"><b>Aim: </b>Compare </text>
<text top="271" left="216" width="101" height="19" font="0">outcomes in pts </text>
<text top="289" left="216" width="125" height="19" font="0">with type I and type </text>
<text top="307" left="216" width="19" height="19" font="0">II 2</text>
<text top="307" left="235" width="10" height="12" font="7">nd</text>
<text top="307" left="245" width="78" height="19" font="0"> degree AVB </text>
<text top="326" left="216" width="3" height="19" font="0"> </text>
<text top="344" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="362" left="216" width="89" height="19" font="0">Observational </text>
<text top="381" left="216" width="3" height="19" font="0"> </text>
<text top="399" left="216" width="128" height="19" font="8"><b>Size: </b>214 (77 Mobitz </text>
<text top="417" left="216" width="109" height="19" font="0">I, 86 Mobitz II, 51 </text>
<text top="436" left="216" width="27" height="19" font="0">2:1)<b> </b></text>
<text top="252" left="359" width="119" height="19" font="8"><b>Inclusion criteria:</b> 2</text>
<text top="252" left="478" width="10" height="12" font="7">nd</text>
<text top="252" left="489" width="3" height="19" font="0"> </text>
<text top="271" left="359" width="75" height="19" font="0">degree AVB </text>
<text top="289" left="359" width="3" height="19" font="8"><b> </b></text>
<text top="252" left="509" width="109" height="19" font="8"><b>Intervention: </b>PM </text>
<text top="271" left="509" width="3" height="19" font="8"><b> </b></text>
<text top="289" left="509" width="128" height="19" font="8"><b>Comparator: </b>No PM<b> </b></text>
<text top="252" left="675" width="199" height="19" font="8"><b>Results:</b> 5-y survival for pts with </text>
<text top="271" left="675" width="198" height="19" font="0">PM=78%; survival for those w/o </text>
<text top="289" left="675" width="68" height="19" font="0">a PM=41% </text>
<text top="253" left="895" width="190" height="20" font="0">• Pts with Mobitz I and Mobitz </text>
<text top="272" left="906" width="144" height="19" font="0">II had similar prognosis </text>
<text top="455" left="95" width="92" height="19" font="0">Wahbi K, et al. </text>
<text top="473" left="95" width="69" height="19" font="0">2012 (202) </text>
<text top="491" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22453570">22453570</a></text>
<text top="491" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22453570"> </a></text>
<text top="454" left="216" width="101" height="19" font="8"><b>Aim: </b>Determine </text>
<text top="473" left="216" width="88" height="19" font="0">whether EPS+ </text>
<text top="491" left="216" width="103" height="19" font="0">prophylactic PM </text>
<text top="510" left="216" width="125" height="19" font="0">improves survival in </text>
<text top="528" left="216" width="25" height="19" font="0">MD </text>
<text top="546" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="564" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="583" left="216" width="124" height="19" font="0">Retrospective study </text>
<text top="601" left="216" width="106" height="19" font="0">using DM1 Heart </text>
<text top="619" left="216" width="52" height="19" font="0">Registry </text>
<text top="638" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="656" left="216" width="61" height="19" font="8"><b>Size: </b>486 <b> </b></text>
<text top="454" left="359" width="131" height="19" font="8"><b>Inclusion criteria: </b>PR </text>
<text top="473" left="359" width="120" height="19" font="0">&gt;200, QRS &gt;100, or </text>
<text top="491" left="359" width="32" height="19" font="0">both </text>
<text top="509" left="359" width="3" height="19" font="8"><b> </b></text>
<text top="528" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="546" left="359" width="116" height="19" font="0">High-grade AVB or </text>
<text top="564" left="359" width="105" height="19" font="0">already have PM<b> </b></text>
<text top="454" left="509" width="137" height="19" font="8"><b>Intervention:</b> EPS and </text>
<text top="473" left="509" width="133" height="19" font="0">implant PM if HV &gt;70 </text>
<text top="491" left="509" width="21" height="19" font="0">ms </text>
<text top="509" left="509" width="3" height="19" font="0"> </text>
<text top="528" left="509" width="83" height="19" font="8"><b>Comparator: </b></text>
<text top="546" left="509" width="131" height="19" font="0">Noninvasive strategy<b> </b></text>
<text top="454" left="673" width="190" height="19" font="8"><b>Results: </b>Overall survival 74.4% </text>
<text top="473" left="675" width="158" height="19" font="0">(95% CI: 69.2–79.9%) The </text>
<text top="491" left="675" width="170" height="19" font="0">EPS+PM group survival was </text>
<text top="510" left="675" width="206" height="19" font="0">76.7% and the noninvasive group </text>
<text top="528" left="675" width="186" height="19" font="0">was 69.2%; when adjusted for </text>
<text top="546" left="675" width="182" height="19" font="0">clinical variables the HR=0.61 </text>
<text top="565" left="675" width="171" height="19" font="0">(95% CI: 0.38–0.98; p=0.04) </text>
<text top="455" left="895" width="169" height="20" font="0">• The HR of dying suddenly </text>
<text top="474" left="906" width="133" height="19" font="0">was 75% lower in the </text>
<text top="492" left="906" width="92" height="19" font="0">invasive group </text>
<text top="510" left="895" width="178" height="20" font="0">• The noninvasive group had </text>
<text top="529" left="906" width="164" height="19" font="0">an incidence if SCD of 18% </text>
<text top="549" left="906" width="80" height="19" font="0">(95% CI: 10.2</text>
<text top="548" left="986" width="8" height="21" font="4">–</text>
<text top="549" left="994" width="45" height="19" font="0">27.4%) </text>
<text top="675" left="95" width="107" height="19" font="0">Buckley AE, et al. </text>
<text top="693" left="95" width="69" height="19" font="0">1999 (203) </text>
<text top="712" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10377322">10377322</a></text>
<text top="712" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10377322"> </a></text>
<text top="675" left="216" width="89" height="19" font="8"><b>Aim: </b>Describe </text>
<text top="693" left="216" width="127" height="19" font="0">cardiac involvement </text>
<text top="712" left="216" width="110" height="19" font="0">in Emery Dreifuss </text>
<text top="730" left="216" width="3" height="19" font="0"> </text>
<text top="748" left="216" width="111" height="19" font="8"><b>Study type: </b>Small </text>
<text top="767" left="216" width="69" height="19" font="0">case series </text>
<text top="675" left="359" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="693" left="359" width="126" height="19" font="0">with Emery Dreifuss </text>
<text top="712" left="359" width="73" height="19" font="0">and cardiac </text>
<text top="730" left="359" width="79" height="19" font="0">involvement </text>
<text top="675" left="509" width="109" height="19" font="8"><b>Intervention:</b> PM<b> </b></text>
<text top="675" left="675" width="196" height="19" font="8"><b>Results: </b>The pts exhibited atrial </text>
<text top="693" left="675" width="162" height="19" font="0">tachycardia, AF, and atrial </text>
<text top="712" left="675" width="153" height="19" font="0">standstill with junctional </text>
<text top="730" left="675" width="83" height="19" font="0">bradycardia.  </text>
<text top="675" left="890" width="44" height="20" font="0">•  N/A  </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 138 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="3" height="19" font="0"> </text>
<text top="105" left="216" width="43" height="19" font="8"><b>Size: </b>3<b> </b></text>
<text top="124" left="95" width="108" height="19" font="0">Kitaguchi T, et al. </text>
<text top="143" left="95" width="69" height="19" font="0">2001 (204) </text>
<text top="161" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11525883">11525883</a></text>
<text top="161" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11525883"> </a></text>
<text top="124" left="216" width="103" height="19" font="8"><b> Aim: </b>Describe a </text>
<text top="143" left="216" width="102" height="19" font="0">proband and his </text>
<text top="161" left="216" width="41" height="19" font="0">family </text>
<text top="179" left="216" width="3" height="19" font="0"> </text>
<text top="197" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="216" left="216" width="89" height="19" font="0">Observational </text>
<text top="234" left="216" width="3" height="19" font="0"> </text>
<text top="252" left="216" width="50" height="19" font="8"><b>Size: </b>14<b> </b></text>
<text top="124" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="143" left="359" width="135" height="19" font="0">Family members with </text>
<text top="161" left="359" width="93" height="19" font="0">limb girdle MD </text>
<text top="124" left="509" width="109" height="19" font="8"><b>Intervention: </b>PM<b> </b></text>
<text top="124" left="675" width="200" height="19" font="8"><b>Results: </b>All family members had </text>
<text top="143" left="675" width="191" height="19" font="0">AVB and arrhythmias requiring </text>
<text top="161" left="675" width="24" height="19" font="0">PM </text>
<text top="124" left="890" width="44" height="20" font="0">•  N/A  </text>
<text top="272" left="95" width="103" height="19" font="0">Finsterer J, et al. </text>
<text top="290" left="95" width="69" height="19" font="0">2016 (205) </text>
<text top="308" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27014341">27014341</a></text>
<text top="308" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27014341"> </a></text>
<text top="271" left="216" width="98" height="19" font="8"><b> Aim: </b>Thorough </text>
<text top="290" left="216" width="78" height="19" font="0">review of all </text>
<text top="308" left="216" width="96" height="19" font="0">neuromuscular </text>
<text top="326" left="216" width="122" height="19" font="0">disease and cardiac </text>
<text top="345" left="216" width="79" height="19" font="0">involvement </text>
<text top="363" left="216" width="3" height="19" font="0"> </text>
<text top="381" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="400" left="216" width="99" height="19" font="8"><b>C</b>omprehensive </text>
<text top="418" left="216" width="104" height="19" font="0">literature search </text>
<text top="436" left="216" width="3" height="19" font="0"> </text>
<text top="454" left="216" width="103" height="19" font="8"><b>Size: </b>224 papers<b> </b></text>
<text top="271" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="290" left="359" width="136" height="19" font="0">Comprehensive list of </text>
<text top="308" left="359" width="109" height="19" font="0">search terms and </text>
<text top="326" left="359" width="106" height="19" font="0">manual searches </text>
<text top="345" left="359" width="3" height="19" font="0"> </text>
<text top="363" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="381" left="359" width="60" height="19" font="0">Abstracts </text>
<text top="271" left="509" width="113" height="19" font="8"><b>Intervention:</b> N/A </text>
<text top="271" left="675" width="165" height="19" font="8"><b>Results: </b>Several aspects of </text>
<text top="290" left="675" width="161" height="19" font="0">cardiac involvement were </text>
<text top="308" left="675" width="206" height="19" font="0">including hypertrophic CM, DCM, </text>
<text top="326" left="675" width="140" height="19" font="0">CHF, SCD, arrhythmias </text>
<text top="272" left="895" width="38" height="20" font="0">• N/A </text>
<text top="291" left="915" width="3" height="19" font="0"> </text>
<text top="474" left="95" width="79" height="19" font="0">Ha AH, et al. </text>
<text top="492" left="95" width="69" height="19" font="0">2012 (206) </text>
<text top="510" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22385162">22385162</a></text>
<text top="510" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22385162"> </a></text>
<text top="474" left="216" width="101" height="19" font="8"><b>Aim:</b> Determine </text>
<text top="492" left="216" width="125" height="19" font="0">predictors of AVB in </text>
<text top="510" left="216" width="48" height="19" font="0">MD pts </text>
<text top="529" left="216" width="3" height="19" font="0"> </text>
<text top="547" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="565" left="216" width="127" height="19" font="0">Observational single </text>
<text top="583" left="216" width="43" height="19" font="0">center </text>
<text top="602" left="216" width="3" height="19" font="0"> </text>
<text top="620" left="216" width="58" height="19" font="8"><b>Size:</b> 236 </text>
<text top="474" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="492" left="359" width="100" height="19" font="0">MD type I and II </text>
<text top="474" left="509" width="136" height="19" font="8"><b>Intervention: </b>PM and </text>
<text top="492" left="509" width="24" height="19" font="0">ICD </text>
<text top="510" left="509" width="3" height="19" font="0"> </text>
<text top="528" left="509" width="146" height="19" font="8"><b>Comparator: </b>No device </text>
<text top="474" left="675" width="168" height="19" font="8"><b>Results: </b>23.8% of DM I and </text>
<text top="492" left="675" width="196" height="19" font="0">16.7% of DM II pts had a severe </text>
<text top="510" left="675" width="196" height="19" font="0">ECG abnormality (defined as PR </text>
<text top="529" left="675" width="193" height="19" font="0">&gt;240 ms or QRS &gt;120 ms). PMs </text>
<text top="547" left="675" width="201" height="19" font="0">and ICDs were implanted in 14% </text>
<text top="565" left="675" width="197" height="19" font="0">overall but in 65% of those with </text>
<text top="583" left="675" width="149" height="19" font="0">severe ECG abnormality </text>
<text top="474" left="895" width="190" height="20" font="0">• Over 44 months of follow-up </text>
<text top="493" left="906" width="157" height="19" font="0">mean rates of ventricular </text>
<text top="511" left="906" width="179" height="19" font="0">pacing in device pts was 24% </text>
<text top="529" left="906" width="152" height="19" font="0">and 13% developed CHB </text>
<text top="548" left="915" width="137" height="19" font="0">3 pts died of SCD, 2 of </text>
<text top="566" left="915" width="171" height="19" font="0">whom had functioning PMs </text>
<text top="584" left="915" width="42" height="19" font="0">(1.3%) </text>
<text top="639" left="95" width="99" height="19" font="0">Lazarus A, et al. </text>
<text top="658" left="95" width="69" height="19" font="0">2002 (207) </text>
<text top="676" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12427418">12427418</a></text>
<text top="676" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12427418"> </a></text>
<text top="639" left="216" width="100" height="19" font="8"><b>Aim:</b> Document </text>
<text top="658" left="216" width="121" height="19" font="0">incidence of AVB in </text>
<text top="676" left="216" width="122" height="19" font="0">MD pts with HV&gt;70 </text>
<text top="694" left="216" width="110" height="19" font="0">but no symptoms </text>
<text top="712" left="216" width="3" height="19" font="0"> </text>
<text top="731" left="216" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="749" left="216" width="106" height="19" font="0">arm, prospective </text>
<text top="767" left="216" width="3" height="19" font="0"> </text>
<text top="639" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="658" left="359" width="125" height="19" font="0">MD pts with HV &gt;70 </text>
<text top="676" left="359" width="82" height="19" font="0">regardless of </text>
<text top="694" left="359" width="67" height="19" font="0">symptoms </text>
<text top="639" left="509" width="109" height="19" font="8"><b>Intervention: </b>PM </text>
<text top="639" left="675" width="182" height="19" font="8"><b>Results: </b>43% developed CHB, </text>
<text top="658" left="675" width="201" height="19" font="0">51% had atrial tachyarrhythmias </text>
<text top="676" left="675" width="121" height="19" font="0">and 26.5% had VA.  </text>
<text top="639" left="895" width="148" height="20" font="0">• No deaths due to AVB </text>
<text top="659" left="895" width="185" height="20" font="0">• 4 sudden deaths; 2 of which </text>
<text top="677" left="906" width="151" height="19" font="0">did not have arrhythmia </text>
<text top="696" left="906" width="170" height="19" font="0">cause per PM interrogation </text>
<text top="714" left="915" width="3" height="19" font="0"> </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 139 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="50" height="19" font="8"><b>Size: </b>49 </text>
<text top="115" left="95" width="107" height="19" font="0">Facenda-Lorenzo </text>
<text top="134" left="95" width="88" height="19" font="0">M, et al. 2013 </text>
<text top="152" left="95" width="35" height="19" font="0">(208) </text>
<text top="170" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24775453">24775453</a></text>
<text top="170" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24775453"> </a></text>
<text top="115" left="216" width="100" height="19" font="8"><b>Aim: </b>Document </text>
<text top="134" left="216" width="81" height="19" font="0">frequency of </text>
<text top="152" left="216" width="117" height="19" font="0">arrhythmias in MD </text>
<text top="170" left="216" width="60" height="19" font="0">type I pts </text>
<text top="188" left="216" width="3" height="19" font="0"> </text>
<text top="207" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="225" left="216" width="87" height="19" font="0">Retrospective </text>
<text top="243" left="216" width="123" height="19" font="0">observational study </text>
<text top="262" left="216" width="3" height="19" font="0"> </text>
<text top="280" left="216" width="50" height="19" font="8"><b>Size: </b>81 </text>
<text top="115" left="359" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="134" left="359" width="121" height="19" font="0">with genetic tested </text>
<text top="152" left="359" width="120" height="19" font="0">Dx of type I MD pts </text>
<text top="170" left="359" width="70" height="19" font="0">referred to </text>
<text top="188" left="359" width="67" height="19" font="0">cardiology </text>
<text top="115" left="509" width="142" height="19" font="8"><b>Intervention: </b>EPS, PM, </text>
<text top="134" left="509" width="109" height="19" font="0">ICD per physician </text>
<text top="152" left="509" width="64" height="19" font="0">discretion<b> </b></text>
<text top="115" left="675" width="196" height="19" font="8"><b>Results: </b>At baseline visit, 71.6% </text>
<text top="134" left="675" width="199" height="19" font="0">had a normal ECG. At follow-up, </text>
<text top="152" left="675" width="203" height="19" font="0">48.8% had sinus bradycardia and </text>
<text top="170" left="675" width="141" height="19" font="0">31.3% had PR &gt;220 ms </text>
<text top="115" left="895" width="119" height="20" font="0">• 8.6% developed 2</text>
<text top="116" left="1014" width="10" height="12" font="7">nd</text>
<text top="116" left="1024" width="28" height="19" font="0"> or 3</text>
<text top="116" left="1052" width="9" height="12" font="7">rd</text>
<text top="116" left="1061" width="3" height="19" font="0"> </text>
<text top="134" left="906" width="179" height="19" font="0">degree AVB during follow-up </text>
<text top="153" left="895" width="100" height="20" font="0">• Holter found 2</text>
<text top="153" left="995" width="10" height="12" font="7">nd</text>
<text top="153" left="1005" width="28" height="19" font="0"> or 3</text>
<text top="153" left="1033" width="9" height="12" font="7">rd</text>
<text top="153" left="1041" width="47" height="19" font="0"> AVB in </text>
<text top="172" left="906" width="33" height="19" font="0">9 pts </text>
<text top="190" left="915" width="132" height="19" font="0">2 pts required an ICD </text>
<text top="299" left="95" width="96" height="19" font="0">Bhakta D, et al. </text>
<text top="317" left="95" width="69" height="19" font="0">2011 (209) </text>
<text top="336" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22035077">22035077</a></text>
<text top="336" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22035077"> </a></text>
<text top="299" left="216" width="76" height="19" font="8"><b>Aim: </b>Assess </text>
<text top="317" left="216" width="122" height="19" font="0">implantation of PM </text>
<text top="336" left="216" width="130" height="19" font="0">and ICD rates in type </text>
<text top="354" left="216" width="55" height="19" font="0">I MD pts </text>
<text top="372" left="216" width="3" height="19" font="0"> </text>
<text top="390" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="409" left="216" width="75" height="19" font="0">Prospective </text>
<text top="427" left="216" width="124" height="19" font="0">multicenter registry </text>
<text top="446" left="216" width="3" height="19" font="0"> </text>
<text top="464" left="216" width="58" height="19" font="8"><b>Size: </b>406<b> </b></text>
<text top="299" left="359" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="317" left="359" width="123" height="19" font="0">seen at 23 different </text>
<text top="336" left="359" width="136" height="19" font="0">neuromuscular clinics </text>
<text top="354" left="359" width="35" height="19" font="0">in US </text>
<text top="299" left="509" width="150" height="19" font="8"><b>Intervention: </b>PM or ICD </text>
<text top="317" left="509" width="148" height="19" font="0">per physician discretion </text>
<text top="299" left="675" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="318" left="675" width="187" height="20" font="0">• 11.3% implanted with a PM, </text>
<text top="337" left="687" width="106" height="19" font="0">5.2% with an ICD </text>
<text top="355" left="675" width="190" height="20" font="0">• 52% of PM pts died in follow-</text>
<text top="374" left="686" width="151" height="19" font="0">up. PM pts often died of </text>
<text top="392" left="686" width="178" height="19" font="0">respiratory failure or sudden </text>
<text top="411" left="686" width="39" height="19" font="0">death </text>
<text top="429" left="675" width="172" height="20" font="0">• None of pts implanted for </text>
<text top="448" left="686" width="59" height="19" font="0">isolated 1</text>
<text top="448" left="745" width="7" height="12" font="7">st</text>
<text top="448" left="752" width="120" height="19" font="0"> AVB progressed to </text>
<text top="466" left="686" width="29" height="19" font="0">CHB </text>
<text top="299" left="895" width="167" height="20" font="0">• PR interval &gt;240 or QRSd </text>
<text top="318" left="906" width="164" height="19" font="0">&gt;120 ms appear to predict </text>
<text top="337" left="906" width="8" height="19" font="0">2</text>
<text top="336" left="914" width="10" height="12" font="7">nd</text>
<text top="337" left="924" width="28" height="19" font="0"> or 3</text>
<text top="336" left="951" width="9" height="12" font="7">rd</text>
<text top="337" left="960" width="112" height="19" font="0"> degree AVB (NPV </text>
<text top="355" left="906" width="159" height="19" font="0">99.6% and PPV of 10.3%)  </text>
<text top="373" left="895" width="178" height="20" font="0">• Almost 1/3 of PM pts were </text>
<text top="392" left="906" width="137" height="19" font="0">PM dependent by last </text>
<text top="411" left="906" width="62" height="19" font="0">follow-up </text>
<text top="485" left="95" width="93" height="19" font="0">Groh WJ, et al. </text>
<text top="504" left="95" width="69" height="19" font="0">2008 (210) </text>
<text top="522" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18565861">18565861</a></text>
<text top="522" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18565861"> </a></text>
<text top="485" left="216" width="118" height="19" font="8"><b> Aim: </b>Assess if ECG </text>
<text top="504" left="216" width="114" height="19" font="0">can predict SCD in </text>
<text top="522" left="216" width="85" height="19" font="0">MD type I pts </text>
<text top="540" left="216" width="3" height="19" font="0"> </text>
<text top="558" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="577" left="216" width="75" height="19" font="0">Prospective </text>
<text top="595" left="216" width="124" height="19" font="0">multicenter registry </text>
<text top="614" left="216" width="3" height="19" font="0"> </text>
<text top="632" left="216" width="118" height="19" font="8"><b>Size: </b>406; of which </text>
<text top="650" left="216" width="117" height="19" font="0">96 had severe ECG </text>
<text top="668" left="216" width="77" height="19" font="0">abnormality </text>
<text top="485" left="359" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="504" left="359" width="123" height="19" font="0">seen at 23 different </text>
<text top="522" left="359" width="136" height="19" font="0">neuromuscular clinics </text>
<text top="540" left="359" width="135" height="19" font="0">in US; including those </text>
<text top="559" left="359" width="121" height="19" font="0">with either non-SR, </text>
<text top="577" left="359" width="107" height="19" font="0">PR &gt;240 ms, QRS </text>
<text top="595" left="359" width="66" height="19" font="0">&gt;120 ms, 2</text>
<text top="595" left="426" width="10" height="12" font="7">nd</text>
<text top="595" left="436" width="13" height="19" font="0">/3</text>
<text top="595" left="449" width="9" height="12" font="7">rd</text>
<text top="595" left="458" width="3" height="19" font="0"> </text>
<text top="614" left="359" width="128" height="19" font="0">degree AVB (termed </text>
<text top="632" left="359" width="78" height="19" font="0">“severe ECG </text>
<text top="650" left="359" width="88" height="19" font="0">abnormality”) </text>
<text top="668" left="359" width="3" height="19" font="0"> </text>
<text top="687" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="705" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="485" left="509" width="150" height="19" font="8"><b>Intervention: </b>PM or ICD </text>
<text top="504" left="509" width="148" height="19" font="0">per physician discretion<b> </b></text>
<text top="485" left="686" width="180" height="19" font="8"><b>Results: </b>20% died; 33% were </text>
<text top="504" left="686" width="193" height="19" font="0">sudden death. 41 received PM; </text>
<text top="522" left="686" width="132" height="19" font="0">27 were prophylactic </text>
<text top="540" left="675" width="187" height="20" font="0">• Severe EKG abnormality had </text>
<text top="559" left="686" width="180" height="19" font="0">sensitivity =74.1%, specificity </text>
<text top="578" left="686" width="182" height="19" font="0">=61.7% for prediction of SCD  </text>
<text top="486" left="895" width="192" height="20" font="0">• Atrial tachyarrhythmias were </text>
<text top="504" left="906" width="96" height="19" font="0">common (30%) </text>
<text top="523" left="895" width="192" height="20" font="0">• Risk factors for sudden death </text>
<text top="542" left="906" width="106" height="19" font="0">were severe ECG </text>
<text top="560" left="906" width="149" height="19" font="0">abnormalities and atrial </text>
<text top="579" left="906" width="110" height="19" font="0">tachyarrhythmias </text>
<text top="724" left="95" width="93" height="19" font="0">Groh WJ, 2012 </text>
<text top="742" left="95" width="35" height="19" font="0">(211) </text>
<text top="761" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22760083">22760083</a></text>
<text top="761" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22760083"> </a></text>
<text top="724" left="216" width="124" height="19" font="8"><b>Aim: </b>Contemporary </text>
<text top="742" left="216" width="114" height="19" font="0">review and expert </text>
<text top="761" left="216" width="50" height="19" font="0">opinion </text>
<text top="779" left="216" width="3" height="19" font="0"> </text>
<text top="724" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="742" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="724" left="509" width="113" height="19" font="8"><b>Intervention: </b>N/A<b> </b></text>
<text top="724" left="675" width="182" height="20" font="0">• Reviews role of PM and ICD </text>
<text top="743" left="675" width="195" height="20" font="0">• Conduction abnormalities are </text>
<text top="762" left="686" width="57" height="19" font="0">frequent </text>
<text top="724" left="895" width="38" height="20" font="0">• N/A </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 140 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="102" height="19" font="8"><b>Study type:</b> N/A </text>
<text top="105" left="216" width="3" height="19" font="0"> </text>
<text top="123" left="216" width="59" height="19" font="8"><b>Size:</b> N/A<b> </b></text>
<text top="87" left="675" width="200" height="20" font="0">• ICDs are often needed to treat </text>
<text top="106" left="686" width="74" height="19" font="0">VA and SCD </text>
<text top="143" left="95" width="105" height="19" font="0">Kabunga P, et al. </text>
<text top="161" left="95" width="69" height="19" font="0">2015 (212) </text>
<text top="179" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25540845">25540845</a></text>
<text top="179" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25540845"> </a></text>
<text top="142" left="216" width="105" height="19" font="8"><b> Aim: </b>Systematic </text>
<text top="161" left="216" width="60" height="19" font="0">review of </text>
<text top="179" left="216" width="92" height="19" font="0">arrhythmias in </text>
<text top="197" left="216" width="105" height="19" font="0">Kearns-Sayre pts </text>
<text top="216" left="216" width="3" height="19" font="0"> </text>
<text top="234" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="252" left="216" width="108" height="19" font="0">Literature review </text>
<text top="271" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="289" left="216" width="97" height="19" font="8"><b>Size: </b>54 studies<b> </b></text>
<text top="142" left="359" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="161" left="359" width="132" height="19" font="0">Specific search terms<b> </b></text>
<text top="142" left="509" width="222" height="19" font="8"><b>Intervention: </b>PM or ICD<b>  Results:  </b></text>
<text top="161" left="675" width="161" height="20" font="0">• 57% of Kearns Sayre pts </text>
<text top="180" left="687" width="148" height="19" font="0">develop cardiac disease </text>
<text top="198" left="686" width="194" height="19" font="0">SCD has been reported in up to </text>
<text top="217" left="686" width="29" height="19" font="0">20% </text>
<text top="235" left="675" width="188" height="20" font="0">• Most common is conduction </text>
<text top="254" left="686" width="185" height="19" font="0">disease which can progress to </text>
<text top="272" left="686" width="141" height="19" font="0">CHB, or PMVT/torsade </text>
<text top="143" left="895" width="131" height="20" font="0">• Most common ECG </text>
<text top="162" left="906" width="177" height="19" font="0">abnormality is LAFB +/-RBBB </text>
<text top="180" left="895" width="171" height="20" font="0">• Progression to high-grade </text>
<text top="199" left="906" width="121" height="19" font="0">AVB can be sudden </text>
<text top="218" left="895" width="167" height="20" font="0">• VA are often bradycardia </text>
<text top="237" left="906" width="47" height="19" font="0">related </text>
<text top="255" left="895" width="3" height="19" font="0"> </text>
<text top="308" left="95" width="96" height="19" font="0">Saxon LA, et al. </text>
<text top="326" left="95" width="69" height="19" font="0">1990 (213) </text>
<text top="345" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1695352">1695352</a></text>
<text top="345" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1695352"> </a></text>
<text top="308" left="216" width="122" height="19" font="8"><b>Aim: </b>Look at Holter </text>
<text top="326" left="216" width="101" height="19" font="0">and correlate to </text>
<text top="345" left="216" width="120" height="19" font="0">cerebral symptoms </text>
<text top="363" left="216" width="3" height="19" font="0"> </text>
<text top="381" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="400" left="216" width="87" height="19" font="0">Retrospective </text>
<text top="418" left="216" width="3" height="19" font="0"> </text>
<text top="436" left="216" width="58" height="19" font="8"><b>Size:</b> 411<b> </b></text>
<text top="308" left="359" width="130" height="19" font="8"><b>Inclusion criteria: </b>All </text>
<text top="326" left="359" width="78" height="19" font="0">Holters with </text>
<text top="345" left="359" width="83" height="19" font="0">persistent AF<b> </b></text>
<text top="308" left="509" width="113" height="19" font="8"><b>Intervention: </b>N/A<b> </b></text>
<text top="308" left="675" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="327" left="674" width="164" height="20" font="0">•  There was no difference </text>
<text top="346" left="687" width="151" height="19" font="0">between the group with </text>
<text top="364" left="687" width="186" height="19" font="0">symptoms and 2-s pauses and </text>
<text top="382" left="687" width="180" height="19" font="0">the group with no symptoms </text>
<text top="401" left="687" width="93" height="19" font="0">and 2-s pauses </text>
<text top="419" left="675" width="179" height="20" font="0">• Many pts had resolution of </text>
<text top="438" left="686" width="169" height="19" font="0">symptoms w/o PM implant </text>
<text top="308" left="895" width="140" height="20" font="0">• 2 s did not appear to </text>
<text top="327" left="906" width="129" height="19" font="0">correlate to cerebral </text>
<text top="346" left="906" width="67" height="19" font="0">symptoms </text>
<text top="457" left="95" width="93" height="19" font="0">Hilgard J, et al. </text>
<text top="475" left="95" width="69" height="19" font="0">1985 (214) </text>
<text top="494" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3984858">3984858</a></text>
<text top="494" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3984858"> </a></text>
<text top="457" left="216" width="101" height="19" font="8"><b>Aim: </b>Look at 3 s </text>
<text top="475" left="216" width="107" height="19" font="0">pauses on Holter </text>
<text top="494" left="216" width="130" height="19" font="0">and correlate clinical </text>
<text top="512" left="216" width="64" height="19" font="0">outcomes </text>
<text top="530" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="548" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="567" left="216" width="87" height="19" font="0">Retrospective </text>
<text top="585" left="216" width="3" height="19" font="0"> </text>
<text top="603" left="216" width="50" height="19" font="8"><b>Size: </b>52<b> </b></text>
<text top="457" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="475" left="359" width="82" height="19" font="0">6470<b> </b>Holters </text>
<text top="494" left="359" width="108" height="19" font="0">screened; 52 had </text>
<text top="512" left="359" width="77" height="19" font="0">pauses ≥3 s.<b> </b></text>
<text top="457" left="509" width="133" height="19" font="8"><b>Intervention: </b>Per the </text>
<text top="475" left="509" width="140" height="19" font="0">physician discretion to </text>
<text top="494" left="509" width="74" height="19" font="0">implant PM<b> </b></text>
<text top="457" left="675" width="167" height="19" font="8"><b>Results: </b>Of 52 Holters with </text>
<text top="475" left="675" width="200" height="19" font="0">pauses, 18 showed AF with slow </text>
<text top="494" left="675" width="203" height="19" font="0">ventricular response, and 12 had </text>
<text top="512" left="675" width="36" height="19" font="0">AVB.  </text>
<text top="457" left="895" width="154" height="20" font="0">• 26 of 52 received a PM </text>
<text top="476" left="895" width="129" height="20" font="0">• 5 out of 52 pts had </text>
<text top="495" left="906" width="173" height="19" font="0">symptoms during the pause </text>
<text top="622" left="95" width="85" height="19" font="0">Ector H, et al. </text>
<text top="641" left="95" width="69" height="19" font="0">1983 (215) </text>
<text top="659" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6191291">6191291</a></text>
<text top="659" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6191291"> </a></text>
<text top="622" left="216" width="79" height="19" font="8"><b> Aim: </b>Assess </text>
<text top="641" left="216" width="114" height="19" font="0">etiology of pauses </text>
<text top="659" left="216" width="117" height="19" font="0">and indications for </text>
<text top="677" left="216" width="24" height="19" font="0">PM </text>
<text top="696" left="216" width="3" height="19" font="0"> </text>
<text top="714" left="216" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="732" left="216" width="87" height="19" font="0">Retrospective </text>
<text top="751" left="216" width="3" height="19" font="0"> </text>
<text top="622" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="641" left="359" width="129" height="19" font="0">Consecutive Holters, </text>
<text top="659" left="359" width="127" height="19" font="0">53 had a pause ≥3 s.<b> </b></text>
<text top="622" left="509" width="122" height="19" font="8"><b>Intervention: </b>None<b> </b></text>
<text top="622" left="675" width="191" height="19" font="8"><b>Results: </b>Of the 53 Holters with </text>
<text top="641" left="675" width="187" height="19" font="0">pauses, 5 had AVB and 29 had </text>
<text top="659" left="675" width="156" height="19" font="0">slow AF. Symptoms were </text>
<text top="677" left="675" width="125" height="19" font="0">reported in 45 of 53 </text>
<text top="622" left="895" width="187" height="19" font="0">Authors propose pauses of 3 s </text>
<text top="641" left="895" width="128" height="19" font="0">as the cutoff for PM  </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 141 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="117" height="19" font="8"><b>Size: </b>2350 Holters; </text>
<text top="105" left="216" width="90" height="19" font="0">53 had pauses </text>
<text top="124" left="95" width="99" height="19" font="0">Michaelsson M, </text>
<text top="143" left="95" width="103" height="19" font="0">et al. 1995 (216) </text>
<text top="161" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7634461">7634461</a></text>
<text top="161" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7634461"> </a></text>
<text top="124" left="216" width="110" height="19" font="8"><b> Aim: </b>Assess long-</text>
<text top="143" left="216" width="107" height="19" font="0">term outcome of </text>
<text top="161" left="216" width="108" height="19" font="0">adults with CCHB </text>
<text top="179" left="216" width="3" height="19" font="0"> </text>
<text top="197" left="216" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="216" left="216" width="75" height="19" font="0">Prospective </text>
<text top="234" left="216" width="87" height="19" font="0">observational </text>
<text top="252" left="216" width="3" height="19" font="0"> </text>
<text top="271" left="216" width="58" height="19" font="8"><b>Size:</b> 102 </text>
<text top="124" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="143" left="359" width="89" height="19" font="0">Isolated CCHB </text>
<text top="161" left="359" width="132" height="19" font="0">diagnosed in pts 15 y </text>
<text top="179" left="359" width="112" height="19" font="0">or younger; mean </text>
<text top="197" left="359" width="130" height="19" font="0">age at follow-up was </text>
<text top="216" left="359" width="29" height="19" font="0">38 y<b> </b></text>
<text top="124" left="509" width="104" height="19" font="8"><b>Intervention: </b>54 </text>
<text top="143" left="509" width="131" height="19" font="0">implanted with a PM </text>
<text top="124" left="675" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="143" left="674" width="206" height="20" font="0">•  Stokes Adams attacks occurred </text>
<text top="162" left="687" width="136" height="19" font="0">in 27, 8 of whom died </text>
<text top="180" left="675" width="199" height="20" font="0">• 24 women w/o PM gave birth, </text>
<text top="199" left="686" width="134" height="19" font="0">6 had syncope during </text>
<text top="217" left="686" width="67" height="19" font="0">pregnancy </text>
<text top="124" left="895" width="192" height="20" font="0">• There were 11 deaths; 2 died </text>
<text top="143" left="906" width="19" height="19" font="0">of  </text>
<text top="162" left="906" width="134" height="19" font="0">PM failure and 6 died </text>
<text top="180" left="906" width="58" height="19" font="0">suddenly </text>
<text top="198" left="915" width="132" height="19" font="0">2 pts required an ICD </text>
<text top="217" left="895" width="143" height="20" font="0">• 8 had BBB, QRS not a </text>
<text top="236" left="906" width="170" height="19" font="0">predictor of syncope/death </text>
<text top="290" left="95" width="103" height="19" font="0">Sholler GF, et al. </text>
<text top="308" left="95" width="69" height="19" font="0">1989 (217) </text>
<text top="326" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2480059">2480059</a></text>
<text top="326" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2480059"> </a></text>
<text top="290" left="216" width="128" height="19" font="8"><b>Aim: </b>Identify factors </text>
<text top="308" left="216" width="130" height="19" font="0">that predict need for </text>
<text top="326" left="216" width="106" height="19" font="0">PM in congenital </text>
<text top="345" left="216" width="51" height="19" font="0">CHB pts </text>
<text top="363" left="216" width="3" height="19" font="0"> </text>
<text top="381" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="400" left="216" width="122" height="19" font="0">Retrospective chart </text>
<text top="418" left="216" width="45" height="19" font="0">review </text>
<text top="436" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="454" left="216" width="50" height="19" font="8"><b>Size: </b>43 </text>
<text top="290" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="308" left="359" width="85" height="19" font="0">Children with </text>
<text top="326" left="359" width="126" height="19" font="0">isolated CCHB 1955–</text>
<text top="345" left="359" width="96" height="19" font="0">1985 at Boston </text>
<text top="363" left="359" width="118" height="19" font="0">Children’s Hospital </text>
<text top="290" left="509" width="131" height="19" font="8"><b>Intervention: </b>PM for </text>
<text top="308" left="509" width="152" height="19" font="0">symptoms only, not EKG </text>
<text top="326" left="509" width="110" height="19" font="0">or Holter findings </text>
<text top="290" left="675" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="308" left="674" width="205" height="20" font="0">•  29 remained free of symptoms </text>
<text top="327" left="675" width="158" height="20" font="0">• 14 had symptoms (near </text>
<text top="346" left="686" width="191" height="19" font="0">syncope, exercise intolerance), </text>
<text top="365" left="686" width="155" height="19" font="0">1 had CHF at birth, 1 had </text>
<text top="383" left="686" width="86" height="19" font="0">cardiac arrest </text>
<text top="290" left="895" width="183" height="20" font="0">• Heart rate on ECG or Holter </text>
<text top="309" left="906" width="173" height="19" font="0">did not predict need for PM </text>
<text top="474" left="95" width="86" height="19" font="0">Ando G, et al. </text>
<text top="492" left="95" width="69" height="19" font="0">2005 (187) </text>
<text top="510" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16091145">16091145</a></text>
<text top="510" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16091145"> </a></text>
<text top="474" left="216" width="76" height="19" font="8"><b>Aim: </b>Assess </text>
<text top="492" left="216" width="112" height="19" font="0">hemodynamics of </text>
<text top="510" left="216" width="86" height="19" font="0">long AV delay </text>
<text top="529" left="216" width="3" height="19" font="0"> </text>
<text top="547" left="216" width="106" height="19" font="8"><b>Study type: </b>Case </text>
<text top="565" left="216" width="42" height="19" font="0">report </text>
<text top="583" left="216" width="3" height="19" font="0"> </text>
<text top="602" left="216" width="43" height="19" font="8"><b>Size: </b>1<b> </b></text>
<text top="474" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="492" left="359" width="74" height="19" font="0">Case report<b> </b></text>
<text top="474" left="509" width="109" height="19" font="8"><b>Intervention: </b>PM<b> </b></text>
<text top="474" left="675" width="197" height="19" font="8"><b>Results: </b>During a hemodynamic </text>
<text top="492" left="675" width="186" height="19" font="0">assessment, atrial contraction </text>
<text top="510" left="675" width="170" height="19" font="0">was seen to occur while AV </text>
<text top="529" left="675" width="195" height="19" font="0">valves are closed, similar to PM </text>
<text top="547" left="675" width="64" height="19" font="0">syndrome </text>
<text top="474" left="895" width="193" height="20" font="0">• AV delay decreased from 290 </text>
<text top="493" left="906" width="159" height="19" font="0">to 150 with PM improved </text>
<text top="511" left="906" width="67" height="19" font="0">symptoms </text>
<text top="621" left="95" width="92" height="19" font="0">Carroz P, et al. </text>
<text top="639" left="95" width="69" height="19" font="0">2010 (191) </text>
<text top="658" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19946114">19946114</a></text>
<text top="658" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19946114"> </a></text>
<text top="621" left="216" width="126" height="19" font="8"><b>Aim:</b> Report pseudo </text>
<text top="639" left="216" width="88" height="19" font="0">PM syndrome </text>
<text top="658" left="216" width="3" height="19" font="0"> </text>
<text top="676" left="216" width="106" height="19" font="8"><b>Study type: </b>Case </text>
<text top="694" left="216" width="42" height="19" font="0">report </text>
<text top="712" left="216" width="3" height="19" font="0"> </text>
<text top="731" left="216" width="43" height="19" font="8"><b>Size:</b> 1<b> </b></text>
<text top="621" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="639" left="359" width="106" height="19" font="0">Case report of pt </text>
<text top="658" left="359" width="88" height="19" font="0">with marked 1</text>
<text top="657" left="447" width="7" height="12" font="7">st</text>
<text top="658" left="454" width="3" height="19" font="0"> </text>
<text top="676" left="359" width="102" height="19" font="0">degree AV block<b> </b></text>
<text top="621" left="509" width="123" height="19" font="8"><b>Intervention:</b> Rapid </text>
<text top="639" left="509" width="104" height="19" font="0">atrial pacing and </text>
<text top="658" left="509" width="112" height="19" font="0">atropine injection<b> </b></text>
<text top="621" left="675" width="197" height="19" font="8"><b>Results: </b>At baseline, pt had PR= </text>
<text top="639" left="675" width="190" height="19" font="0">480 ms, intermittent cannon A </text>
<text top="658" left="675" width="186" height="19" font="0">waves. Symptoms of dizziness </text>
<text top="676" left="675" width="197" height="19" font="0">and dyspnea improved with PM<b> </b></text>
<text top="621" left="895" width="38" height="20" font="0">• N/A </text>
<text top="640" left="915" width="3" height="19" font="0"> </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 142 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="84" height="19" font="0">Kim YH, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">1993 (218) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8269289">8269289</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8269289"> </a></text>
<text top="87" left="216" width="89" height="19" font="8"><b>Aim: </b>Describe </text>
<text top="105" left="216" width="83" height="19" font="0">symptoms of </text>
<text top="123" left="216" width="73" height="19" font="0">pseudo-PM </text>
<text top="142" left="216" width="64" height="19" font="0">syndrome </text>
<text top="160" left="216" width="3" height="19" font="0"> </text>
<text top="178" left="216" width="106" height="19" font="8"><b>Study type</b>: Case </text>
<text top="197" left="216" width="42" height="19" font="0">report </text>
<text top="215" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="233" left="216" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="87" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="105" left="359" width="90" height="19" font="8"><b>C</b>ase report of </text>
<text top="123" left="359" width="74" height="19" font="0">pseudo-PM </text>
<text top="142" left="359" width="123" height="19" font="0">syndrome after fast </text>
<text top="160" left="359" width="104" height="19" font="0">PW ablation and </text>
<text top="178" left="359" width="107" height="19" font="0">resultant long PR </text>
<text top="87" left="509" width="138" height="19" font="8"><b>Intervention: </b>Fast PW </text>
<text top="105" left="509" width="53" height="19" font="0">ablation<b> </b></text>
<text top="87" left="675" width="111" height="19" font="8"><b>Results: </b>Marked 1</text>
<text top="87" left="786" width="7" height="12" font="7">st</text>
<text top="87" left="793" width="82" height="19" font="0"> degree AVB, </text>
<text top="105" left="675" width="184" height="19" font="0">very symptomatic. Symptoms </text>
<text top="123" left="675" width="116" height="19" font="0">improved with PM<b> </b></text>
<text top="87" left="895" width="38" height="20" font="0">• N/A </text>
<text top="106" left="915" width="3" height="19" font="0"> </text>
<text top="252" left="95" width="98" height="19" font="0">Barold SS, 1996 </text>
<text top="271" left="95" width="35" height="19" font="0">(193) </text>
<text top="289" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8734740">8734740</a></text>
<text top="289" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8734740"> </a></text>
<text top="252" left="216" width="103" height="19" font="8"><b>Aim: </b>Editorial to </text>
<text top="271" left="216" width="129" height="19" font="0">discuss role of PM in </text>
<text top="289" left="216" width="8" height="19" font="0">1</text>
<text top="289" left="224" width="7" height="12" font="7">st</text>
<text top="289" left="231" width="78" height="19" font="0"> degree AVB </text>
<text top="307" left="216" width="3" height="19" font="0"> </text>
<text top="326" left="216" width="102" height="19" font="8"><b>Study type: </b>N/A </text>
<text top="344" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="362" left="216" width="59" height="19" font="8"><b>Size: </b>N/A<b> </b></text>
<text top="252" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="271" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="252" left="509" width="109" height="19" font="8"><b>Intervention: </b>PM </text>
<text top="271" left="509" width="50" height="19" font="0">implant<b> </b></text>
<text top="252" left="675" width="163" height="19" font="8"><b>Opinion: </b>PMs can be used </text>
<text top="271" left="675" width="177" height="19" font="0">especially in pts with normal </text>
<text top="289" left="675" width="32" height="19" font="0">LVEF<b> </b></text>
<text top="253" left="895" width="38" height="20" font="0">• N/A </text>
<text top="272" left="895" width="3" height="19" font="0"> </text>
<text top="381" left="95" width="91" height="19" font="0">Alboni P, et al. </text>
<text top="400" left="95" width="69" height="19" font="0">2013 (219) </text>
<text top="418" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23286970">23286970</a></text>
<text top="418" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23286970"> </a></text>
<text top="381" left="216" width="92" height="19" font="8"><b> Aim: </b>Describe </text>
<text top="400" left="216" width="107" height="19" font="0">vagally mediated </text>
<text top="418" left="216" width="29" height="19" font="0">AVB </text>
<text top="436" left="216" width="3" height="19" font="0"> </text>
<text top="454" left="216" width="102" height="19" font="8"><b>Study type:</b> N/A </text>
<text top="473" left="216" width="3" height="19" font="0"> </text>
<text top="491" left="216" width="59" height="19" font="8"><b>Size:</b> N/A<b> </b></text>
<text top="381" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="400" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="381" left="509" width="122" height="19" font="8"><b>Intervention: </b>None<b> </b></text>
<text top="382" left="675" width="193" height="20" font="0">• PMs are not warranted in asx </text>
<text top="401" left="686" width="188" height="19" font="0">pts with vagally mediated AVB </text>
<text top="419" left="675" width="162" height="20" font="0">• Typically, these pts have </text>
<text top="438" left="686" width="139" height="19" font="0">normal AV conduction </text>
<text top="382" left="895" width="38" height="20" font="0">• N/A </text>
<text top="401" left="915" width="3" height="19" font="0"> </text>
<text top="510" left="95" width="95" height="19" font="0">Massie B, et al. </text>
<text top="529" left="95" width="69" height="19" font="0">1978 (220) </text>
<text top="547" left="95" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=668079">668079</a></text>
<text top="547" left="140" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=668079"> </a></text>
<text top="510" left="216" width="114" height="19" font="8"><b>Aim: </b>Describe EPS </text>
<text top="529" left="216" width="119" height="19" font="0">findings in pts with </text>
<text top="547" left="216" width="86" height="19" font="0">Mobitz II AVB </text>
<text top="565" left="216" width="3" height="19" font="0"> </text>
<text top="583" left="216" width="106" height="19" font="8"><b>Study type: </b>Case </text>
<text top="602" left="216" width="39" height="19" font="0">series </text>
<text top="620" left="216" width="3" height="19" font="0"> </text>
<text top="638" left="216" width="50" height="19" font="8"><b>Size: </b>13<b> </b></text>
<text top="510" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="529" left="359" width="118" height="19" font="0">Mobitz type II with </text>
<text top="547" left="359" width="115" height="19" font="0">concomitant sinus </text>
<text top="565" left="359" width="50" height="19" font="0">slowing </text>
<text top="583" left="359" width="3" height="19" font="0"> </text>
<text top="602" left="359" width="134" height="19" font="8"><b>Exclusion criteria:</b> No </text>
<text top="620" left="359" width="102" height="19" font="0">associated sinus </text>
<text top="638" left="359" width="50" height="19" font="0">slowing<b> </b></text>
<text top="510" left="509" width="139" height="19" font="8"><b>Intervention: </b>EPS; PM </text>
<text top="529" left="509" width="152" height="19" font="0">for persistent symptoms<b> </b></text>
<text top="510" left="675" width="205" height="19" font="8"><b>Results:</b> Mobitz type II with sinus </text>
<text top="529" left="675" width="200" height="19" font="0">slowing appears related to vagal </text>
<text top="547" left="675" width="32" height="19" font="0">tone<b> </b></text>
<text top="510" left="895" width="123" height="20" font="0">• These episodes of </text>
<text top="529" left="906" width="179" height="19" font="0">bradycardia were responsive </text>
<text top="548" left="906" width="72" height="19" font="0">to atropine </text>
<text top="566" left="895" width="163" height="20" font="0">• Dx of Mobitz type II best </text>
<text top="585" left="906" width="153" height="19" font="0">when sinus rate is stable </text>
<text top="658" left="95" width="70" height="19" font="0">Mosqueda-</text>
<text top="676" left="95" width="91" height="19" font="0">Garcia, R et al. </text>
<text top="694" left="95" width="69" height="19" font="0">2000 (221) </text>
<text top="712" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11104751">11104751</a></text>
<text top="712" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11104751"> </a></text>
<text top="657" left="216" width="103" height="19" font="8"><b>Aim: </b>Attempt to </text>
<text top="676" left="216" width="71" height="19" font="0">explain the </text>
<text top="694" left="216" width="120" height="19" font="0">pathophysiology of </text>
<text top="712" left="216" width="114" height="19" font="0">neurally mediated </text>
<text top="731" left="216" width="54" height="19" font="0">syncope </text>
<text top="749" left="216" width="3" height="19" font="0"> </text>
<text top="657" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="676" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="657" left="519" width="113" height="19" font="8"><b>Intervention: </b>N/A<b> </b></text>
<text top="657" left="675" width="196" height="19" font="8"><b>Conclusions: </b>neurally mediated </text>
<text top="676" left="675" width="153" height="19" font="0">syncope is not a uniform </text>
<text top="694" left="675" width="198" height="19" font="0">syndrome in all pts and involves </text>
<text top="712" left="675" width="122" height="19" font="0">baroreceptor reflex </text>
<text top="731" left="675" width="205" height="19" font="0">abnormalities and neurohumoral </text>
<text top="749" left="675" width="83" height="19" font="0">mechanisms <b> </b></text>
<text top="658" left="895" width="38" height="20" font="0">• N/A </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 143 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="105" left="216" width="99" height="19" font="0">Comprehensive </text>
<text top="123" left="216" width="45" height="19" font="0">review </text>
<text top="142" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="160" left="216" width="59" height="19" font="8"><b>Size: </b>N/A<b> </b></text>
<text top="179" left="95" width="60" height="19" font="0">Guerrero-</text>
<text top="197" left="95" width="93" height="19" font="0">Marquez FJ, et </text>
<text top="216" left="95" width="87" height="19" font="0">al. 2016<b> </b>(183) </text>
<text top="234" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28496928">28496928</a></text>
<text top="234" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28496928"> </a></text>
<text top="179" left="216" width="97" height="19" font="8"><b>Aim: </b>To write a </text>
<text top="197" left="216" width="117" height="19" font="0">featured review of </text>
<text top="216" left="216" width="102" height="19" font="0">paroxysmal AVB </text>
<text top="234" left="216" width="3" height="19" font="0"> </text>
<text top="252" left="216" width="122" height="19" font="8"><b>Study type: </b>Review </text>
<text top="271" left="216" width="3" height="19" font="0"> </text>
<text top="289" left="216" width="59" height="19" font="8"><b>Size: </b>N/A<b> </b></text>
<text top="179" left="359" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="197" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="179" left="509" width="113" height="19" font="8"><b>Intervention: </b>N/A<b> </b></text>
<text top="179" left="675" width="187" height="19" font="8"><b>Conclusions: </b>Idiopathic AVB is </text>
<text top="197" left="686" width="81" height="19" font="0">paroxysmal 3</text>
<text top="197" left="767" width="9" height="12" font="7">rd</text>
<text top="197" left="775" width="86" height="19" font="0"> degree heart </text>
<text top="216" left="686" width="171" height="19" font="0">block with no other rhythm </text>
<text top="234" left="686" width="195" height="19" font="0">abnormalities pre or post in pts </text>
<text top="252" left="686" width="168" height="19" font="0">with normal heart and EKG </text>
<text top="179" left="895" width="179" height="19" font="0">Other causes of AVB include; </text>
<text top="197" left="895" width="157" height="19" font="0">extrinsic vagal effect, Lev-</text>
<text top="216" left="895" width="189" height="19" font="0">Lenegre disease, SLE, bacterial </text>
<text top="234" left="895" width="163" height="19" font="0">endocarditis with abscess, </text>
<text top="252" left="895" width="176" height="19" font="0">sarcoid, Lyme disease, sickle </text>
<text top="271" left="895" width="24" height="19" font="0">cell </text>
<text top="308" left="95" width="80" height="19" font="0">Kato Y, et al. </text>
<text top="326" left="95" width="69" height="19" font="0">2003 (222) </text>
<text top="345" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12870723">12870723</a></text>
<text top="345" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12870723"> </a></text>
<text top="308" left="216" width="126" height="19" font="8"><b>Aim: </b>Assess efficacy </text>
<text top="326" left="216" width="89" height="19" font="0">of steroids for </text>
<text top="345" left="216" width="125" height="19" font="0">resolution of AVB in </text>
<text top="363" left="216" width="70" height="19" font="0">sarcoidosis </text>
<text top="381" left="216" width="3" height="19" font="0"> </text>
<text top="400" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="418" left="216" width="84" height="19" font="0">retrospective </text>
<text top="436" left="216" width="3" height="19" font="0"> </text>
<text top="454" left="216" width="50" height="19" font="8"><b>Size: </b>20<b> </b></text>
<text top="308" left="359" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="326" left="359" width="129" height="19" font="0">with cardiac sarcoid, </text>
<text top="345" left="359" width="120" height="19" font="0">AVB and normal EF<b> </b></text>
<text top="308" left="509" width="139" height="19" font="8"><b>Intervention: S</b>teroids </text>
<text top="326" left="509" width="148" height="19" font="0">per physician discretion </text>
<text top="308" left="675" width="195" height="20" font="0">• <b>Results: </b>Of the 7 treated with </text>
<text top="327" left="686" width="171" height="19" font="0">steroids 4 had resolution of </text>
<text top="346" left="686" width="189" height="19" font="0">AVB, 6 had steroid side effects </text>
<text top="308" left="895" width="192" height="20" font="0">• None of the 13 untreated pts </text>
<text top="327" left="906" width="108" height="19" font="0">resolved the AVB </text>
<text top="346" left="915" width="3" height="19" font="0"> </text>
<text top="474" left="95" width="94" height="19" font="0">Takaya Y, et al. </text>
<text top="492" left="95" width="69" height="19" font="0">2015 (223) </text>
<text top="510" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25529542">25529542</a></text>
<text top="510" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25529542"> </a></text>
<text top="474" left="216" width="79" height="19" font="8"><b> Aim: </b>Assess </text>
<text top="492" left="216" width="127" height="19" font="0">outcomes of sarcoid </text>
<text top="510" left="216" width="98" height="19" font="0">pts with AVB as </text>
<text top="529" left="216" width="129" height="19" font="0">initial manifestation  </text>
<text top="547" left="216" width="3" height="19" font="0"> </text>
<text top="565" left="216" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="583" left="216" width="87" height="19" font="0">Retrospective </text>
<text top="602" left="216" width="127" height="19" font="0">observational study  </text>
<text top="620" left="216" width="3" height="19" font="0"> </text>
<text top="638" left="216" width="50" height="19" font="8"><b>Size: </b>53 </text>
<text top="474" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="492" left="359" width="125" height="19" font="0">Consecutive cardiac </text>
<text top="510" left="359" width="100" height="19" font="0">sarcoid pts with </text>
<text top="529" left="359" width="121" height="19" font="0">either AVB or VT or </text>
<text top="547" left="359" width="28" height="19" font="0">CHF<b> </b></text>
<text top="474" left="509" width="150" height="19" font="8"><b>Intervention: </b>PM or ICD </text>
<text top="492" left="509" width="84" height="19" font="0">per physician<b> </b></text>
<text top="474" left="675" width="196" height="20" font="0">• in general pts presenting with </text>
<text top="493" left="686" width="147" height="19" font="0">AVB have fewer cardiac </text>
<text top="511" left="686" width="195" height="19" font="0">adverse events than those with </text>
<text top="529" left="686" width="181" height="19" font="0">VT/HF (mostly HFH) however </text>
<text top="548" left="686" width="182" height="19" font="0">cardiac mortality is about the </text>
<text top="566" left="686" width="36" height="19" font="0">same </text>
<text top="584" left="675" width="199" height="20" font="0">• Of the 17 with high-grade AVB </text>
<text top="603" left="686" width="146" height="19" font="0">treated with steroids, 7 </text>
<text top="622" left="686" width="72" height="19" font="0">responded  </text>
<text top="474" left="895" width="167" height="20" font="0">• Of the 17 pts with AVB, 7 </text>
<text top="493" left="906" width="174" height="19" font="0">died of fatal SCD including 3 </text>
<text top="511" left="906" width="167" height="19" font="0">who responded to steroids </text>
<text top="529" left="906" width="50" height="19" font="0">for AVB </text>
<text top="658" left="95" width="100" height="19" font="0">Padala SK, et al. </text>
<text top="676" left="95" width="69" height="19" font="0">2017 (224) </text>
<text top="694" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27836297">27836297</a></text>
<text top="694" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27836297"> </a></text>
<text top="657" left="216" width="121" height="19" font="8"><b>Aim: </b>Assess impact </text>
<text top="676" left="216" width="104" height="19" font="0">of steroids given </text>
<text top="694" left="216" width="110" height="19" font="0">early on AVB, VA, </text>
<text top="712" left="216" width="59" height="19" font="0">and LVEF </text>
<text top="731" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="749" left="216" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="767" left="216" width="84" height="19" font="0">retrospective </text>
<text top="657" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="676" left="359" width="118" height="19" font="0">Cardiac sarcoid pts </text>
<text top="694" left="359" width="122" height="19" font="0">given steroids early </text>
<text top="712" left="359" width="52" height="19" font="0">after Dx<b> </b></text>
<text top="657" left="509" width="138" height="19" font="8"><b>Intervention: </b>Steroids<b> </b></text>
<text top="657" left="675" width="164" height="19" font="8"><b>Results:</b> Only those where </text>
<text top="676" left="686" width="171" height="19" font="0">steroids started within 30 d </text>
<text top="694" left="686" width="160" height="19" font="0">had improvement in LVEF </text>
<text top="713" left="675" width="159" height="20" font="0">• Some with early steroid </text>
<text top="732" left="686" width="176" height="19" font="0">treatment had no VT or AVB </text>
<text top="750" left="686" width="73" height="19" font="0">recurrence  </text>
<text top="658" left="895" width="191" height="20" font="0">• Pts who did not receive early </text>
<text top="677" left="906" width="159" height="19" font="0">steroid treatment did not </text>
<text top="695" left="906" width="144" height="19" font="0">have any improvement </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 144 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="3" height="19" font="0"> </text>
<text top="105" left="216" width="50" height="19" font="8"><b>Size:</b> 30<b> </b></text>
<text top="151" left="95" width="98" height="19" font="0">Birnie DH, et al. </text>
<text top="169" left="95" width="69" height="19" font="0">2016 (225) </text>
<text top="188" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27443438">27443438</a></text>
<text top="188" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27443438"> </a></text>
<text top="151" left="216" width="80" height="19" font="8"><b>Aim: </b>Review </text>
<text top="169" left="216" width="127" height="19" font="0">literature on cardiac </text>
<text top="188" left="216" width="47" height="19" font="0">sarcoid </text>
<text top="206" left="216" width="3" height="19" font="0"> </text>
<text top="224" left="216" width="102" height="19" font="8"><b>Study type: </b>N/A </text>
<text top="243" left="216" width="3" height="19" font="0"> </text>
<text top="261" left="216" width="59" height="19" font="8"><b>Size:</b> N/A<b> </b></text>
<text top="151" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="169" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="151" left="509" width="113" height="19" font="8"><b>Intervention: </b>N/A<b> </b></text>
<text top="151" left="675" width="205" height="20" font="0">• <b>Results: </b>RBBB is more common </text>
<text top="170" left="686" width="181" height="19" font="0">than LBBB. Epsilon waves are </text>
<text top="188" left="686" width="36" height="19" font="0">rare.  </text>
<text top="151" left="895" width="160" height="20" font="0">• Sarcoidosis with cardiac </text>
<text top="170" left="906" width="149" height="19" font="0">involvement portends a </text>
<text top="188" left="906" width="103" height="19" font="0">worse prognosis </text>
<text top="280" left="95" width="106" height="19" font="0">Sadek MM, et al. </text>
<text top="298" left="95" width="69" height="19" font="0">2013 (155) </text>
<text top="317" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23623644">23623644</a></text>
<text top="317" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23623644"> </a></text>
<text top="280" left="216" width="102" height="19" font="8"><b>Aim:</b> Systematic </text>
<text top="298" left="216" width="107" height="19" font="0">review and meta-</text>
<text top="317" left="216" width="114" height="19" font="0">analysis of cardiac </text>
<text top="335" left="216" width="97" height="19" font="0">sarcoidosis and </text>
<text top="353" left="216" width="52" height="19" font="0">steroids </text>
<text top="372" left="216" width="3" height="19" font="0"> </text>
<text top="390" left="216" width="102" height="19" font="8"><b>Study type: </b>N/A </text>
<text top="408" left="216" width="3" height="19" font="0"> </text>
<text top="426" left="216" width="97" height="19" font="8"><b>Size:</b> 10 studies<b> </b></text>
<text top="280" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="298" left="359" width="129" height="19" font="0">Published studies on </text>
<text top="317" left="359" width="120" height="19" font="0">steroids for cardiac </text>
<text top="335" left="359" width="70" height="19" font="0">sarcoidosis<b> </b></text>
<text top="280" left="502" width="142" height="19" font="8"><b> Intervention: </b>Steroids<b> </b></text>
<text top="280" left="675" width="162" height="20" font="0">• <b>Results: </b>Overall steroids </text>
<text top="299" left="686" width="185" height="19" font="0">beneficial for recovery of AVB </text>
<text top="317" left="686" width="171" height="19" font="0">with 47.4% of pts improved </text>
<text top="280" left="895" width="182" height="20" font="0">• There are no RCT looking at </text>
<text top="299" left="906" width="180" height="19" font="0">steroid use in cardiac sarcoid </text>
<text top="446" left="95" width="82" height="19" font="0">Zhou Y, et al. </text>
<text top="464" left="95" width="69" height="19" font="0">2017 (226) </text>
<text top="482" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27614001">27614001</a></text>
<text top="482" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27614001"> </a></text>
<text top="445" left="216" width="101" height="19" font="8"><b>Aim: </b>Determine </text>
<text top="464" left="216" width="121" height="19" font="0">outcome of cardiac </text>
<text top="482" left="216" width="96" height="19" font="0">sarcoidosis in a </text>
<text top="500" left="216" width="105" height="19" font="0">single institution </text>
<text top="519" left="216" width="3" height="19" font="0"> </text>
<text top="537" left="216" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="555" left="216" width="87" height="19" font="0">Retrospective </text>
<text top="574" left="216" width="3" height="19" font="0"> </text>
<text top="592" left="216" width="50" height="19" font="8"><b>Size: </b>73<b> </b></text>
<text top="445" left="359" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="464" left="359" width="127" height="19" font="0">pts who met criteria </text>
<text top="482" left="359" width="72" height="19" font="0">for sarcoid <b> </b></text>
<text top="445" left="502" width="113" height="19" font="8"><b> Intervention: </b>Per </text>
<text top="464" left="509" width="124" height="19" font="0">physician discretion<b> </b></text>
<text top="446" left="675" width="164" height="20" font="0">• <b>Results: </b>Heart block was </text>
<text top="465" left="686" width="170" height="19" font="0">present in 19.2% of pts. 5-y </text>
<text top="483" left="686" width="170" height="19" font="0">survival overall was 95.5%.  </text>
<text top="446" left="895" width="184" height="20" font="0">• Lack of ICD or PM predicted </text>
<text top="465" left="906" width="122" height="19" font="0">increased mortality </text>
<text top="611" left="95" width="98" height="19" font="0">Sayed RH, et al. </text>
<text top="629" left="95" width="69" height="19" font="0">2015 (227) </text>
<text top="648" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25549725">25549725</a></text>
<text top="648" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25549725"> </a></text>
<text top="611" left="216" width="112" height="19" font="8"><b>Aim: </b>Characterize </text>
<text top="629" left="216" width="24" height="19" font="0">the </text>
<text top="648" left="216" width="127" height="19" font="0">bradyarrhythmias in </text>
<text top="666" left="216" width="117" height="19" font="0">cardiac AL amyloid </text>
<text top="684" left="216" width="22" height="19" font="0">pts </text>
<text top="703" left="216" width="3" height="19" font="0"> </text>
<text top="721" left="216" width="114" height="19" font="8"><b>Study type: </b>Single </text>
<text top="739" left="216" width="102" height="19" font="0">arm prospective </text>
<text top="758" left="216" width="3" height="19" font="0"> </text>
<text top="776" left="216" width="50" height="19" font="8"><b>Size: </b>20<b> </b></text>
<text top="611" left="359" width="130" height="19" font="8"><b>Inclusion criteria: </b>AL </text>
<text top="629" left="359" width="119" height="19" font="0">amyloidosis + (pre) </text>
<text top="648" left="359" width="120" height="19" font="0">syncope symptoms<b> </b></text>
<text top="611" left="509" width="127" height="19" font="8"><b>Intervention:</b> All pts </text>
<text top="629" left="509" width="77" height="19" font="0">received ILR<b> </b></text>
<text top="611" left="675" width="190" height="19" font="8"><b>Results: </b>13 of the 20 died with </text>
<text top="629" left="686" width="129" height="19" font="0">median survival 60 d </text>
<text top="648" left="675" width="182" height="20" font="0">• 8 of the 13 had bradycardia </text>
<text top="667" left="686" width="195" height="19" font="0">(heart rate &lt;35 bpm) preceding </text>
<text top="685" left="686" width="27" height="19" font="0">PEA </text>
<text top="611" left="915" width="141" height="19" font="0">Baseline ECG showed 1</text>
<text top="611" left="1057" width="7" height="12" font="7">st</text>
<text top="611" left="1064" width="3" height="19" font="0"> </text>
<text top="629" left="915" width="172" height="19" font="0">degree AVB in 45% and 1 pt </text>
<text top="648" left="915" width="126" height="19" font="0">had Mobitz type I at </text>
<text top="666" left="915" width="54" height="19" font="0">baseline </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 145 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="105" height="19" font="0">Reisinger J, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">1997 (228) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9316537">9316537</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9316537"> </a></text>
<text top="87" left="216" width="76" height="19" font="8"><b>Aim: </b>Assess </text>
<text top="105" left="216" width="95" height="19" font="0">spectrum of EP </text>
<text top="123" left="216" width="121" height="19" font="0">abnormalities in AL </text>
<text top="142" left="216" width="52" height="19" font="0">amyloid </text>
<text top="160" left="216" width="3" height="19" font="0"> </text>
<text top="178" left="216" width="106" height="19" font="8"><b>Study type:</b> Case </text>
<text top="197" left="216" width="39" height="19" font="0">series </text>
<text top="215" left="216" width="3" height="19" font="0"> </text>
<text top="233" left="216" width="50" height="19" font="8"><b>Size: </b>25<b> </b></text>
<text top="87" left="359" width="130" height="19" font="8"><b>Inclusion criteria: </b>AL </text>
<text top="105" left="359" width="52" height="19" font="0">amyloid </text>
<text top="87" left="509" width="139" height="19" font="8"><b>Intervention: </b>EPS. ICD </text>
<text top="105" left="509" width="125" height="19" font="0">or PM per physician </text>
<text top="123" left="509" width="64" height="19" font="0">discretion </text>
<text top="87" left="675" width="206" height="19" font="8"><b>Results: </b>All 25 had abnormal EKG </text>
<text top="105" left="686" width="151" height="19" font="0">with conduction disease </text>
<text top="123" left="686" width="50" height="19" font="0">present </text>
<text top="142" left="675" width="194" height="20" font="0">• 23 of 25 had HV &gt;55ms (most </text>
<text top="161" left="686" width="107" height="19" font="0">had narrow QRS) </text>
<text top="87" left="895" width="176" height="20" font="0">• 23 died; 10 died of SCD (of </text>
<text top="106" left="906" width="165" height="19" font="0">which 2 had PM and 1 had </text>
<text top="124" left="906" width="29" height="19" font="0">ICD) </text>
<text top="252" left="95" width="86" height="19" font="0">Panic G, et al. </text>
<text top="271" left="95" width="69" height="19" font="0">2011 (190) </text>
<text top="289" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226549">20226549</a></text>
<text top="289" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226549"> </a></text>
<text top="252" left="216" width="122" height="19" font="8"><b>Aim: </b>Case report of </text>
<text top="271" left="216" width="108" height="19" font="0">AVB due to Lyme </text>
<text top="289" left="216" width="49" height="19" font="0">disease </text>
<text top="307" left="216" width="3" height="19" font="0"> </text>
<text top="326" left="216" width="106" height="19" font="8"><b>Study type: </b>Case </text>
<text top="344" left="216" width="42" height="19" font="0">report </text>
<text top="362" left="216" width="3" height="19" font="0"> </text>
<text top="381" left="216" width="43" height="19" font="8"><b>Size:</b> 1<b> </b></text>
<text top="252" left="359" width="127" height="19" font="8"><b>Inclusion criteria: </b>Pt </text>
<text top="271" left="359" width="115" height="19" font="0">with Lyme disease </text>
<text top="289" left="359" width="103" height="19" font="0">and high-grade 2</text>
<text top="289" left="462" width="10" height="12" font="7">nd</text>
<text top="289" left="473" width="3" height="19" font="0"> </text>
<text top="307" left="359" width="75" height="19" font="0">degree AVB<b> </b></text>
<text top="252" left="509" width="85" height="19" font="8"><b>Intervention: </b></text>
<text top="271" left="509" width="68" height="19" font="0">Antibiotics<b> </b></text>
<text top="252" left="675" width="196" height="19" font="8"><b>Results: </b>Pt presented with high-</text>
<text top="271" left="675" width="195" height="19" font="0">grade AVB which resolved after </text>
<text top="289" left="675" width="113" height="19" font="0">12 d of antibiotics </text>
<text top="252" left="895" width="186" height="19" font="0">Pt presented for symptoms of </text>
<text top="271" left="895" width="171" height="19" font="0">fatigue and heart rate of 31 </text>
<text top="289" left="895" width="31" height="19" font="0">bpm </text>
<text top="400" left="95" width="95" height="19" font="0">Maeno K, et al. </text>
<text top="418" left="95" width="69" height="19" font="0">2009 (188) </text>
<text top="436" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19466526">19466526</a></text>
<text top="436" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19466526"> </a></text>
<text top="400" left="216" width="101" height="19" font="8"><b>Aim: </b>Report the </text>
<text top="418" left="216" width="115" height="19" font="0">interaction of OSA </text>
<text top="436" left="216" width="26" height="19" font="0">and </text>
<text top="455" left="216" width="106" height="19" font="0">bradyarrhythmia </text>
<text top="473" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="491" left="216" width="106" height="19" font="8"><b>Study type</b>: Case </text>
<text top="509" left="216" width="129" height="19" font="0">report and literature </text>
<text top="528" left="216" width="45" height="19" font="0">review </text>
<text top="546" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="564" left="216" width="43" height="19" font="8"><b>Size: </b>1<b> </b></text>
<text top="400" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="418" left="359" width="28" height="19" font="0">N/A<b> </b></text>
<text top="400" left="509" width="121" height="19" font="8"><b>Intervention: </b>CPAP<b> </b></text>
<text top="400" left="675" width="152" height="20" font="0">• <b>Results</b>: Profound AVB </text>
<text top="419" left="686" width="121" height="19" font="0">resolved with CPAP<b> </b></text>
<text top="400" left="895" width="173" height="20" font="0">• In this case, AVB was seen </text>
<text top="419" left="906" width="178" height="19" font="0">prior to hypoxia and was not </text>
<text top="437" left="906" width="85" height="19" font="0">simultaneous<b> </b></text>
<text top="583" left="95" width="108" height="19" font="0">Benditt DG, et al. </text>
<text top="602" left="95" width="69" height="19" font="0">1983 (229) </text>
<text top="620" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6359850">6359850</a></text>
<text top="620" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6359850"> </a></text>
<text top="583" left="216" width="94" height="19" font="8"><b>Aim: </b>Assess EP </text>
<text top="602" left="216" width="124" height="19" font="0">effects of IV and PO </text>
<text top="620" left="216" width="80" height="19" font="0">theophylline </text>
<text top="638" left="216" width="3" height="19" font="0"> </text>
<text top="657" left="216" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="675" left="216" width="28" height="19" font="0">arm </text>
<text top="693" left="216" width="3" height="19" font="0"> </text>
<text top="712" left="216" width="50" height="19" font="8"><b>Size: </b>10<b> </b></text>
<text top="583" left="359" width="132" height="19" font="8"><b>Inclusion criteria: </b>No </text>
<text top="602" left="359" width="128" height="19" font="0">significant structural </text>
<text top="620" left="359" width="111" height="19" font="0">heart disease and </text>
<text top="638" left="359" width="106" height="19" font="0">bradycardia with </text>
<text top="657" left="359" width="116" height="19" font="0">symptoms. All had </text>
<text top="675" left="359" width="90" height="19" font="0">prior syncope <b> </b></text>
<text top="583" left="509" width="140" height="19" font="8"><b>Intervention: </b>Acute IV </text>
<text top="602" left="509" width="115" height="19" font="0">theophylline, then </text>
<text top="620" left="509" width="149" height="19" font="0">chronic PO theophylline </text>
<text top="584" left="675" width="179" height="20" font="0">• <b>Results: </b>Chronic treatment </text>
<text top="603" left="686" width="171" height="19" font="0">with level 9–12 tolerated in </text>
<text top="621" left="686" width="167" height="19" font="0">8/10 (80%); suppression of </text>
<text top="639" left="686" width="190" height="19" font="0">symptoms achieved in 6 of the </text>
<text top="658" left="686" width="11" height="19" font="0">8 </text>
<text top="584" left="895" width="38" height="20" font="0">• N/A<b> </b></text>
<text top="731" left="95" width="98" height="19" font="0">Nimura A, et al. </text>
<text top="749" left="95" width="69" height="19" font="0">2011 (230) </text>
<text top="767" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21921376">21921376</a></text>
<text top="767" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21921376"> </a></text>
<text top="731" left="216" width="80" height="19" font="8"><b>Aim: </b>Discuss </text>
<text top="749" left="216" width="53" height="19" font="0">possible </text>
<text top="767" left="216" width="124" height="19" font="0">mechanisms of AVB </text>
<text top="731" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="749" left="359" width="74" height="19" font="0">Case report<b> </b></text>
<text top="731" left="509" width="147" height="19" font="8"><b>Intervention: </b>Cilostazol<b> </b></text>
<text top="731" left="675" width="189" height="20" font="0">• <b>Results</b>: In an elderly pt with </text>
<text top="750" left="686" width="154" height="19" font="0">high-grade AVB, the AVB </text>
<text top="731" left="895" width="38" height="20" font="0">• N/A<b> </b></text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 146 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="96" height="19" font="0">resolution with </text>
<text top="105" left="216" width="60" height="19" font="0">cilostazol </text>
<text top="123" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="216" width="106" height="19" font="8"><b>Study type: </b>Case </text>
<text top="160" left="216" width="42" height="19" font="0">report </text>
<text top="178" left="216" width="3" height="19" font="0"> </text>
<text top="197" left="216" width="35" height="19" font="8"><b>Size:  </b></text>
<text top="87" left="686" width="148" height="19" font="0">resolved after cilostazol </text>
<text top="105" left="686" width="66" height="19" font="0">treatment<b> </b></text>
<text top="216" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="236" left="86" width="792" height="23" font="5"><b>Data Supplement 35. RCTs of meds/reversible/transient causes of bradycardia due to AVB (Section 6.4.2)  </b></text>
<text top="259" left="122" width="39" height="19" font="8"><b>Study </b></text>
<text top="277" left="115" width="64" height="19" font="8"><b>Acronym; </b></text>
<text top="295" left="122" width="51" height="19" font="8"><b>Author; </b></text>
<text top="313" left="126" width="32" height="19" font="8"><b>Year </b></text>
<text top="332" left="115" width="65" height="19" font="8"><b>Published </b></text>
<text top="259" left="224" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="277" left="230" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="295" left="223" width="86" height="19" font="8"><b>Study Size (N)</b></text>
<text top="294" left="309" width="4" height="21" font="2"><b> </b></text>
<text top="259" left="353" width="117" height="19" font="8"><b>Patient Population</b></text>
<text top="257" left="469" width="4" height="21" font="2"><b> </b></text>
<text top="259" left="511" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="277" left="550" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="295" left="512" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="313" left="555" width="56" height="19" font="8"><b>patients)</b></text>
<text top="312" left="610" width="4" height="21" font="2"><b> </b></text>
<text top="259" left="726" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="277" left="711" width="156" height="19" font="8"><b>(Absolute Event Rates, P </b></text>
<text top="295" left="710" width="165" height="19" font="8"><b>value; OR or RR; &amp; 95% CI)</b></text>
<text top="294" left="874" width="4" height="21" font="2"><b> </b></text>
<text top="259" left="903" width="66" height="19" font="8"><b>Relevant 2</b></text>
<text top="258" left="969" width="5" height="12" font="13"><b>0</b></text>
<text top="259" left="974" width="114" height="19" font="8"><b> Endpoint (if any); </b></text>
<text top="277" left="937" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="295" left="954" width="99" height="19" font="8"><b>Adverse Events</b> </text>
<text top="351" left="95" width="80" height="19" font="8"><b>Birmingham </b></text>
<text top="369" left="95" width="31" height="19" font="8"><b>Trial </b></text>
<text top="388" left="95" width="91" height="19" font="0">Watson RD, et </text>
<text top="406" left="95" width="87" height="19" font="0">al. 1984 (231) </text>
<text top="424" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475712">6475712</a></text>
<text top="424" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475712"> </a></text>
<text top="351" left="202" width="116" height="19" font="8"><b> Aim: </b>Determine if </text>
<text top="369" left="202" width="111" height="19" font="0">PM in post MI pts </text>
<text top="388" left="202" width="102" height="19" font="0">with conduction </text>
<text top="406" left="202" width="100" height="19" font="0">disease reduces </text>
<text top="424" left="202" width="59" height="19" font="0">mortality </text>
<text top="443" left="202" width="3" height="19" font="0"> </text>
<text top="461" left="202" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="479" left="202" width="3" height="19" font="0"> </text>
<text top="497" left="202" width="50" height="19" font="8"><b>Size: </b>50 </text>
<text top="351" left="347" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="369" left="347" width="116" height="19" font="0">Survived 14 d post </text>
<text top="388" left="347" width="109" height="19" font="0">MI, have RBBB or </text>
<text top="406" left="347" width="68" height="19" font="0">RBBB+ left </text>
<text top="424" left="347" width="67" height="19" font="0">hemiblock </text>
<text top="443" left="347" width="3" height="19" font="0"> </text>
<text top="461" left="347" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="479" left="347" width="105" height="19" font="0">Prior conduction </text>
<text top="497" left="347" width="76" height="19" font="0">disease, PM </text>
<text top="351" left="491" width="156" height="19" font="8"><b>Intervention: </b>Ventricular </text>
<text top="369" left="491" width="55" height="19" font="0">PM<b> </b>(27)  </text>
<text top="388" left="491" width="3" height="19" font="8"><b> </b></text>
<text top="406" left="491" width="159" height="19" font="8"><b>Comparator: </b>Control (23) </text>
<text top="351" left="679" width="197" height="20" font="0">• <b>Results: </b>At 5-y follow-up, 61% </text>
<text top="370" left="690" width="184" height="19" font="0">of PM pts had died compared </text>
<text top="388" left="690" width="131" height="19" font="0">to 41% of control pts<b> </b></text>
<text top="351" left="894" width="147" height="20" font="0">• Over 5-y follow-up no </text>
<text top="370" left="905" width="120" height="19" font="0">progression of AVB </text>
<text top="389" left="894" width="117" height="20" font="0">• PM of no benefit </text>
<text top="408" left="894" width="195" height="20" font="0">• VT was an important cause of </text>
<text top="427" left="905" width="39" height="19" font="0">death </text>
<text top="517" left="86" width="4" height="21" font="4"> </text>
<text top="537" left="86" width="971" height="23" font="5"><b>Data Supplement 36. Nonrandomized data of Medications/Reversible/Transient Causes of Bradycardia due to AVB (Section 6.4.2) </b></text>
<text top="559" left="100" width="113" height="21" font="2"><b>Study Acronym; </b></text>
<text top="580" left="116" width="91" height="21" font="2"><b>Author; Year </b></text>
<text top="600" left="126" width="71" height="21" font="2"><b>Published </b></text>
<text top="620" left="136" width="42" height="21" font="2"><b>PMID </b></text>
<text top="559" left="231" width="180" height="21" font="2"><b>Study Type/Design; Study </b></text>
<text top="580" left="299" width="55" height="21" font="2"><b>Size (N) </b></text>
<text top="559" left="434" width="132" height="21" font="2"><b>Patient Population </b></text>
<text top="559" left="613" width="206" height="21" font="2"><b>Primary Endpoint and Results </b></text>
<text top="559" left="874" width="155" height="21" font="2"><b>Summary/Conclusion; </b></text>
<text top="580" left="884" width="74" height="21" font="2"><b>Comments</b></text>
<text top="581" left="958" width="3" height="19" font="0"> </text>
<text top="641" left="96" width="89" height="19" font="0">Tans AC, et al. </text>
<text top="659" left="96" width="69" height="19" font="0">1980 (232) </text>
<text top="677" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7350750">7350750</a></text>
<text top="677" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7350750"> </a></text>
<text top="641" left="229" width="148" height="19" font="8"><b>Aim: </b>Prognosis of acute </text>
<text top="659" left="229" width="171" height="19" font="0">inferior MI with heart block </text>
<text top="677" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="696" left="229" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="714" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="732" left="229" width="58" height="19" font="8"><b>Size: </b>144 </text>
<text top="641" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="659" left="425" width="119" height="19" font="0">Acute inferior MI, 2</text>
<text top="659" left="544" width="10" height="12" font="7">nd</text>
<text top="659" left="554" width="3" height="19" font="0"> </text>
<text top="677" left="425" width="34" height="19" font="0">and 3</text>
<text top="677" left="459" width="9" height="12" font="7">rd</text>
<text top="677" left="468" width="85" height="19" font="0"> AVB, AF with </text>
<text top="696" left="425" width="142" height="19" font="0">rate &lt;60, 2:1 AVB, AVB </text>
<text top="714" left="425" width="93" height="19" font="0">lasted &gt;30 min </text>
<text top="641" left="587" width="235" height="19" font="8"><b>1</b>°<b> endpoint:</b> AVB was associated with </text>
<text top="660" left="587" width="202" height="19" font="0">increased mortality (22% vs. 9%) </text>
<text top="678" left="587" width="3" height="19" font="0"> </text>
<text top="696" left="587" width="254" height="19" font="8"><b>Results:</b> AVB developed between 1 and 5 </text>
<text top="715" left="587" width="64" height="19" font="0">d after MI<b> </b></text>
<text top="641" left="857" width="195" height="20" font="0">• 94 had CHB, 84 recovered 1:1 </text>
<text top="660" left="868" width="124" height="19" font="0">conduction, 10 died </text>
<text top="678" left="857" width="219" height="20" font="0">• Duration of AVB was 30 min–16 d </text>
<text top="697" left="857" width="200" height="20" font="0">• AVB after MI typically resolves </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 147 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="99" height="19" font="0">Ginks WR, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">1977 (233) </text>
<text top="123" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=836733">836733</a></text>
<text top="123" left="141" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=836733"> </a></text>
<text top="87" left="229" width="180" height="19" font="8"><b>Aim: </b>Determine the need for </text>
<text top="105" left="229" width="163" height="19" font="0">permanent PM in pts with </text>
<text top="123" left="229" width="140" height="19" font="0">Anterior MI and temp. </text>
<text top="142" left="229" width="93" height="19" font="0">pacing for CHB </text>
<text top="160" left="229" width="3" height="19" font="0"> </text>
<text top="178" left="229" width="163" height="19" font="8"><b>Study type</b>: Observational </text>
<text top="197" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="215" left="229" width="50" height="19" font="8"><b>Size: </b>52 </text>
<text top="87" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="105" left="425" width="107" height="19" font="0">Anterior MI, CHB </text>
<text top="123" left="425" width="146" height="19" font="0">2 had CHB, narrow QRS </text>
<text top="142" left="425" width="107" height="19" font="0">50 had QRS &gt;120<b> </b></text>
<text top="88" left="587" width="215" height="19" font="8"><b>1</b>°<b> endpoint:</b> Of the 25 survivors, 4 </text>
<text top="106" left="587" width="170" height="19" font="0">required permanent pacing </text>
<text top="124" left="587" width="3" height="19" font="0"> </text>
<text top="143" left="587" width="159" height="19" font="8"><b>Results:</b> 27 of the 52 died<b> </b></text>
<text top="87" left="857" width="228" height="20" font="0">• Of the surviving 25 pts, 1 remained </text>
<text top="106" left="868" width="209" height="19" font="0">in CHB and underwent PM before </text>
<text top="124" left="868" width="218" height="19" font="0">discharge and 2 pts developed CHB </text>
<text top="143" left="868" width="82" height="19" font="0">months later </text>
<text top="161" left="857" width="197" height="20" font="0">• Do not recommend PM if CHB </text>
<text top="180" left="868" width="53" height="19" font="0">resolves </text>
<text top="234" left="96" width="97" height="19" font="0">Singh SM, et al. </text>
<text top="252" left="96" width="69" height="19" font="0">2015 (234) </text>
<text top="271" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25205530">25205530</a></text>
<text top="271" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25205530"> </a></text>
<text top="234" left="229" width="179" height="19" font="8"><b>Aim: </b>Determine incidence of </text>
<text top="252" left="229" width="139" height="19" font="0">high-grade AVB in ACS </text>
<text top="271" left="229" width="3" height="19" font="0"> </text>
<text top="289" left="229" width="167" height="19" font="8"><b>Study type:</b> Global registry </text>
<text top="307" left="229" width="57" height="19" font="0">(GRACE)  </text>
<text top="326" left="229" width="3" height="19" font="0"> </text>
<text top="344" left="229" width="131" height="19" font="8"><b>Size:</b> 1701 (of 59,229 </text>
<text top="362" left="229" width="118" height="19" font="0">subjects in GRACE) </text>
<text top="234" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="252" left="425" width="145" height="19" font="0">GRACE<b> </b>Registry subject </text>
<text top="271" left="425" width="128" height="19" font="0">with high-grade AVB<b> </b></text>
<text top="289" left="425" width="3" height="19" font="8"><b> </b></text>
<text top="307" left="425" width="144" height="19" font="8"><b>Exclusion criteria:</b> Lack </text>
<text top="326" left="425" width="114" height="19" font="0">of high-grade AVB<b> </b></text>
<text top="235" left="587" width="241" height="19" font="8"><b>1</b>°<b> endpoint:</b> 2.9% of subjects had high-</text>
<text top="253" left="587" width="67" height="19" font="0">grade AVB </text>
<text top="272" left="587" width="3" height="19" font="0"> </text>
<text top="290" left="586" width="197" height="19" font="8"><b>Results:</b> Rate of high-grade AVB </text>
<text top="308" left="586" width="135" height="19" font="0">decreased over time. <b> </b></text>
<text top="234" left="857" width="223" height="20" font="0">• 46% present initially with AVB and </text>
<text top="253" left="868" width="164" height="19" font="0">54% developed in hospital </text>
<text top="272" left="857" width="221" height="20" font="0">• 23% of high-grade AVB pts died in </text>
<text top="292" left="868" width="200" height="19" font="0">the hospital (OR: 4.2; 95% CI: 3.6</text>
<text top="291" left="1068" width="8" height="21" font="4">–</text>
<text top="311" left="868" width="84" height="19" font="0">4.9; p&lt;0.001) </text>
<text top="329" left="857" width="214" height="20" font="0">• Of the 1701, 100 (5.9%) required </text>
<text top="348" left="868" width="95" height="19" font="0">permanent PM </text>
<text top="381" left="96" width="112" height="19" font="0">Osmonov D, et al. </text>
<text top="400" left="96" width="69" height="19" font="0">2012 (151)<b> </b></text>
<text top="418" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22530749">22530749</a></text>
<text top="418" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22530749"> </a></text>
<text top="381" left="229" width="158" height="19" font="8"><b>Study type:</b> Single-center </text>
<text top="400" left="229" width="166" height="19" font="0">retrospective cohort of pts </text>
<text top="418" left="229" width="143" height="19" font="0">with drug induced AVB </text>
<text top="436" left="229" width="3" height="19" font="0"> </text>
<text top="454" left="229" width="169" height="19" font="8"><b>Size:</b> N=108 (16% of all 668 </text>
<text top="473" left="229" width="102" height="19" font="0">pts admit AVB). <b> </b></text>
<text top="381" left="425" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="400" left="425" width="112" height="19" font="0">pts admitted with </text>
<text top="418" left="425" width="112" height="19" font="0">Mobitz type II or 3</text>
<text top="418" left="537" width="9" height="12" font="7">rd</text>
<text top="418" left="546" width="3" height="19" font="0"> </text>
<text top="436" left="425" width="143" height="19" font="0">degree AVB or 2:1 AVB </text>
<text top="455" left="425" width="142" height="19" font="0">who were on AV nodal </text>
<text top="473" left="425" width="92" height="19" font="0">blocking drugs </text>
<text top="491" left="425" width="3" height="19" font="0"> </text>
<text top="509" left="425" width="137" height="19" font="8"><b>Exclusion criteria:</b> MI, </text>
<text top="528" left="425" width="69" height="19" font="0">electrolyte </text>
<text top="546" left="425" width="133" height="19" font="0">disturbances, digoxin </text>
<text top="564" left="425" width="48" height="19" font="0">toxicity<b> </b></text>
<text top="382" left="587" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution/ recurrence </text>
<text top="401" left="587" width="119" height="19" font="0">AVB, need for PPM </text>
<text top="419" left="587" width="3" height="19" font="0"> </text>
<text top="437" left="587" width="252" height="19" font="8"><b>Results:</b> Resolution of AVB within 72 h in </text>
<text top="455" left="587" width="256" height="19" font="0">72%. 21/78 (27%) had recurrence of AVB. </text>
<text top="474" left="587" width="239" height="19" font="0">Overall 51/108 (48%) had persistent of </text>
<text top="492" left="587" width="246" height="19" font="0">recurrent AVB despite drug withdrawal.<b> </b></text>
<text top="382" left="857" width="194" height="20" font="0">• Half of pts with AVB on nodal-</text>
<text top="401" left="868" width="207" height="19" font="0">blocking drugs require PM before </text>
<text top="419" left="868" width="217" height="19" font="0">discharge despite drug withdrawal. </text>
<text top="437" left="857" width="221" height="20" font="0">• Limited follow-up – other pts may </text>
<text top="456" left="868" width="199" height="19" font="0">have required PPM at later date </text>
<text top="583" left="96" width="95" height="19" font="0">Zeltser D, et al. </text>
<text top="602" left="96" width="69" height="19" font="0">2004 (152)<b> </b></text>
<text top="620" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15234417">15234417</a></text>
<text top="620" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15234417"> </a></text>
<text top="583" left="229" width="158" height="19" font="8"><b>Study type:</b> Single-center </text>
<text top="602" left="229" width="132" height="19" font="0">retrospective cohort  </text>
<text top="620" left="229" width="3" height="19" font="0"> </text>
<text top="638" left="229" width="146" height="19" font="8"><b>Size:</b> N=169 (60% male, </text>
<text top="657" left="229" width="103" height="19" font="0">mean age 78 y). <b> </b></text>
<text top="583" left="425" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="602" left="425" width="120" height="19" font="0">pts admitted with 2</text>
<text top="602" left="545" width="10" height="12" font="7">nd</text>
<text top="602" left="555" width="3" height="19" font="0"> </text>
<text top="620" left="425" width="24" height="19" font="0">or 3</text>
<text top="620" left="450" width="9" height="12" font="7">rd</text>
<text top="620" left="458" width="78" height="19" font="0"> degree AVB </text>
<text top="638" left="425" width="75" height="19" font="0">1999–2003. </text>
<text top="657" left="425" width="3" height="19" font="0"> </text>
<text top="675" left="425" width="137" height="19" font="8"><b>Exclusion criteria:</b> MI, </text>
<text top="693" left="425" width="95" height="19" font="0">digoxin toxicity<b> </b></text>
<text top="584" left="587" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution/ recurrence </text>
<text top="603" left="587" width="183" height="19" font="0">AVB, need for permanent PM </text>
<text top="621" left="587" width="3" height="19" font="0"> </text>
<text top="639" left="587" width="251" height="19" font="8"><b>Results:</b> 92/169 (54%) were receiving AV </text>
<text top="658" left="587" width="232" height="19" font="0">nodal blockers; 79/92 (86%) had drug </text>
<text top="676" left="587" width="252" height="19" font="0">discontinued. 41% had resolution of AVB </text>
<text top="694" left="587" width="242" height="19" font="0">with stopping drug; 56% had relapse of </text>
<text top="713" left="587" width="32" height="19" font="0">AVB <b> </b></text>
<text top="584" left="857" width="217" height="20" font="0">• Overall, only 15% of pts with AVB </text>
<text top="603" left="868" width="203" height="19" font="0">on nodal blocking drugs had AVB </text>
<text top="621" left="868" width="114" height="19" font="0">“caused by drugs” </text>
<text top="639" left="857" width="218" height="20" font="0">• AVB may recur despite remaining </text>
<text top="658" left="868" width="76" height="19" font="0">off the drug </text>
<text top="732" left="96" width="118" height="19" font="0">Knudsen MB, et al. </text>
<text top="750" left="96" width="69" height="19" font="0">2013 (150)<b> </b></text>
<text top="768" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746">23869746</a></text>
<text top="768" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23869746"> </a></text>
<text top="731" left="229" width="162" height="19" font="8"><b>Study type:</b> Single-center, </text>
<text top="750" left="229" width="132" height="19" font="0">retrospective cohort  </text>
<text top="768" left="229" width="3" height="19" font="0"> </text>
<text top="731" left="425" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="750" left="425" width="97" height="19" font="0">admitted with 2</text>
<text top="750" left="523" width="10" height="12" font="7">nd</text>
<text top="750" left="533" width="28" height="19" font="0"> or 3</text>
<text top="750" left="561" width="9" height="12" font="7">rd</text>
<text top="750" left="569" width="3" height="19" font="0"> </text>
<text top="768" left="425" width="105" height="19" font="0">degree AVB, had </text>
<text top="732" left="587" width="234" height="19" font="8"><b>1</b>°<b> endpoint:</b> Need for permanent PM </text>
<text top="751" left="587" width="255" height="19" font="0">after drug discontinuation; complications </text>
<text top="769" left="587" width="47" height="19" font="0">of TPM </text>
<text top="732" left="857" width="230" height="20" font="0">• Pts with AVB on AADs or digoxin do </text>
<text top="751" left="868" width="194" height="19" font="0">not benefit from temp. PM and </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 148 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="229" width="71" height="19" font="8"><b>Size:</b> N=55 <b> </b></text>
<text top="87" left="425" width="145" height="19" font="0">temporary pacing wire, </text>
<text top="105" left="425" width="113" height="19" font="0">were on class II-IV </text>
<text top="123" left="425" width="107" height="19" font="0">AADs or digoxin.  </text>
<text top="142" left="425" width="3" height="19" font="0"> </text>
<text top="160" left="425" width="142" height="19" font="8"><b>Exclusion criteria:</b> AVB </text>
<text top="178" left="425" width="142" height="19" font="0">due to other identified </text>
<text top="197" left="425" width="99" height="19" font="0">cause, prior PM </text>
<text top="215" left="425" width="124" height="19" font="0">explant, died within </text>
<text top="233" left="425" width="78" height="19" font="0">several days<b> </b></text>
<text top="87" left="587" width="3" height="19" font="0"> </text>
<text top="105" left="587" width="186" height="19" font="8"><b>Results:</b> 47/55 (85%) required </text>
<text top="123" left="587" width="224" height="19" font="0">permanent PM in hospital. 2/55 had </text>
<text top="142" left="587" width="253" height="19" font="0">recurrent AVB and required PPM. 11% of </text>
<text top="160" left="587" width="210" height="19" font="0">pts had complication of temp. PM </text>
<text top="178" left="587" width="151" height="19" font="0">(infection/ dislodgment)<b> </b></text>
<text top="87" left="868" width="206" height="19" font="0">drug washout. Should proceed to </text>
<text top="105" left="868" width="100" height="19" font="0">PPM w/o delay. </text>
<text top="252" left="96" width="96" height="19" font="0">Ozcan KS, et al. </text>
<text top="271" left="96" width="69" height="19" font="0">2012 (157)<b> </b></text>
<text top="289" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22738687">22738687</a></text>
<text top="289" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22738687"> </a></text>
<text top="252" left="229" width="158" height="19" font="8"><b>Study type:</b> Single-center </text>
<text top="271" left="229" width="132" height="19" font="0">retrospective cohort  </text>
<text top="289" left="229" width="3" height="19" font="0"> </text>
<text top="307" left="229" width="173" height="19" font="8"><b>Size:</b> N=50 (29 hypothyroid, </text>
<text top="326" left="229" width="106" height="19" font="0">21 hyperthyroid)<b> </b></text>
<text top="252" left="425" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="271" left="425" width="64" height="19" font="0">pts. with 2</text>
<text top="271" left="489" width="10" height="12" font="7">nd</text>
<text top="271" left="500" width="13" height="19" font="0">/3</text>
<text top="271" left="513" width="8" height="12" font="7">rd</text>
<text top="271" left="522" width="49" height="19" font="0"> degree </text>
<text top="289" left="425" width="145" height="19" font="0">AVB who had hyper- or </text>
<text top="307" left="425" width="99" height="19" font="0">hypothyroidism </text>
<text top="326" left="425" width="3" height="19" font="0"> </text>
<text top="344" left="425" width="137" height="19" font="8"><b>Exclusion criteria:</b> MI, </text>
<text top="362" left="425" width="75" height="19" font="0">electrolytes </text>
<text top="381" left="425" width="139" height="19" font="0">abnormalities, digoxin </text>
<text top="399" left="425" width="110" height="19" font="0">toxicity, on AADs <b> </b></text>
<text top="253" left="587" width="223" height="19" font="8"><b>1</b>°<b> endpoint:</b> Persistent AVB despite </text>
<text top="272" left="587" width="217" height="19" font="0">treatment of thyroid abnormalities </text>
<text top="290" left="587" width="3" height="19" font="0"> </text>
<text top="308" left="587" width="208" height="19" font="8"><b>Results:</b> 46/50 (92%) pts required </text>
<text top="326" left="587" width="224" height="19" font="0">permanent PM; 2 additional pts had </text>
<text top="345" left="587" width="247" height="19" font="0">persistent AVB. 76% of hypothyroid and </text>
<text top="363" left="587" width="227" height="19" font="0">86% of hyperthyroid had irreversible </text>
<text top="381" left="587" width="33" height="19" font="0">AVB.<b> </b></text>
<text top="252" left="857" width="213" height="19" font="0"> Thyroid abnormalities are rarely a </text>
<text top="271" left="857" width="150" height="19" font="0">cause of reversible AVB. </text>
<text top="418" left="96" width="120" height="19" font="0">Farre N, et al. 2014 </text>
<text top="436" left="96" width="35" height="19" font="0">(154) </text>
<text top="455" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24491864">24491864</a></text>
<text top="455" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24491864"> </a></text>
<text top="418" left="229" width="178" height="19" font="8"><b>Aim: </b>Assess outcome of CHB </text>
<text top="436" left="229" width="177" height="19" font="0">due to ACS and other causes </text>
<text top="454" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="473" left="229" width="162" height="19" font="8"><b>Study type</b>: Retrospective<b> </b></text>
<text top="491" left="229" width="3" height="19" font="0"> </text>
<text top="509" left="229" width="167" height="19" font="8"><b>Size:</b> 79 pts with reversible </text>
<text top="528" left="229" width="36" height="19" font="0">AVB;  </text>
<text top="546" left="229" width="106" height="19" font="0">grp A=ACS, N=52 </text>
<text top="564" left="229" width="136" height="19" font="0">Grp B=non-ACS, N=27<b> </b></text>
<text top="418" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="436" left="425" width="116" height="19" font="0">reversible CHB, no </text>
<text top="455" left="425" width="90" height="19" font="0">indwelling PM </text>
<text top="473" left="425" width="3" height="19" font="0"> </text>
<text top="491" left="425" width="140" height="19" font="8"><b>Exclusion criteria: </b>Felt </text>
<text top="509" left="425" width="123" height="19" font="0">not to be<b> </b>reversible<b> </b></text>
<text top="418" left="587" width="253" height="19" font="8"><b>Results: </b>For the ACS group 1/52 received </text>
<text top="436" left="587" width="113" height="19" font="0">a permanent PM.  </text>
<text top="455" left="587" width="205" height="19" font="0">For the non-ACS, AVB was due to </text>
<text top="473" left="587" width="216" height="19" font="0">hyperkalemia, AVN blockers, acute </text>
<text top="491" left="587" width="243" height="19" font="0">infection, 1 PE; 9/27 had recurrent AVB </text>
<text top="510" left="587" width="178" height="19" font="0">and required permanent PM<b> </b></text>
<text top="418" left="857" width="175" height="20" font="0">• If ACS, syncope presenting </text>
<text top="437" left="868" width="208" height="19" font="0">symptom of CHB 6%; for non-ACS </text>
<text top="455" left="868" width="33" height="19" font="0">33%. </text>
<text top="474" left="857" width="223" height="20" font="0">• 39% of reversible non-ACS pts had </text>
<text top="493" left="868" width="220" height="19" font="0">recurrent AVB requiring permanent </text>
<text top="511" left="868" width="24" height="19" font="0">PM </text>
<text top="530" left="857" width="192" height="20" font="0">• 2% of ACS had recurrent AVB </text>
<text top="549" left="857" width="216" height="20" font="0">• Many non-ACS had residual LBBB </text>
<text top="583" left="96" width="120" height="19" font="0">Panic G, et al. 2011 </text>
<text top="602" left="96" width="35" height="19" font="0">(190) </text>
<text top="620" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226549">20226549</a></text>
<text top="620" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226549"> </a></text>
<text top="583" left="229" width="178" height="19" font="8"><b>Aim: </b>Case report of AVB due </text>
<text top="602" left="229" width="101" height="19" font="0">to Lyme disease </text>
<text top="620" left="229" width="3" height="19" font="0"> </text>
<text top="638" left="229" width="148" height="19" font="8"><b>Study type: </b>Case report </text>
<text top="657" left="229" width="3" height="19" font="0"> </text>
<text top="675" left="229" width="43" height="19" font="8"><b>Size:</b> 1<b> </b></text>
<text top="583" left="425" width="127" height="19" font="8"><b>Inclusion criteria: </b>Pt </text>
<text top="602" left="425" width="141" height="19" font="0">with Lyme disease and </text>
<text top="620" left="425" width="77" height="19" font="0">high-grade 2</text>
<text top="620" left="502" width="10" height="12" font="7">nd</text>
<text top="620" left="512" width="49" height="19" font="0"> degree </text>
<text top="638" left="425" width="29" height="19" font="0">AVB<b> </b></text>
<text top="583" left="587" width="234" height="19" font="8"><b>Results: </b>Pt presented with high-grade </text>
<text top="602" left="587" width="202" height="19" font="0">AVB which resolved after 12 d of </text>
<text top="620" left="587" width="67" height="19" font="0">antibiotics<b> </b></text>
<text top="584" left="857" width="225" height="20" font="0">• Pt<b> </b>presented with high-grade AVB, </text>
<text top="603" left="868" width="195" height="19" font="0">resolution after 12 d antibiotics<b> </b></text>
<text top="621" left="857" width="194" height="20" font="0">• 5% of pts with Lyme will have </text>
<text top="640" left="868" width="213" height="19" font="0">cardiac involvement, typically AVB </text>
<text top="694" left="96" width="88" height="19" font="0">Kostic T, et al. </text>
<text top="712" left="96" width="69" height="19" font="0">2017 (235) </text>
<text top="731" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28082088">28082088</a></text>
<text top="731" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28082088"> </a></text>
<text top="694" left="229" width="174" height="19" font="8"><b>Study type: </b>Review of Lyme </text>
<text top="712" left="229" width="163" height="19" font="0">carditis and clinical course<b> </b></text>
<text top="694" left="425" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="694" left="587" width="209" height="19" font="8"><b>Results: </b>AVB is the most common </text>
<text top="712" left="598" width="240" height="19" font="0">conduction disorder with Lyme carditis<b> </b></text>
<text top="694" left="857" width="180" height="20" font="0">• Manifestations of AVB may </text>
<text top="713" left="868" width="202" height="19" font="0">progress rapidly in hours or days<b> </b></text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 149 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="120" height="19" font="0">Robinson ML, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2015 (236) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25999222">25999222</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25999222"> </a></text>
<text top="87" left="229" width="122" height="19" font="8"><b>Study type: </b>Review </text>
<text top="105" left="229" width="3" height="19" font="0"> </text>
<text top="123" left="229" width="59" height="19" font="8"><b>Size: </b>N/A<b> </b></text>
<text top="87" left="425" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="87" left="587" width="243" height="19" font="8"><b>Results: </b>1.1% of Lyme disease reported </text>
<text top="105" left="587" width="230" height="19" font="0">to CDC between 2000–2010 included </text>
<text top="123" left="587" width="141" height="19" font="0">cardiac manifestations<b> </b></text>
<text top="87" left="857" width="38" height="20" font="0">• N/A<b> </b></text>
<text top="146" left="96" width="97" height="19" font="0">Carano N, et al. </text>
<text top="164" left="96" width="69" height="19" font="0">2012 (186) </text>
<text top="182" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23110777">23110777</a></text>
<text top="182" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23110777"> </a></text>
<text top="146" left="229" width="177" height="19" font="8"><b>Aim: </b>Case report and review </text>
<text top="164" left="229" width="159" height="19" font="0">of rheumatic HD and CHB </text>
<text top="182" left="229" width="3" height="19" font="0"> </text>
<text top="200" left="229" width="183" height="19" font="8"><b>Study type: </b>Literature review </text>
<text top="219" left="229" width="99" height="19" font="0">and case report </text>
<text top="237" left="229" width="3" height="19" font="0"> </text>
<text top="255" left="229" width="43" height="19" font="8"><b>Size: </b>1 </text>
<text top="146" left="425" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="146" left="587" width="202" height="19" font="8"><b>Results:</b> Pt presented with acute </text>
<text top="164" left="598" width="202" height="19" font="0">rheumatic carditis and CHB; CHB </text>
<text top="182" left="598" width="210" height="19" font="0">resolved within 24 h of antibiotics<b> </b></text>
<text top="146" left="857" width="185" height="20" font="0">• Of the 25 cases found in the </text>
<text top="165" left="868" width="190" height="19" font="0">literature, the AVB lasted from </text>
<text top="183" left="868" width="147" height="19" font="0">minutes to several days </text>
<text top="202" left="857" width="212" height="20" font="0">• PM implant typically not needed </text>
<text top="220" left="868" width="105" height="19" font="0">(in 7 of 25 cases) </text>
<text top="275" left="96" width="101" height="19" font="0">Koehler U, et al. </text>
<text top="293" left="96" width="62" height="19" font="0">1998 (67) </text>
<text top="311" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9551750">9551750</a></text>
<text top="311" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9551750"> </a></text>
<text top="274" left="229" width="177" height="19" font="8"><b>Aim: </b>Assess effect of OSA Rx </text>
<text top="293" left="229" width="58" height="19" font="0">on brady </text>
<text top="311" left="229" width="3" height="19" font="0"> </text>
<text top="329" left="229" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="348" left="229" width="66" height="19" font="0">single arm </text>
<text top="366" left="229" width="3" height="19" font="0"> </text>
<text top="384" left="229" width="54" height="19" font="8"><b>Size:</b> 16  </text>
<text top="274" left="425" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="293" left="425" width="145" height="19" font="0">with OSA, and negative </text>
<text top="311" left="425" width="136" height="19" font="0">EPS, echo, EKG, stress </text>
<text top="330" left="425" width="27" height="19" font="0">test </text>
<text top="275" left="587" width="231" height="19" font="8"><b>1</b>°<b> endpoint:</b> Assess effect of CPAP or </text>
<text top="294" left="587" width="149" height="19" font="0">BiPAP on nocturnal AVB </text>
<text top="312" left="587" width="3" height="19" font="0"> </text>
<text top="330" left="587" width="231" height="19" font="8"><b>Results:</b> CPAP and BiPAP reduced the </text>
<text top="349" left="587" width="248" height="19" font="0">number of AVB episodes from 651 to 72 </text>
<text top="367" left="587" width="54" height="19" font="0">(p&lt;0.01)<b> </b></text>
<text top="275" left="857" width="210" height="20" font="0">• 4 pts received PM for continued </text>
<text top="294" left="868" width="179" height="19" font="0">pauses despite effective OSA </text>
<text top="312" left="868" width="51" height="19" font="0">therapy </text>
<text top="403" left="96" width="95" height="19" font="0">Maeno K, et al. </text>
<text top="422" left="96" width="69" height="19" font="0">2009 (188) </text>
<text top="440" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19466526">19466526</a></text>
<text top="440" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19466526"> </a></text>
<text top="403" left="229" width="172" height="19" font="8"><b>Aim: </b>Report the interaction </text>
<text top="422" left="229" width="122" height="19" font="0">of hypoxia and AVB </text>
<text top="440" left="229" width="3" height="19" font="0"> </text>
<text top="458" left="229" width="152" height="19" font="8"><b>Study type: </b>Case report, </text>
<text top="477" left="229" width="105" height="19" font="0">literature review </text>
<text top="495" left="229" width="3" height="19" font="0"> </text>
<text top="513" left="229" width="43" height="19" font="8"><b>Size: </b>1<b> </b></text>
<text top="403" left="425" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A </text>
<text top="404" left="587" width="225" height="19" font="8"><b>1</b>°<b> endpoint:</b> Resolution of AVB with </text>
<text top="423" left="587" width="36" height="19" font="0">CPAP </text>
<text top="441" left="587" width="3" height="19" font="0"> </text>
<text top="459" left="587" width="235" height="19" font="8"><b>Results:</b> AVB occurred prior to oxygen </text>
<text top="477" left="587" width="229" height="19" font="0">desaturation and resolved with CPAP<b> </b></text>
<text top="404" left="857" width="228" height="20" font="0">• AVB may be due to increased vagal </text>
<text top="423" left="868" width="32" height="19" font="0">tone </text>
<text top="532" left="96" width="95" height="19" font="0">Becker H, et al. </text>
<text top="551" left="96" width="62" height="19" font="0">1995 (66) </text>
<text top="569" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7812557">7812557</a></text>
<text top="569" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7812557"> </a></text>
<text top="532" left="229" width="166" height="19" font="8"><b>Aim: </b>Assess effect of CPAP </text>
<text top="551" left="229" width="150" height="19" font="0">on AVB and bradycardia </text>
<text top="569" left="229" width="3" height="19" font="0"> </text>
<text top="587" left="229" width="149" height="19" font="8"><b>Study type</b>: Prospective </text>
<text top="606" left="229" width="153" height="19" font="0">single arm observational </text>
<text top="624" left="229" width="3" height="19" font="0"> </text>
<text top="642" left="229" width="54" height="19" font="8"><b>Size:</b> 17  </text>
<text top="532" left="425" width="130" height="19" font="8"><b>Inclusion criteria: </b>All </text>
<text top="551" left="425" width="112" height="19" font="0">referrals for sleep </text>
<text top="569" left="425" width="86" height="19" font="0">apnea and if 2</text>
<text top="569" left="512" width="10" height="12" font="7">nd</text>
<text top="569" left="522" width="28" height="19" font="0"> or 3</text>
<text top="569" left="549" width="9" height="12" font="7">rd</text>
<text top="569" left="558" width="3" height="19" font="0"> </text>
<text top="587" left="425" width="144" height="19" font="0">degree AVB or asystole </text>
<text top="606" left="425" width="114" height="19" font="0">&gt;2 s. noted during </text>
<text top="624" left="425" width="72" height="19" font="0">sleep study<b> </b></text>
<text top="533" left="587" width="248" height="19" font="8"><b>1</b>°<b> endpoint:</b> CPAP reduced incidence of </text>
<text top="552" left="587" width="72" height="19" font="0">heart block </text>
<text top="570" left="587" width="3" height="19" font="0"> </text>
<text top="588" left="586" width="229" height="19" font="8"><b>Results:</b> 12 of 17 had AVB eliminated </text>
<text top="606" left="587" width="254" height="19" font="0">with CPAP, 3 had substantial reduction in </text>
<text top="625" left="587" width="236" height="19" font="0">AVB, and 2 had persistent bradycardia<b> </b></text>
<text top="533" left="857" width="213" height="20" font="0">• 7.1% of sleep apnea pts referred </text>
<text top="552" left="868" width="191" height="19" font="0">for sleep study had AVB during </text>
<text top="570" left="868" width="36" height="19" font="0">sleep </text>
<text top="588" left="857" width="217" height="20" font="0">• Most had normal baseline EKG (1 </text>
<text top="607" left="868" width="58" height="19" font="0">RBBB, 1 1</text>
<text top="607" left="927" width="7" height="12" font="7">st</text>
<text top="607" left="934" width="37" height="19" font="0"> AVB) </text>
<text top="626" left="857" width="129" height="20" font="0">• Mean duration of 3</text>
<text top="626" left="986" width="9" height="12" font="7">rd</text>
<text top="626" left="995" width="91" height="19" font="0"> AVB was 8.4 s<b> </b></text>
<text top="661" left="96" width="100" height="19" font="0">Grimm W, et al. </text>
<text top="680" left="96" width="62" height="19" font="0">2000 (68) </text>
<text top="698" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10980227">10980227</a></text>
<text top="698" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10980227"> </a></text>
<text top="661" left="229" width="177" height="19" font="8"><b>Aim: </b>Assess outcomes of pts </text>
<text top="680" left="229" width="108" height="19" font="0">with OSA-related </text>
<text top="698" left="229" width="79" height="19" font="0">bradycardia  </text>
<text top="716" left="229" width="3" height="19" font="0"> </text>
<text top="734" left="229" width="149" height="19" font="8"><b>Study type</b>: Prospective </text>
<text top="753" left="229" width="66" height="19" font="0">single arm </text>
<text top="771" left="229" width="3" height="19" font="0"> </text>
<text top="661" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="680" left="425" width="109" height="19" font="0">Negative EPS and </text>
<text top="698" left="425" width="92" height="19" font="0">Holter for AVB </text>
<text top="716" left="425" width="3" height="19" font="0"> </text>
<text top="734" left="425" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="753" left="425" width="143" height="19" font="0">Taking digoxin/BB/CCB<b> </b></text>
<text top="662" left="587" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> Effect of CPAP </text>
<text top="680" left="587" width="3" height="19" font="0"> </text>
<text top="699" left="587" width="232" height="19" font="8"><b>Results:</b> CPAP resolved &gt;3 s pauses in </text>
<text top="717" left="598" width="40" height="19" font="0">21/29<b> </b></text>
<text top="662" left="857" width="214" height="20" font="0">• 7 out of 8 with continued pauses </text>
<text top="680" left="868" width="90" height="19" font="0">received a PM </text>
<text top="699" left="857" width="202" height="20" font="0">• PM had no effect on outcomes </text>
<text top="718" left="868" width="198" height="19" font="0">(syncope) and prognosis is good </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 150 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="229" width="50" height="19" font="8"><b>Size:</b> 29 </text>
<text top="172" left="96" width="115" height="19" font="0">Unterberg C, et al. </text>
<text top="190" left="96" width="69" height="19" font="0">2005 (237) </text>
<text top="209" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16126716">16126716</a></text>
<text top="209" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16126716"> </a></text>
<text top="172" left="229" width="178" height="19" font="8"><b>Aim: </b>Compare CPAP to atrial </text>
<text top="190" left="229" width="105" height="19" font="0">overdrive pacing </text>
<text top="209" left="229" width="3" height="19" font="0"> </text>
<text top="227" left="229" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="245" left="229" width="62" height="19" font="0">crossover </text>
<text top="264" left="229" width="3" height="19" font="0"> </text>
<text top="282" left="229" width="50" height="19" font="8"><b>Size: </b>10 </text>
<text top="172" left="425" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="190" left="425" width="128" height="19" font="0">on CPAP for OSA, no </text>
<text top="209" left="425" width="88" height="19" font="0">PM indication<b> </b></text>
<text top="173" left="587" width="232" height="19" font="8"><b>1</b>°<b> endpoint:</b> Assess if atrial overdrive </text>
<text top="191" left="587" width="240" height="19" font="0">pacing or CPAP is superior for reducing </text>
<text top="209" left="587" width="101" height="19" font="0">apneic episodes </text>
<text top="228" left="587" width="3" height="19" font="0"> </text>
<text top="246" left="587" width="235" height="19" font="8"><b>Results:</b> The apneas were significantly </text>
<text top="264" left="587" width="233" height="19" font="0">reduced with CPAP but not with atrial </text>
<text top="283" left="587" width="43" height="19" font="0">pacing<b> </b></text>
<text top="172" left="857" width="223" height="20" font="0">• CPAP improved apneas but pacing </text>
<text top="191" left="868" width="184" height="19" font="0">did not despite elimination of </text>
<text top="209" left="868" width="202" height="19" font="0">bradycardia or asystole episodes<b> </b></text>
<text top="302" left="96" width="104" height="19" font="0">Garrigue S, et al. </text>
<text top="320" left="96" width="69" height="19" font="0">2002 (238) </text>
<text top="338" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11832528">11832528</a></text>
<text top="338" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11832528"> </a></text>
<text top="302" left="229" width="154" height="19" font="8"><b>Aim: </b>Assess utility of PM </text>
<text top="320" left="229" width="181" height="19" font="0">overdrive pacing for OSA and </text>
<text top="338" left="229" width="126" height="19" font="0">central sleep apnea  </text>
<text top="356" left="229" width="3" height="19" font="8"><b> </b></text>
<text top="375" left="229" width="149" height="19" font="8"><b>Study type</b>: Prospective </text>
<text top="393" left="229" width="99" height="19" font="0">crossover study </text>
<text top="411" left="229" width="3" height="19" font="0"> </text>
<text top="430" left="229" width="50" height="19" font="8"><b>Size: </b>15<b> </b></text>
<text top="302" left="425" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="320" left="425" width="128" height="19" font="0">with DC pacemakers </text>
<text top="338" left="425" width="142" height="19" font="0">with symptoms of OSA </text>
<text top="357" left="425" width="131" height="19" font="0">and had positive test </text>
<text top="375" left="425" width="50" height="19" font="0">for OSA<b> </b></text>
<text top="302" left="587" width="241" height="19" font="8"><b>1</b>°<b> endpoint:</b> Compare ventricular back </text>
<text top="321" left="587" width="218" height="19" font="0">up pacing to atrial overdrive pacing </text>
<text top="339" left="587" width="3" height="19" font="0"> </text>
<text top="357" left="587" width="206" height="19" font="8"><b>Results:</b> The hypopnea index was </text>
<text top="376" left="586" width="252" height="19" font="0">reduced from 9 to 3 with atrial overdrive </text>
<text top="394" left="586" width="105" height="19" font="0">pacing (p&lt;0.001) </text>
<text top="302" left="857" width="229" height="20" font="0">• Atrial overdrive pacing reduced the </text>
<text top="321" left="868" width="220" height="19" font="0">number of apneic episodes &gt;50% in </text>
<text top="339" left="868" width="93" height="19" font="0">majority of pts </text>
<text top="449" left="96" width="111" height="19" font="0">Stegman SS, et al. </text>
<text top="467" left="96" width="62" height="19" font="0">1996 (70) </text>
<text top="486" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8774819">8774819</a></text>
<text top="486" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8774819"> </a></text>
<text top="449" left="229" width="135" height="19" font="8"><b>Aim: </b>Determine if asx </text>
<text top="467" left="229" width="167" height="19" font="0">bradycardia during sleep is </text>
<text top="486" left="229" width="72" height="19" font="0">due to OSA </text>
<text top="504" left="229" width="3" height="19" font="0"> </text>
<text top="522" left="229" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="540" left="229" width="66" height="19" font="0">single arm </text>
<text top="559" left="229" width="3" height="19" font="0"> </text>
<text top="577" left="229" width="43" height="19" font="8"><b>Size:</b> 8<b> </b></text>
<text top="449" left="425" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="467" left="425" width="129" height="19" font="0">with asx bradycardia </text>
<text top="486" left="425" width="99" height="19" font="0">referred for PM<b> </b></text>
<text top="450" left="587" width="256" height="19" font="8"><b>1</b>°<b> endpoint:</b> Determine incidence of OSA </text>
<text top="468" left="587" width="74" height="19" font="0">in these pts </text>
<text top="486" left="587" width="3" height="19" font="0"> </text>
<text top="505" left="587" width="251" height="19" font="8"><b>Results:</b> 7 of 8 had a positive sleep study </text>
<text top="523" left="587" width="195" height="19" font="0">for OSA and did not receive PM<b> </b></text>
<text top="449" left="857" width="206" height="20" font="0">• Pts remained asx and improved </text>
<text top="468" left="868" width="102" height="19" font="0">sleep symptoms </text>
<text top="596" left="86" width="3" height="19" font="0"> </text>
<text top="614" left="86" width="743" height="23" font="5"><b>Data Supplement 37. RCT data of additional testing for Bradycardia due to AV block (Section 6.4.3)  </b></text>
<text top="637" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="655" left="136" width="51" height="19" font="8"><b>Author; </b></text>
<text top="674" left="109" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="692" left="138" width="38" height="19" font="8"><b>PMID </b></text>
<text top="637" left="244" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="655" left="250" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="674" left="244" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="637" left="368" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="637" left="518" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="655" left="556" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="674" left="519" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="692" left="561" width="59" height="19" font="8"><b>patients) </b></text>
<text top="637" left="724" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="655" left="680" width="197" height="19" font="8"><b>(Absolute Event Rates, P value; </b></text>
<text top="674" left="721" width="127" height="19" font="8"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="638" left="896" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="656" left="931" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="674" left="939" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="711" left="96" width="112" height="19" font="0">Sivakumaran S, et </text>
<text top="729" left="96" width="79" height="19" font="0">al. 2003 (17) </text>
<text top="748" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12867227">12867227</a></text>
<text top="748" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12867227"> </a></text>
<text top="711" left="230" width="92" height="19" font="8"><b>Aim</b>: Compare </text>
<text top="729" left="230" width="85" height="19" font="0">utility of loop </text>
<text top="748" left="230" width="76" height="19" font="0">recorder vs. </text>
<text top="766" left="230" width="42" height="19" font="0">Holter </text>
<text top="784" left="230" width="3" height="19" font="0"> </text>
<text top="711" left="359" width="111" height="19" font="8"><b>Inclusion criteria</b>: </text>
<text top="729" left="359" width="71" height="19" font="0">Syncope or </text>
<text top="748" left="359" width="74" height="19" font="0">presyncope </text>
<text top="711" left="509" width="115" height="19" font="8"><b>Intervention: </b>48 h </text>
<text top="729" left="509" width="135" height="19" font="0">Holter (n=51) vs. 30 d </text>
<text top="748" left="509" width="81" height="19" font="0">event (n=49) </text>
<text top="711" left="675" width="177" height="19" font="0">Diagnostic yield was 63% for </text>
<text top="729" left="686" width="146" height="19" font="0">loop vs. 24 % for Holter </text>
<text top="748" left="686" width="70" height="19" font="0">(p&lt;0.0001) </text>
<text top="711" left="895" width="165" height="20" font="0">• 23% of loop recorder pts </text>
<text top="730" left="906" width="148" height="19" font="0">failed to activate during </text>
<text top="749" left="906" width="67" height="19" font="0">symptoms </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="14" size="14" family="Times" color="#0000ff"/>
<text top="804" left="566" width="59" height="19" font="0">Page 151 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="105" left="230" width="3" height="19" font="0"> </text>
<text top="123" left="230" width="58" height="19" font="8"><b>Size: </b>100 </text>
<text top="143" left="96" width="88" height="19" font="0">Kinlay S, et al. </text>
<text top="161" left="96" width="69" height="19" font="0">1996 (239) </text>
<text top="179" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7503472">7503472</a></text>
<text top="179" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7503472"> </a></text>
<text top="142" left="230" width="107" height="19" font="8"><b>Aim: </b>Compare 3- </text>
<text top="161" left="230" width="82" height="19" font="0">month event </text>
<text top="179" left="230" width="100" height="19" font="0">monitor to 48-h </text>
<text top="197" left="230" width="48" height="19" font="0">Holters </text>
<text top="216" left="230" width="3" height="19" font="0"> </text>
<text top="234" left="230" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="252" left="230" width="79" height="19" font="0">Randomized </text>
<text top="271" left="230" width="91" height="19" font="0">Crossover trial </text>
<text top="289" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="307" left="230" width="50" height="19" font="8"><b>Size: </b>43 </text>
<text top="142" left="359" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="161" left="359" width="133" height="19" font="0">with palpitations and </text>
<text top="179" left="359" width="97" height="19" font="0">no prior testing </text>
<text top="142" left="509" width="144" height="19" font="8"><b>Intervention:</b> Received </text>
<text top="161" left="509" width="132" height="19" font="0">a 90-d Event monitor </text>
<text top="142" left="675" width="183" height="19" font="8"><b>Results:</b> Event monitors were </text>
<text top="161" left="675" width="201" height="19" font="0">more likely to provide a Dx (67% </text>
<text top="179" left="675" width="191" height="19" font="0">vs. 35%; p&lt;0.001). Holter not a </text>
<text top="197" left="675" width="160" height="19" font="0">good test for intermittent </text>
<text top="216" left="675" width="127" height="19" font="0">symptoms or events </text>
<text top="143" left="895" width="176" height="20" font="0">• The event monitor is more </text>
<text top="162" left="906" width="170" height="19" font="0">cost effective due to higher </text>
<text top="180" left="906" width="159" height="19" font="0">yield ($213 per additional </text>
<text top="198" left="906" width="84" height="19" font="0">rhythm strip) </text>
<text top="326" left="96" width="120" height="19" font="0">Giada F, et al. 2007 </text>
<text top="345" left="96" width="35" height="19" font="0">(240) </text>
<text top="363" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17498580">17498580</a></text>
<text top="363" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17498580"> </a></text>
<text top="326" left="230" width="92" height="19" font="8"><b>Aim: </b>Compare </text>
<text top="345" left="230" width="117" height="19" font="0">Holter+event+ EPS </text>
<text top="363" left="230" width="59" height="19" font="0">to ILR for </text>
<text top="381" left="230" width="98" height="19" font="0">diagnostic yield </text>
<text top="400" left="230" width="3" height="19" font="0"> </text>
<text top="418" left="230" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="436" left="230" width="3" height="19" font="0"> </text>
<text top="454" left="230" width="50" height="19" font="8"><b>Size: </b>50 </text>
<text top="326" left="359" width="111" height="19" font="8"><b>Inclusion</b> <b>criteria</b>: </text>
<text top="345" left="359" width="69" height="19" font="0">Infrequent </text>
<text top="363" left="359" width="129" height="19" font="0">palpitations that last </text>
<text top="381" left="359" width="45" height="19" font="0">&gt;1 min </text>
<text top="400" left="359" width="3" height="19" font="0"> </text>
<text top="418" left="359" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="436" left="359" width="130" height="19" font="0">Abnormal H&amp;P, ECG, </text>
<text top="455" left="359" width="33" height="19" font="0">echo </text>
<text top="326" left="509" width="110" height="19" font="8"><b>Intervention: </b>ILR  </text>
<text top="345" left="509" width="3" height="19" font="8"><b> </b></text>
<text top="363" left="509" width="143" height="19" font="8"><b>Control: </b>24-h Holter, 4-</text>
<text top="381" left="509" width="131" height="19" font="0">wk external monitor, </text>
<text top="400" left="509" width="141" height="19" font="0">and if negative, an EPS<b> </b></text>
<text top="326" left="675" width="181" height="19" font="8"><b>Results:</b> ILR more effective in </text>
<text top="345" left="675" width="144" height="19" font="0">establishing etiology of </text>
<text top="363" left="675" width="163" height="19" font="0">palpitations (73% vs. 21%; </text>
<text top="381" left="675" width="61" height="19" font="0">p&lt;0.001)  </text>
<text top="327" left="895" width="176" height="20" font="0">• The event monitor is more </text>
<text top="346" left="906" width="88" height="19" font="0">cost effective  </text>
<text top="474" left="94" width="43" height="19" font="8"><b>FRESH </b></text>
<text top="492" left="94" width="118" height="19" font="0">Podoleanu C, et al. </text>
<text top="510" left="94" width="62" height="19" font="0">2014 (74) </text>
<text top="529" left="96" width="67" height="21" font="14"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25241220">25241220</a></text>
<text top="530" left="163" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25241220"> </a></text>
<text top="474" left="230" width="100" height="19" font="8"><b>Aim: </b>Role of ILR </text>
<text top="492" left="230" width="75" height="19" font="0">for syncope </text>
<text top="510" left="230" width="68" height="19" font="0">evaluation </text>
<text top="529" left="230" width="3" height="19" font="0"> </text>
<text top="547" left="230" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="565" left="230" width="3" height="19" font="0"> </text>
<text top="583" left="230" width="50" height="19" font="8"><b>Size: </b>78<b> </b></text>
<text top="474" left="359" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="492" left="359" width="55" height="19" font="0">Syncope<b> </b></text>
<text top="474" left="509" width="107" height="19" font="8"><b>Intervention: </b>ILR </text>
<text top="492" left="509" width="3" height="19" font="8"><b> </b></text>
<text top="510" left="509" width="128" height="19" font="8"><b>Control</b>: Standard of </text>
<text top="529" left="509" width="117" height="19" font="0">care, per physician </text>
<text top="547" left="509" width="64" height="19" font="0">discretion<b> </b></text>
<text top="474" left="675" width="174" height="19" font="8"><b>Results: </b>ILR yield is superior </text>
<text top="492" left="686" width="189" height="19" font="0">(cause of syncope identified in </text>
<text top="510" left="686" width="144" height="19" font="0">46.2% vs. 5%; p&lt;0.001)<b> </b></text>
<text top="474" left="895" width="150" height="20" font="0">• The ILR was more cost </text>
<text top="493" left="906" width="126" height="19" font="0">effective with fewer </text>
<text top="511" left="906" width="150" height="19" font="0">hospitalization days and </text>
<text top="529" left="906" width="72" height="19" font="0">fewer tests </text>
<text top="603" left="86" width="3" height="19" font="0"> </text>
<text top="621" left="86" width="4" height="21" font="4"> </text>
<text top="641" left="86" width="831" height="23" font="5"><b>Data Supplement 38. Nonrandomized data of additional testing for Bradycardia due to AV block (Section 6.4.3) </b></text>
<text top="664" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="682" left="136" width="51" height="19" font="8"><b>Author; </b></text>
<text top="700" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="719" left="137" width="38" height="19" font="8"><b>PMID </b></text>
<text top="664" left="267" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="682" left="273" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="700" left="266" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="664" left="437" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="664" left="621" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="682" left="660" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="700" left="622" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="719" left="665" width="59" height="19" font="8"><b>patients) </b></text>
<text top="664" left="889" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="682" left="791" width="304" height="19" font="8"><b>(Absolute Event Rates, P value; OR or RR; &amp; 95% </b></text>
<text top="700" left="939" width="20" height="19" font="8"><b>CI) </b></text>
<text top="738" left="93" width="112" height="19" font="0">Katritsis DG, et al. </text>
<text top="756" left="93" width="69" height="19" font="0">2017 (241) </text>
<text top="774" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28507743">28507743</a></text>
<text top="774" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28507743"> </a></text>
<text top="738" left="230" width="147" height="19" font="8"><b>Aim: </b>Review the role of </text>
<text top="756" left="230" width="116" height="19" font="0">EPS in bradycardia </text>
<text top="774" left="230" width="3" height="19" font="0"> </text>
<text top="738" left="405" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A </text>
<text top="756" left="405" width="3" height="19" font="0"> </text>
<text top="774" left="405" width="141" height="19" font="8"><b>Exclusion criteria: </b>N/A </text>
<text top="738" left="601" width="113" height="19" font="8"><b>Intervention: </b>N/A </text>
<text top="756" left="601" width="3" height="19" font="0"> </text>
<text top="774" left="601" width="110" height="19" font="8"><b>Comparator: </b>N/A </text>
<text top="738" left="790" width="264" height="20" font="0">• 30% of Mobitz II blocks have narrow QRS </text>
<text top="757" left="790" width="215" height="20" font="0">• 20% of 2:1 AVB is in the AV Node </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 152 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="102" height="19" font="8"><b>Study type:</b> N/A </text>
<text top="105" left="230" width="3" height="19" font="0"> </text>
<text top="123" left="230" width="59" height="19" font="8"><b>Size:</b> N/A </text>
<text top="87" left="790" width="288" height="20" font="0">• HV &gt;70 is nonspecific, HV &gt;100 is specific but </text>
<text top="106" left="801" width="68" height="19" font="0">insensitive </text>
<text top="124" left="790" width="265" height="20" font="0">• Proposed indications for EPS of AV Block: </text>
<text top="144" left="790" width="282" height="20" font="0">• (1) Asymptomatic 2nd degree AVB with BBB </text>
<text top="163" left="801" width="238" height="19" font="0">(type I or not sure) (2) suspect phase 4 </text>
<text top="181" left="801" width="266" height="19" font="0">infranodal block (3) suspect type II but QRS </text>
<text top="199" left="801" width="278" height="19" font="0">narrow (4) symptomatic type I block and BBB </text>
<text top="218" left="93" width="108" height="19" font="0">Mangiardi LM, et </text>
<text top="237" left="93" width="87" height="19" font="0">al. 1982 (242) </text>
<text top="255" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7064840">7064840</a></text>
<text top="255" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7064840"> </a></text>
<text top="218" left="230" width="161" height="19" font="8"><b>Aim:</b> Assess utility of CSM </text>
<text top="237" left="230" width="82" height="19" font="0">and atropine </text>
<text top="255" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="273" left="230" width="153" height="19" font="8"><b>Study type: </b>Prospective, </text>
<text top="291" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="310" left="230" width="3" height="19" font="0"> </text>
<text top="328" left="230" width="155" height="19" font="8"><b>Size: </b>25 (15 with intraHis </text>
<text top="346" left="230" width="111" height="19" font="0">block and 10 with </text>
<text top="365" left="230" width="107" height="19" font="0">intranodal block)<b> </b></text>
<text top="218" left="405" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="237" left="405" width="179" height="19" font="0">Documented AVB at EPS and </text>
<text top="255" left="405" width="76" height="19" font="0">narrow QRS<b> </b></text>
<text top="218" left="601" width="168" height="19" font="8"><b>Intervention: </b>Carotid sinus </text>
<text top="237" left="601" width="136" height="19" font="0">massage × 10 s., 2 mg </text>
<text top="255" left="601" width="84" height="19" font="0">atropine, EPS<b> </b></text>
<text top="218" left="790" width="289" height="20" font="0">• Atropine and carotid massage yielded a Dx in </text>
<text top="237" left="801" width="163" height="19" font="0">22 (13/15 and in 9/10) pts </text>
<text top="256" left="790" width="285" height="20" font="0">• Atropine and carotid sinus did yield differing </text>
<text top="275" left="801" width="230" height="19" font="0">results at bedside vs. EPS in some pts </text>
<text top="384" left="93" width="101" height="19" font="0">Twidale N, et al. </text>
<text top="402" left="93" width="69" height="19" font="0">1988 (243) </text>
<text top="420" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2462213">2462213</a></text>
<text top="420" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2462213"> </a></text>
<text top="384" left="230" width="147" height="19" font="8"><b>Aim: </b>Determine use for </text>
<text top="402" left="230" width="89" height="19" font="0">assessing AVB </text>
<text top="420" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="439" left="230" width="153" height="19" font="8"><b>Study type: </b>Prospective, </text>
<text top="457" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="475" left="230" width="3" height="19" font="0"> </text>
<text top="494" left="230" width="54" height="19" font="8"><b>Size: </b>89 <b> </b></text>
<text top="384" left="405" width="160" height="19" font="8"><b>Inclusion criteria: </b>51 with </text>
<text top="402" left="405" width="134" height="19" font="0">bifascicular block and </text>
<text top="420" left="405" width="159" height="19" font="0">syncope or transient high-</text>
<text top="439" left="405" width="84" height="19" font="0">grade AVB or </text>
<text top="457" left="405" width="177" height="19" font="0">tachyarrhythmia; 38 with no </text>
<text top="475" left="405" width="155" height="19" font="0">syncope and normal ECG </text>
<text top="494" left="405" width="96" height="19" font="0">(control group)<b> </b></text>
<text top="384" left="601" width="157" height="19" font="8"><b>Intervention: </b>EPS with<b> </b>IV </text>
<text top="402" left="601" width="87" height="19" font="0">procainamide<b> </b></text>
<text top="384" left="790" width="293" height="20" font="0">• In those with bifascicular block, procainamide </text>
<text top="403" left="801" width="275" height="19" font="0">prolonged HV, developed high-grade AVB; in </text>
<text top="421" left="801" width="292" height="19" font="0">control group HV only minimally prolonged and </text>
<text top="439" left="801" width="80" height="19" font="0">no AVB seen </text>
<text top="513" left="93" width="115" height="19" font="0">Bogossian H, et al. </text>
<text top="531" left="93" width="69" height="19" font="0">2017 (244) </text>
<text top="549" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28294370">28294370</a></text>
<text top="549" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28294370"> </a></text>
<text top="513" left="230" width="159" height="19" font="8"><b>Aim: </b>Assess role of EPS in </text>
<text top="531" left="230" width="50" height="19" font="0">BBB pts </text>
<text top="549" left="230" width="3" height="19" font="0"> </text>
<text top="568" left="230" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="586" left="230" width="66" height="19" font="0">single arm </text>
<text top="604" left="230" width="3" height="19" font="0"> </text>
<text top="622" left="230" width="47" height="19" font="8"><b>Size:</b>30 </text>
<text top="513" left="405" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="531" left="405" width="156" height="19" font="0">Symptomatic bifascicular </text>
<text top="549" left="405" width="152" height="19" font="0">block (RBBB+LAFB) and 1</text>
<text top="549" left="558" width="7" height="12" font="7">st</text>
<text top="549" left="565" width="3" height="19" font="0"> </text>
<text top="568" left="405" width="29" height="19" font="0">AVB </text>
<text top="513" left="601" width="111" height="19" font="8"><b>Intervention: </b>EPS </text>
<text top="513" left="790" width="211" height="20" font="0">• All pts had long HV, mean 82 ms </text>
<text top="532" left="790" width="18" height="20" font="0">• 1</text>
<text top="533" left="808" width="7" height="12" font="7">st</text>
<text top="533" left="815" width="255" height="19" font="0"> AVB in symptomatic pts with bifascicular </text>
<text top="551" left="801" width="218" height="19" font="0">block likely due to infraHisian delay </text>
<text top="642" left="93" width="111" height="19" font="0">Kalscheur MM, et </text>
<text top="660" left="93" width="87" height="19" font="0">al. 2016 (245) </text>
<text top="678" left="93" width="11" height="18" font="0">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27565449"> </a></text>
<text top="679" left="106" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27565449">27565449</a></text>
<text top="679" left="167" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27565449"> </a></text>
<text top="642" left="230" width="130" height="19" font="8"><b>Aim:</b> Examine the IIa </text>
<text top="660" left="230" width="130" height="19" font="0">indication for PM for </text>
<text top="678" left="230" width="108" height="19" font="0">bifascicular block </text>
<text top="697" left="230" width="61" height="19" font="0">+syncope </text>
<text top="715" left="230" width="3" height="19" font="0"> </text>
<text top="733" left="230" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="751" left="230" width="3" height="19" font="0"> </text>
<text top="770" left="230" width="54" height="19" font="8"><b>Size:</b> 43 <b> </b></text>
<text top="642" left="405" width="164" height="19" font="8"><b>Inclusion criteria: </b>Pts with </text>
<text top="660" left="405" width="134" height="19" font="0">bifascicular block and </text>
<text top="678" left="405" width="178" height="19" font="0">syncope who underwent PM </text>
<text top="697" left="405" width="3" height="19" font="0"> </text>
<text top="715" left="405" width="180" height="19" font="8"><b>Exclusion criteria: </b>vasovagal, </text>
<text top="733" left="405" width="178" height="19" font="0">orthostatic cause of syncope<b> </b></text>
<text top="642" left="601" width="172" height="19" font="8"><b>Intervention: </b>Negative<b> </b>EPS, </text>
<text top="660" left="601" width="99" height="19" font="0">and empiric PM </text>
<text top="678" left="601" width="94" height="19" font="0">Implant (n=26) </text>
<text top="697" left="601" width="3" height="19" font="0"> </text>
<text top="715" left="601" width="176" height="19" font="8"><b>Comparator: </b>Positive EPS or </text>
<text top="733" left="601" width="173" height="19" font="0">ILR findings for AVB and PM </text>
<text top="751" left="601" width="93" height="19" font="0">implant (n=17)<b> </b></text>
<text top="642" left="790" width="180" height="20" font="0">• Primary endpoint: time to 1</text>
<text top="642" left="970" width="7" height="12" font="7">st</text>
<text top="642" left="977" width="89" height="19" font="0"> recurrence of </text>
<text top="661" left="801" width="54" height="19" font="0">syncope </text>
<text top="679" left="790" width="303" height="20" font="0">• Syncope recurrence was 18%/5 y in empiric grp </text>
<text top="698" left="801" width="174" height="19" font="0">vs. 0% in pos. EPS/ILR group </text>
<text top="717" left="790" width="283" height="20" font="0">• Progression to high-grade AVB in 53% of the </text>
<text top="736" left="801" width="295" height="19" font="0">pos. EPS/ILR group vs. 27% of the empiric group </text>
<text top="754" left="801" width="54" height="19" font="0">(p=0.11) </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 153 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="93" width="99" height="19" font="0">Morady F, et al. </text>
<text top="105" left="93" width="69" height="19" font="0">1984 (246) </text>
<text top="123" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475778">6475778</a></text>
<text top="123" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475778"> </a></text>
<text top="87" left="230" width="159" height="19" font="8"><b>Aim: </b>Assess role of EPS in </text>
<text top="105" left="230" width="160" height="19" font="0">pts with BBB and syncope </text>
<text top="123" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="230" width="153" height="19" font="8"><b>Study type: </b>Prospective, </text>
<text top="160" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="178" left="230" width="3" height="19" font="0"> </text>
<text top="197" left="230" width="50" height="19" font="8"><b>Size: </b>32<b> </b></text>
<text top="87" left="405" width="166" height="19" font="8"><b>Inclusion criteria: </b>BBB and </text>
<text top="105" left="405" width="54" height="19" font="0">syncope </text>
<text top="123" left="405" width="3" height="19" font="0"> </text>
<text top="142" left="405" width="181" height="19" font="8"><b>Exclusion criteria:</b> 2nd or 3rd </text>
<text top="160" left="405" width="150" height="19" font="0">degree AVB or SVT, SND<b> </b></text>
<text top="87" left="601" width="111" height="19" font="8"><b>Intervention: </b>EPS<b> </b></text>
<text top="87" left="790" width="145" height="20" font="0">• 12/32 had HV ≥70 ms </text>
<text top="106" left="790" width="145" height="20" font="0">• 44% had inducible VT </text>
<text top="216" left="93" width="120" height="19" font="0">Click RL, et al. 1987 </text>
<text top="234" left="93" width="35" height="19" font="0">(247) </text>
<text top="252" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3825942">3825942</a></text>
<text top="252" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3825942"> </a></text>
<text top="216" left="230" width="148" height="19" font="8"><b>Aim: </b>Assess role of EPS  </text>
<text top="234" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="252" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="271" left="230" width="3" height="19" font="0"> </text>
<text top="289" left="230" width="58" height="19" font="8"><b>Size: </b>112 </text>
<text top="289" left="338" width="3" height="19" font="8"><b> </b></text>
<text top="216" left="405" width="161" height="19" font="8"><b>Inclusion criteria: </b>Chronic </text>
<text top="234" left="405" width="129" height="19" font="0">BBB, with symptoms<b> </b></text>
<text top="216" left="601" width="111" height="19" font="8"><b>Intervention:</b> EPS<b> </b></text>
<text top="216" left="790" width="184" height="20" font="0">• 34 received PM for long HV  </text>
<text top="235" left="790" width="299" height="20" font="0">• 39 had ventricular arrhythmias induced and 21 </text>
<text top="254" left="801" width="196" height="19" font="0">had conduction disease and VT  </text>
<text top="308" left="93" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="326" left="93" width="69" height="19" font="0">1995 (248) </text>
<text top="345" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7618623">7618623</a></text>
<text top="345" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7618623"> </a></text>
<text top="308" left="230" width="149" height="19" font="8"><b>Aim: </b>Look at role of EPS </text>
<text top="326" left="230" width="90" height="19" font="0">in syncope pts </text>
<text top="345" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="363" left="230" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="381" left="230" width="3" height="19" font="0"> </text>
<text top="400" left="230" width="50" height="19" font="8"><b>Size: </b>25<b> </b></text>
<text top="308" left="405" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="326" left="405" width="164" height="19" font="0">Unexplained syncope who </text>
<text top="345" left="405" width="140" height="19" font="0">during monitoring had </text>
<text top="363" left="405" width="157" height="19" font="0">documented bradycardia </text>
<text top="381" left="405" width="103" height="19" font="0">causing syncope<b> </b></text>
<text top="308" left="601" width="335" height="20" font="8"><b>Intervention: </b>EPS, TTT, CSM<b>  </b>• EPS useful for AVB Dx </text>
<text top="327" left="790" width="281" height="20" font="0">• Carotid massage and TTT useful for neurally </text>
<text top="346" left="801" width="81" height="19" font="0">mediated Dx </text>
<text top="365" left="790" width="285" height="20" font="0">• These 3 tests are complimentary when done </text>
<text top="384" left="801" width="255" height="19" font="0">together; if all 3 are negative bradycardia </text>
<text top="402" left="801" width="174" height="19" font="0">unlikely as cause of syncope </text>
<text top="421" left="93" width="108" height="19" font="0">Dhingra RC, et al. </text>
<text top="439" left="93" width="69" height="19" font="0">1979 (249) </text>
<text top="458" left="93" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=498473">498473</a></text>
<text top="458" left="138" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=498473"> </a></text>
<text top="421" left="230" width="119" height="19" font="8"><b>Aim: </b>Role of EPS in </text>
<text top="439" left="230" width="111" height="19" font="0">bifascicular block  </text>
<text top="458" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="476" left="230" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="494" left="230" width="100" height="19" font="0">nonrandomized </text>
<text top="513" left="230" width="3" height="19" font="0"> </text>
<text top="531" left="230" width="58" height="19" font="8"><b>Size: </b>531<b> </b></text>
<text top="421" left="405" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="439" left="405" width="179" height="19" font="0">Bifascicular block w/o 2nd or </text>
<text top="458" left="405" width="106" height="19" font="0">3rd degree block<b> </b></text>
<text top="421" left="601" width="176" height="19" font="8"><b>Intervention: </b>EPS with atrial </text>
<text top="439" left="601" width="43" height="19" font="0">pacing<b> </b></text>
<text top="421" left="790" width="253" height="20" font="0">• Pacing induced infraHisian block during </text>
<text top="440" left="801" width="267" height="19" font="0">Wenckebach was functional but if occurred </text>
<text top="459" left="801" width="281" height="19" font="0">during normal AV conduction, was pathologic </text>
<text top="550" left="93" width="93" height="19" font="0">Zipes DP, et al. </text>
<text top="568" left="93" width="69" height="19" font="0">1979 (250) </text>
<text top="587" left="93" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=378457">378457</a></text>
<text top="587" left="138" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=378457"> </a></text>
<text top="550" left="230" width="161" height="19" font="8"><b>Aim:</b> Physiology review of </text>
<text top="568" left="230" width="8" height="19" font="0">2</text>
<text top="568" left="237" width="10" height="12" font="7">nd</text>
<text top="568" left="248" width="78" height="19" font="0"> degree AVB </text>
<text top="587" left="230" width="3" height="19" font="0"> </text>
<text top="605" left="230" width="102" height="19" font="8"><b>Study type:</b> N/A </text>
<text top="623" left="230" width="3" height="19" font="0"> </text>
<text top="642" left="230" width="59" height="19" font="8"><b>Size:</b> N/A </text>
<text top="550" left="405" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="550" left="601" width="113" height="19" font="8"><b>Intervention: </b>N/A<b> </b></text>
<text top="550" left="790" width="289" height="20" font="0">• Described maneuvers to distinguish type I vs. </text>
<text top="569" left="801" width="49" height="19" font="0">type II 2</text>
<text top="569" left="850" width="10" height="12" font="7">nd</text>
<text top="569" left="860" width="78" height="19" font="0"> degree AVB </text>
<text top="661" left="93" width="96" height="19" font="0">Shetty RK, et al.</text>
<text top="659" left="188" width="4" height="21" font="4"> </text>
<text top="679" left="93" width="29" height="21" font="4">015 </text>
<text top="680" left="121" width="35" height="19" font="0">(251) </text>
<text top="699" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25819829">25819829</a></text>
<text top="699" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25819829"> </a></text>
<text top="661" left="230" width="156" height="19" font="8"><b>Aim: </b>Describe worsening </text>
<text top="679" left="230" width="112" height="19" font="0">AVB with exercise </text>
<text top="697" left="230" width="3" height="19" font="0"> </text>
<text top="715" left="230" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="734" left="230" width="3" height="19" font="0"> </text>
<text top="752" left="230" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="661" left="405" width="158" height="19" font="8"><b>Inclusion criteria: </b>Pt with </text>
<text top="679" left="405" width="167" height="19" font="0">RBBB, LAFB and 1st degree </text>
<text top="697" left="405" width="29" height="19" font="0">AVB<b> </b></text>
<text top="661" left="601" width="146" height="19" font="8"><b>Intervention: </b>Treadmill </text>
<text top="679" left="601" width="153" height="19" font="0">which induced complete </text>
<text top="697" left="601" width="29" height="19" font="0">AVB<b> </b></text>
<text top="661" left="790" width="284" height="20" font="0">• 1:1 AV conduction present at rest; CHB seen </text>
<text top="680" left="801" width="146" height="19" font="0">during treadmill testing </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 154 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="93" width="123" height="19" font="0">Toeda T, et al. 2000 </text>
<text top="105" left="93" width="35" height="19" font="0">(252) </text>
<text top="123" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10793447">10793447</a></text>
<text top="123" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10793447"> </a></text>
<text top="87" left="230" width="150" height="19" font="8"><b>Aim: </b>Assess for exercise </text>
<text top="105" left="230" width="81" height="19" font="0">induced AVB </text>
<text top="123" left="230" width="3" height="19" font="0"> </text>
<text top="142" left="230" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="160" left="230" width="3" height="19" font="0"> </text>
<text top="178" left="230" width="43" height="19" font="8"><b>Size: </b>1 </text>
<text top="87" left="405" width="158" height="19" font="8"><b>Inclusion criteria: </b>Pt with </text>
<text top="105" left="405" width="134" height="19" font="0">exercise induced AVB<b> </b></text>
<text top="87" left="601" width="162" height="19" font="8"><b>Intervention: </b>EPS showed </text>
<text top="105" left="601" width="95" height="19" font="0">infranodal AVB<b> </b></text>
<text top="87" left="790" width="249" height="20" font="0">• EPS showed gap phenomenon with AV </text>
<text top="106" left="801" width="72" height="19" font="0">conduction </text>
<text top="197" left="93" width="107" height="19" font="0">Chokshi SK, et al. </text>
<text top="216" left="93" width="69" height="19" font="0">1990 (253) </text>
<text top="234" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2360528">2360528</a></text>
<text top="234" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2360528"> </a></text>
<text top="197" left="230" width="149" height="19" font="8"><b>Aim: </b>Assess importance </text>
<text top="216" left="230" width="150" height="19" font="0">of exercise induced AVB </text>
<text top="234" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="252" left="230" width="145" height="19" font="8"><b>Study type: </b>Case series </text>
<text top="271" left="230" width="3" height="19" font="0"> </text>
<text top="289" left="230" width="43" height="19" font="8"><b>Size: </b>3 </text>
<text top="197" left="405" width="183" height="19" font="8"><b>Inclusion criteria: </b>AVB during </text>
<text top="216" left="405" width="98" height="19" font="0">exercise testing<b> </b></text>
<text top="197" left="601" width="162" height="19" font="8"><b>Intervention: </b>EPS showed </text>
<text top="216" left="601" width="149" height="19" font="0">prolonged HV and block </text>
<text top="234" left="601" width="75" height="19" font="0">distal to His<b> </b></text>
<text top="198" left="790" width="236" height="20" font="0">• All 3 had negative Holter monitoring </text>
<text top="217" left="790" width="300" height="20" font="0">• All 3 had prolonged HV interval and infraHisian </text>
<text top="236" left="801" width="77" height="19" font="0">block at EPS </text>
<text top="308" left="93" width="120" height="19" font="0">Bakst A, et al. 1975 </text>
<text top="326" left="93" width="35" height="19" font="0">(254) </text>
<text top="345" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1191459">1191459</a></text>
<text top="345" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1191459"> </a></text>
<text top="308" left="230" width="129" height="19" font="8"><b>Aim:</b> Assess exercise </text>
<text top="326" left="230" width="84" height="19" font="0">induced AVB  </text>
<text top="345" left="230" width="3" height="19" font="0"> </text>
<text top="363" left="230" width="148" height="19" font="8"><b>Study type</b>: Case report </text>
<text top="381" left="230" width="92" height="19" font="0">and discussion </text>
<text top="400" left="230" width="3" height="19" font="0"> </text>
<text top="418" left="230" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="308" left="405" width="158" height="19" font="8"><b>Inclusion criteria: </b>Pt with </text>
<text top="326" left="405" width="174" height="19" font="0">exertional dyspnea and EKG </text>
<text top="345" left="405" width="125" height="19" font="0">with 1:1 conduction<b> </b></text>
<text top="308" left="601" width="173" height="19" font="8"><b>Intervention: </b>Treadmill and </text>
<text top="326" left="601" width="55" height="19" font="0">atropine<b> </b></text>
<text top="308" left="790" width="263" height="20" font="0">• Exercise improves Mobitz type I AVB and </text>
<text top="327" left="801" width="273" height="19" font="0">worsens AV conduction if underlying Mobitz </text>
<text top="346" left="801" width="70" height="19" font="0">type II AVB </text>
<text top="364" left="790" width="306" height="20" font="0">• Atropine similarly worsens AV conduction when </text>
<text top="383" left="801" width="156" height="19" font="0">underlying Mobitz type II </text>
<text top="437" left="93" width="92" height="19" font="0">Egred M, et al. </text>
<text top="455" left="93" width="69" height="19" font="0">2004 (255) </text>
<text top="474" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15561349">15561349</a></text>
<text top="474" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15561349"> </a></text>
<text top="437" left="230" width="149" height="19" font="8"><b>Aim:</b> Assess importance </text>
<text top="455" left="230" width="150" height="19" font="0">of exercise induced AVB </text>
<text top="474" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="492" left="230" width="148" height="19" font="8"><b>Study type</b>: Case report </text>
<text top="510" left="230" width="3" height="19" font="0"> </text>
<text top="528" left="230" width="43" height="19" font="8"><b>Size: </b>1 </text>
<text top="437" left="405" width="166" height="19" font="8"><b>Inclusion criteria: </b>Syncope </text>
<text top="455" left="405" width="93" height="19" font="0">during walking<b> </b></text>
<text top="437" left="601" width="146" height="19" font="8"><b>Intervention: </b>Treadmill<b> </b></text>
<text top="437" left="790" width="244" height="20" font="0">• Treadmill testing can be an important </text>
<text top="456" left="801" width="262" height="19" font="0">diagnostic tool when evaluating exertional </text>
<text top="474" left="801" width="54" height="19" font="0">syncope </text>
<text top="548" left="93" width="95" height="19" font="0">Fisher JD, 1981 </text>
<text top="566" left="93" width="35" height="19" font="0">(256) </text>
<text top="584" left="93" width="57" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7019962">7019962 </a></text>
<text top="584" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7019962"> </a></text>
<text top="548" left="230" width="144" height="19" font="8"><b>Aim: </b>Assess role of EPS </text>
<text top="566" left="230" width="3" height="19" font="0"> </text>
<text top="584" left="230" width="138" height="19" font="8"><b>Study type: </b>Review of </text>
<text top="603" left="230" width="147" height="19" font="0">EPS, its role in SSS, AVN </text>
<text top="621" left="230" width="49" height="19" font="0">disease </text>
<text top="548" left="405" width="139" height="19" font="8"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="548" left="601" width="140" height="19" font="8"><b>Intervention: </b>Detailed </text>
<text top="566" left="601" width="159" height="19" font="0">account of how to do EPS<b> </b></text>
<text top="548" left="790" width="288" height="20" font="0">• Reviews role of CSM, exercise testing, breath </text>
<text top="567" left="801" width="49" height="19" font="0">holding </text>
<text top="640" left="103" width="3" height="19" font="0"> </text>
<text top="658" left="103" width="4" height="21" font="2"><b> </b></text>
<text top="678" left="86" width="578" height="23" font="5"><b>Data Supplement 39. RCTs for Permanent Pacing for AV block (Section 6.4.4)  </b></text>
<text top="701" left="98" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="719" left="130" width="51" height="19" font="8"><b>Author; </b></text>
<text top="738" left="102" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="701" left="239" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="719" left="245" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="738" left="238" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="701" left="370" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="701" left="522" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="719" left="561" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="738" left="523" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="756" left="566" width="59" height="19" font="8"><b>patients) </b></text>
<text top="701" left="753" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="719" left="686" width="243" height="19" font="8"><b>(Absolute Event Rates, P value; OR RR; </b></text>
<text top="738" left="781" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="702" left="954" width="135" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint </b></text>
<text top="720" left="1001" width="51" height="19" font="8"><b>(if any); </b></text>
<text top="738" left="964" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="757" left="972" width="99" height="19" font="8"><b>Adverse Events </b></text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 155 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="51" height="19" font="8"><b>UKPace </b></text>
<text top="105" left="95" width="91" height="19" font="0">Toff WD, et al. </text>
<text top="123" left="95" width="69" height="19" font="0">2005 (257) </text>
<text top="142" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16014884">16014884</a></text>
<text top="142" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16014884"> </a></text>
<text top="87" left="217" width="76" height="19" font="8"><b>Aim: </b>Assess </text>
<text top="105" left="217" width="107" height="19" font="0">mortality benefit </text>
<text top="123" left="217" width="83" height="19" font="0">from dual vs. </text>
<text top="142" left="217" width="127" height="19" font="0">ventricular pacing in </text>
<text top="160" left="217" width="81" height="19" font="0">pts with AVB </text>
<text top="178" left="217" width="3" height="19" font="0"> </text>
<text top="197" left="217" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="215" left="217" width="3" height="19" font="0"> </text>
<text top="233" left="217" width="69" height="19" font="8"><b>Size: </b>2,021<b> </b></text>
<text top="87" left="361" width="138" height="19" font="8"><b>Inclusion criteria</b>: Age </text>
<text top="105" left="361" width="48" height="19" font="0">&gt;70 y, 2</text>
<text top="105" left="409" width="10" height="12" font="7">nd</text>
<text top="105" left="419" width="28" height="19" font="0"> or 3</text>
<text top="105" left="446" width="8" height="12" font="7">rd</text>
<text top="105" left="455" width="3" height="19" font="0"> </text>
<text top="123" left="361" width="120" height="19" font="0">degree AVB (73.3% </text>
<text top="142" left="361" width="60" height="19" font="0">had CHB) </text>
<text top="160" left="361" width="3" height="19" font="0"> </text>
<text top="178" left="361" width="136" height="19" font="8"><b>Exclusion criteria:</b> AF, </text>
<text top="197" left="361" width="86" height="19" font="0">NYHA class IV </text>
<text top="87" left="512" width="85" height="19" font="8"><b>Intervention: </b></text>
<text top="105" left="512" width="153" height="19" font="0">Randomized to dual PM, </text>
<text top="123" left="512" width="144" height="19" font="0">or ventricular PM-fixed </text>
<text top="142" left="512" width="134" height="19" font="0">rate, or to ventricular </text>
<text top="160" left="512" width="110" height="19" font="0">PM-adaptive rate </text>
<text top="178" left="512" width="3" height="19" font="0"> </text>
<text top="197" left="512" width="142" height="19" font="8"><b>Comparator: </b>Compare </text>
<text top="215" left="512" width="150" height="19" font="0">DC pacing to ventricular </text>
<text top="233" left="512" width="43" height="19" font="0">pacing<b> </b></text>
<text top="88" left="681" width="219" height="19" font="8"><b>1</b>°<b> endpoint:</b> No all-cause mortality </text>
<text top="106" left="681" width="226" height="19" font="0">benefit for DC pacing at 3 y (7.2% vs. </text>
<text top="126" left="681" width="122" height="19" font="0">7.4%; p=NS; CI: 0.83</text>
<text top="124" left="803" width="8" height="21" font="4">–</text>
<text top="126" left="811" width="34" height="19" font="0">1.11) </text>
<text top="87" left="947" width="117" height="20" font="0">• More procedural </text>
<text top="106" left="958" width="127" height="19" font="0">complications in the </text>
<text top="124" left="958" width="60" height="19" font="0">DC group </text>
<text top="143" left="947" width="130" height="19" font="0">Slightly higher risk of </text>
<text top="161" left="947" width="127" height="19" font="0">CVA/TIA/TE event in </text>
<text top="179" left="947" width="131" height="19" font="0">fixed rate ventricular </text>
<text top="198" left="947" width="137" height="19" font="0">pacing group (p=0.04) </text>
<text top="216" left="947" width="115" height="19" font="0">but not in the rate </text>
<text top="234" left="947" width="126" height="19" font="0">adaptive ventricular </text>
<text top="252" left="947" width="83" height="19" font="0">pacing group </text>
<text top="271" left="95" width="35" height="19" font="8"><b>PASE </b></text>
<text top="290" left="95" width="101" height="19" font="0">Lamas GA, et al. </text>
<text top="308" left="95" width="69" height="19" font="0">1998 (140) </text>
<text top="326" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9545357">9545357</a></text>
<text top="326" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9545357"> </a></text>
<text top="271" left="217" width="101" height="19" font="8"><b>Aim: </b>Determine </text>
<text top="290" left="217" width="123" height="19" font="0">difference in health </text>
<text top="308" left="217" width="92" height="19" font="0">related QOL in </text>
<text top="326" left="217" width="110" height="19" font="0">ventricular vs. DC </text>
<text top="345" left="217" width="116" height="19" font="0">pacing in pts &gt;65 y </text>
<text top="363" left="217" width="3" height="19" font="0"> </text>
<text top="381" left="217" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="400" left="217" width="3" height="19" font="0"> </text>
<text top="418" left="217" width="58" height="19" font="8"><b>Size:</b> 407 </text>
<text top="271" left="361" width="137" height="19" font="8"><b>Inclusion criteria: </b>&gt;65 </text>
<text top="290" left="361" width="137" height="19" font="0">y, SR (49% had AVB at </text>
<text top="308" left="361" width="59" height="19" font="0">baseline) </text>
<text top="326" left="361" width="3" height="19" font="0"> </text>
<text top="345" left="361" width="132" height="19" font="8"><b>Exclusion criteria: </b>AF </text>
<text top="271" left="512" width="151" height="19" font="8"><b>Intervention: </b>Implanted </text>
<text top="290" left="512" width="155" height="19" font="0">with DC PM; randomized </text>
<text top="308" left="512" width="123" height="19" font="0">to ventricular or DC </text>
<text top="326" left="512" width="43" height="19" font="0">pacing </text>
<text top="345" left="512" width="3" height="19" font="0"> </text>
<text top="363" left="512" width="154" height="19" font="8"><b>Comparator: </b>Ventricular </text>
<text top="381" left="512" width="43" height="19" font="0">pacing </text>
<text top="272" left="681" width="226" height="19" font="8"><b>1</b>°<b> endpoint:</b> QOL improved for both </text>
<text top="291" left="681" width="243" height="19" font="0">groups compared to baseline (p&lt;0.001) </text>
<text top="309" left="681" width="210" height="19" font="0">but no difference between pacing </text>
<text top="327" left="681" width="48" height="19" font="0">modes. </text>
<text top="272" left="947" width="112" height="20" font="0">• No difference in </text>
<text top="291" left="958" width="107" height="19" font="0">death, stroke, AF </text>
<text top="309" left="958" width="34" height="19" font="0">rates </text>
<text top="327" left="947" width="147" height="20" font="0">• AVB subgroup did not </text>
<text top="346" left="958" width="112" height="19" font="0">experience better </text>
<text top="365" left="958" width="111" height="19" font="0">QOL or functional </text>
<text top="383" left="958" width="40" height="19" font="0">status </text>
<text top="437" left="95" width="41" height="19" font="8"><b>MOST </b></text>
<text top="455" left="95" width="101" height="19" font="0">Lamas GA, et al. </text>
<text top="474" left="95" width="69" height="19" font="0">2002 (141) </text>
<text top="492" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12063369">12063369</a></text>
<text top="492" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12063369"> </a></text>
<text top="437" left="217" width="76" height="19" font="8"><b>Aim:</b> Assess </text>
<text top="455" left="217" width="128" height="19" font="0">mortality and stroke </text>
<text top="474" left="217" width="98" height="19" font="0">benefit with DC </text>
<text top="492" left="217" width="47" height="19" font="0">pacing  </text>
<text top="510" left="217" width="3" height="19" font="0"> </text>
<text top="529" left="217" width="105" height="19" font="8"><b>Study type:</b> RCT  </text>
<text top="547" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="565" left="217" width="69" height="19" font="8"><b>Size:</b> 2,010 </text>
<text top="437" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="455" left="361" width="94" height="19" font="0">SND (21% with </text>
<text top="474" left="361" width="114" height="19" font="0">concomitant AVB) </text>
<text top="492" left="361" width="3" height="19" font="0"> </text>
<text top="510" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="529" left="361" width="48" height="19" font="0">Non-SR </text>
<text top="437" left="512" width="151" height="19" font="8"><b>Intervention</b>: Implanted </text>
<text top="455" left="512" width="155" height="19" font="0">with DC PM, randomized </text>
<text top="474" left="512" width="98" height="19" font="0">to pacing mode </text>
<text top="492" left="512" width="3" height="19" font="0"> </text>
<text top="510" left="512" width="154" height="19" font="8"><b>Comparator: </b>Ventricular </text>
<text top="529" left="512" width="43" height="19" font="0">pacing </text>
<text top="438" left="681" width="206" height="19" font="8"><b>1</b>°<b> endpoint:</b> All-cause mortality+ </text>
<text top="456" left="681" width="244" height="19" font="0">nonfatal stroke in DC pacing (21.5%) vs. </text>
<text top="474" left="681" width="202" height="19" font="0">ventricular pacing (23%) was not </text>
<text top="493" left="681" width="120" height="19" font="0">significant (p=0.48) </text>
<text top="437" left="947" width="149" height="19" font="0">No subgroup<b> </b>analysis of </text>
<text top="455" left="947" width="103" height="19" font="0">AVB group done </text>
<text top="584" left="95" width="88" height="19" font="8"><b>MOST Vp40% </b></text>
<text top="603" left="95" width="104" height="19" font="0">Sweeney MO, et </text>
<text top="621" left="95" width="87" height="19" font="0">al. 2003 (146) </text>
<text top="639" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12782566">12782566</a></text>
<text top="639" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12782566"> </a></text>
<text top="584" left="217" width="99" height="19" font="8"><b>Aim: </b>Use MOST </text>
<text top="603" left="217" width="117" height="19" font="0">database to assess </text>
<text top="621" left="217" width="118" height="19" font="0">whether RV pacing </text>
<text top="639" left="217" width="115" height="19" font="0">increases HFH and </text>
<text top="658" left="217" width="19" height="19" font="0">AF </text>
<text top="676" left="217" width="3" height="19" font="0"> </text>
<text top="694" left="217" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="713" left="217" width="109" height="19" font="0">Reanalysis of RCT </text>
<text top="731" left="217" width="31" height="19" font="0">data </text>
<text top="749" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="767" left="217" width="69" height="19" font="8"><b>Size: </b>1,339<b> </b></text>
<text top="584" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="603" left="361" width="122" height="19" font="0">MOST trial subjects </text>
<text top="621" left="361" width="114" height="19" font="0">with % ventricular </text>
<text top="639" left="361" width="74" height="19" font="0">pacing data </text>
<text top="658" left="361" width="3" height="19" font="0"> </text>
<text top="676" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="694" left="361" width="122" height="19" font="0">MOST trial subjects </text>
<text top="713" left="361" width="97" height="19" font="0">w/o ventricular </text>
<text top="731" left="361" width="74" height="19" font="0">pacing data </text>
<text top="584" left="512" width="151" height="19" font="8"><b>Intervention</b>: Implanted </text>
<text top="603" left="512" width="141" height="19" font="0">DC PM, randomized to </text>
<text top="621" left="512" width="82" height="19" font="0">pacing mode </text>
<text top="639" left="512" width="3" height="19" font="0"> </text>
<text top="657" left="512" width="86" height="19" font="8"><b>Comparator:  </b></text>
<text top="585" left="681" width="248" height="19" font="8"><b>1</b>°<b> endpoint:</b> Ventricular pacing &gt;40% of </text>
<text top="603" left="681" width="221" height="19" font="0">the time increases risk of a HFH (HR </text>
<text top="622" left="681" width="69" height="19" font="0">2.56–2.99) </text>
<text top="640" left="681" width="209" height="19" font="0">and AF risk linearly increases as % </text>
<text top="658" left="681" width="239" height="19" font="0">ventricular pacing increases regardless </text>
<text top="677" left="681" width="98" height="19" font="0">of pacing mode </text>
<text top="584" left="947" width="143" height="20" font="0">• The increasing risk of </text>
<text top="603" left="958" width="125" height="19" font="0">HFH with increasing </text>
<text top="622" left="958" width="112" height="19" font="0">ventricular pacing </text>
<text top="640" left="958" width="120" height="19" font="0">levels off after 40% </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 156 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="45" height="19" font="8"><b>CTOPP </b></text>
<text top="105" left="95" width="109" height="19" font="0">Connolly SJ, et al. </text>
<text top="123" left="95" width="69" height="19" font="0">2000 (142) </text>
<text top="142" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10805823">10805823</a></text>
<text top="142" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10805823"> </a></text>
<text top="87" left="217" width="97" height="19" font="8"><b>Aim: </b>Assess for </text>
<text top="105" left="217" width="119" height="19" font="0">reduction in stroke </text>
<text top="123" left="217" width="106" height="19" font="0">and CV mortality </text>
<text top="142" left="217" width="114" height="19" font="0">with DC pacing vs. </text>
<text top="160" left="217" width="116" height="19" font="0">ventricular pacing  </text>
<text top="178" left="217" width="3" height="19" font="0"> </text>
<text top="197" left="217" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="215" left="217" width="3" height="19" font="0"> </text>
<text top="233" left="217" width="69" height="19" font="8"><b>Size: </b>2,568<b> </b></text>
<text top="87" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="105" left="361" width="105" height="19" font="0">Indicated for PM </text>
<text top="123" left="361" width="93" height="19" font="0">(60% had AVB) </text>
<text top="142" left="361" width="3" height="19" font="8"><b> </b></text>
<text top="160" left="361" width="132" height="19" font="8"><b>Exclusion criteria: </b>AF </text>
<text top="87" left="512" width="85" height="19" font="8"><b>Intervention: </b></text>
<text top="105" left="512" width="95" height="19" font="0">Randomized to </text>
<text top="123" left="512" width="130" height="19" font="0">ventricular or DC PM </text>
<text top="142" left="512" width="3" height="19" font="0"> </text>
<text top="160" left="512" width="154" height="19" font="8"><b>Comparator: </b>Ventricular </text>
<text top="178" left="512" width="43" height="19" font="0">pacing </text>
<text top="88" left="681" width="244" height="19" font="8"><b>1</b>°<b> endpoint:</b> First occurrence of CVA or </text>
<text top="106" left="681" width="230" height="19" font="0">CV mortality over 3 y was 5.5% in the </text>
<text top="124" left="681" width="227" height="19" font="0">ventricular group and 4.9% in the DC </text>
<text top="143" left="681" width="94" height="19" font="0">group (p=0.33) </text>
<text top="161" left="681" width="175" height="20" font="0">• Less AF with DDD (p=0.05) </text>
<text top="87" left="947" width="129" height="19" font="0">• All-cause mortality </text>
<text top="105" left="958" width="106" height="19" font="0">was 6.6% vs6.3% </text>
<text top="123" left="958" width="54" height="19" font="0">(p=0.92) </text>
<text top="142" left="947" width="145" height="19" font="0">• Annual AF rates were </text>
<text top="160" left="958" width="107" height="19" font="0">lower in the dual </text>
<text top="178" left="958" width="120" height="19" font="0">pacing group (5.3% </text>
<text top="197" left="958" width="99" height="19" font="0">vs. 6.6%; p=0.5) </text>
<text top="215" left="947" width="141" height="20" font="0">• No difference in HFH </text>
<text top="234" left="958" width="62" height="19" font="0">or stroke  </text>
<text top="253" left="95" width="107" height="19" font="8"><b>CTOPP Extended </b></text>
<text top="272" left="95" width="86" height="19" font="0">Kerr CR, et al. </text>
<text top="290" left="95" width="69" height="19" font="0">2004 (258) </text>
<text top="308" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14707022">14707022</a></text>
<text top="308" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14707022"> </a></text>
<text top="253" left="217" width="90" height="19" font="8"><b>Aim: </b>Reassess </text>
<text top="272" left="217" width="126" height="19" font="0">primary endpoint of </text>
<text top="290" left="217" width="88" height="19" font="0">stroke and CV </text>
<text top="308" left="217" width="112" height="19" font="0">mortality at 6 y of </text>
<text top="326" left="217" width="62" height="19" font="0">follow-up </text>
<text top="345" left="217" width="3" height="19" font="0"> </text>
<text top="363" left="217" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="381" left="217" width="3" height="19" font="0"> </text>
<text top="400" left="217" width="65" height="19" font="8"><b>Size</b>: 1995<b> </b></text>
<text top="253" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="272" left="361" width="120" height="19" font="0">Undergoing PM for </text>
<text top="290" left="361" width="76" height="19" font="0">bradycardia </text>
<text top="308" left="361" width="93" height="19" font="0">(60% had AVB) </text>
<text top="326" left="361" width="3" height="19" font="8"><b> </b></text>
<text top="345" left="361" width="132" height="19" font="8"><b>Exclusion criteria: </b>AF<b> </b></text>
<text top="253" left="512" width="85" height="19" font="8"><b>Intervention: </b></text>
<text top="272" left="512" width="95" height="19" font="0">Randomized to </text>
<text top="290" left="512" width="130" height="19" font="0">ventricular or DC PM </text>
<text top="308" left="512" width="3" height="19" font="0"> </text>
<text top="326" left="512" width="154" height="19" font="8"><b>Comparator: </b>Ventricular </text>
<text top="345" left="512" width="43" height="19" font="0">pacing<b> </b></text>
<text top="255" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="254" left="688" width="7" height="20" font="4">°</text>
<text top="255" left="695" width="209" height="19" font="8"><b> endpoint</b>: No change from above </text>
<text top="274" left="681" width="230" height="19" font="0">(combined endpoint of CV mortality+ </text>
<text top="292" left="681" width="182" height="19" font="0">stroke 6.1% vs. 5.5%; p=0.26) </text>
<text top="253" left="947" width="133" height="19" font="0">Annual risk of AF was </text>
<text top="272" left="947" width="120" height="19" font="0">less with DC pacing </text>
<text top="290" left="947" width="95" height="19" font="0">(4.5% vs. 5.7%; </text>
<text top="308" left="947" width="57" height="19" font="0">p=0.009) </text>
<text top="419" left="95" width="65" height="19" font="8"><b>BLOCK-HF </b></text>
<text top="437" left="95" width="97" height="19" font="0">Curtis AB, et al. </text>
<text top="455" left="95" width="69" height="19" font="0">2013 (259) </text>
<text top="474" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23614585">23614585</a></text>
<text top="474" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23614585"> </a></text>
<text top="419" left="217" width="114" height="19" font="8"><b>Aim: </b>Whether BiV </text>
<text top="437" left="217" width="95" height="19" font="0">pacing reduces </text>
<text top="455" left="217" width="130" height="19" font="0">mortality+ morbidity </text>
<text top="474" left="217" width="123" height="19" font="0">or LV remodeling in </text>
<text top="492" left="217" width="54" height="19" font="0">AVB pts  </text>
<text top="510" left="217" width="3" height="19" font="0"> </text>
<text top="529" left="217" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="547" left="217" width="3" height="19" font="0"> </text>
<text top="565" left="217" width="61" height="19" font="8"><b>Size: </b>691  </text>
<text top="419" left="361" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="437" left="361" width="119" height="19" font="0">with AVB indicated </text>
<text top="455" left="361" width="118" height="19" font="0">for PM, LVEF ≤50% </text>
<text top="474" left="361" width="3" height="19" font="0"> </text>
<text top="492" left="361" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="510" left="361" width="108" height="19" font="0">Indicated for CRT<b> </b></text>
<text top="419" left="512" width="149" height="19" font="8"><b>Intervention: </b>BiV PM or </text>
<text top="437" left="512" width="141" height="19" font="0">ICD, randomized to RV </text>
<text top="455" left="512" width="83" height="19" font="0">or BiV pacing </text>
<text top="474" left="512" width="3" height="19" font="0"> </text>
<text top="492" left="512" width="86" height="19" font="8"><b>Comparator:  </b></text>
<text top="510" left="512" width="132" height="19" font="0">Dual chamber pacing<b> </b></text>
<text top="421" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="419" left="688" width="7" height="20" font="4">°</text>
<text top="421" left="695" width="209" height="19" font="8"><b> endpoint</b>: Composite of all-cause </text>
<text top="439" left="681" width="239" height="19" font="0">mortality, HF event, or 15% increase in </text>
<text top="458" left="681" width="234" height="19" font="0">LVESV was met (HR: 0.74; 95% CI: 0.6–</text>
<text top="476" left="681" width="30" height="19" font="0">0.9) <b> </b></text>
<text top="420" left="947" width="18" height="20" font="0">• <b>2</b></text>
<text top="419" left="965" width="7" height="20" font="4">°</text>
<text top="421" left="972" width="67" height="19" font="8"><b> endpoint</b>: </text>
<text top="439" left="958" width="124" height="19" font="0">Composite of death </text>
<text top="458" left="958" width="130" height="19" font="0">or HFH was met (HR: </text>
<text top="476" left="958" width="117" height="19" font="0">0.78; 95% CI: 0.61–</text>
<text top="494" left="958" width="38" height="19" font="0">0.99)  </text>
<text top="584" left="95" width="93" height="19" font="0">Gierula J, et al. </text>
<text top="603" left="95" width="69" height="19" font="0">2013 (260) </text>
<text top="621" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23736807">23736807</a></text>
<text top="621" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23736807"> </a></text>
<text top="584" left="217" width="123" height="19" font="8"><b>Aim: </b>Assess benefit </text>
<text top="603" left="217" width="112" height="19" font="0">of CRT upgrade in </text>
<text top="621" left="217" width="75" height="19" font="0">CHB PM pts </text>
<text top="639" left="217" width="3" height="19" font="0"> </text>
<text top="657" left="217" width="101" height="19" font="8"><b>Study type</b>: RCT </text>
<text top="676" left="217" width="3" height="19" font="0"> </text>
<text top="694" left="217" width="50" height="19" font="8"><b>Size: </b>50<b> </b></text>
<text top="584" left="361" width="135" height="19" font="8"><b>Inclusion criteria: </b>PM </text>
<text top="603" left="361" width="96" height="19" font="0">dep pts (pacing </text>
<text top="621" left="361" width="114" height="19" font="0">&gt;80%), LVEF &lt;50% </text>
<text top="639" left="361" width="3" height="19" font="0"> </text>
<text top="657" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="676" left="361" width="120" height="19" font="0">Symptomatic HF or </text>
<text top="694" left="361" width="72" height="19" font="0">recent HFH </text>
<text top="584" left="512" width="141" height="19" font="8"><b>Intervention: </b>Upgrade </text>
<text top="603" left="512" width="64" height="19" font="0">to BiV PM </text>
<text top="621" left="512" width="3" height="19" font="0"> </text>
<text top="639" left="512" width="150" height="19" font="8"><b>Comparator:</b> DC pacing  </text>
<text top="587" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="585" left="688" width="7" height="20" font="4">°</text>
<text top="587" left="695" width="190" height="19" font="8"><b> endpoint</b>: Change in LVEF at 6 </text>
<text top="605" left="691" width="230" height="19" font="0">months was significantly improved in </text>
<text top="623" left="691" width="178" height="19" font="0">the CRT group (9% vs. -1.5%; </text>
<text top="642" left="691" width="65" height="19" font="0">p&lt;0.0001)<b> </b></text>
<text top="586" left="947" width="18" height="20" font="0">• <b>2</b></text>
<text top="585" left="965" width="7" height="20" font="4">°</text>
<text top="587" left="972" width="77" height="19" font="8"><b> endpoints:  </b></text>
<text top="605" left="947" width="26" height="19" font="0">pVO</text>
<text top="612" left="973" width="5" height="12" font="7">2</text>
<text top="605" left="978" width="89" height="19" font="0">, QOL, and NT-</text>
<text top="623" left="947" width="143" height="19" font="0">proBNP improved with </text>
<text top="642" left="947" width="126" height="19" font="0">CRT (p≤0.03 for all 3 </text>
<text top="660" left="947" width="72" height="19" font="0">outcomes)  </text>
<text top="678" left="947" width="135" height="20" font="0">• Reduction in LVEDD </text>
<text top="697" left="958" width="84" height="19" font="0">did not reach </text>
<text top="716" left="958" width="136" height="19" font="0">statistical significance </text>
<text top="735" left="95" width="68" height="19" font="8"><b>HOBIPACE </b></text>
<text top="753" left="95" width="98" height="19" font="0">Kindermann M, </text>
<text top="771" left="95" width="103" height="19" font="0">et al. 2006 (261) </text>
<text top="735" left="217" width="123" height="19" font="8"><b>Aim: </b>Assess benefit </text>
<text top="753" left="217" width="110" height="19" font="0">of CRT in pts with </text>
<text top="771" left="217" width="129" height="19" font="0">depressed LVEF who </text>
<text top="735" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="753" left="361" width="117" height="19" font="0">LVEF ≤40%<b>,</b> LVEDD </text>
<text top="735" left="512" width="112" height="19" font="8"><b>Intervention: </b>CRT </text>
<text top="753" left="512" width="114" height="19" font="0">devices implanted </text>
<text top="771" left="512" width="3" height="19" font="0"> </text>
<text top="737" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="735" left="688" width="7" height="20" font="4">°</text>
<text top="737" left="695" width="198" height="19" font="8"><b> endpoints</b>: (1) With CRT, LVESV </text>
<text top="755" left="681" width="214" height="19" font="0">decreased 17% (p&lt;0.001), (2) LVEF </text>
<text top="735" left="947" width="136" height="20" font="0">• NT-proBNP reduced </text>
<text top="754" left="958" width="87" height="19" font="0">31% with CRT </text>
<text top="772" left="958" width="62" height="19" font="0">(p&lt;0.002) </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 157 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16697307">16697307</a></text>
<text top="87" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16697307"> </a></text>
<text top="87" left="217" width="104" height="19" font="0">are indicated for </text>
<text top="105" left="217" width="47" height="19" font="0">pacing  </text>
<text top="123" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="217" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="160" left="217" width="75" height="19" font="0">Prospective </text>
<text top="178" left="217" width="76" height="19" font="0">randomized </text>
<text top="197" left="217" width="62" height="19" font="0">crossover </text>
<text top="215" left="217" width="3" height="19" font="0"> </text>
<text top="233" left="217" width="50" height="19" font="8"><b>Size: </b>30<b> </b></text>
<text top="87" left="361" width="81" height="19" font="0">≥60 mm, PM </text>
<text top="105" left="361" width="123" height="19" font="0">indication with AVB </text>
<text top="123" left="361" width="3" height="19" font="0"> </text>
<text top="142" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="160" left="361" width="137" height="19" font="0">Not meeting inclusion </text>
<text top="178" left="361" width="47" height="19" font="0">criteria<b> </b></text>
<text top="87" left="512" width="129" height="19" font="8"><b>Comparator: </b>After 3-</text>
<text top="105" left="512" width="141" height="19" font="0">month run in period, 3 </text>
<text top="123" left="512" width="129" height="19" font="0">months of RV pacing </text>
<text top="142" left="512" width="143" height="19" font="0">compared to 3 months </text>
<text top="160" left="512" width="43" height="19" font="0">of CRT<b> </b></text>
<text top="87" left="681" width="211" height="19" font="0">increased 22% (p&lt;0.0002), (3) pVO</text>
<text top="93" left="892" width="5" height="12" font="7">2</text>
<text top="87" left="897" width="3" height="19" font="0"> </text>
<text top="105" left="681" width="164" height="19" font="0">increased 12% (p&lt;0.0003) <b> </b></text>
<text top="252" left="95" width="44" height="19" font="8"><b>DAVID </b></text>
<text top="271" left="95" width="103" height="19" font="0">Wilkoff BL, et al. </text>
<text top="289" left="95" width="69" height="19" font="0">2002 (262) </text>
<text top="307" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12495391">12495391</a></text>
<text top="307" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12495391"> </a></text>
<text top="252" left="217" width="112" height="19" font="8"><b>Aim: </b>Compare DC </text>
<text top="271" left="217" width="84" height="19" font="0">pacing to VVI </text>
<text top="289" left="217" width="130" height="19" font="0">backup pacing in ICD </text>
<text top="307" left="217" width="112" height="19" font="0">indicated pts with </text>
<text top="326" left="217" width="126" height="19" font="0">no pacing indication </text>
<text top="344" left="217" width="3" height="19" font="0"> </text>
<text top="362" left="217" width="101" height="19" font="8"><b>Study type: </b>RCT<b> </b></text>
<text top="381" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="399" left="217" width="58" height="19" font="8"><b>Size: </b>506<b> </b></text>
<text top="252" left="361" width="136" height="19" font="8"><b>Inclusion criteria: </b>ICD </text>
<text top="271" left="361" width="133" height="19" font="0">indicated, LVEF ≤40% </text>
<text top="289" left="361" width="3" height="19" font="0"> </text>
<text top="307" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="326" left="361" width="115" height="19" font="0">Any PM indication<b> </b></text>
<text top="252" left="512" width="127" height="19" font="8"><b>Intervention: </b>All pts </text>
<text top="271" left="512" width="141" height="19" font="0">were implanted with a </text>
<text top="289" left="512" width="45" height="19" font="0">DC ICD </text>
<text top="307" left="512" width="3" height="19" font="0"> </text>
<text top="326" left="512" width="154" height="19" font="8"><b>Comparator: </b>Ventricular </text>
<text top="344" left="512" width="134" height="19" font="0">back up pacing vs. DC </text>
<text top="362" left="512" width="43" height="19" font="0">pacing<b> </b></text>
<text top="255" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="253" left="688" width="7" height="20" font="4">°</text>
<text top="255" left="695" width="226" height="19" font="8"><b> endpoint</b>: Freedom from composite </text>
<text top="273" left="681" width="252" height="19" font="0">of time to death or 1st HFH at 1 y (83.9% </text>
<text top="291" left="681" width="240" height="19" font="0">for ventricular backup vs. 73.3% for DC </text>
<text top="310" left="681" width="223" height="19" font="0">pacing; HR: 1.61; 95% CI: 1.06–2.44) </text>
<text top="252" left="947" width="135" height="19" font="0">HFH was 13.3% in the </text>
<text top="271" left="947" width="120" height="19" font="0">ventricular back up </text>
<text top="289" left="947" width="129" height="19" font="0">group vs. 22.6% (HR: </text>
<text top="307" left="947" width="117" height="19" font="0">1.54; 95% CI: 0.97–</text>
<text top="326" left="947" width="35" height="19" font="0">2.46) </text>
<text top="418" left="95" width="37" height="19" font="8"><b>PAVE </b></text>
<text top="436" left="95" width="96" height="19" font="0">Doshi RN, et al. </text>
<text top="455" left="95" width="69" height="19" font="0">2005 (263) </text>
<text top="473" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16302897">16302897 </a></text>
<text top="473" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16302897"> </a></text>
<text top="418" left="217" width="128" height="19" font="8"><b>Aim: </b>Compare RV to </text>
<text top="436" left="217" width="104" height="19" font="0">BiV pacing in pts </text>
<text top="455" left="217" width="114" height="19" font="0">with AVN ablation </text>
<text top="473" left="217" width="40" height="19" font="0">for AF </text>
<text top="491" left="217" width="3" height="19" font="0"> </text>
<text top="509" left="217" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="528" left="217" width="3" height="19" font="0"> </text>
<text top="546" left="217" width="58" height="19" font="8"><b>Size: </b>184 </text>
<text top="418" left="361" width="138" height="19" font="8"><b>Inclusion criteria: </b>Any </text>
<text top="436" left="361" width="89" height="19" font="0">LVEF, AF, AVN </text>
<text top="455" left="361" width="60" height="19" font="0">ablation,  </text>
<text top="473" left="361" width="3" height="19" font="0"> </text>
<text top="491" left="361" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="509" left="361" width="86" height="19" font="0">NYHA class IV<b> </b></text>
<text top="418" left="512" width="116" height="19" font="8"><b>Intervention</b>: AVN </text>
<text top="436" left="512" width="155" height="19" font="0">ablation +dual or BiV PM </text>
<text top="455" left="512" width="3" height="19" font="0"> </text>
<text top="473" left="512" width="146" height="19" font="8"><b>Comparator: </b>RV pacing<b> </b></text>
<text top="420" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="418" left="688" width="7" height="20" font="4">°</text>
<text top="420" left="695" width="215" height="19" font="8"><b> endpoint</b>: BiV group had a greater </text>
<text top="439" left="681" width="224" height="19" font="0">improvement at 6 months in 6MHW </text>
<text top="457" left="681" width="191" height="19" font="0">(31% increase vs. 24%; p=0.04) </text>
<text top="418" left="947" width="142" height="20" font="0">• No difference in QOL </text>
<text top="437" left="947" width="145" height="20" font="0">• No difference in LVEF </text>
<text top="456" left="947" width="143" height="19" font="0">The benefit of BiV with </text>
<text top="474" left="947" width="83" height="19" font="0">6MHW more </text>
<text top="493" left="947" width="130" height="19" font="0">pronounced in those </text>
<text top="511" left="947" width="100" height="19" font="0">with LVEF &lt;45% </text>
<text top="565" left="95" width="36" height="19" font="8"><b>APAF</b> </text>
<text top="583" left="95" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="602" left="95" width="73" height="19" font="0">2011 (264)  </text>
<text top="620" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21606084">21606084</a></text>
<text top="620" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21606084"><b> </b></a></text>
<text top="565" left="217" width="112" height="19" font="8"><b>Aim: </b>Compare RV </text>
<text top="583" left="217" width="123" height="19" font="0">pacing to CRT in pts </text>
<text top="602" left="217" width="128" height="19" font="0">undergoing AV node </text>
<text top="620" left="217" width="57" height="19" font="0">ablation  </text>
<text top="638" left="217" width="3" height="19" font="0"> </text>
<text top="657" left="217" width="101" height="19" font="8"><b>Study type: </b>RCT </text>
<text top="675" left="217" width="3" height="19" font="0"> </text>
<text top="693" left="217" width="58" height="19" font="8"><b>Size: </b>186<b> </b></text>
<text top="565" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="583" left="361" width="90" height="19" font="0">Permanent AF </text>
<text top="602" left="361" width="128" height="19" font="0">undergoing AV node </text>
<text top="620" left="361" width="128" height="19" font="0">ablation with or w/o </text>
<text top="638" left="361" width="110" height="19" font="0">refractory HF and </text>
<text top="657" left="361" width="71" height="19" font="0">reduced EF </text>
<text top="675" left="361" width="3" height="19" font="8"><b> </b></text>
<text top="693" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="712" left="361" width="117" height="19" font="0">NYHA class IV with </text>
<text top="730" left="361" width="121" height="19" font="0">systolic BP ≤80 mm </text>
<text top="748" left="361" width="81" height="19" font="0">Hg, prior PM<b> </b></text>
<text top="565" left="512" width="104" height="19" font="8"><b>Intervention: </b>All </text>
<text top="583" left="512" width="149" height="19" font="0">subjects implanted with </text>
<text top="602" left="512" width="27" height="19" font="0">CRT </text>
<text top="620" left="512" width="3" height="19" font="8"><b> </b></text>
<text top="638" left="512" width="146" height="19" font="8"><b>Comparator: </b>RV pacing </text>
<text top="657" left="512" width="109" height="19" font="0">to CRT pacing 1:1 </text>
<text top="675" left="512" width="92" height="19" font="0">randomization<b> </b></text>
<text top="567" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="565" left="688" width="7" height="20" font="4">°</text>
<text top="567" left="695" width="211" height="19" font="8"><b> endpoint</b>: Composite endpoint of </text>
<text top="586" left="681" width="252" height="19" font="0">death due to HF, HFH, worsening HF was </text>
<text top="604" left="681" width="245" height="19" font="0">lower with CRT (11% vs. 26% event rate </text>
<text top="622" left="681" width="174" height="19" font="0">p=0.005; 95% CI: 0.18–0.73)<b> </b></text>
<text top="565" left="947" width="18" height="20" font="0">• <b>2</b></text>
<text top="566" left="965" width="5" height="12" font="13"><b>0</b></text>
<text top="566" left="970" width="121" height="19" font="8"><b> endpoint: </b>CRT had </text>
<text top="584" left="958" width="88" height="19" font="0">lower rates of </text>
<text top="603" left="958" width="87" height="19" font="0">worsening HF </text>
<text top="621" left="958" width="110" height="19" font="0">(p=0.001; 95% CI: </text>
<text top="639" left="958" width="124" height="19" font="0">0.12–0.58) and HFH </text>
<text top="658" left="958" width="110" height="19" font="0">(p=0.013; 95% CI: </text>
<text top="676" left="958" width="69" height="19" font="0">0.06–0.72) </text>
<text top="694" left="947" width="91" height="20" font="0">• No mortality </text>
<text top="713" left="958" width="123" height="19" font="0">difference between </text>
<text top="732" left="958" width="45" height="19" font="0">groups </text>
<text top="750" left="947" width="149" height="20" font="0">• CRT benefit evident in </text>
<text top="769" left="958" width="130" height="19" font="0">LVEF &gt;35% subgroup </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 158 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="47" height="19" font="8"><b>OPSITE</b> </text>
<text top="105" left="95" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="123" left="95" width="73" height="19" font="0">2005 (265)  </text>
<text top="142" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15618036">15618036</a></text>
<text top="142" left="156" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15618036"><b> </b></a></text>
<text top="87" left="217" width="128" height="19" font="8"><b>Aim: </b>Compare RV to </text>
<text top="105" left="217" width="128" height="19" font="0">LV and to BiV pacing </text>
<text top="123" left="217" width="67" height="19" font="0">in pts with </text>
<text top="142" left="217" width="117" height="19" font="0">permanent AF and </text>
<text top="160" left="217" width="108" height="19" font="0">AV node ablation </text>
<text top="178" left="217" width="3" height="19" font="0"> </text>
<text top="197" left="217" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="215" left="217" width="75" height="19" font="0">Prospective </text>
<text top="233" left="217" width="76" height="19" font="0">randomized </text>
<text top="252" left="217" width="62" height="19" font="0">crossover </text>
<text top="270" left="217" width="3" height="19" font="0"> </text>
<text top="288" left="217" width="50" height="19" font="8"><b>Size: </b>56<b> </b></text>
<text top="87" left="361" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="105" left="361" width="137" height="19" font="0">Permanent AF and AV </text>
<text top="123" left="361" width="88" height="19" font="0">node ablation </text>
<text top="142" left="361" width="3" height="19" font="8"><b> </b></text>
<text top="160" left="361" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="178" left="361" width="90" height="19" font="0">NYHA class IV, </text>
<text top="197" left="361" width="136" height="19" font="0">unsuccessful AV node </text>
<text top="215" left="361" width="53" height="19" font="0">ablation<b> </b></text>
<text top="87" left="512" width="140" height="19" font="8"><b>Intervention: </b>AV node </text>
<text top="105" left="512" width="106" height="19" font="0">ablation and CRT </text>
<text top="123" left="512" width="54" height="19" font="0">implant  </text>
<text top="142" left="512" width="3" height="19" font="8"><b> </b></text>
<text top="160" left="512" width="115" height="19" font="8"><b>Comparator: </b>Each </text>
<text top="178" left="512" width="131" height="19" font="0">subject paces RV, LV, </text>
<text top="197" left="512" width="50" height="19" font="0">and BiV<b> </b></text>
<text top="89" left="681" width="8" height="19" font="8"><b>1</b></text>
<text top="87" left="688" width="7" height="20" font="4">°</text>
<text top="89" left="695" width="194" height="19" font="8"><b> endpoint</b>: QOL measures were </text>
<text top="107" left="681" width="251" height="19" font="0">minimally improved with BiV (MLHFQ up </text>
<text top="126" left="681" width="199" height="19" font="0">10%, NYHA improved 11%, LVEF </text>
<text top="144" left="681" width="210" height="19" font="0">increased 5%; all with p&lt;0.05) but </text>
<text top="162" left="681" width="230" height="19" font="0">exercise capacity at 3 months did not </text>
<text top="181" left="681" width="61" height="19" font="0">improve. <b> </b></text>
<text top="87" left="947" width="124" height="20" font="0">• Large interpatient </text>
<text top="106" left="958" width="113" height="19" font="0">variability present </text>
<text top="124" left="947" width="148" height="20" font="0">• LV only pacing did not </text>
<text top="143" left="958" width="97" height="19" font="0">confer as much </text>
<text top="162" left="958" width="130" height="19" font="0">benefit as BiV pacing </text>
<text top="307" left="86" width="4" height="21" font="4"> </text>
<text top="328" left="86" width="4" height="21" font="4"> </text>
<text top="348" left="86" width="700" height="23" font="5"><b>Data Supplement 40. Nonrandomized data for Permanent Pacing for AV block (Section 6.4.4)  </b></text>
<text top="370" left="103" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="389" left="134" width="51" height="19" font="8"><b>Author; </b></text>
<text top="407" left="106" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="370" left="261" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="389" left="267" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="407" left="261" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="370" left="420" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="370" left="590" width="136" height="19" font="8"><b>Study Intervention (# </b></text>
<text top="389" left="629" width="69" height="19" font="8"><b>patients) / </b></text>
<text top="407" left="592" width="133" height="19" font="8"><b>Study Comparator (# </b></text>
<text top="425" left="634" width="59" height="19" font="8"><b>patients) </b></text>
<text top="370" left="871" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="389" left="763" width="324" height="19" font="8"><b>(Absolute Event Rates, P value; OR or RR; &amp; 95% CI) </b></text>
<text top="444" left="93" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="463" left="93" width="73" height="19" font="0">2012 (266) <b> </b></text>
<text top="481" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22095616">22095616</a></text>
<text top="481" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22095616"> </a></text>
<text top="444" left="226" width="148" height="19" font="8"><b>Aim: </b>Identify predictors </text>
<text top="463" left="226" width="156" height="19" font="0">of improvement after AV </text>
<text top="481" left="226" width="88" height="19" font="0">node ablation </text>
<text top="499" left="226" width="3" height="19" font="0"> </text>
<text top="517" left="226" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="536" left="226" width="139" height="19" font="0">observational study of </text>
<text top="554" left="226" width="71" height="19" font="0">RCT cohort </text>
<text top="572" left="226" width="3" height="19" font="0"> </text>
<text top="591" left="226" width="58" height="19" font="8"><b>Size: </b>171<b> </b></text>
<text top="444" left="397" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="463" left="397" width="159" height="19" font="0">Subjects enrolled in APAF </text>
<text top="481" left="397" width="115" height="19" font="0">with 2-y follow-up </text>
<text top="499" left="397" width="3" height="19" font="8"><b> </b></text>
<text top="517" left="397" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="536" left="397" width="135" height="19" font="0">Inadequate follow-up<b> </b></text>
<text top="444" left="575" width="152" height="19" font="8"><b>Intervention: </b>CRT vs. RV </text>
<text top="463" left="575" width="131" height="19" font="0">pacing after AV node </text>
<text top="481" left="575" width="53" height="19" font="0">ablation </text>
<text top="499" left="575" width="3" height="19" font="8"><b> </b></text>
<text top="517" left="575" width="150" height="19" font="8"><b>Comparator: </b>Compared </text>
<text top="536" left="575" width="98" height="19" font="0">responders and </text>
<text top="554" left="575" width="96" height="19" font="0">nonresponders<b> </b></text>
<text top="447" left="753" width="8" height="19" font="8"><b>1</b></text>
<text top="445" left="761" width="7" height="20" font="4">°</text>
<text top="447" left="768" width="267" height="19" font="8"><b> endpoint</b>: RV 63% responder rate and 83% </text>
<text top="465" left="753" width="208" height="19" font="0">responder rate for CRT (p=0.003)  </text>
<text top="483" left="753" width="3" height="19" font="8"><b> </b></text>
<text top="502" left="753" width="310" height="20" font="0">• On multivariate Cox regression analysis, the only </text>
<text top="521" left="764" width="324" height="19" font="0">predictor of response was CRT mode and having CRT </text>
<text top="539" left="764" width="97" height="19" font="0">echo optimized </text>
<text top="610" left="95" width="96" height="19" font="0">Dretzke J, et al. </text>
<text top="628" left="95" width="69" height="19" font="0">2004 (267) </text>
<text top="647" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15106214">15106214</a></text>
<text top="647" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15106214"> </a></text>
<text top="610" left="226" width="142" height="19" font="8"><b>Aim:</b> Cochrane review: </text>
<text top="628" left="226" width="102" height="19" font="0">compare clinical </text>
<text top="647" left="226" width="150" height="19" font="0">effectiveness of VVI and </text>
<text top="665" left="226" width="147" height="19" font="0">DC PMs in pts with SND </text>
<text top="683" left="226" width="45" height="19" font="0">or AVB </text>
<text top="701" left="226" width="3" height="19" font="0"> </text>
<text top="720" left="226" width="138" height="19" font="8"><b>Study type: </b>Review of </text>
<text top="738" left="226" width="115" height="19" font="0">RCT and crossover </text>
<text top="756" left="226" width="3" height="19" font="8"><b> </b></text>
<text top="775" left="226" width="118" height="19" font="8"><b>Size</b>: N= 31 studies </text>
<text top="610" left="397" width="165" height="19" font="8"><b>Inclusion criteria: </b>RCT and </text>
<text top="628" left="397" width="109" height="19" font="0">crossover studies </text>
<text top="647" left="397" width="150" height="19" font="0">comparing DDD and VVI </text>
<text top="665" left="397" width="30" height="19" font="0">PMs </text>
<text top="683" left="397" width="3" height="19" font="0"> </text>
<text top="701" left="397" width="150" height="19" font="8"><b>Exclusion criteria: </b>Atrial </text>
<text top="720" left="397" width="139" height="19" font="0">single chamber pacing </text>
<text top="610" left="575" width="113" height="19" font="8"><b>Intervention: </b>N/A </text>
<text top="628" left="575" width="3" height="19" font="0"> </text>
<text top="646" left="575" width="110" height="19" font="8"><b>Comparator: </b>N/A </text>
<text top="610" left="753" width="288" height="20" font="0">• There is significantly less AF with DDD pacing </text>
<text top="629" left="753" width="315" height="20" font="0">• Dual chamber pacing is favored for PM syndrome </text>
<text top="648" left="753" width="343" height="20" font="0">• Trend (NS) for less stroke, HF, mortality and improved </text>
<text top="667" left="764" width="107" height="19" font="0">exercise capacity </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 159 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="108" height="19" font="0">Dhingra RC, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">1974 (196) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4817704">4817704</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4817704"> </a></text>
<text top="87" left="226" width="124" height="19" font="8"><b>Aim: </b>Natural Hx of 2</text>
<text top="87" left="350" width="5" height="12" font="7">0</text>
<text top="87" left="355" width="3" height="19" font="0"> </text>
<text top="105" left="226" width="61" height="19" font="0">AVB+BBB </text>
<text top="123" left="226" width="3" height="19" font="0"> </text>
<text top="142" left="226" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="160" left="226" width="87" height="19" font="0">observational </text>
<text top="178" left="226" width="3" height="19" font="8"><b> </b></text>
<text top="197" left="226" width="68" height="19" font="8"><b>Size: </b>N=15<b> </b></text>
<text top="87" left="397" width="147" height="19" font="8"><b>Inclusion criteria: </b>BBB+ </text>
<text top="105" left="397" width="8" height="19" font="0">2</text>
<text top="105" left="405" width="10" height="12" font="7">nd</text>
<text top="105" left="415" width="78" height="19" font="0"> degree AVB </text>
<text top="123" left="397" width="3" height="19" font="0"> </text>
<text top="142" left="397" width="153" height="19" font="8"><b>Exclusion criteria: A</b>cute </text>
<text top="160" left="397" width="20" height="19" font="0">MI </text>
<text top="87" left="575" width="157" height="19" font="8"><b>Intervention: </b>EPS; follow-</text>
<text top="105" left="575" width="19" height="19" font="0">up </text>
<text top="123" left="575" width="3" height="19" font="0"> </text>
<text top="142" left="575" width="110" height="19" font="8"><b>Comparator: </b>N/A </text>
<text top="87" left="753" width="208" height="20" font="0">• Only 3 were asx at presentation </text>
<text top="106" left="753" width="310" height="20" font="0">• Permanent PM indicated for severe bradycardia, </text>
<text top="125" left="764" width="85" height="19" font="0">syncope, CHF </text>
<text top="144" left="753" width="337" height="20" font="0">• All 9 pts with infra-His block got PM for syncope, CHF </text>
<text top="163" left="753" width="320" height="20" font="0">• 2 of 4 with supra-Hisian block got PM for syncope, </text>
<text top="182" left="764" width="322" height="19" font="0">CHF, 1 developed interim CHB but refused PM, 1 asx </text>
<text top="216" left="95" width="94" height="19" font="0">Shaw DB, et al. </text>
<text top="234" left="95" width="69" height="19" font="0">1970 (197) </text>
<text top="252" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5413952">5413952</a></text>
<text top="252" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5413952"> </a></text>
<text top="216" left="226" width="101" height="19" font="8"><b>Aim: </b>Determine </text>
<text top="234" left="226" width="139" height="19" font="0">prevalence of pts with </text>
<text top="252" left="226" width="8" height="19" font="0">2</text>
<text top="252" left="234" width="10" height="12" font="7">nd</text>
<text top="252" left="244" width="37" height="19" font="0"> and 3</text>
<text top="252" left="281" width="9" height="12" font="7">rd</text>
<text top="252" left="290" width="78" height="19" font="0"> degree AVB </text>
<text top="271" left="226" width="124" height="19" font="0">pts and record their </text>
<text top="289" left="226" width="67" height="19" font="0">symptoms </text>
<text top="307" left="226" width="3" height="19" font="0"> </text>
<text top="326" left="226" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="344" left="226" width="89" height="19" font="0">Observational </text>
<text top="362" left="226" width="3" height="19" font="0"> </text>
<text top="381" left="226" width="75" height="19" font="8"><b>Size: </b>N=100<b> </b></text>
<text top="216" left="397" width="119" height="19" font="8"><b>Inclusion criteria: </b>2</text>
<text top="216" left="516" width="10" height="12" font="7">nd</text>
<text top="216" left="526" width="11" height="19" font="0"> 3</text>
<text top="216" left="537" width="9" height="12" font="7">rd</text>
<text top="216" left="546" width="3" height="19" font="0"> </text>
<text top="234" left="397" width="75" height="19" font="0">degree AVB </text>
<text top="252" left="397" width="3" height="19" font="0"> </text>
<text top="271" left="397" width="162" height="19" font="8"><b>Exclusion criteria: </b>Digoxin </text>
<text top="289" left="397" width="157" height="19" font="0">or propranolol use, acute </text>
<text top="307" left="397" width="20" height="19" font="0">MI<b> </b></text>
<text top="216" left="575" width="122" height="19" font="8"><b>Intervention: </b>None </text>
<text top="234" left="575" width="3" height="19" font="0"> </text>
<text top="252" left="575" width="110" height="19" font="8"><b>Comparator: </b>N/A </text>
<text top="216" left="753" width="167" height="20" font="0">• 48% had syncopal events </text>
<text top="235" left="753" width="86" height="20" font="0">• 9% had CHF </text>
<text top="254" left="753" width="134" height="20" font="0">• No reported deaths </text>
<text top="400" left="95" width="99" height="19" font="0">Simon AB, et al. </text>
<text top="418" left="95" width="69" height="19" font="0">1978 (198) </text>
<text top="436" left="95" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=626128">626128</a></text>
<text top="436" left="140" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=626128"> </a></text>
<text top="400" left="226" width="143" height="19" font="8"><b>Aim: </b>Follow natural Hx </text>
<text top="418" left="226" width="143" height="19" font="0">and survival<b> </b>of AVB pts </text>
<text top="436" left="226" width="125" height="19" font="0">who underwent PM </text>
<text top="455" left="226" width="50" height="19" font="0">implant </text>
<text top="473" left="226" width="3" height="19" font="0"> </text>
<text top="491" left="226" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="509" left="226" width="87" height="19" font="0">Retrospective </text>
<text top="528" left="226" width="3" height="19" font="0"> </text>
<text top="546" left="226" width="75" height="19" font="8"><b>Size: </b>N=246<b> </b></text>
<text top="400" left="397" width="119" height="19" font="8"><b>Inclusion criteria: </b>2</text>
<text top="400" left="516" width="10" height="12" font="7">nd</text>
<text top="400" left="526" width="20" height="19" font="0"> or </text>
<text top="418" left="397" width="8" height="19" font="0">3</text>
<text top="418" left="405" width="9" height="12" font="7">rd</text>
<text top="418" left="413" width="78" height="19" font="0"> degree AVB<b> </b></text>
<text top="436" left="397" width="3" height="19" font="8"><b> </b></text>
<text top="454" left="397" width="143" height="19" font="8"><b>Exclusion criteria: </b>SND<b> </b></text>
<text top="400" left="575" width="156" height="19" font="8"><b>Intervention: </b>Ventricular </text>
<text top="418" left="575" width="24" height="19" font="0">PM </text>
<text top="436" left="575" width="3" height="19" font="0"> </text>
<text top="454" left="575" width="143" height="19" font="8"><b>Comparator: </b>Historical </text>
<text top="473" left="575" width="152" height="19" font="0">reports of pts w/o a PM<b>  </b></text>
<text top="400" left="753" width="321" height="20" font="0">• Natural Hx of CHB is 50% mortality in the first year </text>
<text top="419" left="764" width="212" height="19" font="0">based on prior historical literature </text>
<text top="437" left="753" width="271" height="20" font="0">• Survival improved to 61% at 5 y with a PM </text>
<text top="456" left="753" width="336" height="20" font="0">• Post PM, new CV events were common including MI, </text>
<text top="475" left="764" width="296" height="19" font="0">CHF, and stroke and SCD was the most common </text>
<text top="494" left="764" width="93" height="19" font="0">mode of death </text>
<text top="565" left="95" width="110" height="19" font="0">Strasberg B, et al. </text>
<text top="583" left="95" width="69" height="19" font="0">1981 (199) </text>
<text top="602" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7471363">7471363</a></text>
<text top="602" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7471363"> </a></text>
<text top="565" left="226" width="158" height="19" font="8"><b>Aim: </b>Assess natural Hx of </text>
<text top="583" left="226" width="8" height="19" font="0">2</text>
<text top="583" left="234" width="10" height="12" font="7">nd</text>
<text top="583" left="244" width="32" height="19" font="0"> AVB </text>
<text top="602" left="226" width="3" height="19" font="0"> </text>
<text top="620" left="226" width="74" height="19" font="8"><b>Study type</b>: </text>
<text top="638" left="226" width="91" height="19" font="0">Retrospective, </text>
<text top="657" left="226" width="87" height="19" font="0">observational </text>
<text top="675" left="226" width="3" height="19" font="0"> </text>
<text top="693" left="226" width="67" height="19" font="8"><b>Size</b>: N=56<b> </b></text>
<text top="565" left="397" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="583" left="397" width="130" height="19" font="0">Consecutive pts with </text>
<text top="602" left="397" width="56" height="19" font="0">chronic 2</text>
<text top="602" left="453" width="10" height="12" font="7">nd</text>
<text top="602" left="464" width="84" height="19" font="0"> AVB and EPS </text>
<text top="620" left="397" width="80" height="19" font="0">positive for 2</text>
<text top="620" left="477" width="10" height="12" font="7">nd</text>
<text top="620" left="487" width="32" height="19" font="0"> AVB </text>
<text top="638" left="397" width="3" height="19" font="8"><b> </b></text>
<text top="657" left="397" width="152" height="19" font="8"><b>Exclusion criteria: </b>Acute </text>
<text top="675" left="397" width="141" height="19" font="0">AVB in setting of MI or </text>
<text top="693" left="397" width="95" height="19" font="0">digoxin toxicity<b> </b></text>
<text top="565" left="575" width="122" height="19" font="8"><b>Intervention: </b>None </text>
<text top="565" left="753" width="64" height="20" font="0">• All had 2</text>
<text top="566" left="817" width="10" height="12" font="7">nd</text>
<text top="566" left="827" width="251" height="19" font="0"> degree type I (Wenckebach) on baseline </text>
<text top="584" left="764" width="140" height="19" font="0">ECG (none had type II) </text>
<text top="603" left="753" width="336" height="20" font="0">• 34% did not have heart disease and had a normal HV </text>
<text top="622" left="764" width="219" height="19" font="0">interval; none died of cardiac cause </text>
<text top="640" left="753" width="338" height="20" font="0">• 66% had heart disease, some had prolonged HV; 25% </text>
<text top="659" left="764" width="90" height="19" font="0">received a PM </text>
<text top="678" left="753" width="175" height="20" font="0">• No one progressed to CHB </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 160 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="110" height="19" font="0">Vatankulu MA, et </text>
<text top="105" left="95" width="87" height="19" font="0">al. 2009 (268) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19406272">19406272</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19406272"> </a></text>
<text top="87" left="226" width="94" height="19" font="8"><b>Aim: </b>Assess LV </text>
<text top="105" left="226" width="141" height="19" font="0">remodeling in CHB PM </text>
<text top="123" left="226" width="149" height="19" font="0">pts after PM upgrade to </text>
<text top="142" left="226" width="27" height="19" font="0">CRT </text>
<text top="160" left="226" width="3" height="19" font="0"> </text>
<text top="178" left="226" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="197" left="226" width="66" height="19" font="0">single arm </text>
<text top="215" left="226" width="3" height="19" font="0"> </text>
<text top="233" left="226" width="68" height="19" font="8"><b>Size: </b>N=26 </text>
<text top="87" left="397" width="144" height="19" font="8"><b>Inclusion criteria: </b>CHB, </text>
<text top="105" left="397" width="152" height="19" font="0">upgraded PM to CRT, on </text>
<text top="123" left="397" width="92" height="19" font="0">optimal GDMT </text>
<text top="142" left="397" width="3" height="19" font="0"> </text>
<text top="160" left="397" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="178" left="397" width="95" height="19" font="0">Asymptomatic, </text>
<text top="197" left="397" width="137" height="19" font="0">medications stable &lt;1 </text>
<text top="215" left="397" width="44" height="19" font="0">month<b> </b></text>
<text top="87" left="575" width="109" height="19" font="8"><b>Intervention: </b>BiV </text>
<text top="105" left="575" width="147" height="19" font="0">upgrade+/- defibrillator </text>
<text top="123" left="575" width="3" height="19" font="0"> </text>
<text top="142" left="575" width="119" height="19" font="8"><b>Comparator: </b>None </text>
<text top="87" left="753" width="290" height="20" font="0">• NYHA improved by one class in most subjects </text>
<text top="106" left="753" width="237" height="20" font="0">• Mean EF increased from 39% to 46% </text>
<text top="125" left="753" width="192" height="20" font="0">• 25% decrease in mean LVESV </text>
<text top="144" left="753" width="198" height="20" font="0">• 18% decrease in mean LVEDV  </text>
<text top="164" left="753" width="326" height="20" font="0">• No clinical hard endpoints such as HFH or mortality </text>
<text top="252" left="95" width="88" height="19" font="0">Kiehl EL, et al. </text>
<text top="271" left="95" width="69" height="19" font="0">2016 (269) </text>
<text top="289" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27855853">27855853</a></text>
<text top="289" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27855853"> </a></text>
<text top="252" left="226" width="101" height="19" font="8"><b>Aim: </b>Determine </text>
<text top="271" left="226" width="155" height="19" font="0">incidence of PM-induced </text>
<text top="289" left="226" width="104" height="19" font="0">CM, and identify </text>
<text top="307" left="226" width="146" height="19" font="0">predictors of RV-pacing </text>
<text top="326" left="226" width="76" height="19" font="0">induced CM </text>
<text top="344" left="226" width="3" height="19" font="0"> </text>
<text top="362" left="226" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="381" left="226" width="87" height="19" font="0">Retrospective </text>
<text top="399" left="226" width="3" height="19" font="8"><b> </b></text>
<text top="417" left="226" width="75" height="19" font="8"><b>Size</b>: N=823 </text>
<text top="252" left="397" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="271" left="397" width="158" height="19" font="0">Consecutive pts receiving </text>
<text top="289" left="397" width="153" height="19" font="0">PM between 2000–2014 </text>
<text top="307" left="397" width="165" height="19" font="0">for CHB; LVEF &gt;50%; many </text>
<text top="326" left="397" width="49" height="19" font="0">pts had </text>
<text top="344" left="397" width="151" height="19" font="0">procedural/surgical AVB </text>
<text top="362" left="397" width="3" height="19" font="0"> </text>
<text top="381" left="397" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="399" left="397" width="114" height="19" font="0">Generator change </text>
<text top="417" left="397" width="164" height="19" font="0">procedure, no echo within </text>
<text top="436" left="397" width="127" height="19" font="0">6 months of implant </text>
<text top="252" left="575" width="112" height="19" font="8"><b>Intervention: </b>CRT </text>
<text top="271" left="575" width="151" height="19" font="0">upgrade in some PM pts </text>
<text top="289" left="575" width="3" height="19" font="0"> </text>
<text top="307" left="575" width="150" height="19" font="8"><b>Comparator: </b>Compared </text>
<text top="326" left="575" width="142" height="19" font="0">those with RV-induced </text>
<text top="344" left="575" width="116" height="19" font="0">CM and those w/o<b> </b></text>
<text top="253" left="753" width="336" height="20" font="0">• 12.3% developed PM-induced CM with mean EF 34% </text>
<text top="272" left="753" width="311" height="20" font="0">• Of the 25 CRT upgrades with post CRT echo, 84% </text>
<text top="291" left="764" width="295" height="19" font="0">were responders with mean LVEF increase 18%, </text>
<text top="309" left="764" width="155" height="19" font="0">LVESV decreased by 45% </text>
<text top="327" left="753" width="295" height="20" font="0">• RV pacing burden of 20% seemed to delineate </text>
<text top="346" left="764" width="193" height="19" font="0">increased risk of developing HF </text>
<text top="454" left="95" width="41" height="19" font="8"><b>MOST </b></text>
<text top="473" left="95" width="111" height="19" font="0">Ellenbogen KA, et </text>
<text top="491" left="95" width="87" height="19" font="0">al. 2003 (270) </text>
<text top="510" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12972124">12972124</a></text>
<text top="509" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12972124"> </a></text>
<text top="454" left="226" width="112" height="19" font="8"><b>Aim:</b> Characterize </text>
<text top="473" left="226" width="142" height="19" font="0">complications from DC </text>
<text top="491" left="226" width="139" height="19" font="0">PM implants using the </text>
<text top="510" left="226" width="99" height="19" font="0">MOST database </text>
<text top="528" left="226" width="3" height="19" font="0"> </text>
<text top="546" left="226" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="564" left="226" width="154" height="19" font="0">Retrospective analysis of </text>
<text top="583" left="226" width="27" height="19" font="0">RCT </text>
<text top="601" left="226" width="3" height="19" font="0"> </text>
<text top="619" left="226" width="83" height="19" font="8"><b>Size: </b>N=2010 </text>
<text top="454" left="397" width="151" height="19" font="8"><b>Inclusion criteria: </b>DDDR </text>
<text top="473" left="397" width="162" height="19" font="0">PM implanted for SND; SR </text>
<text top="491" left="397" width="3" height="19" font="8"><b> </b></text>
<text top="509" left="397" width="162" height="19" font="8"><b>Exclusion criteria: </b>Serious </text>
<text top="528" left="397" width="87" height="19" font="0">comorbidities<b> </b></text>
<text top="454" left="575" width="117" height="19" font="8"><b>Intervention: </b>Dual </text>
<text top="473" left="575" width="81" height="19" font="0">chamber PM </text>
<text top="491" left="575" width="3" height="19" font="0"> </text>
<text top="509" left="575" width="154" height="19" font="8"><b>Comparator: </b>Ventricular </text>
<text top="528" left="575" width="120" height="19" font="0">single chamber PM<b> </b></text>
<text top="455" left="753" width="335" height="20" font="0">• Most common complication in the DC PM group was </text>
<text top="474" left="764" width="193" height="19" font="0">atrial lead dislodgement (1.7%) </text>
<text top="492" left="753" width="319" height="20" font="0">• Female sex seemed to predict risk of complication </text>
<text top="638" left="93" width="89" height="19" font="8"><b>FOLLOWPACE </b></text>
<text top="657" left="93" width="87" height="19" font="0">Udo EO, et al. </text>
<text top="675" left="93" width="69" height="19" font="0">2012 (271) </text>
<text top="693" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22182495">22182495</a></text>
<text top="693" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22182495"> </a></text>
<text top="638" left="226" width="101" height="19" font="8"><b>Aim:</b> Determine </text>
<text top="657" left="226" width="154" height="19" font="0">incidence and predictors </text>
<text top="675" left="226" width="128" height="19" font="0">of PM complications </text>
<text top="693" left="226" width="3" height="19" font="0"> </text>
<text top="712" left="226" width="153" height="19" font="8"><b>Study type: </b>Prospective, </text>
<text top="730" left="226" width="75" height="19" font="0">multicenter </text>
<text top="748" left="226" width="3" height="19" font="0"> </text>
<text top="767" left="226" width="83" height="19" font="8"><b>Size: </b>N=1517 </text>
<text top="638" left="397" width="152" height="19" font="8"><b>Inclusion criteria: </b>All pts </text>
<text top="657" left="397" width="134" height="19" font="0">undergoing initial PM </text>
<text top="675" left="397" width="50" height="19" font="0">implant </text>
<text top="693" left="397" width="3" height="19" font="8"><b> </b></text>
<text top="712" left="397" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="730" left="397" width="114" height="19" font="0">Generator change </text>
<text top="748" left="397" width="77" height="19" font="0">procedures; </text>
<text top="638" left="575" width="160" height="19" font="8"><b>Intervention: </b>PM implant </text>
<text top="657" left="575" width="3" height="19" font="0"> </text>
<text top="675" left="575" width="119" height="19" font="8"><b>Comparator: </b>None<b> </b></text>
<text top="639" left="753" width="206" height="20" font="0">• 69% of implanted PMs were DC </text>
<text top="658" left="753" width="308" height="20" font="0">• There were 5.54% lead related problems in the 1</text>
<text top="658" left="1062" width="7" height="12" font="7">st</text>
<text top="658" left="1069" width="14" height="19" font="0"> 2 </text>
<text top="677" left="764" width="50" height="19" font="0">months </text>
<text top="695" left="753" width="327" height="20" font="0">• 12.4% of pts had a complication within 2 months of </text>
<text top="714" left="764" width="50" height="19" font="0">implant </text>
<text top="733" left="753" width="310" height="20" font="0">• Multivariate analysis showed a HR of 3.09 for DC </text>
<text top="752" left="764" width="296" height="19" font="0">devices compared to single chamber devices for </text>
<text top="770" left="764" width="257" height="19" font="0">complications within 2 months of implant </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 161 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="397" width="116" height="19" font="0">investigational PM </text>
<text top="105" left="397" width="66" height="19" font="0">implanted<b> </b></text>
<text top="167" left="95" width="111" height="19" font="0">Ellenbogen KA, et </text>
<text top="185" left="95" width="87" height="19" font="0">al. 2000 (272) </text>
<text top="204" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10867093">10867093</a></text>
<text top="204" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10867093"> </a></text>
<text top="167" left="226" width="101" height="19" font="8"><b>Aim:</b> Determine </text>
<text top="185" left="226" width="105" height="19" font="0">predictors of PM </text>
<text top="204" left="226" width="137" height="19" font="0">syndrome in the PASE </text>
<text top="222" left="226" width="37" height="19" font="0">study </text>
<text top="240" left="226" width="3" height="19" font="0"> </text>
<text top="259" left="226" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="277" left="226" width="154" height="19" font="0">Retrospective analysis of </text>
<text top="295" left="226" width="27" height="19" font="0">RCT </text>
<text top="314" left="226" width="3" height="19" font="0"> </text>
<text top="332" left="226" width="79" height="19" font="8"><b>Size: </b>N=<b> </b>407 </text>
<text top="167" left="397" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="185" left="397" width="164" height="19" font="0">Indication for PM implant; </text>
<text top="204" left="397" width="33" height="19" font="0">in SR </text>
<text top="222" left="397" width="3" height="19" font="8"><b> </b></text>
<text top="240" left="397" width="158" height="19" font="8"><b>Exclusion criteria: </b>Severe </text>
<text top="259" left="397" width="51" height="19" font="0">CHF; AF<b> </b></text>
<text top="167" left="575" width="164" height="19" font="8"><b>Intervention: </b>Randomized </text>
<text top="185" left="575" width="116" height="19" font="0">to single or DC PM </text>
<text top="204" left="575" width="3" height="19" font="0"> </text>
<text top="222" left="575" width="142" height="19" font="8"><b>Comparator: </b>Compare </text>
<text top="240" left="575" width="68" height="19" font="0">the 2 arms<b> </b></text>
<text top="167" left="753" width="309" height="20" font="0">• Predictors of PM syndrome in a Cox multivariate </text>
<text top="186" left="764" width="312" height="19" font="0">regression model include: reduced systolic BP with </text>
<text top="205" left="764" width="172" height="19" font="0">VVI pacing, use of BB, DCM  </text>
<text top="223" left="753" width="303" height="20" font="0">• 26% crossed over from ventricular to DC pacing </text>
<text top="351" left="95" width="45" height="19" font="8"><b>MOST  </b></text>
<text top="369" left="95" width="88" height="19" font="0">Link MS, et al. </text>
<text top="388" left="95" width="69" height="19" font="0">2004 (273) </text>
<text top="406" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15172414">15172414</a></text>
<text top="406" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15172414"> </a></text>
<text top="351" left="226" width="101" height="19" font="8"><b>Aim:</b> Determine </text>
<text top="369" left="226" width="154" height="19" font="0">incidence and predictors </text>
<text top="388" left="226" width="148" height="19" font="0">of PM syndrome in SND </text>
<text top="406" left="226" width="101" height="19" font="0">pts treated with </text>
<text top="424" left="226" width="148" height="19" font="0">ventricular pacing using </text>
<text top="443" left="226" width="123" height="19" font="0">the MOST database </text>
<text top="461" left="226" width="3" height="19" font="0"> </text>
<text top="479" left="226" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="498" left="226" width="154" height="19" font="0">Retrospective analysis of </text>
<text top="516" left="226" width="27" height="19" font="0">RCT </text>
<text top="534" left="226" width="3" height="19" font="0"> </text>
<text top="552" left="226" width="82" height="19" font="8"><b>Size: </b>N= 996  </text>
<text top="351" left="397" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="369" left="397" width="165" height="19" font="0">Randomized to ventricular </text>
<text top="388" left="397" width="152" height="19" font="0">pacing and meet criteria </text>
<text top="406" left="397" width="110" height="19" font="0">for PM syndrome<b> </b></text>
<text top="424" left="397" width="3" height="19" font="8"><b> </b></text>
<text top="443" left="397" width="139" height="19" font="8"><b>Exclusion criteria: </b>Not </text>
<text top="461" left="397" width="129" height="19" font="0">meeting pre-defined </text>
<text top="479" left="397" width="156" height="19" font="0">criteria for PM syndrome<b> </b></text>
<text top="351" left="575" width="109" height="19" font="8"><b>Intervention: </b>PM </text>
<text top="369" left="575" width="137" height="19" font="0">syndrome pts crossed </text>
<text top="388" left="575" width="111" height="19" font="0">over to DC pacing </text>
<text top="406" left="575" width="3" height="19" font="0"> </text>
<text top="424" left="575" width="105" height="19" font="8"><b>Comparator: </b>Pts </text>
<text top="443" left="575" width="154" height="19" font="0">compared to themselves </text>
<text top="461" left="575" width="87" height="19" font="0">pre-crossover<b> </b></text>
<text top="351" left="753" width="236" height="20" font="0">• 18.3% met criteria for PM syndrome </text>
<text top="370" left="753" width="333" height="20" font="0">• Predictors of PM syndrome include lower sinus rate, </text>
<text top="389" left="764" width="248" height="19" font="0">higher paced rate, higher % paced beats </text>
<text top="572" left="99" width="107" height="19" font="0">Arbustini E, et al. </text>
<text top="590" left="99" width="73" height="19" font="0">2002 (274)  </text>
<text top="608" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11897440">11897440</a></text>
<text top="608" left="160" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11897440"><b> </b></a></text>
<text top="571" left="226" width="146" height="19" font="8"><b>Aim:</b> Assess prevalence </text>
<text top="590" left="226" width="148" height="19" font="0">of LMNA mutations in a </text>
<text top="608" left="226" width="77" height="19" font="0">DCM cohort </text>
<text top="626" left="226" width="3" height="19" font="0"> </text>
<text top="645" left="226" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="663" left="226" width="3" height="19" font="0"> </text>
<text top="681" left="226" width="120" height="19" font="8"><b>Size: </b>N=73 and 107 </text>
<text top="700" left="226" width="53" height="19" font="0">controls<b> </b></text>
<text top="571" left="397" width="145" height="19" font="8"><b>Inclusion criteria:</b> DCM </text>
<text top="590" left="397" width="139" height="19" font="0">(familial and sporadic) </text>
<text top="608" left="397" width="117" height="19" font="0">with and w/o AVB. </text>
<text top="627" left="397" width="141" height="19" font="0">Control group=29 with </text>
<text top="645" left="397" width="124" height="19" font="0">ischemic or valvular </text>
<text top="663" left="397" width="140" height="19" font="0">disease and 107 blood </text>
<text top="681" left="397" width="155" height="19" font="0">donors w/o known heart </text>
<text top="700" left="397" width="49" height="19" font="0">disease </text>
<text top="718" left="397" width="3" height="19" font="0"> </text>
<text top="736" left="397" width="147" height="19" font="8"><b>Exclusion criteria:</b> DCM </text>
<text top="755" left="397" width="131" height="19" font="0">pts who do not meet </text>
<text top="773" left="397" width="83" height="19" font="0">WHO criteria<b> </b></text>
<text top="571" left="575" width="136" height="19" font="8"><b>Intervention: </b>Genetic </text>
<text top="590" left="575" width="73" height="19" font="0">testing (73) </text>
<text top="608" left="575" width="3" height="19" font="0"> </text>
<text top="626" left="575" width="133" height="19" font="8"><b>Comparator: G</b>enetic </text>
<text top="645" left="575" width="84" height="19" font="0">testing (107)<b>  </b></text>
<text top="572" left="753" width="330" height="20" font="0">• LMNA gene mutations accounted for 33% of the pts </text>
<text top="591" left="764" width="123" height="19" font="0">with DCM with AVB </text>
<text top="609" left="753" width="335" height="20" font="0">• AVB associated with DCM is a reason for LMNA gene </text>
<text top="628" left="764" width="126" height="19" font="0">molecular screening </text>
<text top="647" left="753" width="330" height="20" font="0">• None of the DCM pts with intact AV conduction had </text>
<text top="665" left="764" width="114" height="19" font="0">any LMNA defects </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 162 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="99" width="108" height="19" font="0">Anselme, F, et al. </text>
<text top="105" left="99" width="73" height="19" font="0">2013 (275)  </text>
<text top="123" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23811080">23811080</a></text>
<text top="123" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23811080"> </a></text>
<text top="142" left="99" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="226" width="130" height="19" font="8"><b>Aim: </b>Assess utility of </text>
<text top="105" left="226" width="146" height="19" font="0">primary prevention ICD </text>
<text top="123" left="226" width="135" height="19" font="0">placement in pts with </text>
<text top="142" left="226" width="156" height="19" font="0">LMNA mutation and AVB </text>
<text top="160" left="226" width="3" height="19" font="0"> </text>
<text top="178" left="226" width="153" height="19" font="8"><b>Study type: </b>Prospective, </text>
<text top="197" left="226" width="66" height="19" font="0">single arm </text>
<text top="215" left="226" width="3" height="19" font="0"> </text>
<text top="233" left="226" width="68" height="19" font="8"><b>Size: </b>N=47<b> </b></text>
<text top="87" left="397" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="105" left="397" width="130" height="19" font="0">Consecutive pts with </text>
<text top="123" left="397" width="127" height="19" font="0">LMNA mutation and </text>
<text top="142" left="397" width="153" height="19" font="0">either a (1) PM, or an (2) </text>
<text top="160" left="397" width="149" height="19" font="0">indication for PM, or (3) </text>
<text top="178" left="397" width="147" height="19" font="0">PR interval&gt;240 ms and </text>
<text top="197" left="397" width="126" height="19" font="0">either LBBB or NSVT </text>
<text top="215" left="397" width="3" height="19" font="0"> </text>
<text top="233" left="397" width="154" height="19" font="8"><b>Exclusion criteria: </b>LMNA </text>
<text top="252" left="397" width="150" height="19" font="0">pts w/o the 3 additional </text>
<text top="270" left="397" width="159" height="19" font="0">criteria were enrolled but </text>
<text top="288" left="397" width="137" height="19" font="0">did not receive an ICD<b> </b></text>
<text top="87" left="575" width="153" height="19" font="8"><b>Intervention: </b>ICD (n=21) </text>
<text top="105" left="575" width="3" height="19" font="8"><b> </b></text>
<text top="123" left="575" width="157" height="19" font="8"><b>Comparator: </b>Standard of </text>
<text top="142" left="575" width="145" height="19" font="0">care w/o ICD (n=24); 2° </text>
<text top="160" left="575" width="130" height="19" font="0">prevention ICD (n=2)<b> </b></text>
<text top="87" left="753" width="329" height="20" font="0">• None of the ICD pts died of SCD over median follow-</text>
<text top="106" left="764" width="104" height="19" font="0">up of 62 months </text>
<text top="124" left="753" width="265" height="20" font="0">• 52% of primary prevention ICD recipients </text>
<text top="143" left="764" width="301" height="19" font="0">experienced sustained VAs requiring ICD therapy </text>
<text top="162" left="753" width="278" height="20" font="0">• Conduction disorders was a predictor of VA </text>
<text top="307" left="99" width="98" height="19" font="0">Hasselberg, NE, </text>
<text top="326" left="99" width="106" height="19" font="0">et al. 2014 (276)  </text>
<text top="344" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24058181">24058181</a></text>
<text top="344" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24058181"> </a></text>
<text top="362" left="99" width="3" height="19" font="8"><b> </b></text>
<text top="307" left="226" width="102" height="19" font="8"><b>Aim: </b>To look for </text>
<text top="326" left="226" width="139" height="19" font="0">predictors of VA in pts </text>
<text top="344" left="226" width="153" height="19" font="0">with lamin A/C mutation </text>
<text top="362" left="226" width="3" height="19" font="0"> </text>
<text top="381" left="226" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="399" left="226" width="87" height="19" font="0">observational </text>
<text top="417" left="226" width="3" height="19" font="0"> </text>
<text top="435" left="226" width="71" height="19" font="8"><b>Size: </b>N=<b> </b>41<b> </b></text>
<text top="307" left="397" width="152" height="19" font="8"><b>Inclusion criteria: </b>LMNA </text>
<text top="326" left="397" width="111" height="19" font="0">mutation positive </text>
<text top="344" left="397" width="3" height="19" font="0"> </text>
<text top="362" left="397" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="381" left="397" width="120" height="19" font="0">Inability to consent<b> </b></text>
<text top="307" left="575" width="163" height="19" font="8"><b>Intervention: </b>ECG, Holter, </text>
<text top="326" left="575" width="125" height="19" font="0">echo, CMRI, genetic </text>
<text top="344" left="575" width="49" height="19" font="0">testing  </text>
<text top="362" left="575" width="3" height="19" font="0"> </text>
<text top="381" left="575" width="110" height="19" font="8"><b>Comparator: </b>N/A<b> </b></text>
<text top="308" left="753" width="292" height="20" font="0">• 7 of the 41 (27%) lamin A/C mutation positive </text>
<text top="326" left="764" width="108" height="19" font="0">subjects had AVB </text>
<text top="345" left="753" width="115" height="20" font="0">• 21 (51%) had VA </text>
<text top="364" left="753" width="316" height="20" font="0">• All 8 pts with sustained VT had AVB and markedly </text>
<text top="383" left="764" width="201" height="19" font="0">prolonged AVB (median 310 ms) </text>
<text top="401" left="753" width="331" height="20" font="0">• Prolonged PR interval and any type of AVB were the </text>
<text top="420" left="764" width="225" height="19" font="0">strongest predictors of sustained VA </text>
<text top="455" left="86" width="3" height="19" font="0"> </text>
<text top="473" left="86" width="908" height="23" font="5"><b>Data Supplement 41. Nonrandomized Trials, Observational Studies, and/or Registries of Conduction Disorders (Section 7) </b></text>
<text top="496" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="514" left="131" width="51" height="19" font="8"><b>Author; </b></text>
<text top="532" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="496" left="265" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="514" left="294" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="496" left="470" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="496" left="649" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="514" left="680" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="532" left="711" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="496" left="917" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="514" left="946" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="551" left="96" width="108" height="19" font="8"><b>The Framingham </b></text>
<text top="570" left="96" width="39" height="19" font="8"><b>Study </b></text>
<text top="588" left="96" width="120" height="19" font="0">Schneider JF, et al.  </text>
<text top="606" left="96" width="62" height="19" font="0">1979 (27) </text>
<text top="625" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/154870">154870</a></text>
<text top="625" left="142" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/154870"> </a></text>
<text top="551" left="230" width="144" height="19" font="8"><b>Aim: </b>Assess the clinical </text>
<text top="570" left="230" width="127" height="19" font="0">implications of LBBB </text>
<text top="588" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="606" left="230" width="153" height="19" font="8"><b>Study type:</b> Nested case-</text>
<text top="625" left="230" width="189" height="19" font="0">control in Framingham cohort  </text>
<text top="643" left="230" width="3" height="19" font="0"> </text>
<text top="661" left="230" width="170" height="19" font="8"><b>Size:</b> 55 pts who developed </text>
<text top="680" left="230" width="174" height="19" font="0">LBBB, 110 matched controls </text>
<text top="698" left="230" width="190" height="19" font="0">Mean age at study onset =50 y </text>
<text top="716" left="230" width="193" height="19" font="0">Mean age at onset of LBBB =62 </text>
<text top="734" left="230" width="10" height="19" font="0">y<b> </b></text>
<text top="551" left="439" width="172" height="19" font="8"><b>Inclusion criteria:</b> LBBB and </text>
<text top="570" left="439" width="138" height="19" font="0">age- and sex-matched </text>
<text top="588" left="439" width="146" height="19" font="0">control pts who did not </text>
<text top="606" left="439" width="120" height="19" font="0">develop LBBB from </text>
<text top="625" left="439" width="124" height="19" font="0">Framingham cohort </text>
<text top="643" left="439" width="3" height="19" font="0"> </text>
<text top="661" left="439" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="552" left="635" width="203" height="19" font="8"><b>1</b>°<b> endpoint:</b> Development of CV </text>
<text top="570" left="635" width="49" height="19" font="0">disease </text>
<text top="589" left="635" width="3" height="19" font="0"> </text>
<text top="607" left="635" width="153" height="19" font="8"><b>Results:</b> 55/5209 people </text>
<text top="625" left="635" width="204" height="19" font="0">developed LBBB in 18 y of follow-</text>
<text top="644" left="635" width="19" height="19" font="0">up </text>
<text top="662" left="635" width="200" height="19" font="0">48% of these develop CAD or HF </text>
<text top="680" left="635" width="53" height="19" font="0">for the 1</text>
<text top="680" left="687" width="7" height="12" font="7">st</text>
<text top="680" left="694" width="142" height="19" font="0"> time with or following </text>
<text top="699" left="635" width="69" height="19" font="0">Dx of LBBB </text>
<text top="717" left="635" width="167" height="19" font="0">Only 11% remained free of </text>
<text top="735" left="635" width="200" height="19" font="0">clinically apparent CV abnormal  </text>
<text top="753" left="635" width="198" height="19" font="0">In men, the appearance of LBBB </text>
<text top="772" left="635" width="202" height="19" font="0">contributed independently to an </text>
<text top="552" left="864" width="198" height="20" font="0">• Comparison with age- and sex-</text>
<text top="570" left="875" width="219" height="19" font="0">matched control subjects free from </text>
<text top="589" left="875" width="215" height="19" font="0">LBBB suggests that newly acquired </text>
<text top="607" left="875" width="200" height="19" font="0">LBBB is most often a hallmark of </text>
<text top="625" left="875" width="217" height="19" font="0">advanced hypertensive or ischemic </text>
<text top="644" left="875" width="137" height="19" font="0">heart disease, or both </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 163 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="635" width="171" height="19" font="0">increased risk of CV disease </text>
<text top="105" left="635" width="59" height="19" font="0">mortality<b> </b></text>
<text top="124" left="96" width="87" height="19" font="0">Fahy GJ, et al. </text>
<text top="143" left="96" width="30" height="19" font="0">1996</text>
<text top="141" left="127" width="4" height="21" font="4"> </text>
<text top="143" left="130" width="28" height="19" font="0">(31) </text>
<text top="161" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8651093">8651093</a></text>
<text top="161" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8651093"> </a></text>
<text top="124" left="230" width="189" height="19" font="8"><b>Aim:</b> Determine the long-term </text>
<text top="143" left="230" width="181" height="19" font="0">outcome of pts with BBB and </text>
<text top="161" left="230" width="158" height="19" font="0">no clinical evidence of CV </text>
<text top="179" left="230" width="49" height="19" font="0">disease </text>
<text top="197" left="230" width="3" height="19" font="0"> </text>
<text top="216" left="230" width="153" height="19" font="8"><b>Study type:</b> Nested case-</text>
<text top="234" left="230" width="51" height="19" font="0">control  </text>
<text top="252" left="230" width="3" height="19" font="0"> </text>
<text top="271" left="230" width="168" height="19" font="8"><b>Size:</b> 310 pts with BBB, 310 </text>
<text top="289" left="230" width="150" height="19" font="0">matched controls out of </text>
<text top="307" left="230" width="185" height="19" font="0">110,000 participant screening </text>
<text top="326" left="230" width="117" height="19" font="0">program in Ireland<b> </b></text>
<text top="124" left="439" width="171" height="19" font="8"><b>Inclusion criteria:</b> BBB/age- </text>
<text top="143" left="439" width="161" height="19" font="0">and sex-matched controls </text>
<text top="161" left="439" width="3" height="19" font="0"> </text>
<text top="179" left="439" width="179" height="19" font="8"><b>Exclusion criteria:</b> Suspected </text>
<text top="197" left="439" width="85" height="19" font="0">heart disease<b> </b></text>
<text top="125" left="635" width="148" height="19" font="8"><b>1</b>°<b> endpoint:</b> Long-term </text>
<text top="143" left="635" width="136" height="19" font="0">“outcome” of BBB pts </text>
<text top="162" left="635" width="3" height="19" font="0"> </text>
<text top="180" left="635" width="172" height="19" font="8"><b>Results:</b> BBB did not impact </text>
<text top="198" left="635" width="104" height="19" font="0">overall mortality </text>
<text top="217" left="635" width="211" height="19" font="0">Cardiac mortality was significantly </text>
<text top="235" left="635" width="174" height="19" font="0">increased in the LBBB group </text>
<text top="253" left="635" width="170" height="19" font="0">compared to their controls  </text>
<text top="272" left="635" width="153" height="19" font="0">LBBB, but not RBBB, was </text>
<text top="290" left="635" width="179" height="19" font="0">associated with an increased </text>
<text top="308" left="635" width="194" height="19" font="0">prevalence of CV disease at the </text>
<text top="326" left="635" width="206" height="19" font="0">follow-up (21% vs. 11%; p=0.04). <b> </b></text>
<text top="124" left="864" width="243" height="20" font="0">• Isolated left BBB is associated with an </text>
<text top="143" left="875" width="229" height="19" font="0">increased risk of developing overt CV </text>
<text top="162" left="875" width="184" height="19" font="0">disease and increased cardiac </text>
<text top="180" left="875" width="63" height="19" font="0">mortality. </text>
<text top="346" left="96" width="95" height="19" font="0">Talreja D, et al. </text>
<text top="364" left="96" width="62" height="19" font="0">2000 (43) </text>
<text top="382" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10689252">10689252</a></text>
<text top="382" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10689252"> </a></text>
<text top="345" left="230" width="179" height="19" font="8"><b>Aim: </b>Assess ability to predict </text>
<text top="364" left="230" width="167" height="19" font="0">LV dysfunction on echo, by </text>
<text top="382" left="230" width="185" height="19" font="0">historic, clinical, radiographic, </text>
<text top="401" left="230" width="128" height="19" font="0">and ECG parameters </text>
<text top="419" left="230" width="3" height="19" font="0"> </text>
<text top="437" left="230" width="173" height="19" font="8"><b>Study type:</b> Cross-sectional  </text>
<text top="455" left="230" width="3" height="19" font="0"> </text>
<text top="474" left="230" width="61" height="19" font="8"><b>Size:</b> 300 <b> </b></text>
<text top="345" left="439" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="364" left="439" width="142" height="19" font="0">Consecutive inpatients </text>
<text top="382" left="439" width="99" height="19" font="0">referred for the </text>
<text top="401" left="439" width="116" height="19" font="0">echocardiographic </text>
<text top="419" left="439" width="162" height="19" font="0">assessment of LV function </text>
<text top="437" left="439" width="7" height="19" font="0"> <b> </b></text>
<text top="346" left="635" width="152" height="19" font="8"><b>1</b>°<b> endpoint:</b> LVER &lt;45% </text>
<text top="365" left="635" width="3" height="19" font="0"> </text>
<text top="383" left="635" width="213" height="19" font="8"><b>Results:</b> 124 (41%) had LVEF &lt;45% </text>
<text top="401" left="635" width="200" height="19" font="0">Presence of LBBB, male sex, and </text>
<text top="420" left="635" width="203" height="19" font="0">CM on CXR were associated with </text>
<text top="438" left="635" width="168" height="19" font="0">presence of LV dysfunction </text>
<text top="456" left="635" width="213" height="19" font="0">Only 2 pts with LVSD had a normal </text>
<text top="475" left="635" width="28" height="19" font="0">ECG </text>
<text top="493" left="635" width="201" height="19" font="0">More than 50% of the predictive </text>
<text top="511" left="635" width="210" height="19" font="0">power of the model rested on the </text>
<text top="529" left="635" width="205" height="19" font="0">discriminatory ability of a normal </text>
<text top="548" left="635" width="32" height="19" font="0">ECG <b> </b></text>
<text top="346" left="864" width="231" height="20" font="0">• When ECG is normal, it is extremely </text>
<text top="365" left="875" width="166" height="19" font="0">unlikely to have LV systolic </text>
<text top="383" left="875" width="79" height="19" font="0">dysfunction. </text>
<text top="401" left="864" width="239" height="20" font="0">• It can be argued that such pts should </text>
<text top="420" left="875" width="118" height="19" font="0">not be referred for </text>
<text top="439" left="875" width="117" height="19" font="0">echocardiography. </text>
<text top="567" left="96" width="102" height="19" font="0">Eriksson P, et al. </text>
<text top="585" left="96" width="62" height="19" font="0">1998 (30) </text>
<text top="603" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9832497">9832497</a></text>
<text top="603" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9832497"> </a></text>
<text top="567" left="230" width="194" height="19" font="8"><b>Aim: </b>Assess prevalence of BBB, </text>
<text top="585" left="230" width="168" height="19" font="0">its impact on mortality and </text>
<text top="603" left="230" width="151" height="19" font="0">coexisting CV conditions </text>
<text top="622" left="230" width="3" height="19" font="0"> </text>
<text top="640" left="230" width="193" height="19" font="8"><b>Study type:</b> Prospective cohort </text>
<text top="658" left="230" width="3" height="19" font="0"> </text>
<text top="677" left="230" width="182" height="19" font="8"><b>Size:</b> 855 men who were 50 y </text>
<text top="695" left="230" width="178" height="19" font="0">old in 1963 followed for 30 y </text>
<text top="713" left="230" width="114" height="19" font="0">82 developed BBB </text>
<text top="732" left="230" width="140" height="19" font="0">22 of those were LBBB </text>
<text top="567" left="439" width="166" height="19" font="8"><b>Inclusion criteria:</b> Random </text>
<text top="585" left="439" width="158" height="19" font="0">sampling of Swedish men </text>
<text top="603" left="439" width="3" height="19" font="0"> </text>
<text top="622" left="439" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="568" left="635" width="188" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality and CV </text>
<text top="586" left="635" width="49" height="19" font="0">disease </text>
<text top="604" left="635" width="3" height="19" font="0"> </text>
<text top="622" left="635" width="193" height="19" font="8"><b>Results:</b> The prevalence of BBB </text>
<text top="641" left="635" width="201" height="19" font="0">increases from 1% at age 50 y to </text>
<text top="659" left="635" width="185" height="19" font="0">17% at age 80 y, resulting in a </text>
<text top="677" left="635" width="185" height="19" font="0">cumulative incidence of 18%.  </text>
<text top="696" left="635" width="214" height="19" font="0">BBB did not predict ischemic heart </text>
<text top="714" left="635" width="128" height="19" font="0">disease or mortality  </text>
<text top="732" left="635" width="183" height="19" font="0">Men who developed BBB had </text>
<text top="751" left="635" width="205" height="19" font="0">bigger LV volume at baseline and </text>
<text top="769" left="635" width="200" height="19" font="0">greater incidence of DM and HF <b> </b></text>
<text top="567" left="864" width="236" height="20" font="0">• BBB correlates strongly to age and is </text>
<text top="586" left="875" width="155" height="19" font="0">common in elderly men.  </text>
<text top="604" left="864" width="177" height="20" font="0">• BBB is a marker of a slowly </text>
<text top="623" left="875" width="207" height="19" font="0">progressing degenerative disease </text>
<text top="642" left="875" width="181" height="19" font="0">that affects the myocardium. </text>
<text top="660" left="864" width="235" height="20" font="0">• BBB is not associated with increased </text>
<text top="679" left="875" width="59" height="19" font="0">mortality </text>
<text top="698" left="864" width="239" height="20" font="0">• I could not find data broken down by </text>
<text top="717" left="875" width="211" height="19" font="0">LBBB vs. RBBB; vast majority were </text>
<text top="735" left="875" width="43" height="19" font="0">RBBB* </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="15" size="13" family="Times" color="#231f20"/>
<text top="804" left="566" width="59" height="19" font="0">Page 164 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="113" height="19" font="0">Mahmod M, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">2012 (277) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21805313">21805313</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21805313"> </a></text>
<text top="87" left="230" width="177" height="19" font="8"><b>Aim: </b>Evaluate the diagnostic </text>
<text top="105" left="230" width="175" height="19" font="0">value of CMR in asx pts with </text>
<text top="123" left="230" width="34" height="19" font="0">LBBB<b> </b></text>
<text top="142" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="160" left="230" width="173" height="19" font="8"><b>Study type:</b> Cross-sectional  </text>
<text top="178" left="230" width="3" height="19" font="0"> </text>
<text top="197" left="230" width="73" height="19" font="8"><b>Size:</b> 54 pts<b> </b></text>
<text top="87" left="439" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="439" width="163" height="19" font="0">Asymptomatic adults with </text>
<text top="123" left="439" width="170" height="19" font="0">complete LBBB referred for </text>
<text top="142" left="439" width="71" height="19" font="0">cardiac MR </text>
<text top="160" left="439" width="3" height="19" font="0"> </text>
<text top="178" left="439" width="168" height="19" font="8"><b>Exclusion criteria:</b> Absence </text>
<text top="197" left="439" width="49" height="19" font="0">of echo<b> </b></text>
<text top="88" left="635" width="200" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pathologic findings </text>
<text top="106" left="635" width="44" height="19" font="0">on MR </text>
<text top="124" left="635" width="3" height="19" font="0"> </text>
<text top="143" left="635" width="211" height="19" font="8"><b>Results:</b> 9/29 (31%) had abnormal </text>
<text top="161" left="635" width="198" height="19" font="0">MR despite normal echo: 6 with </text>
<text top="179" left="635" width="106" height="19" font="0">DCM, 2 with LVH </text>
<text top="198" left="635" width="204" height="19" font="0">19/25 (76%) with abnormal echo </text>
<text top="216" left="635" width="194" height="19" font="0">also had abnormal MR; in 13 of </text>
<text top="234" left="635" width="210" height="19" font="0">them (52%) the MR provided new </text>
<text top="252" left="635" width="188" height="19" font="0">“clinically relevant” findings: 8 </text>
<text top="271" left="635" width="142" height="19" font="0">DCM, 1 cardiac sarcoid<b> </b></text>
<text top="87" left="864" width="229" height="20" font="0">• CMR detects subclinical CMP in 1/3 </text>
<text top="106" left="875" width="232" height="19" font="0">of asx pts with LBBB and normal echo </text>
<text top="124" left="864" width="218" height="20" font="0">• CMR provides additional clinically </text>
<text top="143" left="875" width="197" height="19" font="0">relevant data in over 50% of pts </text>
<text top="162" left="864" width="232" height="20" font="0">• CMR is valuable adjuvant diagnostic </text>
<text top="181" left="875" width="156" height="19" font="0">tool for pt with asx LBBB  </text>
<text top="290" left="96" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="308" left="96" width="69" height="19" font="0">2001 (185) </text>
<text top="326" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11673344">11673344</a></text>
<text top="326" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11673344"> </a></text>
<text top="345" left="96" width="3" height="19" font="0"> </text>
<text top="290" left="230" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="308" left="230" width="89" height="19" font="0">Observational </text>
<text top="326" left="230" width="3" height="19" font="0"> </text>
<text top="345" left="230" width="73" height="19" font="8"><b>Size:</b> 52 pts<b> </b></text>
<text top="290" left="439" width="166" height="19" font="8"><b>Inclusion criteria:</b> BBB and </text>
<text top="308" left="439" width="138" height="19" font="0">negative conventional </text>
<text top="326" left="439" width="50" height="19" font="0">workup </text>
<text top="345" left="439" width="7" height="19" font="0"> <b> </b></text>
<text top="291" left="635" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Rhythm at syncope </text>
<text top="309" left="635" width="183" height="19" font="0">recurrence as assessed by ILR </text>
<text top="327" left="635" width="3" height="19" font="0"> </text>
<text top="345" left="635" width="134" height="19" font="8"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="290" left="864" width="241" height="19" font="0">In pts with BBB and negative EPS, most </text>
<text top="308" left="864" width="204" height="19" font="0">syncopal recurrences result from </text>
<text top="326" left="864" width="215" height="19" font="0">prolonged asystolic pauses, mainly </text>
<text top="345" left="864" width="198" height="19" font="0">attributable to paroxysmal AVB. </text>
<text top="365" left="96" width="88" height="19" font="0">Moya A, et al. </text>
<text top="383" left="96" width="69" height="19" font="0">2011 (189) </text>
<text top="401" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21444367">21444367</a></text>
<text top="401" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21444367"> </a></text>
<text top="365" left="230" width="169" height="19" font="8"><b>Aim:</b> To analyze the clinical </text>
<text top="383" left="230" width="186" height="19" font="0">outcomes of pts with syncope </text>
<text top="401" left="230" width="193" height="19" font="0">and BBB following a systematic </text>
<text top="420" left="230" width="186" height="19" font="0">diagnostic approach: 3-phase: </text>
<text top="438" left="230" width="167" height="19" font="0">clinical evaluation, EPS, ILR </text>
<text top="456" left="230" width="3" height="19" font="0"> </text>
<text top="474" left="230" width="165" height="19" font="8"><b>Study type:</b> Multicentered </text>
<text top="493" left="230" width="189" height="19" font="0">prospective observational trial </text>
<text top="511" left="230" width="3" height="19" font="0"> </text>
<text top="529" left="230" width="149" height="19" font="8"><b>Size:</b> 323 patients (after </text>
<text top="548" left="230" width="71" height="19" font="0">exclusions)<b> </b></text>
<text top="365" left="439" width="130" height="19" font="8"><b>Inclusion criteria:</b> ≥1 </text>
<text top="383" left="439" width="181" height="19" font="0">syncope in the last 6 mo. and </text>
<text top="401" left="439" width="170" height="19" font="0">BBB on EGG with a QRSd of </text>
<text top="420" left="439" width="55" height="19" font="0">≥120 ms </text>
<text top="438" left="439" width="178" height="19" font="8"><b>Exclusion criteria</b>: Indication </text>
<text top="456" left="439" width="167" height="19" font="0">for prophylactic ICD due to </text>
<text top="474" left="439" width="29" height="19" font="0">low  </text>
<text top="493" left="439" width="180" height="19" font="0">LVEF; pre-excitation; long QT </text>
<text top="511" left="439" width="122" height="19" font="0">syndrome; Brugada </text>
<text top="529" left="439" width="130" height="19" font="0">syndrome; acute MI; </text>
<text top="548" left="439" width="166" height="19" font="0">pregnancy; life expectancy </text>
<text top="566" left="439" width="142" height="19" font="0">&lt;1 y due to noncardiac </text>
<text top="584" left="439" width="150" height="19" font="0">cause; geographically or </text>
<text top="603" left="439" width="162" height="19" font="0">otherwise inaccessible for </text>
<text top="621" left="439" width="141" height="19" font="0">follow-up; unwilling or </text>
<text top="639" left="439" width="149" height="19" font="0">unable to give informed </text>
<text top="658" left="439" width="55" height="19" font="0">consent <b> </b></text>
<text top="365" left="635" width="147" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical Dx </text>
<text top="384" left="635" width="172" height="19" font="0">(established in 267 patients </text>
<text top="402" left="635" width="50" height="19" font="0">(82.7%) </text>
<text top="420" left="635" width="216" height="19" font="0">-recurrent syncope: in 15/215 (7%) </text>
<text top="439" left="635" width="162" height="19" font="0">after phase 1/2; 36 of 108 </text>
<text top="457" left="635" width="117" height="19" font="0">(33% after phase 3 </text>
<text top="475" left="634" width="168" height="19" font="0">-documented spontaneous </text>
<text top="494" left="634" width="77" height="19" font="0">arrhythmias </text>
<text top="512" left="634" width="173" height="19" font="0">-death due to any cause: no </text>
<text top="530" left="634" width="168" height="19" font="0">difference in mortality rate </text>
<text top="549" left="634" width="208" height="19" font="0">between pts diagnosed at Phase I </text>
<text top="567" left="634" width="31" height="19" font="0">or II, </text>
<text top="585" left="634" width="190" height="19" font="0">compared with those who had </text>
<text top="604" left="634" width="172" height="19" font="0">implanted ILR (6.0 vs. 6.5%) </text>
<text top="622" left="634" width="3" height="19" font="0"> </text>
<text top="640" left="635" width="134" height="19" font="8"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="365" left="864" width="7" height="18" font="0">•</text>
<text top="365" left="871" width="3" height="19" font="15"> </text>
<text top="365" left="875" width="183" height="19" font="0">In pts with syncope, BBB, and </text>
<text top="384" left="875" width="180" height="19" font="0">preserved LVEF, a systematic </text>
<text top="402" left="875" width="218" height="19" font="0">diagnostic strategy (ESC guidelines) </text>
<text top="420" left="875" width="209" height="19" font="0">achieves a high rate of Dx (82.6%) </text>
<text top="439" left="875" width="205" height="19" font="0">with a low rate of mortality (6%), </text>
<text top="457" left="875" width="184" height="19" font="0">allowing clinicians to institute </text>
<text top="475" left="875" width="172" height="19" font="0">etiology-specific treatment. </text>
<text top="494" left="864" width="7" height="18" font="0">•</text>
<text top="494" left="871" width="3" height="19" font="15"> </text>
<text top="494" left="875" width="225" height="19" font="0">The most common cause of syncope </text>
<text top="513" left="875" width="225" height="19" font="0">was bradyarrhythmia, mostly due to </text>
<text top="531" left="875" width="177" height="19" font="0">paroxysmal A-V block. Other </text>
<text top="549" left="875" width="166" height="19" font="0">etiologies of syncope were </text>
<text top="568" left="875" width="125" height="19" font="0">recognized in 17.6% </text>
<text top="586" left="864" width="7" height="18" font="0">•</text>
<text top="587" left="871" width="3" height="19" font="15"> </text>
<text top="587" left="875" width="218" height="19" font="0">initial clinical evaluation achieved a </text>
<text top="605" left="875" width="217" height="19" font="0">Dx in 25%; the most frequent Dx at </text>
<text top="623" left="875" width="231" height="19" font="0">EPS was a bradyarrhythmia (76%), VT </text>
<text top="642" left="875" width="170" height="19" font="0">or SVT was induced in 14%. </text>
<text top="660" left="864" width="7" height="18" font="0">•</text>
<text top="661" left="871" width="3" height="19" font="15"> </text>
<text top="661" left="875" width="189" height="19" font="0">The study was not designed to </text>
<text top="679" left="877" width="213" height="19" font="0">determine whether this diagnostic </text>
<text top="697" left="877" width="222" height="19" font="0">strategy was better than implanting </text>
<text top="716" left="877" width="166" height="19" font="0">a PM in the majority of pts </text>
<text top="735" left="96" width="117" height="19" font="0">McAnulty JH, et al. </text>
<text top="753" left="96" width="69" height="19" font="0">1982 (278) </text>
<text top="771" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7088050">7088050</a></text>
<text top="771" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7088050"> </a></text>
<text top="735" left="230" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="753" left="230" width="89" height="19" font="0">Observational<b> </b></text>
<text top="771" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="735" left="439" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="753" left="439" width="164" height="19" font="0">Bifascicular or trifascicular </text>
<text top="771" left="439" width="36" height="19" font="0">block<b> </b></text>
<text top="735" left="635" width="214" height="19" font="8"><b>1</b>°<b> endpoint:</b> Major clinical events, </text>
<text top="754" left="635" width="209" height="19" font="0">death, heart block, need for PPM, </text>
<text top="772" left="635" width="54" height="19" font="0">syncope </text>
<text top="735" left="863" width="209" height="20" font="0">•  A higher percentage of pts with </text>
<text top="754" left="877" width="229" height="19" font="0">syncope were shown to develop CHB </text>
<text top="772" left="877" width="211" height="19" font="0">(17%) vs. those w/o syncope (2%)<b>  </b></text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 165 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="230" width="80" height="19" font="8"><b>Size: </b>554 pts </text>
<text top="105" left="230" width="192" height="19" font="0">351 had EPS and 203 refused it<b> </b></text>
<text top="87" left="439" width="3" height="19" font="8"><b> </b></text>
<text top="105" left="439" width="171" height="19" font="8"><b>Exclusion criteria: </b>Terminal </text>
<text top="123" left="439" width="128" height="19" font="0">non-cardiac disease; </text>
<text top="142" left="439" width="115" height="19" font="0">symptoms already </text>
<text top="160" left="439" width="141" height="19" font="0">documented as due to </text>
<text top="178" left="439" width="162" height="19" font="0">bradycardia prior to study<b> </b></text>
<text top="197" left="439" width="3" height="19" font="0"> </text>
<text top="215" left="439" width="3" height="19" font="0"> </text>
<text top="233" left="439" width="3" height="19" font="0"> </text>
<text top="252" left="439" width="3" height="19" font="0"> </text>
<text top="87" left="689" width="3" height="19" font="8"><b> </b></text>
<text top="105" left="635" width="134" height="19" font="8"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="87" left="863" width="208" height="20" font="0">•  Heart block occurred in 4.9% of </text>
<text top="106" left="877" width="201" height="19" font="0">those with long HV compared to </text>
<text top="124" left="877" width="132" height="19" font="0">1.9% with normal HV<b> </b></text>
<text top="143" left="863" width="220" height="20" font="0">•  A prolonged PR interval (found in </text>
<text top="162" left="877" width="185" height="19" font="0">13%) was associated with and </text>
<text top="180" left="877" width="211" height="19" font="0">increased risk of all death, sudden </text>
<text top="198" left="877" width="211" height="19" font="0">death, major clinical events or HF, </text>
<text top="217" left="877" width="225" height="19" font="0">but not development of heart block. </text>
<text top="235" left="863" width="237" height="20" font="0">•  Bundle branch block occurs in 1% of </text>
<text top="254" left="877" width="218" height="19" font="0">population, and requires no special </text>
<text top="272" left="877" width="127" height="19" font="0">evaluation in asx pts </text>
<text top="291" left="96" width="92" height="19" font="0">Kwok CS, et al. </text>
<text top="310" left="96" width="69" height="19" font="0">2016 (279) </text>
<text top="328" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26879241">26879241</a></text>
<text top="328" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26879241"> </a></text>
<text top="291" left="230" width="179" height="19" font="8"><b>Aim: </b>Determine if prolonged </text>
<text top="310" left="230" width="180" height="19" font="0">PR interval is associated with </text>
<text top="328" left="230" width="161" height="19" font="0">adverse CV outcomes and </text>
<text top="346" left="230" width="63" height="19" font="0">mortality.<b> </b></text>
<text top="365" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="383" left="230" width="187" height="19" font="8"><b>Study type: </b>Systemic review + </text>
<text top="401" left="230" width="87" height="19" font="0">meta-analysis<b> </b></text>
<text top="419" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="438" left="230" width="176" height="19" font="8"><b>Size: 1</b>4 studies, 400,750 pts<b> </b></text>
<text top="291" left="439" width="159" height="19" font="8"><b>Inclusion criteria: </b>Studies </text>
<text top="310" left="439" width="137" height="19" font="0">that evaluated clinical </text>
<text top="328" left="439" width="162" height="19" font="0">outcomes associated with </text>
<text top="346" left="439" width="159" height="19" font="0">prolonged and normal PR </text>
<text top="365" left="439" width="56" height="19" font="0">intervals </text>
<text top="383" left="439" width="3" height="19" font="0"> </text>
<text top="401" left="439" width="183" height="19" font="8"><b>Exclusion criteria: </b>From main </text>
<text top="420" left="439" width="172" height="19" font="0">analysis:<b> </b>Studies of pts with </text>
<text top="438" left="439" width="170" height="19" font="0">specific cardiac pathologies </text>
<text top="456" left="439" width="147" height="19" font="0">(such as AS, sinus nodal </text>
<text top="475" left="439" width="180" height="19" font="0">dysfunction and HF) or of pts </text>
<text top="493" left="439" width="112" height="19" font="0">who had received </text>
<text top="511" left="439" width="179" height="19" font="0">intervention (angiography or </text>
<text top="529" left="439" width="35" height="19" font="0">CRT) <b> </b></text>
<text top="292" left="635" width="141" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality </text>
<text top="311" left="635" width="3" height="19" font="0"> </text>
<text top="329" left="635" width="215" height="19" font="8"><b>Results:</b> Increased risk of mortality </text>
<text top="347" left="635" width="190" height="19" font="0">with prolonged PR interval risk </text>
<text top="365" left="635" width="211" height="19" font="0">ratio (RR: 1.24; 95% CI: 1.02–1.51, </text>
<text top="384" left="635" width="65" height="19" font="0">5 studies.  </text>
<text top="402" left="635" width="162" height="19" font="0">Prolonged PR interval was </text>
<text top="420" left="635" width="204" height="19" font="0">associated with significant risk of </text>
<text top="439" left="635" width="192" height="19" font="0">HF or LV dysfunction (RR: 1.39; </text>
<text top="457" left="635" width="205" height="19" font="0">95% CI: 1.18–1.65, 3 studies) and </text>
<text top="475" left="635" width="209" height="19" font="0">AF (RR: 1.45; 95% CI: 1.23–1.71, 8 </text>
<text top="494" left="635" width="183" height="19" font="0">studies) but not CV mortality, </text>
<text top="512" left="635" width="196" height="19" font="0">coronary heart disease or MI or </text>
<text top="530" left="635" width="89" height="19" font="0">stroke or TIA.<b>  </b></text>
<text top="292" left="864" width="192" height="20" font="0">•<b> </b>Possible association between </text>
<text top="311" left="875" width="227" height="19" font="0">prolonged PR interval and significant </text>
<text top="329" left="875" width="210" height="19" font="0">increases in AF, HF and mortality. <b> </b></text>
<text top="549" left="96" width="97" height="19" font="0">Boriani G, et al. </text>
<text top="568" left="96" width="30" height="19" font="0">2003</text>
<text top="566" left="127" width="4" height="21" font="4"> </text>
<text top="568" left="130" width="35" height="19" font="0">(280) </text>
<text top="586" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12649505">12649505</a></text>
<text top="586" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12649505"> </a></text>
<text top="549" left="230" width="181" height="19" font="8"><b>Size:</b> 18 pts (age 42.8±19.6 y) </text>
<text top="568" left="230" width="178" height="19" font="0">with genetically confirmed X-</text>
<text top="586" left="230" width="170" height="19" font="0">linked (N=10) or autosomal </text>
<text top="604" left="230" width="142" height="19" font="0">dominant (N=8) EDMD </text>
<text top="549" left="439" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="568" left="439" width="3" height="19" font="0"> </text>
<text top="586" left="439" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="549" left="635" width="163" height="19" font="8"><b>Results:</b> Pacemakers were </text>
<text top="568" left="635" width="209" height="19" font="0">required by 10 of 18 (56%) pts for </text>
<text top="586" left="635" width="106" height="19" font="0">bradyarrhythmia </text>
<text top="550" left="864" width="243" height="19" font="0"> •<b> </b>&gt;50% of pts with muscular dystrophy </text>
<text top="568" left="875" width="177" height="19" font="0">(EDMD) require PM implant. </text>
<text top="587" left="864" width="211" height="20" font="0">•<b> </b>Survival after PM implant is very </text>
<text top="606" left="875" width="71" height="19" font="0">reasonable </text>
<text top="625" left="96" width="96" height="19" font="0">Mymin D, et al. </text>
<text top="643" left="96" width="30" height="19" font="0">1986</text>
<text top="642" left="127" width="4" height="21" font="4"> </text>
<text top="643" left="130" width="35" height="19" font="0">(281) </text>
<text top="662" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3762641">3762641</a></text>
<text top="662" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3762641"> </a></text>
<text top="625" left="230" width="157" height="19" font="8"><b>Study type:</b> Longitudinal, </text>
<text top="643" left="230" width="92" height="19" font="0">Observational  </text>
<text top="662" left="230" width="3" height="19" font="0"> </text>
<text top="680" left="230" width="145" height="19" font="8"><b>Size:</b> 3983 healthy men<b> </b></text>
<text top="625" left="439" width="162" height="19" font="8"><b>Inclusion criteria:</b> Healthy </text>
<text top="643" left="439" width="39" height="19" font="0">males </text>
<text top="662" left="439" width="3" height="19" font="0"> </text>
<text top="680" left="439" width="167" height="19" font="8"><b>Exclusion criteria:</b> Females<b> </b></text>
<text top="626" left="635" width="123" height="19" font="8"><b>1</b>°<b> endpoint:</b> 1°AVB </text>
<text top="644" left="635" width="3" height="19" font="0"> </text>
<text top="662" left="635" width="199" height="19" font="8"><b>Results:</b> 52 initial cases plus 124 </text>
<text top="681" left="635" width="216" height="19" font="0">new cases over 30 y. No difference </text>
<text top="699" left="635" width="131" height="19" font="0">in all-cause mortality<b> </b></text>
<text top="625" left="864" width="241" height="20" font="0">• Primary first-degree heart block with </text>
<text top="644" left="877" width="188" height="19" font="0">moderate PR prolongation is a </text>
<text top="662" left="877" width="106" height="19" font="0">benign condition </text>
<text top="681" left="864" width="205" height="20" font="0">• may not apply to more marked </text>
<text top="700" left="877" width="191" height="19" font="0">prolongation of the PR interval </text>
<text top="719" left="96" width="94" height="19" font="0">Huhta JC, et al. </text>
<text top="737" left="96" width="69" height="19" font="0">1983 (282) </text>
<text top="755" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6851033">6851033</a></text>
<text top="755" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6851033"> </a></text>
<text top="719" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="737" left="230" width="45" height="19" font="0">review </text>
<text top="719" left="439" width="120" height="19" font="0">107 pts with ccTGA </text>
<text top="719" left="635" width="167" height="19" font="0">23 of 107 (21%) developed </text>
<text top="737" left="635" width="201" height="19" font="0">naturally occurring AVB at a rate </text>
<text top="755" left="635" width="172" height="19" font="0">of 2% per yr. 12 of 49 (24%) </text>
<text top="774" left="635" width="191" height="19" font="0">developed AVB at VSD closure. </text>
<text top="719" left="864" width="239" height="20" font="0">• Pts with ccTGA are at a constant and </text>
<text top="738" left="877" width="228" height="19" font="0">elevated risk of developing complete </text>
<text top="756" left="877" width="168" height="19" font="0">AVB throughout their lives. </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 166 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="117" height="19" font="0">Connelly MS, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">1996 (283) </text>
<text top="123" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8609349">8609349</a></text>
<text top="123" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8609349"> </a></text>
<text top="87" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="105" left="230" width="45" height="19" font="0">review<b> </b></text>
<text top="87" left="439" width="113" height="19" font="0">52 pts with ccTGA </text>
<text top="87" left="635" width="164" height="19" font="0">9 or 52 (17.3%) developed </text>
<text top="105" left="635" width="210" height="19" font="0">spontaneous AVB; 9 of 52 (17.3%) </text>
<text top="123" left="635" width="185" height="19" font="0">developed postoperative AVB </text>
<text top="87" left="864" width="221" height="20" font="0">• 17% of pts developed progressive </text>
<text top="106" left="877" width="157" height="19" font="0">AVB unrelated to surgery </text>
<text top="143" left="96" width="105" height="19" font="0">Weindling SN, et </text>
<text top="161" left="96" width="87" height="19" font="0">al.<i> </i>1998 (284) </text>
<text top="179" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9723647">9723647</a></text>
<text top="179" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9723647"> </a></text>
<text top="142" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="161" left="230" width="45" height="19" font="0">review </text>
<text top="143" left="439" width="160" height="19" font="0">54 pts with postoperative </text>
<text top="161" left="439" width="132" height="19" font="0">heart block following </text>
<text top="179" left="439" width="152" height="19" font="0">congenital heart surgery </text>
<text top="143" left="635" width="191" height="19" font="0">31 of 32 pts who recovered AV </text>
<text top="161" left="635" width="161" height="19" font="0">conduction did so by the 9</text>
<text top="161" left="796" width="8" height="12" font="7">th</text>
<text top="161" left="804" width="3" height="19" font="0"> </text>
<text top="179" left="635" width="118" height="19" font="0">postoperative day. </text>
<text top="143" left="864" width="210" height="20" font="0">• 43% did not recover conduction </text>
<text top="162" left="864" width="190" height="20" font="0">• 97% of those who recovered </text>
<text top="181" left="877" width="163" height="19" font="0">conduction – did so by d 9 </text>
<text top="200" left="96" width="96" height="19" font="0">Meune C, et al. </text>
<text top="217" left="96" width="34" height="20" font="6"><i>2</i>006.</text>
<text top="217" left="131" width="4" height="21" font="4"> </text>
<text top="218" left="134" width="35" height="19" font="0">(285) </text>
<text top="236" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16407522">16407522</a></text>
<text top="236" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16407522"> </a></text>
<text top="200" left="230" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="218" left="230" width="87" height="19" font="0">observational </text>
<text top="200" left="439" width="121" height="19" font="0">19 pts with lamin A </text>
<text top="218" left="439" width="141" height="19" font="0">mutations referred for </text>
<text top="236" left="439" width="171" height="19" font="0">pacing and receiving an ICD </text>
<text top="200" left="635" width="146" height="19" font="0">9 pts (46%) received an </text>
<text top="218" left="635" width="204" height="19" font="0">appropriate shock for ventricular </text>
<text top="236" left="635" width="110" height="19" font="0">tachyarrhythmias </text>
<text top="200" left="864" width="224" height="20" font="0">• The implantation of an ICD, rather </text>
<text top="219" left="877" width="225" height="19" font="0">than a PM, should be considered for </text>
<text top="237" left="877" width="59" height="19" font="0">these pts </text>
<text top="256" left="96" width="107" height="19" font="0">van Rijsingen, IA, </text>
<text top="275" left="96" width="68" height="19" font="0">et al. 2012.</text>
<text top="273" left="164" width="4" height="21" font="4"> </text>
<text top="275" left="168" width="35" height="19" font="0">(286) </text>
<text top="293" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22281253">22281253</a></text>
<text top="293" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22281253"> </a></text>
<text top="256" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="275" left="230" width="134" height="19" font="0">multicentered cohort </text>
<text top="256" left="439" width="120" height="19" font="0">269 pts with LMNA </text>
<text top="275" left="439" width="66" height="19" font="0">mutations </text>
<text top="256" left="635" width="212" height="19" font="0">Malignant ventricular arrhythmias </text>
<text top="275" left="635" width="207" height="19" font="0">occurred (5%/y) in pts with ≥2 of: </text>
<text top="293" left="635" width="176" height="19" font="0">NSVT, LVEF &lt;45% at the first </text>
<text top="311" left="635" width="213" height="19" font="0">clinical contact, male sex, and non-</text>
<text top="330" left="635" width="125" height="19" font="0">missense mutations </text>
<text top="257" left="864" width="238" height="20" font="0">• Specific risk factors portend a higher </text>
<text top="275" left="877" width="196" height="19" font="0">risk of ventricular arrhythmia in </text>
<text top="294" left="877" width="175" height="19" font="0">carriers of LMNA mutations  </text>
<text top="349" left="96" width="92" height="19" font="0">Maury P, et al. </text>
<text top="367" left="96" width="34" height="19" font="0">2013.</text>
<text top="366" left="131" width="4" height="21" font="4"> </text>
<text top="367" left="134" width="35" height="19" font="0">(287) </text>
<text top="385" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24011739">24011739</a></text>
<text top="385" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24011739"> </a></text>
<text top="349" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="367" left="230" width="45" height="19" font="0">review </text>
<text top="349" left="439" width="48" height="19" font="0">325 pts </text>
<text top="349" left="635" width="132" height="19" font="0">First degree AVB was </text>
<text top="367" left="635" width="190" height="19" font="0">independently associated with </text>
<text top="385" left="635" width="180" height="19" font="0">sudden death or implantable </text>
<text top="404" left="635" width="155" height="19" font="0">cardioverter-defibrillator </text>
<text top="422" left="635" width="208" height="19" font="0">appropriated therapies (OR: 2.41; </text>
<text top="440" left="635" width="174" height="19" font="0">95% CI: 1.01–0.73; p=0.046) </text>
<text top="349" left="864" width="222" height="20" font="0">• First degree AVB is independently </text>
<text top="368" left="877" width="189" height="19" font="0">linked to outcome and may be </text>
<text top="386" left="877" width="213" height="19" font="0">proposed to be used for individual </text>
<text top="404" left="877" width="106" height="19" font="0">risk stratification </text>
<text top="459" left="96" width="98" height="19" font="0">O'Mahony C, et </text>
<text top="478" left="96" width="52" height="19" font="0">al. 2011.</text>
<text top="476" left="148" width="4" height="21" font="4"> </text>
<text top="478" left="152" width="35" height="19" font="0">(288)<b> </b></text>
<text top="496" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21856674">21856674</a></text>
<text top="496" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21856674"> </a></text>
<text top="459" left="230" width="167" height="19" font="8"><b>Study type: </b>Observational, </text>
<text top="478" left="230" width="164" height="19" font="0">longitudinal, retrospective </text>
<text top="496" left="230" width="81" height="19" font="0">cohort study </text>
<text top="459" left="439" width="140" height="19" font="0">204 pts; 12 had device </text>
<text top="478" left="439" width="176" height="19" font="0">implant during follow-up for </text>
<text top="496" left="439" width="112" height="19" font="0">bradyarrhythmias </text>
<text top="459" left="635" width="205" height="19" font="0">Independent predictors of future </text>
<text top="478" left="635" width="207" height="19" font="0">antibradycardia pacing were (in a </text>
<text top="496" left="635" width="197" height="19" font="0">multivariable Cox model): QRSd </text>
<text top="514" left="635" width="155" height="19" font="0">and PR interval duration  </text>
<text top="459" left="863" width="242" height="20" font="0">•  Pacing for AV and sinus node disease </text>
<text top="478" left="877" width="108" height="19" font="0">is common (±8%) </text>
<text top="497" left="863" width="212" height="20" font="0">•  Pts with QRS ≥110 ms should be </text>
<text top="516" left="877" width="134" height="19" font="0">closely monitored for </text>
<text top="534" left="877" width="112" height="19" font="0">bradyarrhythmias </text>
<text top="553" left="96" width="92" height="19" font="0">Polak PE, et al. </text>
<text top="571" left="96" width="69" height="19" font="0">1989 (289) </text>
<text top="590" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2707275">2707275</a></text>
<text top="590" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2707275"> </a></text>
<text top="553" left="230" width="145" height="19" font="8"><b>Study type: </b>Case series </text>
<text top="553" left="439" width="33" height="19" font="0">2 pts </text>
<text top="553" left="635" width="149" height="19" font="0">Pts with fascicular block </text>
<text top="571" left="635" width="183" height="19" font="0">progressed to PM-dependent </text>
<text top="590" left="635" width="97" height="19" font="0">complete block </text>
<text top="553" left="864" width="38" height="20" font="0">• N/A </text>
<text top="609" left="96" width="118" height="19" font="0">Khambatta S, et al. </text>
<text top="627" left="96" width="30" height="19" font="0">2014</text>
<text top="626" left="127" width="4" height="21" font="4"> </text>
<text top="627" left="130" width="35" height="19" font="0">(290) </text>
<text top="645" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25061332">25061332</a></text>
<text top="645" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25061332"> </a></text>
<text top="609" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="627" left="230" width="45" height="19" font="0">review </text>
<text top="609" left="439" width="41" height="19" font="0">35 pts </text>
<text top="609" left="635" width="204" height="19" font="0">PM/ICD required in 31 % (11 pts) </text>
<text top="627" left="635" width="207" height="19" font="0">4 pts (11%) in the series died, but </text>
<text top="645" left="635" width="178" height="19" font="0">all deaths were from sudden </text>
<text top="664" left="635" width="95" height="19" font="0">cardiac events. </text>
<text top="609" left="864" width="243" height="20" font="0">• High incidence of device implantation </text>
<text top="628" left="875" width="167" height="19" font="0">implant and sudden death  </text>
<text top="646" left="864" width="3" height="19" font="0"> </text>
<text top="683" left="96" width="100" height="19" font="0">Ali H, et al. 2017</text>
<text top="681" left="196" width="4" height="21" font="4"> </text>
<text top="701" left="96" width="35" height="19" font="0">(291) </text>
<text top="719" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28583850">28583850</a></text>
<text top="719" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28583850"> </a></text>
<text top="683" left="230" width="337" height="19" font="8"><b>Study type: </b>Systematic Review  Case reports on CHB </text>
<text top="701" left="439" width="181" height="19" font="0">following blunt cardiac injury </text>
<text top="719" left="439" width="154" height="19" font="0">were available for 50 pts </text>
<text top="683" left="635" width="215" height="19" font="0">PPM implantation was indicated in </text>
<text top="701" left="635" width="201" height="20" font="0">∼50% of early survivors because </text>
<text top="719" left="634" width="198" height="19" font="0">of recurrent or permanent CHB. </text>
<text top="738" left="635" width="195" height="19" font="0">BBB was present in &gt;70% of pts </text>
<text top="756" left="635" width="202" height="19" font="0">A fatal outcome occurred in 20% </text>
<text top="774" left="635" width="193" height="19" font="0">of pts; structural damage of AV </text>
<text top="683" left="864" width="206" height="20" font="0">• CHB secondary to blunt cardiac </text>
<text top="702" left="877" width="178" height="19" font="0">injury is associated with 20% </text>
<text top="720" left="877" width="203" height="19" font="0">mortality mainly occurring in the </text>
<text top="739" left="877" width="197" height="19" font="0">early post-traumatic period and </text>
<text top="757" left="877" width="185" height="19" font="0">most of the deaths are due to </text>
<text top="775" left="877" width="78" height="19" font="0">arrhythmia.  </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 167 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="635" width="178" height="19" font="0">conduction system in 50% of </text>
<text top="105" left="635" width="69" height="19" font="0">necropsies </text>
<text top="87" left="864" width="193" height="20" font="0">• Recurrent or permanent CHB </text>
<text top="106" left="877" width="222" height="19" font="0">requiring PM implantation occurs in </text>
<text top="125" left="877" width="121" height="20" font="0">∼50% of survivors.  </text>
<text top="143" left="864" width="199" height="20" font="0">• A structural damage of the AV </text>
<text top="162" left="877" width="215" height="19" font="0">conductive system can be found in </text>
<text top="180" left="877" width="92" height="19" font="0">50% of victims </text>
<text top="199" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="219" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="239" left="86" width="713" height="23" font="5"><b>Data Supplement 42. Randomized Data for Predicting Perioperative Bradycardia (Section 8.1.1) </b></text>
<text top="262" left="100" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="280" left="131" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="299" left="104" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="262" left="246" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="280" left="251" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="299" left="245" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="262" left="389" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="262" left="552" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="280" left="570" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="299" left="554" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="317" left="575" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="262" left="731" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="280" left="713" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="299" left="717" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="317" left="760" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="263" left="898" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="281" left="933" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="299" left="941" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="336" left="95" width="99" height="19" font="0">Chierichini A, et </text>
<text top="354" left="95" width="87" height="19" font="0">al. 2015 (292) </text>
<text top="373" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25953222">25953222</a></text>
<text top="373" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25953222"> </a></text>
<text top="391" left="95" width="7" height="19" font="0">  </text>
<text top="336" left="221" width="137" height="19" font="8"><b>Aim:</b> Evaluate the use </text>
<text top="354" left="221" width="106" height="19" font="0">of irrigation fluid </text>
<text top="373" left="221" width="134" height="19" font="0">using norepinephrine </text>
<text top="391" left="221" width="131" height="19" font="0">or epinephrine in pts </text>
<text top="409" left="221" width="73" height="19" font="0">undergoing </text>
<text top="428" left="221" width="98" height="19" font="0">arthroscopy for </text>
<text top="446" left="221" width="123" height="19" font="0">rotator cuff surgery </text>
<text top="464" left="221" width="3" height="19" font="0"> </text>
<text top="482" left="221" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="501" left="221" width="75" height="19" font="0">Prospective </text>
<text top="519" left="221" width="122" height="19" font="0">randomized double </text>
<text top="537" left="221" width="137" height="19" font="0">blind controlled study </text>
<text top="556" left="221" width="3" height="19" font="0"> </text>
<text top="574" left="221" width="80" height="19" font="8"><b>Size:</b> 120 pts </text>
<text top="336" left="371" width="139" height="19" font="8"><b>Inclusion criteria:</b> ASA </text>
<text top="354" left="371" width="123" height="19" font="0">status 1 or 2, &gt;18 y, </text>
<text top="373" left="371" width="134" height="19" font="0">scheduled for rotator </text>
<text top="391" left="371" width="106" height="19" font="0">cuff surgery with </text>
<text top="409" left="371" width="130" height="19" font="0">interscalene brachial </text>
<text top="428" left="371" width="78" height="19" font="0">plexus block </text>
<text top="446" left="371" width="3" height="19" font="0"> </text>
<text top="464" left="371" width="146" height="19" font="8"><b>Exclusion criteria:</b> CAD, </text>
<text top="483" left="371" width="119" height="19" font="0">cardiac conduction </text>
<text top="501" left="371" width="127" height="19" font="0">defects, BB or ACEI<b>:</b>  </text>
<text top="336" left="540" width="85" height="19" font="8"><b>Intervention:</b> </text>
<text top="354" left="540" width="135" height="19" font="0">Norepinephrine (0.66 </text>
<text top="373" left="540" width="139" height="19" font="0">mg/L) to the irrigation </text>
<text top="391" left="540" width="26" height="19" font="0">bag </text>
<text top="409" left="540" width="7" height="19" font="0">  </text>
<text top="428" left="540" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="446" left="540" width="112" height="19" font="0">Epinephrine (0.33 </text>
<text top="464" left="540" width="139" height="19" font="0">mg/L) to the irrigation </text>
<text top="483" left="540" width="26" height="19" font="0">bag<b> </b></text>
<text top="337" left="697" width="167" height="19" font="8"><b>1</b>°<b> endpoint:</b> Development </text>
<text top="355" left="697" width="112" height="19" font="0">of hypotension or </text>
<text top="374" left="697" width="171" height="19" font="0">bradycardia (&lt;30 bpm in ≤5 </text>
<text top="392" left="697" width="104" height="19" font="0">min or &lt;50 bpm  </text>
<text top="410" left="697" width="3" height="19" font="0"> </text>
<text top="428" left="697" width="151" height="19" font="8"><b>Safety endpoint:</b> Timing </text>
<text top="447" left="697" width="126" height="19" font="0">and safety of events<b> </b></text>
<text top="336" left="884" width="138" height="20" font="0">• Hypotension and/or </text>
<text top="355" left="897" width="76" height="19" font="0">bradycardia </text>
<text top="379" left="897" width="9" height="12" font="0">o</text>
<text top="377" left="906" width="4" height="14" font="0"> </text>
<text top="374" left="925" width="87" height="19" font="0">NE: 5/60 (8%) </text>
<text top="397" left="897" width="9" height="12" font="0">o</text>
<text top="396" left="906" width="4" height="14" font="0"> </text>
<text top="392" left="925" width="93" height="19" font="0">E: 15/59 (25%) </text>
<text top="410" left="884" width="193" height="20" font="0">• Did not separate bradycardia </text>
<text top="429" left="897" width="44" height="19" font="0">events </text>
<text top="448" left="884" width="178" height="20" font="0">• Timing similar (30–35 min) </text>
<text top="593" left="86" width="4" height="21" font="4"> </text>
<text top="613" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="635" left="86" width="469" height="23" font="5"><b>Data Supplement 43. RCTs of Conduction Disorders (Section 7) </b></text>
<text top="657" left="86" width="744" height="23" font="5"><b>Data Supplement 44. Nonrandomized Data for predicting perioperative bradycardia (Section 8.1.1)  </b></text>
<text top="680" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="698" left="137" width="51" height="19" font="8"><b>Author; </b></text>
<text top="716" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="680" left="263" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="698" left="292" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="680" left="447" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="680" left="666" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="698" left="696" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="716" left="728" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="680" left="942" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="698" left="971" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="736" left="93" width="124" height="19" font="0">Marrocco-Trischitta </text>
<text top="754" left="93" width="136" height="19" font="0">MM, et al. 2016 (293) </text>
<text top="772" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27177706">27177706</a></text>
<text top="772" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27177706"> </a></text>
<text top="736" left="244" width="129" height="19" font="8"><b>Aim:</b> Evaluate use of </text>
<text top="754" left="244" width="147" height="19" font="0">temporary transvenous </text>
<text top="772" left="244" width="160" height="19" font="0">pacing (TTVP) for pts with </text>
<text top="736" left="420" width="172" height="19" font="8"><b>Inclusion criteria:</b> Database </text>
<text top="754" left="420" width="160" height="19" font="0">searched for pts with CEA </text>
<text top="772" left="420" width="61" height="19" font="0">and TTVP </text>
<text top="736" left="608" width="291" height="19" font="8"><b>1</b>°<b> endpoint:</b> 4/34 CEA surgeries with TTVP had </text>
<text top="755" left="618" width="88" height="19" font="0">PM activation </text>
<text top="773" left="608" width="3" height="19" font="0"> </text>
<text top="736" left="925" width="160" height="20" font="0">• Temporary transvenous </text>
<text top="755" left="936" width="147" height="19" font="0">pacing may be useful in </text>
<text top="773" left="936" width="123" height="19" font="0">pts undergoing CEA </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 168 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="244" width="110" height="19" font="0">trifascicular block </text>
<text top="105" left="244" width="100" height="19" font="0">undergoing CEA </text>
<text top="123" left="244" width="3" height="19" font="0"> </text>
<text top="142" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="160" left="244" width="143" height="19" font="0">with historical controls </text>
<text top="178" left="244" width="148" height="19" font="0">(other pts with vascular </text>
<text top="197" left="244" width="110" height="19" font="0">surgery and TTVP </text>
<text top="215" left="244" width="3" height="19" font="0"> </text>
<text top="233" left="244" width="149" height="19" font="8"><b>Size:</b> 31 CEAs compared </text>
<text top="252" left="244" width="125" height="19" font="0">to 37 other vascular </text>
<text top="270" left="244" width="109" height="19" font="0">surgery (68 total) </text>
<text top="87" left="420" width="3" height="19" font="0"> </text>
<text top="105" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="87" left="608" width="52" height="19" font="8"><b>Results: </b></text>
<text top="105" left="607" width="144" height="20" font="0">•  Adverse events were </text>
<text top="124" left="607" width="295" height="20" font="0">•  Defined as follows: PM activation, occurrence </text>
<text top="144" left="607" width="166" height="20" font="0">•  Of block progression to 2</text>
<text top="144" left="773" width="10" height="12" font="7">nd</text>
<text top="144" left="783" width="94" height="19" font="0"> degree AVB of </text>
<text top="163" left="620" width="253" height="19" font="0">Mobitz type II, or third-degree A-V block, </text>
<text top="181" left="607" width="298" height="20" font="0">•  bradycardia 40 bpm with a minimum duration </text>
<text top="200" left="620" width="283" height="19" font="0">10 s and/or a hemodynamic compromise (i.e., </text>
<text top="218" left="620" width="243" height="19" font="0">systolic BP &lt;90 mm Hg), asystole with a </text>
<text top="237" left="620" width="84" height="19" font="0">duration &gt;5 s </text>
<text top="255" left="607" width="165" height="20" font="0">•  4 pts with PM activation </text>
<text top="274" left="607" width="278" height="20" font="0">•  In 2 pts procedure stopped due to asystole<b> </b></text>
<text top="294" left="95" width="106" height="19" font="0">Cheung CC, et al. </text>
<text top="312" left="95" width="69" height="19" font="0">2015 (294) </text>
<text top="330" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25541033">25541033</a></text>
<text top="330" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25541033"> </a></text>
<text top="294" left="244" width="159" height="19" font="8"><b>Aim:</b> Evaluate prevalence </text>
<text top="312" left="244" width="122" height="19" font="0">of hypotension and </text>
<text top="330" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="349" left="244" width="122" height="19" font="0">elective noncardiac </text>
<text top="367" left="244" width="49" height="19" font="0">surgery </text>
<text top="385" left="244" width="3" height="19" font="0"> </text>
<text top="404" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="422" left="244" width="3" height="19" font="0"> </text>
<text top="440" left="244" width="153" height="19" font="8"><b>Size:</b> 193 pts undergoing </text>
<text top="459" left="244" width="122" height="19" font="0">noncardiac elective </text>
<text top="477" left="244" width="49" height="19" font="0">surgery </text>
<text top="294" left="420" width="168" height="19" font="8"><b>Inclusion criteria:</b> Post-hoc </text>
<text top="312" left="420" width="152" height="19" font="0">analysis of prospectively </text>
<text top="330" left="420" width="168" height="19" font="0">acquired data from a study </text>
<text top="349" left="420" width="67" height="19" font="0">evaluating </text>
<text top="367" left="420" width="159" height="19" font="0">withdrawal/management </text>
<text top="385" left="420" width="157" height="19" font="0">of a loop diuretic prior to </text>
<text top="404" left="420" width="49" height="19" font="0">surgery </text>
<text top="422" left="420" width="3" height="19" font="0"> </text>
<text top="440" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="295" left="608" width="280" height="19" font="8"><b>1</b>°<b> endpoint:</b> 67 pts developed intraoperative </text>
<text top="313" left="608" width="240" height="19" font="0">bradycardia (&lt; 60 bpm for 2 sequential </text>
<text top="331" left="608" width="180" height="19" font="0">measurements &gt;5 min apart) </text>
<text top="350" left="608" width="3" height="19" font="0"> </text>
<text top="368" left="608" width="298" height="19" font="8"><b>Results:</b> Developed a HEART score for predicting </text>
<text top="386" left="608" width="284" height="19" font="0">hypotension or bradycardia based on baseline </text>
<text top="404" left="608" width="247" height="19" font="0">heart rate and BP, Age, Drug Rx, Cardiac </text>
<text top="423" left="608" width="289" height="19" font="0">complications score, and complexity of surgery </text>
<text top="441" left="608" width="282" height="19" font="0">(OR: 2.51; 95% CI: 1.79–3.53; C-statistic: 0.75)<b> </b></text>
<text top="294" left="925" width="108" height="20" font="0">• Surgical risk for </text>
<text top="313" left="936" width="106" height="19" font="0">hypotension and </text>
<text top="331" left="936" width="119" height="19" font="0">bradycardia can be </text>
<text top="350" left="936" width="149" height="19" font="0">assessed preoperatively </text>
<text top="496" left="93" width="136" height="19" font="0">Bauer AM, et al. 2014 </text>
<text top="514" left="93" width="35" height="19" font="0">(295) </text>
<text top="533" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24651937">24651937</a></text>
<text top="533" left="156" width="7" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24651937"> </a> </text>
<text top="537" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24651937"> </a></text>
<text top="496" left="244" width="36" height="19" font="8"><b>Aim:</b>  </text>
<text top="514" left="244" width="3" height="19" font="0"> </text>
<text top="533" left="244" width="78" height="19" font="8"><b>Study type:</b>  </text>
<text top="551" left="244" width="74" height="19" font="0">Case report </text>
<text top="569" left="244" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="496" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="514" left="420" width="3" height="19" font="0"> </text>
<text top="533" left="420" width="153" height="19" font="8"><b>Exclusion criteria:</b> None  </text>
<text top="497" left="608" width="112" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A  </text>
<text top="515" left="608" width="3" height="19" font="0"> </text>
<text top="533" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="552" left="608" width="300" height="19" font="0">Single pt with a carotid body tumor who became </text>
<text top="570" left="608" width="147" height="19" font="0">asystolic during surgery </text>
<text top="496" left="925" width="143" height="19" font="0">Single pt with a carotid </text>
<text top="514" left="925" width="157" height="19" font="0">body tumor who became </text>
<text top="533" left="925" width="147" height="19" font="0">asystolic during surgery </text>
<text top="589" left="93" width="128" height="19" font="0">Fritsch G, et al. 2012 </text>
<text top="607" left="93" width="35" height="19" font="0">(296) </text>
<text top="626" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22188223">22188223 </a></text>
<text top="626" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22188223"> </a></text>
<text top="630" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22188223"> </a></text>
<text top="589" left="244" width="128" height="19" font="8"><b>Aim:</b> Identify factors </text>
<text top="607" left="244" width="148" height="19" font="0">associated with surgical </text>
<text top="626" left="244" width="88" height="19" font="0">complications </text>
<text top="644" left="244" width="3" height="19" font="0"> </text>
<text top="662" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="681" left="244" width="54" height="19" font="0">analysis  </text>
<text top="699" left="244" width="3" height="19" font="0"> </text>
<text top="717" left="244" width="145" height="19" font="8"><b>Size:</b> 1,363 consecutive </text>
<text top="736" left="244" width="26" height="19" font="0">pts  </text>
<text top="589" left="420" width="149" height="19" font="8"><b>Inclusion criteria:</b> 1,363 </text>
<text top="607" left="420" width="158" height="19" font="0">consecutive pts in a 3 mo </text>
<text top="626" left="420" width="130" height="19" font="0">period scheduled for </text>
<text top="644" left="420" width="100" height="19" font="0">elective surgery </text>
<text top="662" left="420" width="3" height="19" font="0"> </text>
<text top="681" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="590" left="608" width="268" height="19" font="8"><b>1</b>°<b> endpoint: </b>86 pts (6.3%) developed some </text>
<text top="608" left="608" width="301" height="19" font="0">complication. Hypotension most common but 20 </text>
<text top="626" left="608" width="297" height="19" font="0">pts (1.5%) developed hemodynamically relevant </text>
<text top="645" left="608" width="79" height="19" font="0">bradycardia<b>  </b></text>
<text top="589" left="925" width="129" height="20" font="0">• Did not specifically </text>
<text top="608" left="936" width="102" height="19" font="0">analyze pts with </text>
<text top="627" left="936" width="76" height="19" font="0">bradycardia </text>
<text top="645" left="925" width="163" height="20" font="0">• Age, type of surgery and </text>
<text top="664" left="936" width="105" height="19" font="0">medical Hx were </text>
<text top="682" left="936" width="87" height="19" font="0">predictors for </text>
<text top="701" left="936" width="152" height="19" font="0">complications in general </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 169 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="106" height="19" font="0">Perreira ID, et al. </text>
<text top="105" left="95" width="73" height="19" font="0">2011 (297)  </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21920207">21920207</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21920207"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21920207"> </a></text>
<text top="87" left="244" width="128" height="19" font="8"><b>Aim: </b>Identify factors </text>
<text top="105" left="244" width="98" height="19" font="0">associated with </text>
<text top="123" left="244" width="91" height="19" font="0">intraoperative </text>
<text top="142" left="244" width="76" height="19" font="0">bradycardia<b> </b></text>
<text top="160" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="178" left="244" width="162" height="19" font="8"><b>Study type: </b>Retrospective<b> </b></text>
<text top="197" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="215" left="244" width="130" height="19" font="8"><b>Size: </b>80,660 pts with </text>
<text top="233" left="244" width="161" height="19" font="0">neuraxial anesthesia from </text>
<text top="252" left="244" width="92" height="19" font="0">a single center<b> </b></text>
<text top="87" left="420" width="170" height="19" font="8"><b>Inclusion criteria: </b>&gt;18 y old </text>
<text top="105" left="420" width="3" height="19" font="8"><b> </b></text>
<text top="123" left="420" width="150" height="19" font="8"><b>Exclusion criteria: </b>None<b> </b></text>
<text top="88" left="608" width="192" height="19" font="8"><b>1</b>°<b> endpoint: </b>Sinus bradycardia </text>
<text top="106" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="124" left="608" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="143" left="607" width="280" height="20" font="0">•  Sinus bradycardia more common with age </text>
<text top="162" left="627" width="109" height="20" font="0">•  18–40 y: 2.5% </text>
<text top="181" left="627" width="109" height="20" font="0">•  41–60 y: 4.1% </text>
<text top="200" left="627" width="94" height="20" font="0">•  &gt;61 y: 5.2% </text>
<text top="219" left="607" width="289" height="20" font="0">•  Sinus bradycardia dependent on anesthesia </text>
<text top="238" left="627" width="276" height="20" font="0">•  SSA (single puncture subarachnoid): 3.4% </text>
<text top="257" left="627" width="251" height="20" font="0">•  CSA (continuous subarachnoid): 3.5% </text>
<text top="277" left="627" width="235" height="20" font="0">•  SE (single puncture epidural): 1.3% </text>
<text top="296" left="627" width="210" height="20" font="0">•  CE (continuous epidural): 3.4% </text>
<text top="315" left="627" width="169" height="20" font="0">•  DB (double block): 1.5% </text>
<text top="334" left="607" width="292" height="20" font="0">•  Variables associated with sinus bradycardia: </text>
<text top="353" left="627" width="47" height="20" font="0">•  Age </text>
<text top="372" left="627" width="179" height="20" font="0">•  Gender (0.74 for women) </text>
<text top="391" left="627" width="245" height="20" font="0">•  Physical status (ASA III/IV 2.49/1.94) </text>
<text top="410" left="627" width="228" height="20" font="0">•  Type of surgery (Emergency 1.98)<b> </b></text>
<text top="87" left="925" width="158" height="20" font="0">• Sinus bradycardia more </text>
<text top="106" left="936" width="144" height="19" font="0">common with age, sex, </text>
<text top="124" left="936" width="151" height="19" font="0">anesthesia, and physical </text>
<text top="143" left="936" width="40" height="19" font="0">status </text>
<text top="430" left="93" width="134" height="19" font="0">Mitar MD, et al. 2015 </text>
<text top="448" left="93" width="35" height="19" font="0">(298) </text>
<text top="467" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25746023">25746023</a></text>
<text top="467" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25746023"> </a></text>
<text top="471" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25746023"> </a></text>
<text top="430" left="244" width="131" height="19" font="8"><b>Aim:</b> Evaluate pacing </text>
<text top="448" left="244" width="101" height="19" font="0">requirement for </text>
<text top="467" left="244" width="145" height="19" font="0">rotational atherectomy </text>
<text top="485" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="503" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="522" left="244" width="3" height="19" font="0"> </text>
<text top="540" left="244" width="80" height="19" font="8"><b>Size:</b> 138 pts </text>
<text top="558" left="244" width="147" height="19" font="0">Temporary pacing in 67 </text>
<text top="576" left="244" width="147" height="19" font="0">No temporary pacing in </text>
<text top="595" left="244" width="19" height="19" font="0">67 </text>
<text top="430" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="448" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="467" left="420" width="145" height="19" font="0">rotational atherectomy </text>
<text top="485" left="420" width="3" height="19" font="0"> </text>
<text top="503" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="431" left="608" width="93" height="19" font="8"><b>1</b>°<b> endpoint:</b> (2</text>
<text top="431" left="701" width="10" height="12" font="7">nd</text>
<text top="431" left="711" width="190" height="19" font="0"> degree AVB or asystole &gt;2 s in </text>
<text top="449" left="618" width="106" height="19" font="0">the no PM group </text>
<text top="467" left="608" width="3" height="19" font="0"> </text>
<text top="486" left="608" width="278" height="19" font="8"><b>Results:</b> Pacemaker activated in PM group or </text>
<text top="504" left="618" width="130" height="19" font="0">AVB in no PM group: </text>
<text top="523" left="607" width="103" height="20" font="0">•  LM: 1/19 (5%) </text>
<text top="542" left="607" width="108" height="20" font="0">•  LAD: 2/38 (5%) </text>
<text top="561" left="607" width="113" height="20" font="0">•  Cx: 10/25 (40%) </text>
<text top="580" left="607" width="124" height="20" font="0">•  RCA: 28/51 (55%) </text>
<text top="599" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="430" left="925" width="157" height="20" font="0">• Pacemaker activated in </text>
<text top="449" left="936" width="143" height="19" font="0">PM group or AVB in no </text>
<text top="467" left="936" width="159" height="19" font="0">PM group in pts with RCA </text>
<text top="486" left="936" width="57" height="19" font="0">or Cx PCI </text>
<text top="504" left="925" width="3" height="19" font="0"> </text>
<text top="522" left="925" width="3" height="19" font="0"> </text>
<text top="618" left="93" width="110" height="19" font="0">Im SH, et al. 2008 </text>
<text top="636" left="93" width="35" height="19" font="0">(299) </text>
<text top="654" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18254669">18254669</a></text>
<text top="654" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18254669"> </a></text>
<text top="659" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18254669"> </a></text>
<text top="618" left="244" width="142" height="19" font="8"><b>Aim:</b> Evaluate utility of </text>
<text top="636" left="244" width="141" height="19" font="0">transcutaneous pacing </text>
<text top="654" left="244" width="150" height="19" font="0">with carotid angioplasty </text>
<text top="673" left="244" width="83" height="19" font="0">and stenting  </text>
<text top="691" left="244" width="3" height="19" font="0"> </text>
<text top="709" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="728" left="244" width="44" height="19" font="0">cohort </text>
<text top="746" left="244" width="3" height="19" font="0"> </text>
<text top="764" left="244" width="118" height="19" font="8"><b>Size:</b> 30 pts and 31 </text>
<text top="783" left="244" width="73" height="19" font="0">procedures </text>
<text top="618" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="636" left="420" width="130" height="19" font="0">Consecutive pts who </text>
<text top="654" left="420" width="168" height="19" font="0">underwent elective carotid </text>
<text top="673" left="420" width="152" height="19" font="0">angioplasty and stenting </text>
<text top="691" left="420" width="121" height="19" font="0">and placement of a </text>
<text top="709" left="420" width="141" height="19" font="0">transcutaneous pacing </text>
<text top="728" left="420" width="54" height="19" font="0">system.  </text>
<text top="746" left="420" width="3" height="19" font="0"> </text>
<text top="764" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="619" left="608" width="249" height="19" font="8"><b>1</b>°<b> endpoint:</b> Transcutaneous pacing use </text>
<text top="637" left="608" width="3" height="19" font="0"> </text>
<text top="655" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="674" left="607" width="289" height="20" font="0">•  24/31 required transcutaneous pacing (77%) </text>
<text top="693" left="607" width="289" height="20" font="0">•  Continuous pacing for 10–30 min required in </text>
<text top="712" left="620" width="93" height="19" font="0">5/31 pts (16%) </text>
<text top="730" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="618" left="925" width="142" height="20" font="0">• Pacing support often </text>
<text top="637" left="936" width="137" height="19" font="0">required with elective </text>
<text top="655" left="936" width="146" height="19" font="0">carotid angioplasty and </text>
<text top="674" left="936" width="53" height="19" font="0">stenting </text>
<text top="692" left="925" width="3" height="19" font="0"> </text>
<text top="710" left="925" width="3" height="19" font="0"> </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 170 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="122" height="19" font="0">Bush RL, et al. 2004 </text>
<text top="105" left="95" width="35" height="19" font="0">(300) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15181504">15181504</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15181504"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15181504"> </a></text>
<text top="87" left="244" width="150" height="19" font="8"><b>Aim:</b> Evaluate incidence </text>
<text top="105" left="244" width="122" height="19" font="0">of bradycardia with </text>
<text top="123" left="244" width="100" height="19" font="0">carotid stenting </text>
<text top="142" left="244" width="73" height="19" font="0">procedures </text>
<text top="160" left="244" width="3" height="19" font="0"> </text>
<text top="178" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="197" left="244" width="3" height="19" font="0"> </text>
<text top="215" left="244" width="103" height="19" font="8"><b>Size:</b> 48 pts who </text>
<text top="233" left="244" width="162" height="19" font="0">underwent 51 procedures </text>
<text top="87" left="420" width="159" height="19" font="8"><b>Inclusion criteria:</b> Carotid </text>
<text top="105" left="420" width="166" height="19" font="0">artery stenting procedures </text>
<text top="123" left="420" width="143" height="19" font="0">in consecutive pts who </text>
<text top="142" left="420" width="137" height="19" font="0">were thought to be of </text>
<text top="160" left="420" width="131" height="19" font="0">unacceptable risk for </text>
<text top="178" left="420" width="87" height="19" font="0">carotid artery </text>
<text top="197" left="420" width="106" height="19" font="0">endarterectomy. </text>
<text top="215" left="420" width="3" height="19" font="0"> </text>
<text top="233" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="88" left="608" width="296" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinically significant bradycardia or </text>
<text top="106" left="608" width="83" height="19" font="0">hypotension  </text>
<text top="124" left="608" width="3" height="19" font="0"> </text>
<text top="143" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="161" left="608" width="234" height="20" font="0">• Access site hematomas in 2 pts (4%) </text>
<text top="180" left="608" width="276" height="20" font="0">• Significant bradycardia or asystole in 11/49 </text>
<text top="199" left="608" width="127" height="19" font="0">(22%) of procedures </text>
<text top="218" left="608" width="289" height="20" font="0">• Mean time of pacing was 6.6±1.2 min (range: </text>
<text top="237" left="608" width="88" height="19" font="0">2.2–20.1 min) </text>
<text top="255" left="608" width="296" height="20" font="0">• No correlation between preprocedural cardiac </text>
<text top="274" left="608" width="297" height="19" font="0">status (History of MI or CABG) and development </text>
<text top="292" left="608" width="197" height="19" font="0">of bradycardia and hypotension<b> </b></text>
<text top="87" left="925" width="170" height="20" font="0">• Significant bradycardia or </text>
<text top="106" left="936" width="122" height="19" font="0">asystole in 11/49 in </text>
<text top="124" left="936" width="100" height="19" font="0">carotid stenting </text>
<text top="143" left="936" width="73" height="19" font="0">procedures </text>
<text top="161" left="925" width="3" height="19" font="0"> </text>
<text top="179" left="925" width="3" height="19" font="0"> </text>
<text top="311" left="93" width="133" height="19" font="0">Harrop JS, et al. 2001 </text>
<text top="330" left="93" width="39" height="19" font="0">(301)  </text>
<text top="348" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11564241">11564241</a></text>
<text top="348" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11564241"> </a></text>
<text top="352" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11564241"> </a></text>
<text top="311" left="244" width="88" height="19" font="8"><b>Aim:</b> Evaluate </text>
<text top="330" left="244" width="106" height="19" font="0">hypotension and </text>
<text top="348" left="244" width="143" height="19" font="0">bradycardia associated </text>
<text top="366" left="244" width="117" height="19" font="0">with carotid artery </text>
<text top="385" left="244" width="162" height="19" font="0">interventional procedures </text>
<text top="403" left="244" width="3" height="19" font="0"> </text>
<text top="421" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="440" left="244" width="3" height="19" font="0"> </text>
<text top="458" left="244" width="162" height="19" font="8"><b>Size:</b> 43 pts underwent 47 </text>
<text top="476" left="244" width="160" height="19" font="0">carotid artery angioplasty </text>
<text top="494" left="244" width="152" height="19" font="0">and stenting procedures </text>
<text top="311" left="420" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="330" left="420" width="160" height="19" font="0">undergoing carotid artery </text>
<text top="348" left="420" width="73" height="19" font="0">procedures </text>
<text top="366" left="420" width="3" height="19" font="0"> </text>
<text top="384" left="420" width="154" height="19" font="8"><b>Exclusion criteria:</b> 10 pts </text>
<text top="403" left="420" width="168" height="19" font="0">excluded; no reasons given </text>
<text top="312" left="608" width="290" height="19" font="8"><b>1</b>°<b> endpoint:</b> Use of pacing for bradycardia and </text>
<text top="330" left="608" width="79" height="19" font="0">hypotension </text>
<text top="349" left="608" width="3" height="19" font="0"> </text>
<text top="367" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="386" left="608" width="272" height="20" font="0">• Pacemaker activation in 23/37 procedures </text>
<text top="404" left="608" width="38" height="19" font="0">(73%) </text>
<text top="423" left="608" width="300" height="20" font="0">• No correlation between PM activation and sex, </text>
<text top="442" left="608" width="300" height="19" font="0">etiology of stenosis, severity of stenosis, number </text>
<text top="460" left="608" width="76" height="19" font="0">of inflations </text>
<text top="478" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="312" left="925" width="146" height="20" font="0">• Pacemaker activation </text>
<text top="330" left="936" width="115" height="19" font="0">common with CEA </text>
<text top="349" left="925" width="3" height="19" font="0"> </text>
<text top="367" left="925" width="3" height="19" font="0"> </text>
<text top="514" left="93" width="123" height="19" font="0">Gauss A, et al. 1999 </text>
<text top="532" left="93" width="35" height="19" font="0">(302) </text>
<text top="550" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10456813">10456813</a></text>
<text top="550" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10456813"> </a></text>
<text top="554" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10456813"> </a></text>
<text top="513" left="244" width="36" height="19" font="8"><b>Aim:</b>  </text>
<text top="532" left="244" width="83" height="19" font="0">Evaluation of </text>
<text top="550" left="244" width="156" height="19" font="0">transcutaneous pacing in </text>
<text top="568" left="244" width="150" height="19" font="0">pts thought to be at risk </text>
<text top="587" left="244" width="97" height="19" font="0">for bradycardia </text>
<text top="605" left="244" width="120" height="19" font="0">(trifascicular block) </text>
<text top="623" left="244" width="3" height="19" font="0"> </text>
<text top="642" left="244" width="155" height="19" font="8"><b>Study type:</b> Consecutive, </text>
<text top="660" left="244" width="75" height="19" font="0">prospective </text>
<text top="678" left="244" width="3" height="19" font="0"> </text>
<text top="696" left="244" width="76" height="19" font="8"><b>Size:</b> 39 pts  </text>
<text top="513" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="532" left="420" width="153" height="19" font="0">Consecutive pts with asx </text>
<text top="550" left="420" width="171" height="19" font="0">chronic 1st degree AVB and </text>
<text top="568" left="420" width="163" height="19" font="0">LBBB or bifascicular block. </text>
<text top="587" left="420" width="3" height="19" font="0"> </text>
<text top="605" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="514" left="608" width="302" height="19" font="8"><b>1</b>°<b> endpoint:</b> Progression of AVB, asystole &gt;5 s or </text>
<text top="533" left="608" width="173" height="19" font="0">bradycardia &lt;40 bpm &gt;10 s) </text>
<text top="551" left="608" width="3" height="19" font="0"> </text>
<text top="569" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="588" left="608" width="290" height="20" font="0">• 37 of 39 pts could be paced transcutaneously </text>
<text top="607" left="608" width="188" height="20" font="0">• 0/39 had progression of AVB </text>
<text top="626" left="608" width="218" height="20" font="0">• 9 pts had bradycardia &lt;40 bpm (6 </text>
<text top="645" left="608" width="241" height="19" font="0">intraoperatively and 3 postoperatively) </text>
<text top="663" left="608" width="268" height="20" font="0">• No pts absolutely required pacing for rate </text>
<text top="682" left="608" width="51" height="19" font="0">support<b> </b></text>
<text top="514" left="925" width="121" height="20" font="0">• No pts absolutely </text>
<text top="533" left="936" width="149" height="19" font="0">required pacing for rate </text>
<text top="551" left="936" width="51" height="19" font="0">support </text>
<text top="716" left="93" width="112" height="19" font="0">Killeavey ES, et al. </text>
<text top="734" left="93" width="69" height="19" font="0">1990 (303) </text>
<text top="752" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15227187">15227187</a></text>
<text top="752" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15227187"> </a></text>
<text top="756" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15227187"> </a></text>
<text top="716" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate the use of </text>
<text top="734" left="244" width="121" height="19" font="0">transvenous pacing </text>
<text top="752" left="244" width="66" height="19" font="0">during PCI </text>
<text top="771" left="244" width="3" height="19" font="0"> </text>
<text top="716" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="734" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="752" left="420" width="23" height="19" font="0">PCI </text>
<text top="771" left="420" width="3" height="19" font="0"> </text>
<text top="716" left="608" width="229" height="19" font="8"><b>1</b>°<b> endpoint:</b> Requirement for pacing </text>
<text top="735" left="608" width="3" height="19" font="0"> </text>
<text top="753" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="716" left="925" width="159" height="20" font="0">• Requirement for pacing </text>
<text top="735" left="936" width="25" height="19" font="0">low </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 171 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="105" left="244" width="3" height="19" font="0"> </text>
<text top="123" left="244" width="139" height="19" font="8"><b>Size:</b> 778 pts (398 w/o </text>
<text top="142" left="244" width="148" height="19" font="0">transvenous pacing and </text>
<text top="160" left="244" width="135" height="19" font="0">379 with prophylactic </text>
<text top="178" left="244" width="144" height="19" font="0">pacing and 1 emergent </text>
<text top="197" left="244" width="48" height="19" font="0">pacing) </text>
<text top="87" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="87" left="608" width="257" height="20" font="0">• 2 pts developed ventricular arrhythmias </text>
<text top="106" left="608" width="262" height="19" font="0">associated with prophylactic pacing (0.5%) </text>
<text top="124" left="608" width="206" height="20" font="0">• 8/379 had pacing required (2%) </text>
<text top="144" left="608" width="204" height="20" font="0">• Overall incidence for pacing for </text>
<text top="163" left="608" width="267" height="19" font="0">hemodynamically significant bradycardia in </text>
<text top="181" left="608" width="251" height="19" font="0">prophylactic situations was 7/777 (0.8%)<b> </b></text>
<text top="216" left="93" width="122" height="19" font="0">Chowdhury T, et al. </text>
<text top="234" left="93" width="69" height="19" font="0">2015 (304) </text>
<text top="252" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26656339">26656339</a></text>
<text top="252" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26656339"> </a></text>
<text top="257" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26656339"> </a></text>
<text top="216" left="244" width="138" height="19" font="8"><b>Aim:</b> Propofol boluses </text>
<text top="234" left="244" width="141" height="19" font="0">aborted the trigeminal </text>
<text top="252" left="244" width="121" height="19" font="0">cardiac reflex (TCR) </text>
<text top="271" left="244" width="96" height="19" font="0">induced severe </text>
<text top="289" left="244" width="153" height="19" font="0">bradycardia during dural </text>
<text top="307" left="244" width="88" height="19" font="0">manipulation. </text>
<text top="326" left="244" width="3" height="19" font="0"> </text>
<text top="344" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="362" left="244" width="3" height="19" font="0"> </text>
<text top="381" left="244" width="59" height="19" font="8"><b>Size:</b> 1 pt </text>
<text top="216" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="234" left="420" width="3" height="19" font="0"> </text>
<text top="252" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="217" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="235" left="608" width="3" height="19" font="0"> </text>
<text top="253" left="608" width="283" height="19" font="8"><b>Results:</b> During dural stimulation, propofol 50 </text>
<text top="272" left="608" width="220" height="19" font="0">mg IV terminated sinus bradycardia<b> </b></text>
<text top="216" left="925" width="150" height="20" font="0">• Case report discussing </text>
<text top="235" left="936" width="106" height="19" font="0">that during dural </text>
<text top="253" left="936" width="151" height="19" font="0">stimulation, propofol 50 </text>
<text top="272" left="936" width="145" height="19" font="0">mg IV terminated sinus </text>
<text top="290" left="936" width="76" height="19" font="0">bradycardia </text>
<text top="400" left="95" width="113" height="19" font="0">Yong J, et al. 2015 </text>
<text top="418" left="95" width="35" height="19" font="0">(305) </text>
<text top="436" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26424701">26424701</a></text>
<text top="436" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26424701"> </a></text>
<text top="440" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26424701"> </a></text>
<text top="400" left="244" width="88" height="19" font="8"><b>Aim:</b> Evaluate </text>
<text top="418" left="244" width="147" height="19" font="0">development of cardiac </text>
<text top="436" left="244" width="162" height="19" font="0">arrest during laparoscopic </text>
<text top="455" left="244" width="49" height="19" font="0">surgery </text>
<text top="473" left="244" width="3" height="19" font="0"> </text>
<text top="491" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="509" left="244" width="156" height="19" font="0">analysis of the Australian </text>
<text top="528" left="244" width="163" height="19" font="0">Incident Monitoring Study </text>
<text top="546" left="244" width="104" height="19" font="0">(AIMS) database </text>
<text top="564" left="244" width="3" height="19" font="0"> </text>
<text top="583" left="244" width="120" height="19" font="8"><b>Size:</b> 14 cases from </text>
<text top="601" left="244" width="128" height="19" font="0">&gt;11,000 pt database </text>
<text top="400" left="420" width="160" height="19" font="8"><b>Inclusion criteria:</b> Cardiac </text>
<text top="418" left="420" width="62" height="19" font="0">arrest pts </text>
<text top="436" left="591" width="3" height="19" font="0"> </text>
<text top="454" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="400" left="608" width="254" height="19" font="8"><b>1</b>°<b> endpoint:</b> Cardiac arrest (bradycardia) </text>
<text top="419" left="608" width="3" height="19" font="0"> </text>
<text top="437" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="456" left="608" width="118" height="20" font="0">• 9/14 bradycardia </text>
<text top="475" left="608" width="218" height="20" font="0">• 2 critical points for cardiac arrest: </text>
<text top="494" left="608" width="195" height="19" font="0">insufflation or establishment of </text>
<text top="512" left="608" width="209" height="19" font="0">pneumoperitoneum (12/14; 86%) </text>
<text top="530" left="608" width="206" height="19" font="0">Anesthesia induction (2/14; 14%) </text>
<text top="549" left="608" width="3" height="19" font="0"> </text>
<text top="567" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="400" left="925" width="145" height="20" font="0">• Bradycardia common </text>
<text top="419" left="936" width="120" height="19" font="0">during laparoscopy </text>
<text top="620" left="95" width="127" height="19" font="0">Vimala S, et al. 2016 </text>
<text top="638" left="95" width="35" height="19" font="0">(306) </text>
<text top="657" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26114985">26114985</a></text>
<text top="657" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26114985"> </a></text>
<text top="661" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26114985"> </a></text>
<text top="620" left="244" width="122" height="19" font="8"><b>Aim:</b> Case report of </text>
<text top="638" left="244" width="131" height="19" font="0">asystole during dural </text>
<text top="657" left="244" width="88" height="19" font="0">manipulation  </text>
<text top="675" left="244" width="3" height="19" font="0"> </text>
<text top="693" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="712" left="244" width="3" height="19" font="0"> </text>
<text top="730" left="244" width="59" height="19" font="8"><b>Size:</b> 1 pt </text>
<text top="620" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="638" left="420" width="3" height="19" font="0"> </text>
<text top="657" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="621" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="639" left="608" width="3" height="19" font="0"> </text>
<text top="657" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="676" left="608" width="244" height="19" font="8"><b>• </b>Bradycardia and asystole during dural </text>
<text top="694" left="608" width="279" height="19" font="0">manipulation and excision of a temporal lobe </text>
<text top="713" left="608" width="207" height="19" font="0">meningioma (near the left insula)<b> </b></text>
<text top="620" left="925" width="101" height="20" font="0">• Case report of </text>
<text top="639" left="936" width="153" height="19" font="0">bradycardia during dural </text>
<text top="658" left="936" width="84" height="19" font="0">manipulation </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 172 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="129" height="19" font="0">Mohan S, et al. 1990 </text>
<text top="105" left="95" width="35" height="19" font="0">(307) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24788865">24788865</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24788865"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24788865"> </a></text>
<text top="87" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate the use of </text>
<text top="105" left="244" width="121" height="19" font="0">transvenous pacing </text>
<text top="123" left="244" width="66" height="19" font="0">during PCI </text>
<text top="142" left="244" width="3" height="19" font="0"> </text>
<text top="160" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="178" left="244" width="3" height="19" font="0"> </text>
<text top="197" left="244" width="46" height="19" font="8"><b>Size:</b> 1  </text>
<text top="87" left="420" width="140" height="19" font="8"><b>Inclusion criteria:</b> 60 y </text>
<text top="105" left="420" width="158" height="19" font="0">undergoing maxillectomy </text>
<text top="123" left="420" width="155" height="19" font="0">for squamous cell cancer </text>
<text top="142" left="420" width="3" height="19" font="0"> </text>
<text top="160" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="608" width="112" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A  </text>
<text top="106" left="608" width="3" height="19" font="0"> </text>
<text top="124" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="143" left="608" width="236" height="20" font="0">• Asystole during posterior osteotomy </text>
<text top="162" left="608" width="289" height="20" font="0">• Bradycardia again during manipulation of the </text>
<text top="181" left="608" width="184" height="19" font="0">posterior maxillary tuberosity </text>
<text top="199" left="608" width="298" height="20" font="0">• Treatment by atropine and minimizing surgical </text>
<text top="218" left="608" width="84" height="19" font="0">manipulation<b> </b></text>
<text top="87" left="925" width="3" height="19" font="0"> </text>
<text top="105" left="925" width="3" height="19" font="0"> </text>
<text top="237" left="93" width="112" height="19" font="0">Ishii D, et al. 1990 </text>
<text top="256" left="93" width="35" height="19" font="0">(308) </text>
<text top="274" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23834853">23834853</a></text>
<text top="274" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23834853"> </a></text>
<text top="278" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23834853"> </a></text>
<text top="237" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate the use of </text>
<text top="256" left="244" width="150" height="19" font="0">cilostazol for preventing </text>
<text top="274" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="292" left="244" width="140" height="19" font="0">carotid artery stenting </text>
<text top="311" left="244" width="3" height="19" font="0"> </text>
<text top="329" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="347" left="244" width="3" height="19" font="0"> </text>
<text top="365" left="244" width="103" height="19" font="8"><b>Size:</b> 53 pts who </text>
<text top="384" left="244" width="136" height="19" font="0">underwent 54 carotid </text>
<text top="402" left="244" width="93" height="19" font="0">artery stenting </text>
<text top="420" left="244" width="148" height="19" font="0">procedures divided into </text>
<text top="439" left="244" width="137" height="19" font="0">procedures where pts </text>
<text top="457" left="244" width="143" height="19" font="0">received cilostazol (26) </text>
<text top="475" left="244" width="141" height="19" font="0">and those who did not </text>
<text top="494" left="244" width="28" height="19" font="0">(28) </text>
<text top="237" left="420" width="163" height="19" font="8"><b>Inclusion criteria:</b> Pts who </text>
<text top="256" left="420" width="157" height="19" font="0">underwent carotid artery </text>
<text top="274" left="420" width="118" height="19" font="0">stenting at a single </text>
<text top="292" left="420" width="66" height="19" font="0">institution </text>
<text top="311" left="420" width="3" height="19" font="0"> </text>
<text top="329" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="238" left="608" width="236" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia (&lt;50 bpm or </text>
<text top="256" left="608" width="162" height="19" font="0">hypotension (&lt;90 mm Hg) </text>
<text top="275" left="608" width="3" height="19" font="0"> </text>
<text top="293" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="312" left="608" width="191" height="20" font="0">• Intraprocedural bradycardia: </text>
<text top="336" left="627" width="9" height="12" font="0">o</text>
<text top="334" left="636" width="4" height="14" font="0"> </text>
<text top="330" left="640" width="136" height="19" font="0">Cilostazol: 4/26 (15%) </text>
<text top="354" left="627" width="9" height="12" font="0">o</text>
<text top="352" left="636" width="4" height="14" font="0"> </text>
<text top="349" left="640" width="163" height="19" font="0">No cilostazol: 15/28 (54%) </text>
<text top="367" left="607" width="182" height="20" font="0">•  Postprocedure bradycardia </text>
<text top="391" left="627" width="9" height="12" font="0">o</text>
<text top="390" left="636" width="4" height="14" font="0"> </text>
<text top="386" left="640" width="98" height="19" font="0">Cilostazol: 0/26 </text>
<text top="410" left="627" width="9" height="12" font="0">o</text>
<text top="408" left="636" width="4" height="14" font="0"> </text>
<text top="404" left="640" width="155" height="19" font="0">No cilostazol: 3/28 (11%)<b> </b></text>
<text top="238" left="925" width="126" height="20" font="0">• Cilostazol reduced </text>
<text top="256" left="936" width="91" height="19" font="0">intraoperative </text>
<text top="275" left="936" width="76" height="19" font="0">bradycardia </text>
<text top="513" left="95" width="105" height="19" font="0">Schipke JD, et al. </text>
<text top="531" left="95" width="69" height="19" font="0">2013 (309) </text>
<text top="549" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23332411">23332411</a></text>
<text top="549" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23332411"> </a></text>
<text top="553" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23332411"> </a></text>
<text top="513" left="244" width="157" height="19" font="8"><b>Aim:</b> 1 pt who developed </text>
<text top="531" left="244" width="158" height="19" font="0">asystole during paranasal </text>
<text top="549" left="244" width="83" height="19" font="0">sinus surgery </text>
<text top="568" left="244" width="3" height="19" font="0"> </text>
<text top="586" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="604" left="244" width="3" height="19" font="0"> </text>
<text top="623" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="513" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="531" left="420" width="3" height="19" font="0"> </text>
<text top="549" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="513" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="532" left="608" width="3" height="19" font="0"> </text>
<text top="550" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="569" left="608" width="251" height="20" font="0">• 15 s of asystole with instrumenting the </text>
<text top="588" left="608" width="110" height="19" font="0">paranasal sinuses </text>
<text top="606" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="513" left="925" width="96" height="20" font="0">• Asystole with </text>
<text top="532" left="936" width="113" height="19" font="0">instrumenting the </text>
<text top="550" left="936" width="110" height="19" font="0">paranasal sinuses </text>
<text top="642" left="95" width="126" height="19" font="0">Haldar R, et al. 2013 </text>
<text top="660" left="95" width="35" height="19" font="0">(310) </text>
<text top="678" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23242253">23242253</a></text>
<text top="678" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23242253"> </a></text>
<text top="682" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23242253"> </a></text>
<text top="642" left="244" width="157" height="19" font="8"><b>Aim:</b> 1 pt who developed </text>
<text top="660" left="244" width="149" height="19" font="0">bradycardia during skull </text>
<text top="678" left="244" width="72" height="19" font="0">pin fixation </text>
<text top="697" left="244" width="3" height="19" font="0"> </text>
<text top="715" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="733" left="244" width="3" height="19" font="0"> </text>
<text top="751" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="642" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="660" left="420" width="3" height="19" font="0"> </text>
<text top="678" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="642" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="661" left="608" width="3" height="19" font="0"> </text>
<text top="679" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="698" left="608" width="291" height="20" font="0">• Heart rate decreased from 88 to 44 bpm with </text>
<text top="716" left="608" width="288" height="19" font="0">skull fixation pin tightening that stopped when </text>
<text top="735" left="608" width="269" height="19" font="0">instrumentation stopped and recurred with </text>
<text top="753" left="608" width="106" height="19" font="0">tightening again.<b> </b></text>
<text top="642" left="925" width="143" height="20" font="0">• Heart rate decreased </text>
<text top="661" left="936" width="133" height="19" font="0">with skull fixation pin </text>
<text top="679" left="936" width="147" height="19" font="0">tightening that stopped </text>
<text top="697" left="936" width="140" height="19" font="0">when instrumentation </text>
<text top="716" left="936" width="136" height="19" font="0">stopped and recurred </text>
<text top="734" left="936" width="136" height="19" font="0">with tightening again. </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 173 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="116" height="19" font="0">Seo KC, et al. 2010 </text>
<text top="105" left="95" width="35" height="19" font="0">(311) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20498810">20498810</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20498810"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20498810"> </a></text>
<text top="87" left="244" width="136" height="19" font="8"><b>Aim:</b> Identify possible </text>
<text top="105" left="244" width="140" height="19" font="0">factors contributing to </text>
<text top="123" left="244" width="102" height="19" font="0">bradycardia and </text>
<text top="142" left="244" width="122" height="19" font="0">hypotension during </text>
<text top="160" left="244" width="106" height="19" font="0">shoulder surgery </text>
<text top="178" left="244" width="3" height="19" font="0"> </text>
<text top="197" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="215" left="244" width="3" height="19" font="0"> </text>
<text top="233" left="244" width="50" height="19" font="8"><b>Size:</b> 63 </text>
<text top="87" left="420" width="159" height="19" font="8"><b>Inclusion criteria:</b> ASA I/II </text>
<text top="105" left="420" width="108" height="19" font="0">pts who received </text>
<text top="123" left="420" width="135" height="19" font="0">interscalene block for </text>
<text top="142" left="420" width="137" height="19" font="0">arthroscopic shoulder </text>
<text top="160" left="420" width="129" height="19" font="0">surgery in the sitting </text>
<text top="178" left="420" width="53" height="19" font="0">position </text>
<text top="197" left="420" width="3" height="19" font="0"> </text>
<text top="215" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="608" width="269" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia (&lt;50 bpm) and/or </text>
<text top="106" left="608" width="292" height="19" font="0">hypotension (&lt;100 mm Hg or use of ephedrine) </text>
<text top="124" left="608" width="3" height="19" font="0"> </text>
<text top="143" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="161" left="608" width="262" height="20" font="0">• 13/63 with bradycardia and hypotension </text>
<text top="180" left="608" width="297" height="20" font="0">• Bradycardia and hypotension more likely with: </text>
<text top="199" left="608" width="253" height="19" font="0">Right sided procedures (R: 27% vs. L: 5%) </text>
<text top="217" left="608" width="229" height="19" font="0">Higher use of fentanyl (54% vs. 0.4%)<b> </b></text>
<text top="87" left="925" width="114" height="20" font="0">• Bradycardia and </text>
<text top="106" left="936" width="115" height="19" font="0">hypotension more </text>
<text top="124" left="936" width="156" height="19" font="0">common with tight sided </text>
<text top="143" left="936" width="73" height="19" font="0">procedures </text>
<text top="252" left="95" width="114" height="19" font="0">Jeyabalan G, et al. </text>
<text top="271" left="95" width="69" height="19" font="0">2010 (312) </text>
<text top="289" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20557186">20557186</a></text>
<text top="289" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20557186"> </a></text>
<text top="293" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20557186"> </a></text>
<text top="252" left="244" width="128" height="19" font="8"><b>Aim:</b> Identify factors </text>
<text top="271" left="244" width="98" height="19" font="0">associated with </text>
<text top="289" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="307" left="244" width="134" height="19" font="0">pharmacomechanical </text>
<text top="326" left="244" width="150" height="19" font="0">thrombectomy for deep </text>
<text top="344" left="244" width="101" height="19" font="0">vein thrombosis </text>
<text top="362" left="244" width="3" height="19" font="0"> </text>
<text top="381" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="399" left="244" width="3" height="19" font="0"> </text>
<text top="417" left="244" width="73" height="19" font="8"><b>Size:</b> 57 pts </text>
<text top="252" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="271" left="420" width="130" height="19" font="0">Consecutive pts who </text>
<text top="289" left="420" width="71" height="19" font="0">underwent </text>
<text top="307" left="420" width="134" height="19" font="0">pharmacomechanical </text>
<text top="326" left="420" width="171" height="19" font="0">(AngioJet) therapy for deep </text>
<text top="344" left="420" width="101" height="19" font="0">vein thrombosis </text>
<text top="362" left="420" width="3" height="19" font="0"> </text>
<text top="381" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="253" left="608" width="161" height="19" font="8"><b>1</b>°<b> endpoint: </b>Bradycardia  </text>
<text top="272" left="608" width="3" height="19" font="0"> </text>
<text top="290" left="608" width="110" height="19" font="8"><b>Safety endpoint:</b>  </text>
<text top="308" left="608" width="230" height="20" font="0">• 7/57 (12.3%) had bradyarrhythmias </text>
<text top="327" left="608" width="64" height="19" font="0">asystole 2 </text>
<text top="346" left="608" width="125" height="19" font="0">sinus bradycardia: 5 </text>
<text top="364" left="608" width="146" height="19" font="0">More than 1 episode: 4 </text>
<text top="382" left="608" width="294" height="20" font="0">• Bradycardia resolved in 5/7 pts with cessation </text>
<text top="401" left="608" width="215" height="19" font="0">of therapy. 2 pts received atropine<b> </b></text>
<text top="253" left="925" width="147" height="20" font="0">• Bradycardia observed </text>
<text top="272" left="936" width="159" height="19" font="0">with AngioJet procedures </text>
<text top="436" left="95" width="124" height="19" font="0">Usami K, et al. 2010 </text>
<text top="455" left="95" width="35" height="19" font="0">(313) </text>
<text top="473" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20448432">20448432</a></text>
<text top="473" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20448432"> </a></text>
<text top="477" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20448432"> </a></text>
<text top="436" left="244" width="152" height="19" font="8"><b>Aim:</b> Describe 3 pts who </text>
<text top="455" left="244" width="143" height="19" font="0">developed bradycardia </text>
<text top="473" left="244" width="101" height="19" font="0">with surgery for </text>
<text top="491" left="244" width="144" height="19" font="0">cerebellopontine angle </text>
<text top="510" left="244" width="85" height="19" font="0">meningiomas </text>
<text top="528" left="244" width="3" height="19" font="0"> </text>
<text top="546" left="244" width="145" height="19" font="8"><b>Study type:</b> Case series </text>
<text top="564" left="244" width="3" height="19" font="0"> </text>
<text top="583" left="244" width="43" height="19" font="8"><b>Size:</b> 3 </text>
<text top="436" left="420" width="143" height="19" font="8"><b>Inclusion criteria:</b> Case </text>
<text top="455" left="420" width="107" height="19" font="0">series of pts with </text>
<text top="473" left="420" width="118" height="19" font="0">bradycardia during </text>
<text top="491" left="420" width="129" height="19" font="0">meningioma surgery </text>
<text top="509" left="420" width="3" height="19" font="0"> </text>
<text top="528" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="437" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="455" left="608" width="3" height="19" font="0"> </text>
<text top="474" left="608" width="52" height="19" font="8"><b>Results: </b></text>
<text top="492" left="608" width="228" height="20" font="0">• Transient bradycardia/asystole and </text>
<text top="511" left="608" width="295" height="19" font="0">hypotension apparently due to activation of the </text>
<text top="529" left="608" width="290" height="19" font="0">trigeminocardiac reflex by direct stimulation of </text>
<text top="548" left="608" width="273" height="19" font="0">the trigeminal nerve or branches in the dura </text>
<text top="566" left="608" width="187" height="19" font="0">mater or cerebellar tentorium </text>
<text top="585" left="608" width="237" height="20" font="0">• Remifentanil suggested as a possible </text>
<text top="603" left="608" width="73" height="19" font="0">contributor<b> </b></text>
<text top="437" left="925" width="72" height="20" font="0">• Transient </text>
<text top="455" left="936" width="157" height="19" font="0">bradycardia/asystole and </text>
<text top="474" left="936" width="149" height="19" font="0">hypotension apparently </text>
<text top="492" left="936" width="146" height="19" font="0">due to activation of the </text>
<text top="510" left="936" width="145" height="19" font="0">trigeminocardiac reflex </text>
<text top="529" left="936" width="145" height="19" font="0">by direct stimulation of </text>
<text top="547" left="936" width="144" height="19" font="0">the trigeminal nerve or </text>
<text top="565" left="936" width="129" height="19" font="0">branches in the dura </text>
<text top="584" left="936" width="121" height="19" font="0">mater or cerebellar </text>
<text top="602" left="936" width="65" height="19" font="0">tentorium </text>
<text top="620" left="925" width="3" height="19" font="0"> </text>
<text top="639" left="93" width="109" height="19" font="0">Lubbers HT, et al. </text>
<text top="658" left="93" width="73" height="19" font="0">2010 (314)  </text>
<text top="676" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20347202">20347202</a></text>
<text top="676" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20347202"> </a></text>
<text top="680" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20347202"> </a></text>
<text top="639" left="244" width="152" height="19" font="8"><b>Aim:</b> Describe 3 pts who </text>
<text top="658" left="244" width="143" height="19" font="0">developed bradycardia </text>
<text top="676" left="244" width="148" height="19" font="0">with craniomaxillofacial </text>
<text top="694" left="244" width="53" height="19" font="0">surgery. </text>
<text top="713" left="244" width="3" height="19" font="0"> </text>
<text top="731" left="244" width="145" height="19" font="8"><b>Study type:</b> Case series </text>
<text top="749" left="244" width="3" height="19" font="0"> </text>
<text top="767" left="244" width="43" height="19" font="8"><b>Size:</b> 3 </text>
<text top="639" left="420" width="143" height="19" font="8"><b>Inclusion criteria:</b> Case </text>
<text top="658" left="420" width="70" height="19" font="0">series, N/A </text>
<text top="676" left="420" width="3" height="19" font="0"> </text>
<text top="694" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="640" left="608" width="161" height="19" font="8"><b>1</b>°<b> endpoint: </b>Bradycardia  </text>
<text top="658" left="608" width="3" height="19" font="0"> </text>
<text top="677" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="695" left="608" width="287" height="20" font="0">• Describe 3 pts identified from a single center </text>
<text top="714" left="608" width="258" height="19" font="0">surgical database with bradycardia during </text>
<text top="732" left="608" width="166" height="19" font="0">craniomaxillofacial surgery </text>
<text top="751" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="639" left="925" width="154" height="20" font="0">• Purely descriptive with </text>
<text top="658" left="936" width="68" height="19" font="0">no specific </text>
<text top="677" left="936" width="132" height="19" font="0">recommendations or </text>
<text top="695" left="936" width="51" height="19" font="0">findings </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 174 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="132" height="19" font="0">Christensen RE, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">2010 (315) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19933174">19933174</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19933174"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19933174"> </a></text>
<text top="87" left="244" width="153" height="19" font="8"><b>Aim:</b> Describe outcomes </text>
<text top="105" left="244" width="128" height="19" font="0">in pts with surgically </text>
<text top="123" left="244" width="159" height="19" font="0">corrected D transposition </text>
<text top="142" left="244" width="144" height="19" font="0">of the great arteries (D-</text>
<text top="160" left="244" width="107" height="19" font="0">TGA) undergoing </text>
<text top="178" left="244" width="120" height="19" font="0">noncardiac surgery </text>
<text top="197" left="244" width="3" height="19" font="0"> </text>
<text top="215" left="244" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="233" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="252" left="244" width="146" height="19" font="8"><b>Size:</b> 50 procedures (34 </text>
<text top="270" left="244" width="27" height="19" font="0">pts) </text>
<text top="87" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="420" width="130" height="19" font="0">Consecutive pts with </text>
<text top="123" left="420" width="165" height="19" font="0">surgically corrected D-TGA </text>
<text top="142" left="420" width="144" height="19" font="0">undergoing noncardiac </text>
<text top="160" left="420" width="167" height="19" font="0">surgery (43 pediatric and 7 </text>
<text top="178" left="420" width="45" height="19" font="0">adults) </text>
<text top="197" left="420" width="3" height="19" font="0"> </text>
<text top="215" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="608" width="237" height="19" font="8"><b>1</b>°<b> endpoint:</b> Adverse events including </text>
<text top="106" left="608" width="76" height="19" font="0">bradycardia </text>
<text top="124" left="608" width="3" height="19" font="0"> </text>
<text top="143" left="608" width="264" height="19" font="8"><b>Results:</b> 4 adverse events. 1 pt with severe </text>
<text top="161" left="608" width="259" height="19" font="0">bradycardia during abdominal insufflation<b> </b></text>
<text top="87" left="925" width="117" height="20" font="0">• 4 adverse events </text>
<text top="106" left="936" width="127" height="19" font="0">observed in pts with </text>
<text top="124" left="936" width="152" height="19" font="0">congenital heart disease </text>
<text top="143" left="936" width="160" height="19" font="0">and noncardiac surgeries. </text>
<text top="289" left="93" width="132" height="19" font="0">Jacques F, et al. 2009 </text>
<text top="307" left="93" width="39" height="19" font="0">(316)  </text>
<text top="326" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18657390">18657390</a></text>
<text top="326" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18657390"> </a></text>
<text top="330" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18657390"> </a></text>
<text top="289" left="244" width="145" height="19" font="8"><b>Aim:</b> Compare regional </text>
<text top="307" left="244" width="144" height="19" font="0">anesthesia and general </text>
<text top="326" left="244" width="117" height="19" font="0">anesthesia for CEA </text>
<text top="344" left="244" width="49" height="19" font="0">surgery </text>
<text top="362" left="244" width="3" height="19" font="0"> </text>
<text top="381" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="399" left="244" width="3" height="19" font="0"> </text>
<text top="417" left="244" width="50" height="19" font="8"><b>Size:</b> 72 </text>
<text top="436" left="244" width="147" height="19" font="0">Regional anesthesia: 25 </text>
<text top="454" left="244" width="143" height="19" font="0">General anesthesia: 47 </text>
<text top="289" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="307" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="326" left="420" width="152" height="19" font="0">CEA from a single center </text>
<text top="344" left="420" width="3" height="19" font="0"> </text>
<text top="362" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="290" left="608" width="295" height="19" font="8"><b>1</b>°<b> endpoint:</b> Hypotension and bradycardia (&lt;60 </text>
<text top="308" left="608" width="36" height="19" font="0">bpm) </text>
<text top="326" left="608" width="3" height="19" font="0"> </text>
<text top="345" left="608" width="301" height="19" font="8"><b>Results:</b> Regional anesthesia associated with less </text>
<text top="363" left="608" width="300" height="19" font="0">intraoperative bradycardia (4%) when compared </text>
<text top="381" left="608" width="173" height="19" font="0">to general anesthesia (63%)<b> </b></text>
<text top="289" left="925" width="136" height="20" font="0">• Regional anesthesia </text>
<text top="308" left="936" width="124" height="19" font="0">associated with less </text>
<text top="326" left="936" width="91" height="19" font="0">intraoperative </text>
<text top="345" left="936" width="79" height="19" font="0">bradycardia  </text>
<text top="473" left="93" width="122" height="19" font="0">Hanss R, et al. 2008 </text>
<text top="491" left="93" width="35" height="19" font="0">(317) </text>
<text top="509" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18211442">18211442</a></text>
<text top="509" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18211442"> </a></text>
<text top="514" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18211442"> </a></text>
<text top="473" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate heart rate </text>
<text top="491" left="244" width="134" height="19" font="0">variability as a tool to </text>
<text top="509" left="244" width="159" height="19" font="0">identify pts who will have </text>
<text top="528" left="244" width="96" height="19" font="0">hypotension or </text>
<text top="546" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="565" left="244" width="49" height="19" font="0">surgery </text>
<text top="583" left="244" width="3" height="19" font="0"> </text>
<text top="601" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="619" left="244" width="128" height="19" font="0">model followed by a </text>
<text top="638" left="244" width="112" height="19" font="0">prospective study </text>
<text top="656" left="244" width="3" height="19" font="0"> </text>
<text top="674" left="244" width="58" height="19" font="8"><b>Size:</b> 100 </text>
<text top="473" left="420" width="142" height="19" font="8"><b>Inclusion criteria:</b> High </text>
<text top="491" left="420" width="143" height="19" font="0">perioperative risk (ASA </text>
<text top="509" left="420" width="150" height="19" font="0">III/IV) undergoing major </text>
<text top="528" left="420" width="138" height="19" font="0">vascular or abdominal </text>
<text top="546" left="420" width="49" height="19" font="0">surgery </text>
<text top="564" left="420" width="3" height="19" font="0"> </text>
<text top="583" left="420" width="154" height="19" font="8"><b>Exclusion criteria:</b> Not in </text>
<text top="601" left="420" width="133" height="19" font="0">SR, &lt;18 y, emergency </text>
<text top="619" left="420" width="49" height="19" font="0">surgery </text>
<text top="474" left="608" width="263" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia and hypotension </text>
<text top="492" left="608" width="3" height="19" font="0"> </text>
<text top="510" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="529" left="608" width="289" height="20" font="0">• No specific data on bradycardia but those pts </text>
<text top="548" left="608" width="288" height="19" font="0">with lower heart rate variability (stratified by a </text>
<text top="566" left="608" width="127" height="19" font="0">total power &lt;500 Ms</text>
<text top="566" left="735" width="5" height="12" font="7">2</text>
<text top="566" left="740" width="15" height="19" font="0">Hz</text>
<text top="566" left="755" width="8" height="12" font="7">-1</text>
<text top="566" left="763" width="129" height="19" font="0">) were more likely to </text>
<text top="584" left="608" width="237" height="19" font="0">develop hypotension and bradycardia  </text>
<text top="603" left="608" width="230" height="20" font="0">• 4/50 pts in the retrospective model </text>
<text top="622" left="608" width="292" height="19" font="0">development group had bradycardia (&lt;50 bpm)<b> </b></text>
<text top="473" left="925" width="121" height="20" font="0">• Small numbers of </text>
<text top="492" left="936" width="125" height="19" font="0">bradycardia (mostly </text>
<text top="510" left="936" width="84" height="19" font="0">hypotension) </text>
<text top="693" left="93" width="137" height="19" font="0">Reddy MK, et al. 2008 </text>
<text top="712" left="93" width="39" height="19" font="0">(318)  </text>
<text top="730" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18157036">18157036</a></text>
<text top="730" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18157036"> </a></text>
<text top="734" left="93" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18157036"> </a></text>
<text top="693" left="244" width="146" height="19" font="8"><b>Aim:</b> Describe a pt who </text>
<text top="712" left="244" width="143" height="19" font="0">developed bradycardia </text>
<text top="730" left="244" width="164" height="19" font="0">during surgical positioning </text>
<text top="748" left="244" width="140" height="19" font="0">of an unstable cervical </text>
<text top="767" left="244" width="36" height="19" font="0">spine </text>
<text top="693" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="712" left="420" width="3" height="19" font="0"> </text>
<text top="730" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="694" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="713" left="608" width="3" height="19" font="0"> </text>
<text top="731" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="749" left="608" width="301" height="20" font="0">• Bradycardia (35 bpm) and hypotension (50 mm </text>
<text top="768" left="608" width="197" height="19" font="0">Hg) with initial skull positioning  </text>
<text top="694" left="925" width="101" height="20" font="0">• Case report of </text>
<text top="713" left="936" width="137" height="19" font="0">bradycardia with skull </text>
<text top="731" left="936" width="71" height="19" font="0">positioning </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 175 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="244" width="3" height="19" font="0"> </text>
<text top="105" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="123" left="244" width="3" height="19" font="0"> </text>
<text top="142" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="87" left="608" width="291" height="20" font="0">• Atropine and beta agonists not successful but </text>
<text top="106" left="608" width="248" height="19" font="0">surgical repositioning of the spine led to </text>
<text top="124" left="608" width="293" height="19" font="0">resolution and development of a heart rate 100 </text>
<text top="143" left="608" width="31" height="19" font="0">bpm<b> </b></text>
<text top="162" left="93" width="137" height="19" font="0">Ardesch JJ, et al. 2007 </text>
<text top="180" left="93" width="39" height="19" font="0">(319)  </text>
<text top="198" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17825483">17825483</a></text>
<text top="198" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17825483"> </a></text>
<text top="202" left="93" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17825483"> </a></text>
<text top="162" left="244" width="136" height="19" font="8"><b>Aim:</b> Describe cardiac </text>
<text top="180" left="244" width="130" height="19" font="0">responses with vagal </text>
<text top="198" left="244" width="111" height="19" font="0">nerve stimulation </text>
<text top="217" left="244" width="3" height="19" font="0"> </text>
<text top="235" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="253" left="244" width="3" height="19" font="0"> </text>
<text top="271" left="244" width="58" height="19" font="8"><b>Size:</b> 111 </text>
<text top="162" left="420" width="163" height="19" font="8"><b>Inclusion criteria:</b> Pts who </text>
<text top="180" left="420" width="139" height="19" font="0">received a vagal nerve </text>
<text top="198" left="420" width="169" height="19" font="0">stimulator for treatment of </text>
<text top="217" left="420" width="54" height="19" font="0">epilepsy </text>
<text top="235" left="420" width="3" height="19" font="0"> </text>
<text top="253" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="162" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="181" left="608" width="3" height="19" font="0"> </text>
<text top="199" left="608" width="234" height="19" font="8"><b>Results:</b> 3 cases of bradycardia during </text>
<text top="217" left="608" width="250" height="19" font="0">intraoperative testing. Not subsequently </text>
<text top="236" left="608" width="220" height="19" font="0">observed on postoperative testing. <b> </b></text>
<text top="162" left="925" width="148" height="20" font="0">• Transient bradycardia </text>
<text top="181" left="936" width="134" height="19" font="0">can be observed with </text>
<text top="199" left="936" width="115" height="19" font="0">vagal stimulation.  </text>
<text top="291" left="93" width="88" height="19" font="0">Jones PM and </text>
<text top="309" left="93" width="128" height="19" font="0">Soderman RM, 2007 </text>
<text top="327" left="93" width="35" height="19" font="0">(320) </text>
<text top="346" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17223834">17223834</a></text>
<text top="346" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17223834"> </a></text>
<text top="291" left="244" width="146" height="19" font="8"><b>Aim:</b> Describe a pt on 2 </text>
<text top="309" left="244" width="153" height="19" font="0">cholinesterase inhibitors </text>
<text top="327" left="244" width="98" height="19" font="0">who developed </text>
<text top="346" left="244" width="91" height="19" font="0">intraoperative </text>
<text top="364" left="244" width="76" height="19" font="0">bradycardia </text>
<text top="382" left="244" width="3" height="19" font="0"> </text>
<text top="400" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="419" left="244" width="3" height="19" font="0"> </text>
<text top="437" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="291" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="309" left="420" width="3" height="19" font="0"> </text>
<text top="327" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="291" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="310" left="608" width="3" height="19" font="0"> </text>
<text top="328" left="608" width="295" height="19" font="8"><b>Results:</b> Bradycardia (35 bpm) with induction of </text>
<text top="346" left="608" width="69" height="19" font="0">anesthesia<b> </b></text>
<text top="291" left="925" width="146" height="20" font="0">• Bradycardia (35 bpm) </text>
<text top="310" left="936" width="107" height="19" font="0">with induction of </text>
<text top="328" left="936" width="69" height="19" font="0">anesthesia </text>
<text top="456" left="93" width="129" height="19" font="0">Wijeysundera DN, et </text>
<text top="474" left="93" width="87" height="19" font="0">al. 2014 (321) </text>
<text top="493" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25091545">25091545</a></text>
<text top="493" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25091545"> </a></text>
<text top="497" left="93" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25091545"> </a></text>
<text top="456" left="244" width="121" height="19" font="8"><b>Aim:</b> ERC report on </text>
<text top="474" left="244" width="130" height="19" font="0">perioperative BB use </text>
<text top="493" left="244" width="3" height="19" font="0"> </text>
<text top="511" left="244" width="162" height="19" font="8"><b>Study type: </b>Meta-analysis </text>
<text top="529" left="244" width="3" height="19" font="0"> </text>
<text top="548" left="244" width="59" height="19" font="8"><b>Size:</b> N/A </text>
<text top="456" left="420" width="154" height="19" font="8"><b>Inclusion criteria:</b> Varied </text>
<text top="474" left="420" width="92" height="19" font="0">among studies </text>
<text top="493" left="420" width="3" height="19" font="0"> </text>
<text top="511" left="420" width="157" height="19" font="8"><b>Exclusion criteria:</b> Varied </text>
<text top="529" left="420" width="92" height="19" font="0">among studies </text>
<text top="457" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="475" left="608" width="3" height="19" font="0"> </text>
<text top="493" left="608" width="274" height="19" font="8"><b>Results:</b> Perioperative beta blockade started </text>
<text top="512" left="608" width="270" height="19" font="0">within 1 d or less before noncardiac surgery </text>
<text top="530" left="608" width="301" height="19" font="0">increases risks of intraoperative bradycardia (RR: </text>
<text top="548" left="608" width="158" height="19" font="0">2.61; 95% CI: 2.18– 3.12). </text>
<text top="456" left="925" width="128" height="20" font="0">• Perioperative beta </text>
<text top="475" left="936" width="158" height="19" font="0">blockade started within 1 </text>
<text top="494" left="936" width="98" height="19" font="0">d or less before </text>
<text top="512" left="936" width="120" height="19" font="0">noncardiac surgery </text>
<text top="530" left="936" width="107" height="19" font="0">increases risks of </text>
<text top="548" left="936" width="91" height="19" font="0">intraoperative </text>
<text top="567" left="936" width="79" height="19" font="0">bradycardia  </text>
<text top="586" left="86" width="4" height="21" font="4"> </text>
<text top="606" left="86" width="1020" height="23" font="5"><b>Data Supplement 45. Nonrandomized Data for predicting complete heart block with pulmonary artery catheter insertion (Section 8.1.1)  </b></text>
<text top="629" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="647" left="137" width="51" height="19" font="8"><b>Author; </b></text>
<text top="665" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="629" left="263" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="647" left="292" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="629" left="454" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="629" left="645" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="647" left="676" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="665" left="707" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="629" left="915" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="647" left="944" width="80" height="19" font="8"><b>Comment(s) </b></text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 176 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="128" height="19" font="0">Morris D, et al. 1987 </text>
<text top="105" left="95" width="35" height="19" font="0">(322) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3675104">3675104</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3675104"> </a></text>
<text top="142" left="95" width="3" height="19" font="0"> </text>
<text top="87" left="244" width="112" height="19" font="8"><b>Aim:</b> Evaluate the </text>
<text top="105" left="244" width="143" height="19" font="0">incidence of CHB in pts </text>
<text top="123" left="244" width="158" height="19" font="0">with LBBB undergoing PA </text>
<text top="142" left="244" width="123" height="19" font="0">catheter placement </text>
<text top="160" left="244" width="3" height="19" font="0"> </text>
<text top="178" left="244" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="197" left="244" width="3" height="19" font="0"> </text>
<text top="215" left="244" width="103" height="19" font="8"><b>Size:</b> 47 pts who </text>
<text top="233" left="244" width="109" height="19" font="0">underwent 82 PA </text>
<text top="252" left="244" width="129" height="19" font="0">catheter placements </text>
<text top="87" left="420" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="105" left="420" width="155" height="19" font="0">LBBB who underwent PA </text>
<text top="123" left="420" width="123" height="19" font="0">catheter placement </text>
<text top="142" left="420" width="3" height="19" font="0"> </text>
<text top="160" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="88" left="620" width="110" height="19" font="8"><b>1</b>°<b> endpoint:</b> CHB </text>
<text top="106" left="620" width="3" height="19" font="0"> </text>
<text top="124" left="620" width="52" height="19" font="8"><b>Results: </b></text>
<text top="143" left="619" width="226" height="20" font="0">•  5 episodes of CHB in the setting of </text>
<text top="162" left="633" width="185" height="19" font="0">old LBBB but none temporally </text>
<text top="180" left="633" width="206" height="19" font="0">related to PA catheter placement </text>
<text top="199" left="619" width="226" height="20" font="0">•  2 episodes of CHB in the setting of </text>
<text top="217" left="633" width="192" height="19" font="0">new LBBB but none temporally </text>
<text top="236" left="633" width="197" height="19" font="0">related to PA catheter insertion-</text>
<text top="254" left="633" width="220" height="19" font="0">though occurred while the catheter </text>
<text top="272" left="633" width="78" height="19" font="0">was in place<b> </b></text>
<text top="87" left="871" width="186" height="20" font="0">•  Authors do not recommend </text>
<text top="106" left="884" width="147" height="19" font="0">prophylactic temporary </text>
<text top="124" left="884" width="125" height="19" font="0">transvenous pacing  </text>
<text top="143" left="871" width="3" height="19" font="0"> </text>
<text top="161" left="871" width="3" height="19" font="0"> </text>
<text top="302" left="95" width="131" height="19" font="0">Elliott CG, et al. 1979 </text>
<text top="320" left="95" width="35" height="19" font="0">(323) </text>
<text top="338" left="95" width="49" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=510002">510002 </a></text>
<text top="338" left="144" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=510002"> </a></text>
<text top="342" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=510002"> </a></text>
<text top="301" left="244" width="88" height="19" font="8"><b>Aim:</b> Evaluate </text>
<text top="320" left="244" width="156" height="19" font="0">complications associated </text>
<text top="338" left="244" width="105" height="19" font="0">with PA catheter </text>
<text top="357" left="244" width="68" height="19" font="0">placement </text>
<text top="375" left="244" width="3" height="19" font="0"> </text>
<text top="393" left="244" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="411" left="244" width="3" height="19" font="0"> </text>
<text top="430" left="244" width="139" height="19" font="8"><b>Size:</b> 116 PA catheters </text>
<text top="301" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="320" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="338" left="420" width="143" height="19" font="0">PA catheter placement </text>
<text top="356" left="420" width="3" height="19" font="0"> </text>
<text top="375" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="302" left="620" width="192" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias, ECG </text>
<text top="321" left="631" width="161" height="19" font="0">changes, or complications </text>
<text top="339" left="620" width="3" height="19" font="0"> </text>
<text top="357" left="620" width="224" height="19" font="8"><b>Results:</b> Transient RBBB in 3% of pts<b> </b></text>
<text top="302" left="871" width="173" height="20" font="0">•  Transient RBBB fairly rare </text>
<text top="449" left="95" width="135" height="19" font="0">Unnikrishnan D, et al. </text>
<text top="467" left="95" width="69" height="19" font="0">2003 (324) </text>
<text top="485" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14570803">14570803</a></text>
<text top="485" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14570803"> </a></text>
<text top="449" left="244" width="89" height="19" font="8"><b>Aim:</b> Describe </text>
<text top="467" left="244" width="156" height="19" font="0">complications associated </text>
<text top="485" left="244" width="105" height="19" font="0">with PA catheter </text>
<text top="504" left="244" width="68" height="19" font="0">placement </text>
<text top="522" left="244" width="3" height="19" font="0"> </text>
<text top="540" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="559" left="244" width="3" height="19" font="0"> </text>
<text top="577" left="244" width="43" height="19" font="8"><b>Size:</b> 1<b> </b></text>
<text top="449" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="467" left="420" width="3" height="19" font="0"> </text>
<text top="485" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="449" left="620" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="468" left="620" width="3" height="19" font="0"> </text>
<text top="486" left="620" width="217" height="19" font="8"><b>Results:</b> Complete heart block with </text>
<text top="504" left="620" width="228" height="19" font="0">central venous line placement in a pt </text>
<text top="523" left="620" width="65" height="19" font="0">with LBBB<b> </b></text>
<text top="449" left="871" width="200" height="20" font="0">•  Transient CHB may occur with </text>
<text top="468" left="884" width="177" height="19" font="0">placement of central venous </text>
<text top="486" left="884" width="55" height="19" font="0">catheter </text>
<text top="596" left="86" width="4" height="21" font="4"> </text>
<text top="616" left="86" width="661" height="23" font="5"><b>Data Supplement 46. Nonrandomized data for Permanent Pacing for TAVI/valve surgery </b></text>
<text top="639" left="98" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="657" left="129" width="51" height="19" font="8"><b>Author; </b></text>
<text top="675" left="101" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="639" left="275" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="657" left="281" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="675" left="275" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="639" left="463" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="639" left="625" width="195" height="19" font="8"><b>Study Intervention (# patients) </b></text>
<text top="657" left="723" width="10" height="19" font="8"><b>/ </b></text>
<text top="675" left="626" width="192" height="19" font="8"><b>Study Comparator (# patients) </b></text>
<text top="639" left="911" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="657" left="835" width="260" height="19" font="8"><b>(Absolute Event Rates, P value; OR or RR; </b></text>
<text top="675" left="939" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="695" left="95" width="105" height="19" font="0">Mouillet G, et al. </text>
<text top="713" left="95" width="69" height="19" font="0">2013 (325) </text>
<text top="731" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22972678">22972678</a></text>
<text top="731" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22972678"> </a></text>
<text top="694" left="216" width="175" height="19" font="8"><b>Aim:</b> Predict which pts need </text>
<text top="713" left="216" width="133" height="19" font="0">PPM after Core Valve </text>
<text top="731" left="216" width="3" height="19" font="0"> </text>
<text top="694" left="435" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="713" left="435" width="115" height="19" font="0">getting Core Valve<b> </b></text>
<text top="695" left="624" width="73" height="19" font="0">Follow for 2</text>
<text top="694" left="697" width="10" height="12" font="7">nd</text>
<text top="695" left="707" width="28" height="19" font="0"> or 3</text>
<text top="694" left="734" width="9" height="12" font="7">rd</text>
<text top="695" left="743" width="350" height="20" font="0"> degree AVB<b>  </b>• All pts got temp pacing x 72 h; of 90 pts, </text>
<text top="714" left="845" width="223" height="19" font="0">11 had immediate AVB and PPM; 21 </text>
<text top="732" left="845" width="229" height="19" font="0">subsequently needed PPM, mostly in </text>
<text top="750" left="845" width="79" height="19" font="0">the first wk.  </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 177 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="149" height="19" font="8"><b>Study type</b>: Prospective </text>
<text top="105" left="216" width="163" height="19" font="0">Observational study of pts </text>
<text top="123" left="216" width="115" height="19" font="0">getting Core Valve </text>
<text top="142" left="216" width="3" height="19" font="0"> </text>
<text top="160" left="216" width="67" height="19" font="8"><b>Size</b>: N=90 </text>
<text top="87" left="834" width="245" height="20" font="0">• Post TAVI QRSd &lt;128 ms predicted no </text>
<text top="106" left="845" width="73" height="19" font="0">PM needed </text>
<text top="179" left="95" width="97" height="19" font="0">Rabinovitz, E et </text>
<text top="197" left="95" width="87" height="19" font="0">al. 2016 (326) </text>
<text top="216" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26936468">26936468</a></text>
<text top="216" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26936468"> </a></text>
<text top="179" left="216" width="155" height="19" font="8"><b>Aim</b>: Assess need for PM </text>
<text top="197" left="216" width="3" height="19" font="0"> </text>
<text top="216" left="216" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="234" left="216" width="3" height="19" font="0"> </text>
<text top="252" left="216" width="75" height="19" font="8"><b>Size</b>: N=302 </text>
<text top="179" left="435" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="197" left="435" width="131" height="19" font="0">Consecutive TAVI pts </text>
<text top="179" left="624" width="117" height="19" font="8"><b>Intervention</b>: TAVI </text>
<text top="179" left="834" width="128" height="20" font="0">• 20% required PPM </text>
<text top="271" left="95" width="62" height="19" font="8"><b>PARTNER </b></text>
<text top="290" left="95" width="95" height="19" font="0">Leon MB, et al. </text>
<text top="308" left="95" width="69" height="19" font="0">2010 (327) </text>
<text top="326" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20961243">20961243</a></text>
<text top="326" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20961243"> </a></text>
<text top="345" left="106" width="3" height="19" font="0"> </text>
<text top="271" left="216" width="184" height="19" font="8"><b>Aim</b>: Assess TAVI in severe AS </text>
<text top="290" left="216" width="22" height="19" font="0">pts </text>
<text top="271" left="435" width="175" height="19" font="8"><b>Inclusion criteria: </b>Severe AS </text>
<text top="290" left="435" width="43" height="19" font="0">N=358 </text>
<text top="272" left="624" width="121" height="19" font="0">TAVI vs. medical Rx </text>
<text top="272" left="834" width="211" height="20" font="0">• 3.4% underwent PPM after TAVI </text>
<text top="364" left="95" width="91" height="19" font="0">Kogan A, et al. </text>
<text top="382" left="95" width="30" height="19" font="0">2015</text>
<text top="381" left="125" width="4" height="21" font="4"> </text>
<text top="382" left="129" width="35" height="19" font="0">(328) </text>
<text top="400" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25583151">25583151</a></text>
<text top="400" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25583151"> </a></text>
<text top="364" left="216" width="185" height="19" font="8"><b>Aim: </b>Assess incidence of PPM </text>
<text top="382" left="216" width="178" height="19" font="0">with SAVR pre and post TAVI </text>
<text top="400" left="216" width="3" height="19" font="0"> </text>
<text top="419" left="216" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="437" left="216" width="3" height="19" font="0"> </text>
<text top="455" left="216" width="75" height="19" font="8"><b>Size</b>: N=290 </text>
<text top="364" left="435" width="171" height="19" font="8"><b>Inclusion criteria: </b>SAVR pre </text>
<text top="382" left="435" width="174" height="19" font="0">and post 2008 and TAVI pts, </text>
<text top="400" left="435" width="81" height="19" font="0">single center </text>
<text top="364" left="624" width="174" height="19" font="0">Retrospective observational </text>
<text top="382" left="624" width="37" height="19" font="0">study </text>
<text top="364" left="834" width="258" height="20" font="0">• <b>Results</b>: 2.48% got PPM within 7 d, over </text>
<text top="383" left="845" width="225" height="19" font="0">half of these had CHB. Pre TAVI, was </text>
<text top="401" left="845" width="204" height="19" font="0">3.79% and post TAVI was 1.47%.<b> </b> </text>
<text top="420" left="834" width="232" height="20" font="0">• <b>PARTNER trial: </b>SAVR had 3.6% PPM </text>
<text top="474" left="95" width="89" height="19" font="0">Rivard L, et al. </text>
<text top="493" left="95" width="69" height="19" font="0">2015 (329) </text>
<text top="511" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25446155">25446155</a></text>
<text top="511" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25446155"> </a></text>
<text top="474" left="216" width="174" height="19" font="8"><b>Aim: </b>Determine if EPS helps </text>
<text top="493" left="216" width="132" height="19" font="0">predict PM post TAVI </text>
<text top="511" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="529" left="216" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="548" left="216" width="3" height="19" font="0"> </text>
<text top="566" left="216" width="67" height="19" font="8"><b>Size</b>: N=75 </text>
<text top="474" left="435" width="130" height="19" font="8"><b>Inclusion criteria:</b> 75 </text>
<text top="493" left="435" width="160" height="19" font="0">consecutive TAVI pts with </text>
<text top="511" left="435" width="76" height="19" font="0">no prior PM </text>
<text top="474" left="624" width="142" height="19" font="0">EPS, assess HV interval </text>
<text top="475" left="834" width="237" height="20" font="0">• Delta HC &gt;13 ms (pre-post TAVI) and </text>
<text top="493" left="845" width="240" height="19" font="0">new LBBB with HV &gt;65 were predictive </text>
<text top="512" left="845" width="40" height="19" font="0">of PM </text>
<text top="530" left="834" width="255" height="20" font="0">• 13 ms delta is 100% sensitivity and 84% </text>
<text top="549" left="845" width="64" height="19" font="0">specificity </text>
<text top="585" left="95" width="93" height="19" font="0">Rene AG, et al. </text>
<text top="603" left="95" width="69" height="19" font="0">2013 (330) </text>
<text top="622" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24028584">24028584</a></text>
<text top="622" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24028584"> </a></text>
<text top="640" left="95" width="3" height="19" font="0"> </text>
<text top="585" left="216" width="169" height="19" font="8"><b>Aim: </b>Assess recovery of AV </text>
<text top="603" left="216" width="189" height="19" font="0">conduction after valve surgery<b> </b></text>
<text top="622" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="640" left="216" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="658" left="216" width="3" height="19" font="0"> </text>
<text top="676" left="216" width="67" height="19" font="8"><b>Size</b>: N=98 </text>
<text top="585" left="435" width="170" height="19" font="8"><b>Inclusion criteria: </b>S/P valve </text>
<text top="603" left="435" width="162" height="19" font="0">surgery and received PPM </text>
<text top="622" left="435" width="95" height="19" font="0">same hospital. <b> </b></text>
<text top="585" left="624" width="117" height="19" font="8"><b>Intervention: </b>PPM<b> </b></text>
<text top="585" left="834" width="239" height="20" font="0">• Of the 98 with CHB, 77% became PM </text>
<text top="604" left="845" width="70" height="19" font="0">dependent </text>
<text top="623" left="834" width="206" height="20" font="0">• 40% who received a PM had no </text>
<text top="642" left="845" width="238" height="19" font="0">evidence of high-grade AVB during PM </text>
<text top="660" left="845" width="62" height="19" font="0">follow-up </text>
<text top="678" left="834" width="209" height="20" font="0">• 26% of those who recovered AV </text>
<text top="697" left="845" width="233" height="19" font="0">conduction in 30 d had recurrent AVB<b> </b></text>
<text top="716" left="95" width="92" height="19" font="0">Steyers CM, et </text>
<text top="735" left="95" width="87" height="19" font="0">al. 2015 (331) </text>
<text top="753" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26470027">26470027</a></text>
<text top="753" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26470027"> </a></text>
<text top="716" left="216" width="191" height="19" font="8"><b>Aim: </b>Comprehensive review of </text>
<text top="735" left="216" width="155" height="19" font="0">AVB post cardiac surgery </text>
<text top="753" left="216" width="3" height="19" font="0"> </text>
<text top="771" left="216" width="122" height="19" font="8"><b>Study type: </b>Review </text>
<text top="716" left="435" width="144" height="19" font="8"><b>Inclusion criteria: </b>AVR, </text>
<text top="735" left="435" width="153" height="19" font="0">MVR, CABG, CABG/valve<b> </b></text>
<text top="716" left="624" width="28" height="19" font="0">N/A<b> </b></text>
<text top="717" left="834" width="232" height="20" font="0">• PM dependency was highly variable </text>
<text top="736" left="834" width="219" height="20" font="0">• Recovery of AV conduction highly </text>
<text top="755" left="845" width="52" height="19" font="0">variable </text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 178 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="3" height="19" font="0"> </text>
<text top="105" left="216" width="166" height="19" font="8"><b>Size</b>: N=10 studies, 780 pts<b> </b></text>
<text top="87" left="834" width="261" height="20" font="0">• Optimal timing for PM (how long to wait </text>
<text top="106" left="845" width="179" height="19" font="0">for recovery) not established<b> </b></text>
<text top="125" left="95" width="102" height="19" font="0">Dawkins S, et al. </text>
<text top="143" left="95" width="69" height="19" font="0">2008 (332) </text>
<text top="162" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18154792">18154792</a></text>
<text top="162" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18154792"> </a></text>
<text top="125" left="216" width="171" height="19" font="8"><b>Aim: </b>Identify incidence and </text>
<text top="143" left="216" width="172" height="19" font="0">predictors of AVB after AVR </text>
<text top="162" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="180" left="216" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="198" left="216" width="87" height="19" font="0">observational </text>
<text top="217" left="216" width="3" height="19" font="0"> </text>
<text top="235" left="216" width="75" height="19" font="8"><b>Size</b>: N=354 </text>
<text top="125" left="435" width="162" height="19" font="8"><b>Inclusion criteria: </b>Surgical </text>
<text top="143" left="435" width="29" height="19" font="0">AVR<b> </b></text>
<text top="125" left="624" width="109" height="19" font="8"><b>Intervention: </b>PM<b> </b></text>
<text top="125" left="834" width="162" height="20" font="0">• 7% needed PM in AS pts </text>
<text top="144" left="834" width="166" height="20" font="0">• 16% needed PM in AI pts<b> </b></text>
<text top="254" left="95" width="92" height="19" font="0">Viles-Gonzalez </text>
<text top="272" left="95" width="86" height="19" font="0">JF, et al. 2014 </text>
<text top="291" left="95" width="35" height="19" font="0">(333) </text>
<text top="309" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24526511">24526511</a></text>
<text top="309" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24526511"> </a></text>
<text top="254" left="216" width="198" height="19" font="8"><b>Aim: </b>Observe natural Hx of AVB </text>
<text top="272" left="216" width="66" height="19" font="0">after MVR<b> </b></text>
<text top="254" left="435" width="170" height="19" font="8"><b>Inclusion criteria: </b>290 MVR </text>
<text top="272" left="435" width="22" height="19" font="0">pts<b> </b></text>
<text top="254" left="624" width="174" height="19" font="0">Retrospective observational </text>
<text top="272" left="624" width="37" height="19" font="0">study </text>
<text top="254" left="834" width="238" height="20" font="0">• <b>Results: </b>2% got PPM mostly for AVB, </text>
<text top="273" left="845" width="232" height="19" font="0">55% recovered conduction abnormal, </text>
<text top="291" left="845" width="122" height="19" font="0">some had residual 1</text>
<text top="291" left="967" width="7" height="12" font="7">st</text>
<text top="291" left="974" width="122" height="19" font="0"> AVB; mean time to </text>
<text top="310" left="845" width="216" height="19" font="0">recover was 3 d. Predictors include </text>
<text top="328" left="845" width="36" height="19" font="0">RBBB </text>
<text top="347" left="95" width="91" height="19" font="0">Merin O, et al. </text>
<text top="365" left="95" width="69" height="19" font="0">2009 (334) </text>
<text top="384" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19140907">19140907</a></text>
<text top="384" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19140907"> </a></text>
<text top="402" left="95" width="3" height="19" font="0"> </text>
<text top="347" left="216" width="36" height="19" font="8"><b>Aim:  </b></text>
<text top="365" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="384" left="216" width="78" height="19" font="8"><b>Study type: </b> </text>
<text top="402" left="216" width="3" height="19" font="0"> </text>
<text top="420" left="216" width="86" height="19" font="8"><b>Size</b>: N=4,999 </text>
<text top="347" left="435" width="153" height="19" font="8"><b>Inclusion criteria: </b>CABG, </text>
<text top="365" left="435" width="65" height="19" font="0">AVR, MVR<b> </b></text>
<text top="384" left="608" width="3" height="19" font="0"> </text>
<text top="347" left="624" width="109" height="19" font="8"><b>Intervention: </b>PM<b> </b></text>
<text top="347" left="834" width="115" height="20" font="0">• 81% had a CABG </text>
<text top="366" left="834" width="154" height="20" font="0">• Predictor for PM=LBBB </text>
<text top="385" left="834" width="102" height="20" font="0">• 1.5% got a PM </text>
<text top="405" left="834" width="235" height="20" font="0">• 1/3 recovered AV conduction at late </text>
<text top="424" left="845" width="62" height="19" font="0">follow-up<b> </b></text>
<text top="443" left="86" width="4" height="21" font="4"> </text>
<text top="463" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="485" left="96" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="504" left="127" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="522" left="99" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="485" left="238" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="504" left="243" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="522" left="237" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="485" left="390" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="485" left="558" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="504" left="576" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="522" left="560" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="540" left="581" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="485" left="734" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="504" left="716" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="522" left="720" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="540" left="763" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="486" left="898" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="505" left="934" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="523" left="942" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="559" left="95" width="26" height="19" font="8"><b>The </b></text>
<text top="578" left="95" width="80" height="19" font="8"><b>Birmingham </b></text>
<text top="596" left="95" width="31" height="19" font="8"><b>Trial </b></text>
<text top="614" left="95" width="91" height="19" font="0">Watson RD, et </text>
<text top="633" left="95" width="87" height="19" font="0">al. 1984 (231) </text>
<text top="651" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475712">6475712</a></text>
<text top="651" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475712"> </a></text>
<text top="559" left="212" width="118" height="19" font="8"><b>Aim:</b> To determine </text>
<text top="578" left="212" width="126" height="19" font="0">whether permanent </text>
<text top="596" left="212" width="95" height="19" font="0">pacing reduces </text>
<text top="614" left="212" width="127" height="19" font="0">mortality in pts with </text>
<text top="633" left="212" width="134" height="19" font="0">fascicular block ≥14 d </text>
<text top="651" left="212" width="137" height="19" font="0">post-MI, and whether </text>
<text top="669" left="212" width="105" height="19" font="0">measurement of </text>
<text top="688" left="212" width="76" height="19" font="0">intracardiac </text>
<text top="706" left="212" width="109" height="19" font="0">conduction times </text>
<text top="724" left="212" width="127" height="19" font="0">predicts later death. </text>
<text top="743" left="212" width="3" height="19" font="0"> </text>
<text top="761" left="212" width="101" height="19" font="8"><b>Study type:</b> RCT </text>
<text top="779" left="212" width="3" height="19" font="0"> </text>
<text top="559" left="365" width="167" height="19" font="8"><b>Inclusion criteria:</b> Survived </text>
<text top="578" left="365" width="144" height="19" font="0">at least 14 d after AMI; </text>
<text top="596" left="365" width="105" height="19" font="0">RBBB alone or in </text>
<text top="614" left="365" width="135" height="19" font="0">combination with left </text>
<text top="633" left="365" width="153" height="19" font="0">anterior or left posterior </text>
<text top="651" left="365" width="166" height="19" font="0">hemiblock or left posterior </text>
<text top="669" left="365" width="104" height="19" font="0">hemiblock alone </text>
<text top="688" left="365" width="3" height="19" font="0"> </text>
<text top="706" left="365" width="166" height="19" font="8"><b>Exclusion criteria:</b> Age ≥70 </text>
<text top="724" left="365" width="102" height="19" font="0">y; previous ECG  </text>
<text top="743" left="365" width="146" height="19" font="0">evidence of conduction </text>
<text top="761" left="365" width="173" height="19" font="0">disorder (before infarction)  </text>
<text top="559" left="547" width="85" height="19" font="8"><b>Intervention:</b> </text>
<text top="578" left="547" width="114" height="19" font="0">Permanent pacing </text>
<text top="596" left="547" width="7" height="19" font="0">  </text>
<text top="614" left="547" width="104" height="19" font="8"><b>Comparator:</b> No </text>
<text top="633" left="547" width="115" height="19" font="0">permanent pacing </text>
<text top="651" left="547" width="3" height="19" font="0"> </text>
<text top="669" left="547" width="124" height="19" font="0">Resting intracardiac </text>
<text top="688" left="547" width="109" height="19" font="0">conduction times </text>
<text top="706" left="547" width="113" height="19" font="0">were measured in </text>
<text top="724" left="547" width="127" height="19" font="0">both groups prior to </text>
<text top="743" left="547" width="43" height="19" font="0">pacing </text>
<text top="560" left="702" width="168" height="19" font="8"><b>1</b>°<b> endpoint:</b> No difference </text>
<text top="579" left="702" width="74" height="19" font="0">in mortality </text>
<text top="597" left="702" width="3" height="19" font="0"> </text>
<text top="615" left="702" width="119" height="19" font="8"><b>Safety endpoint (if </b></text>
<text top="633" left="702" width="95" height="19" font="8"><b>relevant):</b> N/A  </text>
<text top="652" left="702" width="3" height="19" font="8"><b> </b></text>
<text top="560" left="887" width="174" height="20" font="0">• Progression of conduction </text>
<text top="579" left="898" width="163" height="19" font="0">disease was not observed  </text>
<text top="597" left="887" width="182" height="20" font="0">• Measurement of infranodal </text>
<text top="616" left="898" width="183" height="19" font="0">conduction time (HV interval) </text>
<text top="634" left="898" width="151" height="19" font="0">did not predict outcome </text>
<text top="653" left="887" width="199" height="20" font="0">• Ventricular arrhythmia was an </text>
<text top="672" left="898" width="158" height="19" font="0">important cause of death </text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 179 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="622" left="82" width="3" height="19" font="0"> </text>
<text top="640" left="82" width="3" height="19" font="0"> </text>
<text top="658" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="681" left="105" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="699" left="131" width="51" height="19" font="8"><b>Author; </b></text>
<text top="718" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="681" left="265" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="699" left="294" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="681" left="470" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="681" left="649" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="699" left="680" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="718" left="711" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="681" left="917" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="699" left="946" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="737" left="96" width="108" height="19" font="8"><b>The Framingham </b></text>
<text top="755" left="96" width="39" height="19" font="8"><b>Study </b></text>
<text top="773" left="96" width="120" height="19" font="0">Schneider JF, et al.  </text>
<text top="737" left="230" width="144" height="19" font="8"><b>Aim: </b>Assess the clinical </text>
<text top="755" left="230" width="127" height="19" font="0">implications of LBBB </text>
<text top="773" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="737" left="439" width="172" height="19" font="8"><b>Inclusion criteria:</b> LBBB and </text>
<text top="755" left="439" width="138" height="19" font="0">age- and sex-matched </text>
<text top="773" left="439" width="146" height="19" font="0">control pts who did not </text>
<text top="737" left="635" width="203" height="19" font="8"><b>1</b>°<b> endpoint:</b> Development of CV </text>
<text top="756" left="635" width="49" height="19" font="0">disease </text>
<text top="774" left="635" width="3" height="19" font="0"> </text>
<text top="737" left="864" width="198" height="20" font="0">• Comparison with age- and sex-</text>
<text top="756" left="875" width="219" height="19" font="0">matched control subjects free from </text>
<text top="774" left="875" width="215" height="19" font="0">LBBB suggests that newly acquired </text>
<text top="87" left="212" width="73" height="19" font="8"><b>Size:</b> 50 pts </text>
<text top="87" left="365" width="168" height="19" font="0">Pts with left bundle branch </text>
<text top="105" left="365" width="150" height="19" font="0">block were not included </text>
<text top="123" left="365" width="138" height="19" font="0">due to the difficulty in </text>
<text top="142" left="365" width="120" height="19" font="0">identifying the ECG </text>
<text top="160" left="365" width="102" height="19" font="0">features of AMI. </text>
<text top="179" left="95" width="39" height="19" font="8"><b>PACE  </b></text>
<text top="197" left="95" width="100" height="19" font="0">Petrac, D., et al. </text>
<text top="216" left="95" width="69" height="19" font="0">1996 (335) </text>
<text top="234" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8734745">8734745</a></text>
<text top="234" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8734745"> </a></text>
<text top="179" left="212" width="36" height="19" font="8"><b>Aim:  </b></text>
<text top="197" left="212" width="3" height="19" font="8"><b> </b></text>
<text top="216" left="212" width="78" height="19" font="8"><b>Study type:  </b></text>
<text top="234" left="212" width="3" height="19" font="8"><b> </b></text>
<text top="252" left="212" width="84" height="19" font="8"><b>Size: </b>192 pts.<b> </b></text>
<text top="179" left="365" width="115" height="19" font="8"><b>Inclusion criteria:  </b></text>
<text top="197" left="365" width="3" height="19" font="8"><b> </b></text>
<text top="216" left="365" width="117" height="19" font="8"><b>Exclusion criteria:  </b></text>
<text top="179" left="547" width="107" height="19" font="8"><b>Intervention: </b>His </text>
<text top="197" left="547" width="108" height="19" font="0">bundle recording </text>
<text top="216" left="547" width="121" height="19" font="0">during atrial pacing<b> </b></text>
<text top="234" left="547" width="7" height="19" font="8"><b>  </b></text>
<text top="252" left="547" width="83" height="19" font="8"><b>Comparator: </b></text>
<text top="271" left="547" width="91" height="19" font="0">Nonfunctional </text>
<text top="289" left="547" width="114" height="19" font="0">infraHisian 2° AVB<b> </b></text>
<text top="180" left="702" width="149" height="19" font="8"><b>1</b>°<b> endpoint: </b>In pts with </text>
<text top="198" left="702" width="170" height="19" font="0">chronic BBB and syncope, a </text>
<text top="217" left="702" width="158" height="19" font="0">nonfunctional infraHisian </text>
<text top="235" left="702" width="99" height="19" font="0">AVB induced by </text>
<text top="253" left="702" width="155" height="19" font="0">incremental atrial pacing </text>
<text top="272" left="702" width="115" height="19" font="0">identified pts with </text>
<text top="290" left="702" width="143" height="19" font="0">particularly high risk of </text>
<text top="308" left="702" width="100" height="19" font="0">development of </text>
<text top="326" left="702" width="151" height="19" font="0">spontaneous infraHisian </text>
<text top="345" left="702" width="33" height="19" font="0">AVB. </text>
<text top="363" left="702" width="3" height="19" font="8"><b> </b></text>
<text top="381" left="702" width="134" height="19" font="8"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="179" left="887" width="166" height="20" font="0">• Incremental atrial pacing </text>
<text top="198" left="898" width="170" height="19" font="0">identified pts at high risk of </text>
<text top="217" left="898" width="182" height="19" font="0">development of spontaneous </text>
<text top="235" left="898" width="98" height="19" font="0">infraHisian AVB </text>
<text top="400" left="95" width="68" height="19" font="8"><b>The PRESS </b></text>
<text top="419" left="95" width="39" height="19" font="8"><b>Study </b></text>
<text top="437" left="95" width="99" height="19" font="0">Santini M, et al. </text>
<text top="455" left="95" width="69" height="19" font="0">2013 (182) </text>
<text top="474" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23390123">23390123</a></text>
<text top="474" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23390123"> </a></text>
<text top="400" left="212" width="133" height="19" font="8"><b>Aim:</b> To demonstrate </text>
<text top="419" left="212" width="88" height="19" font="0">a reduction in </text>
<text top="437" left="212" width="127" height="19" font="0">symptomatic events </text>
<text top="455" left="212" width="140" height="19" font="0">in pts with bifascicular </text>
<text top="474" left="212" width="132" height="19" font="0">block and syncope of </text>
<text top="492" left="212" width="129" height="19" font="0">undetermined origin </text>
<text top="510" left="212" width="132" height="19" font="0">implanted with PPM. </text>
<text top="529" left="212" width="3" height="19" font="0"> </text>
<text top="547" left="212" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="565" left="212" width="83" height="19" font="0">Randomized  </text>
<text top="584" left="212" width="3" height="19" font="0"> </text>
<text top="602" left="212" width="80" height="19" font="8"><b>Size:</b> 100 pts </text>
<text top="400" left="365" width="115" height="19" font="8"><b>Inclusion criteria:</b>  </text>
<text top="419" left="365" width="3" height="19" font="0"> </text>
<text top="437" left="365" width="117" height="19" font="8"><b>Exclusion criteria:</b>  </text>
<text top="400" left="547" width="85" height="19" font="8"><b>Intervention:</b> </text>
<text top="419" left="547" width="102" height="19" font="0">Permanent DDD </text>
<text top="437" left="547" width="138" height="19" font="0">pacing with a low rate </text>
<text top="455" left="547" width="66" height="19" font="0">of 60 bpm </text>
<text top="474" left="547" width="7" height="19" font="0">  </text>
<text top="492" left="547" width="83" height="19" font="8"><b>Comparator: </b></text>
<text top="510" left="547" width="140" height="19" font="0">Permanent DDI pacing </text>
<text top="529" left="547" width="129" height="19" font="0">with a low rate of 30 </text>
<text top="547" left="547" width="31" height="19" font="0">bpm<b> </b></text>
<text top="401" left="702" width="159" height="19" font="8"><b>1</b>°<b> endpoint:</b> (1) syncope, </text>
<text top="420" left="702" width="103" height="19" font="0">(2) symptomatic </text>
<text top="438" left="702" width="77" height="19" font="0">presyncopal </text>
<text top="456" left="702" width="166" height="19" font="0">episodes associated with a </text>
<text top="474" left="702" width="122" height="19" font="0">device intervention </text>
<text top="493" left="702" width="152" height="19" font="0">(ventricular pacing), and </text>
<text top="511" left="702" width="160" height="19" font="0">(3) symptomatic episodes </text>
<text top="529" left="702" width="98" height="19" font="0">associated with </text>
<text top="548" left="702" width="166" height="19" font="0">intermittent or permanent </text>
<text top="566" left="702" width="113" height="19" font="0">AVB (any degree). </text>
<text top="584" left="702" width="3" height="19" font="0"> </text>
<text top="603" left="702" width="3" height="19" font="8"><b> </b></text>
<text top="401" left="887" width="171" height="20" font="0">• DDD60 led to a significant </text>
<text top="420" left="898" width="148" height="19" font="0">reduction of syncope or </text>
<text top="438" left="898" width="194" height="19" font="0">symptomatic events associated </text>
<text top="456" left="898" width="183" height="19" font="0">with a cardioinhibitory origin, </text>
<text top="475" left="898" width="137" height="19" font="0">compared with DDI30 </text>
<text top="493" left="898" width="86" height="19" font="0">programming </text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 180 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="62" height="19" font="0">1979 (27) </text>
<text top="105" left="96" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/154870">154870</a></text>
<text top="105" left="142" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/154870"> </a></text>
<text top="87" left="230" width="153" height="19" font="8"><b>Study type:</b> Nested case-</text>
<text top="105" left="230" width="189" height="19" font="0">control in Framingham cohort  </text>
<text top="123" left="230" width="3" height="19" font="0"> </text>
<text top="142" left="230" width="170" height="19" font="8"><b>Size:</b> 55 pts who developed </text>
<text top="160" left="230" width="174" height="19" font="0">LBBB, 110 matched controls </text>
<text top="178" left="230" width="190" height="19" font="0">Mean age at study onset =50 y </text>
<text top="197" left="230" width="193" height="19" font="0">Mean age at onset of LBBB =62 </text>
<text top="215" left="230" width="10" height="19" font="0">y<b> </b></text>
<text top="87" left="439" width="120" height="19" font="0">develop LBBB from </text>
<text top="105" left="439" width="124" height="19" font="0">Framingham cohort </text>
<text top="123" left="439" width="3" height="19" font="0"> </text>
<text top="142" left="439" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="87" left="635" width="153" height="19" font="8"><b>Results:</b> 55/5209 people </text>
<text top="105" left="635" width="204" height="19" font="0">developed LBBB in 18 y of follow-</text>
<text top="123" left="635" width="19" height="19" font="0">up </text>
<text top="142" left="635" width="200" height="19" font="0">48% of these develop CAD or HF </text>
<text top="160" left="635" width="53" height="19" font="0">for the 1</text>
<text top="160" left="687" width="7" height="12" font="7">st</text>
<text top="160" left="694" width="142" height="19" font="0"> time with or following </text>
<text top="178" left="635" width="69" height="19" font="0">Dx of LBBB </text>
<text top="197" left="635" width="167" height="19" font="0">Only 11% remained free of </text>
<text top="215" left="635" width="200" height="19" font="0">clinically apparent CV abnormal  </text>
<text top="233" left="635" width="198" height="19" font="0">In men, the appearance of LBBB </text>
<text top="252" left="635" width="202" height="19" font="0">contributed independently to an </text>
<text top="270" left="635" width="171" height="19" font="0">increased risk of CV disease </text>
<text top="288" left="635" width="59" height="19" font="0">mortality<b> </b></text>
<text top="87" left="875" width="200" height="19" font="0">LBBB is most often a hallmark of </text>
<text top="105" left="875" width="217" height="19" font="0">advanced hypertensive or ischemic </text>
<text top="123" left="875" width="137" height="19" font="0">heart disease, or both </text>
<text top="307" left="96" width="87" height="19" font="0">Fahy GJ, et al. </text>
<text top="326" left="96" width="30" height="19" font="0">1996</text>
<text top="324" left="127" width="4" height="21" font="4"> </text>
<text top="326" left="130" width="28" height="19" font="0">(31) </text>
<text top="344" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8651093">8651093</a></text>
<text top="344" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8651093"> </a></text>
<text top="307" left="230" width="189" height="19" font="8"><b>Aim:</b> Determine the long-term </text>
<text top="326" left="230" width="181" height="19" font="0">outcome of pts with BBB and </text>
<text top="344" left="230" width="158" height="19" font="0">no clinical evidence of CV </text>
<text top="362" left="230" width="49" height="19" font="0">disease </text>
<text top="381" left="230" width="3" height="19" font="0"> </text>
<text top="399" left="230" width="153" height="19" font="8"><b>Study type:</b> Nested case-</text>
<text top="417" left="230" width="51" height="19" font="0">control  </text>
<text top="436" left="230" width="3" height="19" font="0"> </text>
<text top="454" left="230" width="169" height="19" font="8"><b>Size:</b> 310 pts with BBB, 310 </text>
<text top="472" left="230" width="150" height="19" font="0">matched controls out of </text>
<text top="491" left="230" width="185" height="19" font="0">110,000 participant screening </text>
<text top="509" left="230" width="117" height="19" font="0">program in Ireland<b> </b></text>
<text top="307" left="439" width="171" height="19" font="8"><b>Inclusion criteria:</b> BBB/age- </text>
<text top="326" left="439" width="161" height="19" font="0">and sex-matched controls </text>
<text top="344" left="439" width="3" height="19" font="0"> </text>
<text top="362" left="439" width="179" height="19" font="8"><b>Exclusion criteria:</b> Suspected </text>
<text top="381" left="439" width="85" height="19" font="0">heart disease<b> </b></text>
<text top="308" left="635" width="148" height="19" font="8"><b>1</b>°<b> endpoint:</b> Long-term </text>
<text top="326" left="635" width="136" height="19" font="0">“outcome” of BBB pts </text>
<text top="345" left="635" width="3" height="19" font="0"> </text>
<text top="363" left="635" width="172" height="19" font="8"><b>Results:</b> BBB did not impact </text>
<text top="381" left="635" width="104" height="19" font="0">overall mortality </text>
<text top="400" left="635" width="211" height="19" font="0">Cardiac mortality was significantly </text>
<text top="418" left="635" width="174" height="19" font="0">increased in the LBBB group </text>
<text top="436" left="635" width="170" height="19" font="0">compared to their controls  </text>
<text top="455" left="635" width="153" height="19" font="0">LBBB, but not RBBB, was </text>
<text top="473" left="635" width="179" height="19" font="0">associated with an increased </text>
<text top="491" left="635" width="194" height="19" font="0">prevalence of CV disease at the </text>
<text top="510" left="635" width="206" height="19" font="0">follow-up (21% vs. 11%; p=0.04). <b> </b></text>
<text top="308" left="864" width="243" height="20" font="0">• Isolated left BBB is associated with an </text>
<text top="326" left="875" width="229" height="19" font="0">increased risk of developing overt CV </text>
<text top="345" left="875" width="184" height="19" font="0">disease and increased cardiac </text>
<text top="363" left="875" width="63" height="19" font="0">mortality. </text>
<text top="529" left="96" width="95" height="19" font="0">Talreja D, et al. </text>
<text top="547" left="96" width="62" height="19" font="0">2000 (43) </text>
<text top="565" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10689252">10689252</a></text>
<text top="565" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10689252"> </a></text>
<text top="529" left="230" width="179" height="19" font="8"><b>Aim: </b>Assess ability to predict </text>
<text top="547" left="230" width="167" height="19" font="0">LV dysfunction on echo, by </text>
<text top="565" left="230" width="185" height="19" font="0">historic, clinical, radiographic, </text>
<text top="584" left="230" width="128" height="19" font="0">and ECG parameters </text>
<text top="602" left="230" width="3" height="19" font="0"> </text>
<text top="620" left="230" width="173" height="19" font="8"><b>Study type:</b> Cross-sectional  </text>
<text top="638" left="230" width="3" height="19" font="0"> </text>
<text top="657" left="230" width="61" height="19" font="8"><b>Size:</b> 300 <b> </b></text>
<text top="529" left="439" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="547" left="439" width="142" height="19" font="0">Consecutive inpatients </text>
<text top="565" left="439" width="99" height="19" font="0">referred for the </text>
<text top="584" left="439" width="116" height="19" font="0">echocardiographic </text>
<text top="602" left="439" width="162" height="19" font="0">assessment of LV function </text>
<text top="620" left="439" width="7" height="19" font="0"> <b> </b></text>
<text top="529" left="635" width="152" height="19" font="8"><b>1</b>°<b> endpoint:</b> LVER &lt;45% </text>
<text top="548" left="635" width="3" height="19" font="0"> </text>
<text top="566" left="635" width="213" height="19" font="8"><b>Results:</b> 124 (41%) had LVEF &lt;45% </text>
<text top="584" left="635" width="200" height="19" font="0">Presence of LBBB, male sex, and </text>
<text top="603" left="635" width="203" height="19" font="0">CM on CXR were associated with </text>
<text top="621" left="635" width="168" height="19" font="0">presence of LV dysfunction </text>
<text top="639" left="635" width="213" height="19" font="0">Only 2 pts with LVSD had a normal </text>
<text top="658" left="634" width="28" height="19" font="0">ECG </text>
<text top="676" left="635" width="201" height="19" font="0">More than 50% of the predictive </text>
<text top="694" left="635" width="210" height="19" font="0">power of the model rested on the </text>
<text top="713" left="635" width="205" height="19" font="0">discriminatory ability of a normal </text>
<text top="731" left="635" width="32" height="19" font="0">ECG <b> </b></text>
<text top="529" left="864" width="231" height="20" font="0">• When ECG is normal, it is extremely </text>
<text top="548" left="875" width="166" height="19" font="0">unlikely to have LV systolic </text>
<text top="566" left="875" width="79" height="19" font="0">dysfunction. </text>
<text top="585" left="864" width="239" height="20" font="0">• It can be argued that such pts should </text>
<text top="603" left="875" width="118" height="19" font="0">not be referred for </text>
<text top="622" left="875" width="117" height="19" font="0">echocardiography. </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 181 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="102" height="19" font="0">Eriksson P, et al. </text>
<text top="105" left="96" width="62" height="19" font="0">1998 (30) </text>
<text top="123" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9832497">9832497</a></text>
<text top="123" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9832497"> </a></text>
<text top="87" left="230" width="194" height="19" font="8"><b>Aim: </b>Assess prevalence of BBB, </text>
<text top="105" left="230" width="168" height="19" font="0">its impact on mortality and </text>
<text top="123" left="230" width="151" height="19" font="0">coexisting CV conditions </text>
<text top="142" left="230" width="3" height="19" font="0"> </text>
<text top="160" left="230" width="193" height="19" font="8"><b>Study type:</b> Prospective cohort </text>
<text top="178" left="230" width="3" height="19" font="0"> </text>
<text top="197" left="230" width="182" height="19" font="8"><b>Size:</b> 855 men who were 50 y </text>
<text top="215" left="230" width="178" height="19" font="0">old in 1963 followed for 30 y </text>
<text top="233" left="230" width="114" height="19" font="0">82 developed BBB </text>
<text top="252" left="230" width="140" height="19" font="0">22 of those were LBBB </text>
<text top="87" left="439" width="166" height="19" font="8"><b>Inclusion criteria:</b> Random </text>
<text top="105" left="439" width="158" height="19" font="0">sampling of Swedish men </text>
<text top="123" left="439" width="3" height="19" font="0"> </text>
<text top="142" left="439" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="88" left="635" width="188" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality and CV </text>
<text top="106" left="635" width="49" height="19" font="0">disease </text>
<text top="124" left="635" width="3" height="19" font="0"> </text>
<text top="143" left="635" width="193" height="19" font="8"><b>Results:</b> The prevalence of BBB </text>
<text top="161" left="635" width="201" height="19" font="0">increases from 1% at age 50 y to </text>
<text top="179" left="635" width="185" height="19" font="0">17% at age 80 y, resulting in a </text>
<text top="198" left="635" width="185" height="19" font="0">cumulative incidence of 18%.  </text>
<text top="216" left="635" width="214" height="19" font="0">BBB did not predict ischemic heart </text>
<text top="234" left="635" width="128" height="19" font="0">disease or mortality  </text>
<text top="252" left="635" width="183" height="19" font="0">Men who developed BBB had </text>
<text top="271" left="635" width="205" height="19" font="0">bigger LV volume at baseline and </text>
<text top="289" left="635" width="200" height="19" font="0">greater incidence of DM and HF <b> </b></text>
<text top="87" left="864" width="236" height="20" font="0">• BBB correlates strongly to age and is </text>
<text top="106" left="875" width="155" height="19" font="0">common in elderly men.  </text>
<text top="124" left="864" width="177" height="20" font="0">• BBB is a marker of a slowly </text>
<text top="143" left="875" width="207" height="19" font="0">progressing degenerative disease </text>
<text top="162" left="875" width="181" height="19" font="0">that affects the myocardium. </text>
<text top="180" left="864" width="235" height="20" font="0">• BBB is not associated with increased </text>
<text top="199" left="875" width="59" height="19" font="0">mortality </text>
<text top="218" left="864" width="239" height="20" font="0">• I could not find data broken down by </text>
<text top="237" left="875" width="211" height="19" font="0">LBBB vs. RBBB; vast majority were </text>
<text top="255" left="875" width="43" height="19" font="0">RBBB* </text>
<text top="308" left="96" width="113" height="19" font="0">Mahmod M, et al. </text>
<text top="326" left="96" width="69" height="19" font="0">2012 (277) </text>
<text top="345" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21805313">21805313</a></text>
<text top="345" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21805313"> </a></text>
<text top="308" left="230" width="177" height="19" font="8"><b>Aim: </b>Evaluate the diagnostic </text>
<text top="326" left="230" width="175" height="19" font="0">value of CMR in asx pts with </text>
<text top="345" left="229" width="34" height="19" font="0">LBBB<b> </b></text>
<text top="363" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="381" left="230" width="173" height="19" font="8"><b>Study type:</b> Cross-sectional  </text>
<text top="400" left="230" width="3" height="19" font="0"> </text>
<text top="418" left="230" width="73" height="19" font="8"><b>Size:</b> 54 pts<b> </b></text>
<text top="308" left="439" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="326" left="439" width="163" height="19" font="0">Asymptomatic adults with </text>
<text top="345" left="439" width="170" height="19" font="0">complete LBBB referred for </text>
<text top="363" left="439" width="71" height="19" font="0">cardiac MR </text>
<text top="381" left="439" width="3" height="19" font="0"> </text>
<text top="400" left="439" width="168" height="19" font="8"><b>Exclusion criteria:</b> Absence </text>
<text top="418" left="439" width="49" height="19" font="0">of echo<b> </b></text>
<text top="309" left="635" width="200" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pathologic findings </text>
<text top="327" left="635" width="44" height="19" font="0">on MR </text>
<text top="346" left="635" width="3" height="19" font="0"> </text>
<text top="364" left="635" width="211" height="19" font="8"><b>Results:</b> 9/29 (31%) had abnormal </text>
<text top="382" left="635" width="198" height="19" font="0">MR despite normal echo: 6 with </text>
<text top="401" left="635" width="106" height="19" font="0">DCM, 2 with LVH </text>
<text top="419" left="635" width="204" height="19" font="0">19/25 (76%) with abnormal echo </text>
<text top="437" left="635" width="194" height="19" font="0">also had abnormal MR; in 13 of </text>
<text top="455" left="635" width="210" height="19" font="0">them (52%) the MR provided new </text>
<text top="474" left="635" width="188" height="19" font="0">“clinically relevant” findings: 8 </text>
<text top="492" left="635" width="142" height="19" font="0">DCM, 1 cardiac sarcoid<b> </b></text>
<text top="308" left="864" width="229" height="20" font="0">• CMR detects subclinical CMP in 1/3 </text>
<text top="327" left="875" width="232" height="19" font="0">of asx pts with LBBB and normal echo </text>
<text top="346" left="864" width="218" height="20" font="0">• CMR provides additional clinically </text>
<text top="365" left="875" width="197" height="19" font="0">relevant data in over 50% of pts </text>
<text top="383" left="864" width="232" height="20" font="0">• CMR is valuable adjuvant diagnostic </text>
<text top="402" left="875" width="156" height="19" font="0">tool for pt with asx LBBB  </text>
<text top="511" left="96" width="108" height="19" font="0">Brignole M, et al. </text>
<text top="529" left="96" width="69" height="19" font="0">2001 (185) </text>
<text top="548" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11673344">11673344</a></text>
<text top="548" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11673344"> </a></text>
<text top="566" left="96" width="3" height="19" font="0"> </text>
<text top="511" left="230" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="529" left="230" width="89" height="19" font="0">Observational </text>
<text top="548" left="230" width="3" height="19" font="0"> </text>
<text top="566" left="230" width="73" height="19" font="8"><b>Size:</b> 52 pts<b> </b></text>
<text top="511" left="439" width="166" height="19" font="8"><b>Inclusion criteria:</b> BBB and </text>
<text top="529" left="439" width="138" height="19" font="0">negative conventional </text>
<text top="548" left="439" width="50" height="19" font="0">workup </text>
<text top="566" left="439" width="7" height="19" font="0"> <b> </b></text>
<text top="512" left="635" width="201" height="19" font="8"><b>1</b>°<b> endpoint:</b> Rhythm at syncope </text>
<text top="530" left="635" width="183" height="19" font="0">recurrence as assessed by ILR </text>
<text top="549" left="635" width="3" height="19" font="0"> </text>
<text top="567" left="635" width="134" height="19" font="8"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="511" left="864" width="241" height="19" font="0">In pts with BBB and negative EPS, most </text>
<text top="529" left="864" width="204" height="19" font="0">syncopal recurrences result from </text>
<text top="548" left="864" width="215" height="19" font="0">prolonged asystolic pauses, mainly </text>
<text top="566" left="864" width="198" height="19" font="0">attributable to paroxysmal AVB. </text>
<text top="586" left="96" width="88" height="19" font="0">Moya A, et al. </text>
<text top="604" left="96" width="69" height="19" font="0">2011 (189) </text>
<text top="623" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21444367">21444367</a></text>
<text top="623" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21444367"> </a></text>
<text top="586" left="230" width="169" height="19" font="8"><b>Aim:</b> To analyze the clinical </text>
<text top="604" left="230" width="186" height="19" font="0">outcomes of pts with syncope </text>
<text top="623" left="229" width="193" height="19" font="0">and BBB following a systematic </text>
<text top="641" left="229" width="186" height="19" font="0">diagnostic approach: 3-phase: </text>
<text top="659" left="229" width="167" height="19" font="0">clinical evaluation, EPS, ILR </text>
<text top="677" left="230" width="3" height="19" font="0"> </text>
<text top="696" left="230" width="165" height="19" font="8"><b>Study type:</b> Multicentered </text>
<text top="714" left="230" width="189" height="19" font="0">prospective observational trial </text>
<text top="732" left="230" width="3" height="19" font="0"> </text>
<text top="751" left="230" width="149" height="19" font="8"><b>Size:</b> 323 patients (after </text>
<text top="769" left="230" width="71" height="19" font="0">exclusions)<b> </b></text>
<text top="586" left="439" width="130" height="19" font="8"><b>Inclusion criteria:</b> ≥1 </text>
<text top="604" left="439" width="181" height="19" font="0">syncope in the last 6 mo. and </text>
<text top="623" left="439" width="170" height="19" font="0">BBB on EGG with a QRSd of </text>
<text top="641" left="439" width="55" height="19" font="0">≥120 ms </text>
<text top="659" left="439" width="178" height="19" font="8"><b>Exclusion criteria</b>: Indication </text>
<text top="677" left="439" width="167" height="19" font="0">for prophylactic ICD due to </text>
<text top="696" left="439" width="29" height="19" font="0">low  </text>
<text top="714" left="439" width="180" height="19" font="0">LVEF; pre-excitation; long QT </text>
<text top="732" left="439" width="122" height="19" font="0">syndrome; Brugada </text>
<text top="751" left="439" width="130" height="19" font="0">syndrome; acute MI; </text>
<text top="769" left="439" width="166" height="19" font="0">pregnancy; life expectancy </text>
<text top="587" left="635" width="147" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical Dx </text>
<text top="605" left="635" width="172" height="19" font="0">(established in 267 patients </text>
<text top="623" left="635" width="50" height="19" font="0">(82.7%) </text>
<text top="642" left="635" width="216" height="19" font="0">-recurrent syncope: in 15/215 (7%) </text>
<text top="660" left="635" width="162" height="19" font="0">after phase 1/2; 36 of 108 </text>
<text top="678" left="635" width="117" height="19" font="0">(33% after phase 3 </text>
<text top="697" left="635" width="168" height="19" font="0">-documented spontaneous </text>
<text top="715" left="635" width="77" height="19" font="0">arrhythmias </text>
<text top="733" left="635" width="173" height="19" font="0">-death due to any cause: no </text>
<text top="752" left="635" width="168" height="19" font="0">difference in mortality rate </text>
<text top="586" left="864" width="7" height="18" font="0">•</text>
<text top="587" left="871" width="3" height="19" font="15"> </text>
<text top="587" left="875" width="183" height="19" font="0">In pts with syncope, BBB, and </text>
<text top="605" left="875" width="180" height="19" font="0">preserved LVEF, a systematic </text>
<text top="623" left="875" width="218" height="19" font="0">diagnostic strategy (ESC guidelines) </text>
<text top="642" left="875" width="209" height="19" font="0">achieves a high rate of Dx (82.6%) </text>
<text top="660" left="875" width="205" height="19" font="0">with a low rate of mortality (6%), </text>
<text top="678" left="875" width="184" height="19" font="0">allowing clinicians to institute </text>
<text top="697" left="875" width="172" height="19" font="0">etiology-specific treatment. </text>
<text top="715" left="864" width="7" height="18" font="0">•</text>
<text top="716" left="871" width="3" height="19" font="15"> </text>
<text top="716" left="875" width="225" height="19" font="0">The most common cause of syncope </text>
<text top="734" left="875" width="225" height="19" font="0">was bradyarrhythmia, mostly due to </text>
<text top="752" left="875" width="177" height="19" font="0">paroxysmal A-V block. Other </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 182 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="439" width="142" height="19" font="0">&lt;1 y due to noncardiac </text>
<text top="105" left="439" width="150" height="19" font="0">cause; geographically or </text>
<text top="123" left="439" width="162" height="19" font="0">otherwise inaccessible for </text>
<text top="142" left="439" width="141" height="19" font="0">follow-up; unwilling or </text>
<text top="160" left="439" width="149" height="19" font="0">unable to give informed </text>
<text top="178" left="439" width="55" height="19" font="0">consent <b> </b></text>
<text top="87" left="635" width="208" height="19" font="0">between pts diagnosed at Phase I </text>
<text top="105" left="635" width="31" height="19" font="0">or II, </text>
<text top="123" left="635" width="190" height="19" font="0">compared with those who had </text>
<text top="142" left="635" width="172" height="19" font="0">implanted ILR (6.0 vs. 6.5%) </text>
<text top="160" left="635" width="3" height="19" font="0"> </text>
<text top="178" left="635" width="134" height="19" font="8"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="87" left="875" width="166" height="19" font="0">etiologies of syncope were </text>
<text top="105" left="875" width="125" height="19" font="0">recognized in 17.6% </text>
<text top="124" left="864" width="7" height="18" font="0">•</text>
<text top="124" left="871" width="3" height="19" font="15"> </text>
<text top="124" left="875" width="218" height="19" font="0">initial clinical evaluation achieved a </text>
<text top="143" left="875" width="217" height="19" font="0">Dx in 25%; the most frequent Dx at </text>
<text top="161" left="875" width="231" height="19" font="0">EPS was a bradyarrhythmia (76%), VT </text>
<text top="179" left="875" width="170" height="19" font="0">or SVT was induced in 14%. </text>
<text top="198" left="864" width="7" height="18" font="0">•</text>
<text top="198" left="871" width="3" height="19" font="15"> </text>
<text top="198" left="875" width="189" height="19" font="0">The study was not designed to </text>
<text top="217" left="877" width="213" height="19" font="0">determine whether this diagnostic </text>
<text top="235" left="877" width="222" height="19" font="0">strategy was better than implanting </text>
<text top="253" left="877" width="166" height="19" font="0">a PM in the majority of pts </text>
<text top="272" left="96" width="117" height="19" font="0">McAnulty JH, et al. </text>
<text top="291" left="96" width="69" height="19" font="0">1982 (278) </text>
<text top="309" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7088050">7088050</a></text>
<text top="309" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7088050"> </a></text>
<text top="272" left="230" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="291" left="230" width="89" height="19" font="0">Observational<b> </b></text>
<text top="309" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="327" left="230" width="80" height="19" font="8"><b>Size: </b>554 pts </text>
<text top="346" left="230" width="192" height="19" font="0">351 had EPS and 203 refused it<b> </b></text>
<text top="272" left="439" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="291" left="439" width="164" height="19" font="0">Bifascicular or trifascicular </text>
<text top="309" left="439" width="36" height="19" font="0">block<b> </b></text>
<text top="327" left="439" width="3" height="19" font="8"><b> </b></text>
<text top="345" left="439" width="171" height="19" font="8"><b>Exclusion criteria: </b>Terminal </text>
<text top="364" left="439" width="128" height="19" font="0">non-cardiac disease; </text>
<text top="382" left="439" width="115" height="19" font="0">symptoms already </text>
<text top="401" left="439" width="141" height="19" font="0">documented as due to </text>
<text top="419" left="439" width="162" height="19" font="0">bradycardia prior to study<b> </b></text>
<text top="437" left="439" width="3" height="19" font="0"> </text>
<text top="455" left="439" width="3" height="19" font="0"> </text>
<text top="474" left="439" width="3" height="19" font="0"> </text>
<text top="492" left="439" width="3" height="19" font="0"> </text>
<text top="273" left="635" width="214" height="19" font="8"><b>1</b>°<b> endpoint:</b> Major clinical events, </text>
<text top="291" left="635" width="209" height="19" font="0">death, heart block, need for PPM, </text>
<text top="310" left="635" width="54" height="19" font="0">syncope </text>
<text top="328" left="689" width="3" height="19" font="8"><b> </b></text>
<text top="346" left="635" width="134" height="19" font="8"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="273" left="863" width="209" height="20" font="0">•  A higher percentage of pts with </text>
<text top="291" left="877" width="229" height="19" font="0">syncope were shown to develop CHB </text>
<text top="310" left="877" width="211" height="19" font="0">(17%) vs. those w/o syncope (2%)<b>  </b></text>
<text top="328" left="863" width="208" height="20" font="0">•  Heart block occurred in 4.9% of </text>
<text top="347" left="877" width="201" height="19" font="0">those with long HV compared to </text>
<text top="366" left="877" width="132" height="19" font="0">1.9% with normal HV<b> </b></text>
<text top="384" left="863" width="220" height="20" font="0">•  A prolonged PR interval (found in </text>
<text top="403" left="877" width="185" height="19" font="0">13%) was associated with and </text>
<text top="421" left="877" width="211" height="19" font="0">increased risk of all death, sudden </text>
<text top="440" left="877" width="211" height="19" font="0">death, major clinical events or HF, </text>
<text top="458" left="877" width="225" height="19" font="0">but not development of heart block. </text>
<text top="476" left="863" width="237" height="20" font="0">•  Bundle branch block occurs in 1% of </text>
<text top="495" left="877" width="218" height="19" font="0">population, and requires no special </text>
<text top="514" left="877" width="127" height="19" font="0">evaluation in asx pts </text>
<text top="533" left="96" width="92" height="19" font="0">Kwok CS, et al. </text>
<text top="551" left="96" width="69" height="19" font="0">2016 (279) </text>
<text top="569" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26879241">26879241</a></text>
<text top="569" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26879241"> </a></text>
<text top="533" left="230" width="179" height="19" font="8"><b>Aim: </b>Determine if prolonged </text>
<text top="551" left="230" width="180" height="19" font="0">PR interval is associated with </text>
<text top="569" left="230" width="161" height="19" font="0">adverse CV outcomes and </text>
<text top="588" left="230" width="63" height="19" font="0">mortality.<b> </b></text>
<text top="606" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="624" left="230" width="187" height="19" font="8"><b>Study type: </b>Systemic review + </text>
<text top="643" left="230" width="87" height="19" font="0">meta-analysis<b> </b></text>
<text top="661" left="230" width="3" height="19" font="8"><b> </b></text>
<text top="679" left="230" width="176" height="19" font="8"><b>Size: 1</b>4 studies, 400,750 pts<b> </b></text>
<text top="533" left="439" width="159" height="19" font="8"><b>Inclusion criteria: </b>Studies </text>
<text top="551" left="439" width="137" height="19" font="0">that evaluated clinical </text>
<text top="569" left="439" width="162" height="19" font="0">outcomes associated with </text>
<text top="588" left="439" width="159" height="19" font="0">prolonged and normal PR </text>
<text top="606" left="439" width="56" height="19" font="0">intervals </text>
<text top="624" left="439" width="3" height="19" font="0"> </text>
<text top="642" left="439" width="183" height="19" font="8"><b>Exclusion criteria: </b>From main </text>
<text top="661" left="439" width="172" height="19" font="0">analysis:<b> </b>Studies of pts with </text>
<text top="679" left="439" width="170" height="19" font="0">specific cardiac pathologies </text>
<text top="697" left="439" width="147" height="19" font="0">(such as AS, sinus nodal </text>
<text top="716" left="439" width="180" height="19" font="0">dysfunction and HF) or of pts </text>
<text top="734" left="439" width="112" height="19" font="0">who had received </text>
<text top="752" left="439" width="179" height="19" font="0">intervention (angiography or </text>
<text top="771" left="439" width="35" height="19" font="0">CRT) <b> </b></text>
<text top="533" left="635" width="141" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality </text>
<text top="552" left="635" width="3" height="19" font="0"> </text>
<text top="570" left="635" width="215" height="19" font="8"><b>Results:</b> Increased risk of mortality </text>
<text top="588" left="635" width="190" height="19" font="0">with prolonged PR interval risk </text>
<text top="607" left="635" width="211" height="19" font="0">ratio (RR: 1.24; 95% CI: 1.02–1.51, </text>
<text top="625" left="635" width="65" height="19" font="0">5 studies.  </text>
<text top="643" left="635" width="162" height="19" font="0">Prolonged PR interval was </text>
<text top="662" left="635" width="204" height="19" font="0">associated with significant risk of </text>
<text top="680" left="635" width="192" height="19" font="0">HF or LV dysfunction (RR: 1.39; </text>
<text top="698" left="634" width="205" height="19" font="0">95% CI: 1.18–1.65, 3 studies) and </text>
<text top="717" left="634" width="209" height="19" font="0">AF (RR: 1.45; 95% CI: 1.23–1.71, 8 </text>
<text top="735" left="634" width="183" height="19" font="0">studies) but not CV mortality, </text>
<text top="753" left="634" width="196" height="19" font="0">coronary heart disease or MI or </text>
<text top="771" left="635" width="89" height="19" font="0">stroke or TIA.<b>  </b></text>
<text top="533" left="864" width="192" height="20" font="0">•<b> </b>Possible association between </text>
<text top="552" left="875" width="227" height="19" font="0">prolonged PR interval and significant </text>
<text top="570" left="875" width="210" height="19" font="0">increases in AF, HF and mortality. <b> </b></text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 183 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="97" height="19" font="0">Boriani G, et al. </text>
<text top="105" left="96" width="30" height="19" font="0">2003</text>
<text top="104" left="127" width="4" height="21" font="4"> </text>
<text top="105" left="130" width="35" height="19" font="0">(280) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12649505">12649505</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12649505"> </a></text>
<text top="87" left="230" width="181" height="19" font="8"><b>Size:</b> 18 pts (age 42.8±19.6 y) </text>
<text top="105" left="230" width="178" height="19" font="0">with genetically confirmed X-</text>
<text top="123" left="230" width="169" height="19" font="0">linked (N=10) or autosomal </text>
<text top="142" left="230" width="142" height="19" font="0">dominant (N=8) EDMD </text>
<text top="87" left="439" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="105" left="439" width="3" height="19" font="0"> </text>
<text top="123" left="439" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="635" width="163" height="19" font="8"><b>Results:</b> Pacemakers were </text>
<text top="105" left="635" width="209" height="19" font="0">required by 10 of 18 (56%) pts for </text>
<text top="123" left="635" width="106" height="19" font="0">bradyarrhythmia </text>
<text top="88" left="864" width="243" height="19" font="0"> •<b> </b>&gt;50% of pts with muscular dystrophy </text>
<text top="106" left="875" width="177" height="19" font="0">(EDMD) require PM implant. </text>
<text top="124" left="864" width="211" height="20" font="0">•<b> </b>Survival after PM implant is very </text>
<text top="143" left="875" width="71" height="19" font="0">reasonable </text>
<text top="162" left="96" width="96" height="19" font="0">Mymin D, et al. </text>
<text top="181" left="96" width="30" height="19" font="0">1986</text>
<text top="179" left="127" width="4" height="21" font="4"> </text>
<text top="181" left="130" width="35" height="19" font="0">(281) </text>
<text top="199" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3762641">3762641</a></text>
<text top="199" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3762641"> </a></text>
<text top="162" left="230" width="157" height="19" font="8"><b>Study type:</b> Longitudinal, </text>
<text top="181" left="230" width="92" height="19" font="0">Observational  </text>
<text top="199" left="230" width="3" height="19" font="0"> </text>
<text top="217" left="230" width="145" height="19" font="8"><b>Size:</b> 3983 healthy men<b> </b></text>
<text top="162" left="439" width="162" height="19" font="8"><b>Inclusion criteria:</b> Healthy </text>
<text top="181" left="439" width="39" height="19" font="0">males </text>
<text top="199" left="439" width="3" height="19" font="0"> </text>
<text top="217" left="439" width="167" height="19" font="8"><b>Exclusion criteria:</b> Females<b> </b></text>
<text top="163" left="635" width="123" height="19" font="8"><b>1</b>°<b> endpoint:</b> 1°AVB </text>
<text top="182" left="635" width="3" height="19" font="0"> </text>
<text top="200" left="635" width="199" height="19" font="8"><b>Results:</b> 52 initial cases plus 124 </text>
<text top="218" left="635" width="216" height="19" font="0">new cases over 30 y. No difference </text>
<text top="237" left="635" width="131" height="19" font="0">in all-cause mortality<b> </b></text>
<text top="163" left="864" width="241" height="20" font="0">• Primary first-degree heart block with </text>
<text top="182" left="877" width="188" height="19" font="0">moderate PR prolongation is a </text>
<text top="200" left="877" width="106" height="19" font="0">benign condition </text>
<text top="218" left="864" width="205" height="20" font="0">• may not apply to more marked </text>
<text top="237" left="877" width="191" height="19" font="0">prolongation of the PR interval </text>
<text top="256" left="96" width="94" height="19" font="0">Huhta JC, et al. </text>
<text top="275" left="96" width="69" height="19" font="0">1983 (282) </text>
<text top="293" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6851033">6851033</a></text>
<text top="293" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6851033"> </a></text>
<text top="256" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="275" left="230" width="45" height="19" font="0">review </text>
<text top="256" left="439" width="120" height="19" font="0">107 pts with ccTGA </text>
<text top="256" left="635" width="167" height="19" font="0">23 of 107 (21%) developed </text>
<text top="275" left="635" width="201" height="19" font="0">naturally occurring AVB at a rate </text>
<text top="293" left="635" width="172" height="19" font="0">of 2% per yr. 12 of 49 (24%) </text>
<text top="311" left="635" width="191" height="19" font="0">developed AVB at VSD closure. </text>
<text top="257" left="864" width="239" height="20" font="0">• Pts with ccTGA are at a constant and </text>
<text top="275" left="877" width="228" height="19" font="0">elevated risk of developing complete </text>
<text top="294" left="877" width="168" height="19" font="0">AVB throughout their lives. </text>
<text top="330" left="96" width="117" height="19" font="0">Connelly MS, et al. </text>
<text top="349" left="96" width="69" height="19" font="0">1996 (283) </text>
<text top="367" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8609349">8609349</a></text>
<text top="367" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8609349"> </a></text>
<text top="330" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="349" left="230" width="45" height="19" font="0">review<b> </b></text>
<text top="330" left="439" width="113" height="19" font="0">52 pts with ccTGA </text>
<text top="330" left="635" width="164" height="19" font="0">9 or 52 (17.3%) developed </text>
<text top="349" left="635" width="210" height="19" font="0">spontaneous AVB; 9 of 52 (17.3%) </text>
<text top="367" left="635" width="185" height="19" font="0">developed postoperative AVB </text>
<text top="331" left="864" width="221" height="20" font="0">• 17% of pts developed progressive </text>
<text top="349" left="877" width="157" height="19" font="0">AVB unrelated to surgery </text>
<text top="386" left="96" width="105" height="19" font="0">Weindling SN, et </text>
<text top="404" left="96" width="87" height="19" font="0">al.<i> </i>1998 (284) </text>
<text top="423" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9723647">9723647</a></text>
<text top="423" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9723647"> </a></text>
<text top="386" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="404" left="230" width="45" height="19" font="0">review </text>
<text top="386" left="439" width="160" height="19" font="0">54 pts with postoperative </text>
<text top="404" left="439" width="132" height="19" font="0">heart block following </text>
<text top="423" left="439" width="152" height="19" font="0">congenital heart surgery </text>
<text top="386" left="635" width="191" height="19" font="0">31 of 32 pts who recovered AV </text>
<text top="404" left="635" width="161" height="19" font="0">conduction did so by the 9</text>
<text top="404" left="796" width="8" height="12" font="7">th</text>
<text top="404" left="804" width="3" height="19" font="0"> </text>
<text top="423" left="635" width="118" height="19" font="0">postoperative day. </text>
<text top="386" left="864" width="210" height="20" font="0">• 43% did not recover conduction </text>
<text top="405" left="864" width="190" height="20" font="0">• 97% of those who recovered </text>
<text top="424" left="877" width="163" height="19" font="0">conduction – did so by d 9 </text>
<text top="443" left="96" width="96" height="19" font="0">Meune C, et al. </text>
<text top="461" left="96" width="34" height="20" font="6"><i>2</i>006.</text>
<text top="460" left="131" width="4" height="21" font="4"> </text>
<text top="462" left="134" width="35" height="19" font="0">(285) </text>
<text top="480" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16407522">16407522</a></text>
<text top="480" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16407522"> </a></text>
<text top="443" left="230" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="462" left="230" width="87" height="19" font="0">observational </text>
<text top="443" left="439" width="121" height="19" font="0">19 pts with lamin A </text>
<text top="462" left="439" width="141" height="19" font="0">mutations referred for </text>
<text top="480" left="439" width="171" height="19" font="0">pacing and receiving an ICD </text>
<text top="443" left="635" width="146" height="19" font="0">9 pts (46%) received an </text>
<text top="462" left="635" width="204" height="19" font="0">appropriate shock for ventricular </text>
<text top="480" left="635" width="110" height="19" font="0">tachyarrhythmias </text>
<text top="444" left="864" width="224" height="20" font="0">• The implantation of an ICD, rather </text>
<text top="462" left="877" width="225" height="19" font="0">than a PM, should be considered for </text>
<text top="481" left="877" width="59" height="19" font="0">these pts </text>
<text top="500" left="96" width="107" height="19" font="0">van Rijsingen, IA, </text>
<text top="518" left="96" width="68" height="19" font="0">et al. 2012.</text>
<text top="517" left="164" width="4" height="21" font="4"> </text>
<text top="518" left="168" width="35" height="19" font="0">(286) </text>
<text top="536" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22281253">22281253</a></text>
<text top="536" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22281253"> </a></text>
<text top="500" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="518" left="230" width="134" height="19" font="0">multicentered cohort </text>
<text top="500" left="439" width="120" height="19" font="0">269 pts with LMNA </text>
<text top="518" left="439" width="66" height="19" font="0">mutations </text>
<text top="500" left="635" width="212" height="19" font="0">Malignant ventricular arrhythmias </text>
<text top="518" left="635" width="207" height="19" font="0">occurred (5%/y) in pts with ≥2 of: </text>
<text top="536" left="635" width="176" height="19" font="0">NSVT, LVEF &lt;45% at the first </text>
<text top="555" left="635" width="213" height="19" font="0">clinical contact, male sex, and non-</text>
<text top="573" left="635" width="125" height="19" font="0">missense mutations </text>
<text top="500" left="864" width="238" height="20" font="0">• Specific risk factors portend a higher </text>
<text top="519" left="877" width="196" height="19" font="0">risk of ventricular arrhythmia in </text>
<text top="537" left="877" width="175" height="19" font="0">carriers of LMNA mutations  </text>
<text top="592" left="96" width="92" height="19" font="0">Maury P, et al. </text>
<text top="610" left="96" width="34" height="19" font="0">2013.</text>
<text top="609" left="131" width="4" height="21" font="4"> </text>
<text top="610" left="134" width="35" height="19" font="0">(287) </text>
<text top="629" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24011739">24011739</a></text>
<text top="629" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24011739"> </a></text>
<text top="592" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="610" left="230" width="45" height="19" font="0">review </text>
<text top="592" left="439" width="48" height="19" font="0">325 pts </text>
<text top="592" left="635" width="132" height="19" font="0">First degree AVB was </text>
<text top="610" left="635" width="190" height="19" font="0">independently associated with </text>
<text top="629" left="635" width="180" height="19" font="0">sudden death or implantable </text>
<text top="647" left="635" width="155" height="19" font="0">cardioverter-defibrillator </text>
<text top="665" left="635" width="208" height="19" font="0">appropriated therapies (OR: 2.41; </text>
<text top="684" left="635" width="174" height="19" font="0">95% CI: 1.01–0.73; p=0.046) </text>
<text top="592" left="864" width="222" height="20" font="0">• First degree AVB is independently </text>
<text top="611" left="877" width="189" height="19" font="0">linked to outcome and may be </text>
<text top="630" left="877" width="213" height="19" font="0">proposed to be used for individual </text>
<text top="648" left="877" width="106" height="19" font="0">risk stratification </text>
<text top="703" left="96" width="98" height="19" font="0">O'Mahony C, et </text>
<text top="721" left="96" width="52" height="19" font="0">al. 2011.</text>
<text top="720" left="148" width="4" height="21" font="4"> </text>
<text top="721" left="152" width="35" height="19" font="0">(288)<b> </b></text>
<text top="739" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21856674">21856674</a></text>
<text top="739" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21856674"> </a></text>
<text top="703" left="230" width="167" height="19" font="8"><b>Study type: </b>Observational, </text>
<text top="721" left="230" width="164" height="19" font="0">longitudinal, retrospective </text>
<text top="739" left="230" width="81" height="19" font="0">cohort study </text>
<text top="703" left="439" width="140" height="19" font="0">204 pts; 12 had device </text>
<text top="721" left="439" width="176" height="19" font="0">implant during follow-up for </text>
<text top="739" left="439" width="112" height="19" font="0">bradyarrhythmias </text>
<text top="703" left="635" width="205" height="19" font="0">Independent predictors of future </text>
<text top="721" left="635" width="207" height="19" font="0">antibradycardia pacing were (in a </text>
<text top="739" left="635" width="197" height="19" font="0">multivariable Cox model): QRSd </text>
<text top="758" left="635" width="155" height="19" font="0">and PR interval duration  </text>
<text top="703" left="863" width="242" height="20" font="0">•  Pacing for AV and sinus node disease </text>
<text top="722" left="877" width="108" height="19" font="0">is common (±8%) </text>
<text top="740" left="863" width="212" height="20" font="0">•  Pts with QRS ≥110 ms should be </text>
<text top="759" left="877" width="134" height="19" font="0">closely monitored for </text>
<text top="778" left="877" width="112" height="19" font="0">bradyarrhythmias </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 184 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="92" height="19" font="0">Polak PE, et al. </text>
<text top="105" left="96" width="69" height="19" font="0">1989 (289) </text>
<text top="123" left="96" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2707275">2707275</a></text>
<text top="123" left="149" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2707275"> </a></text>
<text top="87" left="230" width="145" height="19" font="8"><b>Study type: </b>Case series </text>
<text top="87" left="439" width="33" height="19" font="0">2 pts </text>
<text top="87" left="635" width="149" height="19" font="0">Pts with fascicular block </text>
<text top="105" left="635" width="183" height="19" font="0">progressed to PM-dependent </text>
<text top="123" left="635" width="97" height="19" font="0">complete block </text>
<text top="87" left="864" width="38" height="20" font="0">• N/A </text>
<text top="143" left="96" width="118" height="19" font="0">Khambatta S, et al. </text>
<text top="161" left="96" width="30" height="19" font="0">2014</text>
<text top="159" left="127" width="4" height="21" font="4"> </text>
<text top="161" left="130" width="35" height="19" font="0">(290) </text>
<text top="179" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25061332">25061332</a></text>
<text top="179" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25061332"> </a></text>
<text top="142" left="230" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="161" left="230" width="45" height="19" font="0">review </text>
<text top="143" left="439" width="41" height="19" font="0">35 pts </text>
<text top="143" left="635" width="204" height="19" font="0">PM/ICD required in 31 % (11 pts) </text>
<text top="161" left="635" width="207" height="19" font="0">4 pts (11%) in the series died, but </text>
<text top="179" left="635" width="178" height="19" font="0">all deaths were from sudden </text>
<text top="197" left="635" width="95" height="19" font="0">cardiac events. </text>
<text top="143" left="864" width="243" height="20" font="0">• High incidence of device implantation </text>
<text top="162" left="875" width="167" height="19" font="0">implant and sudden death  </text>
<text top="180" left="864" width="3" height="19" font="0"> </text>
<text top="217" left="96" width="100" height="19" font="0">Ali H, et al. 2017</text>
<text top="215" left="196" width="4" height="21" font="4"> </text>
<text top="235" left="96" width="35" height="19" font="0">(291) </text>
<text top="253" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28583850">28583850</a></text>
<text top="253" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28583850"> </a></text>
<text top="216" left="230" width="337" height="19" font="8"><b>Study type: </b>Systematic Review  Case reports on CHB </text>
<text top="235" left="439" width="181" height="19" font="0">following blunt cardiac injury </text>
<text top="253" left="439" width="154" height="19" font="0">were available for 50 pts </text>
<text top="217" left="635" width="215" height="19" font="0">PPM implantation was indicated in </text>
<text top="235" left="635" width="201" height="20" font="0">∼50% of early survivors because </text>
<text top="253" left="634" width="198" height="19" font="0">of recurrent or permanent CHB. </text>
<text top="272" left="635" width="195" height="19" font="0">BBB was present in &gt;70% of pts </text>
<text top="290" left="634" width="202" height="19" font="0">A fatal outcome occurred in 20% </text>
<text top="308" left="634" width="193" height="19" font="0">of pts; structural damage of AV </text>
<text top="326" left="634" width="178" height="19" font="0">conduction system in 50% of </text>
<text top="345" left="634" width="69" height="19" font="0">necropsies </text>
<text top="217" left="864" width="206" height="20" font="0">• CHB secondary to blunt cardiac </text>
<text top="236" left="877" width="178" height="19" font="0">injury is associated with 20% </text>
<text top="254" left="877" width="203" height="19" font="0">mortality mainly occurring in the </text>
<text top="272" left="877" width="197" height="19" font="0">early post-traumatic period and </text>
<text top="291" left="877" width="185" height="19" font="0">most of the deaths are due to </text>
<text top="309" left="877" width="78" height="19" font="0">arrhythmia.  </text>
<text top="327" left="864" width="193" height="20" font="0">• Recurrent or permanent CHB </text>
<text top="346" left="877" width="222" height="19" font="0">requiring PM implantation occurs in </text>
<text top="365" left="877" width="121" height="20" font="0">∼50% of survivors.  </text>
<text top="383" left="864" width="199" height="20" font="0">• A structural damage of the AV </text>
<text top="402" left="877" width="215" height="19" font="0">conductive system can be found in </text>
<text top="420" left="877" width="92" height="19" font="0">50% of victims </text>
<text top="439" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="460" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="480" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="502" left="100" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="521" left="131" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="539" left="104" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="502" left="246" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="521" left="251" width="77" height="19" font="8"><b>Study Type; </b></text>
<text top="539" left="245" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="502" left="389" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="502" left="552" width="123" height="19" font="8"><b>Study Intervention  </b></text>
<text top="521" left="570" width="88" height="19" font="8"><b>(# patients) /  </b></text>
<text top="539" left="554" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="557" left="575" width="75" height="19" font="8"><b>(# patients) </b></text>
<text top="502" left="731" width="108" height="19" font="8"><b>Endpoint Results </b></text>
<text top="521" left="713" width="148" height="19" font="8"><b>(Absolute Event Rates,  </b></text>
<text top="539" left="717" width="136" height="19" font="8"><b>P values; OR or RR; &amp; </b></text>
<text top="557" left="760" width="50" height="19" font="8"><b>95% CI) </b></text>
<text top="503" left="898" width="186" height="19" font="8"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="521" left="933" width="116" height="19" font="8"><b>Study Limitations; </b></text>
<text top="540" left="941" width="99" height="19" font="8"><b>Adverse Events </b></text>
<text top="576" left="95" width="100" height="19" font="0">Chierichini A, et </text>
<text top="595" left="95" width="87" height="19" font="0">al. 2015 (292) </text>
<text top="613" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25953222">25953222</a></text>
<text top="613" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25953222"> </a></text>
<text top="631" left="95" width="7" height="19" font="0">  </text>
<text top="576" left="221" width="137" height="19" font="8"><b>Aim:</b> Evaluate the use </text>
<text top="595" left="221" width="106" height="19" font="0">of irrigation fluid </text>
<text top="613" left="221" width="134" height="19" font="0">using norepinephrine </text>
<text top="631" left="221" width="131" height="19" font="0">or epinephrine in pts </text>
<text top="650" left="221" width="73" height="19" font="0">undergoing </text>
<text top="668" left="221" width="98" height="19" font="0">arthroscopy for </text>
<text top="686" left="221" width="123" height="19" font="0">rotator cuff surgery </text>
<text top="705" left="221" width="3" height="19" font="0"> </text>
<text top="723" left="221" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="741" left="221" width="75" height="19" font="0">Prospective </text>
<text top="760" left="221" width="122" height="19" font="0">randomized double </text>
<text top="778" left="221" width="137" height="19" font="0">blind controlled study </text>
<text top="576" left="371" width="139" height="19" font="8"><b>Inclusion criteria:</b> ASA </text>
<text top="595" left="371" width="123" height="19" font="0">status 1 or 2, &gt;18 y, </text>
<text top="613" left="371" width="134" height="19" font="0">scheduled for rotator </text>
<text top="631" left="371" width="106" height="19" font="0">cuff surgery with </text>
<text top="650" left="371" width="130" height="19" font="0">interscalene brachial </text>
<text top="668" left="371" width="78" height="19" font="0">plexus block </text>
<text top="686" left="371" width="3" height="19" font="0"> </text>
<text top="705" left="371" width="146" height="19" font="8"><b>Exclusion criteria:</b> CAD, </text>
<text top="723" left="371" width="119" height="19" font="0">cardiac conduction </text>
<text top="741" left="371" width="127" height="19" font="0">defects, BB or ACEI<b>:</b>  </text>
<text top="576" left="540" width="85" height="19" font="8"><b>Intervention:</b> </text>
<text top="595" left="540" width="135" height="19" font="0">Norepinephrine (0.66 </text>
<text top="613" left="540" width="139" height="19" font="0">mg/L) to the irrigation </text>
<text top="631" left="540" width="26" height="19" font="0">bag </text>
<text top="650" left="540" width="7" height="19" font="0">  </text>
<text top="668" left="540" width="83" height="19" font="8"><b>Comparator:</b> </text>
<text top="686" left="540" width="112" height="19" font="0">Epinephrine (0.33 </text>
<text top="705" left="540" width="139" height="19" font="0">mg/L) to the irrigation </text>
<text top="723" left="540" width="26" height="19" font="0">bag<b> </b></text>
<text top="577" left="697" width="167" height="19" font="8"><b>1</b>°<b> endpoint:</b> Development </text>
<text top="596" left="697" width="112" height="19" font="0">of hypotension or </text>
<text top="614" left="697" width="171" height="19" font="0">bradycardia (&lt;30 bpm in ≤5 </text>
<text top="632" left="697" width="104" height="19" font="0">min or &lt;50 bpm  </text>
<text top="650" left="697" width="3" height="19" font="0"> </text>
<text top="669" left="697" width="151" height="19" font="8"><b>Safety endpoint:</b> Timing </text>
<text top="687" left="697" width="126" height="19" font="0">and safety of events<b> </b></text>
<text top="577" left="884" width="138" height="20" font="0">• Hypotension and/or </text>
<text top="596" left="897" width="76" height="19" font="0">bradycardia </text>
<text top="619" left="897" width="9" height="12" font="0">o</text>
<text top="617" left="906" width="4" height="14" font="0"> </text>
<text top="614" left="925" width="87" height="19" font="0">NE: 5/60 (8%) </text>
<text top="637" left="897" width="9" height="12" font="0">o</text>
<text top="636" left="906" width="4" height="14" font="0"> </text>
<text top="632" left="925" width="93" height="19" font="0">E: 15/59 (25%) </text>
<text top="651" left="884" width="193" height="20" font="0">• Did not separate bradycardia </text>
<text top="670" left="897" width="44" height="19" font="0">events </text>
<text top="688" left="884" width="178" height="20" font="0">• Timing similar (30–35 min) </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 185 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="221" width="3" height="19" font="0"> </text>
<text top="105" left="221" width="80" height="19" font="8"><b>Size:</b> 120 pts </text>
<text top="173" left="86" width="4" height="21" font="4"> </text>
<text top="193" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="215" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="238" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="256" left="137" width="51" height="19" font="8"><b>Author; </b></text>
<text top="274" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="238" left="263" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="256" left="292" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="238" left="447" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="238" left="666" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="256" left="696" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="274" left="728" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="238" left="942" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="256" left="971" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="294" left="93" width="124" height="19" font="0">Marrocco-Trischitta </text>
<text top="312" left="93" width="136" height="19" font="0">MM, et al. 2016 (293) </text>
<text top="330" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27177706">27177706</a></text>
<text top="330" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27177706"> </a></text>
<text top="294" left="244" width="129" height="19" font="8"><b>Aim:</b> Evaluate use of </text>
<text top="312" left="244" width="147" height="19" font="0">temporary transvenous </text>
<text top="330" left="244" width="160" height="19" font="0">pacing (TTVP) for pts with </text>
<text top="349" left="244" width="110" height="19" font="0">trifascicular block </text>
<text top="367" left="244" width="100" height="19" font="0">undergoing CEA </text>
<text top="385" left="244" width="3" height="19" font="0"> </text>
<text top="403" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="422" left="244" width="143" height="19" font="0">with historical controls </text>
<text top="440" left="244" width="148" height="19" font="0">(other pts with vascular </text>
<text top="458" left="244" width="110" height="19" font="0">surgery and TTVP </text>
<text top="477" left="244" width="3" height="19" font="0"> </text>
<text top="495" left="244" width="149" height="19" font="8"><b>Size:</b> 31 CEAs compared </text>
<text top="513" left="244" width="125" height="19" font="0">to 37 other vascular </text>
<text top="532" left="244" width="109" height="19" font="0">surgery (68 total) </text>
<text top="294" left="420" width="172" height="19" font="8"><b>Inclusion criteria:</b> Database </text>
<text top="312" left="420" width="160" height="19" font="0">searched for pts with CEA </text>
<text top="330" left="420" width="61" height="19" font="0">and TTVP </text>
<text top="349" left="420" width="3" height="19" font="0"> </text>
<text top="367" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="294" left="608" width="291" height="19" font="8"><b>1</b>°<b> endpoint:</b> 4/34 CEA surgeries with TTVP had </text>
<text top="313" left="618" width="88" height="19" font="0">PM activation </text>
<text top="331" left="608" width="3" height="19" font="0"> </text>
<text top="349" left="608" width="52" height="19" font="8"><b>Results: </b></text>
<text top="368" left="607" width="144" height="20" font="0">•  Adverse events were </text>
<text top="387" left="607" width="295" height="20" font="0">•  Defined as follows: PM activation, occurrence </text>
<text top="406" left="607" width="166" height="20" font="0">•  Of block progression to 2</text>
<text top="407" left="773" width="10" height="12" font="7">nd</text>
<text top="407" left="783" width="94" height="19" font="0"> degree AVB of </text>
<text top="425" left="620" width="253" height="19" font="0">Mobitz type II, or third-degree A-V block, </text>
<text top="444" left="607" width="298" height="20" font="0">•  bradycardia 40 bpm with a minimum duration </text>
<text top="462" left="620" width="283" height="19" font="0">10 s and/or a hemodynamic compromise (i.e., </text>
<text top="481" left="620" width="243" height="19" font="0">systolic BP &lt;90 mm Hg), asystole with a </text>
<text top="499" left="620" width="84" height="19" font="0">duration &gt;5 s </text>
<text top="518" left="607" width="165" height="20" font="0">•  4 pts with PM activation </text>
<text top="537" left="607" width="278" height="20" font="0">•  In 2 pts procedure stopped due to asystole<b> </b></text>
<text top="294" left="925" width="160" height="20" font="0">• Temporary transvenous </text>
<text top="313" left="936" width="147" height="19" font="0">pacing may be useful in </text>
<text top="331" left="936" width="123" height="19" font="0">pts undergoing CEA </text>
<text top="556" left="95" width="106" height="19" font="0">Cheung CC, et al. </text>
<text top="575" left="95" width="69" height="19" font="0">2015 (294) </text>
<text top="593" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25541033">25541033</a></text>
<text top="593" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25541033"> </a></text>
<text top="556" left="244" width="159" height="19" font="8"><b>Aim:</b> Evaluate prevalence </text>
<text top="575" left="244" width="122" height="19" font="0">of hypotension and </text>
<text top="593" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="611" left="244" width="122" height="19" font="0">elective noncardiac </text>
<text top="630" left="244" width="49" height="19" font="0">surgery </text>
<text top="648" left="244" width="3" height="19" font="0"> </text>
<text top="666" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="685" left="244" width="3" height="19" font="0"> </text>
<text top="703" left="244" width="153" height="19" font="8"><b>Size:</b> 193 pts undergoing </text>
<text top="721" left="244" width="122" height="19" font="0">noncardiac elective </text>
<text top="739" left="244" width="49" height="19" font="0">surgery </text>
<text top="556" left="420" width="168" height="19" font="8"><b>Inclusion criteria:</b> Post-hoc </text>
<text top="575" left="420" width="152" height="19" font="0">analysis of prospectively </text>
<text top="593" left="420" width="168" height="19" font="0">acquired data from a study </text>
<text top="611" left="420" width="67" height="19" font="0">evaluating </text>
<text top="630" left="420" width="159" height="19" font="0">withdrawal/management </text>
<text top="648" left="420" width="157" height="19" font="0">of a loop diuretic prior to </text>
<text top="666" left="420" width="49" height="19" font="0">surgery </text>
<text top="685" left="420" width="3" height="19" font="0"> </text>
<text top="703" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="557" left="608" width="280" height="19" font="8"><b>1</b>°<b> endpoint:</b> 67 pts developed intraoperative </text>
<text top="575" left="608" width="240" height="19" font="0">bradycardia (&lt; 60 bpm for 2 sequential </text>
<text top="594" left="608" width="180" height="19" font="0">measurements &gt;5 min apart) </text>
<text top="612" left="608" width="3" height="19" font="0"> </text>
<text top="630" left="608" width="298" height="19" font="8"><b>Results:</b> Developed a HEART score for predicting </text>
<text top="649" left="608" width="284" height="19" font="0">hypotension or bradycardia based on baseline </text>
<text top="667" left="608" width="247" height="19" font="0">heart rate and BP, Age, Drug Rx, Cardiac </text>
<text top="685" left="608" width="289" height="19" font="0">complications score, and complexity of surgery </text>
<text top="704" left="608" width="282" height="19" font="0">(OR: 2.51; 95% CI: 1.79–3.53; C-statistic: 0.75)<b> </b></text>
<text top="556" left="925" width="108" height="20" font="0">• Surgical risk for </text>
<text top="575" left="936" width="106" height="19" font="0">hypotension and </text>
<text top="594" left="936" width="119" height="19" font="0">bradycardia can be </text>
<text top="612" left="936" width="149" height="19" font="0">assessed preoperatively </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 186 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="93" width="135" height="19" font="0">Bauer AM, et al. 2014 </text>
<text top="105" left="93" width="35" height="19" font="0">(295) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24651937">24651937</a></text>
<text top="123" left="156" width="7" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24651937"> </a> </text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24651937"> </a></text>
<text top="87" left="244" width="36" height="19" font="8"><b>Aim:</b>  </text>
<text top="105" left="244" width="3" height="19" font="0"> </text>
<text top="123" left="244" width="78" height="19" font="8"><b>Study type:</b>  </text>
<text top="142" left="244" width="74" height="19" font="0">Case report </text>
<text top="160" left="244" width="35" height="19" font="8"><b>Size:</b>  </text>
<text top="87" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="105" left="420" width="3" height="19" font="0"> </text>
<text top="123" left="420" width="153" height="19" font="8"><b>Exclusion criteria:</b> None  </text>
<text top="88" left="608" width="112" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A  </text>
<text top="106" left="608" width="3" height="19" font="0"> </text>
<text top="124" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="143" left="608" width="300" height="19" font="0">Single pt with a carotid body tumor who became </text>
<text top="161" left="608" width="147" height="19" font="0">asystolic during surgery </text>
<text top="87" left="925" width="143" height="19" font="0">Single pt with a carotid </text>
<text top="105" left="925" width="157" height="19" font="0">body tumor who became </text>
<text top="123" left="925" width="147" height="19" font="0">asystolic during surgery </text>
<text top="180" left="93" width="128" height="19" font="0">Fritsch G, et al. 2012 </text>
<text top="198" left="93" width="35" height="19" font="0">(296) </text>
<text top="217" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22188223">22188223 </a></text>
<text top="217" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22188223"> </a></text>
<text top="221" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22188223"> </a></text>
<text top="180" left="244" width="128" height="19" font="8"><b>Aim:</b> Identify factors </text>
<text top="198" left="244" width="148" height="19" font="0">associated with surgical </text>
<text top="217" left="244" width="88" height="19" font="0">complications </text>
<text top="235" left="244" width="3" height="19" font="0"> </text>
<text top="253" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="272" left="244" width="54" height="19" font="0">analysis  </text>
<text top="290" left="244" width="3" height="19" font="0"> </text>
<text top="308" left="244" width="145" height="19" font="8"><b>Size:</b> 1,363 consecutive </text>
<text top="326" left="244" width="26" height="19" font="0">pts  </text>
<text top="180" left="420" width="149" height="19" font="8"><b>Inclusion criteria:</b> 1,363 </text>
<text top="198" left="420" width="158" height="19" font="0">consecutive pts in a 3 mo </text>
<text top="217" left="420" width="130" height="19" font="0">period scheduled for </text>
<text top="235" left="420" width="100" height="19" font="0">elective surgery </text>
<text top="253" left="420" width="3" height="19" font="0"> </text>
<text top="271" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="181" left="608" width="268" height="19" font="8"><b>1</b>°<b> endpoint: </b>86 pts (6.3%) developed some </text>
<text top="199" left="608" width="301" height="19" font="0">complication. Hypotension most common but 20 </text>
<text top="217" left="608" width="297" height="19" font="0">pts (1.5%) developed hemodynamically relevant </text>
<text top="236" left="608" width="79" height="19" font="0">bradycardia<b>  </b></text>
<text top="180" left="925" width="129" height="20" font="0">• Did not specifically </text>
<text top="199" left="936" width="102" height="19" font="0">analyze pts with </text>
<text top="217" left="936" width="76" height="19" font="0">bradycardia </text>
<text top="236" left="925" width="163" height="20" font="0">• Age, type of surgery and </text>
<text top="255" left="936" width="105" height="19" font="0">medical Hx were </text>
<text top="273" left="936" width="87" height="19" font="0">predictors for </text>
<text top="291" left="936" width="152" height="19" font="0">complications in general </text>
<text top="346" left="95" width="106" height="19" font="0">Perreira ID, et al. </text>
<text top="364" left="95" width="73" height="19" font="0">2011 (297)  </text>
<text top="382" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21920207">21920207</a></text>
<text top="382" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21920207"> </a></text>
<text top="386" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21920207"> </a></text>
<text top="345" left="244" width="128" height="19" font="8"><b>Aim: </b>Identify factors </text>
<text top="364" left="244" width="98" height="19" font="0">associated with </text>
<text top="382" left="244" width="91" height="19" font="0">intraoperative </text>
<text top="401" left="244" width="76" height="19" font="0">bradycardia<b> </b></text>
<text top="419" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="437" left="244" width="162" height="19" font="8"><b>Study type: </b>Retrospective<b> </b></text>
<text top="455" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="474" left="244" width="130" height="19" font="8"><b>Size: </b>80,660 pts with </text>
<text top="492" left="244" width="161" height="19" font="0">neuraxial anesthesia from </text>
<text top="510" left="244" width="92" height="19" font="0">a single center<b> </b></text>
<text top="345" left="420" width="170" height="19" font="8"><b>Inclusion criteria: </b>&gt;18 y old </text>
<text top="364" left="420" width="3" height="19" font="8"><b> </b></text>
<text top="382" left="420" width="150" height="19" font="8"><b>Exclusion criteria: </b>None<b> </b></text>
<text top="346" left="608" width="192" height="19" font="8"><b>1</b>°<b> endpoint: </b>Sinus bradycardia </text>
<text top="365" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="383" left="608" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="401" left="607" width="280" height="20" font="0">•  Sinus bradycardia more common with age </text>
<text top="421" left="627" width="109" height="20" font="0">•  18–40 y: 2.5% </text>
<text top="440" left="627" width="109" height="20" font="0">•  41–60 y: 4.1% </text>
<text top="459" left="627" width="94" height="20" font="0">•  &gt;61 y: 5.2% </text>
<text top="478" left="607" width="289" height="20" font="0">•  Sinus bradycardia dependent on anesthesia </text>
<text top="497" left="627" width="276" height="20" font="0">•  SSA (single puncture subarachnoid): 3.4% </text>
<text top="516" left="627" width="251" height="20" font="0">•  CSA (continuous subarachnoid): 3.5% </text>
<text top="535" left="627" width="235" height="20" font="0">•  SE (single puncture epidural): 1.3% </text>
<text top="554" left="627" width="210" height="20" font="0">•  CE (continuous epidural): 3.4% </text>
<text top="573" left="627" width="169" height="20" font="0">•  DB (double block): 1.5% </text>
<text top="593" left="607" width="292" height="20" font="0">•  Variables associated with sinus bradycardia: </text>
<text top="612" left="627" width="47" height="20" font="0">•  Age </text>
<text top="631" left="627" width="179" height="20" font="0">•  Gender (0.74 for women) </text>
<text top="650" left="627" width="245" height="20" font="0">•  Physical status (ASA III/IV 2.49/1.94) </text>
<text top="669" left="627" width="228" height="20" font="0">•  Type of surgery (Emergency 1.98)<b> </b></text>
<text top="346" left="925" width="158" height="20" font="0">• Sinus bradycardia more </text>
<text top="365" left="936" width="144" height="19" font="0">common with age, sex, </text>
<text top="383" left="936" width="151" height="19" font="0">anesthesia, and physical </text>
<text top="401" left="936" width="40" height="19" font="0">status </text>
<text top="689" left="93" width="134" height="19" font="0">Mitar MD, et al. 2015 </text>
<text top="707" left="93" width="35" height="19" font="0">(298) </text>
<text top="725" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25746023">25746023</a></text>
<text top="725" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25746023"> </a></text>
<text top="729" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25746023"> </a></text>
<text top="689" left="244" width="131" height="19" font="8"><b>Aim:</b> Evaluate pacing </text>
<text top="707" left="244" width="101" height="19" font="0">requirement for </text>
<text top="725" left="244" width="145" height="19" font="0">rotational atherectomy </text>
<text top="743" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="762" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="780" left="244" width="3" height="19" font="0"> </text>
<text top="689" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="707" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="725" left="420" width="145" height="19" font="0">rotational atherectomy </text>
<text top="744" left="420" width="3" height="19" font="0"> </text>
<text top="762" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="689" left="608" width="93" height="19" font="8"><b>1</b>°<b> endpoint:</b> (2</text>
<text top="689" left="701" width="10" height="12" font="7">nd</text>
<text top="689" left="711" width="190" height="19" font="0"> degree AVB or asystole &gt;2 s in </text>
<text top="708" left="618" width="106" height="19" font="0">the no PM group </text>
<text top="726" left="608" width="3" height="19" font="0"> </text>
<text top="744" left="608" width="278" height="19" font="8"><b>Results:</b> Pacemaker activated in PM group or </text>
<text top="763" left="618" width="130" height="19" font="0">AVB in no PM group: </text>
<text top="781" left="607" width="103" height="20" font="0">•  LM: 1/19 (5%) </text>
<text top="689" left="925" width="157" height="20" font="0">• Pacemaker activated in </text>
<text top="708" left="936" width="143" height="19" font="0">PM group or AVB in no </text>
<text top="726" left="936" width="159" height="19" font="0">PM group in pts with RCA </text>
<text top="744" left="936" width="57" height="19" font="0">or Cx PCI </text>
<text top="763" left="925" width="3" height="19" font="0"> </text>
<text top="781" left="925" width="3" height="19" font="0"> </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 187 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="244" width="80" height="19" font="8"><b>Size:</b> 138 pts </text>
<text top="105" left="244" width="147" height="19" font="0">Temporary pacing in 67 </text>
<text top="123" left="244" width="147" height="19" font="0">No temporary pacing in </text>
<text top="142" left="244" width="19" height="19" font="0">67 </text>
<text top="87" left="607" width="108" height="20" font="0">•  LAD: 2/38 (5%) </text>
<text top="106" left="607" width="113" height="20" font="0">•  Cx: 10/25 (40%) </text>
<text top="125" left="607" width="124" height="20" font="0">•  RCA: 28/51 (55%) </text>
<text top="144" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="173" left="93" width="110" height="19" font="0">Im SH, et al. 2008 </text>
<text top="191" left="93" width="35" height="19" font="0">(299) </text>
<text top="210" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18254669">18254669</a></text>
<text top="210" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18254669"> </a></text>
<text top="214" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18254669"> </a></text>
<text top="173" left="244" width="142" height="19" font="8"><b>Aim:</b> Evaluate utility of </text>
<text top="191" left="244" width="141" height="19" font="0">transcutaneous pacing </text>
<text top="210" left="244" width="150" height="19" font="0">with carotid angioplasty </text>
<text top="228" left="244" width="83" height="19" font="0">and stenting  </text>
<text top="246" left="244" width="3" height="19" font="0"> </text>
<text top="265" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="283" left="244" width="44" height="19" font="0">cohort </text>
<text top="301" left="244" width="3" height="19" font="0"> </text>
<text top="319" left="244" width="118" height="19" font="8"><b>Size:</b> 30 pts and 31 </text>
<text top="338" left="244" width="73" height="19" font="0">procedures </text>
<text top="173" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="191" left="420" width="130" height="19" font="0">Consecutive pts who </text>
<text top="210" left="420" width="168" height="19" font="0">underwent elective carotid </text>
<text top="228" left="420" width="152" height="19" font="0">angioplasty and stenting </text>
<text top="246" left="420" width="121" height="19" font="0">and placement of a </text>
<text top="265" left="420" width="141" height="19" font="0">transcutaneous pacing </text>
<text top="283" left="420" width="54" height="19" font="0">system.  </text>
<text top="301" left="420" width="3" height="19" font="0"> </text>
<text top="319" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="174" left="608" width="249" height="19" font="8"><b>1</b>°<b> endpoint:</b> Transcutaneous pacing use </text>
<text top="192" left="608" width="3" height="19" font="0"> </text>
<text top="210" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="229" left="607" width="289" height="20" font="0">•  24/31 required transcutaneous pacing (77%) </text>
<text top="248" left="607" width="289" height="20" font="0">•  Continuous pacing for 10–30 min required in </text>
<text top="267" left="620" width="93" height="19" font="0">5/31 pts (16%) </text>
<text top="285" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="173" left="925" width="142" height="20" font="0">• Pacing support often </text>
<text top="192" left="936" width="137" height="19" font="0">required with elective </text>
<text top="211" left="936" width="146" height="19" font="0">carotid angioplasty and </text>
<text top="229" left="936" width="53" height="19" font="0">stenting </text>
<text top="247" left="925" width="3" height="19" font="0"> </text>
<text top="266" left="925" width="3" height="19" font="0"> </text>
<text top="357" left="95" width="122" height="19" font="0">Bush RL, et al. 2004 </text>
<text top="375" left="95" width="35" height="19" font="0">(300) </text>
<text top="394" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15181504">15181504</a></text>
<text top="394" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15181504"> </a></text>
<text top="398" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15181504"> </a></text>
<text top="357" left="244" width="150" height="19" font="8"><b>Aim:</b> Evaluate incidence </text>
<text top="375" left="244" width="122" height="19" font="0">of bradycardia with </text>
<text top="394" left="244" width="100" height="19" font="0">carotid stenting </text>
<text top="412" left="244" width="73" height="19" font="0">procedures </text>
<text top="430" left="244" width="3" height="19" font="0"> </text>
<text top="448" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="467" left="244" width="3" height="19" font="0"> </text>
<text top="485" left="244" width="103" height="19" font="8"><b>Size:</b> 48 pts who </text>
<text top="503" left="244" width="162" height="19" font="0">underwent 51 procedures </text>
<text top="357" left="420" width="159" height="19" font="8"><b>Inclusion criteria:</b> Carotid </text>
<text top="375" left="420" width="166" height="19" font="0">artery stenting procedures </text>
<text top="394" left="420" width="143" height="19" font="0">in consecutive pts who </text>
<text top="412" left="420" width="137" height="19" font="0">were thought to be of </text>
<text top="430" left="420" width="131" height="19" font="0">unacceptable risk for </text>
<text top="449" left="420" width="87" height="19" font="0">carotid artery </text>
<text top="467" left="420" width="106" height="19" font="0">endarterectomy. </text>
<text top="485" left="420" width="3" height="19" font="0"> </text>
<text top="503" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="358" left="608" width="296" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinically significant bradycardia or </text>
<text top="376" left="608" width="83" height="19" font="0">hypotension  </text>
<text top="394" left="608" width="3" height="19" font="0"> </text>
<text top="413" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="431" left="608" width="234" height="20" font="0">• Access site hematomas in 2 pts (4%) </text>
<text top="450" left="608" width="276" height="20" font="0">• Significant bradycardia or asystole in 11/49 </text>
<text top="469" left="608" width="127" height="19" font="0">(22%) of procedures </text>
<text top="488" left="608" width="289" height="20" font="0">• Mean time of pacing was 6.6±1.2 min (range: </text>
<text top="507" left="608" width="88" height="19" font="0">2.2–20.1 min) </text>
<text top="525" left="608" width="296" height="20" font="0">• No correlation between preprocedural cardiac </text>
<text top="544" left="608" width="297" height="19" font="0">status (History of MI or CABG) and development </text>
<text top="562" left="608" width="197" height="19" font="0">of bradycardia and hypotension<b> </b></text>
<text top="357" left="925" width="170" height="20" font="0">• Significant bradycardia or </text>
<text top="376" left="936" width="122" height="19" font="0">asystole in 11/49 in </text>
<text top="394" left="936" width="100" height="19" font="0">carotid stenting </text>
<text top="413" left="936" width="73" height="19" font="0">procedures </text>
<text top="431" left="925" width="3" height="19" font="0"> </text>
<text top="449" left="925" width="3" height="19" font="0"> </text>
<text top="581" left="93" width="132" height="19" font="0">Harrop JS, et al. 2001 </text>
<text top="600" left="93" width="39" height="19" font="0">(301)  </text>
<text top="618" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11564241">11564241</a></text>
<text top="618" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11564241"> </a></text>
<text top="622" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11564241"> </a></text>
<text top="581" left="244" width="88" height="19" font="8"><b>Aim:</b> Evaluate </text>
<text top="600" left="244" width="106" height="19" font="0">hypotension and </text>
<text top="618" left="244" width="143" height="19" font="0">bradycardia associated </text>
<text top="636" left="244" width="117" height="19" font="0">with carotid artery </text>
<text top="655" left="244" width="162" height="19" font="0">interventional procedures </text>
<text top="673" left="244" width="3" height="19" font="0"> </text>
<text top="691" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="710" left="244" width="3" height="19" font="0"> </text>
<text top="728" left="244" width="162" height="19" font="8"><b>Size:</b> 43 pts underwent 47 </text>
<text top="746" left="244" width="160" height="19" font="0">carotid artery angioplasty </text>
<text top="765" left="244" width="152" height="19" font="0">and stenting procedures </text>
<text top="581" left="420" width="152" height="19" font="8"><b>Inclusion criteria:</b> All pts </text>
<text top="600" left="420" width="160" height="19" font="0">undergoing carotid artery </text>
<text top="618" left="420" width="73" height="19" font="0">procedures </text>
<text top="636" left="420" width="3" height="19" font="0"> </text>
<text top="655" left="420" width="154" height="19" font="8"><b>Exclusion criteria:</b> 10 pts </text>
<text top="673" left="420" width="168" height="19" font="0">excluded; no reasons given </text>
<text top="582" left="608" width="290" height="19" font="8"><b>1</b>°<b> endpoint:</b> Use of pacing for bradycardia and </text>
<text top="601" left="608" width="79" height="19" font="0">hypotension </text>
<text top="619" left="608" width="3" height="19" font="0"> </text>
<text top="637" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="656" left="608" width="272" height="20" font="0">• Pacemaker activation in 23/37 procedures </text>
<text top="675" left="608" width="38" height="19" font="0">(73%) </text>
<text top="693" left="608" width="300" height="20" font="0">• No correlation between PM activation and sex, </text>
<text top="712" left="608" width="300" height="19" font="0">etiology of stenosis, severity of stenosis, number </text>
<text top="730" left="608" width="76" height="19" font="0">of inflations </text>
<text top="749" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="582" left="925" width="146" height="20" font="0">• Pacemaker activation </text>
<text top="601" left="936" width="115" height="19" font="0">common with CEA </text>
<text top="619" left="925" width="3" height="19" font="0"> </text>
<text top="637" left="925" width="3" height="19" font="0"> </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 188 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="93" width="123" height="19" font="0">Gauss A, et al. 1999 </text>
<text top="105" left="93" width="35" height="19" font="0">(302) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10456813">10456813</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10456813"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10456813"> </a></text>
<text top="87" left="244" width="36" height="19" font="8"><b>Aim:</b>  </text>
<text top="105" left="244" width="83" height="19" font="0">Evaluation of </text>
<text top="123" left="244" width="156" height="19" font="0">transcutaneous pacing in </text>
<text top="142" left="244" width="150" height="19" font="0">pts thought to be at risk </text>
<text top="160" left="244" width="97" height="19" font="0">for bradycardia </text>
<text top="178" left="244" width="120" height="19" font="0">(trifascicular block) </text>
<text top="197" left="244" width="3" height="19" font="0"> </text>
<text top="215" left="244" width="155" height="19" font="8"><b>Study type:</b> Consecutive, </text>
<text top="233" left="244" width="75" height="19" font="0">prospective </text>
<text top="252" left="244" width="3" height="19" font="0"> </text>
<text top="270" left="244" width="76" height="19" font="8"><b>Size:</b> 39 pts  </text>
<text top="87" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="420" width="153" height="19" font="0">Consecutive pts with asx </text>
<text top="123" left="420" width="172" height="19" font="0">chronic 1st degree AVB and </text>
<text top="142" left="420" width="163" height="19" font="0">LBBB or bifascicular block. </text>
<text top="160" left="420" width="3" height="19" font="0"> </text>
<text top="178" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="88" left="608" width="302" height="19" font="8"><b>1</b>°<b> endpoint:</b> Progression of AVB, asystole &gt;5 s or </text>
<text top="106" left="608" width="173" height="19" font="0">bradycardia &lt;40 bpm &gt;10 s) </text>
<text top="124" left="608" width="3" height="19" font="0"> </text>
<text top="143" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="161" left="608" width="290" height="20" font="0">• 37 of 39 pts could be paced transcutaneously </text>
<text top="180" left="608" width="188" height="20" font="0">• 0/39 had progression of AVB </text>
<text top="199" left="608" width="218" height="20" font="0">• 9 pts had bradycardia &lt;40 bpm (6 </text>
<text top="218" left="608" width="241" height="19" font="0">intraoperatively and 3 postoperatively) </text>
<text top="237" left="608" width="268" height="20" font="0">• No pts absolutely required pacing for rate </text>
<text top="256" left="608" width="51" height="19" font="0">support<b> </b></text>
<text top="87" left="925" width="121" height="20" font="0">• No pts absolutely </text>
<text top="106" left="936" width="149" height="19" font="0">required pacing for rate </text>
<text top="124" left="936" width="51" height="19" font="0">support </text>
<text top="289" left="93" width="112" height="19" font="0">Killeavey ES, et al. </text>
<text top="307" left="93" width="69" height="19" font="0">1990 (303) </text>
<text top="326" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15227187">15227187</a></text>
<text top="326" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15227187"> </a></text>
<text top="330" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15227187"> </a></text>
<text top="289" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate the use of </text>
<text top="307" left="244" width="121" height="19" font="0">transvenous pacing </text>
<text top="326" left="244" width="66" height="19" font="0">during PCI </text>
<text top="344" left="244" width="3" height="19" font="0"> </text>
<text top="362" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="381" left="244" width="3" height="19" font="0"> </text>
<text top="399" left="244" width="139" height="19" font="8"><b>Size:</b> 778 pts (398 w/o </text>
<text top="417" left="244" width="148" height="19" font="0">transvenous pacing and </text>
<text top="436" left="244" width="135" height="19" font="0">379 with prophylactic </text>
<text top="454" left="244" width="144" height="19" font="0">pacing and 1 emergent </text>
<text top="472" left="244" width="48" height="19" font="0">pacing) </text>
<text top="289" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="307" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="326" left="420" width="23" height="19" font="0">PCI </text>
<text top="344" left="420" width="3" height="19" font="0"> </text>
<text top="362" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="290" left="608" width="229" height="19" font="8"><b>1</b>°<b> endpoint:</b> Requirement for pacing </text>
<text top="308" left="608" width="3" height="19" font="0"> </text>
<text top="326" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="345" left="608" width="257" height="20" font="0">• 2 pts developed ventricular arrhythmias </text>
<text top="364" left="608" width="262" height="19" font="0">associated with prophylactic pacing (0.5%) </text>
<text top="382" left="608" width="206" height="20" font="0">• 8/379 had pacing required (2%) </text>
<text top="401" left="608" width="204" height="20" font="0">• Overall incidence for pacing for </text>
<text top="420" left="608" width="267" height="19" font="0">hemodynamically significant bradycardia in </text>
<text top="439" left="608" width="251" height="19" font="0">prophylactic situations was 7/777 (0.8%)<b> </b></text>
<text top="289" left="925" width="159" height="20" font="0">• Requirement for pacing </text>
<text top="308" left="936" width="25" height="19" font="0">low </text>
<text top="491" left="93" width="122" height="19" font="0">Chowdhury T, et al. </text>
<text top="509" left="93" width="69" height="19" font="0">2015 (304) </text>
<text top="528" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26656339">26656339</a></text>
<text top="528" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26656339"> </a></text>
<text top="532" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26656339"> </a></text>
<text top="491" left="244" width="138" height="19" font="8"><b>Aim:</b> Propofol boluses </text>
<text top="509" left="244" width="141" height="19" font="0">aborted the trigeminal </text>
<text top="528" left="244" width="121" height="19" font="0">cardiac reflex (TCR) </text>
<text top="546" left="244" width="96" height="19" font="0">induced severe </text>
<text top="565" left="244" width="153" height="19" font="0">bradycardia during dural </text>
<text top="583" left="244" width="88" height="19" font="0">manipulation. </text>
<text top="601" left="244" width="3" height="19" font="0"> </text>
<text top="619" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="638" left="244" width="3" height="19" font="0"> </text>
<text top="656" left="244" width="59" height="19" font="8"><b>Size:</b> 1 pt </text>
<text top="491" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="509" left="420" width="3" height="19" font="0"> </text>
<text top="528" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="492" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="510" left="608" width="3" height="19" font="0"> </text>
<text top="529" left="608" width="283" height="19" font="8"><b>Results:</b> During dural stimulation, propofol 50 </text>
<text top="547" left="608" width="220" height="19" font="0">mg IV terminated sinus bradycardia<b> </b></text>
<text top="491" left="925" width="150" height="20" font="0">• Case report discussing </text>
<text top="510" left="936" width="106" height="19" font="0">that during dural </text>
<text top="529" left="936" width="151" height="19" font="0">stimulation, propofol 50 </text>
<text top="547" left="936" width="145" height="19" font="0">mg IV terminated sinus </text>
<text top="565" left="936" width="76" height="19" font="0">bradycardia </text>
<text top="675" left="95" width="113" height="19" font="0">Yong J, et al. 2015 </text>
<text top="693" left="95" width="35" height="19" font="0">(305) </text>
<text top="712" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26424701">26424701</a></text>
<text top="712" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26424701"> </a></text>
<text top="716" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26424701"> </a></text>
<text top="675" left="244" width="88" height="19" font="8"><b>Aim:</b> Evaluate </text>
<text top="693" left="244" width="147" height="19" font="0">development of cardiac </text>
<text top="712" left="244" width="162" height="19" font="0">arrest during laparoscopic </text>
<text top="730" left="244" width="49" height="19" font="0">surgery </text>
<text top="748" left="244" width="3" height="19" font="0"> </text>
<text top="675" left="420" width="160" height="19" font="8"><b>Inclusion criteria:</b> Cardiac </text>
<text top="693" left="420" width="62" height="19" font="0">arrest pts </text>
<text top="712" left="591" width="3" height="19" font="0"> </text>
<text top="730" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="676" left="608" width="254" height="19" font="8"><b>1</b>°<b> endpoint:</b> Cardiac arrest (bradycardia) </text>
<text top="694" left="608" width="3" height="19" font="0"> </text>
<text top="712" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="731" left="608" width="118" height="20" font="0">• 9/14 bradycardia </text>
<text top="750" left="608" width="218" height="20" font="0">• 2 critical points for cardiac arrest: </text>
<text top="675" left="925" width="145" height="20" font="0">• Bradycardia common </text>
<text top="694" left="936" width="120" height="19" font="0">during laparoscopy </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 189 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="105" left="244" width="156" height="19" font="0">analysis of the Australian </text>
<text top="123" left="244" width="163" height="19" font="0">Incident Monitoring Study </text>
<text top="142" left="244" width="104" height="19" font="0">(AIMS) database </text>
<text top="160" left="244" width="3" height="19" font="0"> </text>
<text top="178" left="244" width="120" height="19" font="8"><b>Size:</b> 14 cases from </text>
<text top="197" left="244" width="128" height="19" font="0">&gt;11,000 pt database </text>
<text top="87" left="608" width="195" height="19" font="0">insufflation or establishment of </text>
<text top="105" left="608" width="209" height="19" font="0">pneumoperitoneum (12/14; 86%) </text>
<text top="123" left="608" width="206" height="19" font="0">Anesthesia induction (2/14; 14%) </text>
<text top="142" left="608" width="3" height="19" font="0"> </text>
<text top="160" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="216" left="95" width="127" height="19" font="0">Vimala S, et al. 2016 </text>
<text top="234" left="95" width="35" height="19" font="0">(306) </text>
<text top="252" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26114985">26114985</a></text>
<text top="252" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26114985"> </a></text>
<text top="257" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26114985"> </a></text>
<text top="216" left="244" width="122" height="19" font="8"><b>Aim:</b> Case report of </text>
<text top="234" left="244" width="131" height="19" font="0">asystole during dural </text>
<text top="252" left="244" width="88" height="19" font="0">manipulation  </text>
<text top="271" left="244" width="3" height="19" font="0"> </text>
<text top="289" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="307" left="244" width="3" height="19" font="0"> </text>
<text top="326" left="244" width="59" height="19" font="8"><b>Size:</b> 1 pt </text>
<text top="216" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="234" left="420" width="3" height="19" font="0"> </text>
<text top="252" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="217" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="235" left="608" width="3" height="19" font="0"> </text>
<text top="253" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="271" left="608" width="244" height="19" font="8"><b>• </b>Bradycardia and asystole during dural </text>
<text top="290" left="608" width="279" height="19" font="0">manipulation and excision of a temporal lobe </text>
<text top="308" left="608" width="207" height="19" font="0">meningioma (near the left insula)<b> </b></text>
<text top="216" left="925" width="101" height="20" font="0">• Case report of </text>
<text top="235" left="936" width="153" height="19" font="0">bradycardia during dural </text>
<text top="253" left="936" width="84" height="19" font="0">manipulation </text>
<text top="345" left="95" width="129" height="19" font="0">Mohan S, et al. 1990 </text>
<text top="363" left="95" width="35" height="19" font="0">(307) </text>
<text top="381" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24788865">24788865</a></text>
<text top="381" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24788865"> </a></text>
<text top="385" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24788865"> </a></text>
<text top="345" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate the use of </text>
<text top="363" left="244" width="121" height="19" font="0">transvenous pacing </text>
<text top="381" left="244" width="66" height="19" font="0">during PCI </text>
<text top="400" left="244" width="3" height="19" font="0"> </text>
<text top="418" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="436" left="244" width="3" height="19" font="0"> </text>
<text top="454" left="244" width="46" height="19" font="8"><b>Size:</b> 1  </text>
<text top="345" left="420" width="140" height="19" font="8"><b>Inclusion criteria:</b> 60 y </text>
<text top="363" left="420" width="158" height="19" font="0">undergoing maxillectomy </text>
<text top="381" left="420" width="155" height="19" font="0">for squamous cell cancer </text>
<text top="400" left="420" width="3" height="19" font="0"> </text>
<text top="418" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="345" left="608" width="112" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A  </text>
<text top="364" left="608" width="3" height="19" font="0"> </text>
<text top="382" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="401" left="608" width="236" height="20" font="0">• Asystole during posterior osteotomy </text>
<text top="420" left="608" width="289" height="20" font="0">• Bradycardia again during manipulation of the </text>
<text top="439" left="608" width="184" height="19" font="0">posterior maxillary tuberosity </text>
<text top="457" left="608" width="298" height="20" font="0">• Treatment by atropine and minimizing surgical </text>
<text top="476" left="608" width="84" height="19" font="0">manipulation<b> </b></text>
<text top="345" left="925" width="3" height="19" font="0"> </text>
<text top="363" left="925" width="3" height="19" font="0"> </text>
<text top="495" left="93" width="112" height="19" font="0">Ishii D, et al. 1990 </text>
<text top="513" left="93" width="35" height="19" font="0">(308) </text>
<text top="532" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23834853">23834853</a></text>
<text top="532" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23834853"> </a></text>
<text top="536" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23834853"> </a></text>
<text top="495" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate the use of </text>
<text top="513" left="244" width="150" height="19" font="0">cilostazol for preventing </text>
<text top="532" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="550" left="244" width="140" height="19" font="0">carotid artery stenting </text>
<text top="568" left="244" width="3" height="19" font="0"> </text>
<text top="587" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="605" left="244" width="3" height="19" font="0"> </text>
<text top="623" left="244" width="103" height="19" font="8"><b>Size:</b> 53 pts who </text>
<text top="642" left="244" width="136" height="19" font="0">underwent 54 carotid </text>
<text top="660" left="244" width="93" height="19" font="0">artery stenting </text>
<text top="678" left="244" width="148" height="19" font="0">procedures divided into </text>
<text top="697" left="244" width="137" height="19" font="0">procedures where pts </text>
<text top="715" left="244" width="143" height="19" font="0">received cilostazol (26) </text>
<text top="733" left="244" width="141" height="19" font="0">and those who did not </text>
<text top="752" left="244" width="28" height="19" font="0">(28) </text>
<text top="495" left="420" width="163" height="19" font="8"><b>Inclusion criteria:</b> Pts who </text>
<text top="513" left="420" width="157" height="19" font="0">underwent carotid artery </text>
<text top="532" left="420" width="118" height="19" font="0">stenting at a single </text>
<text top="550" left="420" width="66" height="19" font="0">institution </text>
<text top="568" left="420" width="3" height="19" font="0"> </text>
<text top="587" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="496" left="608" width="236" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia (&lt;50 bpm or </text>
<text top="514" left="608" width="162" height="19" font="0">hypotension (&lt;90 mm Hg) </text>
<text top="533" left="608" width="3" height="19" font="0"> </text>
<text top="551" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="569" left="608" width="191" height="20" font="0">• Intraprocedural bradycardia: </text>
<text top="593" left="627" width="9" height="12" font="0">o</text>
<text top="592" left="636" width="4" height="14" font="0"> </text>
<text top="588" left="640" width="136" height="19" font="0">Cilostazol: 4/26 (15%) </text>
<text top="612" left="627" width="9" height="12" font="0">o</text>
<text top="610" left="636" width="4" height="14" font="0"> </text>
<text top="607" left="640" width="163" height="19" font="0">No cilostazol: 15/28 (54%) </text>
<text top="625" left="607" width="182" height="20" font="0">•  Postprocedure bradycardia </text>
<text top="649" left="627" width="9" height="12" font="0">o</text>
<text top="648" left="636" width="4" height="14" font="0"> </text>
<text top="644" left="640" width="98" height="19" font="0">Cilostazol: 0/26 </text>
<text top="667" left="627" width="9" height="12" font="0">o</text>
<text top="666" left="636" width="4" height="14" font="0"> </text>
<text top="662" left="640" width="155" height="19" font="0">No cilostazol: 3/28 (11%)<b> </b></text>
<text top="495" left="925" width="126" height="20" font="0">• Cilostazol reduced </text>
<text top="514" left="936" width="91" height="19" font="0">intraoperative </text>
<text top="533" left="936" width="76" height="19" font="0">bradycardia </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 190 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="105" height="19" font="0">Schipke JD, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">2013 (309) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23332411">23332411</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23332411"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23332411"> </a></text>
<text top="87" left="244" width="157" height="19" font="8"><b>Aim:</b> 1 pt who developed </text>
<text top="105" left="244" width="158" height="19" font="0">asystole during paranasal </text>
<text top="123" left="244" width="83" height="19" font="0">sinus surgery </text>
<text top="142" left="244" width="3" height="19" font="0"> </text>
<text top="160" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="178" left="244" width="3" height="19" font="0"> </text>
<text top="197" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="87" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="105" left="420" width="3" height="19" font="0"> </text>
<text top="123" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="106" left="608" width="3" height="19" font="0"> </text>
<text top="124" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="143" left="608" width="251" height="20" font="0">• 15 s of asystole with instrumenting the </text>
<text top="162" left="608" width="110" height="19" font="0">paranasal sinuses </text>
<text top="180" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="925" width="96" height="20" font="0">• Asystole with </text>
<text top="106" left="936" width="113" height="19" font="0">instrumenting the </text>
<text top="124" left="936" width="110" height="19" font="0">paranasal sinuses </text>
<text top="216" left="95" width="126" height="19" font="0">Haldar R, et al. 2013 </text>
<text top="234" left="95" width="35" height="19" font="0">(310) </text>
<text top="252" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23242253">23242253</a></text>
<text top="252" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23242253"> </a></text>
<text top="257" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23242253"> </a></text>
<text top="216" left="244" width="157" height="19" font="8"><b>Aim:</b> 1 pt who developed </text>
<text top="234" left="244" width="149" height="19" font="0">bradycardia during skull </text>
<text top="252" left="244" width="72" height="19" font="0">pin fixation </text>
<text top="271" left="244" width="3" height="19" font="0"> </text>
<text top="289" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="307" left="244" width="3" height="19" font="0"> </text>
<text top="326" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="216" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="234" left="420" width="3" height="19" font="0"> </text>
<text top="252" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="217" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="235" left="608" width="3" height="19" font="0"> </text>
<text top="253" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="272" left="608" width="291" height="20" font="0">• Heart rate decreased from 88 to 44 bpm with </text>
<text top="291" left="608" width="288" height="19" font="0">skull fixation pin tightening that stopped when </text>
<text top="309" left="608" width="269" height="19" font="0">instrumentation stopped and recurred with </text>
<text top="327" left="608" width="106" height="19" font="0">tightening again.<b> </b></text>
<text top="216" left="925" width="143" height="20" font="0">• Heart rate decreased </text>
<text top="235" left="936" width="133" height="19" font="0">with skull fixation pin </text>
<text top="253" left="936" width="147" height="19" font="0">tightening that stopped </text>
<text top="272" left="936" width="140" height="19" font="0">when instrumentation </text>
<text top="290" left="936" width="136" height="19" font="0">stopped and recurred </text>
<text top="308" left="936" width="136" height="19" font="0">with tightening again. </text>
<text top="346" left="95" width="116" height="19" font="0">Seo KC, et al. 2010 </text>
<text top="365" left="95" width="35" height="19" font="0">(311) </text>
<text top="383" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20498810">20498810</a></text>
<text top="383" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20498810"> </a></text>
<text top="387" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20498810"> </a></text>
<text top="346" left="244" width="136" height="19" font="8"><b>Aim:</b> Identify possible </text>
<text top="365" left="244" width="140" height="19" font="0">factors contributing to </text>
<text top="383" left="244" width="102" height="19" font="0">bradycardia and </text>
<text top="401" left="244" width="122" height="19" font="0">hypotension during </text>
<text top="420" left="244" width="106" height="19" font="0">shoulder surgery </text>
<text top="438" left="244" width="3" height="19" font="0"> </text>
<text top="456" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="474" left="244" width="3" height="19" font="0"> </text>
<text top="493" left="244" width="50" height="19" font="8"><b>Size:</b> 63 </text>
<text top="346" left="420" width="159" height="19" font="8"><b>Inclusion criteria:</b> ASA I/II </text>
<text top="365" left="420" width="108" height="19" font="0">pts who received </text>
<text top="383" left="420" width="135" height="19" font="0">interscalene block for </text>
<text top="401" left="420" width="137" height="19" font="0">arthroscopic shoulder </text>
<text top="420" left="420" width="129" height="19" font="0">surgery in the sitting </text>
<text top="438" left="420" width="53" height="19" font="0">position </text>
<text top="456" left="420" width="3" height="19" font="0"> </text>
<text top="474" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="347" left="608" width="269" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia (&lt;50 bpm) and/or </text>
<text top="365" left="608" width="292" height="19" font="0">hypotension (&lt;100 mm Hg or use of ephedrine) </text>
<text top="384" left="608" width="3" height="19" font="0"> </text>
<text top="402" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="421" left="608" width="262" height="20" font="0">• 13/63 with bradycardia and hypotension </text>
<text top="440" left="608" width="297" height="20" font="0">• Bradycardia and hypotension more likely with: </text>
<text top="459" left="608" width="253" height="19" font="0">Right sided procedures (R: 27% vs. L: 5%) </text>
<text top="477" left="608" width="229" height="19" font="0">Higher use of fentanyl (54% vs. 0.4%)<b> </b></text>
<text top="347" left="925" width="114" height="20" font="0">• Bradycardia and </text>
<text top="365" left="936" width="115" height="19" font="0">hypotension more </text>
<text top="384" left="936" width="156" height="19" font="0">common with tight sided </text>
<text top="402" left="936" width="73" height="19" font="0">procedures </text>
<text top="512" left="95" width="113" height="19" font="0">Jeyabalan G, et al. </text>
<text top="530" left="95" width="69" height="19" font="0">2010 (312) </text>
<text top="548" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20557186">20557186</a></text>
<text top="548" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20557186"> </a></text>
<text top="553" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20557186"> </a></text>
<text top="512" left="244" width="128" height="19" font="8"><b>Aim:</b> Identify factors </text>
<text top="530" left="244" width="98" height="19" font="0">associated with </text>
<text top="548" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="567" left="244" width="134" height="19" font="0">pharmacomechanical </text>
<text top="585" left="244" width="150" height="19" font="0">thrombectomy for deep </text>
<text top="603" left="244" width="101" height="19" font="0">vein thrombosis </text>
<text top="622" left="244" width="3" height="19" font="0"> </text>
<text top="640" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="658" left="244" width="3" height="19" font="0"> </text>
<text top="677" left="244" width="73" height="19" font="8"><b>Size:</b> 57 pts </text>
<text top="512" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="530" left="420" width="130" height="19" font="0">Consecutive pts who </text>
<text top="548" left="420" width="71" height="19" font="0">underwent </text>
<text top="567" left="420" width="134" height="19" font="0">pharmacomechanical </text>
<text top="585" left="420" width="171" height="19" font="0">(AngioJet) therapy for deep </text>
<text top="603" left="420" width="101" height="19" font="0">vein thrombosis </text>
<text top="622" left="420" width="3" height="19" font="0"> </text>
<text top="640" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="513" left="608" width="161" height="19" font="8"><b>1</b>°<b> endpoint: </b>Bradycardia  </text>
<text top="531" left="608" width="3" height="19" font="0"> </text>
<text top="549" left="608" width="110" height="19" font="8"><b>Safety endpoint:</b>  </text>
<text top="568" left="608" width="230" height="20" font="0">• 7/57 (12.3%) had bradyarrhythmias </text>
<text top="587" left="608" width="64" height="19" font="0">asystole 2 </text>
<text top="605" left="608" width="125" height="19" font="0">sinus bradycardia: 5 </text>
<text top="623" left="608" width="146" height="19" font="0">More than 1 episode: 4 </text>
<text top="642" left="608" width="294" height="20" font="0">• Bradycardia resolved in 5/7 pts with cessation </text>
<text top="661" left="608" width="215" height="19" font="0">of therapy. 2 pts received atropine<b> </b></text>
<text top="512" left="925" width="147" height="20" font="0">• Bradycardia observed </text>
<text top="531" left="936" width="159" height="19" font="0">with AngioJet procedures </text>
<text top="696" left="95" width="124" height="19" font="0">Usami K, et al. 2010 </text>
<text top="714" left="95" width="35" height="19" font="0">(313) </text>
<text top="732" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20448432">20448432</a></text>
<text top="732" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20448432"> </a></text>
<text top="736" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20448432"> </a></text>
<text top="696" left="244" width="152" height="19" font="8"><b>Aim:</b> Describe 3 pts who </text>
<text top="714" left="244" width="143" height="19" font="0">developed bradycardia </text>
<text top="732" left="244" width="101" height="19" font="0">with surgery for </text>
<text top="751" left="244" width="144" height="19" font="0">cerebellopontine angle </text>
<text top="769" left="244" width="85" height="19" font="0">meningiomas </text>
<text top="696" left="420" width="143" height="19" font="8"><b>Inclusion criteria:</b> Case </text>
<text top="714" left="420" width="107" height="19" font="0">series of pts with </text>
<text top="732" left="420" width="118" height="19" font="0">bradycardia during </text>
<text top="751" left="420" width="129" height="19" font="0">meningioma surgery </text>
<text top="769" left="420" width="3" height="19" font="0"> </text>
<text top="696" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="715" left="608" width="3" height="19" font="0"> </text>
<text top="733" left="608" width="52" height="19" font="8"><b>Results: </b></text>
<text top="752" left="608" width="228" height="20" font="0">• Transient bradycardia/asystole and </text>
<text top="771" left="608" width="295" height="19" font="0">hypotension apparently due to activation of the </text>
<text top="696" left="925" width="72" height="20" font="0">• Transient </text>
<text top="715" left="936" width="157" height="19" font="0">bradycardia/asystole and </text>
<text top="733" left="936" width="149" height="19" font="0">hypotension apparently </text>
<text top="751" left="936" width="146" height="19" font="0">due to activation of the </text>
<text top="770" left="936" width="145" height="19" font="0">trigeminocardiac reflex </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 191 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="244" width="3" height="19" font="0"> </text>
<text top="105" left="244" width="145" height="19" font="8"><b>Study type:</b> Case series </text>
<text top="123" left="244" width="3" height="19" font="0"> </text>
<text top="142" left="244" width="43" height="19" font="8"><b>Size:</b> 3 </text>
<text top="87" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="87" left="608" width="290" height="19" font="0">trigeminocardiac reflex by direct stimulation of </text>
<text top="105" left="608" width="273" height="19" font="0">the trigeminal nerve or branches in the dura </text>
<text top="123" left="608" width="187" height="19" font="0">mater or cerebellar tentorium </text>
<text top="142" left="608" width="237" height="20" font="0">• Remifentanil suggested as a possible </text>
<text top="161" left="608" width="73" height="19" font="0">contributor<b> </b></text>
<text top="87" left="936" width="145" height="19" font="0">by direct stimulation of </text>
<text top="105" left="936" width="144" height="19" font="0">the trigeminal nerve or </text>
<text top="123" left="936" width="129" height="19" font="0">branches in the dura </text>
<text top="142" left="936" width="121" height="19" font="0">mater or cerebellar </text>
<text top="160" left="936" width="65" height="19" font="0">tentorium </text>
<text top="178" left="925" width="3" height="19" font="0"> </text>
<text top="197" left="93" width="109" height="19" font="0">Lubbers HT, et al. </text>
<text top="216" left="93" width="73" height="19" font="0">2010 (314)  </text>
<text top="234" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20347202">20347202</a></text>
<text top="234" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20347202"> </a></text>
<text top="238" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20347202"> </a></text>
<text top="197" left="244" width="152" height="19" font="8"><b>Aim:</b> Describe 3 pts who </text>
<text top="216" left="244" width="143" height="19" font="0">developed bradycardia </text>
<text top="234" left="244" width="148" height="19" font="0">with craniomaxillofacial </text>
<text top="252" left="244" width="53" height="19" font="0">surgery. </text>
<text top="271" left="244" width="3" height="19" font="0"> </text>
<text top="289" left="244" width="145" height="19" font="8"><b>Study type:</b> Case series </text>
<text top="307" left="244" width="3" height="19" font="0"> </text>
<text top="326" left="244" width="43" height="19" font="8"><b>Size:</b> 3 </text>
<text top="197" left="420" width="143" height="19" font="8"><b>Inclusion criteria:</b> Case </text>
<text top="216" left="420" width="70" height="19" font="0">series, N/A </text>
<text top="234" left="420" width="3" height="19" font="0"> </text>
<text top="252" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="198" left="608" width="161" height="19" font="8"><b>1</b>°<b> endpoint: </b>Bradycardia  </text>
<text top="217" left="608" width="3" height="19" font="0"> </text>
<text top="235" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="253" left="608" width="287" height="20" font="0">• Describe 3 pts identified from a single center </text>
<text top="272" left="608" width="258" height="19" font="0">surgical database with bradycardia during </text>
<text top="291" left="608" width="166" height="19" font="0">craniomaxillofacial surgery </text>
<text top="309" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="198" left="925" width="154" height="20" font="0">• Purely descriptive with </text>
<text top="217" left="936" width="68" height="19" font="0">no specific </text>
<text top="235" left="936" width="132" height="19" font="0">recommendations or </text>
<text top="253" left="936" width="51" height="19" font="0">findings </text>
<text top="345" left="95" width="132" height="19" font="0">Christensen RE, et al. </text>
<text top="363" left="95" width="69" height="19" font="0">2010 (315) </text>
<text top="381" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19933174">19933174</a></text>
<text top="381" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19933174"> </a></text>
<text top="385" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19933174"> </a></text>
<text top="345" left="244" width="153" height="19" font="8"><b>Aim:</b> Describe outcomes </text>
<text top="363" left="244" width="128" height="19" font="0">in pts with surgically </text>
<text top="381" left="244" width="159" height="19" font="0">corrected D transposition </text>
<text top="400" left="244" width="144" height="19" font="0">of the great arteries (D-</text>
<text top="418" left="244" width="107" height="19" font="0">TGA) undergoing </text>
<text top="436" left="244" width="120" height="19" font="0">noncardiac surgery </text>
<text top="455" left="244" width="3" height="19" font="0"> </text>
<text top="473" left="244" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="491" left="244" width="3" height="19" font="8"><b> </b></text>
<text top="509" left="244" width="146" height="19" font="8"><b>Size:</b> 50 procedures (34 </text>
<text top="528" left="244" width="27" height="19" font="0">pts) </text>
<text top="345" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="363" left="420" width="130" height="19" font="0">Consecutive pts with </text>
<text top="381" left="420" width="165" height="19" font="0">surgically corrected D-TGA </text>
<text top="400" left="420" width="144" height="19" font="0">undergoing noncardiac </text>
<text top="418" left="420" width="167" height="19" font="0">surgery (43 pediatric and 7 </text>
<text top="436" left="420" width="45" height="19" font="0">adults) </text>
<text top="455" left="420" width="3" height="19" font="0"> </text>
<text top="473" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="345" left="608" width="237" height="19" font="8"><b>1</b>°<b> endpoint:</b> Adverse events including </text>
<text top="364" left="608" width="76" height="19" font="0">bradycardia </text>
<text top="382" left="608" width="3" height="19" font="0"> </text>
<text top="400" left="608" width="264" height="19" font="8"><b>Results:</b> 4 adverse events. 1 pt with severe </text>
<text top="419" left="608" width="259" height="19" font="0">bradycardia during abdominal insufflation<b> </b></text>
<text top="345" left="925" width="117" height="20" font="0">• 4 adverse events </text>
<text top="364" left="936" width="127" height="19" font="0">observed in pts with </text>
<text top="382" left="936" width="152" height="19" font="0">congenital heart disease </text>
<text top="401" left="936" width="160" height="19" font="0">and noncardiac surgeries. </text>
<text top="547" left="93" width="132" height="19" font="0">Jacques F, et al. 2009 </text>
<text top="565" left="93" width="39" height="19" font="0">(316)  </text>
<text top="583" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18657390">18657390</a></text>
<text top="583" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18657390"> </a></text>
<text top="588" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18657390"> </a></text>
<text top="547" left="244" width="145" height="19" font="8"><b>Aim:</b> Compare regional </text>
<text top="565" left="244" width="144" height="19" font="0">anesthesia and general </text>
<text top="583" left="244" width="117" height="19" font="0">anesthesia for CEA </text>
<text top="602" left="244" width="49" height="19" font="0">surgery </text>
<text top="620" left="244" width="3" height="19" font="0"> </text>
<text top="638" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="657" left="244" width="3" height="19" font="0"> </text>
<text top="675" left="244" width="50" height="19" font="8"><b>Size:</b> 72 </text>
<text top="693" left="244" width="147" height="19" font="0">Regional anesthesia: 25 </text>
<text top="712" left="244" width="143" height="19" font="0">General anesthesia: 47 </text>
<text top="547" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="565" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="583" left="420" width="152" height="19" font="0">CEA from a single center </text>
<text top="602" left="420" width="3" height="19" font="0"> </text>
<text top="620" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="548" left="608" width="295" height="19" font="8"><b>1</b>°<b> endpoint:</b> Hypotension and bradycardia (&lt;60 </text>
<text top="566" left="608" width="36" height="19" font="0">bpm) </text>
<text top="584" left="608" width="3" height="19" font="0"> </text>
<text top="603" left="608" width="301" height="19" font="8"><b>Results:</b> Regional anesthesia associated with less </text>
<text top="621" left="608" width="300" height="19" font="0">intraoperative bradycardia (4%) when compared </text>
<text top="639" left="608" width="173" height="19" font="0">to general anesthesia (63%)<b> </b></text>
<text top="547" left="925" width="136" height="20" font="0">• Regional anesthesia </text>
<text top="566" left="936" width="124" height="19" font="0">associated with less </text>
<text top="584" left="936" width="91" height="19" font="0">intraoperative </text>
<text top="603" left="936" width="79" height="19" font="0">bradycardia  </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 192 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="93" width="122" height="19" font="0">Hanss R, et al. 2008 </text>
<text top="105" left="93" width="35" height="19" font="0">(317) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18211442">18211442</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18211442"> </a></text>
<text top="128" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18211442"> </a></text>
<text top="87" left="244" width="153" height="19" font="8"><b>Aim:</b> Evaluate heart rate </text>
<text top="105" left="244" width="134" height="19" font="0">variability as a tool to </text>
<text top="123" left="244" width="159" height="19" font="0">identify pts who will have </text>
<text top="142" left="244" width="96" height="19" font="0">hypotension or </text>
<text top="160" left="244" width="118" height="19" font="0">bradycardia during </text>
<text top="178" left="244" width="49" height="19" font="0">surgery </text>
<text top="197" left="244" width="3" height="19" font="0"> </text>
<text top="215" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="233" left="244" width="128" height="19" font="0">model followed by a </text>
<text top="252" left="244" width="112" height="19" font="0">prospective study </text>
<text top="270" left="244" width="3" height="19" font="0"> </text>
<text top="288" left="244" width="58" height="19" font="8"><b>Size:</b> 100 </text>
<text top="87" left="420" width="142" height="19" font="8"><b>Inclusion criteria:</b> High </text>
<text top="105" left="420" width="143" height="19" font="0">perioperative risk (ASA </text>
<text top="123" left="420" width="150" height="19" font="0">III/IV) undergoing major </text>
<text top="142" left="420" width="138" height="19" font="0">vascular or abdominal </text>
<text top="160" left="420" width="49" height="19" font="0">surgery </text>
<text top="178" left="420" width="3" height="19" font="0"> </text>
<text top="197" left="420" width="154" height="19" font="8"><b>Exclusion criteria:</b> Not in </text>
<text top="215" left="420" width="133" height="19" font="0">SR, &lt;18 y, emergency </text>
<text top="233" left="420" width="49" height="19" font="0">surgery </text>
<text top="88" left="608" width="263" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia and hypotension </text>
<text top="106" left="608" width="3" height="19" font="0"> </text>
<text top="124" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="143" left="608" width="289" height="20" font="0">• No specific data on bradycardia but those pts </text>
<text top="162" left="608" width="288" height="19" font="0">with lower heart rate variability (stratified by a </text>
<text top="180" left="608" width="127" height="19" font="0">total power &lt;500 Ms</text>
<text top="180" left="735" width="5" height="12" font="7">2</text>
<text top="180" left="740" width="15" height="19" font="0">Hz</text>
<text top="180" left="755" width="8" height="12" font="7">-1</text>
<text top="180" left="763" width="129" height="19" font="0">) were more likely to </text>
<text top="198" left="608" width="237" height="19" font="0">develop hypotension and bradycardia  </text>
<text top="217" left="608" width="230" height="20" font="0">• 4/50 pts in the retrospective model </text>
<text top="236" left="608" width="292" height="19" font="0">development group had bradycardia (&lt;50 bpm)<b> </b></text>
<text top="87" left="925" width="121" height="20" font="0">• Small numbers of </text>
<text top="106" left="936" width="125" height="19" font="0">bradycardia (mostly </text>
<text top="124" left="936" width="84" height="19" font="0">hypotension) </text>
<text top="307" left="93" width="137" height="19" font="0">Reddy MK, et al. 2008 </text>
<text top="326" left="93" width="39" height="19" font="0">(318)  </text>
<text top="344" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18157036">18157036</a></text>
<text top="344" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18157036"> </a></text>
<text top="348" left="93" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18157036"> </a></text>
<text top="307" left="244" width="146" height="19" font="8"><b>Aim:</b> Describe a pt who </text>
<text top="326" left="244" width="143" height="19" font="0">developed bradycardia </text>
<text top="344" left="244" width="164" height="19" font="0">during surgical positioning </text>
<text top="362" left="244" width="140" height="19" font="0">of an unstable cervical </text>
<text top="381" left="244" width="36" height="19" font="0">spine </text>
<text top="399" left="244" width="3" height="19" font="0"> </text>
<text top="417" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="436" left="244" width="3" height="19" font="0"> </text>
<text top="454" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="307" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="326" left="420" width="3" height="19" font="0"> </text>
<text top="344" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="308" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="326" left="608" width="3" height="19" font="0"> </text>
<text top="345" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="363" left="608" width="301" height="20" font="0">• Bradycardia (35 bpm) and hypotension (50 mm </text>
<text top="382" left="608" width="197" height="19" font="0">Hg) with initial skull positioning  </text>
<text top="401" left="608" width="291" height="20" font="0">• Atropine and beta agonists not successful but </text>
<text top="420" left="608" width="248" height="19" font="0">surgical repositioning of the spine led to </text>
<text top="438" left="608" width="293" height="19" font="0">resolution and development of a heart rate 100 </text>
<text top="456" left="608" width="31" height="19" font="0">bpm<b> </b></text>
<text top="308" left="925" width="101" height="20" font="0">• Case report of </text>
<text top="326" left="936" width="137" height="19" font="0">bradycardia with skull </text>
<text top="345" left="936" width="71" height="19" font="0">positioning </text>
<text top="475" left="93" width="137" height="19" font="0">Ardesch JJ, et al. 2007 </text>
<text top="494" left="93" width="39" height="19" font="0">(319)  </text>
<text top="512" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17825483">17825483</a></text>
<text top="512" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17825483"> </a></text>
<text top="516" left="93" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17825483"> </a></text>
<text top="475" left="244" width="136" height="19" font="8"><b>Aim:</b> Describe cardiac </text>
<text top="494" left="244" width="130" height="19" font="0">responses with vagal </text>
<text top="512" left="244" width="111" height="19" font="0">nerve stimulation </text>
<text top="530" left="244" width="3" height="19" font="0"> </text>
<text top="548" left="244" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="567" left="244" width="3" height="19" font="0"> </text>
<text top="585" left="244" width="58" height="19" font="8"><b>Size:</b> 111 </text>
<text top="475" left="420" width="163" height="19" font="8"><b>Inclusion criteria:</b> Pts who </text>
<text top="494" left="420" width="139" height="19" font="0">received a vagal nerve </text>
<text top="512" left="420" width="169" height="19" font="0">stimulator for treatment of </text>
<text top="530" left="420" width="54" height="19" font="0">epilepsy </text>
<text top="549" left="420" width="3" height="19" font="0"> </text>
<text top="567" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="476" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="494" left="608" width="3" height="19" font="0"> </text>
<text top="513" left="608" width="234" height="19" font="8"><b>Results:</b> 3 cases of bradycardia during </text>
<text top="531" left="608" width="250" height="19" font="0">intraoperative testing. Not subsequently </text>
<text top="549" left="608" width="220" height="19" font="0">observed on postoperative testing. <b> </b></text>
<text top="475" left="925" width="148" height="20" font="0">• Transient bradycardia </text>
<text top="494" left="936" width="134" height="19" font="0">can be observed with </text>
<text top="513" left="936" width="115" height="19" font="0">vagal stimulation.  </text>
<text top="604" left="93" width="88" height="19" font="0">Jones PM and </text>
<text top="623" left="93" width="128" height="19" font="0">Soderman RM, 2007 </text>
<text top="641" left="93" width="35" height="19" font="0">(320) </text>
<text top="659" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17223834">17223834</a></text>
<text top="659" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17223834"> </a></text>
<text top="604" left="244" width="146" height="19" font="8"><b>Aim:</b> Describe a pt on 2 </text>
<text top="623" left="244" width="153" height="19" font="0">cholinesterase inhibitors </text>
<text top="641" left="244" width="98" height="19" font="0">who developed </text>
<text top="659" left="244" width="91" height="19" font="0">intraoperative </text>
<text top="677" left="244" width="76" height="19" font="0">bradycardia </text>
<text top="696" left="244" width="3" height="19" font="0"> </text>
<text top="714" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="732" left="244" width="3" height="19" font="0"> </text>
<text top="751" left="244" width="43" height="19" font="8"><b>Size:</b> 1 </text>
<text top="604" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="623" left="420" width="3" height="19" font="0"> </text>
<text top="641" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="605" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="623" left="608" width="3" height="19" font="0"> </text>
<text top="642" left="608" width="295" height="19" font="8"><b>Results:</b> Bradycardia (35 bpm) with induction of </text>
<text top="660" left="608" width="69" height="19" font="0">anesthesia<b> </b></text>
<text top="604" left="925" width="146" height="20" font="0">• Bradycardia (35 bpm) </text>
<text top="623" left="936" width="107" height="19" font="0">with induction of </text>
<text top="642" left="936" width="69" height="19" font="0">anesthesia </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 193 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="93" width="129" height="19" font="0">Wijeysundera DN, et </text>
<text top="105" left="93" width="87" height="19" font="0">al. 2014 (321) </text>
<text top="123" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25091545">25091545</a></text>
<text top="123" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25091545"> </a></text>
<text top="128" left="93" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25091545"> </a></text>
<text top="87" left="244" width="121" height="19" font="8"><b>Aim:</b> ERC report on </text>
<text top="105" left="244" width="130" height="19" font="0">perioperative BB use </text>
<text top="123" left="244" width="3" height="19" font="0"> </text>
<text top="142" left="244" width="162" height="19" font="8"><b>Study type: </b>Meta-analysis </text>
<text top="160" left="244" width="3" height="19" font="0"> </text>
<text top="178" left="244" width="59" height="19" font="8"><b>Size:</b> N/A </text>
<text top="87" left="420" width="154" height="19" font="8"><b>Inclusion criteria:</b> Varied </text>
<text top="105" left="420" width="92" height="19" font="0">among studies </text>
<text top="123" left="420" width="3" height="19" font="0"> </text>
<text top="142" left="420" width="157" height="19" font="8"><b>Exclusion criteria:</b> Varied </text>
<text top="160" left="420" width="92" height="19" font="0">among studies </text>
<text top="88" left="608" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Bradycardia </text>
<text top="106" left="608" width="3" height="19" font="0"> </text>
<text top="124" left="608" width="274" height="19" font="8"><b>Results:</b> Perioperative beta blockade started </text>
<text top="143" left="608" width="270" height="19" font="0">within 1 d or less before noncardiac surgery </text>
<text top="161" left="608" width="301" height="19" font="0">increases risks of intraoperative bradycardia (RR: </text>
<text top="179" left="608" width="158" height="19" font="0">2.61; 95% CI: 2.18– 3.12). </text>
<text top="87" left="925" width="128" height="20" font="0">• Perioperative beta </text>
<text top="106" left="936" width="158" height="19" font="0">blockade started within 1 </text>
<text top="124" left="936" width="98" height="19" font="0">d or less before </text>
<text top="143" left="936" width="120" height="19" font="0">noncardiac surgery </text>
<text top="161" left="936" width="107" height="19" font="0">increases risks of </text>
<text top="179" left="936" width="91" height="19" font="0">intraoperative </text>
<text top="198" left="936" width="79" height="19" font="0">bradycardia  </text>
<text top="217" left="86" width="4" height="21" font="4"> </text>
<text top="237" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="259" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="278" left="137" width="51" height="19" font="8"><b>Author; </b></text>
<text top="296" left="115" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="259" left="263" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="278" left="292" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="259" left="454" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="259" left="645" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="278" left="676" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="296" left="707" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="259" left="915" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="278" left="944" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="315" left="95" width="128" height="19" font="0">Morris D, et al. 1987 </text>
<text top="333" left="95" width="35" height="19" font="0">(322) </text>
<text top="352" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3675104">3675104</a></text>
<text top="352" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3675104"> </a></text>
<text top="370" left="95" width="3" height="19" font="0"> </text>
<text top="315" left="244" width="112" height="19" font="8"><b>Aim:</b> Evaluate the </text>
<text top="333" left="244" width="143" height="19" font="0">incidence of CHB in pts </text>
<text top="352" left="244" width="158" height="19" font="0">with LBBB undergoing PA </text>
<text top="370" left="244" width="123" height="19" font="0">catheter placement </text>
<text top="388" left="244" width="3" height="19" font="0"> </text>
<text top="407" left="244" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="425" left="244" width="3" height="19" font="0"> </text>
<text top="443" left="244" width="103" height="19" font="8"><b>Size:</b> 47 pts who </text>
<text top="462" left="244" width="109" height="19" font="0">underwent 82 PA </text>
<text top="480" left="244" width="129" height="19" font="0">catheter placements </text>
<text top="315" left="420" width="183" height="19" font="8"><b>Inclusion criteria:</b> All pts with </text>
<text top="333" left="420" width="155" height="19" font="0">LBBB who underwent PA </text>
<text top="352" left="420" width="123" height="19" font="0">catheter placement </text>
<text top="370" left="420" width="3" height="19" font="0"> </text>
<text top="388" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="316" left="620" width="110" height="19" font="8"><b>1</b>°<b> endpoint:</b> CHB </text>
<text top="334" left="620" width="3" height="19" font="0"> </text>
<text top="352" left="620" width="52" height="19" font="8"><b>Results: </b></text>
<text top="371" left="619" width="226" height="20" font="0">•  5 episodes of CHB in the setting of </text>
<text top="390" left="633" width="185" height="19" font="0">old LBBB but none temporally </text>
<text top="408" left="633" width="206" height="19" font="0">related to PA catheter placement </text>
<text top="427" left="619" width="226" height="20" font="0">•  2 episodes of CHB in the setting of </text>
<text top="446" left="633" width="192" height="19" font="0">new LBBB but none temporally </text>
<text top="464" left="633" width="197" height="19" font="0">related to PA catheter insertion-</text>
<text top="482" left="633" width="220" height="19" font="0">though occurred while the catheter </text>
<text top="501" left="633" width="78" height="19" font="0">was in place<b> </b></text>
<text top="315" left="871" width="186" height="20" font="0">•  Authors do not recommend </text>
<text top="334" left="884" width="147" height="19" font="0">prophylactic temporary </text>
<text top="353" left="884" width="125" height="19" font="0">transvenous pacing  </text>
<text top="371" left="871" width="3" height="19" font="0"> </text>
<text top="389" left="871" width="3" height="19" font="0"> </text>
<text top="530" left="95" width="131" height="19" font="0">Elliott CG, et al. 1979 </text>
<text top="548" left="95" width="35" height="19" font="0">(323) </text>
<text top="566" left="95" width="49" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=510002">510002 </a></text>
<text top="566" left="144" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=510002"> </a></text>
<text top="571" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=510002"> </a></text>
<text top="530" left="244" width="88" height="19" font="8"><b>Aim:</b> Evaluate </text>
<text top="548" left="244" width="156" height="19" font="0">complications associated </text>
<text top="566" left="244" width="105" height="19" font="0">with PA catheter </text>
<text top="585" left="244" width="68" height="19" font="0">placement </text>
<text top="603" left="244" width="3" height="19" font="0"> </text>
<text top="621" left="244" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="640" left="244" width="3" height="19" font="0"> </text>
<text top="658" left="244" width="139" height="19" font="8"><b>Size:</b> 116 PA catheters </text>
<text top="530" left="420" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="548" left="420" width="173" height="19" font="0">Consecutive pts undergoing </text>
<text top="566" left="420" width="143" height="19" font="0">PA catheter placement </text>
<text top="585" left="420" width="3" height="19" font="0"> </text>
<text top="603" left="420" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="531" left="620" width="192" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias, ECG </text>
<text top="549" left="631" width="161" height="19" font="0">changes, or complications </text>
<text top="567" left="620" width="3" height="19" font="0"> </text>
<text top="585" left="620" width="224" height="19" font="8"><b>Results:</b> Transient RBBB in 3% of pts<b> </b></text>
<text top="530" left="871" width="173" height="20" font="0">•  Transient RBBB fairly rare </text>
<text top="677" left="95" width="135" height="19" font="0">Unnikrishnan D, et al. </text>
<text top="695" left="95" width="69" height="19" font="0">2003 (324) </text>
<text top="714" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14570803">14570803</a></text>
<text top="714" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14570803"> </a></text>
<text top="677" left="244" width="89" height="19" font="8"><b>Aim:</b> Describe </text>
<text top="695" left="244" width="156" height="19" font="0">complications associated </text>
<text top="714" left="244" width="105" height="19" font="0">with PA catheter </text>
<text top="732" left="244" width="68" height="19" font="0">placement </text>
<text top="750" left="244" width="3" height="19" font="0"> </text>
<text top="768" left="244" width="148" height="19" font="8"><b>Study type:</b> Case report </text>
<text top="677" left="420" width="139" height="19" font="8"><b>Inclusion criteria:</b> N/A </text>
<text top="695" left="420" width="3" height="19" font="0"> </text>
<text top="714" left="420" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="678" left="620" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="696" left="620" width="3" height="19" font="0"> </text>
<text top="714" left="620" width="217" height="19" font="8"><b>Results:</b> Complete heart block with </text>
<text top="733" left="620" width="228" height="19" font="0">central venous line placement in a pt </text>
<text top="751" left="620" width="65" height="19" font="0">with LBBB<b> </b></text>
<text top="677" left="871" width="200" height="20" font="0">•  Transient CHB may occur with </text>
<text top="696" left="884" width="177" height="19" font="0">placement of central venous </text>
<text top="714" left="884" width="55" height="19" font="0">catheter </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 194 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="244" width="3" height="19" font="0"> </text>
<text top="105" left="244" width="43" height="19" font="8"><b>Size:</b> 1<b> </b></text>
<text top="173" left="86" width="4" height="21" font="4"> </text>
<text top="193" left="86" width="831" height="23" font="5"><b>Data Supplement 47. Nonrandomized Trials, Observational Studies, and/or Registries of CABG (Section 8.1.2.1) </b></text>
<text top="216" left="99" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="234" left="125" width="51" height="19" font="8"><b>Author; </b></text>
<text top="253" left="100" width="100" height="19" font="8"><b>Year Published’ </b></text>
<text top="271" left="131" width="38" height="19" font="8"><b>PMID </b></text>
<text top="216" left="223" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="234" left="252" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="216" left="379" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="216" left="602" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="234" left="601" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="216" left="919" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="234" left="948" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="290" left="95" width="100" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Bougioukas%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28122567">Bougioukas </a>I, et </text>
<text top="308" left="95" width="18" height="19" font="0">al. </text>
<text top="327" left="95" width="69" height="19" font="0">2017 (336) </text>
<text top="345" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28122567">28122567</a></text>
<text top="345" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28122567"> </a></text>
<text top="290" left="219" width="121" height="19" font="8"><b>Aim:</b> Correlation of </text>
<text top="308" left="219" width="111" height="19" font="0">temporary pacing </text>
<text top="327" left="219" width="110" height="19" font="0">wire removal and </text>
<text top="345" left="219" width="56" height="19" font="0">bleeding </text>
<text top="363" left="219" width="3" height="19" font="0"> </text>
<text top="381" left="219" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="400" left="219" width="89" height="19" font="0">Observational </text>
<text top="418" left="219" width="3" height="19" font="0"> </text>
<text top="436" left="219" width="69" height="19" font="8"><b>Size:</b> 4244  </text>
<text top="290" left="365" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="308" left="365" width="120" height="19" font="0">undergoing cardiac </text>
<text top="327" left="365" width="49" height="19" font="0">surgery </text>
<text top="290" left="526" width="183" height="19" font="8"><b>Intervention:</b> Cardiac surgery </text>
<text top="308" left="526" width="7" height="19" font="0">  </text>
<text top="327" left="526" width="296" height="19" font="8"><b>Comparator:</b> Pts who underwent re-exploration </text>
<text top="345" left="526" width="173" height="19" font="0">unrelated to pacer removal<b>  </b></text>
<text top="363" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="382" left="526" width="322" height="19" font="8"><b>1</b>°<b> endpoint:</b> 0.18% bleeding after temporary pacing </text>
<text top="401" left="526" width="84" height="19" font="0">wire removal </text>
<text top="419" left="526" width="3" height="19" font="0"> </text>
<text top="437" left="526" width="289" height="19" font="8"><b>Safety endpoint:</b> 2 pts died after removal from </text>
<text top="456" left="526" width="74" height="19" font="0">tamponade </text>
<text top="290" left="879" width="143" height="20" font="0">• Retrospective review </text>
<text top="309" left="879" width="12" height="20" font="4">• </text>
<text top="311" left="890" width="195" height="19" font="0">Not clear of decision to leave in </text>
<text top="330" left="890" width="199" height="19" font="0">and cut wires instead of removal</text>
<text top="328" left="1089" width="4" height="21" font="4"> </text>
<text top="475" left="95" width="103" height="19" font="0">Bethea BT, et al. </text>
<text top="493" left="95" width="69" height="19" font="0">2005 (337) </text>
<text top="511" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15620924">15620924</a></text>
<text top="511" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15620924"> </a></text>
<text top="530" left="95" width="3" height="19" font="0"> </text>
<text top="475" left="219" width="101" height="19" font="8"><b>Aim:</b> Determine </text>
<text top="493" left="219" width="123" height="19" font="0">need for temporary </text>
<text top="511" left="219" width="43" height="19" font="0">pacing </text>
<text top="530" left="219" width="3" height="19" font="0"> </text>
<text top="548" left="219" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="566" left="219" width="89" height="19" font="0">Observational </text>
<text top="584" left="219" width="3" height="19" font="0"> </text>
<text top="603" left="219" width="58" height="19" font="8"><b>Size:</b> 222 </text>
<text top="475" left="365" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="493" left="365" width="38" height="19" font="0">CABG </text>
<text top="511" left="365" width="3" height="19" font="0"> </text>
<text top="529" left="365" width="136" height="19" font="8"><b>Exclusion criteria:</b> OP-</text>
<text top="548" left="365" width="38" height="19" font="0">CABG </text>
<text top="475" left="526" width="123" height="19" font="8"><b>Intervention:</b> CABG </text>
<text top="493" left="526" width="7" height="19" font="0">  </text>
<text top="512" left="526" width="328" height="19" font="8"><b>1</b>°<b> endpoint:</b> 3 risk factors related to need for pacing: </text>
<text top="530" left="526" width="282" height="19" font="0">DM, need for pacing at CPB separation, preop </text>
<text top="549" left="526" width="71" height="19" font="0">arrhythmia<b> </b></text>
<text top="475" left="879" width="135" height="20" font="0">• Small, retrospective </text>
<text top="494" left="879" width="12" height="20" font="4">• </text>
<text top="496" left="890" width="205" height="19" font="0">Even after risk factors eliminated </text>
<text top="514" left="890" width="144" height="19" font="0">2.6% still needed wires.</text>
<text top="513" left="1033" width="4" height="21" font="4"> </text>
<text top="622" left="95" width="100" height="19" font="0">Puskas JD, et al. </text>
<text top="640" left="95" width="69" height="19" font="0">2003 (338) </text>
<text top="659" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14721993">14721993</a></text>
<text top="659" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14721993"> </a></text>
<text top="622" left="219" width="113" height="19" font="8"><b>Aim:</b> Compare off-</text>
<text top="640" left="219" width="117" height="19" font="0">pump vs. on pump </text>
<text top="659" left="219" width="38" height="19" font="0">CABG </text>
<text top="677" left="219" width="3" height="19" font="0"> </text>
<text top="695" left="219" width="127" height="19" font="8"><b>Study type:</b> RCT sub-</text>
<text top="713" left="219" width="51" height="19" font="0">analysis </text>
<text top="732" left="219" width="3" height="19" font="0"> </text>
<text top="750" left="219" width="58" height="19" font="8"><b>Size:</b> 200 </text>
<text top="622" left="365" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="640" left="365" width="111" height="19" font="0">undergoing CABG </text>
<text top="659" left="365" width="3" height="19" font="0"> </text>
<text top="677" left="365" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="695" left="365" width="106" height="19" font="0">Addition of valve </text>
<text top="713" left="365" width="135" height="19" font="0">surgery recognized at </text>
<text top="732" left="365" width="111" height="19" font="0">time of operation </text>
<text top="622" left="526" width="319" height="19" font="8"><b>Intervention:</b> Temporary pacing wires only placed if </text>
<text top="640" left="526" width="177" height="19" font="0">needed before chest closure </text>
<text top="659" left="526" width="7" height="19" font="0">  </text>
<text top="678" left="526" width="250" height="19" font="8"><b>1</b>°<b> endpoint:</b> Only 17% of pts need wires </text>
<text top="696" left="526" width="3" height="19" font="0"> </text>
<text top="714" left="526" width="327" height="19" font="8"><b>Safety endpoint:</b> No adverse event in the non-pacing </text>
<text top="733" left="526" width="70" height="19" font="0">wire group<b> </b></text>
<text top="622" left="879" width="192" height="20" font="0">• Not intervention randomized </text>
<text top="641" left="879" width="135" height="20" font="0">• Small, retrospective </text>
<text top="660" left="879" width="196" height="20" font="0">• Does not discuss any need for </text>
<text top="679" left="890" width="87" height="19" font="0">pacing Swann </text>
<text top="698" left="879" width="12" height="20" font="4">• </text>
<text top="700" left="890" width="201" height="19" font="0">No adverse event reported from </text>
<text top="718" left="890" width="77" height="19" font="0">pulling wires</text>
<text top="717" left="967" width="4" height="21" font="4"> </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 195 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="84" height="19" font="0">Caspi Y, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">1987 (339) </text>
<text top="123" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3493391">3493391</a></text>
<text top="123" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3493391"> </a></text>
<text top="87" left="219" width="83" height="19" font="8"><b>Aim:</b> Identify </text>
<text top="105" left="219" width="77" height="19" font="0">incidence of </text>
<text top="123" left="219" width="108" height="19" font="0">conduction block </text>
<text top="142" left="219" width="69" height="19" font="0">after CABB </text>
<text top="160" left="219" width="3" height="19" font="0"> </text>
<text top="178" left="219" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="197" left="219" width="89" height="19" font="0">Observational </text>
<text top="215" left="219" width="3" height="19" font="0"> </text>
<text top="233" left="219" width="58" height="19" font="8"><b>Size:</b> 316 </text>
<text top="87" left="365" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="105" left="365" width="111" height="19" font="0">undergoing CABG </text>
<text top="87" left="526" width="123" height="19" font="8"><b>Intervention:</b> CABG </text>
<text top="105" left="526" width="7" height="19" font="0">  </text>
<text top="123" left="526" width="325" height="19" font="8"><b>Comparator:</b> Pts who did not have conduction block<b>  </b></text>
<text top="142" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="161" left="526" width="294" height="19" font="8"><b>1</b>°<b> endpoint:</b> 17% had new bundle branch block </text>
<text top="179" left="526" width="305" height="19" font="0">associated with preop MI, low cardiac output and </text>
<text top="198" left="526" width="39" height="19" font="0">death<b> </b></text>
<text top="88" left="879" width="11" height="18" font="0">• </text>
<text top="87" left="890" width="8" height="21" font="4">S</text>
<text top="88" left="897" width="118" height="19" font="0">mall. retrospective </text>
<text top="107" left="879" width="19" height="22" font="4">• P</text>
<text top="109" left="898" width="196" height="19" font="0">otentially dated due to changes </text>
<text top="128" left="890" width="126" height="19" font="0">in surgical technique</text>
<text top="127" left="1015" width="4" height="21" font="4"> </text>
<text top="252" left="95" width="99" height="19" font="0">Zeldis SM, et al. </text>
<text top="271" left="95" width="69" height="19" font="0">1978 (340) </text>
<text top="289" left="95" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=306190">306190</a></text>
<text top="289" left="140" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=306190"> </a></text>
<text top="252" left="219" width="83" height="19" font="8"><b>Aim:</b> Identify </text>
<text top="271" left="219" width="110" height="19" font="0">frequency of new </text>
<text top="289" left="219" width="133" height="19" font="0">fascicular conduction </text>
<text top="307" left="219" width="114" height="19" font="0">disturbances after </text>
<text top="326" left="219" width="38" height="19" font="0">CABG </text>
<text top="344" left="219" width="3" height="19" font="0"> </text>
<text top="362" left="219" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="381" left="219" width="92" height="19" font="0">Observational  </text>
<text top="252" left="365" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="271" left="365" width="90" height="19" font="0">Isolated CABG </text>
<text top="252" left="526" width="123" height="19" font="8"><b>Intervention:</b> CABG </text>
<text top="271" left="526" width="7" height="19" font="0">  </text>
<text top="289" left="526" width="325" height="19" font="8"><b>Comparator:</b> Pts who did not have conduction block<b>  </b></text>
<text top="307" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="326" left="526" width="340" height="19" font="8"><b>1</b>°<b> endpoint:</b> 20% new disturbances, 6% RBBB, 6% LAH. </text>
<text top="345" left="526" width="297" height="19" font="0">Pts with transient or persistent LBB or L anterior </text>
<text top="363" left="526" width="287" height="19" font="0">hemiblock had increased late mortality and MI </text>
<text top="253" left="879" width="135" height="20" font="0">• Small, retrospective </text>
<text top="272" left="879" width="12" height="20" font="4">• </text>
<text top="274" left="890" width="204" height="19" font="0">Potentially dated due to changes </text>
<text top="292" left="890" width="126" height="19" font="0">in surgical technique</text>
<text top="291" left="1015" width="4" height="21" font="4"> </text>
<text top="400" left="95" width="89" height="19" font="0">Cook DJ, et al. </text>
<text top="418" left="95" width="69" height="19" font="0">2005 (341) </text>
<text top="436" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16242447">16242447</a></text>
<text top="436" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16242447"> </a></text>
<text top="400" left="219" width="76" height="19" font="8"><b>Aim: </b>Assess </text>
<text top="418" left="219" width="107" height="19" font="0">incidence of<b> n</b>ew </text>
<text top="436" left="219" width="120" height="19" font="0">conduction defects </text>
<text top="455" left="219" width="95" height="19" font="0">over time after </text>
<text top="473" left="219" width="89" height="19" font="0">isolated CABG </text>
<text top="491" left="219" width="3" height="19" font="0"> </text>
<text top="509" left="219" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="528" left="219" width="92" height="19" font="0">Observational  </text>
<text top="546" left="219" width="3" height="19" font="8"><b> </b></text>
<text top="564" left="219" width="58" height="19" font="8"><b>Size: </b>800<b> </b></text>
<text top="400" left="365" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="418" left="365" width="112" height="19" font="0">Isolated CABG pts<b> </b></text>
<text top="436" left="365" width="3" height="19" font="8"><b> </b></text>
<text top="454" left="365" width="138" height="19" font="8"><b>Exclusion criteria: </b>Pre-</text>
<text top="473" left="365" width="122" height="19" font="0">existing conduction </text>
<text top="491" left="365" width="140" height="19" font="0">defect, PM, peri-op AF </text>
<text top="400" left="526" width="126" height="19" font="8"><b>Intervention:</b> CABG<b>  </b></text>
<text top="418" left="526" width="7" height="19" font="8"><b>  </b></text>
<text top="436" left="526" width="335" height="19" font="8"><b>Comparator: </b>Pts whose operations were performed in </text>
<text top="455" left="526" width="87" height="19" font="0">1991 vs. 2001 </text>
<text top="473" left="526" width="3" height="19" font="0"> </text>
<text top="492" left="526" width="327" height="19" font="8"><b>1</b>°<b> endpoint: </b>Decline in conduction defects from 19% </text>
<text top="510" left="526" width="315" height="19" font="0">to 6%. Associated with year of operation, age, IABP </text>
<text top="529" left="526" width="295" height="19" font="0">use, number of vessels bypassed and crystalloid </text>
<text top="547" left="526" width="78" height="19" font="0">cardioplegia </text>
<text top="565" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="583" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="400" left="879" width="135" height="20" font="0">• Small, retrospective<b> </b></text>
<text top="603" left="95" width="100" height="19" font="0">Tuzcu EM, et al. </text>
<text top="621" left="95" width="69" height="19" font="0">1990 (342) </text>
<text top="639" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2387933">2387933</a></text>
<text top="639" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2387933"> </a></text>
<text top="603" left="219" width="83" height="19" font="8"><b>Aim: </b>Identify </text>
<text top="621" left="219" width="88" height="19" font="0">incidence and </text>
<text top="639" left="219" width="120" height="19" font="0">significance of new </text>
<text top="658" left="219" width="120" height="19" font="0">conduction defects </text>
<text top="676" left="219" width="71" height="19" font="0">after CABG </text>
<text top="694" left="219" width="3" height="19" font="8"><b> </b></text>
<text top="712" left="219" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="731" left="219" width="92" height="19" font="0">Observational, </text>
<text top="749" left="219" width="57" height="19" font="0">matched </text>
<text top="767" left="219" width="3" height="19" font="8"><b> </b></text>
<text top="603" left="365" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="621" left="365" width="140" height="19" font="0">Isolated elective CABG<b> </b></text>
<text top="603" left="526" width="123" height="19" font="8"><b>Intervention: </b>CABG<b> </b></text>
<text top="621" left="526" width="7" height="19" font="8"><b>  </b></text>
<text top="639" left="526" width="314" height="19" font="8"><b>Comparator: </b>Matched pts w/o conduction defects<b>  </b></text>
<text top="657" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="677" left="526" width="324" height="19" font="8"><b>1</b>°<b> endpoint: </b>5.5% new conduction block, 85% RBBB, </text>
<text top="695" left="526" width="319" height="19" font="0">4% LBBB. No difference in late mortality or need for </text>
<text top="713" left="526" width="151" height="19" font="0">PM with matched group<b> </b></text>
<text top="603" left="879" width="135" height="20" font="0">• Small, retrospective </text>
<text top="622" left="879" width="3" height="19" font="8"><b> </b></text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 196 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="219" width="69" height="19" font="8"><b>Size: </b>2,000<b> </b></text>
<text top="173" left="95" width="109" height="19" font="0">Ngaage DL, et al.  </text>
<text top="191" left="95" width="69" height="19" font="0">2007 (343) </text>
<text top="210" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17198809">17198809</a></text>
<text top="210" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17198809"> </a></text>
<text top="173" left="219" width="108" height="19" font="8"><b>Aim</b>: Influence of </text>
<text top="191" left="219" width="78" height="19" font="0">preop AF on </text>
<text top="210" left="219" width="97" height="19" font="0">outcomes after </text>
<text top="228" left="219" width="38" height="19" font="0">CABG </text>
<text top="246" left="219" width="3" height="19" font="8"><b> </b></text>
<text top="265" left="219" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="283" left="219" width="90" height="19" font="0">observational, </text>
<text top="301" left="219" width="57" height="19" font="0">matched </text>
<text top="319" left="219" width="3" height="19" font="8"><b> </b></text>
<text top="338" left="219" width="58" height="19" font="8"><b>Size: </b>526<b> </b></text>
<text top="173" left="365" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="191" left="365" width="141" height="19" font="0">undergoing CABG with </text>
<text top="210" left="365" width="62" height="19" font="0">preop AF <b> </b></text>
<text top="173" left="526" width="123" height="19" font="8"><b>Intervention: </b>CABG<b> </b></text>
<text top="191" left="526" width="7" height="19" font="8"><b>  </b></text>
<text top="210" left="526" width="166" height="19" font="8"><b>Comparator</b>: Matched pts<b>  </b></text>
<text top="228" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="247" left="526" width="325" height="19" font="8"><b>1</b>°<b> endpoint: </b>AF pts: higher MACE, late mortality and </text>
<text top="266" left="526" width="187" height="19" font="0">late PM implantation (RR: 2.1)<b> </b></text>
<text top="173" left="879" width="135" height="20" font="0">• Small, retrospective </text>
<text top="192" left="879" width="3" height="19" font="8"><b> </b></text>
<text top="357" left="95" width="85" height="19" font="0">Yesil M, et al. </text>
<text top="375" left="95" width="69" height="19" font="0">2008 (344) </text>
<text top="394" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18855876">18855876</a></text>
<text top="394" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18855876"> </a></text>
<text top="412" left="95" width="3" height="19" font="0"> </text>
<text top="357" left="219" width="101" height="19" font="8"><b>Aim: </b>Determine </text>
<text top="375" left="219" width="55" height="19" font="0">effect of </text>
<text top="394" left="219" width="126" height="19" font="0">revascularization on </text>
<text top="412" left="219" width="122" height="19" font="0">present conduction </text>
<text top="430" left="219" width="81" height="19" font="0">disturbances </text>
<text top="448" left="219" width="3" height="19" font="8"><b> </b></text>
<text top="467" left="219" width="74" height="19" font="8"><b>Study type: </b></text>
<text top="485" left="219" width="89" height="19" font="0">Observational </text>
<text top="503" left="219" width="3" height="19" font="0"> </text>
<text top="522" left="219" width="50" height="19" font="8"><b>Size: </b>53<b> </b></text>
<text top="357" left="365" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="375" left="365" width="94" height="19" font="0">with CAD and 3</text>
<text top="375" left="459" width="9" height="12" font="7">rd</text>
<text top="375" left="468" width="3" height="19" font="0"> </text>
<text top="394" left="365" width="82" height="19" font="0">degree block<b> </b></text>
<text top="412" left="365" width="3" height="19" font="8"><b> </b></text>
<text top="430" left="365" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="449" left="365" width="97" height="19" font="0">Acute coronary </text>
<text top="467" left="365" width="64" height="19" font="0">syndrome </text>
<text top="357" left="526" width="195" height="19" font="8"><b>Intervention: </b>Revascularization<b> </b></text>
<text top="375" left="526" width="7" height="19" font="8"><b>  </b></text>
<text top="393" left="526" width="264" height="19" font="8"><b>Comparator</b>: Medical management of CAD </text>
<text top="412" left="526" width="3" height="19" font="8"><b> </b></text>
<text top="431" left="526" width="268" height="19" font="8"><b>1</b>°<b> endpoint: </b>81% in medical arm vs. 73% in </text>
<text top="449" left="526" width="287" height="19" font="0">revascularized arm still in 3 degree heart block<b> </b></text>
<text top="357" left="879" width="135" height="20" font="0">• Small, retrospective </text>
<text top="376" left="879" width="3" height="19" font="8"><b> </b></text>
<text top="541" left="93" width="108" height="19" font="0">Satinsky JD, et al. </text>
<text top="559" left="93" width="69" height="19" font="0">1974 (345) </text>
<text top="577" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/4843620">4843620</a></text>
<text top="577" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/4843620"> </a></text>
<text top="541" left="219" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="559" left="219" width="118" height="19" font="0">Retrospective case </text>
<text top="577" left="219" width="39" height="19" font="0">series </text>
<text top="596" left="219" width="3" height="19" font="0"> </text>
<text top="614" left="219" width="80" height="19" font="8"><b>Size:</b> 280 pts<b> </b></text>
<text top="541" left="365" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="559" left="365" width="120" height="19" font="0">undergoing cardiac </text>
<text top="577" left="365" width="49" height="19" font="0">surgery<b> </b></text>
<text top="542" left="526" width="312" height="19" font="8"><b>1</b>°<b> endpoint:</b> New conduction defects after cardiac </text>
<text top="560" left="537" width="49" height="19" font="0">surgery </text>
<text top="578" left="526" width="3" height="19" font="0"> </text>
<text top="597" left="526" width="338" height="19" font="8"><b>Results:</b> 6% of all pts had new conduction defects, 12% </text>
<text top="615" left="526" width="321" height="19" font="0">after valve surgery-only 0.7% of total, both valve pts </text>
<text top="633" left="526" width="80" height="19" font="0">required PM<b> </b></text>
<text top="541" left="879" width="180" height="20" font="0">• Small, retrospective, mixed </text>
<text top="560" left="890" width="39" height="19" font="0">group </text>
<text top="652" left="86" width="4" height="21" font="4"> </text>
<text top="672" left="86" width="4" height="23" font="5"><b> </b></text>
<text top="672" left="302" width="4" height="23" font="5"><b> </b></text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 197 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="1007" height="23" font="5"><b>Data Supplement 48. Nonrandomized Trials, Observational Studies, and/or Registries of Open Surgery for Atrial Fibrillation or Valvular </b></text>
<text top="108" left="86" width="279" height="23" font="5"><b>Surgery (Section 8.1.2.2. and 8.1.2.3) </b></text>
<text top="131" left="98" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="124" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="100" width="100" height="19" font="8"><b>Year Published’ </b></text>
<text top="186" left="131" width="38" height="19" font="8"><b>PMID </b></text>
<text top="131" left="249" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="278" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="436" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="659" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="658" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="131" left="945" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="974" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="217" left="95" width="106" height="19" font="0">Dawkins S, et al.  </text>
<text top="235" left="95" width="69" height="19" font="0">2008 (332) </text>
<text top="254" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18154792">18154792</a></text>
<text top="254" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18154792"> </a></text>
<text top="217" left="217" width="163" height="19" font="8"><b>Aim: </b>Determine incidence </text>
<text top="235" left="217" width="173" height="19" font="0">and predictors of PPM after </text>
<text top="254" left="217" width="29" height="19" font="0">AVR </text>
<text top="272" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="290" left="217" width="166" height="19" font="8"><b>Study type: </b>Observational  </text>
<text top="309" left="217" width="3" height="19" font="0"> </text>
<text top="327" left="217" width="58" height="19" font="8"><b>Size: </b>354<b> </b></text>
<text top="217" left="419" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="235" left="419" width="102" height="19" font="0">undergoing AVR<b> </b></text>
<text top="254" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="272" left="419" width="135" height="19" font="8"><b>Exclusion criteria: </b>Pts </text>
<text top="290" left="419" width="111" height="19" font="0">with preop pacer<b>  </b></text>
<text top="217" left="587" width="177" height="19" font="8"><b>Intervention: </b>PM placement<b> </b></text>
<text top="235" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="254" left="587" width="197" height="19" font="8"><b>Comparator</b>: No pacer required<b> </b></text>
<text top="273" left="587" width="314" height="19" font="8"><b>1</b>°<b> endpoint: </b>8.5% required permanent pacer. Only </text>
<text top="291" left="587" width="299" height="19" font="0">predictor: preop conduction system disease (RR: </text>
<text top="309" left="587" width="38" height="19" font="0">2.88).<b> </b></text>
<text top="217" left="932" width="135" height="20" font="0">• Small, retrospective </text>
<text top="236" left="932" width="3" height="19" font="8"><b> </b></text>
<text top="346" left="95" width="98" height="19" font="0">Limongelli G, et </text>
<text top="364" left="95" width="87" height="19" font="0">al. 2003 (346) </text>
<text top="383" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12860869">12860869</a></text>
<text top="383" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12860869"> </a></text>
<text top="346" left="217" width="171" height="19" font="8"><b>Aim: </b>Identify incidence and </text>
<text top="364" left="217" width="175" height="19" font="0">predictors of PPM after AVR </text>
<text top="383" left="217" width="3" height="19" font="0"> </text>
<text top="401" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="419" left="217" width="44" height="19" font="0">cohort </text>
<text top="438" left="217" width="3" height="19" font="0"> </text>
<text top="456" left="217" width="58" height="19" font="8"><b>Size: </b>276 </text>
<text top="346" left="419" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="364" left="419" width="102" height="19" font="0">undergoing AVR<b> </b></text>
<text top="346" left="587" width="117" height="19" font="8"><b>Intervention: </b>PPM<b> </b></text>
<text top="364" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="382" left="587" width="135" height="19" font="8"><b>Comparator: </b>No PPM<b> </b></text>
<text top="402" left="587" width="323" height="19" font="8"><b>1</b>°<b> endpoint: </b>3.2% required PPM. Risk factors: preop </text>
<text top="420" left="587" width="317" height="19" font="0">AI, MI, PHTN, and postop electrolyte abnormalities.<b> </b></text>
<text top="346" left="932" width="135" height="20" font="0">• Small, retrospective<b> </b></text>
<text top="365" left="932" width="127" height="20" font="0">• Did not control for </text>
<text top="384" left="942" width="112" height="19" font="0">preop conduction </text>
<text top="403" left="942" width="87" height="19" font="0">abnormalities </text>
<text top="421" left="932" width="3" height="19" font="8"><b> </b></text>
<text top="475" left="95" width="88" height="19" font="0">Bagur R, et al. </text>
<text top="493" left="95" width="69" height="19" font="0">2011 (347) </text>
<text top="512" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21828221">21828221</a></text>
<text top="512" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21828221"> </a></text>
<text top="475" left="217" width="171" height="19" font="8"><b>Aim: </b>Identify incidence and </text>
<text top="493" left="217" width="175" height="19" font="0">predictors of PPM after AVR </text>
<text top="512" left="217" width="60" height="19" font="0">in elderly </text>
<text top="530" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="548" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="566" left="217" width="47" height="19" font="0">cohort<b>  </b></text>
<text top="585" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="603" left="217" width="58" height="19" font="8"><b>Size: </b>780<b> </b></text>
<text top="475" left="419" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="493" left="419" width="109" height="19" font="0">≥70 y undergoing </text>
<text top="512" left="419" width="80" height="19" font="0">isolated AVR </text>
<text top="530" left="419" width="3" height="19" font="0"> </text>
<text top="548" left="419" width="140" height="19" font="8"><b>Exclusion criteria: </b>Age </text>
<text top="566" left="419" width="151" height="19" font="0">&lt;70 y, preop PPM/AICD, </text>
<text top="585" left="419" width="103" height="19" font="0">ascending aortic </text>
<text top="603" left="419" width="81" height="19" font="0">replacement </text>
<text top="475" left="587" width="117" height="19" font="8"><b>Intervention: </b>PPM<b> </b></text>
<text top="493" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="511" left="587" width="141" height="19" font="8"><b>Comparator: </b>NO PPM<b>  </b></text>
<text top="531" left="587" width="319" height="19" font="8"><b>1</b>°<b> endpoint: </b>3.2% needed PPM, predicted by preop </text>
<text top="549" left="587" width="327" height="19" font="0">LBB or RBB. PPM associated with longer hospital stay </text>
<text top="567" left="587" width="243" height="19" font="0">but no survival difference at 30d or 5 y.<b> </b></text>
<text top="475" left="932" width="135" height="20" font="0">• Small, retrospective </text>
<text top="494" left="932" width="3" height="19" font="8"><b> </b></text>
<text top="622" left="95" width="92" height="19" font="0">Baraki H, et al. </text>
<text top="640" left="95" width="69" height="19" font="0">2013 (348) </text>
<text top="659" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23300203">23300203 </a></text>
<text top="659" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23300203"> </a></text>
<text top="622" left="217" width="143" height="19" font="8"><b>Aim: </b>Determine if AVN </text>
<text top="640" left="217" width="175" height="19" font="0">function recovers after PPM </text>
<text top="659" left="217" width="59" height="19" font="0">post AVR </text>
<text top="677" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="695" left="217" width="163" height="19" font="8"><b>Study type:</b> Observational </text>
<text top="714" left="217" width="44" height="19" font="0">cohort </text>
<text top="732" left="217" width="7" height="19" font="8"><b>  </b></text>
<text top="750" left="217" width="98" height="19" font="8"><b>Size: </b>138/2,106<b> </b></text>
<text top="622" left="419" width="143" height="19" font="8"><b>Inclusion criteria: </b>PPM </text>
<text top="640" left="419" width="59" height="19" font="0">post AVR </text>
<text top="659" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="677" left="419" width="154" height="19" font="8"><b>Exclusion criteria: </b>Death<b> </b></text>
<text top="622" left="587" width="193" height="19" font="8"><b>Intervention: </b>PM interrogation </text>
<text top="640" left="587" width="7" height="19" font="0">  </text>
<text top="640" left="659" width="3" height="19" font="0"> </text>
<text top="660" left="587" width="310" height="19" font="8"><b>1</b>°<b> endpoint: </b>only 10% of survivors were no longer </text>
<text top="678" left="587" width="109" height="19" font="0">pacer-dependent </text>
<text top="696" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="622" left="932" width="135" height="20" font="0">• Small, retrospective </text>
<text top="641" left="932" width="3" height="19" font="8"><b> </b></text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 198 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="113" height="19" font="0">Greason KL, et al.  </text>
<text top="105" left="95" width="69" height="19" font="0">2017 (349) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28433222">28433222</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28433222"> </a></text>
<text top="87" left="217" width="177" height="19" font="8"><b>Aim: </b>Determine if PPM after </text>
<text top="105" left="217" width="123" height="19" font="0">AVR effects survival </text>
<text top="123" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="160" left="217" width="47" height="19" font="0">cohort<b>  </b></text>
<text top="178" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="197" left="217" width="69" height="19" font="8"><b>Size: </b>5,482 </text>
<text top="87" left="419" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="105" left="419" width="102" height="19" font="0">undergoing AVR<b> </b></text>
<text top="87" left="587" width="306" height="19" font="8"><b>Intervention: </b>PPM within 30 d of surgery (N=146) </text>
<text top="105" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="123" left="587" width="135" height="19" font="8"><b>Comparator: </b>No PPM </text>
<text top="142" left="587" width="3" height="19" font="0"> </text>
<text top="161" left="587" width="273" height="19" font="8"><b>1</b>°<b> endpoint: </b>PPM associated with increased </text>
<text top="179" left="587" width="127" height="19" font="0">mortality (HR: 1.49).<b> </b></text>
<text top="87" left="932" width="135" height="20" font="0">• Small, retrospective </text>
<text top="106" left="932" width="3" height="19" font="8"><b> </b></text>
<text top="216" left="95" width="102" height="19" font="0">Berdajs D, et al.  </text>
<text top="234" left="95" width="69" height="19" font="0">2008 (350) </text>
<text top="252" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18482844">18482844</a></text>
<text top="252" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18482844"> </a></text>
<text top="216" left="217" width="137" height="19" font="8"><b>Aim: </b>Identify cause of </text>
<text top="234" left="217" width="165" height="19" font="0">conduction block after MV </text>
<text top="252" left="217" width="52" height="19" font="0">surgery<b>  </b></text>
<text top="271" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="289" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="307" left="217" width="103" height="19" font="0">cohort, autopsy<b>  </b></text>
<text top="326" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="344" left="217" width="103" height="19" font="8"><b>Size: </b>391/92/55<b>  </b></text>
<text top="216" left="419" width="122" height="19" font="8"><b>Inclusion criteria: </b>2 </text>
<text top="234" left="419" width="137" height="19" font="0">populations: (1) those </text>
<text top="252" left="419" width="98" height="19" font="0">undergoing MV </text>
<text top="271" left="419" width="116" height="19" font="0">operations and (2) </text>
<text top="289" left="419" width="116" height="19" font="0">cadaver dissection<b> </b></text>
<text top="216" left="587" width="280" height="19" font="8"><b>Intervention: </b>(1) MVR +/- PPM: (2) dissection </text>
<text top="234" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="253" left="587" width="319" height="19" font="8"><b>1</b>°<b> endpoint: </b>(1)<b> </b>23% AVB, 4% needed PPM. (2) 23% </text>
<text top="272" left="587" width="305" height="19" font="0">of cadavers had AV nodal artery running near MV </text>
<text top="290" left="587" width="51" height="19" font="0">annulus<b> </b></text>
<text top="216" left="932" width="141" height="20" font="0">• Amiodarone, sotalol, </text>
<text top="235" left="942" width="132" height="19" font="0">cross-clamp time risk </text>
<text top="253" left="942" width="150" height="19" font="0">factors for PPM; digoxin </text>
<text top="272" left="942" width="66" height="19" font="0">protective </text>
<text top="290" left="932" width="148" height="20" font="0">• AV nodal artery injury </text>
<text top="309" left="942" width="148" height="19" font="0">possible mechanism for </text>
<text top="327" left="942" width="36" height="19" font="0">block<b> </b></text>
<text top="346" left="932" width="139" height="20" font="0">• Small, retrospective, </text>
<text top="365" left="942" width="114" height="19" font="0">dissections not on </text>
<text top="383" left="942" width="76" height="19" font="0">surgical pts.<b> </b></text>
<text top="402" left="95" width="94" height="19" font="0">Goldstein D, et </text>
<text top="420" left="95" width="21" height="19" font="0">al.  </text>
<text top="439" left="95" width="69" height="19" font="0">2016 (351) </text>
<text top="457" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26550689">26550689</a></text>
<text top="457" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26550689"> </a></text>
<text top="402" left="217" width="155" height="19" font="8"><b>Aim: </b>Compare outcomes </text>
<text top="420" left="217" width="156" height="19" font="0">between chordal-sparing </text>
<text top="439" left="217" width="186" height="19" font="0">mitral replacement and mitral </text>
<text top="457" left="217" width="40" height="19" font="0">repair </text>
<text top="475" left="217" width="3" height="19" font="0"> </text>
<text top="494" left="217" width="178" height="19" font="8"><b>Study type: </b>RCT sub-analysis </text>
<text top="512" left="217" width="3" height="19" font="0"> </text>
<text top="530" left="217" width="58" height="19" font="8"><b>Size: </b>256 </text>
<text top="402" left="419" width="31" height="19" font="0">N/A  </text>
<text top="402" left="587" width="298" height="19" font="8"><b>Intervention:</b> Mitral valve repair or replacement<b> </b></text>
<text top="420" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="439" left="587" width="323" height="19" font="8"><b>1</b>°<b> endpoint: </b>Readmission higher in MV repair group </text>
<text top="458" left="587" width="309" height="19" font="0">largely due to higher rate of PPM/AICD placement </text>
<text top="476" left="587" width="66" height="19" font="0">(59 vs. 38)<b> </b></text>
<text top="402" left="932" width="47" height="20" font="0">• Small </text>
<text top="421" left="932" width="12" height="20" font="4">• </text>
<text top="424" left="942" width="149" height="19" font="0">Not designed to answer </text>
<text top="442" left="942" width="53" height="19" font="0">question</text>
<text top="440" left="996" width="4" height="21" font="4"> </text>
<text top="549" left="95" width="91" height="19" font="0">Saint LL, et al.  </text>
<text top="568" left="95" width="69" height="19" font="0">2013 (352) </text>
<text top="586" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23998785">23998785</a></text>
<text top="586" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23998785"> </a></text>
<text top="549" left="217" width="184" height="19" font="8"><b>Aim: </b>Identify incremental risk </text>
<text top="568" left="217" width="185" height="19" font="0">of adding a maze operation in </text>
<text top="586" left="217" width="74" height="19" font="0">MV surgery </text>
<text top="604" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="622" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="641" left="217" width="44" height="19" font="0">cohort </text>
<text top="659" left="217" width="3" height="19" font="0"> </text>
<text top="677" left="217" width="58" height="19" font="8"><b>Size: </b>213 </text>
<text top="549" left="419" width="31" height="19" font="0">N/A  </text>
<text top="549" left="587" width="224" height="19" font="8"><b>Intervention: </b>MV surgery plus Maze </text>
<text top="568" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="586" left="587" width="224" height="19" font="8"><b>Comparator</b>: MV surgery w/o Maze<b>  </b></text>
<text top="604" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="623" left="587" width="331" height="19" font="8"><b>1</b>°<b> endpoint: </b>No difference in mortality, no difference </text>
<text top="642" left="587" width="39" height="19" font="0">in PM </text>
<text top="660" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="678" left="587" width="311" height="19" font="8"><b>Safety endpoint: </b>Pts not offered a Maze had more<b> </b></text>
<text top="549" left="932" width="135" height="20" font="0">• Small, retrospective </text>
<text top="569" left="932" width="165" height="20" font="0">• PPM 11% in Maze vs. 6% </text>
<text top="588" left="942" width="125" height="19" font="0">w/o-study likely not </text>
<text top="606" left="942" width="110" height="19" font="0">powered to show </text>
<text top="624" left="942" width="66" height="19" font="0">difference </text>
<text top="643" left="932" width="153" height="20" font="0">• Pts not offered a Maze </text>
<text top="662" left="942" width="109" height="19" font="0">had more serious </text>
<text top="680" left="942" width="87" height="19" font="0">comorbidities<b> </b></text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 199 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="111" height="19" font="0">Gammie JS, et al.  </text>
<text top="105" left="95" width="69" height="19" font="0">2008 (353) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18291169">18291169</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18291169"> </a></text>
<text top="87" left="217" width="162" height="19" font="8"><b>Aim: </b>Identify if AF surgery </text>
<text top="105" left="217" width="124" height="19" font="0">increased risk in pts </text>
<text top="123" left="217" width="162" height="19" font="0">undergoing mitral surgery </text>
<text top="142" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="160" left="217" width="159" height="19" font="8"><b>Study type: </b>STS Database </text>
<text top="178" left="217" width="81" height="19" font="0">sub-analysis<b>  </b></text>
<text top="197" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="215" left="217" width="77" height="19" font="8"><b>Size: </b>12,235 </text>
<text top="87" left="419" width="152" height="19" font="8"><b>Inclusion criteria: </b>All pts </text>
<text top="105" left="419" width="74" height="19" font="0">in database<b> </b></text>
<text top="123" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="419" width="144" height="19" font="8"><b>Exclusion criteria: </b>Non-</text>
<text top="160" left="419" width="89" height="19" font="0">mitral surgery<b> </b></text>
<text top="87" left="587" width="325" height="19" font="8"><b>Intervention: </b>MV surgery + preop AF + AF correction </text>
<text top="105" left="587" width="3" height="19" font="0"> </text>
<text top="123" left="587" width="319" height="19" font="8"><b>Comparator: </b>MV surgery + preop AF - AF correction </text>
<text top="142" left="587" width="3" height="19" font="0"> </text>
<text top="161" left="587" width="307" height="19" font="8"><b>1</b>°<b> endpoint: </b>Mortality same: PPM higher in Maze </text>
<text top="179" left="587" width="113" height="19" font="0">group (AOR: 1.26)<b> </b></text>
<text top="87" left="932" width="140" height="20" font="0">• Non-randomized, no </text>
<text top="106" left="942" width="114" height="19" font="0">propensity match, </text>
<text top="124" left="942" width="144" height="19" font="0">probable selection bias<b> </b></text>
<text top="234" left="95" width="94" height="19" font="0">Gillinov AM, et </text>
<text top="252" left="95" width="21" height="19" font="0">al.  </text>
<text top="271" left="95" width="69" height="19" font="0">2015 (354) </text>
<text top="289" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25853744">25853744</a></text>
<text top="289" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25853744"> </a></text>
<text top="234" left="217" width="136" height="19" font="8"><b>Aim: </b>Determine if the </text>
<text top="252" left="217" width="179" height="19" font="0">addition of AF surgery to MV </text>
<text top="271" left="217" width="118" height="19" font="0">surgery is effective </text>
<text top="289" left="217" width="3" height="19" font="0"> </text>
<text top="307" left="217" width="101" height="19" font="8"><b>Study type: </b>RCT<b> </b></text>
<text top="326" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="344" left="217" width="58" height="19" font="8"><b>Size: </b>260 </text>
<text top="234" left="419" width="155" height="19" font="8"><b>Inclusion criteria: </b>Pre-op </text>
<text top="252" left="419" width="103" height="19" font="0">AF + MV surgery </text>
<text top="271" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="289" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="234" left="587" width="185" height="19" font="8"><b>Intervention: </b>MV+ AF surgery </text>
<text top="252" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="271" left="587" width="186" height="19" font="8"><b>Comparator: </b>MV – AF surgery </text>
<text top="289" left="587" width="3" height="19" font="0"> </text>
<text top="308" left="587" width="305" height="19" font="8"><b>1</b>°<b> endpoint: </b>Lower rate of AF post maze (63% vs. </text>
<text top="326" left="587" width="303" height="19" font="0">24%), Higher need for PPM (21 vs. 8 per 100 pt y) </text>
<text top="345" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="363" left="587" width="268" height="19" font="8"><b>Safety endpoint: </b>No difference in mortality<b> </b></text>
<text top="234" left="932" width="138" height="20" font="0">• Not standardized AF </text>
<text top="253" left="942" width="49" height="19" font="0">surgery </text>
<text top="272" left="932" width="158" height="20" font="0">• No analysis of repair vs. </text>
<text top="291" left="942" width="48" height="19" font="0">replace </text>
<text top="309" left="931" width="152" height="20" font="0">• Unclear if powered for </text>
<text top="328" left="942" width="90" height="19" font="0">PPM endpoint<b> </b></text>
<text top="382" left="95" width="86" height="19" font="0">Phan K, et al.  </text>
<text top="401" left="95" width="69" height="19" font="0">2014 (355) </text>
<text top="419" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24650881">24650881</a></text>
<text top="419" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24650881"> </a></text>
<text top="382" left="217" width="186" height="19" font="8"><b>Aim: </b>Determine efficacy of AF </text>
<text top="401" left="217" width="49" height="19" font="0">surgery </text>
<text top="419" left="217" width="3" height="19" font="0"> </text>
<text top="437" left="217" width="178" height="19" font="8"><b>Study type: </b>Meta-analysis of </text>
<text top="455" left="217" width="49" height="19" font="0">16 RCT<b>  </b></text>
<text top="474" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="492" left="217" width="69" height="19" font="8"><b>Size: </b>1,082 </text>
<text top="382" left="419" width="138" height="19" font="8"><b>Inclusion criteria: </b>RCT </text>
<text top="401" left="419" width="3" height="19" font="0"> </text>
<text top="419" left="419" width="140" height="19" font="8"><b>Exclusion criteria: </b>RCT </text>
<text top="437" left="419" width="123" height="19" font="0">that did not include </text>
<text top="455" left="419" width="143" height="19" font="0">sinus restoration or AF-</text>
<text top="474" left="419" width="82" height="19" font="0">free survival<b>  </b></text>
<text top="382" left="587" width="153" height="19" font="8"><b>Intervention: </b>AF surgery </text>
<text top="400" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="419" left="587" width="175" height="19" font="8"><b>Comparator:</b> No AF surgery<b>  </b></text>
<text top="437" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="456" left="587" width="331" height="19" font="8"><b>1</b>°<b> endpoint: </b>No difference in mortality, no difference </text>
<text top="474" left="587" width="288" height="19" font="0">in PPM, higher prevalence of SR in Maze group<b> </b></text>
<text top="382" left="932" width="159" height="20" font="0">• Not standardized lesion </text>
<text top="401" left="942" width="22" height="19" font="0">set </text>
<text top="420" left="932" width="143" height="20" font="0">• Subgroup analysis on </text>
<text top="439" left="942" width="151" height="19" font="0">cardiac surgery type not </text>
<text top="457" left="942" width="57" height="19" font="0">available </text>
<text top="475" left="932" width="150" height="20" font="0">• Follow-up ECG or 24 h </text>
<text top="494" left="942" width="42" height="19" font="0">Holter<b> </b></text>
<text top="513" left="95" width="97" height="19" font="0">Chikwe J, et al.  </text>
<text top="532" left="95" width="69" height="19" font="0">2015 (356) </text>
<text top="550" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25936265">25936265</a></text>
<text top="550" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25936265"> </a></text>
<text top="513" left="217" width="157" height="19" font="8"><b>Aim: </b>To assess long-term </text>
<text top="532" left="217" width="117" height="19" font="0">effect of TV repair<b>  </b></text>
<text top="550" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="568" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="587" left="217" width="47" height="19" font="0">cohort<b>  </b></text>
<text top="605" left="217" width="3" height="19" font="0"> </text>
<text top="623" left="217" width="58" height="19" font="8"><b>Size: </b>645 </text>
<text top="513" left="419" width="152" height="19" font="8"><b>Inclusion criteria: </b>Mitral </text>
<text top="532" left="419" width="49" height="19" font="0">surgery </text>
<text top="550" left="419" width="3" height="19" font="0"> </text>
<text top="568" left="419" width="136" height="19" font="8"><b>Exclusion criteria: </b>3 V </text>
<text top="587" left="419" width="103" height="19" font="0">CAD, AV surgery </text>
<text top="513" left="587" width="187" height="19" font="8"><b>Intervention: </b>Tricuspid repair  </text>
<text top="532" left="587" width="3" height="19" font="0"> </text>
<text top="550" left="587" width="163" height="19" font="8"><b>Comparator: </b>No TV repair </text>
<text top="568" left="587" width="3" height="19" font="0"> </text>
<text top="587" left="587" width="325" height="19" font="8"><b>1</b>°<b> endpoint: </b>No difference in morbidity, mortality or </text>
<text top="606" left="587" width="127" height="19" font="0">PPM (2.4% vs. 1.3%)<b> </b></text>
<text top="514" left="932" width="98" height="20" font="0">• Selection Bias </text>
<text top="533" left="932" width="143" height="20" font="0">• 99% MV repair, likely </text>
<text top="552" left="942" width="147" height="19" font="0">avoided anterior leaflet </text>
<text top="570" left="932" width="152" height="20" font="0">• Likely not powered for </text>
<text top="589" left="942" width="112" height="19" font="0">difference in PPM<b> </b></text>
<text top="642" left="95" width="99" height="19" font="0">Scully HE, et al.  </text>
<text top="661" left="95" width="69" height="19" font="0">1995 (357) </text>
<text top="679" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7776666">7776666</a></text>
<text top="679" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7776666"> </a></text>
<text top="642" left="217" width="175" height="19" font="8"><b>Aim: </b>Describe early and late </text>
<text top="661" left="217" width="168" height="19" font="0">results after tricuspid valve </text>
<text top="679" left="217" width="81" height="19" font="0">replacement </text>
<text top="697" left="217" width="3" height="19" font="0"> </text>
<text top="715" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="734" left="217" width="47" height="19" font="0">cohort<b>  </b></text>
<text top="752" left="217" width="3" height="19" font="0"> </text>
<text top="770" left="217" width="50" height="19" font="8"><b>Size: </b>60 </text>
<text top="642" left="419" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="661" left="419" width="129" height="19" font="0">undergoing tricuspid </text>
<text top="679" left="419" width="84" height="19" font="0">valve surgery </text>
<text top="697" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="715" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="642" left="587" width="225" height="19" font="8"><b>Intervention: </b>Tricuspid replacement </text>
<text top="661" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="679" left="587" width="86" height="19" font="8"><b>Comparator:  </b></text>
<text top="697" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="716" left="587" width="330" height="19" font="8"><b>1</b>°<b> endpoint: </b>22% required permanent epicardial lead </text>
<text top="735" left="587" width="68" height="19" font="0">placement<b> </b></text>
<text top="643" left="932" width="135" height="20" font="0">• Small, retrospective<b> </b></text>
<text top="662" left="932" width="12" height="20" font="4">• </text>
<text top="664" left="942" width="128" height="19" font="0">Potentially outdated </text>
<text top="682" left="942" width="111" height="19" font="0">surgical technique</text>
<text top="681" left="1053" width="4" height="21" font="4"> </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 200 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="103" height="19" font="0">Jokinen JJ, et al.  </text>
<text top="105" left="95" width="69" height="19" font="0">2009 (358) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19463599">19463599</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19463599"> </a></text>
<text top="87" left="217" width="173" height="19" font="8"><b>Aim: </b>Need for PPM after TV </text>
<text top="105" left="217" width="172" height="19" font="0">surgery and implications on </text>
<text top="123" left="217" width="63" height="19" font="0">morbidity </text>
<text top="142" left="217" width="3" height="19" font="0"> </text>
<text top="160" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="178" left="217" width="47" height="19" font="0">cohort<b> </b> </text>
<text top="197" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="215" left="217" width="58" height="19" font="8"><b>Size: </b>136 </text>
<text top="87" left="419" width="133" height="19" font="8"><b>Inclusion criteria: </b>Pts </text>
<text top="105" left="419" width="129" height="19" font="0">undergoing tricuspid </text>
<text top="123" left="419" width="115" height="19" font="0">valve surgery-94% </text>
<text top="142" left="418" width="55" height="19" font="0">repaired </text>
<text top="160" left="419" width="3" height="19" font="0"> </text>
<text top="178" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="587" width="185" height="19" font="8"><b>Intervention: </b>PPM placement </text>
<text top="105" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="123" left="587" width="282" height="19" font="8"><b>Comparator: </b>TV surgery w/o PPM placement<b>  </b></text>
<text top="142" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="161" left="587" width="328" height="19" font="8"><b>1</b>°<b> endpoint: </b>21% needed PPM, PPM pts had better 5 </text>
<text top="179" left="587" width="279" height="19" font="0">y survival, MORE TIA and worse CHF and QOL<b> </b></text>
<text top="87" left="932" width="135" height="20" font="0">• Small, retrospective<b> </b></text>
<text top="106" left="932" width="12" height="20" font="4">• </text>
<text top="108" left="942" width="128" height="19" font="0">Potentially outdated </text>
<text top="127" left="942" width="111" height="19" font="0">surgical technique</text>
<text top="125" left="1053" width="4" height="21" font="4"> </text>
<text top="234" left="95" width="106" height="19" font="0">McCarthy PM, et </text>
<text top="252" left="95" width="87" height="19" font="0">al. 2004 (359) </text>
<text top="271" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15001895">15001895</a></text>
<text top="271" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15001895"> </a></text>
<text top="289" left="95" width="3" height="19" font="0"> </text>
<text top="234" left="217" width="172" height="19" font="8"><b>Aim: </b>Assess durability of TV </text>
<text top="252" left="217" width="40" height="19" font="0">repair </text>
<text top="271" left="217" width="3" height="19" font="0"> </text>
<text top="289" left="217" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="307" left="217" width="44" height="19" font="0">cohort </text>
<text top="326" left="217" width="3" height="19" font="8"><b> </b></text>
<text top="344" left="217" width="58" height="19" font="8"><b>Size: </b>790 </text>
<text top="234" left="419" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="252" left="419" width="98" height="19" font="0">Tricuspid repair </text>
<text top="271" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="289" left="419" width="3" height="19" font="8"><b> </b></text>
<text top="234" left="587" width="184" height="19" font="8"><b>Intervention: </b>Tricuspid repair </text>
<text top="252" left="587" width="7" height="19" font="8"><b>  </b></text>
<text top="271" left="587" width="226" height="19" font="8"><b>Comparator: </b>Use of Ring vs. No ring<b>  </b></text>
<text top="289" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="308" left="587" width="328" height="19" font="8"><b>1</b>°<b> endpoint: </b>Freedom from TR. In pts who need PPM </text>
<text top="326" left="587" width="234" height="19" font="0">after repair, Incidence of TR ≥3 is 42%<b> </b></text>
<text top="234" left="932" width="135" height="20" font="0">• Small, retrospective<b> </b></text>
<text top="254" left="932" width="12" height="20" font="4">• </text>
<text top="256" left="942" width="128" height="19" font="0">Potentially outdated </text>
<text top="274" left="942" width="111" height="19" font="0">surgical technique</text>
<text top="272" left="1053" width="4" height="21" font="4"> </text>
<text top="292" left="932" width="3" height="19" font="8"><b> </b></text>
<text top="363" left="86" width="4" height="21" font="4"> </text>
<text top="383" left="86" width="1011" height="23" font="5"><b>Data Supplement 49. Nonrandomized Trials, Observational Studies, and/or Registries of Conduction Abnormalities After TAVR (Section </b></text>
<text top="405" left="86" width="61" height="23" font="5"><b>8.1.2.4) </b></text>
<text top="428" left="112" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="446" left="138" width="51" height="19" font="8"><b>Author; </b></text>
<text top="464" left="113" width="100" height="19" font="8"><b>Year Published’ </b></text>
<text top="483" left="144" width="38" height="19" font="8"><b>PMID </b></text>
<text top="428" left="265" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="446" left="294" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="428" left="440" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="428" left="649" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="446" left="648" width="190" height="19" font="8"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="428" left="935" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="446" left="964" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="502" left="96" width="294" height="19" font="8"><b>Incidence of Conduction Abnormality and PPM </b></text>
<text top="521" left="96" width="95" height="19" font="0">Piazza N, et al.  </text>
<text top="539" left="96" width="69" height="19" font="0">2008 (360)<b> </b></text>
<text top="558" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19463319">19463319</a></text>
<text top="558" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19463319"> </a></text>
<text top="521" left="243" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="539" left="243" width="3" height="19" font="0"> </text>
<text top="557" left="243" width="50" height="19" font="8"><b>Size:</b> 40 </text>
<text top="521" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="539" left="425" width="101" height="19" font="0">CoreValve TAVR </text>
<text top="558" left="425" width="102" height="19" font="0">11/2005 3/2008 </text>
<text top="576" left="425" width="7" height="19" font="8"><b>  </b></text>
<text top="522" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="520" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="522" left="605" width="275" height="19" font="8"><b>endpoint: </b>Conduction abnormalities and the </text>
<text top="540" left="587" width="98" height="19" font="0">need for pacing </text>
<text top="558" left="587" width="3" height="19" font="0"> </text>
<text top="577" left="587" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="595" left="587" width="226" height="20" font="0">• LBBB: 15% pre, 55% post (p&lt;0.001) </text>
<text top="614" left="587" width="126" height="20" font="0">• 18% required PPM </text>
<text top="633" left="587" width="233" height="19" font="0">2 pts with RBBB required PPM (100%) </text>
<text top="521" left="911" width="182" height="20" font="0">• Significant increase in LBBB </text>
<text top="540" left="911" width="164" height="20" font="0">• Pts with RBBB may be at </text>
<text top="559" left="923" width="75" height="19" font="0">risk for CHB </text>
<text top="652" left="96" width="121" height="19" font="0">Roten L, et al. 2010 </text>
<text top="671" left="96" width="35" height="19" font="0">(361) </text>
<text top="689" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21059439">21059439</a></text>
<text top="689" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21059439"> </a></text>
<text top="707" left="96" width="3" height="19" font="0"> </text>
<text top="652" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="671" left="243" width="3" height="19" font="0"> </text>
<text top="689" left="243" width="50" height="19" font="8"><b>Size:</b> 67 </text>
<text top="652" left="425" width="115" height="19" font="8"><b>Inclusion criteria:  </b></text>
<text top="671" left="425" width="137" height="19" font="0">MDT or Edwards TAVI </text>
<text top="689" left="424" width="105" height="19" font="0">Follow-up: &gt;30 d </text>
<text top="707" left="425" width="3" height="19" font="0"> </text>
<text top="725" left="425" width="138" height="19" font="8"><b>Exclusion criteria: </b>Pre-</text>
<text top="744" left="424" width="82" height="19" font="0">existing PPM </text>
<text top="653" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="652" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="653" left="605" width="279" height="19" font="8"><b>endpoint: </b>AV conduction abnormality and/or </text>
<text top="671" left="587" width="87" height="19" font="0">need for PPM </text>
<text top="690" left="587" width="3" height="19" font="0"> </text>
<text top="709" left="587" width="210" height="19" font="8"><b>Results: </b>PPM in 34%, 3°HB in 22% </text>
<text top="728" left="587" width="190" height="19" font="0">2° HB in 6%, new LBBB in 22%, </text>
<text top="747" left="587" width="308" height="19" font="0">3°HB resolved in 64%, RBBB only predictor of CHB </text>
<text top="765" left="587" width="117" height="19" font="0">(OR: 7.3; 2.4–22.2) </text>
<text top="652" left="911" width="162" height="20" font="0">• TAVI associated with AV </text>
<text top="671" left="923" width="147" height="19" font="0">conduction impairment </text>
<text top="691" left="911" width="20" height="20" font="0">• 3</text>
<text top="690" left="931" width="7" height="20" font="4">°</text>
<text top="692" left="937" width="146" height="19" font="0">HB resolves in over half </text>
<text top="710" left="923" width="22" height="19" font="0">pts </text>
<text top="729" left="911" width="180" height="20" font="0">• Preexisting RBBB at risk for </text>
<text top="750" left="923" width="8" height="19" font="0">3</text>
<text top="748" left="931" width="7" height="20" font="4">°</text>
<text top="750" left="937" width="21" height="19" font="0">HB </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 201 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="132" height="19" font="0">van der Boon, RM, et </text>
<text top="105" left="96" width="48" height="19" font="0">al. 2013</text>
<text top="104" left="145" width="4" height="21" font="4"> </text>
<text top="105" left="148" width="35" height="19" font="0">(362) </text>
<text top="123" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23295037">23295037</a></text>
<text top="123" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23295037"> </a></text>
<text top="87" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="105" left="243" width="3" height="19" font="0"> </text>
<text top="123" left="243" width="113" height="19" font="8"><b>Size</b>: 167 pts from </text>
<text top="142" left="243" width="106" height="19" font="0">11/2005–2/2011 </text>
<text top="87" left="425" width="130" height="19" font="8"><b>Inclusion criteria: </b>36 </text>
<text top="105" left="424" width="147" height="19" font="0">who received new PPM </text>
<text top="123" left="424" width="69" height="19" font="0">after TAVR </text>
<text top="142" left="425" width="3" height="19" font="0"> </text>
<text top="160" left="425" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="178" left="424" width="147" height="19" font="0">Existing PPM or no new </text>
<text top="197" left="424" width="32" height="19" font="0">PPM </text>
<text top="88" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="86" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="88" left="605" width="290" height="19" font="8"><b>endpoint: </b>Number pacer dependent at median </text>
<text top="106" left="587" width="183" height="19" font="0">follow-up 11.5 mo (IQR 5–18) </text>
<text top="124" left="587" width="3" height="19" font="0"> </text>
<text top="143" left="587" width="183" height="19" font="8"><b>Results</b> (number dependent): </text>
<text top="161" left="587" width="181" height="19" font="0">16 of 30 (53.3%) with HDAVB </text>
<text top="179" left="587" width="153" height="19" font="0">Overall 20 of 36 (55.6%)  </text>
<text top="87" left="911" width="134" height="20" font="0">• Improvement in AV </text>
<text top="106" left="923" width="160" height="19" font="0">conduction occurs in over </text>
<text top="124" left="923" width="65" height="19" font="0">half of pts </text>
<text top="216" left="96" width="106" height="19" font="0">Siontis, GC, et al. </text>
<text top="234" left="96" width="69" height="19" font="0">2014 (363) </text>
<text top="252" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25011716">25011716</a></text>
<text top="252" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25011716"> </a></text>
<text top="216" left="243" width="166" height="19" font="8"><b>Study type: </b>Meta-analysis  </text>
<text top="234" left="243" width="3" height="19" font="0"> </text>
<text top="252" left="243" width="97" height="19" font="8"><b>Size: </b>41 studies </text>
<text top="271" left="243" width="161" height="19" font="0">encompassing 11,210 pts  </text>
<text top="216" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="234" left="425" width="108" height="19" font="0">Studies reporting </text>
<text top="252" left="425" width="142" height="19" font="0">incidence of PPM after </text>
<text top="271" left="425" width="36" height="19" font="0">TAVR </text>
<text top="289" left="425" width="3" height="19" font="0"> </text>
<text top="307" left="425" width="140" height="19" font="8"><b>Exclusion criteria: </b>194 </text>
<text top="326" left="424" width="89" height="19" font="0">of 235 studies </text>
<text top="217" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="215" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="217" left="605" width="162" height="19" font="8"><b>endpoint: </b>PPM post TAVR </text>
<text top="235" left="587" width="3" height="19" font="0"> </text>
<text top="253" left="587" width="187" height="19" font="8"><b>Results:</b> Increased risk of PPM </text>
<text top="272" left="587" width="139" height="19" font="0">Men- RR: 1.23; p&lt;0.01 </text>
<text top="291" left="587" width="157" height="19" font="0">1°block- RR: 1.52; p&lt;0.01 </text>
<text top="309" left="587" width="204" height="19" font="0">L ant hemiblock-RR: 2.89; p&lt;0.01 </text>
<text top="327" left="587" width="144" height="19" font="0">RBBB- RR: 2.89; p&lt;0.01 </text>
<text top="346" left="587" width="136" height="19" font="0">AVB- RR: 3.49; p&lt;0.01 </text>
<text top="216" left="911" width="176" height="20" font="0">• Male, baseline conduction </text>
<text top="235" left="923" width="106" height="19" font="0">disturbance, and </text>
<text top="253" left="923" width="151" height="19" font="0">intraprocedural AVB are </text>
<text top="272" left="923" width="113" height="19" font="0">predictors of PPM </text>
<text top="365" left="96" width="127" height="19" font="0">Boerlage-Van Dijk K, </text>
<text top="384" left="96" width="30" height="19" font="0">2014</text>
<text top="383" left="127" width="42" height="21" font="4"> (364) </text>
<text top="403" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25040838">25040838</a></text>
<text top="403" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25040838"> </a></text>
<text top="421" left="96" width="3" height="19" font="8"><b> </b></text>
<text top="365" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="383" left="243" width="3" height="19" font="0"> </text>
<text top="401" left="243" width="58" height="19" font="8"><b>Size:</b> 121 </text>
<text top="365" left="425" width="115" height="19" font="8"><b>Inclusion criteria:  </b></text>
<text top="383" left="425" width="118" height="19" font="0">Single center TAVR </text>
<text top="401" left="425" width="106" height="19" font="0">10/2007–6/2011 </text>
<text top="420" left="425" width="135" height="19" font="0">Follow-up 1, 3 and 12 </text>
<text top="438" left="425" width="23" height="19" font="0">mo </text>
<text top="456" left="425" width="3" height="19" font="0"> </text>
<text top="474" left="425" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="493" left="424" width="87" height="19" font="0">Valve in valve </text>
<text top="365" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="364" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="365" left="605" width="281" height="19" font="8"><b>endpoint: </b>Conduction abnormalities and new </text>
<text top="384" left="598" width="32" height="19" font="0">PPM </text>
<text top="402" left="587" width="3" height="19" font="0"> </text>
<text top="420" left="587" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="439" left="587" width="292" height="19" font="0">38.8% new LBBB, half of which were temporary </text>
<text top="457" left="587" width="157" height="19" font="0">New PPM in 23 pts (19%) </text>
<text top="475" left="587" width="304" height="19" font="0">Predictors of new PPM: MAC (OR: 1.3, 1.05–1.56; </text>
<text top="494" left="587" width="271" height="19" font="0">p=0.02), RBBB (OR: 8.8, 1.61–44.91; p=0.01) </text>
<text top="512" left="587" width="277" height="19" font="0">At follow-up: 52% pacer dependent, 22% not </text>
<text top="530" left="587" width="151" height="19" font="0">paced, 26% intermittent </text>
<text top="365" left="911" width="173" height="20" font="0">• MAC and RBBB predictors </text>
<text top="384" left="923" width="77" height="19" font="0">of new PPM </text>
<text top="402" left="911" width="127" height="20" font="0">• Prosthesis size is a </text>
<text top="421" left="923" width="110" height="19" font="0">predictor of LBBB </text>
<text top="549" left="96" width="223" height="19" font="8"><b>Mortality and new PPM after TAVR </b></text>
<text top="568" left="96" width="126" height="19" font="0">Nazif TM, et al. 2015</text>
<text top="567" left="222" width="4" height="21" font="4"> </text>
<text top="587" left="96" width="39" height="21" font="4">(365) </text>
<text top="607" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25616819">25616819</a></text>
<text top="607" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25616819"><b> </b></a></text>
<text top="625" left="96" width="3" height="19" font="0"> </text>
<text top="568" left="243" width="127" height="19" font="8"><b>Study type: </b>Registry </text>
<text top="587" left="243" width="3" height="19" font="0"> </text>
<text top="605" left="243" width="66" height="19" font="8"><b>Size: </b>1973 </text>
<text top="568" left="425" width="126" height="19" font="8"><b>Inclusion criteria: </b>In </text>
<text top="587" left="425" width="113" height="19" font="0">PARTNER Registry </text>
<text top="605" left="425" width="3" height="19" font="0"> </text>
<text top="623" left="425" width="138" height="19" font="8"><b>Exclusion criteria: </b>Pre-</text>
<text top="642" left="425" width="102" height="19" font="0">procedure PPM  </text>
<text top="569" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="568" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="569" left="605" width="127" height="19" font="8"><b>endpoint: </b>New PPM </text>
<text top="587" left="587" width="3" height="19" font="0"> </text>
<text top="606" left="587" width="135" height="19" font="8"><b>Results:</b> 8% new PPM </text>
<text top="624" left="587" width="245" height="19" font="0">Predictors: RBBB (OR: 7.03, 4.92–10.06; </text>
<text top="642" left="587" width="279" height="19" font="0">p&lt;0.0001), prosthesis/outflow tract diameter </text>
<text top="661" left="587" width="229" height="19" font="0">ratio (OR: 1.29, 1.10–1.51; p=0.002),  </text>
<text top="679" left="587" width="268" height="19" font="0">New PPM not associated with increased 1 y </text>
<text top="697" left="587" width="63" height="19" font="0">mortality. </text>
<text top="716" left="587" width="207" height="19" font="0">EF at 1 y same in PPM vs. no PPM </text>
<text top="569" left="911" width="162" height="20" font="0">• 8.8% required new PPM </text>
<text top="588" left="911" width="177" height="20" font="0">• New PPM associated with: </text>
<text top="607" left="923" width="126" height="19" font="0">longer LOS, more re-</text>
<text top="625" left="923" width="93" height="19" font="0">hospitalization </text>
<text top="643" left="911" width="167" height="20" font="0">• New PPM not associated </text>
<text top="662" left="923" width="169" height="19" font="0">with increased mortality or </text>
<text top="681" left="923" width="121" height="19" font="0">decreased EF at 1 y </text>
<text top="699" left="911" width="3" height="19" font="0"> </text>
<text top="735" left="96" width="64" height="19" font="8"><b>FRANCE 2 </b></text>
<text top="753" left="96" width="105" height="19" font="0">Mouillet G, et al. </text>
<text top="771" left="96" width="69" height="19" font="0">2015 (366) </text>
<text top="735" left="243" width="127" height="19" font="8"><b>Study type: </b>Registry </text>
<text top="753" left="243" width="3" height="19" font="0"> </text>
<text top="771" left="243" width="58" height="19" font="8"><b>Size: </b>833 </text>
<text top="735" left="425" width="130" height="19" font="8"><b>Inclusion criteria: </b>29 </text>
<text top="753" left="425" width="127" height="19" font="0">centers in FRANCE 2 </text>
<text top="771" left="425" width="49" height="19" font="0">registry </text>
<text top="735" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="734" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="735" left="605" width="68" height="19" font="8"><b>endpoint:  </b></text>
<text top="754" left="587" width="155" height="19" font="0">Incidence of new PPM or </text>
<text top="772" left="587" width="144" height="19" font="0">Mortality at 242±179 d </text>
<text top="735" left="911" width="180" height="20" font="0">• All-cause mortality same in </text>
<text top="754" left="923" width="156" height="19" font="0">PPM vs. no PPM at mean </text>
<text top="772" left="923" width="112" height="19" font="0">follow-up of 8 mo </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 202 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25573445">25573445</a></text>
<text top="87" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25573445"><b> </b></a></text>
<text top="105" left="96" width="3" height="19" font="0"> </text>
<text top="87" left="243" width="106" height="19" font="0">1/2010–10/2011 </text>
<text top="87" left="425" width="3" height="19" font="0"> </text>
<text top="105" left="425" width="138" height="19" font="8"><b>Exclusion criteria: </b>Pre-</text>
<text top="123" left="425" width="82" height="19" font="0">existing PPM </text>
<text top="87" left="587" width="3" height="19" font="0"> </text>
<text top="105" left="587" width="52" height="19" font="8"><b>Results: </b></text>
<text top="123" left="587" width="135" height="19" font="0">30% rate of new PPM </text>
<text top="142" left="587" width="292" height="19" font="0">Mortality PPM vs.no PPM: 16.3 vs. 16.9; p=0.83 </text>
<text top="161" left="96" width="280" height="19" font="8"><b>Impact of Mitral Annular Calcification (MAC) </b></text>
<text top="180" left="96" width="126" height="19" font="0">Abramowitz Y, et al. </text>
<text top="198" left="96" width="30" height="19" font="0">2017</text>
<text top="197" left="127" width="4" height="21" font="4"> </text>
<text top="198" left="130" width="35" height="19" font="0">(367)<b> </b></text>
<text top="217" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28039339">28039339</a></text>
<text top="217" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28039339"> </a></text>
<text top="235" left="96" width="3" height="19" font="0"> </text>
<text top="180" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="198" left="243" width="3" height="19" font="0"> </text>
<text top="216" left="243" width="35" height="19" font="8"><b>Size:  </b></text>
<text top="235" left="243" width="52" height="19" font="0">761 pts: </text>
<text top="253" left="243" width="74" height="19" font="0">49.3% MAC </text>
<text top="272" left="243" width="105" height="19" font="0">Mild MAC 30.4% </text>
<text top="290" left="243" width="98" height="19" font="0">Mod MAC 9.5% </text>
<text top="308" left="243" width="111" height="19" font="0">Severe MAC 9.5% </text>
<text top="180" left="424" width="133" height="19" font="8"><b>Inclusion criteria: </b>3 y </text>
<text top="198" left="425" width="106" height="19" font="0">series of TAVR at </text>
<text top="217" left="425" width="78" height="19" font="0">Cedars-Sinai </text>
<text top="235" left="425" width="3" height="19" font="0"> </text>
<text top="253" left="425" width="144" height="19" font="8"><b>Exclusion criteria: </b>N/A  </text>
<text top="181" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="179" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="181" left="605" width="197" height="19" font="8"><b>endpoint: </b>30 d mortality ± MAC </text>
<text top="199" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="217" left="587" width="233" height="19" font="8"><b>Results</b>: Severe MAC is a predictor of: </text>
<text top="236" left="587" width="289" height="19" font="0">overall mortality HR: 1.95 (1.24–3.07; p=0.004) </text>
<text top="254" left="587" width="280" height="19" font="0">Cardiovascular mortality HR: 2.35 (1.99–4.66; </text>
<text top="272" left="587" width="50" height="19" font="0">p=0.01) </text>
<text top="291" left="587" width="240" height="19" font="0">New PPM HR: 2.83 (1.08–7.47; p=0.03) </text>
<text top="180" left="910" width="171" height="20" font="0">•  Severe MAC is associated </text>
<text top="199" left="923" width="149" height="19" font="0">with increased all-cause </text>
<text top="217" left="923" width="159" height="19" font="0">and cardiac mortality and </text>
<text top="236" left="923" width="102" height="19" font="0">with conduction </text>
<text top="254" left="923" width="156" height="19" font="0">abnormalities after TAVR </text>
<text top="272" left="910" width="167" height="20" font="0">•  Mild and moderate MAC </text>
<text top="291" left="923" width="129" height="19" font="0">are not predictors of </text>
<text top="310" left="923" width="115" height="19" font="0">adverse outcomes </text>
<text top="329" left="96" width="292" height="19" font="8"><b>Predictors and impact of new LBBB after TAVR </b></text>
<text top="348" left="96" width="100" height="19" font="0">Franzoni I, et al. </text>
<text top="366" left="96" width="69" height="19" font="0">2013 (368) </text>
<text top="384" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23726173">23726173</a></text>
<text top="384" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23726173"> </a></text>
<text top="348" left="243" width="163" height="19" font="8"><b>Study type:</b> Observational </text>
<text top="366" left="243" width="7" height="19" font="0">  </text>
<text top="384" left="243" width="164" height="19" font="8"><b>Size</b>: 238 (2007–2011) San </text>
<text top="403" left="243" width="95" height="19" font="0">Raffaele, Milan </text>
<text top="421" left="243" width="75" height="19" font="0">MCRS N=87 </text>
<text top="439" left="243" width="69" height="19" font="0">ESV N=151 </text>
<text top="348" left="425" width="147" height="19" font="8"><b>Inclusion criteria: </b>TAVR </text>
<text top="366" left="425" width="3" height="19" font="0"> </text>
<text top="384" left="425" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="403" left="424" width="135" height="19" font="0">Previous: PPM, RBBB, </text>
<text top="421" left="424" width="34" height="19" font="0">LBBB </text>
<text top="349" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="347" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="349" left="605" width="130" height="19" font="8"><b>endpoint: </b>New LBBB </text>
<text top="367" left="587" width="3" height="19" font="0"> </text>
<text top="385" left="587" width="52" height="19" font="8"><b>Results: </b></text>
<text top="404" left="587" width="269" height="19" font="0">New LBBB in 26.5% (ESV 13.5%, MCVS 50%) </text>
<text top="422" left="587" width="224" height="19" font="0">Persistent LBBB at discharge= 17.2% </text>
<text top="441" left="587" width="242" height="19" font="0">New PPM=12.7% (2° CHB, bradycardia) </text>
<text top="348" left="910" width="176" height="20" font="0">•  LBBB was NOT a predictor </text>
<text top="367" left="923" width="138" height="19" font="0">of: PPM, overall mort, </text>
<text top="385" left="923" width="121" height="19" font="0">cardiac mort, at 1 y </text>
<text top="460" left="96" width="128" height="19" font="0">Urena M, et al. 2012 </text>
<text top="478" left="96" width="35" height="19" font="0">(369) </text>
<text top="497" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23040577">23040577</a></text>
<text top="497" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23040577"> </a></text>
<text top="515" left="96" width="3" height="19" font="8"><b> </b></text>
<text top="460" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="478" left="243" width="3" height="19" font="0"> </text>
<text top="497" left="243" width="154" height="19" font="8"><b>Size:</b> 202, median follow-</text>
<text top="515" left="243" width="61" height="19" font="0">up 12 mo </text>
<text top="460" left="425" width="147" height="19" font="8"><b>Inclusion criteria: </b>TAVR </text>
<text top="478" left="425" width="3" height="19" font="0"> </text>
<text top="497" left="425" width="134" height="19" font="8"><b>Exclusion criteria: </b>No </text>
<text top="515" left="424" width="126" height="19" font="0">baseline conduction </text>
<text top="533" left="424" width="81" height="19" font="0">disturbances </text>
<text top="461" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="459" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="461" left="605" width="163" height="19" font="8"><b>endpoint </b>New onset LBBB </text>
<text top="479" left="587" width="3" height="19" font="0"> </text>
<text top="497" left="587" width="157" height="19" font="8"><b>Results:</b> 30.2% new LBBB </text>
<text top="516" left="587" width="222" height="19" font="0">LBBB resolved in 37.7% at discharge </text>
<text top="534" left="587" width="218" height="19" font="0">LBBB resolved in 57.3% at 6–12 mo </text>
<text top="552" left="587" width="214" height="19" font="0">LBBB at discharge associated with: </text>
<text top="571" left="587" width="301" height="19" font="0">Higher rate of syncope (16.0% vs. 0.7%; p=0.001) </text>
<text top="589" left="587" width="237" height="19" font="0">CHB needing PPI (20 vs. 0.7%; p&lt;0.001 </text>
<text top="607" left="587" width="252" height="19" font="0">no increase in global or cardiac mortality </text>
<text top="460" left="910" width="145" height="20" font="0">•  Pts with new LBBB at </text>
<text top="479" left="923" width="171" height="19" font="0">discharge are at 20% risk of </text>
<text top="497" left="923" width="155" height="19" font="0">receiving a new PPM but </text>
<text top="516" left="923" width="157" height="19" font="0">do not have increased all-</text>
<text top="534" left="923" width="161" height="19" font="0">cause or cardiac mortality </text>
<text top="553" left="910" width="128" height="20" font="0">•  LBBB persistent at </text>
<text top="572" left="923" width="173" height="19" font="0">discharge is associated with </text>
<text top="590" left="923" width="148" height="19" font="0">increased syncope, CHB </text>
<text top="626" left="96" width="117" height="19" font="0">Testa L, et al. 2013 </text>
<text top="645" left="96" width="35" height="19" font="0">(370)<b> </b></text>
<text top="663" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23443735">23443735</a></text>
<text top="663" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23443735"><b> </b></a></text>
<text top="626" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="645" left="243" width="3" height="19" font="0"> </text>
<text top="663" left="243" width="129" height="19" font="8"><b>Size: </b>818 10/2007 to </text>
<text top="681" left="243" width="47" height="19" font="0">4/2011 </text>
<text top="626" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="645" left="425" width="101" height="19" font="0">CoreValve TAVR </text>
<text top="663" left="425" width="3" height="19" font="0"> </text>
<text top="681" left="425" width="113" height="19" font="8"><b>Exclusion criteria: </b></text>
<text top="700" left="425" width="140" height="19" font="0">Baseline PPM or LBBB  </text>
<text top="718" left="425" width="146" height="19" font="0">Received new PPM &lt;48 </text>
<text top="736" left="425" width="57" height="19" font="0">h postop </text>
<text top="627" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="626" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="627" left="605" width="130" height="19" font="8"><b>endpoint: </b>New LBBB </text>
<text top="645" left="587" width="3" height="19" font="0"> </text>
<text top="664" left="587" width="157" height="19" font="8"><b>Results:</b> 27.4% new LBBB </text>
<text top="682" left="587" width="297" height="19" font="0">At 30 d and 1 y, LBBB not associated with higher </text>
<text top="700" left="587" width="183" height="19" font="0">all-cause or cardiac mortality  </text>
<text top="719" left="587" width="300" height="19" font="0">At 30 d LBBB had higher rate of PPI (4.9% vs. 2%; </text>
<text top="737" left="587" width="50" height="19" font="0">p=0.02) </text>
<text top="627" left="910" width="167" height="20" font="0">•  new LBBB post TAVR not </text>
<text top="645" left="923" width="159" height="19" font="0">associated with higher all-</text>
<text top="664" left="923" width="161" height="19" font="0">cause or cardiac mortality </text>
<text top="682" left="910" width="169" height="20" font="0">•  New LBBB at discharge is </text>
<text top="701" left="923" width="151" height="19" font="0">associated with a higher </text>
<text top="720" left="923" width="112" height="19" font="0">rate of PPI at 30 d </text>
<text top="756" left="96" width="119" height="19" font="0">Egger F, et al. 2014 </text>
<text top="774" left="96" width="35" height="19" font="0">(371)<b> </b></text>
<text top="756" left="243" width="157" height="19" font="8"><b>Study type: </b>Single center </text>
<text top="774" left="243" width="75" height="19" font="0">prospective </text>
<text top="756" left="425" width="176" height="20" font="8"><b>Inclusion criteria: </b>TAVR  <b>1</b>°</text>
<text top="755" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="757" left="605" width="270" height="19" font="8"><b>endpoint: </b>Development of high degree AVB </text>
<text top="775" left="587" width="3" height="19" font="0"> </text>
<text top="756" left="910" width="148" height="20" font="0">•  In pts with LBBB after </text>
<text top="775" left="923" width="108" height="19" font="0">TAVR, intensified </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 203 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25034184">25034184</a></text>
<text top="87" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25034184"><b> </b></a></text>
<text top="87" left="243" width="3" height="19" font="0"> </text>
<text top="105" left="243" width="54" height="19" font="8"><b>Size:</b> 50  </text>
<text top="87" left="425" width="124" height="19" font="0">10 with pre-existing </text>
<text top="105" left="425" width="132" height="19" font="0">LBBB and 7 with new </text>
<text top="123" left="425" width="119" height="19" font="0">LBBB received new </text>
<text top="142" left="425" width="59" height="19" font="0">DDD PMI<b> </b></text>
<text top="87" left="587" width="56" height="19" font="8"><b>Results: </b> </text>
<text top="105" left="587" width="282" height="19" font="0">10 of 17 with LBBB developed episode of high </text>
<text top="123" left="587" width="294" height="19" font="0">degree AVB. In 5/17 (29.4%) the first episode of </text>
<text top="142" left="587" width="299" height="19" font="0">high degree AVB occurred after discharge (mean </text>
<text top="160" left="587" width="104" height="19" font="0">follow-up 578 d) </text>
<text top="87" left="923" width="119" height="19" font="0">monitoring may be </text>
<text top="105" left="923" width="71" height="19" font="0">reasonable </text>
<text top="179" left="96" width="104" height="19" font="0">Schymik G, et al. </text>
<text top="197" left="96" width="30" height="19" font="0">2015</text>
<text top="196" left="127" width="4" height="21" font="4"> </text>
<text top="197" left="130" width="35" height="19" font="0">(372) </text>
<text top="216" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25388650">25388650</a></text>
<text top="216" left="157" width="7" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25388650"> </a><b> </b></text>
<text top="179" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="197" left="243" width="106" height="19" font="0">10/2008–4/2012 </text>
<text top="216" left="243" width="3" height="19" font="0"> </text>
<text top="234" left="243" width="58" height="19" font="8"><b>Size:</b> 197 </text>
<text top="179" left="425" width="143" height="19" font="8"><b>Inclusion criteria: </b>New </text>
<text top="197" left="425" width="141" height="19" font="0">onset LBBB after TAVR </text>
<text top="216" left="425" width="3" height="19" font="0"> </text>
<text top="234" left="425" width="144" height="19" font="8"><b>Exclusion criteria: </b>N/A  </text>
<text top="180" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="178" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="180" left="605" width="124" height="19" font="8"><b>endpoint:</b> Mortality </text>
<text top="198" left="587" width="3" height="19" font="0"> </text>
<text top="217" left="587" width="145" height="19" font="8"><b>Results:</b> 31% new LBBB </text>
<text top="235" left="587" width="279" height="19" font="0">New LBBB independent predictor of all-cause </text>
<text top="253" left="587" width="228" height="19" font="0">mortality at 1 y (HR: 1.84; 1.35–2.02) </text>
<text top="272" left="587" width="264" height="19" font="0">At 1-y survival with PPM not different than </text>
<text top="290" left="587" width="277" height="19" font="0">survival w/o PPM (81.2% vs. 85.0%; p=0.377) </text>
<text top="179" left="910" width="140" height="20" font="0">•  New onset LBBB is a </text>
<text top="198" left="923" width="159" height="19" font="0">predictor of increased 1 y </text>
<text top="217" left="923" width="144" height="19" font="0">all-cause mortality, but </text>
<text top="235" left="923" width="162" height="19" font="0">mortality is not altered by </text>
<text top="253" left="923" width="23" height="19" font="0">PPI </text>
<text top="309" left="96" width="107" height="19" font="0">Regueiro A, et al. </text>
<text top="327" left="96" width="69" height="19" font="0">2016 (373) </text>
<text top="346" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27169577">27169577</a></text>
<text top="346" left="157" width="7" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27169577"> </a><b> </b></text>
<text top="309" left="243" width="162" height="19" font="8"><b>Study type: </b>Meta-analysis </text>
<text top="327" left="243" width="3" height="19" font="0"> </text>
<text top="345" left="243" width="97" height="19" font="8"><b>Size:</b> 17 studies </text>
<text top="364" left="243" width="140" height="19" font="0">4,756 pts w/new LBBB </text>
<text top="382" left="243" width="169" height="19" font="0">7,032 pts w/new LBBB&amp;PPI </text>
<text top="309" left="425" width="143" height="19" font="8"><b>Inclusion criteria: </b>New </text>
<text top="327" left="425" width="100" height="19" font="0">LBBB post TAVR </text>
<text top="346" left="425" width="3" height="19" font="0"> </text>
<text top="364" left="425" width="144" height="19" font="8"><b>Exclusion criteria: </b>N/A  </text>
<text top="310" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="308" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="310" left="605" width="200" height="19" font="8"><b>endpoint: </b>PPI or mortality at 1 y </text>
<text top="328" left="587" width="3" height="19" font="0"> </text>
<text top="346" left="587" width="257" height="19" font="8"><b>Results: </b>New onset LBBB associated with: </text>
<text top="365" left="587" width="153" height="19" font="0">PPI (RR: 2.18, 1.28–3.70) </text>
<text top="383" left="587" width="218" height="19" font="0">Cardiac death (RR: 1.39, 1.04–1.86) </text>
<text top="401" left="587" width="311" height="19" font="0">No increase in all-cause mort (RR: 1.21, 0.98–1.50) </text>
<text top="420" left="587" width="291" height="19" font="0">Peri-procedural PPI post TAVR -&gt; NO protective </text>
<text top="438" left="587" width="267" height="19" font="0">effect on cardiac death (RR: 0.78, 0.6–1.03) </text>
<text top="309" left="910" width="183" height="20" font="0">•  New onset LBBB post TAVR </text>
<text top="328" left="923" width="173" height="19" font="0">is associated with increased </text>
<text top="346" left="923" width="167" height="19" font="0">cardiac death and need for </text>
<text top="365" left="923" width="59" height="19" font="0">PPI at 1 y </text>
<text top="383" left="910" width="165" height="20" font="0">•  Peri-procedural PPI post </text>
<text top="402" left="923" width="165" height="19" font="0">TAVR did not decrease the </text>
<text top="420" left="923" width="170" height="19" font="0">risk of cardiac death at 1 y.  </text>
<text top="457" left="96" width="222" height="19" font="8"><b>RBBB as predictor of PPI post TAVR </b></text>
<text top="476" left="96" width="123" height="19" font="0">Mauri V, et al. 2016 </text>
<text top="494" left="96" width="35" height="19" font="0">(374) </text>
<text top="513" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27832845">27832845</a></text>
<text top="513" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27832845"><b> </b></a></text>
<text top="476" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="494" left="243" width="3" height="19" font="0"> </text>
<text top="513" left="243" width="156" height="19" font="8"><b>Size</b>: 229 8/2013–1/2016 </text>
<text top="476" left="425" width="147" height="19" font="8"><b>Inclusion criteria: </b>TAVR </text>
<text top="494" left="425" width="144" height="19" font="0">with Edwards SAPIEN 3 </text>
<text top="513" left="425" width="3" height="19" font="0"> </text>
<text top="531" left="425" width="144" height="19" font="8"><b>Exclusion criteria: </b>N/A  </text>
<text top="477" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="475" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="477" left="605" width="87" height="19" font="8"><b>endpoint: </b>PPI </text>
<text top="495" left="587" width="3" height="19" font="0"> </text>
<text top="513" left="587" width="224" height="19" font="8"><b>Results: </b>Among other preprocedure </text>
<text top="532" left="586" width="293" height="19" font="0">nonconduction factors, RBBB is an independent </text>
<text top="550" left="586" width="132" height="19" font="0">predictor of 30 d PPI  </text>
<text top="476" left="910" width="130" height="20" font="0">•  Confusing and self-</text>
<text top="495" left="923" width="132" height="19" font="0">contradictory paper.  </text>
<text top="514" left="910" width="185" height="20" font="0">•  Abstract says that RBBB is a </text>
<text top="533" left="923" width="98" height="19" font="0">predictor of PPI </text>
<text top="551" left="910" width="181" height="20" font="0">•  Body of the paper just says </text>
<text top="570" left="923" width="133" height="19" font="0">that prior conduction </text>
<text top="588" left="923" width="111" height="19" font="0">abnormalities are </text>
<text top="607" left="923" width="68" height="19" font="0">predictive. </text>
<text top="625" left="96" width="82" height="19" font="8"><b>OCEAN-TAVI </b></text>
<text top="644" left="96" width="126" height="19" font="0">Wantanabe, Y, et al. </text>
<text top="662" left="96" width="69" height="19" font="0">2016 (375) </text>
<text top="681" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27832846">27832846</a></text>
<text top="680" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27832846"><b> </b></a></text>
<text top="699" left="96" width="3" height="19" font="8"><b> </b></text>
<text top="625" left="243" width="127" height="19" font="8"><b>Study type</b>: Registry </text>
<text top="644" left="243" width="3" height="19" font="0"> </text>
<text top="662" left="243" width="154" height="19" font="8"><b>Size</b>: 749, 102 with RBBB </text>
<text top="681" left="243" width="106" height="19" font="0">10/2013–8/2015 </text>
<text top="625" left="425" width="147" height="19" font="8"><b>Inclusion criteria</b>: TAVR </text>
<text top="644" left="425" width="134" height="19" font="0">at 8 Japanese centers </text>
<text top="662" left="425" width="3" height="19" font="0"> </text>
<text top="680" left="425" width="144" height="19" font="8"><b>Exclusion criteria</b>: N/A  </text>
<text top="626" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="625" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="626" left="605" width="285" height="19" font="8"><b>endpoint</b>: Incidence of PPI and death with pre-</text>
<text top="645" left="587" width="88" height="19" font="0">existent RBBB </text>
<text top="663" left="587" width="3" height="19" font="0"> </text>
<text top="681" left="587" width="52" height="19" font="8"><b>Results: </b></text>
<text top="700" left="587" width="303" height="20" font="0">• New PPI higher in RBBB (17.6% vs. 2.9%; p&lt;.01) </text>
<text top="719" left="587" width="294" height="20" font="0">• Early survival RBBB vs. no RBBB (96% vs. 98.6; </text>
<text top="738" left="599" width="50" height="19" font="0">p=0.09) </text>
<text top="756" left="587" width="308" height="20" font="0">• Overall survival at 24mo lower in RBBB, log rank </text>
<text top="775" left="599" width="45" height="19" font="0">p=0.03 </text>
<text top="626" left="911" width="158" height="20" font="0">• Pts with RBBB with and </text>
<text top="645" left="924" width="158" height="19" font="0">w/o PPM at higher risk of </text>
<text top="663" left="924" width="152" height="19" font="0">cardiac death early after </text>
<text top="681" left="924" width="62" height="19" font="0">discharge </text>
<text top="700" left="911" width="164" height="20" font="0">• Pts with RBBB should be </text>
<text top="719" left="924" width="124" height="19" font="0">carefully monitored </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 204 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="587" width="293" height="20" font="0">• Cardiac survival lower in RBBB, log rank p&lt;.01 </text>
<text top="106" left="587" width="291" height="20" font="0">• RBBB is a predictor of cardiac death: HR: 2.59 </text>
<text top="125" left="599" width="130" height="19" font="0">(1.15–5.86; p=0.021) </text>
<text top="144" left="96" width="95" height="19" font="0">Nazif TM, et al. </text>
<text top="162" left="96" width="69" height="19" font="0">2015 (365) </text>
<text top="181" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25616819">25616819</a></text>
<text top="181" left="157" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25616819"><b> </b></a></text>
<text top="199" left="96" width="3" height="19" font="8"><b> </b></text>
<text top="144" left="243" width="143" height="19" font="8"><b>Study type: </b>Analysis of </text>
<text top="162" left="242" width="169" height="19" font="0">PARTNER Trial and Registry </text>
<text top="181" left="242" width="56" height="19" font="0">post hoc </text>
<text top="199" left="243" width="3" height="19" font="0"> </text>
<text top="217" left="243" width="66" height="19" font="8"><b>Size:</b> 2559 </text>
<text top="144" left="425" width="147" height="19" font="8"><b>Inclusion criteria: </b>TAVR </text>
<text top="162" left="425" width="3" height="19" font="0"> </text>
<text top="181" left="425" width="141" height="19" font="8"><b>Exclusion criteria: </b>N/A </text>
<text top="145" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="143" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="145" left="605" width="157" height="19" font="8"><b>endpoint: </b>Requiring ppm </text>
<text top="163" left="587" width="3" height="19" font="0"> </text>
<text top="182" left="587" width="291" height="19" font="8"><b>Results: </b>New PPM RBBB vs. no RBBB: 47.6% vs. </text>
<text top="200" left="587" width="98" height="19" font="0">12.8%; p&lt;0.001 </text>
<text top="144" left="911" width="147" height="20" font="0">• Pre-existing RBBB is a </text>
<text top="163" left="924" width="167" height="19" font="0">predictor of PPI after TAVR </text>
<text top="236" left="96" width="92" height="19" font="0">Auffret V, et al </text>
<text top="255" left="96" width="30" height="19" font="0">2017</text>
<text top="253" left="127" width="4" height="21" font="4"> </text>
<text top="255" left="130" width="35" height="19" font="0">(376) </text>
<text top="273" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28734885">28734885</a></text>
<text top="273" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28734885"> </a></text>
<text top="236" left="243" width="153" height="19" font="8"><b>Study type: </b>Multicenter  </text>
<text top="255" left="243" width="3" height="19" font="0"> </text>
<text top="273" left="243" width="152" height="19" font="8"><b>Size: </b>3,527 pts, 362 with </text>
<text top="291" left="242" width="107" height="19" font="0">preexisting RBBB<b> </b></text>
<text top="236" left="425" width="176" height="20" font="8"><b>Inclusion criteria: </b>TAVR<b>  1</b>°</text>
<text top="236" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="237" left="605" width="219" height="19" font="8"><b>endpoint: </b>Complications and death </text>
<text top="255" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="274" left="587" width="257" height="19" font="8"><b>Results: </b>Preexisting RBBB associated with </text>
<text top="292" left="587" width="288" height="19" font="0">increased all-cause mortality (HR: 1.31) and CV </text>
<text top="311" left="587" width="285" height="19" font="0">mortality (HR: 1.45). Baseline RBBB associated </text>
<text top="329" left="587" width="294" height="19" font="0">with a higher 30-d rate of PPM implant (40% vs. </text>
<text top="347" left="587" width="102" height="19" font="0">13.5%; p&lt;0.001)<b> </b></text>
<text top="237" left="911" width="119" height="20" font="0">• Preexisting RBBB </text>
<text top="256" left="924" width="143" height="19" font="0">associated with poorer </text>
<text top="274" left="924" width="101" height="19" font="0">outcomes in pts </text>
<text top="292" left="924" width="109" height="19" font="0">undergoing TAVR </text>
<text top="366" left="96" width="134" height="19" font="0">Rampat R, et al. 2017 </text>
<text top="384" left="96" width="35" height="19" font="0">(377) </text>
<text top="403" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28641846">28641846</a></text>
<text top="403" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28641846"> </a></text>
<text top="366" left="243" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="384" left="243" width="75" height="19" font="0">multicenter </text>
<text top="403" left="243" width="3" height="19" font="8"><b> </b></text>
<text top="421" left="243" width="80" height="19" font="8"><b>Size: </b>228 pts<b> </b></text>
<text top="366" left="425" width="111" height="19" font="8"><b>Inclusion criteria: </b></text>
<text top="384" left="425" width="80" height="19" font="0">LOTUS TAVR<b> </b></text>
<text top="367" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="366" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="367" left="605" width="96" height="19" font="8"><b>endpoint: </b>PPM </text>
<text top="385" left="587" width="3" height="19" font="8"><b> </b></text>
<text top="403" left="587" width="294" height="19" font="8"><b>Results: </b>PPM in 64 pts for AVB or LBBB and first </text>
<text top="422" left="587" width="241" height="19" font="0">degree AVB. Preprocedural conduction </text>
<text top="440" left="587" width="302" height="19" font="0">abnormality associated with higher likelihood for </text>
<text top="459" left="587" width="32" height="19" font="0">PPM<b> </b></text>
<text top="366" left="910" width="156" height="20" font="0">•  Pts with preprocedural </text>
<text top="385" left="924" width="147" height="19" font="0">conduction disturbance </text>
<text top="404" left="924" width="160" height="19" font="0">and noncalcified AV more </text>
<text top="422" left="924" width="164" height="19" font="0">likely to require PPM after </text>
<text top="440" left="924" width="80" height="19" font="0">LOTUS TAVR </text>
<text top="478" left="96" width="230" height="19" font="8"><b>Predictors of readmission post TAVR </b></text>
<text top="497" left="96" width="119" height="19" font="0">Nombela-Franco L, </text>
<text top="515" left="96" width="64" height="19" font="0">et al. 2015</text>
<text top="514" left="160" width="4" height="21" font="4"> </text>
<text top="515" left="164" width="35" height="19" font="0">(378) </text>
<text top="533" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26476610">26476610</a></text>
<text top="533" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26476610"> </a></text>
<text top="497" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="515" left="243" width="3" height="19" font="8"><b> </b></text>
<text top="533" left="243" width="156" height="19" font="8"><b>Size:</b> 720 consecutive pts </text>
<text top="552" left="243" width="159" height="19" font="0">at 2 centers, follow-up 23 </text>
<text top="570" left="243" width="27" height="19" font="0">mo  </text>
<text top="497" left="425" width="147" height="19" font="8"><b>Inclusion criteria: </b>TAVR </text>
<text top="515" left="425" width="3" height="19" font="0"> </text>
<text top="533" left="425" width="141" height="19" font="8"><b>Exclusion criteria: </b>N/A </text>
<text top="497" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="496" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="497" left="605" width="64" height="19" font="8"><b>endpoint: </b></text>
<text top="516" left="587" width="148" height="19" font="0">Early readmission &lt;30 d </text>
<text top="534" left="587" width="167" height="19" font="0">Late readmission 30–365 d </text>
<text top="552" left="587" width="3" height="19" font="0"> </text>
<text top="571" left="587" width="52" height="19" font="8"><b>Results: </b></text>
<text top="589" left="587" width="105" height="19" font="0">4.9% readmitted </text>
<text top="607" left="587" width="155" height="19" font="0">Average 1.6 readmits /pt </text>
<text top="626" left="587" width="198" height="19" font="0">Noncardiac 59% vs. cardiac 41% </text>
<text top="644" left="587" width="286" height="19" font="0">BBB not a predictor of readmission but AF was </text>
<text top="662" left="587" width="62" height="19" font="0">(p=0.012) </text>
<text top="497" left="910" width="121" height="20" font="0">•  Although rhythm </text>
<text top="516" left="923" width="160" height="19" font="0">disturbances cause 21.2% </text>
<text top="534" left="923" width="168" height="19" font="0">of readmissions, BBB is not </text>
<text top="552" left="923" width="74" height="19" font="0">a predictor. </text>
<text top="681" left="96" width="225" height="19" font="8"><b>Predictors of Late Death after TAVR </b></text>
<text top="700" left="96" width="132" height="19" font="0">Urena, M, et al. 2015 </text>
<text top="719" left="96" width="35" height="19" font="0">(379)<b> </b></text>
<text top="737" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25660921">25660921</a></text>
<text top="737" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25660921"> </a></text>
<text top="700" left="243" width="163" height="19" font="8"><b>Study type: </b>Observational </text>
<text top="719" left="243" width="3" height="19" font="0"> </text>
<text top="737" left="243" width="66" height="19" font="8"><b>Size:</b> 3726 </text>
<text top="700" left="425" width="147" height="19" font="8"><b>Inclusion criteria: </b>TAVR </text>
<text top="719" left="425" width="83" height="19" font="0">at 18 centers </text>
<text top="737" left="425" width="3" height="19" font="0"> </text>
<text top="755" left="425" width="141" height="19" font="8"><b>Exclusion criteria: </b>N/A </text>
<text top="701" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="700" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="701" left="605" width="277" height="19" font="8"><b>endpoint:</b> Death from HF and SCD post TAVR </text>
<text top="719" left="587" width="142" height="19" font="0">mean follow-up 22 mo </text>
<text top="738" left="587" width="3" height="19" font="0"> </text>
<text top="756" left="587" width="52" height="19" font="8"><b>Results: </b></text>
<text top="701" left="911" width="180" height="20" font="0">• New onset persistent LBBB </text>
<text top="719" left="923" width="157" height="19" font="0">is a predictor of SCD post </text>
<text top="738" left="923" width="36" height="19" font="0">TAVR </text>
<text top="756" left="911" width="121" height="20" font="0">• PPI in LBBB is not </text>
<text top="775" left="923" width="140" height="19" font="0">protective against SCD </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 205 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="587" width="305" height="19" font="0">4% died of HF (15% of total deaths, 46.1% cardiac </text>
<text top="105" left="587" width="49" height="19" font="0">deaths) </text>
<text top="123" left="587" width="279" height="19" font="0">15% died of SCD (5.6% of all deaths, 16.9% of </text>
<text top="142" left="587" width="52" height="19" font="0">cardiac) </text>
<text top="160" left="587" width="113" height="19" font="0">Predictors of SCD: </text>
<text top="178" left="587" width="249" height="19" font="0">new LBBB HR: 2.26 (1.23–4.14; p=0.009) </text>
<text top="197" left="587" width="309" height="19" font="0">new LBBB and QRS &gt;160 ms HR: 4.78 (1.56–14.63; </text>
<text top="215" left="587" width="57" height="19" font="0">p=0.006) </text>
<text top="233" left="587" width="281" height="19" font="0">NO difference in SCD between LBBB w/o ppm </text>
<text top="252" left="587" width="270" height="19" font="0">(N=471) and LBBB with PPI (N=92): HR: 3.13 </text>
<text top="270" left="587" width="138" height="19" font="0">(0.38–25.63; p=0.287) </text>
<text top="289" left="96" width="130" height="19" font="0">Dizon JM, et al. 2015 </text>
<text top="307" left="96" width="35" height="19" font="0">(380) </text>
<text top="326" left="96" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26261157">26261157</a></text>
<text top="326" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26261157"> </a></text>
<text top="344" left="96" width="3" height="19" font="8"><b> </b></text>
<text top="289" left="243" width="167" height="19" font="8"><b>Study type: </b>Series of pts in </text>
<text top="307" left="243" width="117" height="19" font="0">PARTNER Trial and </text>
<text top="326" left="243" width="164" height="19" font="0">Registry- post hoc analysis </text>
<text top="344" left="243" width="3" height="19" font="0"> </text>
<text top="362" left="243" width="32" height="19" font="8"><b>Size: </b></text>
<text top="381" left="243" width="91" height="19" font="0">Prior ppm:586 </text>
<text top="399" left="243" width="89" height="19" font="0">New ppm:173 </text>
<text top="417" left="243" width="90" height="19" font="0">No ppm: 1612 </text>
<text top="436" left="243" width="125" height="19" font="0">LBBB&amp; no ppm: 160 </text>
<text top="289" left="425" width="141" height="19" font="8"><b>Inclusion criteria:</b> Trial </text>
<text top="307" left="425" width="145" height="19" font="0">and registry, 1-y follow-</text>
<text top="326" left="425" width="19" height="19" font="0">up </text>
<text top="344" left="425" width="3" height="19" font="0"> </text>
<text top="362" left="425" width="144" height="19" font="8"><b>Exclusion criteria: </b>N/A  </text>
<text top="290" left="587" width="14" height="19" font="8"><b>1</b>°</text>
<text top="288" left="601" width="4" height="21" font="2"><b> </b></text>
<text top="290" left="605" width="281" height="19" font="8"><b>endpoint: </b>1 y mortality and re-hospitalization </text>
<text top="308" left="587" width="3" height="19" font="0"> </text>
<text top="326" left="587" width="48" height="19" font="8"><b>Results </b></text>
<text top="345" left="587" width="272" height="19" font="0">Prior PPM (p=0.001), new PPM (p=0.05) and </text>
<text top="363" left="587" width="292" height="19" font="0">LBBB/no ppm (p=0.02) all had higher mort than </text>
<text top="381" left="587" width="54" height="19" font="0">no PPM  </text>
<text top="400" left="587" width="204" height="19" font="0">LBBB not a predictor of mortality </text>
<text top="418" left="587" width="286" height="19" font="0">new ppm HR: 1.38(1.0–1.89; p=0.05) and prior </text>
<text top="436" left="587" width="310" height="19" font="0">ppm HR: 1.31 (1.08–1.6; p=0.006) predict 1 y mort </text>
<text top="289" left="910" width="152" height="20" font="0">•  LBBB/no ppm was not </text>
<text top="308" left="923" width="148" height="19" font="0">compared to LBBB/new </text>
<text top="326" left="923" width="31" height="19" font="0">ppm </text>
<text top="345" left="910" width="186" height="20" font="0">•  LBBB associated with worse </text>
<text top="364" left="923" width="131" height="19" font="0">outcomes but not an </text>
<text top="382" left="923" width="157" height="19" font="0">independent predictor of </text>
<text top="401" left="923" width="34" height="19" font="0">mort </text>
<text top="419" left="910" width="139" height="20" font="0">•  Any PPM: higher 1 y </text>
<text top="438" left="923" width="63" height="19" font="0">mortality  </text>
<text top="457" left="86" width="4" height="21" font="4"> </text>
<text top="477" left="97" width="4" height="21" font="4"> </text>
<text top="477" left="313" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="206" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 206 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="947" height="23" font="5"><b>Data Supplement 50. Nonrandomized Trials, Observational Studies, and/or Registries of Pacing after Heart Transplant (Section </b></text>
<text top="108" left="86" width="79" height="23" font="5"><b>8.1.2.5.1)  </b></text>
<text top="131" left="123" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="149" left="149" width="51" height="19" font="8"><b>Author; </b></text>
<text top="167" left="127" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="131" left="279" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="149" left="308" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="131" left="454" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="131" left="651" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="149" left="682" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="167" left="713" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="131" left="925" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="149" left="954" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="186" left="93" width="137" height="19" font="0">Mallidi HR, et al. 2017 </text>
<text top="205" left="93" width="35" height="19" font="0">(381)<b> </b></text>
<text top="223" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28331443">28331443</a></text>
<text top="223" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28331443"> </a></text>
<text top="186" left="266" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="205" left="266" width="126" height="19" font="0">Retrospective single </text>
<text top="223" left="266" width="83" height="19" font="0">center study  </text>
<text top="241" left="266" width="3" height="19" font="0"> </text>
<text top="260" left="266" width="141" height="19" font="8"><b>Size:</b> 1,450 transplants </text>
<text top="186" left="430" width="149" height="19" font="8"><b>Inclusion criteria:</b> Heart </text>
<text top="205" left="430" width="138" height="19" font="0">transplant at Stanford </text>
<text top="223" left="430" width="3" height="19" font="0"> </text>
<text top="241" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="187" left="612" width="202" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pacemaker implant </text>
<text top="206" left="612" width="3" height="19" font="0"> </text>
<text top="224" left="612" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="242" left="607" width="249" height="20" font="0">•  84/1,450 pts (5.8%) had a PPM placed </text>
<text top="262" left="607" width="251" height="20" font="0">•  Of these 55 (65%) had the PPM placed </text>
<text top="280" left="620" width="72" height="19" font="0">within 30 d </text>
<text top="299" left="607" width="257" height="20" font="0">•  Early PPM implant with shorter survival </text>
<text top="318" left="620" width="234" height="19" font="0">compared to late PPM (6.4 y vs. 7.7 y) </text>
<text top="336" left="607" width="265" height="20" font="0">•  Incidence of PPM was 2% for bicaval and </text>
<text top="355" left="620" width="166" height="19" font="0">9.1% for biatrial transplant </text>
<text top="374" left="607" width="227" height="20" font="0">•  More rejection episodes with PPM </text>
<text top="187" left="889" width="177" height="20" font="0">•  Decreased PPM need with </text>
<text top="206" left="903" width="112" height="19" font="0">bicaval transplant </text>
<text top="224" left="889" width="182" height="20" font="0">•  PPM more likely with older </text>
<text top="243" left="903" width="79" height="19" font="0">donor grafts </text>
<text top="393" left="93" width="148" height="19" font="0">Wellmann P, et al. 2017 </text>
<text top="412" left="93" width="35" height="19" font="0">(382)<b> </b></text>
<text top="430" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28101990">28101990</a></text>
<text top="430" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28101990"> </a></text>
<text top="393" left="266" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="412" left="266" width="126" height="19" font="0">Retrospective single </text>
<text top="430" left="266" width="83" height="19" font="0">center study<b> </b> </text>
<text top="448" left="266" width="3" height="19" font="0"> </text>
<text top="467" left="266" width="141" height="19" font="8"><b>Size:</b> 1,179 transplants </text>
<text top="393" left="430" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="412" left="430" width="68" height="19" font="0">Transplant </text>
<text top="430" left="430" width="3" height="19" font="0"> </text>
<text top="448" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="394" left="612" width="113" height="19" font="8"><b>1</b>°<b> endpoint:</b> PPM </text>
<text top="413" left="612" width="3" height="19" font="0"> </text>
<text top="431" left="612" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="449" left="607" width="250" height="20" font="0">•  135/1,179 pts (11.5%) required a PPM </text>
<text top="468" left="607" width="213" height="20" font="0">•  PPM more likely with prolonged </text>
<text top="487" left="620" width="239" height="19" font="0">operation and biatrial transplant (9.4% </text>
<text top="506" left="620" width="61" height="19" font="0">vs. 4.4 %) </text>
<text top="524" left="607" width="251" height="20" font="0">•  Approximately 85% with SND and 15% </text>
<text top="543" left="620" width="59" height="19" font="0">with AVB </text>
<text top="562" left="607" width="156" height="20" font="0">•  No survival differences </text>
<text top="394" left="889" width="140" height="20" font="0">•  PPM mainly for SND </text>
<text top="413" left="889" width="174" height="20" font="0">•  Requirement for PPM has </text>
<text top="432" left="903" width="142" height="19" font="0">decreased with bicaval </text>
<text top="450" left="903" width="66" height="19" font="0">transplant </text>
<text top="468" left="889" width="3" height="19" font="0"> </text>
<text top="581" left="93" width="148" height="19" font="0">Lee W, et al. 2016 (383) </text>
<text top="600" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26847073">26847073</a></text>
<text top="600" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26847073"> </a></text>
<text top="581" left="266" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="600" left="266" width="126" height="19" font="0">Retrospective single </text>
<text top="618" left="266" width="43" height="19" font="0">center </text>
<text top="636" left="266" width="3" height="19" font="0"> </text>
<text top="654" left="266" width="109" height="19" font="8"><b>Size:</b> 33 (2 pacing </text>
<text top="673" left="266" width="75" height="19" font="0">dependent) </text>
<text top="581" left="430" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="600" left="430" width="148" height="19" font="0">Requirement for pacing </text>
<text top="618" left="430" width="102" height="19" font="0">after transplant  </text>
<text top="636" left="430" width="3" height="19" font="0"> </text>
<text top="654" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="582" left="612" width="233" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical HF or LVEF &lt;35% </text>
<text top="600" left="612" width="3" height="19" font="0"> </text>
<text top="619" left="612" width="240" height="19" font="8"><b>Results:</b> 2 pts were PM dependent and </text>
<text top="637" left="612" width="87" height="19" font="0">developed HF </text>
<text top="655" left="612" width="217" height="19" font="0">31 pts with a PPM but did not pace </text>
<text top="674" left="612" width="181" height="19" font="0">continuously did not have HF </text>
<text top="582" left="889" width="166" height="20" font="0">•  AVB with high RV pacing </text>
<text top="600" left="903" width="165" height="19" font="0">burden associated with HF </text>
<text top="619" left="889" width="108" height="20" font="0">•  Numbers small </text>
<text top="638" left="889" width="3" height="19" font="0"> </text>
<text top="693" left="93" width="140" height="19" font="0">El-Assaad I, et al. 2015 </text>
<text top="711" left="93" width="35" height="19" font="0">(384)<b> </b></text>
<text top="729" left="93" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25956965">25956965 </a></text>
<text top="729" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25956965"> </a></text>
<text top="693" left="266" width="74" height="19" font="8"><b>Study type:</b> </text>
<text top="711" left="266" width="127" height="19" font="0">Retrospective UNOS </text>
<text top="729" left="266" width="59" height="19" font="0">database </text>
<text top="748" left="266" width="3" height="19" font="0"> </text>
<text top="766" left="266" width="69" height="19" font="8"><b>Size:</b> 6,156 </text>
<text top="693" left="430" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="711" left="430" width="167" height="19" font="0">Transplant UNOS &lt;18 y old </text>
<text top="729" left="430" width="3" height="19" font="0"> </text>
<text top="748" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="693" left="612" width="220" height="19" font="8"><b>1</b>°<b> endpoint:</b> Acute PPM placement </text>
<text top="712" left="612" width="3" height="19" font="0"> </text>
<text top="730" left="612" width="231" height="19" font="8"><b>Results:</b> 69/6,156 pts required a PPM </text>
<text top="748" left="612" width="47" height="19" font="0">acutely </text>
<text top="767" left="612" width="185" height="19" font="0">PPM use decreased over time </text>
<text top="693" left="889" width="206" height="20" font="0">•  PPM recipients with higher risk </text>
<text top="712" left="903" width="171" height="19" font="0">of infection and dialysis but </text>
<text top="730" left="903" width="94" height="19" font="0">similar survival </text>
<text top="748" left="889" width="3" height="19" font="0"> </text>
</page>
<page number="207" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 207 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="612" width="190" height="19" font="0">PPM more likely with a biatrial </text>
<text top="105" left="612" width="191" height="19" font="0">anastomosis, higher donor age </text>
<text top="123" left="612" width="205" height="19" font="0">PPM pts more likely to have post-</text>
<text top="142" left="612" width="211" height="19" font="0">transplant infection (48% vs. 26%) </text>
<text top="160" left="612" width="3" height="19" font="0"> </text>
<text top="179" left="93" width="98" height="19" font="0">Knight CS, et al.<b> </b></text>
<text top="197" left="93" width="69" height="19" font="0">2010 (385)<b> </b></text>
<text top="216" left="93" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19144548">19144548 </a></text>
<text top="216" left="157" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19144548"> </a></text>
<text top="179" left="266" width="145" height="19" font="8"><b>Study type:</b> Case series </text>
<text top="197" left="266" width="3" height="19" font="0"> </text>
<text top="216" left="266" width="145" height="19" font="8"><b>Size:</b> 6 (2 with autopsy) </text>
<text top="179" left="430" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="197" left="430" width="106" height="19" font="0">identified from a </text>
<text top="216" left="430" width="156" height="19" font="0">transplant database with </text>
<text top="234" left="430" width="96" height="19" font="0">syncope due to </text>
<text top="252" left="430" width="79" height="19" font="0">bradycardia  </text>
<text top="271" left="430" width="3" height="19" font="0"> </text>
<text top="289" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="180" left="612" width="216" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pathologic evaluation </text>
<text top="198" left="612" width="3" height="19" font="0"> </text>
<text top="217" left="612" width="238" height="19" font="8"><b>Results:</b> Autopsy revealed preferential </text>
<text top="235" left="612" width="259" height="19" font="0">severe rejection in the cardiac conduction </text>
<text top="253" left="612" width="46" height="19" font="0">system </text>
<text top="272" left="612" width="3" height="19" font="0"> </text>
<text top="179" left="889" width="185" height="20" font="0">•  Rejection can preferentially </text>
<text top="198" left="903" width="181" height="19" font="0">affect the conduction system </text>
<text top="308" left="93" width="137" height="19" font="0">Braith RW, et al. 2000 </text>
<text top="326" left="93" width="35" height="19" font="0">(386)<b> </b></text>
<text top="345" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11144044">11144044</a></text>
<text top="345" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11144044"> </a></text>
<text top="308" left="266" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="326" left="266" width="104" height="19" font="0">treadmill testing </text>
<text top="345" left="266" width="3" height="19" font="0"> </text>
<text top="363" left="266" width="127" height="19" font="8"><b>Size:</b> 8 pts with PPM </text>
<text top="308" left="430" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="326" left="430" width="130" height="19" font="0">Transplant with PPM </text>
<text top="345" left="430" width="3" height="19" font="0"> </text>
<text top="363" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="309" left="612" width="228" height="19" font="8"><b>1</b>°<b> endpoint:</b> Treadmill performance  </text>
<text top="327" left="612" width="3" height="19" font="0"> </text>
<text top="345" left="612" width="248" height="19" font="8"><b>Results:</b> Chronotropic support improves </text>
<text top="364" left="612" width="264" height="19" font="0">treadmill times (14.6 min vs. 12.4 min) and </text>
<text top="382" left="612" width="51" height="19" font="0">peak VO</text>
<text top="389" left="663" width="5" height="12" font="7">2</text>
<text top="382" left="668" width="163" height="19" font="0"> (18.9 vs. 15.4 mL/kg/min) </text>
<text top="308" left="889" width="148" height="20" font="0">•  Rate adaption helpful </text>
<text top="401" left="93" width="153" height="19" font="0">Bacal F, et al. 2000 (387)<b> </b></text>
<text top="419" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10904516">10904516</a></text>
<text top="419" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10904516"> </a></text>
<text top="401" left="266" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="419" left="266" width="127" height="19" font="0">center retrospective </text>
<text top="438" left="266" width="3" height="19" font="0"> </text>
<text top="456" left="266" width="84" height="19" font="8"><b>Size:</b> 114 pts  </text>
<text top="401" left="430" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="419" left="430" width="68" height="19" font="0">Transplant </text>
<text top="438" left="430" width="3" height="19" font="0"> </text>
<text top="456" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="402" left="612" width="240" height="19" font="8"><b>1</b>°<b> endpoint:</b> Temporary or permanent </text>
<text top="420" left="612" width="43" height="19" font="0">pacing </text>
<text top="439" left="612" width="3" height="19" font="0"> </text>
<text top="457" left="612" width="262" height="19" font="8"><b>Results:</b> 14/114 (12%) required temporary </text>
<text top="475" left="612" width="224" height="19" font="0">pacing mainly for SND (78.5%), 4 pts </text>
<text top="494" left="612" width="153" height="19" font="0">required PPM, 3 for SND </text>
<text top="512" left="612" width="110" height="19" font="0">Rejection with AF </text>
<text top="530" left="612" width="3" height="19" font="0"> </text>
<text top="401" left="889" width="191" height="20" font="0">•  SND main reason for PPM or </text>
<text top="420" left="903" width="144" height="19" font="0">temporary pacing after </text>
<text top="439" left="903" width="66" height="19" font="0">transplant </text>
<text top="549" left="93" width="130" height="19" font="0">Nagele H, et al. 1998<b> </b></text>
<text top="568" left="93" width="69" height="19" font="0">1998 (388)<b> </b></text>
<text top="586" left="93" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9773864">9773864</a></text>
<text top="586" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9773864"> </a></text>
<text top="549" left="266" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="568" left="266" width="127" height="19" font="0">center retrospective </text>
<text top="586" left="266" width="3" height="19" font="0"> </text>
<text top="604" left="266" width="84" height="19" font="8"><b>Size:</b> 112 pts <b> </b></text>
<text top="549" left="430" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="568" left="430" width="163" height="19" font="0">Transplant and placement </text>
<text top="586" left="430" width="168" height="19" font="0">of epicardial biatrial pacing </text>
<text top="604" left="430" width="3" height="19" font="0"> </text>
<text top="622" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="550" left="612" width="246" height="19" font="8"><b>1</b>°<b> endpoint:</b> NYHA class, hemodynamic </text>
<text top="568" left="612" width="74" height="19" font="0">parameters </text>
<text top="587" left="612" width="3" height="19" font="0"> </text>
<text top="605" left="612" width="266" height="19" font="8"><b>Results:</b> Modest improvement with biatrial </text>
<text top="623" left="612" width="43" height="19" font="0">pacing </text>
<text top="642" left="612" width="3" height="19" font="8"><b> </b></text>
<text top="549" left="889" width="151" height="20" font="0">•  Biatrial pacing may be </text>
<text top="568" left="903" width="63" height="19" font="0">beneficial </text>
<text top="661" left="93" width="97" height="19" font="0">Jones DG, et al.<b> </b></text>
<text top="679" left="93" width="69" height="19" font="0">2011 (389)<b> </b></text>
<text top="697" left="93" width="67" height="21" font="14"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21783383">21783383</a></text>
<text top="699" left="160" width="3" height="19" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21783383"><b> </b></a></text>
<text top="661" left="266" width="114" height="19" font="8"><b>Study type:</b> Single </text>
<text top="679" left="266" width="127" height="19" font="0">center retrospective </text>
<text top="697" left="266" width="3" height="19" font="0"> </text>
<text top="715" left="266" width="76" height="19" font="8"><b>Size:</b> 48 pts <b> </b></text>
<text top="661" left="430" width="143" height="19" font="8"><b>Inclusion criteria:</b> PPM </text>
<text top="679" left="430" width="99" height="19" font="0">after transplant </text>
<text top="697" left="430" width="3" height="19" font="0"> </text>
<text top="715" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="661" left="612" width="144" height="19" font="8"><b>1</b>°<b> endpoint:</b> Prognosis </text>
<text top="680" left="612" width="3" height="19" font="0"> </text>
<text top="698" left="612" width="242" height="19" font="8"><b>Results:</b> 48/309 pts required PPM after </text>
<text top="716" left="612" width="116" height="19" font="0">transplant (12.3%) </text>
<text top="735" left="612" width="261" height="19" font="0">30 with PPM during hospitalization and 18 </text>
<text top="753" left="612" width="218" height="19" font="0">with late PPM (3 y after transplant) </text>
<text top="771" left="612" width="250" height="19" font="0">SND more common early and AVB later.  </text>
<text top="661" left="889" width="178" height="20" font="0">•  Late pacing not associated </text>
<text top="680" left="903" width="88" height="19" font="0">with rejection </text>
</page>
<page number="208" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 208 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="612" width="253" height="19" font="0">Late pacing not associated with rejection </text>
<text top="105" left="612" width="3" height="19" font="8"><b> </b></text>
<text top="124" left="93" width="146" height="19" font="0">Cantillon DJ, et al. 2010 </text>
<text top="143" left="93" width="35" height="19" font="0">(390)<b> </b></text>
<text top="161" left="93" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20601151">20601151</a></text>
<text top="161" left="154" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20601151"> </a></text>
<text top="124" left="266" width="114" height="19" font="8"><b>Study type:</b> UNOS </text>
<text top="143" left="266" width="3" height="19" font="0"> </text>
<text top="161" left="266" width="102" height="19" font="8"><b>Size:</b> 35,998 pts <b> </b></text>
<text top="124" left="430" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="143" left="430" width="126" height="19" font="0">Transplant and PPM </text>
<text top="161" left="430" width="3" height="19" font="0"> </text>
<text top="179" left="430" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="125" left="612" width="147" height="19" font="8"><b>1</b>°<b> endpoint:</b> Outcomes </text>
<text top="143" left="612" width="3" height="19" font="0"> </text>
<text top="162" left="612" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="180" left="607" width="236" height="20" font="0">•  3,940/35,987 (10.9%) required PPM </text>
<text top="199" left="607" width="267" height="20" font="0">•  PPM recipients with improved survival (8 </text>
<text top="218" left="620" width="64" height="19" font="0">y vs.5.2 y) </text>
<text top="237" left="607" width="262" height="20" font="0">•  Bicaval implant with less PPM (OR: 0.33; </text>
<text top="256" left="620" width="117" height="19" font="0">95% CI: 0.29–0.36) </text>
<text top="274" left="607" width="249" height="20" font="0">•  PPM associated with increasing donor </text>
<text top="293" left="620" width="206" height="19" font="0">age (OR: 1.04; 95% CI: 1.00–1.09; </text>
<text top="311" left="620" width="230" height="19" font="0">p&lt;0.001) and recipient age (OR: 1.09; </text>
<text top="330" left="620" width="166" height="19" font="0">95% CI: 1.0–1.12; p&lt;0.001) </text>
<text top="348" left="607" width="141" height="20" font="0">•  Transplant CAD (OR: </text>
<text top="367" left="607" width="266" height="20" font="0">•  2.12; 95% CI: 0.92–2.33; p=0.409), donor </text>
<text top="386" left="620" width="236" height="19" font="0">heart ischemic time (OR: 1.03; 95% CI: </text>
<text top="404" left="620" width="246" height="19" font="0">0.97–1.04; p=0.880), and graft rejection </text>
<text top="423" left="620" width="237" height="19" font="0">requiring treatment (OR: 0.95; 95% CI: </text>
<text top="441" left="620" width="236" height="19" font="0">0.84–1.07, P.367) were not associated </text>
<text top="459" left="620" width="146" height="19" font="0">with PPM requirement.<b> </b></text>
<text top="124" left="889" width="205" height="20" font="0">•  PPM less common with bicaval </text>
<text top="144" left="889" width="168" height="20" font="0">•  PPM not associated with </text>
<text top="162" left="903" width="58" height="19" font="0">rejection </text>
<text top="181" left="889" width="3" height="19" font="0"> </text>
<text top="479" left="82" width="3" height="19" font="0"> </text>
<text top="497" left="86" width="4" height="21" font="4"> </text>
<text top="517" left="86" width="827" height="23" font="5"><b>Data Supplement 51. Nonrandomized Studies for Alcohol Septal Ablation/Septal Myectomy (Section 8.1.2.5.2) </b></text>
<text top="540" left="98" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="558" left="129" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="576" left="101" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="540" left="238" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="558" left="267" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="540" left="437" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="540" left="646" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="558" left="676" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="576" left="708" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="540" left="922" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="558" left="950" width="80" height="19" font="8"><b>Comment(s) </b></text>
</page>
<page number="209" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 209 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="95" height="19" font="0">Liebregts M, et </text>
<text top="105" left="95" width="87" height="19" font="0">al. 2017 (391) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28595881">28595881</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28595881"> </a></text>
<text top="87" left="216" width="156" height="19" font="8"><b>Aim:</b> Evaluate use of ASA </text>
<text top="105" left="216" width="163" height="19" font="0">particularly in younger pts </text>
<text top="123" left="216" width="3" height="19" font="0"> </text>
<text top="142" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="160" left="216" width="137" height="19" font="0">analysis of 3 registries </text>
<text top="178" left="216" width="3" height="19" font="0"> </text>
<text top="197" left="216" width="121" height="19" font="8"><b>Size:</b> 1,197 pts who </text>
<text top="215" left="216" width="98" height="19" font="0">underwent ASA </text>
<text top="87" left="398" width="194" height="19" font="8"><b>Inclusion criteria:</b> International </text>
<text top="105" left="398" width="179" height="19" font="0">multicenter study of pts who </text>
<text top="123" left="398" width="158" height="19" font="0">underwent ASA (National </text>
<text top="142" left="398" width="139" height="19" font="0">registries of Germany, </text>
<text top="160" left="398" width="146" height="19" font="0">Netherlands, Denmark) </text>
<text top="178" left="398" width="3" height="19" font="0"> </text>
<text top="197" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="88" left="608" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="106" left="608" width="118" height="19" font="0">All-cause mortality </text>
<text top="124" left="608" width="211" height="19" font="0">Adverse arrhythmic event (VT, VF, </text>
<text top="143" left="608" width="149" height="19" font="0">appropriate ICD shocks) </text>
<text top="161" left="608" width="3" height="19" font="0"> </text>
<text top="180" left="608" width="85" height="19" font="8"><b>2</b>°<b> endpoint:</b>  </text>
<text top="198" left="608" width="169" height="19" font="0">Periprocedural AVB (&lt;30 d) </text>
<text top="217" left="608" width="32" height="19" font="0">PPM </text>
<text top="235" left="608" width="3" height="19" font="0"> </text>
<text top="253" left="608" width="48" height="19" font="8"><b>Results</b> </text>
<text top="272" left="608" width="145" height="20" font="0">• Mean follow-up 5.4 y </text>
<text top="291" left="608" width="148" height="20" font="0">• Complete Heart block </text>
<text top="315" left="634" width="9" height="12" font="0">o</text>
<text top="313" left="643" width="4" height="14" font="0"> </text>
<text top="310" left="647" width="123" height="19" font="0">&lt;50: 119/369 (32%) </text>
<text top="333" left="634" width="9" height="12" font="0">o</text>
<text top="332" left="643" width="4" height="14" font="0"> </text>
<text top="328" left="647" width="138" height="19" font="0">51–64: 161/423 (39%) </text>
<text top="351" left="634" width="9" height="12" font="0">o</text>
<text top="350" left="643" width="4" height="14" font="0"> </text>
<text top="346" left="647" width="123" height="19" font="0">&gt;65: 169/405 (42%) </text>
<text top="365" left="608" width="44" height="20" font="0">• PPM </text>
<text top="389" left="633" width="9" height="12" font="0">o</text>
<text top="388" left="642" width="4" height="14" font="0"> </text>
<text top="384" left="647" width="108" height="19" font="0">&lt;50: 29/369 (8%) </text>
<text top="407" left="633" width="9" height="12" font="0">o</text>
<text top="406" left="642" width="4" height="14" font="0"> </text>
<text top="402" left="647" width="131" height="19" font="0">51–64: 53/423 (13%) </text>
<text top="426" left="633" width="9" height="12" font="0">o</text>
<text top="424" left="642" width="4" height="14" font="0"> </text>
<text top="421" left="647" width="116" height="19" font="0">&gt;65: 65/405 (16%) </text>
<text top="439" left="608" width="132" height="20" font="0">• ICD (rate support?) </text>
<text top="463" left="633" width="9" height="12" font="0">o</text>
<text top="462" left="642" width="4" height="14" font="0"> </text>
<text top="458" left="654" width="108" height="19" font="0">&lt;50: 21/369 (6%) </text>
<text top="481" left="633" width="9" height="12" font="0">o</text>
<text top="480" left="642" width="4" height="14" font="0"> </text>
<text top="476" left="654" width="123" height="19" font="0">51–64: 18/423 (4%) </text>
<text top="499" left="634" width="9" height="12" font="0">o</text>
<text top="498" left="643" width="4" height="14" font="0"> </text>
<text top="494" left="654" width="108" height="19" font="0">&gt;65: 11/405 (3%)<b> </b></text>
<text top="87" left="883" width="195" height="20" font="0">•  Heart block more common in </text>
<text top="106" left="896" width="57" height="19" font="0">older pts </text>
<text top="124" left="883" width="195" height="20" font="0">•  Authors conclude ASA safe in </text>
<text top="143" left="896" width="76" height="19" font="0">younger pts </text>
<text top="162" left="883" width="191" height="20" font="0">•  Do not discuss PPM use 30 d </text>
<text top="181" left="896" width="123" height="19" font="0">after the procedure </text>
<text top="199" left="883" width="204" height="20" font="0">•  Note that outcomes are better </text>
<text top="218" left="896" width="173" height="19" font="0">with lower dose alcohol use </text>
<text top="237" left="883" width="3" height="19" font="0"> </text>
<text top="514" left="95" width="89" height="19" font="0">Poon SS, et al. </text>
<text top="532" left="95" width="69" height="19" font="0">2017 (392) </text>
<text top="550" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28329292">28329292</a></text>
<text top="550" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28329292"> </a></text>
<text top="569" left="95" width="3" height="19" font="0"> </text>
<text top="513" left="216" width="152" height="19" font="8"><b>Aim:</b> Evaluate outcomes </text>
<text top="532" left="216" width="111" height="19" font="0">between ASA and </text>
<text top="550" left="216" width="68" height="19" font="0">myectomy </text>
<text top="569" left="216" width="3" height="19" font="0"> </text>
<text top="587" left="216" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="605" left="216" width="43" height="19" font="0">search </text>
<text top="623" left="216" width="3" height="19" font="0"> </text>
<text top="642" left="216" width="118" height="19" font="8"><b>Size:</b> 15 articles-14 </text>
<text top="660" left="216" width="160" height="19" font="0">observational and 1 meta-</text>
<text top="678" left="216" width="51" height="19" font="0">analysis </text>
<text top="513" left="398" width="181" height="19" font="8"><b>Inclusion criteria:</b> Systematic </text>
<text top="532" left="398" width="111" height="19" font="0">search-keywords: </text>
<text top="550" left="398" width="131" height="19" font="0">Cardiomyopathy and </text>
<text top="569" left="398" width="147" height="19" font="0">myectomy and ablation </text>
<text top="587" left="398" width="73" height="19" font="0">218 studies </text>
<text top="605" left="398" width="3" height="19" font="0"> </text>
<text top="623" left="398" width="179" height="19" font="8"><b>Exclusion criteria:</b> 15 studies </text>
<text top="642" left="398" width="192" height="19" font="0">chosen as best nonoverlapping </text>
<text top="660" left="398" width="47" height="19" font="0">studies </text>
<text top="514" left="608" width="260" height="19" font="8"><b>1</b>°<b> endpoint:</b> Multiple depending on study </text>
<text top="533" left="608" width="3" height="19" font="0"> </text>
<text top="551" left="608" width="48" height="19" font="8"><b>Results</b> </text>
<text top="569" left="608" width="86" height="19" font="0">PPM implant: </text>
<text top="588" left="608" width="100" height="20" font="0">• ASA: 1.7–22% </text>
<text top="607" left="608" width="163" height="20" font="0">• Myectomy: 2.4%–12.5% </text>
<text top="626" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="514" left="883" width="156" height="20" font="0">•  Authors conclude both </text>
<text top="533" left="896" width="154" height="19" font="0">procedures reduce LVOT </text>
<text top="551" left="896" width="55" height="19" font="0">gradient </text>
<text top="569" left="883" width="3" height="19" font="0"> </text>
<text top="588" left="883" width="3" height="19" font="0"> </text>
<text top="697" left="95" width="106" height="19" font="0">Axelsson A, et al. </text>
<text top="716" left="95" width="69" height="19" font="0">2014 (393) </text>
<text top="734" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24662414">24662414</a></text>
<text top="734" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24662414"> </a></text>
<text top="697" left="216" width="109" height="19" font="8"><b>Aim:</b> Evaluate AV </text>
<text top="716" left="216" width="167" height="19" font="0">conduction over time after </text>
<text top="734" left="216" width="28" height="19" font="0">ASA </text>
<text top="752" left="216" width="3" height="19" font="0"> </text>
<text top="771" left="216" width="78" height="19" font="8"><b>Study type:</b>  </text>
<text top="697" left="398" width="163" height="19" font="8"><b>Inclusion criteria:</b> Pts who </text>
<text top="716" left="398" width="98" height="19" font="0">underwent ASA </text>
<text top="734" left="398" width="3" height="19" font="0"> </text>
<text top="752" left="398" width="168" height="19" font="8"><b>Exclusion criteria:</b> Baseline </text>
<text top="771" left="398" width="32" height="19" font="0">CIED </text>
<text top="698" left="608" width="243" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pacing and AV conduction </text>
<text top="716" left="618" width="62" height="19" font="0">over time </text>
<text top="735" left="608" width="3" height="19" font="0"> </text>
<text top="753" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="698" left="883" width="190" height="20" font="0">•  Late PPM in 3 pts at variable </text>
<text top="716" left="896" width="98" height="19" font="0">times after ASA </text>
<text top="735" left="883" width="186" height="20" font="0">•  About 40% of pts who need </text>
<text top="754" left="896" width="193" height="19" font="0">PPM will have recurrent 1:1 AV </text>
</page>
<page number="210" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 210 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="167" height="19" font="0">Single center retrospective </text>
<text top="105" left="216" width="37" height="19" font="0">study </text>
<text top="123" left="216" width="3" height="19" font="0"> </text>
<text top="142" left="216" width="73" height="19" font="8"><b>Size:</b> 87 pts </text>
<text top="87" left="608" width="244" height="20" font="0">• 24/87 (28%) pts had PPM paced after </text>
<text top="106" left="620" width="28" height="19" font="0">ASA </text>
<text top="124" left="608" width="135" height="20" font="0">• 10 lost to follow-up </text>
<text top="144" left="608" width="251" height="20" font="0">• 6/14 remaining pts had recovery of AV </text>
<text top="163" left="620" width="250" height="19" font="0">conduction at follow-up 6.2 y (2.1–9.4 y) </text>
<text top="181" left="608" width="245" height="20" font="0">• Pts with persistent AVB after ASA had </text>
<text top="200" left="620" width="187" height="19" font="0">longer PR intervals at baseline </text>
<text top="218" left="608" width="263" height="20" font="0">• Permanent AV conduction abnormalities </text>
<text top="237" left="620" width="244" height="19" font="0">in pts with baseline 1st degree AVB and </text>
<text top="256" left="620" width="93" height="19" font="0">persistent CHB </text>
<text top="274" left="608" width="246" height="20" font="0">• 3 pts who initially did not need a PPM </text>
<text top="293" left="620" width="233" height="19" font="0">later had a PPM implanted (8 mo, 9 y, </text>
<text top="311" left="620" width="173" height="19" font="0">and 9 y after the index ASA)<b> </b></text>
<text top="87" left="896" width="191" height="19" font="0">conduction at extended follow-</text>
<text top="105" left="896" width="19" height="19" font="0">up </text>
<text top="123" left="883" width="3" height="19" font="0"> </text>
<text top="330" left="95" width="96" height="19" font="0">Veselka J, et al. </text>
<text top="349" left="95" width="69" height="19" font="0">2014 (394) </text>
<text top="367" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24360153">24360153 </a></text>
<text top="367" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24360153"> </a></text>
<text top="330" left="216" width="167" height="19" font="8"><b>Aim:</b> Evaluate outcomes in </text>
<text top="349" left="216" width="167" height="19" font="0">pts with PPM for AVB after </text>
<text top="367" left="216" width="31" height="19" font="0">ASA  </text>
<text top="385" left="216" width="3" height="19" font="0"> </text>
<text top="404" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="422" left="216" width="54" height="19" font="0">analysis  </text>
<text top="440" left="216" width="3" height="19" font="0"> </text>
<text top="459" left="216" width="84" height="19" font="8"><b>Size:</b> 167 pts  </text>
<text top="330" left="398" width="137" height="19" font="8"><b>Inclusion criteria:</b> 167 </text>
<text top="349" left="398" width="192" height="19" font="0">consecutive pts with HCM who </text>
<text top="367" left="398" width="155" height="19" font="0">underwent ASA for LVOT </text>
<text top="385" left="398" width="60" height="19" font="0">gradients </text>
<text top="404" left="398" width="3" height="19" font="0"> </text>
<text top="422" left="398" width="168" height="19" font="8"><b>Exclusion criteria:</b> Baseline </text>
<text top="440" left="398" width="32" height="19" font="0">CIED </text>
<text top="331" left="608" width="248" height="19" font="8"><b>1</b>°<b> endpoint: </b>17 pts (10%) required PPM </text>
<text top="350" left="618" width="149" height="19" font="0">placed 3–15 d after ASA </text>
<text top="368" left="608" width="3" height="19" font="0"> </text>
<text top="386" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="405" left="608" width="250" height="20" font="0">• At follow-up 11/17 (65%) had recovery </text>
<text top="424" left="618" width="162" height="19" font="0">of AV conduction at 6 mo. </text>
<text top="442" left="608" width="245" height="20" font="0">• In the nonpaced group 3/150 pts (2%) </text>
<text top="461" left="618" width="102" height="19" font="0">had PPM placed </text>
<text top="480" left="608" width="240" height="20" font="0">• Similar outcomes between the paced </text>
<text top="498" left="618" width="135" height="19" font="0">and nonpaced groups </text>
<text top="331" left="883" width="208" height="20" font="0">•  Recovery of AV conduction was </text>
<text top="350" left="896" width="83" height="19" font="0">high at 6 mo. </text>
<text top="368" left="883" width="145" height="20" font="0">•  Pacemakers placed if </text>
<text top="387" left="896" width="145" height="19" font="0">conduction block &gt;24 h </text>
<text top="405" left="883" width="195" height="20" font="0">•  In the nonpaced group 3/150 </text>
<text top="424" left="896" width="196" height="19" font="0">pts (2%) had PPM placed 12–53 </text>
<text top="443" left="896" width="84" height="19" font="0">mo after ASA </text>
<text top="461" left="883" width="200" height="20" font="0">•  Pacing vs. nonpacing does not </text>
<text top="480" left="896" width="156" height="19" font="0">change clinical outcomes </text>
<text top="518" left="95" width="98" height="19" font="0">El-Jack SS, et al. </text>
<text top="536" left="95" width="69" height="19" font="0">2007 (395) </text>
<text top="554" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17300408">17300408</a></text>
<text top="554" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17300408"> </a></text>
<text top="517" left="216" width="169" height="19" font="8"><b>Aim: </b>Evaluate ECG changes </text>
<text top="536" left="216" width="61" height="19" font="0">after ASA<b> </b></text>
<text top="554" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="572" left="216" width="162" height="19" font="8"><b>Study type: </b>Retrospective<b> </b></text>
<text top="591" left="216" width="3" height="19" font="8"><b> </b></text>
<text top="609" left="216" width="103" height="19" font="8"><b>Size: </b>50 pts who </text>
<text top="627" left="216" width="98" height="19" font="0">underwent ASA<b> </b></text>
<text top="517" left="398" width="182" height="19" font="8"><b>Inclusion criteria: </b>50 pts who </text>
<text top="536" left="398" width="98" height="19" font="0">underwent ASA </text>
<text top="554" left="398" width="3" height="19" font="8"><b> </b></text>
<text top="572" left="398" width="141" height="19" font="8"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="518" left="608" width="166" height="19" font="8"><b>1</b>°<b> endpoint: </b>ECG changes <b> </b></text>
<text top="536" left="608" width="3" height="19" font="8"><b> </b></text>
<text top="555" left="608" width="56" height="19" font="8"><b>Results:  </b></text>
<text top="573" left="608" width="92" height="20" font="0">•<b> </b>ECG changes </text>
<text top="593" left="627" width="116" height="20" font="0">•<b> </b>New RBBB (57%) </text>
<text top="612" left="627" width="228" height="20" font="0">•<b> </b>Transient CHB with recovery &lt;24 h: </text>
<text top="631" left="640" width="79" height="19" font="0">10 pts (20%) </text>
<text top="649" left="627" width="245" height="20" font="0">•<b> </b>Persistent CHB (&gt;24 h) requiring PPM: </text>
<text top="668" left="640" width="72" height="19" font="0">9 pts (18%) </text>
<text top="686" left="608" width="231" height="20" font="0">•<b> </b>PPM more likely with baseline LBBB<b> </b></text>
<text top="518" left="883" width="166" height="20" font="0">•  PPM placed if CHB &gt;24 h </text>
<text top="537" left="883" width="200" height="20" font="0">•  PPM more likely with baseline </text>
<text top="556" left="896" width="34" height="19" font="0">LBBB </text>
<text top="574" left="883" width="199" height="20" font="0">•  7/9 were still PPM dependent </text>
<text top="593" left="896" width="46" height="19" font="0">at 14 d </text>
<text top="612" left="883" width="177" height="20" font="0">•  New RBBB common (57%)<b> </b></text>
<text top="706" left="95" width="94" height="19" font="0">McCann, GP et </text>
<text top="725" left="95" width="87" height="19" font="0">al. 2007 (396) </text>
<text top="743" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17293204">17293204</a></text>
<text top="743" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17293204"> </a></text>
<text top="706" left="216" width="140" height="19" font="8"><b>Aim:</b> Evaluate scarring </text>
<text top="725" left="216" width="61" height="19" font="0">after ASA </text>
<text top="743" left="216" width="3" height="19" font="0"> </text>
<text top="761" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="779" left="216" width="3" height="19" font="0"> </text>
<text top="706" left="398" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="725" left="398" width="123" height="19" font="0">pts undergoing ASA </text>
<text top="743" left="398" width="3" height="19" font="0"> </text>
<text top="761" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="707" left="608" width="163" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG changes </text>
<text top="725" left="608" width="3" height="19" font="0"> </text>
<text top="743" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="762" left="607" width="102" height="20" font="0">•  ECG after ASA </text>
<text top="781" left="640" width="156" height="20" font="0">•  2 with persistent RBBB </text>
<text top="706" left="883" width="200" height="20" font="0">•  New RBBB suggestive of more </text>
<text top="725" left="896" width="145" height="19" font="0">extensive septal infarct </text>
<text top="744" left="883" width="208" height="20" font="0">•  At 6-mo follow-up no new PPM </text>
</page>
<page number="211" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 211 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="167" height="19" font="8"><b>Size:</b> 27 pts evaluated with </text>
<text top="105" left="216" width="151" height="19" font="0">MRI at baseline and at 1 </text>
<text top="123" left="216" width="167" height="19" font="0">mo. 25 pts with baseline, 1 </text>
<text top="142" left="216" width="61" height="19" font="0">mo, 6 mo </text>
<text top="87" left="640" width="138" height="20" font="0">•  30 with normal QRS </text>
<text top="106" left="640" width="220" height="20" font="0">•  17 with new RBBB (1/17 required </text>
<text top="125" left="654" width="36" height="19" font="0">PPM) </text>
<text top="144" left="640" width="72" height="20" font="0">•  9 normal </text>
<text top="163" left="640" width="59" height="20" font="0">•  1 LBBB </text>
<text top="182" left="607" width="240" height="20" font="0">•  New RBBB associated with &gt;CPK and </text>
<text top="201" left="620" width="113" height="19" font="0">larger scar by MRI<b> </b></text>
<text top="219" left="607" width="249" height="20" font="0">•  No change in status at 6 mo (1 PPM in </text>
<text top="238" left="620" width="86" height="19" font="0">new RBBB pt)<b> </b></text>
<text top="257" left="95" width="85" height="19" font="0">Faber L, et al. </text>
<text top="275" left="95" width="69" height="19" font="0">2007 (397) </text>
<text top="294" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17067708">17067708</a></text>
<text top="294" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17067708"> </a></text>
<text top="257" left="216" width="167" height="19" font="8"><b>Aim:</b> Evaluate post ASA AV </text>
<text top="275" left="216" width="163" height="19" font="0">conduction abnormalities  </text>
<text top="294" left="216" width="3" height="19" font="0"> </text>
<text top="312" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="330" left="216" width="44" height="19" font="0">cohort </text>
<text top="349" left="216" width="3" height="19" font="0"> </text>
<text top="367" left="216" width="80" height="19" font="8"><b>Size:</b> 155 pts </text>
<text top="257" left="398" width="137" height="19" font="8"><b>Inclusion criteria:</b> 155 </text>
<text top="275" left="398" width="130" height="19" font="0">Consecutive pts who </text>
<text top="294" left="398" width="102" height="19" font="0">underwent ASA  </text>
<text top="312" left="398" width="3" height="19" font="0"> </text>
<text top="330" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="258" left="608" width="163" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG changes </text>
<text top="276" left="608" width="3" height="19" font="0"> </text>
<text top="295" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="313" left="607" width="215" height="20" font="0">•  Transient AVB: 71/155 pts (46%) </text>
<text top="332" left="606" width="246" height="20" font="0">•  Permanent pacing in 11/155 pts (7%)  </text>
<text top="351" left="606" width="260" height="20" font="0">•  4/11 pt who required PPM had baseline </text>
<text top="370" left="620" width="38" height="19" font="0">LBBB  </text>
<text top="389" left="606" width="262" height="20" font="0">•  AV conduction returned in 4/11 pts who </text>
<text top="408" left="620" width="105" height="19" font="0">had PPM placed  </text>
<text top="426" left="607" width="190" height="20" font="0">•  No late development of AVB<b> </b></text>
<text top="257" left="883" width="151" height="20" font="0">•  Used a point score for </text>
<text top="276" left="896" width="189" height="19" font="0">identifying whether to put in a </text>
<text top="295" left="896" width="183" height="19" font="0">PPM rather than a prescribed </text>
<text top="313" left="896" width="168" height="19" font="0">time. Point score used AVB </text>
<text top="331" left="896" width="191" height="19" font="0">recovery but also baseline ECG </text>
<text top="350" left="896" width="153" height="19" font="0">and LVOT characteristics </text>
<text top="368" left="883" width="208" height="20" font="0">•  Pt assessed at 48 h for whether </text>
<text top="387" left="896" width="160" height="19" font="0">PPM should be implanted </text>
<text top="446" left="95" width="103" height="19" font="0">Talreja DR, et al. </text>
<text top="464" left="95" width="69" height="19" font="0">2004 (398) </text>
<text top="482" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15607394">15607394</a></text>
<text top="482" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15607394"> </a></text>
<text top="446" left="216" width="143" height="19" font="8"><b>Aim:</b> Evaluate effect of </text>
<text top="464" left="216" width="164" height="19" font="0">septal reduction therapies </text>
<text top="482" left="216" width="130" height="19" font="0">on conduction tissue </text>
<text top="501" left="216" width="3" height="19" font="0"> </text>
<text top="519" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="537" left="216" width="3" height="19" font="0"> </text>
<text top="556" left="216" width="103" height="19" font="8"><b>Size:</b> 58 pts who </text>
<text top="574" left="216" width="151" height="19" font="0">underwent ASA; 117 pts </text>
<text top="592" left="216" width="168" height="19" font="0">who underwent myectomy </text>
<text top="446" left="398" width="196" height="19" font="8"><b>Inclusion criteria:</b> Myectomy or </text>
<text top="464" left="398" width="82" height="19" font="0">ASA for HCM </text>
<text top="482" left="398" width="3" height="19" font="0"> </text>
<text top="501" left="398" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="447" left="608" width="163" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG changes </text>
<text top="465" left="608" width="3" height="19" font="0"> </text>
<text top="483" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="502" left="607" width="45" height="20" font="0">•  ASA: </text>
<text top="521" left="620" width="132" height="20" font="0">•  RBBB: 21/58 (36%) </text>
<text top="540" left="620" width="238" height="20" font="0">•  CHB requiring PPM: 6/58 (12%); 3 of </text>
<text top="559" left="634" width="178" height="19" font="0">these pts with baseline LBBB </text>
<text top="577" left="606" width="82" height="20" font="0">•  Myectomy </text>
<text top="597" left="620" width="169" height="20" font="0">•  New LBBB: 47/117 (40%) </text>
<text top="616" left="620" width="230" height="20" font="0">•  CHB requiring PPM: 4/117 pts (3%)<b> </b></text>
<text top="446" left="883" width="191" height="20" font="0">•  Can use baseline conduction </text>
<text top="465" left="896" width="150" height="19" font="0">abnormalities to predict </text>
<text top="483" left="896" width="164" height="19" font="0">whether CHB will develop. </text>
<text top="502" left="883" width="194" height="20" font="0">•  No specific protocol listed on </text>
<text top="521" left="896" width="135" height="19" font="0">when PPM implanted </text>
<text top="635" left="95" width="87" height="19" font="0">Wang S, et al. </text>
<text top="654" left="95" width="69" height="19" font="0">2013 (399) </text>
<text top="672" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22761504">22761504</a></text>
<text top="672" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22761504"> </a></text>
<text top="690" left="95" width="3" height="19" font="0"> </text>
<text top="635" left="216" width="143" height="19" font="8"><b>Aim:</b> Evaluate pts after </text>
<text top="654" left="216" width="68" height="19" font="0">myectomy </text>
<text top="672" left="216" width="3" height="19" font="0"> </text>
<text top="690" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="709" left="216" width="3" height="19" font="0"> </text>
<text top="727" left="216" width="143" height="19" font="8"><b>Size:</b> 93 pts underwent </text>
<text top="745" left="216" width="68" height="19" font="0">myectomy </text>
<text top="635" left="398" width="189" height="19" font="8"><b>Inclusion criteria:</b> Consecutive </text>
<text top="654" left="398" width="163" height="19" font="0">pts undergoing myectomy </text>
<text top="672" left="398" width="3" height="19" font="0"> </text>
<text top="690" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="636" left="608" width="163" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG changes </text>
<text top="654" left="608" width="3" height="19" font="0"> </text>
<text top="673" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="691" left="607" width="95" height="20" font="0">•  ECG changes </text>
<text top="710" left="620" width="161" height="20" font="0">•  New LBBB: 44/93 (40%) </text>
<text top="729" left="620" width="200" height="20" font="0">•  CHB requiring PPM: 3/93 (3%) </text>
<text top="749" left="620" width="138" height="20" font="0">•  RBBB: 2/93 pts (2%) </text>
<text top="636" left="883" width="203" height="20" font="0">•  No late PPM identified-though </text>
<text top="654" left="896" width="132" height="19" font="0">follow-up only to 1 y. </text>
</page>
<page number="212" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 212 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="607" width="205" height="20" font="0">•  During follow-up (10.7 mo), no </text>
<text top="106" left="620" width="183" height="19" font="0">progression of AV conduction </text>
<text top="124" left="620" width="136" height="19" font="0">abnormalities or PPM<b> </b></text>
<text top="173" left="95" width="101" height="19" font="0">Agarwal S, et al. </text>
<text top="191" left="95" width="69" height="19" font="0">2013 (400) </text>
<text top="210" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20170823">20170823</a></text>
<text top="210" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20170823"> </a></text>
<text top="173" left="216" width="137" height="19" font="8"><b>Aim:</b> Meta-analysis of </text>
<text top="191" left="216" width="115" height="19" font="0">myectomy vs. ASA </text>
<text top="210" left="216" width="3" height="19" font="0"> </text>
<text top="228" left="216" width="162" height="19" font="8"><b>Study type:</b> Meta-analysis </text>
<text top="246" left="216" width="3" height="19" font="0"> </text>
<text top="265" left="216" width="97" height="19" font="8"><b>Size:</b> 12 studies </text>
<text top="173" left="398" width="130" height="19" font="8"><b>Inclusion criteria:</b> All </text>
<text top="191" left="398" width="162" height="19" font="0">observational studies that </text>
<text top="210" left="398" width="191" height="19" font="0">compared ASA with myectomy </text>
<text top="228" left="398" width="3" height="19" font="0"> </text>
<text top="246" left="398" width="140" height="19" font="8"><b>Exclusion criteria:</b> 288 </text>
<text top="265" left="398" width="196" height="19" font="0">abstracts, 177 excluded for lack </text>
<text top="283" left="398" width="194" height="19" font="0">of a control/comparison group, </text>
<text top="301" left="398" width="161" height="19" font="0">39 excluded because case </text>
<text top="320" left="398" width="113" height="19" font="0">report/case series </text>
<text top="174" left="608" width="227" height="19" font="8"><b>1</b>°<b> endpoint:</b> 30 d all-cause mortality </text>
<text top="192" left="608" width="3" height="19" font="0"> </text>
<text top="210" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="229" left="607" width="240" height="20" font="0">•  No significant difference in mortality </text>
<text top="248" left="620" width="163" height="19" font="0">(long-term or short-term), </text>
<text top="266" left="620" width="206" height="19" font="0">postintervention functional class, </text>
<text top="285" left="620" width="175" height="19" font="0">postintervention ventricular </text>
<text top="303" left="620" width="77" height="19" font="0">arrhythmias </text>
<text top="321" left="606" width="247" height="20" font="0">•  ASA associated with increased risk for </text>
<text top="340" left="620" width="212" height="19" font="0">new RBBB (OR: 56.3; 95% CI: 11.6–</text>
<text top="359" left="620" width="42" height="19" font="0">273.9) </text>
<text top="377" left="607" width="247" height="20" font="0">•  ASA associated with increased risk for </text>
<text top="396" left="620" width="190" height="19" font="0">PPM (OR: 2.6; 95% CI: 1.7–3.9)<b> </b></text>
<text top="173" left="883" width="181" height="20" font="0">•  No significant difference in </text>
<text top="192" left="896" width="181" height="19" font="0">mortality (long-term or short-</text>
<text top="211" left="896" width="147" height="19" font="0">term), postintervention </text>
<text top="229" left="896" width="101" height="19" font="0">functional class, </text>
<text top="247" left="896" width="175" height="19" font="0">postintervention ventricular </text>
<text top="266" left="896" width="77" height="19" font="0">arrhythmias </text>
<text top="284" left="883" width="201" height="20" font="0">•  ASA associated with increased </text>
<text top="303" left="896" width="169" height="19" font="0">risk for new RBBB and PPM </text>
<text top="415" left="95" width="104" height="19" font="0">Schuller JL, et al. </text>
<text top="433" left="95" width="69" height="19" font="0">2015 (401) </text>
<text top="452" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25689552">25689552</a></text>
<text top="452" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25689552"> </a></text>
<text top="415" left="216" width="154" height="19" font="8"><b>Aim:</b> Evaluate predictors </text>
<text top="433" left="216" width="132" height="19" font="0">of late CHB after ASA </text>
<text top="452" left="216" width="3" height="19" font="0"> </text>
<text top="470" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="488" left="216" width="3" height="19" font="0"> </text>
<text top="507" left="216" width="158" height="19" font="8"><b>Size:</b> 145 pts followed for </text>
<text top="525" left="216" width="59" height="19" font="0">3.2±2.3 y </text>
<text top="415" left="398" width="190" height="19" font="8"><b>Inclusion criteria:</b> 145 pts who </text>
<text top="433" left="398" width="98" height="19" font="0">underwent ASA </text>
<text top="452" left="398" width="3" height="19" font="0"> </text>
<text top="470" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="416" left="608" width="262" height="19" font="8"><b>1</b>°<b> endpoint:</b> Late CHB (First identified &gt;48 </text>
<text top="434" left="618" width="76" height="19" font="0">h after ASA) </text>
<text top="453" left="608" width="3" height="19" font="0"> </text>
<text top="471" left="608" width="110" height="19" font="8"><b>Safety endpoint:</b>  </text>
<text top="489" left="607" width="198" height="20" font="0">•  Late CHB in 15/168 pts (8.9%) </text>
<text top="508" left="607" width="146" height="20" font="0">•  Late CHB more likely: </text>
<text top="528" left="620" width="232" height="20" font="0">•  Multiple ASA procedures (OR: 4.14; </text>
<text top="546" left="634" width="114" height="19" font="0">95% CI:1.24–13.9) </text>
<text top="565" left="620" width="239" height="20" font="0">•  High resting or provocable LVOT (OR </text>
<text top="584" left="633" width="187" height="19" font="0">for each 10 mm Hg: 1.14; 95% </text>
<text top="602" left="633" width="84" height="19" font="0">CI:1.00–1.20) </text>
<text top="621" left="606" width="239" height="20" font="0">•  High provocable LVOT gradient after </text>
<text top="640" left="620" width="129" height="19" font="0">Multivariate analysis </text>
<text top="658" left="607" width="260" height="20" font="0">•  3 unexplained deaths: new RBBB, found </text>
<text top="677" left="620" width="109" height="19" font="0">dead 5 mo after 2</text>
<text top="677" left="729" width="10" height="12" font="7">nd</text>
<text top="677" left="739" width="102" height="19" font="0"> ASA, new LBBB, </text>
<text top="695" left="620" width="213" height="19" font="0">found dead 3 d after discharge, no </text>
<text top="714" left="620" width="235" height="19" font="0">change in QRS, found dead after 5 mo<b> </b></text>
<text top="415" left="883" width="207" height="20" font="0">•  Late CHB can be seen in almost </text>
<text top="434" left="896" width="67" height="19" font="0">10% of pts </text>
<text top="453" left="883" width="207" height="20" font="0">•  Authors suggest post discharge </text>
<text top="472" left="896" width="104" height="19" font="0">ECG surveillance </text>
</page>
<page number="213" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 213 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="96" height="19" font="0">Veselka J, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">2013 (402) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23927866">23927866</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23927866"> </a></text>
<text top="87" left="216" width="154" height="19" font="8"><b>Aim:</b> Evaluate predictors </text>
<text top="105" left="216" width="164" height="19" font="0">of complications after ASA </text>
<text top="123" left="216" width="3" height="19" font="0"> </text>
<text top="142" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="160" left="216" width="75" height="19" font="0">multicenter </text>
<text top="178" left="216" width="3" height="19" font="0"> </text>
<text top="197" left="216" width="124" height="19" font="8"><b>Size:</b> 421 pts from 8 </text>
<text top="215" left="216" width="112" height="19" font="0">European Centers </text>
<text top="87" left="398" width="190" height="19" font="8"><b>Inclusion criteria:</b> 421 pts who </text>
<text top="105" left="398" width="98" height="19" font="0">underwent ASA </text>
<text top="123" left="398" width="3" height="19" font="0"> </text>
<text top="142" left="398" width="174" height="19" font="8"><b>Exclusion criteria:</b> If outside </text>
<text top="160" left="398" width="179" height="19" font="0">2003–5 (to include only “low </text>
<text top="178" left="398" width="67" height="19" font="0">dose” era) </text>
<text top="88" left="608" width="246" height="19" font="8"><b>1</b>°<b> endpoint:</b> CHB &gt;10 s Early &lt;24 h, late </text>
<text top="106" left="618" width="37" height="19" font="0">&gt;24 h </text>
<text top="124" left="608" width="3" height="19" font="0"> </text>
<text top="143" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="161" left="607" width="229" height="20" font="0">•  Transient CHB in 70/421 pts (17%), </text>
<text top="180" left="620" width="173" height="20" font="0">•  Intraprocedural: 51 (12%) </text>
<text top="199" left="620" width="128" height="20" font="0">•  Transient: 33 (8%) </text>
<text top="218" left="620" width="96" height="20" font="0">•  Late: 12 (3%) </text>
<text top="237" left="620" width="123" height="20" font="0">•  Recurrent: 9 (2%) </text>
<text top="257" left="606" width="115" height="20" font="0">•  97% CHB up to 5</text>
<text top="257" left="721" width="8" height="12" font="7">th</text>
<text top="257" left="730" width="75" height="19" font="0"> d after ASA </text>
<text top="276" left="607" width="127" height="20" font="0">•  PPM in 35% of pts </text>
<text top="295" left="607" width="245" height="20" font="0">•  6 pts required resuscitation, one 10 d </text>
<text top="314" left="620" width="61" height="19" font="0">after ASA<b> </b></text>
<text top="87" left="883" width="180" height="20" font="0">•  Authors suggest close post </text>
<text top="106" left="896" width="190" height="19" font="0">procedural monitoring and 5 d </text>
<text top="124" left="896" width="159" height="19" font="0">hospitalizations after ASA </text>
<text top="333" left="95" width="82" height="19" font="0">Kim LK, et al. </text>
<text top="351" left="95" width="69" height="19" font="0">2016 (403) </text>
<text top="369" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27438114">27438114</a></text>
<text top="369" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27438114"> </a></text>
<text top="333" left="216" width="143" height="19" font="8"><b>Aim:</b> Evaluate effect of </text>
<text top="351" left="216" width="120" height="19" font="0">hospital volume on </text>
<text top="369" left="216" width="165" height="19" font="0">complications after ASA or </text>
<text top="388" left="216" width="68" height="19" font="0">myectomy </text>
<text top="406" left="216" width="3" height="19" font="0"> </text>
<text top="424" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="443" left="216" width="107" height="19" font="0">evaluation of the </text>
<text top="461" left="216" width="133" height="19" font="0">Nationwide Inpatient </text>
<text top="479" left="216" width="165" height="19" font="0">Sample from 2003 to 2011 </text>
<text top="498" left="216" width="3" height="19" font="0"> </text>
<text top="516" left="216" width="130" height="19" font="8"><b>Size:</b> 11,248 patients </text>
<text top="534" left="216" width="111" height="19" font="0">underwent septal </text>
<text top="553" left="216" width="135" height="19" font="0">reduction procedures </text>
<text top="333" left="398" width="182" height="19" font="8"><b>Inclusion criteria:</b> All pts who </text>
<text top="351" left="398" width="174" height="19" font="0">underwent septal reduction </text>
<text top="369" left="398" width="73" height="19" font="0">procedures </text>
<text top="388" left="398" width="3" height="19" font="0"> </text>
<text top="406" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="334" left="608" width="236" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality, PPM, bleeding </text>
<text top="352" left="608" width="3" height="19" font="0"> </text>
<text top="370" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="389" left="607" width="120" height="20" font="0">•  PPM: myectomy  </text>
<text top="408" left="627" width="85" height="20" font="0">•  Total: 9.8% </text>
<text top="427" left="627" width="117" height="20" font="0">•  First tertile: 10% </text>
<text top="446" left="627" width="150" height="20" font="0">•  Second tertile: 13.8%  </text>
<text top="465" left="627" width="130" height="20" font="0">•  Third tertile: 8.9%  </text>
<text top="484" left="606" width="77" height="20" font="0">•  PPM: ASA </text>
<text top="503" left="627" width="96" height="20" font="0">•  Total: 11.9 % </text>
<text top="523" left="627" width="132" height="20" font="0">•  First tertile: 14.2 % </text>
<text top="542" left="627" width="153" height="20" font="0">•  Second tertile: 12.4 %  </text>
<text top="561" left="627" width="137" height="20" font="0">•  Third tertile: 11.5 %<b> </b></text>
<text top="333" left="883" width="150" height="20" font="0">•  PPM common in both </text>
<text top="352" left="896" width="199" height="19" font="0">myectomy and ASA at discharge </text>
<text top="370" left="883" width="176" height="20" font="0">•  No data on post discharge </text>
<text top="389" left="896" width="191" height="19" font="0">outcomes after myectomy and </text>
<text top="408" left="896" width="31" height="19" font="0">ASA. </text>
<text top="580" left="95" width="95" height="19" font="0">Liebregts M, et </text>
<text top="599" left="95" width="87" height="19" font="0">al. 2015 (404) </text>
<text top="617" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26454847">26454847</a></text>
<text top="617" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26454847"> </a></text>
<text top="580" left="216" width="132" height="19" font="8"><b>Aim:</b> Evaluate ASA or </text>
<text top="599" left="216" width="68" height="19" font="0">myectomy </text>
<text top="617" left="216" width="3" height="19" font="0"> </text>
<text top="635" left="216" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="654" left="216" width="45" height="19" font="0">review </text>
<text top="672" left="216" width="3" height="19" font="0"> </text>
<text top="690" left="216" width="168" height="19" font="8"><b>Size:</b> 16 myectomy cohorts </text>
<text top="709" left="216" width="122" height="19" font="0">and 15 ASA cohorts </text>
<text top="580" left="398" width="175" height="19" font="8"><b>Inclusion criteria:</b> Studies of </text>
<text top="599" left="398" width="111" height="19" font="0">myectomy of ASA </text>
<text top="617" left="398" width="3" height="19" font="0"> </text>
<text top="635" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="581" left="608" width="208" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality, PPM, SCD </text>
<text top="599" left="608" width="3" height="19" font="0"> </text>
<text top="618" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="636" left="607" width="53" height="20" font="0">•  PPM:  </text>
<text top="655" left="607" width="78" height="20" font="0">•  ASA: 10 % </text>
<text top="675" left="607" width="119" height="20" font="0">•  Myectomy: 4.4%<b> </b></text>
<text top="581" left="883" width="175" height="20" font="0">•  ASA with similar mortality </text>
<text top="599" left="896" width="190" height="19" font="0">compared to septal myectomy </text>
<text top="618" left="896" width="183" height="19" font="0">but with higher PPM rate and </text>
<text top="636" left="896" width="165" height="19" font="0">higher likelihood of repeat </text>
<text top="655" left="896" width="76" height="19" font="0">procedures  </text>
</page>
<page number="214" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 214 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="81" height="19" font="0">Balt JC, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">2015 (405) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25073885">25073885</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25073885"> </a></text>
<text top="87" left="216" width="129" height="19" font="8"><b>Aim:</b> Evaluate use of </text>
<text top="105" left="216" width="100" height="19" font="0">continuous ECG </text>
<text top="123" left="216" width="132" height="19" font="0">monitoring after ASA </text>
<text top="142" left="216" width="3" height="19" font="0"> </text>
<text top="160" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="178" left="216" width="3" height="19" font="0"> </text>
<text top="197" left="216" width="73" height="19" font="8"><b>Size:</b> 44 pts </text>
<text top="87" left="398" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="105" left="398" width="180" height="19" font="0">undergoing ASA with PPM or </text>
<text top="123" left="398" width="22" height="19" font="0">ILR </text>
<text top="142" left="398" width="3" height="19" font="0"> </text>
<text top="160" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="88" left="608" width="219" height="19" font="8"><b>1</b>°<b> endpoint:</b> VT/VF or other events </text>
<text top="106" left="618" width="123" height="19" font="0">recorded on the ILR </text>
<text top="124" left="608" width="3" height="19" font="0"> </text>
<text top="143" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="161" left="608" width="236" height="20" font="0">• Pts with VT/VF often had associated </text>
<text top="180" left="620" width="174" height="19" font="0">CHB (during hospitalization) </text>
<text top="199" left="608" width="151" height="20" font="0">• No late AVB identified<b> </b></text>
<text top="87" left="883" width="157" height="20" font="0">•  ILR did not identify any </text>
<text top="106" left="896" width="200" height="19" font="0">arrhythmias with 3 y monitoring </text>
<text top="124" left="896" width="61" height="19" font="0">after ASA </text>
<text top="218" left="95" width="78" height="19" font="0">Qin JX, et al. </text>
<text top="237" left="95" width="69" height="19" font="0">2004 (406) </text>
<text top="255" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14715342">14715342</a></text>
<text top="255" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14715342"> </a></text>
<text top="218" left="216" width="160" height="19" font="8"><b>Aim:</b> Evaluate conduction </text>
<text top="237" left="216" width="116" height="19" font="0">tissue after ASA or </text>
<text top="255" left="216" width="68" height="19" font="0">myectomy </text>
<text top="273" left="216" width="3" height="19" font="0"> </text>
<text top="291" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="310" left="216" width="3" height="19" font="0"> </text>
<text top="328" left="216" width="130" height="19" font="8"><b>Size:</b> 70 pts ASA; 134 </text>
<text top="346" left="216" width="68" height="19" font="0">myectomy </text>
<text top="218" left="398" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="237" left="398" width="185" height="19" font="0">undergoing ASA or myectomy </text>
<text top="255" left="398" width="3" height="19" font="0"> </text>
<text top="273" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A </text>
<text top="219" left="608" width="109" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG </text>
<text top="237" left="608" width="3" height="19" font="0"> </text>
<text top="255" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="274" left="607" width="255" height="20" font="0">•  146 pts with normal QRS preprocedure </text>
<text top="293" left="620" width="215" height="19" font="0">had prolongation of the QRS (72%) </text>
<text top="312" left="620" width="192" height="20" font="0">•  RBBB in 62% of pts after ASA </text>
<text top="331" left="620" width="234" height="20" font="0">•  LBBB in 93 % of pts after myectomy </text>
<text top="350" left="608" width="3" height="19" font="0"> </text>
<text top="368" left="606" width="203" height="20" font="0">•  174 pts w/o a preexisting CIED </text>
<text top="387" left="607" width="162" height="20" font="0">•  ASA: 22% required PPM </text>
<text top="406" left="607" width="115" height="20" font="0">•  Myectomy: 10%<b> </b></text>
<text top="218" left="883" width="184" height="20" font="0">•  In pts with preexisting BBB, </text>
<text top="237" left="896" width="195" height="19" font="0">PPM more likely-approximately </text>
<text top="256" left="896" width="70" height="19" font="0">60% (7/12) </text>
<text top="274" left="883" width="198" height="20" font="0">•  Although PPM in 25 pts in the </text>
<text top="293" left="896" width="146" height="19" font="0">entire cohort-33% PPM </text>
<text top="311" left="896" width="148" height="19" font="0">dependent at follow-up </text>
<text top="444" left="95" width="102" height="19" font="0">Chang SM, et al. </text>
<text top="463" left="95" width="69" height="19" font="0">2003 (407) </text>
<text top="481" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12875767">12875767</a></text>
<text top="481" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12875767"> </a></text>
<text top="444" left="216" width="160" height="19" font="8"><b>Aim:</b> Evaluate conduction </text>
<text top="463" left="216" width="103" height="19" font="0">tissue after ASA  </text>
<text top="481" left="216" width="3" height="19" font="0"> </text>
<text top="499" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="518" left="216" width="3" height="19" font="0"> </text>
<text top="536" left="216" width="166" height="19" font="8"><b>Size:</b> 261 pts ASA, 224 w/o </text>
<text top="554" left="216" width="42" height="19" font="0">a CIED<b> </b></text>
<text top="444" left="398" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="463" left="398" width="101" height="19" font="0">undergoing ASA </text>
<text top="481" left="398" width="3" height="19" font="0"> </text>
<text top="499" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="445" left="608" width="144" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG/PPM </text>
<text top="463" left="608" width="3" height="19" font="0"> </text>
<text top="482" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="500" left="607" width="218" height="20" font="0">•  Independent predictors for CHB:  </text>
<text top="519" left="620" width="130" height="20" font="0">•  Women (OR: 4.33) </text>
<text top="538" left="620" width="160" height="20" font="0">•  Bolus injection (OR: 51) </text>
<text top="558" left="620" width="126" height="20" font="0">•  &gt;1septal (OR: 4.6) </text>
<text top="577" left="620" width="155" height="20" font="0">•  Baseline LBBB (OR: 39) </text>
<text top="596" left="620" width="218" height="20" font="0">•  Baseline 1st degree AVB (OR: 14) </text>
<text top="615" left="607" width="246" height="20" font="0">•  Describe 1 pt who developed AVB 5 d </text>
<text top="634" left="620" width="54" height="19" font="0">after DC </text>
<text top="652" left="607" width="224" height="20" font="0">•  31/224 (14%) required new PPM:  </text>
<text top="671" left="607" width="260" height="20" font="0">•  At 2-y follow-up 25/31 PPM dependent <b> </b></text>
<text top="445" left="883" width="196" height="20" font="0">•  Similar hemodynamic benefit </text>
<text top="463" left="896" width="179" height="19" font="0">regardless of whether a PPM </text>
<text top="482" left="896" width="97" height="19" font="0">required or not </text>
<text top="691" left="95" width="93" height="19" font="0">Chen AA, et al. </text>
<text top="709" left="95" width="69" height="19" font="0">2006 (408) </text>
<text top="728" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16442376">16442376</a></text>
<text top="728" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16442376"> </a></text>
<text top="691" left="216" width="160" height="19" font="8"><b>Aim:</b> Evaluate conduction </text>
<text top="709" left="216" width="103" height="19" font="0">tissue after ASA  </text>
<text top="728" left="216" width="3" height="19" font="0"> </text>
<text top="746" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="764" left="216" width="3" height="19" font="0"> </text>
<text top="691" left="398" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="709" left="398" width="101" height="19" font="0">undergoing ASA </text>
<text top="728" left="398" width="3" height="19" font="0"> </text>
<text top="746" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="692" left="608" width="144" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG/PPM </text>
<text top="710" left="608" width="3" height="19" font="0"> </text>
<text top="728" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="747" left="607" width="256" height="20" font="0">•  Acute CHB in 62% of pts; all normalized </text>
<text top="766" left="620" width="72" height="19" font="0">within 24 h </text>
<text top="691" left="883" width="192" height="20" font="0">•  Authors conclude temporary </text>
<text top="710" left="896" width="171" height="19" font="0">pacing for 48 h ASA or after </text>
<text top="729" left="896" width="110" height="19" font="0">resolution of CHB </text>
<text top="747" left="883" width="202" height="20" font="0">•  Authors conclude that pts w/o </text>
<text top="766" left="897" width="184" height="19" font="0">acute CHB or new IVCD are at </text>
<text top="784" left="896" width="159" height="19" font="0">low risk for subacute CHB </text>
</page>
<page number="215" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 215 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="216" width="169" height="19" font="8"><b>Size:</b> 52 pts ASA, 224 w/o a </text>
<text top="105" left="216" width="32" height="19" font="0">CIED<b> </b></text>
<text top="87" left="607" width="265" height="20" font="0">•  Recurrent CHB in 13 pts (25%), 36±22 h) <b> </b></text>
<text top="124" left="95" width="102" height="19" font="0">Lawrenz T, et al. </text>
<text top="143" left="95" width="69" height="19" font="0">2007 (409) </text>
<text top="161" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17572252">17572252</a></text>
<text top="161" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17572252"> </a></text>
<text top="124" left="216" width="160" height="19" font="8"><b>Aim:</b> Evaluate conduction </text>
<text top="143" left="216" width="103" height="19" font="0">tissue after ASA  </text>
<text top="161" left="216" width="3" height="19" font="0"> </text>
<text top="179" left="216" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="197" left="216" width="3" height="19" font="0"> </text>
<text top="216" left="216" width="151" height="19" font="8"><b>Size:</b> 172 pts underwent </text>
<text top="234" left="216" width="165" height="19" font="0">simultaneous ASA and EPS<b> </b></text>
<text top="124" left="398" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="143" left="398" width="101" height="19" font="0">undergoing ASA </text>
<text top="161" left="398" width="3" height="19" font="0"> </text>
<text top="179" left="398" width="141" height="19" font="8"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="125" left="608" width="144" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG/PPM </text>
<text top="143" left="608" width="3" height="19" font="0"> </text>
<text top="162" left="608" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="180" left="607" width="145" height="20" font="0">•  Intraprocedural AVB  </text>
<text top="199" left="607" width="251" height="20" font="0">•  Delayed AVB occurred in 15 pts (8.7%) </text>
<text top="218" left="620" width="247" height="19" font="0">1–6 d after ASA. All of these pts showed </text>
<text top="237" left="620" width="139" height="19" font="0">lack of VA conduction  </text>
<text top="255" left="607" width="245" height="20" font="0">•  No pt with intact VA conduction after </text>
<text top="274" left="620" width="176" height="19" font="0">ASA developed delayed CHB </text>
<text top="292" left="607" width="222" height="20" font="0">•  Risk factors for delayed AVB were </text>
<text top="311" left="620" width="248" height="19" font="0">advanced age, intraprocedural CHB, and </text>
<text top="330" left="620" width="223" height="19" font="0">prolonged QRSd before or after ASA </text>
<text top="348" left="607" width="101" height="20" font="0">•  PPM in 20 pts<b> </b></text>
<text top="124" left="883" width="201" height="20" font="0">•  Intact VA conduction a helpful </text>
<text top="143" left="896" width="193" height="19" font="0">sign for determining whether a </text>
<text top="162" left="896" width="134" height="19" font="0">PPM will be required  </text>
<text top="368" left="86" width="4" height="21" font="4"> </text>
<text top="388" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="408" left="86" width="890" height="23" font="5"><b>Data Supplement 52. Nonrandomized Studies for ICDs for Alcohol Septal Ablation/Septal Myectomy (Section 8.1.2.5.2) </b></text>
<text top="431" left="101" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="449" left="132" width="55" height="19" font="8"><b>Author;  </b></text>
<text top="467" left="105" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="431" left="252" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="449" left="281" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="431" left="440" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="431" left="656" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="449" left="686" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="467" left="718" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="431" left="939" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="449" left="967" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="487" left="95" width="93" height="19" font="0">Wang W, et al. </text>
<text top="505" left="95" width="69" height="19" font="0">2017 (410) </text>
<text top="523" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28314849">28314849</a></text>
<text top="523" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28314849"> </a></text>
<text top="541" left="95" width="3" height="19" font="0"> </text>
<text top="486" left="223" width="151" height="19" font="8"><b>Aim:</b> Evaluate NSVT as a </text>
<text top="505" left="223" width="181" height="19" font="0">predictor for appropriate ICD </text>
<text top="523" left="223" width="51" height="19" font="0">therapy </text>
<text top="541" left="223" width="3" height="19" font="0"> </text>
<text top="560" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="578" left="223" width="54" height="19" font="0">analysis  </text>
<text top="596" left="223" width="3" height="19" font="0"> </text>
<text top="615" left="223" width="181" height="19" font="8"><b>Size:</b> 160 pts who underwent </text>
<text top="633" left="223" width="75" height="19" font="0">ICD implant </text>
<text top="486" left="419" width="151" height="19" font="8"><b>Inclusion criteria:</b> Single </text>
<text top="505" left="419" width="46" height="19" font="0">center  </text>
<text top="523" left="419" width="3" height="19" font="0"> </text>
<text top="541" left="419" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="487" left="594" width="85" height="19" font="8"><b>1</b>°<b> endpoint:</b>  </text>
<text top="506" left="594" width="114" height="19" font="0">ICD treated VT/VF </text>
<text top="524" left="594" width="3" height="19" font="0"> </text>
<text top="542" left="594" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="561" left="594" width="289" height="19" font="0">NSVT associated with appropriate ICD therapy: </text>
<text top="579" left="594" width="101" height="19" font="0">No NSVT: 10.2% </text>
<text top="597" left="594" width="81" height="19" font="0">NSVT: 47.4%<b> </b></text>
<text top="487" left="917" width="161" height="20" font="0">•  NSVT confirmed to be a </text>
<text top="506" left="930" width="162" height="19" font="0">risk factor in pts with ICDs </text>
<text top="524" left="917" width="3" height="19" font="0"> </text>
<text top="652" left="95" width="104" height="19" font="0">Thavilkulwat AC, </text>
<text top="670" left="95" width="103" height="19" font="0">et al. 2016 (411) </text>
<text top="689" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27138377">27138377 </a></text>
<text top="689" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27138377"> </a></text>
<text top="652" left="223" width="164" height="19" font="8"><b>Aim:</b> Evaluate appropriate </text>
<text top="670" left="223" width="101" height="19" font="0">ICD use in HCM  </text>
<text top="689" left="223" width="3" height="19" font="0"> </text>
<text top="707" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="725" left="223" width="3" height="19" font="0"> </text>
<text top="743" left="223" width="135" height="19" font="8"><b>Size:</b> 135 pts with ICD </text>
<text top="652" left="419" width="151" height="19" font="8"><b>Inclusion criteria:</b> Single </text>
<text top="670" left="419" width="156" height="19" font="0">center review of pts with </text>
<text top="689" left="419" width="135" height="19" font="0">HCM receiving an ICD </text>
<text top="707" left="419" width="3" height="19" font="0"> </text>
<text top="725" left="419" width="135" height="19" font="8"><b>Exclusion criteria:</b> NR </text>
<text top="653" left="594" width="195" height="19" font="8"><b>1</b>°<b> endpoint:</b> ICD treated VT/VF </text>
<text top="671" left="594" width="3" height="19" font="0"> </text>
<text top="689" left="594" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="708" left="594" width="208" height="19" font="0">Appropriate ICD therapy in 25 pts </text>
<text top="726" left="594" width="171" height="19" font="0">Primary prevention: 2.6%/y </text>
<text top="744" left="594" width="187" height="19" font="0">Secondary prevention: 9.8%/y<b> </b></text>
<text top="652" left="917" width="166" height="20" font="0">•  Appropriate ICD therapy </text>
<text top="671" left="930" width="136" height="19" font="0">lower than previously </text>
<text top="690" left="930" width="57" height="19" font="0">reported </text>
<text top="708" left="917" width="3" height="19" font="0"> </text>
<text top="726" left="917" width="3" height="19" font="0"> </text>
</page>
<page number="216" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 216 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="98" height="19" font="0">Maron BJ, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">2007 (412) </text>
<text top="124" left="95" width="67" height="21" font="14"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17652294">17652294</a></text>
<text top="125" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17652294"> </a></text>
<text top="87" left="223" width="164" height="19" font="8"><b>Aim:</b> Evaluate appropriate </text>
<text top="105" left="223" width="101" height="19" font="0">ICD use in HCM  </text>
<text top="123" left="223" width="3" height="19" font="0"> </text>
<text top="142" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="160" left="223" width="3" height="19" font="0"> </text>
<text top="178" left="223" width="135" height="19" font="8"><b>Size:</b> 506 pts with ICD </text>
<text top="87" left="419" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="419" width="144" height="19" font="0">Multicenter Registry of </text>
<text top="123" left="419" width="145" height="19" font="0">pts with HCM receiving </text>
<text top="142" left="419" width="43" height="19" font="0">an ICD </text>
<text top="160" left="419" width="3" height="19" font="0"> </text>
<text top="178" left="419" width="135" height="19" font="8"><b>Exclusion criteria:</b> NR </text>
<text top="88" left="594" width="195" height="19" font="8"><b>1</b>°<b> endpoint:</b> ICD treated VT/VF </text>
<text top="106" left="594" width="3" height="19" font="0"> </text>
<text top="124" left="594" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="143" left="594" width="156" height="19" font="0">Appropriate ICD therapy: </text>
<text top="161" left="594" width="171" height="19" font="0">Primary prevention: 3.6%/y </text>
<text top="179" left="594" width="281" height="19" font="0">Secondary prevention: 10.6%/y. Similar event </text>
<text top="198" left="594" width="228" height="19" font="0">rates for 1,2, or 3 risk factors for SCD<b> </b></text>
<text top="87" left="917" width="178" height="20" font="0">•  Presence of any risk factor </text>
<text top="106" left="930" width="144" height="19" font="0">sufficient to confer risk </text>
<text top="124" left="917" width="3" height="19" font="0"> </text>
<text top="143" left="917" width="3" height="19" font="0"> </text>
<text top="217" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="237" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="257" left="86" width="1019" height="23" font="5"><b>Data Supplement 53. Nonrandomized Trials, Observational Studies, and/or Registries of Adult Congenital Heart Disease (ACHD) (Section </b></text>
<text top="279" left="86" width="33" height="23" font="5"><b>8.2) </b></text>
<text top="321" left="95" width="154" height="19" font="8"><b>Study Acronym; Author; </b></text>
<text top="339" left="106" width="51" height="19" font="8"><b>Year</b>   </text>
<text top="339" left="203" width="3" height="19" font="0"> </text>
<text top="321" left="361" width="83" height="19" font="8"><b>Aim of Study </b></text>
<text top="339" left="366" width="72" height="19" font="8"><b>Study Type </b></text>
<text top="358" left="358" width="89" height="19" font="8"><b>Study Size (N) </b></text>
<text top="376" left="342" width="120" height="19" font="8"><b>Patient population </b></text>
<text top="321" left="533" width="158" height="19" font="8"><b>Primary endpoint results </b></text>
<text top="339" left="529" width="166" height="19" font="8"><b>(p values OR or RR; &amp; 95% </b></text>
<text top="358" left="602" width="20" height="19" font="8"><b>CI) </b></text>
<text top="321" left="710" width="134" height="19" font="8"><b>Relevant 2° Endpoint </b></text>
<text top="339" left="754" width="47" height="19" font="8"><b>(if any) </b></text>
<text top="358" left="723" width="109" height="19" font="8"><b>Study limitations </b></text>
<text top="376" left="728" width="99" height="19" font="8"><b>Adverse events </b></text>
<text top="321" left="944" width="67" height="19" font="8"><b>Outcomes </b></text>
<text top="395" left="95" width="164" height="19" font="0">Gelatt M, et al. 1997 (413) </text>
<text top="413" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8996314">8996314</a></text>
<text top="413" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8996314"> </a></text>
<text top="395" left="290" width="220" height="19" font="8"><b>Aim</b>: Examination of mortality after </text>
<text top="413" left="290" width="55" height="19" font="0">Mustard </text>
<text top="432" left="290" width="3" height="19" font="0"> </text>
<text top="450" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="468" left="290" width="188" height="19" font="0">observational; 534 pts – single </text>
<text top="487" left="290" width="43" height="19" font="0">center </text>
<text top="395" left="528" width="165" height="19" font="0">Pacemaker implantation is </text>
<text top="413" left="528" width="153" height="19" font="0">required in 11% of these </text>
<text top="432" left="528" width="148" height="19" font="0">pts over 35-y follow-up. </text>
<text top="395" left="709" width="99" height="19" font="0">No PM implant  </text>
<text top="395" left="859" width="226" height="20" font="0">• Loss of SR is associated with higher </text>
<text top="414" left="868" width="59" height="19" font="0">mortality </text>
<text top="433" left="859" width="212" height="20" font="0">• Late SND and PM implantation is </text>
<text top="452" left="868" width="57" height="19" font="0">common </text>
<text top="506" left="95" width="182" height="19" font="0">Helbing WA, et al. 1994 (414) </text>
<text top="524" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8041184">8041184</a></text>
<text top="524" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8041184"> </a></text>
<text top="506" left="290" width="200" height="19" font="8"><b>Aim</b>: Assess long-term results of </text>
<text top="524" left="290" width="78" height="19" font="0">atrial switch </text>
<text top="542" left="290" width="3" height="19" font="0"> </text>
<text top="561" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="579" left="290" width="217" height="19" font="0">observational; 122 atrial switch pts </text>
<text top="597" left="290" width="209" height="19" font="0">followed for a median duration of </text>
<text top="616" left="290" width="29" height="19" font="0">16 y </text>
<text top="506" left="528" width="159" height="19" font="0">Loss of SR occurred in 50–</text>
<text top="524" left="528" width="155" height="19" font="0">80% of pts depending on </text>
<text top="542" left="528" width="99" height="19" font="0">type of surgery  </text>
<text top="506" left="709" width="84" height="19" font="0">Sinus rhythm </text>
<text top="524" left="709" width="73" height="19" font="0">maintained </text>
<text top="506" left="859" width="181" height="19" font="0">Loss of sinus node function is </text>
<text top="524" left="859" width="200" height="19" font="0">especially common in this group </text>
<text top="635" left="95" width="163" height="19" font="0">Anand N, et al. 2006 (415) </text>
<text top="653" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16762984">16762984</a></text>
<text top="653" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16762984"> </a></text>
<text top="635" left="290" width="199" height="19" font="8"><b>Aim</b>: Evaluate the association of </text>
<text top="653" left="290" width="183" height="19" font="0">bradycardia with atrial flutter </text>
<text top="671" left="290" width="3" height="19" font="0"> </text>
<text top="689" left="290" width="193" height="19" font="8"><b>Study type</b>: Retrospective case-</text>
<text top="708" left="290" width="199" height="19" font="0">control; 84 pts; CHD and with or </text>
<text top="726" left="290" width="143" height="19" font="0">w/o atrial arrhythmias  </text>
<text top="635" left="528" width="137" height="19" font="0">Development of atrial </text>
<text top="653" left="528" width="77" height="19" font="0">arrhythmias </text>
<text top="635" left="709" width="121" height="19" font="0">Pacemaker implant </text>
<text top="635" left="859" width="233" height="19" font="0">Late postop atrial flutter is associated </text>
<text top="653" left="859" width="218" height="19" font="0">with chronotropic incompetence in </text>
<text top="671" left="859" width="56" height="19" font="0">CHD pts. </text>
<text top="745" left="95" width="155" height="19" font="0">Diller G, et al. 2006 (416) </text>
<text top="764" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16979014">16979014</a></text>
<text top="764" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16979014"> </a></text>
<text top="745" left="290" width="163" height="19" font="8"><b>Aim</b>: Assess the long-term </text>
<text top="764" left="290" width="182" height="19" font="0">outcomes in atrial switch pts  </text>
<text top="782" left="290" width="3" height="19" font="0"> </text>
<text top="745" left="528" width="115" height="19" font="0">Heart rate reserve </text>
<text top="764" left="528" width="121" height="19" font="0">predicted mortality </text>
<text top="782" left="528" width="108" height="19" font="0">independently of </text>
<text top="745" left="709" width="99" height="19" font="0">Pts who did not </text>
<text top="764" left="709" width="81" height="19" font="0">develop CHB </text>
<text top="745" left="859" width="199" height="19" font="0">Blunted heart rate with exercise </text>
<text top="764" left="859" width="219" height="19" font="0">predicts an enhanced mortality risk </text>
</page>
<page number="217" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 217 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="105" left="290" width="215" height="19" font="0">observational; 727 consecutive pts </text>
<text top="123" left="290" width="202" height="19" font="0">with CHD; longitudinal follow-up </text>
<text top="87" left="528" width="149" height="19" font="0">antiarrhythmic therapy, </text>
<text top="105" left="528" width="160" height="19" font="0">functional class, and peak </text>
<text top="123" left="528" width="19" height="19" font="0">VO</text>
<text top="130" left="546" width="5" height="12" font="7">2</text>
<text top="123" left="551" width="3" height="19" font="0"> </text>
<text top="87" left="859" width="201" height="19" font="0">independently of antiarrhythmic </text>
<text top="105" left="859" width="72" height="19" font="0">medication </text>
<text top="143" left="95" width="174" height="19" font="0">Janousek J, et al. 1994 (417) </text>
<text top="161" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7846933">7846933</a></text>
<text top="161" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7846933"> </a></text>
<text top="142" left="290" width="217" height="19" font="8"><b>Aim</b>: Determine the natural history </text>
<text top="161" left="290" width="170" height="19" font="0">for pts with an atrial switch </text>
<text top="179" left="290" width="3" height="19" font="0"> </text>
<text top="197" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="216" left="290" width="170" height="19" font="0">observational; 359 pts with </text>
<text top="234" left="290" width="192" height="19" font="0">transposition and atrial switch; </text>
<text top="252" left="290" width="138" height="19" font="0">longitudinal follow-up </text>
<text top="143" left="528" width="29" height="19" font="0">SND </text>
<text top="143" left="709" width="28" height="19" font="0">N/A </text>
<text top="143" left="859" width="169" height="19" font="0">SND occurred in 51% of pts </text>
<text top="272" left="95" width="149" height="19" font="0">Fishberger S, et al. 1997 </text>
<text top="290" left="95" width="35" height="19" font="0">(418) </text>
<text top="308" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9011705">9011705</a></text>
<text top="308" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9011705"> </a></text>
<text top="271" left="290" width="217" height="19" font="8"><b>Aim</b>: Identify factors that influence </text>
<text top="290" left="290" width="201" height="19" font="0">the development of atrial flutter </text>
<text top="308" left="290" width="142" height="19" font="0">after Fontan operation </text>
<text top="326" left="290" width="3" height="19" font="0"> </text>
<text top="345" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="363" left="290" width="202" height="19" font="0">observational; 334 pts with prior </text>
<text top="381" left="290" width="218" height="19" font="0">Fontan surgery; longitudinal follow-</text>
<text top="400" left="290" width="19" height="19" font="0">up </text>
<text top="272" left="528" width="137" height="19" font="0">Development of atrial </text>
<text top="290" left="528" width="77" height="19" font="0">arrhythmias </text>
<text top="272" left="709" width="28" height="19" font="0">N/A </text>
<text top="272" left="859" width="225" height="19" font="0">The presence of SND was associated </text>
<text top="290" left="859" width="196" height="19" font="0">with a higher incidence of atrial </text>
<text top="308" left="859" width="108" height="19" font="0">flutter (p&lt;0.001). </text>
<text top="419" left="95" width="167" height="19" font="0">Michaëlsson M, et al. 1995 </text>
<text top="437" left="95" width="35" height="19" font="0">(216) </text>
<text top="455" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7634461">7634461</a></text>
<text top="455" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7634461"> </a></text>
<text top="474" left="95" width="3" height="19" font="0"> </text>
<text top="492" left="95" width="3" height="19" font="0"> </text>
<text top="419" left="290" width="215" height="19" font="8"><b>Aim</b>: Longitudinal study of isolated </text>
<text top="437" left="290" width="157" height="19" font="0">congenital complete AVB </text>
<text top="455" left="290" width="75" height="19" font="0"> in adult life </text>
<text top="474" left="290" width="3" height="19" font="0"> </text>
<text top="492" left="290" width="210" height="19" font="8"><b>Study type</b>: Prospective follow-up </text>
<text top="510" left="290" width="48" height="19" font="0">102 pts </text>
<text top="419" left="528" width="160" height="20" font="0">• Mean age at death: 38 y </text>
<text top="438" left="528" width="150" height="20" font="0">• SA attacks in 27 pts, (8 </text>
<text top="457" left="537" width="35" height="19" font="0">fatal) </text>
<text top="475" left="528" width="113" height="20" font="0">• 6 was first event </text>
<text top="495" left="528" width="151" height="20" font="0">• PM reduced the risk of </text>
<text top="513" left="537" width="42" height="19" font="0">death  </text>
<text top="419" left="709" width="28" height="19" font="0">N/A </text>
<text top="419" left="859" width="216" height="19" font="0">High incidence of unpredictable SA </text>
<text top="437" left="859" width="47" height="19" font="0">attacks </text>
<text top="533" left="95" width="171" height="19" font="0">Dewey RC, et al. 1987 (419) </text>
<text top="551" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3821827">3821827</a></text>
<text top="551" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3821827"> </a></text>
<text top="569" left="95" width="3" height="19" font="0"> </text>
<text top="587" left="95" width="3" height="19" font="0"> </text>
<text top="532" left="290" width="222" height="19" font="8"><b>Aim</b>: Define long-term natural Hx of </text>
<text top="551" left="290" width="96" height="19" font="0">congenital CHB </text>
<text top="569" left="290" width="3" height="19" font="0"> </text>
<text top="587" left="290" width="200" height="19" font="8"><b>Study type</b>: 27 pts prospectively </text>
<text top="606" left="290" width="223" height="19" font="0">followed with frequent Holters for a </text>
<text top="624" left="290" width="217" height="19" font="0">mean of 8 y; longitudinal follow-up </text>
<text top="533" left="528" width="122" height="19" font="0">No pts with a mean </text>
<text top="551" left="528" width="152" height="19" font="0">daytime heart rate of 50 </text>
<text top="569" left="528" width="129" height="19" font="0">bpm or more had an </text>
<text top="587" left="528" width="154" height="19" font="0">adverse clinical outcome </text>
<text top="533" left="709" width="28" height="19" font="0">N/A </text>
<text top="533" left="859" width="225" height="19" font="0">Mean daytime junctional rate below </text>
<text top="551" left="859" width="153" height="19" font="0">50 bpm may represent a </text>
<text top="569" left="859" width="231" height="19" font="0">manifestation of junctional instability </text>
<text top="587" left="859" width="228" height="19" font="0">and should be viewed as a risk factor </text>
<text top="606" left="859" width="237" height="19" font="0">for sudden death or eventual need for </text>
<text top="624" left="859" width="42" height="19" font="0">a PPM </text>
<text top="643" left="95" width="154" height="19" font="0">Lundtsrom U, et al. 1990 </text>
<text top="661" left="95" width="35" height="19" font="0">(420) </text>
<text top="680" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2337032">2337032</a></text>
<text top="680" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2337032"> </a></text>
<text top="698" left="95" width="3" height="19" font="0"> </text>
<text top="643" left="290" width="158" height="19" font="8"><b>Aim</b>: Natural Hx of ccTGA </text>
<text top="661" left="290" width="3" height="19" font="0"> </text>
<text top="680" left="290" width="195" height="19" font="8"><b>Study type</b>: 111 pts with ccTGA </text>
<text top="698" left="290" width="95" height="19" font="0">20-y follow-up  </text>
<text top="643" left="528" width="159" height="19" font="0">Major risk factor for early </text>
<text top="661" left="528" width="118" height="19" font="0">death: heart block  </text>
<text top="643" left="709" width="28" height="19" font="0">N/A </text>
<text top="643" left="859" width="28" height="19" font="0">N/A </text>
<text top="717" left="95" width="151" height="19" font="0">Connelly MS, et al. 1996 </text>
<text top="735" left="95" width="35" height="19" font="0">(283) </text>
<text top="754" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8609349">8609349</a></text>
<text top="754" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8609349"> </a></text>
<text top="717" left="290" width="194" height="19" font="8"><b>Aim</b>: Clinical outcome of ccTGA </text>
<text top="735" left="290" width="3" height="19" font="0"> </text>
<text top="754" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="772" left="290" width="131" height="19" font="0">observational; 52 pts </text>
<text top="717" left="528" width="117" height="19" font="0">40% required PPM </text>
<text top="717" left="709" width="28" height="19" font="0">N/A </text>
<text top="717" left="859" width="104" height="19" font="0">High rate of AVB </text>
</page>
<page number="218" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 218 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="177" height="19" font="0">Graham TP, et al. 2000 (421) </text>
<text top="105" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10898443">10898443</a></text>
<text top="105" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10898443"> </a></text>
<text top="87" left="290" width="213" height="19" font="8"><b>Aim</b>: Long-term outcome in ccTGA </text>
<text top="105" left="290" width="3" height="19" font="0"> </text>
<text top="123" left="290" width="150" height="19" font="8"><b>Study type</b>: Multicenter </text>
<text top="142" left="290" width="88" height="19" font="0">retrospective  </text>
<text top="160" left="290" width="172" height="19" font="0">182 pts from 19 institutions </text>
<text top="87" left="528" width="117" height="19" font="0">41% required PPM </text>
<text top="87" left="709" width="28" height="19" font="0">N/A </text>
<text top="87" left="859" width="196" height="19" font="0">PM implantation common. Also </text>
<text top="105" left="859" width="224" height="19" font="0">associated with systemic ventricular </text>
<text top="123" left="859" width="78" height="19" font="0">dysfunction  </text>
<text top="179" left="95" width="90" height="19" font="0">Khairy P, et al. </text>
<text top="197" left="95" width="73" height="19" font="0"> 2006 (422) </text>
<text top="216" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16702467">16702467</a></text>
<text top="216" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16702467"> </a></text>
<text top="179" left="290" width="215" height="19" font="8"><b>Aim</b>: Assess risk of thromboemboli </text>
<text top="197" left="290" width="224" height="19" font="0">in pts with transvenous pacing leads </text>
<text top="216" left="290" width="146" height="19" font="0">and intracardiac shunts </text>
<text top="234" left="290" width="3" height="19" font="0"> </text>
<text top="252" left="290" width="153" height="19" font="8"><b>Study type</b>: Multicenter, </text>
<text top="271" left="290" width="207" height="19" font="0">retrospective cohort study of 202 </text>
<text top="289" left="290" width="172" height="19" font="0">pts with intracardiac shunts </text>
<text top="179" left="528" width="134" height="19" font="0">Transvenous leads an </text>
<text top="197" left="528" width="157" height="19" font="0">independent predictor of </text>
<text top="216" left="528" width="156" height="19" font="0">systemic thromboemboli </text>
<text top="234" left="528" width="121" height="19" font="0">(HR: 2.6; p=0.0265) </text>
<text top="179" left="709" width="28" height="19" font="0">N/A </text>
<text top="179" left="859" width="208" height="19" font="0">Transvenous leads incur a &gt;2-fold </text>
<text top="197" left="859" width="159" height="19" font="0">increased risk of systemic </text>
<text top="216" left="859" width="167" height="19" font="0">thromboemboli in pts with </text>
<text top="234" left="859" width="120" height="19" font="0">intracardiac shunts </text>
<text top="308" left="95" width="157" height="19" font="0">DeSimone CV, et al. 2013 </text>
<text top="326" left="95" width="35" height="19" font="0">(423) </text>
<text top="345" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23946264">23946264</a></text>
<text top="345" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23946264"> </a></text>
<text top="308" left="290" width="182" height="19" font="8"><b>Aim</b>: Stroke or TIA in pts with </text>
<text top="326" left="290" width="175" height="19" font="0">endocardial leads and a PFO </text>
<text top="345" left="290" width="3" height="19" font="0"> </text>
<text top="363" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="381" left="290" width="211" height="19" font="0">observational; 6,075 pts (364 with </text>
<text top="400" left="290" width="36" height="19" font="0">PFO)  </text>
<text top="309" left="528" width="157" height="19" font="8"><b>1</b>°<b> endpoint:</b> Stroke/TIA:  </text>
<text top="327" left="528" width="134" height="19" font="0">30/364 (8.2%) PFO vs </text>
<text top="346" left="528" width="161" height="19" font="0">117/5711 (2.0%) non-PFO </text>
<text top="364" left="528" width="146" height="19" font="0">(HR: 3.49; 95% CI: 2.33–</text>
<text top="382" left="528" width="99" height="19" font="0">5.25; p&lt;0.0001) </text>
<text top="308" left="709" width="28" height="19" font="0">N/A </text>
<text top="308" left="859" width="235" height="19" font="0">Presence of a PFO is associated with a </text>
<text top="326" left="859" width="235" height="19" font="0">substantially increased risk of embolic </text>
<text top="345" left="859" width="67" height="19" font="0">stroke/TIA </text>
<text top="419" left="95" width="159" height="19" font="0">Kim MH, et al. 2001 (424) </text>
<text top="437" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11230857">11230857 </a></text>
<text top="437" left="159" width="7" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11230857"> </a> </text>
<text top="455" left="95" width="3" height="19" font="0"> </text>
<text top="419" left="290" width="219" height="19" font="8"><b>Aim</b>: Assess prevalence and natural </text>
<text top="437" left="290" width="184" height="19" font="0">history of complete AVB after </text>
<text top="455" left="290" width="207" height="19" font="0">valvular heart surgery. Assess the </text>
<text top="474" left="290" width="214" height="19" font="0">optimal timing of PM implantation </text>
<text top="492" left="290" width="3" height="19" font="0"> </text>
<text top="510" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="529" left="290" width="221" height="19" font="0">observational; 155 pts with valvular </text>
<text top="547" left="290" width="219" height="19" font="0">surgery; 17 (11%) pts had complete </text>
<text top="565" left="290" width="156" height="19" font="0">AVB in the postop period </text>
<text top="419" left="528" width="114" height="20" font="0">• At 1-y follow-up: </text>
<text top="438" left="528" width="108" height="20" font="0">• 5 of 9 pts (56%) </text>
<text top="457" left="537" width="138" height="19" font="0">remained in complete </text>
<text top="475" left="537" width="29" height="19" font="0">AVB </text>
<text top="494" left="528" width="134" height="20" font="0">• 2 of 9 pts (22%) had </text>
<text top="513" left="537" width="110" height="19" font="0">resolution of AVB </text>
<text top="531" left="528" width="127" height="20" font="0">• 2 of 9 (22%) lost to </text>
<text top="550" left="537" width="62" height="19" font="0">follow-up </text>
<text top="419" left="709" width="28" height="19" font="0">N/A </text>
<text top="419" left="859" width="236" height="19" font="0">If complete AVB is present after aortic </text>
<text top="437" left="859" width="216" height="19" font="0">and mitral valve surgery within the </text>
<text top="455" left="859" width="227" height="19" font="0">first 24 h postop and persists for &gt;48 </text>
<text top="474" left="859" width="220" height="19" font="0">h, it is unlikely to resolve within the </text>
<text top="492" left="859" width="77" height="19" font="0">next 1–2 wk </text>
<text top="584" left="95" width="171" height="19" font="0">Glikson M, et al. 1997 (425) </text>
<text top="603" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9388104">9388104</a></text>
<text top="603" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9388104"> </a></text>
<text top="621" left="95" width="3" height="19" font="0"> </text>
<text top="639" left="95" width="3" height="19" font="0"> </text>
<text top="658" left="95" width="3" height="19" font="0"> </text>
<text top="584" left="290" width="218" height="19" font="8"><b>Aim</b>: Define long-term dependency </text>
<text top="603" left="290" width="209" height="19" font="0">in permanent pacing after cardiac </text>
<text top="621" left="290" width="49" height="19" font="0">surgery </text>
<text top="639" left="290" width="3" height="19" font="0"> </text>
<text top="657" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="676" left="290" width="189" height="19" font="0">observational; 120 adults post-</text>
<text top="694" left="290" width="213" height="19" font="0">cardiac surgery who received PPM </text>
<text top="584" left="528" width="148" height="19" font="0">Postop complete AVB is </text>
<text top="603" left="528" width="123" height="19" font="0">the most important </text>
<text top="621" left="528" width="100" height="19" font="0">predictor of PM </text>
<text top="639" left="528" width="78" height="19" font="0">dependency </text>
<text top="584" left="709" width="28" height="19" font="0">N/A </text>
<text top="584" left="859" width="213" height="19" font="0">In pts with complete AVB, an early </text>
<text top="603" left="859" width="226" height="19" font="0">decision to implant a permanent PM </text>
<text top="621" left="859" width="123" height="19" font="0">is probably justified </text>
<text top="713" left="95" width="143" height="19" font="0">Edwards W, et al. 1978 </text>
<text top="732" left="95" width="39" height="19" font="0"> (426) </text>
<text top="750" left="95" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=625125">625125</a></text>
<text top="750" left="140" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=625125"> </a></text>
<text top="768" left="95" width="3" height="19" font="0"> </text>
<text top="713" left="290" width="207" height="19" font="8"><b>Aim</b>: Examination of postmortem </text>
<text top="732" left="290" width="217" height="19" font="0">findings of the sinus nodal tissue in </text>
<text top="750" left="290" width="215" height="19" font="0">pts with an atrial switch procedure </text>
<text top="768" left="290" width="3" height="19" font="0"> </text>
<text top="713" left="528" width="208" height="19" font="0">Sinus nodal artery damage  N/A </text>
<text top="713" left="859" width="192" height="20" font="0">• The sinus node showed acute </text>
<text top="732" left="868" width="211" height="19" font="0">necrosis or compression in 77% of </text>
<text top="751" left="868" width="36" height="19" font="0">cases </text>
</page>
<page number="219" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 219 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="290" width="223" height="19" font="8"><b>Study type</b>: 32 pts; atrial switch pts; </text>
<text top="105" left="290" width="213" height="19" font="0">postmortem pathological analyses </text>
<text top="87" left="859" width="224" height="20" font="0">• Para-nodal areas were damaged in </text>
<text top="106" left="868" width="78" height="19" font="0">100% of pts  </text>
<text top="125" left="95" width="100" height="19" font="0">Sanders P, et al. </text>
<text top="143" left="95" width="69" height="19" font="0">2004 (427) </text>
<text top="162" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15007004">15007004</a></text>
<text top="162" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15007004"> </a></text>
<text top="125" left="290" width="222" height="19" font="8"><b>Aim</b>: Atrial mapping in pts with SND </text>
<text top="143" left="290" width="3" height="19" font="0"> </text>
<text top="162" left="290" width="223" height="19" font="8"><b>Study type</b>: 32 pts, 16 pts with SND, </text>
<text top="180" left="290" width="153" height="19" font="0">16 controls; case control </text>
<text top="198" left="290" width="131" height="19" font="0">comparative analysis </text>
<text top="125" left="528" width="29" height="19" font="0">SND </text>
<text top="125" left="709" width="121" height="19" font="0">Normal hearts with </text>
<text top="143" left="709" width="122" height="19" font="0">no evidence of SND </text>
<text top="125" left="859" width="220" height="19" font="0">SND is associated with diffuse atrial </text>
<text top="143" left="859" width="177" height="19" font="0">remodeling characterized by </text>
<text top="162" left="859" width="185" height="19" font="0">structural change, conduction </text>
<text top="180" left="859" width="212" height="19" font="0">abnormalities, and increased right </text>
<text top="198" left="859" width="224" height="19" font="0">atrial refractoriness. Also associated </text>
<text top="217" left="859" width="147" height="19" font="0">with caudal shift of PM  </text>
<text top="236" left="95" width="139" height="19" font="0">Bolens M and Friedli B </text>
<text top="254" left="95" width="69" height="19" font="0">1984 (428) </text>
<text top="272" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6720586">6720586</a></text>
<text top="272" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6720586"> </a></text>
<text top="236" left="290" width="205" height="19" font="8"><b>Aim</b>: EP mapping of sinus and AV </text>
<text top="254" left="290" width="159" height="19" font="0">nodal function in pts with </text>
<text top="272" left="290" width="95" height="19" font="0">secundum ASD </text>
<text top="291" left="290" width="3" height="19" font="0"> </text>
<text top="309" left="290" width="153" height="19" font="8"><b>Study type</b>: Case control </text>
<text top="327" left="290" width="225" height="19" font="0">comparative analysis; 18 pts studied </text>
<text top="346" left="290" width="200" height="19" font="0">before and after surgical closure </text>
<text top="236" left="528" width="98" height="19" font="0">Prior to surgery </text>
<text top="236" left="709" width="130" height="19" font="0">Following ASD repair </text>
<text top="236" left="859" width="231" height="20" font="0">• Sinus nodal, atrial conduction, atrial </text>
<text top="255" left="868" width="213" height="19" font="0">refractory and AV nodal refractory </text>
<text top="273" left="868" width="208" height="19" font="0">times improved following surgery </text>
<text top="292" left="859" width="213" height="20" font="0">• Ectopic atrial rhythms developed </text>
<text top="311" left="868" width="145" height="19" font="0">postop in a third of pts  </text>
<text top="365" left="95" width="174" height="19" font="0">Gillette PC, et al. 1974 (429) </text>
<text top="383" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4818151">4818151</a></text>
<text top="383" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4818151"> </a></text>
<text top="364" left="290" width="157" height="19" font="8"><b>Aim</b>: Electrophysiological </text>
<text top="383" left="290" width="215" height="19" font="0">examination of atrial, sinus and AV </text>
<text top="401" left="290" width="92" height="19" font="0">nodal function </text>
<text top="419" left="290" width="3" height="19" font="0"> </text>
<text top="438" left="290" width="149" height="19" font="8"><b>Study type</b>: Prospective </text>
<text top="456" left="290" width="87" height="19" font="0">observational </text>
<text top="474" left="290" width="184" height="19" font="0">16 pts studied following atrial </text>
<text top="493" left="290" width="156" height="19" font="0">switch surgery (Mustard) </text>
<text top="365" left="528" width="3" height="19" font="0"> </text>
<text top="365" left="709" width="28" height="19" font="0">N/A </text>
<text top="365" left="859" width="209" height="19" font="0">SND was the primary abnormality </text>
<text top="383" left="859" width="58" height="19" font="0">detected </text>
<text top="512" left="95" width="166" height="19" font="0">Garson A, et al. 1985 (430) </text>
<text top="530" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4031302">4031302</a></text>
<text top="530" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4031302"> </a></text>
<text top="512" left="290" width="218" height="19" font="8"><b>Aim</b>: Identify predictors of death in </text>
<text top="530" left="290" width="208" height="19" font="0">younger pts (predominantly CHD) </text>
<text top="548" left="290" width="103" height="19" font="0">and atrial flutter </text>
<text top="567" left="290" width="3" height="19" font="0"> </text>
<text top="585" left="290" width="153" height="19" font="8"><b>Study type</b>: Longitudinal </text>
<text top="603" left="290" width="223" height="19" font="0">retrospective observational; 380 pts </text>
<text top="622" left="290" width="205" height="19" font="0">followed long-term for morbidity </text>
<text top="640" left="290" width="86" height="19" font="0">and mortality </text>
<text top="512" left="528" width="3" height="19" font="0"> </text>
<text top="512" left="709" width="28" height="19" font="0">N/A </text>
<text top="512" left="859" width="233" height="20" font="0">• Effective control of atrial flutter was </text>
<text top="531" left="868" width="224" height="19" font="0">associated with improved outcomes </text>
<text top="549" left="859" width="232" height="20" font="0">• Surgical repair in CHD pts with atrial </text>
<text top="568" left="868" width="162" height="19" font="0">flutter results in a marked </text>
<text top="587" left="868" width="165" height="19" font="0">improvement in outcomes </text>
<text top="659" left="95" width="154" height="19" font="0">Albin G, et al. 1985 (431) </text>
<text top="677" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4033231">4033231</a></text>
<text top="677" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4033231"> </a></text>
<text top="659" left="290" width="178" height="19" font="8"><b>Aim</b>: SND in young adult pts: </text>
<text top="677" left="290" width="224" height="19" font="0">treatment by implantation of a PPM </text>
<text top="696" left="290" width="3" height="19" font="0"> </text>
<text top="714" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="732" left="290" width="217" height="19" font="0">observational; 39 pts, mean age 23 </text>
<text top="751" left="290" width="187" height="19" font="0">y; most commonly TGA; mean </text>
<text top="769" left="290" width="131" height="19" font="0">follow-up of 50.5 mo </text>
<text top="659" left="528" width="138" height="19" font="0">No PM-related deaths </text>
<text top="659" left="709" width="28" height="19" font="0">N/A </text>
<text top="659" left="855" width="216" height="20" font="0">•  Permanent pacing is an effective </text>
<text top="678" left="868" width="131" height="19" font="0">therapeutic modality </text>
<text top="697" left="855" width="211" height="20" font="0">•  Prognosis seems to be excellent </text>
<text top="716" left="855" width="196" height="20" font="0">•  Mortality unrelated to pacing </text>
</page>
<page number="220" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 220 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="175" height="19" font="0">McLeod CJ, et al. 2010 (432) </text>
<text top="105" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20563634">20563634</a></text>
<text top="105" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20563634"> </a></text>
<text top="123" left="95" width="3" height="19" font="0"> </text>
<text top="87" left="290" width="213" height="19" font="8"><b>Aim</b>: Epicardial versus endocardial </text>
<text top="105" left="290" width="200" height="19" font="0">permanent pacing in adults with </text>
<text top="123" left="290" width="152" height="19" font="0">congenital heart disease </text>
<text top="142" left="290" width="3" height="19" font="0"> </text>
<text top="160" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="178" left="290" width="216" height="19" font="0">observational; 106 pts and 259 PM </text>
<text top="197" left="290" width="190" height="19" font="0">procedures: SND in 20%, heart </text>
<text top="215" left="290" width="219" height="19" font="0">block (25%); followed for 11.6±14 y </text>
<text top="87" left="528" width="126" height="19" font="0">Re-intervention was </text>
<text top="105" left="528" width="148" height="19" font="0">driven primarily by lead </text>
<text top="123" left="528" width="81" height="19" font="0">failure (49%) </text>
<text top="87" left="709" width="28" height="19" font="0">N/A </text>
<text top="87" left="859" width="235" height="19" font="0">Epicardial systems were most likely to </text>
<text top="105" left="859" width="236" height="19" font="0">develop lead failure, predominantly in </text>
<text top="123" left="859" width="126" height="19" font="0">the ventricular lead  </text>
<text top="234" left="95" width="164" height="19" font="0">Walker F, et al. 2004 (433) </text>
<text top="252" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15145118">15145118</a></text>
<text top="252" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15145118"> </a></text>
<text top="234" left="290" width="179" height="19" font="8"><b>Aim</b>: Long-term outcomes of </text>
<text top="252" left="290" width="176" height="19" font="0">cardiac pacing in adults with </text>
<text top="271" left="290" width="152" height="19" font="0">congenital heart disease </text>
<text top="289" left="290" width="3" height="19" font="0"> </text>
<text top="307" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="326" left="290" width="222" height="19" font="0">observational; 168 adults with CHD, </text>
<text top="344" left="290" width="220" height="19" font="0">and with PMs; mean age at implant </text>
<text top="362" left="290" width="216" height="19" font="0">was 28 y; mean pacing duration 11 </text>
<text top="381" left="290" width="88" height="19" font="0">y at follow-up </text>
<text top="234" left="528" width="3" height="19" font="0"> </text>
<text top="234" left="709" width="28" height="19" font="0">N/A </text>
<text top="234" left="859" width="179" height="19" font="0">Lead complications were not </text>
<text top="252" left="859" width="237" height="19" font="0">significantly different for epicardial vs. </text>
<text top="271" left="859" width="75" height="19" font="0">endocardial </text>
<text top="289" left="859" width="209" height="19" font="0">improved lead survival in pts with </text>
<text top="307" left="859" width="111" height="19" font="0">endocardial leads </text>
<text top="400" left="95" width="143" height="19" font="0">Bink-Boelkens M, et al. </text>
<text top="418" left="95" width="69" height="19" font="0">1983 (434) </text>
<text top="436" left="95" width="59" height="21" font="14"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6869177">6869177</a></text>
<text top="438" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6869177"> </a></text>
<text top="456" left="95" width="3" height="19" font="0"> </text>
<text top="400" left="290" width="183" height="19" font="8"><b>Aim</b>: Identification of surgical </text>
<text top="418" left="290" width="147" height="19" font="0">factors which affect the </text>
<text top="436" left="290" width="202" height="19" font="0">development of bradycardia and </text>
<text top="455" left="290" width="77" height="19" font="0">arrhythmias </text>
<text top="473" left="290" width="3" height="19" font="0"> </text>
<text top="491" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="509" left="290" width="170" height="19" font="0">observational; 204 pts with </text>
<text top="528" left="290" width="210" height="19" font="0">secundum ASD repair, 50 pts with </text>
<text top="546" left="290" width="142" height="19" font="0">atrial switch (Mustard) </text>
<text top="400" left="528" width="3" height="19" font="0"> </text>
<text top="400" left="709" width="28" height="19" font="0">N/A </text>
<text top="400" left="859" width="193" height="19" font="0">Postop atrial flutter is common </text>
<text top="418" left="859" width="206" height="19" font="0">occurring in 20–40% of the group </text>
<text top="436" left="859" width="227" height="19" font="0">Damage to the sinus node at surgery </text>
<text top="455" left="859" width="224" height="19" font="0">was considered a major predictor of </text>
<text top="473" left="859" width="29" height="19" font="0">SND </text>
<text top="565" left="95" width="157" height="19" font="0">Stephenson E, et al. 2003 </text>
<text top="583" left="95" width="35" height="19" font="0">(435) </text>
<text top="602" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14516898">14516898 </a></text>
<text top="602" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14516898"> </a></text>
<text top="565" left="290" width="175" height="19" font="8"><b>Aim</b>: Efficacy of atrial ATP in </text>
<text top="583" left="290" width="204" height="19" font="0">treating atrial flutter in ACHD pts </text>
<text top="602" left="290" width="3" height="19" font="0"> </text>
<text top="620" left="290" width="173" height="19" font="8"><b>Study type:</b> 5 pts with atrial </text>
<text top="638" left="290" width="77" height="19" font="0">arrhythmias </text>
<text top="565" left="528" width="133" height="19" font="0">AT was appropriately </text>
<text top="583" left="528" width="139" height="19" font="0">detected and ATP was </text>
<text top="602" left="528" width="159" height="19" font="0">enabled for 167 treatable </text>
<text top="620" left="528" width="136" height="19" font="0">episodes, successfully </text>
<text top="638" left="528" width="125" height="19" font="0">converting 90 (54%) </text>
<text top="565" left="709" width="28" height="19" font="0">N/A </text>
<text top="565" left="859" width="234" height="19" font="0">Atrial tachycardias in congenital heart </text>
<text top="583" left="859" width="179" height="19" font="0">disease are amenable to ATP </text>
<text top="602" left="859" width="72" height="19" font="0">algorithms  </text>
<text top="658" left="95" width="173" height="19" font="0">Rhodes LA, et al. 1995 (436) </text>
<text top="676" left="95" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7659551">7659551</a></text>
<text top="676" left="148" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7659551"> </a></text>
<text top="657" left="290" width="222" height="19" font="8"><b>Aim</b>: Atrial ATP in ACHD after repair </text>
<text top="676" left="290" width="168" height="19" font="0">of congenital heart disease </text>
<text top="694" left="290" width="3" height="19" font="0"> </text>
<text top="712" left="290" width="192" height="19" font="8"><b>Study type</b>: Prospective cohort </text>
<text top="731" left="290" width="191" height="19" font="0">18 pts (2–32 y with a variety of </text>
<text top="749" left="290" width="201" height="19" font="0">antitachycardia congenital heart </text>
<text top="767" left="290" width="175" height="19" font="0">lesions underwent atrial PM </text>
<text top="658" left="528" width="153" height="19" font="0">Over 4–30 mo, 6 pts had </text>
<text top="676" left="528" width="99" height="19" font="0">189 episodes of </text>
<text top="694" left="528" width="149" height="19" font="0">tachycardia successfully </text>
<text top="712" left="528" width="158" height="19" font="0">converted with atrial ATP </text>
<text top="658" left="709" width="28" height="19" font="0">N/A </text>
<text top="658" left="859" width="235" height="19" font="0">In selected cases, atrial ATP is a useful </text>
<text top="676" left="859" width="219" height="19" font="0">tool in the management of pts with </text>
<text top="694" left="859" width="213" height="19" font="0">congenital heart disease and atrial </text>
<text top="712" left="859" width="77" height="19" font="0">arrhythmias </text>
</page>
<page number="221" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 221 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="681" left="86" width="4" height="21" font="4"> </text>
<text top="702" left="86" width="4" height="21" font="4"> </text>
<text top="722" left="86" width="1018" height="23" font="5"><b>Data Supplement 54. RCTs, Nonrandomized Trials, Observational Studies, and/or Registries of Bradycardia and Pacemaker Implantation </b></text>
<text top="743" left="86" width="313" height="23" font="5"><b>in Patients with an Acute MI (Section 8.3) </b></text>
<text top="87" left="290" width="185" height="19" font="0">placement for recurrent atrial </text>
<text top="105" left="290" width="77" height="19" font="0">tachycardia  </text>
<text top="124" left="95" width="157" height="19" font="0">Weindling SN, et al. 1998 </text>
<text top="143" left="95" width="35" height="19" font="0">(284) </text>
<text top="161" left="95" width="59" height="21" font="14"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9723647">9723647</a></text>
<text top="162" left="153" width="3" height="19" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9723647"> </a></text>
<text top="181" left="95" width="3" height="19" font="0"> </text>
<text top="124" left="290" width="201" height="19" font="8"><b>Study type</b>: Out of 2,698 cardiac </text>
<text top="143" left="290" width="221" height="19" font="0">surgeries 54 (2%) were complicated </text>
<text top="161" left="290" width="47" height="19" font="0">by CHB </text>
<text top="124" left="528" width="168" height="19" font="0">Recovery of AV conduction </text>
<text top="143" left="528" width="164" height="19" font="0">occurred by postoperative </text>
<text top="161" left="528" width="135" height="19" font="0">d 9 in 97% of pts with </text>
<text top="179" left="528" width="130" height="19" font="0">transient heart block </text>
<text top="124" left="709" width="126" height="19" font="0">The greatest risk for </text>
<text top="143" left="709" width="101" height="19" font="0">CHB occurred in </text>
<text top="161" left="709" width="74" height="19" font="0">surgery for: </text>
<text top="179" left="706" width="49" height="20" font="0">•  LVOT </text>
<text top="198" left="706" width="55" height="20" font="0">•  ccTGA </text>
<text top="218" left="706" width="42" height="20" font="0">•  VSD </text>
<text top="237" left="706" width="131" height="20" font="0">•  Tetralogy of Fallot  </text>
<text top="256" left="709" width="90" height="19" font="0">Majority were </text>
<text top="274" left="709" width="53" height="19" font="0">children </text>
<text top="124" left="859" width="203" height="19" font="0">Heart block following surgery for </text>
<text top="143" left="859" width="220" height="19" font="0">congenital heart disease resolves in </text>
<text top="161" left="859" width="224" height="19" font="0">2/3 of pts, usually by the 9th postop </text>
<text top="179" left="859" width="25" height="19" font="0">day </text>
<text top="293" left="95" width="167" height="19" font="0">Ayyildiz P, et al. 2015 (437) </text>
<text top="311" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26517970">26517970</a></text>
<text top="311" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26517970"> </a></text>
<text top="293" left="290" width="210" height="19" font="8"><b>Aim</b>: Evaluation for AVB following </text>
<text top="311" left="290" width="208" height="19" font="0">pediatric cardiac surgery for CHD  </text>
<text top="330" left="290" width="3" height="19" font="0"> </text>
<text top="348" left="290" width="162" height="19" font="8"><b>Study type</b>: Retrospective </text>
<text top="366" left="290" width="211" height="19" font="0">observational; 1,550 pts with CHD </text>
<text top="385" left="290" width="182" height="19" font="0">surgery between 2010–2015; </text>
<text top="403" left="290" width="122" height="19" font="0">median age 0.5–1 y </text>
<text top="293" left="528" width="158" height="20" font="0">• Complete AVB occurred </text>
<text top="312" left="537" width="114" height="19" font="0">(6.2%) in the early </text>
<text top="330" left="537" width="89" height="19" font="0">postop period </text>
<text top="349" left="528" width="141" height="20" font="0">• 97% of transient AVB </text>
<text top="368" left="537" width="146" height="19" font="0">recovered by d 10; 84% </text>
<text top="386" left="537" width="47" height="19" font="0">at 1 wk </text>
<text top="404" left="528" width="3" height="19" font="0"> </text>
<text top="293" left="709" width="114" height="19" font="0">Tetralogy of Fallot </text>
<text top="311" left="709" width="108" height="19" font="0">and complete AV </text>
<text top="330" left="709" width="121" height="19" font="0">septal defect are at </text>
<text top="348" left="709" width="73" height="19" font="0">highest risk </text>
<text top="293" left="859" width="221" height="19" font="0">Transient AVB occurred in 12%, and </text>
<text top="311" left="859" width="126" height="19" font="0">complete AVB in 6% </text>
<text top="330" left="859" width="199" height="19" font="0">Transient AVB recovered almost </text>
<text top="348" left="859" width="98" height="19" font="0">entirely by 10 d </text>
<text top="424" left="95" width="152" height="19" font="0">Aziz PF, et al. 2013 (438) </text>
<text top="442" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23179430">23179430</a></text>
<text top="442" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23179430"> </a></text>
<text top="423" left="290" width="210" height="19" font="8"><b>Aim</b>: Evaluation for AVB following </text>
<text top="442" left="290" width="208" height="19" font="0">pediatric cardiac surgery for CHD  </text>
<text top="460" left="290" width="3" height="19" font="0"> </text>
<text top="478" left="290" width="165" height="19" font="8"><b>Study type</b>: Retrospective, </text>
<text top="497" left="290" width="223" height="19" font="0">observational, single center, cohort; </text>
<text top="515" left="290" width="215" height="19" font="0">pediatric not adult group; 44 pts in </text>
<text top="533" left="290" width="215" height="19" font="0">this study who experienced TCHB - </text>
<text top="552" left="290" width="155" height="19" font="0">37 recovered completely </text>
<text top="424" left="528" width="121" height="19" font="0">All 37 subjects with </text>
<text top="442" left="528" width="130" height="19" font="0">transient heart block </text>
<text top="460" left="528" width="158" height="19" font="0">recovered AV conduction </text>
<text top="478" left="528" width="72" height="19" font="0">within 12 d </text>
<text top="424" left="709" width="28" height="19" font="0">N/A </text>
<text top="424" left="859" width="230" height="19" font="0">Delayed recovery of conduction after </text>
<text top="442" left="859" width="225" height="19" font="0">transient AVB (≥7 d) is a predictor of </text>
<text top="460" left="859" width="62" height="19" font="0">late block </text>
<text top="571" left="95" width="140" height="19" font="0">Lin A, et al. 2010 (439) </text>
<text top="589" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20381087">20381087</a></text>
<text top="589" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20381087"> </a></text>
<text top="571" left="290" width="210" height="19" font="8"><b>Aim</b>: Evaluation for AVB following </text>
<text top="589" left="290" width="208" height="19" font="0">pediatric cardiac surgery for CHD  </text>
<text top="607" left="290" width="3" height="19" font="0"> </text>
<text top="626" left="290" width="165" height="19" font="8"><b>Study type</b>: Retrospective, </text>
<text top="644" left="290" width="202" height="19" font="0">observational, single center; 922 </text>
<text top="662" left="290" width="135" height="19" font="0">pts, median age 6 mo </text>
<text top="571" left="528" width="157" height="19" font="0">Postop AVB developed in </text>
<text top="589" left="528" width="126" height="19" font="0">2.3% transient, with </text>
<text top="607" left="528" width="163" height="19" font="0">recovery at mean of 3 d in </text>
<text top="626" left="528" width="139" height="19" font="0">1.4% permanent, with </text>
<text top="644" left="528" width="151" height="19" font="0">PPM implanted at mean </text>
<text top="662" left="528" width="63" height="19" font="0">10 d 0.9% </text>
<text top="571" left="709" width="28" height="19" font="0">N/A </text>
<text top="571" left="859" width="232" height="19" font="0">By 10 d minimal recovery of transient </text>
<text top="589" left="859" width="92" height="19" font="0">AVB is present </text>
</page>
<page number="222" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 222 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="105" left="106" width="83" height="19" font="8"><b>Author; Year </b></text>
<text top="87" left="266" width="88" height="19" font="8"><b>Aim of Study; </b></text>
<text top="105" left="274" width="72" height="19" font="8"><b>Study Type </b></text>
<text top="87" left="412" width="269" height="19" font="8"><b>Patient Population  Study Intervention /  </b></text>
<text top="105" left="555" width="121" height="19" font="8"><b>Study Comparator  </b></text>
<text top="87" left="692" width="217" height="19" font="8"><b>Primary endpoint results (p values </b></text>
<text top="105" left="742" width="127" height="19" font="8"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="87" left="941" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="105" left="979" width="71" height="19" font="8"><b>Comments </b></text>
<text top="124" left="99" width="100" height="19" font="0">Domenghetti G, </text>
<text top="143" left="99" width="103" height="19" font="0">et al. 1980 (440) </text>
<text top="161" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7363920">7363920</a></text>
<text top="161" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7363920"> </a></text>
<text top="124" left="223" width="149" height="19" font="8"><b>Aim:</b> Examine impact of </text>
<text top="143" left="223" width="135" height="19" font="0">acute intraventricular </text>
<text top="161" left="223" width="159" height="19" font="0">conduction abnormalities </text>
<text top="179" left="223" width="166" height="19" font="0">on survival following acute </text>
<text top="197" left="223" width="20" height="19" font="0">MI </text>
<text top="216" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="234" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="252" left="223" width="87" height="19" font="0">observational </text>
<text top="124" left="410" width="116" height="19" font="0">59 pts admitted to </text>
<text top="143" left="410" width="121" height="19" font="0">CCU – single center </text>
<text top="124" left="548" width="28" height="19" font="0">N/A </text>
<text top="124" left="692" width="186" height="20" font="0">•  IV conduction disturbances  </text>
<text top="144" left="692" width="194" height="20" font="0">•  Mortality 13% if AVB present </text>
<text top="124" left="922" width="153" height="20" font="0">• Higher mortality in the </text>
<text top="143" left="932" width="164" height="19" font="0">context of intraventricular </text>
<text top="162" left="932" width="159" height="19" font="0">conduction abnormalities </text>
<text top="180" left="932" width="102" height="19" font="0">following an MI. </text>
<text top="198" left="922" width="151" height="20" font="0">• This was evident short </text>
<text top="217" left="932" width="126" height="19" font="0">term and long term. </text>
<text top="236" left="922" width="160" height="20" font="0">• Mortality rate twice the </text>
<text top="255" left="932" width="115" height="19" font="0">comparator group </text>
<text top="274" left="99" width="62" height="19" font="0">Col JJ and </text>
<text top="292" left="99" width="80" height="19" font="0">Weinberg SL </text>
<text top="311" left="99" width="69" height="19" font="0">1972 (441) </text>
<text top="329" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5060806">5060806</a></text>
<text top="329" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5060806"> </a></text>
<text top="274" left="223" width="163" height="19" font="8"><b>Aim:</b> Assess incidence and </text>
<text top="292" left="223" width="147" height="19" font="0">mortality of conduction </text>
<text top="311" left="223" width="137" height="19" font="0">defects following AMI </text>
<text top="329" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="347" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="365" left="223" width="87" height="19" font="0">observational </text>
<text top="274" left="410" width="124" height="19" font="0">212 consecutive pts </text>
<text top="292" left="410" width="105" height="19" font="0">admitted to CCU </text>
<text top="311" left="410" width="50" height="19" font="0">with MI </text>
<text top="274" left="548" width="28" height="19" font="0">N/A </text>
<text top="274" left="692" width="186" height="20" font="0">•  IV conduction disturbances  </text>
<text top="274" left="922" width="173" height="20" font="0">• Most common defect was </text>
<text top="293" left="932" width="28" height="19" font="0">LAH </text>
<text top="312" left="922" width="145" height="20" font="0">• Mortality rate among </text>
<text top="330" left="932" width="156" height="19" font="0">those with IV conduction </text>
<text top="349" left="932" width="151" height="19" font="0">abnormal – 47% vs. 21% </text>
<text top="384" left="99" width="99" height="19" font="0">Ritter WS, et al. </text>
<text top="403" left="99" width="69" height="19" font="0">1976 (442) </text>
<text top="421" left="99" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=952264">952264</a></text>
<text top="421" left="145" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=952264"> </a></text>
<text top="384" left="223" width="151" height="19" font="8"><b>Aim:</b> Evaluate prognosis </text>
<text top="403" left="223" width="131" height="19" font="0">following permanent </text>
<text top="421" left="223" width="111" height="19" font="0">pacing in pts with </text>
<text top="439" left="223" width="170" height="19" font="0">trifascicular block following </text>
<text top="458" left="223" width="29" height="19" font="0">AMI </text>
<text top="476" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="494" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="513" left="223" width="87" height="19" font="0">observational </text>
<text top="384" left="410" width="111" height="19" font="0">18 pts with RBBB, </text>
<text top="403" left="410" width="112" height="19" font="0">LAH and transient </text>
<text top="421" left="410" width="100" height="19" font="0">CHB during AMI </text>
<text top="384" left="548" width="118" height="19" font="0">Pts who received a </text>
<text top="403" left="548" width="32" height="19" font="0">PPM </text>
<text top="385" left="692" width="214" height="20" font="0">•  5/6 pts w/o PPM died within 2.4 </text>
<text top="404" left="706" width="101" height="19" font="0">mo of discharge </text>
<text top="422" left="692" width="196" height="20" font="0">•  6/12 pts with a PPM survived </text>
<text top="441" left="706" width="139" height="19" font="0">(mean survival 18 mo) </text>
<text top="385" left="922" width="161" height="20" font="0">• Prophylactic permanent </text>
<text top="404" left="932" width="119" height="19" font="0">pacing significantly </text>
<text top="422" left="932" width="146" height="19" font="0">improves the prognosis </text>
<text top="440" left="932" width="132" height="19" font="0">after MI in this select </text>
<text top="459" left="932" width="64" height="19" font="0">subgroup  </text>
<text top="532" left="99" width="101" height="19" font="0">Lamas GA, et al. </text>
<text top="550" left="99" width="69" height="19" font="0">1986 (443) </text>
<text top="568" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3717016">3717016</a></text>
<text top="568" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3717016"> </a></text>
<text top="532" left="223" width="145" height="19" font="8"><b>Aim:</b> Development of a </text>
<text top="550" left="223" width="144" height="19" font="0">method to predict CHB </text>
<text top="568" left="223" width="88" height="19" font="0">following AMI </text>
<text top="587" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="605" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="623" left="223" width="87" height="19" font="0">observational </text>
<text top="532" left="410" width="111" height="19" font="0">698 pts with AMI. </text>
<text top="532" left="548" width="28" height="19" font="0">N/A </text>
<text top="532" left="692" width="163" height="20" font="0">•  Pts who developed CHB </text>
<text top="532" left="922" width="172" height="20" font="0">• CHB risk score can predict </text>
<text top="551" left="932" width="154" height="19" font="0">risk of CHB development </text>
<text top="569" left="932" width="142" height="19" font="0">based on ECG findings. </text>
<text top="642" left="99" width="94" height="19" font="0">Shaw, DB et al. </text>
<text top="661" left="99" width="69" height="19" font="0">1980 (444) </text>
<text top="679" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7357290">7357290</a></text>
<text top="679" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7357290"> </a></text>
<text top="642" left="223" width="172" height="19" font="8"><b>Aim:</b> Determine the natural </text>
<text top="661" left="223" width="154" height="19" font="0">Hx for pts with sick-sinus </text>
<text top="679" left="223" width="64" height="19" font="0">syndrome </text>
<text top="697" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="715" left="223" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="734" left="223" width="43" height="19" font="0">survey </text>
<text top="642" left="410" width="79" height="19" font="0">381 pts with </text>
<text top="661" left="410" width="109" height="19" font="0">sinoatrial disease </text>
<text top="642" left="548" width="28" height="19" font="0">N/A </text>
<text top="643" left="692" width="198" height="20" font="0">•  Longitudinal study of pts with </text>
<text top="661" left="706" width="117" height="19" font="0">sinus node disease </text>
<text top="643" left="922" width="171" height="20" font="0">• Sinoatrial dysfunction has </text>
<text top="661" left="932" width="148" height="19" font="0">a benign prognosis, and </text>
<text top="680" left="932" width="160" height="19" font="0">PPM implantation did not </text>
<text top="698" left="932" width="154" height="19" font="0">affect mortality – yet did </text>
<text top="716" left="932" width="121" height="19" font="0">improve symptoms </text>
<text top="735" left="922" width="138" height="20" font="0">• Acute MI during this </text>
<text top="754" left="932" width="147" height="19" font="0">follow-up did not affect </text>
</page>
<page number="223" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 223 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="932" width="150" height="19" font="0">mortality in a significant </text>
<text top="105" left="932" width="55" height="19" font="0">manner. </text>
<text top="124" left="99" width="103" height="19" font="0">Hindman MC, et </text>
<text top="143" left="99" width="86" height="19" font="0">al. 1978 (445, </text>
<text top="161" left="99" width="31" height="19" font="0">446) </text>
<text top="179" left="99" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=688580">688580</a></text>
<text top="179" left="145" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=688580"> </a></text>
<text top="197" left="99" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=688579">688579</a></text>
<text top="197" left="145" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=688579"> </a></text>
<text top="124" left="223" width="101" height="19" font="8"><b>Aim:</b> To identify </text>
<text top="143" left="223" width="146" height="19" font="0">determinants of SCD or </text>
<text top="161" left="223" width="166" height="19" font="0">recurrent high degree AVB </text>
<text top="179" left="223" width="147" height="19" font="0">in pts following MI with </text>
<text top="197" left="223" width="28" height="19" font="0">BBB </text>
<text top="216" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="234" left="223" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="252" left="223" width="87" height="19" font="0">observational </text>
<text top="124" left="410" width="108" height="19" font="0">432 pts with AMI </text>
<text top="143" left="410" width="58" height="19" font="0">and BBB. </text>
<text top="124" left="548" width="28" height="19" font="0">N/A </text>
<text top="124" left="692" width="77" height="20" font="0">•  Mortality  </text>
<text top="124" left="922" width="155" height="20" font="0">• Pts with progression to </text>
<text top="143" left="932" width="8" height="19" font="0">2</text>
<text top="143" left="940" width="10" height="12" font="7">nd</text>
<text top="143" left="950" width="28" height="19" font="0"> or 3</text>
<text top="143" left="978" width="9" height="12" font="7">rd</text>
<text top="143" left="986" width="103" height="19" font="0"> degree AV have </text>
<text top="162" left="933" width="125" height="19" font="0">increased mortality  </text>
<text top="180" left="922" width="151" height="20" font="0">• Pts with transient high </text>
<text top="199" left="932" width="164" height="19" font="0">degree AVB during MI had </text>
<text top="217" left="932" width="117" height="19" font="0">a 28% incidence of </text>
<text top="236" left="932" width="103" height="19" font="0">sudden death or </text>
<text top="254" left="932" width="137" height="19" font="0">recurrent high degree </text>
<text top="272" left="932" width="160" height="19" font="0">block during the first year </text>
<text top="291" left="932" width="78" height="19" font="0">of follow-up </text>
<text top="309" left="922" width="172" height="20" font="0">• At highest risk were those </text>
<text top="328" left="932" width="139" height="19" font="0">pts with RBBB and left </text>
<text top="346" left="932" width="97" height="19" font="0">fascicular block </text>
<text top="365" left="99" width="99" height="19" font="0">Ginks WR, et al. </text>
<text top="384" left="99" width="69" height="19" font="0">1977 (233) </text>
<text top="402" left="99" width="46" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=836733">836733</a></text>
<text top="402" left="145" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=836733"> </a></text>
<text top="365" left="223" width="140" height="19" font="8"><b>Aim:</b> Assess long-term </text>
<text top="384" left="223" width="166" height="19" font="0">prognosis of AMI with AVB </text>
<text top="402" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="420" left="223" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="439" left="223" width="87" height="19" font="0">observational </text>
<text top="365" left="410" width="100" height="19" font="0">52 pts with CHB </text>
<text top="384" left="410" width="55" height="19" font="0">and AMI </text>
<text top="365" left="548" width="129" height="19" font="0">21 hospital survivors </text>
<text top="384" left="548" width="116" height="19" font="0">w/o PPM followed </text>
<text top="402" left="548" width="90" height="19" font="0">for 49 months </text>
<text top="366" left="692" width="168" height="20" font="0">• 10 /14 survived w/o PPM </text>
<text top="385" left="692" width="196" height="20" font="0">• PPM failed to prevent sudden </text>
<text top="404" left="702" width="81" height="19" font="0">death in 2/4  </text>
<text top="422" left="692" width="3" height="19" font="0"> </text>
<text top="366" left="922" width="159" height="20" font="0">• Recommendation: PPM </text>
<text top="385" left="932" width="155" height="19" font="0">implant is not justified in </text>
<text top="403" left="932" width="149" height="19" font="0">pts with partial bilateral </text>
<text top="421" left="932" width="129" height="19" font="0">bundle-branch block </text>
<text top="439" left="932" width="88" height="19" font="0">following AMI </text>
<text top="458" left="99" width="106" height="19" font="8"><b>The Birmingham </b></text>
<text top="477" left="99" width="31" height="19" font="8"><b>Trial </b></text>
<text top="495" left="99" width="112" height="19" font="0">Watson RD, et al.  </text>
<text top="513" left="99" width="69" height="19" font="0">1984 (231) </text>
<text top="532" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475712">6475712</a></text>
<text top="532" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6475712"> </a></text>
<text top="458" left="223" width="173" height="19" font="8"><b>Aim:</b> To determine whether </text>
<text top="477" left="223" width="166" height="19" font="0">permanent pacing reduces </text>
<text top="495" left="223" width="127" height="19" font="0">mortality in pts with </text>
<text top="513" left="223" width="165" height="19" font="0">fascicular block ≥14 d post-</text>
<text top="532" left="223" width="105" height="19" font="0">MI, and whether </text>
<text top="550" left="223" width="105" height="19" font="0">measurement of </text>
<text top="568" left="223" width="148" height="19" font="0">intracardiac conduction </text>
<text top="587" left="223" width="164" height="19" font="0">times predicts later death. </text>
<text top="605" left="223" width="3" height="19" font="0"> </text>
<text top="623" left="223" width="101" height="19" font="8"><b>Study type: </b>RCT<b> </b></text>
<text top="642" left="223" width="3" height="19" font="0"> </text>
<text top="660" left="223" width="73" height="19" font="8"><b>Size: </b>50 pts </text>
<text top="458" left="410" width="111" height="19" font="8"><b>Inclusion criteria</b>: </text>
<text top="477" left="410" width="122" height="19" font="0">Survived at least 14 </text>
<text top="495" left="410" width="113" height="19" font="0">d after AMI; RBBB </text>
<text top="513" left="410" width="69" height="19" font="0">alone or in </text>
<text top="532" left="410" width="111" height="19" font="0">combination with </text>
<text top="550" left="410" width="117" height="19" font="0">left anterior or left </text>
<text top="568" left="410" width="59" height="19" font="0">posterior </text>
<text top="587" left="410" width="107" height="19" font="0">hemiblock or left </text>
<text top="605" left="410" width="59" height="19" font="0">posterior </text>
<text top="623" left="410" width="104" height="19" font="0">hemiblock alone </text>
<text top="642" left="410" width="3" height="19" font="0"> </text>
<text top="660" left="410" width="113" height="19" font="8"><b>Exclusion criteria</b>: </text>
<text top="678" left="410" width="123" height="19" font="0">Age ≥70 y; previous </text>
<text top="697" left="410" width="102" height="19" font="0">ECG evidence of </text>
<text top="715" left="410" width="72" height="19" font="0">conduction </text>
<text top="733" left="410" width="92" height="19" font="0">disorder, LBBB </text>
<text top="458" left="548" width="85" height="19" font="8"><b>Intervention</b>: </text>
<text top="477" left="548" width="114" height="19" font="0">Permanent pacing </text>
<text top="495" left="548" width="7" height="19" font="0">  </text>
<text top="513" left="548" width="103" height="19" font="8"><b>Comparator</b>: No </text>
<text top="532" left="548" width="115" height="19" font="0">permanent pacing </text>
<text top="550" left="548" width="3" height="19" font="0"> </text>
<text top="568" left="548" width="124" height="19" font="0">Resting intracardiac </text>
<text top="587" left="548" width="109" height="19" font="0">conduction times </text>
<text top="605" left="548" width="113" height="19" font="0">were measured in </text>
<text top="623" left="548" width="127" height="19" font="0">both groups prior to </text>
<text top="642" left="548" width="43" height="19" font="0">pacing </text>
<text top="459" left="692" width="183" height="19" font="8"><b>1</b>°<b> endpoint</b>: No difference in </text>
<text top="478" left="702" width="59" height="19" font="0">mortality </text>
<text top="496" left="692" width="3" height="19" font="0"> </text>
<text top="514" left="692" width="138" height="19" font="8"><b>Safety endpoint</b>: N/A  </text>
<text top="459" left="922" width="174" height="19" font="0">• Progression of conduction </text>
<text top="477" left="932" width="163" height="19" font="0">disease was not observed  </text>
<text top="495" left="922" width="116" height="19" font="0">• Measurement of </text>
<text top="513" left="932" width="138" height="19" font="0">infranodal conduction </text>
<text top="532" left="932" width="158" height="19" font="0">time (HV interval) did not </text>
<text top="550" left="932" width="105" height="19" font="0">predict outcome </text>
<text top="568" left="922" width="153" height="19" font="0">• Ventricular arrhythmia </text>
<text top="587" left="933" width="149" height="19" font="0">was an important cause </text>
<text top="605" left="933" width="55" height="19" font="0">of death<b> </b></text>
<text top="752" left="99" width="95" height="19" font="0">Meine TJ, et al. </text>
<text top="771" left="99" width="69" height="19" font="0">2005 (447) </text>
<text top="752" left="223" width="168" height="19" font="8"><b>Aim:</b> Incidence, predictors, </text>
<text top="771" left="223" width="137" height="19" font="0">and outcomes of high-</text>
<text top="752" left="410" width="98" height="19" font="0">70,742 pts with </text>
<text top="771" left="410" width="107" height="19" font="0">STEMI compared </text>
<text top="752" left="548" width="28" height="19" font="0">N/A </text>
<text top="752" left="692" width="184" height="20" font="0">•   Incidence of AVB was 6.9% </text>
<text top="752" left="922" width="148" height="19" font="0">In the thrombolytic era: </text>
</page>
<page number="224" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 224 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15990751">15990751</a></text>
<text top="87" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15990751"> </a></text>
<text top="105" left="99" width="3" height="19" font="0"> </text>
<text top="87" left="223" width="152" height="19" font="0">degree AVB AMI treated </text>
<text top="105" left="223" width="119" height="19" font="0">with thrombolytics </text>
<text top="123" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="142" left="223" width="163" height="19" font="8"><b>Study type: </b>Meta-analysis </text>
<text top="160" left="223" width="91" height="19" font="0">from 4 studies </text>
<text top="87" left="410" width="121" height="19" font="0">with 5,251 pts with </text>
<text top="105" left="410" width="97" height="19" font="0">STEMI and AVB </text>
<text top="87" left="692" width="204" height="20" font="0">•   AVB and inferior MI, mortality </text>
<text top="106" left="706" width="154" height="19" font="0">OR: 2.2 (95% CI: 1.7–2.7) </text>
<text top="124" left="692" width="205" height="20" font="0">•  AVB and anterior MI, mortality </text>
<text top="143" left="706" width="154" height="19" font="0">OR: 3.0 (95% CI: 2.2–4.1) </text>
<text top="87" left="922" width="139" height="20" font="0">• AVB in the setting of </text>
<text top="106" left="932" width="112" height="19" font="0">STEMI is common </text>
<text top="124" left="922" width="134" height="20" font="0">• It is associated with </text>
<text top="143" left="932" width="102" height="19" font="0">higher mortality </text>
<text top="179" left="99" width="90" height="19" font="0">Gang UJ, et al. </text>
<text top="197" left="99" width="69" height="19" font="0">2012 (448) </text>
<text top="216" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22645234">22645234</a></text>
<text top="216" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22645234"> </a></text>
<text top="179" left="223" width="147" height="19" font="8"><b>Aim:</b> High-grade AVB in </text>
<text top="197" left="223" width="166" height="19" font="0">STEMI pts treated with PCI </text>
<text top="216" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="234" left="223" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="252" left="223" width="87" height="19" font="0">observational </text>
<text top="179" left="410" width="97" height="19" font="0">2073 STEMI pts </text>
<text top="197" left="410" width="105" height="19" font="0">with primary PCI </text>
<text top="216" left="410" width="78" height="19" font="0">from Danish </text>
<text top="234" left="410" width="108" height="19" font="0">National Registry </text>
<text top="179" left="548" width="118" height="19" font="0">All-cause mortality </text>
<text top="197" left="548" width="102" height="19" font="0">was the primary </text>
<text top="216" left="548" width="59" height="19" font="0">endpoint </text>
<text top="179" left="692" width="151" height="20" font="0">•  High-grade AVB: 3.2% </text>
<text top="198" left="692" width="149" height="20" font="0">•  Early mortality higher </text>
<text top="218" left="692" width="180" height="20" font="0">•  Yet equal mortality at 30 d </text>
<text top="237" left="706" width="174" height="19" font="0">compared with pts w/o AVB </text>
<text top="179" left="922" width="116" height="19" font="0">In primary PCI era: </text>
<text top="198" left="922" width="134" height="20" font="0">•  incidence of AVB in </text>
<text top="217" left="935" width="143" height="19" font="0">STEMI pts treated with </text>
<text top="235" left="935" width="135" height="19" font="0">PCI has been reduced </text>
<text top="253" left="922" width="144" height="20" font="0">•  If pts survive to 30 d: </text>
<text top="272" left="935" width="154" height="19" font="0">mortality is equal to non-</text>
<text top="291" left="935" width="51" height="19" font="0">AVB pts </text>
<text top="310" left="99" width="96" height="19" font="0">Auffret V, et al. </text>
<text top="328" left="99" width="69" height="19" font="0">2016 (449) </text>
<text top="346" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26660871">26660871</a></text>
<text top="346" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26660871"> </a></text>
<text top="310" left="223" width="132" height="19" font="8"><b>Aim:</b> High-grade AVB </text>
<text top="328" left="223" width="165" height="19" font="0">complicating STEMI (2006–</text>
<text top="346" left="223" width="38" height="19" font="0">2013) </text>
<text top="365" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="383" left="223" width="111" height="19" font="8"><b>Study type: </b>Large </text>
<text top="401" left="223" width="124" height="19" font="0">prospective registry </text>
<text top="310" left="410" width="90" height="19" font="0">6,662 pts with </text>
<text top="328" left="410" width="42" height="19" font="0">STEMI </text>
<text top="310" left="548" width="28" height="19" font="0">N/A </text>
<text top="310" left="692" width="91" height="20" font="0">•  AVB in 3.5% </text>
<text top="329" left="692" width="212" height="20" font="0">•  AVB at admission or in first 24 h </text>
<text top="348" left="706" width="162" height="19" font="0">had higher mortality rates </text>
<text top="366" left="706" width="117" height="19" font="0">(18.1% and 28.6%) </text>
<text top="310" left="922" width="167" height="19" font="0">Combine thrombolytic and </text>
<text top="328" left="932" width="78" height="19" font="0">primary PCI: </text>
<text top="347" left="922" width="103" height="20" font="0">•  HAVB was not </text>
<text top="365" left="935" width="159" height="19" font="0">independently associated </text>
<text top="384" left="935" width="158" height="19" font="0">with in-hospital mortality </text>
<text top="420" left="99" width="83" height="19" font="0">Kim HL, et al. </text>
<text top="439" left="99" width="69" height="19" font="0">2014 (450) </text>
<text top="457" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25304975">25304975</a></text>
<text top="457" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25304975"> </a></text>
<text top="420" left="223" width="171" height="19" font="8"><b>Aim:</b> High-grade AVB on 30-</text>
<text top="439" left="223" width="172" height="19" font="0">d outcome following AMI in </text>
<text top="457" left="223" width="160" height="19" font="0">the drug-eluting stent era </text>
<text top="475" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="493" left="223" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="512" left="223" width="87" height="19" font="0">observational </text>
<text top="420" left="410" width="98" height="19" font="0">13,862 pts with </text>
<text top="439" left="410" width="113" height="19" font="0">AMI, registered in </text>
<text top="457" left="410" width="101" height="19" font="0">the nation-wide </text>
<text top="475" left="410" width="121" height="19" font="0">AMI database from </text>
<text top="494" left="410" width="72" height="19" font="0">2005–2013 </text>
<text top="420" left="548" width="28" height="19" font="0">N/A </text>
<text top="420" left="692" width="193" height="20" font="0">•  Heart block occurred in 2.7% </text>
<text top="440" left="692" width="190" height="20" font="0">•  Pts with heart block showed </text>
<text top="459" left="706" width="175" height="19" font="0">worse clinical parameters at </text>
<text top="477" left="706" width="72" height="19" font="0">admission,  </text>
<text top="495" left="692" width="216" height="20" font="0">•  presence of AVB associated with </text>
<text top="514" left="706" width="198" height="19" font="0">30 d MACE in univariate but not </text>
<text top="533" left="706" width="183" height="19" font="0">multivariate after adjustment </text>
<text top="420" left="922" width="152" height="19" font="0">STEMI treated with DES: </text>
<text top="439" left="922" width="156" height="20" font="0">•  Heart block was not an </text>
<text top="458" left="935" width="146" height="19" font="0">independent risk factor </text>
<text top="476" left="935" width="107" height="19" font="0">for 30-d MACE in </text>
<text top="494" left="935" width="111" height="19" font="0">adjusted analyses </text>
<text top="513" left="922" width="129" height="20" font="0">•  LAD culprit was an </text>
<text top="532" left="935" width="146" height="19" font="0">independent risk factor </text>
<text top="550" left="935" width="160" height="19" font="0">for 30-d MACE among pts </text>
<text top="568" left="935" width="102" height="19" font="0">with heart block </text>
<text top="587" left="99" width="97" height="19" font="0">Singh SM, et al. </text>
<text top="606" left="99" width="69" height="19" font="0">2015 (234) </text>
<text top="624" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25205530">25205530</a></text>
<text top="624" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25205530"> </a></text>
<text top="587" left="223" width="147" height="19" font="8"><b>Aim:</b> High-grade AVB in </text>
<text top="606" left="223" width="165" height="19" font="0">acute coronary syndromes </text>
<text top="624" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="642" left="223" width="169" height="19" font="8"><b>Study type: </b>GRACE registry </text>
<text top="587" left="410" width="125" height="19" font="0">59,229 pts with ACS </text>
<text top="606" left="410" width="117" height="19" font="0">between 1999 and </text>
<text top="624" left="410" width="34" height="19" font="0">2007 </text>
<text top="587" left="548" width="28" height="19" font="0">N/A </text>
<text top="588" left="692" width="150" height="20" font="0">•  2.9% of pts had HAVB </text>
<text top="607" left="692" width="190" height="20" font="0">•  High in-hospital death (23%) </text>
<text top="626" left="692" width="170" height="20" font="0">•  Pts with AVB surviving to </text>
<text top="645" left="706" width="188" height="19" font="0">discharge had similar adjusted </text>
<text top="663" left="706" width="196" height="19" font="0">survival at 6 mo compared with </text>
<text top="681" left="706" width="94" height="19" font="0">those w/o AVB </text>
<text top="588" left="922" width="134" height="20" font="0">•  AVB is continues to </text>
<text top="607" left="935" width="58" height="19" font="0">decrease </text>
<text top="625" left="922" width="145" height="20" font="0">•  Mortality dictated by </text>
<text top="644" left="935" width="140" height="19" font="0">type of MI and time to </text>
<text top="662" left="935" width="78" height="19" font="0">reperfusion  </text>
<text top="700" left="99" width="101" height="19" font="0">Ranganathan N, </text>
<text top="719" left="99" width="103" height="19" font="0">et al. 1972 (451) </text>
<text top="737" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5009474">5009474</a></text>
<text top="737" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5009474"> </a></text>
<text top="700" left="223" width="172" height="19" font="8"><b>Aim:</b> Determine the validity </text>
<text top="719" left="223" width="166" height="19" font="0">of His bundle recordings in </text>
<text top="737" left="223" width="91" height="19" font="0">managing BBB </text>
<text top="755" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="700" left="410" width="99" height="19" font="0">20 pts with BBB </text>
<text top="719" left="410" width="123" height="19" font="0">and 13 pts w/o BBB </text>
<text top="700" left="548" width="25" height="19" font="0">EPS </text>
<text top="701" left="692" width="154" height="20" font="0">•  Abnormal His-Purkinje </text>
<text top="720" left="706" width="72" height="19" font="0">conduction </text>
<text top="701" left="921" width="157" height="20" font="0">•  BBB may be associated </text>
<text top="720" left="935" width="101" height="19" font="0">with infra-nodal </text>
<text top="738" left="935" width="159" height="19" font="0">conduction abnormalities </text>
<text top="756" left="935" width="119" height="19" font="0">as evidenced by an </text>
<text top="775" left="935" width="146" height="19" font="0">abnormal His recording </text>
</page>
<page number="225" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 225 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="223" width="149" height="19" font="8"><b>Study type: </b>Prospective </text>
<text top="105" left="223" width="87" height="19" font="0">observational </text>
<text top="124" left="99" width="103" height="19" font="0">Scheinman MM, </text>
<text top="143" left="99" width="95" height="19" font="0">et al. 1975 (82) </text>
<text top="161" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1157275">1157275</a></text>
<text top="161" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1157275"> </a></text>
<text top="124" left="223" width="167" height="19" font="8"><b>Aim:</b> Use of atropine in pts </text>
<text top="143" left="223" width="148" height="19" font="0">with acute MI and sinus </text>
<text top="161" left="223" width="76" height="19" font="0">bradycardia </text>
<text top="179" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="197" left="223" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="216" left="223" width="87" height="19" font="0">observational </text>
<text top="124" left="410" width="123" height="19" font="0">56pts with AMI and </text>
<text top="143" left="410" width="73" height="19" font="0">sinus brady </text>
<text top="124" left="548" width="28" height="19" font="0">N/A </text>
<text top="124" left="692" width="153" height="20" font="0">•  Atropine improved AV </text>
<text top="143" left="706" width="200" height="19" font="0">conduction in 11 of 13 pts (85%) </text>
<text top="162" left="706" width="154" height="19" font="0">acute inferior MIs (with 2</text>
<text top="162" left="860" width="10" height="12" font="7">nd</text>
<text top="162" left="870" width="20" height="19" font="0"> or </text>
<text top="180" left="706" width="8" height="19" font="0">3</text>
<text top="180" left="713" width="9" height="12" font="7">rd</text>
<text top="180" left="722" width="78" height="19" font="0"> degree AVB </text>
<text top="124" left="921" width="163" height="20" font="0">•  Atropine recommended </text>
<text top="143" left="935" width="128" height="19" font="0">as drug of choice for </text>
<text top="162" left="935" width="128" height="19" font="0">sinus brady and AMI </text>
<text top="180" left="921" width="161" height="20" font="0">•  7 pts developed 10 side </text>
<text top="199" left="935" width="93" height="19" font="0">effects: VT/VF, </text>
<text top="217" left="935" width="114" height="19" font="0">ventricular ectopy </text>
<text top="236" left="99" width="89" height="19" font="0">Swart G, et al. </text>
<text top="255" left="99" width="62" height="19" font="0">1999 (80) </text>
<text top="273" left="99" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10597081">10597081</a></text>
<text top="273" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10597081"> </a></text>
<text top="236" left="223" width="145" height="19" font="8"><b>Aim:</b> Use of atropine in </text>
<text top="255" left="223" width="145" height="19" font="0">acute MI in prehospital </text>
<text top="273" left="223" width="45" height="19" font="0">setting </text>
<text top="291" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="310" left="223" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="328" left="223" width="89" height="19" font="0">Observational </text>
<text top="236" left="410" width="116" height="19" font="0">131 pts with acute </text>
<text top="255" left="410" width="114" height="19" font="0">MI and associated </text>
<text top="273" left="410" width="76" height="19" font="0">bradycardia </text>
<text top="236" left="548" width="57" height="19" font="0">Atropine </text>
<text top="236" left="692" width="28" height="19" font="0">N/A </text>
<text top="237" left="921" width="174" height="20" font="0">•  No difference in response </text>
<text top="256" left="935" width="158" height="19" font="0">to atropine between AMI </text>
<text top="274" left="935" width="99" height="19" font="0">vs. non-AMI pts </text>
<text top="292" left="921" width="166" height="20" font="0">•  MI pts are more likely to </text>
<text top="311" left="935" width="136" height="19" font="0">recover conduction in </text>
<text top="330" left="935" width="55" height="19" font="0">hospital  </text>
<text top="349" left="99" width="82" height="19" font="0">Feigl D, et al. </text>
<text top="367" left="99" width="69" height="19" font="0">1984 (160) </text>
<text top="385" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6736451">6736451</a></text>
<text top="385" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6736451"> </a></text>
<text top="349" left="223" width="162" height="19" font="8"><b>Aim:</b> Early and late AVB in </text>
<text top="367" left="223" width="106" height="19" font="0">acute inferior MI </text>
<text top="385" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="403" left="223" width="157" height="19" font="8"><b>Study type: </b>Single center </text>
<text top="422" left="223" width="128" height="19" font="0">retrospective cohort </text>
<text top="349" left="410" width="115" height="19" font="0">34 pts with 2nd or </text>
<text top="367" left="410" width="99" height="19" font="0">3rd degree AVB </text>
<text top="385" left="410" width="85" height="19" font="0">developing in </text>
<text top="404" left="410" width="119" height="19" font="0">course of AMI who </text>
<text top="422" left="410" width="95" height="19" font="0">survived &gt;72 h  </text>
<text top="349" left="548" width="57" height="19" font="0">Atropine </text>
<text top="349" left="692" width="205" height="20" font="0">• Of 15 pts with early AVB (&lt;6 h). </text>
<text top="368" left="702" width="201" height="19" font="0">Atropine normalized conduction </text>
<text top="386" left="702" width="166" height="19" font="0">in 20%, increased V-rate in </text>
<text top="404" left="702" width="202" height="19" font="0">others. 5 had normalization with </text>
<text top="423" left="702" width="183" height="19" font="0">isoproterenol. 14 pts had late </text>
<text top="441" left="702" width="196" height="19" font="0">AVB – less response to atropine </text>
<text top="459" left="702" width="186" height="19" font="0">(mean 16 bpm). 50% required </text>
<text top="478" left="702" width="31" height="19" font="0">TPM </text>
<text top="349" left="921" width="146" height="20" font="0">•  No adverse events to </text>
<text top="368" left="935" width="140" height="19" font="0">drug therapy reported </text>
<text top="497" left="99" width="94" height="19" font="0">Bertolet BD, et </text>
<text top="515" left="99" width="87" height="19" font="0">al. 1995 (163) </text>
<text top="533" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7661495">7661495</a></text>
<text top="533" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7661495"> </a></text>
<text top="552" left="99" width="3" height="19" font="0"> </text>
<text top="497" left="223" width="160" height="19" font="8"><b>Aim:</b> Theophylline for the </text>
<text top="515" left="223" width="163" height="19" font="0">treatment of AVB after MI </text>
<text top="533" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="552" left="223" width="157" height="19" font="8"><b>Study type: </b>Single center </text>
<text top="570" left="223" width="128" height="19" font="0">retrospective cohort </text>
<text top="497" left="410" width="64" height="19" font="0">8 pts with </text>
<text top="515" left="410" width="94" height="19" font="0">significant AVB </text>
<text top="533" left="410" width="123" height="19" font="0">developing within 4 </text>
<text top="552" left="410" width="113" height="19" font="0">h of admission for </text>
<text top="570" left="410" width="110" height="19" font="0">acute inferior MI, </text>
<text top="588" left="410" width="73" height="19" font="0">resistant to </text>
<text top="607" left="410" width="111" height="19" font="0">atropine, given IV </text>
<text top="625" left="410" width="115" height="19" font="0">theophylline up to </text>
<text top="643" left="410" width="49" height="19" font="0">250 mg </text>
<text top="497" left="548" width="95" height="19" font="0">Aminophylline  </text>
<text top="497" left="692" width="203" height="20" font="0">• All 8 pts had restoration of 1–1 </text>
<text top="516" left="702" width="172" height="19" font="0">AV conduction within 3 min </text>
<text top="534" left="702" width="121" height="19" font="0">lasting at least 24 h </text>
<text top="497" left="921" width="111" height="20" font="0">•  Potentially safe </text>
<text top="516" left="921" width="143" height="20" font="0">•  Efficacy in very small </text>
<text top="535" left="935" width="37" height="19" font="0">study </text>
<text top="662" left="99" width="86" height="19" font="0">Altun A, et al. </text>
<text top="681" left="99" width="69" height="19" font="0">1998 (164)<b> </b></text>
<text top="699" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9789698">9789698</a></text>
<text top="699" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9789698"> </a></text>
<text top="662" left="223" width="87" height="19" font="8"><b>Aim:</b> Effect of </text>
<text top="681" left="223" width="157" height="19" font="0">aminophylline in pts with </text>
<text top="699" left="223" width="145" height="19" font="0">atropine-resistant later </text>
<text top="717" left="223" width="171" height="19" font="0">advanced AVB during acute </text>
<text top="736" left="223" width="69" height="19" font="0">inferior MI </text>
<text top="754" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="662" left="410" width="71" height="19" font="0">8 pts with 2</text>
<text top="662" left="481" width="10" height="12" font="7">nd</text>
<text top="662" left="491" width="28" height="19" font="0"> or 3</text>
<text top="662" left="519" width="9" height="12" font="7">rd</text>
<text top="662" left="527" width="3" height="19" font="0"> </text>
<text top="681" left="410" width="108" height="19" font="0">degree AVB after </text>
<text top="699" left="410" width="119" height="19" font="0">IMI for at least 1 h, </text>
<text top="717" left="410" width="73" height="19" font="0">resistant to </text>
<text top="736" left="410" width="63" height="19" font="0">atropine.  </text>
<text top="662" left="548" width="104" height="19" font="0">Given 2 doses of </text>
<text top="681" left="548" width="116" height="19" font="0">aminophylline 240 </text>
<text top="699" left="548" width="81" height="19" font="0">mg 1 h apart </text>
<text top="662" left="692" width="201" height="20" font="0">• Aminophylline restored 1-1 AV </text>
<text top="681" left="702" width="200" height="19" font="0">conduction in 7 pts and Mobitz I </text>
<text top="700" left="702" width="179" height="19" font="0">AVB in 1. No adverse effects. </text>
<text top="718" left="702" width="156" height="19" font="0">AVB relapsed in 1 pt only </text>
<text top="662" left="922" width="166" height="20" font="0">•  Very small, single-center </text>
<text top="681" left="935" width="71" height="19" font="0">experience </text>
</page>
<page number="226" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 226 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="223" width="162" height="19" font="8"><b>Study type: </b>Retrospective </text>
<text top="105" left="223" width="87" height="19" font="0">observational </text>
<text top="124" left="99" width="83" height="19" font="0">Hatle L, et al. </text>
<text top="143" left="99" width="69" height="19" font="0">1971 (167) </text>
<text top="161" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5557475">5557475</a></text>
<text top="161" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=5557475"> </a></text>
<text top="124" left="223" width="115" height="19" font="8"><b>Aim:</b> Conservative </text>
<text top="143" left="223" width="154" height="19" font="0">treatment of AVB in AMI </text>
<text top="161" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="179" left="223" width="162" height="19" font="8"><b>Study type: </b>Results in 105 </text>
<text top="197" left="223" width="98" height="19" font="0">consecutive pts </text>
<text top="124" left="410" width="110" height="19" font="0">Pts with acute MI </text>
<text top="143" left="410" width="87" height="19" font="0">treated with 2</text>
<text top="142" left="497" width="10" height="12" font="7">nd</text>
<text top="143" left="507" width="20" height="19" font="0"> or </text>
<text top="161" left="410" width="8" height="19" font="0">3</text>
<text top="161" left="418" width="9" height="12" font="7">rd</text>
<text top="161" left="426" width="81" height="19" font="0"> degree AVB  </text>
<text top="124" left="548" width="82" height="19" font="0">Treated with </text>
<text top="143" left="548" width="90" height="19" font="0">isoproterenol, </text>
<text top="161" left="548" width="85" height="19" font="0">generally 1–3 </text>
<text top="179" left="548" width="58" height="19" font="0">mcg/min </text>
<text top="124" left="692" width="211" height="20" font="0">• In hospital mortality 48%. 60 pts </text>
<text top="143" left="702" width="203" height="19" font="0">received isoproterenol: 38 (63%) </text>
<text top="162" left="702" width="186" height="19" font="0">had increase in heart rate and </text>
<text top="180" left="702" width="183" height="19" font="0">BP; 12 (20%) had increased in </text>
<text top="198" left="702" width="203" height="19" font="0">heart rate but minimal change in </text>
<text top="217" left="702" width="203" height="19" font="0">BP; 8 (13%) had minimal change; </text>
<text top="235" left="702" width="200" height="19" font="0">2 (3%) isoproterenol terminated </text>
<text top="253" left="702" width="194" height="19" font="0">due to ventricular ectopy. 3 pts </text>
<text top="272" left="702" width="181" height="19" font="0">had ventricular fibrillation on </text>
<text top="290" left="702" width="190" height="19" font="0">isoproterenol, 1 of which died. </text>
<text top="308" left="702" width="178" height="19" font="0">14 pts treated with TVP, 3 of </text>
<text top="326" left="702" width="174" height="19" font="0">whom died from ventricular </text>
<text top="345" left="702" width="66" height="19" font="0">fibrillation </text>
<text top="124" left="922" width="164" height="20" font="0">• Extremely high mortality </text>
<text top="144" left="922" width="94" height="20" font="0">• In this group, </text>
<text top="162" left="932" width="148" height="19" font="0">isoproterenol appeared </text>
<text top="181" left="932" width="151" height="19" font="0">safe compared with TVP </text>
<text top="364" left="99" width="94" height="19" font="0">Hynes JK, et al. </text>
<text top="382" left="99" width="69" height="19" font="0">1983 (115)<b> </b></text>
<text top="401" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157">6823157</a></text>
<text top="401" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6823157"> </a></text>
<text top="364" left="223" width="156" height="19" font="8"><b>Aim:</b> 5-y experience with </text>
<text top="382" left="223" width="121" height="19" font="0">TPM therapy in the </text>
<text top="401" left="223" width="119" height="19" font="0">coronary care unit.<b> </b></text>
<text top="419" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="437" left="223" width="166" height="19" font="8"><b>Study type: </b>Retrospective, </text>
<text top="455" left="223" width="176" height="19" font="0">observational, single-center  </text>
<text top="474" left="223" width="3" height="19" font="0"> </text>
<text top="492" left="223" width="93" height="19" font="8"><b>Size</b>: N = 1,022 </text>
<text top="364" left="410" width="98" height="19" font="0">1,022 pts in the </text>
<text top="382" left="410" width="115" height="19" font="0">coronary care unit </text>
<text top="401" left="410" width="69" height="19" font="0">with TTVP. </text>
<text top="364" left="548" width="70" height="19" font="0">Temporary </text>
<text top="382" left="548" width="122" height="19" font="0">transvenous pacing </text>
<text top="365" left="692" width="191" height="19" font="8"><b>1</b>°<b> endpoint:</b> Clinical outcomes </text>
<text top="383" left="702" width="3" height="19" font="0"> </text>
<text top="401" left="692" width="211" height="19" font="8"><b>Results:</b> Access was antecubital in </text>
<text top="420" left="692" width="180" height="19" font="0">59%, subclavian in 17%, right </text>
<text top="438" left="692" width="171" height="19" font="0">internal jugular in 11%, and </text>
<text top="456" left="692" width="181" height="19" font="0">femoral in 5%. Complications </text>
<text top="475" left="692" width="211" height="19" font="0">occurred in 13.7% with no deaths. </text>
<text top="493" left="692" width="216" height="19" font="0">The right internal jugular approach </text>
<text top="511" left="692" width="202" height="19" font="0">was associated with a decreased </text>
<text top="529" left="692" width="132" height="19" font="0">risk of complications. </text>
<text top="364" left="922" width="170" height="20" font="0">• TTVP was associated with </text>
<text top="383" left="932" width="104" height="19" font="0">an overall risk of </text>
<text top="401" left="932" width="103" height="19" font="0">complications in </text>
<text top="420" left="932" width="162" height="19" font="0">approximately 14% of pts. </text>
<text top="548" left="99" width="99" height="19" font="0">Jowett NI, et al. </text>
<text top="567" left="99" width="69" height="19" font="0">1989 (120) </text>
<text top="585" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2594596">2594596</a></text>
<text top="585" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2594596"> </a></text>
<text top="548" left="223" width="103" height="19" font="8"><b>Aim:</b> Temporary </text>
<text top="567" left="223" width="173" height="19" font="0">transvenous cardiac pacing: </text>
<text top="585" left="223" width="117" height="19" font="0">6 y experience in 1 </text>
<text top="603" left="223" width="115" height="19" font="0">coronary care unit </text>
<text top="622" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="640" left="223" width="165" height="19" font="8"><b>Study type</b>: Retrospective, </text>
<text top="658" left="223" width="176" height="19" font="0">observational, single-center  </text>
<text top="548" left="410" width="124" height="19" font="0">162 pts admitted to </text>
<text top="567" left="410" width="115" height="19" font="0">coronary care unit </text>
<text top="585" left="410" width="101" height="19" font="0">who underwent </text>
<text top="603" left="410" width="38" height="19" font="0">TTVP. </text>
<text top="548" left="548" width="70" height="19" font="0">Temporary </text>
<text top="567" left="548" width="122" height="19" font="0">transvenous pacing </text>
<text top="549" left="692" width="190" height="20" font="0">• The majority of TTVP was for </text>
<text top="568" left="702" width="185" height="19" font="0">CHB and MI (84.6%). 15.4% of </text>
<text top="586" left="702" width="139" height="19" font="0">TTVPs were placed for </text>
<text top="604" left="702" width="162" height="19" font="0">symptomatic bradycardia, </text>
<text top="623" left="702" width="181" height="19" font="0">including SND. Complications </text>
<text top="641" left="702" width="175" height="19" font="0">occurred in 19.8%, including </text>
<text top="659" left="702" width="181" height="19" font="0">arrhythmias during insertion, </text>
<text top="677" left="702" width="188" height="19" font="0">dislodgement, pneumothorax, </text>
<text top="696" left="702" width="103" height="19" font="0">and perforation.<b> </b></text>
<text top="549" left="922" width="170" height="20" font="0">• TTVP was associated with </text>
<text top="568" left="932" width="133" height="19" font="0">a 19.8% complication </text>
<text top="586" left="932" width="131" height="19" font="0">rate. Some TTVP was </text>
<text top="604" left="932" width="159" height="19" font="0">prophylactic and may not </text>
<text top="623" left="932" width="131" height="19" font="0">have been indicated. </text>
<text top="641" left="922" width="155" height="20" font="0">• A minority of TTVP was </text>
<text top="660" left="932" width="158" height="19" font="0">performed for SND (15%) </text>
<text top="715" left="99" width="105" height="19" font="0">Rotman M, et al. </text>
<text top="733" left="99" width="69" height="19" font="0">1972 (452) </text>
<text top="751" left="99" width="53" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4551931">4551931</a></text>
<text top="751" left="153" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=4551931"> </a></text>
<text top="715" left="223" width="160" height="19" font="8"><b>Aim:</b> Bradyarrhythmias in </text>
<text top="733" left="223" width="29" height="19" font="0">AMI </text>
<text top="751" left="223" width="3" height="19" font="8"><b> </b></text>
<text top="715" left="410" width="116" height="19" font="0">539 pts with acute </text>
<text top="733" left="410" width="20" height="19" font="0">MI </text>
<text top="751" left="410" width="107" height="19" font="0">(prethrombolytic </text>
<text top="770" left="410" width="79" height="19" font="0">and pre-PCI) </text>
<text top="715" left="548" width="98" height="19" font="0">Short- and long-</text>
<text top="733" left="548" width="97" height="19" font="0">term outcomes </text>
<text top="715" left="692" width="199" height="20" font="0">• Incidence of sinus bradycardia </text>
<text top="734" left="702" width="29" height="19" font="0">26% </text>
<text top="752" left="692" width="182" height="20" font="0">• 3-fold more frequent in the </text>
<text top="771" left="702" width="172" height="19" font="0">setting of inferior infarction </text>
<text top="715" left="922" width="152" height="20" font="0">• Sinus brady is common </text>
<text top="734" left="922" width="143" height="20" font="0">• Sinus bradycardia not </text>
<text top="753" left="930" width="139" height="19" font="0">associated with worse </text>
<text top="771" left="930" width="64" height="19" font="0">outcomes </text>
</page>
<page number="227" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 227 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="223" width="166" height="19" font="8"><b>Study type: </b>Retrospective, </text>
<text top="105" left="223" width="176" height="19" font="0">observational, single-center  </text>
<text top="87" left="692" width="209" height="20" font="0">• Overall mortality of 539 pts was </text>
<text top="106" left="702" width="37" height="19" font="0">20%.  </text>
<text top="124" left="692" width="150" height="20" font="0">• In those pts with sinus </text>
<text top="143" left="702" width="186" height="19" font="0">bradycardia the mortality was </text>
<text top="162" left="702" width="33" height="19" font="0">10%. </text>
<text top="181" left="86" width="4" height="21" font="2"><b> </b></text>
<text top="201" left="86" width="823" height="23" font="5"><b>Data Supplement 55. Nonrandomized Data for Predicting Bradycardia Associated with Seizures (Section 8.4.1) </b></text>
<text top="224" left="104" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="242" left="130" width="51" height="19" font="8"><b>Author; </b></text>
<text top="260" left="108" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="224" left="261" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="242" left="290" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="224" left="458" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="224" left="672" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="242" left="703" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="260" left="734" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="224" left="942" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="242" left="971" width="80" height="19" font="8"><b>Comment(s) </b></text>
<text top="279" left="95" width="120" height="19" font="0">Bestawros M, et al. </text>
<text top="298" left="95" width="69" height="19" font="0">2015 (453) </text>
<text top="316" left="95" width="67" height="21" font="14"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25391254">25391254</a></text>
<text top="317" left="162" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25391254"> </a></text>
<text top="279" left="230" width="166" height="19" font="8"><b>Aim:</b> Evaluate incidence of </text>
<text top="298" left="230" width="82" height="19" font="0">ictal asystole </text>
<text top="316" left="230" width="3" height="19" font="0"> </text>
<text top="334" left="230" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="353" left="230" width="156" height="19" font="0">evaluation of an epilepsy </text>
<text top="371" left="230" width="59" height="19" font="0">database </text>
<text top="389" left="230" width="3" height="19" font="0"> </text>
<text top="407" left="230" width="176" height="19" font="8"><b>Size:</b> 10 ictal asystole events </text>
<text top="426" left="230" width="167" height="19" font="0">from 5,312 video-EEG/ECG </text>
<text top="444" left="230" width="47" height="19" font="0">studies </text>
<text top="279" left="429" width="172" height="19" font="8"><b>Inclusion criteria:</b> Database </text>
<text top="298" left="429" width="161" height="19" font="0">searched for pts with ictal </text>
<text top="316" left="429" width="139" height="19" font="0">asystole defined as RR </text>
<text top="334" left="429" width="147" height="19" font="0">interval &gt;3s and &gt;2-fold </text>
<text top="353" left="429" width="164" height="19" font="0">lengthening over the prior </text>
<text top="371" left="429" width="70" height="19" font="0">RR interval </text>
<text top="389" left="429" width="3" height="19" font="0"> </text>
<text top="407" left="429" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="280" left="621" width="163" height="19" font="8"><b>1</b>°<b> endpoint:</b> Ictal asystole </text>
<text top="298" left="621" width="3" height="19" font="0"> </text>
<text top="317" left="621" width="52" height="19" font="8"><b>Results: </b></text>
<text top="335" left="621" width="284" height="20" font="0">• 10 pts with 76 seizures with 26 ictal asystole </text>
<text top="354" left="631" width="269" height="19" font="0">events, 15 of which had associated syncope </text>
<text top="373" left="621" width="225" height="20" font="0">• Seizure with asystole duration &gt;6 s </text>
<text top="392" left="631" width="152" height="19" font="0">associated with syncope </text>
<text top="410" left="621" width="196" height="20" font="0">• All with temporal lobe seizure </text>
<text top="429" left="621" width="254" height="20" font="0">• 8 pts received a PPM with resolution of </text>
<text top="448" left="631" width="54" height="19" font="0">syncope<b> </b></text>
<text top="280" left="925" width="169" height="20" font="0">• Permanent pacing can be </text>
<text top="298" left="935" width="129" height="19" font="0">considered if seizure </text>
<text top="317" left="935" width="158" height="19" font="0">poorly controlled by drug </text>
<text top="335" left="935" width="65" height="19" font="0">or surgery </text>
<text top="480" left="95" width="118" height="19" font="0">Lanz M, et al. 2011 </text>
<text top="498" left="95" width="35" height="19" font="0">(454) </text>
<text top="516" left="95" width="64" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21183363">21183363 </a></text>
<text top="516" left="159" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21183363"> </a></text>
<text top="480" left="230" width="166" height="19" font="8"><b>Aim:</b> Evaluate incidence of </text>
<text top="498" left="230" width="82" height="19" font="0">ictal asystole </text>
<text top="516" left="230" width="3" height="19" font="0"> </text>
<text top="535" left="230" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="553" left="230" width="3" height="19" font="0"> </text>
<text top="571" left="230" width="165" height="19" font="8"><b>Size:</b> 2,003 pts undergoing </text>
<text top="590" left="230" width="142" height="19" font="0">video EEG/ECG studies </text>
<text top="480" left="429" width="139" height="19" font="8"><b>Inclusion criteria:</b> &gt;3 s </text>
<text top="498" left="429" width="3" height="19" font="0"> </text>
<text top="516" left="429" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="480" left="621" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> &gt;3 s pause </text>
<text top="499" left="621" width="3" height="19" font="0"> </text>
<text top="517" left="621" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="536" left="621" width="190" height="20" font="0">• 7/2,003 pts with bradycardia </text>
<text top="555" left="621" width="280" height="20" font="0">• 1 pt with insular seizure prolonged, the rest </text>
<text top="574" left="631" width="261" height="19" font="0">were self-limited though durations of 5, 6, </text>
<text top="592" left="631" width="227" height="19" font="0">25, 29, 34, 35, and 77 s and from the </text>
<text top="610" left="631" width="90" height="19" font="0">temporal lobe </text>
<text top="629" left="621" width="170" height="20" font="0">• Sinus arrest in 3. CHB in 4 </text>
<text top="648" left="621" width="113" height="20" font="0">• Pacemakers in 6<b> </b></text>
<text top="480" left="923" width="135" height="20" font="0">•  No cases of sudden </text>
<text top="499" left="936" width="129" height="19" font="0">unexpected death in </text>
<text top="517" left="936" width="133" height="19" font="0">epilepsy with a mean </text>
<text top="536" left="936" width="110" height="19" font="0">follow-up of 5.6 y </text>
<text top="668" left="95" width="108" height="19" font="0">Schuele SU, et al. </text>
<text top="686" left="95" width="69" height="19" font="0">2007 (455) </text>
<text top="704" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17664402">17664402</a></text>
<text top="704" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17664402"> </a></text>
<text top="708" left="95" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17664402"> </a></text>
<text top="668" left="230" width="166" height="19" font="8"><b>Aim:</b> Evaluate incidence of </text>
<text top="686" left="230" width="82" height="19" font="0">ictal asystole </text>
<text top="704" left="230" width="3" height="19" font="0"> </text>
<text top="723" left="230" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="741" left="230" width="3" height="19" font="0"> </text>
<text top="759" left="230" width="165" height="19" font="8"><b>Size:</b> 6,825 pts undergoing </text>
<text top="778" left="230" width="142" height="19" font="0">video EEG/ECG studies </text>
<text top="668" left="429" width="165" height="19" font="8"><b>Inclusion criteria:</b> &gt;3 s and </text>
<text top="686" left="429" width="177" height="19" font="0">&gt;2-fold lengthening over the </text>
<text top="704" left="429" width="103" height="19" font="0">prior RR interval </text>
<text top="723" left="429" width="3" height="19" font="0"> </text>
<text top="741" left="429" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="668" left="621" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> &gt;3 s pause </text>
<text top="687" left="621" width="3" height="19" font="0"> </text>
<text top="705" left="621" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="724" left="621" width="164" height="20" font="0">• 10 pts with ictal asystole </text>
<text top="743" left="621" width="81" height="20" font="0">• 8 temporal </text>
<text top="762" left="621" width="162" height="20" font="0">• Pacemakers in 6 of 8 pts<b> </b></text>
<text top="668" left="925" width="130" height="20" font="0">• No specific data on </text>
<text top="687" left="935" width="119" height="19" font="0">response to pacing </text>
</page>
<page number="228" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 228 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="120" height="19" font="0">Tenyi D, et al. 2017 </text>
<text top="105" left="95" width="35" height="19" font="0">(456) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27988965">27988965</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27988965"> </a></text>
<text top="87" left="230" width="166" height="19" font="8"><b>Aim:</b> Evaluate incidence of </text>
<text top="105" left="230" width="128" height="19" font="0">ictal asystole using a </text>
<text top="123" left="230" width="113" height="19" font="0">systematic review </text>
<text top="142" left="230" width="3" height="19" font="0"> </text>
<text top="160" left="230" width="144" height="19" font="8"><b>Study type:</b> Systematic </text>
<text top="178" left="230" width="45" height="19" font="0">review </text>
<text top="197" left="230" width="3" height="19" font="0"> </text>
<text top="215" left="230" width="139" height="19" font="8"><b>Size:</b> 157 cases of ictal </text>
<text top="233" left="230" width="185" height="19" font="0">asystole pts undergoing video </text>
<text top="252" left="230" width="105" height="19" font="0">EEG/ECG studies </text>
<text top="87" left="429" width="165" height="19" font="8"><b>Inclusion criteria:</b> &gt;3 s and </text>
<text top="105" left="429" width="177" height="19" font="0">&gt;2-fold lengthening over the </text>
<text top="123" left="429" width="103" height="19" font="0">prior RR interval </text>
<text top="142" left="429" width="3" height="19" font="0"> </text>
<text top="160" left="429" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="88" left="621" width="149" height="19" font="8"><b>1</b>°<b> endpoint:</b> &gt;3 s pause </text>
<text top="106" left="621" width="3" height="19" font="0"> </text>
<text top="124" left="621" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="143" left="619" width="93" height="20" font="0">•  Localization: </text>
<text top="167" left="646" width="9" height="12" font="0">o</text>
<text top="165" left="655" width="4" height="14" font="0"> </text>
<text top="162" left="667" width="118" height="19" font="0">Temporal: 80–82% </text>
<text top="185" left="646" width="9" height="12" font="0">o</text>
<text top="184" left="655" width="4" height="14" font="0"> </text>
<text top="180" left="667" width="95" height="19" font="0">Frontal: 6–10% </text>
<text top="203" left="646" width="9" height="12" font="0">o</text>
<text top="202" left="655" width="4" height="14" font="0"> </text>
<text top="198" left="667" width="85" height="19" font="0">Insular: 3–5% </text>
<text top="222" left="647" width="9" height="12" font="0">o</text>
<text top="220" left="656" width="4" height="14" font="0"> </text>
<text top="217" left="667" width="83" height="19" font="0">Other 3–11% </text>
<text top="235" left="621" width="70" height="20" font="0">• Duration </text>
<text top="259" left="647" width="9" height="12" font="0">o</text>
<text top="258" left="656" width="4" height="14" font="0"> </text>
<text top="254" left="667" width="69" height="19" font="0">&lt;30 s: 90% </text>
<text top="277" left="647" width="9" height="12" font="0">o</text>
<text top="276" left="656" width="4" height="14" font="0"> </text>
<text top="272" left="667" width="69" height="19" font="0">&gt;30 s: 10% </text>
<text top="291" left="621" width="34" height="20" font="0">• Rx: </text>
<text top="310" left="621" width="127" height="20" font="0">• Pacemaker: 35/68 </text>
<text top="329" left="621" width="289" height="20" font="0">• Adjusted AED: 25/33 pts who did not receive </text>
<text top="348" left="633" width="42" height="19" font="0">a PPM </text>
<text top="367" left="621" width="98" height="20" font="0">• Surgery: 8/33 </text>
<text top="391" left="647" width="9" height="12" font="0">o</text>
<text top="389" left="656" width="4" height="14" font="0"> </text>
<text top="385" left="667" width="81" height="19" font="0">Rx response: </text>
<text top="409" left="647" width="9" height="12" font="0">o</text>
<text top="407" left="656" width="4" height="14" font="0"> </text>
<text top="404" left="667" width="215" height="19" font="0">Pacemaker: no asystole falls,14/33 </text>
<text top="422" left="667" width="215" height="19" font="0">with recurrent seizures, 19/33 w/o </text>
<text top="440" left="667" width="117" height="19" font="0">recurrent seizures  </text>
<text top="464" left="647" width="9" height="12" font="0">o</text>
<text top="462" left="656" width="4" height="14" font="0"> </text>
<text top="459" left="667" width="212" height="19" font="0">Adjusted AED: 5/23 with recurring </text>
<text top="477" left="667" width="211" height="19" font="0">asystolic falls, 6/23 with recurrent </text>
<text top="495" left="667" width="214" height="19" font="0">seizures (w/o asystole), 12/23 w/o </text>
<text top="514" left="667" width="114" height="19" font="0">recurrent seizures </text>
<text top="537" left="647" width="9" height="12" font="0">o</text>
<text top="536" left="656" width="4" height="14" font="0"> </text>
<text top="532" left="667" width="54" height="19" font="0">Surgery: </text>
<text top="555" left="646" width="9" height="12" font="0">o</text>
<text top="554" left="655" width="4" height="14" font="0"> </text>
<text top="550" left="667" width="222" height="19" font="0">No asystolic falls, 2/8 with recurring </text>
<text top="569" left="667" width="187" height="19" font="0">nonasystolic seizures, 6/8 w/o </text>
<text top="587" left="667" width="114" height="19" font="0">recurrent seizures<b> </b></text>
<text top="87" left="925" width="131" height="20" font="0">• No specific data on </text>
<text top="106" left="935" width="119" height="19" font="0">response to pacing </text>
<text top="606" left="86" width="4" height="21" font="4"> </text>
<text top="626" left="86" width="529" height="23" font="5"><b>Data Supplement 56. Nonrandomized Data for Device Type (Section 9) </b></text>
<text top="649" left="121" width="103" height="19" font="8"><b>Study Acronym; </b></text>
<text top="667" left="147" width="51" height="19" font="8"><b>Author; </b></text>
<text top="685" left="125" width="96" height="19" font="8"><b>Year Published </b></text>
<text top="649" left="336" width="125" height="19" font="8"><b>Study Type/Design; </b></text>
<text top="667" left="365" width="67" height="19" font="8"><b>Study Size </b></text>
<text top="649" left="564" width="120" height="19" font="8"><b>Patient Population </b></text>
<text top="649" left="731" width="187" height="19" font="8"><b>Primary Endpoint and Results </b></text>
<text top="667" left="762" width="130" height="19" font="8"><b>(P values; OR or RR;  </b></text>
<text top="685" left="793" width="64" height="19" font="8"><b>&amp; 95% CI) </b></text>
<text top="649" left="954" width="137" height="19" font="8"><b>Summary/Conclusion </b></text>
<text top="667" left="983" width="80" height="19" font="8"><b>Comment(s) </b></text>
</page>
<page number="229" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 229 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="95" width="126" height="19" font="0">Ogunbayo GO, et al. </text>
<text top="105" left="95" width="69" height="19" font="0">2017 (457) </text>
<text top="123" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28735733">28735733</a></text>
<text top="123" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28735733"> </a></text>
<text top="87" left="263" width="260" height="19" font="8"><b>Aim:</b> Evaluate incidence of pneumothorax </text>
<text top="105" left="263" width="180" height="19" font="0">associated with CIED implant </text>
<text top="123" left="263" width="3" height="19" font="0"> </text>
<text top="142" left="263" width="245" height="19" font="8"><b>Study type:</b> Retrospective evaluation of </text>
<text top="160" left="263" width="162" height="19" font="0">National Inpatient Sample </text>
<text top="178" left="263" width="3" height="19" font="0"> </text>
<text top="197" left="263" width="247" height="19" font="8"><b>Size:</b> 3.7 million people underwent CIED </text>
<text top="215" left="263" width="50" height="19" font="0">implant </text>
<text top="87" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="547" width="140" height="19" font="0">Database searched for </text>
<text top="123" left="547" width="104" height="19" font="0">pts with primary </text>
<text top="142" left="547" width="140" height="19" font="0">implantation of a CIED </text>
<text top="160" left="547" width="143" height="19" font="0">with at least 1 vascular </text>
<text top="178" left="547" width="42" height="19" font="0">access </text>
<text top="197" left="547" width="3" height="19" font="0"> </text>
<text top="215" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="88" left="714" width="175" height="19" font="8"><b>1</b>°<b> endpoint:</b> Pneumothorax </text>
<text top="106" left="714" width="3" height="19" font="0"> </text>
<text top="124" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="143" left="714" width="210" height="20" font="0">• Pneumothorax occurred in 1.6% </text>
<text top="162" left="724" width="52" height="19" font="0">of cases </text>
<text top="180" left="714" width="203" height="20" font="0">• Pneumothorax associated with </text>
<text top="199" left="724" width="175" height="19" font="0">increased length of stay and </text>
<text top="217" left="724" width="179" height="19" font="0">increased mortality (1.2% vs. </text>
<text top="236" left="724" width="38" height="19" font="0">0.7%) </text>
<text top="254" left="714" width="203" height="20" font="0">• Pneumothorax associated with </text>
<text top="273" left="724" width="185" height="19" font="0">older age, female sex, chronic </text>
<text top="292" left="724" width="175" height="19" font="0">obstructive lung disease, DC </text>
<text top="310" left="725" width="43" height="19" font="0">device<b> </b></text>
<text top="87" left="949" width="105" height="20" font="0">• Pneumothorax </text>
<text top="106" left="960" width="136" height="19" font="0">remains an important </text>
<text top="124" left="960" width="82" height="19" font="0">complication </text>
<text top="329" left="93" width="138" height="19" font="0">Sochala M, et al. 2017 </text>
<text top="347" left="93" width="35" height="19" font="0">(458) </text>
<text top="365" left="95" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28598855">28598855</a></text>
<text top="365" left="156" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28598855"> </a></text>
<text top="329" left="263" width="244" height="19" font="8"><b>Aim:</b> Evaluate risk of complication after </text>
<text top="347" left="263" width="228" height="19" font="0">CIED implant for myotonic dystrophy </text>
<text top="365" left="263" width="3" height="19" font="0"> </text>
<text top="384" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="402" left="263" width="3" height="19" font="0"> </text>
<text top="420" left="263" width="269" height="19" font="8"><b>Size:</b> 914 pts with myotonic dystrophy Type </text>
<text top="439" left="263" width="225" height="19" font="0">1–23 with an ICD and 46 with a PPM </text>
<text top="329" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="347" left="547" width="126" height="19" font="0">Myotonic dystrophy </text>
<text top="365" left="547" width="100" height="19" font="0">type 1 and CIED </text>
<text top="384" left="547" width="68" height="19" font="0">placement </text>
<text top="402" left="547" width="3" height="19" font="0"> </text>
<text top="420" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="330" left="714" width="171" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications </text>
<text top="348" left="714" width="3" height="19" font="0"> </text>
<text top="366" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="385" left="714" width="219" height="20" font="0">• After 6-y follow-up device related </text>
<text top="404" left="724" width="160" height="19" font="0">complications in 9 ICD pts </text>
<text top="422" left="724" width="180" height="19" font="0">(Inappropriate shocks 5, lead </text>
<text top="440" left="724" width="200" height="19" font="0">dysfunction 5, infection 2) and 3 </text>
<text top="459" left="725" width="167" height="19" font="0">PPM pts (lead dysfunction)<b> </b></text>
<text top="329" left="949" width="114" height="20" font="0">• Increased risk of </text>
<text top="348" left="960" width="118" height="19" font="0">complications with </text>
<text top="366" left="960" width="107" height="19" font="0">ICD though small </text>
<text top="385" left="960" width="58" height="19" font="0">numbers </text>
<text top="478" left="100" width="139" height="19" font="0">Bai Y, et al. 2017 (459) </text>
<text top="496" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28587353">28587353</a></text>
<text top="496" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28587353"> </a></text>
<text top="478" left="263" width="269" height="19" font="8"><b>Aim:</b> Evaluate incidence of hematoma after </text>
<text top="496" left="263" width="32" height="19" font="0">CIED </text>
<text top="514" left="263" width="3" height="19" font="0"> </text>
<text top="533" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="551" left="263" width="3" height="19" font="0"> </text>
<text top="569" left="263" width="205" height="19" font="8"><b>Size:</b> 339 pts from a single center </text>
<text top="588" left="263" width="173" height="19" font="0">undergoing CIED placement </text>
<text top="478" left="547" width="133" height="19" font="8"><b>Inclusion criteria:</b> Pts </text>
<text top="496" left="547" width="105" height="19" font="0">undergoing CIED </text>
<text top="514" left="547" width="68" height="19" font="0">placement </text>
<text top="533" left="547" width="3" height="19" font="0"> </text>
<text top="551" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="478" left="714" width="153" height="19" font="8"><b>1</b>°<b> endpoint:</b> Hematoma </text>
<text top="497" left="714" width="3" height="19" font="0"> </text>
<text top="515" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="534" left="714" width="216" height="20" font="0">• History of allergy associated with </text>
<text top="553" left="724" width="70" height="19" font="0">hematoma </text>
<text top="571" left="714" width="206" height="20" font="0">• Hematoma more common with </text>
<text top="590" left="724" width="208" height="19" font="0">larger devices (ICD and CRT): 30% </text>
<text top="608" left="725" width="46" height="19" font="0">vs. 8%)<b> </b></text>
<text top="478" left="949" width="132" height="20" font="0">• Larger devices type </text>
<text top="497" left="960" width="90" height="19" font="0">though do not </text>
<text top="515" left="960" width="104" height="19" font="0">address vascular </text>
<text top="533" left="960" width="42" height="19" font="0">access </text>
<text top="552" left="949" width="114" height="20" font="0">• Only 27 pts with </text>
<text top="571" left="960" width="82" height="19" font="0">larger device </text>
<text top="627" left="100" width="149" height="19" font="0">Hosseini SM, et al. 2017 </text>
<text top="646" left="100" width="35" height="19" font="0">(460) </text>
<text top="664" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28329322">28329322</a></text>
<text top="664" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28329322"> </a></text>
<text top="627" left="263" width="244" height="19" font="8"><b>Aim:</b> Evaluate complications associated </text>
<text top="646" left="263" width="57" height="19" font="0">with CRT </text>
<text top="664" left="263" width="3" height="19" font="0"> </text>
<text top="682" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="701" left="263" width="3" height="19" font="0"> </text>
<text top="719" left="263" width="254" height="19" font="8"><b>Size:</b> 439,010 pts from National Inpatient </text>
<text top="737" left="263" width="148" height="19" font="0">Sample undergoing CRT </text>
<text top="627" left="547" width="138" height="19" font="8"><b>Inclusion criteria:</b> CRT </text>
<text top="646" left="547" width="43" height="19" font="0">device </text>
<text top="664" left="547" width="3" height="19" font="0"> </text>
<text top="682" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="628" left="714" width="150" height="19" font="8"><b>1</b>°<b> endpoint:</b> In-hospital </text>
<text top="646" left="725" width="88" height="19" font="0">complications </text>
<text top="665" left="714" width="3" height="19" font="0"> </text>
<text top="683" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="702" left="714" width="187" height="20" font="0">• 6.1% of pts with at least one </text>
<text top="720" left="724" width="82" height="19" font="0">complication </text>
<text top="739" left="714" width="221" height="20" font="0">• Complications more likely in older </text>
<text top="758" left="725" width="198" height="19" font="0">pts, women, elective admission, </text>
<text top="627" left="949" width="73" height="20" font="0">• Increased </text>
<text top="646" left="960" width="111" height="19" font="0">complication rate </text>
<text top="665" left="960" width="62" height="19" font="0">over time </text>
<text top="683" left="949" width="98" height="20" font="0">• No difference </text>
<text top="702" left="960" width="123" height="19" font="0">between CRT-P and </text>
<text top="720" left="960" width="41" height="19" font="0">CRT-D </text>
</page>
<page number="230" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 230 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="725" width="176" height="19" font="0">and increased comorbidities </text>
<text top="105" left="725" width="66" height="19" font="0">(Charlson)<b> </b></text>
<text top="127" left="100" width="125" height="19" font="0">Gupta N, et al. 2016 </text>
<text top="146" left="100" width="35" height="19" font="0">(461) </text>
<text top="164" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26961369">26961369</a></text>
<text top="164" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26961369"> </a></text>
<text top="127" left="263" width="244" height="19" font="8"><b>Aim:</b> Evaluate complications associated </text>
<text top="146" left="263" width="89" height="19" font="0">different CIED </text>
<text top="164" left="263" width="3" height="19" font="0"> </text>
<text top="182" left="263" width="262" height="19" font="8"><b>Study type:</b> Retrospective-Kaiser database </text>
<text top="201" left="263" width="3" height="19" font="0"> </text>
<text top="219" left="263" width="262" height="19" font="8"><b>Size:</b> 11,924 ICDs, 33,519 PPMs, 4,472 CRT </text>
<text top="127" left="547" width="143" height="19" font="8"><b>Inclusion criteria:</b> CIED </text>
<text top="146" left="547" width="50" height="19" font="0">implant </text>
<text top="164" left="547" width="3" height="19" font="0"> </text>
<text top="182" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="128" left="714" width="150" height="19" font="8"><b>1</b>°<b> endpoint:</b> In-hospital </text>
<text top="147" left="725" width="202" height="19" font="0">complications, 30 d failure rates, </text>
<text top="165" left="724" width="64" height="19" font="0">outcomes </text>
<text top="183" left="714" width="3" height="19" font="0"> </text>
<text top="201" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="220" left="714" width="85" height="20" font="0">• CIED failure </text>
<text top="244" left="746" width="9" height="12" font="0">o</text>
<text top="243" left="755" width="4" height="14" font="0"> </text>
<text top="239" left="757" width="69" height="19" font="0">PM: 0.85% </text>
<text top="262" left="746" width="9" height="12" font="0">o</text>
<text top="261" left="755" width="4" height="14" font="0"> </text>
<text top="257" left="757" width="69" height="19" font="0">ICD: 2.17% </text>
<text top="281" left="746" width="9" height="12" font="0">o</text>
<text top="279" left="755" width="4" height="14" font="0"> </text>
<text top="275" left="757" width="72" height="19" font="0">CRT: 4.93%<b> </b></text>
<text top="128" left="949" width="73" height="20" font="0">• Increased </text>
<text top="147" left="960" width="111" height="19" font="0">complication rate </text>
<text top="165" left="960" width="62" height="19" font="0">over time </text>
<text top="183" left="949" width="98" height="20" font="0">• No difference </text>
<text top="202" left="960" width="123" height="19" font="0">between CRT-P and </text>
<text top="221" left="960" width="41" height="19" font="0">CRT-D </text>
<text top="294" left="100" width="150" height="19" font="0">Friedman DJ, et al. 2015 </text>
<text top="313" left="100" width="35" height="19" font="0">(462) </text>
<text top="331" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26670062">26670062</a></text>
<text top="331" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26670062"> </a></text>
<text top="335" left="100" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26670062"> </a></text>
<text top="294" left="263" width="244" height="19" font="8"><b>Aim:</b> Evaluate complications associated </text>
<text top="313" left="263" width="267" height="19" font="0">CRT in pts with moderate renal dysfunction </text>
<text top="331" left="263" width="3" height="19" font="0"> </text>
<text top="349" left="263" width="228" height="19" font="8"><b>Study type:</b> Retrospective-NCDR and </text>
<text top="368" left="263" width="135" height="19" font="0">matched to Medicare </text>
<text top="386" left="263" width="3" height="19" font="0"> </text>
<text top="404" left="263" width="256" height="19" font="8"><b>Size:</b> 9.525 CRT-D vs. propensity matched </text>
<text top="423" left="263" width="104" height="19" font="0">ICD only (1,421)  </text>
<text top="294" left="547" width="138" height="19" font="8"><b>Inclusion criteria:</b> CRT </text>
<text top="313" left="547" width="151" height="19" font="0">eligible pts with stage 3–</text>
<text top="331" left="547" width="39" height="19" font="0">5 CKD </text>
<text top="349" left="547" width="3" height="19" font="0"> </text>
<text top="368" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="295" left="714" width="174" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality, HFH </text>
<text top="314" left="714" width="3" height="19" font="0"> </text>
<text top="332" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="350" left="714" width="216" height="20" font="0">• HFH or death: 0.84; 95% CI: 0.78–</text>
<text top="369" left="724" width="30" height="19" font="0">0.91 </text>
<text top="388" left="714" width="201" height="20" font="0">• Death: 0.85; 95% CI: 0.77–0.93<b> </b></text>
<text top="295" left="949" width="136" height="20" font="0">• CRT associated with </text>
<text top="314" left="960" width="126" height="19" font="0">improved outcomes </text>
<text top="442" left="100" width="120" height="19" font="0">Witt CT, et al. 2016 </text>
<text top="460" left="100" width="35" height="19" font="0">(463) </text>
<text top="478" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26378089">26378089</a></text>
<text top="478" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26378089"> </a></text>
<text top="442" left="263" width="268" height="19" font="8"><b>Aim:</b> Evaluate complications associated ICD </text>
<text top="460" left="263" width="75" height="19" font="0">Rx with CRT </text>
<text top="478" left="263" width="3" height="19" font="0"> </text>
<text top="497" left="263" width="244" height="19" font="8"><b>Study type:</b> Retrospective-single center </text>
<text top="515" left="263" width="3" height="19" font="0"> </text>
<text top="533" left="263" width="248" height="19" font="8"><b>Size:</b> 917 HF pts-427 with NICM and 490 </text>
<text top="552" left="263" width="62" height="19" font="0">with ICM  </text>
<text top="442" left="547" width="138" height="19" font="8"><b>Inclusion criteria:</b> CRT </text>
<text top="460" left="547" width="46" height="19" font="0">and HF </text>
<text top="478" left="547" width="3" height="19" font="0"> </text>
<text top="497" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="442" left="714" width="141" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality </text>
<text top="461" left="714" width="3" height="19" font="0"> </text>
<text top="479" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="498" left="714" width="144" height="20" font="0">• Median follow-up 4 y </text>
<text top="517" left="714" width="75" height="20" font="0">• Mortality: </text>
<text top="541" left="735" width="9" height="12" font="0">o</text>
<text top="539" left="744" width="4" height="14" font="0"> </text>
<text top="536" left="746" width="158" height="19" font="0">NICM: 0.96; 95% CI: 0.60–</text>
<text top="554" left="746" width="79" height="19" font="0">1.51; p=0.85 </text>
<text top="577" left="735" width="9" height="12" font="0">o</text>
<text top="576" left="744" width="4" height="14" font="0"> </text>
<text top="572" left="746" width="183" height="19" font="0">ICM: 0.74; 95% CI: 0.56–0.97; </text>
<text top="591" left="746" width="45" height="19" font="0">p=0.03<b> </b></text>
<text top="442" left="949" width="133" height="20" font="0">• ICD associated with </text>
<text top="461" left="960" width="120" height="19" font="0">better outcomes in </text>
<text top="479" left="960" width="114" height="19" font="0">ICM but not NICM </text>
<text top="610" left="100" width="126" height="19" font="0">Gadler F, et al. 2015 </text>
<text top="628" left="100" width="35" height="19" font="0">(464) </text>
<text top="646" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25336667">25336667</a></text>
<text top="646" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25336667"> </a></text>
<text top="610" left="263" width="244" height="19" font="8"><b>Aim:</b> Evaluate complications associated </text>
<text top="628" left="263" width="112" height="19" font="0">with CIED implant </text>
<text top="646" left="263" width="3" height="19" font="0"> </text>
<text top="665" left="263" width="237" height="19" font="8"><b>Study type:</b> Retrospective-multicenter </text>
<text top="683" left="263" width="110" height="19" font="0">registry (Sweden) </text>
<text top="701" left="263" width="3" height="19" font="0"> </text>
<text top="719" left="263" width="170" height="19" font="8"><b>Size:</b> 6,617 PPM. 1,298 ICD  </text>
<text top="610" left="547" width="141" height="19" font="8"><b>Inclusion criteria:</b> First </text>
<text top="628" left="547" width="82" height="19" font="0">CIED implant </text>
<text top="646" left="547" width="3" height="19" font="0"> </text>
<text top="665" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="610" left="714" width="174" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications  </text>
<text top="629" left="714" width="3" height="19" font="0"> </text>
<text top="647" left="714" width="172" height="19" font="8"><b>Results:</b> Complications (1 y) </text>
<text top="666" left="714" width="72" height="20" font="0">• PM: 5.3% </text>
<text top="685" left="714" width="80" height="20" font="0">• ICD: 10.1%<b> </b></text>
<text top="610" left="949" width="133" height="20" font="0">• ICD associated with </text>
<text top="629" left="960" width="125" height="19" font="0">higher complication </text>
<text top="647" left="960" width="28" height="19" font="0">rate </text>
</page>
<page number="231" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 231 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="100" width="135" height="19" font="0">Essebag V, et al. 2015 </text>
<text top="105" left="100" width="35" height="19" font="0">(465) </text>
<text top="123" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25417892">25417892</a></text>
<text top="123" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25417892"> </a></text>
<text top="87" left="263" width="244" height="19" font="8"><b>Aim:</b> Evaluate complications associated </text>
<text top="105" left="263" width="234" height="19" font="0">with CRT upgrade vs. de novo implant </text>
<text top="123" left="263" width="3" height="19" font="0"> </text>
<text top="142" left="263" width="227" height="19" font="8"><b>Study type:</b> Subgroup analysis of the </text>
<text top="160" left="263" width="104" height="19" font="0">Canadian cohort </text>
<text top="178" left="263" width="3" height="19" font="0"> </text>
<text top="197" left="263" width="241" height="19" font="8"><b>Size:</b> Pts with CRT: 644 de Novo and 80 </text>
<text top="215" left="263" width="54" height="19" font="0">upgrade </text>
<text top="87" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="547" width="136" height="19" font="0">Randomized to CRT-D </text>
<text top="123" left="547" width="3" height="19" font="0"> </text>
<text top="142" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="88" left="714" width="174" height="19" font="8"><b>1</b>°<b> endpoint:</b> Complications  </text>
<text top="106" left="714" width="3" height="19" font="0"> </text>
<text top="124" left="714" width="131" height="19" font="8"><b>Results:</b> Success rate </text>
<text top="143" left="714" width="99" height="20" font="0">• de Novo: 95% </text>
<text top="162" left="714" width="100" height="20" font="0">• Upgrade: 96%<b> </b></text>
<text top="87" left="949" width="121" height="20" font="0">• Similar results for </text>
<text top="106" left="960" width="115" height="19" font="0">CRT-D whether de </text>
<text top="124" left="960" width="87" height="19" font="0">Novo or as an </text>
<text top="143" left="960" width="54" height="19" font="0">upgrade </text>
<text top="234" left="100" width="137" height="19" font="0">Chung MK, et al. 2014 </text>
<text top="252" left="100" width="39" height="19" font="0">(466)  </text>
<text top="271" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25221331">25221331</a></text>
<text top="271" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25221331"> </a></text>
<text top="234" left="263" width="246" height="19" font="8"><b>Aim:</b> Evaluate mortality associated with </text>
<text top="252" left="263" width="176" height="19" font="0">different cardiac procedures </text>
<text top="271" left="263" width="3" height="19" font="0"> </text>
<text top="289" left="263" width="234" height="19" font="8"><b>Study type:</b> Retrospective subanalysis </text>
<text top="307" left="263" width="3" height="19" font="0"> </text>
<text top="326" left="263" width="235" height="19" font="8"><b>Size:</b> 1,744 pts with CIED replacement </text>
<text top="234" left="547" width="143" height="19" font="8"><b>Inclusion criteria:</b> CIED </text>
<text top="252" left="547" width="81" height="19" font="0">replacement </text>
<text top="271" left="547" width="3" height="19" font="0"> </text>
<text top="289" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="235" left="714" width="81" height="19" font="8"><b>1</b>°<b> endpoint:</b> </text>
<text top="253" left="725" width="152" height="19" font="0">Complications/mortality </text>
<text top="272" left="714" width="3" height="19" font="0"> </text>
<text top="290" left="714" width="156" height="19" font="8"><b>Results:</b> Mortality due to </text>
<text top="308" left="714" width="211" height="19" font="0">comorbidities and not device type<b> </b></text>
<text top="234" left="949" width="104" height="20" font="0">• Complications, </text>
<text top="253" left="960" width="102" height="19" font="0">mortality due to </text>
<text top="272" left="960" width="87" height="19" font="0">comorbidities </text>
<text top="345" left="100" width="143" height="19" font="0">Adelstein E, et al. 2014 </text>
<text top="363" left="100" width="35" height="19" font="0">(467) </text>
<text top="381" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24657426">24657426</a></text>
<text top="381" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24657426"> </a></text>
<text top="345" left="263" width="229" height="19" font="8"><b>Aim:</b> Evaluate risks and benefits with </text>
<text top="363" left="263" width="103" height="19" font="0">device upgrades </text>
<text top="381" left="263" width="3" height="19" font="0"> </text>
<text top="400" left="263" width="234" height="19" font="8"><b>Study type: </b>Retrospective subanalysis </text>
<text top="418" left="263" width="3" height="19" font="0"> </text>
<text top="436" left="263" width="80" height="19" font="8"><b>Size:</b> 157 pts </text>
<text top="345" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="363" left="547" width="141" height="19" font="0">Pacemaker dependent </text>
<text top="381" left="547" width="111" height="19" font="0">with CRT upgrade </text>
<text top="400" left="547" width="3" height="19" font="0"> </text>
<text top="418" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="345" left="714" width="81" height="19" font="8"><b>1</b>°<b> endpoint:</b> </text>
<text top="364" left="725" width="152" height="19" font="0">Complications/mortality </text>
<text top="382" left="714" width="3" height="19" font="0"> </text>
<text top="400" left="714" width="197" height="19" font="8"><b>Results:</b> Pts w/o CAD had fewer </text>
<text top="419" left="714" width="214" height="19" font="0">comorbidities, longer survival, and </text>
<text top="437" left="714" width="186" height="19" font="0">low risk of appropriate shocks<b> </b></text>
<text top="345" left="949" width="131" height="20" font="0">• Better outcomes in </text>
<text top="364" left="960" width="122" height="19" font="0">the absence of CAD </text>
<text top="456" left="100" width="145" height="19" font="0">Kirkfeldt RE, et al. 2014 </text>
<text top="474" left="100" width="35" height="19" font="0">(468) </text>
<text top="493" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24347317">24347317</a></text>
<text top="493" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24347317"> </a></text>
<text top="456" left="263" width="229" height="19" font="8"><b>Aim:</b> Evaluate risks and benefits with </text>
<text top="474" left="263" width="136" height="19" font="0">different device types </text>
<text top="493" left="263" width="3" height="19" font="0"> </text>
<text top="511" left="263" width="238" height="19" font="8"><b>Study type:</b> Retrospective subanalysis  </text>
<text top="529" left="263" width="3" height="19" font="0"> </text>
<text top="548" left="263" width="92" height="19" font="8"><b>Size:</b> 5,918 pts </text>
<text top="456" left="547" width="143" height="19" font="8"><b>Inclusion criteria:</b> CIED </text>
<text top="474" left="547" width="124" height="19" font="0">implant in Denmark </text>
<text top="493" left="547" width="3" height="19" font="0"> </text>
<text top="511" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None </text>
<text top="457" left="714" width="81" height="19" font="8"><b>1</b>°<b> endpoint:</b> </text>
<text top="475" left="725" width="152" height="19" font="0">Complications/mortality </text>
<text top="494" left="714" width="3" height="19" font="0"> </text>
<text top="512" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="530" left="714" width="195" height="20" font="0">• Overall complication rate was </text>
<text top="549" left="724" width="33" height="19" font="0">9.5% </text>
<text top="568" left="714" width="206" height="20" font="0">• More complex procedures with </text>
<text top="587" left="724" width="104" height="19" font="0">worse outcomes </text>
<text top="610" left="746" width="9" height="12" font="0">o</text>
<text top="609" left="755" width="4" height="14" font="0"> </text>
<text top="605" left="757" width="167" height="19" font="0">Dual chamber: 2.0; 95% CI: </text>
<text top="623" left="757" width="49" height="19" font="0">1.4–2.7 </text>
<text top="647" left="746" width="9" height="12" font="0">o</text>
<text top="645" left="755" width="4" height="14" font="0"> </text>
<text top="642" left="757" width="168" height="19" font="0">CRT-D: 2.6; 95% CI: 1.9–3.4<b> </b></text>
<text top="456" left="949" width="124" height="20" font="0">• Complications are </text>
<text top="475" left="960" width="121" height="19" font="0">relatively common, </text>
<text top="494" left="960" width="103" height="19" font="0">particularly with </text>
<text top="512" left="960" width="104" height="19" font="0">complex devices </text>
<text top="661" left="100" width="124" height="19" font="0">Acosta J, et al. 2017 </text>
<text top="679" left="100" width="35" height="19" font="0">(469) </text>
<text top="697" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28780194">28780194</a></text>
<text top="697" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28780194"> </a></text>
<text top="661" left="263" width="204" height="19" font="8"><b>Aim:</b> Evaluate use of defibrillator </text>
<text top="679" left="263" width="271" height="19" font="0">capabilities in pts who were eligible for CRT  </text>
<text top="697" left="263" width="3" height="19" font="0"> </text>
<text top="715" left="263" width="253" height="19" font="8"><b>Study type:</b> Prospective, nonrandomized </text>
<text top="734" left="263" width="3" height="19" font="0"> </text>
<text top="752" left="263" width="80" height="19" font="8"><b>Size:</b> 217 pts<b> </b></text>
<text top="661" left="547" width="152" height="19" font="8"><b>Inclusion criteria:</b> Class I </text>
<text top="679" left="547" width="138" height="19" font="0">indication for CRT and </text>
<text top="697" left="547" width="75" height="19" font="0">cardiac MRI </text>
<text top="716" left="547" width="3" height="19" font="0"> </text>
<text top="734" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="661" left="714" width="183" height="19" font="8"><b>1</b>°<b> endpoint:</b> Appropriate ICD </text>
<text top="680" left="725" width="95" height="19" font="0">therapy or SCD </text>
<text top="698" left="714" width="3" height="19" font="0"> </text>
<text top="716" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="735" left="714" width="193" height="20" font="0">• 1° endpoint in 11.5% of cases </text>
<text top="754" left="714" width="171" height="20" font="0">• No 1° endpoint in pts w/o </text>
<text top="773" left="725" width="99" height="19" font="0">myocardial scar<b> </b></text>
<text top="661" left="949" width="133" height="20" font="0">• MRI may be helpful </text>
<text top="680" left="960" width="127" height="19" font="0">for identifying those </text>
<text top="698" left="960" width="84" height="19" font="0">pts at risk for </text>
<text top="716" left="960" width="131" height="19" font="0">sustained ventricular </text>
<text top="735" left="960" width="77" height="19" font="0">arrhythmias </text>
</page>
<page number="232" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 232 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="714" width="214" height="20" font="0">• Scar mass, “channel mass,” were </text>
<text top="106" left="725" width="156" height="19" font="0">predictors of 1° endpoint<b> </b></text>
<text top="173" left="100" width="137" height="19" font="0">Martens P, et al. 2017 </text>
<text top="191" left="100" width="35" height="19" font="0">(470) </text>
<text top="210" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28716973">28716973</a></text>
<text top="210" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28716973"> </a></text>
<text top="173" left="263" width="204" height="19" font="8"><b>Aim:</b> Evaluate use of defibrillator </text>
<text top="191" left="263" width="271" height="19" font="0">capabilities in pts who were eligible for CRT  </text>
<text top="210" left="263" width="3" height="19" font="0"> </text>
<text top="228" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="246" left="263" width="3" height="19" font="0"> </text>
<text top="265" left="263" width="80" height="19" font="8"><b>Size:</b> 687 pts<b> </b></text>
<text top="173" left="547" width="138" height="19" font="8"><b>Inclusion criteria:</b> CRT </text>
<text top="191" left="547" width="50" height="19" font="0">implant </text>
<text top="210" left="547" width="3" height="19" font="0"> </text>
<text top="228" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="174" left="714" width="141" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality </text>
<text top="192" left="714" width="3" height="19" font="0"> </text>
<text top="210" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="229" left="714" width="213" height="20" font="0">• All-cause mortality was higher in </text>
<text top="248" left="725" width="206" height="19" font="0">pts with CRT-P vs. CRT-D (21% vs. </text>
<text top="266" left="725" width="160" height="19" font="0">12%; p=0.003), even after </text>
<text top="285" left="725" width="134" height="19" font="0">adjusting for baseline </text>
<text top="303" left="725" width="196" height="19" font="0">characteristics (HR: 2.5; 95% CI: </text>
<text top="321" left="725" width="133" height="19" font="0">1.36–4.60; p=0.003). <b> </b></text>
<text top="340" left="714" width="197" height="20" font="0">• Multivariate analysis revealed </text>
<text top="359" left="725" width="193" height="19" font="0">that age &gt;80 y, New York Heart </text>
<text top="377" left="725" width="197" height="19" font="0">Association class IV, intolerance </text>
<text top="395" left="725" width="137" height="19" font="0">to BBs and underlying </text>
<text top="414" left="725" width="146" height="19" font="0">nonischemic CMP were </text>
<text top="432" left="725" width="190" height="19" font="0">independently associated with </text>
<text top="450" left="725" width="171" height="19" font="0">little incremental value of a </text>
<text top="468" left="725" width="205" height="19" font="0">primary prevention ICD on top of </text>
<text top="487" left="725" width="31" height="19" font="0">CRT.<b> </b></text>
<text top="173" left="949" width="136" height="20" font="0">• Weighing the risk of </text>
<text top="192" left="960" width="98" height="19" font="0">arrhythmia and </text>
<text top="211" left="960" width="120" height="19" font="0">nonarrhythmia risk </text>
<text top="229" left="960" width="46" height="19" font="0">helpful </text>
<text top="506" left="100" width="145" height="19" font="0">Yokoshiki H, et al. 2017 </text>
<text top="524" left="100" width="35" height="19" font="0">(471) </text>
<text top="543" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28626201">28626201</a></text>
<text top="543" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28626201"> </a></text>
<text top="506" left="263" width="204" height="19" font="8"><b>Aim:</b> Evaluate use of defibrillator </text>
<text top="524" left="263" width="271" height="19" font="0">capabilities in pts who were eligible for CRT  </text>
<text top="543" left="263" width="3" height="19" font="0"> </text>
<text top="561" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="579" left="263" width="3" height="19" font="0"> </text>
<text top="597" left="263" width="80" height="19" font="8"><b>Size:</b> 717 pts<b> </b></text>
<text top="506" left="547" width="138" height="19" font="8"><b>Inclusion criteria:</b> CRT </text>
<text top="524" left="547" width="50" height="19" font="0">implant </text>
<text top="543" left="547" width="3" height="19" font="0"> </text>
<text top="561" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="507" left="714" width="141" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality </text>
<text top="525" left="714" width="3" height="19" font="0"> </text>
<text top="543" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="562" left="714" width="199" height="20" font="0">• Combined events for all-cause </text>
<text top="581" left="725" width="192" height="19" font="0">death or HFH (whichever came </text>
<text top="599" left="725" width="198" height="19" font="0">first) diverged between the CRT-</text>
<text top="617" left="725" width="172" height="19" font="0">D (N=620) and CRT-P(N=97) </text>
<text top="636" left="725" width="180" height="19" font="0">groups with a rate of 22% vs. </text>
<text top="654" left="725" width="171" height="19" font="0">42%, respectively, at 24 mo </text>
<text top="672" left="725" width="77" height="19" font="0">(p=0.0011).  </text>
<text top="691" left="714" width="180" height="20" font="0">•  Did not remain statistically </text>
<text top="710" left="727" width="189" height="19" font="0">significant after controlling for </text>
<text top="728" left="727" width="112" height="19" font="0">baseline variables<b> </b></text>
<text top="506" left="949" width="136" height="20" font="0">• Weighing the risk of </text>
<text top="525" left="960" width="98" height="19" font="0">arrhythmia and </text>
<text top="543" left="960" width="120" height="19" font="0">nonarrhythmia risk </text>
<text top="562" left="960" width="46" height="19" font="0">helpful </text>
</page>
<page number="233" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 233 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="100" width="137" height="19" font="0">Ip JE, et al. 2017 (472) </text>
<text top="105" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28185354">28185354</a></text>
<text top="105" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28185354"> </a></text>
<text top="87" left="263" width="206" height="19" font="8"><b>Aim:</b> Evaluate ECG suitability of a </text>
<text top="105" left="263" width="213" height="19" font="0">subcutaneous ICD in pts with PMs  </text>
<text top="123" left="263" width="3" height="19" font="0"> </text>
<text top="142" left="263" width="149" height="19" font="8"><b>Study type:</b> Prospective </text>
<text top="160" left="263" width="3" height="19" font="0"> </text>
<text top="178" left="263" width="80" height="19" font="8"><b>Size:</b> 100 pts<b> </b></text>
<text top="87" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="547" width="112" height="19" font="0">Transvenous CIED </text>
<text top="123" left="547" width="3" height="19" font="0"> </text>
<text top="142" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="88" left="714" width="160" height="19" font="8"><b>1</b>°<b> endpoint:</b> ECG analysis </text>
<text top="106" left="714" width="3" height="19" font="0"> </text>
<text top="124" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="143" left="714" width="216" height="20" font="0">• 58% of pts would still be possible </text>
<text top="162" left="725" width="203" height="19" font="0">candidates for subcutaneous ICD </text>
<text top="180" left="725" width="172" height="19" font="0">based on ECG morphology.  </text>
<text top="199" left="714" width="194" height="20" font="0">• RV septal pacing or CRT more </text>
<text top="217" left="725" width="175" height="19" font="0">likely to qualify vs. RV apical </text>
<text top="236" left="725" width="186" height="19" font="0">pacing (67% and 80% vs. 37%)<b> </b></text>
<text top="87" left="949" width="135" height="20" font="0">• Transvenous pacing </text>
<text top="106" left="960" width="115" height="19" font="0">and subcutaneous </text>
<text top="124" left="960" width="73" height="19" font="0">ICD may be </text>
<text top="143" left="960" width="72" height="19" font="0">compatible </text>
<text top="255" left="100" width="141" height="19" font="0">Maisel WH, et al. 2006 </text>
<text top="273" left="100" width="35" height="19" font="0">(473) </text>
<text top="291" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16639048">16639048</a></text>
<text top="291" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16639048"> </a></text>
<text top="255" left="263" width="248" height="19" font="8"><b>Aim:</b> Evaluate ICD and PPM malfunction </text>
<text top="273" left="263" width="241" height="19" font="0">from annual manufacturer FDA reports </text>
<text top="291" left="263" width="3" height="19" font="0"> </text>
<text top="310" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="328" left="263" width="3" height="19" font="0"> </text>
<text top="346" left="263" width="266" height="19" font="8"><b>Size:</b> 2.25 million PM implants and 416,000 </text>
<text top="365" left="263" width="248" height="19" font="0">ICDs from 1990–2002; 17,323 explanted </text>
<text top="383" left="263" width="120" height="19" font="0">due to malfunction<b> </b></text>
<text top="255" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="273" left="547" width="151" height="19" font="0">Manufacturer report for </text>
<text top="291" left="547" width="49" height="19" font="0">explant </text>
<text top="310" left="547" width="3" height="19" font="0"> </text>
<text top="328" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="255" left="714" width="222" height="19" font="8"><b>1</b>°<b> endpoint:</b> Device failures, deaths </text>
<text top="274" left="714" width="3" height="19" font="0"> </text>
<text top="292" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="311" left="714" width="209" height="20" font="0">• Battery/capacitor abnormalities </text>
<text top="330" left="725" width="206" height="19" font="0">(4,085 malfunctions [23.6%]) and </text>
<text top="348" left="725" width="141" height="19" font="0">electrical issues (4,708 </text>
<text top="366" left="725" width="205" height="19" font="0">malfunctions [27.1%]) accounted </text>
<text top="385" left="725" width="162" height="19" font="0">for half of the total device </text>
<text top="403" left="725" width="52" height="19" font="0">failures. </text>
<text top="421" left="707" width="88" height="20" font="0">•  Overall, the </text>
<text top="440" left="720" width="146" height="19" font="0">annual ICD malfunction </text>
<text top="459" left="720" width="212" height="19" font="0">replacement rate was significantly </text>
<text top="477" left="720" width="198" height="19" font="0">higher than the PM malfunction </text>
<text top="495" left="720" width="214" height="19" font="0">replacement rate (mean [SD]: 20.7 </text>
<text top="514" left="720" width="200" height="19" font="0">[11.6] vs. 4.6 [2.2] replacements </text>
<text top="532" left="720" width="207" height="19" font="0">per 1,000 implants; p&lt;0.001; rate </text>
<text top="550" left="720" width="173" height="19" font="0">ratio, 5.9; 95% CI: 2.7–9.1]).<b> </b></text>
<text top="255" left="949" width="132" height="20" font="0">• Device malfunction </text>
<text top="274" left="960" width="95" height="19" font="0">has affected pt </text>
<text top="292" left="960" width="132" height="19" font="0">healthcare outcomes </text>
<text top="569" left="100" width="146" height="19" font="0">Maisel WH, 2006. (474) </text>
<text top="588" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16639052">16639052</a></text>
<text top="588" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16639052"> </a></text>
<text top="569" left="263" width="248" height="19" font="8"><b>Aim:</b> Evaluate ICD and PPM malfunction </text>
<text top="588" left="263" width="187" height="19" font="0">from published meta-analyses </text>
<text top="606" left="263" width="3" height="19" font="0"> </text>
<text top="624" left="263" width="166" height="19" font="8"><b>Study type:</b> Meta-analyses </text>
<text top="643" left="263" width="3" height="19" font="0"> </text>
<text top="661" left="263" width="80" height="19" font="8"><b>Size:</b> 100 pts<b> </b></text>
<text top="569" left="547" width="152" height="19" font="8"><b>Inclusion criteria:</b> ICD or </text>
<text top="588" left="547" width="82" height="19" font="0">PPM implant </text>
<text top="606" left="547" width="3" height="19" font="0"> </text>
<text top="624" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="570" left="714" width="168" height="19" font="8"><b>1</b>°<b> endpoint:</b> Device failure </text>
<text top="588" left="714" width="3" height="19" font="0"> </text>
<text top="607" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="625" left="714" width="172" height="20" font="0">• There were 2,981 PM and </text>
<text top="644" left="725" width="201" height="19" font="0">384 ICD generator malfunctions. </text>
<text top="663" left="714" width="89" height="20" font="0">• Morphology </text>
<text top="681" left="725" width="112" height="19" font="0">Overall, the mean </text>
<text top="700" left="727" width="202" height="19" font="0">annual ICD malfunction rate was </text>
<text top="718" left="727" width="160" height="19" font="0">about 20-fold higher than </text>
<text top="736" left="727" width="188" height="19" font="0">the PM malfunction rate (26.5 </text>
<text top="755" left="727" width="205" height="19" font="0">[3.8] vs1.3 [0.1] malfunctions per </text>
<text top="773" left="727" width="159" height="19" font="0">1000 person-y; p&lt;0.001). <b> </b></text>
<text top="569" left="949" width="116" height="20" font="0">• CD failures more </text>
<text top="588" left="960" width="113" height="19" font="0">common than PM </text>
<text top="607" left="960" width="48" height="19" font="0">failures </text>
</page>
<page number="234" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 234 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="100" width="132" height="19" font="0">Maron BJ, et al. 2007 </text>
<text top="105" left="100" width="35" height="19" font="0">(412) </text>
<text top="124" left="100" width="11" height="18" font="0">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/17652294"> </a></text>
<text top="124" left="113" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17652294">17652294</a></text>
<text top="124" left="174" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17652294"> </a></text>
<text top="143" left="100" width="3" height="19" font="0"> </text>
<text top="87" left="263" width="265" height="19" font="8"><b>Aim:</b> Evaluate appropriate ICD use in HCM  </text>
<text top="105" left="263" width="3" height="19" font="0"> </text>
<text top="123" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="142" left="263" width="3" height="19" font="0"> </text>
<text top="160" left="263" width="135" height="19" font="8"><b>Size:</b> 506 pts with ICD<b> </b></text>
<text top="87" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="547" width="144" height="19" font="0">Multicenter Registry of </text>
<text top="123" left="547" width="145" height="19" font="0">pts with HCM receiving </text>
<text top="142" left="547" width="43" height="19" font="0">an ICD </text>
<text top="160" left="547" width="3" height="19" font="0"> </text>
<text top="178" left="547" width="135" height="19" font="8"><b>Exclusion criteria:</b> NR<b> </b></text>
<text top="88" left="714" width="195" height="19" font="8"><b>1</b>°<b> endpoint:</b> ICD treated VT/VF </text>
<text top="106" left="714" width="3" height="19" font="0"> </text>
<text top="124" left="714" width="56" height="19" font="8"><b>Results:</b>  </text>
<text top="143" left="714" width="167" height="20" font="0">• Appropriate ICD therapy: </text>
<text top="162" left="714" width="182" height="20" font="0">• Primary prevention: 3.6%/y </text>
<text top="181" left="714" width="205" height="20" font="0">• Secondary prevention: 10.6%/y </text>
<text top="200" left="714" width="217" height="19" font="0">Similar event rates for 1,2, or 3 risk </text>
<text top="218" left="725" width="94" height="19" font="0">factors for SCD<b> </b></text>
<text top="87" left="949" width="136" height="20" font="0">• Presence of any risk </text>
<text top="106" left="960" width="116" height="19" font="0">factor sufficient to </text>
<text top="124" left="960" width="68" height="19" font="0">confer risk </text>
<text top="237" left="100" width="138" height="19" font="0">Sochala M, et al. 2017 </text>
<text top="256" left="100" width="35" height="19" font="0">(458) </text>
<text top="274" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28598855">28598855</a></text>
<text top="274" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28598855"> </a></text>
<text top="237" left="263" width="233" height="19" font="8"><b>Aim:</b> Evaluate arrhythmias in pts with </text>
<text top="256" left="263" width="129" height="19" font="0">myotonic dystrophy  </text>
<text top="274" left="263" width="3" height="19" font="0"> </text>
<text top="292" left="263" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="311" left="263" width="3" height="19" font="0"> </text>
<text top="329" left="263" width="225" height="19" font="8"><b>Size:</b> 914 pts with 23 pts with an ICD </text>
<text top="347" left="263" width="201" height="19" font="0">matched with 46 pts with a PPM<b> </b></text>
<text top="237" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="256" left="547" width="126" height="19" font="0">Myotonic dystrophy </text>
<text top="274" left="547" width="3" height="19" font="0"> </text>
<text top="292" left="547" width="113" height="19" font="8"><b>Exclusion criteria:</b> </text>
<text top="311" left="547" width="58" height="19" font="0">Matched<b> </b></text>
<text top="238" left="714" width="160" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias </text>
<text top="256" left="725" width="166" height="19" font="0">(bradycardia, tachycardia), </text>
<text top="275" left="725" width="88" height="19" font="0">complications </text>
<text top="293" left="714" width="3" height="19" font="0"> </text>
<text top="311" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="330" left="714" width="206" height="20" font="0">• Over a 6-y follow-up period, we </text>
<text top="349" left="725" width="151" height="19" font="0">observed device-related </text>
<text top="367" left="725" width="202" height="19" font="0">complications in 9 ICD recipients </text>
<text top="385" left="725" width="194" height="19" font="0">(inappropriate shocks in 5, lead </text>
<text top="404" left="725" width="192" height="19" font="0">dysfunction in 5, infection in 2) </text>
<text top="422" left="725" width="173" height="19" font="0">and in 3 PM recipients (lead </text>
<text top="440" left="725" width="204" height="19" font="0">dysfunction in 3). Pts with an ICD </text>
<text top="459" left="725" width="190" height="19" font="0">had, compared to those with a </text>
<text top="477" left="725" width="208" height="19" font="0">PM, higher rates of complications </text>
<text top="495" left="725" width="194" height="19" font="0">(39.1% vs. 6.5%; p=0.0006) and </text>
<text top="514" left="725" width="181" height="19" font="0">more frequent complications </text>
<text top="532" left="725" width="197" height="19" font="0">requiring hospitalization and/or </text>
<text top="550" left="725" width="177" height="19" font="0">re-intervention (respectively </text>
<text top="569" left="725" width="158" height="19" font="0">30.4% and 21.7% vs. 0%).<b> </b></text>
<text top="238" left="949" width="133" height="20" font="0">• ICD associated with </text>
<text top="256" left="960" width="125" height="19" font="0">higher complication </text>
<text top="275" left="960" width="34" height="19" font="0">rates </text>
<text top="588" left="100" width="148" height="19" font="0">Benhayon D, et al. 2015 </text>
<text top="606" left="100" width="35" height="19" font="0">(475) </text>
<text top="624" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25546341">25546341</a></text>
<text top="624" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25546341"> </a></text>
<text top="587" left="263" width="233" height="19" font="8"><b>Aim:</b> Evaluate arrhythmias in pts with </text>
<text top="606" left="263" width="129" height="19" font="0">myotonic dystrophy  </text>
<text top="624" left="263" width="3" height="19" font="0"> </text>
<text top="642" left="263" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="661" left="263" width="3" height="19" font="0"> </text>
<text top="679" left="263" width="73" height="19" font="8"><b>Size:</b> 37 pts<b> </b></text>
<text top="587" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="606" left="547" width="126" height="19" font="0">Myotonic dystrophy </text>
<text top="624" left="547" width="3" height="19" font="0"> </text>
<text top="642" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="588" left="714" width="160" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias </text>
<text top="607" left="725" width="162" height="19" font="0">(bradycardia, tachycardia) </text>
<text top="625" left="714" width="3" height="19" font="0"> </text>
<text top="643" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="662" left="714" width="217" height="20" font="0">• Pts with MD1 were more likely to </text>
<text top="681" left="725" width="179" height="19" font="0">have evidence of conduction </text>
<text top="699" left="725" width="190" height="19" font="0">disease abnormalities (40% vs. </text>
<text top="717" left="725" width="201" height="19" font="0">8.3%; p=NS) and had a higher all-</text>
<text top="736" left="725" width="209" height="19" font="0">cause mortality (16% vs. 0%) than </text>
<text top="754" left="725" width="101" height="19" font="0">those with MD2 </text>
<text top="772" left="714" width="3" height="19" font="8"><b> </b></text>
<text top="588" left="949" width="106" height="20" font="0">• Presence of AV </text>
<text top="607" left="960" width="72" height="19" font="0">conduction </text>
<text top="625" left="960" width="126" height="19" font="0">abnormalities in the </text>
<text top="643" left="960" width="122" height="19" font="0">setting of myotonic </text>
<text top="662" left="960" width="132" height="19" font="0">dystrophy associated </text>
<text top="680" left="960" width="100" height="19" font="0">with ventricular </text>
<text top="698" left="960" width="77" height="19" font="0">arrhythmias </text>
</page>
<page number="235" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 235 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="100" width="128" height="19" font="0">Takaya Y, et al. 2015 </text>
<text top="105" left="100" width="35" height="19" font="0">(223) </text>
<text top="123" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25529542">25529542</a></text>
<text top="123" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25529542"> </a></text>
<text top="87" left="263" width="233" height="19" font="8"><b>Aim:</b> Evaluate arrhythmias in pts with </text>
<text top="105" left="263" width="121" height="19" font="0">cardiac sarcoidosis  </text>
<text top="123" left="263" width="3" height="19" font="0"> </text>
<text top="142" left="263" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="160" left="263" width="3" height="19" font="0"> </text>
<text top="178" left="263" width="73" height="19" font="8"><b>Size:</b> 53 pts<b> </b></text>
<text top="87" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="105" left="547" width="119" height="19" font="0">Cardiac sarcoidosis </text>
<text top="123" left="547" width="3" height="19" font="0"> </text>
<text top="142" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="88" left="714" width="160" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias </text>
<text top="106" left="725" width="162" height="19" font="0">(bradycardia, tachycardia) </text>
<text top="124" left="714" width="3" height="19" font="0"> </text>
<text top="143" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="161" left="714" width="215" height="20" font="0">• Similar rates of SCD regardless of </text>
<text top="180" left="725" width="154" height="19" font="0">whether presenting with </text>
<text top="198" left="725" width="185" height="19" font="0">HF/ventricular arrhythmias or </text>
<text top="217" left="725" width="98" height="19" font="0">high-grade AVB </text>
<text top="235" left="714" width="3" height="19" font="8"><b> </b></text>
<text top="87" left="949" width="98" height="20" font="0">• ICD should be </text>
<text top="106" left="960" width="125" height="19" font="0">considered in all pts </text>
<text top="124" left="960" width="78" height="19" font="0">with cardiac </text>
<text top="143" left="960" width="70" height="19" font="0">sarcoidosis </text>
<text top="254" left="100" width="138" height="19" font="0">Anselme F, et al. 2013 </text>
<text top="272" left="100" width="35" height="19" font="0">(275) </text>
<text top="291" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23811080">23811080</a></text>
<text top="291" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23811080"> </a></text>
<text top="254" left="263" width="270" height="19" font="8"><b>Aim:</b> Evaluate arrhythmias in pts with lamin </text>
<text top="272" left="263" width="89" height="19" font="0">A/C mutation  </text>
<text top="291" left="263" width="3" height="19" font="0"> </text>
<text top="309" left="263" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="327" left="263" width="3" height="19" font="0"> </text>
<text top="345" left="263" width="73" height="19" font="8"><b>Size:</b> 47 pts<b> </b></text>
<text top="254" left="547" width="151" height="19" font="8"><b>Inclusion criteria:</b> Lamin </text>
<text top="272" left="547" width="86" height="19" font="0">A/C mutation </text>
<text top="291" left="547" width="3" height="19" font="0"> </text>
<text top="309" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="255" left="714" width="160" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias </text>
<text top="273" left="725" width="162" height="19" font="0">(bradycardia, tachycardia) </text>
<text top="291" left="714" width="3" height="19" font="0"> </text>
<text top="310" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="328" left="714" width="214" height="20" font="0">• 21 pts received an ICD for severe </text>
<text top="347" left="725" width="132" height="19" font="0">conduction disorders </text>
<text top="366" left="714" width="214" height="20" font="0">• Among ICD recipients, no pt died </text>
<text top="385" left="725" width="164" height="19" font="0">suddenly and 11 (52%) pts </text>
<text top="403" left="725" width="207" height="19" font="0">required appropriate ICD therapy </text>
<text top="421" left="725" width="199" height="19" font="0">during a median follow-up of 62 </text>
<text top="440" left="725" width="27" height="19" font="0">mo.<b> </b></text>
<text top="254" left="949" width="98" height="20" font="0">• ICD should be </text>
<text top="273" left="960" width="125" height="19" font="0">considered in all pts </text>
<text top="291" left="960" width="94" height="19" font="0">with lamin A/C </text>
<text top="310" left="960" width="66" height="19" font="0">mutations </text>
<text top="459" left="100" width="148" height="19" font="0">Ha AH, et al. 2012 (206) </text>
<text top="477" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22385162">22385162</a></text>
<text top="477" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22385162"> </a></text>
<text top="458" left="263" width="233" height="19" font="8"><b>Aim:</b> Evaluate arrhythmias in pts with </text>
<text top="477" left="263" width="129" height="19" font="0">myotonic dystrophy  </text>
<text top="495" left="263" width="3" height="19" font="0"> </text>
<text top="513" left="263" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="532" left="263" width="3" height="19" font="0"> </text>
<text top="550" left="263" width="80" height="19" font="8"><b>Size:</b> 226 pts<b> </b></text>
<text top="458" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="477" left="547" width="126" height="19" font="0">Myotonic dystrophy </text>
<text top="495" left="547" width="3" height="19" font="0"> </text>
<text top="513" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="459" left="714" width="160" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias </text>
<text top="478" left="725" width="162" height="19" font="0">(bradycardia, tachycardia) </text>
<text top="496" left="714" width="3" height="19" font="0"> </text>
<text top="514" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="533" left="714" width="219" height="20" font="0">• Pacemakers or defibrillators were </text>
<text top="552" left="725" width="169" height="19" font="0">implanted in 14% of all pts, </text>
<text top="570" left="725" width="200" height="19" font="0">including 65% of pts with severe </text>
<text top="588" left="725" width="119" height="19" font="0">ECG abnormalities. </text>
<text top="607" left="714" width="194" height="20" font="0">• During 57±46 mo, 13 pts died </text>
<text top="626" left="725" width="188" height="19" font="0">(1.16%/y), including 3 pts who </text>
<text top="644" left="725" width="187" height="19" font="0">died suddenly, 2 of whom had </text>
<text top="662" left="725" width="164" height="19" font="0">normally functioning PMs.<b> </b></text>
<text top="459" left="949" width="117" height="20" font="0">• Pts with PM may </text>
<text top="478" left="960" width="128" height="19" font="0">have sudden cardiac </text>
<text top="496" left="960" width="39" height="19" font="0">death </text>
<text top="681" left="100" width="129" height="19" font="0">Bhakta D, et al. 2012 </text>
<text top="700" left="100" width="35" height="19" font="0">(209) </text>
<text top="718" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22035077">22035077</a></text>
<text top="718" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22035077"> </a></text>
<text top="681" left="263" width="233" height="19" font="8"><b>Aim:</b> Evaluate arrhythmias in pts with </text>
<text top="700" left="263" width="129" height="19" font="0">myotonic dystrophy  </text>
<text top="718" left="263" width="3" height="19" font="0"> </text>
<text top="736" left="263" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="755" left="263" width="3" height="19" font="0"> </text>
<text top="773" left="263" width="80" height="19" font="8"><b>Size:</b> 406 pts<b> </b></text>
<text top="681" left="547" width="111" height="19" font="8"><b>Inclusion criteria:</b> </text>
<text top="700" left="547" width="126" height="19" font="0">Myotonic dystrophy </text>
<text top="718" left="547" width="3" height="19" font="0"> </text>
<text top="736" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="682" left="714" width="160" height="19" font="8"><b>1</b>°<b> endpoint:</b> Arrhythmias </text>
<text top="701" left="725" width="162" height="19" font="0">(bradycardia, tachycardia) </text>
<text top="719" left="714" width="3" height="19" font="0"> </text>
<text top="737" left="714" width="52" height="19" font="8"><b>Results: </b></text>
<text top="682" left="949" width="117" height="20" font="0">• Pts with PM may </text>
<text top="701" left="960" width="128" height="19" font="0">have sudden cardiac </text>
<text top="719" left="960" width="39" height="19" font="0">death </text>
</page>
<page number="236" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 236 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="87" left="714" width="177" height="20" font="0">• 46 (11.3%) had or received </text>
<text top="106" left="725" width="196" height="19" font="0">a PM and 21 (5.2%) received an </text>
<text top="124" left="725" width="32" height="19" font="0">ICD.  </text>
<text top="143" left="714" width="188" height="20" font="0">• 5 (10.9%) PM pts underwent </text>
<text top="162" left="725" width="167" height="19" font="0">upgrade to an ICD, 3 for LV </text>
<text top="180" left="725" width="203" height="19" font="0">systolic dysfunction, 1 for VT/VF, </text>
<text top="198" left="725" width="204" height="19" font="0">and 1 for progressive conduction </text>
<text top="217" left="725" width="52" height="19" font="0">disease. </text>
<text top="235" left="714" width="214" height="20" font="0">• 24 (52.2%) PM pts died including </text>
<text top="254" left="725" width="201" height="19" font="0">13 of respiratory failure and 7 of </text>
<text top="272" left="725" width="198" height="19" font="0">sudden death. 7 (33.3%) ICD pts </text>
<text top="291" left="725" width="186" height="19" font="0">died including 2 of respiratory </text>
<text top="309" left="725" width="187" height="19" font="0">failure and 3 of sudden death. </text>
<text top="327" left="725" width="184" height="19" font="0">The pts with ICDs and sudden </text>
<text top="346" left="725" width="149" height="19" font="0">death all had LV systolic </text>
<text top="364" left="725" width="178" height="19" font="0">dysfunction and 1 death was </text>
<text top="382" left="725" width="211" height="19" font="0">documented due to inappropriate </text>
<text top="401" left="725" width="65" height="19" font="0">therapies.<b> </b></text>
<text top="420" left="100" width="127" height="19" font="0">Faber TS, et al. 2007 </text>
<text top="438" left="100" width="35" height="19" font="0">(476) </text>
<text top="456" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17636308">17636308</a></text>
<text top="456" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17636308"> </a></text>
<text top="475" left="100" width="3" height="19" font="0"> </text>
<text top="419" left="263" width="232" height="19" font="8"><b>Aim:</b> Evaluate presence of ventricular </text>
<text top="438" left="263" width="208" height="19" font="0">arrhythmias in pts with a PPM for </text>
<text top="456" left="263" width="79" height="19" font="0">bradycardia  </text>
<text top="475" left="263" width="3" height="19" font="0"> </text>
<text top="493" left="263" width="165" height="19" font="8"><b>Study type:</b> Retrospective  </text>
<text top="511" left="263" width="3" height="19" font="0"> </text>
<text top="529" left="263" width="80" height="19" font="8"><b>Size:</b> 231 pts<b> </b></text>
<text top="419" left="547" width="143" height="19" font="8"><b>Inclusion criteria:</b> PPM </text>
<text top="438" left="547" width="3" height="19" font="0"> </text>
<text top="456" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="420" left="714" width="152" height="19" font="8"><b>1</b>°<b> endpoint:</b> Ventricular </text>
<text top="439" left="725" width="77" height="19" font="0">arrhythmias </text>
<text top="457" left="714" width="3" height="19" font="0"> </text>
<text top="475" left="714" width="200" height="19" font="8"><b>Results:</b> In 54 (25.7%) of 210 pts </text>
<text top="494" left="725" width="155" height="19" font="0">with at least 1 follow-up, </text>
<text top="512" left="725" width="178" height="19" font="0">episodes of nonsustained VT </text>
<text top="530" left="725" width="176" height="19" font="0">were documented by stored </text>
<text top="549" left="725" width="163" height="19" font="0">ECGs. 1 pt received an ICD<b> </b></text>
<text top="420" left="949" width="144" height="20" font="0">• Pts with PM will have </text>
<text top="439" left="960" width="36" height="19" font="0">NSVT </text>
<text top="568" left="100" width="102" height="19" font="0">Lazarus A, et al.  </text>
<text top="586" left="100" width="69" height="19" font="0">2002 (207) </text>
<text top="604" left="100" width="61" height="19" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12427418">12427418</a></text>
<text top="604" left="160" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12427418"> </a></text>
<text top="568" left="263" width="233" height="19" font="8"><b>Aim:</b> Evaluate arrhythmias in pts with </text>
<text top="586" left="263" width="125" height="19" font="0">myotonic dystrophy </text>
<text top="604" left="263" width="3" height="19" font="0"> </text>
<text top="623" left="263" width="162" height="19" font="8"><b>Study type:</b> Retrospective </text>
<text top="641" left="263" width="3" height="19" font="0"> </text>
<text top="659" left="263" width="73" height="19" font="8"><b>Size:</b> 49 pts<b> </b></text>
<text top="568" left="547" width="143" height="19" font="8"><b>Inclusion criteria:</b> PPM </text>
<text top="586" left="547" width="50" height="19" font="0">implant </text>
<text top="604" left="547" width="3" height="19" font="0"> </text>
<text top="623" left="547" width="150" height="19" font="8"><b>Exclusion criteria:</b> None<b> </b></text>
<text top="568" left="714" width="141" height="19" font="8"><b>1</b>°<b> endpoint:</b> Mortality </text>
<text top="587" left="714" width="3" height="19" font="0"> </text>
<text top="605" left="714" width="218" height="19" font="8"><b>Results:</b> Paroxysmal arrhythmias in </text>
<text top="623" left="725" width="67" height="19" font="0">84% of pts<b> </b></text>
<text top="568" left="949" width="90" height="20" font="0">•  Arrhythmias </text>
<text top="587" left="957" width="111" height="19" font="0">particularly in the </text>
<text top="605" left="957" width="130" height="19" font="0">setting of infraHisian </text>
<text top="623" left="957" width="116" height="19" font="0">disease associated </text>
<text top="642" left="957" width="108" height="19" font="0">with arrhythmias </text>
<text top="678" left="86" width="87" height="23" font="5"><b>References </b></text>
<text top="700" left="86" width="4" height="21" font="4"> </text>
<text top="721" left="86" width="16" height="21" font="4">1. </text>
<text top="721" left="140" width="936" height="21" font="4">Linzer M, Yang EH, Estes NA, 3rd, et al. Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical </text>
<text top="741" left="86" width="684" height="21" font="4">Efficacy Assessment Project of the American College of Physicians. Ann Intern Med. 1997;126:989-96. </text>
<text top="761" left="86" width="16" height="21" font="4">2. </text>
<text top="761" left="140" width="913" height="21" font="4">Thiruganasambandamoorthy V, Hess EP, Turko E, et al. Defining abnormal electrocardiography in adult emergency department syncope </text>
<text top="781" left="86" width="500" height="21" font="4">patients: the Ottawa Electrocardiographic Criteria. CJEM. 2012;14:248-58. </text>
</page>
<page number="237" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 237 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="16" height="21" font="4">3. </text>
<text top="86" left="140" width="908" height="21" font="4">Del Rosso A, Ungar A, Maggi R, et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general </text>
<text top="106" left="86" width="336" height="21" font="4">hospital: the EGSYS score. Heart. 2008;94:1620-6. </text>
<text top="127" left="86" width="16" height="21" font="4">4. </text>
<text top="127" left="140" width="941" height="21" font="4">Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in patients with syncope: data from the </text>
<text top="147" left="86" width="629" height="21" font="4">group for syncope study in the emergency room (GESINUR). Heart Rhythm. 2014;11:2035-44. </text>
<text top="167" left="86" width="16" height="21" font="4">5. </text>
<text top="167" left="140" width="867" height="21" font="4">Lauer MS, Francis GS, Okin PM, et al. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA. </text>
<text top="187" left="86" width="114" height="21" font="4">1999;281:524-9. </text>
<text top="207" left="86" width="16" height="21" font="4">6. </text>
<text top="207" left="140" width="963" height="21" font="4">Savonen KP, Kiviniemi V, Laukkanen JA, et al. Chronotropic incompetence and mortality in middle-aged men with known or suspected coronary </text>
<text top="227" left="86" width="309" height="21" font="4">heart disease. Eur Heart J. 2008;29:1896-902. </text>
<text top="247" left="86" width="16" height="21" font="4">7. </text>
<text top="247" left="140" width="892" height="21" font="4">Doi A, Tsuchihashi K, Kyuma M, et al. Diagnostic implications of modified treadmill and head-up tilt tests in exercise-related syncope: </text>
<text top="268" left="86" width="628" height="21" font="4">comparative studies with situational and/or vasovagal syncope. Can J Cardiol. 2002;18:960-6. </text>
<text top="288" left="86" width="16" height="21" font="4">8. </text>
<text top="288" left="141" width="829" height="21" font="4">Woelfel AK, Simpson RJ, Jr., Gettes LS, et al. Exercise-induced distal atrioventricular block. J Am Coll Cardiol. 1983;2:578-81. </text>
<text top="308" left="86" width="16" height="21" font="4">9. </text>
<text top="308" left="141" width="957" height="21" font="4">Boran KJ, Oliveros RA, Boucher CA, et al. Ischemia-associated intraventricular conduction disturbances during exercise testing as a predictor of </text>
<text top="328" left="86" width="614" height="21" font="4">proximal left anterior descending coronary artery disease. Am J Cardiol. 1983;51:1098-102. </text>
<text top="348" left="86" width="25" height="21" font="4">10. </text>
<text top="348" left="141" width="909" height="21" font="4">Oliveros RA, Seaworth J, Weiland FL, et al. Intermittent left anterior hemiblock during treadmill exercise test. Correlation with coronary </text>
<text top="368" left="86" width="239" height="21" font="4">arteriogram. Chest. 1977;72:492-4. </text>
<text top="388" left="86" width="25" height="21" font="4">11. </text>
<text top="388" left="141" width="931" height="21" font="4">Bobba P, Salerno JA, Casari A. Transient left posterior hemiblock. Report of four cases induced by exercise test. Circulation. 1972;46:931-8. </text>
<text top="409" left="86" width="25" height="21" font="4">12. </text>
<text top="409" left="141" width="950" height="21" font="4">Bharati S, Dhingra RC, Lev M, et al. Conduction system in a patient with Prinzmetal's angina and transient atrioventricular block. Am J Cardiol. </text>
<text top="429" left="87" width="105" height="21" font="4">1977;39:120-5. </text>
<text top="449" left="87" width="25" height="21" font="4">13. </text>
<text top="449" left="141" width="961" height="21" font="4">Coplan NL, Morales MC, Romanello P, et al. Exercise-related atrioventricular block. Influence of myocardial ischemia. Chest. 1991;100:1728-30. </text>
<text top="469" left="87" width="25" height="21" font="4">14. </text>
<text top="469" left="141" width="888" height="21" font="4">Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. Am J Cardiol. 1984;53:1013-7. </text>
<text top="489" left="87" width="25" height="21" font="4">15. </text>
<text top="489" left="141" width="953" height="21" font="4">Linzer M, Yang EH, Estes NA, 3rd, et al. Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American </text>
<text top="509" left="87" width="375" height="21" font="4">College of Physicians. Ann Intern Med. 1997;127:76-86. </text>
<text top="529" left="87" width="25" height="21" font="4">16. </text>
<text top="529" left="141" width="965" height="21" font="4">Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter </text>
<text top="550" left="87" width="443" height="21" font="4">monitors for arrhythmia detection. Am J Cardiol. 2005;95:1055-9. </text>
<text top="570" left="87" width="25" height="21" font="4">17. </text>
<text top="570" left="141" width="920" height="21" font="4">Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomized comparison of loop recorders versus Holter monitors in patients with </text>
<text top="590" left="87" width="334" height="21" font="4">syncope or presyncope. Am J Med. 2003;115:1-5. </text>
<text top="610" left="87" width="25" height="21" font="4">18. </text>
<text top="610" left="141" width="957" height="21" font="4">Brown AP, Dawkins KD, Davies JG. Detection of arrhythmias: use of a patient-activated ambulatory electrocardiogram device with a solid-state </text>
<text top="630" left="87" width="276" height="21" font="4">memory loop. Br Heart J. 1987;58:251-3. </text>
<text top="650" left="87" width="25" height="21" font="4">19. </text>
<text top="650" left="141" width="952" height="21" font="4">Cumbee SR, Pryor RE, Linzer M. Cardiac loop ECG recording: a new noninvasive diagnostic test in recurrent syncope. South Med J. 1990;83:39-</text>
<text top="670" left="87" width="25" height="21" font="4">43. </text>
<text top="691" left="87" width="25" height="21" font="4">20. </text>
<text top="691" left="141" width="948" height="21" font="4">Locati ET, Moya A, Oliveira M, et al. External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the </text>
<text top="711" left="87" width="335" height="21" font="4">SYNARR-Flash study. Europace. 2016;18:1265-72. </text>
<text top="731" left="87" width="25" height="21" font="4">21. </text>
<text top="731" left="141" width="945" height="21" font="4">Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic </text>
<text top="751" left="87" width="291" height="21" font="4">monitoring. Am J Med. 2014;127:95.e11-7. </text>
</page>
<page number="238" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 238 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="25" height="21" font="4">22. </text>
<text top="86" left="140" width="952" height="21" font="4">Rosenberg MA, Samuel M, Thosani A, et al. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot </text>
<text top="106" left="86" width="337" height="21" font="4">study. Pacing Clin Electrophysiol. 2013;36:328-33. </text>
<text top="127" left="86" width="25" height="21" font="4">23. </text>
<text top="127" left="140" width="957" height="21" font="4">Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol. 2013;112:520-4. </text>
<text top="147" left="86" width="25" height="21" font="4">24. </text>
<text top="147" left="140" width="939" height="21" font="4">Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and </text>
<text top="167" left="86" width="449" height="21" font="4">management of cardiac arrhythmia. Am J Cardiol. 2005;95:878-81. </text>
<text top="187" left="86" width="25" height="21" font="4">25. </text>
<text top="187" left="140" width="955" height="21" font="4">Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile </text>
<text top="207" left="86" width="757" height="21" font="4">cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol. 2007;18:241-7. </text>
<text top="227" left="86" width="25" height="21" font="4">26. </text>
<text top="227" left="140" width="929" height="21" font="4">Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J </text>
<text top="247" left="86" width="161" height="21" font="4">Cardiol. 1990;66:214-9. </text>
<text top="268" left="86" width="25" height="21" font="4">27. </text>
<text top="268" left="140" width="949" height="21" font="4">Schneider JF, Thomas HE, Jr., Kreger BE, et al. Newly acquired left bundle-branch block: the Framingham study. Ann Intern Med. 1979;90:303-</text>
<text top="288" left="86" width="25" height="21" font="4">10. </text>
<text top="308" left="86" width="25" height="21" font="4">28. </text>
<text top="308" left="140" width="955" height="21" font="4">Schneider JF, Thomas HE, Kreger BE, et al. Newly acquired right bundle-branch block: The Framingham Study. Ann Intern Med. 1980;92:37-44. </text>
<text top="328" left="86" width="25" height="21" font="4">29. </text>
<text top="328" left="140" width="891" height="21" font="4">Schneider JF, Thomas HE, Jr., Sorlie P, et al. Comparative features of newly acquired left and right bundle branch block in the general </text>
<text top="348" left="86" width="445" height="21" font="4">population: the Framingham study. Am J Cardiol. 1981;47:931-40. </text>
<text top="368" left="86" width="25" height="21" font="4">30. </text>
<text top="368" left="140" width="895" height="21" font="4">Eriksson P, Hansson PO, Eriksson H, et al. Bundle-branch block in a general male population: the study of men born 1913. Circulation. </text>
<text top="388" left="86" width="130" height="21" font="4">1998;98:2494-500. </text>
<text top="409" left="86" width="25" height="21" font="4">31. </text>
<text top="409" left="140" width="766" height="21" font="4">Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block. Am J Cardiol. 1996;77:1185-90. </text>
<text top="429" left="86" width="25" height="21" font="4">32. </text>
<text top="429" left="140" width="960" height="21" font="4">Imanishi R, Seto S, Ichimaru S, et al. Prognostic significance of incident complete left bundle branch block observed over a 40-year period. Am J </text>
<text top="449" left="86" width="161" height="21" font="4">Cardiol. 2006;98:644-8. </text>
<text top="469" left="86" width="25" height="21" font="4">33. </text>
<text top="469" left="140" width="960" height="21" font="4">Dhingra R, Pencina MJ, Wang TJ, et al. Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. </text>
<text top="489" left="86" width="204" height="21" font="4">Hypertension. 2006;47:861-7. </text>
<text top="509" left="86" width="25" height="21" font="4">34. </text>
<text top="509" left="140" width="833" height="21" font="4">Rotman M, Triebwasser JH. A clinical and follow-up study of right and left bundle branch block. Circulation. 1975;51:477-84. </text>
<text top="529" left="86" width="25" height="21" font="4">35. </text>
<text top="529" left="140" width="958" height="21" font="4">Froelicher VF, Jr., Thompson AJ, Wolthuis R, et al. Angiographic findings in asymptomatic aircrewmen with electrocardiographic abnormalities. </text>
<text top="550" left="86" width="188" height="21" font="4">Am J Cardiol. 1977;39:32-8. </text>
<text top="570" left="86" width="25" height="21" font="4">36. </text>
<text top="570" left="140" width="719" height="21" font="4">Rabkin SW, Mathewson FA, Tate RB. Natural history of left bundle-branch block. Br Heart J. 1980;43:164-9. </text>
<text top="590" left="86" width="25" height="21" font="4">37. </text>
<text top="590" left="141" width="964" height="21" font="4">Zhang ZM, Rautaharju PM, Soliman EZ, et al. Mortality risk associated with bundle branch blocks and related repolarization abnormalities (from </text>
<text top="610" left="87" width="477" height="21" font="4">the Women's Health Initiative [WHI]). Am J Cardiol. 2012;110:1489-95. </text>
<text top="630" left="87" width="25" height="21" font="4">38. </text>
<text top="630" left="141" width="942" height="21" font="4">Bogale N, Orn S, James M, et al. Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting </text>
<text top="650" left="87" width="579" height="21" font="4">death in patients following acute myocardial infarction. Am J Cardiol. 2007;99:647-50. </text>
<text top="670" left="87" width="25" height="21" font="4">39. </text>
<text top="670" left="141" width="957" height="21" font="4">Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 </text>
<text top="691" left="87" width="906" height="21" font="4">outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J. 2002;143:398-405. </text>
<text top="711" left="87" width="25" height="21" font="4">40. </text>
<text top="711" left="141" width="956" height="21" font="4">Erne P, Iglesias JF, Urban P, et al. Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in </text>
<text top="731" left="87" width="576" height="21" font="4">outcome from 1997 to 2016 in routine clinical practice. Am Heart J. 2017;184:106-13. </text>
<text top="751" left="87" width="25" height="21" font="4">41. </text>
<text top="751" left="141" width="899" height="21" font="4">Yeo KK, Li S, Amsterdam EA, et al. Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute </text>
<text top="771" left="87" width="937" height="21" font="4">myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR(R)). Am J Cardiol. 2012;109:497-501. </text>
</page>
<page number="239" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 239 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="25" height="21" font="4">42. </text>
<text top="86" left="140" width="924" height="21" font="4">Dhingra R, Ho Nam B, Benjamin EJ, et al. Cross-sectional relations of electrocardiographic QRS duration to left ventricular dimensions: the </text>
<text top="106" left="86" width="400" height="21" font="4">Framingham Heart Study. J Am Coll Cardiol. 2005;45:685-9. </text>
<text top="127" left="86" width="25" height="21" font="4">43. </text>
<text top="127" left="140" width="956" height="21" font="4">Talreja D, Gruver C, Sklenar J, et al. Efficient utilization of echocardiography for the assessment of left ventricular systolic function. Am Heart J. </text>
<text top="147" left="86" width="114" height="21" font="4">2000;139:394-8. </text>
<text top="167" left="86" width="25" height="21" font="4">44. </text>
<text top="167" left="140" width="882" height="21" font="4">Mendu ML, McAvay G, Lampert R, et al. Yield of diagnostic tests in evaluating syncopal episodes in older patients. Arch Intern Med. </text>
<text top="187" left="86" width="139" height="21" font="4">2009;169:1299-305. </text>
<text top="207" left="86" width="25" height="21" font="4">45. </text>
<text top="207" left="140" width="793" height="21" font="4">Recchia D, Barzilai B. Echocardiography in the evaluation of patients with syncope. J Gen Intern Med. 1995;10:649-55. </text>
<text top="227" left="86" width="25" height="21" font="4">46. </text>
<text top="227" left="140" width="920" height="21" font="4">Sarasin FP, Junod AF, Carballo D, et al. Role of echocardiography in the evaluation of syncope: a prospective study. Heart. 2002;88:363-7. </text>
<text top="247" left="86" width="25" height="21" font="4">47. </text>
<text top="247" left="140" width="937" height="21" font="4">Dagres N, Bongiorni MG, Dobreanu D, et al. Current investigation and management of patients with syncope: results of the European Heart </text>
<text top="268" left="86" width="373" height="21" font="4">Rhythm Association survey. Europace. 2013;15:1812-5. </text>
<text top="288" left="86" width="25" height="21" font="4">48. </text>
<text top="288" left="140" width="963" height="21" font="4">Badheka AO, Singh V, Patel NJ, et al. QRS duration on electrocardiography and cardiovascular mortality (from the National Health and Nutrition </text>
<text top="308" left="86" width="367" height="21" font="4">Examination Survey-III). Am J Cardiol. 2013;112:671-7. </text>
<text top="328" left="86" width="25" height="21" font="4">49. </text>
<text top="328" left="140" width="919" height="21" font="4">Chiu DT, Shapiro NI, Sun BC, et al. Are echocardiography, telemetry, ambulatory electrocardiography monitoring, and cardiac enzymes in </text>
<text top="348" left="86" width="865" height="21" font="4">emergency department patients presenting with syncope useful tests? A preliminary investigation. J Emerg Med. 2014;47:113-8. </text>
<text top="368" left="86" width="25" height="21" font="4">50. </text>
<text top="368" left="140" width="930" height="21" font="4">Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus syndrome and identification of the variables predictive of </text>
<text top="388" left="86" width="357" height="21" font="4">unfavorable outcome. Am J Cardiol. 1998;82:1205-9. </text>
<text top="409" left="86" width="25" height="21" font="4">51. </text>
<text top="409" left="140" width="903" height="21" font="4">Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical </text>
<text top="429" left="86" width="477" height="21" font="4">students without apparent heart disease. Am J Cardiol. 1977;39:390-5. </text>
<text top="449" left="86" width="25" height="21" font="4">52. </text>
<text top="449" left="140" width="669" height="21" font="4">Bjerregaard P. Premature beats in healthy subjects 40-79 years of age. Eur Heart J. 1982;3:493-503. </text>
<text top="469" left="86" width="25" height="21" font="4">53. </text>
<text top="469" left="140" width="678" height="21" font="4">Clarke JM, Hamer J, Shelton JR, et al. The rhythm of the normal human heart. Lancet. 1976;1:508-12. </text>
<text top="489" left="86" width="25" height="21" font="4">54. </text>
<text top="489" left="140" width="904" height="21" font="4">Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. Chest. </text>
<text top="509" left="86" width="105" height="21" font="4">1982;81:302-7. </text>
<text top="529" left="86" width="25" height="21" font="4">55. </text>
<text top="529" left="141" width="963" height="21" font="4">Meytes I, Kaplinsky E, Yahini JH, et al. Wenckebach A-V block: a frequent feature following heavy physical training. Am Heart J. 1975;90:426-30. </text>
<text top="550" left="86" width="25" height="21" font="4">56. </text>
<text top="550" left="141" width="833" height="21" font="4">Viitasalo MT, Kala R, Eisalo A. Ambulatory electrocardiographic recording in endurance athletes. Br Heart J. 1982;47:213-20. </text>
<text top="570" left="87" width="25" height="21" font="4">57. </text>
<text top="570" left="141" width="903" height="21" font="4">Northcote RJ, Canning GP, Ballantyne D. Electrocardiographic findings in male veteran endurance athletes. Br Heart J. 1989;61:155-60. </text>
<text top="590" left="87" width="25" height="21" font="4">58. </text>
<text top="590" left="141" width="924" height="21" font="4">Tilkian AG, Guilleminault C, Schroeder JS, et al. Sleep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after </text>
<text top="610" left="87" width="289" height="21" font="4">tracheostomy. Am J Med. 1977;63:348-58. </text>
<text top="630" left="87" width="25" height="21" font="4">59. </text>
<text top="630" left="141" width="907" height="21" font="4">Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea </text>
<text top="650" left="87" width="271" height="21" font="4">syndrome. Am J Cardiol. 1983;52:490-4. </text>
<text top="670" left="87" width="25" height="21" font="4">60. </text>
<text top="670" left="141" width="956" height="21" font="4">Shepard JW, Jr., Garrison MW, Grither DA, et al. Relationship of ventricular ectopy to oxyhemoglobin desaturation in patients with obstructive </text>
<text top="691" left="87" width="248" height="21" font="4">sleep apnea. Chest. 1985;88:335-40. </text>
<text top="711" left="87" width="25" height="21" font="4">61. </text>
<text top="711" left="141" width="642" height="21" font="4">Hoffstein V, Mateika S. Cardiac arrhythmias, snoring, and sleep apnea. Chest. 1994;106:466-71. </text>
<text top="731" left="87" width="25" height="21" font="4">62. </text>
<text top="731" left="141" width="911" height="21" font="4">Boudoulas H, Schmidt HS, Clark RW, et al. Anthropometric characteristics, cardiac abnormalities and adrenergic activity in patients with </text>
<text top="751" left="87" width="345" height="21" font="4">primary disorders of sleep. J Med. 1983;14:223-38. </text>
</page>
<page number="240" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 240 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="25" height="21" font="4">63. </text>
<text top="86" left="140" width="961" height="21" font="4">Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am </text>
<text top="106" left="86" width="269" height="21" font="4">J Respir Crit Care Med. 2006;173:910-6. </text>
<text top="127" left="86" width="25" height="21" font="4">64. </text>
<text top="127" left="140" width="878" height="21" font="4">Miller WP. Cardiac arrhythmias and conduction disturbances in the sleep apnea syndrome. Prevalence and significance. Am J Med. </text>
<text top="147" left="86" width="114" height="21" font="4">1982;73:317-21. </text>
<text top="167" left="86" width="25" height="21" font="4">65. </text>
<text top="167" left="140" width="917" height="21" font="4">Flemons WW, Remmers JE, Gillis AM. Sleep apnea and cardiac arrhythmias. Is there a relationship? Am Rev Respir Dis. 1993;148:618-21. </text>
<text top="187" left="86" width="25" height="21" font="4">66. </text>
<text top="187" left="140" width="931" height="21" font="4">Becker H, Brandenburg U, Peter JH, et al. Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during </text>
<text top="207" left="86" width="583" height="21" font="4">nasal continuous positive airway pressure. Am J Respir Crit Care Med. 1995;151:215-8. </text>
<text top="227" left="86" width="25" height="21" font="4">67. </text>
<text top="227" left="140" width="932" height="21" font="4">Koehler U, Fus E, Grimm W, et al. Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment. Eur </text>
<text top="247" left="86" width="164" height="21" font="4">Respir J. 1998;11:434-9. </text>
<text top="268" left="86" width="25" height="21" font="4">68. </text>
<text top="268" left="140" width="952" height="21" font="4">Grimm W, Koehler U, Fus E, et al. Outcome of patients with sleep apnea-associated severe bradyarrhythmias after continuous positive airway </text>
<text top="288" left="86" width="351" height="21" font="4">pressure therapy. Am J Cardiol. 2000;86:688-92, a9. </text>
<text top="308" left="86" width="25" height="21" font="4">69. </text>
<text top="308" left="140" width="921" height="21" font="4">Harbison J, O'Reilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous </text>
<text top="328" left="86" width="386" height="21" font="4">positive airway pressure therapy. Chest. 2000;118:591-5. </text>
<text top="348" left="86" width="25" height="21" font="4">70. </text>
<text top="348" left="140" width="896" height="21" font="4">Stegman SS, Burroughs JM, Henthorn RW. Asymptomatic bradyarrhythmias as a marker for sleep apnea: appropriate recognition and </text>
<text top="368" left="86" width="680" height="21" font="4">treatment may reduce the need for pacemaker therapy. Pacing Clin Electrophysiol. 1996;19:899-904. </text>
<text top="388" left="86" width="25" height="21" font="4">71. </text>
<text top="388" left="140" width="935" height="21" font="4">Garrigue S, Pepin JL, Defaye P, et al. High prevalence of sleep apnea syndrome in patients with long-term pacing: the European Multicenter </text>
<text top="409" left="86" width="376" height="21" font="4">Polysomnographic Study. Circulation. 2007;115:1703-9. </text>
<text top="429" left="86" width="25" height="21" font="4">72. </text>
<text top="429" left="140" width="914" height="21" font="4">Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring </text>
<text top="449" left="86" width="257" height="21" font="4">strategy. Circulation. 2001;104:46-51. </text>
<text top="469" left="86" width="25" height="21" font="4">73. </text>
<text top="469" left="140" width="866" height="21" font="4">Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J. </text>
<text top="489" left="86" width="122" height="21" font="4">2004;25:1257-63. </text>
<text top="509" left="86" width="25" height="21" font="4">74. </text>
<text top="509" left="140" width="958" height="21" font="4">Podoleanu C, DaCosta A, Defaye P, et al. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of </text>
<text top="529" left="86" width="564" height="21" font="4">the French healthcare system (FRESH study). Arch Cardiovasc Dis. 2014;107:546-52. </text>
<text top="550" left="86" width="25" height="21" font="4">75. </text>
<text top="550" left="140" width="893" height="21" font="4">Denniss AR, Ross DL, Richards DA, et al. Electrophysiologic studies in patients with unexplained syncope. Int J Cardiol. 1992;35:211-7. </text>
<text top="570" left="86" width="25" height="21" font="4">76. </text>
<text top="570" left="140" width="910" height="21" font="4">Smith I, Monk TG, White PF. Comparison of transesophageal atrial pacing with anticholinergic drugs for the treatment of intraoperative </text>
<text top="590" left="86" width="297" height="21" font="4">bradycardia. Anesth Analg. 1994;78:245-52. </text>
<text top="610" left="86" width="25" height="21" font="4">77. </text>
<text top="610" left="140" width="956" height="21" font="4">Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency department. Resuscitation. 2007;73:96-</text>
<text top="630" left="86" width="33" height="21" font="4">102. </text>
<text top="650" left="86" width="25" height="21" font="4">78. </text>
<text top="650" left="140" width="958" height="21" font="4">Aghamohammadi H, Mehrabi S, Mohammad Ali Beigi F. Prevention of bradycardia by atropine sulfate during urological laparoscopic surgery: a </text>
<text top="670" left="86" width="325" height="21" font="4">randomized controlled trial. Urol J. 2009;6:92-5. </text>
<text top="691" left="86" width="25" height="21" font="4">79. </text>
<text top="691" left="140" width="961" height="21" font="4">Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular </text>
<text top="711" left="86" width="624" height="21" font="4">block: prehospital and emergency department considerations. Resuscitation. 1999;41:47-55. </text>
<text top="731" left="86" width="25" height="21" font="4">80. </text>
<text top="731" left="140" width="886" height="21" font="4">Swart G, Brady WJ, Jr., DeBehnke DJ, et al. Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: </text>
<text top="751" left="86" width="536" height="21" font="4">prehospital and ED treatment with atropine. Am J Emerg Med. 1999;17:647-52. </text>
<text top="771" left="86" width="25" height="21" font="4">81. </text>
<text top="771" left="140" width="825" height="21" font="4">Warren JV, Lewis RP. Beneficial effects of atropine in the pre-hospital phase of coronary care. Am J Cardiol. 1976;37:68-72. </text>
</page>
<page number="241" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 241 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="25" height="21" font="4">82. </text>
<text top="86" left="140" width="908" height="21" font="4">Scheinman MM, Thorburn D, Abbott JA. Use of atropine in patients with acute myocardial infarction and sinus bradycardia. Circulation. </text>
<text top="106" left="86" width="114" height="21" font="4">1975;52:627-33. </text>
<text top="127" left="86" width="25" height="21" font="4">83. </text>
<text top="127" left="140" width="857" height="21" font="4">Ogawa H, Inoue T, Miwa S, et al. Heart rate responses to autonomic drugs in sick sinus syndrome--correlation with syncope and </text>
<text top="147" left="86" width="337" height="21" font="4">electrophysiologic data. Jpn Circ J. 1991;55:15-23. </text>
<text top="167" left="86" width="25" height="21" font="4">84. </text>
<text top="167" left="140" width="958" height="21" font="4">Mandel WJ, Hayakawa H, Allen HN, et al. Assessment of sinus node function in patients with the sick sinus syndrome. Circulation. 1972;46:761-</text>
<text top="187" left="86" width="16" height="21" font="4">9. </text>
<text top="207" left="86" width="25" height="21" font="4">85. </text>
<text top="207" left="140" width="955" height="21" font="4">Strauss HC, Bigger JT, Saroff AL, et al. Electrophysiologic evaluation of sinus node function in patients with sinus node dysfunction. Circulation. </text>
<text top="227" left="86" width="114" height="21" font="4">1976;53:763-76. </text>
<text top="247" left="86" width="25" height="21" font="4">86. </text>
<text top="247" left="140" width="925" height="21" font="4">Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and effectiveness of prehospital pacing </text>
<text top="268" left="86" width="490" height="21" font="4">versus conventional treatment: 'PrePACE'. Resuscitation. 2008;76:341-9. </text>
<text top="288" left="86" width="25" height="21" font="4">87. </text>
<text top="288" left="140" width="922" height="21" font="4">Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol. 1994;13:161-6. </text>
<text top="308" left="86" width="25" height="21" font="4">88. </text>
<text top="308" left="140" width="957" height="21" font="4">Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med. </text>
<text top="328" left="86" width="122" height="21" font="4">1993;22:196-200. </text>
<text top="348" left="86" width="25" height="21" font="4">89. </text>
<text top="348" left="140" width="953" height="21" font="4">St-Onge M, Dube PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila). 2014;52:926-</text>
<text top="368" left="86" width="25" height="21" font="4">44. </text>
<text top="388" left="86" width="25" height="21" font="4">90. </text>
<text top="388" left="140" width="921" height="21" font="4">Love JN, Sachdeva DK, Bessman ES, et al. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. Chest. </text>
<text top="409" left="86" width="114" height="21" font="4">1998;114:323-6. </text>
<text top="429" left="86" width="25" height="21" font="4">91. </text>
<text top="429" left="140" width="908" height="21" font="4">Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41:595-602. </text>
<text top="449" left="86" width="25" height="21" font="4">92. </text>
<text top="449" left="140" width="960" height="21" font="4">Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol </text>
<text top="469" left="86" width="164" height="21" font="4">(Phila). 2011;49:277-83. </text>
<text top="489" left="86" width="25" height="21" font="4">93. </text>
<text top="489" left="140" width="964" height="21" font="4">Greene SL, Gawarammana I, Wood DM, et al. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel </text>
<text top="509" left="86" width="617" height="21" font="4">blocker overdose: a prospective observational study. Intensive Care Med. 2007;33:2019-24. </text>
<text top="529" left="86" width="25" height="21" font="4">94. </text>
<text top="529" left="140" width="890" height="21" font="4">Eddleston M, Rajapakse S, Rajakanthan, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a </text>
<text top="550" left="86" width="365" height="21" font="4">randomised controlled trial. Lancet. 2000;355:967-72. </text>
<text top="570" left="86" width="25" height="21" font="4">95. </text>
<text top="570" left="140" width="906" height="21" font="4">Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. </text>
<text top="590" left="86" width="114" height="21" font="4">2008;36:3014-8. </text>
<text top="610" left="86" width="25" height="21" font="4">96. </text>
<text top="610" left="141" width="964" height="21" font="4">Lapostolle F, Borron SW, Verdier C, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute </text>
<text top="630" left="86" width="330" height="21" font="4">exposure. Intensive Care Med. 2008;34:1448-53. </text>
<text top="650" left="86" width="25" height="21" font="4">97. </text>
<text top="650" left="141" width="875" height="21" font="4">Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52:824-36. </text>
<text top="670" left="87" width="25" height="21" font="4">98. </text>
<text top="670" left="141" width="911" height="21" font="4">Smith TW, Butler VP, Jr., Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: </text>
<text top="691" left="87" width="383" height="21" font="4">experience in 26 cases. N Engl J Med. 1982;307:1357-62. </text>
<text top="711" left="87" width="25" height="21" font="4">99. </text>
<text top="711" left="141" width="938" height="21" font="4">Wenger TL, Butler VP, Jr., Haber E, et al. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J Am Coll </text>
<text top="731" left="87" width="177" height="21" font="4">Cardiol. 1985;5:118a-23a. </text>
<text top="751" left="87" width="33" height="21" font="4">100. </text>
<text top="751" left="141" width="954" height="21" font="4">Antman EM, Wenger TL, Butler VP, Jr., et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody </text>
<text top="771" left="87" width="516" height="21" font="4">fragments. Final report of a multicenter study. Circulation. 1990;81:1744-52. </text>
</page>
<page number="242" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 242 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">101. </text>
<text top="86" left="140" width="958" height="21" font="4">Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results </text>
<text top="106" left="86" width="486" height="21" font="4">of an observational surveillance study. J Am Coll Cardiol. 1991;17:590-8. </text>
<text top="127" left="86" width="33" height="21" font="4">102. </text>
<text top="127" left="140" width="934" height="21" font="4">Wenger TL. Experience with digoxin immune Fab (ovine) in patients with renal impairment. Am J Emerg Med. 1991;9:21-3; discussion 33-4. </text>
<text top="147" left="86" width="33" height="21" font="4">103. </text>
<text top="147" left="140" width="957" height="21" font="4">Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the </text>
<text top="167" left="86" width="378" height="21" font="4">EXTRIP Workgroup. Clin Toxicol (Phila). 2016;54:103-14. </text>
<text top="187" left="86" width="33" height="21" font="4">104. </text>
<text top="187" left="140" width="920" height="21" font="4">Abu-Laban RB, McIntyre CM, Christenson JM, et al. Aminophylline in bradyasystolic cardiac arrest: a randomised placebo-controlled trial. </text>
<text top="207" left="86" width="183" height="21" font="4">Lancet. 2006;367:1577-84. </text>
<text top="227" left="86" width="33" height="21" font="4">105. </text>
<text top="227" left="140" width="894" height="21" font="4">Hurley KF, Magee K, Green R. Aminophylline for bradyasystolic cardiac arrest in adults. Cochrane Database Syst Rev. 2015;Cd006781. </text>
<text top="247" left="86" width="33" height="21" font="4">106. </text>
<text top="247" left="140" width="934" height="21" font="4">Redmond JM, Zehr KJ, Gillinov MA, et al. Use of theophylline for treatment of prolonged sinus node dysfunction in human orthotopic heart </text>
<text top="268" left="86" width="484" height="21" font="4">transplantation. J Heart Lung Transplant. 1993;12:133-8; discussion 8-9. </text>
<text top="288" left="86" width="33" height="21" font="4">107. </text>
<text top="288" left="140" width="930" height="21" font="4">Bertolet BD, Eagle DA, Conti JB, et al. Bradycardia after heart transplantation: reversal with theophylline. J Am Coll Cardiol. 1996;28:396-9. </text>
<text top="308" left="86" width="33" height="21" font="4">108. </text>
<text top="308" left="140" width="960" height="21" font="4">Rothman SA, Jeevanandam V, Seeber CP, et al. Electrophysiologic effects of intravenous aminophylline in heart transplant recipients with sinus </text>
<text top="328" left="86" width="404" height="21" font="4">node dysfunction. J Heart Lung Transplant. 1995;14:429-35. </text>
<text top="348" left="86" width="33" height="21" font="4">109. </text>
<text top="348" left="140" width="897" height="21" font="4">Heinz G, Kratochwill C, Buxbaum P, et al. Immediate normalization of profound sinus node dysfunction by aminophylline after cardiac </text>
<text top="368" left="86" width="307" height="21" font="4">transplantation. Am J Cardiol. 1993;71:346-9. </text>
<text top="388" left="86" width="33" height="21" font="4">110. </text>
<text top="388" left="140" width="896" height="21" font="4">Pasnoori VR, Leesar MA. Use of aminophylline in the treatment of severe symptomatic bradycardia resistant to atropine. Cardiol Rev. </text>
<text top="409" left="86" width="97" height="21" font="4">2004;12:65-8. </text>
<text top="429" left="86" width="33" height="21" font="4">111. </text>
<text top="429" left="140" width="921" height="21" font="4">Sadaka F, Naydenov SK, Ponzillo JJ. Theophylline for bradycardia secondary to cervical spinal cord injury. Neurocrit Care. 2010;13:389-92. </text>
<text top="449" left="86" width="33" height="21" font="4">112. </text>
<text top="449" left="140" width="906" height="21" font="4">Schulz-Stubner S. The use of small-dose theophylline for the treatment of bradycardia in patients with spinal cord injury. Anesth Analg. </text>
<text top="469" left="86" width="130" height="21" font="4">2005;101:1809-11. </text>
<text top="489" left="86" width="33" height="21" font="4">113. </text>
<text top="489" left="140" width="926" height="21" font="4">Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and balloon-flotation electrode catheters. </text>
<text top="509" left="86" width="161" height="21" font="4">Lancet. 1997;349:1883. </text>
<text top="529" left="86" width="33" height="21" font="4">114. </text>
<text top="529" left="140" width="912" height="21" font="4">López Ayerbe J, Villuendas Sabaté R, García García C, et al. Temporary Pacemakers: Current Use and Complications. Revista Española de </text>
<text top="550" left="86" width="317" height="21" font="4">Cardiología (English Edition). 2004;57:1045-52. </text>
<text top="570" left="86" width="33" height="21" font="4">115. </text>
<text top="570" left="140" width="923" height="21" font="4">Hynes JK, Holmes DR, Jr., Harrison CE. Five-year experience with temporary pacemaker therapy in the coronary care unit. Mayo Clin Proc. </text>
<text top="590" left="86" width="105" height="21" font="4">1983;58:122-6. </text>
<text top="610" left="86" width="33" height="21" font="4">116. </text>
<text top="610" left="140" width="739" height="21" font="4">Murphy JJ. Current practice and complications of temporary transvenous cardiac pacing. Bmj. 1996;312:1134. </text>
<text top="630" left="86" width="33" height="21" font="4">117. </text>
<text top="630" left="140" width="962" height="21" font="4">Austin JL, Preis LK, Crampton RS, et al. Analysis of pacemaker malfunction and complications of temporary pacing in the coronary care unit. Am </text>
<text top="650" left="86" width="170" height="21" font="4">J Cardiol. 1982;49:301-6. </text>
<text top="670" left="86" width="33" height="21" font="4">118. </text>
<text top="670" left="140" width="949" height="21" font="4">Muñoz Bono J, Prieto Palomino MA, Macías Guarasa I, et al. Efficacy and safety of non-permanent transvenous pacemaker implantation in an </text>
<text top="691" left="86" width="483" height="21" font="4">intensive care unit. Medicina Intensiva (English Edition). 2011;35:410-6. </text>
<text top="711" left="86" width="33" height="21" font="4">119. </text>
<text top="711" left="140" width="825" height="21" font="4">Betts TR. Regional survey of temporary transvenous pacing procedures and complications. Postgrad Med J. 2003;79:463-5. </text>
<text top="731" left="86" width="33" height="21" font="4">120. </text>
<text top="731" left="141" width="911" height="21" font="4">Jowett NI, Thompson DR, Pohl JE. Temporary transvenous cardiac pacing: 6 years experience in one coronary care unit. Postgrad Med J. </text>
<text top="751" left="87" width="105" height="21" font="4">1989;65:211-5. </text>
</page>
<page number="243" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 243 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">121. </text>
<text top="86" left="140" width="950" height="21" font="4">Weinstein J, Gnoj J, Mazzara JT, et al. Temporary transvenous pacing via the percutaneous femoral vein approach. A prospective study of 100 </text>
<text top="106" left="86" width="247" height="21" font="4">cases. Am Heart J. 1973;85:695-705. </text>
<text top="127" left="86" width="33" height="21" font="4">122. </text>
<text top="127" left="140" width="939" height="21" font="4">Garcia Guerrero JJ, Fernandez de la Concha Castaneda J, Lopez Quero D, et al. Lower incidence of venous thrombosis with temporary active-</text>
<text top="147" left="86" width="490" height="21" font="4">fixation lead implantation in mobile patients. Europace. 2010;12:1604-7. </text>
<text top="167" left="86" width="33" height="21" font="4">123. </text>
<text top="167" left="140" width="870" height="21" font="4">Nolewajka AJ, Goddard MD, Brown TC. Temporary transvenous pacing and femoral vein thrombosis. Circulation. 1980;62:646-50. </text>
<text top="187" left="86" width="33" height="21" font="4">124. </text>
<text top="187" left="140" width="886" height="21" font="4">Jou YL, Hsu HP, Tuan TC, et al. Trends of temporary pacemaker implant and underlying disease substrate. Pacing Clin Electrophysiol. </text>
<text top="207" left="86" width="122" height="21" font="4">2010;33:1475-84. </text>
<text top="227" left="86" width="33" height="21" font="4">125. </text>
<text top="227" left="140" width="666" height="21" font="4">McCann P. A review of temporary cardiac pacing wires. Indian Pacing Electrophysiol J. 2007;7:40-9. </text>
<text top="247" left="86" width="33" height="21" font="4">126. </text>
<text top="247" left="140" width="935" height="21" font="4">Bjornstad CC, Gjertsen E, Thorup F, et al. Temporary cardiac pacemaker treatment in five Norwegian regional hospitals. Scand Cardiovasc J. </text>
<text top="268" left="86" width="114" height="21" font="4">2012;46:137-43. </text>
<text top="288" left="86" width="33" height="21" font="4">127. </text>
<text top="288" left="140" width="952" height="21" font="4">Barthell E, Troiano P, Olson D, et al. Prehospital external cardiac pacing: a prospective, controlled clinical trial. Ann Emerg Med. 1988;17:1221-</text>
<text top="308" left="86" width="16" height="21" font="4">6. </text>
<text top="328" left="86" width="33" height="21" font="4">128. </text>
<text top="328" left="140" width="960" height="21" font="4">Sherbino J, Verbeek PR, MacDonald RD, et al. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia or bradyasystolic cardiac </text>
<text top="348" left="86" width="407" height="21" font="4">arrest: a systematic review. Resuscitation. 2006;70:193-200. </text>
<text top="368" left="86" width="33" height="21" font="4">129. </text>
<text top="368" left="140" width="898" height="21" font="4">Hedges JR, Feero S, Shultz B, et al. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia. Pacing Clin Electrophysiol. </text>
<text top="388" left="86" width="114" height="21" font="4">1991;14:1473-8. </text>
<text top="409" left="86" width="33" height="21" font="4">130. </text>
<text top="409" left="140" width="813" height="21" font="4">Zoll PM, Zoll RH, Falk RH, et al. External noninvasive temporary cardiac pacing: clinical trials. Circulation. 1985;71:937-44. </text>
<text top="429" left="86" width="33" height="21" font="4">131. </text>
<text top="429" left="140" width="736" height="21" font="4">Clinton JE, Zoll PM, Zoll R, et al. Emergency noninvasive external cardiac pacing. J Emerg Med. 1985;2:155-62. </text>
<text top="449" left="86" width="33" height="21" font="4">132. </text>
<text top="449" left="140" width="964" height="21" font="4">Lamas GA, Knight JD, Sweeney MO, et al. Impact of rate-modulated pacing on quality of life and exercise capacity--evidence from the Advanced </text>
<text top="469" left="86" width="603" height="21" font="4">Elements of Pacing Randomized Controlled Trial (ADEPT). Heart Rhythm. 2007;4:1125-32. </text>
<text top="489" left="86" width="33" height="21" font="4">133. </text>
<text top="489" left="140" width="940" height="21" font="4">Alboni P, Menozzi C, Brignole M, et al. Effects of permanent pacemaker and oral theophylline in sick sinus syndrome the THEOPACE study: a </text>
<text top="509" left="86" width="376" height="21" font="4">randomized controlled trial. Circulation. 1997;96:260-6. </text>
<text top="529" left="86" width="33" height="21" font="4">134. </text>
<text top="529" left="140" width="925" height="21" font="4">Sasaki Y, Shimotori M, Akahane K, et al. Long-term follow-up of patients with sick sinus syndrome: a comparison of clinical aspects among </text>
<text top="550" left="86" width="783" height="21" font="4">unpaced, ventricular inhibited paced, and physiologically paced groups. Pacing Clin Electrophysiol. 1988;11:1575-83. </text>
<text top="570" left="86" width="33" height="21" font="4">135. </text>
<text top="570" left="140" width="909" height="21" font="4">Goldberger JJ, Johnson NP, Gidea C. Significance of asymptomatic bradycardia for subsequent pacemaker implantation and mortality in </text>
<text top="590" left="86" width="389" height="21" font="4">patients &gt;60 years of age. Am J Cardiol. 2011;108:857-61. </text>
<text top="610" left="86" width="33" height="21" font="4">136. </text>
<text top="610" left="140" width="934" height="21" font="4">Teichman SL, Felder SD, Matos JA, et al. The value of electrophysiologic studies in syncope of undetermined origin: report of 150 cases. Am </text>
<text top="630" left="86" width="177" height="21" font="4">Heart J. 1985;110:469-79. </text>
<text top="650" left="86" width="33" height="21" font="4">137. </text>
<text top="650" left="140" width="950" height="21" font="4">Seidl K, Rameken M, Breunung S, et al. Diagnostic assessment of recurrent unexplained syncope with a new subcutaneously implantable loop </text>
<text top="670" left="86" width="386" height="21" font="4">recorder. Reveal-Investigators. Europace. 2000;2:256-62. </text>
<text top="691" left="86" width="33" height="21" font="4">138. </text>
<text top="691" left="140" width="953" height="21" font="4">Nielsen JC, Thomsen PE, Hojberg S, et al. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. Eur Heart </text>
<text top="711" left="86" width="127" height="21" font="4">J. 2011;32:686-96. </text>
<text top="731" left="86" width="33" height="21" font="4">139. </text>
<text top="731" left="140" width="956" height="21" font="4">Andersen HR, Nielsen JC, Thomsen PE, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-</text>
<text top="751" left="86" width="287" height="21" font="4">sinus syndrome. Lancet. 1997;350:1210-6. </text>
</page>
<page number="244" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 244 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">140. </text>
<text top="86" left="140" width="957" height="21" font="4">Lamas GA, Orav EJ, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with </text>
<text top="106" left="86" width="711" height="21" font="4">dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med. 1998;338:1097-104. </text>
<text top="127" left="86" width="33" height="21" font="4">141. </text>
<text top="127" left="140" width="958" height="21" font="4">Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346:1854-62. </text>
<text top="147" left="86" width="33" height="21" font="4">142. </text>
<text top="147" left="140" width="956" height="21" font="4">Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular </text>
<text top="167" left="86" width="614" height="21" font="4">causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000;342:1385-91. </text>
<text top="187" left="86" width="33" height="21" font="4">143. </text>
<text top="187" left="140" width="873" height="21" font="4">Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med. </text>
<text top="207" left="86" width="122" height="21" font="4">2007;357:1000-8. </text>
<text top="227" left="86" width="33" height="21" font="4">144. </text>
<text top="227" left="140" width="928" height="21" font="4">Healey JS, Toff WD, Lamas GA, et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of </text>
<text top="247" left="86" width="508" height="21" font="4">randomized trials, using individual patient data. Circulation. 2006;114:11-7. </text>
<text top="268" left="86" width="33" height="21" font="4">145. </text>
<text top="268" left="140" width="912" height="21" font="4">Andersen HR, Thuesen L, Bagger JP, et al. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet. </text>
<text top="288" left="86" width="122" height="21" font="4">1994;344:1523-8. </text>
<text top="308" left="86" width="33" height="21" font="4">146. </text>
<text top="308" left="140" width="962" height="21" font="4">Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with </text>
<text top="328" left="86" width="851" height="21" font="4">normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-7. </text>
<text top="348" left="86" width="33" height="21" font="4">147. </text>
<text top="348" left="140" width="954" height="21" font="4">Nielsen JC, Kristensen L, Andersen HR, et al. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick </text>
<text top="368" left="86" width="620" height="21" font="4">sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol. 2003;42:614-23. </text>
<text top="388" left="86" width="33" height="21" font="4">148. </text>
<text top="388" left="140" width="964" height="21" font="4">Brandt NH, Kirkfeldt RE, Nielsen JC, et al. Single lead atrial vs. dual chamber pacing in sick sinus syndrome: extended register-based follow-up in </text>
<text top="409" left="86" width="242" height="21" font="4">the DANPACE trial. Europace. 2016; </text>
<text top="429" left="86" width="33" height="21" font="4">149. </text>
<text top="429" left="140" width="939" height="21" font="4">Kenneback G, Tabrizi F, Lindell P, et al. High-degree atrioventricular block during anti-arrhythmic drug treatment: use of a pacemaker with a </text>
<text top="449" left="86" width="719" height="21" font="4">bradycardia-detection algorithm to study the time course after drug withdrawal. Europace. 2007;9:186-91. </text>
<text top="469" left="86" width="33" height="21" font="4">150. </text>
<text top="469" left="140" width="925" height="21" font="4">Knudsen MB, Thogersen AM, Hjortshoj SP, et al. The impact of drug discontinuation in patients treated with temporary pacemaker due to </text>
<text top="489" left="86" width="453" height="21" font="4">atrioventricular block. J Cardiovasc Electrophysiol. 2013;24:1255-8. </text>
<text top="509" left="86" width="33" height="21" font="4">151. </text>
<text top="509" left="140" width="886" height="21" font="4">Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. Pacing Clin Electrophysiol. </text>
<text top="529" left="86" width="114" height="21" font="4">2012;35:804-10. </text>
<text top="550" left="86" width="33" height="21" font="4">152. </text>
<text top="550" left="140" width="932" height="21" font="4">Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol. </text>
<text top="570" left="86" width="105" height="21" font="4">2004;44:105-8. </text>
<text top="590" left="86" width="33" height="21" font="4">153. </text>
<text top="590" left="140" width="726" height="21" font="4">Risgaard B, Elming H, Jensen GV, et al. Waiting for a pacemaker: is it dangerous? Europace. 2012;14:975-80. </text>
<text top="610" left="86" width="33" height="21" font="4">154. </text>
<text top="610" left="140" width="958" height="21" font="4">Farre N, Bazan V, Garcia-Garcia C, et al. Long-term outcome of transitory &#34;reversible&#34; complete atrio-ventricular block unrelated to myocardial </text>
<text top="630" left="86" width="267" height="21" font="4">ischemia. Int J Cardiol. 2014;172:503-5. </text>
<text top="650" left="86" width="33" height="21" font="4">155. </text>
<text top="650" left="140" width="910" height="21" font="4">Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034-41. </text>
<text top="670" left="86" width="33" height="21" font="4">156. </text>
<text top="670" left="140" width="943" height="21" font="4">Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged </text>
<text top="691" left="86" width="346" height="21" font="4">adults. Circ Arrhythm Electrophysiol. 2011;4:303-9. </text>
<text top="711" left="86" width="33" height="21" font="4">157. </text>
<text top="711" left="140" width="932" height="21" font="4">Ozcan KS, Osmonov D, Erdinler I, et al. Atrioventricular block in patients with thyroid dysfunction: prognosis after treatment with hormone </text>
<text top="731" left="86" width="476" height="21" font="4">supplementation or antithyroid medication. J Cardiol. 2012;60:327-32. </text>
<text top="751" left="86" width="33" height="21" font="4">158. </text>
<text top="751" left="140" width="928" height="21" font="4">Forrester JD, Mead P. Third-degree heart block associated with lyme carditis: review of published cases. Clin Infect Dis. 2014;59:996-1000. </text>
<text top="771" left="86" width="33" height="21" font="4">159. </text>
<text top="771" left="140" width="723" height="21" font="4">van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. Scand J Infect Dis Suppl. 1991;77:81-4. </text>
</page>
<page number="245" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 245 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">160. </text>
<text top="86" left="140" width="917" height="21" font="4">Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol. 1984;4:35-8. </text>
<text top="106" left="86" width="33" height="21" font="4">161. </text>
<text top="106" left="140" width="927" height="21" font="4">Sclarovsky S, Strasberg B, Hirshberg A, et al. Advanced early and late atrioventricular block in acute inferior wall myocardial infarction. Am </text>
<text top="127" left="86" width="168" height="21" font="4">Heart J. 1984;108:19-24. </text>
<text top="147" left="86" width="33" height="21" font="4">162. </text>
<text top="147" left="140" width="961" height="21" font="4">Chihrin SM, Mohamed U, Yee R, et al. Utility of isoproterenol in unmasking latent escape rhythm in pacemaker dependent patients undergoing </text>
<text top="167" left="86" width="375" height="21" font="4">pacemaker replacement. Am J Cardiol. 2008;101:631-3. </text>
<text top="187" left="86" width="33" height="21" font="4">163. </text>
<text top="187" left="140" width="949" height="21" font="4">Bertolet BD, McMurtrie EB, Hill JA, et al. Theophylline for the treatment of atrioventricular block after myocardial infarction. Ann Intern Med. </text>
<text top="207" left="86" width="122" height="21" font="4">1995;123:509-11. </text>
<text top="227" left="86" width="33" height="21" font="4">164. </text>
<text top="227" left="140" width="959" height="21" font="4">Altun A, Kirdar C, Ozbay G. Effect of aminophylline in patients with atropine-resistant late advanced atrioventricular block during acute inferior </text>
<text top="247" left="86" width="348" height="21" font="4">myocardial infarction. Clin Cardiol. 1998;21:759-62. </text>
<text top="268" left="86" width="33" height="21" font="4">165. </text>
<text top="268" left="140" width="962" height="21" font="4">Goodfellow J, Walker PR. Reversal of atropine-resistant atrioventricular block with intravenous aminophylline in the early phase of inferior wall </text>
<text top="288" left="86" width="644" height="21" font="4">acute myocardial infarction following treatment with streptokinase. Eur Heart J. 1995;16:862-5. </text>
<text top="308" left="86" width="33" height="21" font="4">166. </text>
<text top="308" left="140" width="898" height="21" font="4">Dhingra RC, Winslow E, Pouget JM, et al. The effect of isoproterenol on atrioventricular and intraventricular conduction. Am J Cardiol. </text>
<text top="328" left="86" width="114" height="21" font="4">1973;32:629-36. </text>
<text top="348" left="86" width="33" height="21" font="4">167. </text>
<text top="348" left="140" width="895" height="21" font="4">Hatle L, Rokseth R. Conservative treatment of AV block in acute myocardial infarction. Results in 105 consecutive patients. Br Heart J. </text>
<text top="368" left="86" width="122" height="21" font="4">1971;33:595-600. </text>
<text top="388" left="86" width="33" height="21" font="4">168. </text>
<text top="388" left="140" width="945" height="21" font="4">Cummins RO, Graves JR, Larsen MP, et al. Out-of-hospital transcutaneous pacing by emergency medical technicians in patients with asystolic </text>
<text top="409" left="86" width="324" height="21" font="4">cardiac arrest. N Engl J Med. 1993;328:1377-82. </text>
<text top="429" left="86" width="33" height="21" font="4">169. </text>
<text top="429" left="140" width="893" height="21" font="4">Hedges JR, Syverud SA, Dalsey WC, et al. Prehospital trial of emergency transcutaneous cardiac pacing. Circulation. 1987;76:1337-43. </text>
<text top="449" left="86" width="33" height="21" font="4">170. </text>
<text top="449" left="140" width="951" height="21" font="4">Birkhahn RH, Gaeta TJ, Tloczkowski J, et al. Emergency medicine-trained physicians are proficient in the insertion of transvenous pacemakers. </text>
<text top="469" left="86" width="230" height="21" font="4">Ann Emerg Med. 2004;43:469-74. </text>
<text top="489" left="86" width="33" height="21" font="4">171. </text>
<text top="489" left="140" width="961" height="21" font="4">Mahapatra S, Bybee KA, Bunch TJ, et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm. </text>
<text top="509" left="86" width="105" height="21" font="4">2005;2:907-11. </text>
<text top="529" left="86" width="33" height="21" font="4">172. </text>
<text top="529" left="140" width="888" height="21" font="4">Lang R, David D, Klein HO, et al. The use of the balloon-tipped floating catheter in temporary transvenous cardiac pacing. Pacing Clin </text>
<text top="550" left="86" width="199" height="21" font="4">Electrophysiol. 1981;4:491-6. </text>
<text top="570" left="86" width="33" height="21" font="4">173. </text>
<text top="570" left="140" width="891" height="21" font="4">Winner S, Boon N. Clinical problems with temporary pacemakers prior to permanent pacing. J R Coll Physicians Lond. 1989;23:161-3. </text>
<text top="590" left="86" width="33" height="21" font="4">174. </text>
<text top="590" left="140" width="876" height="21" font="4">Pinneri F, Frea S, Najd K, et al. Echocardiography-guided versus fluoroscopy-guided temporary pacing in the emergency setting: an </text>
<text top="610" left="86" width="464" height="21" font="4">observational study. J Cardiovasc Med (Hagerstown). 2013;14:242-6. </text>
<text top="630" left="86" width="33" height="21" font="4">175. </text>
<text top="630" left="140" width="949" height="21" font="4">Braun MU, Rauwolf T, Bock M, et al. Percutaneous lead implantation connected to an external device in stimulation-dependent patients with </text>
<text top="650" left="86" width="655" height="21" font="4">systemic infection--a prospective and controlled study. Pacing Clin Electrophysiol. 2006;29:875-9. </text>
<text top="670" left="86" width="33" height="21" font="4">176. </text>
<text top="670" left="140" width="932" height="21" font="4">de Cock CC, Van Campen CM, In't Veld JA, et al. Utility and safety of prolonged temporary transvenous pacing using an active-fixation lead: </text>
<text top="691" left="86" width="547" height="21" font="4">comparison with a conventional lead. Pacing Clin Electrophysiol. 2003;26:1245-8. </text>
<text top="711" left="86" width="33" height="21" font="4">177. </text>
<text top="711" left="141" width="940" height="21" font="4">Kawata H, Pretorius V, Phan H, et al. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent </text>
<text top="731" left="87" width="422" height="21" font="4">pacemakers after lead extraction. Europace. 2013;15:1287-91. </text>
<text top="751" left="87" width="33" height="21" font="4">178. </text>
<text top="751" left="141" width="948" height="21" font="4">Chihrin SM, Mohammed U, Yee R, et al. Utility and cost effectiveness of temporary pacing using active fixation leads and an externally placed </text>
<text top="771" left="87" width="427" height="21" font="4">reusable permanent pacemaker. Am J Cardiol. 2006;98:1613-5. </text>
</page>
<page number="246" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 246 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">179. </text>
<text top="86" left="140" width="965" height="21" font="4">Lever N, Ferguson JD, Bashir Y, et al. Prolonged temporary cardiac pacing using subcutaneous tunnelled active-fixation permanent pacing leads. </text>
<text top="106" left="86" width="159" height="21" font="4">Heart. 2003;89:209-10. </text>
<text top="127" left="86" width="33" height="21" font="4">180. </text>
<text top="127" left="140" width="930" height="21" font="4">Kornberger A, Schmid E, Kalender G, et al. Bridge to recovery or permanent system implantation: an eight-year single-center experience in </text>
<text top="147" left="86" width="557" height="21" font="4">transvenous semipermanent pacing. Pacing Clin Electrophysiol. 2013;36:1096-103. </text>
<text top="167" left="86" width="33" height="21" font="4">181. </text>
<text top="167" left="140" width="912" height="21" font="4">Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using transvenous active fixation leads and external re-sterilized pulse </text>
<text top="187" left="86" width="314" height="21" font="4">generators. J Am Coll Cardiol. 2006;47:1487-9. </text>
<text top="207" left="86" width="33" height="21" font="4">182. </text>
<text top="207" left="140" width="952" height="21" font="4">Santini M, Castro A, Giada F, et al. Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of </text>
<text top="227" left="86" width="545" height="21" font="4">unexplained origin: the PRESS study. Circ Arrhythm Electrophysiol. 2013;6:101-7. </text>
<text top="247" left="86" width="33" height="21" font="4">183. </text>
<text top="247" left="140" width="929" height="21" font="4">Guerrero-Marquez FJ, Arana-Rueda E, Pedrote A. Idiopathic Paroxysmal Atrio-Ventricular Block. What is The Mechanism? J Atr Fibrillation. </text>
<text top="268" left="86" width="92" height="21" font="4">2016;9:1449. </text>
<text top="288" left="86" width="33" height="21" font="4">184. </text>
<text top="288" left="140" width="943" height="21" font="4">Brignole M, Deharo JC, De Roy L, et al. Syncope due to idiopathic paroxysmal atrioventricular block: long-term follow-up of a distinct form of </text>
<text top="308" left="86" width="385" height="21" font="4">atrioventricular block. J Am Coll Cardiol. 2011;58:167-73. </text>
<text top="328" left="86" width="33" height="21" font="4">185. </text>
<text top="328" left="140" width="922" height="21" font="4">Brignole M, Menozzi C, Moya A, et al. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. </text>
<text top="348" left="86" width="211" height="21" font="4">Circulation. 2001;104:2045-50. </text>
<text top="368" left="86" width="33" height="21" font="4">186. </text>
<text top="368" left="140" width="957" height="21" font="4">Carano N, Bo I, Tchana B, et al. Adams-Stokes attack as the first symptom of acute rheumatic fever: report of an adolescent case and review of </text>
<text top="388" left="86" width="271" height="21" font="4">the literature. Ital J Pediatr. 2012;38:61. </text>
<text top="409" left="86" width="33" height="21" font="4">187. </text>
<text top="409" left="140" width="917" height="21" font="4">Ando G, Versaci F. Ventriculo-atrial gradient due to first degree atrio-ventricular block: a case report. BMC Cardiovasc Disord. 2005;5:23. </text>
<text top="429" left="86" width="33" height="21" font="4">188. </text>
<text top="429" left="140" width="932" height="21" font="4">Maeno K, Kasai A, Setsuda M, et al. Advanced atrioventricular block induced by obstructive sleep apnea before oxygen desaturation. Heart </text>
<text top="449" left="86" width="171" height="21" font="4">Vessels. 2009;24:236-40. </text>
<text top="469" left="86" width="33" height="21" font="4">189. </text>
<text top="469" left="140" width="950" height="21" font="4">Moya A, Garcia-Civera R, Croci F, et al. Diagnosis, management, and outcomes of patients with syncope and bundle branch block. Eur Heart J. </text>
<text top="489" left="86" width="122" height="21" font="4">2011;32:1535-41. </text>
<text top="509" left="86" width="33" height="21" font="4">190. </text>
<text top="509" left="140" width="944" height="21" font="4">Panic G, Stanulovic V, Popov T. Atrio-ventricular block as the first presentation of disseminated Lyme disease. Int J Cardiol. 2011;150:e104-6. </text>
<text top="529" left="86" width="33" height="21" font="4">191. </text>
<text top="529" left="141" width="960" height="21" font="4">Carroz P, Delay D, Girod G. Pseudo-pacemaker syndrome in a young woman with first-degree atrio-ventricular block. Europace. 2010;12:594-6. </text>
<text top="550" left="86" width="33" height="21" font="4">192. </text>
<text top="550" left="141" width="963" height="21" font="4">Marti-Almor J, Cladellas M, Bazan V, et al. Long-term mortality predictors in patients with chronic bifascicular block. Europace. 2009;11:1201-7. </text>
<text top="570" left="86" width="33" height="21" font="4">193. </text>
<text top="570" left="141" width="911" height="21" font="4">Barold SS. Indications for permanent cardiac pacing in first-degree AV block: class I, II, or III? Pacing Clin Electrophysiol. 1996;19:747-51. </text>
<text top="590" left="86" width="33" height="21" font="4">194. </text>
<text top="590" left="141" width="954" height="21" font="4">Barold SS, Ilercil A, Leonelli F, et al. First-degree atrioventricular block. Clinical manifestations, indications for pacing, pacemaker management </text>
<text top="610" left="86" width="644" height="21" font="4">&amp; consequences during cardiac resynchronization. J Interv Card Electrophysiol. 2006;17:139-52. </text>
<text top="630" left="86" width="33" height="21" font="4">195. </text>
<text top="630" left="141" width="949" height="21" font="4">Barra SN, Providencia R, Paiva L, et al. A review on advanced atrioventricular block in young or middle-aged adults. Pacing Clin Electrophysiol. </text>
<text top="650" left="86" width="130" height="21" font="4">2012;35:1395-405. </text>
<text top="670" left="86" width="33" height="21" font="4">196. </text>
<text top="670" left="141" width="964" height="21" font="4">Dhingra RC, Denes P, Wu D, et al. The significance of second degree atrioventricular block and bundle branch block. Observations regarding site </text>
<text top="691" left="87" width="318" height="21" font="4">and type of block. Circulation. 1974;49:638-46. </text>
<text top="711" left="87" width="33" height="21" font="4">197. </text>
<text top="711" left="141" width="627" height="21" font="4">Shaw DB, Eraut D. Prevalence and morbidity of heart block in Devon. Br Med J. 1970;1:144-7. </text>
<text top="731" left="87" width="33" height="21" font="4">198. </text>
<text top="731" left="141" width="830" height="21" font="4">Simon AB, Zloto AE. Atrioventricular block: natural history after permanent ventricular pacing. Am J Cardiol. 1978;41:500-7. </text>
<text top="751" left="87" width="33" height="21" font="4">199. </text>
<text top="751" left="141" width="938" height="21" font="4">Strasberg B, Amat YLF, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular nodal block. Circulation. 1981;63:1043-9. </text>
</page>
<page number="247" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 247 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">200. </text>
<text top="86" left="140" width="952" height="21" font="4">Edhag O, Swahn A. Prognosis of patients with complete heart block or arrhythmic syncope who were not treated with artificial pacemakers. A </text>
<text top="106" left="86" width="526" height="21" font="4">long-term follow-up study of 101 patients. Acta Med Scand. 1976;200:457-63. </text>
<text top="127" left="86" width="33" height="21" font="4">201. </text>
<text top="127" left="140" width="760" height="21" font="4">Shaw DB, Kekwick CA, Veale D, et al. Survival in second degree atrioventricular block. Br Heart J. 1985;53:587-93. </text>
<text top="147" left="86" width="33" height="21" font="4">202. </text>
<text top="147" left="140" width="933" height="21" font="4">Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and </text>
<text top="167" left="86" width="369" height="21" font="4">conduction system disease. Jama. 2012;307:1292-301. </text>
<text top="187" left="86" width="33" height="21" font="4">203. </text>
<text top="187" left="140" width="840" height="21" font="4">Buckley AE, Dean J, Mahy IR. Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series. Heart. 1999;82:105-8. </text>
<text top="207" left="86" width="33" height="21" font="4">204. </text>
<text top="207" left="140" width="946" height="21" font="4">Kitaguchi T, Matsubara S, Sato M, et al. A missense mutation in the exon 8 of lamin A/C gene in a Japanese case of autosomal dominant limb-</text>
<text top="227" left="86" width="631" height="21" font="4">girdle muscular dystrophy and cardiac conduction block. Neuromuscul Disord. 2001;11:542-6. </text>
<text top="247" left="86" width="33" height="21" font="4">205. </text>
<text top="247" left="140" width="945" height="21" font="4">Finsterer J, Stollberger C. Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves. Korean Circ J. 2016;46:117-34. </text>
<text top="268" left="86" width="33" height="21" font="4">206. </text>
<text top="268" left="140" width="944" height="21" font="4">Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with myotonic </text>
<text top="288" left="86" width="456" height="21" font="4">dystrophy types I and II. Pacing Clin Electrophysiol. 2012;35:1262-9. </text>
<text top="308" left="86" width="33" height="21" font="4">207. </text>
<text top="308" left="140" width="938" height="21" font="4">Lazarus A, Varin J, Babuty D, et al. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter </text>
<text top="328" left="86" width="436" height="21" font="4">diagnostic pacemaker study. J Am Coll Cardiol. 2002;40:1645-52. </text>
<text top="348" left="86" width="33" height="21" font="4">208. </text>
<text top="348" left="140" width="948" height="21" font="4">Facenda-Lorenzo M, Hernandez-Afonso J, Rodriguez-Esteban M, et al. Cardiac manifestations in myotonic dystrophy type 1 patients followed </text>
<text top="368" left="86" width="592" height="21" font="4">using a standard protocol in a specialized unit. Rev Esp Cardiol (Engl Ed). 2013;66:193-7. </text>
<text top="388" left="86" width="33" height="21" font="4">209. </text>
<text top="388" left="140" width="919" height="21" font="4">Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population. J </text>
<text top="409" left="86" width="301" height="21" font="4">Cardiovasc Electrophysiol. 2011;22:1369-75. </text>
<text top="429" left="86" width="33" height="21" font="4">210. </text>
<text top="429" left="141" width="884" height="21" font="4">Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. </text>
<text top="449" left="86" width="130" height="21" font="4">2008;358:2688-97. </text>
<text top="469" left="86" width="33" height="21" font="4">211. </text>
<text top="469" left="141" width="552" height="21" font="4">Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890-5. </text>
<text top="489" left="86" width="33" height="21" font="4">212. </text>
<text top="489" left="141" width="946" height="21" font="4">Kabunga P, Lau AK, Phan K, et al. Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy. Int J </text>
<text top="509" left="87" width="177" height="21" font="4">Cardiol. 2015;181:303-10. </text>
<text top="529" left="87" width="33" height="21" font="4">213. </text>
<text top="529" left="141" width="938" height="21" font="4">Saxon LA, Albert BH, Uretz EF, et al. Permanent pacemaker placement in chronic atrial fibrillation associated with intermittent AV block and </text>
<text top="550" left="87" width="421" height="21" font="4">cerebral symptoms. Pacing Clin Electrophysiol. 1990;13:724-9. </text>
<text top="570" left="87" width="33" height="21" font="4">214. </text>
<text top="570" left="141" width="952" height="21" font="4">Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour Holter recordings. Am J </text>
<text top="590" left="87" width="169" height="21" font="4">Cardiol. 1985;55:1005-8. </text>
<text top="610" left="87" width="33" height="21" font="4">215. </text>
<text top="610" left="141" width="883" height="21" font="4">Ector H, Rolies L, De Geest H. Dynamic electrocardiography and ventricular pauses of 3 seconds and more: etiology and therapeutic </text>
<text top="630" left="87" width="373" height="21" font="4">implications. Pacing Clin Electrophysiol. 1983;6:548-51. </text>
<text top="650" left="87" width="33" height="21" font="4">216. </text>
<text top="650" left="141" width="915" height="21" font="4">Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation. </text>
<text top="670" left="87" width="105" height="21" font="4">1995;92:442-9. </text>
<text top="691" left="87" width="33" height="21" font="4">217. </text>
<text top="691" left="141" width="877" height="21" font="4">Sholler GF, Walsh EP. Congenital complete heart block in patients without anatomic cardiac defects. Am Heart J. 1989;118:1193-8. </text>
<text top="711" left="87" width="33" height="21" font="4">218. </text>
<text top="711" left="141" width="921" height="21" font="4">Kim YH, O'Nunain S, Trouton T, et al. Pseudo-pacemaker syndrome following inadvertent fast pathway ablation for atrioventricular nodal </text>
<text top="731" left="87" width="446" height="21" font="4">reentrant tachycardia. J Cardiovasc Electrophysiol. 1993;4:178-82. </text>
<text top="751" left="87" width="33" height="21" font="4">219. </text>
<text top="751" left="141" width="831" height="21" font="4">Alboni P, Holz A, Brignole M. Vagally mediated atrioventricular block: pathophysiology and diagnosis. Heart. 2013;99:904-8. </text>
</page>
<page number="248" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 248 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">220. </text>
<text top="86" left="140" width="929" height="21" font="4">Massie B, Scheinman MM, Peters R, et al. Clinical and electrophysiologic findings in patients with paroxysmal slowing of the sinus rate and </text>
<text top="106" left="86" width="507" height="21" font="4">apparent Mobitz type II atrioventricular block. Circulation. 1978;58:305-14. </text>
<text top="127" left="86" width="33" height="21" font="4">221. </text>
<text top="127" left="140" width="908" height="21" font="4">Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation. 2000;102:2898-906. </text>
<text top="147" left="86" width="33" height="21" font="4">222. </text>
<text top="147" left="140" width="944" height="21" font="4">Kato Y, Morimoto S, Uemura A, et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse </text>
<text top="167" left="86" width="169" height="21" font="4">Lung Dis. 2003;20:133-7. </text>
<text top="187" left="86" width="33" height="21" font="4">223. </text>
<text top="187" left="140" width="933" height="21" font="4">Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac </text>
<text top="207" left="86" width="286" height="21" font="4">sarcoidosis. Am J Cardiol. 2015;115:505-9. </text>
<text top="227" left="86" width="33" height="21" font="4">224. </text>
<text top="227" left="140" width="964" height="21" font="4">Padala SK, Peaslee S, Sidhu MS, et al. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac </text>
<text top="247" left="86" width="290" height="21" font="4">sarcoidosis. Int J Cardiol. 2017;227:565-70. </text>
<text top="268" left="86" width="33" height="21" font="4">225. </text>
<text top="268" left="140" width="587" height="21" font="4">Birnie DH, Nery PB, Ha AC, et al. Cardiac Sarcoidosis. J Am Coll Cardiol. 2016;68:411-21. </text>
<text top="288" left="86" width="33" height="21" font="4">226. </text>
<text top="288" left="140" width="868" height="21" font="4">Zhou Y, Lower EE, Li HP, et al. Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival. Chest. 2017;151:139-48. </text>
<text top="308" left="86" width="33" height="21" font="4">227. </text>
<text top="308" left="140" width="868" height="21" font="4">Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. </text>
<text top="328" left="86" width="130" height="21" font="4">2015;36:1098-105. </text>
<text top="348" left="86" width="33" height="21" font="4">228. </text>
<text top="348" left="140" width="925" height="21" font="4">Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll </text>
<text top="368" left="86" width="177" height="21" font="4">Cardiol. 1997;30:1046-51. </text>
<text top="388" left="86" width="33" height="21" font="4">229. </text>
<text top="388" left="140" width="873" height="21" font="4">Benditt DG, Benson DW, Jr., Kreitt J, et al. Electrophysiologic effects of theophylline in young patients with recurrent symptomatic </text>
<text top="409" left="86" width="332" height="21" font="4">bradyarrhythmias. Am J Cardiol. 1983;52:1223-9. </text>
<text top="429" left="86" width="33" height="21" font="4">230. </text>
<text top="429" left="140" width="833" height="21" font="4">Nimura A, Sato N, Sakuragi H, et al. Recovery of advanced atrioventricular block by cilostazol. Intern Med. 2011;50:1957-61. </text>
<text top="449" left="86" width="33" height="21" font="4">231. </text>
<text top="449" left="140" width="941" height="21" font="4">Watson RD, Glover DR, Page AJ, et al. The Birmingham Trial of permanent pacing in patients with intraventricular conduction disorders after </text>
<text top="469" left="86" width="403" height="21" font="4">acute myocardial infarction. Am Heart J. 1984;108:496-501. </text>
<text top="489" left="86" width="33" height="21" font="4">232. </text>
<text top="489" left="140" width="893" height="21" font="4">Tans AC, Lie KI, Durrer D. Clinical setting and prognostic significance of high degree atrioventricular block in acute inferior myocardial </text>
<text top="509" left="86" width="404" height="21" font="4">infarction: a study of 144 patients. Am Heart J. 1980;99:4-8. </text>
<text top="529" left="86" width="33" height="21" font="4">233. </text>
<text top="529" left="140" width="929" height="21" font="4">Ginks WR, Sutton R, Oh W, et al. Long-term prognosis after acute anterior infarction with atrioventricular block. Br Heart J. 1977;39:186-9. </text>
<text top="550" left="86" width="33" height="21" font="4">234. </text>
<text top="550" left="140" width="960" height="21" font="4">Singh SM, FitzGerald G, Yan AT, et al. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute </text>
<text top="570" left="86" width="312" height="21" font="4">Coronary Events. Eur Heart J. 2015;36:976-83. </text>
<text top="590" left="86" width="33" height="21" font="4">235. </text>
<text top="590" left="140" width="685" height="21" font="4">Kostic T, Momcilovic S, Perisic ZD, et al. Manifestations of Lyme carditis. Int J Cardiol. 2017;232:24-32. </text>
<text top="610" left="86" width="33" height="21" font="4">236. </text>
<text top="610" left="140" width="667" height="21" font="4">Robinson ML, Kobayashi T, Higgins Y, et al. Lyme carditis. Infect Dis Clin North Am. 2015;29:255-68. </text>
<text top="630" left="86" width="33" height="21" font="4">237. </text>
<text top="630" left="140" width="961" height="21" font="4">Unterberg C, Luthje L, Szych J, et al. Atrial overdrive pacing compared to CPAP in patients with obstructive sleep apnoea syndrome. Eur Heart J. </text>
<text top="650" left="86" width="122" height="21" font="4">2005;26:2568-75. </text>
<text top="670" left="86" width="33" height="21" font="4">238. </text>
<text top="670" left="140" width="775" height="21" font="4">Garrigue S, Bordier P, Jais P, et al. Benefit of atrial pacing in sleep apnea syndrome. N Engl J Med. 2002;346:404-12. </text>
<text top="691" left="86" width="33" height="21" font="4">239. </text>
<text top="691" left="140" width="946" height="21" font="4">Kinlay S, Leitch JW, Neil A, et al. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in </text>
<text top="711" left="86" width="577" height="21" font="4">patients with palpitations. A controlled clinical trial. Ann Intern Med. 1996;124:16-20. </text>
<text top="731" left="86" width="33" height="21" font="4">240. </text>
<text top="731" left="140" width="899" height="21" font="4">Giada F, Gulizia M, Francese M, et al. Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus </text>
<text top="751" left="86" width="458" height="21" font="4">conventional diagnostic strategy. J Am Coll Cardiol. 2007;49:1951-6. </text>
<text top="771" left="86" width="33" height="21" font="4">241. </text>
<text top="771" left="140" width="918" height="21" font="4">Katritsis DG, Josephson ME. Electrophysiological Testing for the Investigation of Bradycardias. Arrhythm Electrophysiol Rev. 2017;6:24-8. </text>
</page>
<page number="249" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 249 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">242. </text>
<text top="86" left="140" width="961" height="21" font="4">Mangiardi LM, Bonamini R, Conte M, et al. Bedside evaluation of atrioventricular block with narrow QRS complexes: usefulness of carotid sinus </text>
<text top="106" left="86" width="471" height="21" font="4">massage and atropine administration. Am J Cardiol. 1982;49:1136-45. </text>
<text top="127" left="86" width="33" height="21" font="4">243. </text>
<text top="127" left="140" width="944" height="21" font="4">Twidale N, Heddle WF, Tonkin AM. Procainamide administration during electrophysiology study--utility as a provocative test for intermittent </text>
<text top="147" left="86" width="452" height="21" font="4">atrioventricular block. Pacing Clin Electrophysiol. 1988;11:1388-97. </text>
<text top="167" left="86" width="33" height="21" font="4">244. </text>
<text top="167" left="140" width="941" height="21" font="4">Bogossian H, Frommeyer G, Gobbert K, et al. Is there a prognostic relevance of electrophysiological studies in bundle branch block patients? </text>
<text top="187" left="86" width="189" height="21" font="4">Clin Cardiol. 2017;40:575-9. </text>
<text top="207" left="86" width="33" height="21" font="4">245. </text>
<text top="207" left="140" width="918" height="21" font="4">Kalscheur MM, Donateo P, Wenzke KE, et al. Long-Term Outcome of Patients with Bifascicular Block and Unexplained Syncope Following </text>
<text top="227" left="86" width="406" height="21" font="4">Cardiac Pacing. Pacing Clin Electrophysiol. 2016;39:1126-31. </text>
<text top="247" left="86" width="33" height="21" font="4">246. </text>
<text top="247" left="140" width="942" height="21" font="4">Morady F, Higgins J, Peters RW, et al. Electrophysiologic testing in bundle branch block and unexplained syncope. Am J Cardiol. 1984;54:587-</text>
<text top="268" left="86" width="25" height="21" font="4">91. </text>
<text top="288" left="86" width="33" height="21" font="4">247. </text>
<text top="288" left="140" width="957" height="21" font="4">Click RL, Gersh BJ, Sugrue DD, et al. Role of invasive electrophysiologic testing in patients with symptomatic bundle branch block. Am J Cardiol. </text>
<text top="308" left="86" width="114" height="21" font="4">1987;59:817-23. </text>
<text top="328" left="86" width="33" height="21" font="4">248. </text>
<text top="328" left="140" width="959" height="21" font="4">Brignole M, Menozzi C, Bottoni N, et al. Mechanisms of syncope caused by transient bradycardia and the diagnostic value of electrophysiologic </text>
<text top="348" left="86" width="528" height="21" font="4">testing and cardiovascular reflexivity maneuvers. Am J Cardiol. 1995;76:273-8. </text>
<text top="368" left="86" width="33" height="21" font="4">249. </text>
<text top="368" left="140" width="934" height="21" font="4">Dhingra RC, Wyndham C, Bauernfeind R, et al. Significance of block distal to the His bundle induced by atrial pacing in patients with chronic </text>
<text top="388" left="86" width="325" height="21" font="4">bifascicular block. Circulation. 1979;60:1455-64. </text>
<text top="409" left="86" width="33" height="21" font="4">250. </text>
<text top="409" left="140" width="515" height="21" font="4">Zipes DP. Second-degree atrioventricular block. Circulation. 1979;60:465-72. </text>
<text top="429" left="86" width="33" height="21" font="4">251. </text>
<text top="429" left="140" width="893" height="21" font="4">Shetty RK, Agarwal S, Ganiga Sanjeeva NC, et al. Trifascicular block progressing to complete AV block on exercise: a rare presentation </text>
<text top="449" left="86" width="513" height="21" font="4">demonstrating the usefulness of exercise testing. BMJ Case Rep. 2015;2015: </text>
<text top="469" left="86" width="33" height="21" font="4">252. </text>
<text top="469" left="140" width="952" height="21" font="4">Toeda T, Suetake S, Tsuchida K, et al. Exercise induced atrioventricular block with gap phenomenon in atrioventricular conduction. Pacing Clin </text>
<text top="489" left="86" width="208" height="21" font="4">Electrophysiol. 2000;23:527-9. </text>
<text top="509" left="86" width="33" height="21" font="4">253. </text>
<text top="509" left="140" width="777" height="21" font="4">Chokshi SK, Sarmiento J, Nazari J, et al. Exercise-provoked distal atrioventricular block. Am J Cardiol. 1990;66:114-6. </text>
<text top="529" left="86" width="33" height="21" font="4">254. </text>
<text top="529" left="140" width="881" height="21" font="4">Bakst A, Goldberg B, Schamroth L. Significance of exercise-induced second degree atrioventricular block. Br Heart J. 1975;37:984-6. </text>
<text top="550" left="86" width="33" height="21" font="4">255. </text>
<text top="550" left="140" width="878" height="21" font="4">Egred M, Jafary F, Rodrigues E. Exercise induced atrio-ventricular (AV) block: important but uncommon phenomenon. Int J Cardiol. </text>
<text top="570" left="86" width="114" height="21" font="4">2004;97:559-60. </text>
<text top="590" left="86" width="33" height="21" font="4">256. </text>
<text top="590" left="140" width="881" height="21" font="4">Fisher JD. Role of electrophysiologic testing in the diagnosis and treatment of patients with known and suspected bradycardias and </text>
<text top="610" left="86" width="336" height="21" font="4">tachycardias. Prog Cardiovasc Dis. 1981;24:25-90. </text>
<text top="630" left="86" width="33" height="21" font="4">257. </text>
<text top="630" left="140" width="950" height="21" font="4">Toff WD, Camm AJ, Skehan JD. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med. 2005;353:145-</text>
<text top="650" left="86" width="25" height="21" font="4">55. </text>
<text top="670" left="86" width="33" height="21" font="4">258. </text>
<text top="670" left="140" width="911" height="21" font="4">Kerr CR, Connolly SJ, Abdollah H, et al. Canadian Trial of Physiological Pacing: Effects of physiological pacing during long-term follow-up. </text>
<text top="691" left="86" width="202" height="21" font="4">Circulation. 2004;109:357-62. </text>
<text top="711" left="86" width="33" height="21" font="4">259. </text>
<text top="711" left="140" width="947" height="21" font="4">Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585-</text>
<text top="731" left="86" width="25" height="21" font="4">93. </text>
<text top="751" left="86" width="33" height="21" font="4">260. </text>
<text top="751" left="140" width="942" height="21" font="4">Gierula J, Cubbon RM, Jamil HA, et al. Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction. </text>
<text top="771" left="86" width="193" height="21" font="4">Europace. 2013;15:1609-14. </text>
</page>
<page number="250" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 250 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">261. </text>
<text top="86" left="140" width="909" height="21" font="4">Kindermann M, Hennen B, Jung J, et al. Biventricular versus conventional right ventricular stimulation for patients with standard pacing </text>
<text top="106" left="86" width="921" height="21" font="4">indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol. 2006;47:1927-37. </text>
<text top="127" left="86" width="33" height="21" font="4">262. </text>
<text top="127" left="140" width="951" height="21" font="4">Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual </text>
<text top="147" left="86" width="556" height="21" font="4">Chamber and VVI Implantable Defibrillator (DAVID) Trial. Jama. 2002;288:3115-23. </text>
<text top="167" left="86" width="33" height="21" font="4">263. </text>
<text top="167" left="140" width="892" height="21" font="4">Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J </text>
<text top="187" left="86" width="292" height="21" font="4">Cardiovasc Electrophysiol. 2005;16:1160-5. </text>
<text top="207" left="86" width="33" height="21" font="4">264. </text>
<text top="207" left="140" width="949" height="21" font="4">Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent </text>
<text top="227" left="86" width="440" height="21" font="4">atrial fibrillation: a randomized trial. Eur Heart J. 2011;32:2420-9. </text>
<text top="247" left="86" width="33" height="21" font="4">265. </text>
<text top="247" left="140" width="938" height="21" font="4">Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial </text>
<text top="268" left="86" width="272" height="21" font="4">fibrillation. Eur Heart J. 2005;26:712-22. </text>
<text top="288" left="86" width="33" height="21" font="4">266. </text>
<text top="288" left="140" width="929" height="21" font="4">Brignole M, Botto GL, Mont L, et al. Predictors of clinical efficacy of 'Ablate and Pace' therapy in patients with permanent atrial fibrillation. </text>
<text top="308" left="86" width="168" height="21" font="4">Heart. 2012;98:297-302. </text>
<text top="328" left="86" width="33" height="21" font="4">267. </text>
<text top="328" left="140" width="926" height="21" font="4">Dretzke J, Toff WD, Lip GY, et al. Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular </text>
<text top="348" left="86" width="354" height="21" font="4">block. Cochrane Database Syst Rev. 2004;Cd003710. </text>
<text top="368" left="86" width="33" height="21" font="4">268. </text>
<text top="368" left="140" width="958" height="21" font="4">Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients </text>
<text top="388" left="86" width="445" height="21" font="4">upgraded to biventricular devices. Am J Cardiol. 2009;103:1280-4. </text>
<text top="409" left="86" width="33" height="21" font="4">269. </text>
<text top="409" left="140" width="914" height="21" font="4">Kiehl EL, Makki T, Kumar R, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete </text>
<text top="429" left="86" width="682" height="21" font="4">atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016;13:2272-8. </text>
<text top="449" left="86" width="33" height="21" font="4">270. </text>
<text top="449" left="140" width="910" height="21" font="4">Ellenbogen KA, Hellkamp AS, Wilkoff BL, et al. Complications arising after implantation of DDD pacemakers: the MOST experience. Am J </text>
<text top="469" left="86" width="161" height="21" font="4">Cardiol. 2003;92:740-1. </text>
<text top="489" left="86" width="33" height="21" font="4">271. </text>
<text top="489" left="140" width="895" height="21" font="4">Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the </text>
<text top="509" left="86" width="349" height="21" font="4">FOLLOWPACE study. Heart Rhythm. 2012;9:728-35. </text>
<text top="529" left="86" width="33" height="21" font="4">272. </text>
<text top="529" left="140" width="886" height="21" font="4">Ellenbogen KA, Stambler BS, Orav EJ, et al. Clinical characteristics of patients intolerant to VVIR pacing. Am J Cardiol. 2000;86:59-63. </text>
<text top="550" left="86" width="33" height="21" font="4">273. </text>
<text top="550" left="140" width="908" height="21" font="4">Link MS, Hellkamp AS, Estes NA, 3rd, et al. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with </text>
<text top="570" left="86" width="653" height="21" font="4">ventricular-based pacing in the Mode Selection Trial (MOST). J Am Coll Cardiol. 2004;43:2066-71. </text>
<text top="590" left="86" width="33" height="21" font="4">274. </text>
<text top="590" left="140" width="932" height="21" font="4">Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related </text>
<text top="610" left="86" width="291" height="21" font="4">disease. J Am Coll Cardiol. 2002;39:981-90. </text>
<text top="630" left="86" width="33" height="21" font="4">275. </text>
<text top="630" left="140" width="912" height="21" font="4">Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction </text>
<text top="650" left="86" width="286" height="21" font="4">disorders. Heart Rhythm. 2013;10:1492-8. </text>
<text top="670" left="86" width="33" height="21" font="4">276. </text>
<text top="670" left="140" width="943" height="21" font="4">Hasselberg NE, Edvardsen T, Petri H, et al. Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive </text>
<text top="691" left="86" width="247" height="21" font="4">subjects. Europace. 2014;16:563-71. </text>
<text top="711" left="86" width="33" height="21" font="4">277. </text>
<text top="711" left="140" width="953" height="21" font="4">Mahmod M, Karamitsos TD, Suttie JJ, et al. Prevalence of cardiomyopathy in asymptomatic patients with left bundle branch block referred for </text>
<text top="731" left="86" width="591" height="21" font="4">cardiovascular magnetic resonance imaging. Int J Cardiovasc Imaging. 2012;28:1133-40. </text>
<text top="751" left="86" width="33" height="21" font="4">278. </text>
<text top="751" left="140" width="941" height="21" font="4">McAnulty JH, Rahimtoola SH, Murphy E, et al. Natural history of &#34;high-risk&#34; bundle-branch block: final report of a prospective study. N Engl J </text>
<text top="771" left="86" width="161" height="21" font="4">Med. 1982;307:137-43. </text>
</page>
<page number="251" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 251 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">279. </text>
<text top="86" left="140" width="953" height="21" font="4">Kwok CS, Rashid M, Beynon R, et al. Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: a systematic review </text>
<text top="106" left="86" width="297" height="21" font="4">and meta-analysis. Heart. 2016;102:672-80. </text>
<text top="127" left="86" width="33" height="21" font="4">280. </text>
<text top="127" left="140" width="914" height="21" font="4">Boriani G, Gallina M, Merlini L, et al. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-</text>
<text top="147" left="86" width="566" height="21" font="4">Dreifuss muscular dystrophy: a long-term longitudinal study. Stroke. 2003;34:901-8. </text>
<text top="167" left="86" width="33" height="21" font="4">281. </text>
<text top="167" left="140" width="952" height="21" font="4">Mymin D, Mathewson FA, Tate RB, et al. The natural history of primary first-degree atrioventricular heart block. N Engl J Med. 1986;315:1183-</text>
<text top="187" left="86" width="16" height="21" font="4">7. </text>
<text top="207" left="86" width="33" height="21" font="4">282. </text>
<text top="207" left="140" width="958" height="21" font="4">Huhta JC, Maloney JD, Ritter DG, et al. Complete atrioventricular block in patients with atrioventricular discordance. Circulation. 1983;67:1374-</text>
<text top="227" left="86" width="16" height="21" font="4">7. </text>
<text top="247" left="86" width="33" height="21" font="4">283. </text>
<text top="247" left="140" width="886" height="21" font="4">Connelly MS, Liu PP, Williams WG, et al. Congenitally corrected transposition of the great arteries in the adult: functional status and </text>
<text top="268" left="86" width="343" height="21" font="4">complications. J Am Coll Cardiol. 1996;27:1238-43. </text>
<text top="288" left="86" width="33" height="21" font="4">284. </text>
<text top="288" left="140" width="918" height="21" font="4">Weindling SN, Saul JP, Gamble WJ, et al. Duration of complete atrioventricular block after congenital heart disease surgery. Am J Cardiol. </text>
<text top="308" left="86" width="105" height="21" font="4">1998;82:525-7. </text>
<text top="328" left="86" width="33" height="21" font="4">285. </text>
<text top="328" left="140" width="906" height="21" font="4">Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. </text>
<text top="348" left="86" width="122" height="21" font="4">2006;354:209-10. </text>
<text top="368" left="86" width="33" height="21" font="4">286. </text>
<text top="368" left="140" width="922" height="21" font="4">van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European </text>
<text top="388" left="86" width="334" height="21" font="4">cohort study. J Am Coll Cardiol. 2012;59:493-500. </text>
<text top="409" left="86" width="33" height="21" font="4">287. </text>
<text top="409" left="140" width="942" height="21" font="4">Maury P, Rollin A, Sacher F, et al. Prevalence and prognostic role of various conduction disturbances in patients with the Brugada syndrome. </text>
<text top="429" left="86" width="213" height="21" font="4">Am J Cardiol. 2013;112:1384-9. </text>
<text top="449" left="86" width="33" height="21" font="4">288. </text>
<text top="449" left="140" width="963" height="21" font="4">O'Mahony C, Coats C, Cardona M, et al. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace. </text>
<text top="469" left="86" width="114" height="21" font="4">2011;13:1781-8. </text>
<text top="489" left="86" width="33" height="21" font="4">289. </text>
<text top="489" left="140" width="878" height="21" font="4">Polak PE, Zijlstra F, Roelandt JR. Indications for pacemaker implantation in the Kearns-Sayre syndrome. Eur Heart J. 1989;10:281-2. </text>
<text top="509" left="86" width="33" height="21" font="4">290. </text>
<text top="509" left="140" width="931" height="21" font="4">Khambatta S, Nguyen DL, Beckman TJ, et al. Kearns-Sayre syndrome: a case series of 35 adults and children. Int J Gen Med. 2014;7:325-32. </text>
<text top="529" left="86" width="33" height="21" font="4">291. </text>
<text top="529" left="140" width="964" height="21" font="4">Ali H, Furlanello F, Lupo P, et al. Clinical and Electrocardiographic Features of Complete Heart Block Following Blunt Cardiac Injury: A Systematic </text>
<text top="550" left="86" width="313" height="21" font="4">Review of the Literature. Heart Rhythm. 2017; </text>
<text top="570" left="86" width="33" height="21" font="4">292. </text>
<text top="570" left="140" width="862" height="21" font="4">Chierichini A, Frassanito L, Vergari A, et al. The effect of norepinephrine versus epinephrine in irrigation fluid on the incidence of </text>
<text top="590" left="86" width="982" height="21" font="4">hypotensive/bradycardic events during arthroscopic rotator cuff repair with interscalene block in the sitting position. Arthroscopy. 2015;31:800-6. </text>
<text top="610" left="86" width="33" height="21" font="4">293. </text>
<text top="610" left="140" width="911" height="21" font="4">Marrocco-Trischitta MM, Mazzone P, Vitale R, et al. Temporary Transvenous Pacemaker Implantation during Carotid Endarterectomy in </text>
<text top="630" left="86" width="437" height="21" font="4">Patients with Trifascicular Block. Ann Vasc Surg. 2016;34:206-11. </text>
<text top="650" left="86" width="33" height="21" font="4">294. </text>
<text top="650" left="140" width="854" height="21" font="4">Cheung CC, Martyn A, Campbell N, et al. Predictors of intraoperative hypotension and bradycardia. Am J Med. 2015;128:532-8. </text>
<text top="670" left="86" width="33" height="21" font="4">295. </text>
<text top="670" left="140" width="962" height="21" font="4">Bauer AM, Smith RB, Thorell WE. Implications of carotid sinus hypersensitivity following preoperative embolization of a carotid body tumor. An </text>
<text top="691" left="86" width="744" height="21" font="4">indication for prophylactic intraoperative cardiac pacing. JAMA Otolaryngol Head Neck Surg. 2014;140:459-63. </text>
<text top="711" left="87" width="33" height="21" font="4">296. </text>
<text top="711" left="141" width="916" height="21" font="4">Fritsch G, Flamm M, Hepner DL, et al. Abnormal pre-operative tests, pathologic findings of medical history, and their predictive value for </text>
<text top="731" left="87" width="480" height="21" font="4">perioperative complications. Acta Anaesthesiol Scand. 2012;56:339-50. </text>
<text top="751" left="87" width="33" height="21" font="4">297. </text>
<text top="751" left="141" width="919" height="21" font="4">Pereira ID, Grando MM, Vianna PT, et al. Retrospective analysis of risk factors and predictors of intraoperative complications in neuraxial </text>
<text top="771" left="87" width="660" height="21" font="4">blocks at Faculdade de Medicina de Botucatu-UNESP. Rev Bras Anestesiol. 2011;61:568-81, 311-8. </text>
</page>
<page number="252" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 252 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">298. </text>
<text top="86" left="140" width="833" height="21" font="4">Mitar MD, Ratner S, Lavi S. Heart block and temporary pacing during rotational atherectomy. Can J Cardiol. 2015;31:335-40. </text>
<text top="106" left="86" width="33" height="21" font="4">299. </text>
<text top="106" left="140" width="933" height="21" font="4">Im SH, Han MH, Kim SH, et al. Transcutaneous temporary cardiac pacing in carotid stenting: noninvasive prevention of angioplasty-induced </text>
<text top="127" left="86" width="423" height="21" font="4">bradycardia and hypotension. J Endovasc Ther. 2008;15:110-6. </text>
<text top="147" left="86" width="33" height="21" font="4">300. </text>
<text top="147" left="140" width="945" height="21" font="4">Bush RL, Lin PH, Bianco CC, et al. Reevaluation of temporary transvenous cardiac pacemaker usage during carotid angioplasty and stenting: a </text>
<text top="167" left="86" width="457" height="21" font="4">safe and valuable adjunct. Vasc Endovascular Surg. 2004;38:229-35. </text>
<text top="187" left="86" width="33" height="21" font="4">301. </text>
<text top="187" left="140" width="910" height="21" font="4">Harrop JS, Sharan AD, Benitez RP, et al. Prevention of carotid angioplasty-induced bradycardia and hypotension with temporary venous </text>
<text top="207" left="86" width="413" height="21" font="4">pacemakers. Neurosurgery. 2001;49:814-20; discussion 20-2. </text>
<text top="227" left="86" width="33" height="21" font="4">302. </text>
<text top="227" left="140" width="935" height="21" font="4">Gauss A, Hubner C, Meierhenrich R, et al. Perioperative transcutaneous pacemaker in patients with chronic bifascicular block or left bundle </text>
<text top="247" left="86" width="700" height="21" font="4">branch block and additional first-degree atrioventricular block. Acta Anaesthesiol Scand. 1999;43:731-6. </text>
<text top="268" left="86" width="33" height="21" font="4">303. </text>
<text top="268" left="140" width="948" height="21" font="4">Killeavy ES, Ferguson JJ, 3rd. The use of temporary transvenous pacing catheters during percutaneous transluminal coronary angioplasty. Tex </text>
<text top="288" left="86" width="188" height="21" font="4">Heart Inst J. 1990;17:37-41. </text>
<text top="308" left="86" width="33" height="21" font="4">304. </text>
<text top="308" left="140" width="918" height="21" font="4">Chowdhury T, Ahuja N, Schaller B. Severe Bradycardia During Neurosurgical Procedure: Depth of Anesthesia Matters and Leads to a New </text>
<text top="328" left="86" width="690" height="21" font="4">Surrogate Model of the Trigeminocardiac Reflex: A Case Report. Medicine (Baltimore). 2015;94:e2118. </text>
<text top="348" left="86" width="33" height="21" font="4">305. </text>
<text top="348" left="140" width="938" height="21" font="4">Yong J, Hibbert P, Runciman WB, et al. Bradycardia as an early warning sign for cardiac arrest during routine laparoscopic surgery. Int J Qual </text>
<text top="368" left="86" width="192" height="21" font="4">Health Care. 2015;27:473-8. </text>
<text top="388" left="86" width="33" height="21" font="4">306. </text>
<text top="388" left="140" width="883" height="21" font="4">Vimala S, Arulvelan A. Sudden Bradycardia and Hypotension in Neurosurgery: Trigeminocardiac Reflex (TCR) and More. J Neurosurg </text>
<text top="409" left="86" width="191" height="21" font="4">Anesthesiol. 2016;28:175-6. </text>
<text top="429" left="86" width="33" height="21" font="4">307. </text>
<text top="429" left="140" width="924" height="21" font="4">Mohan S, Flis DW, O'Leary MA. A Case of Trigeminocardiac Reflex During Infrastructure Maxillectomy. JAMA Otolaryngol Head Neck Surg. </text>
<text top="449" left="86" width="114" height="21" font="4">2014;140:563-4. </text>
<text top="469" left="86" width="33" height="21" font="4">308. </text>
<text top="469" left="140" width="920" height="21" font="4">Ishii D, Satow T, Murao K, et al. Efficacy of cilostazol in prevention of bradycardia during carotid artery stenting. J Stroke Cerebrovasc Dis. </text>
<text top="489" left="86" width="105" height="21" font="4">2014;23:662-6. </text>
<text top="509" left="86" width="33" height="21" font="4">309. </text>
<text top="509" left="140" width="956" height="21" font="4">Schipke JD, Cleveland S, Caspers C. Computer-assisted paranasal sinus operation induces diving bradycardia. Am J Otolaryngol. 2013;34:353-4. </text>
<text top="529" left="86" width="33" height="21" font="4">310. </text>
<text top="529" left="140" width="881" height="21" font="4">Haldar R, Gyanesh P, Bettaswamy G. Isolated bradycardia due to skull pin fixation: an unusual occurrence. J Neurosurg Anesthesiol. </text>
<text top="550" left="86" width="105" height="21" font="4">2013;25:206-7. </text>
<text top="570" left="86" width="33" height="21" font="4">311. </text>
<text top="570" left="141" width="914" height="21" font="4">Seo KC, Park JS, Roh WS. Factors contributing to episodes of bradycardia hypotension during shoulder arthroscopic surgery in the sitting </text>
<text top="590" left="86" width="475" height="21" font="4">position after interscalene block. Korean J Anesthesiol. 2010;58:38-44. </text>
<text top="610" left="86" width="33" height="21" font="4">312. </text>
<text top="610" left="141" width="906" height="21" font="4">Jeyabalan G, Saba S, Baril DT, et al. Bradyarrhythmias during rheolytic pharmacomechanical thrombectomy for deep vein thrombosis. J </text>
<text top="630" left="86" width="219" height="21" font="4">Endovasc Ther. 2010;17:416-22. </text>
<text top="650" left="86" width="33" height="21" font="4">313. </text>
<text top="650" left="141" width="853" height="21" font="4">Usami K, Kamada K, Kunii N, et al. Transient asystole during surgery for posterior fossa meningioma caused by activation of the </text>
<text top="670" left="86" width="581" height="21" font="4">trigeminocardiac reflex: three case reports. Neurol Med Chir (Tokyo). 2010;50:339-42. </text>
<text top="691" left="86" width="33" height="21" font="4">314. </text>
<text top="691" left="141" width="939" height="21" font="4">Lubbers HT, Zweifel D, Gratz KW, et al. Classification of potential risk factors for trigeminocardiac reflex in craniomaxillofacial surgery. J Oral </text>
<text top="711" left="86" width="233" height="21" font="4">Maxillofac Surg. 2010;68:1317-21. </text>
<text top="731" left="86" width="33" height="21" font="4">315. </text>
<text top="731" left="141" width="948" height="21" font="4">Christensen RE, Reynolds PI, Bukowski BK, et al. Anaesthetic management and outcomes in patients with surgically corrected D-transposition </text>
<text top="751" left="87" width="555" height="21" font="4">of the great arteries undergoing non-cardiac surgery. Br J Anaesth. 2010;104:12-5. </text>
</page>
<page number="253" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 253 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">316. </text>
<text top="86" left="140" width="962" height="21" font="4">Jacques F, Elkouri S, Bracco D, et al. Regional anesthesia for carotid surgery: less intraoperative hypotension and vasopressor requirement. Ann </text>
<text top="106" left="86" width="178" height="21" font="4">Vasc Surg. 2009;23:324-9. </text>
<text top="127" left="86" width="33" height="21" font="4">317. </text>
<text top="127" left="140" width="945" height="21" font="4">Hanss R, Renner J, Ilies C, et al. Does heart rate variability predict hypotension and bradycardia after induction of general anaesthesia in high </text>
<text top="147" left="86" width="397" height="21" font="4">risk cardiovascular patients? Anaesthesia. 2008;63:129-35. </text>
<text top="167" left="86" width="33" height="21" font="4">318. </text>
<text top="167" left="140" width="948" height="21" font="4">Reddy MK, Arivazhagan A, Chandramouli BA. Intractable hypotension and bradycardia during surgical positioning in atlantoaxial dislocation. J </text>
<text top="187" left="86" width="244" height="21" font="4">Neurosurg Anesthesiol. 2008;20:71. </text>
<text top="207" left="86" width="33" height="21" font="4">319. </text>
<text top="207" left="140" width="942" height="21" font="4">Ardesch JJ, Buschman HP, van der Burgh PH, et al. Cardiac responses of vagus nerve stimulation: intraoperative bradycardia and subsequent </text>
<text top="227" left="86" width="416" height="21" font="4">chronic stimulation. Clin Neurol Neurosurg. 2007;109:849-52. </text>
<text top="247" left="86" width="33" height="21" font="4">320. </text>
<text top="247" left="140" width="901" height="21" font="4">Jones PM, Soderman RM. Intra-operative bradycardia in a patient with Alzheimer's disease treated with two cholinesterase inhibitors. </text>
<text top="268" left="86" width="181" height="21" font="4">Anaesthesia. 2007;62:201. </text>
<text top="288" left="86" width="33" height="21" font="4">321. </text>
<text top="288" left="140" width="912" height="21" font="4">Wijeysundera DN, Duncan D, Nkonde-Price C, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 </text>
<text top="308" left="86" width="1005" height="21" font="4">ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American </text>
<text top="328" left="86" width="808" height="21" font="4">College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:2406-25. </text>
<text top="348" left="86" width="33" height="21" font="4">322. </text>
<text top="348" left="140" width="943" height="21" font="4">Morris D, Mulvihill D, Lew WY. Risk of developing complete heart block during bedside pulmonary artery catheterization in patients with left </text>
<text top="368" left="86" width="394" height="21" font="4">bundle-branch block. Arch Intern Med. 1987;147:2005-10. </text>
<text top="388" left="86" width="33" height="21" font="4">323. </text>
<text top="388" left="140" width="940" height="21" font="4">Elliott CG, Zimmerman GA, Clemmer TP. Complications of pulmonary artery catheterization in the care of critically ill patients. A prospective </text>
<text top="409" left="86" width="204" height="21" font="4">study. Chest. 1979;76:647-52. </text>
<text top="429" left="86" width="33" height="21" font="4">324. </text>
<text top="429" left="140" width="960" height="21" font="4">Unnikrishnan D, Idris N, Varshneya N. Complete heart block during central venous catheter placement in a patient with pre-existing left bundle </text>
<text top="449" left="86" width="290" height="21" font="4">branch block. Br J Anaesth. 2003;91:747-9. </text>
<text top="469" left="86" width="33" height="21" font="4">325. </text>
<text top="469" left="140" width="934" height="21" font="4">Mouillet G, Lellouche N, Lim P, et al. Patients without prolonged QRS after TAVI with CoreValve device do not experience high-degree atrio-</text>
<text top="489" left="86" width="411" height="21" font="4">ventricular block. Catheter Cardiovasc Interv. 2013;81:882-7. </text>
<text top="509" left="86" width="33" height="21" font="4">326. </text>
<text top="509" left="140" width="937" height="21" font="4">Rabinovitz E, Finkelstein A, Ben Assa E, et al. Norton scale for predicting prognosis in elderly patients undergoing trans-catheter aortic valve </text>
<text top="529" left="86" width="477" height="21" font="4">implantation: A historical prospective study. J Cardiol. 2016;67:519-25. </text>
<text top="550" left="86" width="33" height="21" font="4">327. </text>
<text top="550" left="140" width="959" height="21" font="4">Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J </text>
<text top="570" left="86" width="178" height="21" font="4">Med. 2010;363:1597-607. </text>
<text top="590" left="86" width="33" height="21" font="4">328. </text>
<text top="590" left="140" width="886" height="21" font="4">Kogan A, Sternik L, Beinart R, et al. Permanent pacemaker insertion following isolated aortic valve replacement before and after the </text>
<text top="610" left="86" width="436" height="21" font="4">introduction of TAVI. Pacing Clin Electrophysiol. 2015;38:424-30. </text>
<text top="630" left="86" width="33" height="21" font="4">329. </text>
<text top="630" left="140" width="947" height="21" font="4">Rivard L, Schram G, Asgar A, et al. Electrocardiographic and electrophysiological predictors of atrioventricular block after transcatheter aortic </text>
<text top="650" left="86" width="339" height="21" font="4">valve replacement. Heart Rhythm. 2015;12:321-9. </text>
<text top="670" left="86" width="33" height="21" font="4">330. </text>
<text top="670" left="140" width="956" height="21" font="4">Rene AG, Sastry A, Horowitz JM, et al. Recovery of atrioventricular conduction after pacemaker placement following cardiac valvular surgery. J </text>
<text top="691" left="86" width="292" height="21" font="4">Cardiovasc Electrophysiol. 2013;24:1383-7. </text>
<text top="711" left="86" width="33" height="21" font="4">331. </text>
<text top="711" left="140" width="903" height="21" font="4">Steyers CM, 3rd, Khera R, Bhave P. Pacemaker Dependency after Cardiac Surgery: A Systematic Review of Current Evidence. PLoS One. </text>
<text top="731" left="86" width="134" height="21" font="4">2015;10:e0140340. </text>
<text top="751" left="86" width="33" height="21" font="4">332. </text>
<text top="751" left="140" width="952" height="21" font="4">Dawkins S, Hobson AR, Kalra PR, et al. Permanent pacemaker implantation after isolated aortic valve replacement: incidence, indications, and </text>
<text top="771" left="86" width="308" height="21" font="4">predictors. Ann Thorac Surg. 2008;85:108-12. </text>
</page>
<page number="254" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 254 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">333. </text>
<text top="86" left="140" width="920" height="21" font="4">Viles-Gonzalez JF, Enriquez AD, Castillo JG, et al. Incidence, predictors, and evolution of conduction disorders and atrial arrhythmias after </text>
<text top="106" left="86" width="407" height="21" font="4">contemporary mitral valve repair. Cardiol J. 2014;21:569-75. </text>
<text top="127" left="86" width="33" height="21" font="4">334. </text>
<text top="127" left="140" width="951" height="21" font="4">Merin O, Ilan M, Oren A, et al. Permanent pacemaker implantation following cardiac surgery: indications and long-term follow-up. Pacing Clin </text>
<text top="147" left="86" width="199" height="21" font="4">Electrophysiol. 2009;32:7-12. </text>
<text top="167" left="86" width="33" height="21" font="4">335. </text>
<text top="167" left="140" width="959" height="21" font="4">Petrac D, Radic B, Birtic K, et al. Prospective evaluation of infrahisal second-degree AV block induced by atrial pacing in the presence of chronic </text>
<text top="187" left="86" width="524" height="21" font="4">bundle branch block and syncope. Pacing Clin Electrophysiol. 1996;19:784-92. </text>
<text top="207" left="86" width="33" height="21" font="4">336. </text>
<text top="207" left="140" width="956" height="21" font="4">Bougioukas I, Jebran AF, Grossmann M, et al. Is there a correlation between late re-exploration after cardiac surgery and removal of epicardial </text>
<text top="227" left="86" width="338" height="21" font="4">pacemaker wires? J Cardiothorac Surg. 2017;12:3. </text>
<text top="247" left="86" width="33" height="21" font="4">337. </text>
<text top="247" left="140" width="930" height="21" font="4">Bethea BT, Salazar JD, Grega MA, et al. Determining the utility of temporary pacing wires after coronary artery bypass surgery. Ann Thorac </text>
<text top="268" left="86" width="143" height="21" font="4">Surg. 2005;79:104-7. </text>
<text top="288" left="86" width="33" height="21" font="4">338. </text>
<text top="288" left="140" width="927" height="21" font="4">Puskas JD, Sharoni E, Williams WH, et al. Is routine use of temporary epicardial pacing wires necessary after either OPCAB or conventional </text>
<text top="308" left="86" width="314" height="21" font="4">CABG/CPB? Heart Surg Forum. 2003;6:E103-6. </text>
<text top="328" left="86" width="33" height="21" font="4">339. </text>
<text top="328" left="140" width="916" height="21" font="4">Caspi Y, Safadi T, Ammar R, et al. The significance of bundle branch block in the immediate postoperative electrocardiograms of patients </text>
<text top="348" left="86" width="520" height="21" font="4">undergoing coronary artery bypass. J Thorac Cardiovasc Surg. 1987;93:442-6. </text>
<text top="368" left="86" width="33" height="21" font="4">340. </text>
<text top="368" left="140" width="939" height="21" font="4">Zeldis SM, Morganroth J, Horowitz LN, et al. Fascicular conduction distrubances after coronary bypass surgery. Am J Cardiol. 1978;41:860-4. </text>
<text top="388" left="86" width="33" height="21" font="4">341. </text>
<text top="388" left="140" width="961" height="21" font="4">Cook DJ, Bailon JM, Douglas TT, et al. Changing incidence, type, and natural history of conduction defects after coronary artery bypass grafting. </text>
<text top="409" left="86" width="232" height="21" font="4">Ann Thorac Surg. 2005;80:1732-7. </text>
<text top="429" left="86" width="33" height="21" font="4">342. </text>
<text top="429" left="140" width="923" height="21" font="4">Tuzcu EM, Emre A, Goormastic M, et al. Incidence and prognostic significance of intraventricular conduction abnormalities after coronary </text>
<text top="449" left="86" width="341" height="21" font="4">bypass surgery. J Am Coll Cardiol. 1990;16:607-10. </text>
<text top="469" left="86" width="33" height="21" font="4">343. </text>
<text top="469" left="140" width="913" height="21" font="4">Ngaage DL, Schaff HV, Mullany CJ, et al. Does preoperative atrial fibrillation influence early and late outcomes of coronary artery bypass </text>
<text top="489" left="86" width="350" height="21" font="4">grafting? J Thorac Cardiovasc Surg. 2007;133:182-9. </text>
<text top="509" left="86" width="33" height="21" font="4">344. </text>
<text top="509" left="140" width="812" height="21" font="4">Yesil M, Bayata S, Arikan E, et al. Should we revascularize before implanting a pacemaker? Clin Cardiol. 2008;31:498-501. </text>
<text top="529" left="86" width="33" height="21" font="4">345. </text>
<text top="529" left="140" width="708" height="21" font="4">Satinsky JD, Collins JJ, Jr., Dalen JE. Conduction defects after cardiac surgery. Circulation. 1974;50:Ii170-4. </text>
<text top="550" left="86" width="33" height="21" font="4">346. </text>
<text top="550" left="140" width="912" height="21" font="4">Limongelli G, Ducceschi V, D'Andrea A, et al. Risk factors for pacemaker implantation following aortic valve replacement: a single centre </text>
<text top="570" left="86" width="233" height="21" font="4">experience. Heart. 2003;89:901-4. </text>
<text top="590" left="86" width="33" height="21" font="4">347. </text>
<text top="590" left="140" width="944" height="21" font="4">Bagur R, Manazzoni JM, Dumont É, et al. Permanent pacemaker implantation following isolated aortic valve replacement in a large cohort of </text>
<text top="610" left="86" width="462" height="21" font="4">elderly patients with severe aortic stenosis. Heart. 2011;97:1687-94. </text>
<text top="630" left="86" width="33" height="21" font="4">348. </text>
<text top="630" left="140" width="940" height="21" font="4">Baraki H, Al Ahmad A, Jeng-Singh S, et al. Pacemaker dependency after isolated aortic valve replacement: do conductance disorders recover </text>
<text top="650" left="86" width="410" height="21" font="4">over time? Interact Cardiovasc Thorac Surg. 2013;16:476-81. </text>
<text top="670" left="86" width="33" height="21" font="4">349. </text>
<text top="670" left="140" width="964" height="21" font="4">Greason KL, Lahr BD, Stulak JM, et al. Long-Term Mortality Effect of Early Pacemaker Implantation After Surgical Aortic Valve Replacement. Ann </text>
<text top="691" left="86" width="218" height="21" font="4">Thorac Surg. 2017;104:1259-64. </text>
<text top="711" left="86" width="33" height="21" font="4">350. </text>
<text top="711" left="140" width="929" height="21" font="4">Berdajs D, Schurr UP, Wagner A, et al. Incidence and pathophysiology of atrioventricular block following mitral valve replacement and ring </text>
<text top="731" left="86" width="363" height="21" font="4">annuloplasty. Eur J Cardiothorac Surg. 2008;34:55-61. </text>
<text top="751" left="86" width="33" height="21" font="4">351. </text>
<text top="751" left="141" width="949" height="21" font="4">Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. New England </text>
<text top="771" left="86" width="262" height="21" font="4">Journal of Medicine. 2016;374:344-53. </text>
</page>
<page number="255" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 255 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">352. </text>
<text top="86" left="140" width="955" height="21" font="4">Saint LL, Damiano RJ, Jr., Cuculich PS, et al. Incremental risk of the Cox-maze IV procedure for patients with atrial fibrillation undergoing mitral </text>
<text top="106" left="86" width="391" height="21" font="4">valve surgery. J Thorac Cardiovasc Surg. 2013;146:1072-7. </text>
<text top="127" left="86" width="33" height="21" font="4">353. </text>
<text top="127" left="140" width="931" height="21" font="4">Gammie JS, Haddad M, Milford-Beland S, et al. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National </text>
<text top="147" left="86" width="356" height="21" font="4">Cardiac Database. Ann Thorac Surg. 2008;85:909-14. </text>
<text top="167" left="86" width="33" height="21" font="4">354. </text>
<text top="167" left="140" width="946" height="21" font="4">Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015;372:1399-409. </text>
<text top="187" left="86" width="33" height="21" font="4">355. </text>
<text top="187" left="140" width="960" height="21" font="4">Phan K, Xie A, La Meir M, et al. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised </text>
<text top="207" left="86" width="281" height="21" font="4">controlled trials. Heart. 2014;100:722-30. </text>
<text top="227" left="86" width="33" height="21" font="4">356. </text>
<text top="227" left="140" width="961" height="21" font="4">Chikwe J, Itagaki S, Anyanwu A, et al. Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation, Right Ventricular Function, and </text>
<text top="247" left="86" width="703" height="21" font="4">Pulmonary Artery Hypertension After Repair of Mitral Valve Prolapse. J Am Coll Cardiol. 2015;65:1931-8. </text>
<text top="268" left="86" width="33" height="21" font="4">357. </text>
<text top="268" left="140" width="929" height="21" font="4">Scully HE, Armstrong CS. Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac </text>
<text top="288" left="86" width="244" height="21" font="4">Cardiovasc Surg. 1995;109:1035-41. </text>
<text top="308" left="86" width="33" height="21" font="4">358. </text>
<text top="308" left="140" width="919" height="21" font="4">Jokinen JJ, Turpeinen AK, Pitkanen O, et al. Pacemaker therapy after tricuspid valve operations: implications on mortality, morbidity, and </text>
<text top="328" left="86" width="336" height="21" font="4">quality of life. Ann Thorac Surg. 2009;87:1806-14. </text>
<text top="348" left="86" width="33" height="21" font="4">359. </text>
<text top="348" left="140" width="877" height="21" font="4">McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg. </text>
<text top="368" left="86" width="122" height="21" font="4">2004;127:674-85. </text>
<text top="388" left="86" width="33" height="21" font="4">360. </text>
<text top="388" left="140" width="934" height="21" font="4">Piazza N, Onuma Y, Jesserun E, et al. Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after </text>
<text top="409" left="86" width="571" height="21" font="4">percutaneous replacement of the aortic valve. JACC Cardiovasc Interv. 2008;1:310-6. </text>
<text top="429" left="86" width="33" height="21" font="4">361. </text>
<text top="429" left="140" width="954" height="21" font="4">Roten L, Wenaweser P, Delacretaz E, et al. Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve </text>
<text top="449" left="86" width="315" height="21" font="4">implantation. Am J Cardiol. 2010;106:1473-80. </text>
<text top="469" left="86" width="33" height="21" font="4">362. </text>
<text top="469" left="140" width="925" height="21" font="4">van der Boon RM, Van Mieghem NM, Theuns DA, et al. Pacemaker dependency after transcatheter aortic valve implantation with the self-</text>
<text top="489" left="86" width="492" height="21" font="4">expanding Medtronic CoreValve System. Int J Cardiol. 2013;168:1269-73. </text>
<text top="509" left="86" width="33" height="21" font="4">363. </text>
<text top="509" left="140" width="954" height="21" font="4">Siontis GC, Juni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a </text>
<text top="529" left="86" width="333" height="21" font="4">meta-analysis. J Am Coll Cardiol. 2014;64:129-40. </text>
<text top="550" left="86" width="33" height="21" font="4">364. </text>
<text top="550" left="140" width="929" height="21" font="4">Boerlage-Van Dijk K, Kooiman KM, Yong ZY, et al. Predictors and permanency of cardiac conduction disorders and necessity of pacing after </text>
<text top="570" left="86" width="562" height="21" font="4">transcatheter aortic valve implantation. Pacing Clin Electrophysiol. 2014;37:1520-9. </text>
<text top="590" left="86" width="33" height="21" font="4">365. </text>
<text top="590" left="140" width="934" height="21" font="4">Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve </text>
<text top="610" left="86" width="851" height="21" font="4">replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60-9. </text>
<text top="630" left="86" width="33" height="21" font="4">366. </text>
<text top="630" left="140" width="942" height="21" font="4">Mouillet G, Lellouche N, Yamamoto M, et al. Outcomes following pacemaker implantation after transcatheter aortic valve implantation with </text>
<text top="650" left="86" width="712" height="21" font="4">CoreValve((R)) devices: Results from the FRANCE 2 Registry. Catheter Cardiovasc Interv. 2015;86:E158-66. </text>
<text top="670" left="86" width="33" height="21" font="4">367. </text>
<text top="670" left="140" width="943" height="21" font="4">Abramowitz Y, Kazuno Y, Chakravarty T, et al. Concomitant mitral annular calcification and severe aortic stenosis: prevalence, characteristics </text>
<text top="691" left="86" width="638" height="21" font="4">and outcome following transcatheter aortic valve replacement. Eur Heart J. 2017;38:1194-203. </text>
<text top="711" left="86" width="33" height="21" font="4">368. </text>
<text top="711" left="140" width="907" height="21" font="4">Franzoni I, Latib A, Maisano F, et al. Comparison of incidence and predictors of left bundle branch block after transcatheter aortic valve </text>
<text top="731" left="86" width="608" height="21" font="4">implantation using the CoreValve versus the Edwards valve. Am J Cardiol. 2013;112:554-9. </text>
<text top="751" left="86" width="33" height="21" font="4">369. </text>
<text top="751" left="140" width="904" height="21" font="4">Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following </text>
<text top="771" left="86" width="732" height="21" font="4">transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012;60:1743-52. </text>
</page>
<page number="256" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 256 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">370. </text>
<text top="86" left="140" width="923" height="21" font="4">Testa L, Latib A, De Marco F, et al. Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with </text>
<text top="106" left="86" width="398" height="21" font="4">CoreValve Revalving System. Circulation. 2013;127:1300-7. </text>
<text top="127" left="86" width="33" height="21" font="4">371. </text>
<text top="127" left="140" width="925" height="21" font="4">Egger F, Nurnberg M, Rohla M, et al. High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch </text>
<text top="147" left="86" width="647" height="21" font="4">block occurring during transcatheter aortic valve implantation. Heart Rhythm. 2014;11:2176-82. </text>
<text top="167" left="86" width="33" height="21" font="4">372. </text>
<text top="167" left="140" width="938" height="21" font="4">Schymik G, Tzamalis P, Bramlage P, et al. Clinical impact of a new left bundle branch block following TAVI implantation: 1-year results of the </text>
<text top="187" left="86" width="329" height="21" font="4">TAVIK cohort. Clin Res Cardiol. 2015;104:351-62. </text>
<text top="207" left="86" width="33" height="21" font="4">373. </text>
<text top="207" left="140" width="887" height="21" font="4">Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, et al. Impact of new-onset left bundle branch block and periprocedural permanent </text>
<text top="227" left="86" width="997" height="21" font="4">pacemaker implantation on clinical outcomes in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. </text>
<text top="247" left="86" width="270" height="21" font="4">Circ Cardiovasc Interv. 2016;9:e003635. </text>
<text top="268" left="86" width="33" height="21" font="4">374. </text>
<text top="268" left="140" width="946" height="21" font="4">Mauri V, Reimann A, Stern D, et al. Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement With the </text>
<text top="288" left="86" width="334" height="21" font="4">SAPIEN 3. JACC Cardiovasc Interv. 2016;9:2200-9. </text>
<text top="308" left="86" width="33" height="21" font="4">375. </text>
<text top="308" left="140" width="902" height="21" font="4">Watanabe Y, Kozuma K, Hioki H, et al. Pre-Existing Right Bundle Branch Block Increases Risk for Death After Transcatheter Aortic Valve </text>
<text top="328" left="86" width="587" height="21" font="4">Replacement With a Balloon-Expandable Valve. JACC Cardiovasc Interv. 2016;9:2210-6. </text>
<text top="348" left="86" width="33" height="21" font="4">376. </text>
<text top="348" left="140" width="932" height="21" font="4">Auffret V, Webb JG, Eltchaninoff H, et al. Clinical Impact of Baseline Right Bundle Branch Block in Patients Undergoing Transcatheter Aortic </text>
<text top="368" left="86" width="419" height="21" font="4">Valve Replacement. JACC Cardiovasc Interv. 2017;10:1564-74. </text>
<text top="388" left="86" width="33" height="21" font="4">377. </text>
<text top="388" left="140" width="939" height="21" font="4">Rampat R, Khawaja MZ, Hilling-Smith R, et al. Conduction Abnormalities and Permanent Pacemaker Implantation After Transcatheter Aortic </text>
<text top="409" left="86" width="909" height="21" font="4">Valve Replacement Using the Repositionable LOTUS Device: The United Kingdom Experience. JACC Cardiovasc Interv. 2017;10:1247-53. </text>
<text top="429" left="86" width="33" height="21" font="4">378. </text>
<text top="429" left="140" width="938" height="21" font="4">Nombela-Franco L, del Trigo M, Morrison-Polo G, et al. Incidence, Causes, and Predictors of Early (&lt;/=30 Days) and Late Unplanned Hospital </text>
<text top="449" left="86" width="684" height="21" font="4">Readmissions After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2015;8:1748-57. </text>
<text top="469" left="86" width="33" height="21" font="4">379. </text>
<text top="469" left="140" width="921" height="21" font="4">Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and </text>
<text top="489" left="86" width="659" height="21" font="4">predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol. 2015;65:437-48. </text>
<text top="509" left="86" width="33" height="21" font="4">380. </text>
<text top="509" left="140" width="947" height="21" font="4">Dizon JM, Nazif TM, Hess PL, et al. Chronic pacing and adverse outcomes after transcatheter aortic valve implantation. Heart. 2015;101:1665-</text>
<text top="529" left="86" width="25" height="21" font="4">71. </text>
<text top="550" left="86" width="33" height="21" font="4">381. </text>
<text top="550" left="140" width="639" height="21" font="4">Mallidi HR, Bates M. Pacemaker Use Following Heart Transplantation. Ochsner J. 2017;17:20-4. </text>
<text top="570" left="86" width="33" height="21" font="4">382. </text>
<text top="570" left="140" width="943" height="21" font="4">Wellmann P, Herrmann FE, Hagl C, et al. A Single Center Study of 1,179 Heart Transplant Patients-Factors Affecting Pacemaker Implantation. </text>
<text top="590" left="86" width="292" height="21" font="4">Pacing Clin Electrophysiol. 2017;40:247-54. </text>
<text top="610" left="86" width="33" height="21" font="4">383. </text>
<text top="610" left="140" width="933" height="21" font="4">Lee W, Tay A, Walker BD, et al. Accelerated graft dysfunction in heart transplant patients with persistent atrioventricular conduction block. </text>
<text top="630" left="86" width="193" height="21" font="4">Europace. 2016;18:1837-41. </text>
<text top="650" left="86" width="33" height="21" font="4">384. </text>
<text top="650" left="140" width="944" height="21" font="4">El-Assaad I, Al-Kindi SG, Oliveira GH, et al. Pacemaker implantation in pediatric heart transplant recipients: Predictors, outcomes, and impact </text>
<text top="670" left="86" width="304" height="21" font="4">on survival. Heart Rhythm. 2015;12:1776-81. </text>
<text top="691" left="86" width="33" height="21" font="4">385. </text>
<text top="691" left="140" width="961" height="21" font="4">Knight CS, Tallaj JA, Rayburn BK, et al. Bradycardia and syncope as a presentation of cardiac allograft rejection involving the conducting system. </text>
<text top="711" left="86" width="241" height="21" font="4">Cardiovasc Pathol. 2010;19:117-20. </text>
<text top="731" left="86" width="33" height="21" font="4">386. </text>
<text top="731" left="140" width="886" height="21" font="4">Braith RW, Clapp L, Brown T, et al. Rate-responsive pacing improves exercise tolerance in heart transplant recipients: a pilot study. J </text>
<text top="751" left="86" width="253" height="21" font="4">Cardiopulm Rehabil. 2000;20:377-82. </text>
</page>
<page number="257" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 257 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">387. </text>
<text top="86" left="140" width="964" height="21" font="4">Bacal F, Bocchi EA, Vieira ML, et al. Permanent and temporary pacemaker implantation after orthotopic heart transplantation. Arq Bras Cardiol. </text>
<text top="106" left="86" width="97" height="21" font="4">2000;74:5-12. </text>
<text top="127" left="86" width="33" height="21" font="4">388. </text>
<text top="127" left="140" width="917" height="21" font="4">Nagele H, Doring V, Kalmar P, et al. Long-term hemodynamic benefit of atrial synchronization with A2A2D or A2A2T pacing in sinus node </text>
<text top="147" left="86" width="612" height="21" font="4">syndrome after orthotopic heart transplantation. J Heart Lung Transplant. 1998;17:906-12. </text>
<text top="167" left="86" width="33" height="21" font="4">389. </text>
<text top="167" left="140" width="956" height="21" font="4">Jones DG, Mortsell DH, Rajaruthnam D, et al. Permanent pacemaker implantation early and late after heart transplantation: clinical indication, </text>
<text top="187" left="86" width="558" height="21" font="4">risk factors and prognostic implications. J Heart Lung Transplant. 2011;30:1257-65. </text>
<text top="207" left="86" width="33" height="21" font="4">390. </text>
<text top="207" left="140" width="910" height="21" font="4">Cantillon DJ, Tarakji KG, Hu T, et al. Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac </text>
<text top="227" left="86" width="708" height="21" font="4">transplantation: analysis of the UNOS/OPTN cardiac transplant database. Heart Rhythm. 2010;7:1567-71. </text>
<text top="247" left="86" width="33" height="21" font="4">391. </text>
<text top="247" left="140" width="854" height="21" font="4">Liebregts M, Faber L, Jensen MK, et al. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic </text>
<text top="268" left="86" width="401" height="21" font="4">Cardiomyopathy. JACC Cardiovasc Interv. 2017;10:1134-43. </text>
<text top="288" left="86" width="33" height="21" font="4">392. </text>
<text top="288" left="140" width="956" height="21" font="4">Poon SS, Field M, Gupta D, et al. Surgical septal myectomy or alcohol septal ablation: which approach offers better outcomes for patients with </text>
<text top="308" left="86" width="624" height="21" font="4">hypertrophic obstructive cardiomyopathy? Interact Cardiovasc Thorac Surg. 2017;24:951-61. </text>
<text top="328" left="86" width="33" height="21" font="4">393. </text>
<text top="328" left="140" width="860" height="21" font="4">Axelsson A, Weibring K, Havndrup O, et al. Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic </text>
<text top="348" left="86" width="450" height="21" font="4">cardiomyopathy. J Cardiovasc Med (Hagerstown). 2014;15:214-21. </text>
<text top="368" left="86" width="33" height="21" font="4">394. </text>
<text top="368" left="140" width="962" height="21" font="4">Veselka J, Krejci J, Tomasov P, et al. Outcome of patients after alcohol septal ablation with permanent pacemaker implanted for periprocedural </text>
<text top="388" left="86" width="350" height="21" font="4">complete heart block. Int J Cardiol. 2014;171:e37-8. </text>
<text top="409" left="86" width="33" height="21" font="4">395. </text>
<text top="409" left="140" width="945" height="21" font="4">El-Jack SS, Nasif M, Blake JW, et al. Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the </text>
<text top="429" left="86" width="441" height="21" font="4">timing of pacemaker implantation. J Interv Cardiol. 2007;20:73-6. </text>
<text top="449" left="86" width="33" height="21" font="4">396. </text>
<text top="449" left="140" width="959" height="21" font="4">McCann GP, Van Dockum WG, Beek AM, et al. Extent of myocardial infarction and reverse remodeling assessed by cardiac magnetic resonance </text>
<text top="469" left="86" width="991" height="21" font="4">in patients with and without right bundle branch block following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. </text>
<text top="489" left="86" width="105" height="21" font="4">2007;99:563-7. </text>
<text top="509" left="86" width="33" height="21" font="4">397. </text>
<text top="509" left="140" width="953" height="21" font="4">Faber L, Welge D, Fassbender D, et al. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the </text>
<text top="529" left="86" width="567" height="21" font="4">risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119:163-7. </text>
<text top="550" left="86" width="33" height="21" font="4">398. </text>
<text top="550" left="140" width="858" height="21" font="4">Talreja DR, Nishimura RA, Edwards WD, et al. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on </text>
<text top="570" left="86" width="476" height="21" font="4">atrioventricular conduction tissue. J Am Coll Cardiol. 2004;44:2329-32. </text>
<text top="590" left="86" width="33" height="21" font="4">399. </text>
<text top="590" left="140" width="861" height="21" font="4">Wang S, Luo M, Sun H, et al. A retrospective clinical study of transaortic extended septal myectomy for obstructive hypertrophic </text>
<text top="610" left="86" width="452" height="21" font="4">cardiomyopathy in China. Eur J Cardiothorac Surg. 2013;43:534-40. </text>
<text top="630" left="86" width="33" height="21" font="4">400. </text>
<text top="630" left="140" width="945" height="21" font="4">Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J </text>
<text top="650" left="86" width="224" height="21" font="4">Am Coll Cardiol. 2010;55:823-34. </text>
<text top="670" left="86" width="33" height="21" font="4">401. </text>
<text top="670" left="140" width="906" height="21" font="4">Schuller JL, Zipse MM, Krantz MJ, et al. Incidence and predictors of late complete heart block after alcohol septal ablation treatment of </text>
<text top="691" left="86" width="492" height="21" font="4">hypertrophic obstructive cardiomyopathy. J Interv Cardiol. 2015;28:90-7. </text>
<text top="711" left="86" width="33" height="21" font="4">402. </text>
<text top="711" left="140" width="921" height="21" font="4">Veselka J, Lawrenz T, Stellbrink C, et al. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for </text>
<text top="731" left="86" width="594" height="21" font="4">symptomatic hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2013;29:1415-21. </text>
<text top="751" left="86" width="33" height="21" font="4">403. </text>
<text top="751" left="141" width="925" height="21" font="4">Kim LK, Swaminathan RV, Looser P, et al. Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of </text>
<text top="771" left="86" width="815" height="21" font="4">Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. JAMA Cardiol. 2016;1:324-32. </text>
</page>
<page number="258" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 258 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">404. </text>
<text top="86" left="140" width="929" height="21" font="4">Liebregts M, Vriesendorp PA, Mahmoodi BK, et al. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction </text>
<text top="106" left="86" width="603" height="21" font="4">Therapy in Patients With Hypertrophic Cardiomyopathy. JACC Heart Fail. 2015;3:896-905. </text>
<text top="127" left="86" width="33" height="21" font="4">405. </text>
<text top="127" left="140" width="962" height="21" font="4">Balt JC, Wijffels MC, Boersma LV, et al. Continuous rhythm monitoring for ventricular arrhythmias after alcohol septal ablation for hypertrophic </text>
<text top="147" left="86" width="293" height="21" font="4">cardiomyopathy. Heart. 2014;100:1865-70. </text>
<text top="167" left="86" width="33" height="21" font="4">406. </text>
<text top="167" left="140" width="950" height="21" font="4">Qin JX, Shiota T, Lever HM, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal </text>
<text top="187" left="86" width="362" height="21" font="4">reduction interventions. Am J Cardiol. 2004;93:171-5. </text>
<text top="207" left="86" width="33" height="21" font="4">407. </text>
<text top="207" left="140" width="885" height="21" font="4">Chang SM, Nagueh SF, Spencer WH, 3rd, et al. Complete heart block: determinants and clinical impact in patients with hypertrophic </text>
<text top="227" left="86" width="768" height="21" font="4">obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42:296-300. </text>
<text top="247" left="86" width="33" height="21" font="4">408. </text>
<text top="247" left="140" width="961" height="21" font="4">Chen AA, Palacios IF, Mela T, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic </text>
<text top="268" left="86" width="313" height="21" font="4">cardiomyopathy. Am J Cardiol. 2006;97:264-9. </text>
<text top="288" left="86" width="33" height="21" font="4">409. </text>
<text top="288" left="140" width="944" height="21" font="4">Lawrenz T, Lieder F, Bartelsmeier M, et al. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a </text>
<text top="308" left="86" width="975" height="21" font="4">prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49:2356-63. </text>
<text top="328" left="86" width="33" height="21" font="4">410. </text>
<text top="328" left="140" width="920" height="21" font="4">Wang W, Lian Z, Rowin EJ, et al. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic </text>
<text top="348" left="86" width="382" height="21" font="4">Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10: </text>
<text top="368" left="86" width="33" height="21" font="4">411. </text>
<text top="368" left="140" width="933" height="21" font="4">Thavikulwat AC, Tomson TT, Knight BP, et al. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy. J </text>
<text top="388" left="86" width="292" height="21" font="4">Cardiovasc Electrophysiol. 2016;27:953-60. </text>
<text top="409" left="86" width="33" height="21" font="4">412. </text>
<text top="409" left="140" width="879" height="21" font="4">Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic </text>
<text top="429" left="86" width="282" height="21" font="4">cardiomyopathy. Jama. 2007;298:405-12. </text>
<text top="449" left="86" width="33" height="21" font="4">413. </text>
<text top="449" left="140" width="954" height="21" font="4">Gelatt M, Hamilton RM, McCrindle BW, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am </text>
<text top="469" left="86" width="206" height="21" font="4">Coll Cardiol. 1997;29:194-201. </text>
<text top="489" left="86" width="33" height="21" font="4">414. </text>
<text top="489" left="140" width="959" height="21" font="4">Helbing WA, Hansen B, Ottenkamp J, et al. Long-term results of atrial correction for transposition of the great arteries. Comparison of Mustard </text>
<text top="509" left="86" width="461" height="21" font="4">and Senning operations. J Thorac Cardiovasc Surg. 1994;108:363-72. </text>
<text top="529" left="86" width="33" height="21" font="4">415. </text>
<text top="529" left="140" width="925" height="21" font="4">Anand N, McCrindle BW, Chiu CC, et al. Chronotropic incompetence in young patients with late postoperative atrial flutter: a case-control </text>
<text top="550" left="86" width="248" height="21" font="4">study. Eur Heart J. 2006;27:2069-73. </text>
<text top="570" left="86" width="33" height="21" font="4">416. </text>
<text top="570" left="140" width="963" height="21" font="4">Diller GP, Dimopoulos K, Okonko D, et al. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll </text>
<text top="590" left="86" width="169" height="21" font="4">Cardiol. 2006;48:1250-6. </text>
<text top="610" left="86" width="33" height="21" font="4">417. </text>
<text top="610" left="140" width="911" height="21" font="4">Janousek J, Paul T, Luhmer I, et al. Atrial baffle procedures for complete transposition of the great arteries: natural course of sinus node </text>
<text top="630" left="86" width="606" height="21" font="4">dysfunction and risk factors for dysrhythmias and sudden death. Z Kardiol. 1994;83:933-8. </text>
<text top="650" left="86" width="33" height="21" font="4">418. </text>
<text top="650" left="140" width="927" height="21" font="4">Fishberger SB, Wernovsky G, Gentles TL, et al. Factors that influence the development of atrial flutter after the Fontan operation. J Thorac </text>
<text top="670" left="86" width="219" height="21" font="4">Cardiovasc Surg. 1997;113:80-6. </text>
<text top="691" left="86" width="33" height="21" font="4">419. </text>
<text top="691" left="140" width="949" height="21" font="4">Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete </text>
<text top="711" left="86" width="291" height="21" font="4">heart block. N Engl J Med. 1987;316:835-9. </text>
<text top="731" left="86" width="33" height="21" font="4">420. </text>
<text top="731" left="140" width="957" height="21" font="4">Lundstrom U, Bull C, Wyse RK, et al. The natural and &#34;unnatural&#34; history of congenitally corrected transposition. Am J Cardiol. 1990;65:1222-9. </text>
<text top="751" left="86" width="33" height="21" font="4">421. </text>
<text top="751" left="140" width="897" height="21" font="4">Graham TP, Jr., Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-</text>
<text top="771" left="86" width="363" height="21" font="4">institutional study. J Am Coll Cardiol. 2000;36:255-61. </text>
</page>
<page number="259" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 259 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">422. </text>
<text top="86" left="140" width="927" height="21" font="4">Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a </text>
<text top="106" left="86" width="329" height="21" font="4">multicenter study. Circulation. 2006;113:2391-7. </text>
<text top="127" left="86" width="33" height="21" font="4">423. </text>
<text top="127" left="140" width="942" height="21" font="4">DeSimone CV, Friedman PA, Noheria A, et al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and </text>
<text top="147" left="86" width="578" height="21" font="4">echocardiographically detected patent foramen ovale. Circulation. 2013;128:1433-41. </text>
<text top="167" left="86" width="33" height="21" font="4">424. </text>
<text top="167" left="140" width="964" height="21" font="4">Kim MH, Deeb GM, Eagle KA, et al. Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. Am J </text>
<text top="187" left="86" width="202" height="21" font="4">Cardiol. 2001;87:649-51, a10. </text>
<text top="207" left="86" width="33" height="21" font="4">425. </text>
<text top="207" left="140" width="957" height="21" font="4">Glikson M, Dearani JA, Hyberger LK, et al. Indications, effectiveness, and long-term dependency in permanent pacing after cardiac surgery. Am </text>
<text top="227" left="86" width="186" height="21" font="4">J Cardiol. 1997;80:1309-13. </text>
<text top="247" left="86" width="33" height="21" font="4">426. </text>
<text top="247" left="140" width="887" height="21" font="4">Edwards WD, Edwards JE. Pathology of the sinus node in d-transposition following the Mustard operation. J Thorac Cardiovasc Surg. </text>
<text top="268" left="86" width="105" height="21" font="4">1978;75:213-8. </text>
<text top="288" left="86" width="33" height="21" font="4">427. </text>
<text top="288" left="140" width="948" height="21" font="4">Sanders P, Morton JB, Kistler PM, et al. Electrophysiological and electroanatomic characterization of the atria in sinus node disease: evidence </text>
<text top="308" left="86" width="401" height="21" font="4">of diffuse atrial remodeling. Circulation. 2004;109:1514-22. </text>
<text top="328" left="86" width="33" height="21" font="4">428. </text>
<text top="328" left="140" width="846" height="21" font="4">Bolens M, Friedli B. Sinus node function and conduction system before and after surgery for secundum atrial septal defect: an </text>
<text top="348" left="86" width="383" height="21" font="4">electrophysiologic study. Am J Cardiol. 1984;53:1415-20. </text>
<text top="368" left="86" width="33" height="21" font="4">429. </text>
<text top="368" left="140" width="947" height="21" font="4">Gillette PC, el-Said GM, Sivarajan N, et al. Electrophysiological abnormalities after Mustard's operation for transposition of the great arteries. </text>
<text top="388" left="86" width="187" height="21" font="4">Br Heart J. 1974;36:186-91. </text>
<text top="409" left="86" width="33" height="21" font="4">430. </text>
<text top="409" left="140" width="961" height="21" font="4">Garson A, Jr., Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol. 1985;6:871-8. </text>
<text top="429" left="86" width="33" height="21" font="4">431. </text>
<text top="429" left="140" width="929" height="21" font="4">Albin G, Hayes DL, Holmes DR, Jr. Sinus node dysfunction in pediatric and young adult patients: treatment by implantation of a permanent </text>
<text top="449" left="86" width="381" height="21" font="4">pacemaker in 39 cases. Mayo Clin Proc. 1985;60:667-72. </text>
<text top="469" left="86" width="33" height="21" font="4">432. </text>
<text top="469" left="140" width="931" height="21" font="4">McLeod CJ, Attenhofer Jost CH, Warnes CA, et al. Epicardial versus endocardial permanent pacing in adults with congenital heart disease. J </text>
<text top="489" left="86" width="295" height="21" font="4">Interv Card Electrophysiol. 2010;28:235-43. </text>
<text top="509" left="86" width="33" height="21" font="4">433. </text>
<text top="509" left="140" width="864" height="21" font="4">Walker F, Siu SC, Woods S, et al. Long-term outcomes of cardiac pacing in adults with congenital heart disease. J Am Coll Cardiol. </text>
<text top="529" left="86" width="130" height="21" font="4">2004;43:1894-901. </text>
<text top="550" left="86" width="33" height="21" font="4">434. </text>
<text top="550" left="140" width="847" height="21" font="4">Bink-Boelkens MT, Velvis H, van der Heide JJ, et al. Dysrhythmias after atrial surgery in children. Am Heart J. 1983;106:125-30. </text>
<text top="570" left="86" width="33" height="21" font="4">435. </text>
<text top="570" left="140" width="909" height="21" font="4">Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with </text>
<text top="590" left="86" width="367" height="21" font="4">congenital heart disease. Am J Cardiol. 2003;92:871-6. </text>
<text top="610" left="86" width="33" height="21" font="4">436. </text>
<text top="610" left="140" width="933" height="21" font="4">Rhodes LA, Walsh EP, Gamble WJ, et al. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. </text>
<text top="630" left="86" width="301" height="21" font="4">Pacing Clin Electrophysiol. 1995;18:1005-16. </text>
<text top="650" left="86" width="33" height="21" font="4">437. </text>
<text top="650" left="140" width="947" height="21" font="4">Ayyildiz P, Kasar T, Ozturk E, et al. Evaluation of Permanent or Transient Complete Heart Block after Open Heart Surgery for Congenital Heart </text>
<text top="670" left="86" width="343" height="21" font="4">Disease. Pacing Clin Electrophysiol. 2016;39:160-5. </text>
<text top="691" left="86" width="33" height="21" font="4">438. </text>
<text top="691" left="140" width="919" height="21" font="4">Aziz PF, Serwer GA, Bradley DJ, et al. Pattern of recovery for transient complete heart block after open heart surgery for congenital heart </text>
<text top="711" left="86" width="680" height="21" font="4">disease: duration alone predicts risk of late complete heart block. Pediatr Cardiol. 2013;34:999-1005. </text>
<text top="731" left="86" width="33" height="21" font="4">439. </text>
<text top="731" left="140" width="960" height="21" font="4">Lin A, Mahle WT, Frias PA, et al. Early and delayed atrioventricular conduction block after routine surgery for congenital heart disease. J Thorac </text>
<text top="751" left="86" width="236" height="21" font="4">Cardiovasc Surg. 2010;140:158-60. </text>
</page>
<page number="260" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 260 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">440. </text>
<text top="86" left="140" width="913" height="21" font="4">Domenighetti G, Perret C. Intraventricular conduction disturbances in acute myocardial infarction: short- and long-term prognosis. Eur J </text>
<text top="106" left="86" width="152" height="21" font="4">Cardiol. 1980;11:51-9. </text>
<text top="127" left="86" width="33" height="21" font="4">441. </text>
<text top="127" left="140" width="882" height="21" font="4">Col JJ, Weinberg SL. The incidence and mortality of intraventricular conduction defects in acute myocardial infarction. Am J Cardiol. </text>
<text top="147" left="86" width="114" height="21" font="4">1972;29:344-50. </text>
<text top="167" left="86" width="33" height="21" font="4">442. </text>
<text top="167" left="140" width="963" height="21" font="4">Ritter WS, Atkins JM, Blomqvist CG, et al. Permanent pacing in patients with transient trifascicular block during acute myocardial infarction. Am </text>
<text top="187" left="86" width="170" height="21" font="4">J Cardiol. 1976;38:205-8. </text>
<text top="207" left="86" width="33" height="21" font="4">443. </text>
<text top="207" left="140" width="961" height="21" font="4">Lamas GA, Muller JE, Turi ZG, et al. A simplified method to predict occurrence of complete heart block during acute myocardial infarction. Am J </text>
<text top="227" left="86" width="169" height="21" font="4">Cardiol. 1986;57:1213-9. </text>
<text top="247" left="86" width="33" height="21" font="4">444. </text>
<text top="247" left="140" width="760" height="21" font="4">Shaw DB, Holman RR, Gowers JI. Survival in sinoatrial disorder (sick-sinus syndrome). Br Med J. 1980;280:139-41. </text>
<text top="268" left="86" width="33" height="21" font="4">445. </text>
<text top="268" left="140" width="963" height="21" font="4">Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications </text>
<text top="288" left="86" width="545" height="21" font="4">for temporary and permanent pacemaker insertion. Circulation. 1978;58:689-99. </text>
<text top="308" left="86" width="33" height="21" font="4">446. </text>
<text top="308" left="140" width="938" height="21" font="4">Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical </text>
<text top="328" left="86" width="590" height="21" font="4">characteristics, hospital mortality, and one-year follow-up. Circulation. 1978;58:679-88. </text>
<text top="348" left="86" width="33" height="21" font="4">447. </text>
<text top="348" left="140" width="922" height="21" font="4">Meine TJ, Al-Khatib SM, Alexander JH, et al. Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute </text>
<text top="368" left="86" width="579" height="21" font="4">myocardial infarction treated with thrombolytic therapy. Am Heart J. 2005;149:670-4. </text>
<text top="388" left="86" width="33" height="21" font="4">448. </text>
<text top="388" left="140" width="956" height="21" font="4">Gang UJ, Hvelplund A, Pedersen S, et al. High-degree atrioventricular block complicating ST-segment elevation myocardial infarction in the era </text>
<text top="409" left="86" width="517" height="21" font="4">of primary percutaneous coronary intervention. Europace. 2012;14:1639-45. </text>
<text top="429" left="86" width="33" height="21" font="4">449. </text>
<text top="429" left="140" width="898" height="21" font="4">Auffret V, Loirat A, Leurent G, et al. High-degree atrioventricular block complicating ST segment elevation myocardial infarction in the </text>
<text top="449" left="86" width="280" height="21" font="4">contemporary era. Heart. 2016;102:40-9. </text>
<text top="469" left="86" width="33" height="21" font="4">450. </text>
<text top="469" left="140" width="963" height="21" font="4">Kim HL, Kim SH, Seo JB, et al. Influence of second- and third-degree heart block on 30-day outcome following acute myocardial infarction in the </text>
<text top="489" left="86" width="375" height="21" font="4">drug-eluting stent era. Am J Cardiol. 2014;114:1658-62. </text>
<text top="509" left="86" width="33" height="21" font="4">451. </text>
<text top="509" left="140" width="840" height="21" font="4">Ranganathan N, Dhurandhar R, Phillips JH, et al. His Bundle electrogram in bundle-branch block. Circulation. 1972;45:282-94. </text>
<text top="529" left="86" width="33" height="21" font="4">452. </text>
<text top="529" left="140" width="771" height="21" font="4">Rotman M, Wagner GS, Wallace AG. Bradyarrhythmias in acute myocardial infarction. Circulation. 1972;45:703-22. </text>
<text top="550" left="86" width="33" height="21" font="4">453. </text>
<text top="550" left="140" width="903" height="21" font="4">Bestawros M, Darbar D, Arain A, et al. Ictal asystole and ictal syncope: insights into clinical management. Circ Arrhythm Electrophysiol. </text>
<text top="570" left="86" width="105" height="21" font="4">2015;8:159-64. </text>
<text top="590" left="86" width="33" height="21" font="4">454. </text>
<text top="590" left="140" width="925" height="21" font="4">Lanz M, Oehl B, Brandt A, et al. Seizure induced cardiac asystole in epilepsy patients undergoing long term video-EEG monitoring. Seizure. </text>
<text top="610" left="86" width="114" height="21" font="4">2011;20:167-72. </text>
<text top="630" left="86" width="33" height="21" font="4">455. </text>
<text top="630" left="141" width="877" height="21" font="4">Schuele SU, Bermeo AC, Alexopoulos AV, et al. Video-electrographic and clinical features in patients with ictal asystole. Neurology. </text>
<text top="650" left="86" width="114" height="21" font="4">2007;69:434-41. </text>
<text top="670" left="86" width="33" height="21" font="4">456. </text>
<text top="670" left="141" width="641" height="21" font="4">Tenyi D, Gyimesi C, Kupo P, et al. Ictal asystole: A systematic review. Epilepsia. 2017;58:356-62. </text>
<text top="691" left="87" width="33" height="21" font="4">457. </text>
<text top="691" left="141" width="957" height="21" font="4">Ogunbayo GO, Charnigo R, Darrat Y, et al. Incidence, predictors, and outcomes associated with pneumothorax during cardiac electronic device </text>
<text top="711" left="87" width="622" height="21" font="4">implantation: A 16-year review in over 3.7 million patients. Heart Rhythm. 2017;14:1764-70. </text>
<text top="731" left="87" width="33" height="21" font="4">458. </text>
<text top="731" left="141" width="911" height="21" font="4">Sochala M, Wahbi K, Sorbets E, et al. Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with </text>
<text top="751" left="87" width="429" height="21" font="4">Myotonic Dystrophy Type 1. J Neuromuscul Dis. 2017;4:175-81. </text>
</page>
<page number="261" position="absolute" top="0" left="0" height="918" width="1188">
<text top="804" left="566" width="59" height="19" font="0">Page 261 </text>
<text top="834" left="86" width="715" height="19" font="0">© 2018 American College of Cardiology Foundation, American Heart Association, Inc., and the Heart Rhythm Society. </text>
<text top="86" left="86" width="33" height="21" font="4">459. </text>
<text top="86" left="140" width="914" height="21" font="4">Bai Y, Duan J, Wang L, et al. Clinical analysis of the effect of anti-allergy treatment on pocket-related complications following pacemaker </text>
<text top="106" left="86" width="317" height="21" font="4">implantation. Exp Ther Med. 2017;13:2876-82. </text>
<text top="127" left="86" width="33" height="21" font="4">460. </text>
<text top="127" left="140" width="943" height="21" font="4">Hosseini SM, Moazzami K, Rozen G, et al. Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United </text>
<text top="147" left="86" width="372" height="21" font="4">States from 2003 to 2013. Eur Heart J. 2017;38:2122-8. </text>
<text top="167" left="86" width="33" height="21" font="4">461. </text>
<text top="167" left="140" width="916" height="21" font="4">Gupta N, Kiley ML, Anthony F, et al. Multi-Center, Community-Based Cardiac Implantable Electronic Devices Registry: Population, Device </text>
<text top="187" left="86" width="422" height="21" font="4">Utilization, and Outcomes. J Am Heart Assoc. 2016;5:e002798. </text>
<text top="207" left="86" width="33" height="21" font="4">462. </text>
<text top="207" left="140" width="946" height="21" font="4">Friedman DJ, Singh JP, Curtis JP, et al. Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe </text>
<text top="227" left="86" width="405" height="21" font="4">Chronic Kidney Disease. J Am Coll Cardiol. 2015;66:2618-29. </text>
<text top="247" left="86" width="33" height="21" font="4">463. </text>
<text top="247" left="140" width="958" height="21" font="4">Witt CT, Kronborg MB, Nohr EA, et al. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with </text>
<text top="268" left="86" width="747" height="21" font="4">improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. Europace. 2016;18:413-9. </text>
<text top="288" left="86" width="33" height="21" font="4">464. </text>
<text top="288" left="140" width="922" height="21" font="4">Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable </text>
<text top="308" left="86" width="406" height="21" font="4">cardioverter-defibrillator registry. Europace. 2015;17:69-77. </text>
<text top="328" left="86" width="33" height="21" font="4">465. </text>
<text top="328" left="140" width="933" height="21" font="4">Essebag V, Joza J, Birnie DH, et al. Incidence, predictors, and procedural results of upgrade to resynchronization therapy: the RAFT upgrade </text>
<text top="348" left="86" width="365" height="21" font="4">substudy. Circ Arrhythm Electrophysiol. 2015;8:152-8. </text>
<text top="368" left="86" width="33" height="21" font="4">466. </text>
<text top="368" left="140" width="946" height="21" font="4">Chung MK, Holcomb RG, Mittal S, et al. REPLACE DARE (Death After Replacement Evaluation) score: determinants of all-cause mortality after </text>
<text top="388" left="86" width="794" height="21" font="4">implantable device replacement or upgrade from the REPLACE registry. Circ Arrhythm Electrophysiol. 2014;7:1048-56. </text>
<text top="409" left="86" width="33" height="21" font="4">467. </text>
<text top="409" left="140" width="943" height="21" font="4">Adelstein E, Schwartzman D, Bazaz R, et al. Outcomes in pacemaker-dependent patients upgraded from conventional pacemakers to cardiac </text>
<text top="429" left="86" width="499" height="21" font="4">resynchronization therapy-defibrillators. Heart Rhythm. 2014;11:1008-14. </text>
<text top="449" left="86" width="33" height="21" font="4">468. </text>
<text top="449" left="140" width="939" height="21" font="4">Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, </text>
<text top="469" left="86" width="416" height="21" font="4">nationwide cohort in Denmark. Eur Heart J. 2014;35:1186-94. </text>
<text top="489" left="86" width="33" height="21" font="4">469. </text>
<text top="489" left="140" width="951" height="21" font="4">Acosta J, Fernandez-Armenta J, Borras R, et al. Scar Characterization to Predict Life-Threatening Arrhythmic Events and Sudden Cardiac Death </text>
<text top="509" left="86" width="723" height="21" font="4">in Patients With Cardiac Resynchronization Therapy: The GAUDI-CRT Study. JACC Cardiovasc Imaging. 2017; </text>
<text top="529" left="86" width="33" height="21" font="4">470. </text>
<text top="529" left="140" width="930" height="21" font="4">Martens P, Verbrugge FH, Nijst P, et al. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator. Heart. </text>
<text top="550" left="86" width="130" height="21" font="4">2017;103:1977-84. </text>
<text top="570" left="86" width="33" height="21" font="4">471. </text>
<text top="570" left="140" width="955" height="21" font="4">Yokoshiki H, Shimizu A, Mitsuhashi T, et al. Survival and Heart Failure Hospitalization in Patients With Cardiac Resynchronization Therapy With </text>
<text top="590" left="86" width="1015" height="21" font="4">or Without a Defibrillator for Primary Prevention in Japan- Analysis of the Japan Cardiac Device Treatment Registry Database. Circ J. 2017;81:1798-806. </text>
<text top="610" left="86" width="33" height="21" font="4">472. </text>
<text top="610" left="140" width="895" height="21" font="4">Ip JE, Wu MS, Kennel PJ, et al. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators. J Cardiovasc </text>
<text top="630" left="86" width="208" height="21" font="4">Electrophysiol. 2017;28:544-8. </text>
<text top="650" left="86" width="33" height="21" font="4">473. </text>
<text top="650" left="140" width="949" height="21" font="4">Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual </text>
<text top="670" left="86" width="221" height="21" font="4">reports. Jama. 2006;295:1901-6. </text>
<text top="691" left="86" width="33" height="21" font="4">474. </text>
<text top="691" left="140" width="758" height="21" font="4">Maisel WH. Pacemaker and ICD generator reliability: meta-analysis of device registries. Jama. 2006;295:1929-34. </text>
<text top="711" left="86" width="33" height="21" font="4">475. </text>
<text top="711" left="140" width="892" height="21" font="4">Benhayon D, Lugo R, Patel R, et al. Long-term arrhythmia follow-up of patients with myotonic dystrophy. J Cardiovasc Electrophysiol. </text>
<text top="731" left="86" width="114" height="21" font="4">2015;26:305-10. </text>
<text top="751" left="86" width="33" height="21" font="4">476. </text>
<text top="751" left="140" width="936" height="21" font="4">Faber TS, Gradinger R, Treusch S, et al. Incidence of ventricular tachyarrhythmias during permanent pacemaker therapy in low-risk patients </text>
<text top="771" left="86" width="554" height="21" font="4">results from the German multicentre EVENTS study. Eur Heart J. 2007;28:2238-42. </text>
</page>
<outline>
<item page="6">Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of 12-Lead Electrocardiography in Bradycardia or Conduction Disturbance (Section 4.2.1)</item>
<item page="9">Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Exercise Stress Testing in Bradycardia and Conduction Disturbances (Section 4.2.2)</item>
<item page="14">Data Supplement 3. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Electrocardiography in Bradycardia or Conduction Disorders (Sections 4.2.3 and 4.2.4)</item>
<item page="47">Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Electrocardiography in Bradycardia or Conduction Disorders (Section 4.2.4)</item>
<item page="49">Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Nocturnal / Sleeping Bradyarrhythmias and Sleep Apnea (Section-4.2.7)</item>
<item page="65">Data Supplement 6. RCTs of Implantable Loop Recorder in Patients With Documented or Suspected Bradycardia or Conduction Disorders (Section 4.3.1)</item>
<item page="67">Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries of Electrophysiology Testing in Patients With Documented or Suspected Bradycardia or Conduction Disorders (Section 4.3.2)</item>
<item page="67">Data Supplement 8. RCTs Comparing Atropine to Placebo for Bradycardia (Section 5.3.2.1)</item>
<item page="69">Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of Atropine in SND and Hemodynamically Significant Bradycardia (Section 5.3.2.1)</item>
<item page="72">Data Supplement 10. Nonrandomized Trials, Observational Studies, and/or Registries of Isoproterenol Effect in Electrophysiology Laboratory (Section 5.3.2.1)</item>
<item page="73">Data Supplement 11. RCTs of Dopamine in Bradycardia (Section 5.3.2.1)</item>
<item page="73">Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of Calcium, Glucagon and High Dose Insulin Therapy to treat Beta-Blocker and Calcium Channel Blocker Toxicity (CCB) (Section 5.3.2.2)</item>
<item page="76">Data Supplement 13. RCTs Comparing Anti-Digoxin Fab to placebo (Section 5.3.2.3)</item>
<item page="77">Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of Digoxin Fab Antibody Fragments (Section 5.3.2.3)</item>
<item page="79">Data Supplement 15. Nonrandomized Trials, Observational Studies, and/or Registries of Dialysis for Digoxin Toxicity (Section 5.3.2.3 – Patton)</item>
<item page="79">Data Supplement 16. RCTs Comparing Methylxanthines in Bradycardic Arrest (Section 5.3.2.4)</item>
<item page="80">Data Supplement 17. Nonrandomized Trials, Observational Studies, and/or Registries of Methylxanthines for acute therapy of bradycardia due to spinal cord injury or post-heart transplant (Section 5.3.2.4)</item>
<item page="81">Data Supplement 18. Trials of Temporary Transesophageal or Transvenous Pacing (Section 5.3.3)</item>
<item page="82">Data Supplement 19. Nonrandomized Trials, Observational Studies, and/or Registries of Temporary Transvenous Pacing (TTVP) (Section 5.3.3)</item>
<item page="87">Data Supplement 20. RCTs of Transcutaneous Pacing (Section 5.3.3)</item>
<item page="87">Data Supplement 21. Nonrandomized Trials, Observational Studies, and/or Registries of Transcutaneous Pacing (Section 5.3.3)</item>
<item page="89">Data Supplement 22. RCTs of General Principles of Chronic Therapy/Management of Bradycardia due to Sinus Node Dysfunction (Section 5.4.1)</item>
<item page="90">Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of General Principles of Chronic Therapy/Management of Bradycardia due to Sinus Node Dysfunction (Section 5.4.1)</item>
<item page="92">Data Supplement 24. RCTs of Clinical Presentation of Bradycardia due to Sinus Node Dysfunction (Section 5.3)</item>
<item page="94">Data Supplement 25. RCTs of Permanent Pacing for Chronic Therapy/Management of Bradycardia due to Sinus Node Dysfunction (Section 5.4.4)</item>
<item page="101">Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Reversible Causes of AV block (Section 6.3.1)</item>
<item page="104">Data Supplement 27. RCTs Comparing Medical treatment for AV block (Section 6.3.2)</item>
<item page="104">Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Medical Treatment for AV block (Section 6.3.2)</item>
<item page="107">Data Supplement 29. RCTs Comparing Temporary Pacing (Section 6.3.3)</item>
<item page="109">Data Supplement 30. Nonrandomized Trials, Observational Studies, and/or Registries of Temporary Pacing (Section 6.3.3)</item>
<item page="116">Data Supplement 31. RCTs of clinical presentation of bradycardia due to AV block (Section 6.3)</item>
<item page="117">Data Supplement 32. Nonrandomized data of Clinical Presentation of Bradycardia due to AV block (Section 6.3)</item>
<item page="135">Data Supplement 33. RCTs of General Principles of Chronic Therapy/Management of Bradycardia due to AV block (Section 6.4.1)</item>
<item page="135">Data Supplement 34. Nonrandomized data of General Principles of Chronic Therapy/Management of Bradycardia due to AV block (Section 6.4)</item>
<item page="146">Data Supplement 35. RCTs of meds/reversible/transient causes of bradycardia due to AVB (Section 6.4.2)</item>
<item page="146">Data Supplement 36. Nonrandomized data of Medications/Reversible/Transient Causes of Bradycardia due to AVB (Section 6.4.2)</item>
<item page="150">Data Supplement 37. RCT data of additional testing for Bradycardia due to AV block (Section 6.4.3)</item>
<item page="151">Data Supplement 38. Nonrandomized data of additional testing for Bradycardia due to AV block (Section 6.4.3)</item>
<item page="154">Data Supplement 39. RCTs for Permanent Pacing for AV block (Section 6.4.4)</item>
<item page="158">Data Supplement 40. Nonrandomized data for Permanent Pacing for AV block (Section 6.4.4)</item>
<item page="162">Data Supplement 41. Nonrandomized Trials, Observational Studies, and/or Registries of Conduction Disorders (Section 7)</item>
<item page="167">Data Supplement 42. Randomized Data for Predicting Perioperative Bradycardia (Section 8.1.1)</item>
<item page="167">Data Supplement 43. RCTs of Conduction Disorders (Section 7)</item>
<item page="167">Data Supplement 44. Nonrandomized Data for predicting perioperative bradycardia (Section 8.1.1)</item>
<item page="175">Data Supplement 45. Nonrandomized Data for predicting complete heart block with pulmonary artery catheter insertion (Section 8.1.1)</item>
<item page="176">Data Supplement 46. Nonrandomized data for Permanent Pacing for TAVI/valve surgery</item>
<item page="194">Data Supplement 47. Nonrandomized Trials, Observational Studies, and/or Registries of CABG (Section 8.1.2.1)</item>
<item page="197">Data Supplement 48. Nonrandomized Trials, Observational Studies, and/or Registries of Open Surgery for Atrial Fibrillation or Valvular Surgery (Section 8.1.2.2. and 8.1.2.3)</item>
<item page="200">Data Supplement 49. Nonrandomized Trials, Observational Studies, and/or Registries of Conduction Abnormalities After TAVR (Section 8.1.2.4)</item>
<item page="206">Data Supplement 50. Nonrandomized Trials, Observational Studies, and/or Registries of Pacing after Heart Transplant (Section 8.1.2.5.1)</item>
<item page="208">Data Supplement 51. Nonrandomized Studies for Alcohol Septal Ablation/Septal Myectomy (Section 8.1.2.5.2)</item>
<item page="215">Data Supplement 52. Nonrandomized Studies for ICDs for Alcohol Septal Ablation/Septal Myectomy (Section 8.1.2.5.2)</item>
<item page="216">Data Supplement 53. Nonrandomized Trials, Observational Studies, and/or Registries of Adult Congenital Heart Disease (ACHD) (Section 8.2)</item>
<item page="221">Data Supplement 54. RCTs, Nonrandomized Trials, Observational Studies, and/or Registries of Bradycardia and Pacemaker Implantation in Patients with an Acute MI (Section 8.3)</item>
<item page="227">Data Supplement 55. Nonrandomized Data for Predicting Bradycardia Associated with Seizures (Section 8.4.1)</item>
<item page="228">Data Supplement 56. Nonrandomized Data for Device Type (Section 9)</item>
<item page="236">References</item>
</outline>
</pdf2xml>
